PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SALERNO, A; LAWRENCE, DS				SALERNO, A; LAWRENCE, DS			COVALENT MODIFICATION WITH CONCOMITANT INACTIVATION OF THE CAMP-DEPENDENT PROTEIN-KINASE BY AFFINITY LABELS CONTAINING ONLY L-AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINYL-L-CYSTEINE; CATALYTIC SUBUNIT; ACTIVE-SITE; SULFHYDRYL-GROUP; BOVINE HEART; CATHEPSIN-B; PEPTIDES; INHIBITORS; RESIDUES; PAPAIN	Affinity labels for proteins that process other proteins (e.g. proteinases and protein kinases) are an amalgam of two components, an active site-directed peptide carrier and a nonpeptidic electrophilic appendage. We have synthesized several affinity labels for the cAMP-dependent protein kinase that are composed solely Of L-amino acids and therefore contain only functionality present in naturally occurring proteins. We have found that 2 adjacent cysteine residues, when covalently linked via a peptide bond and an intramolecular disulfide loop (abbreviated as Cys double line arrow pointing left and right Cys), serves as a potent electrophile. The peptides Leu-Arg-Arg-Cys double line arrow pointing left and right Cys-Leu-Gly (1), Leu-Arg-Arg-Ala-Cys double line arrow pointing left and right Cys-Gly (2), and Leu-Arg-Arg-Ala-Ala-Cys double line arrow pointing left and right Cys-Gly (3) inactivate the cAMP-dependent protein kinase in a time-dependent fashion. Since dialysis does not restore activity, but dithiothreitol does, this strongly suggests that covalent modification of the target enzyme has occurred at a cysteine residue. Although there are 2 cysteine moieties contained within the protein kinase, the C-14-acetylated affinity labels modify the enzyme only once. In addition, since ATP blocks inactivation of the protein kinase, this implies that it is the active site cysteine residue (Cys-199) that has undergone covalent modification. Based on the K(I(inact)) values obtained from inactivation kinetics, we conclude that the optimal site on the affinity label for the electrophilic Cys double line arrow pointing left and right Cys is 1 amino acid removed from the 2 arginine residues (i.e. 2). In addition, the efficacy of these inhibitors is also dependent upon the size of the disulfide ring. The eight-membered disulfide ring-containing peptides 1-3 are relatively poor affinity labels compared to the 12-membered ring-containing inhibitor, [GRAPHICS]	SUNY Buffalo, DEPT CHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; BLAKESLEY RW, 1977, ANAL BIOCHEM, V82, P580, DOI 10.1016/0003-2697(77)90197-X; BODANSZK.M, 1974, P NATL ACAD SCI USA, V71, P2791, DOI 10.1073/pnas.71.7.2791; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BRAMSON HN, 1983, CRC CRIT REV BIOCH, V15, P93; CAPASSO S, 1977, ACTA CRYSTALLOGR B, V33, P2080, DOI 10.1107/S0567740877007778; CHANDRAS.R, 1969, BIOCHIM BIOPHYS ACTA, V188, P1, DOI 10.1016/0005-2795(69)90039-7; CHANDRASEKHARAN R, 1968, Proceedings of the Indian Academy of Sciences Section A, V68, P13; EVANS B, 1983, J BIOL CHEM, V258, P227; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; FUJII N, 1987, J CHEM SOC CHEM COMM, P163, DOI 10.1039/c39870000163; HATA Y, 1977, ACTA CRYSTALLOGR B, V33, P3561, DOI 10.1107/S0567740877011480; JAKOBY WB, 1977, METHOD ENZYMOL, V46, P1; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KAO PN, 1986, J BIOL CHEM, V261, P8085; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEARY R, 1977, BIOCHEMISTRY-US, V16, P5857, DOI 10.1021/bi00645a033; MILLER SM, 1989, BIOCHEMISTRY-US, V28, P1194, DOI 10.1021/bi00429a037; MISE T, 1980, J BIOL CHEM, V255, P8516; MOBASHERY S, 1988, BIOCHEMISTRY-US, V27, P3691, DOI 10.1021/bi00410a025; MOORE S, 1954, J BIOL CHEM, V211, P907; ONG EB, 1965, J BIOL CHEM, V240, P694; OVICHINNIKOV YA, 1985, FEBS LETT, V179, P107; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; PROROK M, 1990, J AM CHEM SOC, V112, P8628; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RIORDAN JF, 1967, METHOD ENZYMOL, V11, P565; SHAW E, 1988, J BIOL CHEM, V263, P2768; SHAW ELLIOTT, 1965, BIOCHEMISTRY, V4, P2219, DOI 10.1021/bi00886a039; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SLUYTERMAN LA, 1973, BIOCHIM BIOPHYS ACTA, V302, P95, DOI 10.1016/0005-2744(73)90012-0; SUKUMARAN DK, 1991, J AM CHEM SOC, V113, P706, DOI 10.1021/ja00002a067; THOMPSON SA, 1986, J MED CHEM, V29, P104, DOI 10.1021/jm00151a018; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WIBERG KB, 1992, J AM CHEM SOC, V114, P831, DOI 10.1021/ja00029a005; YABE Y, 1988, J AM CHEM SOC, V110, P4043, DOI 10.1021/ja00220a056; ZHANG RM, 1989, J BIOL CHEM, V264, P18472; ZHANG RM, 1988, BIOCHEMISTRY-US, V27, P3785, DOI 10.1021/bi00410a040	41	10	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13043	13049						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514745				2022-12-27	WOS:A1993LH55300008
J	BIANCHI, R; GIAMBANCO, I; DONATO, R				BIANCHI, R; GIAMBANCO, I; DONATO, R			S-100 PROTEIN, BUT NOT CALMODULIN, BINDS TO THE GLIAL FIBRILLARY ACIDIC PROTEIN AND INHIBITS ITS POLYMERIZATION IN A CA2+-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; BOVINE BRAIN; S100 PROTEIN; HEAD DOMAIN; CALCIUM; INVITRO; PHOSPHORYLATION; FILAMENTS; IDENTITY; SEQUENCE	S-100 protein, a Ca2+-binding protein of the EF-hand type, interacts with the glial fibrillary acidic protein (GFAP) in a Ca2+-dependent manner. The binding of S-100 protein to GFAP was investigated by fluorescence spectroscopy using acrylodan-S-100 protein and cross-linking experiments using the bifunctional cross-linker, disuccinimidyl suberate. The binding affinity was observed to be in the nanomolar range with a stoichiometry of 2 mol of GFAP/mol of S-100 protein (dimer). S-100 protein was found to inhibit the polymerization of GFAP in a dose- and Ca2+-dependent manner, with a half-maximal effect at an S-100 protein/GFAP molar ratio of 0.2 and maximal effect at a molar ratio of 0.5. Identical results were obtained irrespective of whether the unfractionated bovine brain S-100 protein mixture (S-100a plus S-100b), S-100a0, S-100a, or S-100b was used. S-100 protein was observed to be maximally effective as an inhibitor of GFAP polymerization at approximately 3 muM free Ca2+. Calmodulin neither bound to GFAP nor inhibited its polymerization. Altogether, the present results suggest that S-100 protein might be involved in the regulation of the state of assembly of glial filaments by binding to and sequestering unpolymerized GFAP.	UNIV PERUGIA,DEPT EXPTL MED & BIOCHEM SCI,ANAT SECT,CP 81 SUCC 3,I-06100 PERUGIA,ITALY	University of Perugia			Donato, Rosario/I-3943-2019	Giambanco, Ileana/0000-0003-0286-6302	Telethon [27] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		BACKHOVENS H, 1987, J NEUROCHEM, V49, P348, DOI 10.1111/j.1471-4159.1987.tb02872.x; BAUDIER J, 1983, BIOCHEMISTRY-US, V22, P3360, DOI 10.1021/bi00283a009; BAUDIER J, 1986, BIOCHEMISTRY-US, V25, P6934, DOI 10.1021/bi00370a029; BAUDIER J, 1988, BIOCHEMISTRY-US, V27, P2728, DOI 10.1021/bi00408a012; BIANCHI R, 1992, BIOCHIM BIOPHYS ACTA, V1160, P67, DOI 10.1016/0167-4838(92)90039-G; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; CALISSANO P, 1969, BIOCHEMISTRY-US, V8, P4318, DOI 10.1021/bi00839a015; DAHL D, 1983, HDB NEUROCHEMISTRY, V5, P127; DONATO R, 1988, CELL BIOL INT REP, V12, P565, DOI 10.1016/0309-1651(88)90044-6; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DONATO R, 1989, J NEUROCHEM, V53, P566, DOI 10.1111/j.1471-4159.1989.tb07371.x; DONATO R, 1988, J BIOL CHEM, V263, P106; DONATO R, 1989, CELL CALCIUM, V10, P81, DOI 10.1016/0143-4160(89)90048-1; DONATO R, 1984, BIOCHEM BIOPH RES CO, V124, P850, DOI 10.1016/0006-291X(84)91035-0; DONATO R, 1986, J NEUROCHEM, V46, P1333, DOI 10.1111/j.1471-4159.1986.tb01743.x; FREEMAN MR, 1989, EXP CELL RES, V182, P370, DOI 10.1016/0014-4827(89)90242-5; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; INAGAKI M, 1989, J BIOL CHEM, V264, P18119; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS CV, 1980, NEUROCHEM RES, V5, P1199, DOI 10.1007/BF00964899; LUCAS CV, 1980, NEUROCHEM RES, V5, P247, DOI 10.1007/BF00964613; MESSENS J, 1992, J NEUROCHEM, V58, P2071, DOI 10.1111/j.1471-4159.1992.tb10948.x; MINURA M, 1990, J NEUROCHEM, V55, P1180; NAKAMURA Y, 1991, GLIA, V4, P101, DOI 10.1002/glia.440040112; Pendergast F. G., 1983, J BIOL CHEM, V258, P7541; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PRITCHARD K, 1991, BIOCHEM J, V277, P819, DOI 10.1042/bj2770819; RAMBOTTI MG, 1990, J HISTOCHEM CYTOCHEM, V38, P1583, DOI 10.1177/38.11.2212618; RUEGER DC, 1979, J MOL BIOL, V135, P53, DOI 10.1016/0022-2836(79)90340-1; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; SHAW G, 1992, NEUROREPORT, V3, P461, DOI 10.1097/00001756-199206000-00001; SKRIPNIKOVA EV, 1989, FEBS LETT, V257, P380, DOI 10.1016/0014-5793(89)81577-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG ZW, 1988, BIOCHEMISTRY-US, V27, P7038, DOI 10.1021/bi00418a055; YANG ZW, 1988, BIOCHEMISTRY-US, V27, P7045, DOI 10.1021/bi00418a056; ZOLESE G, 1993, BIOCHIM BIOPHYS ACTA, V1162, P47, DOI 10.1016/0167-4838(93)90126-C	43	114	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12669	12674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509402				2022-12-27	WOS:A1993LG65800066
J	GROCHULSKI, P; LI, YG; SCHRAG, JD; BOUTHILLIER, F; SMITH, P; HARRISON, D; RUBIN, B; CYGLER, M				GROCHULSKI, P; LI, YG; SCHRAG, JD; BOUTHILLIER, F; SMITH, P; HARRISON, D; RUBIN, B; CYGLER, M			INSIGHTS INTO INTERFACIAL ACTIVATION FROM AN OPEN STRUCTURE OF CANDIDA-RUGOSA LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC LIPASE; ORGANIC MEDIA; HYDROLYSIS; CATALYSIS; SERINE	The structure of the Candida rugosa lipase determined at 2.06-angstrom resolution reveals a conformation with a solvent-accessible active site. Comparison with the crystal structure of the homologous lipase from Geotrichum candidum, in which the active site is covered by surface loops and is inaccessible from the solvent, shows that the largest structural differences occur in the vicinity of the active site. Three loops in this region differ significantly in conformation, and the interfacial activation of these lipases is likely to be associated with conformational rearrangements of these loops. The ''open'' structure provides a new image of the substrate binding region and active site access, which is different from that inferred from the structure of the ''closed'' form of the G. candidum lipase.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,PQ,CANADA; TECH UNIV LODZ,INST PHYS,PL-93005 LODZ,POLAND; EASTMAN KODAK CO,ROCHESTER,NY 14650	National Research Council Canada; Lodz University of Technology; Eastman Kodak								BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BROCKMAN HL, 1973, J BIOL CHEM, V248, P4965; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CYGLER M, 1993, PROTEIN SCI, V2, P366; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DESNUELLE P, 1960, BIOCHIM BIOPHYS ACTA, V37, P570, DOI 10.1016/0006-3002(60)90532-1; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAWAGUCHI Y, 1989, NATURE, V341, P164, DOI 10.1038/341164a0; LONGHI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P227, DOI 10.1016/0167-4781(92)90085-E; Macrae A. R., 1983, MICROBIAL ENZYMES BI, P225; MARTINEZ C, 1992, NATURE, V356, P615, DOI 10.1038/356615a0; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MATSUURA Y, 1991, J APPL CRYSTALLOGR, V24, P1063, DOI 10.1107/S002188989100554X; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PARIDA S, 1991, J AM CHEM SOC, V113, P2253, DOI 10.1021/ja00006a051; RANGHEARD MS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P20, DOI 10.1016/0005-2760(89)90207-5; RUBIN B, 1991, LIPASES STRUCTURE ME, P63; SCHRAG JD, 1991, NATURE, V351, P671; SCHRAG JD, 1993, IN PRESS J MOL BIOL, V220; SONNET PE, 1991, J AM OIL CHEM SOC, V68, P11, DOI 10.1007/BF02660300; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R, 1980, Methods Enzymol, V64, P340; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	26	511	527	0	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12843	12847						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509417				2022-12-27	WOS:A1993LG65800090
J	MEGRAW, TL; CHAE, CB				MEGRAW, TL; CHAE, CB			FUNCTIONAL COMPLEMENTARITY BETWEEN THE HMG1-LIKE YEAST MITOCHONDRIAL HISTONE HM AND THE BACTERIAL HISTONE-LIKE PROTEIN HU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA; TYPHIMURIUM; SIMILARITY; MUTANTS; IMPORT	The mitochondrial histone HM is the major DNA-binding protein in mitochondria and is necessary for maintenance of the mitochondrial genome in the yeast Saccharomyces cerevisiae during growth on fermentable sugars. HM and the Escherichia coli histone-like protein HU have similar activities in vitro, including DNA supercoiling, but share no sequence similarity. We show that HU can functionally complement the respiration deficiency associated with yeast strains lacking HM. Conversely, phenotypes of E. coli cells lacking HU protein, including nucleoid loss and a filamentous cell morphology, were alleviated by expression of HM in these cells. The HU protein of bacteria and the HM protein of mitochondria are therefore functionally complementary in vivo. Functional similarities among HM, HU, and the nuclear HMG1 proteins are implicated and discussed.			MEGRAW, TL (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.		Megraw, Tim/U-1442-2019; Megraw, Timothy/T-5186-2019	Megraw, Timothy/0000-0001-7455-7483	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043814] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43814] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK JC, 1968, P NATL ACAD SCI USA, V60, P186, DOI 10.1073/pnas.60.1.186; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BRIAT JF, 1984, FEBS LETT, V172, P75, DOI 10.1016/0014-5793(84)80877-7; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FALCONI M, 1991, NEW BIOL, V3, P615; FISHER RP, 1992, J BIOL CHEM, V267, P3358; GASSER SM, 1983, METHOD ENZYMOL, V97, P329; GHRIR R, 1992, BIOCHIMIE, V73, P615; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; GRIFFITH JD, 1976, P NATL ACAD SCI USA, V73, P563, DOI 10.1073/pnas.73.2.563; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HILLYARD DR, 1990, J BACTERIOL, V172, P5402, DOI 10.1128/jb.172.9.5402-5407.1990; HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989; KOVAC L, 1967, SCIENCE, V158, P1564, DOI 10.1126/science.158.3808.1564; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SIKORSKI RS, 1989, GENETICS, V122, P19; Van Holde K.A., 1988, CHROMATIN, P69; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9	32	96	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12758	12763						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509411				2022-12-27	WOS:A1993LG65800079
J	GRILLEY, M; GRIFFITH, J; MODRICH, P				GRILLEY, M; GRIFFITH, J; MODRICH, P			BIDIRECTIONAL EXCISION IN METHYL-DIRECTED MISMATCH REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA; PURIFICATION; SEQUENCES; EXTRACTS; INVITRO	Using electron microscopy and indirect end-labeling methods, we have examined excision tracts produced by the Escherichia coli methyl-directed mismatch repair system on a closed circular G-T heteroduplex that contains a single d(GATC) site. Despite differing polarities of the unmodified strand in the two hemimethylated derivatives of the heteroduplex, that portion of the unmethylated strand spanning the shorter path between the d(GATC) site and mismatch is targeted for excision in both cases. Mismatch-provoked excision occurring on both hemimethylated DNAs requires DNA helicase II, but exonuclease requirements for the reaction depend on heteroduplex orientation. When the d(GATC) sequence on the unmodified strand resides 3' to the mismatch as viewed along the shorter path, excision requires exonuclease I. Excision occurring on the alternate hemimethylated heteroduplex depends on the 5' --> 3' hydrolytic activity of exonuclease VII. Coupled with the previous demonstration that repair initiates via the mismatch-provoked, MutHLS-dependent incision of the unmethylated strand at a d(GATC) sequence (Au, K. G., Welsh, K., and Modrich, P. (1992) J. Biol. Chem. 267, 12142-12148), these findings indicate an excision mechanism in which helicase II displacement renders the incised strand sensitive to the appropriate single-strand exonuclease. Our data imply that hydrolysis commences at the d(GATC) site, proceeds to a point beyond the mismatch, and terminates at a number of discrete sites within a 100-nucleotide region just beyond this site. The extent of excision is therefore controlled by one or more components of the repair system.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM,CHAPEL HILL,NC 27599	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819, R01GM023719, R37GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31819, GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1992, J BIOL CHEM, V267, P12142; CHASE JW, 1974, J BIOL CHEM, V249, P4553; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER DL, 1993, J BIOL CHEM, V268, P11823; FANG WH, 1993, J BIOL CHEM, V268, P11838; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LAHUE RS, 1987, UCLA S MOL CELLULAR, V47, P125; LANGLEROUAULT F, 1987, EMBO J, V6, P1121, DOI 10.1002/j.1460-2075.1987.tb04867.x; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SU SS, 1989, GENOME, V31, P104, DOI 10.1139/g89-020; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744	20	129	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11830	11837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505311				2022-12-27	WOS:A1993LF28400057
J	ROSE, JR; SALTO, R; CRAIK, CS				ROSE, JR; SALTO, R; CRAIK, CS			REGULATION OF AUTOPROTEOLYSIS OF THE HIV-1 AND HIV-2 PROTEASES WITH ENGINEERED AMINO-ACID SUBSTITUTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; SUBSTRATE; SITE; POLYPROTEIN; PROTEINASE	Autoproteolysis of the retroviral aspartyl proteases is a major obstacle to purification and analysis of these enzymes. A mutagenic approach to rendering autolytic cleavage sites less labile was applied to the primary. cleavage site between Leu5 and Trp6 in human immunodeficiency virus-1 (HIV-1) protease. From predictions based on known substrates it was concluded that amino acids Lys or Ser in place of Gln at position 7 would prevent cleavage at the Leu5-Trp6 peptide bond, therefore stabilizing the protein. Autoproteolytic stability was enhanced at least 100-fold by these mutations. At longer time points the protease was degraded at secondary sites which contained adequate substrate sequences but were conformationally restricted. Conversely, a mutation in HIV-2 protease which changed Lys7 to Gln rendered the protein 3-fold less stable and shifted the position of the initial autoproteolytic cleavage from Phe3-Ser4 to Leu5-Trp6. The effects of these mutations demonstrate that small changes in protein sequence can have a major impact on their autoproteolytic stability. The work described here suggests a general method for stabilizing proteases and perhaps other recombinantly produced proteins to autolysis.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Salto, Rafael/A-6486-2011	Salto, Rafael/0000-0002-7044-3611	NIGMS NIH HHS [GM 39552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABE LM, 1990, UCLA SYM BI, V110, P71; BABE LM, 1991, STRUCTURE FUNCTION A, P543; BRAXTON S, 1992, BIOCHEMISTRY-US, V31, P7796, DOI 10.1021/bi00149a008; GRANT SK, 1991, BIOCHEMISTRY-US, V30, P8424, DOI 10.1021/bi00098a021; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; JUPP RA, 1991, FEBS LETT, V283, P180, DOI 10.1016/0014-5793(91)80583-O; KNOWLES JR, 1987, SCIENCE, V236, P1252; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; MARGOLIN N, 1990, BIOCHEM BIOPH RES CO, V167, P554, DOI 10.1016/0006-291X(90)92060-D; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NORTH MJ, 1989, PROTEOLYTIC ENZYMES, P1105; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; PICHUANTES S, 1990, J BIOL CHEM, V265, P13890; PICHUANTES S, 1989, PROTEINS, V6, P324, DOI 10.1002/prot.340060315; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; SHARMA SK, 1981, BIOORG CHEM, V10, P357, DOI 10.1016/0045-2068(81)90049-3; SMITH RL, 1969, J BIOL CHEM, V244, P4704; STRICKLER JE, 1989, PROTEINS, V6, P139, DOI 10.1002/prot.340060205; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1991, INT J CHEM BIOTE MAY; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	27	97	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11939	11945						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505318				2022-12-27	WOS:A1993LF28400072
J	BALDWIN, TO; ZIEGLER, MM; CHAFFOTTE, AF; GOLDBERG, ME				BALDWIN, TO; ZIEGLER, MM; CHAFFOTTE, AF; GOLDBERG, ME			CONTRIBUTION OF FOLDING STEPS INVOLVING THE INDIVIDUAL SUBUNITS OF BACTERIAL LUCIFERASE TO THE ASSEMBLY OF THE ACTIVE HETERODIMERIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; VIBRIO-HARVEYI; DENATURED SUBTILISIN; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNIT; BETA-SUBUNIT; PRO-REGION; LUXB GENE; REQUIRE; INVIVO	Bacterial luciferase is an alphabeta heterodimer with a single active center in which the reaction of reduced FMN, O2, and an aliphatic aldehyde yields a photon of blue-green light. We have shown that refolding of the luciferase subunits from 5 M urea occurs via the intermediacy of several species, one of which is an inactive heterodimeric structure, resulting from the dimerization of alpha and beta, which isomerizes to the active alphabeta structure in a first-order reaction (Ziegler, M. M., Goldberg, M. E., Chaffotte, A. F., and Baldwin, T. O. (1993) J. Biol. Chem. 268, 10760-10765). We have also demonstrated the existence of an inactive heterodimeric species that is well populated at equilibrium in the presence of 1.6-2.8 M urea (Clark, A. C., Sinclair, J. F., and Baldwin, T. O. (1993) J. Biol. Chem. 268, 10773-10779). We have separated the alpha and beta subunits by ion exchange chromatography and investigated the effects on reformation of active luciferase of allowing the individual subunits to refold separately prior to mixing. These investigations show that the lag in formation of active luciferase is due to slow steps in folding of the individual subunits. The beta subunit appears to fold faster than the alpha subunit, but folding of the beta subunit also shows a distinct lag. When the alpha and beta subunits were allowed to refold from urea for periods of several hours or more prior to mixing, the yield of active heterodimeric luciferase was compromised, which is consistent with the finding that individual subunits produced in vivo fold into structures incompetent to interact with each other to form the active heterodimer (Waddle, J. J., Johnston, T. C., and Baldwin, T. O. (1987) Biochemistry 26, 4917-4921). It appeared that the rate with which the beta subunit assumed the heterodimerization-incompetent structure was faster than the rate with which the alpha subunit became heterodimerization-incompetent. These observations support a model for folding and assembly of the subunits of luciferase in which the two subunits fold into assembly-competent structures that associate to form the heterodimer. In a slow competing process, the subunits undergo a conformational rearrangement to form stable structures incompetent to form heterodimers. It appears that the association of the luciferase subunits might constitute an example of one polypeptide modifying the folding pathway of another, a model that is consistent with the suggestion that the formation of the heterodimeric structure of luciferase is a kinetic trap on the folding pathway of the individual subunits (Sugihara, J., and Baldwin, T. O. (1988) Biochemistry 27, 2872-2880).	TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,CTR MACROMOLEC DESIGN,COLL STN,TX 77843; INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE	Texas A&M University System; Texas A&M University College Station; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BALDWIN, TO (corresponding author), TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843, USA.				FIC NIH HHS [1 FO6 TW016066-01] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P4303, DOI 10.1021/bi00132a022; CLARK AC, 1993, J BIOL CHEM, V268, P10773; COHN DH, 1985, J BIOL CHEM, V260, P6139; FRIEDLAND J, 1967, P NATL ACAD SCI USA, V58, P2336, DOI 10.1073/pnas.58.6.2336; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GUNSALUSMIGUEL A, 1972, J BIOL CHEM, V247, P398; HASTINGS JW, 1969, BIOCHEMISTRY-US, V8, P4681, DOI 10.1021/bi00840a004; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SINCLAIR JF, 1993, IN PRESS BIOCHEMISTR, V32; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TU SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P342, DOI 10.1016/0003-9861(77)90120-5; TU SC, 1978, METHOD ENZYMOL, V57, P171; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WADDLE JJ, 1990, THESIS TEXAS AM U CO; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760	27	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10766	10772						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496143				2022-12-27	WOS:A1993LD46600012
J	KONRAD, M				KONRAD, M			MOLECULAR ANALYSIS OF THE ESSENTIAL GENE FOR ADENYLATE KINASE FROM THE FISSION YEAST SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GTP-AMP PHOSPHOTRANSFERASE; BEEF-HEART MITOCHONDRIA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ENERGY CHARGE; BAKERS-YEAST; X-RAY; PROTEIN; EXPRESSION	The enzyme-catalyzed transfer of the terminal phosphoryl group from ATP to an acceptor molecule is an important reaction in a wide variety of biological processes. I demonstrate here the essential function of an ATP:AMP phosphotransferase (adenylate kinase) in the fission yeast Schizosaccharomyces pombe. A cDNA clone encoding immunoreactive adenylate kinase from S. pombe was isolated from a lambdagt11 expression library by cross-reaction with antibodies raised against the recently characterized ADK1 enzyme from the budding yeast Saccharomyces cerevisiae. Subsequent cloning and nucleotide sequence analysis of the S. pombe adenylate kinase gene, adk1, revealed a coding region of 660 nucleotides. The alignment of the two amino acid sequences from S. cerevisiae and S. pombe shows 67% identity. By gene disruption and tetrad analysis it is demonstrated that adk1 is absolutely essential for cell viability. This is in contrast to the ADK1 gene of S. cerevisiae, the deletion of which was shown to lead to a slower cell growth rate rather than to a lethal phenotype. Expression of adk1 in the S. cerevisiae ADK1 deletion strain restored normal cell growth, demonstrating that ADK1 and adk1 are functionally interchangeable. However, despite lack of absolute substrate specificity of adenylate kinases, adk1 could not complement the loss of function of the guanylate kinase encoding gene in a S. cerevisiae null mutant strain, thus highlighting the functional uniqueness of each nucleoside monophosphate kinase. Using suitable expression vectors, large amounts of active adk1 enzyme were produced in either yeast species and in E. coli. The purified enzyme exhibits a high preference for adenine nucleotides, with ATP being a 10 times more efficient phosphoryl donor than GTP.			KONRAD, M (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, POB 2841, W-3400 GOTTINGEN, GERMANY.							ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; ATKINSON DE, 1967, J BIOL CHEM, V242, P3239; BALL WJ, 1975, J BACTERIOL, V121, P975, DOI 10.1128/JB.121.3.975-982.1975; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; Boyer P.D, 1973, ENZYMES, P279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLE K, 1990, BIOCHEMISTRY-US, V29, P3295, DOI 10.1021/bi00465a021; BROKER M, 1989, FEBS LETT, V248, P105, DOI 10.1016/0014-5793(89)80441-7; BRUNE M, 1985, NUCLEIC ACIDS RES, V13, P7139, DOI 10.1093/nar/13.19.7139; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRABTREE B, 1985, CURR TOP CELL REGUL, V25, P21; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; DIEDERICHS K, 1991, J MOL BIOL, V217, P541, DOI 10.1016/0022-2836(91)90756-V; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FRANK R, 1986, EUR J BIOCHEM, V154, P205, DOI 10.1111/j.1432-1033.1986.tb09380.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLASER M, 1975, J BACTERIOL, V123, P128, DOI 10.1128/JB.123.1.128-136.1975; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HAASE GHW, 1989, J MOL BIOL, V207, P151, DOI 10.1016/0022-2836(89)90446-4; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITO Y, 1980, EUR J BIOCHEM, V105, P85, DOI 10.1111/j.1432-1033.1980.tb04477.x; KARL DM, 1980, MICROBIOL REV, V44, P739, DOI 10.1128/MMBR.44.4.739-796.1980; KISHI F, 1987, J BIOL CHEM, V262, P11785; KONRAD M, 1992, J BIOL CHEM, V267, P25652; KONRAD M, 1988, J BIOL CHEM, V263, P19468; KUBY SA, 1984, BIOCHEMISTRY-US, V23, P2393, DOI 10.1021/bi00306a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1981, Curr Top Cell Regul, V18, P301; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MOYER JD, 1985, CRC CR REV BIOCH MOL, V19, P45, DOI 10.3109/10409238509086787; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; Nasim A., 1989, MOL BIOL FISSION YEA; OHKUBO S, 1987, MOL GEN GENET, V210, P314, DOI 10.1007/BF00325700; PURICH DL, 1972, J BIOL CHEM, V247, P249; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; ROSE AB, 1990, METHOD ENZYMOL, V185, P234; Rose MD., 1990, METHODS YEAST GENETI; ROSE T, 1991, J BIOL CHEM, V266, P10781; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SPURGIN P, 1989, EUR J BIOCHEM, V179, P621, DOI 10.1111/j.1432-1033.1989.tb14592.x; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P343; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STRYER L, 1988, BIOCHEMISTRY-US, P325; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOMASSELLI AG, 1986, FEBS LETT, V202, P303, DOI 10.1016/0014-5793(86)80706-2; TOMASSELLI AG, 1986, EUR J BIOCHEM, V155, P111, DOI 10.1111/j.1432-1033.1986.tb09465.x; TOMASSELLI AG, 1984, EUR J BIOCHEM, V142, P287, DOI 10.1111/j.1432-1033.1984.tb08283.x; TRAUT TW, 1988, CRC CR REV BIOCH MOL, V23, P121, DOI 10.3109/10409238809088318; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VETTER IR, 1991, BIOCHEMISTRY-US, V30, P4137, DOI 10.1021/bi00231a005; WINE JJ, 1992, NATURE, V360, P18, DOI 10.1038/360018a0; YAMADA M, 1989, J BIOL CHEM, V264, P19192	71	37	39	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11326	11334						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496185				2022-12-27	WOS:A1993LD46600089
J	WICK, PF; SENTER, RA; PARSELS, LA; UHLER, MD; HOLZ, RW				WICK, PF; SENTER, RA; PARSELS, LA; UHLER, MD; HOLZ, RW			TRANSIENT TRANSFECTION STUDIES OF SECRETION IN BOVINE CHROMAFFIN CELLS AND PC12 CELLS - GENERATION OF KAINATE-SENSITIVE CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTOR CHANNELS; HUMAN GROWTH-HORMONE; CATECHOLAMINE SECRETION; ADRENAL-MEDULLA; PROTEIN-KINASE; MAMMALIAN-CELLS; CALCIUM; SUBUNIT; CA-2+; IDENTIFICATION	We have developed a transient transfection method to measure protein secretion from non-dividing, primary bovine chromaffin cells and from the continuous cell line, PC12. A plasmid coding human growth hormone (GH) was expressed in sufficient amounts in bovine chromaffin and PC12 cells to allow precise measurements of secretion from the small fraction (less than 1%) of transfected cells in a dish. GH was secreted in a similar proportion to endogenous catecholamine upon nicotinic stimulation, depolarization with elevated K+, and upon permeabilization with digitonin and subsequent stimulation with micromolar Ca2+. GH in homogenates from GH-transfected chromaffin cells cosedimented with catecholamine on discontinuous sucrose gradients. The data indicate that transiently expressed human GH in chromaffin and PC12 cells is localized predominantly in secretory vesicles in the regulated secretory pathway. With transient transfection there is a high probability of coexpression in the same cell of two plasmids which are cotransfected. Coexpression of a plasmid for GH and a plasmid for the non-N-methyl-D-aspartate glutamate receptor, GluR1, created chromaffin cells in which Ca2+-dependent GH secretion could be stimulated by the glutamatergic agonist kainate. The ability to coexpress a plasmid of interest with a plasmid for GH will allow the investigation of the role of other cloned proteins in the regulated secretory pathway in differentiated, non-dividing cells.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,M6222 MED SCI I,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,MENTAL HLTH RES INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK27599] Funding Source: Medline; NIGMS NIH HHS [5T32GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS JC, 1983, J NEUROCHEM, V40, P468, DOI 10.1111/j.1471-4159.1983.tb11306.x; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORCORAN JJ, 1990, AM J PHYSIOL, V259, pC161, DOI 10.1152/ajpcell.1990.259.1.C161; DUNN LA, 1983, J BIOL CHEM, V258, P4989; GORMAN CM, 1991, DNA PROTEIN ENG TECH, V2, P3; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HENNEBERRY RC, 1992, BIOESSAYS, V14, P465, DOI 10.1002/bies.950140707; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLZ RW, 1985, J NEUROCHEM, V45, P1548, DOI 10.1111/j.1471-4159.1985.tb07226.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KILPATRICK DL, 1981, J NEUROCHEM, V36, P1245, DOI 10.1111/j.1471-4159.1981.tb01724.x; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; MA WJ, 1992, J BIOL CHEM, V267, P22728; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; ROGERS SW, 1991, J NEUROSCI, V11, P2713; ROSS ME, 1990, J NEUROSCI, V10, P520; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCANGOS G, 1981, GENE, V14, P1, DOI 10.1016/0378-1119(81)90143-8; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101; WAGNER PD, 1990, J BIOL CHEM, V265, P10352; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WILSON SP, 1983, J BIOL CHEM, V258, P4994; WILSON SP, 1977, J NEUROCHEM, V28, P687, DOI 10.1111/j.1471-4159.1977.tb10615.x; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J	42	124	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10983	10989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496162				2022-12-27	WOS:A1993LD46600043
J	MOREL, L; DUFAURE, JP; DEPEIGES, A				MOREL, L; DUFAURE, JP; DEPEIGES, A			LESP, AN ANDROGEN-REGULATED LIZARD EPIDIDYMAL SECRETORY PROTEIN FAMILY IDENTIFIED AS A NEW MEMBER OF THE LIPOCALIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; AMINO-ACID-SEQUENCE; A-DEFICIENT RATS; MANDUCA-SEXTA L; BETA-LACTOGLOBULIN; LACERTA-VIVIPARA; VITAMIN-A; ALPHA-2U-GLOBULIN SUPERFAMILY; ALPHA-1-ACID GLYCOPROTEIN; SEMINIFEROUS EPITHELIUM	The sperm coating lizard epididymal secretory protein (LESP) family forms a complex of nine elements that are specifically synthesized under androgenic control and secreted by the epididymal epithelial cells of the lizard Lacerta vivipara. We report here the cloning and sequencing of an 806-base pair full-length cDNA (C731) encoding one of the elements of the LESP family. Southern blot hybridization analysis of lizard total genomic DNA revealed a complex band pattern, suggesting that LESPs are encoded by a multigenic family. The cDNA open reading frame of 516 nucleotides, starting at an ATG codon, encodes a protein precursor of 172 amino acids with a calculated M(r) = 19,500. The corresponding mature form of M(r) = 17,200 and pI = 5.2 has been identified as the element LESP IV, and presents significant similarities to the different members of the large lipocalin protein superfamily, and especially to mouse epididymal protein ESP I. Lipocalins are extracellular proteins that share a common basic framework for the transport of small hydrophobic molecules like retinoids, thus suggesting that LESPs could be such transporters into the epididymal fluid during the sperm maturation.	UNIV CLERMONT FERRAND, BIOL CELLULAIRE LAB, CNRS, U360, F-63177 CLERMONT FERRAND, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA)								ALI S, 1988, J MOL BIOL, V199, P415, DOI 10.1016/0022-2836(88)90614-6; BENNETT KL, 1982, P NATL ACAD SCI-BIOL, V79, P1220, DOI 10.1073/pnas.79.4.1220; BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; BERNHARD G, 1987, METHOD ENZYMOL, V152, P180; BLUDAU H, 1986, EXP CELL RES, V165, P269, DOI 10.1016/0014-4827(86)90551-3; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BRAUNITZ.G, 1973, H-S Z PHYSIOL CHEM, V354, P867, DOI 10.1515/bchm2.1973.354.2.867; BROOKS DE, 1987, BIOCHEM INT, V14, P235; BROOKS DE, 1986, J BIOL CHEM, V261, P4956; BROOKS DE, 1983, J REPROD FERTIL, V69, P651, DOI 10.1530/jrf.0.0690651; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; CLARK AJ, 1985, EMBO J, V4, P3167, DOI 10.1002/j.1460-2075.1985.tb04060.x; CLARK AJ, 1984, EMBO J, V3, P2055, DOI 10.1002/j.1460-2075.1984.tb02091.x; COOPER TG, 1986, EPIDIDYMIS SPERM MAT, P368; COURTY Y, 1987, J REPROD FERTIL, V81, P443; DEPEIGES A, 1985, J REPROD FERTIL, V74, P23; DEPEIGES A, 1988, BIOCHIM BIOPHYS ACTA, V964, P383, DOI 10.1016/0304-4165(88)90039-6; DEPEIGES A, 1983, GAMETE RES, V7, P401, DOI 10.1002/mrd.1120070411; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOLAN KP, 1982, J BIOL CHEM, V257, P13527; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; DRAYNA DT, 1987, DNA-J MOLEC CELL BIO, V6, P199, DOI 10.1089/dna.1987.6.199; DUFAURE JP, 1986, BIOL REPROD, V35, P667, DOI 10.1095/biolreprod35.3.667; ECHEVERRIA FMG, 1982, J REPROD FERTIL, V64, P1, DOI 10.1530/jrf.0.0640001; EDDY EM, 1988, PHYSL REPRODUCTION, V1, P27; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; GIROTTI M, 1992, BIOCHEM J, V281, P203, DOI 10.1042/bj2810203; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GODOVAC-ZIMMERMANN J, 1988, BIOL CHEM H-S, V369, P171, DOI 10.1515/bchm3.1988.369.1.171; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; HAEFLIGER JA, 1987, BIOCHEM BIOPH RES CO, V149, P750, DOI 10.1016/0006-291X(87)90431-1; HAMILTON DW, 1986, BIOL REPROD, V34, P925, DOI 10.1095/biolreprod34.5.925; HANEJI T, 1984, ENDOCRINOLOGY, V114, P801, DOI 10.1210/endo-114-3-801; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUANG HFS, 1979, BIOL REPROD, V21, P891, DOI 10.1095/biolreprod21.4.891; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; Jones PD, 1989, J CLIMATE, V2, P285, DOI 10.1175/1520-0442(1989)002<0285:TEOUWO>2.0.CO;2; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; KATO M, 1985, BIOL REPROD, V32, P173, DOI 10.1095/biolreprod32.1.173; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSAGNE H, 1993, IN PRESS EXP EYE RES; LAURENT BC, 1985, J BIOL CHEM, V260, P1476; LAURENT M, 1991, CELL MOL BIOL, V37, P757; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LIAO YCJ, 1985, MOL CELL BIOL, V5, P3634, DOI 10.1128/MCB.5.12.3634; LOPEZ C, 1981, BIOCHEM BIOPH RES CO, V103, P919, DOI 10.1016/0006-291X(81)90898-6; Maniatis T., 1982, MOL CLONING; MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEWCOMER ME, 1990, J BIOL CHEM, V265, P12876; NORTH ACT, 1989, INT J BIOL MACROMOL, V11, P56, DOI 10.1016/0141-8130(89)90041-X; Orgebin-Crist M.-C., 1975, HDB PHYSIOLOGY, P319; ORGEBINCRIST MC, 1978, ENDOCRINOLOGY, V103, P46, DOI 10.1210/endo-103-1-46; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; PORTER SB, 1983, P NATL ACAD SCI-BIOL, V80, P6586, DOI 10.1073/pnas.80.21.6586; PORTER SB, 1985, J ANDROL, V6, P197; RAJAN N, 1990, BIOL REPROD, V43, P835, DOI 10.1095/biolreprod43.5.835; REDL B, 1992, J BIOL CHEM, V267, P20282; RILEY CT, 1984, J BIOL CHEM, V259, P3159; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER L, 1987, NATURE, V327, P659, DOI 10.1038/327659a0; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; URADE Y, 1989, J BIOL CHEM, V264, P1041; VANBEEK MEAB, 1991, BIOL REPROD, V45, P235, DOI 10.1095/biolreprod45.2.235; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; VOGLMAYR JK, 1985, BIOL REPROD, V33, P165, DOI 10.1095/biolreprod33.1.165; WASSALL SR, 1990, METHOD ENZYMOL, V189, P383; ZWAIN IH, 1992, ENDOCRINOLOGY, V131, P1511, DOI 10.1210/en.131.3.1511	74	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10274	10281						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486691				2022-12-27	WOS:A1993LB80000049
J	CZECH, MP; BUXTON, JM				CZECH, MP; BUXTON, JM			INSULIN ACTION ON THE INTERNALIZATION OF THE GLUT4 GLUCOSE TRANSPORTER IN ISOLATED RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE; TRANSLOCATION; CELLS; PROTEIN; FAMILY	A novel method was developed to measure relative amounts of the GLUT4 glucose transporter on the surface of intact fat cells and to monitor the action of insulin on cell surface glucose transporters as they internalize into intracellular membranes. The method takes advantage of two predicted trypsin cleavage sites in the major exofacial loop of this transporter protein. Treatment of cyanide-poisoned rat adipocytes with 1 mg/ml trypsin at 37-degrees-C for 30 min produced an immunoreactive GLUT4 protein species in subsequently isolated plasma membranes that migrated with higher mobility (apparent M(r) = 35,000) than native GLUT4 (apparent M(r)= 46,000) on SDS-polyacrylamide gel electrophoresis. This proteolyzed GLUT4 protein was absent in the intracellular low density microsomes. Insulin treatment of adipocytes for 20 min prior to sequential additions of cyanide and trypsin caused a 16-fold increase in the proteolytically cleaved GLUT4 species. Incubation of fresh fat cells with trypsin caused a rapid and progressive appearance of the proteolyzed GLUT4 species in the intracellular low density membranes as well as plasma membranes. After 5 min of trypsinization, 66% of the total cleaved GLUT4 in these cells had moved into the low density membranes. Insulin treatment markedly decreased the internalized cleaved GLUT4 to 20% of the total. These data indicate the following: 1) trypsinization of the GLUT4 transporter protein on intact fat cells is a convenient means to monitor the extent of transporter recruitment to the plasma membrane by insulin, as well as to estimate GLUT4 internalization rates; and 2) the action of insulin on glucose transporter redistribution to the cell surface is associated with a marked inhibition of the fraction of cell surface GLUT4 transporters internalized per unit time.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	CZECH, MP (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKEEL DW, 1970, J CELL BIOL, V44, P417, DOI 10.1083/jcb.44.2.417; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; OKA Y, 1988, J BIOL CHEM, V263, P13432; POKU J, 1992, DIABETES S1, V41, pA151; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	25	132	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9187	9190						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486618				2022-12-27	WOS:A1993LA68900009
J	PHAN, LD; PERENTESIS, JP; BODLEY, JW				PHAN, LD; PERENTESIS, JP; BODLEY, JW			SACCHAROMYCES-CEREVISIAE ELONGATION FACTOR-II - MUTAGENESIS OF THE HISTIDINE PRECURSOR OF DIPHTHAMIDE YIELDS A FUNCTIONAL PROTEIN THAT IS RESISTANT TO DIPHTHERIA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; FACTOR-II; ADP-RIBOSYLATION; HYDROLYSIS PRODUCTS; TRANSLOCATION; YEAST; MUTANTS; INVITRO; CELLS; SITE	Protein synthesis elongation factor 2 (EF-2) is the target of the ADP-ribosylating activity of diphtheria toxin which is responsible for cell killing. Diphthamide, an unique post-translationally modified histidine residue, is both required for and the site of this ADP-ribosylation. Although present in the EF-2 of all eukaryotes and archaebacteria, the function of diphthamide is unknown. Here we describe the site-specific mutagenesis of the histidine precursor of diphthamide, histidine 699, in yeast EF-2. Plasmid-borne EFT was randomly mutagenized at the histidine 699 codon, and the technique of plasmid shuffling was utilized to select strains that were maintained by the mutant EFT. These mutants were screened for diphtheria toxin resistance. Sequence analysis of the EFT in 49 toxin-resistant isolates showed that histidine 699 had been replaced by 1 of 4 amino acids: asparagine, glutamine, leucine, or methionine. All 11 of the possible codons corresponding to these 4 amino acids were found. The growth rates of cells sustained by the mutant forms of EF-2 were slightly slower than those of isogenic wild-type cells. We conclude that despite its strict conservation and universal post-translational modification, the histidine precursor of diphthamide is not essential to the function of yeast EF-2 in protein synthesis.	UNIV MINNESOTA, SCH MED,DEPT BIOCHEM,RM 4-225,MILLARD HALL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Perentesis, John/0000-0002-4237-8226	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI00793] Funding Source: Medline; NIGMS NIH HHS [GM-26832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AONUMA S, 1991, MUTAT RES, V250, P375, DOI 10.1016/0027-5107(91)90194-S; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BODLEY JW, 1984, ARCH BIOCHEM BIOPHYS, V230, P590, DOI 10.1016/0003-9861(84)90439-9; BODLEY JW, 1990, SCIENCE, V250, P832; BODLEY JW, 1990, ADP RIBOSYLATING TOX, P21; BROWN BA, 1979, FEBS LETT, V103, P253, DOI 10.1016/0014-5793(79)81339-3; CHEN JYC, 1985, MOL CELL BIOL, V5, P3357, DOI 10.1128/MCB.5.12.3357; CHEN JYC, 1988, J BIOL CHEM, V263, P11692; DUNN B, 1990, CURRENT PROTOCOLS MO; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; EVANS DA, 1992, J AM CHEM SOC, V114, P1495, DOI 10.1021/ja00030a063; KESSEL M, 1980, NATURE, V287, P250, DOI 10.1038/287250a0; KOHNO K, 1987, J BIOL CHEM, V262, P12298; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MOEHRING JM, 1980, P NATL ACAD SCI-BIOL, V77, P1010, DOI 10.1073/pnas.77.2.1010; MOEHRING TJ, 1984, MOL CELL BIOL, V4, P642, DOI 10.1128/MCB.4.4.642; MOEHRING TJ, 1979, SOMAT CELL GENET, V5, P469, DOI 10.1007/BF01538881; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; OPPENHEIMER NJ, 1981, J BIOL CHEM, V256, P8579; PAPPENHEIMER AM, 1983, J BACTERIOL, V153, P1342, DOI 10.1128/JB.153.3.1342-1347.1983; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PERENTESIS JP, 1988, P NATL ACAD SCI USA, V85, P8386, DOI 10.1073/pnas.85.22.8386; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; ROBINSON EA, 1974, J BIOL CHEM, V249, P5088; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; TRECO DA, 1990, CURRENT PROTOCOLS MO; VANNESS BG, 1980, J BIOL CHEM, V255, P710; VANNESS BG, 1980, J BIOL CHEM, V255, P717	36	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8665	8668						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473309				2022-12-27	WOS:A1993KX81100045
J	YANOFSKY, C; YEE, MC; HORN, V				YANOFSKY, C; YEE, MC; HORN, V			PARTIAL REVERTANTS OF TRYPTOPHAN SYNTHETASE-ALPHA CHAIN ACTIVE-SITE MUTANT ASP60-]ASN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BIENZYME COMPLEX; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MULTIENZYME COMPLEX; CATALYTIC RESIDUE; BETA-SUBUNIT; MECHANISM; PROTEINS; DNA	Residue Asp60 of the tryptophan synthetase alpha chain of Escherichia coli is thought to interact with the pyrrole NH of substrate indole-3-glycerol phosphate and facilitate its cleavage to indole and glyceraldehyde 3-phosphate. Two distinguishable partial revertants of DN60 tryptophan synthetase alpha mutant trpA34 were analyzed. The slower growing partial revertant, PR1, had the second-site change, YD102. The other partial revertant, PR2, lacked three consecutive base pairs, resulting in replacement of Ala59 and Asn60 of the DN60 mutant alpha polypeptide by Asp. Inspection of the three-dimensional structure of the enzyme-substrate analog complex (1) revealed that Tyr102 is in the vicinity of the pyrrole NH of the substrate. The PR1 alpha chain has a near normal K(m) for substrate, whereas the PR2 polypeptide has greatly reduced substrate affinity. The PR2 polypeptide is more active than the PR1 polypeptide in the alphabeta reaction in vitro and appears to be more active than the PR1 polypeptide in vivo. Attempts to obtain repeat occurrences of the PR2 deletion mutation were unsuccessful. A third type of trpA34 partial revertant, PR3, that grows very poorly in minimal medium, also has a Tyr102 replacement: YF102. These findings demonstrate that each of the second-site mutations affects a residue located in the vicinity of the active site residue altered by the primary mutation. Slightly leaky mutant trpA89, genetically altered near the site of the trpA34 mutation, was found to have a GS61 substitution.			YANOFSKY, C (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.							AHMED SA, 1991, J BIOL CHEM, V266, P21548; ALLEN MK, 1963, GENETICS, V48, P1065; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BURNS DM, 1990, J BIOL CHEM, V265, P2060; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; CRAWFORD IP, 1989, ANNU REV MICROBIOL, V43, P567, DOI 10.1146/annurev.mi.43.100189.003031; CRAWFORD IP, 1958, P NATL ACAD SCI USA, V44, P1161, DOI 10.1073/pnas.44.12.1161; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; GOLDBERG ME, 1966, J MOL BIOL, V21, P71, DOI 10.1016/0022-2836(66)90080-5; HELINSKI DR, 1963, J BIOL CHEM, V238, P1043; HENNING U, 1963, J MOL BIOL, V6, P16, DOI 10.1016/S0022-2836(63)80077-7; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IBEL K, 1985, EUR J BIOCHEM, V151, P505, DOI 10.1111/j.1432-1033.1985.tb09131.x; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V133, P531, DOI 10.1111/j.1432-1033.1983.tb07496.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LIM WK, 1991, J BIOL CHEM, V266, P20205; LIM WK, 1992, ARCH BIOCHEM BIOPHYS, V292, P34, DOI 10.1016/0003-9861(92)90047-Z; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; NAGATA S, 1989, J BIOL CHEM, V264, P6288; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; ROSS CM, 1988, J BACTERIOL, V170, P757, DOI 10.1128/jb.170.2.757-768.1988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER WP, 1981, P NATL ACAD SCI-BIOL, V78, P2169, DOI 10.1073/pnas.78.4.2169; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; SMITH OH, 1962, METHOD ENZYMOL, V5, P794, DOI 10.1016/S0076-6879(62)05315-X; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; TWEEDY NB, 1990, BIOCHEMISTRY-US, V29, P1539, DOI 10.1021/bi00458a027; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WILHELM P, 1982, EUR J BIOCHEM, V129, P51, DOI 10.1111/j.1432-1033.1982.tb07019.x; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANOFSKY C, 1961, COLD SPRING HARB SYM, V26, P11, DOI 10.1101/SQB.1961.026.01.006; YANOFSKY C, 1969, 12TH P INT C GEN, V3, P155; Yanofsky C., 1972, ENZYMES, VVII; YAP EPH, 1992, TRENDS GENET, V8, P49, DOI 10.1016/0168-9525(92)90339-6; YUTANI K, 1987, J BIOL CHEM, V262, P13429	52	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8213	8220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463331				2022-12-27	WOS:A1993KW97900091
J	KASPRZAK, AA				KASPRZAK, AA			MYOSIN SUBFRAGMENT-1 INHIBITS DISSOCIATION OF NUCLEOTIDE AND CALCIUM FROM G-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MONOMERIC ACTIN; CONFORMATIONAL CHANGE; ROTATIONAL-DYNAMICS; SLIDING MOVEMENT; BINDING REGION; METAL-ION; MUSCLE; POLYMERIZATION; COMPLEX	The dissociation rates of 1,N6-ethenoadenosine 5'-triphosphate (epsilonATP) and of Ca2+ from G-actin and its complex with myosin subfragment 1 (S1) were measured by recording a large decrease in the fluorescence intensity of the dissociating nucleotide. Under the experimental conditions employed, the binary G-acto-S1A2 complex does not polymerize (Chaussepied, P., and Kasprzak, A. A. (1989) Nature 342, 950-953). The released nucleotide was hydrolyzed either by alkaline phosphatase or by apyrase; to trap Ca2+, EDTA was used. From the anisotropy of N-iodoacetyl-N'-(5-sulfo-1-naphthyl)ethylenediamine (1,5-IAEDANS)-actin, it was established that during the dissociation of epsilonATP, the G-acto-S1 complex remained stable and the equilibrium of the system was unaltered. The reactions followed first order kinetics. The dissociation rate constant, k(d) for epsilonATP decreased from 5.5 x 10(-2) s-1 for free G-actin to 1 x 10(-4) s-1 for G-acto-S1A2; for Ca2+, k(d) was also similarly reduced from 2.8 x 10(-2) s-1 to 4 x 10(-3) s-1. Two proteolytically derived actin variants were also examined. For free subtilisin-cleaved actin, k(d) for epsilonATP was elevated 2-fold but was almost unchanged for Ca2+. In the complex of the cleaved G-actin with S1A2, k(d) for both epsilonATP and for Ca2+ were reduced. The removal of the last 3 amino acids from actin produced a derivative whose behavior in binding to S1, as well as in the kinetics of epsilonATP and Ca2+ dissociation, was undistinguishable from the unmodified protein.	UNIV MONTPELLIER 1, CNRS, CTR RECH BIOCHIM MACROMOLEC, INSERM, U249, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	KASPRZAK, AA (corresponding author), CNRS, CRBM, BP 5051, ROUTE MENDE, F-34033 MONTPELLIER 1, FRANCE.		Kasprzak, Andrzej A. A/R-4476-2016	Kasprzak, Andrzej A. A/0000-0002-3602-5379				ADAMS SB, 1993, BIOPHYS J, V64, pA147; ANDO T, 1989, J BIOCHEM-TOKYO, V105, P818, DOI 10.1093/oxfordjournals.jbchem.a122751; BARDEN JA, 1990, BIOCHEMISTRY-US, V29, P1348, DOI 10.1021/bi00457a034; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHAUSSEPIED P, 1989, J BIOL CHEM, V264; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; CHEN T, 1992, BIOCHEMISTRY-US, V31, P2941, DOI 10.1021/bi00126a014; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DASGUPTA G, 1992, BIOCHEMISTRY-US, V31, P1836, DOI 10.1021/bi00121a036; DETMERS P, 1981, J BIOL CHEM, V256, P99; ESTES JE, 1987, J BIOL CHEM, V262, P4952; ESTES JE, 1978, BIOCHEMISTRY-US, V17, P2495, DOI 10.1021/bi00606a006; FORNE T, 1992, J MUSCLE RES CELL M, V13, P233; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; HARVEY SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P391, DOI 10.1016/0003-9861(77)90126-6; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; HOZUMI T, 1992, BIOCHEMISTRY-US, V31, P10070, DOI 10.1021/bi00156a029; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P4512, DOI 10.1021/bi00412a044; KASPRZAK AA, 1993, BIOPHYS J, V64, pA231; KNIGHT P, 1980, BIOCHEMISTRY-US, V19, P4682, DOI 10.1021/bi00561a022; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KUEHL WM, 1969, J BIOL CHEM, V244, P4720; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MEJEAN C, 1987, BIOCHEM J, V244, P571, DOI 10.1042/bj2440571; MIKI M, 1984, BIOCHIM BIOPHYS ACTA, V786, P188, DOI 10.1016/0167-4838(84)90088-8; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; MILLER L, 1987, BIOCHEMISTRY-US, V26, P6064, DOI 10.1021/bi00393a018; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; MOSSAKOWSKA M, 1993, BIOCHEM J, V289, P897, DOI 10.1042/bj2890897; MOSSAKOWSKA M, 1988, EUR J BIOCHEM, V175, P557, DOI 10.1111/j.1432-1033.1988.tb14228.x; MULHERN S, 1975, BIOCHEMISTRY-US, V14, P3863, DOI 10.1021/bi00688a020; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; OFFER G, 1972, J MOL BIOL, V66, P435, DOI 10.1016/0022-2836(72)90425-1; OSTAP EM, 1992, BIOPHYS J, V63, P966, DOI 10.1016/S0006-3495(92)81684-3; PARDEE JD, 1982, J CELL BIOL, V93, P648, DOI 10.1083/jcb.93.3.648; PROCHNIEWICZ E, 1990, J MOL BIOL, V216, P761, DOI 10.1016/0022-2836(90)90397-5; PURICH DL, 1978, FEBS LETT, V96, P83, DOI 10.1016/0014-5793(78)81067-9; RICH SA, 1976, J MOL BIOL, V104, P777, DOI 10.1016/0022-2836(76)90181-9; ROUAYRENC JF, 1985, EUR J BIOCHEM, V146, P391, DOI 10.1111/j.1432-1033.1985.tb08665.x; ROUAYRENC JF, 1981, EUR J BIOCHEM, V116, P73, DOI 10.1111/j.1432-1033.1981.tb05302.x; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THOMAS DD, 1979, J MOL BIOL, V132, P257, DOI 10.1016/0022-2836(79)90259-6; TIRION MM, 1993, BIOPHYS J, V64, pA146; VALENTINRANC C, 1991, J BIOL CHEM, V266, P7668; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; ZIMMERLE CT, 1988, BIOCHEMISTRY-US, V27, P7759, DOI 10.1021/bi00420a026	57	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13261	13266						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514764				2022-12-27	WOS:A1993LH55300038
J	KELLEY, CA; TAKAHASHI, M; YU, JH; ADELSTEIN, RS				KELLEY, CA; TAKAHASHI, M; YU, JH; ADELSTEIN, RS			AN INSERT OF 7 AMINO-ACIDS CONFERS FUNCTIONAL DIFFERENCES BETWEEN SMOOTH-MUSCLE MYOSINS FROM THE INTESTINES AND VASCULATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN MESSENGER-RNAS; LIGHT CHAIN; HEAVY-CHAIN; CYTOPLASMIC MYOSINS; DNA-SEQUENCE; SINGLE GENE; NONMUSCLE; ISOFORMS; CHICKEN; KINASE	The molecular mechanisms underlying the heterogeneity in contractile properties observed among smooth muscle tissues are unknown. We examined whether part of this diversity might be intrinsic to myosin by comparing structural and enzymatic properties of myosins from two physiologically diverse tissues. Using the reverse transcriptase polymerase chain reaction, we compared avian intestinal smooth muscle and vascular smooth muscle myosin heavy chain (MHC) mRNA. We found that intestinal, but not vascular, MHC mRNA contains an insert of 21 nucleotides, encoding 7 amino acids, in a region near the ATP binding site in the myosin head. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of purified myosin revealed that the relative mobilities of the previously described intestinal MHC isoforms SM1 (204 kDa) and SM2 (200 kDa) were slower than the corresponding vascular SM1 and SM2 isoforms. Furthermore, antibodies raised against a synthetic peptide corresponding to the deduced amino acid sequence of the intestinal insert strongly recognized intestinal SM1 and SM2 but only weakly recognized the vascular isoforms. The presence of the insert in intestinal myosin correlated with a higher velocity of movement of actin filaments in vitro and a higher actin-activated Mg2+-ATPase activity, compared with vascular myosin. Other than the MHC insert, one other structural difference distinguished intestinal and vascular myosins: two isoforms of the 17-kDa myosin light chain were found in vascular myosin, whereas a single isoform was found in intestinal myosin. Exchange of the intestinal myosin light chains onto the vascular MHC did not alter its activity in the in vitro motility assay, suggesting that the 7-amino acid MHC insert is responsible for the different enzymatic activities of vascular and intestinal myosins.			KELLEY, CA (corresponding author), NHLBI,MOLEC CARDIOL LAB,BLDG 10,RM 8N202,BETHESDA,MD 20892, USA.		Takahashi, Masayuki/D-8079-2012	Adelstein, Robert/0000-0002-8683-2144; Takahashi, Masayuki/0000-0002-5923-2813				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; CAVAILLE F, 1986, EUR J BIOCHEM, V160, P507, DOI 10.1111/j.1432-1033.1986.tb10068.x; CHACKO S, 1982, P NATL ACAD SCI-BIOL, V79, P292, DOI 10.1073/pnas.79.2.292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EBISAWA K, 1983, J BIOCHEM-TOKYO, V93, P1615, DOI 10.1093/oxfordjournals.jbchem.a134300; EDDINGER TJ, 1988, BIOCHEMISTRY-US, V27, P3807, DOI 10.1021/bi00410a043; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HASEGAWA Y, 1992, J BIOCHEM-TOKYO, V111, P798, DOI 10.1093/oxfordjournals.jbchem.a123839; HASEGAWA Y, 1992, J BIOCHEM-TOKYO, V111, P804, DOI 10.1093/oxfordjournals.jbchem.a123840; HELPER DJ, 1988, J BIOL CHEM, V263, P15748; HMSHER E, 1992, AM J PHYSIOL, V262, pC714; HOLT JC, 1975, BIOCHEMISTRY-US, V14, P4600, DOI 10.1021/bi00692a007; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KELLEY CA, 1990, J BIOL CHEM, V265, P17876; KELLEY CA, 1992, J BIOL CHEM, V267, P2127; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1990, NUCLEIC ACIDS RES, V18, P7176, DOI 10.1093/nar/18.23.7176; LENZ S, 1989, J BIOL CHEM, V264, P9009; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MAITA T, 1981, EUR J BIOCHEM, V117, P417, DOI 10.1111/j.1432-1033.1981.tb06354.x; MALMQVIST U, 1991, PFLUG ARCH EUR J PHY, V418, P523, DOI 10.1007/BF00370566; MOUGIOS V, 1986, BIOCHIM BIOPHYS ACTA, V872, P305, DOI 10.1016/0167-4838(86)90284-0; NABESHIMA Y, 1987, J BIOL CHEM, V262, P10608; NAGAI R, 1989, J BIOL CHEM, V264, P9734; PEARSON RB, 1984, FEBS LETT, V168, P108, DOI 10.1016/0014-5793(84)80216-1; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; ROVNER AS, 1986, AM J PHYSIOL, V250, pC861, DOI 10.1152/ajpcell.1986.250.6.C861; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELLERS JR, 1988, BIOCHEMISTRY-US, V27, P6977, DOI 10.1021/bi00418a046; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1989, CELL REGUL, V1, P1; STAFFORD WF, 1983, BIOPHYS J, V41, P93; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WATANABE M, 1992, J BIOCHEM-TOKYO, V112, P431, DOI 10.1093/oxfordjournals.jbchem.a123917; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	46	238	238	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12848	12854						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509418				2022-12-27	WOS:A1993LG65800091
J	RIETVELD, AG; KILLIAN, JA; DOWHAN, W; DEKRUIJFF, B				RIETVELD, AG; KILLIAN, JA; DOWHAN, W; DEKRUIJFF, B			POLYMORPHIC REGULATION OF MEMBRANE PHOSPHOLIPID-COMPOSITION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREEZE-FRACTURE TECHNIQUES; PHASE-BEHAVIOR; LIPID-COMPOSITION; P-31 NMR; ELECTRON-MICROSCOPY; MAGNETIC-RESONANCE; BILAYER STABILITY; PHOSPHATIDYLETHANOLAMINE; CARDIOLIPIN; GLYCOPHORIN	To investigate whether the phase preference of Escherichia coli membrane lipids is regulated by adjustment of the ratio of bilayer to non-bilayer lipids, the lipid biosynthetic mutant AD93 was used. This strain lacks the ability to synthesize phosphatidylethanolamine, a non-bilayer lipid which normally accounts for 70-80% of the phospholipids in the E. coli membrane. The lack of phosphatidylethanolamine is compensated by a large increase in the levels of phosphatidylglycerol and cardiolipin. This strain has an absolute requirement for high concentrations of divalent cations. Since divalent cations are known to induce H(II) phase formation in cardiolipin model systems, this suggests that cardiolipin in combination with divalent cations replaces phosphatidylethanolamine in the membrane and that it is the non-bilayer forming property of the latter which is important for membrane functioning. The growth of the mutant strain was found to be dependent on the type and concentration of divalent cations present in the growth medium. In media supplemented with MgCl2 and CaCl2, growth was maximal at concentrations of 30-50 mM. In the presence of SrCl2 a growth optimum was observed at 15 mM. The cells did not grow in the presence of BaCl2 oral high concentrations of SrCl2. Furthermore, this strain was found to adapt the lipid composition of the membrane in reaction to the type of cation present during growth. The phase behavior of dispersions of mutant and parental E. coli derived lipids was studied under a variety of conditions, using P-31 NMR. In the presence of the growth-promoting cations at concentrations where there is maximal growth, a bilayer to non-bilayer transition was observed in the lipid dispersions in a narrow temperature range, approximately 10-degrees-C above the growth temperature, whereas at concentrations where there is no growth, a bilayer structure was observed at all temperatures tested. This suggests a polymorphic regulation of membrane lipid composition in order to maintain a propensity toward type II structure formation in the membrane.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System	RIETVELD, AG (corresponding author), UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT BIOCHEM MEMBRANES,3584 CH UTRECHT,NETHERLANDS.		Killian, J. Antoinette/I-3001-2016	Killian, J. Antoinette/0000-0001-8010-3816	NIGMS NIH HHS [GM 20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURNELL E, 1980, BIOCHIM BIOPHYS ACTA, V597, P492, DOI 10.1016/0005-2736(80)90222-9; CRONAN JE, 1972, BIOCHIM BIOPHYS ACTA, V265, P25, DOI 10.1016/0304-4157(72)90018-4; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V507, P207, DOI 10.1016/0005-2736(78)90417-0; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P11, DOI 10.1016/0005-2736(78)90107-4; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DEKRUIJFF B, 1987, NATURE, V329, P587, DOI 10.1038/329587a0; FINE JB, 1982, J LIPID RES, V23, P660; GALLY HU, 1980, BIOCHEMISTRY-US, V19, P1638, DOI 10.1021/bi00549a018; GOLDFINE H, 1987, BIOCHEMISTRY-US, V26, P2814, DOI 10.1021/bi00384a024; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; IANZINI F, 1990, ARCH BIOCHEM BIOPHYS, V278, P1, DOI 10.1016/0003-9861(90)90223-L; ISRAELACHVILI JN, 1977, BIOCHIM BIOPHYS ACTA, V469, P221, DOI 10.1016/0005-2736(77)90185-7; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; KELLENBERGER E, 1990, MOL MICROBIOL, V4, P697, DOI 10.1111/j.1365-2958.1990.tb00640.x; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1105, P253, DOI 10.1016/0005-2736(92)90202-W; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; MENDELSOHN R, 1981, BIOCHEMISTRY-US, V20, P6699, DOI 10.1021/bi00526a027; NORRIS V, 1992, J THEOR BIOL, V154, P91, DOI 10.1016/S0022-5193(05)80190-0; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; SABELNIKOV AG, 1985, BIOCHEM BIOPH RES CO, V127, P464, DOI 10.1016/S0006-291X(85)80183-2; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; SIEGEL DP, 1986, CHEM PHYS LIPIDS, V42, P279, DOI 10.1016/0009-3084(86)90087-3; SIEGEL J, 1977, Q REV BIOPHYS, V10, P353; SMAAL EB, 1985, J LIPID RES, V26, P633; TILCOCK CPS, 1986, CHEM PHYS LIPIDS, V40, P47, DOI 10.1016/0009-3084(86)90061-7; VANDERSTEEN ATM, 1982, BIOCHIM BIOPHYS ACTA, V691, P13, DOI 10.1016/0005-2736(82)90208-5; VASILENKO I, 1982, BIOCHIM BIOPHYS ACTA, V684, P282, DOI 10.1016/0005-2736(82)90018-9; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002	32	128	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12427	12433						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509382				2022-12-27	WOS:A1993LG65800033
J	SCHNETKAMP, PPM; SZERENCSEI, RT				SCHNETKAMP, PPM; SZERENCSEI, RT			INTRACELLULAR CA2+ SEQUESTRATION AND RELEASE IN INTACT BOVINE RETINAL ROD OUTER SEGMENTS - ROLE IN INACTIVATION OF NA-CA+K EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; K EXCHANGE; PLASMA-MEMBRANE; CALCIUM; PHOTORECEPTORS; SODIUM; EXTRUSION; TRANSPORT; BINDING; GRADIENTS	Intracellular Ca2+ sequestration and Ca2+ release was analyzed in intact rod outer segments (ROS) purified from bovine retinas. Ca2+ influx in Ca2+-depleted and fully bleached ROS was mediated exclusively by the Na-Ca+K exchanger and was measured both as a rise in cytosolic free Ca2+ with fluo 3 and as a total transmembrane Ca2+ flux with Ca-45. Ca2+ fluxes across the ROS plasma membrane were not completely reversible, in small part due to inactivation of the Ca2+ extrusion mode of the Na-Ca+K exchanger but mostly due to sequestration of cytosolic Ca2+ into the intradiskal space. Ca2+ release from the intradiskal space into the cytosol could be induced by low concentrations of the Ca2+ ionophore A23187 which gave rise to increases in cytosolic free Ca2+ by several hundred nanomolar (low A23187 concentrations did not affect the Ca2+ permeability of the ROS plasma membrane). We have used intracellular Ca2+ release induced by A23187 to examine inactivation of the rapid Ca2+ efflux mode mediated by the plasma membrane Na-Ca+K exchanger. Inactivation of Na-Ca+K exchange appeared to be dependent on intradiskal Ca2+ as it was abolished by selective Ca2+ permeabilization of the disk membrane by A23187. We discuss possible physiological roles for Ca2+ sequestration and release from ROS disks.			SCHNETKAMP, PPM (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY T2N 4N1,AB,CANADA.							BAUER PJ, 1988, J PHYSIOL-LONDON, V401, P309, DOI 10.1113/jphysiol.1988.sp017164; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; LAGNADO L, 1991, J GEN PHYSIOL, V98, P479, DOI 10.1085/jgp.98.3.479; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MINTA A, 1989, J BIOL CHEM, V264, P8171; NICOL GD, 1987, J GEN PHYSIOL, V89, P297, DOI 10.1085/jgp.89.2.297; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1985, J MEMBRANE BIOL, V88, P249, DOI 10.1007/BF01871089; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P198; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1987, BIOCHEMISTRY-US, V26, P3249, DOI 10.1021/bi00386a002; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1991, ANN NY ACAD SCI, V639, P10, DOI 10.1111/j.1749-6632.1991.tb17285.x; SCHNETKAMP PPM, 1990, J GEN PHYSIOL, V96, P517, DOI 10.1085/jgp.96.3.517; SCHNETKAMP PPM, 1987, J GEN PHYSIOL, V89, P481, DOI 10.1085/jgp.89.3.481; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0	26	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12449	12457						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509384				2022-12-27	WOS:A1993LG65800036
J	ARMSTRONG, SA; SEABRA, MC; SUDHOF, TC; GOLDSTEIN, JL; BROWN, MS				ARMSTRONG, SA; SEABRA, MC; SUDHOF, TC; GOLDSTEIN, JL; BROWN, MS			CDNA CLONING AND EXPRESSION OF THE ALPHA-SUBUNIT AND BETA-SUBUNIT OF RAT RAB GERANYLGERANYL TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21RAS PROTEIN FARNESYLTRANSFERASE; PEPTIDE-BINDING; YEAST; GENE; DEPENDENCE; FARNESYL; BRAIN; DPR1	Rab geranylgeranyl transferase (Rab GG transferase) attaches 20-carbon geranylgeranyl groups to cysteine residues in Rab proteins that contain the COOH-terminal sequence Cys-X-Cys or Cys-Cys. Rab GG transferase consists of two components that are separable in high salt solutions. Component A is a 95-kDa protein, and Component B is a heterodimer consisting of a 60-kDa alpha subunit and a 38-kDa beta subunit. In the current paper, we have cloned cDNAs for the alpha and beta subunits of Component B. The cDNAs for the rat alpha and beta subunits predict proteins of 567 and 331 amino acids, respectively. The mRNAs for both subunits are expressed in many tissues. When transfected together in embryonic kidney 293 cells, the alpha and beta subunit cDNAs produced Rab GG transferase activity that was stimulated in vitro by the addition of purified Component A. Comparisons of the amino acid sequences suggest that the proteins encoded by the Saccharomyces cerevisiae genes MAD2 and BET2 are the yeast counterparts of the mammalian Rab GG transferase alpha and beta subunits, respectively.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ARMSTRONG, SA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MED GENET,DALLAS,TX 75235, USA.		Seabra, Miguel/AAC-3099-2019; Seabra, Miguel/M-3280-2013	Seabra, Miguel/0000-0002-6404-4892	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BOGUSKI MS, 1992, NEW BIOL, V4, P408; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FODOR E, 1991, NATURE, V351, P614, DOI 10.1038/351614b0; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HARLOW E, 1988, ANTIBODIES LABORATOR; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; OHYA Y, 1991, J BIOL CHEM, V266, P12356; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	42	97	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12221	12229						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505342				2022-12-27	WOS:A1993LF28400111
J	AVELDANO, MI; ROBINSON, BS; JOHNSON, DW; POULOS, A				AVELDANO, MI; ROBINSON, BS; JOHNSON, DW; POULOS, A			LONG AND VERY LONG-CHAIN POLYUNSATURATED FATTY-ACIDS OF THE N-6 SERIES IN RAT SEMINIFEROUS TUBULES - ACTIVE DESATURATION OF 24/4N-6 TO 24/5N-6 AND CONCOMITANT FORMATION OF ODD AND EVEN CHAIN TETRAENOIC AND PENTAENOIC FATTY-ACIDS UP TO C32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; METABOLISM; RETINA; SPERMATOZOA; SEPARATION; TESTES; LIVER	The formation of long and very long chain (VLC) n-6 polyunsaturated fatty acids (PUFA) in isolated rat seminiferous tubules was investigated by following the metabolism of three 1-C-14-labeled n-6 tetraenoic fatty acids (20:4, 24:4, and 32:4) and [U-C-14]acetate. In contrast to [C-14]32:4, which was poorly incorporated and altered, [C-14]20:4 and [C-14]24:4 were efficiently taken up by the tubules, esterified into lipids, elongated to VLCPUFA, and desaturated to pentaenoic fatty acids; the rate of [C-14]24:4 desaturation to [C-14]24:5 was notably high. The main products with [C-14]acetate as precursor were labeled saturates and VLCPUFA, most of the label in tetraenoic and pentaenoic acids appearing in 24:4 and 24:5, respectively. These two C24 polyenes, connected by a DELTA6 desaturation, may play a central role in n-6 PUFA metabolism, in their capacity as potential precursors of longer polyenes via elongation and of shorter ones, such as 22:5n-6, via retro-conversion. Triacylglycerols, rich in C22 and C24 polyenes, incorporated the greatest amounts of both [C-14] acetate-derived and exogenous C-14-PUFA, suggesting that this lipid class is involved in the traffic and metabolism of testicular PUFA. The detection of a series of unusual odd-chain tetraenoic and pentaenoic acids, also labeled with [U-C-14]acetate, suggests that a PUFA chain shortening mechanism occurs in testis involving alpha- in addition to beta-oxidation. We speculate that alpha-oxidation plays a role in the retroconversion of PUFA.	ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA		AVELDANO, MI (corresponding author), UNS,CONICET,INST BIOCHEM RES,CC 857,RA-8000 BAHIA BLANCA,ARGENTINA.							ALBERT DH, 1977, BIOCHIM BIOPHYS ACTA, V489, P390, DOI 10.1016/0005-2760(77)90159-X; ARVIDSON GA, 1968, EUR J BIOCHEM, V4, P478, DOI 10.1111/j.1432-1033.1968.tb00237.x; AVELDANO MI, 1983, J LIPID RES, V24, P83; AVELDANO MI, 1992, BIOCHEM J, V283, P235, DOI 10.1042/bj2830235; AVELDANO MI, 1987, J BIOL CHEM, V262, P1180; AVELDANO MI, 1987, J BIOL CHEM, V262, P1172; AYALA S, 1973, J LIPID RES, V14, P296; BREMER J, 1984, FATTY ACID METABOLIS, P113; BRIDGES RB, 1970, J BIOL CHEM, V245, P46; BRIDGES RB, 1970, BIOCHIM BIOPHYS ACTA, V218, P29, DOI 10.1016/0005-2760(70)90089-5; CONIGLIO JG, 1977, FUNCTION BIOSYNTHESI, P575; CONIGLIO JG, 1977, LIPID METABOLISM MAM, V2, P83; EVANS OB, 1971, LIPIDS, V6, P706, DOI 10.1007/BF02531294; FOLCH J, 1957, J BIOL CHEM, V226, P497; GROGAN WM, 1984, LIPIDS, V19, P341, DOI 10.1007/BF02534785; JOHNSON DW, 1990, CHEM PHYS LIPIDS, V56, P65, DOI 10.1016/0009-3084(90)90089-A; MORRISON WR, 1964, J LIPID RES, V5, P600; POTTER JER, 1981, J BIOL CHEM, V256, P7150; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; POULOS A, 1986, BIOCHEM J, V240, P891, DOI 10.1042/bj2400891; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; ROBINSON BS, 1990, BIOCHEM J, V267, P561, DOI 10.1042/bj2670561; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; ROSENTHAL MD, 1991, BIOCHIM BIOPHYS ACTA, V1083, P29, DOI 10.1016/0005-2760(91)90121-W; ROTSTEIN NP, 1988, BIOCHEM J, V249, P191, DOI 10.1042/bj2490191; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; ROUSER G, 1969, METHOD ENZYMOL, V14, P272; SPRECHER H, 1975, BIOCHIM BIOPHYS ACTA, V388, P113, DOI 10.1016/0005-2760(75)90067-3; STREET JM, 1989, BIOCHEM J, V260, P647, DOI 10.1042/bj2600647; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361; VOSS A, 1991, J BIOL CHEM, V266, P19995; WORTHON AR, 1974, FED PROC, V33, P685	32	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11663	11669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505297				2022-12-27	WOS:A1993LF28400033
J	CHOWDHURY, NR; WU, CH; WU, GY; YERNENI, PC; BOMMINENI, VR; CHOWDHURY, JR				CHOWDHURY, NR; WU, CH; WU, GY; YERNENI, PC; BOMMINENI, VR; CHOWDHURY, JR			FATE OF DNA TARGETED TO THE LIVER BY ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ENDOCYTOSIS INVIVO - PROLONGED PERSISTENCE IN CYTOPLASMIC VESICLES AFTER PARTIAL-HEPATECTOMY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DELIVERY; EXPRESSION	After intravenous injection, DNA complexed with asialoglycoprotein-polylysine conjugates is endocytosed by hepatocytes via asialoglycoprotein receptors and is expressed transiently. Long term persistence and expression occurs when partial hepatectomy is performed after gene delivery. To determine the intracellular location of the persisting DNA, we transferred a plasmid expressing bacterial chloramphenicol acetyltransferase into the liver of rats in vivo by asialoglycoprotein receptor-mediated endocytosis. The internalized DNA was measured by Southern blot. Twenty min after administration, 80-85% of the plasmid appeared in the liver, 80% of which was within hepatocytes (12,000-18,000 copies/hepatocyte). In sham-operated control rats, the transgene concentration decreased to 8-12 and 2-4% of the initial levels in 4 and 24 h, respectively, and became undetectable at 7 days. In rats subjected to 66% hepatectomy 20 min after DNA administration, 20, 9, and 7% of the plasmid in the residual liver persisted at 4 h, 24 h, and 7 days, respectively. Liver homogenates were fractionated by differential centrifugation and Percoll gradient centrifugation. In 66% hepatectomized rats, the plasmid persisted in an undegraded, transfection-competent form in plasma membrane/endosome-enriched fractions throughout the duration of the experiment (7 days), indicating that cytoplasmic vesicles are the main site of persistence of the endocytosed DNA.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,ULLMAN BLDG,RM 625,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV GASTROENTEROL & LIVER DIS,BRONX,NY 10461; UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL & HEPATOL,FARMINGTON,CT 06030	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Connecticut					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK039137, R01DK042182] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 42182, R01-DK 39137, P30-DK 41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBER N, 1988, LIVER, V8, P80; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; DEBORA SL, 1988, CELL MOTIL CYTOSKEL, V10, P482; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATTON MWC, 1979, BIOCHEM J, V181, P633, DOI 10.1042/bj1810633; JANSEN PLM, 1977, J BIOL CHEM, V252, P2710; KOLBBACHOFEN V, 1984, BIOL CELL, V51, P219, DOI 10.1111/j.1768-322X.1984.tb00302.x; LEVVY GA, 1959, ADV CARBOHYD CHEM, V14, P381; LIPMAN BJ, 1990, J BIOL CHEM, V265, P2142; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELGAR E, 1968, J BIOL CHEM, V243, P4409; PERTOFT H, 1979, J IMMUNOL METHODS, V27, P159; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; WAYNFORTH HB, 1980, EXPT SURGICAL TECHNI, P137; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WILSON JM, 1992, J BIOL CHEM, V267, P963; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P1314; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338	24	147	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11265	11271						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496181				2022-12-27	WOS:A1993LD46600080
J	COPELAND, WC; WANG, TSF				COPELAND, WC; WANG, TSF			MUTATIONAL ANALYSIS OF THE HUMAN DNA POLYMERASE-ALPHA - THE MOST CONSERVED REGION IN ALPHA-LIKE DNA-POLYMERASES IS INVOLVED IN METAL-SPECIFIC CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; HUMAN KB-CELLS; ESCHERICHIA-COLI; ENZYMOLOGICAL CHARACTERIZATION; HOMOGENEOUS ENZYME; LARGE FRAGMENT; MECHANISM; BINDING; GENE; PURIFICATION	Five site-directed mutations were introduced at the most conserved amino acids in region I (YGDTDS) of the human DNA polymerase alpha catalytic subunit. Mutant proteins were expressed in the baculovirus system by an improved method and purified by a rapid one-step purification in high yield and high specific activity. The Asp1004 to Asn mutation produced a protein with no detectable polymerase activity while other mutations gave activities from 1 to 20% of the wild type polymerase activity. Steady state kinetic analysis of the active mutants indicates that none of the mutations caused a change in K(m(dNTP)) or K(D(DNA)), but all active mutants showed a decrease in k(cat). Thus, the effect of these conserved mutations is manifest in altered rates of catalysis. Two mutations, Asp1002 to Asn and Thr1003 to Ser, caused the enzyme to utilize Mn2+ more effectively in catalysis than Mg2+, suggesting that these amino acids are involved in metal binding. Rates of catalysis by the D1002N and T1003S mutants, as well as Y1000F mutant were improved 80-, 30-, and 70-fold, respectively, on homopolymer templates when Mn2+ replaced Mg2+ as the activator metal. The results from these mutational studies suggest that this highly conserved region binds the metal which is essential for catalysis. The Asp1002 may participate directly in chelating the metal. Results from the T1003S mutant suggest that the beta-methyl group of the threonine side chain might be locked in a hydrophobic pocket preventing free rotation around the C(alpha)-C(beta) bond, thus positioning the Thr1003 hydroxyl group to form a crucial bond with the metal ion. In addition, D1002N and T1003S displayed a 20-fold resistance to aphidicolin compared to the wild type polymerase alpha, and all of the active mutants displayed altered sensitivity to butylphenyl-dGTP. Models of the involvement of region I in catalysis and aphidicolin interaction are proposed. The mutational studies presented in this report will serve as a prototype for the functional role of region I in catalysis for all alpha-like DNA polymerases.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER; NCI NIH HHS [CA14835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHANG LMS, 1984, J BIOL CHEM, V259, P4679; CHIN DT, 1988, J BIOL CHEM, V263, P11718; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DORSKY DI, 1990, J VIROL, V64, P1394, DOI 10.1128/JVI.64.3.1394-1397.1990; ENGLUND PT, 1969, J BIOL CHEM, V244, P3045; FISHER PA, 1977, J BIOL CHEM, V252, P6528; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; FISHER PA, 1979, J BIOL CHEM, V254, P6128; FRY, 1986, ANIMAL CELL DNA POLY, P49; HSI KL, 1990, NUCLEIC ACIDS RES, V18, P6231, DOI 10.1093/nar/18.21.6231; IRVING H, 1953, J CHEM SOC, V637, P3192; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; KHAN NN, 1991, NUCLEIC ACIDS RES, V19, P1627, DOI 10.1093/nar/19.7.1627; KHAN NN, 1984, NUCLEIC ACIDS RES, V12, P3695, DOI 10.1093/nar/12.8.3695; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1992, DNA REPLICATION, P126; KORNBERG A, 1992, DNA REPLICATION, P135; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MARCY AI, 1990, J VIROL, V64, P5883, DOI 10.1128/JVI.64.12.5883-5890.1990; MULLEN GP, 1990, J BIOL CHEM, V265, P14327; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SEAL G, 1979, J BIOL CHEM, V254, P5229; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; TANAKA S, 1982, J BIOL CHEM, V257, P8386; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG TSF, 1977, BIOCHEMISTRY-US, V16, P4927, DOI 10.1021/bi00641a029; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1982, BIOCHEMISTRY-US, V21, P1597, DOI 10.1021/bi00536a021; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B	43	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11028	11040						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496164				2022-12-27	WOS:A1993LD46600049
J	NUOFFER, C; HORVATH, A; RIEZMAN, H				NUOFFER, C; HORVATH, A; RIEZMAN, H			ANALYSIS OF THE SEQUENCE REQUIREMENTS FOR GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORING OF SACCHAROMYCES-CEREVISIAE GAS1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; GLYCOPHOSPHOLIPID MEMBRANE ANCHOR; CLEAVAGE ATTACHMENT SITE; TRYPANOSOMA-BRUCEI; THY-1 GLYCOPROTEIN; SIGNAL; BIOSYNTHESIS; MUTAGENESIS; PATHWAY	The Saccharomyces cerevisiae Gas1 protein is synthesized as a precursor with a hydrophobic extension at the carboxyl terminus which is removed and replaced with an inositol containing glycolipid that anchors the protein to the plasma membrane. We performed saturation mutagenesis on the anchor attachment site (Asn506) and showed that only a subset of amino acids with small side chains could act as substrates for peptide cleavage and glycolipid addition. After Asn, which is the most efficient anchor attachment site, Ser, Gly, Ala, Asp, and Cys function with decreasing effectiveness. Mutational analysis also revealed that the 2 adjacent amino acids to the carboxyl side of the anchor attachment site are important for efficient anchoring. These two amino acids should have relatively short side chains with the second position being more critical. Analysis of the region between the anchor attachment site and the carboxyl-terminal hydrophobic region indicated that this region may not simply perform a spacer function.	UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND	University of Basel			Horvath, Anton/I-3626-2014; Horvath, Anton/V-1097-2018	Horvath, Anton/0000-0003-0785-4204; Riezman, Howard/0000-0003-4680-9422				BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DULIC V, 1991, METHOD ENZYMOL, V194, P687; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MENON AK, 1990, J BIOL CHEM, V265, P9033; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1991, J CELL BIOL, V115, P329, DOI 10.1083/jcb.115.2.329; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SEKI T, 1985, NATURE, V313, P485, DOI 10.1038/313485a0; Sherman F., 1986, METHODS YEAST GENETI; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	29	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10558	10563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486709				2022-12-27	WOS:A1993LB80000084
J	HAZEN, SL; GROSS, RW				HAZEN, SL; GROSS, RW			THE SPECIFIC ASSOCIATION OF A PHOSPHOFRUCTOKINASE ISOFORM WITH MYOCARDIAL CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2 - IMPLICATIONS FOR THE COORDINATED REGULATION OF PHOSPHOLIPOLYSIS AND GLYCOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; PLATELET PHOSPHOLIPASE-A2; CANINE MYOCARDIUM; CELL-LINE; PURIFICATION; IDENTIFICATION; ACTIVATION; GLYCEROPHOSPHOLIPIDS; MEMBRANE; FORM	We have demonstrated previously that myocardial cytosolic calcium-independent phospholipase A2 is a 40-kDa polypeptide regulated by ligand-modulated protein-protein interactions (Hazen, S. L., and Gross, R. W. (1991) J. Biol. Chem. 266, 14526-14534). We now demonstrate that an 85-kDa polypeptide which possesses sequence homology to and chemical, physical, immunological, and chromatographic similarities with phosphofructokinase (PFK) specifically interacts with the 40-kDa phospholipase A2 catalytic subunit and represents the putative protein regulatory element identified in previous work. Multiple independent lines of evidence document the association between the 85-kDa phosphofructokinase isoform and the 40-kDa myocardial cytosolic calcium-independent phospholipase A2 catalytic polypeptide, including 1) the coelution of the 85- and 40-kDa polypeptides which migrate as a 400-kDa complex during gel filtration chromatography, 2) the stoichiometry between the 85- and 40-kDa polypeptides which corresponds to a complex comprised of a tetrameric PFK isoform and a 40-kDa phospholipase A2 catalytic polypeptide, 3) the demonstration that the 85-kDa phosphofructokinase isoform acts as a specific and reversible affinity adsorbant for myocardial cytosolic phospholipase A2 catalytic activity, 4) the immunoprecipitation of myocardial cytosolic phospholipase A2 activity utilizing chicken anti-rabbit skeletal muscle PFK IgG, 5) the specific release of phospholipase A2 from ATP-agarose after formation of a ternary complex comprised of allosteric modifiers of phosphofructokinase, and 6) the selective attenuation of the denaturation of purified homogeneous calcium-independent cytosolic phospholipase A2 with PFK. Collectively, these results demonstrate the highly specific association of a phosphofructokinase isoform with myocardial cytosolic calcium-independent phospholipase A2 and suggest a novel biochemical mechanism underlying the coordinated regulation of phospholipolysis and glycolysis previously observed in myocardium and in other mammalian tissues.	WASHINGTON UNIV, SCH MED,DEPT MED, DIV BIOORGAN CHEM & MOLEC PHARMACOL,660 S EUCLID, BOX 8020, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CHEM & MOLEC BIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Hazen, Stanley L/ABD-5845-2021		PHS HHS [34839] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; BLACKSHEAR PJ, 1984, METHOD ENZYMOL, V104, P237; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; Dennis EA, 1983, ENZYMES, P307; DIEZ E, 1990, J BIOL CHEM, V265, P14654; EMERK K, 1975, ARCH BIOCHEM BIOPHYS, V168, P210, DOI 10.1016/0003-9861(75)90243-X; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; Goldhammer A R, 1979, Curr Top Cell Regul, V15, P109; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAZEN SL, 1991, METHOD ENZYMOL, V197, P400; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1992, CIRC RES, V70, P486, DOI 10.1161/01.RES.70.3.486; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HUSEBYE ES, 1987, BIOCHIM BIOPHYS ACTA, V920, P120, DOI 10.1016/0005-2760(87)90251-7; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; JESSE RL, 1976, BIOCHEM J, V158, P283, DOI 10.1042/bj1580283; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LOEB LA, 1986, J BIOL CHEM, V261, P467; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; PETTIGREW DW, 1979, J BIOL CHEM, V254, P1896; PIERIK AJ, 1988, BIOCHIM BIOPHYS ACTA, V962, P345, DOI 10.1016/0005-2760(88)90264-0; RAMADOSS CS, 1976, ARCH BIOCHEM BIOPHYS, V175, P487, DOI 10.1016/0003-9861(76)90536-1; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SMITH JB, 1970, BRIT J PHARMACOL, V40, pP545; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707; ZUPAN LA, 1991, FEBS LETT, V284, P27, DOI 10.1016/0014-5793(91)80753-P	41	71	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9892	9900						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486669				2022-12-27	WOS:A1993LA68900105
J	IWAMOTO, M; YAGAMI, K; VALLE, PL; OLSEN, BR; PETROPOULOS, CJ; EWERT, DL; PACIFICI, M				IWAMOTO, M; YAGAMI, K; VALLE, PL; OLSEN, BR; PETROPOULOS, CJ; EWERT, DL; PACIFICI, M			EXPRESSION AND ROLE OF C-MYC IN CHONDROCYTES UNDERGOING ENDOCHONDRAL OSSIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CHICK CHONDROCYTES; COLLAGEN GENE-EXPRESSION; FIBROBLAST GROWTH-FACTOR; X COLLAGEN; EMBRYONIC CHICK; MESSENGER-RNA; TERMINAL DIFFERENTIATION; EPIPHYSEAL CARTILAGE; MAMMALIAN-CELLS; DNA	To analyze the relationship between c-myc gene expression and chondrocyte proliferation and maturation during endochondral ossification, Day 18-19 chick embryo sterna were pulse-labeled with [H-3]thymidine, and serial sections were processed for autoradiography and in situ hybridization. Proliferating chondrocytes, located in four distinct areas of the developing sternum, all contained high levels of c-myc transcripts, whereas postmitotic chondrocytes (such as hypertrophic chondrocytes) contained undetectable amounts. These findings were confirmed by Northern blot analysis and by the observation that antisense c-myc oligomer treatment inhibited proliferation in cultured chondrocytes. Constitutive overexpression of c-myc by retroviral vectors in immature chondrocyte cultures (c-myc cultures) maintained the cells in a proliferative state and blocked their maturation into hypertrophic chondrocytes. The lack of maturation in the c-myc cultures was corroborated by analysis of type X collagen gene regulation. Control immature cultures contained strong repressor activity for the type X collagen gene promoter, as revealed by transfection assays; repressor activity was lost upon maturation and activation of type X collagen synthesis. In the c-myc cultures, however, repressor activity persisted. Thus, c-myc participates in the normal changes in proliferation accompanying chondrocyte maturation in vivo and in culture. The decreases in c-myc expression and cell proliferation appear to be required for completion of maturation.	HARVARD UNIV,SCH MED,DEPT ANAT & CELL BIOL,BOSTON,MA 02115; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; The Wistar Institute	IWAMOTO, M (corresponding author), UNIV PENN,SCH DENT,DEPT ANAT HISTOL,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, R01AR039705, R37AR036820, R01AR036819, R37AR036819] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 36819, AR 39705, AR 36820] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS SL, 1991, EXP CELL RES, V193, P190, DOI 10.1016/0014-4827(91)90555-9; ALEMA S, 1985, MOL CELL BIOL, V5, P538, DOI 10.1128/MCB.5.3.538; ALI SY, 1976, FED PROC, V35, P135; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CAPASSO O, 1984, MOL CELL BIOL, V4, P1163, DOI 10.1128/MCB.4.6.1163; CASTAGNOLA P, 1987, DEV BIOL, V123, P332, DOI 10.1016/0012-1606(87)90391-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EWERT DL, 1990, LAB INVEST, V62, P156; FISHER JA, 1988, NATURE, P853; GIARETTI W, 1988, CYTOMETRY, V9, P281, DOI 10.1002/cyto.990090403; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; GIONTI E, 1985, P NATL ACAD SCI USA, V82, P2756, DOI 10.1073/pnas.82.9.2756; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIRVONEN H, 1990, ONCOGENE, V5, P1787; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; HOWLETT CR, 1979, J ANAT, V128, P377; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; JAFFREDO T, 1989, DEVELOPMENT, V105, P679; KATO Y, 1990, J BIOL CHEM, V265, P5903; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kember N.F., 1983, CARTILAGE, VI, P149; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; LEBOY PS, 1988, J BIOL CHEM, V263, P8515; Lis J T, 1980, Methods Enzymol, V65, P347; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAYNE R, 1993, IN PRESS EXTRACELLUL; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; OSHIMA O, 1989, CALCIFIED TISSUE INT, V45, P182, DOI 10.1007/BF02556062; PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014-4827(91)90497-I; PACIFICI M, 1990, ANN NY ACAD SCI, V599, P45, DOI 10.1111/j.1749-6632.1990.tb42363.x; PACIFICI M, 1983, J CELL BIOL, V97, P1724, DOI 10.1083/jcb.97.6.1724; QUARTO R, 1992, DEV BIOL, V149, P168, DOI 10.1016/0012-1606(92)90273-J; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SMALE G, 1992, ANAL BIOCHEM, V203, P352, DOI 10.1016/0003-2697(92)90324-Z; STOCUM DL, 1979, J EMBRYOL EXP MORPH, V54, P155; VALLE PL, 1993, IN PRESS J CELL BIOL; VALLE PL, 1988, J BIOL CHEM, V263, P18378; VALLE PL, 1991, J CELL BIOL, V115, pA286; VINCENT F, 1991, EXP CELL RES, V192, P333, DOI 10.1016/0014-4827(91)90049-Z; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146	55	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9645	9652						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486652				2022-12-27	WOS:A1993LA68900074
J	KANG, T; MARTINS, T; SADOWSKI, I				KANG, T; MARTINS, T; SADOWSKI, I			WILD-TYPE GAL4 BINDS COOPERATIVELY TO THE GAL1-10 UASG INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; REGULATORY PROTEIN; DNA-BINDING; YEAST; GENE; DERIVATIVES; MECHANISM; SITES	Transcription of the genes required for utilization of galactose in Saccharomyces cerevisiae is controlled primarily by the transcriptional activator protein GAL4. The upstream activating sequences for galactose (UAS(G)) of most GAL genes have multiple sites to which GAL4 can bind. In this report we compare the binding properties of wild type GAL4 and derivatives of GAL4 bearing the N-terminal DNA-binding domain to multiple DNA-binding sites in vitro. To produce wild type GAL4, we constructed a recombinant baculovirus for expression in insect cells. Recombinant wild type GAL4 was found to bind efficiently to an oligonucleotide containing a near-consensus 17-mer GAL4 DNA-binding site in electrophoretic mobility shift assays. Footprinting experiments revealed that wild type GAL4 binds cooperatively to the four GAL4 DNA-binding sites of the GAL1-10 UAS(G); however, in contrast an N-terminal fragment of GAL4 containing only the DNA-binding/dimerization domains binds to each of these sites with slightly different affinity. With increasing concentrations of GAL4(1-147), the four sites become filled in the following order: site II, site IV, site I, and site III. In experiments with wild type GAL4, these four sites become fully occupied at approximately the same concentration of protein. In footprints of wild type GAL4 on the UAS(G), enhancements and protections of DNase I-sensitive cleavages are detectable between sites III and IV, indicative of formation of a loop between these distantly spaced sites. Binding of wild type GAL4 to a strong near-consensus binding site assists binding to an adjacent mutant site in both electrophoretic mobility shift and footprinting assays. GAL4(1-147) and GAL4(1-147) fused to portions of GAL4's activating region II were incapable of cooperative DNA binding in our assays. We conclude from these observations that wild type GAL4 has a cooperative DNA-binding function that is distinct from the DNA binding and dimerization or transcriptional activation functions, and likely plays and important role in precise regulation of GAL gene transcription.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,2146 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	University of British Columbia; Harvard University								BHAT PJ, 1990, GENETICS, V125, P281; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; FLICK JS, 1992, GENETICS, V130, P295; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUDEN DM, 1988, P NATL ACAD SCI USA, V85, P4262, DOI 10.1073/pnas.85.12.4262; RUDEN DM, 1990, MOL CELL BIOL, V10, P1432, DOI 10.1128/MCB.10.4.1432; SADOWSKI I, 1991, P NATL ACAD SCI USA, V88, P10510, DOI 10.1073/pnas.88.23.10510; SHIMADA H, 1985, GENE, V39, P1; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991	31	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9629	9635						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486650				2022-12-27	WOS:A1993LA68900072
J	TANGIRALA, RK; MAHLBERG, FH; GLICK, JM; JEROME, WG; ROTHBLAT, GH				TANGIRALA, RK; MAHLBERG, FH; GLICK, JM; JEROME, WG; ROTHBLAT, GH			LYSOSOMAL ACCUMULATION OF UNESTERIFIED CHOLESTEROL IN MODEL MACROPHAGE FOAM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; LADEN AORTIC-CELLS; HAMSTER OVARY CELLS; FAT-FED RABBITS; ATHEROSCLEROTIC LESIONS; INTRACELLULAR-TRANSPORT; EARLY ATHEROGENESIS; LIPID-ACCUMULATION; ESTER ACCUMULATION; CULTURE MODEL	Lysosomal accumulation of unesterified (free) cholesterol, following the phagocytic incorporation of cholesteryl oleate lipid droplets, was quantitatively characterized in a murine J774 macrophage foam cell model. The induction of phagocytic incorporation by the macrophages, using an inverted culture technique, allowed the rapid delivery of large amounts of cholesteryl ester droplets to the lysosomes, leading to the subsequent generation of free cholesterol. The lysosomally generated free cholesterol was differentiated from the membrane cholesterol by a double radiolabeling procedure. Free cholesterol accumulation was quantitated in a population of low density lipid-filled lysosomes prepared by ultracentrifugal isolation of a floating lipid fraction from a homogenate of the cholesteryl ester-loaded cells. About 10% of the total N-acetyl-beta-glucosaminidase activity, a lysosomal marker, was recovered in the lipid fraction. Negligible amounts of alkaline phosphodiesterase-1, a plasma membrane marker, or membrane cholesterol were present in this fraction. Electron microscopic and cytochemical analysis of the isolated lipid fraction revealed the presence of lysosomes in the fraction with a diameter ranging from 1.5 to 4 mum. Continued hydrolysis of incorporated cholesteryl ester over a 24-h incubation resulted in approximately 30% of the generated free cholesterol in lipid-filled lysosomes. The accumulation of free cholesterol occurred whether or not the cholesterol esterifying enzyme, acyl-CoA: cholesterol acyltransferase, was inhibited. In addition, substantial amounts of free cholesterol accumulated even in the presence of efficient cholesterol acceptor particles, apolipoprotein high density lipoprotein-phosphatidylcholine complexes which stimulate cholesterol efflux. Also, increased accumulation of free cholesterol in the lipid fraction was observed when cholesteryl ester-loaded cells were treated with the compound U-18666A which blocks the movement of lysosomal cholesterol. The data demonstrate that the phagocytic incorporation and hydrolysis of cholesteryl ester lipid droplets by macrophage foam cells lead to a substantial accumulation of free cholesterol in the liPid-filled lysosomes. This process could result in a build-up of lysosomal free cholesterol in macrophage foam cells during the progression of atheroselerotic plaque.	MED COLL PENN, DEPT BIOCHEM, PHILADELPHIA, PA 19129 USA; BOWMAN GRAY SCH MED, DEPT PATHOL, WINSTON SALEM, NC 27157 USA	Drexel University; Wake Forest University; Wake Forest Baptist Medical Center					NHLBI NIH HHS [HL-22633, HL-07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, T32HL007443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; FALCONE DJ, 1984, J CELL BIOL, V99, P1266, DOI 10.1083/jcb.99.4.1266; FOWLER S, 1979, LAB INVEST, V41, P372; FOWLER S, 1978, INT C ATHEROSCLEROSI, P19; Gomori G., 1952, MICROSCOPIC HISTOCHE; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; JEROME WG, 1985, AM J PATHOL, V119, P210; JEROME WG, 1991, EXP MOL PATHOL, V54, P144; JEROME WG, 1987, AM J PATHOL, V128, P253; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONES NL, 1991, AM J PATHOL, V139, P383; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOVANEN PT, 1991, ANN MED, V23, P551, DOI 10.3109/07853899109150517; LEWIS JC, 1988, EXP MOL PATHOL, V48, P103, DOI 10.1016/0014-4800(88)90049-4; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LUPU F, 1987, ATHEROSCLEROSIS, V67, P127, DOI 10.1016/0021-9150(87)90273-5; MACKIE EJB, 1989, BIOCHIM BIOPHYS ACTA, V1006, P219, DOI 10.1016/0005-2760(89)90200-2; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1990, BIOCHIM BIOPHYS ACTA, V1045, P291, DOI 10.1016/0005-2760(90)90133-I; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; MINOR LK, 1991, EXP MOL PATHOL, V54, P159, DOI 10.1016/0014-4800(91)90028-V; MINOR LK, 1989, J LIPID RES, V30, P189; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P24, DOI 10.1161/01.ATV.7.1.24; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SHIO H, 1979, LAB INVEST, V41, P160; SHIO H, 1978, LAB INVEST, V39, P390; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; VIJAYAGOPAL P, 1985, BIOCHIM BIOPHYS ACTA, V837, P251, DOI 10.1016/0005-2760(85)90048-7; WOLFBAUER G, 1986, P NATL ACAD SCI USA, V83, P7760, DOI 10.1073/pnas.83.20.7760	46	36	37	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9653	9660						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486653				2022-12-27	WOS:A1993LA68900075
J	DOMIN, J; ROZENGURT, E				DOMIN, J; ROZENGURT, E			PLATELET-DERIVED GROWTH-FACTOR STIMULATES A BIPHASIC MOBILIZATION OF ARACHIDONIC-ACID IN SWISS 3T3 CELLS - THE ROLE OF PHOSPHOLIPASE-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; RECEPTOR-MEDIATED ACTIVATION; SIGNAL TRANSDUCTION; MESSENGER-RNA; PROSTAGLANDIN; RELEASE; CYCLOOXYGENASE; ACCUMULATION; METABOLITES; EXPRESSION	Stimulation of quiescent Swiss 3T3 cells with platelet-derived growth factor (PDGF) increased the initial rate of cytosolic phospholipase A2 activity by 95 +/- 6% over extracts from control cells. Cytosolic phospholipase A2 activity increased rapidly following PDGF treatment (near maximum stimulation by 2.5 min) and was dose-dependent (EC50 = 2 ng/ml). Epidermal growth factor, vasopressin, and phorbol 12,13-dibutyrate also increased cytosolic phospholipase A2 activity but did not produce a sustained mobilization of arachidonic acid in these cells. Detailed kinetic analysis of PDGF-induced arachidonic acid mobilization revealed a biphasic release of H-3 radioactivity into the extracellular medium. A first, rapid phase, occurred within 15 min which, like the activation of cytosolic phospholipase A2 activity, was independent of de novo RNA and protein synthesis. After 20 min of stimulation, a second phase became evident which accounts for the majority of arachidonic acid mobilized by PDGF. This second phase was abolished in the presence of either cycloheximide or actinomycin D. Both inhibitors blocked the release of arachidonic acid rather than inhibiting cyclooxygenase activity and consequently prostaglandin E2 production. These findings demonstrate a biphasic mobilization of arachidonic acid in Swiss 3T3 cells by PDGF. Cytosolic phospholipase A2 activity could contribute to the rapid first phase but not the second major phase, which is dependent upon de novo protein synthesis.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BURCH RM, 1988, P NATL ACAD SCI USA, V85, P6306, DOI 10.1073/pnas.85.17.6306; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COCHRAN BH, 1985, ADV CANCER RES, V45, P183, DOI 10.1016/S0065-230X(08)60269-9; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOMIN J, 1992, J BIOL CHEM, V267, P15217; EXTON JH, 1990, J BIOL CHEM, V265, P1; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HEINSOHN C, 1987, ARCH BIOCHEM BIOPHYS, V257, P251, DOI 10.1016/0003-9861(87)90564-9; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LIN AH, 1989, J BIOL CHEM, V264, P17379; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MEHMET H, 1991, BRIT MED BULL, V47, P76, DOI 10.1093/oxfordjournals.bmb.a072463; Mehmet H, 1990, GROWTH FACTORS, V3, P83, DOI 10.3109/08977199009108271; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1991, CANCER CELL-MON REV, V3, P397; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHALKWIJK CG, 1990, BIOCHIM BIOPHYS ACTA, V1044, P139, DOI 10.1016/0005-2760(90)90229-Q; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIER WT, 1982, J CELL PHYSIOL, V112, P171, DOI 10.1002/jcp.1041120204; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	44	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8927	8934						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473335				2022-12-27	WOS:A1993KX81100080
J	KVALNESKRICK, K; LABDON, JE; MA, XY; NIEVES, E; SCHRAMM, VL				KVALNESKRICK, K; LABDON, JE; MA, XY; NIEVES, E; SCHRAMM, VL			MUTAGENIC ANALYSIS OF AMP NUCLEOSIDASE FROM ESCHERICHIA-COLI - DELETION OF A REGION SIMILAR TO AMP DEAMINASE AND PEPTIDE CHARACTERIZATION BY MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ENZYME; GENE; HYDROLYSIS; ACID; DEGRADATION; PROTEIN; YEAST	AMP nucleosidase (EC 3.2.2.4) from Escherichia coli and AMP deaminase (EC 3.5.4.6) from bakers' yeast are proposed to regulate cellular AMP levels under allosteric control of the activator ATP and the inhibitor, PO4. Both enzymes contain catalytic sites which bind AMP and regulatory sites which bind ATP. The deduced amino acid sequences of the proteins revealed only one region of homology in which six of eight amino acids are identical. A similar sequence is found in glyceraldehyde-3-phosphate dehydrogenase, phoE, ras proteins, RNA polymerase, K+-ATPase, nucleolin, and other proteins expected to have nucleotide or phosphate binding properties. In the crystal structure of glyceraldehyde-3-phosphate dehydrogenase, this sequence is part of the NAD+-binding site. The function of these amino acids was explored with a deletion mutant of AMP nucleosidase. The protein was over-produced in a pTZ construct using the AMP nucleosidase promoter which resulted in approximately 30% of the total protein as the desired enzyme. The mutation was characterized by DNA sequence analysis and by direct analysis of the peptides using high performance liquid chromatography-mass spectrometry. Deletion of amino acids 128-135, corresponding to DGSELTLD, produced an enzyme with a 20-fold decrease in V(max) but with smaller changes in substrate saturation kinetics, activation by MgATP, inhibition by inorganic phosphate, and inhibition by the tight-binding inhibitor, formycin 5-phosphate. The deletion mutant of AMP nucleosidase exhibits hysteresis in establishing a steady-state rate of product formation which is most pronounced in the absence of MgATP. These results establish that the sequence DGSELTLD in E. coli AMP nucleosidase is not required for binding of AMP, MgATP, or inorganic phosphate. However, the mutant enzyme has a structural defect related to the polymerization state which delays the onset of catalysis and decreases the catalytic efficiency.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			kvalnes, kalla/F-9380-2013					BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Battey, 1986, BASIC METHODS MOL BI; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHAPMAN AG, 1973, J BIOL CHEM, V248, P8309; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DEHAAN P, 1991, J GEN VIROL, V71, P2207; DEWOLF WE, 1979, J BIOL CHEM, V254, P868; FERRI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P36, DOI 10.1016/0167-4838(90)90119-Z; GIRANDA VL, 1989, J BIOL CHEM, V264, P15674; KVALNESKRICK K, 1986, BIOCHEMISTRY-US, V25, P6061, DOI 10.1021/bi00368a034; LEUNG HB, 1984, J BIOL CHEM, V259, P6972; LEUNG HB, 1989, BIOCHEMISTRY-US, V28, P8726, DOI 10.1021/bi00448a008; LEUNG HB, 1980, J BIOL CHEM, V255, P867; Maniatis T., 1982, MOL CLONING; MCCLEARY WR, 1990, P NATL ACAD SCI USA, V87, P5898, DOI 10.1073/pnas.87.15.5898; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; MEYER SL, 1989, BIOCHEMISTRY-US, V28, P8734, DOI 10.1021/bi00448a009; PARKIN DW, 1984, J BIOL CHEM, V259, P9411; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Schramm V L, 1978, Methods Enzymol, V51, P263; SCHRAMM VL, 1971, BIOCHEMISTRY-US, V10, P3411, DOI 10.1021/bi00794a015; SCHRAMM VL, 1974, J BIOL CHEM, V249, P1729; SCHRAMM VL, 1978, ARCH BIOCHEM BIOPHYS, V190, P263; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; VANDERLEY P, 1987, PHOSPHATE METABOLISM, P159; YAMAMOTO J, 1991, AGR BIOL CHEM TOKYO, V55, P1615, DOI 10.1080/00021369.1991.10870805; [No title captured]	32	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8717	8726						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473316				2022-12-27	WOS:A1993KX81100053
J	LU, ZC; NAGATA, S; MCPHIE, P; MILES, EW				LU, ZC; NAGATA, S; MCPHIE, P; MILES, EW			LYSINE-87 IN THE BETA-SUBUNIT OF TRYPTOPHAN SYNTHASE THAT FORMS AN INTERNAL ALDIMINE WITH PYRIDOXAL-PHOSPHATE SERVES CRITICAL ROLES IN TRANSIMINATION, CATALYSIS, AND PRODUCT RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ULTRAVIOLET VISIBLE SPECTROSCOPY; COLI ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LYSYL RESIDUE; L-SERINE; CIRCULAR-DICHROISM; BRONSTED ANALYSIS; EXOGENOUS AMINES	This study provides valuable insights into the functions of the lysine residue that forms an internal aldimine with pyridoxal phosphate in the beta subunit of tryptophan synthase from Salmonella typhimurium. Our spectroscopic and kinetic studies demonstrate that a mutant alpha2beta2 complex having beta subunit lysine 87 replaced by threonine forms external aldimines with several amino acids including L-serine, beta-chloro-1-alanine, L-tryptophan, and D-tryptophan. Because the rates of aldimine formation are very slow, we conclude that one role of lysine 87 in the wild type enzyme is to facilitate formation of external aldimines by transimination. Lysine 87 is an essential catalytic residue because the mutant alpha2beta2 complex has no measurable activity in reactions catalyzed by the beta subunit and does not convert external aldimines to products. The mutant enzyme carries out two slow partial beta-elimination reactions: the conversion of beta-chloro-L-alanine and L-serine to enzyme-bound aminoacrylate. The reaction with L-serine is catalyzed by ammonia, which partially replaces the deleted epsilon-amino group. Lysine 87 is important for substrate and product release because L-serine, L-tryptophan, and aminoacrylate dissociate very slowly from the mutant alpha2beta2 complex. Our ability to prepare very stable derivatives of the mutant alpha2beta2 complex containing tightly bound aldimines with a substrate, a product, or a reaction intermediate provides valuable materials for ongoing x-ray crystallographic investigations and future kinetic analyses of the allosteric activation of the alpha subunit by beta subunit ligands.	NIDDKD, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A09, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; BALK H, 1981, BIOCHEMISTRY-US, V20, P6391, DOI 10.1021/bi00525a017; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; BRZOVLC P, 1991, INT UNION B, V199, P277; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CORDES EH, 1962, BIOCHEMISTRY-US, V1, P773, DOI 10.1021/bi00911a007; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DREWE WF, 1989, BIOCHIMIE, V71, P509, DOI 10.1016/0300-9084(89)90182-X; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; FLURI R, 1971, J BIOL CHEM, V246, P6620; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GREGERMAN RI, 1956, J BIOL CHEM, V220, P765; HAYASHI H, 1990, BIOCHEM BIOPH RES CO, V167, P407, DOI 10.1016/0006-291X(90)92037-Z; HIGGINS W, 1980, J BIOL CHEM, V255, P512; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; INOUE Y, 1989, J BIOL CHEM, V264, P9673; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; KIRSCH JF, 1990, UCLA SYM BI, V110, P105; KIRSCH JF, 1990, ANN NY ACAD SCI, V585, P48, DOI 10.1111/j.1749-6632.1990.tb28040.x; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KIRSCH JF, 1990, ENZYMES DEPENDENT PY, P161; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; KURAMITSU S, 1987, BIOCHEM BIOPH RES CO, V146, P416, DOI 10.1016/0006-291X(87)90545-6; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LONGENECKER JB, 1957, J BIOL CHEM, V225, P409; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1978, J BIOL CHEM, V253, P6266; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1982, J BIOL CHEM, V257, P4203; MILES EW, 1975, BIOCHEM BIOPH RES CO, V66, P94, DOI 10.1016/S0006-291X(75)80299-3; MILES EW, 1980, BIOCH MED ASPECTS TR, P137; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, INT UNION B, V199, P273; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; ROBERTS WJ, 1988, J BIOL CHEM, V263, P7196; SCHLOSS JV, 1988, ACCOUNTS CHEM RES, V21, P348, DOI 10.1021/ar00153a005; SLEBE JC, 1976, J BIOL CHEM, V251, P5663; TATSUMOTO K, 1981, J AM CHEM SOC, V103, P6197, DOI 10.1021/ja00410a036; TATSUMOTO K, 1977, J AM CHEM SOC, V99, P6082, DOI 10.1021/ja00460a040; TONEY MD, 1992, PROTEIN SCI, V1, P107; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; WADA H, 1962, J BIOL CHEM, V237, P127; YANOFSKY C, 1972, ENZYMES, V7, P1; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029; ZIAK M, 1990, EUR J BIOCHEM, V187, P329, DOI 10.1111/j.1432-1033.1990.tb15309.x	65	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8727	8734						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473317				2022-12-27	WOS:A1993KX81100054
J	KAWASAKI, S; MIZUSHIMA, S; TOKUDA, H				KAWASAKI, S; MIZUSHIMA, S; TOKUDA, H			MEMBRANE-VESICLES CONTAINING OVERPRODUCED SECY AND SECE EXHIBIT HIGH TRANSLOCATION ATPASE ACTIVITY AND COUNTERMOVEMENT OF PROTONS IN A SECA-DEPENDENT AND PRESECRETORY PROTEIN-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR DISULFIDE BRIDGE; ESCHERICHIA-COLI; MOTIVE FORCE; INVITRO TRANSLOCATION; SECRETORY PROTEINS; SIGNAL PEPTIDE; RECONSTITUTION; ENERGIZATION; COMPONENTS; MACHINERY	Everted membrane vesicles were prepared from Escherichia coli cells containing either overproduced amounts (OP-membrane vesicles) or normal amounts (normal membrane vesicles) of SecY and SecE, both of which are essential components of the protein translocation apparatus. The rates of translocation of pro-OmpA were similar in the two types of membrane vesicles, whereas translocation ATPase activity, which requires SecA, a precursor protein (pro-OmpA), and membrane vesicles, was appreciably higher with OP-membrane vesicles than with normal membrane vesicles. Since ATP hydrolysis has been shown to take place at an earlier part of the translocation reaction, these results suggest that the overproduction of SecY and SecE enhanced the activity of the earlier process, but not the entire process, of the translocation reaction. The addition of pro-OmpA in the presence of SecA caused the partial collapse of DELTApH (inside acidic) generated on OP-membrane vesicles, suggesting that protons come out from the inside of the membrane vesicles in a pro-OmpA-dependent manner. The collapse of DELTApH caused by pro-OmpA required SecA, ATP, and SecY and was not detected when normal membrane vesicles were used. These results indicate that the early event of protein translocation, which requires the functioning of SecA, SecY, and SecE, causes the countermovement of protons.	UNIV TOKYO,INST APPL MICROBIOL,1-1-1 YAYOI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; KATO M, 1992, J BIOL CHEM, V267, P413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OZAWA Y, 1987, J BACTERIOL, V169, P1331, DOI 10.1128/jb.169.3.1331-1334.1987; PANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953; SCHIEBEL E, 1992, J BIOL CHEM, V267, P7505; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHATZ PJ, 1989, GENE DEV, V3, P1035; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YAMANE K, 1988, J BIOL CHEM, V263, P5368	36	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8193	8198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463329				2022-12-27	WOS:A1993KW97900088
J	CERVERA, J; CONEJEROLARA, F; RUIZSANZ, J; GALISTEO, ML; MATEO, PL; LUSTY, CJ; RUBIO, V				CERVERA, J; CONEJEROLARA, F; RUIZSANZ, J; GALISTEO, ML; MATEO, PL; LUSTY, CJ; RUBIO, V			THE INFLUENCE OF EFFECTORS AND SUBUNIT INTERACTIONS ON ESCHERICHIA-COLI CARBAMOYL-PHOSPHATE SYNTHETASE STUDIED BY DIFFERENTIAL SCANNING CALORIMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL DOMAIN; ACETYL-L-GLUTAMATE; ATP BINDING-SITES; THERMAL-DENATURATION; MECHANISM; PROTEIN; LIVER; PROTEOLYSIS; INHIBITION; ACTIVATION	Differential scanning calorimetry of Escherichia coli carbamoyl-phosphate synthetase and its isolated large and small subunits reveals in each case an irreversible, kinetically controlled transition, at a temperature 14-degrees-C higher for the holoenzyme than for the subunits, indicating dramatic stabilization of the subunits in the heterodimer. The deletion of the COOH-terminal 171 (mutant CarB'2373) or 385 (mutant CarB2177) residues of the large subunit results in more asymmetric transitions at a temperature 7-degrees-C lower than for the wild type. The allosteric effectors IMP, UMP, and ornithine induce small reversible transitions at low temperature in the endotherm for the wild-type enzyme, but not for CarB'2373, as expected if the effectors bind in the 171-residue, COOH-terminal region. In contrast, two ligands that bind outside the deleted region, Ap5A (a ligand of both ATP sites) and glycine (an analog of glutamine) decrease and increase, respectively, the stability of the two mutants and of the wild type. The stabilization by glycine requires that the subunits are associated. The results support the implication of the 20-kDa COOH-terminal domain of the large subunit in the allosteric modulation by all the effectors and are consistent with the folding of the large subunit as a pseudohomodimer of its two homologous halves.	UNIV GRANADA, FAC CIENCIAS, DEPT QUIM FIS, GRANADA, SPAIN; PUBL HLTH RES INST CITY NEW YORK INC, DEPT MOLEC GENET, NEW YORK, NY 10016 USA	University of Granada	CERVERA, J (corresponding author), CSIC, CTR ASOCIADO, FDN VALENCIANA INVEST BIOMED, INST INVEST CITOL, AMADEO SABOYA, E-446010 VALENCIA, SPAIN.		Rubio, Vicente/K-7919-2014; Lara, Francisco Conejero/F-2962-2016	Rubio, Vicente/0000-0001-8124-1196; Lara, Francisco Conejero/0000-0002-8282-2168; Ruiz Sanz, Javier/0000-0002-4336-1274	NIGMS NIH HHS [GM25846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO E, 1992, J BIOL CHEM, V267, P4524; ANDERSON PM, 1970, BIOCHEMISTRY-US, V9, P171, DOI 10.1021/bi00803a022; BOETTCHER B, 1982, J BIOL CHEM, V257, P3971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CONEJEROLARA F, 1991, EUR J BIOCHEM, V200, P663, DOI 10.1111/j.1432-1033.1991.tb16230.x; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; GUADALAJARA A, 1987, EUR J BIOCHEM, V165, P163, DOI 10.1111/j.1432-1033.1987.tb11207.x; GUADALAJARA AM, 1987, THESIS U VALENCIA SP; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUZMANCASADO M, 1990, EUR J BIOCHEM, V188, P181, DOI 10.1111/j.1432-1033.1990.tb15386.x; HAN BD, 1990, J BACTERIOL, V172, P5089, DOI 10.1128/jb.172.9.5089-5096.1990; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KLIVANOV AM, 1987, PROTEIN ENG, P213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZMAYORGA O, 1987, BIOPHYS CHEM, V87, P87; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MANLY SP, 1985, BIOCHEMISTRY-US, V24, P3842, DOI 10.1021/bi00336a004; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MATEO PL, 1984, THERMOCHEMISTRY ITS, P541; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PASCUALSALCEDO MD, 1979, THESIS U AUTONOMA MA; PIERARD A, 1978, J BACTERIOL, V134, P167; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1980, PURE APPL CHEM, V52, P479, DOI 10.1351/pac198052020479; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SANCHEZRUIZ JM, 1988, EUR J BIOCHEM, V176, P225, DOI 10.1111/j.1432-1033.1988.tb14272.x; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P6185, DOI 10.1021/bi00524a042	40	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12504	12511						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509390				2022-12-27	WOS:A1993LG65800043
J	MURTHARIEL, P; DAVIES, MV; SCHERER, BJ; CHOI, SY; HERSHEY, JWB; KAUFMAN, RJ				MURTHARIEL, P; DAVIES, MV; SCHERER, BJ; CHOI, SY; HERSHEY, JWB; KAUFMAN, RJ			EXPRESSION OF A PHOSPHORYLATION-RESISTANT EUKARYOTIC INITIATION FACTOR-II ALPHA-SUBUNIT MITIGATES HEAT-SHOCK INHIBITION OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; HAMSTER OVARY CELLS; FACTOR-II; FACTOR EIF-2; TRANSLATIONAL CONTROL; MOLECULAR-CLONING; PHORBOL ESTERS; HELA-CELLS; RNA; COMPLEX	Protein synthesis is dramatically reduced upon exposure of cells to elevated temperature. Concordant with this inhibition, multiple phosphorylation and dephosphorylation reactions occur on specific eukaryotic initiation factors that are required for protein synthesis. Most notably, phosphorylation of the alpha-subunit of eukaryotic initiation factor-2 (eIF-2alpha) on serine residue 51 occurs. To identify the importance of phosphorylation in control of protein synthesis, we have evaluated the effects of expression of a mutant eIF-2alpha which is resistant to phosphorylation. Expression of a serine to alanine mutant at residue 51 of eIF-2alpha partially protected cells from the inhibition of protein synthesis in response to heat treatment. The overexpressed serine to alanine 51 mutant subunit was incorporated into the eIF-2 heterotrimer and was resistant to phosphorylation. These results are consistent with the hypothesis that heat shock inhibition of translation is mediated in part through phosphorylation of eIF-2alpha. Expression of the wild type or mutant eIF-2alpha did not affect cell survival or induction of hsp70 mRNA upon heat shock, indicating that although eIF-2alpha is a heat shock-induced protein, its increased synthesis during heat shock does not alter the heat-shock response.	GENET INST INC,CAMBRIDGE,MA 02140; UNIV CALIF DAVIS,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07577, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI SY, 1992, J BIOL CHEM, V267, P286; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; COLBERT RA, 1987, J BIOL CHEM, V262, P16763; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1987, MOL CELL BIOL, V7, P1293, DOI 10.1128/MCB.7.3.1293; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KAUFMAN RJ, 1987, P NATL ACAD SCI USA, V83, P1568; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	42	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12946	12951						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509427				2022-12-27	WOS:A1993LG65800103
J	SWART, JR; GRIEP, MA				SWART, JR; GRIEP, MA			PRIMASE FROM ESCHERICHIA-COLI PRIMES SINGLE-STRANDED TEMPLATES IN THE ABSENCE OF SINGLE-STRANDED DNA-BINDING PROTEIN OR OTHER AUXILIARY PROTEINS - TEMPLATE SEQUENCE REQUIREMENTS BASED ON THE BACTERIOPHAGE-G4 COMPLEMENTARY STRAND ORIGIN AND OKAZAKI FRAGMENT INITIATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; PHAGE G4 DNA; NUCLEOTIDE-SEQUENCES; REPLICATION ORIGIN; RNA-POLYMERASE; GENE-PRODUCT; PURIFICATION; DYNAMICS; COMPLEX; MUTANTS	We find that neither the hairpins nor bound single-stranded DNA-binding protein (SSB) are required for in vitro primase activity at the G4 complementary strand origin. Primase has the ability to prime synthetic DNA templates in the absence of any auxiliary proteins, including SSB, and in the absence of any DNA secondary structure. Primase does, however, initiate primer synthesis starting at a specific nucleotide sequence present in both the G4 origin system and at sites of Okazaki fragment initiation. We tested a series of single-stranded DNA templates that consisted of various portions of the G4 complementary strand origin for the ability to support primer synthesis. Primer synthesis activity was determined using an assay in which primer length and quantity are monitored by the incorporation of [gamma-P-32]ATP once per primer and the products analyzed on a denaturing polyacrylamide gel. We find that primase requires only a short DNA template, 5'-(AC)7CTG CAA AGC-3', to synthesize a 17-nucleotide primer starting at the thymidine residue. We also report primase's ability to incorporate dideoxyribonucleotide triphosphates into primers, which has allowed us to determine directly both length and sequence of primers synthesized.	UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	University of Nebraska System; University of Nebraska Lincoln								BENZ EW, 1980, J BIOL CHEM, V255, P1096; BLUMBERG DD, 1987, METHOD ENZYMOL, V152, P20; Borer P. N., 1975, CRC HDB BIOCH MOL BI, V1, P589; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFCAVITCH JW, 1990, GEL ELECTROPHORESIS, P125; FIDDES JC, 1978, P NATL ACAD SCI USA, V75, P1081, DOI 10.1073/pnas.75.3.1081; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GODSON GN, 1978, NATURE, V276, P236, DOI 10.1038/276236a0; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; HIRAO I, 1990, BIOCHIM BIOPHYS ACTA, V1087, P199, DOI 10.1016/0167-4781(90)90205-G; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT PF, 1987, GENE, V53, P257, DOI 10.1016/0378-1119(87)90014-X; LARK KG, 1972, NATURE-NEW BIOL, V240, P237, DOI 10.1038/newbio240237a0; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LOUARN JM, 1974, MOL GEN GENET, V133, P193, DOI 10.1007/BF00267668; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; ROWEN L, 1978, J BIOL CHEM, V253, P758; ROWEN L, 1978, J BIOL CHEM, V253, P770; SAKAI H, 1987, GENE, V53, P265; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAPER A, 1991, J BIOMOL STRUCT DYN, V8, P1233, DOI 10.1080/07391102.1991.10507880; SIMS J, 1980, P NATL ACAD SCI-BIOL, V77, P900, DOI 10.1073/pnas.77.2.900; SIMS J, 1979, J BIOL CHEM, V254, P2615; SIMS J, 1978, P NATL ACAD SCI USA, V75, P3094, DOI 10.1073/pnas.75.7.3094; SUN WL, 1993, J BIOL CHEM, V268, P8026; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; WILSON DH, 1990, BIOPOLYMERS, V29, P357, DOI 10.1002/bip.360290208; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; YODA KY, 1988, NUCLEIC ACIDS RES, V16, P6531, DOI 10.1093/nar/16.14.6531	40	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12970	12976						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509429				2022-12-27	WOS:A1993LG65800107
J	PALMER, DJ; HELMS, JB; BECKERS, CJM; ORCI, L; ROTHMAN, JE				PALMER, DJ; HELMS, JB; BECKERS, CJM; ORCI, L; ROTHMAN, JE			BINDING OF COATOMER TO GOLGI MEMBRANES REQUIRES ADP-RIBOSYLATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; COATED VESICLES; CHOLERA-TOXIN; REGULATORY COMPONENT; PROTEIN COFACTOR; BREFELDIN-A; BETA-COP; TRANSPORT; PURIFICATION; COMPLEX	Coatomer, a complex of seven proteins, appears to be the precursor of the coat structure of non-clathrin-coated Golgi-derived vesicles. Another component of this vesicle coat is the cytosolic protein ADP-ribosylation factor (ARF). Like coatomer, ARF appears to reversibly associate with Golgi membranes. We now report that ARF is required for coatomer binding to Golgi membranes and that myristoylated, but not non-myristoylated, ARF is the required species. We utilize an antibody directed against the beta-subunit of coatomer (beta-COP) to follow coatomer binding. ARF and beta-COP bind stoichiometrically to Golgi membranes. ARF-dependent beta-COP binding requires a membrane-associated protein, is saturable, and is enhanced in the presence of stable GTP analogues like guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). ARF and beta-COP bind sequentially to Golgi membranes, since beta-COP can be bound to reisolated membranes that had been previously incubated with ARF and GTPgammaS. We conclude that membrane-bound ARF confers to Golgi membranes all of the requirements for specific beta-COP binding.	SLOAN KETTERING INST CANC RES, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA; UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, CH-1211 GENEVA 4, SWITZERLAND	Memorial Sloan Kettering Cancer Center; University of Geneva								ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1992, J BIOL CHEM, V267, P13053; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P182; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, IN PRESS J CELL BIOL; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, IN PRESS NATURE; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	38	296	298	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12083	12089						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505331				2022-12-27	WOS:A1993LF28400093
J	ROBERDS, SL; ERVASTI, JM; ANDERSON, RD; OHLENDIECK, K; KAHL, SD; ZOLOTO, D; CAMPBELL, KP				ROBERDS, SL; ERVASTI, JM; ANDERSON, RD; OHLENDIECK, K; KAHL, SD; ZOLOTO, D; CAMPBELL, KP			DISRUPTION OF THE DYSTROPHIN-GLYCOPROTEIN COMPLEX IN THE CARDIOMYOPATHIC HAMSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE RECEPTOR; CALCIUM CHANNELS; PROTEINS; HEART; BRAIN; ORGANIZATION; DEFICIENCY; MYOPATHY	Cardiomyopathies are a diverse group of primary cardiac diseases, most of which have a poorly understood etiology. One type of hereditary cardiomyopathy is caused by defects in the dystrophin gene in Duchenne and Becker muscular dystrophy patients. Our laboratory has identified a complex of dystrophin-associated proteins in skeletal and cardiac muscle which span the sarcolemma, linking the subsarcolemmal cytoskeleton to the extracellular matrix. The absence of dystrophin in Duchenne muscular dystrophy patients leads to the loss of dystrophin-associated proteins in both skeletal and cardiac muscle, suggesting that a primary loss of one or more dystrophin-associated proteins might lead to other forms of cardiomyopathy. Here we report the specific deficiency of the 50-kDa dystrophin-associated glycoprotein in cardiac and skeletal muscles of the BIO 14.6 strain of cardiomyopathic hamsters, which experience both autosomal recessive cardiomyopathy and myopathy. Other dystrophin-associated proteins are well preserved in myopathic hamster skeletal muscle, but the link between dystrophin and dystroglycan is disrupted. All dystrophin-associated proteins are decreased in abundance in the cardiomyopathic hamster heart, perhaps explaining why the cardiomyopathy is more severe than the myopathy. Thus, the disruption of the dystrophin-glycoprotein complex may play a role in skeletal and cardiac myocyte necrosis of the cardiomyopathic hamster.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, 400 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa			Ervasti, James/AAZ-4786-2020; Roberds, Steven L/AAP-4985-2020	Roberds, Steven L/0000-0003-0676-272X; Kahl, Steven/0000-0001-7085-9556; Ohlendieck, Kay/0000-0002-6266-4510; Campbell, Kevin/0000-0003-2066-5889				ANAN R, 1992, AM HEART J, V123, P1088, DOI 10.1016/0002-8703(92)90732-B; BAJUSZ E, 1969, ANN NY ACAD SCI, V156, P105, DOI 10.1111/j.1749-6632.1969.tb16721.x; BAJUSZ E, 1969, AM HEART J, V77, P686, DOI 10.1016/0002-8703(69)90556-0; BAZAN E, 1991, J MOL CELL CARDIOL, V23, P111, DOI 10.1016/0022-2828(91)90098-7; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P610, DOI 10.1097/00005344-199204000-00019; FINKEL MS, 1987, LIFE SCI, V41, P153, DOI 10.1016/0024-3205(87)90488-7; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; Homburger F, 1979, Ann N Y Acad Sci, V317, P1, DOI 10.1111/j.1749-6632.1979.tb56503.x; HOWLETT SE, 1987, BIOCHEM PHARMACOL, V36, P2653, DOI 10.1016/0006-2952(87)90547-8; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IWATA Y, 1993, BIOCHEM BIOPH RES CO, V190, P589, DOI 10.1006/bbrc.1993.1089; Jasmin G, 1979, Ann N Y Acad Sci, V317, P46, DOI 10.1111/j.1749-6632.1979.tb56509.x; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; KAWAGUCHI H, 1991, CIRC RES, V69, P1015, DOI 10.1161/01.RES.69.4.1015; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PALMUCCI L, 1992, J NEUROL SCI, V111, P218, DOI 10.1016/0022-510X(92)90073-T; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; SEN LY, 1990, CIRC RES, V67, P1182, DOI 10.1161/01.RES.67.5.1182; SHARP AH, 1989, J BIOL CHEM, V264, P2816; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330	38	131	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11496	11499						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505286				2022-12-27	WOS:A1993LF28400007
J	THOIDIS, G; KOTLIAR, N; PILCH, PF				THOIDIS, G; KOTLIAR, N; PILCH, PF			IMMUNOLOGICAL ANALYSIS OF GLUT4-ENRICHED VESICLES - IDENTIFICATION OF NOVEL PROTEINS REGULATED BY INSULIN AND DIABETES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; RECEPTOR-MEDIATED ENDOCYTOSIS; VESICULAR TRANSPORT; BINDING PROTEINS; PLASMA-MEMBRANE; RAT ADIPOCYTES; FUSION PROTEIN; MESSENGER-RNA; ADIPOSE-CELLS; TRANSLOCATION	In adipocytes and muscle, insulin stimulates the translocation of glucose transporter proteins from an intracellular vesicle pool to the plasma membrane. To study the molecular basis of this process, we used the anti-GLUT4 antibody 1F8 to isolate intracellular vesicles from rat adipocytes that are enriched in the muscle/fat glucose transporter isoform. These vesicles were then used as immunogens to generate monoclonal antibodies against their protein components. We isolated an antibody, 3F8, that recognizes three polypeptides, designated GTV3, migrating in the 36-40-kDa range as analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting. These proteins are enriched in GLUT4-containing vesicles, and the two smallest of the polypeptides recognized by 3F8 translocate to the cell surface in response to insulin. GTV3 proteins are also present in plasma membranes of fat cells and liver as well as in a wide number of tissues, red blood cells being the only exception. In adipocytes from streptozotocin-induced diabetic rats, GTV3 protein levels decrease dramatically and return to normal levels when animals are treated with insulin. The localization of GTV3 in glucose transporter-containing vesicles as well as their wide tissue distribution suggests that these proteins may be involved in vesicle mediated transport and regulated trafficking between membrane compartments.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Pilch, Paul/0000-0003-1997-0499	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07035] Funding Source: Medline; NIDDK NIH HHS [R01 DK30425-11] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAND SH, 1991, J BIOL CHEM, V266, P18949; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; Fleischer S, 1974, Methods Enzymol, V31, P3; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Galfre G, 1981, Methods Enzymol, V73, P3; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1988, BIOCHEM J, V256, P725, DOI 10.1042/bj2560725; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; RODBELL M, 1964, J BIOL CHEM, V239, P375; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	43	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11691	11696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505298				2022-12-27	WOS:A1993LF28400037
J	AHMED, S; LEE, J; KOZMA, R; BEST, A; MONFRIES, C; LIM, L				AHMED, S; LEE, J; KOZMA, R; BEST, A; MONFRIES, C; LIM, L			A NOVEL FUNCTIONAL TARGET FOR TUMOR-PROMOTING PHORBOL ESTERS AND LYSOPHOSPHATIDIC ACID - THE P21RAC-GTPASE ACTIVATING PROTEIN N-CHIMAERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-C; BINDING; BRAIN; RECEPTOR; PRODUCT; ENCODES; DOMAIN; ZINC; GENE; BCR	Phorbol esters are potent tumor promoters widely used for investigating mechanisms of cell transformation with protein kinase C (PKC) generally considered as being their only protein target. Lysophosphatidic acid (LPA) can act as a mitogen, affecting cell shape and the actin cytoskeleton. There is no identified functional target for LPA. We have isolated a cDNA encoding a protein n-chimaerin that is a high affinity phorbol ester receptor and a p21rac-GTPase activating protein (rac-GAP). p21rac is a member of the ras superfamily of small molecular weight GTP-binding proteins, which stimulates actin microfilament formation in Swiss 3T3 cells and superoxide production by the neutrophil oxidase. We now show that the rac-GAP activity of n-chimaerin is stimulated by phosphatidylserine (PS) and phosphatidic acid (PA) and that phorbol esters can synergize with PS and PA. LPA, in contrast, was found to inhibit n-chimaerin. The phospholipid/phorbol ester modulation of the rac-GAP activity requires the PKC-like cysteine-rich domain of n-chimaerin. Thus, n-chimaerin is a novel functional target (distinct from PKC) for both phorbol esters and LPA. These data suggest that the physiological role of n-chimaerin is to link events initiating at the cell surface/membrane with p21rac effector pathways.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	AHMED, S (corresponding author), INST NEUROL,DEPT NEUROCHEM,1 WAKEFIELD ST,LONDON WC1N 1PJ,ENGLAND.		Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768				AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ANDO S, 1992, J BIOL CHEM, V267, P25709; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Diamond L, 1980, Adv Cancer Res, V32, P1, DOI 10.1016/S0065-230X(08)60360-7; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; NAKANISHI N, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1992, CELL, V70, P411; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TIGYI G, 1992, J BIOL CHEM, V267, P21360; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND R, 1992, EMBO J, V7, P2495; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	34	173	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10709	10712						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496137				2022-12-27	WOS:A1993LD46600003
J	LI, CW; MOORE, DS; ROSENBERG, RC				LI, CW; MOORE, DS; ROSENBERG, RC			CIRCULAR-DICHROISM STUDIES OF DIETHYL PYROCARBONATE-MODIFIED HISTIDINE IN HEN EGG-WHITE LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; CHEMICAL MODIFICATION; ETHOXYFORMIC ANHYDRIDE; RESIDUES; DIETHYLPYROCARBONATE; PROTEINS; SITE; INACTIVATION; BINDING; ENZYME	The single histidine residue (His- 15) in hen egg white lysozyme (EC 3.2.1.17) was chemically modified by diethyl pyrocarbonate (DEPC) to form exclusively the mono-N-carbethoxyimidazole adduct (second order rate constant of 252 +/- 16 M-1 min-1). Irreversible biscarbethoxylation of the His-15 imidazole ring by DEPC was observed when lysozyme was pretreated with 2-mercaptoethanol (2-ME), 2-ME plus 8 M urea, or 2-ME plus 1% (w/v) sodium dodecyl sulfate (SDS). Circular dichroism difference spectra were measured for the mono-N-carbethoxyimidazole derivatives of lysozyme, N(alpha)-acetyl-L-histidine, angiotensin-II, and O-carbethoxy-N(alpha)-acetyl-L-tyrosine. The circular dichroism difference spectrum for mono-N-carbethoxy lysozyme had one main band (DELTA[theta]244 nm = +17,000 degree.cm2.dmol-1) in the 240-260 nm region. Denaturing mono-N-carbethoxy lysozyme with 2-ME and 8 M urea (55-degrees-C) or 1% SDS (100-degrees-C) essentially abolished its circular dichroism difference spectrum in the 240-260 nm region without any decarbethoxylation. In this same region the circular dichroism difference spectra of DEPC-modified N(alpha)-acetyl-L-histidine and DEPC-modified angiotensin-II had two much weaker bands (DELTA[theta]233 nm = +1000 degree.cm2.dmol-1 and DELTA[theta]252 nm = -600 degree.cm2.dmol-1 for N(alpha)-acetyl-L-histidine). This study reports the first characterization of circular dichroism associated with mono-N-carbethoxyhistidine in an enzyme (lysozyme), a peptide (angiotensin-II), and a model compound (N(alpha)-acetyl-L-histidine).	HOWARD UNIV,DEPT CHEM,WASHINGTON,DC 20059	Howard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008016] Funding Source: NIH RePORTER; NIGMS NIH HHS [S06GM08016] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULWAJID AW, 1986, BIOCHEMISTRY-US, V25, P8167, DOI 10.1021/bi00373a007; ANDERSEN TT, 1979, J BIOL CHEM, V254, P995; BANYARD SH, 1974, LYSOZYME, P71; BATEMAN RC, 1987, BIOCHEMISTRY-US, V26, P4237, DOI 10.1021/bi00388a009; BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CARRILLO N, 1983, BIOCHEMISTRY-US, V22, P5889, DOI 10.1021/bi00294a031; CHENG KC, 1989, J BIOL CHEM, V264, P19666; DARON HH, 1982, BIOCHEMISTRY-US, V21, P737, DOI 10.1021/bi00533a024; DICKERSON RE, 1969, STRUCTURE ACTION PRO, P69; FAVOROVA OO, 1978, EUR J BIOCHEM, V86, P193, DOI 10.1111/j.1432-1033.1978.tb12299.x; GEORGE AL, 1979, BIOCHIM BIOPHYS ACTA, V569, P63, DOI 10.1016/0005-2744(79)90081-0; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; GREENFIELD NJ, 1974, BIOCHEMISTRY-US, V13, P4494, DOI 10.1021/bi00719a004; HEGIY G, 1974, EUR J BIOCHEM, V44, P7; HERMANN J, 1971, EUR J BIOCHEM, V24, P12, DOI 10.1111/j.1432-1033.1971.tb19650.x; IGLESIAS AA, 1983, BIOCHIM BIOPHYS ACTA, V749, P9, DOI 10.1016/0167-4838(83)90144-9; JAWALI N, 1987, PHYTOCHEMISTRY, V26, P1859, DOI 10.1016/S0031-9422(00)81716-1; JOLLES J, 1983, FEBS LETT, V162, P120, DOI 10.1016/0014-5793(83)81061-8; KITA Y, 1982, J BIOCHEM-TOKYO, V92, P1499, DOI 10.1093/oxfordjournals.jbchem.a134074; KRAVCHENKO NA, 1964, BIOCHIM BIOPHYS ACTA, V92, P412, DOI 10.1016/0926-6569(64)90205-6; LAMBIRIS SK, 1981, BIOCHIM BIOPHYS ACTA, V660, P271, DOI 10.1016/0005-2744(81)90170-4; LOCQUET JP, 1968, BIOCHIM BIOPHYS ACTA, V167, P150, DOI 10.1016/0005-2744(68)90284-2; LOOSEMORE MJ, 1976, FEBS LETT, V72, P155, DOI 10.1016/0014-5793(76)80834-4; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MORRIS DL, 1972, EUR J BIOCHEM, V29, P515, DOI 10.1111/j.1432-1033.1972.tb02016.x; NAKANISHI Y, 1984, AGR BIOL CHEM TOKYO, V48, P2951, DOI 10.1080/00021369.1984.10866627; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSTERMANGOLKAR S, 1974, ACTA CHEM SCAND B, VB 28, P215, DOI 10.3891/acta.chem.scand.28b-0215; PELTON PD, 1992, J BIOL CHEM, V267, P5916; Phillips C, 1974, LYSOZYME, P9; PISZKIEWICZ D, 1968, BIOCHEMISTRY-US, V7, P3037, DOI 10.1021/bi00849a003; ROOSEMONT JL, 1978, ANAL BIOCHEM, V88, P314, DOI 10.1016/0003-2697(78)90424-4; SAMS CF, 1984, BIOCHIM BIOPHYS ACTA, P61; SCHMIDT PG, 1984, BIOCHEMISTRY-US, V23, P4261, DOI 10.1021/bi00313a038; TAKEDA K, 1989, J PROTEIN CHEM, V8, P487, DOI 10.1007/BF01026433; VINCENT JP, 1975, BIOCHEMISTRY-US, V14, P2521, DOI 10.1021/bi00682a035; WALLIS RB, 1973, BIOCHEM J, V133, P183, DOI 10.1042/bj1330183; WIEN RW, 1972, BIOCHEMISTRY-US, V11, P3707, DOI 10.1021/bi00770a008; WIJNANDS RA, 1982, BIOCHEMISTRY-US, V21, P6639, DOI 10.1021/bi00269a005; WILLIAMS AL, 1983, BIOPOLYMERS, V22, P755, DOI 10.1002/bip.360220214; YAMASAKI N, 1968, AGR BIOL CHEM TOKYO, V32, P55, DOI 10.1080/00021369.1968.10859011; ZHANG XH, 1992, BIOCHEMISTRY-US, V31, P2528, DOI 10.1021/bi00124a013	45	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11090	11096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496171				2022-12-27	WOS:A1993LD46600057
J	BAUMANN, H; MORELLA, KK; CAMPOS, SP				BAUMANN, H; MORELLA, KK; CAMPOS, SP			INTERLEUKIN-6 SIGNAL COMMUNICATION TO THE ALPHA-1-ACID GLYCOPROTEIN GENE, BUT NOT JUNB GENE, IS IMPAIRED IN HTC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-PROTEIN GENES; GLUCOCORTICOID-RESPONSE ELEMENTS; HEPATOCYTE-STIMULATING FACTORS; RAT-LIVER; REGULATED EXPRESSION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; CYTOKINE-RESPONSE; NUCLEAR FACTOR; C/EBP FAMILY	In the rat hepatoma (HTC) cell line, transcription of the alpha1-acid glycoprotein (AGP) gene is prominently stimulated by dexamethasone. Although interleukin (IL)-1 and IL-6 synergistically enhance expression of the AGP gene in liver, they have no detectable effect on this gene in HTC cells. Nevertheless, HTC cells have mRNA encoding the IL-6 receptor subunits and respond to IL-6 by increasing expression of the junB gene. The mRNA for the 80-kDa IL-6 receptors is increased severalfold following dexamethasone treatment. Even with elevated IL-6 receptor expression, no IL-6 regulation of the AGP gene is observed. The lack of response to IL-6 is also found with the transfected AGP gene sequence, suggesting the absence of specific trans-acting factors. Since IL-6 promotes only a minimal stimulation of the CCAAT/enhancer-binding protein beta, HTC cells lack the indirect IL-6 signaling pathway to acute phase plasma protein genes that has been found to be crucial in other hepatoma cell lines. Considering that a similar IL-6 regulation of the junB gene is manifested in HTC cells and normal liver, a separate IL-6 signal-transducing pathway controlling the AGP gene is assumed to be missing in HTC cells.	SUNY Buffalo, DEPT PEDIAT, BUFFALO, NY 14260 USA; CHILDRENS HOSP BUFFALO, DIV ENDOCRINOL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	BAUMANN, H (corresponding author), ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, ELM & CARLTON ST, BUFFALO, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1990, J BIOL CHEM, V265, P19420; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BAUMANN H, 1989, GENETICS BIOCH PHYSL, P99; BAUMANN H, 1993, IN PRESS ACUTE PHASE; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DILORENZO D, 1991, BIOCHEM BIOPH RES CO, V176, P1326, DOI 10.1016/0006-291X(91)90431-6; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; KISHIMOTO T, 1992, CIBA F SYMP, V167, P5; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; SEIFERT SC, 1979, J CELL PHYSIOL, V99, P333, DOI 10.1002/jcp.1040990308; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WON KA, 1991, MOL CELL BIOL, V11, P3001, DOI 10.1128/MCB.11.6.3001	43	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10495	10500						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486702				2022-12-27	WOS:A1993LB80000075
J	WASLEY, LC; REHEMTULLA, A; BRISTOL, JA; KAUFMAN, RJ				WASLEY, LC; REHEMTULLA, A; BRISTOL, JA; KAUFMAN, RJ			PACE FURIN CAN PROCESS THE VITAMIN-K-DEPENDENT PRO-FACTOR-IX PRECURSOR WITHIN THE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; MOLECULAR-BASIS; EXPRESSION; PROPEPTIDE; MUTATION; ENZYME; INITIATION; PROALBUMIN; GLUTAMINE; SEQUENCES	Factor IX is synthesized as a precursor polypeptide which requires proteolytic cleavage of the propeptide for functional activity. Expression of factor IX at high levels in Chinese hamster ovary (CHO) cells results in the secretion of a mixture of profactor IX and mature factor IX. We have studied whether the processing of profactor IX may be mediated by the recently discovered subtilisin-like serine proteases PACE/furin and/or PACE4. Co-transfection of a PACE expression vector with a profactor IX expression vector resulted in the secretion of fully processed factor IX. In contrast, co-transfection of a PACE4 expression vector with a profactor IX expression vector did not increase processing of profactor IX to the mature form. A factor IX Arg-to-Thr mutation at the P1 position (residue 39) destroyed the ability for PACE to process profactor IX. Amino-terminal sequence analysis demonstrated that processing mediated by PACE occurred at the authentic site within profactor IX. The specificity of profactor IX processing by PACE was also evaluated by transfection of a vector encoding the serine protease inhibitor alpha1-antitrypsin. Expression of wild-type alpha1-antitrypsin, which does not inhibit PACE, did not influence processing of profactor IX mediated by co-expression of PACE. In contrast, the alpha1-antitrypsin Pittsburgh mutant, which inhibits PACE, inhibited profactor IX processing activity mediated by transfected PACE as well as the endogenous CHO cell propeptide processing enzyme. Pulse-chase labeling indicated that PACE processed profactor IX late within the secretory pathway, although a secreted soluble mutant PACE was also capable of processing profactor IX in the conditioned medium. The results implicate PACE as a candidate for the enzyme that processes profactor IX in vivo.	GENET INST,CAMBRIDGE,MA 02140; NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University					NHLBI NIH HHS [HL 42433] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1984, BIOCHIM BIOPHYS ACTA, V802, P24, DOI 10.1016/0304-4165(84)90029-1; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRISTOL JA, 1991, BLOOD, V78, pA224; CHASIN LA, 1980, P NATL ACAD SCI USA, V77, P4216; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Davies Monique V., 1992, Current Opinion in Biotechnology, V3, P512, DOI 10.1016/0958-1669(92)90079-X; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FURIE B, 1990, BLOOD, V75, P1753; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; MCCLURE DB, 1992, J BIOL CHEM, V267, P19710; MISUMI Y, 1990, BIOCHEM BIOPH RES CO, V171, P236, DOI 10.1016/0006-291X(90)91382-3; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1992, BLOOD, V79, P2349; REHEMTULLA A, 1993, IN PRESS P NATL ACAD; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; STANTON C, 1992, BIOCHEM J, V284, P25, DOI 10.1042/bj2840025; STANTON C, 1991, BIOCHEM J, V277, P59, DOI 10.1042/bj2770059; SUGIMOTO M, 1989, BRIT J HAEMATOL, V72, P216, DOI 10.1111/j.1365-2141.1989.tb07685.x; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VIDAUD D, 1992, J CLIN INVEST, V89, P1537, DOI 10.1172/JCI115746; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	39	109	145	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8458	8465						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473289				2022-12-27	WOS:A1993KX81100016
J	WOOLFORD, CA; NOBLE, JA; GARMAN, JD; TAM, MF; INNIS, MA; JONES, EW				WOOLFORD, CA; NOBLE, JA; GARMAN, JD; TAM, MF; INNIS, MA; JONES, EW			PHENOTYPIC ANALYSIS OF PROTEINASE-A MUTANTS - IMPLICATIONS FOR AUTOACTIVATION AND THE MATURATION PATHWAY OF THE VACUOLAR HYDROLASES OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-Y; PEP4 GENE; ALKALINE-PHOSPHATASE; INVIVO BIOSYNTHESIS; ONE-STEP; YEAST; INHIBITORS; ACTIVATION; DNA; AMINOPEPTIDASE	We have isolated a number of mutants deficient in activity of the vacuolar hydrolase proteinase A (PrA). The mutations were sequenced and although they all map in the PEP4 gene, which encodes the precursor to PrA, three distinguishable phenotypes have surfaced. The properties of the pep4-7 missense mutant suggested that the activation of the precursor to proteinase A is due to an autocatalytic cleavage. PrA active site mutations were constructed and resulted in accumulation of PrA antigen in the inactive precursor form. Although protease B (PrB), another vacuolar hydrolase, is not required for the production of active PrA, the active form of PrA that accumulates in a strain lacking PrB is larger than that found in a strain containing active PrB. We have purified this larger form of PrA and determined that it bears 7 additional amino acids at its NH2 terminus. It has become apparent from all the studies performed on the maturation pathway of the vacuolar hydrolases that there is a great deal of redundancy built into the system.	CHIRON CORP, EMERYVILLE, CA 94608 USA; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Novartis; Academia Sinica - Taiwan	WOOLFORD, CA (corresponding author), CARNEGIE MELLON UNIV, DEPT BIOL SCI, 4400 5TH AVE, PITTSBURGH, PA 15213 USA.			Woolford, Carol/0000-0001-6261-3468	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018090, R37DK018090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029713] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18090] Funding Source: Medline; NIGMS NIH HHS [GM29713] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1982, BIOCHEM BIOPH RES CO, V109, P341, DOI 10.1016/0006-291X(82)91726-0; Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; AIBARA S, 1971, AGR BIOL CHEM TOKYO, V35, P658, DOI 10.1080/00021369.1971.10859972; ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BECK I, 1980, J BIOL CHEM, V255, P4821; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CABIB E, 1975, J BACTERIOL, V124, P1604, DOI 10.1128/JB.124.3.1604-1606.1975; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; Cryer D R, 1975, Methods Cell Biol, V12, P39; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DREYER T, 1989, CARLSBERG RES COMMUN, V54, P85, DOI 10.1007/BF02908301; DREYER T, 1986, CARLSBERG RES COMMUN, V51, P27, DOI 10.1007/BF02907993; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; HARRIS SD, 1987, CURR MICROBIOL, V15, P247, DOI 10.1007/BF01589375; HASILIK A, 1976, BIOCHEM BIOPH RES CO, V72, P1430, DOI 10.1016/S0006-291X(76)80173-8; HAWTHORNE DC, 1960, GENETICS, V45, P1085; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P867, DOI 10.1111/j.1432-1033.1992.tb17118.x; HOLZER H, 1976, Tokai Journal of Experimental and Clinical Medicine, V1, P115; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; JONES EW, 1982, GENETICS, V102, P665; JONES EW, 1977, GENETICS, V85, P23; JONES EW, 1989, UCLA S CELLULAR PROT, P141; JONES EW, 1981, A BENZON S, V16, P182; KAGEYAMA T, 1987, EUR J BIOCHEM, V165, P483, DOI 10.1111/j.1432-1033.1987.tb11464.x; KAGEYAMA T, 1982, BIOCHEM BIOPH RES CO, V107, P1117, DOI 10.1016/0006-291X(82)90637-4; KANEKO Y, 1987, GENE, V58, P137; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNEY JF, 1974, BIOCHEM BIOPH RES CO, V60, P1378, DOI 10.1016/0006-291X(74)90350-7; Maniatis T., 1982, MOL CLONING; MATERN H, 1974, BIOCHEM BIOPH RES CO, V60, P1051, DOI 10.1016/0006-291X(74)90419-7; MECHLER B, 1982, BIOCHEM BIOPH RES CO, V107, P770, DOI 10.1016/0006-291X(82)90590-3; MECHLER B, 1982, J BIOL CHEM, V257, P1203; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MOEHLE CM, 1989, J CELL BIOL, V108, P309, DOI 10.1083/jcb.108.2.309; NEBES VL, 1991, J BIOL CHEM, V266, P22851; RENDUELES MPS, 1981, FEBS LETT, V131, P296; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; RUPP S, 1991, FEBS LETT, V293, P62, DOI 10.1016/0014-5793(91)81153-Y; SAHEKI T, 1975, BIOCHIM BIOPHYS ACTA, V384, P203, DOI 10.1016/0005-2744(75)90109-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STILES JI, 1983, METHOD ENZYMOL, V101, P290; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; TURK V, 1985, ASPARTIC PROTEINASES, P283; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; WILCHEK M, 1971, BIOCHEMISTRY-US, V10, P2828; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WOOLFORD CA, 1990, GENETICS, V125, P739; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUBENKO GS, 1979, P NATL ACAD SCI USA, V76, P2395, DOI 10.1073/pnas.76.5.2395; ZUBENKO GS, 1982, GENETICS, V102, P679; ZUBENKO GS, 1981, GENETICS, V97, P45; ZUBENKO GS, 1983, P NATL ACAD SCI-BIOL, V80, P510, DOI 10.1073/pnas.80.2.510	66	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8990	8998						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473342				2022-12-27	WOS:A1993KX81100088
J	AKIYAMA, Y; ITO, K				AKIYAMA, Y; ITO, K			FOLDING AND ASSEMBLY OF BACTERIAL ALKALINE-PHOSPHATASE INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN EXPORT; MEMBRANE-PROTEINS; DISULFIDE BOND; SECY	Alkaline phosphatase (PhoA), localized in the periplasmic space of Escherichia coli, is a homodimeric metalloprotein containing two intramolecular disulfide bonds. We attempted to clarify the folding-assembly pathways of this enzyme by allowing in vitro-synthesized PhoA polypeptide to fold into active enzyme and by examining the occurrence of similar pathways in vivo by pulse-chase experiments. PhoA (lacking the signal sequence) that was synthesized in a coupled transcription-translation system was effectively converted into active enzyme when incubated with either oxidized glutathione, periplasmic proteins, or purified DsbA protein in the presence of Zn2+. The first appreciable event in the activation of initially unfolded translation product (species I) was the disulfide bond formation, which was immediately followed by folding into a partially trypsin-resistant monomer (species II), and then by assembly into active dimer (species III). The species II PhoA molecules, but not the species III molecules, were found to be sensitized to trypsin in the presence of a reducing agent, dithiothreitol. Pulse-chase studies showed that PhoA acquires disulfide bonds immediately after the biosynthesis, whereas it acquires resistance to both dithiothreitol and certain endogenous protease over some 2 min at 15-degrees-C. These results indicate that PhoA undergoes a series of folding-assembly steps, some of which are of measurable speeds in vivo and mimicable in vitro.			AKIYAMA, Y (corresponding author), KYOTO UNIV, INST VIRUS RES, DEPT CELL BIOL, KYOTO 60601, JAPAN.							AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; APPLEBURY ML, 1969, J BIOL CHEM, V244, P308; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Boyd D, 1987, PHOSPHATE METABOLISM, P89; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; FALK MC, 1982, BIOCHEMISTRY-US, V21, P1471, DOI 10.1021/bi00536a001; INOUYE H, 1977, J MOL BIOL, V110, P75, DOI 10.1016/S0022-2836(77)80099-5; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; NEU HC, 1965, J BIOL CHEM, V240, P3685; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P3552, DOI 10.1021/bi00863a029; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4284; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4293; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Wyckoff HW, 1987, PHOSPHATE METABOLISM, P118	28	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8146	8150						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463326				2022-12-27	WOS:A1993KW97900080
J	OSTMAN, A; ANDERSSON, M; BACKSTROM, G; HELDIN, CH				OSTMAN, A; ANDERSSON, M; BACKSTROM, G; HELDIN, CH			ASSIGNMENT OF INTRACHAIN DISULFIDE BONDS IN PLATELET-DERIVED GROWTH-FACTOR B-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; FACTOR PDGF; A-CHAIN; CYSTEINE RESIDUES; RECEPTORS; PROTEIN; CDNA; IDENTIFICATION; LOCALIZATION; RETENTION	Platelet-derived growth factor (PDGF)-BB is a dimeric protein held together by two disulfide bonds involving the 2nd and 4th cysteine residues from the NH2 terminus. To localize the three intrachain disulfide bonds in PDGF, a method was devised that made it possible to cleave PDGF at specific sites. A set of PDGF derivatives in which specific amino acids were mutated to methionine residues was generated. The recombinant proteins, immunoprecipitated from metabolically labeled transfected COS cells, were then subjected to CNBr cleavage and analyzed by SDS-gel electrophoresis under nonreducing conditions. Based on whether the mutated proteins remained in one piece or fell apart after CNBr cleavage, it was possible to deduce the disulfide bond arrangement in the PDGF B-chain; one bond involves the 1st and 6th cysteine residues, another the 3rd and 7th, and the last the 5th and 8th. The latter disulfide bond was found to be dispensable for receptor binding, whereas the former two were found to be essential for the correct folding or stability of the PDGF B-chain.	LUDWIG INST CANC RES, CTR BIOMED, BOX 595, S-75124 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research								ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; JAUMANN M, 1991, BIOCHEMISTRY-US, V30, P3303, DOI 10.1021/bi00227a019; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROBSON MC, 1992, LANCET, V339, P23, DOI 10.1016/0140-6736(92)90143-Q; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; THYBERG J, 1990, J CELL SCI, V97, P219; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	22	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13372	13377						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514775				2022-12-27	WOS:A1993LH55300053
J	SEISER, C; TEIXEIRA, S; KUHN, LC				SEISER, C; TEIXEIRA, S; KUHN, LC			INTERLEUKIN-2-DEPENDENT TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF TRANSFERRIN RECEPTOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; 3' UNTRANSLATED REGION; HUMAN LYMPHOCYTES-T; 4F2 HEAVY-CHAIN; CELL-PROLIFERATION; C-FOS; SEQUENTIAL EXPRESSION; GENE-EXPRESSION; BINDING-PROTEIN; DNA-SYNTHESIS	Interleukin-2 (IL-2) controls the proliferation of the murine T cell line B6.1 and induces transferrin receptor (TfR) mRNA steady-state levels 50-fold when added to arrested, IL-2-deprived cells. In addition, TfR mRNA is post-transcriptionally regulated by intracellular iron. Low iron levels activate a cytoplasmic RNA-binding protein, called iron regulatory factor (IRF) or iron-responsive element-binding protein, which coordinately stabilizes TfR mRNA and inhibits ferritin mRNA translation. Since ferritin expression is known to be modulated by cytokines, we decided to investigate the mechanism by which IL-2 activates TfR gene expression in B6.1 cells. Induction by IL-2 of both nuclear and cytoplasmic TfR RNA was compared with run-on transcription rates in isolated nuclei. The results revealed a 3-fold increase in TfR gene transcription and a 6-fold rise in nuclear TfR RNA reaching its steady-state level within 2 h. The main accumulation of mature mRNA in the cytoplasm occurred after 6 h in parallel with the activation of IRF. However, stimulation of IRF binding activity by the iron chelator desferrioxamine, in the absence of IL-2, failed to induce TfR mRNA. Moreover, deprivation of growing B6.1 cells of IL-2 resulted in cell arrest and a rapid decay of TfR mRNA, which was not prevented by the activation of IRF with desferrioxamine. TfR mRNA stabilization appears, therefore, to depend on IL-2. We conclude that TfR mRNA expression is controlled by at least three steps at the onset of cell proliferation: (i) the growth factor-dependent activation of transcription; (ii) mRNA stabilization by IRF in the cytoplasm; and (iii) an additional IL-2-dependent activity which prevents TfR mRNA degradation. Our results indicate that expression of TfR, like ferritin, is controlled by both iron and cytokines.	SWISS INST EXPTL CANC RES, 155 CHEMIN BOVERESSES, CH-1066 EPALINGES, SWITZERLAND	Swiss Institute Experimental Cancer Research			TEIXEIRA, SANTUZA MR/I-8137-2013	Seiser, Christian/0000-0002-7046-9352				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BEARD P, 1992, NUCLEIC ACIDS RES, V19, P7117; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; HOFBAUER R, 1991, EUKARYOTIC GENE EXPR, V1, P247; KEHRL JH, 1984, J IMMUNOL, V132, P2857; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUMAGAI N, 1988, J IMMUNOL, V140, P37; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LINDSTEN T, 1988, MOL CELL BIOL, V8, P3820, DOI 10.1128/MCB.8.9.3820; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCER WE, 1989, EXP CELL RES, V181, P531, DOI 10.1016/0014-4827(89)90109-2; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; NECKERS LM, 1986, MOL CELL BIOL, V6, P4244, DOI 10.1128/MCB.6.12.4244; NECKERS LM, 1984, J IMMUNOL, V133, P2437; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; PELOSI E, 1986, J BIOL CHEM, V261, P3036; PELOSITESTA E, 1988, IMMUNOLOGY, V64, P273; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SEKALY RP, 1982, J IMMUNOL, V129, P1407; SHIMUZU A, 1985, NUCLEIC ACIDS RES, V13, P1505, DOI 10.1093/nar/13.5.1505; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEARNE PA, 1985, J IMMUNOL, V134, P3474; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1991, J BIOL CHEM, V266, P13925; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; VONBOEHMER H, 1979, EUR J IMMUNOL, V9, P592, DOI 10.1002/eji.1830090804; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	60	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13074	13080						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514748				2022-12-27	WOS:A1993LH55300013
J	GARDNER, PR; FRIDOVICH, I				GARDNER, PR; FRIDOVICH, I			NADPH INHIBITS TRANSCRIPTION OF THE ESCHERICHIA-COLI MANGANESE SUPEROXIDE-DISMUTASE GENE (SODA) INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC UPTAKE REGULATION; PROTEIN-SYNTHESIS; ANAEROBIC BIOSYNTHESIS; REDUCTIVE ACTIVATION; INDUCTION; OXYGEN; REDOX; THIOREDOXIN; SYSTEMS; GLUCOSE-6-PHOSPHATE	We have previously reported that the thiols glutathione, dithiothreitol, and beta-mercaptoethanol suppress transcription of the Escherichia coli manganese-containing superoxide dismutase gene (sodA) in an in vitro coupled transcription plus translation system (Gardner, P. R., and Fridovich, I. (1987) J. Biol. Chem. 262, 17591-17595). We now report that NADPH, but not NADH, selectively decreases transcription of sodA in vitro and that an NADPH generating system utilizing glucose 6-phosphate and the corresponding dehydrogenase markedly augments this suppressive effect. A redox buffer containing various ratios of oxidized and reduced glutathione also modulated transcription of sodA thus demonstrating the existence of a redox-sensitive mechanism controlling sodA transcription. Fusion of a 120-base pair fragment, containing 90 base pairs of DNA upstream of the sodA transcription initiation site, to a promoterless galactokinase gene (galK) conferred redox-sensitivity to GalK synthesis. We propose that these redox effects act through a redox-sensitive regulator of sodA and that the anabolic reduction charge, [NADPH]/([NADPH] + [NADP+]), is one cellular signal controlling sodA transcription.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University				Gardner, Paul/0000-0001-8189-0903				AKKARAJU GR, 1991, J BIOL CHEM, V266, P24451; ALONSOMORAGA A, 1987, MOL CELL BIOCHEM, V73, P61; AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; ANDERSEN KB, 1977, J BIOL CHEM, V252, P4151; BANERJEE S, 1972, J BACTERIOL, V110, P155, DOI 10.1128/JB.110.1.155-160.1972; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; ERNST V, 1978, J BIOL CHEM, V253, P7163; GARDNER PR, 1987, J BIOL CHEM, V262, P17591; GARDNER PR, 1988, OXY RADICALS MOL BIO, P163; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; GREGORY EM, 1973, J BACTERIOL, V114, P543, DOI 10.1128/JB.114.2.543-548.1973; HASSAN HM, 1987, J BIOL CHEM, V262, P17173; HASSAN HM, 1992, P NATL ACAD SCI USA, V89, P3217, DOI 10.1073/pnas.89.8.3217; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; HASSAN HM, 1977, J BACTERIOL, V132, P505, DOI 10.1128/JB.132.2.505-510.1977; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HSIE AW, 1969, J BACTERIOL, V98, P1407, DOI 10.1128/JB.98.3.1407-1408.1969; HUNT T, 1983, EUR J BIOCHEM, V131, P303, DOI 10.1111/j.1432-1033.1983.tb07263.x; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P289, DOI 10.1111/j.1432-1033.1983.tb07262.x; JACKSON RJ, 1983, EUR J BIOCHEM, V131, P313, DOI 10.1111/j.1432-1033.1983.tb07264.x; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LUNDQUIST R, 1971, J BIOL CHEM, V246, P1107; Maniatis T., 1982, MOL CLONING; MARCUS F, 1988, P NATL ACAD SCI USA, V85, P5379, DOI 10.1073/pnas.85.15.5379; McKenney K, 1981, Gene Amplif Anal, V2, P383; MICHELSON AM, 1984, J BIOL CHEM, V259, P8529; MIYAKE K, 1988, J GEN APPL MICROBIOL, V34, P105, DOI 10.2323/jgam.34.105; MIYAKE K, 1986, J GEN APPL MICROBIOL, V32, P527, DOI 10.2323/jgam.32.527; MOODY CS, 1984, J BIOL CHEM, V259, P2821; NETTLETON CJ, 1984, P NATL ACAD SCI-BIOL, V81, P4970, DOI 10.1073/pnas.81.15.4970; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; PUGH SYR, 1985, J BACTERIOL, V162, P196, DOI 10.1128/JB.162.1.196-202.1985; ROWLEY DL, 1992, J BACTERIOL, V174, P623, DOI 10.1128/jb.174.2.623-626.1992; SAPORITO SM, 1988, J BACTERIOL, V170, P5141, DOI 10.1128/jb.170.11.5141-5145.1988; SCHIAVONE JR, 1988, J BIOL CHEM, V263, P4269; SHARROCKS AD, 1991, P ROY SOC B-BIOL SCI, V245, P219, DOI 10.1098/rspb.1991.0113; SMITH MW, 1983, J BACTERIOL, V154, P344, DOI 10.1128/JB.154.1.344-350.1983; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; TAKEDA Y, 1986, NUCLEIC ACIDS RES, V14, P4577, DOI 10.1093/nar/14.11.4577; TARDAT B, 1991, MOL MICROBIOL, V5, P455, DOI 10.1111/j.1365-2958.1991.tb02129.x; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; TOUATI D, 1983, J BACTERIOL, V155, P1078, DOI 10.1128/JB.155.3.1078-1087.1983; TSAVENA IR, 1990, J BACTERIOL, V172, P4197; UNDEN G, 1990, MOL MICROBIOL, V4, P315, DOI 10.1111/j.1365-2958.1990.tb00598.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	56	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12958	12963						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509428				2022-12-27	WOS:A1993LG65800105
J	MARCHOT, P; KHELIF, A; JI, YH; MANSUELLE, P; BOUGIS, PE				MARCHOT, P; KHELIF, A; JI, YH; MANSUELLE, P; BOUGIS, PE			BINDING OF I-125 FASCICULIN TO RAT-BRAIN ACETYLCHOLINESTERASE - THE COMPLEX STILL BINDS DIISOPROPYL FLUOROPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAJA-NIGRICOLLIS <H-3>ALPHA-TOXIN; DENDROASPIS-ANGUSTICEPS VENOM; TRITIATED ALPHA-NEUROTOXIN; TORPEDO ELECTRIC ORGANS; AMINO-ACID-SEQUENCE; SNAKE-VENOM; PERIPHERAL-SITE; MOLECULAR-FORMS; MEMBRANE FRAGMENTS; MAMBA VENOMS	Iodination of fasciculin 3 (FAS3) from Dendroaspis viridis venom provided us with a fully active specific probe of fasciculin binding sites on rat brain acetylcholinesterase (AChE). Binding and inhibition are concomitant, as association and inhibition rate constants k1 and k(i) are identical. The I-125-FAS3.AChE complex dissociates very slowly (t1/2 = 48 h) and is characterized by a dissociation constant, K(d), of 0.4 pM. All the specific binding of I-125-FAS3 to AChE is prevented by FAS3 as well as by the two other fasciculins, FAS1 and FAS2, from D. angusticeps venom (K(d) = 0.4, 14, and 25 pM, respectively). It is also prevented by propidium iodide, BW284C51, and d-tubocurarine, which bind to peripheral anionic sites of AChE, by Ca2+ and Mg2+, known to enhance AChE activity through an allosteric phenomenon and by acetylthiocholine concentrations which lead to excess substrate inhibition of the enzyme. Diisopropyl fluorophosphate and paraoxon, which inhibit AChE by phosphorylating the catalytic serine, have no effect on either the binding rate or the number of binding sites of I-125-FAS3. O-Ethyl-S2-diisopropylaminoethyl methylphosphonothionate, however, which binds irreversibly to the AChE catalytic site but reversibly to a peripheral site, induces a 130% increase in the binding rate of I-125-FAS3, without changing the total number of I-125-FAS3 binding sites. Our results demonstrate that fasciculins bind on a peripheral site of AChE, distinct from the catalytic site and, at least partly, common with the sites on which some cationic inhibitors and the substrate in excess bind. Since phosphorylation of the catalytic serine (esteratic subsite) by [1,3-H-3]diisopropyl fluorophosphate can still occur on the FAS3.AChE complex, the structural modification induced by fasciculins may affect the anionic subsite of AChE catalytic site.			MARCHOT, P (corresponding author), UNIV AIX MARSEILLE 2,FAC MED,SECT NORD,BIOCHIM LAB,CNRS,URA 1455,BD PIERRE DRAMARD,F-13916 MARSEILLE 20,FRANCE.		MARCHOT, Pascale/AAC-4752-2022; BOUGIS, Pierre E/I-2111-2013	MARCHOT, Pascale/0000-0003-0630-0541; mansuelle, pascal/0000-0002-4504-6809				ALDRIDGE WN, 1969, BIOCHEM J, V115, P147, DOI 10.1042/bj1150147; ANDERSON AJ, 1985, NEUROSCI LETT, V54, P123, DOI 10.1016/S0304-3940(85)80066-5; Augustinsson K-B, 1963, HDB EXPERIMENTELLEN, V15, P89; AUSTIN L, 1953, BIOCHEM J, V54, P695, DOI 10.1042/bj0540695; BECHIS G, 1976, EUR J BIOCHEM, V68, P445, DOI 10.1111/j.1432-1033.1976.tb10832.x; BECHIS G, 1984, BIOCHEM BIOPH RES CO, V122, P1146, DOI 10.1016/0006-291X(84)91211-7; BERMAN HA, 1978, BIOCHEMISTRY-US, V17, P1704, DOI 10.1021/bi00602a019; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BISSO GM, 1991, NEUROCHEM RES, V16, P571, DOI 10.1007/BF00974876; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P5; BOUGIS P, 1983, MOL CELL BIOCHEM, V55, P49, DOI 10.1007/BF00229242; BOUGIS PE, 1986, BIOCHEMISTRY-US, V25, P7235, DOI 10.1021/bi00370a070; Cervenansky C., 1991, P303; CERVENANSKY C, 1991, Toxicon, V29, P1163; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; COHEN JA, 1963, HDB EXPERIMENTELLEN, V15, P299; DUCANCEL F, 1991, SNAKE TOXINS, P395; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EPSTEIN DJ, 1979, BIOCHEMISTRY-US, V18, P4749, DOI 10.1021/bi00588a040; FAURE G, 1983, BIOCHEMISTRY-US, V22, P2068, DOI 10.1021/bi00278a006; FISHBEIN JC, 1980, ANAL BIOCHEM, V108, P193, DOI 10.1016/0003-2697(80)90712-5; FRIBOULET A, 1986, NEUROCHEM INT, V9, P323, DOI 10.1016/0197-0186(86)90069-0; FRIBOULET A, 1990, BIOCHEMISTRY-US, V29, P914, DOI 10.1021/bi00456a010; GATINEAU E, 1990, BIOCHEMISTRY-US, V29, P6480, DOI 10.1021/bi00479a021; GRAY EG, 1962, J ANAT, V96, P79; Gros E., 1967, METHOD ENZYMOL, V11, P238; HARVEY AL, 1984, J TOXICOL-TOXIN REV, V3, P91, DOI 10.3109/15569548409097923; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; JOUBERT FJ, 1978, S AFR J CHEM, V31, P107; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KOPEYAN C, 1975, EUR J BIOCHEM, V58, P117, DOI 10.1111/j.1432-1033.1975.tb02355.x; LEDU MH, 1989, J BIOL CHEM, V264, P21401; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LIN WW, 1987, ASIA PAC J PHARMACOL, V2, P79; LONG JP, 1963, CHOLINESTERASE ANTIC, V15, P374; MARCHOT P, 1988, EUR J BIOCHEM, V174, P537, DOI 10.1111/j.1432-1033.1988.tb14132.x; MARCHOT P, 1986, THESIS U AIX MARSEIL; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MOOSER G, 1974, BIOCHEMISTRY-US, V13, P2299, DOI 10.1021/bi00708a010; MURPHY SD, 1984, CELL MOL NEUROTOXICO, P165; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; PATTISON S, 1978, P NATL ACAD SCI USA, V75, P3613, DOI 10.1073/pnas.75.8.3613; PUU G, 1990, BIOCHEM PHARMACOL, V40, P2209, DOI 10.1016/0006-2952(90)90713-U; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RIEGER F, 1976, J NEUROCHEM, V27, P121, DOI 10.1111/j.1471-4159.1976.tb01553.x; ROBAIRE B, 1974, BIOCHEM PHARMACOL, V23, P2476, DOI 10.1016/0006-2952(74)90246-9; ROCHAT H, 1977, ANAL BIOCHEM, V82, P532, DOI 10.1016/0003-2697(77)90192-0; RODRIGUEZITHURRALDE D, 1983, NEUROCHEM INT, V5, P267, DOI 10.1016/0197-0186(83)90028-1; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SATO D, 1970, J BIOCHEM-TOKYO, V68, P867; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SINDHUPHAK R, 1988, J NEUROL SCI, V86, P195, DOI 10.1016/0022-510X(88)90098-6; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TOMLINSON G, 1980, MOL PHARMACOL, V18, P33; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; VILJOEN CC, 1973, J BIOL CHEM, V248, P4915; WEBER M, 1974, MOL PHARMACOL, V10, P15; WEBER M, 1974, MOL PHARMACOL, V10, P1; ZORKO M, 1986, BIOCHEM PHARMACOL, V35, P2287, DOI 10.1016/0006-2952(86)90453-3	65	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12458	12467						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509385				2022-12-27	WOS:A1993LG65800037
J	ROSENBERG, IM; IYER, R; CHERAYIL, B; CHIODINO, C; PILLAI, S				ROSENBERG, IM; IYER, R; CHERAYIL, B; CHIODINO, C; PILLAI, S			STRUCTURE OF THE MURINE MAC-2 GENE - SPLICE VARIANTS ENCODE PROTEINS LACKING FUNCTIONAL SIGNAL PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; MONOCLONAL-ANTIBODIES; ENDOGENOUS LECTINS; INITIATION; ANTIGEN; CELLS; SEQUENCE; PATHWAY; IGE; EXPRESSION	The murine Mac-2 gene is composed of six exons dispersed over 10.5 kilobases. Sl nuclease mapping showed multiple transcription initiation sites, clustered within a 30-base pair region. Sequence analysis revealed that a consensus initiator sequence is located in this area which lacks a TATA motif. The untranslated first exon contains an alternative splice donor site, confirming the existence of two cDNA species with the potential to encode proteins differing at their NH2 termini. In vitro expression and translocation experiments demonstrate that both of the alternatively spliced variants of Mac-2 encode proteins which lack a functional signal peptide. Subcellular fractionation studies indicate that most of the Mac-2 protein is present in the cytosol. These results support the view that Mac-2 is exported from the cell by an unusual mechanism which does not depend on the presence of a signal peptide.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET GRP,MOLEC IMMUNOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NIAID NIH HHS [AI-27835] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027835] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HO MK, 1982, J IMMUNOL, V128, P1221; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; IRIMURA T, 1991, CANCER RES, V51, P387; JIA SH, 1988, J BIOL CHEM, V263, P6009; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; Maniatis T., 1982, MOL CLONING; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; ODA Y, 1991, GENE, V99, P279; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; RAZ A, 1987, INT J CANCER, V39, P353, DOI 10.1002/ijc.2910390314; RAZ A, 1986, CANCER RES, V46, P3667; RAZ A, 1989, CANCER RES, V49, P3489; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WOO HJ, 1990, J BIOL CHEM, V265, P7097	34	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12393	12400						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509379				2022-12-27	WOS:A1993LG65800029
J	WILLIAMS, AM; ENNS, CA				WILLIAMS, AM; ENNS, CA			A REGION OF THE C-TERMINAL PORTION OF THE HUMAN TRANSFERRIN RECEPTOR CONTAINS AN ASPARAGINE-LINKED GLYCOSYLATION SITE CRITICAL FOR RECEPTOR STRUCTURE AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; SECRETION; PROTEIN; CELLS; IMMUNOGLOBULIN; BIOSYNTHESIS	The transferrin receptor is a cell surface protein and is responsible for the uptake of iron into many eukaryotic cells. In its mature form, the receptor possesses three asparagine-linked oligosaccharides. The effect of asparagine-linked glycosylation on the processing and cell surface localization of the human transferrin receptor is examined here by site-directed mutagenesis. Each of the extracellular consensus sequences (Asn-X-Ser/Thr) for asparagine-linked glycosylation was mutated individually and in all possible combinations. The constructs were transfected stably into NIH-3T3 cells and a Chinese hamster ovary cell line lacking endogenous transferrin receptors. Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor. Eliminating both of these sites together has a small effect on the behavior of the receptor. However, mutation of the C-terminal glycosylation site (Asn727) has the most profound negative effect on the appearance of the receptor at the cell surface. The mutants lacking glycosylation at Asn727 appear to be retained in the endoplasmic reticulum as an increased association with binding immunoglobulin protein (BiP) is observed. Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT L215,PORTLAND,OR 97201	Oregon Health & Science University					NIDDK NIH HHS [DK-40608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA J, 1990, J BIOL CHEM, V265, P13955; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ENNS CA, 1982, P NATL ACAD SCI-BIOL, V79, P3241, DOI 10.1073/pnas.79.10.3241; ENNS CA, 1981, P NATL ACAD SCI-BIOL, V78, P4222, DOI 10.1073/pnas.78.7.4222; HOE MH, 1992, J BIOL CHEM, V267, P4916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Maniatis T., 1982, MOL CLONING; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RECKHOW CL, 1988, J BIOL CHEM, V263, P7297; RUTLEDGE EA, 1991, J BIOL CHEM, V266, P21125; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; TROWBRIDGE IS, 1984, BIOCHEM PHARMACOL, V33, P925, DOI 10.1016/0006-2952(84)90447-7; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648	19	37	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12780	12786						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509412				2022-12-27	WOS:A1993LG65800082
J	FANG, WH; MODRICH, P				FANG, WH; MODRICH, P			HUMAN STRAND-SPECIFIC MISMATCH REPAIR OCCURS BY A BIDIRECTIONAL MECHANISM SIMILAR TO THAT OF THE BACTERIAL REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; DNA; EXTRACTS; CELLS; REPLICATION; PROTEIN; SYSTEM; ORIGIN	Nuclear extracts prepared from a HeLa cell line have been previously shown to support strand-specific repair of heteroduplex DNAs containing a site-specific, strand-specific incision (Holmes, J. J., Clark, S., and Modrich, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5837-5841; Thomas, D. C., Roberts, J. D., and Kunkel, T. A. (1991) J. Biol. Chem. 266, 3744-3751). Further analysis of the substrate specificity of the reaction has shown that in addition to G-T, A-C, G-G, and C-C, nuclear extracts also recognize and correct in a strand-specific manner A-A, A-G, T-T, and C-T mismatches, with repair in each case being inhibited by aphidicolin. The rate of repair of a circular G-T heteroduplex was found to decrease monotonically with increasing separation between the mismatch and the strand break that targets repair, as viewed along the shorter path joining the two sites in the circular substrate. This decrease is independent of the polarity of the incised strand, suggesting that the human pathway of mismatch correction may possess a bidirectional excision capability similar to that of the Escherichia coli methyl-directed system. This possibility was confirmed by analysis of excision tracts associated with the reaction. Inhibition of DNA synthesis by aphidicolin or by omission of exogenous dNTPs leads to the mismatch-provoked formation of a single-strand gap that spans the shorter path between the strand break and the mismatch, irrespective of the polarity of the incised strand. Formation of these gaps, which extend from the site of the strand break to terminate at a number of discrete sites in the region 90 to 170 nucleotides beyond the mismatch, is therefore independent of the relative orientation of the two sites. Based on similar mismatch specificities and common features of mechanism, we have concluded that the human strand-specific mismatch repair system is functionally homologous to the bacterial methyl-directed pathway.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University				FANG, WOEI-HORNG/0000-0003-4728-5931; Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1992, J BIOL CHEM, V267, P12142; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER DL, 1993, J BIOL CHEM, V268, P11823; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Maxam A M, 1980, Methods Enzymol, V65, P499; MEYER TF, 1979, NATURE, V278, P365, DOI 10.1038/278365a0; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PETIT MA, 1991, GENETICS, V129, P327; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; SU SS, 1989, GENOME, V31, P104, DOI 10.1139/g89-020; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883	22	197	208	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11838	11844						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505312				2022-12-27	WOS:A1993LF28400058
J	VANDERSPEK, JC; MINDELL, JA; FINKELSTEIN, A; MURPHY, JR				VANDERSPEK, JC; MINDELL, JA; FINKELSTEIN, A; MURPHY, JR			STRUCTURE-FUNCTION ANALYSIS OF THE TRANSMEMBRANE DOMAIN OF DAB389-INTERLEUKIN-2, AN INTERLEUKIN-2 RECEPTOR-TARGETED FUSION TOXIN - THE AMPHIPATHIC HELICAL REGION OF THE TRANSMEMBRANE DOMAIN IS ESSENTIAL FOR THE EFFICIENT DELIVERY OF THE CATALYTIC DOMAIN TO THE CYTOSOL OF TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; SECONDARY STRUCTURE; FRAGMENT-B; PROTEIN; BINDING; RESOLUTION; TOXICITY; DNA	Cassette and deletion mutagenesis were used to analyze the function of the amphipathic alpha-helices in the transmembrane domain of DAB389-interleukin-2 (IL-2), a fusion protein which is targeted to the interleukin-2 receptor. We demonstrate that the in-frame deletion of 60 amino acids, from Asn204 to Glu263 in DAB389-IL-2, results in complete loss of cytotoxic activity, whereas when the amphipathic regions from Asp208 to Ser220 and Ala244 to His258 are replaced with idealized amphipathic helices composed of repeating Glu, Lys, and Leu residues, the mutant fusion toxin has low but detectable activity. DAB389-IL-2 and both variants form channels in artificial phospholipid bilayers with conductances identical to those formed by diphtheria toxin. Both mutant fusion toxins bind to the high affinity IL-2 receptor with affinities similar to that of DAB389-IL-2. The fact that these mutants have markedly reduced or absent cytotoxic activity, but possess ''wild type'' catalytic activity, binding affinities, and channel conductances, suggests the existence of a step in the intoxication pathway, defective in the mutants, which occurs after DAB389-IL-2 binds to the IL-2 receptor. It is unknown whether this step occurs prior or subsequent to channel formation, but it is essential for the efficient delivery of the ADPL-ribosyltransferase from DAB389-IL-2 to the cytosol of target cells.	UNIV HOSP BOSTON,MED CTR,DEPT MED,BOSTON,MA 02118; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461	Boston Medical Center; Yeshiva University; Albert Einstein College of Medicine	VANDERSPEK, JC (corresponding author), UNIV HOSP BOSTON,MED CTR,EVANS DEPT CLIN RES,88 E NEWTON ST,BOSTON,MA 02118, USA.		Mindell, Joseph/P-4461-2017	Mindell, Joseph/0000-0002-6952-8247	NATIONAL CANCER INSTITUTE [U01CA048626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029210, T32GM007288, R37GM029210] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA-48626] Funding Source: Medline; NIGMS NIH HHS [GM 29210, T32 GM 07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BACHA P, 1992, EUR J IMMUNOL, V22, P1673, DOI 10.1002/eji.1830220702; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DEBOER H, 1986, MAXIMIZING GENE EXPR; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; ITTLESON TR, 1973, NATURE, V242, P330; JAKES KS, 1989, J BIOL CHEM, V265, P6984; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KANE JF, 1988, TRENDS BIOTECHNOL, V6, P95, DOI 10.1016/0167-7799(88)90065-0; KIYOKAWA T, 1991, PROTEIN ENG, V4, P463, DOI 10.1093/protein/4.4.463; LAMBOTTE P, 1980, J CELL BIOL, V87, P837, DOI 10.1083/jcb.87.3.837; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; Montal M, 1974, Methods Enzymol, V32, P545; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILD HO, 1957, PHARMACOL REV, V9, P242; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; WONDERLIN WF, 1990, BIOPHYS J, V58, P289, DOI 10.1016/S0006-3495(90)82376-6	32	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12077	12082						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505330				2022-12-27	WOS:A1993LF28400092
J	HINKES, MT; GOLDBERGER, OA; NEUMANN, PE; KOKENYESI, R; BERNFIELD, M				HINKES, MT; GOLDBERGER, OA; NEUMANN, PE; KOKENYESI, R; BERNFIELD, M			ORGANIZATION AND PROMOTER ACTIVITY OF THE MOUSE SYNDECAN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; NF-KAPPA-B; INTEGRAL MEMBRANE PROTEOGLYCAN; MESENCHYMAL INTERACTIONS; EXPRESSION; DIFFERENTIATION; RECEPTOR	Syndecan-1, the prototype of a family of heparan sulfate-containing integral membrane proteoglycans, associates extracellularly with a variety of matrix molecules and growth factors and intracellularly with the actin cytoskeleton. Expressed constitutively on epithelia in mature tissues and in a developmentally regulated manner on epithelial and induced mesenchymal cells during embryogenesis, syndecan-1 appears to be involved in controlling the shape and organization of cells and tissues. To better understand the function and regulation of syndecan- 1, we determined the structure of the mouse syndecan-1 gene (Synd-1). Synd-1 is approximately 19.5 kilobases in size and is organized into five exons that appear conserved in other family members. Exon 1 encodes the signal peptide; exon 2, the N-terminal glycosaminoglycan attachment region; exon 3, the bulk of the extracellular domain; exon 4, the protease-susceptible site; and exon 5, the transmembrane and cytoplasmic domains which are highly homologous between syndecan family members. Synd-1 has three transcriptional start sites, two polyadenylation sites, and is not alternatively spliced to produce its 2.6- and 3.4-kilobase mRNA species. Upstream sequences have promoter activity and contain TATA and CAAT boxes as well as a variety of other potential binding sites for transcription factors, including Sp1 (GC box), NF-kappaB, MyoD (E box), and Antennapedia. The structure of the promoter region suggests that control of Synd-1 expression is both constitutive and developmentally regulated. Because Synd-1 exons encode discrete functional domains of the syndecan-1 protein that are conserved throughout the syndecan family, all syndecan genes are likely derived from a common ancestor.	HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOINT PROGRAM NEONATOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	HINKES, MT (corresponding author), CHILDRENS HOSP MED CTR, JOINT PROGRAM NEONATOL, ENDERS BLDG, RM 950, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.			Neumann, Paul/0000-0002-8480-4799	NCI NIH HHS [CA28735] Funding Source: Medline; NIAMS NIH HHS [K11AR01816] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BACIU PC, 1992, MOL BIOL CELL, V3, pA64; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLANAR MA, 1989, MOL CELL BIOL, V9, P844, DOI 10.1128/MCB.9.2.844; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DAVID G, 1979, P NATL ACAD SCI USA, V76, P786, DOI 10.1073/pnas.76.2.786; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HINKES M T, 1991, Journal of Cell Biology, V115, p125A; HIRSCH MR, 1991, FEBS LETT, V287, P197, DOI 10.1016/0014-5793(91)80050-D; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1992, MOL BIOL CELL, V3, pA64; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OETTINGER HF, 1991, GENOMICS, V11, P334, DOI 10.1016/0888-7543(91)90140-A; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; RAPRAEGER AC, 1983, J BIOL CHEM, V258, P3632; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAUNDERS S, 1989, Journal of Cell Biology, V109, p5A; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; TRAUTMAN MS, 1991, DEVELOPMENT, V111, P213; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIDERA G, 1987, CELL, V51, P175, DOI 10.1016/0092-8674(87)90145-0; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEAMAN C, 1992, MOL BIOL CELL, V3, pA64	79	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11440	11448						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496192				2022-12-27	WOS:A1993LD46600104
J	KEARNS, AE; VERTEL, BM; SCHWARTZ, NB				KEARNS, AE; VERTEL, BM; SCHWARTZ, NB			TOPOGRAPHY OF GLYCOSYLATION AND UDP-XYLOSE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; ROUGH ENDOPLASMIC-RETICULUM; SEMI-INTACT CELLS; RAT-LIVER GOLGI; CORE PROTEIN; SUBCELLULAR-LOCALIZATION; TRANSPORT; MEMBRANE; SECRETION; APPARATUS	In order to define the location and organization of the numerous reactions involved in polysaccharide assembly during synthesis of proteoglycans and glycoproteins, the topography of some of the glycosylation reactions in chondroitin sulfate synthesis was examined using a relatively new technique for generating permeable cells. Permeable chondrocytes were shown to directly take up nucleotide sugar precursors and incorporate them into chondroitin sulfate proteoglycan (CSPG), allowing specific labeling at each step in chondroitin sulfate synthesis. Subcellular fractionation following labeling with UDP-[C-14]xylose, UDP-[C-14]galactose, UDP-[C-14]glucuronic acid, or [S-35]PAPS localized the labeled CSPG to the compartment where each glycosylation reaction occurred. From these experiments it appears that xylose addition begins in the endoplasmic reticulum and continues in the Golgi apparatus where galactose, glucuronic acid, and sulfate are added. This conclusion was confirmed by direct visualization of xylose incorporation using electron microscopic autoradiography (Vertel, B. M., Walters, L. M., Flay, N., Kearns, A. E., and Schwartz, N. B. (1993) J. Biol. Chem. 268, 11105-11112). Further examination of xylose addition showed that permeable chondrocytes can utilize both exogenous UDP-xylose transported into the lumen and UDP-xylose generated from UDP-glucuronic acid within the lumen. The enzyme responsible for this reaction, UDP-glucuronate carboxy-lyase, co-localized with xylosyltransferase activity in subcellular fractions. Orientation toward the lumen in subcellular compartments was determined by trypsin sensitivity in the permeable chondrocytes. Therefore, we conclude that UDP-xylose can be produced in the lumen of the compartment where it is utilized in CSPG synthesis, obviating the need for a direct transport mechanism for this nucleotide sugar and providing close regulation of UDP-xylose and UDP-glucuronic acid levels.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV HLTH SCI CHICAGO MED SCH,DEPT CELL BIOL & ANAT,N CHICAGO,IL 60064	University of Chicago; University of Chicago; Chicago Medical School					NIAMS NIH HHS [AR-19266] Funding Source: Medline; NICHD NIH HHS [HD-09402, HD-17332] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARION WJ, 1976, J BIOL CHEM, V251, P4901; BAUER HC, 1985, BIOCHEM BIOPH RES CO, V128, P368, DOI 10.1016/0006-291X(85)91688-2; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMAN LW, 1977, BIOCHEMISTRY-US, V16, P4490, DOI 10.1021/bi00639a025; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREW K, 1975, J BIOL CHEM, V250, P1434; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CAREY DJ, 1981, J BIOL CHEM, V256, P989; COATES SW, 1980, J BIOL CHEM, V255, P9225; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DELUCA G, 1976, CONNECT TISSUE RES, V4, P247; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; GELLER DH, 1987, J BIOL CHEM, V262, P7374; HAUSER SC, 1988, BIOCHIM BIOPHYS ACTA, V967, P149, DOI 10.1016/0304-4165(88)90004-9; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; HORWITZ AL, 1968, J CELL BIOL, V38, P358, DOI 10.1083/jcb.38.2.358; HUTCHISON W, 1961, ANALYST, V86, P768, DOI 10.1039/an9618600768; JOHN KV, 1977, J BIOL CHEM, V252, P6707; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MAYOREK N, 1989, J BIOL CHEM, V264, P4450; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MUNRO HN, 1966, ANALYST, V91, P78, DOI 10.1039/an9669100078; MUNRO JR, 1975, ARCH BIOCHEM BIOPHYS, V169, P269, DOI 10.1016/0003-9861(75)90341-0; NG K, 1991, ANAL BIOCHEM, V198, P60, DOI 10.1016/0003-2697(91)90506-O; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PARTRIDGE SM, 1948, BIOCHEM J, V42, P238, DOI 10.1042/bj0420238; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PERSAT F, 1984, BIOCHIM BIOPHYS ACTA, V769, P377, DOI 10.1016/0005-2736(84)90320-1; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWARTZ NB, 1976, J BIOL CHEM, V251, P3346; SCHWARTZ NB, 1979, J BIOL CHEM, V254, P2271; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SWANSON MA, 1974, METHOD ENZYMOL, V31, P92; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; YEO TK, 1989, BIOCHEM BIOPH RES CO, V160, P1421, DOI 10.1016/S0006-291X(89)80163-9	46	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11097	11104						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496172				2022-12-27	WOS:A1993LD46600058
J	LIN, ZH; EDENBERG, HJ; CARR, LG				LIN, ZH; EDENBERG, HJ; CARR, LG			A NOVEL NEGATIVE ELEMENT IN THE PROMOTER OF THE MOUSE ALCOHOL-DEHYDROGENASE GENE ADH-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; HEAVY-CHAIN ENHANCER; DNA-BINDING PROTEIN; MAJOR LATE PROMOTER; TATA BOX; ALDEHYDE DEHYDROGENASES; INVITRO TRANSCRIPTION; NUCLEAR FACTOR; LIVER ALCOHOL; SV40 ENHANCER	The mouse alcohol dehydrogenase gene, Adh-1, is expressed in a tissue-specific manner. We examined the promoter activity of a series of 5' deletions extending from bp -473 to -47 and demonstrated that there are positive regulatory elements between bp -229 and +54 and a negative regulatory element between bp -323 and -229. To identify the sequence of the negative regulatory element, gel retardation and DNase I footprint assays were performed using nuclear proteins from mouse liver and from a hepatoma cell line, H4IIE-C3. A specific protein-binding site covered bp -324 and -297. Within this region, we identified sites of close protein-DNA contact by methylation interference assays, located in the sequence TGGAAGTTTCAGGTT (nt -316 to -302). Site-directed mutagenesis of four protein-DNA contact sites within this sequence eliminated the specific protein-DNA binding, assayed by gel retardation, and restored expression of Adh-1 in transient transfection assays to the levels seen when the entire region containing the negative element was deleted. Thus, we have identified a negative regulatory element within the Adh-1 promoter. No homology was found between this negative element and other regulatory elements, suggesting that this is a novel negative element.	INDIANA UNIV,SCH MED,DEPT MED,975 W WALNUT ST,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PHARMACOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Edenberg, Howard/0000-0003-0344-9690	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA007611, P50AA007611, R01AA006460, P01AA008553] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA06460, AA08553, AA07611] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BALAK KJ, 1982, J BIOL CHEM, V257, P5000; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CJ, 1992, GENE, V121, P313, DOI 10.1016/0378-1119(92)90136-D; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CARR LG, 1989, ALCOHOL CLIN EXP RES, V13, P594, DOI 10.1111/j.1530-0277.1989.tb00383.x; CARR LG, 1989, GENE, V78, P277, DOI 10.1016/0378-1119(89)90230-8; CARR LG, 1990, J BIOL CHEM, V265, P1658; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; Duester G., 1991, LIVER PATHOLOGY ALCO, P375; EDENBERG HJ, 1992, PHARMACOGENETICS, V2, P185, DOI 10.1097/00008571-199210000-00001; EDENBERG HJ, 1992, ENZYMOLOGY MOL BIOL, V4; EDENBERG HJ, 1991, ADV EXP MED BIOL, V284, P254; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6506; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5410; HERBST RS, 1990, MOL CELL BIOL, V10, P3896, DOI 10.1128/MCB.10.8.3896; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1554; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES RS, 1986, ALCOHOL ALCOHOLISM, V21, P41; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Maniatis T., 1982, MOL CLONING; MARDH G, 1985, P NATL ACAD SCI USA, V82, P4979, DOI 10.1073/pnas.82.15.4979; MARDH G, 1986, BIOCHEMISTRY-US, V25, P7279, DOI 10.1021/bi00371a005; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEZEY E, 1971, EXP MOL PATHOL, V15, P148, DOI 10.1016/0014-4800(71)90095-5; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7654; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; POTTER JJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P246, DOI 10.1016/0003-9861(91)90356-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMITH M, 1986, ADV HUM GENET, V15, P249; STEWART MJ, 1990, MOL CELL BIOL, V10, P5007, DOI 10.1128/MCB.10.9.5007; STEWART MJ, 1990, GENE, V90, P271, DOI 10.1016/0378-1119(90)90190-3; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9	59	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10260	10267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486690				2022-12-27	WOS:A1993LB80000047
J	HANAZAWA, S; TAKESHITA, A; AMANO, S; SEMBA, T; NIRAZUKA, T; KATOH, H; KITANO, S				HANAZAWA, S; TAKESHITA, A; AMANO, S; SEMBA, T; NIRAZUKA, T; KATOH, H; KITANO, S			TUMOR-NECROSIS-FACTOR-ALPHA INDUCES EXPRESSION OF MONOCYTE CHEMOATTRACTANT JE VIA FOS AND JUN GENES IN CLONAL OSTEOBLASTIC MC3T3-E1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL CELLS; BONE-RESORPTION; GROWTH-FACTOR; C-FOS; TRANSCRIPTIONAL REGULATION; ALKALINE-PHOSPHATASE; COLLAGEN-SYNTHESIS; HUMAN FIBROBLASTS; PROTEIN-1 MCP-1; CYTOKINES	The mechanism by which circulating monocytes are attracted to sites of bone remodeling is unknown. We now report that tumor necrosis factor-alpha (TNF-alpha), a potent osteotrophic cytokine, was stimulatory for expression of the monocyte chemoattractant JE gene in osteoblastic MC3T3-E1 cells. TNF-alpha stimulated this JE gene expression transcriptionally. The presence of JE gene product in conditioned medium of the cytokine-treated cells was evidenced by an immunoprecipitation assay with antiserum specific for JE/MCP-1. The stimulated JE gene expression was markedly inhibited by H-7, a potent inhibitor of protein kinase C. Phorbol 12-myristate 13-acetate induced the JE gene expression, and the cytokine-induced JE gene expression was down-regulated by the phorbol ester pretreatment. TNF-alpha induced expression of both early protooncogenes, c-fos and c-jun, in the cells. Antisense oligonucleotides to these oncogenes significantly inhibited the cytokine-induced monocyte chemotactic activity. Furthermore, curcumin, a specific inhibitor of c-jun/AP-1, markedly inhibited JE gene expression and monocyte chemotactic activity induced by the cytokine. These results suggest that TNF-alpha may contribute to the regulation of remodeling and inflammation of bone tissues through the JE gene product.	APPL BIOSYST JAPAN INC, KOTO KU, TOKYO, JAPAN; NISSUI PHARMACEUT CO LTD, RES LAB, YUKI, IBARAKI, JAPAN	Thermo Fisher Scientific; Applied Biosystems	HANAZAWA, S (corresponding author), MEIKAI UNIV, SCH DENT, DEPT ORAL MICROBIOL, SAKADO, SAITAMA 35002, JAPAN.							ANISOWICZ A, 1991, J IMMUNOL, V147, P520; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANAZAWA S, 1991, BIOCHEM BIOPH RES CO, V180, P1130, DOI 10.1016/S0006-291X(05)81184-2; HONG MH, 1991, ENDOCRINOLOGY, V129, P2774, DOI 10.1210/endo-129-5-2774; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Maniatis T., 1982, MOL CLONING LABORATO, P86; MARK HT, 1990, NUCLEIC ACIDS RES, V18, P23; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; MUNDY GR, 1978, NATURE, V275, P132, DOI 10.1038/275132a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NANES MS, 1991, ENDOCRINOLOGY, V128, P2577, DOI 10.1210/endo-128-5-2577; OHMORI Y, 1988, BIOCHIM BIOPHYS ACTA, V970, P22, DOI 10.1016/0167-4889(88)90218-2; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SATO K, 1987, BIOCHEM BIOPH RES CO, V145, P323, DOI 10.1016/0006-291X(87)91324-6; SMITH DD, 1987, ENDOCRINOLOGY, V120, P2494, DOI 10.1210/endo-120-6-2494; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STASHENKO P, 1987, J IMMUNOL, V138, P1464; THOMSON BM, 1987, J IMMUNOL, V138, P775; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZHANG YH, 1988, J BIOL CHEM, V263, P6177	44	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9526	9532						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486642				2022-12-27	WOS:A1993LA68900059
J	HIRAIZUMI, S; SPOHR, U; SPIRO, RG				HIRAIZUMI, S; SPOHR, U; SPIRO, RG			CHARACTERIZATION OF ENDOMANNOSIDASE INHIBITORS AND EVALUATION OF THEIR EFFECT ON N-LINKED OLIGOSACCHARIDE PROCESSING DURING GLYCOPROTEIN-BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-MANNOSIDASE; RAT-LIVER; ENDOPLASMIC-RETICULUM; SYNCYTIUM FORMATION; GLUCOSE REMOVAL; CELL-LINE; 1-DEOXYNOJIRIMYCIN; CASTANOSPERMINE; SECRETION; COMPLEX	Endo-alpha-D-mannosidase is a Golgi-located processing enzyme that achieves deglucosylation of N-linked carbohydrate units through its unique property of cleaving the oligosaccharide chain internally with the release of glucose-substituted mannose (Glc1-3Man). By chemically modifying the characteristic disaccharide product, Glcalpha1-->3Man, a number of potent inhibitors of the endomannosidase were obtained, foremost among which were Glcalpha1-->3(1-deoxy)mannojirimycin (Glcalpha1-->3DMJ) and Glcalpha1-->3(1,2-dideoxy)mannose (IC50 = 1.7 and 3.8 muM, respectively), which, while blocking the in vitro action of the enzyme, had negligible effect on other endoplasmic reticulum- and Golgi-processing glycosidases. Although preparation of a large number of Glcalpha1-->3DMJ derivatives did not yield a more effective endomannosidase inhibitor it provided valuable information relating to the structural requirements for the enzyme-substrate interaction. Glcalpha1-->3DMJ was found to be active not only on rat liver endomannosidase but also on the enzyme from a number of other sources including mouse lymphoma (BW5147.3), HepG2, baby hamster kidney, and Madin-Darby canine kidney cell lines. When tested in vivo in lymphoma and Madin-Darby canine kidney cells during a castanospermine-imposed glucosidase blockade, Glcalpha1-->3DMJ interrupted the endomannosidase processing pathway as evident from a concomitant inhibition of complex oligosaccharide formation and Glc3Man release; similarly the capacity of the glucosidase II-deficient mouse lymphoma cell line (PHA(R)2.7) to synthesize complex oligosaccharides was blocked by Glcalpha1-->3DMJ. Endomannosidase could not be detected in Chinese hamster ovary cells by in vitro assay and consistent with this these cells produced only glucosylated polymannose N-linked oligosaccharides during glucosidase blockade. It would appear that by acting in conjunction with a glucosidase inhibitor, Glcalpha1--> 3DMJ and related endomannosidase-blocking agents could have the potential of influencing the exit of glycoproteins from the endoplasmic reticulum and interfering with viral replication.	JOSLIN DIABET CTR,ELLIOTT P JOSLIN RES LAB,ONE JOSLIN PL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; CHEM BIOMED LTD,EDMONTON T6G 2G2,AB,CANADA; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alberta					NIDDK NIH HHS [DK 17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; DURONIO V, 1988, J BIOL CHEM, V263, P5436; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FRANC JL, 1986, EUR J BIOCHEM, V157, P225, DOI 10.1111/j.1432-1033.1986.tb09660.x; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GROSS V, 1983, J BIOL CHEM, V258, P2203; GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0; HUGHES RC, 1987, BIOCHEM J, V247, P537, DOI 10.1042/bj2470537; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4056, DOI 10.1021/ja00847a032; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MATTER K, 1989, J BIOL CHEM, V264, P13131; MONTEFIORI DC, 1988, P NATL ACAD SCI USA, V85, P9248, DOI 10.1073/pnas.85.23.9248; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; OGIERDENIS E, 1990, J BIOL CHEM, V265, P5366; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; REARICK JI, 1981, J BIOL CHEM, V256, P6255; REITMAN ML, 1982, J BIOL CHEM, V257, P357; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; SASAK VW, 1985, BIOCHEM J, V232, P759, DOI 10.1042/bj2320759; SCHWEDEN J, 1986, ARCH BIOCHEM BIOPHYS, V248, P335, DOI 10.1016/0003-9861(86)90429-7; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO RG, 1982, PHILOS T ROY SOC B, V300, P117, DOI 10.1098/rstb.1982.0160; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; STANNARD BS, 1988, J BIOL CHEM, V263, P8309; SUNKARA PS, 1989, LANCET, V1, P1206; TAN A, 1991, J BIOL CHEM, V266, P14504; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; VARKI A, 1983, J BIOL CHEM, V258, P2808; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120	47	60	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9927	9935						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486671				2022-12-27	WOS:A1993LA68900109
J	UTSUMI, T; LEVITAN, A; HUNG, MC; KLOSTERGAARD, J				UTSUMI, T; LEVITAN, A; HUNG, MC; KLOSTERGAARD, J			EFFECTS OF TRUNCATION OF HUMAN PRO-TUMOR NECROSIS FACTOR TRANSMEMBRANE DOMAIN ON CELLULAR TARGETING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; DETERMINANTS; ORIENTATION; MECHANISMS; RESIDUES; CELLS; FORM	Human tumor necrosis factor is initially synthesized as a transmembrane prohormone anchored by a hydrophobic region of the leader sequence. This hydrophobic domain has been previously localized to extend from Leu-46 to Ile-21 based on hydropathy calculations. To functionally determine the nature of this domain, we have generated a series of pro-TNF mutant cDNAs in which either half or both halves of this encoding domain is deleted. These cDNAs were analyzed both by the ability of their mRNAs to direct translation in a microsomal system and by cellular localization of their encoded TNFs following transfection of NIH/3T3 cells. We determined that the mutant protein with deletion of the periluminal region of the transmembrane domain (Thr-32 to Ile-21) was translocated into microsomes and localized on the inner surface of the microsomal membrane in a fashion identical to that of the parental TNF. In contrast, the mutants with deletion of either the pericytoplasmic aspect (Leu-46 to Gly-34) or of virtually the entire transmembrane domain were not localized in the microsomes. Transfection experiments indicated that only the cDNAs whose peptide products were translocated across microsomal membranes gave rise to transmembrane prohormones and matured TNFs. Thus, the functions of membrane targeting and orientation prior to proteolytic processing can be fulfilled by the sequence Leu-46 to Ala-33 of the transmembrane domain, but not by the sequence Ala-33 to Ile-21.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				BELTZER JP, 1991, J BIOL CHEM, V266, P973; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CSEH K, 1989, J BIOL CHEM, V264, P16256; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KLOSTERGAARD J, 1992, TUMOR NECROSIS FACTOR : STRUCTURE-FUNCTION RELATIONSHIP AND CLINICAL APPLICATION, P101; KLOSTERGAARD J, 1987, CANCER RES, V47, P2014; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LUETTIG B, 1989, J IMMUNOL, V143, P4034; MULLER R, 1986, FEBS LETT, V197, P99, DOI 10.1016/0014-5793(86)80306-4; NIITSU Y, 1985, JPN J CANCER RES, V76, P1193; OKAMOTO T, 1992, CANCER RES, V52, P5278; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; SMITH MR, 1990, J IMMUNOL, V144, P162; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745	17	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9511	9516						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486641				2022-12-27	WOS:A1993LA68900056
J	WISNIEWSKI, E; KUNZ, WS; GELLERICH, FN				WISNIEWSKI, E; KUNZ, WS; GELLERICH, FN			PHOSPHATE AFFECTS THE DISTRIBUTION OF FLUX CONTROL AMONG THE ENZYMES OF OXIDATIVE-PHOSPHORYLATION IN RAT SKELETAL-MUSCLE MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRA-MITOCHONDRIAL; LIVER-MITOCHONDRIA; HEART-MITOCHONDRIA; CONTROL COEFFICIENTS; RESPIRATORY CONTROL; ADP-RATIO; ATP; TRANSLOCATOR; STATE; POTENTIALS	The flux control coefficients of adenine nucleotide translocase, the phosphate transporter, and H+-ATPase were determined in rat skeletal muscle mitochondria using glutamate plus malate as substrates and soluble F1-ATPase as load enzyme. It was observed that the flux control coefficients of adenine nucleotide translocase, H+-ATPase, and the load enzyme F1-ATPase, at comparable rates of respiration, strongly depend on the phosphate concentration in the incubation medium. So, the flux control exerted by adenine nucleotide translocase, in the intermediate states of mitochondrial respiration (approximately 120 nmol of O2/min/mg) at 10 mM phosphate, was found to be about 0.37. At a phosphate concentration of 1 mM and comparable rates of respiration the flux control coefficient of the translocase decreased to about 0.20. Under these conditions, a sharp increase in the controlling influence of H+-ATPase from 0.10 to 0.74 was detected. Furthermore, at this flux rate, the sum of flux control coefficients of adenine nucleotide translocase, H+-ATPase, phosphate transporter, and the load enzyme F1-ATPase was noted to be very close to unity. This indicates that under the conditions of intermediate state respiration, all of the other reactions have a negligible controlling influence on oxidative phosphorylation in skeletal muscle mitochondria.	MED ACAD MAGDEBURG,INST BIOCHEM,LEIPZIGER STR 44,O-3090 MAGDEBURG,GERMANY				Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493				CHANCE B, 1955, J BIOL CHEM, V217, P383; DAVIS EJ, 1975, J BIOL CHEM, V250, P2275; DAVIS EJ, 1984, ARCH BIOCHEM BIOPHYS, V233, P573, DOI 10.1016/0003-9861(84)90481-8; DOUSSIERE J, 1984, BIOCHIM BIOPHYS ACTA, V766, P492, DOI 10.1016/0005-2728(84)90265-2; DRAHOTA Z, 1977, BIOCHIM BIOPHYS ACTA, V460, P541, DOI 10.1016/0005-2728(77)90093-7; EBEL RE, 1975, J BIOL CHEM, V250, P191; FROM AHL, 1990, BIOCHEMISTRY-US, V29, P3731, DOI 10.1021/bi00467a020; GELLERICH FN, 1983, BIOCHIM BIOPHYS ACTA, V722, P381, DOI 10.1016/0005-2728(83)90086-5; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; GELLERICHH FN, 1987, BIOMED BIOCHIM ACTA, V89, P545; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; HASSINEN IE, 1986, BIOCHIM BIOPHYS ACTA, V853, P135, DOI 10.1016/0304-4173(86)90008-X; HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x; JACOBUS WE, 1982, J BIOL CHEM, V257, P2397; KACSER H, 1973, RATE CONTROL BIOL PR, P65; KAMP G, 1987, BIOCHIM BIOPHYS ACTA, V929, P121, DOI 10.1016/0167-4889(87)90166-2; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KAWANO Y, 1988, J PHYSIOL-LONDON, V407, P243, DOI 10.1113/jphysiol.1988.sp017413; KHOLODENKO B, 1987, FEBS LETT, V223, P247, DOI 10.1016/0014-5793(87)80298-3; KUNZ W, 1988, FEBS LETT, V233, P17, DOI 10.1016/0014-5793(88)81347-4; KUNZ W, 1981, ARCH BIOCHEM BIOPHYS, V209, P219, DOI 10.1016/0003-9861(81)90274-5; KUNZ WS, 1991, ARCH BIOCHEM BIOPHYS, V284, P40, DOI 10.1016/0003-9861(91)90260-P; KUSTER U, 1976, BIOCHIM BIOPHYS ACTA, V440, P391, DOI 10.1016/0005-2728(76)90073-6; MORENOSANCHEZ R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P284, DOI 10.1016/S0005-2728(05)80318-4; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P2554; OWEN CS, 1974, ARCH BIOCHEM BIOPHYS, V161, P581, DOI 10.1016/0003-9861(74)90341-5; REICHERT M, 1978, ACTA BIOL MED GER, V37, P1167; Sokolowski A, 1973, Z Med Labortech, V14, P247; WISNIEWSKI E, 1991, BIOL CHEM H-S, V372, P780	29	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9343	9346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486629				2022-12-27	WOS:A1993LA68900032
J	WALKER, MS; DEMOSS, JA				WALKER, MS; DEMOSS, JA			PHOSPHORYLATION AND DEPHOSPHORYLATION CATALYZED INVITRO BY PURIFIED COMPONENTS OF THE NITRATE SENSING SYSTEM, NARX AND NARL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI K-12; SIGNAL TRANSDUCTION; OMPC GENES; CONSTRUCTION; EXPRESSION; PROTEINS	The regulation of specific gene expression by nitrate in Escherichia coli is mediated by the NarX/NarQ-NarL system. Based on sequence homologies with a family of two-component regulatory systems in bacteria, NarL has been identified as a putative response regulator while NarX and NarQ were proposed to be alternative membrane-associated sensors that activate NarL in the presence of nitrate. To investigate the interaction of NarX and NarL in vitro, both proteins were purified from overproducing strains. Purified NarX was rapidly labeled when incubated with [gamma-P-32] ATP but not with [alpha-P-32]ATP in a reaction that required Mg2+ but was unaffected by nitrate. Incubation of the labeled NarX with purified NarL resulted in the transient phosphorylation of NarL. Both the phosphorylation and dephosphorylation of NarL required Mg2+, and neither reaction was affected by the presence of nitrate. NarL-phosphate, stabilized by the addition of EDTA, ran as a monomer on gel filtration. Dephosphorylation of the isolated NarL-phosphate required the addition of both Mg2+ and the NarX protein. The relative stabilities of the phosphorylated forms of the two proteins at different pH values were consistent with the proposal that, in analogy to other related two-component regulatory systems, NarX and NarL were phosphorylated on specific histidine and aspartate residues, respectively.			WALKER, MS (corresponding author), UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019511] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19511] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P8563; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CHIANG RC, 1992, MOL MICROBIOL, V6, P1913, DOI 10.1111/j.1365-2958.1992.tb01364.x; COLLINS LA, 1992, J BACTERIOL, V174, P3667, DOI 10.1128/JB.174.11.3667-3675.1992; DONG XR, 1992, J BIOL CHEM, V267, P14122; EGAN SM, 1991, J BACTERIOL, V173, P4424, DOI 10.1128/JB.173.14.4424-4432.1991; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GUNSALUS RP, 1989, NUCLEIC ACIDS RES, V17, P1965, DOI 10.1093/nar/17.5.1965; LI J, 1992, J BACTERIOL, V174, P4935, DOI 10.1128/JB.174.15.4935-4942.1992; NOHNO T, 1989, NUCLEIC ACIDS RES, V17, P2947, DOI 10.1093/nar/17.8.2947; RABIN RS, 1992, P NATL ACAD SCI USA, V89, P8419, DOI 10.1073/pnas.89.18.8419; RONDEAU SS, 1984, J BACTERIOL, V159, P159, DOI 10.1128/JB.159.1.159-166.1984; RUSSELL DR, 1982, GENE, V20, P231, DOI 10.1016/0378-1119(82)90042-7; STEWART V, 1989, J BACTERIOL, V171, P2229, DOI 10.1128/jb.171.4.2229-2234.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0	17	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8391	8393						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473280				2022-12-27	WOS:A1993KX81100003
J	DEANCOS, JG; CORREAS, I; AVILA, J				DEANCOS, JG; CORREAS, I; AVILA, J			DIFFERENCES IN MICROTUBULE BINDING AND SELF-ASSOCIATION ABILITIES OF BOVINE BRAIN TAU-ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN KINASE-C; ALZHEIMERS-DISEASE; TUBULIN POLYMERIZATION; LIVING CELLS; PHOSPHORYLATION; EXPRESSION; CALMODULIN; PHOSPHOPROTEINS; IDENTIFICATION	We have fractionated tau isoforms by elution at increasing pH values using iron-chelated affinity chromatography, which discriminates between isoforms phosphorylated to different extents. Microtubule-associated tau elutes from the column at a pH gradient narrower than that of total brain tau. Neither under-phosphorylated nor highly phosphorylated isoforms are found in the microtubule-associated tau protein preparation. This indicates that phosphorylation at certain sites is needed for tau binding to microtubules, whereas phosphorylation at some other sites may prevent the association. The self-association ability of the different tau isoforms has also been analyzed. Tau isoforms containing three tubulin binding motifs form covalently bound dimers more efficiently than tau isoforms containing four motifs. This dimer-forming ability is notably diminished in the presence of a reducing agent, as determined by SDS-polyacrylamide gel electrophoresis, thus suggesting the involvement of cysteine residues. Additionally, tau forms larger aggregates, as detected by gel permeation chromatography, which are solubilized by SDS and cannot, therefore, be observed by SDS-polyacrylamide gel electrophoresis. These tau aggregates are observed even in the presence of reducing agents. These results support the idea that other regions in the tau molecule, besides the Cys-containing tubulin binding region, also contribute to tau self-association. Tau dimerization and aggregation may be prior steps to the formation of paired helical filaments.	UNIV AUTONOMA MADRID, CTR BIOL MOLEC, CANTO BLANCO, E-28049 MADRID, SPAIN	Autonomous University of Madrid			Correas, Isabel/O-4061-2018; Avila, Jesus/I-2610-2015	Correas, Isabel/0000-0002-2286-186X; Avila, Jesus/0000-0002-6288-0571				ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DEGARCINI EM, 1988, FEBS LETT, V236, P150, DOI 10.1016/0014-5793(88)80304-1; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GONZALEZ PJ, 1992, NEUROSCIENCE, V50, P491, DOI 10.1016/0306-4522(92)90440-D; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HERNANDEZ MA, 1987, J NEUROCHEM, V48, P84, DOI 10.1111/j.1471-4159.1987.tb13130.x; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; Kosik KS, 1990, CURR OPIN CELL BIOL, V2, P101, DOI 10.1016/S0955-0674(05)80038-9; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LICHTENBERGKRAAG B, 1990, J STRUCT BIOL, V105, P46, DOI 10.1016/1047-8477(90)90097-V; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; NUNEZ J, 1986, DEV NEUROSCI-BASEL, V8, P125, DOI 10.1159/000112248; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; SCHOENLE EJ, 1984, J BIOL CHEM, V259, P2112; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	48	80	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7976	7982						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463318				2022-12-27	WOS:A1993KW97900060
J	WEE, SF; GROGAN, WM				WEE, SF; GROGAN, WM			TESTICULAR TEMPERATURE-LABILE CHOLESTERYL ESTER HYDROLASE - RELATIONSHIP TO ISOENZYMES FROM OTHER TISSUES, CORRELATION WITH SPERMATOGENESIS, AND INHIBITION BY PHYSIOLOGICAL CONCENTRATIONS OF DIVALENT-CATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEINS; RAT TESTIS; LIVER; ACTIVATION; METABOLISM; EXPRESSION; SEQUENCE; IDENTITY; CLONING; FORMS	Temperature-labile cholesterol ester hydrolase (TLCEH) was purified 2,000-fold from rat testis cytosol using sequential ammonium sulfate precipitation, cation exchange chromatography, and isoelectric focusing chromatography. The purified enzyme, which exhibited a single silver-stained band (66 kDa) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, was inhibited 89% by the elevation of the temperature from 32 to 37-degrees-C and 65% by treatment with alkaline phosphatase. Its amino acid composition and amino-terminal sequence differed markedly from those of isoenzymes from other tissues, although 6 of 20 residues were conserved. Polyclonal antibodies raised to TLCEH exhibited no cross-immunoreactivity with cytosolic proteins from other rat tissues and inhibited 70% of testis cytosolic CEH. Western blot analysis demonstrated a high correlation between immunoreactive protein and catalytic activity in the testis during maturation of the rat, with a marked increase at the onset of spermatogenesis. TLCEH was inhibited by physiological levels of Cu2+ (I50 = 0.60 muM) and Zn2+ (I50 = 0.75 muM) and by Cd2+ (I50 = 0.15 muM) but not by 0.5-5 mM Mn2+.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044613] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44613] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUAKIL NA, 1988, BIOCHIM BIOPHYS ACTA, V161, P299; BAILEY ML, 1986, J BIOL CHEM, V261, P7717; BARTKE A, 1973, PROSTAGLANDINS, V3, P97, DOI 10.1016/0090-6980(73)90141-X; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CARTER RJ, 1979, J IMMUNOL METHODS, V26, P213, DOI 10.1016/0022-1759(79)90246-1; CHAN WY, 1986, P SOC EXP BIOL MED, V182, P549; CLERMONT Y, 1972, PHYSIOL REV, V52, P198, DOI 10.1152/physrev.1972.52.1.198; COX DG, 1990, BIOCHEMISTRY-US, V29, P3842, DOI 10.1021/bi00468a006; DEYKIN D, 1962, J BIOL CHEM, V237, P3649; DURHAM LA, 1982, LIPIDS, V17, P970, DOI 10.1007/BF02534594; DURHAM LA, 1984, J BIOL CHEM, V259, P7433; Fredrikson G, 1981, Methods Enzymol, V71 Pt C, P636; GHANADIAN R, 1975, STEROIDS, V25, P753, DOI 10.1016/0039-128X(75)90039-2; GHOSH S, 1992, BIOCHEM CELL BIOL, V70, P800, DOI 10.1139/o92-121; GHOSH S, 1991, LIPIDS, V26, P793, DOI 10.1007/BF02536160; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; HEUDSEN GPH, 1990, BIOCHIM BIOPHYS ACTA, V1046, P315; HUI DY, 1990, FEBS LETT, V276, P131, DOI 10.1016/0014-5793(90)80525-N; JOHNSON AD, 1970, TESTIS, V4, P517; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDBERG BB, 1990, BIOCHIM BIOPHYS ACTA, V1046, P301; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLER L, 1986, TOXICOLOGY, V39, P187, DOI 10.1016/0300-483X(86)90135-6; TANAKA M, 1984, LIPIDS, V19, P714, DOI 10.1007/BF02534464; TANAKA M, 1987, LIPIDS, V22, P1016, DOI 10.1007/BF02536442; VANDEMARK N, 1970, TESTIS, V4, P233; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; WEE SF, 1989, LIPIDS, V24, P824, DOI 10.1007/BF02544591	32	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8158	8163						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463327				2022-12-27	WOS:A1993KW97900082
J	NARHI, LO; ROSENFELD, R; TALVENHEIMO, J; PRESTRELSKI, SJ; ARAKAWA, T; LARY, JW; KOLVENBACH, CG; HECHT, R; BOONE, T; MILLER, JA; YPHANTIS, DA				NARHI, LO; ROSENFELD, R; TALVENHEIMO, J; PRESTRELSKI, SJ; ARAKAWA, T; LARY, JW; KOLVENBACH, CG; HECHT, R; BOONE, T; MILLER, JA; YPHANTIS, DA			COMPARISON OF THE BIOPHYSICAL CHARACTERISTICS OF HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR, NEUROTROPHIN-3, AND NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; MOLECULAR-CLONING; FACTOR FAMILY; PROTEIN; EQUILIBRIUM; EXPRESSION; SPECTRA; SEDIMENTATION; MEMBER	The structural properties of human brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) were studied using sedimentation equilibrium and circular dichroism (CD), fluorescence and Fourier-transform infrared spectroscopies, and compared with those of human nerve growth factor (NGF). Both the far UV CD and infrared spectra indicate that these three proteins have similar, but not identical, secondary structures which contain primarily beta-sheet and irregular structures. NGF appears to contain the most beta-sheet while NT-3 contains a small fraction of alpha-helix. The near UV CD spectra appear to indicate that the three proteins contain disulfide bonds in similar environments, suggesting a resemblance in tertiary structure. The fluorescent tryptophans found in the molecules are relatively solvent exposed, while Trp102 found only in NT-3 is possibly quenched. The fluorescent Trp(s) in NGF are significantly quenched relative to those in the other two neurotrophic factors. Both NT-3 and BDNF have very hydrophilic surfaces at neutral pH, as indicated by a low binding affinity to a hydrophobic probe, anilinonaphthalenesulfonate. Sedimentation equilibrium showed that BDNF, NT-3, and NGF exist as strongly associated dimers in phosphate-buffered saline, pH 7.1. Fits of the observed fringe displacements to various association models suggested that the BDNF, NT-3, and NGF samples contain, in addition to the principal dimeric species, some oligomers, and that NT-3 contains a small fraction of incompetent monomer.	UNIV CONNECTICUT, DEPT MOLEC & CELL BIOL, STORRS, CT 06269 USA; UNIV CRETE, DEPT BIOL, IRAKLION, GREECE; UNIV CRETE, INST MOLEC BIOL & BIOTECHNOL, IRAKLION, GREECE	University of Connecticut; University of Crete; University of Crete	NARHI, LO (corresponding author), AMGEN CORP, AMGEN CTR, THOUSAND OAKS, CA 91320 USA.							ANGELETT.RH, 1971, BIOCHEMISTRY-US, V10, P463; ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; ARNOLD GE, 1992, BIOCHEMISTRY-US, V31, P7948, DOI 10.1021/bi00149a028; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CORREIA JJ, 1980, FED PROC, V39, P1604; CORREIA JJ, 1991, ANAL ULTRACENTRIFUGA, P231; CORREIA JJ, 1981, ANAL ULTRACENTRIFUGE; CORREIA JJ, 1981, FED P FED AM SOC EXP; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GREENE L A, 1971, Neurobiology (Copenhagen), V1, P37; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; LARY J, 1990, BIOPHYS J, V57, P377; LARY J, 1991, BIOPHYS J, V58, P169; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P446; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PRESTELSKI SJ, 1991, BIOCHEMISTRY; PRESTRELSKI SJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P111, DOI 10.1016/0003-9861(91)90335-G; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; ROARK DE, 1969, ANN NY ACAD SCI, V164, P245, DOI 10.1111/j.1749-6632.1969.tb14043.x; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SQUIRE PG, 1961, J AM CHEM SOC, V83, P3521, DOI 10.1021/ja01477a039; STAFFORD WF, 1972, BIOPHYS J, V12, P1359, DOI 10.1016/S0006-3495(72)86167-8; STRICKLAND GH, 1974, CRC CRIT REV BIOCH, V47, P113; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1983, BIOCHEM BIOPH RES CO, V115, P391, DOI 10.1016/0006-291X(83)91016-1; TELLER DC, 1969, ANN NY ACAD SCI, V164, P66, DOI 10.1111/j.1749-6632.1969.tb14033.x; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; YPHANTIS DA, 1979, PROTEIN INTERACTIONS, P275	39	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13309	13317						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514769				2022-12-27	WOS:A1993LH55300045
J	ULLU, E; TSCHUDI, C				ULLU, E; TSCHUDI, C			2'-O-METHYL RNA OLIGONUCLEOTIDES IDENTIFY 2 FUNCTIONAL ELEMENTS IN THE TRYPANOSOME SPLICED LEADER RIBONUCLEOPROTEIN PARTICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; 5' END; PROTEIN-COMPONENTS; C-ELEGANS; BRUCEI; U2; TRANSCRIPTION; SEQUENCES; SYSTEM; SITE	Using permeable trypanosomes as an in vivo model system for trans-splicing, we have searched for functional elements in the Trypanosoma brucei spliced leader (SL) RNA by masking various regions of the molecule with short antisense 2'-O-methyl RNA oligomers. Initial probing of the structure of newly synthesized SL RNA by deoxyoligonucleotide-directed ribonuclease (RNase) H cleavage revealed three accessible regions: the 5' end, sequences downstream of the 5' splice site, and a putative single-stranded sequence between stem-loops II and III, which is thought to be analogous to the mammalian Sm-binding site of U small nuclear RNAs. Using antisense 2'-O-methyl RNA oligomers, two functional elements of the SL RNA became apparent. Masking of positions 1-18 inhibited modification of the cap 4 structure of newly synthesized SL RNA and, thereby, blocked utilization of the SL RNA in trans-splicing. In addition, nucleotides +1 to +4 relative to the 5' splice site, which include the invariant GU dinucleotide were accessible to oligomer binding in the SL ribonucleoprotein particle, and their blockade resulted in complete inhibition of trans-splicing. In contrast, RNA oligomer binding to the single-stranded region between stem-loop II and III of the SL RNA had no detectable effect on trans-splicing activity of the SL RNA.	YALE UNIV, SCH MED, YALE MACARTHUR CTR MOLEC PARASITOL, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University					NIAID NIH HHS [AI 28798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1992, J BIOL CHEM, V267, P9805; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; DELANGE T, 1983, CELL, V34, P891, DOI 10.1016/0092-8674(83)90546-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LECUYER KA, 1993, IN PRESS BIOCHEMISTR; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MAYEDA A, 1990, J BIOCHEM-TOKYO, V108, P399, DOI 10.1093/oxfordjournals.jbchem.a123213; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	31	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13068	13073						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514747				2022-12-27	WOS:A1993LH55300012
J	PEJLER, G; KARLSTROM, A				PEJLER, G; KARLSTROM, A			THROMBIN IS INACTIVATED BY MAST-CELL SECRETORY GRANULE CHYMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELAYED-TYPE HYPERSENSITIVITY; HEPARIN PROTEOGLYCAN; NEUTRAL PROTEASES; MOUSE; BINDING; PROTEINS; TRYPTASE; RAT; ANAPHYLATOXIN; MACROPHAGES	In a recent paper we demonstrated that cultures of murine adherent peritoneal cells expressed cell surface-associated serine protease activity that specifically inactivated thrombin by cleaving the enzyme into defined proteolytic fragments (Pejler, G., and Seljelid, R. (1992) J. Biol. Chem. 267, 3136-3142). In the present report, the purification and further characterization of the thrombin-inactivating serine protease is described. The serine protease is shown to be expressed by mast cells. Purification of the thrombin-inactivating serine protease by a combination of anion-exchange chromatography and Superdex 75 chromatography showed that the enzyme had an apparent molecular mass of 28 kDa. N-terminal sequence analysis of the purified protein demonstrated 100% identity of the thrombin-inactivating serine protease with the secretory granule chymases: murine mast cell protease 3 and murine mast cell protease 4. The serine protease showed chymotrypsin-like substrate specificity. The thrombin-inactivating activity was markedly enhanced by optimal concentrations of heparin.	KABI PHARMACIA, CTR BIOSCI, DEPT BIOCHEM, S-11287 STOCKHOLM, SWEDEN		PEJLER, G (corresponding author), BIOMED CTR, DEPT VET MED CHEM, POB 575, S-75123 UPPSALA, SWEDEN.							BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; CLOHISY DR, 1990, J BIOL CHEM, V265, P7729; COLVIN RB, 1975, J IMMUNOL, V114, P377; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; DVORAK HF, 1979, J EXP MED, V150, P322, DOI 10.1084/jem.150.2.322; EKRE HPT, 1986, INT J IMMUNOPHARMACO, V8, P277, DOI 10.1016/0192-0561(86)90109-8; GECZY CL, 1982, J IMMUNOL, V128, P331; GECZY CL, 1983, LYMPHOKINES, V8, P201; GERVASONI JE, 1986, J IMMUNOL, V136, P285; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOLDSWORTH SR, 1979, CLIN EXP IMMUNOL, V37, P38; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NELSON DS, 1963, LANCET, V2, P175; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PEJLER G, 1992, J BIOL CHEM, V267, P3136; RAZIN E, 1985, EXP CELL RES, V160, P380, DOI 10.1016/0014-4827(85)90184-3; REILLY CF, 1985, BIOCHEM BIOPH RES CO, V127, P443, DOI 10.1016/S0006-291X(85)80180-7; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; STERK AR, 1982, J IMMUNOL, V128, P838; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; ZACHARSKI LR, 1992, CLIN IMMUNOL IMMUNOP, V63, P155, DOI 10.1016/0090-1229(92)90008-C; Zvaifler N J, 1973, Adv Immunol, V16, P265, DOI 10.1016/S0065-2776(08)60299-0	38	47	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11817	11822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505310				2022-12-27	WOS:A1993LF28400055
J	SHUMAN, S				SHUMAN, S			VACCINIA VIRUS-RNA HELICASE - DIRECTIONALITY AND SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION FACTOR; MESSENGER-RNA; VIRION COMPONENT; PURIFICATION; ATP; TRIPHOSPHATE; POLYMERASE; INVITRO; ACID	Vaccinia virus RNA helicase (NPH-II) catalyzes unidirectional unwinding of 3'-tailed duplex RNAs in the presence of a divalent cation and any one of the eight common nucleoside triphosphates (NTP). The helicase binds stably to the tailed RNA in the absence of any cofactor; strand displacement by the bound protein is coupled to NTP hydrolysis. Although the helicase is capable of binding to tailed duplex DNA as well as to tailed RNA, the enzyme is unable to unwind duplex DNA. It is suggested that NTP hydrolysis by RNA-bound NPH-II drives processive translocation of the protein in a 3' to 5' direction along the RNA strand, whereas energy utilization by DNA-bound enzyme leads to dissociation without extensive protein movement. A role for the RNA helicase in vaccinia mRNA synthesis is proposed.			SHUMAN, S (corresponding author), SLOAN KETTERING INST CANC RES,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.							BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BROYLES SS, 1991, J BIOL CHEM, V266, P15545; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; FATHI Z, 1991, VIROLOGY, V181, P258, DOI 10.1016/0042-6822(91)90491-S; FATHI Z, 1991, VIROLOGY, V181, P273, DOI 10.1016/0042-6822(91)90492-T; GERSHOWITZ A, 1978, J VIROL, V27, P399, DOI 10.1128/JVI.27.2.399-408.1978; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; LEE CG, 1992, J BIOL CHEM, V267, P4398; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PAOLETTI E, 1978, VIROLOGY, V87, P317, DOI 10.1016/0042-6822(78)90137-X; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SPENCER E, 1980, J BIOL CHEM, V255, P5388; VEOMETT GE, 1973, ICN UCL S MOL BIOL, P127	21	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11798	11802						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505308				2022-12-27	WOS:A1993LF28400052
J	SCHTEINGART, CD; HAGEY, LR; SETCHELL, KDR; HOFMANN, AF				SCHTEINGART, CD; HAGEY, LR; SETCHELL, KDR; HOFMANN, AF			5-BETA-HYDROXYLATION BY THE LIVER - IDENTIFICATION OF 3,5,7-TRIHYDROXY NOR-BILE ACIDS AS NEW MAJOR BIOTRANSFORMATION PRODUCTS OF 3,7-DIHYDROXY NOR-BILE ACIDS IN RODENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS SPECTROMETRY; SIDE-CHAIN; URSODEOXYCHOLIC ACID; BILIARY-SECRETION; HEPATIC TRANSPORT; RAT-LIVER; DERIVATIVES; CONJUGATION; CHOLESTASIS; METABOLISM	24-Norursodeoxycholic acid (nor-UDCA), when administered into the anesthetized biliary fistula hamster or injected into the perfusate of an isolated liver, was hydroxylated at C-5 to give 5beta-hydroxynorursodeoxycholic acid 2 (3alpha,5,7beta-trihydroxy-24-nor-5beta-cholan-23-oic acid), which was secreted into bile mainly as such. Similarly, 24-norchenodeoxycholic acid (nor-CDCA) was 5beta-hydroxylated to give 5beta-hydroxynorchenodeoxycholic acid 4 (3alpha,5,7alpha-trihydroxy-24-nor-5beta-cholan-23-oic acid), which was also secreted into bile without appreciable further biotransformation. The site of hydroxylation was assigned by C-13 and H-1 NMR and mass spectrometry. 5-Hydroxylation was a major biotransformation pathway at physiological bile acid loads. 5-Hydroxylation of UDCA also occurred in the perfused rat liver but to a lesser extent. 5-Hydroxylation of nor-UDCA was not observed in rabbit, dog, or man, indicating that its formation is species-specific. 5-Hydroxylation of nor-CDCA and nor-UDCA is the first reported example of hydroxylation of a tertiary carbon atom of bile acids. Nor-dihydroxy bile acids appear to be useful for the detection of minor hydroxylation pathways, because their prolonged hepatobiliary retention exposes them repeatedly to hydroxylases present in the hepatobiliary system.	CHILDRENS HOSP MED CTR, DEPT PEDIAT, CINCINNATI, OH 45229 USA	Cincinnati Children's Hospital Medical Center	SCHTEINGART, CD (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, DIV GASTROENTEROL, BILE ACID RES SECT, LA JOLLA, CA 92093 USA.				NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [DK21506, DK32130] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021506, R01DK032130] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALME B, 1977, J LIPID RES, V18, P339; ARINGER L, 1981, BIOMED MASS SPECTROM, V8, P183, DOI 10.1002/bms.1200080502; BAUMGARTNER U, 1986, AM J PHYSIOL, V251, pG431, DOI 10.1152/ajpgi.1986.251.4.G431; BEIERBECK H, 1977, CAN J CHEM, V55, P2813, DOI 10.1139/v77-391; BREMMELGAARD A, 1980, J LIPID RES, V21, P1072; BROOKS CJW, 1973, BIOCHIM BIOPHYS ACTA, V296, P431, DOI 10.1016/0005-2760(73)90101-X; BULGER WH, 1973, BIOCHEM PHARMACOL, V22, P1745, DOI 10.1016/0006-2952(73)90388-2; BULL JR, 1977, S AFR J CHEM, V30, P105; CLAYTON LM, 1989, J PHARMACOL EXP THER, V248, P1130; COHEN BI, 1986, GASTROENTEROLOGY, V91, P189, DOI 10.1016/0016-5085(86)90457-9; COOKSON DJ, 1981, ORG MAGN RESONANCE, V16, P111, DOI 10.1002/mrc.1270160209; DEMARCO PV, 1968, J AM CHEM SOC, V90, P5480, DOI 10.1021/ja01022a027; DUMASWALA R, 1989, J LIPID RES, V30, P847; ELLIOTT WH, 1985, STEROLS BILE ACIDS, P303; HOFMANN AF, 1968, J LIPID RES, V9, P707; HOFMANN AF, 1978, JAMA-J AM MED ASSOC, V239, P1138, DOI 10.1001/jama.239.12.1138; HOFMANN AF, 1962, J LIPID RES, V3, P127; IIDA T, 1983, ORG MAGN RESONANCE, V21, P305, DOI 10.1002/omr.1270210504; KIRKPATRICK RB, 1988, HEPATOLOGY, V8, P353, DOI 10.1002/hep.1840080227; KOCOVSKY P, 1983, COLLECT CZECH CHEM C, V48, P3643, DOI 10.1135/cccc19833643; KOOPMAN BJ, 1987, BIOCHIM BIOPHYS ACTA, V917, P238, DOI 10.1016/0005-2760(87)90128-7; LAKE JR, 1988, GASTROENTEROLOGY, V95, P454, DOI 10.1016/0016-5085(88)90504-5; LAWSON AM, 1988, BILE ACIDS, V4, P1; LINDSTEDT S, 1957, ARK KEMI, V11, P137; MATOBA N, 1986, J LIPID RES, V27, P1154; MIHAILOVIC ML, 1981, HELV CHIM ACTA, V64, P1032, DOI 10.1002/hlca.19810640409; MUNOZ J, 1990, GASTROENTEROLOGY, V98, P613; NAKATOMI F, 1985, J PHARMACOBIO-DYNAM, V8, P557; OMAILLE ERL, 1984, AM J PHYSIOL, V246, pG67, DOI 10.1152/ajpgi.1984.246.1.G67; PALMER KR, 1987, AM J PHYSIOL, V252, pG219, DOI 10.1152/ajpgi.1987.252.2.G219; POPOVITZBIRO R, 1985, J AM CHEM SOC, V107, P4043, DOI 10.1021/ja00299a047; ROSSI SS, 1987, J LIPID RES, V28, P589; SCHNEIDER HJ, 1988, MAGN RESON CHEM, V26, P679, DOI 10.1002/mrc.1260260808; SCHTEINGART CD, 1988, J LIPID RES, V29, P1387; SETCHELL KDR, 1983, CLIN CHIM ACTA, V127, P1, DOI 10.1016/0009-8981(83)90070-0; SETCHELL KDR, 1988, CLIN BIOCH PRINCIPLE, V1, P54; SHOPPEE CW, 1957, J CHEM SOC, P3107, DOI 10.1039/jr9570003107; SJOVALL J, 1985, METHOD ENZYMOL, V111, P63, DOI 10.1016/S0076-6879(85)11006-2; STARY I, 1985, COLLECT CZECH CHEM C, V50, P1227, DOI 10.1135/cccc19851227; STELLAARD F, 1985, J LAB CLIN MED, V105, P504; SUMMERFIELD JA, 1976, BIOCHEM J, V154, P507, DOI 10.1042/bj1540507; TOHMA M, 1986, CHEM PHARM BULL, V34, P2890; TSERNG KY, 1977, J LIPID RES, V18, P400; VANANTWERP CL, 1977, J ORG CHEM, V42, P789, DOI 10.1021/jo00425a005; VANBERGEHENEGOUWEN GP, 1976, GUT, V17, P861, DOI 10.1136/gut.17.11.861; VESSEY DA, 1983, BIOCHEM J, V214, P923, DOI 10.1042/bj2140923; WATERHOUS DV, 1985, J LIPID RES, V26, P1068; YOON YB, 1986, GASTROENTEROLOGY, V90, P837, DOI 10.1016/0016-5085(86)90859-0; ZAKKO SF, 1987, GASTROENTEROLOGY, V92, P1792	49	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11239	11246						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496179				2022-12-27	WOS:A1993LD46600077
J	IKEDA, M; OGATA, F; CURTIS, SW; LUBAHN, DB; FRENCH, FS; WILSON, EM; KORACH, KS				IKEDA, M; OGATA, F; CURTIS, SW; LUBAHN, DB; FRENCH, FS; WILSON, EM; KORACH, KS			CHARACTERIZATION OF THE DNA-BINDING DOMAIN OF THE MOUSE UTERINE ESTROGEN-RECEPTOR USING SITE-SPECIFIC POLYCLONAL ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR; DEOXYRIBONUCLEIC-ACID; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; STEROID-RECEPTORS; COMPLEXES; FORM; SUPERFAMILY; ESTRADIOL	The DNA-binding domain of the mouse uterine estrogen receptor (ER) was characterized using site-specific polyclonal antibodies. The peptides used as antigens have sequences corresponding to amino acids 185-199 and 227-245, the two zinc finger regions of the DNA-binding domain of the human ER, and produced antisera designated A-1542 and A-1554, respectively. Mouse uterine nuclear ER and salt-activated 4 S cytosol receptor, as well as 8 S untransformed cytosol receptor, were observed to react with the antisera by Western blot and sucrose density gradient centrifugation analyses indicating that the DNA-binding domain of the 8 S cytosol receptor is not completely masked by heat shock protein 90 or other proteins. Only A-1554 detected a nuclear-specific doublet form of the ER on Western blot analysis. In a gel shift assay, neither antisera altered the pattern of the nuclear ER interaction with the vitellogenin A2 estrogen response element (VRE). In contrast, antiserum A-1554 partially shifted the 8 S cytosol receptor-VRE complex. This concurs with mutational analysis and x-ray crystallography studies with the human ER that have shown that the second finger is not in contact with the DNA. The results of the gel shift assay were confirmed by sucrose density gradient analysis using the same buffer conditions. The nuclear receptor-VRE complex did not react with either antisera, suggesting that when the dimeric nuclear receptor form binds the VRE, the specific receptor epitopes involved with the DNA binding may be blocked and unable to bind the antisera. The cytosol receptor-VRE complex reacted only partially with the second finger antisera A-1554, suggesting that on receptor monomers the second finger epitope is not completely blocked by DNA binding or dimer formation.	NIEHS,REPROD & DEV TOXICOL LAB,RECEPTOR BIOL SECT,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,SCH MED,REPROD BIOL LAB,CHAPEL HILL,NC 27514	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Korach, Kenneth/0000-0002-7765-418X	NICHD NIH HHS [HD16910, HD04466, P30-HD18968] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, R37HD004466, R01HD016910, R01HD004466, R37HD016910] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CURTIS SW, 1991, MOL ENDOCRINOL, V5, P959, DOI 10.1210/mend-5-7-959; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; EDWARDS DP, 1991, STEROIDS, V56, P271, DOI 10.1016/0039-128X(91)90046-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOLDING TS, 1988, P NATL ACAD SCI USA, V85, P69, DOI 10.1073/pnas.85.1.69; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HORIGOME T, 1987, ENDOCRINOLOGY, V121, P2099; HOUSLEY PR, 1985, J BIOL CHEM, V260, P3810; JENSEN EV, 1973, SCIENCE, V182, P126, DOI 10.1126/science.182.4108.126; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; REDEUILH G, 1987, J BIOL CHEM, V262, P6969; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRAISH A, 1989, ENDOCRINOLOGY, V125, P172, DOI 10.1210/endo-125-1-172; TRAISH AM, 1990, STEROIDS, V55, P551, DOI 10.1016/0039-128X(90)90051-C; TRAISH AM, 1990, STEROIDS, V55, P196, DOI 10.1016/0039-128X(90)90017-6; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; WILSON EM, 1988, MOL ENDOCRINOL, V2, P1018, DOI 10.1210/mend-2-11-1018	34	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10296	10302						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486692				2022-12-27	WOS:A1993LB80000051
J	PEDERSEN, PL; AMZEL, LM				PEDERSEN, PL; AMZEL, LM			ATP SYNTHASES - STRUCTURE, REACTION CENTER, MECHANISM, AND REGULATION OF ONE OF NATURES MOST UNIQUE MACHINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RAT-LIVER MITOCHONDRIA; ION MOTIVE ATPASES; COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; ALPHA-SUBUNIT; MOLECULAR ARCHITECTURE; HEART-MITOCHONDRIA		JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & PHYS CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University	PEDERSEN, PL (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA.			Amzel, L. Mario/0000-0002-0129-9572	NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025432] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10951] Funding Source: Medline; NIGMS NIH HHS [GM 25432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLFSEN R, 1976, ARCH BIOCHEM BIOPHYS, V172, P425, DOI 10.1016/0003-9861(76)90094-1; AGGELER R, 1992, J BIOL CHEM, V267, P21355; ALLISON S, 1992, J BIOENERG BIOMEMBR, V24, P469; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CAIN BD, 1989, J BIOL CHEM, V264, P3292; CAPALDI RA, 1992, J BIOENERG BIOMEMBR, V24, P435, DOI 10.1007/BF00762359; Catterall W. A., 1974, BIOCHEM SOC SPEC PUB, V4, P63; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; ERECINSKA M, 1978, TRENDS BIOCHEM SCI, V3, P219, DOI 10.1016/S0968-0004(78)94515-2; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRABER P, 1990, BIOELECTROCHEMISTRY, V3, P247; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GROMETELHANAN Z, 1992, J BIOENERG BIOMEMBR, V24, P447, DOI 10.1007/BF00762361; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HARADA M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P279, DOI 10.1016/S0005-2728(05)80059-3; HASIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; JOSHI S, 1981, J BIOL CHEM, V256, P1112; KAGAWA Y, 1992, J BIOENERG BIOMEMBR, V24, P441, DOI 10.1007/BF00762360; LANOUE KF, 1992, J BIOENERG BIOMEMBR, V24, P499, DOI 10.1007/BF00762368; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; LEE RSF, 1992, ARCH BIOCHEM BIOPHYS, V297, P334, DOI 10.1016/0003-9861(92)90681-L; LIN SH, 1989, J BIOL CHEM, V264, P408; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MITCHELL P, 1985, FEBS LETT, V182, P1, DOI 10.1016/0014-5793(85)81142-X; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; OMOTE H, 1992, J BIOL CHEM, V267, P20571; OSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; PAI EF, 1977, J MOL BIOL, V114, P34; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PENIN F, 1990, BIOCHEMISTRY-US, V29, P9358, DOI 10.1021/bi00492a008; REPKE KRH, 1974, ACTA BIOL MED GER, V33, P527; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROUSLIN W, 1991, J BIOENERG BIOMEMBR, V23, P873, DOI 10.1007/BF00786006; ROY H, 1971, P NATL ACAD SCI USA, V68, P2720, DOI 10.1073/pnas.68.11.2720; SCHWERZMANN K, 1986, ARCH BIOCHEM BIOPHYS, V250, P1, DOI 10.1016/0003-9861(86)90695-8; SENIOR AE, 1971, FEBS LETT, V17, P327, DOI 10.1016/0014-5793(71)80178-3; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SOPER JW, 1979, J BIOL CHEM, V254, P1170; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; THOMAS PJ, 1992, J BIOL CHEM, V267, P20331; TIEDGE H, 1985, P NATL ACAD SCI USA, V82, P7874, DOI 10.1073/pnas.82.23.7874; TSUPRUN VL, 1989, FEBS LETT, V244, P279, DOI 10.1016/0014-5793(89)80545-9; VIK SB, 1988, J BIOL CHEM, V263, P6599; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBB MR, 1980, J BIOL CHEM, V255, P1637; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WILLIAMS N, 1987, BIOCHEMISTRY-US, V26, P162, DOI 10.1021/bi00375a023; WILLIAMS N, 1984, BIOCHEMISTRY-US, V23, P780, DOI 10.1021/bi00299a030; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	73	179	185	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9937	9940						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486720				2022-12-27	WOS:A1993LB80000001
J	STOLZ, A; HAMMOND, L; LOU, H; TAKIKAWA, H; RONK, M; SHIVELY, JE				STOLZ, A; HAMMOND, L; LOU, H; TAKIKAWA, H; RONK, M; SHIVELY, JE			CDNA CLONING AND EXPRESSION OF THE HUMAN HEPATIC BILE ACID-BINDING PROTEIN - A MEMBER OF THE MONOMERIC REDUCTASE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; CYCLICAL OXIDATION REDUCTION; GLUTATHIONE S-TRANSFERASES; RAT-LIVER; DIHYDRODIOL DEHYDROGENASE; CHOLESTEROL 7-ALPHA-HYDROXYLASE; ALDOSE REDUCTASE; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; MICROSEQUENCE ANALYSIS; ALCOHOL-DEHYDROGENASE	In human liver, we previously identified one isoform of dihydrodiol dehydrogenase activity that expresses high affinity bile acid binding (HBAB) with minimal 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD) activity for bile acids. This protein may assist in the rapid intracellular transport of bile acids from the sinusoidal to the canalicular pole of the cell. We now report the cDNA cloning and bacterial expression of this novel, multifunctional protein. A 1252-base pair HBAB cDNA was cloned from a HepG2 lambdaGT11 library using a rat hepatic bile acid binder cDNA probe. Bacterial expressed recombinant HBAB oxidized racemic trans dihydrodiol benzene (0.455 mumol NADPH/mg/min) with minimal 3alpha-HSD activity for bile acids (<0.003 mumol NADPH/mg/min). Lithocholic acid and chenodeoxycholic acid dissociation constants as determined by displacement of the fluorescent probe, bis-1-anilino-8 sulfonate, were higher than those previously reported for the native protein (1 muM versus 10 nM). Significant amino acid sequence homology was found with the human chlordecone reductase, bovine prostaglandin F synthetase, and rat hepatic-3alpha-HSD suggesting, that HBAB is also a member of the recently identified, monomeric oxidoreductase gene family. Future studies will define the physiologic significance of this novel, multifunctional protein in bile acid transport and xenobiotic metabolism.	LOS ANGELES VET ADM OUTPATIENT FACIL,LOS ANGELES,CA 90013; TEIKYO UNIV,SCH MED,DEPT MED,TOKYO 173,JAPAN; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	Teikyo University; City of Hope; Beckman Research Institute of City of Hope	STOLZ, A (corresponding author), UNIV SO CALIF,SCH MED,DIV GASTROINTESTINAL & LIVER DIS,2025 ZONAL AVE,LOS ANGELES,CA 90033, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041014, R01DK041014] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41014] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER ME, 1990, FASEB J, V4, P222, DOI 10.1096/fasebj.4.2.2153594; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BORRAS T, 1989, BIOCHEMISTRY-US, V28, P6133, DOI 10.1021/bi00441a001; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHENG KC, 1991, MOL ENDOCRINOL, V5, P823, DOI 10.1210/mend-5-6-823; CHUNG S, 1989, J BIOL CHEM, V264, P14775; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEYASHIKI Y, 1992, BIOCHEM J, V282, P741, DOI 10.1042/bj2820741; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; ENSOR CM, 1991, BIOCHEM BIOPH RES CO, V176, P840, DOI 10.1016/S0006-291X(05)80262-1; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GLATT HR, 1982, SCIENCE, V215, P1507, DOI 10.1126/science.7038877; GLATT HR, 1979, NATURE, V277, P319, DOI 10.1038/277319a0; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HARA A, 1990, J BIOCHEM-TOKYO, V108, P250, DOI 10.1093/oxfordjournals.jbchem.a123189; HAWKE DH, 1985, ANAL BIOCHEM, V147, P315, DOI 10.1016/0003-2697(85)90278-7; JARRELL J, 1982, J STEROID BIOCHEM, V16, P725, DOI 10.1016/0022-4731(82)90027-9; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JOERNVALL H, 1987, EUR J BIOCHEM, V167, P195; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; OLD SE, 1990, P NATL ACAD SCI USA, V87, P4942, DOI 10.1073/pnas.87.13.4942; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENNING TM, 1986, STEROIDS, V47, P221; PENNING TM, 1990, CARCINOGENESIS, V11, P1203, DOI 10.1093/carcin/11.7.1203; PENNING TM, 1991, J BIOL CHEM, V266, P8826; PEREZ AG, 1989, J BIOL CHEM, V264, P16815; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHGALL TE, 1988, CANCER RES, V48, P1227; STOLZ A, 1984, FEBS LETT, V177, P31, DOI 10.1016/0014-5793(84)80975-8; STOLZ A, 1991, J BIOL CHEM, V266, P15253; STOLZ A, 1987, J CLIN INVEST, V79, P427, DOI 10.1172/JCI112829; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; SUGIYAMA Y, 1983, J BIOL CHEM, V258, P3602; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; TAKIKAWA H, 1988, BIOCHIM BIOPHYS ACTA, V954, P37, DOI 10.1016/0167-4838(88)90052-0; TAKIKAWA H, 1986, J LIPID RES, V27, P955; TAKIKAWA H, 1987, J CLIN INVEST, V80, P852, DOI 10.1172/JCI113143; TAKIKAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1043, P153, DOI 10.1016/0005-2760(90)90289-A; TAKIKAWA H, 1986, J LIPID RES, V27, P652; TAKIKAWA H, 1987, J CLIN INVEST, V80, P861, DOI 10.1172/JCI113144; TAKIKAWA H, 1990, J BIOL CHEM, V265, P2132; TAUROG JD, 1975, BIOCHEMISTRY-US, V14, P810, DOI 10.1021/bi00675a026; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WILSON CM, 1991, METHOD ENZYMOL, V91, P231; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034; WOERNER W, 1984, Febs Letters, V170, P263	62	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10448	10457						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486699				2022-12-27	WOS:A1993LB80000069
J	KAR, L; LAI, CS; WOLFF, CE; NETTESHEIM, D; SHERMAN, S; JOHNSON, ME				KAR, L; LAI, CS; WOLFF, CE; NETTESHEIM, D; SHERMAN, S; JOHNSON, ME			H-1 NMR-BASED DETERMINATION OF THE 3-DIMENSIONAL STRUCTURE OF THE HUMAN PLASMA FIBRONECTIN FRAGMENT CONTAINING INTER-CHAIN DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PROTEIN CONFORMATIONS; SPECTROSCOPY DATA; SEMINAL PLASMA; H-1-NMR	Human plasma fibronectin is a plasma glycoprotein that plays an important role in many biological processes. It consists of two identical 230-250-kDa subunits that are joined by two disulfide bonds near their carboxyl termini. Each subunit contains various binding domains composed of three types of homologous repeats. Recent work has determined the three-dimensional structures of various repeat fragments, but little is known about the three-dimensional structure of the carboxyl-terminal region. A recent NMR study of a plasmin-digested carboxyl-terminal inter-chain disulfide-linked heptapeptide dimer has proposed that the two subunits are arranged in an antiparallel fashion (An et al. (1992) Biochemistry 31, 9927-9933). We have now determined the three-dimensional structure for a substantial portion of a trypsin-digested inter-chain disulfide-linked 52-residue (6 kDa) fragment of the carboxyl-terminal of human plasma fibronectin (which includes the above-mentioned heptapeptide dimer) using two-dimensional NMR methods and a new strategy for NMR-based protein structure determination. The NMR data requires that the two chains in the dimer be linked in a symmetric, antiparallel arrangement. The resulting monomer conformation consists of two twisted or coiled segments, Thr3-Asn6 and Ile9-Phe12, connected by the Cys7-Pro8 residues in extended conformations, with the two monomer chains cross-linked at residues Cys7 and Cys11. The conformation of the heptapeptide dimer region differs substantially from the conformations proposed by An et al.	UNIV ILLINOIS,CTR PHARMACEUT BIOTECHNOL,POB 6998,CHICAGO,IL 60680; UNIV ILLINOIS,DEPT MEDICINAL CHEM & PHARMACOGNOSY,CHICAGO,IL 60680; MED COLL WISCONSIN,DEPT RADIOL,BIOPHYS SECT,MILWAUKEE,WI 53226; UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Milwaukee			Johnson, Michael E/F-5141-2013	Johnson, Michael E/0000-0002-8246-4081	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035719] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01008] Funding Source: Medline; NHLBI NIH HHS [HL45977] Funding Source: Medline; NIGMS NIH HHS [GM-35719] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1987, ADV ENZYMOL RAMB, V59, P1; AN SSA, 1992, BIOCHEMISTRY-US, V31, P9927, DOI 10.1021/bi00156a010; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CONSTANTINE KL, 1992, BIOCHEM J, V283, P247, DOI 10.1042/bj2830247; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GARCIAPARDO A, 1984, BIOCHEM BIOPH RES CO, V120, P1015, DOI 10.1016/S0006-291X(84)80208-9; Hoffmann-Ostenhof O., 1974, PURE APPL CHEM, V40, P291; HOLLAND SK, 1987, EMBO J, V6, P1875, DOI 10.1002/j.1460-2075.1987.tb02446.x; HORMANN H, 1982, KLIN WOCHENSCHR, V60, P1265, DOI 10.1007/BF01727483; Hynes RO, 1990, FIBRONECTINS; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LARIVE CK, 1992, J AM CHEM SOC, V114, P7331, DOI 10.1021/ja00045a001; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Mosher DF, 1989, FIBRONECTIN; NERDAL W, 1988, J MOL BIOL, V201, P717, DOI 10.1016/0022-2836(88)90469-X; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; SHERMAN SA, 1987, J BIOMOL STRUCT DYN, V4, P869, DOI 10.1080/07391102.1987.10507684; SHERMAN SA, 1988, J BIOMOL STRUCT DYN, V5, P785, DOI 10.1080/07391102.1988.10506427; SHERMAN SA, 1991, PROTEINS : STRUCTURE, DYNAMICS AND DESIGN, P62; SHERMAN SA, 1993, PROG BIOPHYS MOL BIO, V59, P285, DOI 10.1016/0079-6107(93)90003-3; SHERMAN SA, 1992, J MAGN RESON, V966, P457; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; VUENTO M, 1980, H-S Z PHYSIOL CHEM, V361, P1453; WAGNER G, 1983, Q REV BIOPHYS, V16, P1, DOI 10.1017/S0033583500004911; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; Wuthrich K, 1976, NMR BIOL RES PEPTIDE	34	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8580	8589						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473304				2022-12-27	WOS:A1993KX81100034
J	VYSOTCHIN, A; MEDVED, LV; INGHAM, KC				VYSOTCHIN, A; MEDVED, LV; INGHAM, KC			DOMAIN-STRUCTURE AND DOMAIN-DOMAIN INTERACTIONS IN HUMAN COAGULATION FACTOR-IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GAMMA-CARBOXYGLUTAMIC ACID; TISSUE PLASMINOGEN-ACTIVATOR; BOVINE FACTOR-IX; BLOOD-COAGULATION; PROTHROMBIN FRAGMENT-1; CALCIUM-BINDING; FACTOR-X; CHRISTMAS FACTOR; CA2+ BINDING	Coagulation factor IX has the modular composition Gla-(EGF)2-SP, where Gla, EGF, and SP represent the gamma-carboxy-Glu-rich, epidermal growth factor-like, and serine protease modules, respectively. The protein melts in two distinct temperature regions. The SP module melts at lower temperature between 42 and 55-degrees-C, depending on the pH, with irreversible loss of esterolytic activity. The endotherm corresponding to this transition is readily described by a two-state transition indicating the melting of a single cooperative unit. A thrombin-generated 12-kDa fragment representing the COOH-terminal half of the SP module and a 45-kDa fragment containing the NH2-terminal half of the SP module and the rest of the molecule can be separated by exclusion chromatography in 3 M urea and recombined in its absence. Both fragments retain a compact structure as evidenced by melting transitions near 60-degrees-C at neutral pH. This indicates that the SP module contains two independently folded domains that strongly interact with each other and seem to merge into one cooperative unit in the intact protein. At low pH at high temperature a second peak appears which is also observed in a 19-kDa fragment containing the EGF modules. Thermodynamic analysis of this second peak showed that the two EGF modules are independently folded and provided evidence for a weak interaction between them. Fluorescence and CD measurements indicated that the secondary structure of the isolated 6-kDa Gla fragment is substantially increased in the presence of Ca2+. The Ca2+-loaded Gla fragment undergoes a sigmoidal unfolding transition as revealed by fluorescence and CD measurements. This same transition in a 25-kDa Gla-(EGF)2 fragment was stabilized by more than 10-degrees-C, indicating a strong interaction between the Ca2+-loaded Gla and EGF domains. Thus, factor IX consists of five independently folded interacting domains.	AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross				Medved, Leonid/0000-0002-3665-9849	NHLBI NIH HHS [HL21791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1992, J BIOL CHEM, V267, P8571; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BARON M, 1992, PROTEIN SCI, V1, P81; BILTONEN RL, 1978, CRC CR REV BIOCH MOL, V5, P85, DOI 10.3109/07388557809148191; CHEUNG WF, 1991, J BIOL CHEM, V266, P8797; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HARLOS K, 1987, FEBS LETT, V224, P97, DOI 10.1016/0014-5793(87)80429-5; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HOLLADAY LA, 1976, BIOCHEMISTRY-US, V15, P2624, DOI 10.1021/bi00657a023; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KISIEL W, 1985, BLOOD, V66, P1302; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; MEDVED LV, 1983, FEBS LETT, V160, P291, DOI 10.1016/0014-5793(83)80985-5; MEDVED LV, 1989, BIOCHEMISTRY-US, V28, P5408, DOI 10.1021/bi00439a014; MENACHE D, 1984, BLOOD, V64, P1220; MITCHELL GA, 1978, THROMB RES, V13, P47, DOI 10.1016/0049-3848(78)90108-1; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; PACE CN, 1988, J BIOL CHEM, V263, P11820; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; THARAKAN J, 1990, VOX SANG, V58, P21, DOI 10.1111/j.1423-0410.1990.tb02050.x; THOMPSON AR, 1986, BLOOD, V67, P565; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; TSALKOVA TN, 1980, BIOCHIM BIOPHYS ACTA, V624, P196, DOI 10.1016/0005-2795(80)90238-X; ULLNER M, 1992, BIOCHEMISTRY-US, V31, P5974, DOI 10.1021/bi00141a004	50	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8436	8446						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473287				2022-12-27	WOS:A1993KX81100014
J	YE, SQ; REARDON, CA; GETZ, GS				YE, SQ; REARDON, CA; GETZ, GS			INHIBITION OF APOLIPOPROTEIN-E DEGRADATION IN A POST-GOLGI COMPARTMENT BY A CYSTEINE PROTEASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN GRANULOSA-CELLS; LOW-DENSITY LIPOPROTEIN; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; CHOLESTEROL TRANSPORT; ENDOPLASMIC-RETICULUM; NEUTRAL PROTEASE; E GENE; CALCIUM; LIVER; EXPRESSION	In our prior studies on lipoprotein stimulation of apolipoprotein E (apoE) secretion in HepG2 cells, it became clear that a proportion of the newly synthesized apoE was degraded intracellularly (Ye, S. Q., Olson, L. M., Reardon, C. A., and Getz, G. S. (1992) J. Biol. Chem. 267, 21961-21966). The present study was designed to determine the nature of the proteases and the intracellular sites involved in newly synthesized apoE degradation. The effect of seven protease inhibitors on total apoE levels was examined. Only N-acetyl-leucyl-leucyl-norleucinal (ALLN), a cysteine protease inhibitor, significantly blocked apoE degradation in HepG2 cells. The amount of total apoE from cells chased with ALLN for 4 h was increased by 1.58 +/- 0.05-fold relative to the controls (n = 11, p < 0.01). ALLN extended the half-life of apoE from 2.61 h to 4.38 h (p < 0.01). This effect occurs in a post-Golgi compartment since in the presence of brefeldin A, ALLN had no effect on intracellular apoE levels. Chloroquine and NH4Cl significantly reduced apoE degradation; however, ALLN plus either of these reagents appear to have an additive effect. The amount of apoE in cells chased in Ca2+-free medium was significantly higher than that in cells chased in Ca2+-containing medium (1.70 +/- 0.07-fold, n = 6, p < 0.01). ALLN plus Ca2+-free medium had no additive effect. ALLN had no significant influence on the degradation of albumin but had a similar effect on transfected apoE in Chinese hamster ovary cells. Overall, these data suggest that apoE may be degraded in a post-Golgi compartment of HepG2 and Chinese hamster ovary cells by lysosomal enzymes and cytosolic Ca2+-dependent cysteine proteases. ALLN inhibits the latter.	UNIV CHICAGO,DEPT PATHOL,MC 6079,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago					NHLBI NIH HHS [HL 15062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMITAY R, 1992, J BIOL CHEM, V267, P20694; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P771; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DORY L, 1991, J LIPID RES, V32, P783; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; ERIKSON SK, 1986, J LIPID RES, V27, P875; GRAIG WY, 1988, J BIOL CHEM, V263, P13880; HAY R, 1979, J LIPID RES, V20, P334; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HUI DY, 1981, J BIOL CHEM, V256, P5646; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; INOUE S, 1991, J BIOL CHEM, V266, P13311; KLENK HD, 1984, EMBO J, V3, P2911, DOI 10.1002/j.1460-2075.1984.tb02231.x; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MAZZONE T, 1989, J LIPID RES, V30, P1055; MENJU M, 1989, J BIOCHEM-TOKYO, V106, P505, DOI 10.1093/oxfordjournals.jbchem.a122882; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; NISHIURA I, 1978, J BIOCHEM-TOKYO, V84, P1657, DOI 10.1093/oxfordjournals.jbchem.a132296; ODA K, 1992, J BIOL CHEM, V267, P17465; ORCI L, 1991, CELL, V64, P1183; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; Sambrook J, 1989, MOL CLONING LABORATO; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WYNE KL, 1989, J BIOL CHEM, V264, P981; YE SQ, 1992, J BIOL CHEM, V267, P21961	43	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8497	8502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473293				2022-12-27	WOS:A1993KX81100021
J	DRAKE, SK; BOURRET, RB; LUCK, LA; SIMON, MI; FALKE, JJ				DRAKE, SK; BOURRET, RB; LUCK, LA; SIMON, MI; FALKE, JJ			ACTIVATION OF THE PHOSPHOSIGNALING PROTEIN CHEY .1. ANALYSIS OF THE PHOSPHORYLATED CONFORMATION BY F-19 NMR AND PROTEIN ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; GALACTOSE CHEMOSENSORY RECEPTOR; D-LACTATE DEHYDROGENASE; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURE; RESPONSE REGULATOR; SALMONELLA-TYPHIMURIUM; CONSERVED ASPARTATE	CheY, the 14-kDa response regulator protein of the Escherichia coli chemotaxis pathway, is activated by phosphorylation of Asp57. In order to probe the structural changes associated with activation, an approach which combines F-19 NMR, protein engineering, and the known crystal structure of one conformer has been utilized. This first of two papers examines the effects of Mg(II) binding and phosphorylation on the conformation of CheY. The molecule was selectively labeled at its six phenylalanine positions by incorporation of 4-fluorophenylalanine, which yielded no significant effect on activity. One of these F-19 probe positions monitored the vicinity of Lys109, which forms a salt bridge to Asp57 in the apoprotein and has been proposed to act as a structural ''switch'' in activation. F-19 NMR chemical shift studies of the labeled protein revealed that the binding of the cofactor Mg(II) triggered local structural changes in the activation site, but did not perturb the probe of the Lys109 region. The structural changes associated with phosphorylation were then examined, utilizing acetyl phosphate to chemically generate phospho-CheY during NMR acquisition. Phosphorylation triggered a long-range conformational change extending from the activation site to a cluster of 4 phenylalanine residues at the other end of the molecule. However, phosphorylation did not perturb the probe of Lys109. The observed phosphorylated conformer is proposed to be the first step in the activation of CheY; later steps appear to perturb Lys109, as evidenced in the following paper. Together these results may give insight into the activation of other prokaryotic response regulators.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Colorado System; University of Colorado Boulder; California Institute of Technology			Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220	NIAID NIH HHS [AI07798, R01 AI019296, AI19296] Funding Source: Medline; NIGMS NIH HHS [R01 GM040731-12, R01 GM040731, GM40731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AUSPURGER J, 1993, J MAGN RESON, V100, P342; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; GAMMON KL, 1972, J AM CHEM SOC, V94, P4573, DOI 10.1021/ja00768a027; GREGORY DH, 1991, BIOPOLYMERS, V31, P845, DOI 10.1002/bip.360310705; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1991, METHOD ENZYMOL, V200, P188; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; KAR L, 1992, BIOCHEM J, V287, P521, DOI 10.1042/bj2870521; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KIM HW, 1990, FEBS LETT, V272, P34, DOI 10.1016/0014-5793(90)80442-L; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2817, DOI 10.1021/bi00225a012; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1990, J BIOL CHEM, V265, P11549; LU P, 1976, P NATL ACAD SCI USA, V73, P3471, DOI 10.1073/pnas.73.10.3471; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4257, DOI 10.1021/bi00231a022; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P6484, DOI 10.1021/bi00240a019; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; Ninfa A J, 1991, Genet Eng (N Y), V13, P39; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pauling L., 1960, NATURE CHEM BOND; PEERSEN OB, 1990, BIOCHEMISTRY-US, V29, P3256, DOI 10.1021/bi00465a017; POST JFM, 1984, J MOL BIOL, V179, P729, DOI 10.1016/0022-2836(84)90164-5; PRATT EA, 1975, BIOCHEMISTRY-US, V14, P3035, DOI 10.1021/bi00684a037; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROBERTSON DE, 1977, BIOCHEMISTRY-US, V16, P1443, DOI 10.1021/bi00626a032; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; RULE GS, 1987, BIOCHEMISTRY-US, V26, P549, DOI 10.1021/bi00376a029; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SIXL F, 1990, BIOCHEM J, V266, P545, DOI 10.1042/bj2660545; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STOCK JB, 1992, J BIOL CHEM, V267, P19753; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; SYKES BD, 1974, P NATL ACAD SCI USA, V71, P469, DOI 10.1073/pnas.71.2.469; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WACKS DB, 1985, J BIOL CHEM, V260, P1651; WESTHEAD EW, 1961, BIOCHIM BIOPHYS ACTA, V54, P145, DOI 10.1016/0006-3002(61)90947-7; WILSON ML, 1985, BIOCHEMISTRY-US, V24, P1920, DOI 10.1021/bi00329a018; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	62	66	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13081	13088						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514749				2022-12-27	WOS:A1993LH55300014
J	JAKUS, J; WOLFF, EC; PARK, MH; FOLK, JE				JAKUS, J; WOLFF, EC; PARK, MH; FOLK, JE			FEATURES OF THE SPERMIDINE-BINDING SITE OF DEOXYHYPUSINE SYNTHASE AS DERIVED FROM INHIBITION STUDIES - EFFECTIVE INHIBITION BY BIS-GUANYLATED AND MONO-GUANYLATED DIAMINES AND POLYAMINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4D; PROTEIN-SYNTHESIS; HYPUSINE FORMATION; AMINO-ACID; FACTOR 4D; IDENTIFICATION; PRECURSOR; SUBSTRATE; CHEMISTRY; SECONDARY	Several types of basic compounds structurally related to spermidine, one of the substrates for deoxyhypusine synthase, were tested as inhibitors of this enzyme. The results indicate that inhibitory compounds associate with the enzyme at the site of spermidine binding and must possess two charged primary amino or guanidino groups, or one of each. The efficiency of inhibition is related to the maximum possible distance between the primary amino groups and is adversely affected by substitutions on the secondary amino group or in the carbon chains of polyamines. The mono-guanyl derivatives are much more effective inhibitors than the parent amines or their bis-guanylated counterparts, N1-guanyl-1,7-diaminoheptane being the most effective compound with a K(i) value of about 10 nM. Based on these observations we have proposed a model for the spermidine-binding site of deoxyhypusine synthase. Studies with Chinese hamster ovary cells reveal a direct correlation between prevention of hypusine formation by several guanyldiamines and their in vitro inhibition of deoxyhypusine synthase. This evidence for disruption of the initial step in the post-translational maturation of eukaryotic initiation factor 5A provides a basis for the potential control of protein biosynthesis and cell proliferation.			JAKUS, J (corresponding author), NIDR, CELLULAR DEV & ONCOL LAB, BLDG 30, RM 211, BETHESDA, MD 20892 USA.							ABBRUZZESE A, 1989, BIOCHIM BIOPHYS ACTA, V997, P248, DOI 10.1016/0167-4838(89)90195-7; BAILLON JG, 1988, EUR J BIOCHEM, V176, P237, DOI 10.1111/j.1432-1033.1988.tb14274.x; BERGERON RJ, 1982, SYNTHESIS-STUTTGART, P689; BROWN HC, 1973, J ORG CHEM, V38, P912, DOI 10.1021/jo00945a015; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CLARKE DD, 1959, ARCH BIOCHEM BIOPHYS, V79, P338, DOI 10.1016/0003-9861(59)90413-8; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DIETRICH B, 1979, HELV CHIM ACTA, V62, P2763, DOI 10.1002/hlca.19790620827; ELORANTA TO, 1990, J BIOCHEM-TOKYO, V108, P593, DOI 10.1093/oxfordjournals.jbchem.a123248; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; GORDON ED, 1987, J BIOL CHEM, V262, P16590; KHOMUTOV AR, 1989, BIOORG KHIM+, V15, P698; KHOMUTOV RM, 1963, CHEM BIOL ASPECTS PY, P313; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; NAGARAJAN S, 1985, J ORG CHEM, V50, P5735, DOI 10.1021/jo00350a059; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; ROBIN Y, 1967, COMP BIOCHEM PHYSIOL, V22, P787, DOI 10.1016/0010-406X(67)90771-2; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SMITH TA, 1983, METHOD ENZYMOL, V94, P311; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TAYLOR GR, 1972, Patent No. 1294443; TORRELIO BM, 1984, EXP CELL RES, V154, P454, DOI 10.1016/0014-4827(84)90169-1; WALSH C, 1983, ADV ENZYMOL RAMB, V55, P197; WOLFF EC, 1990, J BIOL CHEM, V265, P4793	33	158	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13151	13159						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514754				2022-12-27	WOS:A1993LH55300023
J	SAUTER, A; RUDIN, M				SAUTER, A; RUDIN, M			DETERMINATION OF CREATINE-KINASE KINETIC-PARAMETERS IN RAT-BRAIN BY NMR MAGNETIZATION-TRANSFER - CORRELATION WITH BRAIN-FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE SPECTROSCOPY; SATURATION TRANSFER; ATP SYNTHESIS; LIVING RAT; P-31; INVIVO; ENERGY; MUSCLE; HEART; CONSUMPTION	The pseudo first-order rate constant k(f) of the creatine kinase (CK) forward reaction as well as the CK forward flux F(CK, f) have been shown to correlate better with cardiac performance than the steady-state levels of ATP and PCr (Bittl, J. A., and Ingwall, J. S. (1985) J. Biol. Chem. 260, 3512-3517). In order to elucidate the relationship between the CK kinetic parameters and brain activity, we have determined, using the noninvasive NMR technique of magnetization transfer, k(f) and F(CK, f) in rats, in which brain activity was experimentally varied by administration of either thiopental sodium or bicuculline to decrease or increase electroencephalogram EEG) intensity, respectively. The steady-state levels of ATP and PCr, as well as the accumulation of deoxyglucose 6-phosphate (DG-6P) in brain following intraperitoneal administration of deoxyglucose, were determined simultaneously by the NMR technique, whereas the cortical EEG was recorded in a separate experiment. The EEG intensity (range, 1-20 Hz), taken as a measure for brain performance, as well as the amount of DG-6P formed in brain, reflecting the synthesis rate of high energy phosphates (ATP and PCr), linearly correlated with k(f). Despite large changes in both EEG intensity (50-250%) and k(f) (0.12-0.69 s-1) between thiopental sodium- and bicuculline-treated rats, the ATP levels remained constant. whereas the PCr levels decreased with high EEG activity. In contrast to the expectation based on model calculations of CK kinetics, the PCr levels did not increase above control values at reduced EEG intensity (50% of controls). At EEG intensities exceeding control values (bicuculline-treated rats) F(CK, f) increased as predicted by CK equilibrium. In conclusion, we have shown that in the rat brain, like in the heart, the CK forward rate constant k(f), in contrast to ATP and PCr levels, is a sensitive reliable indicator of both increased and reduced function.			SAUTER, A (corresponding author), SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND.		Rudin, Markus/F-2417-2010					ALGER JR, 1984, Q REV BIOPHYS, V17, P83, DOI 10.1017/S0033583500005266; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BITTL JA, 1985, J BIOL CHEM, V260, P3512; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; BITTL JA, 1987, J CLIN INVEST, V79, P1852, DOI 10.1172/JCI113027; BITTL JA, 1986, CIRC RES, V58, P378, DOI 10.1161/01.RES.58.3.378; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; DEGANI H, 1987, MAGNET RESON MED, V5, P1, DOI 10.1002/mrm.1910050102; DEUEL RK, 1985, SCIENCE, V228, P1329, DOI 10.1126/science.4001946; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; EVELHOCH JL, 1985, MAGNET RESON MED, V2, P410, DOI 10.1002/mrm.1910020409; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; HOULT DI, 1974, NATURE, V252, P285, DOI 10.1038/252285a0; KINGSLEYHICKMAN PB, 1987, BIOCHEMISTRY-US, V26, P7501, DOI 10.1021/bi00397a045; KOGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1258, DOI 10.1016/S0006-291X(88)81010-6; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; MORRISON JF, 1966, J BIOL CHEM, V241, P673; PETROFF OAC, 1984, ANN NEUROL, V16, P169, DOI 10.1002/ana.410160203; PRICHARD JW, 1983, P NATL ACAD SCI-BIOL, V80, P2748, DOI 10.1073/pnas.80.9.2748; RUDIN M, 1989, J PHARMACOL EXP THER, V251, P700; RUDIN M, 1992, NMR BASIC PRINCIPLES, V27, P257; SAUTER A, 1987, MAGNET RESON MED, V4, P1, DOI 10.1002/mrm.1910040102; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; Siesjo B.K., 1978, BRAIN ENERGY METABOL; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Taylor D J, 1983, Mol Biol Med, V1, P77	27	92	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13166	13171						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514755				2022-12-27	WOS:A1993LH55300025
J	CAROFF, M; DEPRUN, C; KARIBIAN, D				CAROFF, M; DEPRUN, C; KARIBIAN, D			CF-252 PLASMA DESORPTION MASS-SPECTROMETRY APPLIED TO THE ANALYSIS OF UNDERIVATIZED ROUGH-TYPE ENDOTOXIN PREPARATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; COMPLETE STRUCTURAL DETERMINATION; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDES; PURIFICATION; POSITION; PROTEIN; ACID	Plasma desorption mass spectrometry has recently been used with success to characterize native, underivatized Re- to Rc-type endotoxins in terms of their constituent lipopolysaccharides. The spectra give masses for the major molecular species of lipopolysaccharide present from which their probable compositions could be inferred using the overall composition determined by chemical analyses. Moreover, the relative intensities of the signals are roughly proportional to the abundance of their corresponding molecular species. Native Rc-, Rb-, and Ra-type enterobacterial endotoxins with 5-10 core sugar units have been rendered amenable to plasma-desorption mass spectrometry analysis by improvement in their solubility and the use of cellobiose as an additive. The spectra of four Salmonella and Escherichia endotoxin preparations demonstrated heterogeneity in acylation and phosphorylation. Since these sources of heterogeneity are critical for many biological activities, the spectra underline the need to define the composition of each preparation of endotoxin used in structure-function studies.	UNIV PARIS 11,INST BIOCHIM,CNRS,URA 1116,EQUIPE ENDOTOXINS,BAT 432,F-91405 ORSAY,FRANCE; INST NATL PHYS NUCL & PHYS PARTICULES,CNRS,INST PHYS NUCL,EQUIPE INTERACT ION SURFACE & MAT,F-91406 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Caroff, Martine/N-4293-2019	CAROFF, Martine/0000-0002-7329-5247				BOLBACH G, 1988, NUCL INSTRUM METH B, V30, P74, DOI 10.1016/0168-583X(88)90082-1; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF MGL, 1990, APPL ENVIRON MICROB, V56, P1957, DOI 10.1128/AEM.56.6.1957-1959.1990; DELLANEGRA S, 1986, REV PHYS APPL, V21, P401, DOI 10.1051/rphysap:01986002106040100; Deprun C, 1989, Rapid Commun Mass Spectrom, V3, P171, DOI 10.1002/rcm.1290030602; GALANOS C, 1975, EUR J BIOCHEM, V54, P603, DOI 10.1111/j.1432-1033.1975.tb04172.x; GALANOS C, 1984, HDB ENDOTOXIN, V1, P46; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; JONSSON GP, 1986, ANAL CHEM, V58, P1084, DOI 10.1021/ac00297a023; KARIBIAN D, 1991, INT J MASS SPECTROM, V111, P273, DOI 10.1016/0168-1176(91)85060-Y; LEHMANN V, 1978, EUR J BIOCHEM, V86, P487, DOI 10.1111/j.1432-1033.1978.tb12332.x; MCFARLANE RD, 1976, SCIENCE, V191, P920; QURESHI N, 1983, J BIOL CHEM, V258, P2947; QURESHI N, 1985, J BIOL CHEM, V260, P5271; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1988, J BIOL CHEM, V263, P5502; RIETSCHEL ET, 1984, HDB ENDOTOXINS, V1, P187; ROWATT E, 1984, BIOCHEM J, V233, P23; SHANDS JW, 1980, J BIOL CHEM, V255, P1221; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; WEISS J, 1986, INFECT IMMUN, V51, P594, DOI 10.1128/IAI.51.2.594-599.1986; WOLLENWEBER HW, 1983, EUR J BIOCHEM, V130, P167	22	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12321	12324						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509370				2022-12-27	WOS:A1993LG65800018
J	GAUT, JR; HENDERSHOT, LM				GAUT, JR; HENDERSHOT, LM			THE IMMUNOGLOBULIN-BINDING PROTEIN INVITRO AUTOPHOSPHORYLATION SITE MAPS TO A THREONINE WITHIN THE ATP BINDING CLEFT BUT IS NOT A DETECTABLE SITE OF INVIVO PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; SODIUM DODECYL SULFATE; HEAT-SHOCK; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; CHAIN; DNAK; EXPRESSION; BIP/GRP78; TRANSPORT	In vitro incubation of immunoprecipitated immunoglobulin-binding protein (BiP) complexes with calcium and [gamma-P-32]ATP resulted in the phosphorylation of BiP on a threonine residue. This autophosphorylation activity did not occur in the presence of magnesium but had the same pH optimum as reported for its magnesium-dependent ATPase activity. This suggested the possibility that both activities could occur through ATP hydrolysis at the same site. In support of this, mutation of either Thr-37 or Thr-229 to a glycine eliminated both autophosphorylation and ATPase activities, and mutation of either residue to a serine significantly reduced both activities. Glutamic acid 175 in HSC71 has been hypothesized to flank the divalent cation complexed with ATP. Mutation of the analogous glutamic acid, Glu-201, in BiP abolished ATPase activity but still supported some autophosphorylation. The in vitro phosphorylation site was mapped to Thr-229 by mutational analysis. This threonine has been hypothesized to interact with the gamma-phosphate of ATP through a polarized water molecule and would be in a position to act as a phosphate acceptor in the ATP hydrolysis reaction. These data imply that both ATPase and autophosphorylation result from ATP hydrolysis at the same site and that the cation associated with BiP determines which activity is observed. Comparison of partial protease digestion or cyanogen bromide cleavage products of in vitro and in vivo phosphorylated BiP demonstrated that Thr-229 is not a detectable site of phosphorylation in cells. Therefore, whatever functional role phosphorylation may have in vivo, it cannot be attributed to autophosphorylation of Thr-229.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE LN, MEMPHIS, TN 38103 USA; UNIV TENNESSEE, MED CTR, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043576] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 43576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BURR FA, 1983, METHOD ENZYMOL, V96, P716; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	26	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12691	12698						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509403				2022-12-27	WOS:A1993LG65800069
J	SCREATON, GR; BELL, MV; BELL, JI; JACKSON, DG				SCREATON, GR; BELL, MV; BELL, JI; JACKSON, DG			THE IDENTIFICATION OF A NEW ALTERNATIVE EXON WITH HIGHLY RESTRICTED TISSUE EXPRESSION IN TRANSCRIPTS ENCODING THE MOUSE PGP-1 (CD44) HOMING RECEPTOR - COMPARISON OF ALL 10 VARIABLE EXONS BETWEEN MOUSE, HUMAN, AND RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODIES; HIGH ENDOTHELIUM; CELLS; GLYCOPROTEIN; HYALURONATE; ADHESION; ACTIVATION; BINDING	The human CD44 cell surface glycoprotein family which has been implicated in lymphocyte homing, tumor metastasis, and extracellular matrix attachment consists of a large number of related isoforms that derive from the differential splicing of a single CD44 gene transcript. Recent mapping of the CD44 locus in man indicated the presence of at least nine alternative exons within the region of the gene encoding the variable membrane proximal extracellular domain. Here we report the identification of a 10th alternative exon (termed V1) in the mouse, human, and rat CD44 genes. We demonstrate tissue-specific patterns of expression for transcripts containing exons V1-V10 in the mouse and a highly restricted usage of exon V1 in transcripts from mouse gastric tissue. Close sequence homology between exons V1-V10 from mouse rat and human points to a specific functional role rather than a purely structural role for the membrane proximal extracellular domain of the CD44 molecule.			SCREATON, GR (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.			Screaton, Gavin/0000-0002-3549-4309; , david/0000-0002-4133-9364	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAZIL V, 1992, J IMMUNOL, V149, P747; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CARTER WG, 1988, J BIOL CHEM, V263, P4193; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; HUET S, 1989, J IMMUNOL, V143, P798; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; KANSAS GS, 1989, J IMMUNOL, V142, P3050; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; OMARY MB, 1988, IMMUNOGENETICS, V27, P460, DOI 10.1007/BF00364434; PALS ST, 1989, J IMMUNOL, V143, P851; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SHTIVELMAN E, 1991, MOL CELL BIOL, V11, P5446, DOI 10.1128/MCB.11.11.5446; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; UNDERHILL C, 1992, J CELL SCI, V103, P293; UNDERHILL CB, 1987, J BIOL CHEM, V262, P13142	27	249	262	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12235	12238						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509359				2022-12-27	WOS:A1993LG65800002
J	PIATIGORSKY, J; HORWITZ, J; NORMAN, BL				PIATIGORSKY, J; HORWITZ, J; NORMAN, BL			J1-CRYSTALLINS OF THE CUBOMEDUSAN JELLYFISH LENS CONSTITUTE A NOVEL FAMILY ENCODED IN AT LEAST 3 INTRONLESS GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEAT-SHOCK PROTEIN; EYE LENS; NUCLEOTIDE-SEQUENCE; HSP70 GENE; CRYSTALLINS; RECRUITMENT; EVOLUTION; IDENTIFICATION; EXPRESSION	The transparent cellular eye lens of the jellyfish (Tripedalia cystophora) contains three major proteins called J1-, J2-, and J3-crystallins. Here we have isolated cDNAs encoding three novel 37-kDa J1-crystallin polypeptides (J1A, J1B, and J1C) sharing 84-98% identity in amino acid sequence among themselves. Each polypeptide is encoded in a separate gene lacking introns. In contrast to the striking similarity of the coding regions, the 5'- and 3'-untranslated sequences of the three J1-crystallin mRNAs are completely different, consistent with an ancient duplication of their genes. Thermostability experiments showed that J1-crystallins remain soluble at 50-degrees-C, but precipitate at 60-degrees-C, suggesting that these major lens proteins are neither heat shock proteins nor unusually heat-resistant as are many vertebrate crystallins. Although J1 mRNAs appear polyadenylated, no typical polyadenylation signal was detected in the cDNAs. Surprisingly, the only obvious similarities among the 5'-flanking regions of the three J1-crystallin genes are putative TATA boxes and several CAAT sequences, consistent with fewer evolutionary constraints on the regulatory sequences than on the coding sequences of these crystallin genes.	UNIV CALIF LOS ANGELES, SCH MED, JULES STEIN EYE INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	PIATIGORSKY, J (corresponding author), NEI, MOLEC & DEV BIOL LAB, BLDG 30, RM 201, BETHESDA, MD 20892 USA.							BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COX RL, 1991, BIOL BULL-US, V181, P333, DOI 10.1086/BBLv181n2p333; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; GOLDMAN A, 1986, ANN REV BIOPHYS CHEM, V15, P321; GUPTA RS, 1989, BIOCHEM BIOPH RES CO, V163, P780, DOI 10.1016/0006-291X(89)92290-0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; JAWORSKI CJ, 1991, J MOL EVOL, V33, P495, DOI 10.1007/BF02102802; KANEHISA M, 1988, IDEAS 88 USER MANUAL; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laska G., 1982, Zoologische Jahrbuecher Abteilung fuer Anatomie und Ontogenie der Tiere, V108, P107; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MCFALLNGAI MJ, 1990, EXP EYE RES, V50, P703, DOI 10.1016/0014-4835(90)90117-D; MIYATA T, 1981, P NATL ACAD SCI-BIOL, V78, P5739, DOI 10.1073/pnas.78.9.5739; MORIMOTO RI, 1986, J BIOL CHEM, V261, P2692; MUES GI, 1986, J BIOL CHEM, V261, P874; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; ROBSON EA, 1985, SYSTEMATICS ASS ORIG, V28, P60; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; TOMAREV SI, 1992, J BIOL CHEM, V267, P8604; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; TOMAREV SI, 1991, J BIOL CHEM, V266, P24226; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WISNIEWSKI J, 1990, BIOCHIM BIOPHYS ACTA, V1048, P93, DOI 10.1016/0167-4781(90)90027-Y; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925	43	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11894	11901						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505315				2022-12-27	WOS:A1993LF28400066
J	MORIYAMA, R; LOMBARDO, CR; WORKMAN, RF; LOW, PS				MORIYAMA, R; LOMBARDO, CR; WORKMAN, RF; LOW, PS			REGULATION OF LINKAGES BETWEEN THE ERYTHROCYTE-MEMBRANE AND ITS SKELETON BY 2,3-DIPHOSPHOGLYCERATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HEREDITARY SPHEROCYTOSIS; STRUCTURAL TRANSITIONS; MECHANICAL STABILITY; CYTOPLASMIC DOMAINS; MOLECULAR DEFECT; BINDING-SITE; 4.1 BINDING; SPECTRIN; ANKYRIN	In addition to reducing hemoglobin-O2 affinity, 2,3-diphosphoglycerate (DPG) is known to modulate the mechanical properties of the erythrocyte membrane. By fluorescence spectroscopy and differential scanning calorimetry, we demonstrate that DPG binds the cytoplasmic domain of erythrocyte membrane band 3 in two stages characterized by apparent K(D) values of approximately approximately 2 and 12 mM. DPG was also shown to perturb the stability of ankyrin, protein 4.1, and protein 4.2 in situ and to directly bind to protein 4.1. In studies of membrane-skeleton interactions, DPG was observed to inhibit the fast and slow phases of ankyrin binding to band 3 and to reduce both the number of ankyrin sites and affinity of ankyrin for each class of site. The inhibition was biphasic, similar to the band 3-DPG binding isotherm; however, at physiological DPG concentrations a reduction in only 15% of the ankyrin sites was observed. In contrast, inhibition of protein 4.1 binding to the membrane reached 65% at physiological DPG concentrations (approximately approximately 5.9 mM); at more elevated concentrations, blockade was nearly quantitative, affecting glycophorin and band 3 sites alike. Taken together with previous observations, these data suggest that DPG's effect on O2 delivery may extend beyond its well recognized impact on hemoglobin-O2 affinity.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, R37GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRE P, 1981, J CLIN INVEST, V68, P1566, DOI 10.1172/JCI110411; ANDERSON RA, 1989, RED BLOOD CELL MEMBR, P187; APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRANDTS JF, 1977, BIOCHEMISTRY-US, V16, P3450, DOI 10.1021/bi00634a024; BRANDTS JF, 1978, BIOCHIM BIOPHYS ACTA, V512, P566, DOI 10.1016/0005-2736(78)90166-9; BUNN HF, 1971, J BIOL CHEM, V246, P5273; CHAO TS, 1991, ARCH BIOCHEM BIOPHYS, V285, P221, DOI 10.1016/0003-9861(91)90352-J; CHASIS JA, 1988, J CELL BIOL, V107, P1351, DOI 10.1083/jcb.107.4.1351; CHASIS JA, 1986, J CELL BIOL, V103, P343, DOI 10.1083/jcb.103.2.343; CHASIS JA, 1988, J CLIN INVEST, V82, P617, DOI 10.1172/JCI113640; COHEN AM, 1988, BIOCHEMISTRY-US, V27, P614, DOI 10.1021/bi00402a018; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P6091, DOI 10.1021/bi00320a029; DALEKE DL, 1989, J CELL BIOL, V108, P1375, DOI 10.1083/jcb.108.4.1375; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DAVIO SR, 1982, BIOCHEMISTRY-US, V21, P3585, DOI 10.1021/bi00258a009; JINBU Y, 1982, BIOCHEM BIOPH RES CO, V104, P1087, DOI 10.1016/0006-291X(82)91361-4; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; LANGE Y, 1982, J CELL BIOL, V92, P714, DOI 10.1083/jcb.92.3.714; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1984, BLOOD, V259, P13070; LUX SE, 1979, NORMAL ABNORMAL RED, P463; LYSKO KA, 1981, BIOCHEMISTRY-US, V20, P5570, DOI 10.1021/bi00522a034; MENTZER WC, 1987, J CLIN INVEST, V79, P943, DOI 10.1172/JCI112905; MOHANDAS N, 1983, SEMIN HEMATOL, V20, P225; MOHANDAS N, 1992, J CLIN INVEST, V89, P686, DOI 10.1172/JCI115636; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PINDER JC, 1989, BIOCHEM J, V264, P423, DOI 10.1042/bj2640423; REID ME, 1987, BLOOD, V69, P1068; REID ME, 1990, BLOOD, V75, P2229; REID ME, 1989, RED CELL, P553; REINHART WH, 1988, AM J HEMATOL, V29, P195, DOI 10.1002/ajh.2830290404; SATO SB, 1983, EUR J BIOCHEM, V130, P19; SCHINDLER M, 1980, P NATL ACAD SCI-BIOL, V77, P1457, DOI 10.1073/pnas.77.3.1457; SHEETZ MP, 1980, J BIOL CHEM, V255, P9955; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WAUGH RE, 1986, BLOOD, V68, P231; WOLFE LC, 1982, NEW ENGL J MED, V307, P1367, DOI 10.1056/NEJM198211253072203	46	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10990	10996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496163				2022-12-27	WOS:A1993LD46600044
J	SEVLEVER, D; ROSENBERRY, TL				SEVLEVER, D; ROSENBERRY, TL			MANNOSAMINE INHIBITS THE SYNTHESIS OF PUTATIVE GLYCOINOSITOL PHOSPHOLIPID ANCHOR PRECURSORS IN MAMMALIAN-CELLS WITHOUT INCORPORATING INTO AN ACCUMULATED INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; TRYPANOSOMA-BRUCEI; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; STRUCTURAL CHARACTERIZATION; BIOSYNTHESIS; PROTEINS; MUTANTS; IDENTIFICATION	Mannosamine (ManN) has been reported to inhibit the formation of Manalpha-1,2Man linkages and to prevent the anchoring of membrane proteins by glycoinositol phospholipids (GPIs). In this paper, the effect of ManN on the synthesis of putative GPI anchor precursors in mammalian cells was studied. Three different cell lines were analyzed: HeLa cells and Thy-1 negative lymphoma mutants B and F that accumulate two-mannosyl GPI (Man2GPI) and three-mannosyl GPI (Man3GPI) species, respectively. ManN did not alter the incorporation of [H-3]Man into the Man2GPI in mutant B cells. However, when either HeLa cells or mutant F cells were labeled with [H-3]Man in the presence of ManN, [H-3]Man incorporation into Man3GPI species was blocked and the TLC profile of [H-3]Man-labeled glycolipids resembled that obtained with mutant B cells. Further characterization of the predominant labeled glycolipid that accumulated in ManN-treated HeLa cells by enzymatic and chromatographic criteria and permethylation analysis confirmed the structure as a Man2GPI indistinguishable from the Man2GPI that accumulates in mutant B cells. Based on previous reports that ManN inhibits Manalpha-1,2Man linkage formation and that in GPI-anchored proteins the third Man residue is attached by a Manalpha-1,2Man linkage, these results indicate that the third Man residue that distinguishes the putative Man2GPI precursor from the Man3GPI precursor also is attached by a Manalpha-1,2Man linkage. Furthermore, the observation that Man2GPI rather than a new GPI species containing ManN accumulated during ManN treatment revealed that the mechanism of ManN inhibition primarily involved inhibition of an alpha1,2-mannosyltransferase rather than incorporation of ManN into an aberrant GPI species.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University					NIDDK NIH HHS [DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEEG MA, 1992, J BIOL CHEM, V267, P18581; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOENER MC, 1990, EUR J BIOCHEM, V190, P593, DOI 10.1111/j.1432-1033.1990.tb15614.x; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HUANG KS, 1990, J BIOL CHEM, V265, P17738; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1992, J BIOL CHEM, V267, P21250; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1989, BIOCHEM SOC T, V17, P746, DOI 10.1042/bst0170746; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; UEDA E, 1993, J BIOL CHEM, V268, P9998; URAKAZE M, 1992, J BIOL CHEM, V267, P6459	40	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10938	10945						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496158				2022-12-27	WOS:A1993LD46600037
J	BELISLE, JT; MCNEIL, MR; CHATTERJEE, D; INAMINE, JM; BRENNAN, PJ				BELISLE, JT; MCNEIL, MR; CHATTERJEE, D; INAMINE, JM; BRENNAN, PJ			EXPRESSION OF THE CORE LIPOPEPTIDE OF THE GLYCOPEPTIDOLIPID SURFACE-ANTIGENS IN ROUGH MUTANTS OF MYCOBACTERIUM-AVIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE HAPTEN; MASS-SPECTROMETRY; INTRACELLULARE; BIOSYNTHESIS; GLYCOLIPIDS; SMOOTH; INFECTION; VARIANTS; COMPLEX; ACIDS	Toward studying the genetics, biosynthesis, and roles in the pathogenesis of the dominant surface glycopeptidolipid antigens of Mycobacterium avium, rough colony variants of M. avium serovar 2 were picked, cultured in quantity, and their lipid composition examined. Two of the rough (Rg) variants, Rg-3 and Rg-4, were devoid of glycopeptidolipids or any more elemental structures and thus were similar to those described previously. Two others, Rg-0 and Rg-1, each contained two novel lipopeptides, devoid of any of the carbohydrate substituents that confer serotypic activity on the glycopeptidolipids. The application of gas chromatography, fast atom bombardment-mass spectrometry and H-1 NMR to lipopeptide I established the structure C32:2-beta-OH-fatty acyl-D-Phe-D-allo-Thr-D-Ala-L-alaninol. Lipopeptide II represented a minor variation of this structure: C32:1-beta-OH-fatty acyl-D-Phe-D-allo-Thr-D-Ala-L-alaninol. These newly discovered lipopeptides are identical to the fatty acyl-tripeptide-amino alcohol ''core'' component of the glycopeptidolipids of the M. avium complex, and thus the Rg-0 and Rg-1 variants represent a form of ''deep rough'' mutation in M. avium. Separately, we report that these rough variants of M. avium differ genetically from the smooth, virulent form by major deletions of portions of the genes responsible for glycopeptidolipid synthesis (Belisle, J. T., Klaczkiewicz, K., Brennan, P. J., Jacobs, W. R., Jr., and Inamine, J. M. (1993) J. Biol. Chem. 268, 10517-10523). The isolation of different sets of spontaneous mutants of M. avium differentially defective in the capacity to synthesize glycopeptidolipids provides the means to explore their biosynthesis and roles in opportunistic pathogenesis.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA	Colorado State University			Belisle, John T/B-8944-2017; McNeil, Michael/G-3325-2019	Belisle, John T/0000-0002-2539-2798; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI018357, U01AI030189, R37AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18357, AI 30189] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARROW WW, 1991, RES MICROBIOL, V142, P427, DOI 10.1016/0923-2508(91)90115-Q; BARROW WW, 1982, J BACTERIOL, V150, P381, DOI 10.1128/JB.150.1.381-384.1982; BARROW WW, 1980, J BACTERIOL, V144, P814, DOI 10.1128/JB.144.2.814-822.1980; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; BELISLE JT, 1991, J BACTERIOL, V173, P6991, DOI 10.1128/jb.173.21.6991-6997.1991; BELISLE JT, 1993, J BIOL CHEM, V268, P10517; BOZIC CM, 1988, J BIOL CHEM, V263, P14984; BRENNAN PJ, 1979, J BIOL CHEM, V254, P4205; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; BRENNAN PJ, 1984, MICROBIOLOGY 1984, P366; BROWNBACK PE, 1988, INFECT IMMUN, V56, P1044, DOI 10.1128/IAI.56.5.1044-1050.1988; CAMPHAUSEN RT, 1986, J BACTERIOL, V168, P660, DOI 10.1128/jb.168.2.660-667.1986; COHN ML, 1968, AM REV RESPIR DIS, V98, P295; DAVID HL, 1988, CURR MICROBIOL, V17, P61, DOI 10.1007/BF01568787; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREGNAN GB, 1962, J BACTERIOL, V83, P828, DOI 10.1128/JB.83.4.828-836.1962; Frehel C, 1989, Acta Leprol, V7 Suppl 1, P173; FREHEL C, 1986, ANN INST PASTEUR MIC, V137B, P239, DOI 10.1016/S0769-2609(86)80115-6; GHUYSEN JM, 1977, CELL SURF REV, V4, P463; Goren M. B., 1979, TUBERCULOSIS, P63; GULIG PA, 1983, INFECT IMMUN, V42, P728; HITCHCOCK PJ, 1986, J BACTERIOL, V166, P699, DOI 10.1128/jb.166.3.699-705.1986; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1337; HUASEK P, 1975, J CHROMATOGR, V113, P139; JARDINE I, 1989, ANAL CHEM, V61, P416, DOI 10.1021/ac00180a008; JOHNSON RS, 1987, BIOCHEMISTRY-US, V26, P1209, DOI 10.1021/bi00379a001; LAMBERT MA, 1983, J CLIN MICROBIOL, V18, P1370, DOI 10.1128/JCM.18.6.1370-1377.1983; LUDERITZ O, 1966, ANGEW CHEM INT EDIT, V5, P198, DOI 10.1002/anie.196601981; MACKENZIE SL, 1977, J CHROMATOGR, V132, P485, DOI 10.1016/S0021-9673(00)82912-X; MAKELA PH, 1984, CHEM ENDOTOXIN, V41, P59; MCNEIL M, 1987, J BIOL CHEM, V262, P2630; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MOEHRING JM, 1965, AM REV RESPIR DIS, V92, P704; MORRISON DC, 1983, REV INFECT DIS S4, V5, P733; PERLMAN D, 1971, ANNU REV BIOCHEM, V40, P449, DOI 10.1146/annurev.bi.40.070171.002313; RAETZ CRH, 1987, ESCHERICHIA COLI SAL, V1, P498; RASTOGI N, 1989, ZBL BAKT-INT J MED M, V270, P345; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIVIERE M, 1991, J BIOL CHEM, V266, P9057; SCHAEFER WB, 1970, AM REV RESPIR DIS, V102, P499; SCHMIDT G, 1968, ZENTRALBL BAKTERIO A, V209, P483; TASSELL SK, 1992, INFECT IMMUN, V60, P706, DOI 10.1128/IAI.60.2.706-711.1992; TERELETSKY MJ, 1983, INFECT IMMUN, V41, P1312, DOI 10.1128/IAI.41.3.1312-1321.1983; TSUYUGUCHI I, 1988, CHEST, V94, P822, DOI 10.1378/chest.94.4.822; VERCELLONE A, 1989, J BIOL CHEM, V264, P7447; WATSON SR, 1980, IMMUNOLOGY, V39, P367; WRIGHT ER, 1991, 91ST GEN M AM SOC MI	48	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10510	10516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486703				2022-12-27	WOS:A1993LB80000077
J	ELHAMMER, AP; POORMAN, RA; BROWN, E; MAGGIORA, LL; HOOGERHEIDE, JG; KEZDY, FJ				ELHAMMER, AP; POORMAN, RA; BROWN, E; MAGGIORA, LL; HOOGERHEIDE, JG; KEZDY, FJ			THE SPECIFICITY OF UDP-GALNAC - POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE AS INFERRED FROM A DATABASE OF INVIVO SUBSTRATES AND FROM THE INVITRO GLYCOSYLATION OF PROTEINS AND PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLYCOSYLATION; D-GALACTOSAMINE; IDENTIFICATION; LOCALIZATION; RECOGNITION; MYELIN; CELLS; COMPARTMENTS; BIOSYNTHESIS; GLYCOPROTEIN	The acceptor substrate specificity of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase (GalNAc-transferase) was inferred from the amino acid sequences surrounding 196 O-glycosylation sites extracted from the National Biomedical Research Foundation Protein Database. When analyzed according to the cumulative enzyme specificity model (Poorman, R. A., Tomasselli, A. G., Heinrikson, R. L., and Kezdy, F. J. (1991) J. Biol. Chem. 266,14554-14561) these data were found to be consistent with an enzymatic active site which interacts with an 8-amino-acid long segment of the substrate, spanning 3 amino acid residues preceding and 4 amino acid residues following the reactive serine or threonine. The model postulates independent interactions of the 8 amino acid moieties with their respective binding sites, designated as subsites P3 through P0 and P1' to P4'. High selectivity is expressed at all subsites toward serine, threonine, and proline. The inferred specificity was confirmed by in vitro bovine colostrum GalNAc-transferase-catalyzed glycosylation of unglycosylated proteins containing predicted sites for O-glycosylation and synthetic peptides designed to be GalNAc acceptors. In synthetic peptides the bovine colostrum GalNAc-transferase glycosylates threonine about 35 times faster than serine. Our results suggest that the specificity of the enzyme is not dependent on any particular secondary structure of the substrate but, rather, it is determined by the amino acids in the acceptor peptide segment as well as by the accessibility of this segment. It also appears likely that bovine colostrum GalNAc-transferase is able to catalyze in vivo the glycosylation of both threonine and serine residues.	UPJOHN CO,DIV CHEM,CANC & INFECT DIS RES UNIT,KALAMAZOO,MI 49001; UPJOHN CO,FAC CHEM,ANALYT BIOCHEM UNIT,KALAMAZOO,MI 49001	Pfizer; Pfizer	ELHAMMER, AP (corresponding author), UPJOHN CO,DIV CHEM,BIOCHEM UNIT,KALAMAZOO,MI 49001, USA.							AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRUZ TF, 1983, BIOCHIM BIOPHYS ACTA, V760, P403, DOI 10.1016/0304-4165(83)90381-1; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER A, 1984, J CELL BIOL, V98, P327; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; HAGOPIAN A, 1971, J BIOL CHEM, V246, P2519; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HANOVER JA, 1982, J BIOL CHEM, V257, P172; HART GW, 1988, TRENDS BIOCHEM SCI, V13, P380, DOI 10.1016/0968-0004(88)90179-X; HEINRIKSON RL, 1973, J BIOL CHEM, V248, P2521; HILL HD, 1977, J BIOL CHEM, V252, P3799; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUSHANSKY K, 1992, BIOCHEMISTRY-US, V31, P1881, DOI 10.1021/bi00121a042; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; PILLER V, 1990, J BIOL CHEM, V265, P9264; PILLER V, 1989, EUR J BIOCHEM, V183, P123, DOI 10.1111/j.1432-1033.1989.tb14904.x; POORMAN RA, 1991, J BIOL CHEM, V266, P14554; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; RODEN L, 1966, J BIOL CHEM, V241, P5949; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SCHMID K, 1992, P NATL ACAD SCI USA, V89, P663, DOI 10.1073/pnas.89.2.663; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; WANG Y, 1992, J BIOL CHEM, V267, P12706; WERTZ GW, 1989, J VIROL, V63, P4767, DOI 10.1128/JVI.63.11.4767-4776.1989; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	36	170	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10029	10038						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486674				2022-12-27	WOS:A1993LB80000017
J	HA, KS; EXTON, JH				HA, KS; EXTON, JH			DIFFERENTIAL TRANSLOCATION OF PROTEIN-KINASE-C ISOZYMES BY THROMBIN AND PLATELET-DERIVED GROWTH-FACTOR - A POSSIBLE FUNCTION FOR PHOSPHATIDYLCHOLINE-DERIVED DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-SPECIES ANALYSIS; ALPHA-THROMBIN; STIMULATED FIBROBLASTS; CULTURED FIBROBLASTS; DNA-SYNTHESIS; CA-2+ INFLUX; 1,2-DIACYLGLYCEROL; HYDROLYSIS; CELLS; ACCUMULATION	The translocation of protein kinase C (PKC) fro the cytosolic to the particulate fraction in IIC9 fibro blasts has been studied to define the functions of 1,2-diacylglycerol (DAG) derived from the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylcholine (PC). Alpha-thrombin caused a biphasic change in DAG, with two peaks at 15-60 s and 5-15 min, derived from PIP2 and PC, respectively, while platelet-derived growth factor (PDGF) induced a monophasic DAG increase from PC at 5-15 min. Alpha-thrombin also induced a rapid, but transient, increase of inositol 1,4,5-trisphosphate and cytosolic Ca2+, whereas PDGF did not. Three PKC isozymes, alpha, epsilon, and zeta, were identified by Western blotting in IIC9 cells and were mainly localized in the cytosol. A fraction of cytosolic PKC alpha was rapidly translocated by alpha-thrombin at 15 s, but its membrane association was lost within 1 min. PKC epsilon was also rapidly translocated; however, its membrane association was sustained for almost 60 min. PKC zeta was not translocated by alpha-thrombin or phorbol 12-myristate 13-acetate. PDGF translocated PKC epsilon at 5 min but had little effect at 15 s and did not translocate PKC alpha or zeta. Incubation with Bacillus cereus PC- or phosphatidylinositol-specific phospholipase C, which increased DAG but not phosphatidic acid, stimulated translocation of PKC epsilon, but not PKC alpha or zeta. Addition of chelators to inhibit the rise in intracellular Ca2+ largely blocked PKC alpha translocation induced by alpha-thrombin but had no effect on PKC epsilon translocation. Addition of ionomycin allowed alpha-thrombin to induce PKC alpha translocation at 5 min. PKC alpha translocation was mimicked by 1,2-dioctanoylglycerol plus ionomycin, but not by either alone. On the other hand, PKC epsilon was translocated by the DAG alone. These results support the conclusion that PIP2 hydrolysis activates both PKC alpha and epsilon at 15 s, whereas PC hydrolysis activates only PKC epsilon at 5 min. The differential activation at 5 min can be attributed to the failure of PC hydrolysis to increase Ca2+ and not to a difference in the molecular species of DAG derived from the phospholipids.	VANDERBILT UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University				Ha, Kwon-Soo/0000-0002-4219-1787	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040919] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40919] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA Y, 1990, J BIOL CHEM, V265, P354; AUGERT G, 1989, J BIOL CHEM, V264, P21689; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BORNER C, 1992, J BIOL CHEM, V267, P12892; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; EXTON JH, 1990, J BIOL CHEM, V265, P1; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GRINDLING KK, 1986, J BIOL CHEM, V261, P5901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HO AK, 1988, J BIOL CHEM, V263, P9292; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEE C, 1991, J BIOL CHEM, V266, P22837; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; RABEN DM, 1990, J CELL BIOCHEM, V44, P117, DOI 10.1002/jcb.240440206; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; UHING RJ, 1989, J BIOL CHEM, V264, P9224; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WOLF M, 1985, J BIOL CHEM, V260, P5718; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	46	204	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10534	10539						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486706				2022-12-27	WOS:A1993LB80000080
J	YAMADA, T; MATSUSHIMA, M; INAKA, K; OHKUBO, T; UYEDA, A; MAEDA, T; TITANI, K; SEKIGUCHI, K; KIKUCHI, M				YAMADA, T; MATSUSHIMA, M; INAKA, K; OHKUBO, T; UYEDA, A; MAEDA, T; TITANI, K; SEKIGUCHI, K; KIKUCHI, M			STRUCTURAL AND FUNCTIONAL ANALYSES OF THE ARG-GLY-ASP SEQUENCE INTRODUCED INTO HUMAN LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; CELL-ADHESION; PROTEIN; FIBRONECTIN; SECRETION; CHAIN; SITE; INTEGRINS; DOMAIN	To determine the functional conformation of the Arg-Gly-Asp (RGD) sequence, we have constructed mutant proteins by inserting 4-12 amino acid residues from the RGD region of human fibronectin between Val74 and Asn75 of human lysozyme. RGDS-, GRGDSP-, TGRGDSPA-, VTGRGDSPAS-, and AVTGRGDS-PASS- introduced mutant lysozymes were expressed in yeast, purified, and designated as RGD4, -6, -8, -10, and -12, respectively. Using baby hamster kidney cells, RGD8, RGD10, and RGD12 were shown to possess high cell adhesion activity nearly equal to 10% of human vitronectin activity. RGD4 and RGD6 exhibited somewhat lower cell adhesion activity. The activities of these mutant proteins were inhibited by the addition of either GRGDSP peptide or polyclonal antibody against vitronectin receptor, as was the case for the vitronectin activity. The results suggest that the cell adhesion signals are transduced to cells through the interaction with the vitronectin receptor. The three-dimensional structures of RGD4 and RGD8 were determined at 1.8-angstrom resolution by x-ray crystallography. A model of the inserted region in RGD4 could be built in the electron density map, but the positions of the preceding residues, Ala73-Val74, were uncertain. The inserted region in RGD8 did not demonstrate continuous electron densities. The results suggest that these RGD sequence-containing regions are highly flexible and that such flexibility could allow the conformation of the RGD regions to be induced to fit into the binding pocket of the integrin receptor.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS,TOYOAKE,AICHI 47011,JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,IZUMI,OSAKA 59002,JAPAN	Fujita Health University	KIKUCHI, M (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.							ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INAKA K, 1991, J BIOL CHEM, V266, P12599; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAEDA T, 1989, J BIOL CHEM, V264, P15165; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OHKUBO T, 1991, J BIOCHEM-TOKYO, V110, P1022, DOI 10.1093/oxfordjournals.jbchem.a123672; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; REED J, 1988, EUR J BIOCHEM, V178, P141, DOI 10.1111/j.1432-1033.1988.tb14439.x; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P5410, DOI 10.1021/bi00591a024; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	24	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10588	10592						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486712				2022-12-27	WOS:A1993LB80000088
J	TARENTINO, AL; QUINONES, G; CHANGCHIEN, LM; PLUMMER, TH				TARENTINO, AL; QUINONES, G; CHANGCHIEN, LM; PLUMMER, TH			MULTIPLE ENDOGLYCOSIDASE-F ACTIVITIES EXPRESSED BY FLAVOBACTERIUM-MENINGOSEPTICUM ENDOGLYCOSIDASES-F2 AND ENDOGLYCOSIDASES-F3 - MOLECULAR-CLONING, PRIMARY SEQUENCE, AND ENZYME EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; AMINO-ACID-SEQUENCE; CHITINASE	The genes for Flavobacterium meningosepticum Endo (endoglycosidase) F2 and Endo F3 were cloned, and their nucleotide sequences were determined. The deduced amino acid sequences were verified independently to a large extent by direct peptide microsequencing of 66 and 84% of native Endo F2 and Endo F3, respectively. Structurally, the Endo F2 and Endo F3 genes code for a typically long leader sequence of 45 and 39 amino acids, respectively, and, in both cases, a mature protein of 290 amino acids. Comparative structural analysis demonstrated minimum overall homology (15-30%) between Endo F1, Endo F2, and Endo F3, but revealed distinct clusters of identical residues distributed throughout the entire sequence, which represent motifs for binding and hydrolysis of beta1,4-di-N-acetylchitobiosyl linkages in complex carbohydrates. The mobility of native Endo F2 and Endo F3 on SDS-polyacrylamide gel electrophoresis, unlike Endo F1, did not correlate with the molecular weights determined from the coding region of the corresponding genes. Mass spectrometry confirmed that Endo F2 and Endo F3 were heterogeneous and contained approximately 4000 and 1200 daltons of mass not accounted for in the gene structure. We presume that Endo F2 and Endo F3 are variably post-translationally modified during secretion by possible linkage to the hydroxyl of serine.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV CLIN SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center					PHS HHS [30471] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AWADE A, 1992, FEBS LETT, V308, P70, DOI 10.1016/0014-5793(92)81053-O; BLAISEAU PL, 1992, GENE, V120, P243, DOI 10.1016/0378-1119(92)90099-B; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GUAN C, 1988, GENE, V67, P21; JONES JDG, 1986, EMBO J, V5, P467, DOI 10.1002/j.1460-2075.1986.tb04235.x; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Maniatis T., 1982, MOL CLONING; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P896, DOI 10.1073/pnas.86.3.896; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; TAKEGAWA K, 1991, EUR J BIOCHEM, V202, P175, DOI 10.1111/j.1432-1033.1991.tb16359.x; Tarentino A. L., 1992, Glycobiology, V2, P459; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TARENTINO AL, 1993, IN PRESS METHODS ENZ; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017	18	56	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9702	9708						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486657				2022-12-27	WOS:A1993LA68900081
J	KASTURI, R; VASULKA, C; JOHNSON, JD				KASTURI, R; VASULKA, C; JOHNSON, JD			CA2+, CALDESMON, AND MYOSIN LIGHT CHAIN KINASE EXCHANGE WITH CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW FLUORESCENCE; WHEAT-GERM CALMODULIN; AMINO-ACID-SEQUENCE; SMOOTH-MUSCLE; MOLECULAR-WEIGHT; PROTEIN-KINASE; BINDING; CALCIUM; PHOSPHORYLATION; PURIFICATION	Wheat calmodulin (CaM) was labeled at Cys-27 with the sulfhydryl-specific fluorescent probe 2-(4'-maleimidoanilino)-naphthalene-6-sulfonic acid (MIANS), to form MIANS.CaM. In the presence of Ca2+, MIANS.CaM undergoes a large fluorescence increase when it binds myosin light chain kinase (MLCK) and caldesmon (CaD), but little fluorescence change when it binds CaM antagonists or Ca2+. MLCK associates with MIANS.CaM at a rate of 2.8 x 10(7) M-1 s-1 and dissociates at 0.031 s-1 (K(d) = 1.1 nM). Protein kinase A phosphorylation of MLCK (P-MLCK) produces a 3.5-fold decrease in its association rate with CaM and a 6-fold increase in its dissociation rate (K(d) = 23 nM). CaD associates with MIANS.CaM with a rate of 5.3 x 10(8) M-1 s-1 and dissociates at 57 s-1 (K(d) = 10(8) nM). EGTA disrupts the CaM.MLCK, CaM.P-MLCK, and the CaM.CaD complexes at rates of 3.5 s-1, 6.5 s-1, and 13.5 s-1, respectively. MLCK, therefore, dissociates from CaM more quickly by Ca2+ removal while the lower affinity CaD is dissociated more quickly by competition from higher affinity CaM target proteins than by Ca2+ removal. MLCK binding to CaM slowed Ca2+ dissociation from CaM's C-terminal Ca2+-binding sites from 30 s-1 to 6 s-1 while CaD had little effect on Ca2+ dissociation from these sites. During a Ca2+ transient, CaM could exchange with MLCK and CaD rapidly enough for these proteins to be directly involved in the contraction/relaxation cycle of smooth muscle.	OHIO STATE UNIV, MED CTR,DEPT MED BIOCHEM,333 HAMILTON HALL, 1645 NEIL AVE, COLUMBUS, OH 43210 USA	Ohio State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK33727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAU V, 1982, CALMODULIN INTRACELL, P199; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CONTI MA, 1981, J BIOL CHEM, V256, P3178; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1986, MED RES REV, V6, P341, DOI 10.1002/med.2610060304; JOHNSON JD, 1981, J BIOL CHEM, V256, P2194; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Klee CB, 1985, CONTROL MANIPULATION, P131; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LUKAS TJ, 1984, PLANT PHYSIOL, V75, P788, DOI 10.1104/pp.75.3.788; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; MALENCIK DA, 1989, BIOCHEMISTRY-US, V28, P8227, DOI 10.1021/bi00446a039; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P3480, DOI 10.1021/bi00257a035; MANN DM, 1989, J BIOL CHEM, V264, P2373; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MARTIN SR, 1992, EUR J BIOCHEM, V205, P1107, DOI 10.1111/j.1432-1033.1992.tb16879.x; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MILLS JS, 1988, BIOCHEMISTRY-US, V27, P991, DOI 10.1021/bi00403a023; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; SOBUE K, 1988, J CELL BIOCHEM, V37, P317, DOI 10.1002/jcb.240370306; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SPARROW MP, 1981, FEBS LETT, V125, P141, DOI 10.1016/0014-5793(81)80704-1; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; STULL JT, 1986, ENZYMES, P113; TODA H, 1985, J BIOCHEM-TOKYO, V98, P833, DOI 10.1093/oxfordjournals.jbchem.a135342; TSURUTA H, 1990, BIOPHYS CHEM, V35, P75, DOI 10.1016/0301-4622(90)80062-C; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; YACKO MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P7, DOI 10.1016/0005-2736(91)90405-W; YAGI K, 1989, CALCIUM PROTEIN SIGN, P147; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; ZOT HG, 1990, J BIOL CHEM, V265, P14796	50	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7958	7964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463316				2022-12-27	WOS:A1993KW97900058
J	EMANUEL, SL; PESTKA, S				EMANUEL, SL; PESTKA, S			HUMAN INTERFERON-ALPHA-A, INTERFERON-ALPHA-2, AND INTERFERON-ALPHA-2(ARG) GENES IN GENOMIC DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; HUMAN-LEUKOCYTE; NEUTRALIZING ANTIBODIES; CLINICAL-SIGNIFICANCE; MYELOGENOUS LEUKEMIA; AMPLIFICATION; FIBROBLAST; FREQUENCY; SEQUENCE	The frequency in human genomic DNA of three human interferon (IFN) alpha genes which differ from each other by a single base substitution was examined in 11 normal individuals. The polymerase chain reaction (PCR) was used to amplify the coding sequence for the Hu-IFN-alpha2, Hu-IFN-alphaA, and Hu-IFN-alpha2(Arg) sequences from genomic DNA. The PCR products were then cloned and individual clones were sequenced. PCR products were also analyzed by restriction endonuclease analysis for the IFN-alpha2 and IFN-alphaA genes by use of a HinfI site which is eliminated by the substitution of an A for a G in IFN-alphaA. The IFN-alphaA gene which was cloned from the myeloblastoid cell line KG-1 was not observed in any of the 201 clones sequenced from normal individuals or in the Namalwa cell line. It was detected in KG-1 cell genomic DNA where it represented 49% of the clones sequenced. Similarly the IFN-alpha2(Arg) gene was not detected in normal individuals or in the KG-1 cell line but only in the lymphoblastoid cell line from which it was cloned. In Namalwa cells the IFN-alpha2(Arg) sequence represented 35% of the clones sequenced while the IFN-alpha2 sequence comprised 59%. Therefore, both the IFN-alpha2 and IFN-alpha2(Arg) sequences represent alleles of the IFN-alpha2 gene.			EMANUEL, SL (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007403] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI07403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLF GR, 1991, BIOCHEM J, V276, P511, DOI 10.1042/bj2760511; ALTINGMEES MA, 1989, NUCLEIC ACIDS RES, V17, P9494, DOI 10.1093/nar/17.22.9494; ANTONELLI G, 1991, J INFECT DIS, V163, P882, DOI 10.1093/infdis/163.4.882; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CAVALIERI RL, 1977, P NATL ACAD SCI USA, V74, P3287, DOI 10.1073/pnas.74.8.3287; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW F, 1981, NUCLEIC ACIDS RES, V9, P2807, DOI 10.1093/nar/9.12.2807; COLAMONICI O, 1991, Journal of Interferon Research, V11, pS54; Desai M., 1992, Journal of Interferon Research, V12, pS138; DIAZ M O, 1991, Journal of Interferon Research, V11, pS85; DWORKINRASTL E, 1982, J INTERFERON RES, V2, P575, DOI 10.1089/jir.1982.2.575; FAMILLETTI PC, 1981, ANTIMICROB AGENTS CH, V20, P5, DOI 10.1128/AAC.20.1.5; FOON KA, 1986, AM J MED, V80, P351, DOI 10.1016/0002-9343(86)90705-9; FREUND M, 1989, BRIT J HAEMATOL, V72, P350, DOI 10.1111/j.1365-2141.1989.tb07715.x; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; GOEDDEL DV, 1989, Patent No. 4801685; GOEDDEL DV, 1982, Patent No. 811050673; GRANDER D, 1992, BLOOD, V79, P2076; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAVELL EA, 1975, P NATL ACAD SCI USA, V72, P2185, DOI 10.1073/pnas.72.6.2185; HENCO K, 1985, J MOL BIOL, V185, P227, DOI 10.1016/0022-2836(85)90401-2; HOSOI H, 1992, 1992 P INT SOC STUD, P113; HOTTA K, 1988, J INTERFERON RES, V8, P51, DOI 10.1089/jir.1988.8.51; HOTTA K, 1986, METHOD ENZYMOL, V119, P481; HUBER C, 1985, ONCOLOGY-BASEL, V42, P7, DOI 10.1159/000226076; ITRI LM, 1987, CANCER, V59, P668, DOI 10.1002/1097-0142(19870201)59:3+<668::AID-CNCR2820591317>3.0.CO;2-J; JOHNSON BA, 1990, BIOTECHNIQUES, V8, P424; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; LANGER JA, 1984, J INVEST DERMATOL, V83, P128; LAWN RM, 1981, P NATL ACAD SCI-BIOL, V78, P5435, DOI 10.1073/pnas.78.9.5435; MAEDA S, 1980, P NATL ACAD SCI-BIOL, V77, P7010, DOI 10.1073/pnas.77.12.7010; MAEDA S, 1981, P NATL ACAD SCI-BIOL, V78, P4648; Maniatis T., 1982, MOL CLONING; McCandliss R, 1981, Methods Enzymol, V79, P51; Moormeier J A, 1989, Leuk Lymphoma, V1, P43, DOI 10.3109/10428198909042457; NADKARNI JS, 1969, CANCER, V23, P64, DOI 10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M; OWERBACH D, 1981, P NATL ACAD SCI-BIOL, V78, P3123, DOI 10.1073/pnas.78.5.3123; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; Pestka S, 1981, Methods Enzymol, V78, P3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; PESTKA S, 1986, METHOD ENZYMOL, V119, P14; QUESADA JR, 1985, J CLIN ONCOL, V3, P1522, DOI 10.1200/JCO.1985.3.11.1522; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEIS RG, 1988, NEW ENGL J MED, V318, P1409, DOI 10.1056/NEJM198806023182201; STREULI M, 1980, SCIENCE, V209, P1343, DOI 10.1126/science.6158094; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRENT JM, 1982, P NATL ACAD SCI-BIOL, V79, P7809, DOI 10.1073/pnas.79.24.7809; VONWUSSOW P, 1987, J INTERFERON RES, V7, P680; ZOON KC, 1992, J BIOL CHEM, V267, P15210	53	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12565	12569						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509397				2022-12-27	WOS:A1993LG65800052
J	FALCONE, DJ; MCCAFFREY, TA; HAIMOVITZFRIEDMAN, A; VERGILIO, JA; NICHOLSON, AC				FALCONE, DJ; MCCAFFREY, TA; HAIMOVITZFRIEDMAN, A; VERGILIO, JA; NICHOLSON, AC			MACROPHAGE AND FOAM CELL RELEASE OF MATRIX-BOUND GROWTH-FACTORS - ROLE OF PLASMINOGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; LOW-DENSITY LIPOPROTEINS; CAPILLARY ENDOTHELIAL-CELLS; HUMAN MONOCYTE-MACROPHAGES; FACTOR-LIKE PROTEIN; FACTOR-BETA; UROKINASE-TYPE; ATHEROSCLEROTIC LESIONS; BASEMENT-MEMBRANES	We have determined whether macrophage derived-foam cells, a prominent component of the atherosclerotic lesion, express more urokinase-type plasminogen activator (uPA) and whether their ability to generate plasmin stimulates the.release of matrix-bound growth factors. Steady state levels of uPA mRNA and both membrane and intracellular uPA activities were significantly increased in foam cells. When cultured on cell-derived matrices containing bound I-125-basic fibroblast growth factor (bFGF), both macrophage and foam cells released intact I-125-bFGF into their media. The release of I-125-bFGF by either cell was significantly enhanced in the presence of plasminogen. However, foam cells, which expressed more membrane uPA, released more I-125-bFGF than control cells. The release of matrix-bound bFGF was independent of heparanase activity, since neither macrophage nor foam cells degraded (SO4)-S-35-labeled heparan sulfate proteoglycans. In addition, media derived from foam cells cultured on cell-derived matrices in the presence of plasminogen had increased levels of transforming growth factor (TGF) beta activity as compared to cells grown in the absence of plasminogen. In contrast, plasminogen had no effect on TGF-beta activity recovered in the media of foam cells grown on plastic. Moreover, when macrophage were cultured on matrices containing bound I-125-TGF-beta, the release of labeled TGF-beta was increased in the presence of plasminogen. This is the first demonstration that foam cells can release two important growth regulators, bFGF and TGF-beta, from the extracellular matrix, and provides a mechanism by which macrophage and foam cells can stimulate atherosclerotic lesion development.	CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT RADIAT ONCOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center	FALCONE, DJ (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT PATHOL C440, NEW YORK, NY 10021 USA.				NHLBI NIH HHS [HL-46403, HL-35724, HL-40819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035724, P01HL046403, R01HL040819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CASTELLOT JJ, 1987, SEMIN THROMB HEMOST, V13, P489, DOI 10.1055/s-2007-1003525; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; CHAPMAN HA, 1985, BIOCHEM J, V230, P109, DOI 10.1042/bj2300109; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; FALCONE DJ, 1984, J CELL BIOL, V99, P1266, DOI 10.1083/jcb.99.4.1266; FALCONE DJ, 1989, J CELL PHYSIOL, V140, P219, DOI 10.1002/jcp.1041400205; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOX PL, 1986, P NATL ACAD SCI USA, V83, P4774, DOI 10.1073/pnas.83.13.4774; FOX PL, 1987, J BIOL CHEM, V262, P6046; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GOLSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOWN AM, 1986, AM J PATHOL, V125, P191; HAIMOVITZFRIEDMAN A, 1991, BLOOD, V78, P789, DOI 10.1182/blood.V78.3.789.bloodjournal783789; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745; HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KELLEY JL, 1988, AM J PATHOL, V131, P539; KIRCHHEIMER JC, 1988, J IMMUNOL, V141, P4229; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MEISSAUER A, 1991, EXP CELL RES, V192, P453, DOI 10.1016/0014-4827(91)90064-2; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MORTON K, 1989, CURR EYE RES, V8, P975, DOI 10.3109/02713688908997390; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAKSELA O, 1985, J CELL PHYSIOL, V122, P125, DOI 10.1002/jcp.1041220119; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SEIFFERT D, 1990, CELL DIFFER DEV, V32, P287, DOI 10.1016/0922-3371(90)90041-T; SHECHTER I, 1981, J LIPID RES, V22, P63; SILVERSTEIN RL, 1988, J CLIN INVEST, V82, P1948, DOI 10.1172/JCI113814; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; YAMADA S, 1989, MED SCI SPORT EXER, V21, pS173; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	79	119	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11951	11958						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505319				2022-12-27	WOS:A1993LF28400074
J	LI, ZP; BURKE, EP; FRANK, JS; BENNETT, V; PHILIPSON, KD				LI, ZP; BURKE, EP; FRANK, JS; BENNETT, V; PHILIPSON, KD			THE CARDIAC NA+-CA2+ EXCHANGER BINDS TO THE CYTOSKELETAL PROTEIN ANKYRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELLS; SPECTRIN; CHANNELS; CALCIUM; BRAIN	Na+-Ca2+ exchange is the major pathway of Ca2+ efflux during excitation-contraction coupling in cardiac muscle. The Na+-Ca2+ exchanger is present in cardiac transverse tubules with an apparent high density (Frank, J. S., Mottino, G., Reid, D., Molday, R. S., and Philipson, K. D. (1992) J. Cell Biol. 117, 337-345). The mechanism for this localization is unknown but may involve interactions with the cytoskeleton. In the present study, we examined the interaction of the Na+-Ca2+ exchanger with the cytoskeletal protein ankyrin. On immunoblots of isolated canine cardiac sarcolemma, an antibody raised against purified rabbit red blood cell-ankyrin (RBC-ankyrin) recognized a 220-kDa protein, which is the same size as RBC-ankyrin. Alkaline extraction of sarcolemma removed this protein. The Na+-Ca2+ exchange protein, purified from recombinant baculovirus-infected insect cells, bound I-125-labeled-RBC-ankyrin with a K(D) of 42 +/- 3 nm. I-125-RBC-ankyrin was co-precipitated by antibodies to the Na+-Ca2+ exchanger after preincubation with solubilized cardiac sarcolemma. Myocardial ankyrin could be localized to both surface and T-tubular sarcolemma by immunofluorescence techniques. These results demonstrate that the cardiac Na+-Ca2+ exchanger binds ankyrin with high affinity. This interaction may be important for localizing the Na+-Ca2+ exchanger to specific domains of the sarcolemma.	UNIV CALIF LOS ANGELES, SCH MED,CARDIOVASC RES LABS,MACDONALD BLDG,RM 3645, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90024 USA; DUKE UNIV, HOWARD HUGHES INST, DURHAM, NC 27710 USA; DUKE UNIV, DEPT BIOCHEM, DURHAM, NC 27710 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University; Howard Hughes Medical Institute; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028791, R01HL027821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029808, R37DK029808] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27821, HL28791] Funding Source: Medline; NIDDK NIH HHS [DK29808] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett V, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P647; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; KIEVAL RS, 1992, AM J PHYSIOL, V263, pC545, DOI 10.1152/ajpcell.1992.263.2.C545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LANGER GA, 1992, AM J PHYSIOL, V262, pC1149, DOI 10.1152/ajpcell.1992.262.5.C1149; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LI ZP, 1992, J BIOL CHEM, V267, P7828; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PHILIPSON KD, 1990, CALCIUM HEART, P85; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307	23	109	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11489	11491						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505285				2022-12-27	WOS:A1993LF28400005
J	SIROIS, J; LEVY, LO; SIMMONS, DL; RICHARDS, JS				SIROIS, J; LEVY, LO; SIMMONS, DL; RICHARDS, JS			CHARACTERIZATION AND HORMONAL-REGULATION OF THE PROMOTER OF THE RAT PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 GENE IN GRANULOSA-CELLS - IDENTIFICATION OF FUNCTIONAL AND PROTEIN-BINDING REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; LUTEINIZING-HORMONE; COMPLEMENTARY-DNA; OVARIAN FOLLICLES; MAMMALIAN-CELLS; RECEPTOR GENE; G/H SYNTHASE; TRANSCRIPTION; CYCLOOXYGENASE; PURIFICATION	Prostaglandin endoperoxide synthase isoform 2 (PGS-2) mRNA and protein are transiently induced by gonadotropins in granulosa cells of preovulatory follicles prior to ovulation. To better understand the hormonal regulation of the rat PGS-2 (rPGS-2) gene in these cells, genomic clones containing rPGS-2 as well as up to 6 kilobases of 5'-flanking DNA were isolated by screening a rat liver genomic library with a labeled 5'-fragment of the mouse PGS-2 cDNA. Primer extension analysis using ovarian follicular mRNA identified the presence of a single rPGS-2 transcription initiation site located 144 nucleotides upstream of the ATG translation initiation codon. To test for promoter activity within the 5'-flanking region of the rPGS-2 gene, a genomic fragment, -2698/32 (1 = cap site), as well as a series of 5'-deletion mutants, were fused upstream of the chloramphenicol acetyltransferase (CAT) reporter gene and transfected into primary cultures of granulosa cells. Forskolin (7.5 muM), follicle-stimulating hormone (500 ng/ml) and luteinizing hormone (500 ng/ml) induced CAT activity following transfection with the -2698/32PGS.CAT, whereas gonadotropin-releasing hormone (10(-6) M) and interleukin-1beta (30 ng/ml) had no effect. Deletion mutants delineated the region spanning from -192 to -54 of the transcription start site to be essential for both basal and forskolin-regulated expression of the reporter gene. The same DNA fragment (-192/-54) exhibited specific binding to granulosa cell nuclear extract proteins as analyzed by electrophoretic mobility shift assays. Additional specific bands were observed in extracts prepared from granulosa cells exposed to an ovulatory dose of gonadotropin. Collectively, these results provide the first structural and functional evidence that the transcriptional regulation of the rat PGS-2 gene by gonadotropins and forskolin in granulosa cells involves 5'-flanking DNA sequences, specifically a region between -192 and -54 of the transcription initiation site.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; BRIGHAM YOUNG UNIV,DEPT CHEM,PROVO,UT 84602	Baylor College of Medicine; Brigham Young University					NCI NIH HHS [CA-55585] Funding Source: Medline; NICHD NIH HHS [HD-16229] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA055585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GADDYKURTEN D, 1989, ENDOCRINOLOGY, V125, P2985; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HICKEY GJ, 1990, MOL ENDOCRINOL, V4, P3, DOI 10.1210/mend-4-1-3; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JELTSCH JM, 1990, J BIOL CHEM, V265, P3967; KNOLL BJ, 1983, NUCLEIC ACIDS RES, V11, P6733, DOI 10.1093/nar/11.19.6733; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LEE SH, 1992, J BIOL CHEM, V267, P25934; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OONK RB, 1990, J BIOL CHEM, V265, P22392; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDS JS, 1993, OVARY; Sambrook J, 1989, MOL CLONING LABORATO; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1992, Biology of Reproduction, V46, P178; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WANG HY, 1992, MOL ENDOCRINOL, V6, P320, DOI 10.1210/me.6.3.320; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE W, 1991, P NATL ACAD SCI USA, P67; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	53	182	184	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12199	12206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505340				2022-12-27	WOS:A1993LF28400108
J	TAKASE, K; YAMATO, I; KAKINUMA, Y				TAKASE, K; YAMATO, I; KAKINUMA, Y			CLONING AND SEQUENCING OF THE GENES-CODING FOR THE A-SUBUNIT AND B-SUBUNIT OF VACUOLAR-TYPE NA+-ATPASE FROM ENTEROCOCCUS-HIRAE - COEXISTENCE OF VACUOLAR-TYPE AND F0F1-TYPE ATPASES IN ONE BACTERIAL-CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI F1-ATPASE; MEMBRANE-ASSOCIATED ATPASE; ION MOTIVE ATPASES; BETA-SUBUNIT; ALPHA-SUBUNIT; H+-ATPASE; STREPTOCOCCUS-FAECALIS; NUCLEOTIDE-SEQUENCE; DIRECTED MUTAGENESIS	The eubacterium Enterococcus hirae ATCC 9790 possesses a H+-translocating ATPase, and the deduced amino acid sequences of the genes coding for this enzyme have indicated that it is a typical F0F1-type ATPase (Shibata, C., Ehara, T., Tomura, K., Igarashi, K., and Kobayashi, H. (1992) J. Bacteriol. 174, 6117-6124). We cloned the ntpA and ntpB genes coding for the A and B subunits, respectively, of Na+-translocating ATPase from the same bacterium, and the full amino acid sequences of the two subunits were deduced from the nucleotide sequence. The A (593 amino acid residues) and B (458 amino acid residues) subunits were highly homologous (48-60% identical) to the A (large or alpha) and the B (small or beta) subunits, respectively, of vacuolar-type H+-ATPases which have been found in eukaryotic endomembrane systems (Neurospora crassa, Saccharomyces cerevisiae, Arabidopsis thaliana, and carrot) and archaebacterial cell membranes (Sulfolobus acidocaldarius and Methanosarcina barkeri). The A and B subunits of Na+-ATPase showed about 23-28% identities with the beta and alpha subunits of E. hirae F1-ATPase and of Escherichia coli F1-ATPase, respectively. These results indicate that E. hirae Na+-ATPase belongs to the vacuolar-type ATPase. This is the first demonstration that both genes for V- and F-type ATPases are functionally expressed in one bacterial cell.	CHIBA UNIV,FAC PHARMACEUT SCI,1-33 YAYOI CHO,INAGE KU,CHIBA 263,JAPAN; SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN	Chiba University; Tokyo University of Science								ABRAMS A, 1985, ENZYMES BIOL MEMBR, V4, P177; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; CHU CP, 1992, J BACTERIOL, V174, P1619, DOI 10.1128/jb.174.5.1619-1625.1992; DEDA K, 1990, J BIOL CHEM, V265, P21509; DEGUCHI Y, 1989, J BACTERIOL, V171, P1314, DOI 10.1128/jb.171.3.1314-1319.1989; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P3919, DOI 10.1093/nar/9.16.3919; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAKINUMA Y, 1991, FEBS LETT, V292, P64, DOI 10.1016/0014-5793(91)80835-Q; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1990, FEBS LETT, V261, P102; KAKINUMA Y, 1990, FEBS LETT, V261, P97; KANAZAWA H, 1982, BIOCHEM BIOPH RES CO, V105, P1257, DOI 10.1016/0006-291X(82)90922-6; KANAZAWA H, 1981, BIOCHEM BIOPH RES CO, V103, P604, DOI 10.1016/0006-291X(81)90494-0; KONISHI J, 1990, J BIOCHEM, V108, P554, DOI 10.1093/oxfordjournals.jbchem.a123241; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAUBINGER W, 1987, EUR J BIOCHEM, V168, P475, DOI 10.1111/j.1432-1033.1987.tb13441.x; LAUBINGER W, 1988, BIOCHEMISTRY-US, V27, P7531, DOI 10.1021/bi00419a053; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; Maniatis T., 1982, MOL CLONING; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON N, 1988, PLANT PHYSIOL, V86, P1, DOI 10.1104/pp.86.1.1; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NOUMI T, 1988, J BIOL CHEM, V263, P8765; NOUMI T, 1984, J BIOL CHEM, V259, P76; NOUMI T, 1986, J BIOL CHEM, V261, P9196; NOUMI T, 1984, J BIOL CHEM, V259, P71; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RAO R, 1988, J BIOL CHEM, V263, P15957; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHIBATA C, 1992, J BACTERIOL, V174, P6117, DOI 10.1128/JB.174.19.6117-6124.1992; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; TSUTSUMI S, 1991, BIOCHIM BIOPHYS ACTA, V1098, P13, DOI 10.1016/0005-2728(91)90003-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	57	57	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11610	11616						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505293				2022-12-27	WOS:A1993LF28400027
J	RAY, P; BERMAN, JD; MIDDLETON, W; BRENDLE, J				RAY, P; BERMAN, JD; MIDDLETON, W; BRENDLE, J			BOTULINUM TOXIN INHIBITS ARACHIDONIC-ACID RELEASE ASSOCIATED WITH ACETYLCHOLINE-RELEASE FROM PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADRENAL CHROMAFFIN CELLS; CATECHOLAMINE SECRETION; DIGLYCERIDE LIPASE; BINDING-PROTEIN; RAT; ACTIVATION; MECHANISM; PLATELET; PHOSPHOLIPASE-A2	The molecular mechanisms of depolarization-induced calcium-dependent acetylcholine (ACh) release and its inhibition by botulinum neurotoxin type A (BoTx) are not clear. We studied these mechanisms in an in vitro cholinergic neuronal pheochromocytoma PC12 cell line model. Cultured monolayer PC12 cells were differentiated by treatment with 50 ng/ml nerve growth factor (NGF) for 4 days to enhance cellular ACh synthesis and release. Stimulation of these cells with high K+ (80 mM) in the perfusion medium caused a marked increase (three to four times) in [H-3]ACh release in a Ca2+-dependent manner. K+-stimulated [H-3]ACh release was totally inhibited by pretreatment of cells with BoTx (2 nM) for 2 h. High K+ also stimulated the release of arachidonic acid ([H-3]AA) from the cell membrane, which was inhibited by BoTx (2 nM). Addition of phospholipase A2 (PLA2) inhibitors (quinacrine, 4-bromophenacyl bromide, manoalide) to the perfusion medium inhibited K+-stimulated [H-3]ACh and [H-3]AA release in a dose-dependent manner. Inclusion of exogenous AA, the PLA2 activator melittin, or PLA2 itself prevented the effect of BoTx. These results demonstrate that in NGF-differentiated PC12 cells, AA release is associated with ACh release, BoTx inhibits both processes, and increased AA can protect against BoTx.	WALTER REED ARMY INST RES, DEPT BIOL, DIV EXPTL THERAPEUT, WASHINGTON, DC 20067 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								ABOUSAMRA AB, 1986, ENDOCRINOLOGY, V119, P1427, DOI 10.1210/endo-119-4-1427; ASHTON AC, 1988, J NEUROCHEM, V50, P1808, DOI 10.1111/j.1471-4159.1988.tb02482.x; BAND AM, 1992, J MOL ENDOCRINOL, V8, P95, DOI 10.1677/jme.0.0080095; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; BOURDEAU A, 1992, ENDOCRINOLOGY, V130, P1339, DOI 10.1210/en.130.3.1339; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOI OH, 1992, J PHARMACOL EXP THER, V260, P369; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CRUETZ CE, 1981, J CELL BIOL, V91, P247; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DOLLY JO, 1988, E H S BIOT, P79; DUNIEC Z, 1983, BIOCHEM PHARMACOL, V32, P2283, DOI 10.1016/0006-2952(83)90239-3; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; FINK DW, 1990, J NEUROCHEM, V55, P1716, DOI 10.1111/j.1471-4159.1990.tb04961.x; FRYE RA, 1984, J NEUROCHEM, V43, P146, DOI 10.1111/j.1471-4159.1984.tb06690.x; FRYE RA, 1983, MOL PHARMACOL, V23, P547; GAN RW, 1984, PROSTAGLANDINS LEUKO, P593; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUNDERSEN CB, 1980, PROG NEUROBIOL, V14, P99, DOI 10.1016/0301-0082(80)90019-2; HEIKKILA JE, 1989, J CELL PHYSIOL, V140, P593, DOI 10.1002/jcp.1041400326; HOFFMAN SL, 1982, ARCH BIOCHEM BIOPHYS, V215, P237; JOPE RS, 1985, MOL PHARMACOL, V29, P45; JUNIER MP, 1990, LIFE SCI, V47, P1829, DOI 10.1016/0024-3205(90)90285-Y; KADIRI C, 1990, MOL PHARMACOL, V38, P418; KANTERMAN RY, 1990, J NEUROCHEM, V54, P1225, DOI 10.1111/j.1471-4159.1990.tb01952.x; KAO I, 1976, SCIENCE, V193, P1256, DOI 10.1126/science.785600; LAPETINA EG, 1981, J BIOL CHEM, V256, P5037; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER AMS, 1988, J PHARMACOL EXP THER, V244, P871; MCGEE R, 1978, P NATL ACAD SCI USA, V75, P1314, DOI 10.1073/pnas.75.3.1314; METZ SA, 1989, BIOCHEM PHARMACOL, V38, P1849, DOI 10.1016/0006-2952(89)90421-8; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MOSKOWITZ N, 1982, SCIENCE, V216, P305, DOI 10.1126/science.6278597; NEGISHI M, 1990, BIOCHEM BIOPH RES CO, V169, P773, DOI 10.1016/0006-291X(90)90398-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; POOLE AR, 1970, NATURE, V227, P810, DOI 10.1038/227810a0; Ray P., 1992, Society for Neuroscience Abstracts, V18, P790; RAY P, 1992, PHARMACOLOGIST, V34, P187; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; SHAFER TJ, 1991, NEUROTOXICOLOGY, V12, P473; SHEN TY, 1977, ADV DRUG RES, V56, P665; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P153; SLACK BE, 1992, BRAIN RES, V585, P169, DOI 10.1016/0006-8993(92)91203-Q; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; WOLF BA, 1986, J BIOL CHEM, V261, P3501	51	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11057	11064						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496167				2022-12-27	WOS:A1993LD46600052
J	SETO, Y; GUENGERICH, FP				SETO, Y; GUENGERICH, FP			PARTITIONING BETWEEN N-DEALKYLATION AND N-OXYGENATION IN THE OXIDATION OF N,N-DIALKYLARYLAMINES CATALYZED BY CYTOCHROME-P450-2B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; FLAVIN-CONTAINING MONOOXYGENASE; MECHANISM-BASED INACTIVATION; HYDROGEN-PEROXIDE FORMATION; ENZYMATIC S-OXYGENATION; RAT-LIVER; ELECTROCHEMICAL GENERATION; PURIFIED CYTOCHROME-P-450; RECONSTITUTED SYSTEM; CATION RADICALS	Aminium radicals have been proposed as intermediates in amine N-dealkylations and N-oxygenations catalyzed by cytochrome P450 (P450) and some other enzymes. P450s can form some N-oxides and hydroxylamines but these are not favored whenever N-dealkylation is possible. However, if a paradigm involving 1-electron oxidation is valid, then some finite level of partitioning of aminium radicals between N-oxygenation and N-dealkylation might be expected in all cases. Methods were developed for the selective and sensitive measurement of N,N-dialkylaniline N-oxides using high performance liquid chromatography, radiochromatography, and TiCl3 reduction. These N-oxides were relatively stable in the presence of P4 50 2B1. In the presence of NADPH and NADPH-P450 reductase some reduction to N,N-dialkylamines occurred, along with N-dealkylation (to monoalkylanilines); there was also slow N-dealkylation in the absence of NADPH, which is interpreted in terms of homolytic scission of the N-O bond; N,N-dialkylanilines were not formed nor did the N-oxides support other oxygenation reactions. P450 2B1 (with its reductase and NADPH) formed N-oxides at low rates from several N,N-dialkylaniline derivatives, including N,N-dimethylaniline, N,N-diethylaniline, N-ethyl-N-methylaniline, 4-methyl-N,N-dimethylaniline, 4-cyano-N,N-dimethylaniline, N-phenylpyrrolidine, and N,N-dimethyl-2-aminofluorene. The ratio of N-dealkylation:N-oxygenation varied from 1020 to 6 in this series. These results are consistent with the view that aminium radicals are a branch point in N-oxygenation and N-dealkylation reactions catalyzed by metalloproteins, although some alternate explanations cannot be ruled out. While N-dealkylation is the dominant process in all of the P450-catalyzed amine oxidations, there should be a finite partition ratio between these reactions depending upon the particular enzyme and substrate. The N-oxygenation reaction is probably more complex than a direct radical recombination event and is postulated to involve one or more intermediates.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, CTR MOLEC TOXICOL, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44353] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; AUGUSTO O, 1982, J BIOL CHEM, V257, P1288; BABA T, 1987, XENOBIOTICA, V17, P1029, DOI 10.3109/00498258709044201; BONDON A, 1989, J BIOL CHEM, V264, P1988; BOWRY VW, 1991, J AM CHEM SOC, V113, P5699, DOI 10.1021/ja00015a025; BRODIE BB, 1958, ANNU REV BIOCHEM, V27, P427, DOI 10.1146/annurev.bi.27.070158.002235; BURKA LT, 1985, J AM CHEM SOC, V107, P2549, DOI 10.1021/ja00294a057; BURSTYN JN, 1991, CHEM RES TOXICOL, V4, P70, DOI 10.1021/tx00019a009; CASHMAN JR, 1989, MOL PHARMACOL, V36, P497; CRAIG JC, 1961, J AM CHEM SOC, V83, P1871, DOI 10.1021/ja01469a023; CRAIG JC, 1970, J ORG CHEM, V35, P1721, DOI 10.1021/jo00830a121; DAMANI LA, 1978, J CHROMATOGR, V155, P337, DOI 10.1016/S0021-9673(00)87994-7; DEMONTELLANO PRO, 1987, J AM CHEM SOC, V109, P3415; DINNOCENZO JP, 1989, J AM CHEM SOC, V111, P8646, DOI 10.1021/ja00205a014; FERRIS JP, 1968, J ORG CHEM, V33, P3493, DOI 10.1021/jo01273a028; FREDERICK CB, 1982, CANCER RES, V42, P2671; FUJIMORI K, 1986, TETRAHEDRON LETT, V27, P1617, DOI 10.1016/S0040-4039(00)84329-4; GORROD J W, 1981, European Journal of Drug Metabolism and Pharmacokinetics, V6, P195; GROVES JT, 1986, INORG CHEM, V25, P123, DOI 10.1021/ic00222a003; GUENGERICH FP, 1988, J BIOL CHEM, V263, P8168; GUENGERICH FP, 1984, J MED CHEM, V27, P1101, DOI 10.1021/jm00375a002; GUENGERICH FP, 1984, J AM CHEM SOC, V106, P6446, DOI 10.1021/ja00333a071; GUENGERICH FP, 1980, ARCH BIOCHEM BIOPHYS, V205, P365, DOI 10.1016/0003-9861(80)90119-8; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; GUENGERICH FP, 1989, J BIOL CHEM, V264, P17198; GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287; GUENGERICH FP, 1977, MOL PHARMACOL, V13, P993; GUENGERICH FP, 1984, ACCOUNTS CHEM RES, V17, P9, DOI 10.1021/ar00097a002; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; Guengerich FP, 1989, PRINCIPLES METHODS T, P777; HAMMONS GJ, 1985, CANCER RES, V45, P3578; HAYASHI Y, 1979, J BIOL CHEM, V254, P9101; HEIMBROOK DC, 1984, J AM CHEM SOC, V106, P1514, DOI 10.1021/ja00317a072; HLAVICA P, 1979, BIOCHEM J, V182, P109, DOI 10.1042/bj1820109; IWASAKI K, 1977, BIOCHEM BIOPH RES CO, V77, P1143, DOI 10.1016/S0006-291X(77)80098-3; KUREBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V270, P320, DOI 10.1016/0003-9861(89)90034-9; LABEQUE R, 1989, J AM CHEM SOC, V111, P6621, DOI 10.1021/ja00199a022; Lashmet Johnson P R, 1986, J Biochem Toxicol, V1, P15; LEE WA, 1985, P NATL ACAD SCI USA, V82, P4301, DOI 10.1073/pnas.82.13.4301; MACDONALD TL, 1989, BIOCHEMISTRY-US, V28, P2071, DOI 10.1021/bi00431a016; MACDONALD TL, 1982, J AM CHEM SOC, V104, P2050, DOI 10.1021/ja00371a056; MANSUY D, 1989, EUR J BIOCHEM, V184, P267, DOI 10.1111/j.1432-1033.1989.tb15017.x; MASUI M, 1971, J CHEM SOC B, P1593, DOI 10.1039/j29710001593; MIWA GT, 1983, J BIOL CHEM, V258, P4445; MULLERENOCH D, 1984, J BIOL CHEM, V259, P8174; NEE MW, 1982, J AM CHEM SOC, V104, P6123, DOI 10.1021/ja00386a052; NELSEN SF, 1986, J AM CHEM SOC, V108, P4879, DOI 10.1021/ja00276a028; NORDBLOM GD, 1977, ARCH BIOCHEM BIOPHYS, V180, P343, DOI 10.1016/0003-9861(77)90047-9; OAE S, 1963, TETRAHEDRON, V19, P1783, DOI 10.1016/S0040-4020(01)99252-X; OKAZAKI O, 1993, J BIOL CHEM, V268, P1546; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSTOVIC D, 1987, J AM CHEM SOC, V109, P3444, DOI 10.1021/ja00245a041; PALMER G, 1992, J BIOL CHEM, V267, P665; PANDEY RN, 1989, BIOCHEM PHARMACOL, V38, P2181, DOI 10.1016/0006-2952(89)90074-9; PLE P, 1989, J BIOL CHEM, V264, P13983; PROUGH RA, 1984, CANCER RES, V44, P543; SHANNON P, 1981, J AM CHEM SOC, V103, P4580, DOI 10.1021/ja00405a049; SHONO T, 1984, TETRAHEDRON, V40, P811, DOI 10.1016/S0040-4020(01)91472-3; SMITH PJ, 1969, J ORG CHEM, V34, P1821, DOI 10.1021/jo01258a063; SUGIURA M, 1976, MOL PHARMACOL, V12, P322; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TRABER W, 1958, HELV CHIM ACTA, V41, P2066, DOI 10.1002/hlca.19580410715; WALSH CT, 1979, ENZYMATIC REACTION M; WATANABE Y, 1982, TETRAHEDRON LETT, V23, P533, DOI 10.1016/S0040-4039(00)86881-1; WATANABE Y, 1982, B CHEM SOC JPN, V55, P188, DOI 10.1246/bcsj.55.188; WATANABE Y, 1980, TETRAHEDRON LETT, V21, P3685, DOI 10.1016/S0040-4039(00)78745-4; WATANABE Y, 1981, B CHEM SOC JPN, V54, P1163, DOI 10.1246/bcsj.54.1163; WEINBERG NL, 1966, J ORG CHEM, V31, P4058, DOI 10.1021/jo01350a041; WILLIAMS DE, 1989, DRUG METAB DISPOS, V17, P387; WITTIG G, 1955, LIEBIGS ANN CHEM, V594, P1; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YASUKOUCHI K, 1979, B CHEM SOC JPN, V52, P3208, DOI 10.1246/bcsj.52.3208; ZIEGLER DM, 1991, DRUG METAB DISPOS, V19, P847; ZIEGLER DM, 1964, BIOCHEM BIOPH RES CO, V15, P188, DOI 10.1016/0006-291X(64)90322-5	75	68	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9986	9997						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486725				2022-12-27	WOS:A1993LB80000011
J	CHEN, WJ; MOOMAW, JF; OVERTON, L; KOST, TA; CASEY, PJ				CHEN, WJ; MOOMAW, JF; OVERTON, L; KOST, TA; CASEY, PJ			HIGH-LEVEL EXPRESSION OF MAMMALIAN PROTEIN FARNESYLTRANSFERASE IN A BACULOVIRUS SYSTEM - THE PURIFIED PROTEIN CONTAINS ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEINS; PEPTIDE-BINDING; ALPHA-SUBUNIT; A-FACTOR; YEAST; FARNESYL; CLONING; GENE	The mammalian enzyme protein farnesyltransferase is a heterodimeric protein that catalyzes the addition of a farnesyl isoprenoid to a cysteine in ras proteins. Since oncogenic forms of ras proteins require the farnesyl group for transforming activity, the structure and mechanism of this enzyme are important to define. However, such studies have been difficult to approach because of the low abundance of the enzyme in mammalian tissues and hence the problems of obtaining large quantities of the protein. We report here the coexpression of the two subunits of protein farnesyltransferase by Sf9 cells infected with a recombinant baculovirus containing the coding sequences of both polypeptides. This results in the production of milligram quantities of enzyme which can be readily purified by conventional chromatographic methods. The individual subunits of the enzyme can also be expressed in the Sf9 cells, but the ability to reconstitute active enzyme from extracts containing individual subunits is quite low. In contrast, the enzyme produced by coexpression of the two subunits is fully active and retains the properties of the mammalian form, including the specificity for the COOH-terminal amino acid of substrate proteins and the ability to bind short peptides encompassing the prenylation site of a ras protein. Furthermore, through atomic absorption analysis of the purified protein, we have confirmed the previous tentative assignment of protein farnesyltransferase as a zinc metalloenzyme by demonstrating that it contains an essentially stoichiometric amount of zinc. The ability to produce and purify milligram quantities of protein farnesyltransferase readily will allow detailed mechanistic and structural studies on this enzyme.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; GLAXO INC,RES INST,DEPT MOLEC BIOL,RES TRIANGLE PK,NC 27709	Duke University; Duke University; GlaxoSmithKline				Casey, Patrick/0000-0002-7366-9309				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIGGINS JA, 1992, FASEB J, V6, P97; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555, P29; VALLEE BL, 1983, ZINC ENZYMES, P25	29	107	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9675	9680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486655				2022-12-27	WOS:A1993LA68900078
J	GORDON, CL; KING, J				GORDON, CL; KING, J			TEMPERATURE-SENSITIVE MUTATIONS IN THE PHAGE-P22 COAT PROTEIN WHICH INTERFERE WITH POLYPEPTIDE-CHAIN FOLDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION BODY FORMATION; TAIL-SPIKE PROTEIN; SCAFFOLDING PROTEIN; BACTERIOPHAGE-T4 LYSOZYME; ESCHERICHIA-COLI; SIMIAN VIRUS-40; SUBUNIT; MUTANTS; GENE; P22	Temperature-sensitive mutations in the coat protein of phage P22 severely restrict formation of infectious particles at restrictive temperature. A set of 25 temperature-sensitive strains, which had been localized to regions of the coat gene (Casjens, S., Eppler, K., Sampson, L., Parr, R., and Wyckofl, E. (1991) Genetics 127, 637-647), define 17 sites of single amino acid substitutions by DNA sequencing. Particles assembled from the mutant proteins at permissive temperature were not thermolabile at restrictive temperature, nor defective in the infectious process. At restrictive temperature, ts mutant polypeptide chains were synthesized at near wild-type rates. These inactive chains were not degraded within the cells. The ts chains failed to interact with scaffolding proteins to form he procapsid precursor shell, and they did not polymerize with each to form aberrant shells. Rather, the mutant coat protein accumulated as insoluble aggregates, with the amorphous morphology of inclusion bodies. The results indicate that the chains fail to reach the conformation needed for subunit-subunit or subunit-scaffolding interaction. These mutations appear to be of the class of temperature-sensitive folding mutations, which destabilize an intermediate in the intracellular folding pathway.	MIT,DEPT BIOL,16-535,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NIGMS NIH HHS [GM17980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, R37GM017980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BEHM M, 1988, P NATL ACAD SCI USA, V85, P9421, DOI 10.1073/pnas.85.24.9421; BOTSTEIN D, 1972, VIROLOGY, V49, P268, DOI 10.1016/S0042-6822(72)80028-X; CASJENS S, 1974, Journal of Supramolecular Structure, V2, P202, DOI 10.1002/jss.400020215; CASJENS S, 1991, GENETICS, V127, P637; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; EARNSHAW W, 1978, J MOL BIOL, V126, P721, DOI 10.1016/0022-2836(78)90017-7; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EDGAR RS, 1964, GENETICS, V49, P649; EDGAR RS, 1964, GENETICS, V49, P635; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; GAME JC, 1976, MOL GEN GENET, V146, P313, DOI 10.1007/BF00701257; GINSBERG HS, 1979, COMPREHENSIVE VIROLO, V13, P409; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOUGH M, 1968, GENETICS, V58, P161; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARRISON SC, 1984, TRENDS BIOCHEM SCI, V9, P345, DOI 10.1016/0968-0004(84)90057-4; HAWKES R, 1984, J MOL BIOL, V175, P195, DOI 10.1016/0022-2836(84)90474-1; HENDRIX RW, 1985, VIRUS STRUCTURE ASSE, P169; HORWITZ M S, 1991, P771; HUBSCHER U, 1980, J BIOL CHEM, V255, P1698; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KATSURA I, 1980, J MOL BIOL, V142, P387, DOI 10.1016/0022-2836(80)90278-8; KING J, 1978, CELL, V15, P551, DOI 10.1016/0092-8674(78)90023-5; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENK E, 1975, VIROLOGY, V68, P182, DOI 10.1016/0042-6822(75)90160-9; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NEWCOMB WW, 1991, J VIROL, V65, P613, DOI 10.1128/JVI.65.2.613-620.1991; PRASAD BVV, 1993, IN PRESS J MOL BIOL; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; SCHAFFER PA, 1978, J VIROL, V27, P490, DOI 10.1128/JVI.27.3.490-504.1978; SMITH DH, 1980, GENETICS, V96, P331; STRAUSS H, 1984, J MOL BIOL, V172, P523, DOI 10.1016/S0022-2836(84)80021-2; STRURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; TRUONG HTN, 1991, BIOCHEMISTRY-US, V30, P10722; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WINSTON F, 1979, J BACTERIOL, V137, P433, DOI 10.1128/JB.137.1.433-439.1979; YU MH, 1988, J BIOL CHEM, V263, P1424; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	51	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9358	9368						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486630				2022-12-27	WOS:A1993LA68900034
J	HUANG, KM; SNIDER, MD				HUANG, KM; SNIDER, MD			GLYCOPROTEIN RECYCLING TO THE GALACTOSYLTRANSFERASE COMPARTMENT OF THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; HAMSTER OVARY CELLS; BREFELDIN-A CAUSES; INTRACELLULAR MOVEMENT; TRANSFERRIN RECEPTOR; MEDIATED ENDOCYTOSIS; MEMBRANE-PROTEINS; MDCK CELLS; NETWORK; ENDOSOMES	The recycling of plasma membrane glycoproteins to the Golgi complex is well established, but it is not clear which Golgi subcompartments receive this traffic. To date, recycling into the trans-Golgi compartment that contains sialyltransferase and the early Golgi region that contains alpha-mannosidase I has been demonstrated. However, transport into other Golgi compartments has not been reported. In this study we tested the return of cell surface glycoproteins to the Golgi galactosyltransferase compartment using the ldlD mutant of Chinese hamster ovary cells. The cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor recycled through this Golgi region with a half-time of 4 h and was transported to the sialyltransferase compartment as well. Because galactosyltransferase and sialyltransferases are probably located in different trans-Golgi regions in Chinese hamster ovary cells, these results suggest that the two compartments each receive recycling traffic or that recycling glycoproteins enter one region and are then transported to the other. The extent of cell surface protein recycling through the galactosyltransferase compartment was also studied. At least 10 different glycoproteins were transported from the cell surface to this Golgi region. Moreover, our results suggest that recycling glycoproteins make up 12-25% of the flux of cell surface glycoproteins through the Golgi galactosyltransferase compartment; the balance is comprised of newly made glycoproteins.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University					NIDDK NIH HHS [DK07319] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BRANDLI AW, 1989, EMBO J, V8, P3207, DOI 10.1002/j.1460-2075.1989.tb08479.x; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; FISHMAN JB, 1987, CELL, V48, P157, DOI 10.1016/0092-8674(87)90366-7; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; JIN M, 1989, J BIOL CHEM, V264, P7675; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; OMARY MB, 1981, J BIOL CHEM, V256, P2888; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; REICHNER JS, 1988, J BIOL CHEM, V263, P16316; ROBBINS AR, 1981, J BIOL CHEM, V256, P623; ROBBINS AR, 1983, J CELL BIOL, V96, P1064, DOI 10.1083/jcb.96.4.1064; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; ROTH J, 1982, J CELL BIOL, V92, P223; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SNIDER MD, 1991, INTRACELLULAR TRAFFI, P361; WARD JH, 1982, J BIOL CHEM, V257, P317; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9302	9310						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486626				2022-12-27	WOS:A1993LA68900026
J	TIESMAN, J; HART, CE				TIESMAN, J; HART, CE			IDENTIFICATION OF A SOLUBLE RECEPTOR FOR PLATELET-DERIVED GROWTH-FACTOR IN CELL-CONDITIONED MEDIUM AND HUMAN PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; FACTOR PDGF; CARCINOMA-CELLS; TRUNCATED FORM; HUMAN-URINE; EXPRESSION; PROTEIN; DOMAIN; PURIFICATION	We have discovered a soluble form of the platelet-derived growth factor (PDGF) alpha receptor, designated sPDGF-Ralpha, that is produced by and secreted into the conditioned medium of the human osteosarcoma cell line, MG-63. Additionally, sPDGF-Ralpha activity has been detected in normal human blood plasma and serum. We have achieved partial purification of this protein by column chromatography using three different affinity matrices: anti-PDGF-Ralpha monoclonal antibody (mAb) 292.15-Sepharose, PDGF-BB-Sepharose, and wheat germ agglutinin-agarose. All three matrices have been shown to purify a 90-kDa protein that is recognized by mAbs specific for the PDGF-Ralpha extracellular domain. sPDGF-Ralpha is capable of binding PDGF ligand in solution and can compete with cell-associated PDGF receptors for ligand binding. We provide three pieces of data suggesting that the sPDGF-Ralpha is generated by proteolytic clipping of the full-length PDGF-Ralpha protein. First, the conditioned medium of an expression cell line transfected with a cDNA construct designed to produce only full-length PDGFRalpha exhibits sPDGF-Ralpha activity. Second, a truncated intracellular fragment of the PDGF-Ralpha, presumably representing the intracellular counterpart of the clipped sPDGF-Ralpha, can be immunoprecipitated from the MG-63 osteosarcoma cell extracts using antiserum raised against an intracellular portion of PDGF-Ralpha. Finally, we have been unable to detect alternative splicing in the PDGF-Ralpha transcript using reverse transcription-polymerase chain reaction.			TIESMAN, J (corresponding author), ZYMOGENET INC,SEATTLE,WA 98105, USA.							BEGUIN Y, 1988, P NATL ACAD SCI USA, V85, P637, DOI 10.1073/pnas.85.2.637; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DUAN DSR, 1991, J BIOL CHEM, V266, P413; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; DUMMER R, 1992, J INVEST DERMATOL, V98, P50, DOI 10.1111/1523-1747.ep12494223; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GATANAGA T, 1990, P NATL ACAD SCI USA, V87, P8781, DOI 10.1073/pnas.87.22.8781; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAUDEWITZ P, 1988, J INVEST DERMATOL, V91, P386; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NILSSON J, 1985, P NATL ACAD SCI USA, V82, P4418, DOI 10.1073/pnas.82.13.4418; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; TENDIJKE P, 1989, BIO-TECHNOL, V7, P793, DOI 10.1038/nbt0889-793; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; TIESMAN J, 1989, Cytotechnology, V2, P333, DOI 10.1007/BF00364997; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	48	44	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9621	9628						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486649				2022-12-27	WOS:A1993LA68900071
J	KOSFELD, MD; FRAZIER, WA				KOSFELD, MD; FRAZIER, WA			IDENTIFICATION OF A NEW CELL-ADHESION MOTIF IN 2 HOMOLOGOUS PEPTIDES FROM THE COOH-TERMINAL CELL BINDING DOMAIN OF HUMAN THROMBOSPONDIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SQUAMOUS CARCINOMA; III CONNECTING SEGMENT; TENASCIN; ATTACHMENT; FIBRONECTIN; SEQUENCE; ANGIOGENESIS; MIGRATION; MOTILITY; TISSUE	Thrombospondin-1 (TS1) contains at least four domains that support cell attachment. The COOH-terminal cell binding domain (CBD) was first identified with a monoclonal antibody against TS1 that blocked secretion-dependent platelet aggregation. Subsequently, this domain of TS1 has been found to bind a number of normal and transformed cells. We have localized attachment sites for human melanoma cells (G361) within the CBD to two noncontiguous 30-residue peptides designated C4 and C7 (Kosfeld, M. D., and Frazier, W. A. (1991) J. Biol. Chem. 267,16230-16236). Here we report studies to define the active sequences within C4 and C7. An octapeptide, RFYVVMWK (4N1-1), from C4 and a pentapeptide, IRVVM (7N3-1), from C7 were found to support attachment of G361 melanomas, K562 erythroleukemia cells, HT1080 fibrosarcomas, C32 amelanotic melanomas, and endothelial cells. These peptides also inhibit the adhesion of cells to the recombinant CBD of TS1. The hexapeptide RFYVVM (4N1-2) also inhibits cell attachment. The inhibitory effect of combinations of C4- and C7-derived peptides is synergistic. The sequences 4N1-1 and 7N3-1 of TS1 share homology with two cell adhesive peptides from laminin (LM), LMF9 and LMPA22-2, respectively. These TS1 and LM peptides are interchangeable in inhibiting the adhesion of G361 cells to LM or TS1, suggesting a possible sharing of receptors by LM and TS1. K562 cells, however, bound only to TS1, and this binding was inhibited preferentially by the TS1 CBD peptides, indicating a receptor specific for TS1 which does not recognize LM. The active TS1 peptides are highly conserved among five species and four isoforms of TS1. Homologs of the TS1 peptides are found in tenascin, a matrix protein that shares several properties with TS1 and in factor VIII, alpha2-macroglobulin, and von Willebrand factor.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,BOX 8231,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FRAZIER WA, 1991, CURR OPIN CELL BIOL, V3, P793; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEUNG LLK, 1984, J CLIN INVEST, V74, P1964; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SKUBITZ APN, 1990, CANCER RES, V50, P7612; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; ULLRICH A, 1990, EMBO J, V10, P2849; VARANI J, 1986, EXP CELL RES, V167, P376, DOI 10.1016/0014-4827(86)90178-3; VAS HL, 1992, J BIOL CHEM, V267, P12192; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	42	64	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8808	8814						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473325				2022-12-27	WOS:A1993KX81100065
J	MATSUKAWA, N; NONAKA, Y; HIGAKI, J; NAGANO, M; MIKAMI, H; OGIHARA, T; OKAMOTO, M				MATSUKAWA, N; NONAKA, Y; HIGAKI, J; NAGANO, M; MIKAMI, H; OGIHARA, T; OKAMOTO, M			DAHLS SALT-RESISTANT NORMOTENSIVE RAT HAS MUTATIONS IN CYTOCHROME-P450(11-BETA), BUT THE SALT-SENSITIVE HYPERTENSIVE RAT DOES NOT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSTERONE SYNTHASE; MOLECULAR-CLONING; ADRENAL-CORTEX; CYTOCHROME-P-45011-BETA; FORMS; INHERITANCE; SEQUENCE	Molecular cloning of cytochrome P450(11beta) cDNAs from the adrenal glands of Dahl's salt-sensitive hypertensive (DS) and salt-resistant normotensive (DR) rats was performed using a combined technique of the first strand cDNA synthesis by reverse transcriptase followed by polymerase chain reaction. The cDNA sequence of P450(11beta)-DS was identical to that of wild type P450(11beta). In contrast, the clone obtained from the DR rat contained six nucleotide substitutions causing five amino acid alterations (Arg-127 --> Cys, Val-351 --> Ala, Val-381 --> Leu, Ile-384 --> Leu, and Val-443 --> Met). When the two cDNAs were expressed in COS-7 cells and steroid conversion rates of the transformed cells were determined, a ratio of 18-hydroxylation to 11beta-hydroxylation of 11-deoxycorticosterone by P450(11beta)-DS-expressed cells was 0.58, whereas that by P450(11beta)-DR-expressed cells was 0.23. Plasma levels of 18-hydroxy-11-deoxycorticosterone and corticosterone (the 11beta-hydroxylation product of 11-deoxycorticosterone) in DS and DR rats well reflected the steroidogenic activities of the two P450s. These results suggest that the characteristic plasma steroid level of the DR rat is caused by the mutations in P450(11beta) gene and may act to maintain the normotensive blood pressure in this rat strain during sodium loading.	OSAKA UNIV,SCH MED,DEPT MOLEC PHYSIOL CHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT GERIATR,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University								CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHL LK, 1962, NATURE, V194, P480, DOI 10.1038/194480b0; DEN K, 1978, ENDOCRINOL JAPON, V25, P171; GOTOH O, 1992, J BIOL CHEM, V267, P83; IWAI J, 1969, J EXP MED, V129, P663, DOI 10.1084/jem.129.4.663; KNUDSEN KD, 1970, J EXP MED, V132, P976, DOI 10.1084/jem.132.5.976; LAUBER M, 1989, ARCH BIOCHEM BIOPHYS, V274, P109, DOI 10.1016/0003-9861(89)90421-9; MATSUKAWA N, 1990, BIOCHEM BIOPH RES CO, V169, P245, DOI 10.1016/0006-291X(90)91460-A; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; NONAKA Y, 1991, EUR J BIOCHEM, V202, P897, DOI 10.1111/j.1432-1033.1991.tb16449.x; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OHTA M, 1988, J STEROID BIOCHEM, V29, P699; OZOLS J, 1981, J BIOL CHEM, V256, P1405; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; RAPP JP, 1972, ENDOCRINOLOGY, V90, P1435, DOI 10.1210/endo-90-6-1435; RAPP JP, 1972, NATURE, V237, P338, DOI 10.1038/237338a0; RAPP JP, 1976, BIOCHEMISTRY-US, V15, P1235, DOI 10.1021/bi00651a010; SUGANO S, 1985, J STEROID BIOCHEM, V23, P1013; WADA A, 1992, J BIOL CHEM, V267, P22877; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	20	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9117	9121						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473350				2022-12-27	WOS:A1993KX81100104
J	STRUBE, KH; KROGER, B; BIALOJAN, S; OTTE, M; DODT, J				STRUBE, KH; KROGER, B; BIALOJAN, S; OTTE, M; DODT, J			ISOLATION, SEQUENCE-ANALYSIS, AND CLONING OF HAEMADIN - AN ANTICOAGULANT PEPTIDE FROM THE INDIAN LEECH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XA; ALPHA-THROMBIN; HIRUDIN; INHIBITOR; BINDING; KINETICS; COMPLEX	A slow, tight-binding inhibitor of thrombin with an apparent molecular mass of about 5 kDa has been isolated from Haemadipsa sylvestris, an Indian leech of the family of Haemadipsidae. The inhibitory activity, called haemadin, is thrombin specific since it does not inhibit other proteases like trypsin, chymotrypsin, factor Xa, or plasmin. NH2-terminal amino acid sequence analysis (residues 1-45) does not reveal any homology to known serine protease inhibitors, including the thrombin-specific inhibitor hirudin. The haemadin cDNA cloned by polymerase chain reaction techniques codes for a polypeptide of 57 amino acid residues preceded by 20 residues of a signal peptide sequence. A synthetic gene coding for the mature haemadin was expressed in Escherichia coli. Recombinant haemadin displays a similar inhibition constant and specific activity as its natural counterpart. Although there is no obvious sequence identity between haemadin and hirudin, both proteins seem to share common mechanisms for thrombin inhibition.	BASF AG,DEPT BIOTECHNOL,W-6700 LUDWIGSHAFEN,GERMANY; TH DARMSTADT,INST BIOCHEM,W-6100 DARMSTADT,GERMANY	BASF; Technical University of Darmstadt								BETZ A, 1992, BIOCHEMISTRY-US, V31, P4557, DOI 10.1021/bi00134a004; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CONDRA C, 1989, THROMB HAEMOSTASIS, V61, P437; DODT J, 1985, BIOL CHEM H-S, V366, P379, DOI 10.1515/bchm3.1985.366.1.379; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; DODT J, 1990, J BIOL CHEM, V265, P713; ELECTRICWALA A, 1991, BLOOD COAGUL FIBRIN, V2, P83, DOI 10.1097/00001721-199102000-00013; FINK E, 1989, SEMIN THROMB HEMOST, V15, P283, DOI 10.1055/s-2007-1002720; FRITZ JD, 1991, NUCLEIC ACIDS RES, V19, P3747, DOI 10.1093/nar/19.13.3747; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; JACOBS JW, 1990, THROMB HAEMOSTASIS, V64, P235; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KOHLER S, 1989, DECHEMA BIO, V3, P405; LAZAR JB, 1991, J BIOL CHEM, V266, P685; Maniatis T, 1989, DECONTAMINATION DILU; Mann K G, 1976, Methods Enzymol, V45, P123; MARKWARDT F, 1967, H-S Z PHYSIOL CHEM, V348, P1381, DOI 10.1515/bchm2.1967.348.1.1381; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NASKI MC, 1990, J BIOL CHEM, V265, P13484; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Sawyer R. T, 1986, LEECH BIOL BEHAVIOUR, VII; SAWYER RT, 1991, BIO-TECHNOL, V9, P513, DOI 10.1038/nbt0691-513; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHARF M, 1989, FEBS LETT, V255, P105, DOI 10.1016/0014-5793(89)81070-1; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; STEINER V, 1992, BIOCHEMISTRY-US, V31, P2294, DOI 10.1021/bi00123a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Tripier D, 1988, Folia Haematol Int Mag Klin Morphol Blutforsch, V115, P30; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Williams J W, 1979, Methods Enzymol, V63, P437	40	77	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8590	8595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473305				2022-12-27	WOS:A1993KX81100035
J	CUI, JS; NI, LY; SOMERVILLE, RL				CUI, JS; NI, LY; SOMERVILLE, RL			ATPASE ACTIVITY OF TYRR, A TRANSCRIPTIONAL REGULATORY PROTEIN FOR SIGMA(70) RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI K-12; GENE; ACTIVATOR; REPRESSOR; PROMOTER; MTR	The TyrR protein of Escherichia coli is the chief transcriptional regulator of several genes essential for aromatic amino acid biosynthesis and transport. It was established in previous studies that this protein binds ATP, that the TyrR . ATP complex has enhanced affinity for tyrosine, and that the susceptibility of the TyrR protein to hydrolysis by trypsin is altered by ATP. Here we show that the TyrR protein has ATPase activity, which is stimulated by tyrosine. In this respect the TyrR protein resembles the transcriptional activator NtrC. The NtrC protein contains an internal polypeptide segment, 220 amino acid residues in length, with a high degree of identity to the TyrR protein, that contains the presumptive ATPase catalytic center.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22131] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ANDREWS AE, 1991, J BACTERIOL, V173, P5079, DOI 10.1128/jb.173.16.5079-5085.1991; ARGYROPOULOS VS, 1989, THESIS U MELBOURNE A; AUSTIN S, 1991, NUCLEIC ACIDS RES, V19, P2281, DOI 10.1093/nar/19.9.2281; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; CORNISH EC, 1986, J BIOL CHEM, V261, P403; CUI JS, 1993, J BACTERIOL, V175, P1777, DOI 10.1128/JB.175.6.1777-1784.1993; CUI JS, 1993, J BIOL CHEM, V268, P5040; CUI JS, 1993, J BACTERIOL, V175, P303, DOI 10.1128/JB.175.1.303-306.1993; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; KASIAN PA, 1986, J BACTERIOL, V167, P556, DOI 10.1128/jb.167.2.556-561.1986; KRISHNAN PS, 1955, METHOD ENZYMOL, V2, P591, DOI 10.1016/S0076-6879(55)02260-X; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WHIPP MJ, 1977, J BACTERIOL, V132, P453, DOI 10.1128/JB.132.2.453-461.1977; YANG J, 1993, J BACTERIOL, V175, P1767, DOI 10.1128/JB.175.6.1767-1776.1993	20	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13023	13025						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514743				2022-12-27	WOS:A1993LH55300004
J	PETERSEN, JGL; MEYN, G; RASMUSSEN, JS; PETERSEN, J; BJORN, SE; JONASSEN, I; CHRISTIANSEN, L; NORDFANG, O				PETERSEN, JGL; MEYN, G; RASMUSSEN, JS; PETERSEN, J; BJORN, SE; JONASSEN, I; CHRISTIANSEN, L; NORDFANG, O			CHARACTERIZATION OF HUMAN TISSUE FACTOR PATHWAY INHIBITOR VARIANTS EXPRESSED IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION INHIBITOR; EXTRINSIC PATHWAY; FACTOR-XA; NUCLEOTIDE-SEQUENCE; MONOCLONAL-ANTIBODY; BLOOD-COAGULATION; ESCHERICHIA-COLI; HEPATOMA CELLS; HEPARIN; GENE	Human tissue factor pathway inhibitor (TFPI) and three derivatives with deletions of 1) the complete COOH-terminal third of the polypeptide including the third Kunitz domain, 2) the third Kunitz domain alone, or 3) the penultimate basic COOH-terminal region alone were expressed in yeast as secreted products. High expression yield was obtained only with the derivative that lacked both the third Kunitz domain and the penultimate COOH tail (TFPI1-161). The purified short form was heterogenously glycosylated with a high mannose glycan. The specific activities of the different mutant polypeptides toward FXa.tissue factor.FVIIa in a chromogenic assay were similar to that of TFPI expressed in baby hamster kidney cells, suggesting that correct folding takes place in yeast and that neither the third Kunitz domain nor the COOH-terminal region is required for this activity. However, in a clotting assay the anticoagulant activities of yeast-produced TFPI and the shortened derivative TFPI1-161 were about 5- and 50-fold lower, respectively, than for full-length TFPI from mammalian cells. Clotting assays with purified short form TFPI showed that it acted mainly via inhibition of FVIIa.tissue factor rather than FXa. The anticoagulant activity of short form TFPI was comparable with that of high affinity antibodies toward tissue factor.			PETERSEN, JGL (corresponding author), NOVO NORD AS, NOVO ALLE, DK-2880 BAGSVAERD, DENMARK.							ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; BARR PJ, 1987, F BIOTECH IND FERMEN, V5, P139; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BROZE GJ, 1987, THROMB RES, V48, P253, DOI 10.1016/0049-3848(87)90422-1; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BROZE GJ, 1987, BLOOD, V69, P150; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DAY KC, 1990, BLOOD, V76, P1538; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; EGELMITANI M, 1987, NUCLEIC ACIDS RES, V15, P6303, DOI 10.1093/nar/15.15.6303; GIRARD TJ, 1989, THROMB RES, V55, P37, DOI 10.1016/0049-3848(89)90454-4; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HAGENBUCHLE O, 1981, NATURE, V289, P643, DOI 10.1038/289643a0; HAMAMOTO T, 1993, J BIOL CHEM, V268, P8704; HOPWOOD DA, 1985, GENETIC MANIPULATION, P13; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAWASAKI G, 1990, Patent No. 4931373; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL AK, 1991, THROMB RES, V62, P607, DOI 10.1016/0049-3848(91)90365-4; LITSKE JG, 1986, NUCLEIC ACIDS RES, V14, P9631, DOI 10.1093/nar/14.24.9631; Maniatis T., 1982, MOL CLONING; MIKKELSEN J, 1987, BIOCHEM J, V248, P709, DOI 10.1042/bj2480709; NEMERSON Y, 1988, BLOOD, V71, P1; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; NORDFANG O, 1991, THROMB HAEMOSTASIS, V66, P464; NOVOTNY WF, 1991, BLOOD, V78, P394; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1987, BLOOD, V69, P645; RAPAPORT SI, 1989, BLOOD, V73, P359; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUSSELL PR, 1985, GENE, V40, P125, DOI 10.1016/0378-1119(85)90031-9; SANDSET PM, 1987, THROMB RES, V47, P389, DOI 10.1016/0049-3848(87)90454-3; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI, P163; SLEEP D, 1990, BIO-TECHNOL, V8, P42, DOI 10.1038/nbt0190-42; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VALENTIN S, 1991, BLOOD COAGUL FIBRIN, V2, P629, DOI 10.1097/00001721-199110000-00007; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISS HJ, 1989, BLOOD, V73, P968; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WUN TC, 1988, J BIOL CHEM, V263, P6001; WUN TC, 1992, BLOOD, V79, P430; WUN TC, 1990, J BIOL CHEM, V265, P16096	49	49	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13344	13351						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514773				2022-12-27	WOS:A1993LH55300049
J	GEORGE, A; SABSAY, B; SIMONIAN, PAL; VEIS, A				GEORGE, A; SABSAY, B; SIMONIAN, PAL; VEIS, A			CHARACTERIZATION OF A NOVEL DENTIN MATRIX ACIDIC PHOSPHOPROTEIN - IMPLICATIONS FOR INDUCTION OF BIOMINERALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT INCISOR DENTIN; MOLECULAR-WEIGHT; PHOSPHOPHORYN; CASEIN; DETERMINANTS; CLONING; LIVER	Acidic phosphorylated proteins have been shown t be prominent constituents of the extracellular matrix of bone and dentin. The acidic phosphoproteins of bon contain more glutamic acid than aspartic acid and a lower serine content than either. On the other hand, the major dentin acidic phosphoproteins, phosphophoryns, have been defined as aspartic acid- and serine-rich proteins, with a lesser content of glutamic acid. Both sets of phosphoproteins have been implicated as key participants in regulating mineralization, but it has been difficult to unify their mechanisms of action. We have now identified, by cDNA cloning, a new serine-rich acidic protein of the dentin matrix, AG1, with a composition intermediate between the bone acidic proteins and dentin phosphophoryns. AG1 has numerous acidic consensus sites for phosphorylation by both casein kinases I and II. Immunochemical and organ culture biosynthetic studies show that AG1 is present in phosphorylated form at low levels in the dentin matrix. If fully phosphorylated, AG1 would bear a net charge of -175/molecule of 473 residues. AG1 contains single RGD integrin binding and N-glycosylation sequences. The overall picture that emerges is that of a matrix-associated acidic phosphoprotein, with a potentially high calcium ion binding capacity, present at levels compatible with a regulatory role in dentin mineralization.	NORTHWESTERN UNIV,DIV ORAL BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University				GEORGE, ANNE/0000-0002-9008-7642	NIAMS NIH HHS [AR-13921] Funding Source: Medline; NIDCR NIH HHS [DE-01374] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR013921, R37AR013921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE001374] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARNES WM, 1983, METHOD ENZYMOL, V101, P98; Butler W T, 1991, J Biol Buccale, V19, P83; CARMICHAEL DJ, 1971, CALC TISS RES, V7, P331, DOI 10.1007/BF02062622; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIMUZIO MT, 1985, CALCIFIED TISSUE INT, V37, P242, DOI 10.1007/BF02554870; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE SL, 1977, BIOCHEMISTRY-US, V16, P2971, DOI 10.1021/bi00632a026; Lowenstam H. A., BIOMINERALIZATION; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEGGIO F, 1989, EUR J BIOCHEM, V186, P459, DOI 10.1111/j.1432-1033.1989.tb15229.x; MEIR UT, 1992, CELL, V70, P127; RAHIMA M, 1988, J HISTOCHEM CYTOCHEM, V36, P153, DOI 10.1177/36.2.3335773; ROACH PJ, 1991, J BIOL CHEM, V266, P3724; SABSAY B, 1991, BIOCHEM J, V276, P699, DOI 10.1042/bj2760699; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHLUETER RJ, 1964, BIOCHEMISTRY-US, V3, P1657, DOI 10.1021/bi00899a010; STETLERSTEVENSON WG, 1987, CALCIFIED TISSUE INT, V40, P97, DOI 10.1007/BF02555712; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; TABOR S, 1989, J BIOL CHEM, V264, P6447; Veis A., 1989, P189; VEIS A, 1983, BIOMINERALIZATION BI, P191; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTON GM, 1985, J BIOL CHEM, V260, P4745; WU CB, 1992, J BIOL CHEM, V267, P16588	30	353	379	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12624	12630						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509401				2022-12-27	WOS:A1993LG65800060
J	LIU, JN; GUREWICH, V				LIU, JN; GUREWICH, V			SUBSTRATE-INHIBITION OF FIBRIN-DEPENDENT PLASMINOGEN ACTIVATION BY TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ONE-CHAIN; KINETICS; CLEAVAGE; BINDING	Tissue plasminogen activator (t-PA) is a poor activator of plasminogen, but its catalytic efficiency is greatly enhanced in the presence of fibrin or certain fibrin derivatives. These two very different rates of plasminogen activation provide a basis for the phenomenon of substrate inhibition, which was the subject of the present study. The reaction mixture contained Glu-plasminogen (0-4.0 muM), +/-D-dimer (0.06-1.0 muM), t-PA (0.05-50.0 nM), and S2251 (1.5 mM). Inhibition of the reaction at higher plasminogen concentrations was seen at lower concentrations of t-PA (< 1.0 nM) and D-dimer (<0.5 muM). The maximum rate of plasminogen activation occurred at 0.2 muM Glu-plasminogen but then decreased progressively above this concentration. At a physiological concentration of plasminogen (2.0 muM), activation was about half that at 0.2 muM. This phenomenon was shown not to be related to Glu-plasminogen aggregation or to a non-competitive inhibiting contaminant. Instead, the non-linear Lineweaver-Burk curve in the presence of D-dimer was consistent with substrate inhibition. Increasing the concentration of D-dimer (1.0 muM) and/or t-PA (50 nM) overcame the inhibition and reestablished linearity in the Lineweaver-Burk plots. However, at the higher concentrations of t-PA, the catalytic efficiency was reduced by 50-120-fold, suggesting that t-PA may be less efficient at pharmacological than at physiological concentrations. In conclusion, substrate inhibition in t-PA-induced plasminogen activation is reported for the first time. This phenomenon was confined to low concentrations of t-PA and D-dimer in the presence of physiological concentrations of plasminogen. The observation suggests that small fibrin clots (hemostatic plugs) may be more resistant to tPA-induced lysis than an occlusive thrombus.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215	Harvard University; Harvard Medical School								CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; FISCHER BE, 1990, BIOCHIM BIOPHYS ACTA, V952, P245; HASAN AAK, 1992, BLOOD, V79, P2313; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIDLER KJ, 1973, CHEM KINETICS ENZYME, P89; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RANBY M, 1983, PROGR FIBRINOLYSIS, V6, P182; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SEGEL I, 1975, ENZYME KINETICS, P149; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; URDEN G, 1984, SCAND J CLIN LAB INV, V44, P495, DOI 10.3109/00365518409083602; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; VARADI A, 1984, BIOCHEMISTRY-US, V23, P2108, DOI 10.1021/bi00304a036; ZAMARRON C, 1984, J BIOL CHEM, V259, P2080	19	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12257	12259						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509362				2022-12-27	WOS:A1993LG65800008
J	PAUL, P; LUTZ, TM; OSBORN, C; KYOSSEVA, S; ELBEIN, AD; TOWBIN, H; RADOMINSKA, A; DRAKE, RR				PAUL, P; LUTZ, TM; OSBORN, C; KYOSSEVA, S; ELBEIN, AD; TOWBIN, H; RADOMINSKA, A; DRAKE, RR			SYNTHESIS AND CHARACTERIZATION OF A NEW CLASS OF INHIBITORS OF MEMBRANE-ASSOCIATED UDP-GLYCOSYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCEREBROSIDE SYNTHETASE; PROTEIN; BRAIN; ANALOGS; OLIGOSACCHARIDES; GLYCOSYLATION; TUNICAMYCIN; AMPHOMYCIN; GLUCOSE; ASSAY	A new class of compounds designed to inhibit membrane-associated glycosyltransferases were synthesized and their biological activities were characterized in liver microsomes and human lymphoma cell lines. These inhibitors are composed of N-acyl phenylaminoalcohol derivatives linked to uridine via different spacers. One inhibitor, termed PP36 (5'-[[N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)-glycyl] amino]-5'-deoxyuridine) competitively inhibited the enzyme glucosyl phosphoryldolichol synthase (Glc-P-Dol synthase) in rat liver microsomes. In rat and human liver microsomes-incubated with PP36 and photolabeled with [beta-P-32]5-azido-UDP-Glc, Glc-P-Dol synthase was the only protein observed to have decreased photoincorporation. Two other inhibitors, PP37 (5'-O-[[(2-decanoylamino-3-hydroxy-3-phenyl-propyloxycarbonyl) amino]sulfonyl]uridine and PP55 (5'-O-[[(2-decanoylamino-3-phenylpropyloxycarbonyl)amino]sulfonyl]uridine), were also shown to be competitive inhibitors of Glc-P-Dol synthase activity and photolabeling. Activities of glycosyltransferases involved in glycosphingolipid biosynthesis were little affected by these compounds. Analysis of the effects of PP36, PP37, and PP55 on the incorporation of [H-3] leucine and [C-14]galactose into glycoprotein and glycolipid fractions from two human cell lines indicated the following: PP36 reduced incorporation into both fractions, PP37 was ineffective, and PP55 only decreased incorporation into glycolipids.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; CIBA GEIGY AG,PHARMACEUT RES LABS,CH-4002 BASEL,SWITZERLAND; UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; Novartis; University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800, R01DK038678] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38678, DK-21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BASU M, 1987, METHOD ENZYMOL, V138, P575; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BOYSE E A, 1964, Methods Med Res, V10, P39; CAMARASA MJ, 1985, J MED CHEM, V28, P40, DOI 10.1021/jm00379a010; CASTRO B, 1975, TETRAHEDRON LETT, V14, P1219; CESTELLI A, 1979, BIOCHIM BIOPHYS ACTA, V572, P283, DOI 10.1016/0005-2760(79)90043-2; DRAKE R, 1990, BIOSCIENCE REP, V10, P61, DOI 10.1007/BF01116852; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; DRAKE RR, 1991, PLANT PHYSIOL, V97, P396, DOI 10.1104/pp.97.1.396; DRAKE RR, 1991, J BIOL CHEM, V266, P23257; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; DUSKIN D, 1982, J BIOL CHEM, V257, P3105; ELBEIN AD, 1991, BIOL CARBOHYDRATES, V3, P119; ERICSON MC, 1978, ARCH BIOCHEM BIOPHYS, V191, P698, DOI 10.1016/0003-9861(78)90409-5; HARRINGTON CR, 1990, ANAL BIOCHEM, V186, P285, DOI 10.1016/0003-2697(90)90081-J; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HORWITZ JP, 1962, J ORG CHEM, V27, P3045, DOI 10.1021/jo01056a013; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KANG MS, 1979, J BIOL CHEM, V254, P37; KEENAN RW, 1981, BIOCHEMISTRY-US, V20, P2968, DOI 10.1021/bi00513a039; KIJIMASUDA I, 1985, CHEM PHARM BULL, V33, P730; KISHIMOTO Y, 1983, ENZYMES, V16, P357; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUAN SF, 1989, J BIOL CHEM, V264, P19721; LONG LM, 1949, J AM CHEM SOC, V71, P2473, DOI 10.1021/ja01175a068; MULLER T, 1981, FEBS LETT, V128, P208, DOI 10.1016/0014-5793(81)80082-8; PACIC MM, 1989, J BIOL CHEM, V264, P17174; PAUL P, 1992, ANAL BIOCHEM, V204, P265, DOI 10.1016/0003-2697(92)90237-2; PULVERTAFT RJV, 1964, LANCET, V1, P238; Radin N S, 1981, Methods Enzymol, V72, P673; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; TIPSON RS, 1968, SYNTHETIC P NUCL ACI, V1, P431; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; VAGHEFI MM, 1987, J MED CHEM, V30, P1383, DOI 10.1021/jm00391a020; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199; 1965, Patent No. 660366	41	28	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12933	12938						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509426				2022-12-27	WOS:A1993LG65800101
J	HIEBER, AD; CHRISTIE, DL				HIEBER, AD; CHRISTIE, DL			CHARACTERIZATION OF GLYCOPROTEIN-II FROM BOVINE ADRENAL-MEDULLARY CHROMAFFIN GRANULES - IDENTIFICATION OF COMPONENTS REPRESENTING THE SECRETORY VESICLE COUNTERPARTS OF THE LYSOSOMAL-ASSOCIATED MEMBRANE-GLYCOPROTEINS (LAMP-1 AND LAMP-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE-ANALYSIS; PLASMA-MEMBRANE; PROTEINS; MOUSE; CDNA; PURIFICATION; SIMILARITY; ENDOCRINE; H-LAMP-1; CLONING	Glycoprotein II (GpII) is a heterogenous glycoprotein isolated from the membranes of bovine chromaffin granules in the adrenal medulla. When viewed by two-dimensional electrophoresis this glycoprotein consists of two components, upper (GpIIa) and lower (GpIIb), with a molecular mass of 80,000-100,000 daltons and a pI of 4.2-4.7. NH2-terminal sequence analysis of GpIIa and GpIIb revealed sequence similarity with lysosomal membrane glycoproteins (lamp-1 and lamp-2), which was supported by sequence data of peptides from trypsin and cyanogen bromide digestions. An oligonucleotide probe was used to isolate a cDNA clone encoding the nucleotide sequence of GpIIa. The predicted amino acid sequence of GpIIa shares a 72% identity with the human lamp-1 type protein, which belongs to a highly conserved group of lysosomal-associated membrane glycoproteins (lamp proteins), whose function is still unknown. The COOH-terminal region of GpIIa was identical to the COOH-terminal region of lamp proteins. This COOH-terminal determinant has been demonstrated to be essential for the intracellular targeting of lamp proteins to lysosomes. A synthetic peptide antisera to the COOH-terminal region of GpIIa was used to show that this region is present on purified chromaffin granules and not proteolytically processed. The sequence analysis of GpIIa and immunological data confirm GpII as the secretory granule counterpart of lamp proteins and raise some questions regarding intracellular targeting between lysosomes and secretory granules within the chromaffin cell.	UNIV AUCKLAND,SCH BIOL SCI,DEPT BIOCHEM,AUCKLAND 92019,NEW ZEALAND	University of Auckland			Christie, David L/C-8065-2009					CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488; CHA Y, 1990, J BIOL CHEM, V265, P5008; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CHRISTIE DL, 1990, BIOCHEM J, V270, P57, DOI 10.1042/bj2700057; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISCHERCOLBRIE R, 1982, J NEUROCHEM, V38, P725, DOI 10.1111/j.1471-4159.1982.tb08691.x; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASLOP A, 1986, NEUROSCI LETT, V72, P300, DOI 10.1016/0304-3940(86)90530-6; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MARGOLIS RU, 1988, J NEUROCHEM, V51, P1819, DOI 10.1111/j.1471-4159.1988.tb01163.x; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OBENDORF D, 1988, NEUROSCIENCE, V25, P343, DOI 10.1016/0306-4522(88)90030-9; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1990, CURRENT PROTOCOLS MO; TU CPD, 1980, GENE, V10, P177, DOI 10.1016/0378-1119(80)90135-3; VANREGENMORTEL MHV, 1988, SYNTHETIC POLYPEPTID, P95; WEILER R, 1990, BRAIN RES, V532, P87, DOI 10.1016/0006-8993(90)91746-4; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WINKLER H, 1990, NEUROCHEM INT, V17, P245, DOI 10.1016/0197-0186(90)90147-L; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5	35	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11073	11078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496169				2022-12-27	WOS:A1993LD46600054
J	BUDEL, LM; HOOGERBRUGGE, H; POUWELS, K; VANBUITENEN, C; DELWEL, R; LOWENBERG, B; TOUW, IP				BUDEL, LM; HOOGERBRUGGE, H; POUWELS, K; VANBUITENEN, C; DELWEL, R; LOWENBERG, B; TOUW, IP			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTORS ALTER THEIR BINDING CHARACTERISTICS DURING MYELOID MATURATION THROUGH UP-REGULATION OF THE AFFINITY CONVERTING BETA-SUBUNIT (KH97)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-3 RECEPTORS; ACUTE MYELOBLASTIC-LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; GROWTH-FACTOR RECEPTORS; FACTOR GM-CSF; EXPRESSION CLONING; MOLECULAR-CLONING; BLAST CELLS; HUMAN IL-3; RADIOACTIVITIES	Acute myeloid leukemia blasts express dual affinity (high and low) granulocyte-macrophage colony-stimulating factor (GM-CSF) binding, and the high affinity GM-CSF binding is counteracted by excess interteukin-3 (IL-3). Neutrophils express a single class of GM-CSF-R with intermediate affinity that lack IL-3 cross-reactivity. Here we demonstrate the differentiation associated changes of GM-CSF binding characteristics in three models representative of different stages of myeloid maturation. We find that high affinity GM-CSF binding is converted into intermediate affinity binding, which still cross-reacts with IL-3, beyond the stage of promyelocytes. During terminal maturation towards neutrophils, IL-3 cross-reactivity is gradually lost. We sought to determine the mechanism underlying the affinity conversion of the GM-CSF-R. Northern and reverse transcriptase-polymerase chain reaction analysis of GM-CSF-Ralpha and -beta(c) (KH97) transcripts did not provide indications for the involvement of GM-CSF-R splice variants in the formation of the intermediate affinity GM-CSFR complex. In COS-cell transfectants with increasing amounts of beta(c) in the presence of a fixed number of GM-CSF-Ralpha chains, the high affinity GM-CSF binding converted into intermediate affinity GM-CSF binding. These results are discussed in view of the concept that increasing expression of beta(c) subunits may cause alternative oligomerization of the GM-CSF-Ralpha and -beta(c) subunits resulting in the formation of intermediate rather than high affinity GM-CSFRalpha.beta(c) complexes.	DR DANIEL DENHOED CANC CTR,PB 5201,3008 AE ROTTERDAM,NETHERLANDS; ERASMUS UNIV,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOT FJ, 1989, EXP HEMATOL, V17, P292; BOT FJ, 1988, BLOOD, V71, P1609; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUDEL LM, 1989, BLOOD, V74, P2668; BUDEL LM, 1990, BLOOD, V75, P1439; BUDEL LM, 1989, BLOOD, V74, P565; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CHIBA S, 1990, LEUKEMIA, V4, P29; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARLING DC, 1989, LEUKEMIA RES, V13, P407, DOI 10.1016/0145-2126(89)90081-7; DELWEL R, 1988, BLOOD, V72, P1944; ELLIOTT MJ, 1989, BLOOD, V74, P2349; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, BLOOD, V67, P257; MUROHASHI I, 1989, LEUKEMIA RES, V13, P599, DOI 10.1016/0145-2126(89)90127-6; Nice E, 1990, GROWTH FACTORS, V3, P159, DOI 10.3109/08977199009108278; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OKUDA K, 1992, BLOOD, V79, P2880; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; ONETTOPOTHIER N, 1990, LEUKEMIA, V4, P329; PARK LS, 1989, J BIOL CHEM, V264, P5420; Sambrook J, 1989, MOL CLONING LABORATO; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SIEFF CA, 1987, J CLIN INVEST, V79, P1549, DOI 10.1172/JCI112988; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAMURA S, 1990, BLOOD, V76, P501; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; 1985, ANN INTERN MED, V103, P620; 1976, BRIT J HAEMATOL, V33, P451	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10154	10159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486685				2022-12-27	WOS:A1993LB80000034
J	CRAWFORD, JA; MUTCHLER, KJ; SULLIVAN, BE; LANIGAN, TM; CLARK, MS; RUSSO, AF				CRAWFORD, JA; MUTCHLER, KJ; SULLIVAN, BE; LANIGAN, TM; CLARK, MS; RUSSO, AF			NEURAL EXPRESSION OF A NOVEL ALTERNATIVELY SPLICED AND POLYADENYLATED GS-ALPHA TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NERVE GROWTH-FACTOR; MESSENGER-RNA; G-PROTEINS; ADENYLYL CYCLASE; RAT-BRAIN; DIFFERENTIAL EXPRESSION; REGULATORY PROTEINS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING	We have isolated an alternative transcript of the rat Gsalpha signal transduction protein gene, referred to as GsalphaN1. GsalphaN1 was isolated by differential hybridization screening of genes induced upon dexamethasone treatment of the neuronal-like CA77 rat thyroid C-cell line. The 1-kilobase GsalphaN1 transcript is generated by alternative splicing and polyadenylation of a novel terminal exon. This exon lies 800 base pairs downstream of exon 3 in the Gsalpha gene. Dexamethasone differentially induced GsalphaN1 severalfold relative to Gsalpha mRNA in the CA77 cells, similar to the bias seen with alternative processing of the calcitonin/calcitonin gene-related peptide transcript. In addition to the differential regulation by dexamethasone, the expression pattern of GsalphaN1 in rat tissues differed markedly from Gsalpha. GsalphaN1 mRNA was much more abundant in the brain, with intermediate levels in skeletal muscle and very low levels in other tissues. This was in contrast to the more ubiquitously expressed Gsalpha mRNA. Within the brain, GsalphaN1 was particularly abundant in discrete regions of the brainstem and hypothalamus that modulate autonomic functions. Examination of rat embryos demonstrated that Gsalpha is expressed in both brain and nonneural tissue at least 1 day before GsalphaN1 mRNA could be detected in the embryonic brain. Based on the regulated expression of the GsalphaN1 transcript and previous studies on Galpha proteins, the predicted GsalphaN1 protein may potentially modulate several heterotrimeric G protein functions in the nervous system.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa				Russo, Andrew/0000-0002-8156-5649	NIDCR NIH HHS [DEOP170] Funding Source: Medline; NIGMS NIH HHS [GM07337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI IU, 1992, NUCLEIC ACIDS RES, V20, P4263, DOI 10.1093/nar/20.16.4263; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; ANDERSON DJ, 1989, TRENDS GENET, V5, P174, DOI 10.1016/0168-9525(89)90072-3; ARONIN N, 1992, J NEUROSCI, V12, P3435; BARASCH JM, 1987, J NEUROSCI, V7, P2874; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRANN MR, 1987, FEBS LETT, V222, P191, DOI 10.1016/0014-5793(87)80218-1; CHANG FH, 1987, ENDOCRINOLOGY, V121, P1711, DOI 10.1210/endo-121-5-1711; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COOPER DMF, 1990, BRAIN RES, V523, P143, DOI 10.1016/0006-8993(90)91648-Z; DENKER BM, 1992, J BIOL CHEM, V267, P6272; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRANNEMAN JG, 1991, J NEUROCHEM, V57, P1019, DOI 10.1111/j.1471-4159.1991.tb08252.x; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; HELPER JR, 1992, TRENDS BIOCHEM SCI, V17, P383; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; JONES DT, 1987, J BIOL CHEM, V262, P14241; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LARGENT BL, 1988, P NATL ACAD SCI USA, V85, P2864, DOI 10.1073/pnas.85.8.2864; Le Douarin N.M., 1982, NEURAL CREST; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; MATSUDA JJ, 1992, CIRC RES, V70, P199, DOI 10.1161/01.RES.70.1.199; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Mutchler K J, 1992, PCR Methods Appl, V1, P195; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NISHIYAMA I, 1992, EXP CELL RES, V198, P214, DOI 10.1016/0014-4827(92)90373-G; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; RIUS RA, 1991, FEBS LETT, V288, P51, DOI 10.1016/0014-5793(91)81001-O; RODAN SB, 1986, ENDOCRINOLOGY, V118, P2510, DOI 10.1210/endo-118-6-2510; RUSSO AF, 1988, NEURON, V1, P311, DOI 10.1016/0896-6273(88)90079-7; RUSSO AF, 1992, MOL ENDOCRINOL, V6, P207, DOI 10.1210/me.6.2.207; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3906, DOI 10.1073/pnas.86.10.3906; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P4725, DOI 10.1093/nar/19.17.4725; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WANG HY, 1991, ENDOCRINOLOGY, V129, P133, DOI 10.1210/endo-129-1-133; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	54	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9879	9885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486667				2022-12-27	WOS:A1993LA68900103
J	KAIKAUS, RM; CHAN, WK; LYSENKO, N; RAY, R; DEMONTELLANO, PRO; BASS, NM				KAIKAUS, RM; CHAN, WK; LYSENKO, N; RAY, R; DEMONTELLANO, PRO; BASS, NM			INDUCTION OF PEROXISOMAL FATTY-ACID BETA-OXIDATION AND LIVER FATTY ACID-BINDING PROTEIN BY PEROXISOME PROLIFERATORS - MEDIATION VIA THE CYTOCHROME P-450IVA1 OMEGA-HYDROXYLASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; RAT-LIVER; DICARBOXYLIC-ACIDS; TREATED RATS; HEPATOCYTES; CLOFIBRATE; MITOCHONDRIAL; INACTIVATION; CULTURE; SYSTEM	Both the enzymes of peroxisomal fatty acid beta-oxidation and the liver fatty acid-binding protein (L-FABP) are induced in the liver by peroxisome proliferators, such as clofibrate (CF), as well as high fat diets. One proposed mechanism for this induction is that it represents an adaptive response to altered intracellular fatty acid fluxes, mediated by dicarboxylic fatty acids formed via the cytochrome P-450IVA1 omega-oxidation pathway. The studies presented in this paper were designed to investigate the role of the products of P-450IVA1 omega-oxidation in the regulation of peroxisomal beta-oxidation and L-FABP. In primary hepatocyte cultures exposed to CF, the increase in P-450IVA1 activity preceded the induction of peroxisomal beta-oxidation and L-FABP. The CF-mediated increases in peroxisomal beta-oxidation and L-FABP, but not P-450IVA1, could be significantly inhibited pretranslationally by concurrent exposure of cultured hepatocytes to inactivators of cytochromes P-450, such as 1-aminobenzotriazole and 10-undecynoic acid. Hexadecanedioic acid, a 16-carbon dicarboxylic fatty acid, that is poorly metabolized in hepatocytes, induced peroxisomal beta-oxidation and L-FABP, but not P-450IVA1, via a pretranslational mechanism that was not inhibited by 1-aminobenzotriazole. Long-chain monocarboxylic acids were without such inducing effect. In further studies, non-beta-oxidizable dicarboxylic acid analogs were found to display greater potency as inducers of peroxisomal beta-oxidation when compared to hexadecanedioic acid. The inducing effects of the dicarboxylic acid analogs were also independent of the P-450 omega-oxidation pathway. The results of these studies suggest that the regulation of peroxisomal beta-oxidation enzymes and L-FABP is mediated, to a significant extent, by poorly metabolized long-chain dicarboxylic acids formed via the P-450IVA1 pathway.	UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0538,HSW 1120,3RD & PARNASSUS AVES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013328, R01DK032926, R01DK013328, K08DK002056] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13328-21, DK-02056, DK-32926] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELKVIST EL, 1980, BIOCHIM BIOPHYS ACTA, V617, P156, DOI 10.1016/0005-2760(80)90233-7; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, J BIOL CHEM, V260, P1432; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BASS NM, 1985, J BIOL CHEM, V260, P9603; BASS NM, 1993, IN PRESS MOL CELL BI; BELL DR, 1991, BIOCHEM J, V280, P249, DOI 10.1042/bj2800249; BELL DR, 1991, BIOCHEM J, V275, P247, DOI 10.1042/bj2750247; BERGE RK, 1989, BIOCHIM BIOPHYS ACTA, V1004, P345, DOI 10.1016/0005-2760(89)90083-0; BISSELL D M, 1975, P119; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BRANDES R, 1990, BIOCHIM BIOPHYS ACTA, V1034, P53, DOI 10.1016/0304-4165(90)90152-M; BRONFMAN M, 1986, BIOCHEM J, V239, P781, DOI 10.1042/bj2390781; CABAUD PG, 1958, AM J CLIN PATHOL, V30, P234, DOI 10.1093/ajcp/30.3.234; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; CAMPBELL CD, 1969, J CHEM SOC C, P742, DOI 10.1039/j39690000742; CHAN WK, 1992, DISS ABS INT B, V53, pB292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMONTELLANO PRO, 1981, ARCH BIOCHEM BIOPHYS, V210, P717, DOI 10.1016/0003-9861(81)90239-3; DEMONTELLANO PRO, 1984, J BIOL CHEM, V259, P4136; DEMONTELLANO PRO, 1984, TETRAHEDRON, V40, P511; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EACHO PI, 1988, BIOCHEM BIOPH RES CO, V157, P1148, DOI 10.1016/S0006-291X(88)80993-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GUZELIAN PS, 1988, P NATL ACAD SCI USA, V85, P9783, DOI 10.1073/pnas.85.24.9783; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HERTZ R, 1985, BIOCHIM BIOPHYS ACTA, V836, P192, DOI 10.1016/0005-2760(85)90066-9; HERTZ R, 1988, BIOCHEM PHARMACOL, V37, P3571, DOI 10.1016/0006-2952(88)90387-5; ICHIHARA K, 1979, J BIOCHEM-TOKYO, V86, P139; ICHIHARA K, 1971, BIOCHIM BIOPHYS ACTA, V239, P178; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KAWASHIMA Y, 1982, J PHARMACOBIO-DYNAM, V5, P771; KONDRUP J, 1985, BIOCHIM BIOPHYS ACTA, V835, P147, DOI 10.1016/0005-2760(85)90041-4; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU AYH, 1968, J BIOL CHEM, V243, P1331; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MEISNER H, 1975, BIOCHEM BIOPH RES CO, V66, P1134, DOI 10.1016/0006-291X(75)90476-3; METCALFE LD, 1961, ANAL CHEM, V33, P363, DOI 10.1021/ac60171a016; MICO BA, 1988, BIOCHEM PHARMACOL, V37, P2515, DOI 10.1016/0006-2952(88)90240-7; MILTON MN, 1990, BIOCHEM PHARMACOL, V40, P2727, DOI 10.1016/0006-2952(90)90594-B; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MORTENSEN PB, 1981, BIOCHIM BIOPHYS ACTA, V666, P394, DOI 10.1016/0005-2760(81)90298-8; MUAKKASSAHKELLY SF, 1987, EXP CELL RES, V171, P37, DOI 10.1016/0014-4827(87)90249-7; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; PAULUSSEN RJA, 1989, BIOCHIM BIOPHYS ACTA, V1001, P201, DOI 10.1016/0005-2760(89)90149-5; REICH NO, 1986, BIOCHEM PHARMACOL, V35, P1227, DOI 10.1016/0006-2952(86)90264-9; REUBSAET FAG, 1990, FEBS LETT, V267, P229, DOI 10.1016/0014-5793(90)80931-8; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SHARMA R, 1988, BIOCHEM PHARMACOL, V37, P1203, DOI 10.1016/0006-2952(88)90771-X; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; TABOR S, 1988, CURRENT PROTOCOLS MO, V1; TANAKA K, 1972, J BIOL CHEM, V247, P7465; TONSGARD JH, 1988, J CLIN INVEST, V82, P1567, DOI 10.1172/JCI113767; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x	65	96	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9593	9603						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486647				2022-12-27	WOS:A1993LA68900068
J	MAYNE, R; BREWTON, RG; MAYNE, PM; BAKER, JR				MAYNE, R; BREWTON, RG; MAYNE, PM; BAKER, JR			ISOLATION AND CHARACTERIZATION OF THE CHAINS OF TYPE-V TYPE-XI COLLAGEN PRESENT IN BOVINE VITREOUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; IX COLLAGEN; CARTILAGE COLLAGENS; HUMOR COLLAGEN; HUMAN-PLACENTA; ALPHA-CHAINS; IDENTIFICATION; GENE; PROTEOGLYCAN; EXPRESSION	Previous studies show that the collagen fibrils of the mammalian vitreous humor are assembled largely from type II collagen with smaller amounts of type IX collagen and either type V or type XI collagen. In this paper, we report the separation of two chains of type V/type XI collagen from type II collagen by heparin-Sepharose chromatography. These chains were characterized by sequencing of selected cyanogen bromide or tryptic peptides with subsequent comparison of these sequences with cDNA-derived amino acid sequences of the alpha1(V), alpha1(XI), alpha2(V), and alpha2(XI) chains. The results show that vitreous fibrils are assembled from molecules containing the alpha1(XI) and alpha2(V) chains. These results, together with recent results from other laboratories, indicate that type V and type XI collagens are not separate collagen types but are part of a larger collagen family in which chains of both type V and type XI collagens participate in the formation of a variety of native molecules.	UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	MAYNE, R (corresponding author), UNIV ALABAMA,DEPT CELL BIOL,BOX 302,BIRMINGHAM,AL 35294, USA.				NEI NIH HHS [EY09908] Funding Source: Medline; NIAMS NIH HHS [AR30481] Funding Source: Medline; NIDCR NIH HHS [DE08228] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030481, R01AR030481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008228] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AYAD S, 1984, BIOCHEM J, V218, P835, DOI 10.1042/bj2180835; BENTZ H, 1978, EUR J BIOCHEM, V92, P563, DOI 10.1111/j.1432-1033.1978.tb12778.x; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BISHOP P, 1992, BIOCHEM BIOPH RES CO, V185, P392, DOI 10.1016/S0006-291X(05)80998-2; BREWTON R, 1993, EXTRACELLULAR MATRIX; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; BROWN KE, 1991, J BIOL CHEM, V266, P23268; BROWN RA, 1978, BIOCHEM BIOPH RES CO, V80, P866, DOI 10.1016/0006-291X(78)91324-4; BURGESON RE, 1976, P NATL ACAD SCI USA, V73, P2579, DOI 10.1073/pnas.73.8.2579; BURGESON RE, 1982, J BIOL CHEM, V257, P7852; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HONG BS, 1979, BIOCHEMISTRY-US, V18, P4278, DOI 10.1021/bi00587a003; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LINSENMAYER TF, 1985, ANN NY ACAD SCI, V460, P232, DOI 10.1111/j.1749-6632.1985.tb51171.x; MANN K, 1992, BIOL CHEM H-S, V373, P69, DOI 10.1515/bchm3.1992.373.1.69; MATOLTSY AG, 1952, J GEN PHYSIOL, V36, P29, DOI 10.1085/jgp.36.1.29; MAYNE R, 1993, IN PRESS EXTRACELLUL; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; NAH HD, 1992, J BIOL CHEM, V267, P22581; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; OLSEN BR, 1965, J ULTRA MOL STRUCT R, V13, P172, DOI 10.1016/S0022-5320(65)80095-8; REESE CA, 1981, BIOCHEMISTRY-US, V20, P5443, DOI 10.1021/bi00522a014; REN ZX, 1991, J STRUCT BIOL, V106, P57, DOI 10.1016/1047-8477(91)90062-2; RHODES RK, 1981, BIOCHEMISTRY-US, V20, P3117, DOI 10.1021/bi00514a020; SAGE H, 1979, BIOCHEMISTRY-US, V18, P3815, DOI 10.1021/bi00584a027; SEERY CM, 1991, INVEST OPHTH VIS SCI, V32, P1540; SMITH GN, 1987, COLLAGEN REL RES, V7, P315; SWANN DA, 1980, BIOCHEM J, V185, P545, DOI 10.1042/bj1850545; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; VANDERREST M, 1985, J BIOL CHEM, V260, P220; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; YADA T, 1990, J BIOL CHEM, V265, P6992; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	43	160	164	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9381	9386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486632				2022-12-27	WOS:A1993LA68900037
J	HAMILTON, BJ; NAGY, E; MALTER, JS; ARRICK, BA; RIGBY, WFC				HAMILTON, BJ; NAGY, E; MALTER, JS; ARRICK, BA; RIGBY, WFC			ASSOCIATION OF HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-A1 AND C-PROTEINS WITH REITERATED AUUUA SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA STABILITY; BINDING PROTEINS; NUCLEOTIDE-SEQUENCE; GENE-REGULATION; RICH SEQUENCES; HNRNP PROTEINS; GM-CSF; CELLS; PARTICLES	Post-transcriptional regulatory mechanisms have been shown to play a major role in gene expression in eukaryotic cells. The presence of a reiterated pentamer (AUUUA) in the 3'-untranslated region (UTR) of mRNAs encoding lymphokines, cytokines, transcription factors, and proto-oncogenes has been shown to be associated with rapid turnover and translation attenuation. Cytoplasmic proteins (70, 50, 43, 36, and 25 kDa) capable of specifically binding to RNAs containing these AU-rich sequences were identified in human peripheral blood T lymphocytes. Levels of the 36-kDa protein were markedly increased following transcriptional, but not translational inhibition, a feature recently reported for hnRNP A1, a protein of comparable mass. Antibodies directed against heterogeneous nuclear ribonucleoproteins (hnRNPs) Al and C immunoprecipitated 36- and 43-kDa proteins that had bound the AUUUA-rich region contained in the 3'-UTR of granulocyte-macrophage colony-stimulating factor mRNA. Recombinant hnRNP A1 was shown to preferentially bind to RNAs containing AUUUA sequences in a specific manner, and displayed comparable patterns to the 36-kDa AU-specific binding proteins following partial proteolysis. These data identify for the first time hnRNP A1 and C as cytoplasmic proteins in human lymphocytes that are capable of specifically associating with reiterated AUUUA sequences present in the 3'-UTR of labile mRNAs. As such, they may play a role as trans-acting factors in the modulation of cytoplasmic mRNA turnover and translation, in addition to their previously characterized roles as pre-mRNA binding proteins involved in nuclear mRNA processing.	DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MED, HANOVER, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MICROBIOL, HANOVER, NH 03756 USA; WHITE RIVER JUNCT VET ADM MED CTR, WHITE RIVER JCT, VT 05001 USA; UNIV WISCONSIN, DEPT PATHOL LAB MED, MADISON, WI 53792 USA	Dartmouth College; Dartmouth College; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045213] Funding Source: NIH RePORTER; NIAID NIH HHS [R0 1 AI2434, K04 AI00910] Funding Source: Medline; NIDDK NIH HHS [R01 DK 45213] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BICKEL M, 1990, J IMMUNOL, V145, P840; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, MOL BIOL REP, V14, P83, DOI 10.1007/BF00360425; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HERRICK G, 1976, J BIOL CHEM, V251, P2124; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NAKAGAWA TY, 1986, P NATL ACAD SCI USA, V83, P2007, DOI 10.1073/pnas.83.7.2007; PANDOLFO M, 1985, NUCLEIC ACIDS RES, V13, P6577, DOI 10.1093/nar/13.18.6577; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; ROSS J, 1988, MOL BIOL MED, V5, P1; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	44	202	205	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8881	8887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473331				2022-12-27	WOS:A1993KX81100074
J	LU, KP; OSMANI, SA; MEANS, AR				LU, KP; OSMANI, SA; MEANS, AR			PROPERTIES AND REGULATION OF THE CELL CYCLE-SPECIFIC NIMA PROTEIN-KINASE OF ASPERGILLUS-NIDULANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ACTIVATION; MITOSIS; CALMODULIN; SERINE; YEAST; DEPHOSPHORYLATION; SEQUENCE; CLONING; ENTRY	NIMA is the protein product of the nimA gene of the filamentous fungus Aspergillus nidulans, required for progression of cells from G2 into mitosis. The protein kinase activity of NIMA, assayed by phosphorylation of beta-casein, varies during the nuclear division cycle, reaching a maximum in late G2 and M. To investigate the biochemical properties of this cell cycle-regulated protein kinase, we have expressed nimA cDNA that encodes full-length NIMA in Escherichia coli as a fusion product with glutathione S-transferase. Purified NIMA phosphorylated beta-casein, with a K(m) of 38 muM and V(max) of 156 nmol/min/mg. NIMA also demonstrated a K(m) of 69 muM for ATP. Both recombinant and cellular NIMA kinases behaved as oligomers on gel filtration chromatography, and their kinase activities were strongly inhibited by various salts. By using both protein and peptide substrates, NIMA demonstrated a serine/threonine-specific protein kinase activity. Cellular NIMA exists as a phosphoprotein, and bacterially expressed NIMA was also phosphorylated on multiple serine/threonine residues. Some of these phosphorylations appeared essential for NIMA activity as the enzyme could be dephosphorylated and inactivated in vitro by protein serine/threonine phosphatases. Use of a kinase-negative mutant of NIMA revealed that the NIMA enzyme undergoes autophosphorylation when expressed at high concentrations in bacteria. Taken together, these data suggest that cellular mechanisms may exist to regulate the phosphorylation state and activity of the NIMA protein kinase during the nuclear division cycle in A. nidulans.	DUKE UNIV, MED CTR, DEPT PHARMACOL, POB 3813, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Duke University; Duke University; Baylor College of Medicine			Osmani, Stephen A./AAS-3904-2021		NIGMS NIH HHS [GM42564] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BARTELT DC, 1988, P NATL ACAD SCI USA, V85, P3279, DOI 10.1073/pnas.85.10.3279; BARTON AB, 1992, GENE, V117, P137, DOI 10.1016/0378-1119(92)90502-G; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8025; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOOVER D, 1991, J BIOL CHEM, V266, P14018; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; KORNSTEIN LB, 1992, GENE, V113, P75, DOI 10.1016/0378-1119(92)90671-B; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KU KP, 1991, J CELL BIOL, V115, pA426; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; LU KP, 1992, MOL ENDOCRINOL, V6, P365, DOI 10.1210/me.6.3.365; MATSUDA S, 1992, EMBO J, V11, P937; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ONO T, 1989, J BIOL CHEM, V264, P2081; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHWEITZER B, 1992, MOL GEN GENET, V234, P164, DOI 10.1007/BF00272358; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBIESZEK A, 1991, J MOL BIOL, V220, P947, DOI 10.1016/0022-2836(91)90365-D; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	45	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8769	8776						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473320				2022-12-27	WOS:A1993KX81100059
J	GEHM, BD; KUO, WL; PERLMAN, RK; ROSNER, MR				GEHM, BD; KUO, WL; PERLMAN, RK; ROSNER, MR			MUTATIONS IN A ZINC-BINDING DOMAIN OF HUMAN INSULIN-DEGRADING ENZYME ELIMINATE CATALYTIC ACTIVITY BUT NOT INSULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; METALLOENDOPROTEASE INHIBITORS; DEGRADATION PRODUCTS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; PROTEASE-III; FACTOR-ALPHA; DIFFERENTIATION; THERMOLYSIN; EXPRESSION	Insulin-degrading enzyme is a nonlysosomal metalloprotease that initiates degradation of internalized insulin in some cells. We previously identified a potential catalytic site containing an inversion of the Zn2+-binding domain of the thermolysin family (Kuo, W.-L., Gehm, B. D., and Rosner, M. R. (1991) Mol. Endocrinol. 4, 1580-1591). The role of this site in catalysis was examined by mutating one of the presumptive Zn2+-coordinating histidines (His108) in human insulin-degrading enzyme to leucine or glutamine, which were predicted to reduce or eliminate Zn2+ binding without substantially altering secondary structure. cDNAs for the mutant and wild-type enzymes were incorporated into an expression vector and transfected into COS cells. Expression of the transfected genes was confirmed by Northern and Western blots. In contrast to the wild-type gene, which increased insulin degradation by cell extracts and intact cells several-fold, the mutated genes had no effect on insulin degradation, indicating a loss of catalytic activity. However, the mutants' ability to bind substrate was unimpaired, as affinity labeling with I-125-insulin was increased compared to the wild type. These results suggest that an intact Zn2+-binding domain in human insulin-degrading enzyme is required for catalytic activity and can affect, but is not required for, substrate binding.	UNIV CHICAGO, BEN MAY INST,DEPT PHARMACOL & PHYSIOL SCI, 5841 S MARYLAND,BOX 424, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago								AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AFFHOLTER JA, 1990, BIOCHEMISTRY-US, V29, P7727, DOI 10.1021/bi00485a022; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BIGNER SH, 1990, CANCER RES, V50, P8017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; DUCKWORTH WC, 1989, BIOCHEMISTRY-US, V28, P2471, DOI 10.1021/bi00432a018; DUCKWORTH WC, 1990, INSULIN HDB EXPT PHA, V92, P143; EBRAHIM A, 1991, BIOCHEM BIOPH RES CO, V181, P1398, DOI 10.1016/0006-291X(91)92094-Z; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLDEN HM, 1988, J BIOL CHEM, V263, P3256; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI D, 1992, J BIOL CHEM, V267, P2414; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; OGAWA W, 1992, J BIOL CHEM, V267, P1310; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; Sambrook J, 1989, MOL CLONING LABORATO; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220	35	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7943	7948						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463315				2022-12-27	WOS:A1993KW97900056
J	CHEN, L; FINCHER, GB; HOJ, PB				CHEN, L; FINCHER, GB; HOJ, PB			EVOLUTION OF POLYSACCHARIDE HYDROLASE SUBSTRATE-SPECIFICITY - CATALYTIC AMINO-ACIDS ARE CONSERVED IN BARLEY 1,3-1,4-GLUCANASE AND 1,3-BETA-GLUCANASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCAN HYDROLASES; SITE-DIRECTED INHIBITION; (1->3)-BETA-GLUCAN ENDOHYDROLASE; NICOTIANA-PLUMBAGINIFOLIA; GERMINATING BARLEY; MOLECULAR-CLONING; LYSOZYME; IDENTIFICATION; PURIFICATION; TOBACCO	Catalytic amino acid residues in a 1,3-beta-D-glucan 3-glucanohydrolase (EC 3.2.1.39) and a homologous 1,3-4-beta-D-glucan 4-glucanohydrolase (EC 3.2.1.73) from barley have been investigated. To identify amino acids responsible for protonation of the glycosidic oxygen during hydrolysis, carbodiimide-mediated labeling of the enzymes with [C-14]glycine ethyl ester was performed. This resulted in loss of activity and specific modification of the Glu288 residues in both enzymes. The stoichiometry of labeling was approximately 1:1, and modification was reduced in the presence of substrate analogues. Based on these data, the Glu288 residues are likely to be present at the active sites of the respective enzymes and may represent the catalytic acids in the hydrolytic reaction. The catalytic nucleophiles of the two enzymes were investigated by labeling with specific, mechanism-based epoxyalkyl-beta-oligoglucosides. Amino acid residues Glu232 and Glu231 were identified as the likely catalytic nucleophiles in the 1,3-1,4- and 1,3-beta-glucanases, respectively. Thus the position of the catalytic nucleophile and the putative proton donating amino acids in the two classes of beta-glucan endohydrolases are conserved. The acquisition of distinct substrate specificities in the evolution of these related enzymes may therefore not require the recruitment of novel catalytic amino acids but rather differences in their positioning at the active site and/or changes in substrate binding residues.	LA TROBE UNIV, DEPT BIOCHEM, BUNDOORA, VIC 3083, AUSTRALIA	La Trobe University			Hoj, Peter B/E-8526-2011					ANDERSON MA, 1975, FEBS LETT, V52, P202, DOI 10.1016/0014-5793(75)80806-4; Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; BANERJEE SK, 1973, J BIOL CHEM, V248, P4786; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CAMPBELL ID, 1975, PROC R SOC SER B-BIO, V189, P485, DOI 10.1098/rspb.1975.0069; CASTRESANA C, 1990, PLANT CELL, V2, P1131, DOI 10.1105/tpc.2.12.1131; DELOOSE M, 1988, GENE, V70, P13, DOI 10.1016/0378-1119(88)90100-X; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DOAN DNP, 1993, DNA CELL BIOL, V12, P97, DOI 10.1089/dna.1993.12.97; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; ESHDAT Y, 1973, J BIOL CHEM, V248, P5892; FINCHER GB, 1989, ANNU REV PLANT PHYS, V40, P305, DOI 10.1146/annurev.pp.40.060189.001513; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; HOARE DG, 1967, J BIOL CHEM, V242, P2447; HOJ PB, 1992, J BIOL CHEM, V267, P25059; HOJ PB, 1991, J BIOL CHEM, V266, P11628; HOJ PB, 1988, FEBS LETT, V230, P67, DOI 10.1016/0014-5793(88)80643-4; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HOJ PB, 1989, J BIOL CHEM, V264, P4939; HOUEN G, 1991, ANAL BIOCHEM, V193, P186, DOI 10.1016/0003-2697(91)90006-F; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KURAMITSU S, 1977, J BIOCHEM-TOKYO, V82, P585; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LEGLER G, 1981, FEBS LETT, V135, P139, DOI 10.1016/0014-5793(81)80962-3; LINTHORST HJM, 1990, P NATL ACAD SCI USA, V87, P8756, DOI 10.1073/pnas.87.22.8756; LUMB KJ, 1992, FEBS LETT, V296, P153, DOI 10.1016/0014-5793(92)80368-Q; MAUCH F, 1988, PLANT PHYSIOL, V87, P325, DOI 10.1104/pp.87.2.325; MOORE AE, 1972, BIOCHIM BIOPHYS ACTA, V258, P248, DOI 10.1016/0005-2744(72)90983-7; MOULT J, 1973, J MOL BIOL, V75, P1, DOI 10.1016/0022-2836(73)90524-X; Nelson N, 1944, J BIOL CHEM, V153, P375; NITTA Y, 1989, J BIOCHEM-TOKYO, V105, P573, DOI 10.1093/oxfordjournals.jbchem.a122706; ORI N, 1990, EMBO J, V9, P3429, DOI 10.1002/j.1460-2075.1990.tb07550.x; PARRISH FW, 1960, CAN J CHEM, V38, P2094, DOI 10.1139/v60-284; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P665, DOI 10.1071/CH9900665; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P1391, DOI 10.1071/CH9901391; RODRIGUEZ EB, 1989, THESIS U W AUSTR NED; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; SLAKESKI N, 1992, FEBS LETT, V306, P98, DOI 10.1016/0014-5793(92)80977-O; SLAKESKI N, 1992, PLANT PHYSIOL, V99, P1226, DOI 10.1104/pp.99.3.1226; SLAKESKI N, 1990, MOL GEN GENET, V224, P437, DOI 10.1007/BF00262439; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; SPERISEN C, 1991, P NATL ACAD SCI USA, V88, P1820, DOI 10.1073/pnas.88.5.1820; SVENSSON B, 1990, EUR J BIOCHEM, V188, P29, DOI 10.1111/j.1432-1033.1990.tb15367.x; SVENSSON B, 1993, IN PRESS J BIOTECHNO, V29; TAKEUCHI Y, 1990, PLANT PHYSIOL, V93, P673, DOI 10.1104/pp.93.2.673; VERNON CA, 1967, PROC R SOC SER B-BIO, V167, P389, DOI 10.1098/rspb.1967.0036; WOODWARD JR, 1982, EUR J BIOCHEM, V121, P663, DOI 10.1111/j.1432-1033.1982.tb05837.x; WOODWARD JR, 1983, THESIS LA TROBE U BU; XU PL, 1992, GENE, V120, P157, DOI 10.1016/0378-1119(92)90089-8; YAMADA H, 1981, BIOCHEMISTRY-US, V20, P4836, DOI 10.1021/bi00520a005; ZIMMERMAN CL, 1977, ANAL BIOCHEM, V77, P569, DOI 10.1016/0003-2697(77)90276-7	58	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13318	13326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514770				2022-12-27	WOS:A1993LH55300046
J	MINGARRO, I; SENDRA, R; SALVADOR, ML; FRANCO, L				MINGARRO, I; SENDRA, R; SALVADOR, ML; FRANCO, L			SITE-SPECIFICITY OF PEA HISTONE ACETYLTRANSFERASE-B INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; LINKING NUMBER CHANGE; ACETYLATION SITES; SACCHAROMYCES-CEREVISIAE; PHYSARUM-POLYCEPHALUM; PARTIAL-PURIFICATION; ZEA-MAYS; TRANSCRIPTION; TETRAHYMENA; YEAST	Histone acetyltransferase B from pea embryonic axes has been purified almost-equal-to 300-fold by a combination of chromatographic procedures, including affinity chromatography on histone-agarose. The enzyme preparation has been used for the in vitro transfer of acetyl groups from [1-C-14]acetyl-CoA to non-acetylated pea histone H4. Up to three acetyl groups can be introduced into the histone. The resulting mono-, di-, and triacetylated H4 isoforms were separated and sequenced to determine the acetylated sites. Only sites 5, 12, and 16 were used by histone acetyltransferase B, but no clear preference among them was observed. The absence of modification of other potentially acetylatable sites is another indication that acetylation of the different lysine residues in the N-terminal H4 tail serves as a specific signal in different nuclear processes.	UNIV VALENCIA, DEPT BIOCHEM & MOLEC BIOL, DR MOLINER 50, E-46100 BURJASSOT, SPAIN	University of Valencia			Sendra, Ramón/K-3549-2014; Mingarro, Ismael/B-4745-2014	Sendra, Ramón/0000-0002-5519-4362; Mingarro, Ismael/0000-0002-1910-1229; Franco, Luis/0000-0001-9610-6448				ALFAGEME CR, 1974, J BIOL CHEM, V249, P3729; BROSCH G, 1992, J BIOL CHEM, V267, P20561; CHAMBERS SAM, 1984, J BIOL CHEM, V259, P3458; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; COUPPEZ M, 1987, J BIOL CHEM, V262, P2854; COUSENS LS, 1982, J BIOL CHEM, V257, P3945; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DELANGE RJ, 1969, J BIOL CHEM, V244, P5669; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; GEORGIEVA EI, 1991, J BIOL CHEM, V266, P18751; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; JACKSON V, 1981, NUCLEIC ACIDS RES, V9, P4563, DOI 10.1093/nar/9.18.4563; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KELNER DN, 1984, J BIOL CHEM, V259, P3413; LAGENBUCH J, 1983, PLANT MOL BIOL, V2, P207; LAZURE C, 1990, HPLC BIOL MACROMOLEC, P263; LIBBY PR, 1980, ARCH BIOCHEM BIOPHYS, V203, P384, DOI 10.1016/0003-9861(80)90190-3; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOPEZRODAS G, 1993, FEBS LETT, V317, P175, DOI 10.1016/0014-5793(93)81271-Z; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; LOPEZRODAS G, 1991, BIOCHEMISTRY-US, V30, P3728, DOI 10.1021/bi00229a020; LOPEZRODAS G, 1985, ARCH BIOCHEM BIOPHYS, V239, P184, DOI 10.1016/0003-9861(85)90825-2; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PESIS KH, 1986, ARCH BIOCHEM BIOPHYS, V251, P665, DOI 10.1016/0003-9861(86)90376-0; PETERSON JD, 1972, J BIOL CHEM, V247, P4866; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; SALVADOR ML, 1985, FEBS LETT, V191, P55, DOI 10.1016/0014-5793(85)80992-3; SENDRA R, 1986, PLANT SCI, V46, P189, DOI 10.1016/0168-9452(86)90191-3; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; SENDRA R, 1991, PLANT SCI, V78, P43, DOI 10.1016/0168-9452(91)90160-A; SHIMAMURA A, 1989, J BIOL CHEM, V264, P14524; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; THWAITS BH, 1976, FEBS LETT, V71, P197, DOI 10.1016/0014-5793(76)80930-1; THWAITS BH, 1976, FEBS LETT, V71, P193, DOI 10.1016/0014-5793(76)80929-5; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; TURNER BM, 1991, J CELL SCI, V99, P13; ULL M A, 1986, Plant Molecular Biology, V7, P25; VIDALI G, 1988, ADV POST TRANSLATION, P583; WATERBORG JH, 1983, EUR J BIOCHEM, V136, P245, DOI 10.1111/j.1432-1033.1983.tb07734.x; WATERBORG JH, 1992, BIOCHEMISTRY-US, V31, P6211, DOI 10.1021/bi00142a006	51	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13248	13252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514763				2022-12-27	WOS:A1993LH55300036
J	MULICHAK, AM; HUI, JO; TOMASSELLI, AG; HEINRIKSON, RL; CURRY, KA; TOMICH, CS; THAISRIVONGS, S; SAWYER, TK; WATENPAUGH, KD				MULICHAK, AM; HUI, JO; TOMASSELLI, AG; HEINRIKSON, RL; CURRY, KA; TOMICH, CS; THAISRIVONGS, S; SAWYER, TK; WATENPAUGH, KD			THE CRYSTALLOGRAPHIC STRUCTURE OF THE PROTEASE FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 WITH 2 SYNTHETIC PEPTIDIC TRANSITION-STATE ANALOG INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HIV-1 PROTEASE; COMPLEX; RESOLUTION; DESIGN	The crystal structure of human immunodeficiency virus (HIV) type 2 protease has been determined in complexes with peptidic inhibitors Noa-His-ChaPSI[CH(OH)CH(OH)]Val-Ile-Amp (U75875) and Qnc-Asn-ChaPSI[CH(OH)CH2]Val-Npt(U92163)(where Noa is naphthyloxyacetyl, Cha is cyclohexylalanine, Amp is 2-aminomethylpyridine, Qnc is quinoline-2-carbonyl, and Npt is neopentylamine), which have dihydroxyethylene and hydroxyethylene moieties, respectively, in place of the normal scissile bond of the natural ligand. The complexes crystallize in space group P2(1)2(1)2(1), with one dimer-inhibitor complex per asymmetric unit and average cell dimensions of a = 33.28 angstrom, b = 45.35 angstrom, c = 135.84 angstrom. Data were collected to approximately 2.5-angstrom resolution. The model structures were refined with resulting R-factors of around 0.19. As expected, the HIV-2 protease structure is approximately C2-symmetric with a gross structure very similar to that of the HIV-1 enzyme. The inhibitors bind in an extended conformation positioned lengthwise in the binding cleft in a manner similar to that found in the HIV-1 protease-inhibitor complexes previously reported. The substitution of the bulkier Ile82 side chain in the HIV-2 protease may help explain the better ability of HIV-2 protease to bind and hydrolyze ligands with small Pl and P1' side groups. It appears that differences in specificity between the proteases of HIV-1 and HIV-2 are not merely a result of simple side chain substitutions, but may be complicated by differences in main chain flexibility as well.	UPJOHN CO, DISCOVERY RES, KALAMAZOO, MI 49007 USA	Pfizer								ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; HALL SR, 1990, XTAL 3 0 REFERENCE M; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, P43; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JONES TA, 1985, METHOD ENZYMOL, V115, P157; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MURTHY KHM, 1992, J BIOL CHEM, V267, P22770; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; THAISRIVONGS S, 1991, J MED CHEM, V34, P1276, DOI 10.1021/jm00108a006; THAISRIVONGS S, 1991, J MED CHEM, V34, P2344, DOI 10.1021/jm00112a005; THANKI N, 1992, PROTEIN SCI, V1, P1061, DOI 10.1002/pro.5560010811; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7	20	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13103	13109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514751				2022-12-27	WOS:A1993LH55300017
J	LAETHEM, RM; BALAZY, M; FALCK, JR; LAETHEM, CL; KOOP, DR				LAETHEM, RM; BALAZY, M; FALCK, JR; LAETHEM, CL; KOOP, DR			FORMATION OF 19(S)-HYDROXYEICOSATETRAENOIC, 19(R)-HYDROXYEICOSATETRAENOIC, AND 18(R)-HYDROXYEICOSATETRAENOIC ACIDS BY ALCOHOL-INDUCIBLE CYTOCHROME-P450 2E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; SPONTANEOUSLY HYPERTENSIVE RATS; ARACHIDONIC-ACID; 20-HYDROXYEICOSATETRAENOIC ACID; ETHANOL OXIDATION; TREATED RABBITS; METABOLISM; HYDROXYLATION; IDENTIFICATION; CYCLOOXYGENASE	When reconstituted with cytochrome b5 and NADPH cytochrome P450 oxidoreductase, cytochrome P450 2E1 metabolized lauric, stearic, oleic, linoleic, linolenic, and arachidonic acid to multiple metabolites. Two major metabolites, accounting for 78% of the total metabolism, were produced with arachidonic acid. The V(max) for total metabolite formation from arachidonic acid was 5 nmol/min/nmol P450 with an apparent K(m) of 62 muM. Gas chromatography-mass spectrometry analysis identified the two major metabolites as mono-hydroxylated eicosatetraenoic acids (HETEs). The major HETE was 19-hydroxyeicosatetraenoic acid (19-HETE) and comprised 46% of the total metabolite produced. The second metabolite was the omega-2 hydroxylated metabolite (18-HETE) and comprised 32% of the total product formed. Chiral analysis demonstrated that 19-HETE was 70% 19(S)-HETE and 30% 19(R)-HETE. In contrast, 18-HETE was essentially 100% R isomer. Approximately 18% of the total metabolite produced from arachidonic acid coeluted with epoxyeicosatrienoic acid (EET) standards. The EET metabolites were 56.4% 14,15-EET and 43.6% as a mixture of 11,12-EET and 8,9-EET. 5,6-EET was not detected. Anti-P450 2E1 IgG inhibited arachidonic acid metabolism by renal and hepatic microsomes prepared from acetone-treated rabbits. With renal cortex microsomes, the formation of 18-HETE and 19-HETE was inhibited 67 and 25%, respectively, by the antibody. Liver microsomal formation of 18-HETE was inhibited by 87% and 19-HETE by 70%. Thus, under conditions where cytochrome P450 2E1 is induced, the enzyme could contribute significantly to the formation of the omega-1 and omega-2 hydroxylated metabolites of arachidonic acid.	OREGON HLTH SCI UNIV, SCH MED,DEPT PHARMACOL,L221, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; NEW YORK MED COLL, DEPT PHARMACOL, VALHALLA, NY 10595 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	Oregon Health & Science University; New York Medical College; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845; Balazy, Ph.D., Michael/0000-0003-0218-8820	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041618, P01HL034300] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34300, HL41618] Funding Source: Medline; NIADDK NIH HHS [T32 AM07139] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1991, BLOOD, V78, P1461; BALAZY M, 1991, J BIOL CHEM, V266, P23561; BAUMERT T, 1989, EUR J BIOCHEM, V182, P223, DOI 10.1111/j.1432-1033.1989.tb14821.x; BONVENTRE JV, 1991, KIDNEY INT, V39, P438, DOI 10.1038/ki.1991.55; BRASH AR, 1990, METHOD ENZYMOL, V187, P187; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; CHUNG SK, 1974, TETRAHEDRON LETT, P3023; CLARE RA, 1991, J CHROMATOGR-BIOMED, V562, P237, DOI 10.1016/0378-4347(91)80581-V; Coon M J, 1978, Methods Enzymol, V52, P109; DIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V921, P82, DOI 10.1016/0005-2760(87)90173-1; DUTTON DR, 1987, ARCH BIOCHEM BIOPHYS, V255, P316, DOI 10.1016/0003-9861(87)90399-7; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; ESCALANTE B, 1989, J PHARMACOL EXP THER, V248, P229; ESCALANTE B, 1990, J CARDIOVASC PHARM, V16, P438, DOI 10.1097/00005344-199009000-00013; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FALCK JR, 1992, TETRAHEDRON LETT, V33, P4893, DOI 10.1016/S0040-4039(00)61226-1; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GIBSON GG, 1989, XENOBIOTICA, V19, P1123; HILL E, 1992, BRIT J PHARMACOL, V106, P267, DOI 10.1111/j.1476-5381.1992.tb14327.x; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; HURST JS, 1991, J BIOL CHEM, V266, P6726; ISHAK KG, 1991, ALCOHOL CLIN EXP RES, V15, P45, DOI 10.1111/j.1530-0277.1991.tb00518.x; KOOP DR, 1984, MOL PHARMACOL, V25, P494; KOOP DR, 1984, ARCH BIOCHEM BIOPHYS, V235, P228, DOI 10.1016/0003-9861(84)90272-8; KOOP DR, 1986, MOL PHARMACOL, V29, P399; KOOP DR, 1986, ALCOHOL CLIN EXP RES, V10, pS44, DOI 10.1111/j.1530-0277.1986.tb05179.x; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; KOOP DR, 1982, J BIOL CHEM, V257, P8472; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LIEBER CS, 1990, PHARMACOL THERAPEUT, V46, P1, DOI 10.1016/0163-7258(90)90032-W; LIN TN, 1988, ALCOHOL CLIN EXP RES, V12, P795, DOI 10.1111/j.1530-0277.1988.tb01348.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OLIW EH, 1981, J BIOL CHEM, V256, P9924; OLIW EH, 1989, J BIOL CHEM, V264, P17845; OMATA K, 1992, AM J PHYSIOL, V262, pF8, DOI 10.1152/ajprenal.1992.262.1.F8; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SCHWARTZMAN ML, 1989, J BIOL CHEM, V264, P11658; SCHWARTZMAN ML, 1990, METHOD ENZYMOL, V187, P372; SCHWARTZMAN ML, 1990, ADV PROSTAG THROMB L, V20, P241; SHI CJ, 1969, J AM CHEM SOC, V91, P3685; Strittmatter P, 1978, Methods Enzymol, V52, P97; STUBBS CD, 1992, LIPIDS, V27, P255, DOI 10.1007/BF02536471; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; TANAKA S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P177, DOI 10.1016/0005-2760(90)90293-7; TOIVANEN J, 1984, THROMB RES, V33, P1, DOI 10.1016/0049-3848(84)90149-X; ZIMMERMAN HJ, 1986, ALCOHOL CLIN EXP RES, V10, P3, DOI 10.1111/j.1530-0277.1986.tb05605.x	55	178	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12912	12918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509425				2022-12-27	WOS:A1993LG65800098
J	SOSA, MA; SCHMIDT, B; VONFIGURA, K; HILLEREHFELD, A				SOSA, MA; SCHMIDT, B; VONFIGURA, K; HILLEREHFELD, A			INVITRO BINDING OF PLASMA MEMBRANE-COATED VESICLE ADAPTERS TO THE CYTOPLASMIC DOMAIN OF LYSOSOMAL ACID-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; PROTEIN COMPLEX; AMINO-ACIDS; CLATHRIN; INTERNALIZATION; IDENTIFICATION; PURIFICATION; SIGNAL; TAIL; ENDOCYTOSIS	Sorting of the newly synthesized membrane-bound precursor of lysosomal acid phosphatase (LAP) involves internalization from the plasma membrane via clathrin-coated pits. Using an in vitro system, we present direct evidence for high affinity interaction of the cytoplasmic domain of LAP with the amino-terminal trunk portion of plasma membrane-coated vesicle adaptors. Coated vesicle adaptors of the trans-Golgi network displayed poor binding to LAP, but high affinity binding to the cytoplasmic tail of the 46-kDa mannose 6-phosphate receptor, which is included in clathrin-coated pits of the trans-Golgi network. Binding of plasma membrane adaptors to the tail peptide of LAP required an internalization signal that contains either tyrosine or phenylalanine.			SOSA, MA (corresponding author), UNIV GOTTINGEN,W-3400 GOTTINGEN,GERMANY.							AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GEUZE H, 1991, HEPATIC ENDOCYTOSIS, P28; GIESELMANN V, 1984, H-S Z PHYSIOL CHEM, V365, P651, DOI 10.1515/bchm2.1984.365.1.651; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; HILLE A, 1992, EUR J CELL BIOL, V59, P106; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KLUMPERMAN J, 1993, IN PRESS J CELL BIOL; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; NADIMPALLI SK, 1991, FEBS LETT, V280, P61, DOI 10.1016/0014-5793(91)80204-G; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; PRILL V, 1993, IN PRESS EMBO J; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x	39	103	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12537	12543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509395				2022-12-27	WOS:A1993LG65800048
J	JOHNSON, WW; LIU, SX; JI, XH; GILLILAND, GL; ARMSTRONG, RN				JOHNSON, WW; LIU, SX; JI, XH; GILLILAND, GL; ARMSTRONG, RN			TYROSINE-115 PARTICIPATES BOTH IN CHEMICAL AND PHYSICAL STEPS OF THE CATALYTIC MECHANISM OF A GLUTATHIONE-S-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER	The participation of the hydroxyl group of tyrosine 115 in the catalytic mechanism of isoenzyme 3-3 of rat glutathione (GSH) S-transferase is implicated by x-ray crystallographic analysis of a product complex and confirmed by comparison of the catalytic properties of the native enzyme and the Y115F mutant. Tyrosine 115 is located in domain II of the protein (the xenobiotic substrate binding domain) and is the first residue in this domain to be shown to play a direct role in catalysis. The 1.8-angstrom structure of isoenzyme 3-3 in complex with (9S,10S-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene, one of the diastereomeric products of the reaction of GSH with phenanthrene 9,10-oxide, indicates that the hydroxyl group of Tyr115 is within hydrogen-bonding distance of the 10-hydroxyl group of the bound product and, by implication, is proximal to the oxirane oxygen of the substrate in the Michaelis complex. Site-specific replacement of Tyr115 with phenylalanine has profoundly different effects on catalysis depending on the type of reaction and whether the rate-limiting step in catalysis is a chemical step or a physical step. Stopped flow measurements of the rate constants for product release and viscosity effects on the steady-state kinetics establish that the rate-limiting step in catalysis with phenanthrene 9,10-oxide (k(cat) = 0.4 s-1) is probably a chemical one, whereas the physical step of product dissociation (k(off)) is rate-limiting in the reaction of 1-chloro-2,4-dinitrobenzene (k(cat) = 20 s-1). The Y115F mutant is severely impaired in catalyzing the addition of GSH to phenanthrene 9,10-oxide (k(cat) = 0.0044 s-1), evidence that the -OH of Tyr115 provides electrophilic assistance in the epoxide ring opening. In contrast, the Y115F mutant is a better catalyst toward 1-chloro-2,4-dinitrobenzene (k(cat) = 72 s-1) than is the native enzyme. The enhanced rates of product release in the mutant are ascribed to the loss of hydrogen bonds between the -OH of Tyr115 and the side chain -OH and main chain NH of serine 209, interactions that block the channel to the active site or inhibit the segmental motion of the protein.	UNIV MARYLAND, DEPT CHEM & BIOCHEM, College Pk, MD 20742 USA; UNIV MARYLAND, CTR ADV RES BIOTECHNOL, MARYLAND BIOTECHNOL INST, SHADY GROVE, MD USA; NATL INST STANDARDS & TECHNOL, ROCKVILLE, MD 20850 USA	University System of Maryland; University of Maryland College Park; National Institute of Standards & Technology (NIST) - USA			Ji, Xinhua/C-9664-2012	Ji, Xinhua/0000-0001-6942-1514	NIGMS NIH HHS [GM 30910] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030910] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; CHUNG H, 1987, J BIOL CHEM, V262, P12448; Cleland W W, 1979, Methods Enzymol, V63, P103; COBB D, 1983, BIOCHEMISTRY-US, V22, P805, DOI 10.1021/bi00273a015; HIGUCHI R, 1991, PCR TECHNOLOGY, P61; JAKOBSON I, 1977, EUR J BIOCHEM, V77, P253, DOI 10.1111/j.1432-1033.1977.tb11664.x; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KATUSZ RM, 1991, BIOCHEMISTRY-US, V30, P11230, DOI 10.1021/bi00111a006; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; WIDERSTEIN M, 1992, BIOCHEM J, V285, P377, DOI 10.1042/bj2850377; ZHANG PH, 1991, J BIOL CHEM, V266, P19475; ZHANG PH, 1990, BIOPOLYMERS, V29, P159, DOI 10.1002/bip.360290121; ZHANG PH, 1992, BIOCHEMISTRY-US, V31, P10185, DOI 10.1021/bi00157a005	24	133	133	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11508	11511						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505287				2022-12-27	WOS:A1993LF28400010
J	MEINS, M; JENO, P; MULLER, D; RICHTER, WJ; ROSENBUSCH, JP; ERNI, B				MEINS, M; JENO, P; MULLER, D; RICHTER, WJ; ROSENBUSCH, JP; ERNI, B			CYSTEINE PHOSPHORYLATION OF THE GLUCOSE TRANSPORTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID SEQUENCE; PROTEIN-KINASE; MANNITOL TRANSPORT; BACILLUS-SUBTILIS; CARRIER PROTEIN; PHOSPHOENOLPYRUVATE; PERMEASE; RESIDUE	The glucose transporter (IIBC(Glc)/IIA(Glc) complex) of the bacterial phosphotransferase system couples vectorial translocation to phosphorylation of the transported sugar. The IIA(Glc) subunit transfers the phosphoryl group from the phosphoryl carrier protein P-HPr to the IIBC(Glc) subunit. IIBC(Glc) translocates and phosphorylates glucose. The site of IIBC(Glc) phosphorylation is cysteine 421 as shown by mass spectrometric and biochemical analyses of phosphorylated peptides. Site-directed mutagenesis of Cys421 (C421S) afforded a stable but completely inactive protein (Nuoffer, C., Zanolari, B., and Erni, B. (1988) J. Biol. Chem. 263, 6647-6655). Cys421 is located in the C-terminal cytoplasmic domain of the IIBC(Glc) subunit in a sequence context (LDACITRL) which is well conserved in other transporters of the bacterial phosphotransferase system. Phosphocysteine has been shown previously to be the catalytic intermediate of the mannitol transporter (Pas, H. H., Meyer, G. H., Kruizinga, W. H., Tamminga, K. S., van Weeghel, R. P., and Robillard, G. T. (1991) J. Biol. Chem. 266, 6690-6692).	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; CIBA GEIGY AG,DEPT PHYS,CH-4002 BASEL,SWITZERLAND	University of Basel; Novartis	MEINS, M (corresponding author), UNIV BASEL,BIOCTR,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND.							AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; ALPERT CA, 1990, J BIOL CHEM, V265, P22561; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; BIEMANN K, 1987, MASS SPECTROM REV, V6, P1, DOI 10.1002/mas.1280060102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUHR A, 1993, J BIOL CHEM, V268, P11599; BURK RR, 1983, METHOD ENZYMOL, V91, P247; Cantor C.R., 1980, BIOPHYS CHEM; COVEY TR, 1991, ANAL CHEM, V63, P1193, DOI 10.1021/ac00013a003; DEREUSE H, 1986, J BACTERIOL, V177, P3827; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1986, J BACTERIOL, V166, P829, DOI 10.1128/jb.166.3.829-836.1986; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1986, J BIOL CHEM, V261, P6398; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; ERNI B, 1989, J BIOL CHEM, V264, P18733; FAIRBROTHER WJ, 1992, BIOCHEMISTRY-US, V31, P4413, DOI 10.1021/bi00133a005; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GIBSON BW, 1990, METHOD ENZYMOL, V193, P480, DOI 10.1016/0076-6879(90)93434-M; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KREIL G, 1964, BIOCHEM BIOPH RES CO, V16, P551, DOI 10.1016/0006-291X(64)90191-3; KURODA Y, 1983, BIOCHEM BIOPH RES CO, V112, P884, DOI 10.1016/0006-291X(83)91700-X; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; Lipmann F, 1941, ADV ENZYMOL REL S BI, V1, P99, DOI 10.1002/9780470122464.ch4; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; POST RL, 1973, J BIOL CHEM, V248, P6993; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WIELAND T, 1956, CHEM BER-RECL, V89, P2476, DOI 10.1002/cber.19560891046; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	51	66	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11604	11609						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505292				2022-12-27	WOS:A1993LF28400026
J	NA, SQ; PERLIN, DS; SETOYOUNG, D; WANG, GF; HABER, JE				NA, SQ; PERLIN, DS; SETOYOUNG, D; WANG, GF; HABER, JE			CHARACTERIZATION OF YEAST PLASMA-MEMBRANE H+-ATPASE MUTANT PMA1-A135V AND ITS REVERTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; SITE-DIRECTED MUTAGENESIS; RESISTANT PMA1 MUTANTS; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; COMPLEMENTARY-DNA; MISMATCH REPAIR; IDENTIFICATION; OUABAIN; CELLS	An A135V substitution in the first transmembrane segment of the yeast plasma membrane H+-ATPase (PMA1) confers cellular resistance to hygromycin B, exhibits growth sensitivity to low external pH, and results in a defective enzyme that hydrolyzes ATP at 33% of wild type level. The importance of the A135 residue was probed genetically by analysis involving both site-directed mutagenesis and randomly generated second-site intragenic suppressor mutations. No other amino acid at position 135 gave either the wild type phenotype or the normal enzyme activity of A135. Substitutions with the bulkier amino acid residues A135L, A135I, and A135F produced more severe cellular phenotypes than the original A135V mutation. The substitution of the smaller side chain residue Gly was also a mutant, although not as severe as the A135V mutant. The introduction of a bulky Trp or a polar Ser residue produced dominant lethality, while charged amino acids produced recessive lethality. Reduced rates of proton transport measured by acidification of the medium by whole cells correlate closely with the severity of cellular phenotype. Some of the mutant enzymes exhibit an apparent instability in vitro. Thus, the localized structure around A135 is highly constrained. The cellular sensitivity to low external pH of the A135V mutant was used to select intragenic revertants. Most full revertants (low pH(R), Hyg(S)) restored A135, but second-site mutations in putative transmembrane segments 2 (V146I and V157F) and 4 (L327V) were also observed. Two partial revertants (low pH(R), Hyg(R)) have secondary mutations at S660C or a double change at F611L-S660F in the putative ATP binding domain. These results provide additional evidence for functional coupling between the cytoplasmic domain catalyzing ATP hydrolysis and transmembrane helices 1 and 2.	BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA; BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA; PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039739, R01GM038225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39739, GM38225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P79, DOI 10.1016/0167-4838(86)90192-5; CALVIN NM, 1988, J BACTERIOL, V170, P2796, DOI 10.1128/jb.170.6.2796-2801.1988; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HASSELBACH W, 1981, MEMBRANE TRANSPORT, P183; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KIRLEY TL, 1991, J BIOL CHEM, V266, P19953; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PERIYASAMY SM, 1983, COMP BIOCHEM PHYS B, V76, P449, DOI 10.1016/0305-0491(83)90274-2; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PERLIN DS, 1992, ACTA PHYSIOL SCAND, V146, P183; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAO US, 1991, J BIOL CHEM, V266, P14740; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; Sherman F., 1983, METHODS YEAST GENETI; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0	37	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11792	11797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505307				2022-12-27	WOS:A1993LF28400051
J	PALMER, M; JURSCH, R; WELLER, U; VALEVA, A; HILGERT, K; KEHOE, M; BHAKDI, S				PALMER, M; JURSCH, R; WELLER, U; VALEVA, A; HILGERT, K; KEHOE, M; BHAKDI, S			STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN - PRODUCTION OF FUNCTIONALLY INTACT, SITE-SPECIFICALLY MODIFIABLE PROTEIN BY INTRODUCTION OF CYSTEINE AT POSITION-69, POSITION-130, AND POSITION-186	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; DAMAGE; CELLS	Staphylococcal alpha-toxin, the prototype of an oligomerizing, pore-forming cytotoxin, is sensitive to biochemical modifications and cannot be labeled with biotin or fluorescein under preservation of its biological activity. In this study, we have used site-directed mutagenesis to introduce cysteine residues at positions 69, 130, and 186. Each mutant was fully and rapidly reactive with several sulfhydryl-specific reagents, indicating superficial location. Coupling of SH-groups with fluorescein-maleimide or biotin-maleimide was tolerated without loss of hemolytic activity at position 130, and the formed hexamers were visible on target cells by fluorescence microscopy and could be detected on electroblots by reaction with streptavidin-peroxidase. At the two other positions, modification caused significant loss of activity. However, the labeled proteins still bound to red cells, as shown by fluorescence microscopy and electroblotting. Intrinsically labeled alpha-toxin represents a novel tool to study the interaction of this pore-former with target membranes.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MICROBIOL,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK	PALMER, M (corresponding author), UNIV MAINZ,INST MED MICROBIOL,AUGUSTUSPL,W-6500 MAINZ,GERMANY.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERNHEIMER AW, 1974, BIOCHIM BIOPHYS ACTA, V344, P27, DOI 10.1016/0304-4157(74)90007-0; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; FAIRWEATHER N, 1983, INFECT IMMUN, V41, P1112, DOI 10.1128/IAI.41.3.1112-1117.1983; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; KEHOE M, 1983, INFECT IMMUN, V41, P1111; MCCARTNEY C, 1978, BACTERIAL TOXINS CEL, P89; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	12	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11959	11962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505320				2022-12-27	WOS:A1993LF28400075
J	SHIBUTANI, S; GROLLMAN, AP				SHIBUTANI, S; GROLLMAN, AP			ON THE MECHANISM OF FRAMESHIFT (DELETION) MUTAGENESIS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE INSERTION FIDELITY; DNA-SYNTHESIS; ESCHERICHIA-COLI; MUTATIONAL SPECIFICITY; TRANSIENT MISALIGNMENT; DEOXYRIBONUCLEIC-ACID; BASE SUBSTITUTION; OLIGODEOXYNUCLEOTIDES; CARCINOGEN; ADDUCTS	An experimental system has been developed to quantify frameshift deletions and base substitutions formed during DNA synthesis in vitro. Oligodeoxynucleotides, modified site-specifically with acetylaminofluorene or other adducts and lesions, were used as templates in primer extension reactions catalyzed by the Klenow fragment of Escherichia coli DNA polymerase I. The influence of DNA sequence context on frameshift mutagenesis was determined by modifying systematically the bases flanking the lesion. Frequencies of nucleotide insertion opposite the lesion and chain extension from the 3'-primer terminus were established by steady state kinetic analysis. The ability of a damaged nucleotide to generate one-base and two-base frameshift deletions was determined primarily by two parameters: the nature of the base inserted opposite the adduct with respect to the sequence context in which the lesion is embedded and the overall rate of translesional DNA synthesis. Frameshift deletions generated during DNA synthesis were greatly enhanced in the absence of proofreading exonuclease. Misinsertion of bases opposite the lesion precedes misalignment of the template-primer. Extending on earlier studies (Kunkel, T. A. (1990) Biochemistry 29, 8003-8011), a model has been proposed and used in various sequence contexts to predict the propensity of aminofluorene adducts, exocyclic DNA adducts, 8-oxopurines, and synthetic abasic sites to generate frameshift deletions in vitro.			SHIBUTANI, S (corresponding author), SUNY,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.			Shibutani, Shinya/0000-0003-4190-9512	NATIONAL CANCER INSTITUTE [R37CA017395, R01CA017395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NCI NIH HHS [CA17395] Funding Source: Medline; NIEHS NIH HHS [ES04068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BODEPUDI V, 1991, NUCLEOS NUCLEOT NUCL, V10, P755, DOI 10.1080/07328319108046660; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BROYDE S, 1983, BIOPOLYMERS, V22, P2423, DOI 10.1002/bip.360221109; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DEBOER JG, 1988, GENETICS, V118, P181; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EVANS FE, 1980, CARCINOGENESIS, V1, P955, DOI 10.1093/carcin/1.11.955; FOWLER RG, 1974, MOL GEN GENET, V133, P179, DOI 10.1007/BF00267667; FRESCO JR, 1960, P NATL ACAD SCI USA, V46, P311, DOI 10.1073/pnas.46.3.311; FUCHS R, 1972, BIOCHEMISTRY-US, V11, P2659, DOI 10.1021/bi00764a017; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; GROLLMAN A P, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P682; GRUNBERG.D, 1970, P NATL ACAD SCI USA, V66, P488, DOI 10.1073/pnas.66.2.488; GUPTA PK, 1989, J BIOL CHEM, V264, P20120; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON F, 1992, J AM CHEM SOC, V114, P4923, DOI 10.1021/ja00038a079; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; MORIYA M, 1988, P NATL ACAD SCI USA, V85, P1586, DOI 10.1073/pnas.85.5.1586; OHANDLEY SF, 1992, 7TH P CONV BIOM STER, V1, P137; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; REID TM, 1990, BIOCHEMISTRY-US, V29, P6153, DOI 10.1021/bi00478a007; RIPLEY LS, 1986, J MOL BIOL, V191, P601, DOI 10.1016/0022-2836(86)90448-1; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Turner DH, 1992, CURR OPIN STRUC BIOL, V2, P334; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016	49	136	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11703	11710						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505300				2022-12-27	WOS:A1993LF28400039
J	BERTHIAUME, L; TOLAN, DR; SYGUSCH, J				BERTHIAUME, L; TOLAN, DR; SYGUSCH, J			DIFFERENTIAL USAGE OF THE CARBOXYL-TERMINAL REGION AMONG ALDOLASE ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MUSCLE ALDOLASE; MESSENGER-RNA; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; MAIZE ALDOLASE; GENOMIC CLONES; B-GENE; RESOLUTION	Sequence homology among nonconserved residues 357-362 of the COOH-terminal region in fructose-1,6-bisphosphate aldolases correlates with isozyme classification of aldolases. Recombinant chimers of human liver and maize aldolases were constructed by exchanging residues 357-362 with those from muscle, maize, and liver isozyme and by insertion in the maize sequence at position 349 rabbit muscle and liver residues 346-349. Activity variation among the chimers relative to native controls ranged from less than 10% to greater than 300% of V(m). Exchange of residues 357-362 significantly affected both V(m) and K(m) without modifiying catalytic efficiency k(cat)/K(m), whereas insertion of residues 346-349 modified V(m) and K(m) and increased catalytic efficiency. Steady state carbanion oxidation rates varied inversely with activity and were differentially affected with respect to equilibrium oxidation rates. Sequence exchange of residues 357-362 appears to modulate carbanion proton exchange, whereas sequence insertion of residues 346-349 modifies substrate and aldehyde interaction with C6 phosphate binding locus. Low intrinsic susceptibility to carboxypeptidase A degradation of the COOH terminus in liver aldolase is consistent with tight association of this COOH terminus in a conformation unfavorable for promoting high catalytic activity. Efficient carbanion protonation promoted by specific sequences 357-362 represents a mechanistic feature which distinguishes catalytically active maize and muscle isozymes from less active liver isozyme. Conservation of active site residues among aldolases suggests that isozyme diversity among aldolases arose from divergent evolution of the COOH-terminal sequence.	UNIV SHERBROOKE,FAC MED,DEPT BIOCHIM,SHERBROOKE J1H 5N4,QUEBEC,CANADA; BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215	University of Sherbrooke; Boston University				Tolan, Dean/0000-0002-0598-7241; Berthiaume, Luc/0000-0003-0926-059X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038821] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38821] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSDEN AB, 1985, THESIS U CALIFORNIA; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; BERTHIAUME L, 1989, ARCH BIOCHEM BIOPHYS, V272, P281, DOI 10.1016/0003-9861(89)90221-X; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P45; BURGESS DG, 1985, J BIOL CHEM, V260, P4604; CERTA U, 1988, SCIENCE, V240, P1036, DOI 10.1126/science.3285469; CLAYTON CE, 1985, EMBO J, V4, P2997, DOI 10.1002/j.1460-2075.1985.tb04035.x; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; GRAZI E, 1975, BIOCHEM J, V151, P167, DOI 10.1042/bj1510167; GRAZI E, 1962, BIOCHEM BIOPH RES CO, V9, P38, DOI 10.1016/0006-291X(62)90083-9; HANNAPPEL E, 1982, ARCH BIOCHEM BIOPHYS, V214, P293, DOI 10.1016/0003-9861(82)90033-9; HARTSUCK JA, 1971, ENZYMES, V3; HEALY MJ, 1973, BIOCHEMISTRY-US, V12, P35, DOI 10.1021/bi00725a006; HESTER G, 1991, FEBS LETT, V292, P237, DOI 10.1016/0014-5793(91)80875-4; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; JOH K, 1986, J MOL BIOL, V190, P401, DOI 10.1016/0022-2836(86)90011-2; KELLEY PM, 1986, PLANT PHYSIOL, V82, P1076, DOI 10.1104/pp.82.4.1076; KITAJIMA Y, 1990, J BIOL CHEM, V265, P17493; KUKITA A, 1988, EUR J BIOCHEM, V171, P471, DOI 10.1111/j.1432-1033.1988.tb13813.x; MALEK AA, 1988, ARCH BIOCHEM BIOPHYS, V266, P10, DOI 10.1016/0003-9861(88)90232-9; MESSING J, 1983, METHOD ENZYMOL, V167, P843; MESTEK A, 1987, NUCLEIC ACIDS RES, V15, P10595, DOI 10.1093/nar/15.24.10595; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4391, DOI 10.1021/bi00839a025; ROSE IA, 1958, J BIOL CHEM, V231, P315; ROSE IA, 1969, J BIOL CHEM, V244, P126; ROSE IA, 1987, J BIOL CHEM, V262, P692; ROTTMANN WH, 1984, P NATL ACAD SCI-BIOL, V81, P2738, DOI 10.1073/pnas.81.9.2738; ROTTMANN WH, 1987, BIOCHIMIE, V69, P137, DOI 10.1016/0300-9084(87)90246-X; RUTTER WJ, 1961, J BIOL CHEM, V236, P3193; RUTTER WJ, 1964, FED PROC, V23, P1248; Sambrook J, 1989, MOL CLONING LABORATO; SHAWLEE R, 1992, J BIOL CHEM, V267, P3959; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; SYGUSCH J, 1990, ARCH BIOCHEM BIOPHYS, V283, P227, DOI 10.1016/0003-9861(90)90636-D; TAKAHASHI I, 1989, J BIOCHEM, V105, P281, DOI 10.1093/oxfordjournals.jbchem.a122654; TOLAN DR, 1987, AM J HUM GENET, V41, P907; TOLAN DR, 1984, J BIOL CHEM, V259, P1127; TSUTSUMI K, 1985, J MOL BIOL, V181, P153, DOI 10.1016/0022-2836(85)90081-6; WHITE A, 1991, AM CRYSTALLOGR ASS, V19, P20	39	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10826	10835						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496148				2022-12-27	WOS:A1993LD46600021
J	MARQUES, G; ANTON, LC; BARRIO, E; SANCHEZ, A; RUIZ, S; GAVILANES, F; VIVANCO, F				MARQUES, G; ANTON, LC; BARRIO, E; SANCHEZ, A; RUIZ, S; GAVILANES, F; VIVANCO, F			ARGININE RESIDUES OF THE GLOBULAR REGIONS OF HUMAN C1Q INVOLVED IN THE INTERACTION WITH IMMUNOGLOBULIN-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; ANION-BINDING-SITES; HUMAN-COMPLEMENT; 1ST COMPONENT; HUMAN-CLQ; SUBCOMPONENT C1Q; B-CHAIN; GLUTAMATE-DEHYDROGENASE; ELECTRON-MICROSCOPY; A-CHAIN	The immunoglobulin G binding site in the globular regions of human complement subcomponent C1q has been investigated by chemical modification of histidine residues with diethylpyrocarbonate and arginine residues with phenylglyoxal and cyclohexane-1,2-dione (CHD). Only the modification of arginine residues with CHD fulfills the requirements of a specific modification without unwanted side reactions. Specific modification of arginine residues with CHD results in loss of immune complex recognition without affecting the binding of C1r2s2 to form C1. The gross structure of C1q is not changed by CHD treatment, and immune complex binding is restored to 82% of the control upon NH2OH treatment. Enzymic digestion and isolation of the modified peptides indicate that the modification by CHD of 4 to 5 arginine residues (A162, B114, B129, C156, and possibly B163) per C1q globular ''head'' abolishes the ability of C1q to interact with immune complexes. These residues define two areas (and possible binding sites for IgG) on the globular region of C1q: B114-B129 (site 1) and A162-(B163)-C156 (site 2). Sequence comparison and solvent exposure predictive studies favor site 2 as the immunoglobulin G binding site on the globular regions of Clq, although the participation of site 1 cannot be ruled out.	FDN JIMENEZ DIAZ,DEPT INMUNOL,AVE REYES CATOLICOS 2,E-28040 MADRID,SPAIN; UNIV COMPLUTENSE MADRID,DEPT BIOQUIM & BIOL MOLEC 1,E-28040 MADRID,SPAIN	Complutense University of Madrid			Gavilanes, Francisco/K-9903-2014; Vivanco, Fernando/Q-6866-2016; Antón, Luis C/C-4740-2013	Gavilanes, Francisco/0000-0003-1047-2362; Antón, Luis C/0000-0001-9665-011X				AITKEN A, 1989, PROTEIN SEQUENCING P, P43; ALCOLEA JM, 1986, MOL IMMUNOL, V23, P39, DOI 10.1016/0161-5890(86)90169-0; ANTON LC, 1989, BIOCHEM J, V257, P831, DOI 10.1042/bj2570831; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; AUSTEN BM, 1976, J BIOL CHEM, V251, P5835; BACHMAYER H, 1968, J BIOL CHEM, V243, P1022; BAUMANN MA, 1990, J BIOL CHEM, V265, P18414; BLUMENTHAL KM, 1975, J BIOL CHEM, V250, P3644; BORDERS CL, 1975, BIOCHEMISTRY-US, V14, P4699, DOI 10.1021/bi00692a021; Bornstein P, 1977, Methods Enzymol, V47, P132; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; BURTON DR, 1980, NATURE, V288, P338, DOI 10.1038/288338a0; CANOVADAVIS E, 1992, BIOCHEM J, V285, P207, DOI 10.1042/bj2850207; Cantor, 1980, BIOPHYS CHEM; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; COMIS A, 1985, BIOCHIM BIOPHYS ACTA, V842, P45, DOI 10.1016/0304-4165(85)90291-0; DUNCAN AR, 1988, NATURE, V332, P778; EASTERBROOKSMITH SB, 1983, BIOSCIENCE REP, V3, P135, DOI 10.1007/BF01121944; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; HEUSSER CH, 1975, IMMUNOCHEMISTRY, V12, P213, DOI 10.1016/0019-2791(75)90234-7; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; Kabat EA, 1991, SEQUENCES PROTEINS I; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; LIBERTI PA, 1981, J IMMUNOL METHODS, V40, P243, DOI 10.1016/0022-1759(81)90071-5; LIN TY, 1978, IMMUNOCHEMISTRY, V15, P107; LIU WH, 1968, BIOCHEMISTRY-US, V7, P2886, DOI 10.1021/bi00848a027; Martin H, 1990, EUR J IMMUNOL, V20, P1641, DOI 10.1002/eji.1830200804; MENENDEZARIAS L, 1990, COMPUT APPL BIOSCI, V6, P101; Miles E W, 1977, Methods Enzymol, V47, P431; PATTHY L, 1975, J BIOL CHEM, V250, P557; PATTHY L, 1979, EUR J BIOCHEM, V99, P309, DOI 10.1111/j.1432-1033.1979.tb13258.x; PATTHY L, 1980, EUR J BIOCHEM, V105, P387, DOI 10.1111/j.1432-1033.1980.tb04512.x; PATTHY L, 1975, J BIOL CHEM, V250, P565; PAUL SM, 1978, J BIOL CHEM, V253, P5658; PERKINS SJ, 1985, BIOCHEM J, V288, P13; PETRY F, 1991, J IMMUNOL, V147, P3988; PETRY F, 1989, FEBS LETT, V258, P89, DOI 10.1016/0014-5793(89)81622-9; PLAPP BV, 1967, J BIOL CHEM, V242, P265; Prevelige P., 1989, PREDICTION PROTEIN S, P391; REID KBM, 1990, IMMUNOL TODAY, V11, P387, DOI 10.1016/0167-5699(90)90150-8; REID KBM, 1981, METHOD ENZYMOL, V80, P16; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019; REID KBM, 1983, BIOCHEM SOC T, V11, P1; Richardson JS., 1989, PREDICT PROTEIN STRU; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; SCHIFFERLI JA, 1987, CLIN EXP IMMUNOL, V69, P188; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V16, P5175; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; SIEGEL RC, 1983, MOL IMMUNOL, V20, P53, DOI 10.1016/0161-5890(83)90105-0; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; SLEDGE CR, 1973, J IMMUNOL, V111, P661; Smith E L, 1977, Methods Enzymol, V47, P156; STRANG CJ, 1982, P NATL ACAD SCI USA, V77, P7014; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; TENNER AJ, 1981, J IMMUNOL, V127, P648; TITANI K, 1975, BIOCHEMISTRY-US, V14, P1358, DOI 10.1021/bi00678a003; TSCHOPP J, 1980, EUR J IMMUNOL, V10, P529, DOI 10.1002/eji.1830100709; ULLAH AHJ, 1991, BIOCHEM BIOPH RES CO, V178, P45, DOI 10.1016/0006-291X(91)91777-A; VIVANCOMARTINEZ F, 1980, MOL IMMUNOL, V17, P327, DOI 10.1016/0161-5890(80)90053-X; WERBER MM, 1975, EUR J BIOCHEM, V53, P207, DOI 10.1111/j.1432-1033.1975.tb04059.x; WINES BD, 1990, MOL IMMUNOL, V27, P321; YONEMASU K, 1981, BIOCHEM J, V193, P621, DOI 10.1042/bj1930621; ZICCARDI RJ, 1985, MOL IMMUNOL, V22, P489, DOI 10.1016/0161-5890(85)90133-6	71	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10393	10402						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486696				2022-12-27	WOS:A1993LB80000063
J	SINGH, I; PAHAN, K; DHAUNSI, GS; LAZO, O; OZAND, P				SINGH, I; PAHAN, K; DHAUNSI, GS; LAZO, O; OZAND, P			PHYTANIC ACID ALPHA-OXIDATION - DIFFERENTIAL SUBCELLULAR-LOCALIZATION IN RAT AND HUMAN TISSUES AND ITS INHIBITION BY NYCODENZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNOCEROYL-COA LIGASES; REFSUMS DISEASE; PEROXISOMAL DISORDERS; ZELLWEGER SYNDROME; STORAGE DISEASE; FATTY-ACIDS; LIVER; ADRENOLEUKODYSTROPHY; FIBROBLASTS; DEFICIENCY	The subcellular site of oxidation of [1-C-14]phytanic acid to pristanic acid and CO2 was examined by measurement of the release of (CO2)-C-14 in different organelles from human and rat tissues prepared by isopycnic density gradient centrifugation in Nycodenz. The activity of phytanic acid oxidation in human tissues (liver and cultured skin fibroblasts) paralleled that of the peroxisomal marker catalase. We also observed that Nycodenz (commonly used gradient material for isolation of subcellular organelles) has a strong inhibitory effect on the alpha-oxidation of phytanic acid. This inhibition is reversible and can be decreased or eliminated by dialysis of isolated organelles against isotonic solution. The dialysis of endoplasmic reticulum, mitochondrial, and peroxisomal fractions from human liver and cultured skin fibroblasts for 2 h against isotonic solution increased the specific activity of phytanic acid oxidation by 1.3-, 1.3-, and 5-21-fold, respectively, after removal of Nycodenz as compared with nondialyzed samples. After dialysis, the rate of oxidation of phytanic acid in peroxisomes from human liver and cultured skin fibroblasts was 4-26 times higher than that in mitochondria and 43-130 times than that in the endoplasmic reticulum, suggesting that, in human tissues, phytanic acid is oxidized to pristanic acid in peroxisomes. On the other hand, the oxidation of phytanic acid in rat liver paralleled the distribution of the mitochondrial marker cytochrome-c oxidase. The 18-fold higher rate of oxidation in dialyzed mitochondria (198.6 +/- 4.20 pmol/h/mg of protein) than in peroxisomes (11.0 +/- 0.5 pmol/h/mg of protein) demonstrates that, in rodents, phytanic acid is oxidized in mitochondria. 2-[5-(4-Chlorophenyl)pentyl]oxiran-2-carboxylic acid, an inhibitor of carnitine palmitoyltransferase I and mitochondrial fatty acid oxidation, inhibits the oxidation of phytanic acid in rat tissues (liver and cultured skin fibroblasts), whereas it has no effect on the oxidation of phytanic acid in human tissues (liver and cultured skin fibroblasts). The higher specific activity of phytanic acid oxidation in peroxisomes compared with that in mitochondria and the endoplasmic reticulum from human tissues and the inhibition of phytanic acid oxidation by 2-[5-(4-chlorophenyl)pentyl]oxiran-2-carboxylic acid in rat tissues (but not human tissues) demonstrate clearly that, in human tissues, phytanic acid is predominantly oxidized in peroxisomes.	KING FAISAL SPECIALIST HOSP & RES CTR,DEPT PEDIAT,RIYADH 11211,SAUDI ARABIA	King Faisal Specialist Hospital & Research Center	SINGH, I (corresponding author), MED UNIV S CAROLINA,DEPT PEDIAT,DIV DEV NEUROGENET,CHARLESTON,SC 29425, USA.				NINDS NIH HHS [NS-22576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022576, R37NS022576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVIGAN J, 1966, BIOCHEM BIOPH RES CO, V24, P838, DOI 10.1016/0006-291X(66)90324-X; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BEARD ME, 1985, J HISTOCHEM CYTOCHEM, V33, P480, DOI 10.1177/33.5.2580885; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; GULATI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P90, DOI 10.1016/0003-9861(92)90492-F; HERNDON JH, 1969, J CLIN INVEST, V48, P1017, DOI 10.1172/JCI106058; HEYMANS HSA, 1985, NEW ENGL J MED, V313, P187; HOSHI M, 1973, J BIOL CHEM, V248, P4123; HUANG S, 1992, ARCH BIOCHEM BIOPHYS, V296, P214, DOI 10.1016/0003-9861(92)90565-E; KLENK E, 1963, H-S Z PHYSIOL CHEM, V333, P133, DOI 10.1515/bchm2.1963.333.1.133; KNIGHTS KM, 1992, BIOCHEM PHARMACOL, V43, P1465, DOI 10.1016/0006-2952(92)90203-U; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZAROW PB, 1989, METABOLIC BASIS INHE, V2, P1501; LAZO O, 1989, ARCH BIOCHEM BIOPHYS, V270, P722, DOI 10.1016/0003-9861(89)90555-9; LAZO O, 1990, J LIPID RES, V31, P583; LAZO O, 1991, MOL CELL BIOCHEM, V100, P159; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LAZO O, 1990, BIOCHEMISTRY-US, V29, P3981, DOI 10.1021/bi00468a027; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MIHALIK SJ, 1989, J BIOL CHEM, V264, P2509; MIZE CE, 1969, BIOCHIM BIOPHYS ACTA, V176, P720, DOI 10.1016/0005-2760(69)90253-7; MIZE CE, 1969, J CLIN INVEST, V48, P1033, DOI 10.1172/JCI106059; MURALIDHARAN VB, 1984, J BIOL CHEM, V259, P3021; POULOS A, 1984, CLIN GENET, V26, P579; POULOS A, 1988, EUR J PEDIATR, V147, P143, DOI 10.1007/BF00442211; Refsum S., 1946, ACTA PSYCHIAT SCAND, V38, P1; SCOTTO JM, 1982, J INHERIT METAB DIS, V5, P83, DOI 10.1007/BF01799998; SINGH H, 1990, J LIPID RES, V31, P217; SINGH I, 1988, AM J DIS CHILD, V142, P1297, DOI 10.1001/archpedi.1988.02150120051039; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SINGH I, 1992, BIOCHIM BIOPHYS ACTA, V1180, P221, DOI 10.1016/0925-4439(92)90072-U; SINGH I, 1992, J BIOL CHEM, V267, P13306; SKJELDAL OH, 1988, SCAND J CLIN LAB INV, V48, P97, DOI 10.3109/00365518809086619; SKJELDAL OH, 1987, BIOCHIM BIOPHYS ACTA, V921, P38, DOI 10.1016/0005-2760(87)90167-6; STEINBER.D, 1965, BIOCHEM BIOPH RES CO, V19, P783, DOI 10.1016/0006-291X(65)90328-1; STEINBER.D, 1965, BIOCHEM BIOPH RES CO, V19, P412, DOI 10.1016/0006-291X(65)90138-5; STEINBERG D, 1967, J CLIN INVEST, V46, P313, DOI 10.1172/JCI105533; Steinberg D, 1989, METABOLIC BASIS INHE, P1533; STOFFEL W, 1965, BIOCHEM BIOPH RES CO, V19, P33, DOI 10.1016/0006-291X(65)90114-2; STOKKE O, 1984, SCAND J CLIN LAB INV, V44, P463, DOI 10.3109/00365518409083839; TSAI SC, 1969, J BIOL CHEM, V244, P2682; TURNBULL DM, 1984, BIOCHEM PHARMACOL, V33, P475, DOI 10.1016/0006-2952(84)90243-0; WANDERS RJA, 1991, J INHERIT METAB DIS, V14, P349, DOI 10.1007/BF01811700; WATKINS PA, 1990, BIOCHEM BIOPH RES CO, V167, P580, DOI 10.1016/0006-291X(90)92064-7	46	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9972	9979						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486724				2022-12-27	WOS:A1993LB80000009
J	POULTER, L; BARRATT, D; SCOTT, CW; CAPUTO, CB				POULTER, L; BARRATT, D; SCOTT, CW; CAPUTO, CB			LOCATIONS AND IMMUNOREACTIVITIES OF PHOSPHORYLATION SITES ON BOVINE AND PORCINE TAU PROTEINS AND A PHF-TAU FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-DISEASE; NEUROFIBRILLARY TANGLES; ABNORMAL PHOSPHORYLATION; MICROTUBULE; KINASE; IDENTIFICATION; PURIFICATION; UBIQUITIN; ISOFORMS	Tau protein is a phosphorylated neuronal microtubule-associated protein. Tau protein is also present in the major pathological lesions of Alzheimer's disease in an insoluble hyperphosphorylated state as paired helical filaments (PHFs). We have investigated the phosphorylation state of control taus and a fragment of PHF-tau. Tau samples were digested with protease, separated by reversed-phase high-performance liquid chromatography, and analyzed by mass spectrometry and Edman microsequencing. The serine homologous with S404 of human tau441 was phosphorylated on bovine and porcine tau and up to two phosphates were present on a peptide of amino acids 182-240 of bovine tau (193-251 of human tau441). The serine within the KSPV motif was not phosphorylated on bovine or porcine tau. PHF-tau fragments, isolated from pronase-treated PHFs encompassed a 93-amino acid region within the microtubule binding domain. Enzymatic digestion and mass spectrometric analysis showed no phosphate was present and a second carboxyl terminus was identified at E380. Antibodies T3P and SMI34, which recognize PHF-tau and peptides phosphorylated at the sequence KSPV, both reacted with bovine and porcine tau even though the KSPV sequence was not phosphorylated. These data indicate that the 93-amino acid sequence of F5.5 tau from PHFs is not phosphorylated, and the serine equivalent to S404 of human tau is phosphorylated in bovine and porcine tau. Antibodies T3P and SMI34 react with phosphorylated epitopes that are not unique to PHF-tau and that are not necessarily at the KSPV site.	ICI AMER INC,ICI PHARMACEUT GRP,DEPT PHARMACOL,WILMINGTON,DE 19897		POULTER, L (corresponding author), ICI PHARMACEUT PLC,DEPT BIOTECHNOL,ALDERLEY PK,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND.							BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CAPUTO CB, 1992, NEUROBIOL AGING, V13, P267, DOI 10.1016/0197-4580(92)90039-Z; CAPUTO CB, 1992, BRAIN RES, V597, P227, DOI 10.1016/0006-8993(92)91478-W; CAPUTO CB, 1989, NEUROBIOL AGING, V10, P451, DOI 10.1016/0197-4580(89)90096-1; COLE GM, 1987, NEUROSCI LETT, V79, P207, DOI 10.1016/0304-3940(87)90698-7; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HARRINGTON CR, 1991, P NATL ACAD SCI USA, V88, P5842, DOI 10.1073/pnas.88.13.5842; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1990, J CELL BIOL, V111; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MUKAETOVALADINSKA EB, 1992, DEMENTIA, V3, P61, DOI 10.1159/000106996; MURPHY DB, 1982, METHOD CELL BIOL, V24, P31; SCHLESINGER DH, 1975, NATURE, V255, P423, DOI 10.1038/255423a0; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	43	22	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9636	9644						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486651				2022-12-27	WOS:A1993LA68900073
J	BURNETTE, B; YU, G; FELSTED, RL				BURNETTE, B; YU, G; FELSTED, RL			PHOSPHORYLATION OF HIV-1 GAG PROTEINS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; RECOMBINANT VACCINIA VIRUS; LONG TERMINAL REPEAT; SUBSTRATE-SPECIFICITY; T-CELLS; PLASMA-MEMBRANE; GENE-PRODUCTS; HTLV-III/LAV; FACTOR-ALPHA	We have demonstrated that the 17-kDa N-terminal matrix protein (p17gag) of HIV-1 Pr55gag is a substrate for protein kinase C (PKC). Phosphorylation of p17gag and Pr55gag was studied in vivo by infecting COS-7 cells with a recombinant vaccinia virus containing the HIV-1 gag-pol gene. Basal gag protein phosphorylation was inhibited up to 75% with the PKC inhibitor, H-7, and stimulated 3-4-fold with phorbol 12-myristate 13-acetate. In experiments using MCF-7 cell lines, p17gag and Pr55gag were dramatically phosphorylated only in clones with high PKC activity. Bacterially expressed and purified non-myristoylated and N-myristoylated p17gag were efficiently phosphorylated in a Ca2+ and phosphatidylserine-dependent manner by purified PKC. The N-myristoylated p17gag exhibited an apparent K(m) = 4 muM for PKC phosphorylation. Both in vitro and in vivo phosphorylated p17gag yielded identical V8 protease digestion phosphopeptide maps, indicating identical PKC phosphorylation sites. Phosphoamino acid analysis of the in vitro phosphorylated p17gag revealed only phosphoserine. These data are consistent with the identification of a highly conserved consensus PKC phosphorylation site motif in the HIV-1 gag protein at Ser111 and suggests that PKC phosphorylation plays an important role in gag protein function.	NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; AQUINO A, 1990, BIOCHEM BIOPH RES CO, V166, P723, DOI 10.1016/0006-291X(90)90869-O; BATIST G, 1986, J BIOL CHEM, V261, P5544; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BURNETTE B, 1992, J PROTEIN EXP PURIF, V3, P395; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; FOLKS T, 1986, J IMMUNOL, V136, P4049; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOWDA SD, 1989, J VIROL, V63, P1451, DOI 10.1128/JVI.63.3.1451-1454.1989; GOWDA SD, 1989, J BIOL CHEM, V264, P8459; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; GUY B, 1990, J ACQ IMMUN DEF SYND, V3, P797; HAMAMOTO Y, 1989, BIOCHEM BIOPH RES CO, V164, P339, DOI 10.1016/0006-291X(89)91723-3; HAMAMOTO Y, 1990, CANCER RES, V50, P5287; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INAGAKI M, 1984, J BIOL CHEM, V259, P4321; JACOBS E, 1989, GENE, V79, P71, DOI 10.1016/0378-1119(89)90093-0; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KINTER AL, 1990, J VIROL, V64, P4306, DOI 10.1128/JVI.64.9.4306-4312.1990; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; KROGSTAD P, 1991, GENETIC STRUCTURE RE, P473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAURENCE J, 1990, BLOOD, V75, P696; LAURENT AG, 1990, J GEN VIROL, V71, P2273, DOI 10.1099/0022-1317-71-10-2273; LEIS J, 1989, EUR J BIOCHEM, V179, P415, DOI 10.1111/j.1432-1033.1989.tb14569.x; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAHONEY CW, 1990, J BIOL CHEM, V265, P5424; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MOHAGHEGHPOUR N, 1991, J BIOL CHEM, V266, P7233; MYERS G, 1990, HUMAN RETROVIRUSES A; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OVERTON HA, 1989, VIROLOGY, V170, P107, DOI 10.1016/0042-6822(89)90357-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STANLEY SK, 1989, AIDS RES HUM RETROV, V5, P375, DOI 10.1089/aid.1989.5.375; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; WISE BC, 1982, J BIOL CHEM, V257, P8489; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	60	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8698	8703						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473314				2022-12-27	WOS:A1993KX81100050
J	DARNAY, BG; RODWELL, VW				DARNAY, BG; RODWELL, VW			HIS(865) IS THE CATALYTICALLY IMPORTANT HISTIDYL RESIDUE OF SYRIAN-HAMSTER 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CHEMICAL MODIFICATION; ARABIDOPSIS-THALIANA; ACTIVE-SITE; PHOSPHORYLATION; ENZYME; CDNA; EXPRESSION	Involvement in catalysis of a histidyl residue of Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase was suggested by the ability of diethyl pyrocarbonate to abolish catalytic activity, accompanying spectral changes, and reactivation by hydroxylamine. The 7 histidines present in the catalytic domain of the hamster enzyme were changed to glutamine (His474, His487, His634, His751, His860, and His865), lysine (His865), or tyrosine (His868). Overexpression in Escherichia coli yielded six soluble mutant proteins, one insoluble protein (H634Q), and one which was degraded in vivo (H487Q). Following purification to homogeneity, mutant enzymes H474Q, H751Q, H860Q, and H868Y had essentially wild-type catalytic activity, while mutant enzymes H865K and H865Q had less than 0.6% wild-type activity. The low activity of mutant enzymes H865K and H865Q is unlikely to reflect altered structural integrity since both chromatographed on affinity supports like wild-type enzyme and had K(m) values for (S)-HMG-CoA (31 and 16 muM) and for NADPH (60 and 24 muM) close to those for wild-type enzyme (31 and 52 muM for (S)-HMG-CoA and NADPH, respectively). His865 of hamster HMG-CoA reductase, the histidine of the consensus Leu-Val-Xaa-Ser-His-Met-Xaa-Xaa-Asn-Arg-Ser motif and the only histidine conserved among the catalytic domains of all HMG-CoA reductases, thus appears to be a general acid/base functional in catalysis.			DARNAY, BG (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BISCHOFF KM, 1992, BIOCHEM MED METAB B, V48, P149, DOI 10.1016/0885-4505(92)90060-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHYE ML, 1991, PLANT MOL BIOL, V16, P567, DOI 10.1007/BF00023422; CLARKE PR, 1991, EMBO J, V9, P2439; DARNAY BG, 1992, J BIOL CHEM, V267, P15064; DRABIKOWSKA AK, 1990, BIOCHEM J, V270, P319, DOI 10.1042/bj2700319; DUGAN RE, 1986, BIOCHEM BIOPH RES CO, V141, P278, DOI 10.1016/S0006-291X(86)80365-5; ENDO A, 1992, J LIPID RES, V33, P1569; FERRER A, 1990, FEBS LETT, V266, P67, DOI 10.1016/0014-5793(90)81508-L; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GIBSON DM, 1987, ENZYMES ENZYME CONTR, V18, P179; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KEITH ML, 1983, J PROTEIN CHEM, V2, P209, DOI 10.1007/BF01025355; KENNELLY PJ, 1985, J LIPID RES, V26, P903; KIM YS, 1988, BIOCHIM BIOPHYS ACTA, V956, P103, DOI 10.1016/0167-4838(88)90255-5; LAM WL, 1992, J BIOL CHEM, V267, P5829; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; MAYER RJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P110, DOI 10.1016/0003-9861(88)90014-8; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; STERMER BA, 1991, PHYSIOL MOL PLANT P, V39, P135, DOI 10.1016/0885-5765(91)90024-C; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSOU C, 1962, SCI SINICA, V11, P1535; VELOSO D, 1981, BIOCHEMISTRY-US, V20, P887, DOI 10.1021/bi00507a036; WANG YL, 1990, J BIOL CHEM, V265, P21634; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411; 1991, PROTOCOLS APPLICATIO, P110; 1983, OLIGONUCLEOTIDE DIRE, P1	44	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8429	8435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473286				2022-12-27	WOS:A1993KX81100013
J	NISHIMURA, H; PALLARDO, FV; SEIDNER, GA; VANNUCCI, S; SIMPSON, IA; BIRNBAUM, MJ				NISHIMURA, H; PALLARDO, FV; SEIDNER, GA; VANNUCCI, S; SIMPSON, IA; BIRNBAUM, MJ			KINETICS OF GLUT1 AND GLUT4 GLUCOSE TRANSPORTERS EXPRESSED IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE CELL; PLASMA-MEMBRANE; 3T3-L1 ADIPOCYTES; HEXOSE-TRANSPORT; INSULIN; TRANSLOCATION; PROTEIN; PARAMETERS; GENE; 3-O-METHYLGLUCOSE	The predominant mechanism by which insulin activates glucose transport in muscle and adipose tissue is by affecting the redistribution of the facilitated hexose carriers, GLUT1 and GLUT4, from an intracellular site to the plasma membrane. A quantitative analysis of this process has been hampered by the lack of reliable determinations for kinetic constants catalyzed by each of these isoforms. In order to obtain such information, each transporter was expressed in Xenopus oocytes by the injection of mRNA encoding rat GLUT1 or GLUT4. Equilibrium exchange 3-O-methylglucose uptake was measured and the data fitted to a two-compartment model, yielding K(m) = 26.2 mM and V(max) = 3.5 nmol/min/cell for GLUT1 and K(m) = 4.3 mM and V(max) = 0.7 nmol/min/cell for GLUT4. Measurement of the abundance of cell surface transporters was accomplished by two independent protocols: photolabeling with the impermeant hexose analog 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine and subcellular fractionation of oocytes. Data obtained by either technique revealed that the ratio of plasma membrane GLUT1 to GLUT4 was about 4; this paralleled the relative maximal velocities for hexose transport, indicating that the turnover numbers for the two isoforms were the same. Moreover, measurement of the concentration of exofacially disposed transporters with 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine allowed calculation of the turnover number to be about 20,000 min-1. These data indicate that, at low substrate concentrations, the catalytic efficiency of GLUT4 is significantly greater than GLUT1. Extrapolation to mammalian systems suggests that GLUT4 is responsible for virtually all of the hexose uptake in insulin-responsive targets, particularly in the presence of hormone.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, 25 SHATTUCK ST, BOSTON, MA 02115 USA; NIDDKD, DIABET BRANCH, EXPTL DIABET METAB & NUTR SECT, BETHESDA, MD 20892 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Pallardo, Federico V./T-1156-2017	Pallardo, Federico V./0000-0003-3715-1980; Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK39519] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1990, BIOCHEM J, V269, P597, DOI 10.1042/bj2690597; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; COLMAN A, 1984, EXPRESSION EXOGENOUS, P49; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KELLER K, 1989, J BIOL CHEM, V264, P18884; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; MARTZ A, 1986, J BIOL CHEM, V261, P3606; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; PALFREYMAN RW, 1992, BIOCHEM J, V284, P275, DOI 10.1042/bj2840275; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAYLOR LP, 1981, BIOCHIM BIOPHYS ACTA, V642, P325, DOI 10.1016/0005-2736(81)90449-1; TOYODA N, 1987, J BIOL CHEM, V262, P2737; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; WHITESELL RR, 1989, BIOCHEMISTRY-US, V28, P6937, DOI 10.1021/bi00443a024	37	114	116	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8514	8520						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473295				2022-12-27	WOS:A1993KX81100024
J	YAMADA, T; AGUI, T; SUZUKI, Y; SATO, M; MATSUMOTO, K				YAMADA, T; AGUI, T; SUZUKI, Y; SATO, M; MATSUMOTO, K			INHIBITION OF THE COPPER INCORPORATION INTO CERULOPLASMIN LEADS TO THE DEFICIENCY IN SERUM CERULOPLASMIN ACTIVITY IN LONG-EVANS CINNAMON MUTANT RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRINDLED MOUSE MODEL; GENE-EXPRESSION; WILSONS-DISEASE; MENKES DISEASE; ESTERASE-D; METABOLISM; HEPATOCYTES; TRANSPORT; PROTEINS; BINDING	Although ceruloplasmin is known to be a copper-transporting protein, little is known about the biochemical mechanisms of copper incorporation into ceruloplasmin during the biosynthesis. We have examined various levels of ceruloplasmin biosynthesis in the Long-Evans Cinnamon (LEC) rat, which possesses a mutation causing the deficiency in serum ceruloplasmin activity associated with excess hepatic copper accumulation. Southern and Northern blot analyses revealed that the gene and mRNA encoding ceruloplasmin resided normally in LEC rat liver. Western blot analysis showed a normal level of ceruloplasmin in LEC rat serum. Following metabolic labeling of hepatocytes with Cu-64, no radioactive copper was detected in the ceruloplasmin fraction in LEC rat hepatocytes using Sephadex G-75 column chromatography, indicating that copper incorporation into ceruloplasmin is deficient in the LEC rat. Furthermore, LEC rat hepatocytes incubated with Cu-64 also showed a reduction in the efficiency of copper transport from cytosolic to noncytosolic fractions and a reduced copper efflux from the hepatocytes, indicating that LEC rat hepatocytes possess an abnormality in copper metabolism. These results suggest that an abnormality of the copper delivery mechanism causes an inhibition of copper incorporation into the ceruloplasmin molecule in the liver, leading to the deficiency in serum ceruloplasmin activity in the LEC rat. In addition, this abnormality also seems to cause an inhibition of biliary copper excretion. The blocking of these two copper exclusion pathways is thought to lead to excess hepatic copper accumulation in the LEC rat. Thus, the LEC rat should be a good model for studying the biochemical process responsible for copper delivery.	UNIV TOKUSHIMA,SCH MED,INST ANIM EXPERIMENTAT,KURAMOTO 3,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,SCH MED,DEPT HYG,TOKUSHIMA 770,JAPAN; AKITA UNIV,SCH MED,DEPT ANAT,AKITA 010,JAPAN	Tokushima University; Tokushima University; Akita University								BONNETAMIR B, 1986, GENET EPIDEMIOL, V3, P201, DOI 10.1002/gepi.1370030307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; DANKS DM, 1991, EUR J PEDIATR, V150, P142, DOI 10.1007/BF01963553; DARWISH HM, 1983, J BIOL CHEM, V258, P3621; DEDOVE C, 1966, ANN REV PHYSL, V28, P435; EPSTEIN O, 1981, LANCET, V1, P303; Ettinger MJ, 1984, COPPER PROTEIN COPPE, V3, P175; EVANS GW, 1970, AM J PHYSIOL, V218, P298, DOI 10.1152/ajplegacy.1970.218.1.298; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; FLEMING RE, 1992, J BIOL CHEM, V267, P479; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIEDEN E, 1986, CLIN PHYSIOL BIOCH, V4, P11; FRYDMAN M, 1985, P NATL ACAD SCI USA, V82, P1819, DOI 10.1073/pnas.82.6.1819; GITLIN D, 1960, NATURE, V185, P693, DOI 10.1038/185693a0; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; GOLDSTEIN IM, 1979, J BIOL CHEM, V254, P4040; GREGORIA.G, 1967, CAN J BIOCHEM CELL B, V45, P1841, DOI 10.1139/o67-217; GUTTERIDGE JMC, 1981, CRC CR REV CL LAB SC, V14, P257, DOI 10.3109/10408368109105866; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2350; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; LI Y, 1991, J CLIN INVEST, V87, P1858, DOI 10.1172/JCI115208; MATSUMOTO K, 1987, TRANSPLANT P, V19, P3207; OBRIEN SJ, 1987, GENETIC MAPS, P564; ORENA SJ, 1986, BIOCHEM BIOPH RES CO, V139, P822, DOI 10.1016/S0006-291X(86)80064-X; PALIDA FA, 1990, BIOCHEM J, V268, P359, DOI 10.1042/bj2680359; PALIDA FA, 1991, J BIOL CHEM, V266, P4586; RYDEN L, 1976, BIOCHEMISTRY-US, V15, P3411, DOI 10.1021/bi00661a003; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; SASAKI M, 1985, RAT NEWS LETT, V14, P4; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHMITT RC, 1983, AM J PHYSIOL, V244, pG183, DOI 10.1152/ajpgi.1983.244.2.G183; SCHOSINSKY KH, 1974, CLIN CHEM, V20, P1556; STERNLIEB I, 1961, J CLIN INVEST, V40, P1834, DOI 10.1172/JCI104407; STERNLIEB I, 1979, GASTROENTEROLOGY, V77, P138; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER FJ, 1990, J BIOL CHEM, V265, P1834; WINGE DR, 1984, SEMIN LIVER DIS, V4, P239, DOI 10.1055/s-2008-1041774; YAMADA T, 1992, BIOCHEM INT, V27, P243; YAMADA T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P188, DOI 10.1016/0167-4781(92)90075-B; [No title captured]	43	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8965	8971						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473340				2022-12-27	WOS:A1993KX81100085
J	RONG, D; LOVEY, AJ; ROSENBERGER, M; DAVIGNON, A; PONDER, J; LI, E				RONG, D; LOVEY, AJ; ROSENBERGER, M; DAVIGNON, A; PONDER, J; LI, E			DIFFERENTIAL BINDING OF RETINOL ANALOGS TO 2 HOMOLOGOUS CELLULAR RETINOL-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ESCHERICHIA-COLI; RAT; ACID; PURIFICATION; EXPRESSION	A comparative study of the interactions of rat cellular retinol-binding protein (CRBP) and cellular retinol-binding protein II (CRBP II) with a number of synthetic phenyl-substituted analogs of all-trans-retinol was performed using fluorescence and nuclear magnetic resonance analysis. These studies indicate that CRBP II is more sensitive to modifications of the ring moiety than CRBP. Removal of the two methyl substituents on the ring which are ortho to the polyene chain abolishes binding to CRBP II. Conformational analysis of the ligands indicates that these two methyl groups influence the planarity of the ligand. The identification of monospecific ligands may prove useful for studying the physiological roles of these two proteins.	WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8051,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63110; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Roche Holding					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040172, R01DK040172] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02004, RR05018] Funding Source: Medline; NIDDK NIH HHS [DK40172] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHENG L, 1991, J BIOL CHEM, V266, P24404; CHYTIL F, 1984, RETINOIDS, V2, P89; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CROW JA, 1985, P NATL ACAD SCI USA, V82, P4707, DOI 10.1073/pnas.82.14.4707; DRAPEAU GR, 1968, J MOL BIOL, V35, P357, DOI 10.1016/S0022-2836(68)80030-0; GORDON JI, 1991, CURR OPIN LIPIDOL, V2, P125; HONIG B, 1971, P NATL ACAD SCI USA, V68, P1289, DOI 10.1073/pnas.68.6.1289; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1987, J BIOL CHEM, V262, P13773; LI E, 1989, J BIOL CHEM, V264, P17041; LI E, 1986, P NATL ACAD SCI USA, V83, P8102; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; OBERHANSLI WE, 1974, ACTA CRYSTALLOGR B, V30, P161, DOI 10.1107/S0567740874002408; ONG DE, 1984, J BIOL CHEM, V259, P1476; PFOERTNER KH, 1987, TETRAHEDRON, V43, P1321, DOI 10.1016/S0040-4020(01)90253-4; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SPORN MB, 1984, RETINOIDS, V1, P235; STAM CH, 1972, ACTA CRYSTALL B-STRU, VB 28, P2936, DOI 10.1107/S0567740872007253; STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024	26	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7929	7934						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463314				2022-12-27	WOS:A1993KW97900054
J	VENABLE, ME; OLSON, SC; NIETO, ML; WYKLE, RL				VENABLE, ME; OLSON, SC; NIETO, ML; WYKLE, RL			ENZYMATIC STUDIES OF LYSO-PLATELET-ACTIVATING-FACTOR ACYLATION IN HUMAN NEUTROPHILS AND CHANGES UPON STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLTRANSFERASE-CATALYZED CLEAVAGE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RABBIT ALVEOLAR MACROPHAGES; ARACHIDONIC-ACID; INDEPENDENT TRANSACYLASE; EICOSAPENTAENOIC ACID; FACTOR PAF; PHOSPHOLIPIDS; PHOSPHATIDYLCHOLINE; PHOSPHOGLYCERIDES	Resting human neutrophils acylate 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (1-O-alkyl-2-lyso-GPC; lyso-PAF) specifically with arachidonate (AA); upon stimulation, however, the specificity is lost and other fatty acid residues are added. The major goals of this study were to compare the various acylation reactions present in the cells and to determine the cause of the specificity loss upon stimulation. The CoA-independent transacylase was active in neutrophil homogenates and was found to be both highly specific for AA and stereospecific, requiring 1-O-alkyl-2-lyso-GPC for activity. Homogenates also contained acyl-CoA:1-radyl-2-lyso-sn-glycero-3-phosphocholine acyltransferase activity, which transferred acyl chains from oleoyl-, linoleoyl-, or linolenoyl-CoA to both 1-alkyl and 1-acyl acceptors, but preferred the 1-acyl acceptor when arachidonoyl-CoA was used. The CoA-dependent and -independent activities co-sedimented on a discontinuous Percoll gradient in a single band containing plasma membrane and possibly other membranes. CoA alone promoted nonspecific acylation in the homogenates. The AA-specific acylation was attenuated up to 80% in sonicates of ionophore-stimulated cells, whereas the CoA-dependent acyltransferase remained unchanged. Potential phospholipid AA donors for the transacylase were substantially depleted in the stimulated cells but could not account for the large decrease in acylation. An accumulation of 1-O-alk-1'-enyl-2-lyso-sn-glycero-3-phosphoethanolamine (alkenyl-2-lyso-GPE), which acts as a competing substrate, appeared to be the major cause of the reduced AA-specific acylation of lyso-PAF observed in the stimulated preparations. Removal of the alkenyl-2-lyso-GPE restored the activity, whereas the addition of alkenyl-2-lyso-GPE (2 muM) to resting membrane preparations resulted in a marked decrease in transacylation of lyso-PAF.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center			Nieto, Maria L/G-7492-2015	Nieto, Maria L/0000-0001-6842-799X; Venable, Mark/0000-0003-1708-9163	NHLBI NIH HHS [HL-26818] Funding Source: Medline; NIAID NIH HHS [AI-17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT DH, 1984, BIOCHIM BIOPHYS ACTA, V796, P92, DOI 10.1016/0005-2760(84)90242-X; BIANTON DF, 1971, J EXP MED, V134, P907; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; BLANK ML, 1984, J CHROMATOGR, V298, P474; BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P473; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; CHABOT MC, 1987, BIOCHIM BIOPHYS ACTA, V922, P214, DOI 10.1016/0005-2760(87)90157-3; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CHILTON FH, 1987, BIOCHIM BIOPHYS ACTA, V917, P48, DOI 10.1016/0005-2760(87)90282-7; CHILTON FH, 1983, J BIOL CHEM, V258, P7268; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COLARD O, 1984, BIOCHIM BIOPHYS ACTA, V793, P42, DOI 10.1016/0005-2760(84)90051-1; COLARD O, 1984, BIOCHEM J, V222, P657, DOI 10.1042/bj2220657; COLEMAN R, 1977, J BIOL CHEM, V252, P3050; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P128, DOI 10.1016/0005-2760(65)90101-3; FLESCH I, 1984, EUR J BIOCHEM, V139, P431, DOI 10.1111/j.1432-1033.1984.tb08023.x; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; IRVINE RF, 1979, BIOCHEM BIOPH RES CO, V91, P1399, DOI 10.1016/0006-291X(79)91222-1; JESAITIS AJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P556, DOI 10.1016/0304-4165(82)90246-X; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; MACDONALD JIS, 1989, J BIOL CHEM, V264, P17718; MACDONALD JIS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P151, DOI 10.1016/0005-2760(89)90263-4; MAHADEVAPPA VG, 1986, BIOCHEM BIOPH RES CO, V134, P1327, DOI 10.1016/0006-291X(86)90395-5; MALONE B, 1985, J BIOL CHEM, V260, P1531; MATTSON FH, 1962, J LIPID RES, V3, P281; MCKEAN ML, 1986, FEBS LETT, V195, P38, DOI 10.1016/0014-5793(86)80125-9; MUELLER HW, 1984, J LIPID RES, V25, P383; NAKAGAWA Y, 1985, BIOCHIM BIOPHYS ACTA, V833, P323; NIETO M, 1990, J CELL BIOL, V111, P257; NIETO ML, 1991, J BIOL CHEM, V266, P18699; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OKITA JR, 1982, J BIOL CHEM, V257, P4029; PATEL KM, 1979, LIPIDS, V14, P596, DOI 10.1007/BF02533539; PATTON GM, 1982, J LIPID RES, V23, P190; RECORD M, 1985, BIOCHIM BIOPHYS ACTA, V819, P1, DOI 10.1016/0005-2736(85)90188-9; REINHOLD SL, 1989, J BIOL CHEM, V264, P21652; ROBINSON BS, 1989, BIOCHEM J, V264, P125, DOI 10.1042/bj2640125; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROCK CO, 1975, J BIOL CHEM, V250, P6564; ROOS D, 1979, BLOOD, V53, P851; ROSENTHAL MD, 1987, PROG LIPID RES, V26, P87, DOI 10.1016/0163-7827(87)90009-9; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; STOFFEL W, 1959, ANAL CHEM, V31, P307, DOI 10.1021/ac60146a047; STOFFEL W, 1975, METHODS ENZYMOLOGY B, V35, P533; SUGIURA T, 1985, BIOCHEM BIOPH RES CO, V127, P384, DOI 10.1016/S0006-291X(85)80171-6; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1990, BIOCHIM BIOPHYS ACTA, V1047, P223, DOI 10.1016/0005-2760(90)90520-8; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; TOU JS, 1987, LIPIDS, V22, P333, DOI 10.1007/BF02534002; TOU JS, 1989, LIPIDS, V24, P812, DOI 10.1007/BF02544589; TOU JS, 1984, LIPIDS, V19, P573, DOI 10.1007/BF02534713; TROTTER J, 1982, J BIOL CHEM, V257, P1816; TROTTER J, 1981, FEBS LETT, V128, P237, DOI 10.1016/0014-5793(81)80089-0; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VANHEUSDEN GPH, 1980, J BIOL CHEM, V255, P9312; VOETMAN AA, 1981, J CLIN INVEST, V67, P1541, DOI 10.1172/JCI110185; WAKU K, 1977, J BIOCHEM-TOKYO, V82, P1779, DOI 10.1093/oxfordjournals.jbchem.a131876; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O; WYKLE RL, 1981, BIOCHEM BIOPH RES CO, V100, P1651, DOI 10.1016/0006-291X(81)90708-7; WYKLE RL, 1987, PLATELET ACTIVATING, P273; WYKLE RL, 1986, ADV INFLAMMAT RES, V11, P71; WYRICK SD, 1985, J LABELLED COMPD RAD, V22, P1169, DOI 10.1002/jlcr.2580221110	70	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7965	7975						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463317				2022-12-27	WOS:A1993KW97900059
J	KAWABATA, S; NAKAGAWA, K; MUTA, T; IWANAGA, S; DAVIE, EW				KAWABATA, S; NAKAGAWA, K; MUTA, T; IWANAGA, S; DAVIE, EW			RABBIT LIVER MICROSOMAL ENDOPEPTIDASE WITH SUBSTRATE-SPECIFICITY FOR PROCESSING PROPROTEINS IS STRUCTURALLY RELATED TO RAT TESTES METALLOENDOPEPTIDASE-24.15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC ENZYMES; PROTEIN; GENE; PROHORMONE; MUTATION; SEQUENCE; HORMONE; PROTEOLYSIS; PROPEPTIDE; ENKEPHALIN	The detergent extract of rabbit liver microsomes contains an endopeptidase (MEP) with substrate specificity for peptides containing Arg residues at the P1 and P4 positions in the cleavage site (Kawabata, S., and Davie, E. W. (1992) J. Biol. Chem. 267, 10331-10336). These sequences occur in many proproteins such as the vitamin K-dependent proproteins and pro-hormones. A cDNA coding for MEP has been obtained from three overlapping clones isolated from two rabbit liver lambdagt10 cDNA libraries. The longest open reading frame of the 3507-base pair cDNA codes for a protein of 704 amino acids, of which 406 residues were confirmed by amino acid sequence analysis. MEP contains a putative active site of -His-Glu-X-X-His-, which is typical of mammalian zinc metallopeptidases. Based on a hydropathy plot, MEP is a hydrophilic protein with no transmembrane domain and no NH2-terminal signal sequence. Amino acid sequence analysis identified Asn at the three potential N-glycosylation sites in the enzyme, indicating that MEP contains no N-linked sugar. MEP is homologous with rat testes metalloendopeptidase 24.15 (60% identity), rat mitochondrial intermediate peptidase (24% identity), Escherichia coli dipeptidyl carboxypeptidase (25% identity), and the open reading frame YCL57w present in yeast chromosome III (35% identity).	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; KYUSHU UNIV 33,FAC SCI,DEPT PATHOL,FUKUOKA 812,JAPAN	University of Washington; University of Washington Seattle; Kyushu University	KAWABATA, S (corresponding author), KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN.							ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; BARRETT AJ, 1989, BIOCHEM J, V261, P1047, DOI 10.1042/bj2611047; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MOLINEAUX CJ, 1988, J NEUROCHEM, V51, P624, DOI 10.1111/j.1471-4159.1988.tb01084.x; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; Sambrook J, 1989, MOL CLONING LABORATO; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984	36	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12498	12503						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509389				2022-12-27	WOS:A1993LG65800042
J	HOANG, T; DELEAN, A; HAMAN, A; BEAUCHEMIN, V; KITAMURA, T; CLARK, SC				HOANG, T; DELEAN, A; HAMAN, A; BEAUCHEMIN, V; KITAMURA, T; CLARK, SC			THE STRUCTURE AND DYNAMICS OF THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR DEFINED BY THE TERNARY COMPLEX MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; ACUTE MYELOBLASTIC-LEUKEMIA; EXPRESSION CLONING; MOLECULAR-CLONING; BLAST CELLS; HUMAN IL-3; BINDING; INTERLEUKIN-3; SUBUNIT; IDENTIFICATION	Myeloid cell lines and primary leukemic myeloblasts express two classes of granulocyte macrophage colony-stimulating factor (GM-CSF) binding sites of high (K(d) 20-50 pM) and low affinity (K(d) 5-10 nM). High affinity binding is caused by the association of two chains, p80alpha and p130beta, whereas p80alpha alone confers low affinity binding only. Furthermore interleukin-3 (IL-3) competes for the binding of GM-CSF to its high affinity receptor (for review see Nicola, N. A., and Metcalf, D. (1991) Cell 67, 1-4). In the present study, we took advantage of the perturbation of GM-CSF binding equilibrium by IL-3 to take a quantitative approach to analysis of the structure and dynamics of the GM-CSF receptor complex. First, cross-linking studies were performed at two concentrations of radioligand. At 200 pM, a concentration sufficient for near saturation of the high affinity binding site R1, the association between p80alpha and p130beta is stoichiometric, and the addition of IL-3 prevents the binding to both chains. At 5 nM, a concentration sufficient for half-occupancy of the low affinity binding site R2, IL-3 prevents cross-linking to the beta chain only. Second, GM-CSF saturation curves were analyzed both at equilibrium and under conditions of perturbation of the equilibrium by IL-3. In the presence of IL-3, the interaction of GM-CSF with its receptor is converted from high to low affinity binding. Computer modeling of binding data with a ternary complex model involving GM-CSF, p80alpha, and p130beta indicates that the model fits the data with accuracy and suggests that ligand binding stabilizes the interaction between p80alpha and p130beta by 3 orders of magnitude. Third, membrane solubilization dissociates p80alpha and p130beta whereas on ligand-stabilized preformed complexes, solubilization did not dissociate the two chains. Finally, upon addition of GM-CSF, there is an increase with time in the proportion of ligand bound to the high affinity receptor, at the expense of that bound to low affinity receptor, suggesting that stabilization of the ternary complex is a time-dependent process.	UNIV MONTREAL, DEPT MED, MONTREAL H2W 1R7, PQ, CANADA; UNIV MONTREAL, DEPT PHARMACOL, MONTREAL H2W 1R7, PQ, CANADA; DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, PALO ALTO, CA 94304 USA; GENET INST INC, CAMBRIDGE, MA 02140 USA	Universite de Montreal; Universite de Montreal; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	HOANG, T (corresponding author), CLIN RES INST MONTREAL, HEMOPOIESIS & LEUKEMIA LAB, 110 PINE AVE W, MONTREAL H2W 1R7, QUEBEC, CANADA.		Kitamura, Toshio/AAA-2071-2021					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDEL LM, 1990, BLOOD, V75, P1439; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CHIBA S, 1990, LEUKEMIA, V4, P29; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DIPERSIO JF, 1991, J BIOL CHEM, V266, P279; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GESNER T, 1989, BLOOD, V74, P2652; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Honjo T, 1991, Curr Biol, V1, P201, DOI 10.1016/0960-9822(91)90055-2; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MELOCHE S, 1986, J BIOL CHEM, V261, P15; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NICOLA NA, 1991, INT CONGR SER, V971, P101; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; ONETTOPOTHIER N, 1990, LEUKEMIA, V4, P329; PARK LS, 1989, BLOOD, V74, P56; PARK LS, 1989, J BIOL CHEM, V264, P5420; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RODRIGUEZCIMADEVILLA JC, 1990, BLOOD, V76, P1481; TAKETAZU F, 1991, J CELL PHYSIOL, V146, P251, DOI 10.1002/jcp.1041460209; WALKER F, 1985, EMBO J, V4, P933, DOI 10.1002/j.1460-2075.1985.tb03721.x; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	28	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11881	11887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505314				2022-12-27	WOS:A1993LF28400064
J	TAFURI, SR; FAMILARI, M; WOLFFE, AP				TAFURI, SR; FAMILARI, M; WOLFFE, AP			A MOUSE-Y BOX PROTEIN, MSY1, IS ASSOCIATED WITH PATERNAL MESSENGER-RNA IN SPERMATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OOCYTE-SPECIFIC PROTEINS; 3' UNTRANSLATED REGION; HISTONE-LIKE PROTEINS; BINDING-PROTEINS; XENOPUS OOCYTES; RIBONUCLEOPROTEIN PARTICLES; MAMMALIAN SPERMATOGENESIS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; BASIC DOMAIN	We have isolated a mouse cDNA clone, which encodes the protein MSY1 (mouse Y box protein 1), a new member of the Y box family of proteins. Northern analysis indicates that MSY1 mRNA accumulates over 100-fold more in testis than in other tissues. Moreover, MSY1 mRNA is developmentally regulated, initially appearing at the pachytene stage of spermatogenesis. This is the stage of maximal transcription and translation in the spermatocyte. In Xenopus laevis, homologous Y box proteins, FRGY1 and FRGY2, positively regulate transcription from promoters containing a Y box (CTGATTGGCCAA). In addition, the germ cell-specific Y box protein FRGY2 binds maternal mRNA within 60-80 S mRNP storage particles and in doing so regulates translation in the developing oocyte and embryo (Smith, L. D., Richter, J. D., and Taylor, M. A. (1984) in Molecular Biology of Development (Davidson, E. R., and Firtel, R. A., eds) pp. 129-141, Alan R. Liss, New York). The MSY1 protein can be isolated from a 60-80 S mRNP fraction of testis which like the frog oocyte contains stored, untranslated mRNAs. Furthermore, cross-linking experiments demonstrate that MSY1 is bound to mRNAs of this fraction. Finally, mobility shift analysis performed using the isolated protein indicates that MSY1 has nucleic acid binding properties similar to those of the FRGY proteins. These data suggest that the mouse Y box protein, MSY1, functions similarly to the FRGY2 protein in regulating the storage and translation of germ cell RNAs.			TAFURI, SR (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.			Familari, Mary/0000-0002-2275-9582				BACHVAROVA R, 1966, J EXP ZOOL, V163, P285, DOI 10.1002/jez.1401630307; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BIENZ M, 1984, EMBO J, V3, P2477, DOI 10.1002/j.1460-2075.1984.tb02159.x; BIENZ M, 1986, CELL, V46, P1037, DOI 10.1016/0092-8674(86)90703-8; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; CUMMINGS A, 1988, J CELL BIOL, V107, P45, DOI 10.1083/jcb.107.1.45; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEARSLEY AL, 1985, EUR J BIOCHEM, V150, P95, DOI 10.1111/j.1432-1033.1985.tb08993.x; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Gerhart J.C., 1980, Biological Regulation and Development, V2, P133; GOLD B, 1981, BIOCHEMISTRY-US, V20, P4871, DOI 10.1021/bi00520a011; GOLD B, 1983, J EXP ZOOL, V225, P123, DOI 10.1002/jez.1402250115; GOLDBERG E, 1977, ISOENZYMES CURRENT T, V1, P79; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HWANG I, 1990, MOL CELL BIOL, V10, P585, DOI 10.1128/MCB.10.2.585; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KIERSZENBAUM AL, 1975, J CELL BIOL, V65, P258, DOI 10.1083/jcb.65.2.258; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MEIER UT, 1992, CELL, V70, P127; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; OLIVA R, 1988, DEV BIOL, V125, P332, DOI 10.1016/0012-1606(88)90216-3; OZER J, 1990, J BIOL CHEM, V265, P22143; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SAKURA H, 1988, GENE, V73, P499; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SCHWARTZ SP, 1992, IN PRESS P NATL ACAD; SINCLAIR GD, 1982, BIOCHEMISTRY-US, V21, P1869, DOI 10.1021/bi00537a026; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SMITH LD, 1984, MOL BIOL DEV, P129; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; STERN L, 1983, EXP CELL RES, V143, P247, DOI 10.1016/0014-4827(83)90125-8; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; SUBRAMANIAN T, 1990, VIROLOGY, V176, P178, DOI 10.1016/0042-6822(90)90242-J; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1992, NEW BIOL, V4, P290; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	59	128	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12213	12220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505341				2022-12-27	WOS:A1993LF28400110
J	ZHANG, L; CASTELLINO, FJ				ZHANG, L; CASTELLINO, FJ			THE CONTRIBUTIONS OF INDIVIDUAL GAMMA-CARBOXYGLUTAMIC ACID RESIDUES IN THE CALCIUM-DEPENDENT BINDING OF RECOMBINANT HUMAN PROTEIN-C TO ACIDIC PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-X; CLOTTING FACTOR-X; CONFORMATION-SPECIFIC ANTIBODIES; FACTOR-IX; FACTOR-VA; BLOOD-COAGULATION; PROTHROMBIN FRAGMENT-1; METAL-BINDING; ACTIVATION; DOMAIN	The dependence on the integrity of the human protein C (PC) gamma-carboxyglutamic acid (Gla) domain on its Ca2+-dependent binding properties to acidic phospholipid (PL) vesicles has been examined by analysis of these interactions with recombinant(r)-PC Gla domain muteins. The concentration of Ca2+ that results in 50% saturation (C50-Ca) of PL with wild-type (wt) r-PC was not altered by more than 2-fold for the following r-variants of PC, viz. [Gla6 --> Asp]r-PC, [Gla14 --> Asp]r-PC, [Gla19 --> Asp]r-PC, [Gla25 --> Asp]r-PC, [Gl29 --> Asp] r-PC, and [Gln32 --> Gla]r-PC. The Cro-Ca was substantially higher than that of wtr-PC for [Gla7 --> Asp]r-PC (8.2 mM), [Arg15 --> Leu]r-PC (4.5 mM), [Gla16 --> Asp] r-PC (> 10 mM), [Gla20 --> Asp]r-PC (>10 mM), and [Gla26 --> Asp]r-PC (> 10 mM), indicating that the Ca2+-induced conformations of these latter variants interacted poorly with these acidic PL vesicles. Titration of the PL vesicles with wtr-PC at a constant concentration of 20 mM Ca2+ leads to calculation of a concentration of PC that results in 50% saturation of the PL (C50-PC) of 0.38 muM. Essentially this same value was determined for the r-mutants, [Gla7 --> Asp] r-PC and [Gln32 --> Gla]r-PC. An approximate 2-fold lower C50-PC was obtained for [Gla14 --> Asp]r-PC (0.14 muM), [Gla25 --> Asp]r-PC (0.16 muM), and [Gla29 --> Asp]r-PC (0.15 muM). Somewhat higher C50-PC values were found for [Gla6 --> Asp]r-PC (1.2 muM), [Arg15 --> Leu]r-PC (1.2 muM), [Gla16 --> Asp]r-PC (1.2 muM), [Gla19 --> Asp]r-PC (1.8 muM), [Gla20 --> Asp]r-PC (1.1 muM), and [Gla26 --> Asp]r-PC (1.6 muM). The results of this investigation, in conjunction with other structural and functional studies with these mutants, and the x-ray crystallographic structure of the prothrombin Gla domain-Ca2+ complex, show that Gla16 and Gla26 are the most indispensable Gla residues for maintenance of the functional Ca2+-dependent structure of the Gla domain of PC, whereas Gla14 is the least critical Gla residue in this regard. Of the non-Gla residues investigated, Arg15 is of great importance for maintenance of a functional Ca2+-dependent structure of PC, and insertion of a Gla residue at position 32, a situation that exists in the cases of some other proteins of this type, does not significantly alter these characteristics of r-PC.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA	University of Notre Dame					NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1978, J BIOL CHEM, V253, P6774; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BAJAJ SP, 1977, J BIOL CHEM, V252, P4758; BAJAJ SP, 1976, J BIOL CHEM, V251, P6294; BEALS JM, 1989, ARCH BIOCHEM BIOPHYS, V268, P485, DOI 10.1016/0003-9861(89)90316-0; BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE BC, 1976, J BIOL CHEM, V251, P3235; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; ISRAELS SJ, 1987, J PEDIATR-US, V111, P562, DOI 10.1016/S0022-3476(87)80122-1; KEYT B, 1982, J BIOL CHEM, V257, P8687; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MANN KG, 1990, BLOOD, V76, P1; MANNUCCI PM, 1982, LANCET, V2, P463; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1984, J BIOL CHEM, V259, P5698; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; SAKATA Y, 1986, BLOOD, V68, P1218; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V199, P61, DOI 10.1016/0003-9861(80)90256-8; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUGO T, 1985, J BIOL CHEM, V260, P453; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WAKABAYASHI K, 1986, J BIOL CHEM, V261, P1097; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	54	42	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12040	12045						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505327				2022-12-27	WOS:A1993LF28400087
J	ZANOTTI, G; BERNI, R; MONACO, HL				ZANOTTI, G; BERNI, R; MONACO, HL			CRYSTAL-STRUCTURE OF LIGANDED AND UNLIGANDED FORMS OF BOVINE PLASMA RETINOL-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY DATA; AMINO-ACID-SEQUENCE; VITAMIN-A TRANSPORT; MACROMOLECULAR STRUCTURES; MOLECULAR-DYNAMICS; REFINEMENT; CRYSTALLIZATION; TRANSTHYRETIN	The three-dimensional structures of bovine plasma retinol-binding protein (bRBP) complexed with retinol (space group P2(1)2(1)2(1), a = 46.08, b = 49.12, c = 76. 10 angstrom) and of the unliganded protein prepared in vitro by extracting retinol with ethyl ether (space group P2(1)2(1)2(1), a = 46.55, b = 48.97, c = 76.87 angstrom) have been solved at 1.9 and 1.7 angstrom resolution, respectively. The final crystallographic R factors are 0.190 for holobRBP and 0.196 for the unliganded bRBP. The model for the bovine holoprotein is quite similar to that of the human protein, with which it exhibits 92% sequence similarity. The root mean square deviation between the alpha-carbons in the two proteins is 0.31 angstrom. The retinol binding site is almost completely preserved. The loops that surround the opening of the beta-barrel are also particularly conserved, in contrast with the presence of several substitutions in parts of the RBP molecule opposite the opening of the calyx that binds retinol. Despite the fact that unliganded bovine RBP was prepared and crystallized using procedures completely different from those used to obtain the unliganded human RBP, the conformational differences between unliganded and liganded forms of bRBP are almost identical to those found previously between the same forms of human RBP. They mainly involve a few residues in the region extending from amino acid residues 32 to 37. Therefore, similar differences are very likely to exist between holoRBP and the physiologically occurring apoprotein. A not yet identified electron density, different in shape and orientation from retinol, also occupies the central cavity of the beta-barrel in the unliganded bRBP, as found for unliganded human RBP. The functional consequences of the conformational change induced by the removal of retinol on the interaction between RBP and transthyretin, coupled with the conservation of the entrance loops of the beta-barrel in mammalian RBPs, are consistent with their participation in molecular interactions.	CNR,BIOPOLYMER RES CTR,I-35100 PADUA,ITALY; UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY; UNIV PAVIA,CTR INTERUNIV STUDIO MACROMOLEC INFORMAZ,I-27100 PAVIA,ITALY; UNIV PAVIA,DEPT GENET & MICROBIOL,I-27100 PAVIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Parma; University of Pavia; University of Pavia	ZANOTTI, G (corresponding author), UNIV PADUA,DEPT ORGAN CHEM,VIA MARZOLO 1,I-35131 PADUA,ITALY.			Monaco, Hugo L./0000-0002-2067-0365; Berni, Rodolfo/0000-0002-1839-0479; Zanotti, Giuseppe/0000-0002-0945-6501				AQVIST J, 1986, J MOL BIOL, V192, P593, DOI 10.1016/0022-2836(86)90279-2; AQVIST J, 1992, J MOL GRAPHICS, V10, P120, DOI 10.1016/0263-7855(92)80065-L; BAVIK CO, 1991, J BIOL CHEM, V266, P14985; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BERNI R, 1992, EUR J BIOCHEM, V204, P99, DOI 10.1111/j.1432-1033.1992.tb16610.x; BERNI R, 1990, EUR J BIOCHEM, V192, P507, DOI 10.1111/j.1432-1033.1990.tb19254.x; BERNI R, 1989, COMP BIOCHEM PHYS B, V94, P79, DOI 10.1016/0305-0491(89)90014-X; BERNI R, 1993, RETINOIDS PROGR RES, P91; BLOW DM, 1959, ACTA CRYSTALLOGR, V12, P794, DOI 10.1107/S0365110X59002274; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; CRAWFORD JL, 1977, THESIS HARVARD U CAM; FEX G, 1979, EUR J BIOCHEM, V94, P307, DOI 10.1111/j.1432-1033.1979.tb12896.x; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HELLER J, 1975, J BIOL CHEM, V250, P6549; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HORWITZ J, 1974, J BIOL CHEM, V249, P7181; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KONNERT JH, 1976, ACTA CRYSTALLOGR A, V32, P614, DOI 10.1107/S0567739476001289; MOKADY S, 1974, BIOCHIM BIOPHYS ACTA, V336, P361, DOI 10.1016/0005-2795(74)90415-2; MONACO HL, 1984, J MOL BIOL, V178, P477, DOI 10.1016/0022-2836(84)90153-0; MUTO Y, 1972, J BIOL CHEM, V247, P2533; NEWCOMER ME, 1984, J BIOL CHEM, V259, P5230; Nyborg J., 1977, ROTATION METHOD CRYS, P139; OTTONELLO S, 1983, J MOL BIOL, V163, P679, DOI 10.1016/0022-2836(83)90118-3; PFLUGRATH JW, 1984, METHODS APPLICATIONS, P407; POOLE AR, 1975, J CELL SCI, V19, P379; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1974, EUR J BIOCHEM, V44, P1, DOI 10.1111/j.1432-1033.1974.tb03451.x; RAZ A, 1970, J BIOL CHEM, V245, P1903; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SHIDOJI Y, 1977, J LIPID RES, V18, P679; SIM GA, 1959, ACTA CRYSTALLOGR, V12, P813, DOI 10.1107/S0365110X59002316; STAM CH, 1972, ACTA CRYSTALL B-STRU, VB 28, P2936, DOI 10.1107/S0567740872007253; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VAHLQUIST A, 1971, EUR J BIOCHEM, V20, P160, DOI 10.1111/j.1432-1033.1971.tb01374.x; ZANOTTI G, 1993, IN PRESS J MOL BIOL; ZAPPONI MC, 1992, EUR J BIOCHEM, V210, P937, DOI 10.1111/j.1432-1033.1992.tb17498.x	45	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10728	10738						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496140				2022-12-27	WOS:A1993LD46600007
J	BUTOR, C; HIGA, HH; VARKI, A				BUTOR, C; HIGA, HH; VARKI, A			STRUCTURAL, IMMUNOLOGICAL, AND BIOSYNTHETIC-STUDIES OF A SIALIC ACID-SPECIFIC O-ACETYLESTERASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH MANNOSE OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYMES; CATHEPSIN-D; MICROSOMAL CARBOXYESTERASE-E1; GLYCOPROTEIN ESTERASE; NUCLEOTIDE-SEQUENCE; ACETYL GROUPS; HEPG2 CELLS; CARBOXYLESTERASES	We have previously described a membrane-associated intralumenal sialic acid-specific 9-O-acetylesterase (LSE) from rat liver (Higa, H. H., Manzi, A., and Varki, A. (1989) J. Biol. Chem. 264, 19435-19442). Unlike a cytosolic sialate:O-acetylesterase (CSE) with similar specificity, the LSE carries N-linked oligosaccharides. A polyclonal monospecific antibody against homogenous LSE does not cross-react with the CSE. Monoclonal antibodies distinguish between the LSE and another N-glycosylated esterase that tends to partially co-purify with it. Amino-terminal sequencing of the LSE subunits indicates that it is distinct from previously described esterases and shows no homology to any other known proteins. In contrast, the esterase that partially co-purifies is similar but not identical to previously described ''microsomal'' esterases from rat liver. The LSE is also expressed in several hepatoma cell lines. Pulse-chase studies indicate that the two LSE subunits arise from a single precursor of approximately 65 kDa which yields a core polypeptide of apparent molecular mass approximately 53 kDa upon deglycosylation with peptide:N-glycosidase F. The protein quickly becomes partly resistant to endo-beta-N-acetylglucosaminidase H but remains sensitive to peptide:N-glycosidase F, indicating N-linked oligosaccharide processing during passage through the Golgi. After several hours, the precursor undergoes proteolysis, generating the mature heterodimeric protein of approximately 58 kDa, with subunits of approximately 38 and approximately 28 kDa. A portion of newly synthesized LSE is secreted into the medium intact, indicating that the cleavage normally takes place after diversion from the secretory pathway. These temporal changes and precursor-product distribution are reminiscent of some lysosomal acid hydrolases. In fact, immunofluorescence studies and Triton WR-1339 shift experiments suggest a lysosomal localization for this enzyme. Additional evidence for this, and the role of the LSE in O-acetylated sialic acid turnover are discussed in the accompanying paper (Butor, C., Diaz, S., and Varki, A. (1993) J. Biol. Chem. 268,10197-10206).	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,0063,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BUTOR C, 1993, J BIOL CHEM, V268, P10197; DICIOCCIO RA, 1992, GLYCOCONJUGATE J, V9, P56, DOI 10.1007/BF00731178; DIMENT S, 1988, J BIOL CHEM, V263, P6901; GAUSTAD R, 1992, BIOCHEM PHARMACOL, V44, P827, DOI 10.1016/0006-2952(92)90423-G; GAUSTAD R, 1991, BIOCHEM J, V274, P693, DOI 10.1042/bj2740693; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; HASILIK A, 1980, J BIOL CHEM, V255, P4946; HIGA HH, 1989, J BIOL CHEM, V264, P19435; HIGA HH, 1987, BIOCHEM BIOPH RES CO, V144, P1099, DOI 10.1016/0006-291X(87)91425-2; HOSOKAWA M, 1990, ARCH BIOCHEM BIOPHYS, V277, P219, DOI 10.1016/0003-9861(90)90572-G; ISIDORO C, 1991, EUR J CLIN CHEM CLIN, V29, P165; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1982, CIBA F SYMP, V92, P138; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORZA G, 1988, J BIOL CHEM, V263, P3486; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGONE JL, 1983, METHOD ENZYMOL, V93, P3; LITTLE L, 1987, BIOCHEM J, V248, P151, DOI 10.1042/bj2480151; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MEDDA S, 1992, EUR J BIOCHEM, V206, P801, DOI 10.1111/j.1432-1033.1992.tb16987.x; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; OKADA S, 1988, BIOCHEM INT, V17, P375; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; OZOLS J, 1987, J BIOL CHEM, V262, P15316; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; REINHARD B, 1992, BIOL CHEM H-S, V373, P63, DOI 10.1515/bchm3.1992.373.1.63; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1992, BIOCHEM BIOPH RES CO, V183, P836, DOI 10.1016/0006-291X(92)90559-4; ROBBI M, 1988, BIOCHEM J, V254, P51, DOI 10.1042/bj2540051; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROBERTS JW, 1975, P NATL ACAD SCI USA, V72, P147, DOI 10.1073/pnas.72.1.147; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; SANDO GN, 1979, EXP CELL RES, V119, P359, DOI 10.1016/0014-4827(79)90364-1; SATOH H, 1989, P NATL ACAD SCI USA, V86, P322, DOI 10.1073/pnas.86.1.322; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; SCHAUER R, 1989, J BIOCHEM-TOKYO, V106, P143, DOI 10.1093/oxfordjournals.jbchem.a122804; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; TABAS I, 1980, J BIOL CHEM, V255, P6633; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; VANLITH HA, 1989, EUR J BIOCHEM, V184, P545; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1986, P NATL ACAD SCI USA, V83, P822; VARKI A, 1992, CELL SURFACE CARBOHY, P25; VARKI NM, 1984, CANCER RES, V44, P681; VLADUTIU GD, 1982, BIOCHEM J, V208, P559, DOI 10.1042/bj2080559; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WILLIAMS FM, 1991, BIOCHEM PHARMACOL, V41, P527, DOI 10.1016/0006-2952(91)90624-E	59	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10207	10213						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486688				2022-12-27	WOS:A1993LB80000040
J	CHAUDRY, GJ; FULTON, RJ; DRAPER, RK				CHAUDRY, GJ; FULTON, RJ; DRAPER, RK			A VARIANT OF EXOTOXIN-A THAT FORMS POTENT AND SPECIFIC CHEMICALLY CONJUGATED IMMUNOTOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; MONOCLONAL-ANTIBODIES; EXPRESSION; RICIN; TOXIN; GENE; PURIFICATION; LOCALIZATION; RECEPTOR; TOXICITY	To introduce a free sulfhydryl into Pseudomonas aeruginosa exotoxin A (ETA), methionine 161 in domain I of the toxin was changed to cysteine by site-directed mutagenesis. The free sulfhydryl provides a convenient site for covalent attachment of ETA to other proteins in the production of chimeric toxins. The mutation was then introduced into a variant of ETA that is impaired in receptor binding, termed ETA-60EF61, that has the dipeptide Glu-Phe inserted between residues 60 and 61. The resulting double mutant, ETA-60EF61Cys161, was conjugated to three different monoclonal antibodies via a thioether linkage, and the immunotoxins were tested for cytotoxicity with cells in culture. Each immunotoxin was extremely potent against cells that expressed surface determinants for the monoclonal antibodies but had little cytotoxicity for cells that did not bind the antibodies. For comparison, we also conjugated ricin A chain to each of the three monoclonal antibodies and found that the resulting immunotoxins were at least two-orders of magnitude less potent than the corresponding immunotoxins made with ETA-60EF61Cys161. This study demonstrates that ETA-60EF61Cys161 makes potent and specific immunotoxins and may potentially be useful in selectively eliminating subpopulations of cells in vitro and in vivo.	UNIV TEXAS,MOLEC & CELL BIOL PROGRAM,POB 830688,RICHARDSON,TX 75083; INLAND LABS INC,DALLAS,TX 75207	University of Texas System; University of Texas Dallas			Chaudry, Ghulam/F-9761-2011					ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BATRA JK, 1989, P NATL ACAD SCI USA, V86, P8545, DOI 10.1073/pnas.86.21.8545; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDRY GJ, 1989, J BIOL CHEM, V264, P15151; CHAUDRY GJ, 1991, THESIS U TEXAS DALLA; CHEN ST, 1987, J GEN MICROBIOL, V133, P3081; FULTON RJ, 1988, CANCER RES, V48, P2618; FULTON RJ, 1986, J BIOL CHEM, V261, P5314; GREGORY JD, 1955, J AM CHEM SOC, V77, P392; Iglewski B H, 1979, Methods Enzymol, V60, P780; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPTIN M, 1984, EUR J IMMUNOL, V14, P534, DOI 10.1002/eji.1830140610; MANIATIS T, 1982, MOL CLONING LABORATO, P113; MARNELL MH, 1984, INFECT IMMUN, V44, P145, DOI 10.1128/IAI.44.1.145-150.1984; MARSH JW, 1988, IMMUNOTOXINS, P213; MOZOLA MA, 1984, J BACTERIOL, V159, P683, DOI 10.1128/JB.159.2.683-687.1984; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; OGATA M, 1990, J BIOL CHEM, V265, P20678; OLSEN RH, 1982, J BACTERIOL, V150, P60, DOI 10.1128/JB.150.1.60-69.1982; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; THEUER CP, 1992, J BIOL CHEM, V267, P16872; THORPE PE, 1985, EUR J BIOCHEM, V147, P197, DOI 10.1111/j.1432-1033.1985.tb08737.x; TSAUR ML, 1989, J BACTERIOL, V171, P2599, DOI 10.1128/jb.171.5.2599-2604.1989; WICK MJ, 1990, MOL MICROBIOL, V4, P527, DOI 10.1111/j.1365-2958.1990.tb00620.x	29	3	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9437	9441						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486636				2022-12-27	WOS:A1993LA68900046
J	KUHM, AE; KNACKMUSS, HJ; STOLZ, A				KUHM, AE; KNACKMUSS, HJ; STOLZ, A			PURIFICATION AND PROPERTIES OF 2'-HYDROXYBENZALPYRUVATE ALDOLASE FROM A BACTERIUM THAT DEGRADES NAPHTHALENESULFONATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; 2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACID; 2-KETO-3-DEOXY-6-PHOSPHOGLUCONATE ALDOLASE; 2-KETO-4-HYDROXYGLUTARATE ALDOLASE; CHEMICAL EVIDENCE; CLASS I; DEGRADATION; 2,3-DIHYDROXYBIPHENYL	2'-Hydroxybenzalpyruvate aldolase catalyzes the cleavage of 2'-hydroxybenzalpyruvate to salicylaldehyde and pyruvate. This reaction is part of the degradative pathways for naphthalene and naphthalenesulfonates by bacteria. 2'-Hydroxybenzalpyruvate aldolase has been purified to homogeneity from a bacterium that degrades naphthalenesulfonates (strain BN6). The enzyme has a molecular weight of about 120,000 and is composed of identical subunits with a molecular weight of about 38,500. Thus the enzyme appears to exist as a trimeric oligomer. The NH2-terminal amino acid sequence did not show significant homology to other published amino acid sequences. Extensive loss of enzyme activity occurred when the enzyme was incubated with 2'-hydroxybenzalpyruvate in the presence of sodium borhydride. This suggested the intermediate formation of a stable Schiff base between enzyme and substrate. 2'-Hydroxybenzalpyruvate aldolase was inhibited by p-chloromercuribenzoate and by the reaction product salicylaldehyde. The enzyme converted 2'-hydroxybenzalpyruvate, 2',4'- and 2',6'-dihydroxybenzalpyruvate.	UNIV STUTTGART,INST MIKROBIOL,AZENBERGSTR 18,W-7000 STUTTGART 1,GERMANY	University of Stuttgart								BARNSLEY EA, 1976, BIOCHEM BIOPH RES CO, V72, P1116, DOI 10.1016/S0006-291X(76)80247-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILON C, 1981, APPL ENVIRON MICROB, V42, P44, DOI 10.1128/AEM.42.1.44-55.1981; BRILON C, 1981, APPL ENVIRON MICROB, V42, P39, DOI 10.1128/AEM.42.1.39-43.1981; CATELANI D, 1974, BIOCHEM J, V143, P431, DOI 10.1042/bj1430431; DAVIES JI, 1964, BIOCHEM J, V91, P251, DOI 10.1042/bj0910251; FRENCH CJ, 1976, PHYTOCHEMISTRY, V15, P564, DOI 10.1016/S0031-9422(00)88979-7; FRIEDMANN E, 1931, HELV CHIM ACTA, V14, P783; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; HARRIS CE, 1969, BIOCHEMISTRY-US, V8, P2442, DOI 10.1021/bi00834a029; HAUG W, 1991, APPL ENVIRON MICROB, V57, P3144, DOI 10.1128/AEM.57.11.3144-3149.1991; HILTON MD, 1990, APPL ENVIRON MICROB, V56, P623, DOI 10.1128/AEM.56.3.623-627.1990; HOFFEE PA, 1968, ARCH BIOCHEM BIOPHYS, V126, P795, DOI 10.1016/0003-9861(68)90473-6; JEFFREY AM, 1975, BIOCHEMISTRY-US, V14, P575, DOI 10.1021/bi00674a018; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; Kuhm A E, 1991, Biodegradation, V2, P115, DOI 10.1007/BF00114601; KUHM AE, 1991, J BACTERIOL, V173, P3795, DOI 10.1128/JB.173.12.3795-3802.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CY, 1975, ARCH BIOCHEM BIOPHYS, V166, P358, DOI 10.1016/0003-9861(75)90398-7; LEBHERZ HG, 1973, J BIOL CHEM, V248, P1650; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; LONDON J, 1974, J BIOL CHEM, V249, P7977; MALEK AA, 1988, ARCH BIOCHEM BIOPHYS, V266, P10, DOI 10.1016/0003-9861(88)90232-9; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NORTEMANN B, 1986, APPL ENVIRON MICROB, V52, P1195; OHE T, 1990, AGR BIOL CHEM TOKYO, V54, P669, DOI 10.1080/00021369.1990.10870006; OHE T, 1986, AGR BIOL CHEM TOKYO, V50, P1419, DOI 10.1080/00021369.1986.10867607; OHE T, 1988, AGR BIOL CHEM TOKYO, V52, P2409, DOI 10.1080/00021369.1988.10869059; OMORI T, 1988, APPL MICROBIOL BIOT, V29, P497, DOI 10.1007/BF00269075; OMORI T, 1986, AGR BIOL CHEM TOKYO, V50, P931, DOI 10.1080/00021369.1986.10867489; PATEL TR, 1974, J BACTERIOL, V119, P879, DOI 10.1128/JB.119.3.879-888.1974; ROBERTSON DC, 1971, J BIOL CHEM, V246, P2075; RUTTER WJ, 1964, FED PROC, V23, P1248; SARIASLANI FS, 1974, BIOCHEM J, V140, P31, DOI 10.1042/bj1400031; STOLZ A, 1992, BIOCHEM J, V282, P675, DOI 10.1042/bj2820675; SUZUKI N, 1980, J BIOL CHEM, V255, P3427; TOLAN DR, 1984, J BIOL CHEM, V259, P1127; TOMS A, 1970, BIOCHEMISTRY-US, V9, P337, DOI 10.1021/bi00804a021; VALENTINHANSEN P, 1982, EUR J BIOCHEM, V125, P561, DOI 10.1111/j.1432-1033.1982.tb06719.x; VANDLEN RL, 1973, J BIOL CHEM, V248, P2251; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; VLAHOS CJ, 1988, J BIOL CHEM, V263, P11683; WANG JK, 1981, J BIOL CHEM, V256, P1793; WITTICH RM, 1988, APPL ENVIRON MICROB, V54, P1842, DOI 10.1128/AEM.54.7.1842-1847.1988; WOOD WA, 1977, TRENDS BIOCHEM SCI, P223; YEN KM, 1988, CRIT REV MICROBIOL, V15, P247, DOI 10.3109/10408418809104459; ZURRER D, 1987, APPL ENVIRON MICROB, V53, P1459	47	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9484	9489						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486638				2022-12-27	WOS:A1993LA68900052
J	MIN, KC; ZVYAGA, TA; CYPESS, AM; SAKMAR, TP				MIN, KC; ZVYAGA, TA; CYPESS, AM; SAKMAR, TP			CHARACTERIZATION OF MUTANT RHODOPSINS RESPONSIBLE FOR AUTOSOMAL-DOMINANT RETINITIS-PIGMENTOSA - MUTATIONS ON THE CYTOPLASMIC SURFACE AFFECT TRANSDUCIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; GENE; SEQUENCE; HETEROGENEITY; CELLS	Rhodopsin mutants responsible for autosomal dominant retinitis pigmentosa (ADRP) were prepared by site-directed mutagenesis and characterized. The aim was to evaluate ADRP mutations that occur at three locations on the cytoplasmic surface of rhodopsin: Thr-58 near the cytoplasmic border of helix A, the tetrapeptide Leu-68 to Pro-71 in the first cytoplasmic loop, and Arg-135 at the cytoplasmic border of helix C. It was hypothesized that amino acid changes at these sites would result in mutant rhodopsins with normal spectral properties but defects in their ability to interact with the rod outer segment G protein, transducin. A set of 12 mutant opsin genes was prepared. Four of the mutants were known to cause ADRP: Thr-58 replaced by Arg, a four-amino acid deletion (Leu-68/Arg-69/Thr-70/Pro-71), Arg-135 replaced by Leu, and Arg-135 replaced by Trp. Eight additional mutants were prepared to provide complementary structure-function information. The four-amino acid deletion mutant failed to bind 11-cis-retinal. However, each of the Thr-58 and Arg- 135 mutants bound 11-cis-retinal to form a pigment with a visible absorbance maximum (lambda(max)) of 500 nm. Upon illumination, each pigment was converted to a metarhodopsin II-like spectral form (lambda(max) = 380 nm). However, each of these spectrally normal ADRP mutants was defective in activating guanine nucleotide exchange by transducin. These results identify a defect in the signal transduction pathway in spectrally normal mutant rhodopsins that cause ADRP.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,BOX 284,1230 YORK AVE,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-T32-GM-07739] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALUAIDI MR, 1990, JJ BIOL CHEM, V265, P20563; COWMAN AF, 1986, CELL, V44, P705, DOI 10.1016/0092-8674(86)90836-6; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; FARRAR GJ, 1990, GENOMICS, V8, P35; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FONG SL, 1992, NUCLEIC ACIDS RES, V20, P2865, DOI 10.1093/nar/20.11.2865; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GAL A, 1991, GENOMICS, V11, P468, DOI 10.1016/0888-7543(91)90159-C; HONG K, 1972, P NATL ACAD SCI USA, V69, P2617, DOI 10.1073/pnas.69.9.2617; HONIG B, 1989, P NATL ACAD SCI USA, V86, P6878; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; INGLEHEARN CF, 1991, AM J HUM GENET, V48, P26; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; MONTELL C, 1987, J NEUROSCI, V7, P1558; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1988, FEBS LETT, V232, P69, DOI 10.1016/0014-5793(88)80388-0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; YOKOYAMA R, 1990, VISION RES, V30, P807, DOI 10.1016/0042-6989(90)90049-Q; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZVYAGA TA, 1993, J BIOL CHEM, V268, P4661	40	114	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9400	9404						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486634				2022-12-27	WOS:A1993LA68900040
J	MYERS, M; FORGAC, M				MYERS, M; FORGAC, M			THE COATED VESICLE VACUOLAR (H+)-ATPASE ASSOCIATES WITH AND IS PHOSPHORYLATED BY THE 50-KDA POLYPEPTIDE OF THE CLATHRIN ASSEMBLY PROTEIN AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE; PROTON PUMP; TRANSLOCATING ATPASE; SUBUNIT COMPOSITION; H+-ATPASE; PURIFICATION; TRIPHOSPHATASE; RECONSTITUTION; TOPOGRAPHY; SEQUENCE	We have previously noted a 50-kDa polypeptide (p50) co-purifying with preparations of the bovine brain clathrin-coated vesicle vacuolar (H+)-ATPase (V-ATPase) (Zhang, J., Myers, M., and Forgac, M. (1992) J. Biol. Chem. 267,9773-9778). We show that p50 is also immunoprecipitated with the V-ATPase, further suggesting its specific association with the proton pump. To determine the identity of this 50-kDa polypeptide and the stoichiometry of its association with the V-ATPase, we performed N-terminal amino acid sequencing and quantitative amino acid analysis of the gel-purified protein. These results revealed the unknown polypeptide to be the 50-kDa subunit of the clathrin assembly protein AP-2 (AP50); we estimate the stoichiometry of association is one AP50 per V-ATPase complex. AP50 is an N-ethylmaleimide (NEM)-inhibitable autokinase and incubation of purified V-ATPase with [gamma-P-32]ATP resulted in the NEM-sensitive phosphorylation of AP50 and the B subunit of the V-ATPase. The same phosphorylation pattern is seen if the labeling reaction is done with intact clathrin-coated vesicles and the V-ATPase subsequently immunoprecipitated from the solubilized vesicles. This represents the first report of phosphorylation of one of the V-ATPase subunits. The functional significance of this phosphorylation for regulation or targeting of the V-ATPase in vivo remains to be determined.	TUFTS UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02111	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07542] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; APPS DK, 1989, BIOCHEM J, V263, P81, DOI 10.1042/bj2630081; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BECK KA, 1991, J BIOL CHEM, V266, P4442; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; KANE PM, 1989, J BIOL CHEM, V264, P19236; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J BIOL CHEM, V262, P3864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, NEWS PHYSIOL SCI, V8, P24; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OAKEY BR, 1980, ANAL BIOCHEM, V105, P361; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PAULOIN A, 1982, NATURE, V298, P574, DOI 10.1038/298574a0; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; PUOLPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590	34	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9184	9186						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486617				2022-12-27	WOS:A1993LA68900008
J	LEE, DH; MITTAG, M; SCZEKAN, S; MORSE, D; HASTINGS, JW				LEE, DH; MITTAG, M; SCZEKAN, S; MORSE, D; HASTINGS, JW			MOLECULAR-CLONING AND GENOMIC ORGANIZATION OF A GENE FOR LUCIFERIN-BINDING PROTEIN FROM THE DINOFLAGELLATE GONYAULAX-POLYEDRA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL CONTROL; MESSENGER-RNA; SEQUENCES; BIOLUMINESCENCE; COHNII; CLOCK; DNA	The circadian expressed luciferin-binding protein (LBP) gene from the marine bioluminescent alga Gonyaulax polyedra represents the first dinoflagellate gene that has been cloned and sequenced at both cDNA and genomic levels. Starting with a fragment from the 3'-end of the LBP cDNA that was found by immuno-screening of a cDNA library, genomic clones were obtained by the inverse polymerase chain reaction technique. Full-length cDNA clones were selected by screening a cDNA library by plaque hybridizations and by polymerase chain reaction amplifications. The LBP sequence has a 2004-nucleotide open reading frame coding for a protein of 668 amino acids (approximately 75 kDa). The reading frame and identity of the clone were confirmed by the sequence of an octapeptide obtained from a purified fragment of CNBr-treated LBP. A variant LBP cDNA was found to differ in sequence by approximately 11% at the DNA level. The untranslated regions of the mRNA are 111 nucleotides (5'-untranslated region) and 158 nucleotides (3'-untranslated region) long, respectively. The LBP gene contains no introns and exhibits certain features not typical for a eukaryotic gene. Its promoter does not include the typical TATA box within approximately 50 nucleotides upstream of the transcription start site, and the usual poly(A+) signal (AAUAAA) is not present on the end of the LBP mRNA. The copy number of the gene is very high (approximately 1000 copies/cell). However, the universal genetic code and conserved positions relevant for the translational apparatus are maintained.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [GM-19536] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; DUNLAP JC, 1981, J BIOL CHEM, V256, P509; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Eckert K A, 1991, PCR Methods Appl, V1, P17; Edmunds LN, 1988, CELLULAR MOL BASES B; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; HAAPALA OK, 1974, HEREDITAS, V76, P83; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; HIMES M, 1975, P NATL ACAD SCI USA, V72, P4546, DOI 10.1073/pnas.72.11.4546; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOFFMAN K, 1981, HDB BEHAVIORAL NEURO, V2, P449; HOLMHANSEN O, 1969, SCIENCE, V163, P87, DOI 10.1126/science.163.3862.87; JOHNSON CH, 1986, AM SCI, V74, P29; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEWIN B, 1990, GENES, V4, P545; LUMSDEN PJ, 1991, ANNU REV PLANT PHYS, V42, P351, DOI 10.1146/annurev.pp.42.060191.002031; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYFIELD SP, 1989, PLANT MOL BIOL, V12, P683, DOI 10.1007/BF00044159; MORSE D, 1989, P NATL ACAD SCI USA, V86, P172, DOI 10.1073/pnas.86.1.172; MORSE D, 1989, J BIOL CHEM, V264, P11822; MORSE DS, 1990, TRENDS BIOCHEM SCI, V15, P262, DOI 10.1016/0968-0004(90)90050-L; NAKAMURA H, 1989, J AM CHEM SOC, V111, P7607, DOI 10.1021/ja00201a050; RAE PMM, 1976, SCIENCE, V194, P1062, DOI 10.1126/science.988637; RIZZO PJ, 1991, J PROTOZOOL, V38, P246, DOI 10.1111/j.1550-7408.1991.tb04437.x; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; SALAROVIRA M, 1991, CHROMOSOMA, V100, P510, DOI 10.1007/BF00352201; Sambrook J, 1989, MOL CLONING LABORATO; SILFLOW CD, 1985, MOL CELL BIOL, V5, P2389, DOI 10.1128/MCB.5.9.2389; SLIGHTOM JL, 1908, PLANT MOL BIOL A, V6, P1; Spector D.L., 1984, P107; STEELE RE, 1982, THESIS YALE U; Taylor F.J.R., 1987, BIOL DINOFLAGELLATES; TAYLOR FJR, 1980, BIOSYSTEMS, V13, P65, DOI 10.1016/0303-2647(80)90006-4; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	35	95	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8842	8850						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473328				2022-12-27	WOS:A1993KX81100069
J	OLEYKOWSKI, CA; MAYERNIK, JA; LIM, SE; GROOPMAN, JD; GROSSMAN, L; WOGAN, GN; YEUNG, AT				OLEYKOWSKI, CA; MAYERNIK, JA; LIM, SE; GROOPMAN, JD; GROSSMAN, L; WOGAN, GN; YEUNG, AT			REPAIR OF AFLATOXIN-B1 DNA ADDUCTS BY THE UVRABC ENDONUCLEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; RAT-LIVER; BIFUNCTIONAL INTERCALATOR; ACTIVATED AFLATOXIN-B1; EXCISION NUCLEASE; GLYCOSYLASE; INCISION; GUANINE; CELLS; BINDING	The repair by UvrABC endonuclease of two major adducts formed by aflatoxin B1 in DNA was found to be similar. Aflatoxin epoxide was used to generate the aflatoxin B1.N7-guanine adduct which can convert to aflatoxin B1-formamidopyrimidine adduct. The reaction of the aflatoxin B1 epoxide with DNA follows pseudo-first order kinetics. The DNA sequence-specific relative reactivity of the epoxide is the same as previously observed for afltoxin B1 activated by liver microsomes, therefore strongly reinforcing the notion that aflatoxin B1 reacts with DNA through the epoxide intermediate. For the majority of lesion sites, a high affinity protein-DNA complex was formed from the UvrA and the UvrB proteins with similar efficiency to both adducts, and to pyrimidine dimers, and then nicks the DNA when UvrC was added. The two incisions are at the eighth phosphodiester moiety 5' and the sixth phosphodiester moiety 3' of a modified guanine nucleotide. Both incisions appeared to be concerted. For some sites, the DNA sequence can alter the relative incision efficiency up to 15-fold. However, the majority of these AFB1 lesion structures in most DNA sequences are similar with respect to recognition by this nucleotide excision repair enzyme. Therefore the observation that the aflatoxin B1.N7-guanine lesion is removed rapidly, while the aflatoxin B1-formamidopyrimidine lesion persists in the mammalian cell may have other mechanistic explanations.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD	Fox Chase Cancer Center; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Johns Hopkins University			/X-4205-2019	/0000-0003-4690-2133	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000597] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline; NIEHS NIH HHS [P01ES00597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAZARD R, 1982, MUTAT RES, V93, P327, DOI 10.1016/0027-5107(82)90148-8; BAERTSCHI SW, 1989, CHEM RES TOXICOL, V2, P114, DOI 10.1021/tx00008a008; BAERTSCHI SW, 1988, J AM CHEM SOC, V110, P7929, DOI 10.1021/ja00231a083; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BENASUTTI M, 1988, BIOCHEMISTRY-US, V27, P472, DOI 10.1021/bi00401a068; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BUSBY WF, 1984, CHEM CARCINOGENS, P945; Bushby WF, 1979, FOOD BORNE INFECTION, P519; CAMPBELL TC, 1976, TOXICOL APPL PHARM, V35, P199, DOI 10.1016/0041-008X(76)90282-9; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CROY RG, 1981, CANCER RES, V41, P197; CROY RG, 1978, P NATL ACAD SCI USA, V75, P1745, DOI 10.1073/pnas.75.4.1745; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P4120, DOI 10.1073/pnas.75.9.4120; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1870, DOI 10.1073/pnas.74.5.1870; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; GOPALAKRISHNAN S, 1989, BIOCHEMISTRY-US, V28, P726, DOI 10.1021/bi00428a047; GROOPMAN JD, 1981, CARCINOGENESIS, V2, P1371, DOI 10.1093/carcin/2.12.1371; GROOPMAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P5445, DOI 10.1073/pnas.78.9.5445; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; HERTZOG PJ, 1982, CARCINOGENESIS, V3, P723, DOI 10.1093/carcin/3.6.723; HOWARDFLANDERS P, 1966, GENETICS, V53, P1119; JOHNSRUD L, 1978, P NATL ACAD SCI USA, V75, P5314, DOI 10.1073/pnas.75.11.5314; JONES BK, 1990, J BIOL CHEM, V265, P3489; LAMBERT B, 1989, P NATL ACAD SCI USA, V86, P6557, DOI 10.1073/pnas.86.17.6557; LAMBERT B, 1988, NUCLEIC ACIDS RES, V16, P1063, DOI 10.1093/nar/16.3.1063; LEADON SA, 1983, NUCLEIC ACIDS RES, V11, P5675, DOI 10.1093/nar/11.16.5675; LIN JK, 1977, CANCER RES, V37, P4430; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MARGISON GP, 1981, P NATL ACAD SCI-BIOL, V78, P861, DOI 10.1073/pnas.78.2.861; MARTIN CN, 1977, NATURE, V267, P863, DOI 10.1038/267863a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MUNN MM, 1991, J BIOL CHEM, V266, P24748; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OTSUJI N, 1972, J BACTERIOL, V109, P475, DOI 10.1128/JB.109.2.475-483.1972; PU WT, 1989, J BIOL CHEM, V264, P20697; Rogers S G, 1980, Methods Enzymol, V65, P201; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SANCAR A, 1985, J MOL BIOL, V184, P725, DOI 10.1016/0022-2836(85)90316-X; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SARASIN A, 1977, MUTAT RES, V42, P205, DOI 10.1016/S0027-5107(77)80024-9; SARASIN AR, 1977, CANCER RES, V37, P1786; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; SWENSON DH, 1977, CANCER RES, V37, P172; TANG MS, 1989, J BIOL CHEM, V264, P14455; TANG MS, 1982, NATURE, V299, P646, DOI 10.1038/299646a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALTER RB, 1988, J MOL BIOL, V203, P939, DOI 10.1016/0022-2836(88)90119-2; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1987, NUCLEIC ACIDS RES, V15, P4957, DOI 10.1093/nar/15.12.4957; YEUNG AT, 1988, NUCLEIC ACIDS RES, V16, P4539, DOI 10.1093/nar/16.10.4539; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	60	32	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7990	8002						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463319				2022-12-27	WOS:A1993KW97900062
J	BOURRET, RB; DRAKE, SK; CHERVITZ, SA; SIMON, MI; FALKE, JJ				BOURRET, RB; DRAKE, SK; CHERVITZ, SA; SIMON, MI; FALKE, JJ			ACTIVATION OF THE PHOSPHOSIGNALING PROTEIN CHEY .2. ANALYSIS OF ACTIVATED MUTANTS BY F-19 NMR AND PROTEIN ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; RESPONSE REGULATOR; CRYSTAL-STRUCTURE; SALMONELLA-TYPHIMURIUM; CONSERVED ASPARTATE; PHOSPHORYLATION; RESOLUTION; GENE	The Escherichia coli CheY protein is activated by phosphorylation, and in turn alters flagellar rotation. To investigate the molecular mechanism of activation, an extensive collection of mutant CheY proteins was analyzed by behavioral assays, in vitro phosphorylation, and F-19 NMR chemical shift measurements. Substitution of a positively charged residue (Arg or Lys) in place of Asp13 in the CheY activation site results in activation, even for mutants which cannot be phosphorylated. Thus phosphorylation plays an indirect role in the activation mechanism. Lys109, a residue proposed to act as a conformational ''switch'' in the activation site, is required for activation of CheY by either phosphorylation or mutation. The F-19 NMR chemical shift assay described in the preceding article (Drake, S. K., Bourret, R. B., Luck, L. A., Simon, M. I., and Falke, J. J. (1993) J. Biol Chem. 268, 13081-13088) was again used to monitor six phenylalanine positions in CheY, including one position which probed the vicinity of Lys109. Mutations which activate CheY were observed to perturb the Lys109 probe, providing further evidence that Lys109 is directly involved in the activating conformational change. Two striking contrasts were observed between activation by mutation and phosphorylation. (i) Each activating mutation generates a relatively localized perturbation in the activation site region, whereas phosphorylation triggers a global structural change. (ii) The perturbation of the Lys109 region observed for activating mutations is not detected in the phosphorylated protein. These results are consistent with a two-step model of activated CheY docking to the flagellar switch.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Colorado System; University of Colorado Boulder; California Institute of Technology			Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220	NIAID NIH HHS [R01 AI019296, AI07798, AI19296] Funding Source: Medline; NIGMS NIH HHS [GM40731, R01 GM040731-12, R01 GM040731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRAY D, 1993, IN PRESS MOL BIOL CE; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DEFRANCO AL, 1979, J BACTERIOL, V139, P107, DOI 10.1128/JB.139.1.107-114.1979; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1991, METHOD ENZYMOL, V200, P188; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2817, DOI 10.1021/bi00225a012; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCCLEARY WR, 1990, J BACTERIOL, V172, P4877, DOI 10.1128/jb.172.9.4877-4887.1990; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; RUSSELL CB, 1989, J BACTERIOL, V171, P2614, DOI 10.1128/jb.171.5.2614-2618.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1992, J BIOL CHEM, V267, P19753; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; VOLZ K, 1991, J BIOL CHEM, V266, P15511	36	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13089	13096						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514750				2022-12-27	WOS:A1993LH55300015
J	RUSH, JS; SHELLING, JG; ZINGG, NS; RAY, PH; WAECHTER, CJ				RUSH, JS; SHELLING, JG; ZINGG, NS; RAY, PH; WAECHTER, CJ			MANNOSYLPHOSPHORYLDOLICHOL-MEDIATED REACTIONS IN OLIGOSACCHARIDE-P-P-DOLICHOL BIOSYNTHESIS - RECOGNITION OF THE SATURATED ALPHA-ISOPRENE UNIT OF THE MANNOSYL DONOR BY PIG BRAIN MANNOSYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; LINKED OLIGOSACCHARIDES; CALF BRAIN; GLYCOSYLATION; PHOSPHATE; PROTEIN; MUTANT; YEAST; SYNTHASE	The specificity of Man-P-Dol:Man5-8GlcNAC2-P-P-Dol (Oligo-P-P-Dol) mannosyltransferase activity in pig brain was investigated by comparing a variety of mannosylphosphorylisoprenols as mannosyl donors. For this comparison the beta-Man-P-isoprenols were synthesized using a partially purified preparation of mannosylphosphorylundecaprenol (Man-P-Undec) synthase from Micrococcus luteus. The bacterial mannosyltransferase efficiently catalyzed the transfer of mannose from GDP-[H-3]Man to a series of defined isoprenyl monophosphate substrates. Two alpha-Man-P-dolichols were synthesized chemically and also examined as substrates. When exogenous beta-[H-3]Man-P-Dol95, was tested as a substrate for Man-P-Dol:Oligo-P-P-Dol mannosyltransferase activity in pig brain microsomes, [H-3]mannose was actively transferred to endogenous Oligo-P-P-Dol acceptors. The major enzymatically labeled product was Man9GlcNAC2-P-P-Dol. Under identical conditions beta-[H-3]mannosylphosphorylpolyprenol (Man-P-Poly95) was an extremely poor substrate, indicating that the saturated alpha-isoprene unit of the dolichyl moiety is critical for recognition of the lipophilic mannosyl donor by the endoplasmic reticulum-associated mannosyltransferase(s). When Man-P-dolichols containing 2, 11, or 19 isoprene units were compared, the initial rates for the mannosyl transfer reactions and the affinity of the enzyme(s) for the mannophospholipid substrate increased with the length and hydrophobicity of the polyisoprenol chain. The anomeric configuration of the mannosyl moiety is apparently essential because the brain mannosyltransferases exhibited a strong preference for beta-Man-P-dolichols over the corresponding chemically synthesized alpha-stereoisomers. These results: 1) describe a simple two-step procedure for obtaining a partially purified preparation of Man-P-Undec synthase that efficiently synthesizes a variety of beta-Man-P-isoprenols; 2) indicate that pig brain Man-P-Dol:Oligo-P-P-Dol mannosyltransferase activity is relatively specific for lipophilic mannosyl donors containing 19 isoprene units with a beta-Man 1-P group attached to the saturated alpha-isoprene unit of dolichol; and 3) emphasize the importance of the reduction of the alpha-isoprene unit in the biosynthesis and function of Dol-P in mammalian cells.	UNIV KENTUCKY, COLL MED, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; BURROUGHS WELLCOME CO, DIV MOLEC GENET & MICROBIOL, RES TRIANGLE PK, NC 27709 USA	University of Kentucky; Burroughs Wellcome Fund					NIGMS NIH HHS [GM 36065] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036065] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERENDES R, 1992, BIOL CHEM H-S, V373, P35, DOI 10.1515/bchm3.1992.373.1.35; BRAELL WA, 1976, ANAL BIOCHEM, V74, P484, DOI 10.1016/0003-2697(76)90229-3; CRANE FL, 1977, ANNU REV BIOCHEM, V46, P439, DOI 10.1146/annurev.bi.46.070177.002255; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; D'Souza-Schorey Crislyn, 1992, Glycobiology, V2, P476; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; DITTMER JC, 1964, J LIPID RES, V5, P126; DUNPHY PJ, 1967, BIOCHIM BIOPHYS ACTA, V136, P136, DOI 10.1016/0304-4165(67)90329-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLASER L, 1966, METHOD ENZYMOL, V8, P183; HARFORD JB, 1979, J NEUROCHEM, V32, P1707; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; JANKOWSKI WJ, 1989, CHEM PHYS LIPIDS, V51, P249, DOI 10.1016/0009-3084(89)90012-1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LENNARZ WJ, 1966, J BIOL CHEM, V241, P2707; MANKOWSKI T, 1977, ARCH BIOCHEM BIOPHYS, V181, P393; MCLACHLAN KR, 1992, GLYCOBIOLOGY, V2, P313, DOI 10.1093/glycob/2.4.313; OCONNOR JV, 1979, BIOCHEMISTRY-US, V18, P500, DOI 10.1021/bi00570a020; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PARODI AJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P1, DOI 10.1016/0304-4157(79)90006-6; PREISS J, 1966, METHOD ENZYMOL, V3, P271; PRESPER KA, 1983, ENZYMES, V16, P449; REARICK JI, 1981, J BIOL CHEM, V256, P3762; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; Rush Jeffrey S., 1992, Glycobiology, V2, P483; RUSH JS, 1992, ANAL BIOCHEM, V206, P328, DOI 10.1016/0003-2697(92)90374-G; SCHER M, 1969, J BIOL CHEM, V244, P2777; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; STOLL J, 1988, J BIOL CHEM, V263, P10766; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; STOLL J, 1988, J BIOL CHEM, V263, P10774; SUMBILLA C, 1985, METHOD ENZYMOL, V111, P471; SZKOPINSKA A, 1992, INT J BIOCHEM, V7, P1151; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; WAECHTER CJ, 1976, ARCH BIOCHEM BIOPHYS, V174, P726, DOI 10.1016/0003-9861(76)90403-3; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WAECHTER CJ, 1989, NEUROBIOLOGY GLYCOCO, P127; WAECHTER CJ, 1981, RES METHODS NEUROCHE, V5, P201; Warren C D, 1978, Methods Enzymol, V50, P122; WARREN CD, 1973, BIOCHEMISTRY-US, V12, P5038, DOI 10.1021/bi00749a002; WEDGWOOD JF, 1974, J BIOL CHEM, V249, P6316	47	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13110	13117						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514752				2022-12-27	WOS:A1993LH55300018
J	TANAKA, M; JINGAMI, H; OTANI, H; CHO, M; UEDA, Y; ARAI, H; NAGANO, Y; DOI, T; YOKODE, M; KITA, T				TANAKA, M; JINGAMI, H; OTANI, H; CHO, M; UEDA, Y; ARAI, H; NAGANO, Y; DOI, T; YOKODE, M; KITA, T			REGULATION OF APOLIPOPROTEIN-B PRODUCTION AND SECRETION IN RESPONSE TO THE CHANGE OF INTRACELLULAR CHOLESTERYL ESTER CONTENTS IN RABBIT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; RAT HEPATOCYTES; WHHL RABBITS; HEPG2 CELLS; INSULIN; ACID; MACROPHAGES; TURNOVER; RECEPTOR	In the present study, we investigated the mechanisms that regulate apolipoprotein B-100 (apoB) secretion in response to the change of intracellular cholesteryl ester contents by adding low density lipoprotein (LDL) and an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (pravastatin) in rabbit hepatocyte culture system. LDL caused a significant dose-dependent increase in apoB secretion. On the other hand, the addition of pravastatin decreased apoB secretion significantly. LDL caused a dose-dependent increase in cellular cholesteryl ester, while cellular cholesteryl ester was decreased by pravastatin significantly. Therefore, these results indicate that the change of apoB secretion was in parallel with the change of cellular cholesteryl ester contents. Cellular contents of free cholesterol, triglyceride, and phospholipid did not change. To investigate intracellular degradation of apoB prior to secretion, pulse-chase experiments were performed. It was shown that the addition of pravastatin accelerated intracellular degradation of apoB, while LDL slowed the apoB intracellular degradation rate. We also investigated whether the change of cellular cholesteryl ester could affect the apoB mRNA level. Northern blot analysis and solution hybridization RNase protection assay demonstrated that neither LDL nor pravastatin caused a significant change in cellular apoB mRNA level. We conclude that intracellular cholesteryl ester contents play a critical role in apoB secretion, and the intracellular apoB degradation rate could be the main mechanism that regulates apoB secretion in response to the change of intracellular cholesteryl ester level.	KYOTO UNIV,FAC MED,DEPT INTERNAL MED,DIV 2,KYOTO 606,JAPAN	Kyoto University	TANAKA, M (corresponding author), KYOTO UNIV,FAC MED,DEPT GERIATR MED,54 SHOGOIN KAWAHARA HO,SAKYO KU,KYOTO 606,JAPAN.							ARAD Y, 1990, J LIPID RES, V31, P567; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16398; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; GINSBERG HN, 1987, J CLIN INVEST, V80, P1692, DOI 10.1172/JCI113259; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P5693, DOI 10.1073/pnas.79.18.5693; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW A, 1990, J LIPID RES, V31, P1109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAGANO Y, 1992, ATHEROSCLEROSIS, V92, P131, DOI 10.1016/0021-9150(92)90272-I; OBRIEN K, 1991, ARTERIOSCLER THROMB, V11, P751, DOI 10.1161/01.ATV.11.3.751; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Sambrook J, 1989, MOL CLONING LABORATO; SATO R, 1990, J BIOL CHEM, V265, P11880; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; YOKODE M, 1988, J CLIN INVEST, V81, P720, DOI 10.1172/JCI113377; 1985, JAMA-J AM MED ASSOC, V253, P2080	31	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12713	12718						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509406				2022-12-27	WOS:A1993LG65800072
J	WOLFE, BL; RICH, CB; GOUD, HD; TERPSTRA, AJ; BASHIR, M; ROSENBLOOM, J; SONENSHEIN, GE; FOSTER, JA				WOLFE, BL; RICH, CB; GOUD, HD; TERPSTRA, AJ; BASHIR, M; ROSENBLOOM, J; SONENSHEIN, GE; FOSTER, JA			INSULIN-LIKE GROWTH FACTOR-I REGULATES TRANSCRIPTION OF THE ELASTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; 5'-FLANKING REGION; MESSENGER-RNA; FUNCTIONAL PROMOTER; RIBONUCLEIC-ACID; SOMATOMEDIN-C; CIS-ELEMENTS; FACTOR-BETA; EXPRESSION; DNA	Neonatal rat aortic smooth muscle cell cultures were used to investigate the mechanisms by which insulin-like growth factor-I (IGF-I) up-regulates aortic elastogenesis. The addition of IGF-I (50 ng/ml) to quiescent smooth muscle cell cultures resulted in a 5-fold increase in the steady-state levels of tropoelastin mRNA beginning between 2 and 4 h and reaching maximal levels at 8 h. Addition of cycloheximide blocked the effect of IGF-I. Nuclear run-on transcription analyses of nuclei isolated from IGF-I-treated cells showed increased synthesis of new tropoelastin transcripts indicating that transcriptional activation is a major component of IGF-I up-regulation. Transient transfections with deletion constructs containing different portions of the elastin 5'-upstream region localized the IGF-I-responsive area to sequences between -195 and -136 base pairs and further showed that this region contains a negative element. Gel retardation assays using nuclear proteins extracted from control and IGF-I-treated cells demonstrated that IGF-I treatment results in the loss of binding complexes. Footprint analyses of specific binding complexes affected by IGF-I show the deprotection of two closely positioned sequences spanning positions -165 to -137 base pairs. These results suggest that IGF-I up-regulation of elastogenesis involves the abrogation of a negative element functionality.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118; UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104	Boston University; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030061, P01HL046902, R01HL046100] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46902, HL 30061, HL 46100] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; BADESCH DB, 1989, BIOCHEM BIOPH RES CO, V160, P382, DOI 10.1016/0006-291X(89)91667-7; BARONE LM, 1988, BIOCHEMISTRY-US, V27, P3175, DOI 10.1021/bi00409a008; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BERK JL, 1991, J BIOL CHEM, V266, P3192; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMMONS DR, 1989, BRIT MED BULL, V45, P465, DOI 10.1093/oxfordjournals.bmb.a072335; DAVIDSON JM, 1986, BIOL EXTRACELLULAR M, V1, P177; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; FOSTER J, 1987, COLLAGEN REL RES, V7, P161; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1990, AM J PHYSIOL, V259, pL13, DOI 10.1152/ajplung.1990.259.2.L13; FOSTER JA, 1989, MATRIX, V9, P328, DOI 10.1016/S0934-8832(89)80009-5; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; FOSTER JA, 1990, J GERONTOL, V13, P113; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; ICHIRO T, 1990, BIOCHEM BIOPH RES CO, V168, P850, DOI 10.1016/0006-291X(90)92399-K; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; LU L, 1989, MOL CELL BIOL, V9, P3411; NARGIS N, 1990, P NATL ACAD SCI USA, V87, P5223; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; RICH CB, 1992, AM J PHYSIOL, V263, pL276, DOI 10.1152/ajplung.1992.263.2.L276; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; VELDHUIS JD, 1986, J BIOL CHEM, V261, P2499; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003; ZUMSTEIN P, 1987, J BIOL CHEM, V262, P11252	43	110	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12418	12426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509381				2022-12-27	WOS:A1993LG65800032
J	BURROUGHS, MH; CHANG, YS; GAGE, DA; TUOMANEN, EI				BURROUGHS, MH; CHANG, YS; GAGE, DA; TUOMANEN, EI			COMPOSITION OF THE PEPTIDOGLYCAN OF HAEMOPHILUS-INFLUENZAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIQUID-CHROMATOGRAPHY; HEMOPHILUS-INFLUENZAE; ESCHERICHIA-COLI; RESISTANCE	The composition of the peptidoglycan of Haemophilus influenzae was determined by analyzing glycopeptides generated by M1 muramidase hydrolysis using high pressure liquid chromatography, fast atom bombardment mass spectrometry, and fast atom bombardment collisionally activated dissociation tandem mass spectrometry, and amino acid analysis. The structures of 17 glycopeptides, representing 96% of the total peptidoglycan, were ascertained. Fifteen glycopeptides resembled species described for Escherichia coli peptidoglycan (Glauner, B., and Schwarz, U. (1983) The Target of Penicillin (Hackenbeck, R., ed), Walter de Gruyter, Berlin pp. 29-34) as compared with 9 in common with Bordetella pertussis (Tuomanen, E., Schwartz, J., Sande, S., Light, K., and Gage, D. (1989) J. Biol. Chem. 264, 11093-11098). Substitutions for L-alanine in the fourth position of the stem peptide included glycine, aspartic acid, and serine. The peptidoglycan was 27% cross-linked, 2% of which formed between diaminopimelic acid residues. No species was identified containing lysyl-arginine residues characteristic of lipoprotein. The peptidoglycan of non-beta-lactamase-mediated antibiotic-resistant H. influenzae differed from that of sensitive strains by an increase in the amount of disaccharide tripeptides and a decrease in 1,6-anhydro dimers. Both changes were transformable properties that changed in a stepwise fashion in parallel with the degree of antibiotic resistance.	ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,1230 YORK AVE,NEW YORK,NY 10021; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Rockefeller University; Michigan State University			Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716; Chang, Yoon-Seok/0000-0002-0623-2932	NCRR NIH HHS [RR00480] Funding Source: Medline; NIAID NIH HHS [R01 AI27913] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027913] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atherton D., 1989, TECHNIQUES PROTEIN C, P273; BURROUGHS M, 1993, J INFECT DIS, V167, P464, DOI 10.1093/infdis/167.2.464; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DOUGHERTY TJ, 1985, J BACTERIOL, V163, P69, DOI 10.1128/JB.163.1.69-74.1985; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1983, TARGET PENICILLIN, P29; GREEN BA, 1987, INFECT IMMUN, V55, P2878, DOI 10.1128/IAI.55.12.2878-2883.1987; HERRIOTT RM, 1970, J BACTERIOL, V101, P517, DOI 10.1128/JB.101.2.517-524.1970; MENDELMAN PM, 1984, ANTIMICROB AGENTS CH, V26, P235, DOI 10.1128/AAC.26.2.235; MENDELMAN PM, 1987, INFECT IMMUN, V55, P2582; SEVERIN A, 1992, J BACTERIOL, V174, P5152, DOI 10.1128/JB.174.15.5152-5155.1992; TUOMANEN E, 1987, J BACTERIOL, V169, P5308, DOI 10.1128/jb.169.11.5308-5310.1987; TUOMANEN E, 1988, J BACTERIOL, V170, P1373, DOI 10.1128/jb.170.3.1373-1376.1988; TUOMANEN E, 1989, J BIOL CHEM, V264, P11093	15	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11594	11598						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505290				2022-12-27	WOS:A1993LF28400024
J	LINDSTEDT, R; APODACA, G; BARONDES, SH; MOSTOV, KE; LEFFLER, H				LINDSTEDT, R; APODACA, G; BARONDES, SH; MOSTOV, KE; LEFFLER, H			APICAL SECRETION OF A CYTOSOLIC PROTEIN BY MADIN-DARBY CANINE KIDNEY-CELLS - EVIDENCE FOR POLARIZED RELEASE OF AN ENDOGENOUS LECTIN BY A NONCLASSICAL SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE-BINDING PROTEIN; CULTURED-CELLS; BREFELDIN-A; VERTEBRATE LECTINS; EPITHELIAL-CELL; TISSUE-SECTIONS; SIGNAL SEQUENCE; MAC-2 ANTIGEN; MDCK CELLS; TRANSPORT	In the classical secretory pathway proteins containing a signal peptide are translocated from the cytoplasm of the cell into the lumen of the endoplasmic reticulum (ER). From the ER they are transported to the Golgi apparatus and finally to the plasma membrane (PM) where they are released into the extracellular compartment. However, some proteins are synthesized without a signal peptide and maintain a predominantly cytosolic distribution until they are released from the cell. As a marker for this nonclassical secretory pathway we have chosen L-29, a soluble lectin of M(r) about 29,000, that has affinity for lactose and other beta-galactoside containing glycoconjugates. We were interested in determining if cultured epithelial cells secrete L-29 and if they do so in a polarized fashion. Madin-Darby canine kidney (MDCK)-II cells were found to express large quantities of L-29 (about 1% of the detergent soluble protein). The lectin was diffusely distributed in the cytosol, with little or none in vesicular compartments. The polarity of L-29 secretion, when analyzed in pulse-chase experiments, was selectively into the apical compartment of filter-grown MDCK cells. This secretion was not inhibited by brefeldin A or monensin, drugs that are known to inhibit protein transport through the ER-Golgi-PM pathway. Secretion of L-29 was augmented 3-5-fold by the calcium ionophore A23187 and by increasing the temperature to 42-degrees-C, whereas lowering the temperature to 20-degrees-C or addition of nocodazole prevented secretion. These results demonstrate the polarized secretion of a cytosolic protein by a nonclassical secretory pathway.	UNIV CALIF SAN FRANCISCO, LANGLEY PORTER NEUROPSYCHIAT INST, BOX F-0984, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019; Apodaca, Gerard/HCJ-0048-2022	Leffler, Hakon/0000-0003-4482-8945; mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI25144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALONSO FV, 1981, J CELL BIOL, V89, P700, DOI 10.1083/jcb.89.3.700; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BENNETT MK, 1989, METHOD CELL BIOL, V31, P103; BEYER EC, 1982, J CELL BIOL, V92, P28, DOI 10.1083/jcb.92.1.28; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRASSART D, 1992, EUR J BIOCHEM, V203, P393, DOI 10.1111/j.1432-1033.1992.tb16563.x; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; CAMERON AA, 1991, NEUROSCI LETT, V131, P249, DOI 10.1016/0304-3940(91)90625-4; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GITT MA, 1992, J BIOL CHEM, V267, P10601; HARRISON FL, 1991, J CELL SCI, V100, P9; HO MK, 1982, J IMMUNOL, V128, P1221; HORIO M, 1989, J BIOL CHEM, V264, P14880; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; LEE EC, 1991, ARCH SURG-CHICAGO, V126, P1498; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LINDSTEDT R, 1991, J CELL BIOL, V11, pA399; LOW SH, 1991, J BIOL CHEM, V266, P17729; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; PINTO M, 1983, BIOL CELL, V47, P323; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SCHNEIDER H, 1991, J EXP MED, V174, P1601, DOI 10.1084/jem.174.6.1601; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WOO HJ, 1990, J BIOL CHEM, V265, P7097	56	171	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11750	11757						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505302				2022-12-27	WOS:A1993LF28400045
J	KANE, SE				KANE, SE			MOUSE PROCATHEPSIN-L LACKING A FUNCTIONAL GLYCOSYLATION SITE IS PROPERLY FOLDED, STABLE, AND SECRETED BY NIH-3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; MULTIDRUG RESISTANCE GENE; MAJOR EXCRETED PROTEIN; LYSOSOMAL-ENZYMES; DEPENDENT SECRETION; CATHEPSIN-D; CARBOXYPEPTIDASE-Y; MURINE FIBROBLASTS; HEPG2 CELLS; BIOSYNTHESIS	The role of glycosylation in the synthesis, transport, and localization of procathepsin L has been analyzed. Procathepsin L is the precursor form of a lysosomal cysteine protease which is synthesized in large amounts by malignantly transformed cells and cells treated with growth factors or tumor promoters. As for other lysosomal hydrolases, procathepsin L is predominantly secreted when it is overexpressed, despite the presence of the lysosomal sorting marker mannose 6-phosphate. To study the role of glycosylation in procathepsin L trafficking, we constructed a cDNA in which the codon for Asn-204 was mutated to encode Gln. When this mutated cDNA was transfected into NIH 3T3 cells, a completely nonglycosylated form of procathepsin L was expressed. The protein appeared to be folded properly, as judged by its ability to be proteolytically processed to a lower molecular weight form during incubation at pH 4. Nonglycosylated protein was stable, both as unprocessed proenzyme and after processing at pH 4, and it was predominantly secreted instead of being delivered to lysosomes. Nonglycosylated and endogenous glycosylated procathepsin L were secreted by NIH 3T3 cells with identical kinetics. These studies therefore confirm that Asn-204 is the normal functional carbohydrate acceptor in procathepsin L and that carbohydrate in wild-type procathepsin L serves predominantly as a lysosomal targeting signal, with little or no role in protein folding or stability. Furthermore, there does not appear to be a major mannose 6-phosphate-independent route of lysosomal localization in NIH 3T3 cells. In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L.			KANE, SE (corresponding author), CITY HOPE NATL MED CTR,DIV SURG,DEPT CELL & TUMOR BIOL,1500 E DUARTE RD,DUARTE,CA 91010, USA.							BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; GOTTESMAN MM, 1981, BIOCHEMISTRY-US, V20, P1659, DOI 10.1021/bi00509a039; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASILIK A, 1980, J BIOL CHEM, V255, P4946; ISODORO C, 1991, BIOCHEM J, V273, P363; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kane S E, 1990, Semin Cancer Biol, V1, P127; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KANE SE, 1989, GENE, V84, P439, DOI 10.1016/0378-1119(89)90518-0; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; Rochefort H, 1990, Semin Cancer Biol, V1, P153; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SMITH SM, 1989, J BIOL CHEM, V264, P20487; SMITH SM, 1989, BIOCHEM J, V262, P931, DOI 10.1042/bj2620931; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x	36	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11456	11462						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496193				2022-12-27	WOS:A1993LD46600106
J	REDWOOD, CS; MARSTON, SB				REDWOOD, CS; MARSTON, SB			BINDING AND REGULATORY PROPERTIES OF EXPRESSED FUNCTIONAL DOMAINS OF CHICKEN GIZZARD SMOOTH-MUSCLE CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-FILAMENTS; ATPASE ACTIVITY; CALMODULIN-BINDING; HEAVY-MEROMYOSIN; ESCHERICHIA-COLI; NONMUSCLE CALDESMON; MOLECULAR-WEIGHT; CA-2+ REGULATION; SKELETAL-MUSCLE; P34CDC2 KINASE	We expressed the following fragments of chicken gizzard caldesmon in the pMW172/BL21(DE3) system at 0.4-2.2 mg of pure protein/liter of culture: full-length smooth muscle caldesmon (CDh) (amino acids 1-756), nonmuscle caldesmon (CDl), amino acids 1-128 (N128), 1-578 (N578), 230-419, 606-756 (606C), and 658-756 (658C). CDh bound tropomyosin with a K(d) of 1.5 muM; N578, 230-419, and 606C bound with affinities at least 2-5-fold lower; N128 bound weakly; and 658C did not bind. Only N128 and N578 bound to smooth muscle myosin, both about 10-fold weaker than CDh and CDl. Only 606C and 658C bound to actin-tropomyosin with affinities CDh = 606C > 658C. The binding to actin-tropomyosin was biphasic, whereas the binding to actin was monophasic, corresponding to the weak binding component found in the presence of tropomyosin. Calmodulin bound only to the C-terminal fragments with the same affinity as CDh. CDh, 606C, and 658C inhibited actin-tropomyosin-activated myosin ATPase, with maximal inhibition correlated with 1 caldesmon bound/14 actins, and inhibition was reversed by Ca2+-calmodulin. Thus, the actomyosin ATPase regulatory function, calmodulin binding, and most actin binding is located within the C-terminal 99 amino acids, whereas tropomyosin binding is distributed throughout the rest of the molecule.	NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND	Imperial College London				Marston, Steven/0000-0001-6054-6070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BRYAN J, 1991, J MUSCLE RES CELL M, V12, P372, DOI 10.1007/BF01738592; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHEN GFT, 1990, NUCLEIC ACIDS RES, V18, P1465, DOI 10.1093/nar/18.6.1465; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; CROSBIE RH, 1992, BIOCHEM BIOPH RES CO, V184, P239, DOI 10.1016/0006-291X(92)91184-R; CZURYLO EA, 1993, IN PRESS BIOCH J; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; FUJII T, 1987, J BIOL CHEM, V262, P2757; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRACEFFA P, 1990, J MUSCLE RES CELL M, V11, P440; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HUBER PAJ, 1993, IN RPESS J MUSCLE RE, V14; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; IKEBE M, 1988, J BIOL CHEM, V263, P3055; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P210, DOI 10.1016/0006-291X(89)91642-2; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON S, 1988, FEBS LETT, V238, P147, DOI 10.1016/0014-5793(88)80245-X; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1989, BIOCHEM J, V259, P303, DOI 10.1042/bj2590303; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MARSTON SB, 1985, ADV PROTEIN PHOSPHAT, V2, P171; MARSTON SB, 1993, IN PRESS J BIOL CHEM; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; NOVY RE, 1991, J BIOL CHEM, V266, P16917; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; REDWOOD CS, 1990, FEBS LETT, V270, P53, DOI 10.1016/0014-5793(90)81233-E; REDWOOD CS, 1993, BIOPHYS J, V64, pA30; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; Straub F.B., 1942, STUDIES I MED CHEM U, P3; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TOROK K, 1990, J MUSCLE RES CELL M, V11, P443; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; VIBERT P, 1992, J CELL BIOL, V115, pA376; Walsh M P, 1989, Adv Exp Med Biol, V255, P337; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; YAMAKITA V, 1992, J BIOL CHEM, V267, P12022; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	69	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10969	10976						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496161				2022-12-27	WOS:A1993LD46600041
J	BELISLE, JT; KLACZKIEWICZ, K; BRENNAN, PJ; JACOBS, WR; INAMINE, JM				BELISLE, JT; KLACZKIEWICZ, K; BRENNAN, PJ; JACOBS, WR; INAMINE, JM			ROUGH MORPHOLOGICAL VARIANTS OF MYCOBACTERIUM-AVIUM - CHARACTERIZATION OF GENOMIC DELETIONS RESULTING IN THE LOSS OF GLYCOPEPTIDOLIPID EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEISSERIA-GONORRHOEAE; ANTIGENIC VARIATION; HUMAN MACROPHAGES; DNA; OPACITY; INTRACELLULARE; ANABAENA; STRAINS; ABILITY	Previously, a gene cluster, termed ser2, which encodes for the synthesis of the specific oligosaccharide of the glycopeptidolipid antigen of Mycobacterium avium serovar 2 strain TMC 724, was defined. DNA probes from this cloned ser2 gene cluster have now been used to clone and characterize the ser2 region from a strain of M. avium which produces rough and smooth colony forms and to identify the genetic differences between these morphotypes. Interstrain differences were seen to exist between the ser2 gene cluster of M. avium strains TMC 724 and 2151. In addition, two distinct rough (Rg) genotypes of strain 2151 were defined by this analysis. The first of these, present in the M. avium Rg-0 and Rg-1 variants, was attributed to a deletion of approximately 28 kilobases from smooth variants, including the entire ser2 gene cluster. This particular deletion is thought to be mediated by recombination between repetitive sequences that flank both sides of the 28-kilobase excised region. The second genotype, seen in M. avium Rg-3 and Rg-4 variants, results from the deletion of an undefined amount of DNA from the right of the ser2 gene cluster. Reported separately (Belisle, J. T., McNeil, M. R., Chatterjee, D., Inamine, J. M., and Brennan, P. J. (1993) J. Biol. Chem. 268, 10510-10516) are the results of biochemical analyses of the glycopeptidolipid/lipopeptide population of the Rg genotypes which revealed that Rg-0 and Rg-1 possess lipopeptides devoid of all of the sugars of the glycopeptidolipids and are obviously biosynthetic precursors of the glycopeptidolipids. These studies help formulate a definition of the physiological effects of glycolipid expression, the biosynthetic and genetic mechanisms involved in their formation, and toward an understanding of the role of M. avium as a serious opportunistic pathogen.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Colorado State University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Belisle, John T/B-8944-2017	Belisle, John T/0000-0002-2539-2798; Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R34AI118537, U01AI030189] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18537, AI 30189] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BARROW WW, 1982, J BACTERIOL, V150, P381, DOI 10.1128/JB.150.1.381-384.1982; BELISLE JT, 1991, J BACTERIOL, V173, P6991, DOI 10.1128/jb.173.21.6991-6997.1991; BELISLE JT, 1993, J BIOL CHEM, V268, P10510; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHANDLER M, 1977, MOL GEN GENET, V153, P289, DOI 10.1007/BF00431594; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; COHN ML, 1968, AM REV RESPIR DIS, V98, P295; CROWLE AJ, 1986, J CLIN MICROBIOL, V24, P812, DOI 10.1128/JCM.24.5.812-821.1986; DUNBAR FP, 1968, SCAND J RESPIR DIS, V49, P153; FREGNAN GB, 1962, J BACTERIOL, V83, P819, DOI 10.1128/JB.83.4.819-827.1962; GALAS DJ, 1989, MOBILE DNA, P109; GOBEL U, 1987, J BIOCHEM BIOPH METH, V14, P245, DOI 10.1016/0165-022X(87)90050-9; GOLDEN JW, 1988, J BACTERIOL, V170, P5034, DOI 10.1128/jb.170.11.5034-5041.1988; HASELKORN R, 1989, MOBILE DNA, P735; HITCHCOCK PJ, 1986, J BACTERIOL, V166, P699, DOI 10.1128/jb.166.3.699-705.1986; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KUNZE ZM, 1991, MOL MICROBIOL, V5, P2265, DOI 10.1111/j.1365-2958.1991.tb02157.x; LAMBDEN PR, 1979, J GEN MICROBIOL, V114, P305, DOI 10.1099/00221287-114-2-305; LAMMERS PJ, 1986, CELL, V44, P905, DOI 10.1016/0092-8674(86)90013-9; Makela P. H., 1984, HDB ENDOTOXIN, P59; Maniatis T., 1982, MOL CLONING; MARTIN C, 1990, MOL BIOL MYCOBACTERI, P121; MCCARTHY C, 1970, Infection and Immunity, V2, P223; MEYLAN PR, 1990, INFECT IMMUN, V58, P2564, DOI 10.1128/IAI.58.8.2564-2568.1990; MOEHRING JM, 1965, AM REV RESPIR DIS, V92, P704; RASTOGI N, 1989, ZBL BAKT-INT J MED M, V270, P345; SCHAEFER WB, 1970, AM REV RESPIR DIS, V102, P499; SCHMIDT G, 1968, ZENTRALBL BAKTERIO A, V209, P483; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; SILVER L, 1980, MOL GEN GENET, V179, P565, DOI 10.1007/BF00271746; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; SWANSON J, 1982, INFECT IMMUN, V37, P359, DOI 10.1128/IAI.37.1.359-368.1982; VESTAL AL, 1966, AM REV RESPIR DIS, V94, P247; WOODLEY CL, 1976, ANTIMICROB AGENTS CH, V9, P113, DOI 10.1128/AAC.9.1.113	37	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10517	10523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486704				2022-12-27	WOS:A1993LB80000078
J	MARTINYBARON, G; KAZANIETZ, MG; MISCHAK, H; BLUMBERG, PM; KOCHS, G; HUG, H; MARME, D; SCHACHTELE, C				MARTINYBARON, G; KAZANIETZ, MG; MISCHAK, H; BLUMBERG, PM; KOCHS, G; HUG, H; MARME, D; SCHACHTELE, C			SELECTIVE-INHIBITION OF PROTEIN-KINASE-C ISOZYMES BY THE INDOLOCARBAZOLE GO 6976	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHORBOL ESTER RECEPTOR; HEMATOPOIETIC-CELLS; ISOTYPE-ALPHA; EXPRESSION; FAMILY; POTENT; STAUROSPORINE; HETEROGENEITY; PURIFICATION; ACTIVATION	Indolocarbazoles have been identified as novel inhibitors of protein kinase C (PKC), with Go 6976 as one of its most potent and selective representatives. Recombinant PKC isozymes alpha, beta1, delta, epsilon, and zeta were used in in vitro kinase assays to investigate Go 6976 with respect to isozyme-specific PKC inhibition. Go 6850, identical with GF 109203X, another PKC-specific kinase inhibitor, was included in this study as a reference compound. Nanomolar concentrations of the indolocarbazole Go 6976 inhibited the Ca2+-dependent isozymes alpha and beta1, whereas even micromolar concentration of Go 6976 had no effect on the kinase activity of the Ca2+-independent PKC subtypes delta, epsilon, and zeta. In contrast, the bisindolymaleimide Go 6850 inhibited all PKC isozymes, however, with a ranked order of potency (alpha > beta1 > epsilon > delta > zeta). Kinetic analysis revealed that PKC inhibition by Go 6976 was competitive with respect to ATP, non-competitive with respect to the protein substrate, and mixed type with respect to phosphatidylserine. Further experiments in the presence of different amounts of free Ca2+ indicated that interference with Ca2+ or its binding site is not responsible for the differential inhibition of PKC isozymes by Go 6976.	GODECKE AG, DEPT BIOCHEM PHARMACOL, MOOSWALDALLEE 1-9, W-7800 FREIBURG, GERMANY; UNIV FREIBURG, INST MOLEC CELL BIOL, W-7800 FREIBURG, GERMANY; NCI, MOLEC MECHANISMS TUMOR PROMOT SECT, BETHESDA, MD 20892 USA; NCI, MOLEC GENET SECT, GENET LAB, BETHESDA, MD 20892 USA	University of Freiburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306				AKINAGA S, 1991, CANCER RES, V51, P4888; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; GOODNIGHT J, 1993, IN PRESS GENE AMST; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARTENSTEIN JH, 1993, PERSPECTIVES MED CHE, P99; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCHS G, 1993, BIOCHEM J, V291, P627, DOI 10.1042/bj2910627; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MCGLYNN E, 1992, J CELL BIOCHEM, V49, P239, DOI 10.1002/jcb.240490306; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PERSONS DA, 1990, CELL, V26, P307; QATSHA KA, 1993, IN PRESS P NATL ACAD; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHACHTELE C, 1989, EUR J PHARMACOL, V163, P151, DOI 10.1016/0014-2999(89)90410-X; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	45	1511	1540	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9194	9197						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486620				2022-12-27	WOS:A1993LA68900011
J	POLAKIS, P; MCCORMICK, F				POLAKIS, P; MCCORMICK, F			STRUCTURAL REQUIREMENTS FOR THE INTERACTION OF P21RAS WITH GAP, EXCHANGE FACTORS, AND ITS BIOLOGICAL EFFECTOR TARGET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GTPASE-ACTIVATING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; ADENYLATE-CYCLASE PATHWAY; RAS-ENCODED PROTEINS; ONCOGENE PRODUCT P21; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; TRIPHOSPHATE CONFORMATION; 3-DIMENSIONAL STRUCTURES; BINDING DOMAIN				POLAKIS, P (corresponding author), ONYX PHARMACEUT, BLDG A, 3031 RES DR, RICHMOND, CA 94806 USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOTWELL D, 1992, P NATL ACAD SCI USA, V89, P6511; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUJITAYOSHIGAKI J, 1991, FEBS LETT, V294, P187, DOI 10.1016/0014-5793(91)80665-P; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAVOUNIS C, 1991, FEBS LETT, V281, P235, DOI 10.1016/0014-5793(91)80401-N; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCCORMICK F, 1988, COLD SPRING HARB SYM, V2, P849; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MITSOU MY, 1992, EMBO J, V11, P2391; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIROUZU M, 1992, ONCOGENE, V7, P475; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1985, EMBO J, V4, P2893, DOI 10.1002/j.1460-2075.1985.tb04019.x; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	79	177	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9157	9160						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486615				2022-12-27	WOS:A1993LA68900001
J	KORETZKY, GA; KOHMETSCHER, M; ROSS, S				KORETZKY, GA; KOHMETSCHER, M; ROSS, S			CD45-ASSOCIATED KINASE-ACTIVITY REQUIRES LCK BUT NOT T-CELL RECEPTOR EXPRESSION IN THE JURKAT T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; LEUKOCYTE-COMMON ANTIGEN; SIGNAL TRANSDUCTION; PHOSPHATASE CD45; PHOSPHORYLATION; P56LCK; ACTIVATION; CD8; STIMULATION; ASSOCIATION	The earliest biochemical event known to be associated with T cell receptor (TCR) engagement is the activation of a protein tyrosine kinase thought to be a member of the src family. Expression of CD45, the major receptor tyrosine phosphatase present on T cells, is required for efficient coupling between the TCR and its signaling machinery. One model to explain the role of CD45 in regulating TCR signaling is that the phosphatase dephosphorylates the regulatory C-terminal tyrosine of lck. In the present report we confirm the finding of a trimolecular complex containing CD45, lck, and a 34-kDa protein (p34) in the Jurkat T cell line. Additionally, we extend this work with the observation that specific in vitro kinase activity associated with CD45 requires the expression of lck in Jurkat-derived clones as does the in vivo phosphorylation of p34. The association between CD45 and lck is shown not to require the expression of or activation of the TCR. Finally, we demonstrate that even in the absence of lck p34 associates with CD45, implying a direct association between this molecule and the phosphatase. These data suggest strongly that lck is the relevant protein tyrosine kinase found in CD45 immunoprecipitates in the Jurkat T cell line and that there is an additional association between CD45 and p34 which does not require the presence of the protein tyrosine kinase.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa	KORETZKY, GA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,540 EMRB,IOWA CITY,IA 52242, USA.		Koretzky, Gary/AAU-5381-2021		NATIONAL CANCER INSTITUTE [R01CA056050, R29CA056843] Funding Source: NIH RePORTER; NCI NIH HHS [1R29 CA56843-02, 1 R01 CA56050-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BELL G M, 1991, Arthritis and Rheumatism, V34, pS79; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284	38	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8958	8964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473339				2022-12-27	WOS:A1993KX81100084
J	PIGNOLO, RJ; CRISTOFALO, VJ; ROTENBERG, MO				PIGNOLO, RJ; CRISTOFALO, VJ; ROTENBERG, MO			SENESCENT WI-38 CELLS FAIL TO EXPRESS EPC-1, A GENE INDUCED IN YOUNG CELLS UPON ENTRY INTO THE G(0) STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; PROTEASE INHIBITORY ACTIVITY; REPLICATIVE LIFE-SPAN; DNA-SYNTHESIS; CELLULAR SENESCENCE; ALZHEIMERS-DISEASE; GROWTH ARREST; NEURITE OUTGROWTH; RIBONUCLEIC-ACID; MEMBRANE-PROTEIN	Recently we reported the isolation of cDNAs for a number of genes that are differentially expressed between nonproliferating early (young) and late (senescent) population doubling level (PDL) WI-38 human, fetal lung-derived, fibroblast-like cells. We now demonstrate that one of these isolates, EPC-1 (early PDL cDNA-1), derives from an approximately 1.4-kilobase mRNA species that is expressed at a greater-than-or-equal-to 100-fold higher level in serum-starved, confluent, young versus similarly treated senescent WI-38 cells. Complete nucleotide sequence analysis of this cDNA confirms its identity with that of a cDNA encoding a secreted, retinal pigmented epithelium differentiation factor as well as similarity of the encoded protein with a number of mammalian serine protease inhibitors. We show that EPC-1 expression is associated with Go growth arrest in WI-38 cells. The mRNA readily accumulates in density-arrested and/or serum-starved young cells but not in log phase, low density young cells. In contrast, EPC-1 transcript abundance and expression of the encoded, secreted protein are both negligible in senescent WI-38 cells under all culture conditions tested. These findings support the hypothesis that senescent WI-38 cells exhibit a state of growth arrest fundamentally distinct from that of quiescent (G0) young cells.	MED COLL PENN,CTR GERONTOL RES,3300 HENRY AVE,PHILADELPHIA,PA 19129; MED COLL PENN,DEPT PHYSIOL & BIOCHEM,PHILADELPHIA,PA 19129	Drexel University; Drexel University					NIA NIH HHS [AG00378] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642; BADERGA R, 1985, BIOL CEL REPRODUCTIO, P23; BAKER JB, 1986, RECEPTORS, V3, P153; BIERMAN EL, 1978, IN VITRO CELL DEV B, V14, P951; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P2487; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BURMER GC, 1984, J CELL PHYSIOL, V118, P97, DOI 10.1002/jcp.1041180116; BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; BURMER GC, 1982, J CELL BIOL, V94, P187, DOI 10.1083/jcb.94.1.187; CARRELL RW, 1988, NATURE, V331, P478, DOI 10.1038/331478a0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRISTOFALO V J, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V27, P65; CRISTOFALO VJ, 1976, GERONTOLOGY, V22, P9, DOI 10.1159/000212122; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; Cristofalo VJ, 1980, J TISSUE CULTURE MET, V6, P117; CRISTOFALO VJ, 1982, ADV CELL CULT, V2, P1; CUNNINGHAM DD, 1989, J CELL BIOCHEM, V39, P55, DOI 10.1002/jcb.240390107; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOGGETT DL, 1992, MECH AGEING DEV, V65, P239, DOI 10.1016/0047-6374(92)90039-G; DRESCHERLINCOLN CK, 1984, EXP CELL RES, V153, P208, DOI 10.1016/0014-4827(84)90462-2; DRESCHERLINCOLN CK, 1983, EXP CELL RES, V144, P455, DOI 10.1016/0014-4827(83)90424-X; GERHARD GS, 1991, EXP CELL RES, V193, P87, DOI 10.1016/0014-4827(91)90541-2; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GLOOR S, 1986, CELL, V47, P687; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GORMAN SD, 1986, EXP CELL RES, V167, P87, DOI 10.1016/0014-4827(86)90206-5; GROVE GL, 1977, J CELL PHYSIOL, V90, P415, DOI 10.1002/jcp.1040900305; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOJ A, 1985, ACUTE PHASE RESPONSE; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MACIEIRA.A, 1966, EXP CELL RES, V42, P673, DOI 10.1016/0014-4827(66)90280-1; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MARTIN GM, 1970, LAB INVEST, V23, P86; MUELLER SN, 1980, SCIENCE, V207, P889, DOI 10.1126/science.7355268; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OLASHAW NE, 1983, EXP CELL RES, V149, P547, DOI 10.1016/0014-4827(83)90365-8; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PEREIRASMITH OM, 1985, EXP CELL RES, V160, P297, DOI 10.1016/0014-4827(85)90177-6; PHILLIPS PD, 1983, J CELL PHYSIOL, V114, P311, DOI 10.1002/jcp.1041140309; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PONTEN J, 1963, J CELL COMPAR PHYSL, V61, P145, DOI 10.1002/jcp.1030610206; PONTEN J, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V27, P53; RABINOVITCH PS, 1980, EXP CELL RES, V130, P101, DOI 10.1016/0014-4827(80)90046-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STEIN GH, 1986, EXP CELL RES, V162, P255, DOI 10.1016/0014-4827(86)90443-X; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SUMI Y, 1986, J BIOCHEM, V100, P1399, DOI 10.1093/oxfordjournals.jbchem.a121846; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TASSIN J, 1979, EXP CELL RES, V123, P388, DOI 10.1016/0014-4827(79)90483-X; TICE RR, 1979, J EXP MED, V149, P1029, DOI 10.1084/jem.149.5.1029; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; TOMBRANTINK J, 1991, EXP EYE RES, V50, P411; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284; WANG E, 1991, J CELL PHYSIOL, V147, P514, DOI 10.1002/jcp.1041470318; WANG E, 1985, J CELL BIOL, V100, P545, DOI 10.1083/jcb.100.2.545; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	78	111	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8949	8957						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473338				2022-12-27	WOS:A1993KX81100083
J	LEVIN, MS				LEVIN, MS			CELLULAR RETINOL-BINDING PROTEINS ARE DETERMINANTS OF RETINOL UPTAKE AND METABOLISM IN STABLY TRANSFECTED CACO-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; TISSUE-SPECIFIC EXPRESSION; ACYLTRANSFERASE ACTIVITY; VITAMIN-A; ESCHERICHIA-COLI; DEVELOPMENTAL REGULATION; ACYL-COA; ACID; ESTERIFICATION; LECITHIN	The mammalian small intestine contains two related cellular retinol-binding proteins, CRBP and CRBP II, which are thought to have distinct functions. The human intestinal cell line, Caco-2, was used as a model system for testing the hypothesis that intracellular levels of these proteins directly modulate the absorption and subsequent metabolism of retinol in enterocytes. Immunoblot and Northern blot hybridization demonstrated that Caco-2 cells express CRBP II and cellular retinoic acid-binding protein I in increasing amounts as the cells become more differentiated but do not express detectable quantities of CRBP. Stably transfected cloned Caco-2 cell lines that over-express CRBP II or coexpress CRBP and CRBP II and a control cell line that contains the expression vector without an insert were established. Retinol uptake and retinyl ester synthesis were increased up to 2-fold by coexpression of CRBP or over-expression of CRBP II. No significant differences were detected in the pattern of retinyl esters synthesized from exogenous [H-3]retinol. This suggests that the fatty acid pools utilized for retinol esterification were the same despite differences in the CRBP and CRBP II phenotype of the cell lines. There were no differences between apical and basolateral [H-3]retinol uptake or metabolism for filter grown transfected or wild type cell monolayers. Thus, neither CRBP II nor CRBP appear to preferentially interact with luminal- or plasma-derived retinol. Notably, in a cell line which over-expressed CRBP, endogenous CRBP II was reduced by 5-10-fold compared with the wild type and control cell lines. These studies indicate that CRBP and CRBP II levels are determinants of intracellular retinol accumulation and esterification, and they suggest that CRBP-bound retinol or a metabolite can regulate the expression of CRBP II in the mammalian intestine.			LEVIN, MS (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8124,ST LOUIS,MO 63110, USA.				NIDDK NIH HHS [DK43029] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043029] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chytil F., 1984, RETINOIDS, V2, P90; CROW JA, 1985, P NATL ACAD SCI USA, V82, P4707, DOI 10.1073/pnas.82.14.4707; ELLER MS, 1992, EXP CELL RES, V199, P328; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GANGL A, 1975, J CLIN INVEST, V55, P803, DOI 10.1172/JCI107991; GOODMAN DS, 1984, RETINOIDS, V2, P1; HELGERUD P, 1983, J CLIN INVEST, V71, P747, DOI 10.1172/JCI110822; HELGERUD P, 1982, J LIPID RES, V23, P609; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS GM, 1990, METHOD ENZYMOL, V189, P70; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LEVIN MS, 1992, J LIPID RES, V33, P9; LEVIN MS, 1990, METHOD ENZYMOL, V189, P506; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1987, J BIOL CHEM, V262, P13773; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; NOY N, 1990, BIOCHEMISTRY-US, V29, P3888, DOI 10.1021/bi00468a014; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P828; ONG DE, 1987, J LIPID RES, V28, P739; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; QUICK TC, 1989, J LIPID RES, V30, P1049; QUICK TC, 1990, BIOCHEMISTRY-US, V29, P11116, DOI 10.1021/bi00502a015; RAJAN N, 1991, J LIPID RES, V32, P1195; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; RANHEIM T, 1992, J LIPID RES, V33, P1281; Sambrook J, 1989, MOL CLONING LABORATO; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	50	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8267	8276						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463337				2022-12-27	WOS:A1993KW97900099
J	ALZANI, R; CORTI, A; GRAZIOLI, L; COZZI, E; GHEZZI, P; MARCUCCI, F				ALZANI, R; CORTI, A; GRAZIOLI, L; COZZI, E; GHEZZI, P; MARCUCCI, F			SURAMIN INDUCES DEOLIGOMERIZATION OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; RECEPTOR; BINDING; TRIMER; FORM	Suramin inhibits the biological activity of human tumor necrosis factor alpha (TNF) through a direct action on the ligand rather than on its receptors (Grazioli, L., Alzani, R., Ciomei, M., Mariani, M., Restivo, A., Cozzi, E., and Marcucci, F. (1992) Int. J. Immunopharmacol. 14, 637-642). In order to clarify the mechanism whereby suramin leads to inhibition of TNF, we investigated the possibility that suramin might modify the quaternary structure of TNF which is biologically active as a trimer. For this purpose we used a new assay (double streptavidin sandwich assay) designed for the rapid detection of oligomer-monomer conversion of proteins. Taking advantage of this assay we observed, upon incubation with suramin, dissociation of TNF. Suramin-induced dissociation of TNF was confirmed by gel filtration chromatography. Under conditions of partial dissociation, two molecular species were separated. One of higher molecular weight, corresponding to trimeric TNF, was biologically active, whereas the other, corresponding to monomeric TNF, was inactive. These results are at variance with others recently reported, where suramin has been shown to induce microaggregation of several polypeptides (Middaugh, C. R., Mach, H., Burke, C. J., Volkin, D. B., Dabora, J. M., Tsai, P. K., Bruner, M. W., Ryan, J. A., and Marfia, K. E. (1992) Biochemistry 31, 9016-9024). This suggests that suramin inhibits the bioactivity of different protein molecules through opposite effects on their quaternary structure. The present results are, to our knowledge, the first demonstration of a drug inhibiting a target molecule through dissociation of its quaternary structure.	TECNOGEN SCPA,MOLEC IMMUNOL & BIOCHEM UNIT,I-20131 MILAN,ITALY; MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	ALZANI, R (corresponding author), FARMITALIA CARLO ERBA SPA,DEPT IMMUNOL,VIA GIOVANNI XXIII 23,I-20014 NERVIANO,ITALY.		Corti, Angelo/F-7046-2012	Corti, Angelo/0000-0002-0893-6191; marcucci, fabrizio/0000-0002-2977-294X; Subba, Rajkrishna/0000-0003-0051-0062; Ghezzi, Pietro/0000-0003-0911-8358				ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P1322, DOI 10.1021/bi00379a018; ECK MJ, 1988, J BIOL CHEM, V263, P12816; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FECK MJ, 1989, J BIOL CHEM, V264, P17595; GRAZIOLI L, 1992, INT J IMMUNOPHARMACO, V14, P637, DOI 10.1016/0192-0561(92)90125-5; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KUNITANI MG, 1988, J CHROMATOGR, V443, P205, DOI 10.1016/S0021-9673(00)94794-0; LAM KS, 1988, J BIOL RESP MODIF, V7, P267; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; LEWITBENTLEY A, 1988, J MOL BIOL, V199, P389, DOI 10.1016/0022-2836(88)90323-3; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; MILLS GB, 1990, CANCER RES, V50, P3036; SEMENZATO G, 1990, BRIT J CANCER, V61, P354, DOI 10.1038/bjc.1990.78; SMITH RA, 1987, J BIOL CHEM, V262, P6951; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1	21	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12526	12529						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509393				2022-12-27	WOS:A1993LG65800046
J	KRUEGER, KM; BARBIERI, JT				KRUEGER, KM; BARBIERI, JT			MOLECULAR CHARACTERIZATION OF THE INVITRO ACTIVATION OF PERTUSSIS TOXIN BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; ADENINE-NUCLEOTIDES; NAD GLYCOHYDROLASE; A-SUBUNIT; PROTEIN; RIBOSYLTRANSFERASE; S1-SUBUNIT; TRANSDUCIN; BINDING; CYCLASE	Pertussis toxin (PT)-catalyzed ADP-ribosylation of transducin (G(t)) is stimulated by ATP. In the absence of ATP, PT exhibited an approximately 20-fold lower linear velocity than the recombinant S1 subunit (rS1) in catalyzing the ADP-ribosylation of G(t). In the presence of 0.1 mM ATP, the linear velocities of rS1 and PT were essentially identical. ATP increased the k(cat) of PT-catalyzed ADP-ribosylation of G(t) without altering the K(mapp) for either G(t) or NAD. Further, in the presence of ATP, PT exhibited similar kinetic constants under conditions of variable G(t) and variable NAD as rS1 in catalyzing the ADP-ribosylation of G(t). The S1 subunit of PT was cleaved by chymotrypsin to a single immunoreactive peptide in the absence of ATP, while three immunoreactive peptides were generated in the presence of ATP. The S1 subunit of PT was not cleaved by trypsin in the absence of ATP, at the concentrations of trypsin used, while two immunoreactive peptides were produced in the presence of ATP. The immunoreactive peptides produced either by chymotrypsin or trypsin cleavage of the S1 subunit of PT in the presence of ATP were indistinguishable from those produced by cleavage of rS1 with the same protease. Chymotryptic and tryptic cleavage of rS1 was not altered by ATP. When PT was incubated with ATP prior to Bio-Gel P-100 gel filtration, approximately 8% of the S1 subunit dissociated from the B oligomer, as determined by ADP-ribosyltransferase assays of the column eluant. This increased to 20% when ATP was included in the column buffer. The presence of dithiothreitol and NAD in addition to ATP did not affect the amount of dissociated S1 subunit. Our data further indicated that activation of PT by ATP was a reversible process. Together, these data showed that ATP quantitatively converted the S1 subunit of PT to a form which was kinetically and conformationally identical with rS1, while only a fraction of the S1 subunit was dissociated from the B oligomer. These results indicate that both S1 subunit which is bound to the B oligomer as well as dissociated S1 subunit are capable of catalyzing the ADP-ribosylation of G(t).	MED COLL WISCONSIN,DEPT MICROBIOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226	Medical College of Wisconsin					NIAID NIH HHS [AI-30162, AI-01087] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162, K04AI001087] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBIERI JT, 1990, INFECT IMMUN, V58, P999, DOI 10.1128/IAI.58.4.999-1003.1990; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS DL, 1987, J BIOL CHEM, V262, P17677; BURNS DL, 1986, J BIOL CHEM, V261, P4324; BURNS DL, 1989, J BIOL CHEM, V264, P564; CORTINA G, 1991, J BIOL CHEM, V266, P3022; CORTINA G, 1991, J BIOL CHEM, V266, P23810; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; HAUSMAN SZ, 1990, BIOCHEMISTRY-US, V29, P6128, DOI 10.1021/bi00478a003; HAUSMAN SZ, 1992, J BIOL CHEM, V267, P13735; KASLOW HR, 1987, BIOCHEMISTRY-US, V26, P123, DOI 10.1021/bi00375a018; KATADA T, 1983, ARCH BIOCHEM BIOPHYS, V224, P290, DOI 10.1016/0003-9861(83)90212-6; KRUEGER KM, 1991, J BIOL CHEM, V266, P8122; LIM LK, 1985, J BIOL CHEM, V260, P2585; MATTERA R, 1986, J BIOL CHEM, V261, P1173; MONTECUCCO C, 1986, FEBS LETT, V194, P301, DOI 10.1016/0014-5793(86)80105-3; MOSS J, 1983, J BIOL CHEM, V258, P1879; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; Peppler M S, 1985, Dev Biol Stand, V61, P75; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; UI M, 1990, ADP RIBOSYLATING TOX, P45; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEST RE, 1985, J BIOL CHEM, V260, P4428	26	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12570	12578						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509398				2022-12-27	WOS:A1993LG65800053
J	ODA, T; WU, HC				ODA, T; WU, HC			CERULENIN INHIBITS THE CYTOTOXICITY OF RICIN, MODECCIN, PSEUDOMONAS TOXIN, AND DIPHTHERIA-TOXIN IN BREFELDIN A-RESISTANT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GOLGI-APPARATUS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; NUCLEOTIDES MODULATE; ANTIBIOTIC CERULENIN; STRUCTURAL PROTEINS; INTERNALIZED RICIN; SECRETORY PROTEINS; RAT HEPATOCYTES	We have found that cerulenin, an antibiotic that inhibits de novo fatty acid and cholesterol biosynthesis and fatty acylation of proteins, strongly inhibited the cytotoxicity of ricin, modeccin, Pseudomonas toxin, and diphtheria toxin in a brefeldin A (BFA)-resistant mutant of Vero cells (BER-40). The protective effect of cerulenin against ricin was also observed in two other BFA-resistant cell lines, Madin-Darby canine kidney, and PtK1 cells. In contrast to BER-40 cells, no significant effect of cerulenin was observed in Vero cells. Cerulenin did not affect the binding of ricin to the cell-surface receptors, but reduced significantly the internalization of ricin in BER-40 cells; no effect of cerulenin on the binding or internalization of ricin was observed in Vero, PtK1, and Madin-Darby canine kidney cells. Endocytic uptake of fluid-phase markers such as horseradish peroxidase and lucifer yellow was inhibited by cerulenin in BER-40 cells, but the endocytosis of transferrin via the coated pit/coated vesicle pathway was slightly increased. Cerulenin inhibited the degradation and excretion of ricin in BER-40 cells, and this effect of cerulenin was not observed in Vero cells. Furthermore, cerulenin inhibited the bulk protein secretion in a dose-dependent manner, with BER-40 cells being more susceptible than Vero cells. These results suggest that in addition to its effect on endocytosis, cerulenin interferes with the intracellular trafficking or processing of toxin molecules, and the vesicle transport system in BER-40 cells appears to be cerulenin-sensitive. Since addition of fatty acids and cholesterol did not reverse the effects of cerulenin, the protective effect of cerulenin against protein toxins is not due to an inhibition of de novo fatty acids and cholesterol biosynthesis.	UNIFORMED SERV UNIV HLTH SCI, DEPT MICROBIOL, BETHESDA, MD 20814 USA	Uniformed Services University of the Health Sciences - USA					NIGMS NIH HHS [GM28810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARISON BH, 1974, J ANTIBIOT, V27, P28, DOI 10.7164/antibiotics.27.28; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHEN C, 1992, EXP CELL RES, V203, P321, DOI 10.1016/0014-4827(92)90005-S; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOLDFINE H, 1978, BIOCHIM BIOPHYS ACTA, V512, P229, DOI 10.1016/0005-2736(78)90249-3; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JACQUES NA, 1983, J GEN MICROBIOL, V129, P3293; KARIN M, 1981, J BIOL CHEM, V256, P3245; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOW SH, 1991, J BIOL CHEM, V266, P17729; MADSHUS IH, 1991, J BIOL CHEM, V266, P17446; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OHNO T, 1974, BIOCHEM BIOPH RES CO, V57, P1119, DOI 10.1016/0006-291X(74)90812-2; Olsnes S, 1988, Cancer Treat Res, V37, P39; OLSNES S, 1987, MEMBRANE MEDIATED CY, P83; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1986, CANCER RES, V46, P6418; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHLESINGER MJ, 1982, J BIOL CHEM, V257, P9887; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P21297; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; WILEMAN T, 1985, BIOCHEM J, V232, P1; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y; YOULE RJ, 1987, J BIOL CHEM, V262, P4676; ZEUZEM S, 1991, FEBS LETT, V288, P143, DOI 10.1016/0014-5793(91)81021-Y	60	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12596	12602						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509400				2022-12-27	WOS:A1993LG65800056
J	GERECKE, DR; FOLEY, JW; CASTAGNOLA, P; GENNARI, M; DUBLET, B; CANCEDDA, R; LINSENMAYER, TF; VANDERREST, M; OLSEN, BR; GORDON, MK				GERECKE, DR; FOLEY, JW; CASTAGNOLA, P; GENNARI, M; DUBLET, B; CANCEDDA, R; LINSENMAYER, TF; VANDERREST, M; OLSEN, BR; GORDON, MK			TYPE-XIV COLLAGEN IS ENCODED BY ALTERNATIVE TRANSCRIPTS WITH DISTINCT 5' REGIONS AND IS A MULTIDOMAIN PROTEIN WITH HOMOLOGIES TO VONWILLEBRAND-FACTOR, FIBRONECTIN, AND OTHER MATRIX PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; IX COLLAGEN; EXTRACELLULAR-MATRIX; MESSENGER-RNA; SMALL-PROTEOGLYCAN; DOMAINS; CDNA; INTEGRINS; RECEPTOR; SEQUENCE	The combined nucleotide sequences of several overlapping cDNAs provide the first complete amino acid sequence of type XIV collagen. Independent confirmation of the deduced sequence is provided by amino acid sequencing of several tryptic peptides isolated from purified chicken skin type XIV collagen. Comparative analyses show that the amino-terminal nontriple-helical region of alpha1(XIV) chains contains sequence motifs that are similar to alpha1(IX) collagen, fibronectin type III repeats, and von Willebrand's factor A-domains. The results also strongly suggest that the alpha1(XIV) collagen gene is identical to the gene encoding the matrix component previously named undulin. cDNAs covering the 5' region of alpha1(XIV) mRNA fall into two classes with distinct sequences in their 5'-untranslated regions. We believe the two alternative sequences result from differential splicing of the primary transcript. Interestingly, one of the untranslated sequences shows a high degree of identity with the cis-regulatory translational control sequence in the 5'-untranslated region of a Drosophila ribosomal protein mRNA. We hypothesize therefore that the sequence in alpha1(XIV) collagen may play a role in the control of alpha1(XIV) protein synthesis.	HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02111 USA; IST NAZL RIC CANC, I-16132 GENOA, ITALY; CNRS, UPR 412, INST BIOL & CHEM PROT, F-69373 LYON, FRANCE	Harvard University; Harvard Medical School; Tufts University; University of Genoa; IRCCS AOU San Martino IST; Centre National de la Recherche Scientifique (CNRS)			Castagnola, Patrizio/H-2029-2012	Castagnola, Patrizio/0000-0003-2008-9199	NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036819, R37AR036819, R01AR036820, R37AR036820] Funding Source: NIH RePORTER; NEI NIH HHS [EY09056] Funding Source: Medline; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; CASTAGNOLA P, 1992, EUR J CELL BIOL, V59, P340; CHANDRASEKHAR S, 1986, P NATL ACAD SCI USA, V83, P5126, DOI 10.1073/pnas.83.14.5126; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRWIN MH, 1985, J CELL BIOL, V101, P814, DOI 10.1083/jcb.101.3.814; JACENKO O, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P327; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; JUST M, 1991, J BIOL CHEM, V266, P17326; KOCH M, 1992, EUR J BIOCHEM, V207, P847, DOI 10.1111/j.1432-1033.1992.tb17116.x; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOLLER E, 1989, EMBO J, V8, P1073, DOI 10.1002/j.1460-2075.1989.tb03475.x; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MANIATIS T, 1986, MOL CLONING; Mayne R., 1987, STRUCTURE FUNCTION C; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; Mosher DF, 1989, FIBRONECTIN; NINOMIYA Y, 1984, P NATL ACAD SCI-BIOL, V81, P3014, DOI 10.1073/pnas.81.10.3014; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P115, DOI 10.3109/03008208909002411; OVERBEEK PA, 1981, BIOCHIM BIOPHYS ACTA, V656, P195, DOI 10.1016/0005-2787(81)90087-3; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PATEL RC, 1992, J BIOL CHEM, V267, P1159; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; SCOTT JE, 1985, BIOSCIENCE REP, V5, P765, DOI 10.1007/BF01119875; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TITANI K, 1988, TRENDS BIOCHEM SCI, V13, P94, DOI 10.1016/0968-0004(88)90048-5; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; VANDERREST M, 1982, EUR J BIOCHEM, V125, P491, DOI 10.1111/j.1432-1033.1982.tb06709.x; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANDERREST M, 1985, J BIOL CHEM, V260, P220; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WATERHOUSE P, 1990, J BIOL CHEM, V265, P5585; WATT SL, 1992, J BIOL CHEM, V267, P20093; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	60	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12177	12184						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505337				2022-12-27	WOS:A1993LF28400105
J	IIJIMA, R; KURATA, S; NATORI, S				IIJIMA, R; KURATA, S; NATORI, S			PURIFICATION, CHARACTERIZATION, AND CDNA CLONING OF AN ANTIFUNGAL PROTEIN FROM THE HEMOLYMPH OF SARCOPHAGA-PEREGRINA (FLESH FLY) LARVAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH POLYPEPTIDES; CELL-FREE IMMUNITY; ANTIBACTERIAL PROTEINS; MOLECULAR-CLONING; SARCOTOXIN-II; GENE-CLUSTER; BARLEY	An antifungal protein (AFP) was purified from the hemolymph of third instar larvae of Sarcophaga peregrina. This protein repressed the growth of Candida albicans in Sabouraud medium in the presence of nitrofurazone. However, in distilled water or saline, AFP alone killed C. albicans. Significant synergism was detected between AFP and sarcotoxin IA, an antibacterial protein of Sarcophaga. The lethal effect of AFP on C. albicans was greatly enhanced by the presence of a small amount of sarcotoxin IA. AFP was shown to bind to C. albicans and cause leakage of a substance(s) with absorbance at 260 nm from the cells. Analysis of its cDNA showed that AFP is a novel histidine-rich protein consisting of 67 amino acid residues.	UNIV TOKYO, FAC PHARMACEUT SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ANDO K, 1987, BIOCHEMISTRY-US, V26, P226, DOI 10.1021/bi00375a030; ANDO K, 1988, BIOCHEMISTRY-US, V27, P1715, DOI 10.1021/bi00405a050; BABA K, 1987, J BIOCHEM-TOKYO, V102, P69, DOI 10.1093/oxfordjournals.jbchem.a122042; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; Chadwick J.S., 1975, P241; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; ISHIKAWA M, 1992, BIOCHEM J, V287, P573, DOI 10.1042/bj2870573; KANAI A, 1989, FEBS LETT, V258, P199, DOI 10.1016/0014-5793(89)81652-7; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKAY BJ, 1984, INFECT IMMUN, V44, P688, DOI 10.1128/IAI.44.3.688-694.1984; MATSUMOTO N, 1986, BIOCHEM J, V239, P717, DOI 10.1042/bj2390717; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; Natori S., 1987, Molecular entomology. Proceedings of a Monsanto-UCLA Symposium held in Steamboat Springs, Colorado, April 6-13, 1986., P369; OHTAKI T, 1966, JPN J MED SCI BIOL, V19, P97, DOI 10.7883/yoken1952.19.97; OKADA M, 1985, J BIOL CHEM, V260, P7174; OKADA M, 1983, BIOCHEM J, V211, P727, DOI 10.1042/bj2110727; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; POSTLETHWAIT JH, 1988, J INSECT PHYSIOL, V34, P91, DOI 10.1016/0022-1910(88)90159-X; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBERTS WK, 1990, J GEN MICROBIOL, V136, P1771, DOI 10.1099/00221287-136-9-1771; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELESTED ME, 1985, INFECT IMMUN, V49, P202; WITHCOMB RF, 1974, PHYSL INSECTA, V5, P447	34	112	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12055	12061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505329				2022-12-27	WOS:A1993LF28400089
J	SCHIAVO, G; SHONE, CC; ROSSETTO, O; ALEXANDER, FCG; MONTECUCCO, C				SCHIAVO, G; SHONE, CC; ROSSETTO, O; ALEXANDER, FCG; MONTECUCCO, C			BOTULINUM NEUROTOXIN SEROTYPE-F IS A ZINC ENDOPEPTIDASE SPECIFIC FOR VAMP/SYNAPTOBREVIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLES; TETANUS; GENES	Botulinum neurotoxin serotype F contains the zinc binding motif of zinc endopeptidases. Atomic adsorption analysis of highly purified toxin preparation revealed the presence of one atom of zinc per molecule of toxin, which could be removed with EDTA or o-phenanthroline. The light chain of the neurotoxin was shown to have a zinc-dependent protease activity specific for VAMP/synaptobrevin, an integral membrane protein of synaptic vesicles. Both isoforms of rat VAMP were cleaved at the same site corresponding to the single Gln-Lys peptide bond present in their sequences. This proteolytic activity was inhibited by EDTA, o-phenanthroline, and captopril as well as by VAMP peptides spanning the cleavage site.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35121 PADUA,ITALY; CTR APPL MICROBIOL & RES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND	University of Padua	SCHIAVO, G (corresponding author), UNIV PADUA,CNR,CTR BIOMEMBRANE,VIA TRIESTE 75,I-35121 PADUA,ITALY.		rossetto, ornella/AAC-3866-2022	rossetto, ornella/0000-0002-6113-3857; Schiavo, Giampietro/0000-0002-4319-8745	Telethon [170] Funding Source: Medline	Telethon(Fondazione Telethon)		ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; CAIN CC, 1992, J BIOL CHEM, V267, P11681; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; EAST AK, 1992, FEMS MICROBIOL LETT, V96, P225, DOI 10.1016/0378-1097(92)90408-G; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KOCHWESER J, 1982, NEW ENGL J MED, V306, P214; LUDLOW CL, 1992, NEW ENGL J MED, V326, P349; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; ROSSETTO O, 1992, BIOCHEM J, V285, P9, DOI 10.1042/bj2850009; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SHONE CC, 1986, NATURAL TOXICANTS FO, P11; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WADSWORTH JDF, 1990, BIOCHEM J, V268, P123, DOI 10.1042/bj2680123; [No title captured]; [No title captured]	26	294	306	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11516	11519						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505288				2022-12-27	WOS:A1993LF28400012
J	TREMETHICK, DJ; DREW, HR				TREMETHICK, DJ; DREW, HR			HIGH-MOBILITY GROUP PROTEIN-14 AND PROTEIN-17 CAN SPACE NUCLEOSOMES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS; CHROMATIN STRUCTURE; XENOPUS-LAEVIS; SEQUENCE; HISTONES; DNA	Recently we partially purified from Xenopus laevis ovaries a novel, ATP-dependent, spacing activity that can convert a DNA template consisting of irregularly spaced nucleosomes into a chromatin structure made up of regularly spaced nucleosomes with a repeat length of 160-165 base pairs. In a second independent step, the longer spacing of higher eukaryotic chromatin can be generated by the addition of histone H1. The partially purified spacing fraction contains several proteins that display chromatographic properties and mobilities on polyacrylamide gels similar to high mobility group (HMG) proteins. For that reason, different HMG proteins were tested for their ability to generate chromatin structures with regularly spaced nucleosomes. In this report, using two different nucleosome assembly systems, we show that the addition of phosphorylated HMGs 14 and 17 to the histone octamer results in the formation of chromatin with a repeat length of 160-165 base pairs. The results are similar to those obtained from studies of chromatin structure in simple cells, such as fungi and yeast, and in active genes.	CSIRO,DIV BIOMOLEC ENGN,MOLEC BIOL LAB,N RYDE,NSW 2113,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	TREMETHICK, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ANNUNZIATO AT, 1982, BIOCHEMISTRY-US, V21, P5431, DOI 10.1021/bi00265a008; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COLLIS C, 1989, NUCLEIC ACIDS RES, V7, P9447; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1993, IN PRESS J MOL BIOL, V240; ESPEL E, 1987, BIOCHIM BIOPHYS ACTA, V909, P190, DOI 10.1016/0167-4781(87)90077-7; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GORDON JS, 1980, BIOCHEMISTRY-US, V19, P4395, DOI 10.1021/bi00560a003; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; RAMAKRISHNAN S, 1982, J BIOL CHEM, V257, P11448; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SHICK VV, 1985, J MOL BIOL, V185, P329, DOI 10.1016/0022-2836(85)90407-3; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037	21	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11389	11393						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496189				2022-12-27	WOS:A1993LD46600097
J	AMATRUDA, TT; GERARD, NP; GERARD, C; SIMON, MI				AMATRUDA, TT; GERARD, NP; GERARD, C; SIMON, MI			SPECIFIC INTERACTIONS OF CHEMOATTRACTANT FACTOR RECEPTORS WITH G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; NUCLEOTIDE REGULATORY PROTEIN; PLATELET-ACTIVATING FACTOR; PERTUSSIS TOXIN; HL-60 CELLS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; C5A RECEPTOR; INOSITOL TRISPHOSPHATE; HUMAN-NEUTROPHILS	Stimulation of leukocytes with chemoattractant ligands activates phospholipid turnover and calcium release, ultimately leading to chemotaxis, degranulation, and the inflammatory response. The leukocyte response to these ligands is transduced by the interaction of transmembrane receptors with GTP-binding regulatory proteins (G-proteins). To examine the mechanisms of signal transduction by these receptors, we transfected cDNA clones encoding the receptors for the active cleavage product of the fifth component of complement (C5a) and platelet-activating factor (PAF) into COS-7 cells, then measured the production of inositol phosphates (IP) in response to stimulation with these chemoattractant ligands. Cells transfected with the C5a receptor showed no increase in IP production when stimulated with ligand (5-120 nm). However, in cells co-transfected with these receptors and with the cDNA for Galpha16, a G-protein alpha subunit that is specific to cells of hematopoietic lineage, addition of ligand caused up to a 5-fold increase in IP production. This interaction was specific, as co-transfection of receptors with the G-proteins Galpha(q), or Galpha11 did not allow ligand-dependent increase in IP production. In contrast, ligand-dependent activation of IP production was seen in COS cells transfected solely with the PAF receptor. These results indicate that the C5a receptor utilizes signaling pathways distinct from the PAF receptor and suggest that a pertussis toxin-resistant G-protein, Galpha16, may play a role in the leukocyte response to inflammatory ligands.	CALTECH,DIV BIOL,PASADENA,CA 91125; CHILDRENS HOSP MED CTR,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,THORNDIKE LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	California Institute of Technology; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School					NHLBI NIH HHS [HL36162] Funding Source: Medline; NIGMS NIH HHS [GM34236] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; COWEN DS, 1990, J BIOL CHEM, V265, P16181; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; GERARD C, 1993, IN PRESS ANN REV IMM; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; GUTOWSKI S, 1991, J BIOL CHEM, V266, P11409; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HWANG SB, 1988, J BIOL CHEM, V263, P3225; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MCLEISH KR, 1989, BIOCHEM J, V260, P427, DOI 10.1042/bj2600427; MURPHY PM, 1990, J IMMUNOL, V145, P2227; OMANN GM, 1991, J IMMUNOL, V146, P1303; OMANN GM, 1987, J IMMUNOL, V138, P2626; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SHIRATO M, 1988, FEBS LETT, V234, P231, DOI 10.1016/0014-5793(88)81341-3; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH CD, 1985, J BIOL CHEM, V260, P5875; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SNYDERMAN R, 1984, J CELL BIOL, V98, P444, DOI 10.1083/jcb.98.2.444; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VERGHESE MW, 1986, J IMMUNOL, V137, P271; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WU DQ, 1992, J BIOL CHEM, V267, P1811	46	200	202	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10139	10144						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486684				2022-12-27	WOS:A1993LB80000032
J	MATSUMOTO, K; NAGATA, K; UI, M; HANAOKA, F				MATSUMOTO, K; NAGATA, K; UI, M; HANAOKA, F			TEMPLATE ACTIVATING FACTOR-I, A NOVEL HOST FACTOR REQUIRED TO STIMULATE THE ADENOVIRUS CORE DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PROTEINS; INFECTED-CELLS; TERMINAL PROTEIN; TYPE-4 DNA; INVITRO; TRANSCRIPTION; PURIFICATION; CHROMATIN; BINDING; INITIATION	The adenovirus (Ad) genome in virion exists in the form of the Ad core, which is a complex of Ad DNA and viral basic proteins. The Ad core supported only initiation and limited elongation in DNA replication in a cell-free system which was developed for DNA replication of naked Ad DNA. We found that addition of a cytoplasmic fraction from uninfected HeLa cells on the top of the system stimulated Ad core DNA replication, although it had no effect on DNA replication of naked Ad DNA. The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation. SDS-polyacrylamide gel electrophoresis of the purified fraction revealed the presence of proteins with molecular masses of 41 and 39 kDa. TAF-I stimulated both initiation and elongation in Ad core DNA replication. Judging from its behavior in purification steps, TAF-I could be acidic. These findings suggest that TAF-I stimulates Ad core DNA replication by interacting with viral basic core proteins.	INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOMOLEC ENGN,YOKOHAMA,KANAGAWA 227,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	RIKEN; Tokyo Institute of Technology; University of Tokyo			Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; CORDEN J, 1976, P NATL ACAD SCI USA, V73, P401, DOI 10.1073/pnas.73.2.401; DERY CV, 1985, J GEN VIROL, V66, P2671, DOI 10.1099/0022-1317-66-12-2671; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P6779, DOI 10.1073/pnas.78.11.6779; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GODING CR, 1983, EMBO J, V2, P339, DOI 10.1002/j.1460-2075.1983.tb01428.x; HARRIS MPG, 1988, J MOL BIOL, V201, P57, DOI 10.1016/0022-2836(88)90438-X; HAY RT, 1985, J MOL BIOL, V186, P129, DOI 10.1016/0022-2836(85)90263-3; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; KAPLAN LM, 1979, P NATL ACAD SCI USA, V76, P5534, DOI 10.1073/pnas.76.11.5534; KOIKEDA S, 1990, BIOCHIM BIOPHYS ACTA, V1048, P85, DOI 10.1016/0167-4781(90)90026-X; KORN R, 1986, VIROLOGY, V150, P342, DOI 10.1016/0042-6822(86)90299-0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEEGWATER PAJ, 1988, BIOCHIM BIOPHYS ACTA, V951, P403, DOI 10.1016/0167-4781(88)90113-3; LEITH IR, 1989, J GEN VIROL, V70, P3235, DOI 10.1099/0022-1317-70-12-3235; MATSUMOTO K, 1991, FEBS LETT, V280, P53, DOI 10.1016/0014-5793(91)80202-E; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NAKANISHI Y, 1986, BIOCHEM BIOPH RES CO, V136, P86, DOI 10.1016/0006-291X(86)90880-6; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRAGE L, 1970, VIROLOGY, V42, P341, DOI 10.1016/0042-6822(70)90278-3; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; RAWLINS DR, 1984, CELL, V37, P309, DOI 10.1016/0092-8674(84)90327-1; RUSSELL WC, 1971, J GEN VIROL, V11, P35, DOI 10.1099/0022-1317-11-1-35; SCHAACK J, 1990, J VIROL, V64, P78, DOI 10.1128/JVI.64.1.78-85.1990; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TEMPERLEY SM, 1991, NUCLEIC ACIDS RES, V19, P3243, DOI 10.1093/nar/19.12.3243; WEBER J, 1984, VIROLOGY, V136, P321, DOI 10.1016/0042-6822(84)90168-5; WONG ML, 1990, J VIROL, V64, P691, DOI 10.1128/JVI.64.2.691-699.1990	36	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10582	10587						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486711				2022-12-27	WOS:A1993LB80000087
J	GIBSON, KR; VANEK, PG; KALOSS, WD; COLLIER, GB; CONNAUGHTON, JF; ANGELICHIO, M; LIVI, GP; FLEMING, PJ				GIBSON, KR; VANEK, PG; KALOSS, WD; COLLIER, GB; CONNAUGHTON, JF; ANGELICHIO, M; LIVI, GP; FLEMING, PJ			EXPRESSION OF DOPAMINE-BETA-HYDROXYLASE IN DROSOPHILA SCHNEIDER 2 CELLS - EVIDENCE FOR A MECHANISM OF MEMBRANE-BINDING OTHER THAN UNCLEAVED SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; CHROMAFFIN GRANULES; INSECT CELLS; MAMMALIAN-CELLS; MESSENGER-RNA; BOUND FORMS; SEQUENCE; VECTOR; CDNA; IMMUNOFLUORESCENCE	To characterize the mechanism of membrane attachment of dopamine beta-hydroxylase, an expression system producing the processed form of this enzyme has been developed. We have replaced the endogenous signal peptide of bovine dopamine beta-hydroxylase with a heterologous signal peptide which is efficiently recognized and cleaved in Drosophila Schneider 2 cells. A cDNA encoding this chimeric recombinant bovine enzyme has been stably transfected into Schneider 2 cells. The inducible expression of active dopamine beta-hydroxylase in these cells has been verified by Western blotting and enzyme activity assays. N-terminal sequence analysis of purified recombinant enzyme demonstrates complete removal of the signal peptide. Subcellular analysis shows that the recombinant enzyme exists as both a soluble and a membrane-bound form in these cells. These data demonstrate that the endogenous signal peptide is not required for the formation of the membranous dopamine beta-hydroxylase and further that the enzyme can be bound to membranes via a mechanism other than uncleaved signal sequence.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21701; ONCOR INC,GAITHERSBURG,MD 20877; SMITHKLINE BEECHAM,KING OF PRUSSIA,PA 19406	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); GlaxoSmithKline			Fleming, Karen/E-7892-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27695] Funding Source: Medline; NIMH NIH HHS [MH10223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BELPAIRE F, 1968, BIOCHEM PHARMACOL, V17, P411, DOI 10.1016/0006-2952(68)90251-7; BERG DT, 1991, BIOCHEM BIOPH RES CO, V179, P1289, DOI 10.1016/0006-291X(91)91713-M; BJERRUM OJ, 1979, BIOCHEM J, V181, P231, DOI 10.1042/bj1810231; BLAKEBOROUGH P, 1981, BIOCHIM BIOPHYS ACTA, V669, P33, DOI 10.1016/0005-2795(81)90220-8; BON S, 1991, J NEUROCHEM, V57, P1100, DOI 10.1111/j.1471-4159.1991.tb08267.x; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CORCORAN JJ, 1990, AM J PHYSIOL, V251, P161; CRAINE JE, 1973, J BIOL CHEM, V248, P7838; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; DEPOTTER WP, 1980, TISSUE CELL, V12, P227, DOI 10.1016/0040-8166(80)90001-4; DUONG LT, 1985, J BIOL CHEM, V260, P2393; FALLON AM, 1985, TRENDS BIOTECHNOL, V3, P217, DOI 10.1016/0167-7799(85)90008-3; FENG ZH, 1992, J BIOL CHEM, V267, P21808; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; HAMOS J, 1987, FASEB J, V1, P143, DOI 10.1096/fasebj.1.2.3609611; HARTMAN BK, 1973, J HISTOCHEM CYTOCHEM, V21, P312, DOI 10.1177/21.4.312; HEGNER M, 1992, J BIOL CHEM, V267, P16928; JOH TH, 1986, ANN NY ACAD SCI, V493, P343; KALVAKOLANU DVR, 1991, BIOTECHNIQUES, V10, P176; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LENGYEL J, 1975, METHOD CELL BIOL, P195; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; LJONES T, 1976, EUR J BIOCHEM, V61, P525, DOI 10.1111/j.1432-1033.1976.tb10047.x; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; NAGATSU T, 1972, CLIN CHEM, V18, P980; OKA M., 1967, LIFE SCI, V6, P461, DOI 10.1016/0024-3205(67)90048-3; OYARCE AM, 1991, ARCH BIOCHEM BIOPHYS, V290, P503, DOI 10.1016/0003-9861(91)90573-2; OYARCE AM, 1989, J MOL NEUROSCI, V1, P171, DOI 10.1007/BF02918903; OYARCE AM, 1991, THESIS GEORGETOWN U; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PATZAK A, 1984, J CELL BIOL, V98, P1817, DOI 10.1083/jcb.98.5.1817; PHILLIPS JH, 1983, J CELL BIOL, V97, P1906, DOI 10.1083/jcb.97.6.1906; POTTER LT, 1963, J PHARMACOL EXP THER, V142, P291; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SAXENA A, 1985, J BIOL CHEM, V260, P3386; Schneider I, 1972, J EMBRYOL EXP MORPH, V27, P363; SKOTLAND T, 1977, BIOCHEM BIOPH RES CO, V74, P1483, DOI 10.1016/0006-291X(77)90609-X; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; STEWART LC, 1988, J BIOL CHEM, V263, P12183; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; TAYLOR CS, 1989, J BIOL CHEM, V264, P15242; TAYLOR CS, THESIS GEORGETOWN U; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIFARO JM, 1969, MOL PHARMACOL, V5, P382; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; VIVEROS OH, 1968, LIFE SCI PT 1 PHYSI, V7, P609, DOI 10.1016/0024-3205(68)90186-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLACE EF, 1973, P NATL ACAD SCI USA, V70, P2253, DOI 10.1073/pnas.70.8.2253; WEINSHILBOUM R, 1971, CIRC RES, V28, P307, DOI 10.1161/01.RES.28.3.307; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303; Winkler H, 1982, SECRETORY GRANULE, P3; WU HJ, 1988, J NEUROCHEM, V55, P97	61	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9490	9495						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486639				2022-12-27	WOS:A1993LA68900053
J	YANG, YQ; BARKER, S; CHEN, MJ; MAYO, KH				YANG, YQ; BARKER, S; CHEN, MJ; MAYO, KH			EFFECT OF LOW-MOLECULAR-WEIGHT ALIPHATIC-ALCOHOLS AND RELATED-COMPOUNDS ON PLATELET FACTOR-IV SUBUNIT ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; THERMODYNAMICS; MECHANISM; PROTEINS	Titration of platelet factor 4 (PF4) with increasing concentrations of various low molecular weight aliphatic alcohols disrupts dimer and tetramer quaternary structure while preserving tertiary structural integrity. Normally observed slow subunit exchange (H-1 NMR time scale) is shifted into the fast chemical exchange regime. The order of effectiveness is butanol > 2-propanol > propanol > ethanol > methanol. Fluorination of ethanol (trifluoroethanol) and 2-propanol (hexafluoro-2-propanol) increases effectiveness by approximately 2 orders of magnitude. Oxidation to 2-propanone or trifluoro-2-propanone produces a less effective compound, suggesting a mechanistic role for the hydroxyl group. Increasing the number of hydroxyls to three, as in glycerol, however, is relatively ineffective in disrupting aggregate states or modifying subunit exchange rates. While F-19 NMR studies indicate that these alcohols specifically interact with PF4, binding alone can not explain their mechanism of action. Dimethyl sulfoxide, structurally similar to 2-propanol, disrupts PF4 aggregation by direct binding, but does not shift subunit exchange kinetics into the NMR fast-exchange regime. Although not fully understood, the effectiveness of these compounds appears to be related to the colligative properties of the solution.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NCRR NIH HHS [RR-04040] Funding Source: Medline; NHLBI NIH HHS [HL-43194] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL143194, R01HL043194] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKAWA T, 1990, BIOCHEMISTRY-US, V29, P1924, DOI 10.1021/bi00459a037; ARAKAWA T, 1985, BIOCHEMISTRY-US, V24, P6756, DOI 10.1021/bi00345a005; BARKER S, 1991, J AM CHEM SOC, V113, P8199, DOI 10.1021/ja00022a001; CHEN MJ, 1991, BIOCHEMISTRY-US, V30, P6402, DOI 10.1021/bi00240a009; CONIO G, 1970, J BIOL CHEM, V245, P3335; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584; FRANKS F, 1967, T FARADAY SOC, V63, P329, DOI 10.1039/tf9676300329; FRANKS F, 1966, Q REV CHEM SOC, V20, P1, DOI 10.1039/qr9662000001; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; HAMMES GG, 1967, J AM CHEM SOC, V89, P442, DOI 10.1021/ja00978a050; HERMODSON M, 1977, J BIOL CHEM, V252, P6276; Jardetzky O., 1981, NMR MOL BIOL; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYO KH, 1992, BIOCHEMISTRY-US, V31, P12255, DOI 10.1021/bi00163a040; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; PARODI RM, 1973, J BIOL CHEM, V248, P4047; PITTZ EP, 1978, BIOCHEMISTRY-US, V17, P615, DOI 10.1021/bi00597a009; PITTZ EP, 1970, ARCH BIOCHEM BIOPHYS, V146, P513; RUCINSKI B, 1979, BLOOD, V53, P47; TIMASHEFF SN, 1988, PROTEIN STRUCTURE PR, P331; VONHIPPEL PH, 1965, J BIOL CHEM, V240, P3609; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WALZ DA, 1977, THROMB RES, V11, P893, DOI 10.1016/0049-3848(77)90117-7	24	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9223	9229						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486623				2022-12-27	WOS:A1993LA68900015
J	YEH, JI; BIEMANN, HP; PANDIT, J; KOSHLAND, DE; KIM, SH				YEH, JI; BIEMANN, HP; PANDIT, J; KOSHLAND, DE; KIM, SH			THE 3-DIMENSIONAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF A WILD-TYPE BACTERIAL CHEMOTAXIS RECEPTOR - STRUCTURAL COMPARISON TO THE CROSS-LINKED MUTANT FORMS AND CONFORMATIONAL-CHANGES UPON LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE RECEPTOR; SENSORY RECEPTOR; CRYSTALLIZATION	The three-dimensional structures of the ligand-binding domain of the wild-type Salmonella typhimurium aspartate receptor have been determined in the absence (apo) and presence of bound aspartate (complex) and compared to a cross-linked mutant containing a cysteine at position 36 which does not change signaling behavior of the intact receptor. The structures of the wild-type forms were determined in order to assess the effects of cross-linking on the structure and its influence on conformational changes upon ligand binding. As in the case of the cross-linked mutant receptor, the non-cross-linked ligand-binding domain is dimeric and is composed of 4-alpha-helical bundle monomer subunits related by a crystallographic 2-fold axis in the unbound form and by a non-crystallographic axis in the aspartate-bound form. A comparative study between the non-cross-linked and cross-linked structures has led to the following observations: 1) The long N-terminal helices of the individual subunits in the cross-linked structures are bent toward each other to accommodate the disulfide bond. 2) The rest of the subunit conformation is very similar to that of the wild-type. 3) The intersubunit angle of the cross-linked apo structure is larger by about 13 degrees when compared to the wild-type apo structure. 4) The nature and magnitude of the aspartate-induced conformational changes in the non-crosslinked wild-type structures are very similar to those of the cross-linked structures.	LAWRENCE BERKELEY LAB,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	YEH, JI (corresponding author), LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720, USA.			Pandit, Jayvardhan/0000-0001-6128-7779	NIAID NIH HHS [AI 30725] Funding Source: Medline; NIDDK NIH HHS [DK09765] Funding Source: Medline; NIGMS NIH HHS [T32 GM08295-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; BRUNGER A, 1992, XPLOR 3 0 SYSTEM CRY; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; HUBER R, 1985, MOL REPLACEMENT, P58; JANCARIK J, 1991, J MOL BIOL, V221, P31, DOI 10.1016/0022-2836(91)80198-4; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MILLIGAN DL, 1991, THESIS U CALIFORNIA; WANG EA, 1980, P NATL ACAD SCI-BIOL, V77, P7157, DOI 10.1073/pnas.77.12.7157	13	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9787	9792						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486661				2022-12-27	WOS:A1993LA68900092
J	YU, C; BASSLER, BL; ROSEMAN, S				YU, C; BASSLER, BL; ROSEMAN, S			CHEMOTAXIS OF THE MARINE BACTERIUM VIBRIO-FURNISSII TO SUGARS - A POTENTIAL MECHANISM FOR INITIATING THE CHITIN CATABOLIC CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSE PHOSPHOTRANSFERASE SYSTEM; ESCHERICHIA-COLI; TRANSPORT	Immense quantities of chitin are catabolized by marine bacteria, and this process involves at least three signal transduction systems in Vibrio furnissii. One system, chemotaxis to chitin oligosaccharides, is probably used to colonize chitin particles. But how do the first few cells find this highly insoluble polysaccharide? The following hypothesis is proposed to answer this question: the bacteria respond to soluble chemoattractants in exudates from injured organisms. Virtually all chitin-producing organisms also contain glucose and/or trehalose, often at high concentrations such as trehalose in insect hemolymph. Chemotaxis of V. furnissii was therefore studied with a variety of sugars. Fructose, ribose, and glycerol are catabolites but not attractants. The cells exhibit weak constitutive taxis to Glc and GlcNAc. After induction, they show a weak response to galactose but are strongly attracted to the following substrates of the phosphoenolpyruvate:glycose phosphotransferase system (PTS): GlcNAc, trehalose, glucose, sucrose, mannose, and mannitol. There is a rough qualitative but no quantitative correlation between the rate of phosphorylation and the chemotactic response to PTS sugars. Trehalose is especially noteworthy because it is phosphorylated at a very rapid rate by uninduced cells but is not an attractant until the cells are induced. We suggest that unidentified inducible factors link the PTS to chemotaxis.	JOHNS HOPKINS UNIV HOSP,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins Medicine	YU, C (corresponding author), JOHNS HOPKINS UNIV HOSP,MCCOLLUM PRATT INST,BALTIMORE,MD 21218, USA.			Bassler, Bonnie/0000-0002-0043-746X	NIGMS NIH HHS [5T32 GM07321, GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J BACTERIOL, V115, P824, DOI 10.1128/JB.115.3.824-847.1973; ALTMAN PL, 1971, BLOOD OTHER BODY FLU, P287; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BOOS W, 1990, J BACTERIOL, V172, P3450, DOI 10.1128/jb.172.6.3450-3461.1990; Colwell R. R., 1984, VIBRIOS ENV, P367; FLORKIN M, 1970, CHEM ZOOL, P147; GACHELIN G, 1969, BIOCHEM BIOPH RES CO, V34, P382, DOI 10.1016/0006-291X(69)90392-1; GRUBL G, 1990, J BACTERIOL, V172, P5871; Jeuniaux C, 1971, COMPREHENSIVE BIOC C, V26, P595; Johnstone J., 1908, CONDITIONS LIFE SEA; KUBOTA Y, 1982, FEMS MICROBIOL LETT, V13, P5; MACNAB RM, 1987, ESCHERICHIA COLI SAL, V1, P732; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1987, J BACTERIOL, V169, P4893, DOI 10.1128/jb.169.11.4893-4900.1987; POULICEK M, 1989, CHITIN CHITOSAN, P151; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; STANK J, 1965, OLIGOSACCHARIDES, P154; TRACEY M. V., 1957, REVS PURE AND APPL CHEM, V7, P1; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WOD WA, 1988, METHODS EZYMOL, V161, P403; YU C, 1991, J BIOL CHEM, V266, P24260; ZOBELL CE, 1937, J BACTERIOL, V35, P275	23	41	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9405	9409						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486635				2022-12-27	WOS:A1993LA68900041
J	HUANG, SM; MULVIHILL, ER; FARRELL, DH; CHUNG, DW; DAVIE, EW				HUANG, SM; MULVIHILL, ER; FARRELL, DH; CHUNG, DW; DAVIE, EW			BIOSYNTHESIS OF HUMAN FIBRINOGEN - SUBUNIT INTERACTIONS AND POTENTIAL INTERMEDIATES IN THE ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; RECOMBINANT HUMAN FIBRINOGEN; INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; ALPHA-CHAIN; BREFELDIN-A; BETA-CHAIN; PROTEINS; BINDING; CONVERSION	Stable transfected baby hamster kidney (BHK) cells expressing human alpha, beta, and gamma fibrinogen chains together, in various combinations of any two, or individually, were established. Several types of subunit interactions were observed in the intracellular extracts of the transfected BHK cell lines as well as in Hep G2 cells. These included: 1) formation of alphagamma dimers linked by a disulfide bond(s), 2) formation of betagamma dimers linked by a disulfide bond(s), 3) formation of alphabetagamma half-molecules linked by disulfide bonds, and 4) formation of mature fibrinogen, which was also secreted into the cell culture medium. Analysis of the chain composition confirmed the stoichiometry of the alphagamma, betagamma, and alphabetagamma complexes. These data are consistent with the proposal that the alphagamma and betagamma dimers as well as the alphabetagamma half-molecules are intermediates in the assembly and biosynthesis of fibrinogen. In contrast, disulfide-linked alphabeta complexes were not found in transfected BHK cells or in Hep G2 cells, suggesting that the formation of disulfide bonds between these two chains most likely occurs when alphabetagamma half-molecules are formed from alphagamma and/or betagamma complexes and when alphabetagamma half-molecules dimerize to generate the mature molecule. Dimers, trimers, and larger oligomers of each individual chain linked by disulfide bonds were also identified when each chain was expressed in the absence of the other two chains. Preferential formation of alphagamma and betagamma complexes, rather than oligomers of individual chains, suggested that the oligomers were less likely to be intermediates in the assembly of fibrinogen. A model for fibrinogen assembly is presented based on these results.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; ZYMOGENET INC, SEATTLE, WA 98105 USA	University of Washington; University of Washington Seattle; Zymogenet Inc.			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NHLBI NIH HHS [HL16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BORNSTEIN P, 1974, ANNU REV BIOCHEM, V43, P567, DOI 10.1146/annurev.bi.43.070174.003031; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CHUNG DW, 1990, ADV EXP MED BIOL, V281, P39; DAVIDSON JM, 1977, EUR J BIOCHEM, V81, P349, DOI 10.1111/j.1432-1033.1977.tb11958.x; Doolittle R F, 1973, Adv Protein Chem, V27, P1, DOI 10.1016/S0065-3233(08)60446-5; Doolittle R.F., 1975, PLASMA PROTEINS STRU, VII, P110; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FARRELL DH, 1992, J CELL BIOCH F, V16, P173; FARRELL DH, 1989, BLOOD, V74, P55; FORMAN WB, 1964, JAMA-J AM MED ASSOC, V187, P128; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1951; HENSCHEN A, 1978, HOPPESEYLERS Z PHYSL, V359, P1751; HUANG S, 1992, BLOOD, V80, P263; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTSPEICH F, 1977, HOPPESEYLERS Z PHYSL, V358, P3787; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MULVILHILL E, 1988, Patent No. 339944; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROY SN, 1991, J BIOL CHEM, V266, P4758; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P68, DOI 10.1021/bi00568a011; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, FIBRINOGEN FIBRIN FO, V4, P665	43	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8919	8926						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473334				2022-12-27	WOS:A1993KX81100079
J	KRAEMER, R; POMERANTZ, KB; JOSEPHSILVERSTEIN, J; HAJJAR, DP				KRAEMER, R; POMERANTZ, KB; JOSEPHSILVERSTEIN, J; HAJJAR, DP			INDUCTION OF BASIC FIBROBLAST GROWTH-FACTOR MESSENGER-RNA AND PROTEIN-SYNTHESIS IN SMOOTH-MUSCLE CELLS BY CHOLESTERYL ESTER ENRICHMENT AND 25-HYDROXYCHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ENDOTHELIAL-CELLS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; HEPARIN; MACROPHAGES; INHIBITION; RELEASE; LDL; ATHEROSCLEROSIS	Basic fibroblast growth factor (bFGF) is a potent smooth muscle cell mitogen. Smooth muscle cell and macrophage-derived foam cells, resulting from cholesteryl ester accretion, are hallmark characteristics of atherosclerosis. We wanted to determine if bFGF synthesis is altered during cholesteryl ester accumulation in smooth muscle cells. Cholesteryl ester enrichment causes a 3-fold increase in bFGF in cellular lysates and a 3-fold increase in steady state mRNA levels for bFGF, as compared with control cells. Conditioned media from cholesteryl ester-enriched smooth muscle cells contains 6 times more mitogenic activity than conditioned media from control cells; this activity is neutralized by an antibody directed against bFGF but not by an antibody directed against platelet-derived growth factor. These results suggest that cholesteryl ester enrichment also enhances bFGF release. Since oxysterols have been implicated in the pathogenesis of atherosclerosis, we determined if oxysterols could affect bFGF production and release. 25-Hydroxycholesterol also increases the release of bFGF-like mitogens from smooth muscle cells, as well as increasing mRNA transcript levels for bFGF. Cholesteryl ester enrichment and 25-hydroxycholesterol did not promote bFGF release secondary to cell injury. In conclusion, these data define a basic mechanism for smooth muscle cell hyperplasia during atherogenesis involving the generation of bFGF by smooth muscle cell-derived foam cells.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439	Cornell University; Cornell University; Saint John's University	KRAEMER, R (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PATHOL,1300 YORK AVE,NEW YORK,NY 10021, USA.			Pomerantz, Kenneth/0000-0001-9443-5301	NHLBI NIH HHS [P01-HL-46403, T32 HL-07423, R01 HL-39701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007423, R01HL039701, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ANDRADEGORDON P, 1990, P NATL ACAD SCI USA, V87, P1865, DOI 10.1073/pnas.87.5.1865; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BROOKS RA, 1991, BIOCHEM J, V276, P113, DOI 10.1042/bj2760113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FLORKIEWICZ R, 1989, P NATL ACAD SCI USA, V86, P3971; FOX PL, 1986, P NATL ACAD SCI USA, V83, P4774, DOI 10.1073/pnas.83.13.4774; FOX PL, 1987, J BIOL CHEM, V262, P6046; GOSPODAROWICZ D, 1988, EUR J CELL BIOL, V46, P144; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HAJJAR DP, 1987, J BIOL CHEM, V262, P6976; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4; INABA T, 1992, J BIOL CHEM, V267, P5693; JOSEPHSILVERSTEIN J, 1988, J IMMUNOL METHODS, V110, P183, DOI 10.1016/0022-1759(88)90102-0; KATSUDA S, 1992, AM J PATHOL, V140, P907; KAUL D, 1987, ATHEROSCLEROSIS, V64, P211, DOI 10.1016/0021-9150(87)90248-6; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KUSUHARA H, 1992, LIPIDS, V27, P478, DOI 10.1007/BF02536393; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARNETT LJ, 1979, ANAL BIOCHEM, V99, P458, DOI 10.1016/S0003-2697(79)80033-0; MAZZONE T, 1991, J LIPID RES, V32, P507; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; OLSON NE, 1992, AM J PATHOL, V140, P1017; PIE JE, 1992, LIPIDS, V27, P270, DOI 10.1007/BF02536474; PITAS RE, 1990, J BIOL CHEM, V265, P12722; POMERANTZ KB, 1984, CIRC RES, V54, P554, DOI 10.1161/01.RES.54.5.554; POMERANTZ KB, 1990, BIOCHEMISTRY-US, V29, P1892, DOI 10.1021/bi00459a033; POMERANTZ KB, 1989, J LIPID RES, V30, P1219; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; TAKAGI K, 1989, J BIOL CHEM, V264, P12353; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; WINKLES JA, 1992, CANCER RES, V52, P1040; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; ZHANG HF, 1990, J LIPID RES, V31, P1361	47	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8040	8045						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463321				2022-12-27	WOS:A1993KW97900067
J	GUNZL, A; CROSS, M; PALFI, Z; BINDEREIF, A				GUNZL, A; CROSS, M; PALFI, Z; BINDEREIF, A			ASSEMBLY OF THE U2 SMALL NUCLEAR RIBONUCLEOPROTEIN FROM TRYPANOSOMA-BRUCEI - A MUTATIONAL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICED LEADER; STRUCTURAL ORGANIZATION; PROTEIN-COMPONENTS; SNRNP; U1; PARTICLES; U4; IDENTIFICATION; PURIFICATION	trans-Splicing in trypanosomes requires the functions of U2 and U4/U6 small nuclear (sn) RNPs. We have analyzed protein binding and assembly of the Trypanosoma brucei U2 snRNP, using specific antibodies against U2 snRNP proteins and in vitro reconstitution assays of U2 deletion derivatives and human-trypanosome hybrid RNAs. Stable binding of both the U2-specific 40-kDa and the common proteins requires only the 3'-terminal domain (stem-loop IIb, single-stranded region, and stem-loop IV), with loop IV providing the critical sequence determinant; stem-loop IV suffices for binding of the 40 kDa-protein, but not of the common proteins; surprisingly, the sequence of the ''Sm-analogous'' single-stranded region between stem-loops IIb and IV is not essential for protein binding. Our mutational analysis further indicates that interactions between common and specific proteins play an important role in the assembly of a stable core complex. Finally, a partially assembled U2 RNP complex could be identified as a kinetic intermediate of U2 snRNP assembly. We propose a model of the domain structure and assembly of the trans-spliceosomal U2 snRNP, which deviates in several aspects from that of the cis-spliceosomal U2 snRNP; these differences may be related to the trans-splicing-specific functions of the trypanosomal U2 snRNP.	MAX PLANCK INST MOLEC GENET, OTTO WARBURG LAB, IHNESTR 73, W-1000 BERLIN 33, GERMANY	Max Planck Society				Gunzl, Arthur/0000-0002-7487-2261				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; BRUN R, 1979, ACTA TROP, V36, P289; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; CROSS M, 1993, EMBO J, V12, P1239, DOI 10.1002/j.1460-2075.1993.tb05765.x; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; GUNZL A, 1992, MOL CELL BIOL, V12, P468; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LIAUTARD JP, 1982, J MOL BIOL, V162, P623, DOI 10.1016/0022-2836(82)90392-8; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, EMBO J, V5, P997, DOI 10.1002/j.1460-2075.1986.tb04314.x; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MIRAGLIA L, 1991, P NATL ACAD SCI USA, V88, P7061, DOI 10.1073/pnas.88.16.7061; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NILSEN TW, 1992, INFECT AGENT DIS, V1, P212; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; REVEILLAUD I, 1984, MOL CELL BIOL, V4, P1890, DOI 10.1128/MCB.4.9.1890; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TSCHUDI C, 1990, GENE, V91, P71, DOI 10.1016/0378-1119(90)90164-M; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, NUCLEIC ACIDS RES, V16, P11375, DOI 10.1093/nar/16.23.11375; VANDOREN K, 1988, NATURE, V335, P556; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WERSIG C, 1992, MOL CELL BIOL, V12, P1460, DOI 10.1128/MCB.12.4.1460; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU JA, 1992, MOL CELL BIOL, V12, P5464, DOI 10.1128/MCB.12.12.5464	42	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13336	13343						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514772				2022-12-27	WOS:A1993LH55300048
J	HARTZOG, PE; CAIN, BD				HARTZOG, PE; CAIN, BD			THE A(LEU207)-]ARG MUTATION IN F(1)F(0)-ATP SYNTHASE FROM ESCHERICHIA-COLI - A MODEL FOR HUMAN MITOCHONDRIAL DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTON-TRANSLOCATING ATPASE; ALPHA-SUBUNIT; H+-ATPASE; A-SUBUNIT; NUCLEOTIDE-SEQUENCE; F1F0-ATP SYNTHASE; UNC OPERON; PORE; F0F1-ATPASE; REGION	The mitochondrial ATPase 6 gene encodes a subunit of F1F0 adenosine triphosphate (ATP) synthase. A mutation in the ATPase 6 gene has been genetically linked to two maternally inherited genetic diseases: neurological muscle weakness, ataxia, and retinitis pigmentosa (NARP) and certain cases of subacute necrotizing encephalopathy (SNE). Although the severity of both NARP and SNE disease were correlated with the quantity of the ATPase 6leu156-->arg mutation in each patient, the mutation could not be shown to alter F1F0-ATP synthase activity. To investigate the biochemical effects of the ATPase 6leu156-->arg mutation on F1F0-ATP synthase, the a(leu207-->arg) mutation was constructed in the F1F0-ATP synthase from Escherichia coli to serve as a model for the disease mutation. Characterization of the model bacterial enzyme revealed that the mutation abolishes detectable ATP synthesis via oxidative phosphorylation. The a(leu207-->arg) mutation results in a structural perturbation blocking proton translocation through F1F0-ATP synthase. The results suggest that a structural defect in human F1F0-ATP synthase is the biochemical basis for NARP and SNE.	UNIV FLORIDA, DEPT BIOCHEM & MOLEC BIOL, BOX 100245 JHMHC, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43495] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1985, J BIOL CHEM, V260, P1207; ASHLEY MV, 1989, NUCLEIC ACIDS RES, V17, P7325, DOI 10.1093/nar/17.18.7325; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; EYA S, 1988, J BIOL CHEM, V263, P10056; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRISI E, 1982, NUCLEIC ACIDS RES, V10, P3531, DOI 10.1093/nar/10.11.3531; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HENNIG J, 1986, MOL GEN GENET, V203, P117, DOI 10.1007/BF00330392; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOWITT SM, 1988, BIOCHIM BIOPHYS ACTA, V936, P74, DOI 10.1016/0005-2728(88)90253-8; KLIONSKY DJ, 1983, J BIOL CHEM, V258, P136; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; MARKWELL MAK, ANAL BIOCHEM, V587, P206; MILLER JH, 1972, EXPT MOL GENETICS, P131; MORELLI G, 1984, J MOL BIOL, V178, P491, DOI 10.1016/0022-2836(84)90235-3; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER EM, 1989, J BACTERIOL, V171, P3901, DOI 10.1128/jb.171.7.3901-3908.1989; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168; TATUCH Y, 1992, AM J HUM GENET, V50, P852; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; VIK SB, 1991, J BACTERIOL, V173, P4544, DOI 10.1128/JB.173.14.4544-4548.1991; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; 1987, K RT SEQUENCING SYST; 1987, STEP BY STEP PROTOCO; 1992, RELEASE 31	37	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12250	12252						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509361				2022-12-27	WOS:A1993LG65800006
J	OHKI, S; IWAMOTO, U; AIMOTO, S; YAZAWA, M; HIKICHI, K				OHKI, S; IWAMOTO, U; AIMOTO, S; YAZAWA, M; HIKICHI, K			MG2+ INHIBITS FORMATION OF 4CA2+-CALMODULIN-ENZYME COMPLEX AT LOWER CA2+ CONCENTRATION - H-1 AND CD-113 NMR-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; NUCLEAR MAGNETIC-RESONANCE; CALMODULIN-BINDING DOMAIN; RABBIT SKELETAL-MUSCLE; 2 GLOBULAR DOMAINS; CONFORMATIONAL CHANGE; CALCIUM-BINDING; MASTOPARAN BINDING; TRYPTIC FRAGMENTS; PROTEOLYTIC FRAGMENTS	Our previous H-1 NMR studies indicated that when mastoparan (MP) is added to Ca2+-half-saturated calmodulin (2Ca2+-CaM) in the absence of Mg2+, ions, Ca2+ ions transfer from the C-terminal-half domain of CaM not interacting with MP to the N-terminal-half domain of CaM interacting with MP at lower MP concentrations (Ohki, S., Yazawa, M., Yagi, K., and Hikichi, K. (1991b) J. Biochem. (Tokyo) 110, 737-742). As a consequence, the active form of 4Ca2+-CaM.MP complex is formed. In the present study, we studied the effect of Mg2+ ions on Ca2+ transfer. In the presence of Mg2+ ions, such Ca2+ transfer does not occur. The effects of Mg2+ ions are also studied by observing Cd-113 NMR in the presence of M13, the 26-residue peptide of the CaM-binding region of myosin light chain kinase. The Cd-113 NMR results show that Mg2+ ions prevent to form the active complex. Mg2+ plays an important role as an inactivating factor to CaM.	HOKKAIDO UNIV,FAC SCI,DEPT POLYMER SCI,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC SCI,DEPT CHEM,SAPPORO,HOKKAIDO 060,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Hokkaido University; Hokkaido University; Osaka University								AULABAUGH A, 1984, BIOCHEM BIOPH RES CO, V118, P225, DOI 10.1016/0006-291X(84)91090-8; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; Cohen P, 1988, CALMODULIN; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DABROWSKA R, 1977, BIOCHEM BIOPH RES CO, V78, P1263, DOI 10.1016/0006-291X(77)91429-2; DRABIKOWSKI W, 1982, J BIOL CHEM, V257, P1584; FORSEN S, 1980, FEBS LETT, V117, P189, DOI 10.1016/0014-5793(80)80942-2; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HUNG CY, 1981, P NATL ACAD SCI USA, V78, P871; HURWITZ MY, 1988, FEBS LETT, V238, P82, DOI 10.1016/0014-5793(88)80230-8; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1983, BIOCHEMISTRY-US, V22, P2573, DOI 10.1021/bi00279a039; IKURA M, 1989, BIOCHEM BIOPH RES CO, V161, P1233, DOI 10.1016/0006-291X(89)91374-0; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KLEVIT RE, 1984, EUR J BIOCHEM, V139, P109, DOI 10.1111/j.1432-1033.1984.tb07983.x; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LINSE S, 1986, FEBS LETT, V199, P28, DOI 10.1016/0014-5793(86)81217-0; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MATSUSHIMA N, 1989, J BIOCHEM, V105, P883, DOI 10.1093/oxfordjournals.jbchem.a122773; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; MUCHMORE DC, 1986, BIOCHEM BIOPH RES CO, V137, P1069, DOI 10.1016/0006-291X(86)90334-7; OGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P19, DOI 10.1093/oxfordjournals.jbchem.a134584; OGAWA Y, 1986, J BIOCHEM-TOKYO, V99, P73, DOI 10.1093/oxfordjournals.jbchem.a135481; OHKI S, 1991, J BIOCHEM-TOKYO, V109, P234; OHKI S, 1991, J BIOCHEM-TOKYO, V110, P737, DOI 10.1093/oxfordjournals.jbchem.a123650; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V25, P4011; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; SUTOO D, 1985, JPN J PHARMACOL, V40, P169; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; TSAI MD, 1987, BIOCHEMISTRY-US, V26, P3635, DOI 10.1021/bi00386a057; TSUDA S, 1990, BIOCHEMISTRY-US, V29, P4951, DOI 10.1021/bi00472a027; YAGI K, 1989, BIOFORMATICS, P27; YAZAWA M, 1984, J BIOCHEM-TOKYO, V95, P443, DOI 10.1093/oxfordjournals.jbchem.a134625; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; YOSHINO H, 1989, J BIOL CHEM, V264, P19706	48	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12388	12392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509378				2022-12-27	WOS:A1993LG65800028
J	SAWADA, R; JARDINE, KA; FUKUDA, M				SAWADA, R; JARDINE, KA; FUKUDA, M			THE GENES OF MAJOR LYSOSOMAL MEMBRANE-GLYCOPROTEINS LAMP-1 AND LAMP-2 - THE 5'-FLANKING SEQUENCE OF LAMP-2 GENE AND COMPARISON OF EXON ORGANIZATION IN 2 GENES (VOL 268, PG 9014, 1993)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition																		SAWADA R, 1993, J BIOL CHEM, V268, P9014	1	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					13010	13010						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509432				2022-12-27	WOS:A1993LG65800114
J	BERNAL, D; QUINONES, S; SAUS, J				BERNAL, D; QUINONES, S; SAUS, J			THE HUMAN MESSENGER-RNA ENCODING THE GOODPASTURE ANTIGEN IS ALTERNATIVELY SPLICED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; SYNDROME TYPE-VII; IV COLLAGEN; ALPHA-3(IV) CHAIN; SEQUENCE-ANALYSIS; GLOBULAR DOMAIN; TRIPLE HELIX; GENE; LOCALIZATION; PROCOLLAGEN	The noncollagenous (NC1) domain of the human collagen alpha3(IV)-chain is the primary target of autoantibodies produced in Goodpasture syndrome and, therefore, has been designated as the Goodpasture antigen. In this report, we show that Goodpasture antigen mRNA undergoes processing to at least two alternatively spliced forms in a variety of human tissues, resulting in the exclusion of sequence encoded by either one or two exons. Interestingly, no alternatively spliced forms were observed in bovine or rat tissues. The derived amino acid sequences of the two variant mRNA forms are identical and significantly shorter than that arising from the complete Goodpasture antigen mRNA. They lack the carboxyl-terminal region contributing to the formation of the Goodpasture epitope and all but one of the cysteines found in the complete form. These sequence characteristics suggest that, if translated, the variant Goodpasture antigen is likely to be defective in triple helix formation and no longer reactive with Goodpasture autoantibodies. Although each tissue expressing Goodpasture antigen displayed a specific mRNA pattern, the complete form was always the most abundant and was present at levels apparently unrelated to whether or not the organ of origin is a potential target in Goodpasture syndrome. Furthermore, the antigen sequence was identical in the kidneys of normal and Goodpasture-affected individuals, and no major differences in the expression of the complete and spliced forms were observed.	INST INVEST CITOLOGICAL CAJA AHORROS VALENCIA,FDN VALENCIANA INVEST BIOMED,C AMADEO SABOYA 4,E-46010 VALENCIA,SPAIN; UNIV VALENCIA,FAC FARM,DEPT BIOQUIM & BIOL MOLEC,E-46100 VALENCIA,SPAIN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854	University of Valencia; Rutgers State University New Brunswick; Rutgers State University Medical Center			Bernal, Dolores/K-7769-2014	Bernal, Dolores/0000-0003-4627-8393; Saus, Juan/0000-0003-2082-1597	NIDDK NIH HHS [DK-42514] Funding Source: Medline; NIEHS NIH HHS [ESO 5022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042514] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; HUDSON BG, 1989, LAB INVEST, V61, P259; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRISON KE, 1991, AM J HUM GENET, V49, P545; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PROCKOP DJ, 1990, ANN NY ACAD SCI, V580, P330, DOI 10.1111/j.1749-6632.1990.tb17942.x; QUINONES S, 1992, J BIOL CHEM, V267, P19780; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STOKES DG, 1991, J BIOL CHEM, V266, P8626; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WEIL D, 1989, J BIOL CHEM, V264, P16804; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564	35	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12090	12094						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505332				2022-12-27	WOS:A1993LF28400094
J	CORDLE, SR; DONALD, R; READ, MA; HAWIGER, J				CORDLE, SR; DONALD, R; READ, MA; HAWIGER, J			LIPOPOLYSACCHARIDE INDUCES PHOSPHORYLATION OF MAD3 AND ACTIVATION OF C-REL AND RELATED NF-KAPPA-B PROTEINS IN HUMAN MONOCYTIC THP-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENHANCER-BINDING-PROTEIN; HUMAN-BLOOD MONOCYTES; NECROSIS-FACTOR-ALPHA; FACTOR MESSENGER-RNA; DNA-BINDING; TRANSCRIPTION FACTOR; P65 SUBUNIT; T-CELLS; MONONUCLEAR PHAGOCYTES	Many effects of lipopolysaccharide (LPS) on gene expression, including that of human immunodeficiency virus (HIV), in monocytic cells are mediated by activation of kappaB DNA-binding proteins. However, the specific members of the NF-kappaB/Rel transcription factor family involved in the LPS response, and the mechanisms through which LPS-generated signals are transduced remain unclear. Here we show that LPS induces nuclear expression of c-Rel/p50 heterodimers as well as p50/p65 (NF-kappaB) kappaB DNA-binding complexes in human monocytic THP-1 cells. Nuclear localization of these proteins occurred concomitantly with a rapid decrease in their cytosolic levels and was independent of phorbol ester-sensitive protein kinase C. Within 24 h following LPS stimulation there was a striking increase in the levels of c-Rel, p105, and p50 in the cytosol. The increased levels of these proteins correlated with increases in the amounts of their mRNAs during LPS activation of THP-1 cells. LPS activation of THP-1 cells resulted in phosphorylation of MAD3 (an IkappaB-like protein), a rapid increase in MAD3 mRNA, and an increase in MAD3 protein by 2 h. Thus, LPS activation of human monocytic cells results in nuclear expression of c-Rel/p50 and p50/p65 (NF-kappaB) and induces phosphorylation of MAD3.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Vanderbilt University					NHLBI NIH HHS [R37 HL30647] Funding Source: Medline; PHS HHS [T32-07186] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1986, CURRENT PROTOCOLS MO; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P423; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BAUER J, 1988, BLOOD, V72, P1134; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOULET I, 1992, ONCOGENE, V7, P703; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BROWNELL E, 1988, ONCOGENE, V3, P93; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DROUET C, 1991, J IMMUNOL, V147, P1694; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INTRONA M, 1986, J IMMUNOL, V137, P2711; IP YT, 1991, CELL, V64, P439; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1992, ONCOGENE, V7, P567; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LEE JH, 1991, ONCOGENE, V6, P665; LINK E, 1992, J BIOL CHEM, V267, P239; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOUCHARDT C, 1992, J VIROL, V66, P244; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN M, 1992, ONCOGENE, V7, P2095; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHWARTZ BS, 1991, J BIOL CHEM, V267, P7089; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	85	233	236	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11803	11810						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505309				2022-12-27	WOS:A1993LF28400053
J	GARROW, TA; BRENNER, AA; WHITEHEAD, VM; CHEN, XN; DUNCAN, RG; KORENBERG, JR; SHANE, B				GARROW, TA; BRENNER, AA; WHITEHEAD, VM; CHEN, XN; DUNCAN, RG; KORENBERG, JR; SHANE, B			CLONING OF HUMAN CDNAS ENCODING MITOCHONDRIAL AND CYTOSOLIC SERINE HYDROXYMETHYLTRANSFERASES AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; INSITU HYBRIDIZATION; FRAGILE SITE; ACTIVE-SITE; HUMAN GENES; GLYA GENE; PURIFICATION; TRANSHYDROXYMETHYLASE; BIOSYNTHESIS; EXPRESSION	Human cDNAs for cytosolic and mitochondrial serine hydroxymethyltransferase (SHMT) were cloned by functional complementation of an Escherichia coli glyA mutant with a human cDNA library. The cDNA for the cytosolic enzyme encodes a 483-residue protein of M(r) 53,020. The cDNA for the mitochondrial enzyme encodes a mature protein of 474 residues of M(r) 52,400. The deduced protein sequences share a high degree of sequence identity to each other (63%), and the individual isozymes are highly homologous to the analogous rabbit liver cytosolic (92% identity) and mitochondrial (97% identity) SHMT isozymes (Martini, F., Angelaccio, S., Pascarella, S., Barra, D., Bossa, F., and Schirch, V. (1987) J. Biol. Chem. 262, 5499-5509; Martini, F., Maras, B., Tanci, P., Angelaccio, S., Pascarella, S., Barra, D., Bossa, F., and Schirch, V. (1989) J. Biol. Chem. 264, 8509-8519). SHMT is a highly conserved protein with the human isozymes retaining about 43% sequence identity with the E. coli protein. The human cytosolic and mitochondrial SHMT genes were localized to chromosome regions 17p11.2 and 12q13, respectively. The high degree of nucleotide sequence identity between the two isozymes, and the presence of keratin genes in both chromosomal regions, is consistent with these regions of chromosome 12 and 17 arising by a duplication event.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; MCGILL UNIV, DEPT PEDIAT, MONTREAL H3H 1P3, QUEBEC, CANADA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, AHMANSON DEPT PEDIAT, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, CTR MED BIRTH DEFECTS, LOS ANGELES, CA 90048 USA	University of California System; University of California Berkeley; McGill University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA041991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042033] Funding Source: NIH RePORTER; NCI NIH HHS [CA41991] Funding Source: Medline; NIDDK NIH HHS [DK42033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; CAPERELLI CA, 1980, J BIOL CHEM, V255, P1885; CHAN VL, 1991, GENE, V101, P51, DOI 10.1016/0378-1119(91)90223-X; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; CRAIG IW, 1991, CYTOGENET CELL GENET, V58, P555, DOI 10.1159/000133172; EICHLER HG, 1981, BIOSCIENCE REP, V1, P101, DOI 10.1007/BF01117006; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GAVILANES F, 1982, J BIOL CHEM, V257, P1431; GAVILANES F, 1983, J BIOL CHEM, V258, P3155; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LAW ML, 1979, CYTOGENET CELL GENET, V24, P102, DOI 10.1159/000131363; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MAGENIS RE, 1985, HUM GENET, V69, P300, DOI 10.1007/BF00291645; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCCLUNG CR, 1992, MOL CELL BIOL, V12, P1412, DOI 10.1128/MCB.12.4.1412; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; ROSSBACH S, 1991, MOL MICROBIOL, V5, P39, DOI 10.1111/j.1365-2958.1991.tb01824.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH L, 1980, J BIOL CHEM, V255, P2986; SCHIRCH L, 1975, J BIOL CHEM, V250, P1939; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SHANE B, 1989, VITAM HORM, V45, P263; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; SNELL K, 1989, FALK SYMP, V51, P375; SNELL K, 1988, BRIT J CANCER, V57, P87, DOI 10.1038/bjc.1988.15; SNELL K, 1987, BIOCHEM J, V245, P609, DOI 10.1042/bj2450609; SOLOMON E, 1991, CYTOGENET CELL GENET, V58, P686, DOI 10.1159/000133177; STAUFFER GV, 1981, GENE, V14, P63, DOI 10.1016/0378-1119(81)90148-7; STETTEN G, 1988, AM J MED GENET, V31, P521, DOI 10.1002/ajmg.1320310306; SUTHERLAND GR, 1981, HUM GENET, V57, P217; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; TURNER SR, 1992, J BIOL CHEM, V267, P13528; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	40	136	142	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11910	11916						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505317				2022-12-27	WOS:A1993LF28400068
J	ROSCIGNO, RF; WEINER, M; GARCIABLANCO, MA				ROSCIGNO, RF; WEINER, M; GARCIABLANCO, MA			A MUTATIONAL ANALYSIS OF THE POLYPYRIMIDINE TRACT OF INTRONS - EFFECTS OF SEQUENCE DIFFERENCES IN PYRIMIDINE TRACTS ON SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; MAMMALIAN INTRONS; SEX-LETHAL; U1 SNRNA; U2 SNRNP; SITE; PROTEIN; INVITRO; COMPLEX	The polypyrimidine (py) tract of introns is required for efficient spliceosome assembly and splicing of pre-mRNAs. A detailed mutational analysis of the py tract of an adenovirus 2 intron was carried out. Utilizing a ''precursor in pieces'' vector system, it was possible to synthesize py tract mutant pre-mRNAs that were otherwise identical. The mutant pre-mRNAs were analyzed for in vitro splicing, for formation of splicing complexes, and for binding to proteins in the HeLa nuclear extract. Chimeric pre-mRNAs that contained the yeast branch point consensus sequence (UAC-UAAC) and altered py tracts were also analyzed. Mutational analysis showed the following. First, any mutation in the py tract that affected splicing did so by interferring with complex A formation in spliceosome assembly. Second, introduction of purines into the py tract is detrimental only if the length of the tract is shortened and if there is a reduction in the number of consecutive uracil residues. Third, uracil and cytosine do not have equivalent functions in the py tract. Our results with chimeric pre-mRNAs also show that a strong py tract can partially replace a weak branch point sequence and a strong branch point sequence can partially replace a weak py tract. Finally, the one surprising finding obtained when examining protein binding was that a mutant pre-mRNA did not bind to heterogeneous nuclear ribonucleoprotein C proteins and yet spliced close to wild type level.	DUKE UNIV, MED CTR, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SCH MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University			Weiner, Michael/M-5185-2013	Weiner, Michael/0000-0002-0877-4583				AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; BRODY J, 1985, SCIENCE, V228, P1344; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FREYER GA, 1989, J BIOL CHEM, V264, P14631; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LANG KM, 1990, MOL CELL BIOL, V10, P4942, DOI 10.1128/MCB.10.9.4942; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RUSKIN B, 1985, CELL, V43, P131, DOI 10.1016/0092-8674(85)90018-2; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEMAKER HJ, 1974, J MOL BIOL, V84, P503, DOI 10.1016/0022-2836(74)90112-0; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1988, JAMA-J AM MED ASSOC, V260, P3035, DOI 10.1001/jama.260.20.3035; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	54	139	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11222	11229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496178				2022-12-27	WOS:A1993LD46600075
J	SAGAMI, H; KURISAKI, A; OGURA, K				SAGAMI, H; KURISAKI, A; OGURA, K			FORMATION OF DOLICHOL FROM DEHYDRODOLICHOL IS CATALYZED BY NADPH-DEPENDENT REDUCTASE LOCALIZED IN MICROSOMES OF RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE SYNTHASE; BIOSYNTHESIS; PYROPHOSPHATES; PHOSPHATASE	The alpha-saturation reaction involved in the biosynthesis of dolichol has been investigated with rat liver preparations. Under improved in vitro conditions with 10,000 x g supernatant of rat liver homogenates in the presence of NADPH at pH 8.0, dolichol was synthesized from isopentenyl diphosphate and Z,E,E-geranylgeranyl diphosphate. Neither dolichyl diphosphate nor dolichyl phosphate was detected. The chain length distribution of the dolicohol was the same as that of dehydrodolichyl products. In an assay system containing dehydrodolichol, dehydrodolichyl phosphate, or dehydrodolichyl diphosphate as a substrate, dehydrodolichol was predominantly converted into dolichol. The enzyme that catalyzes the conversion of dehydrodolichol to dolichol was localized in microsomes. The reductase activity was stimulated 9-fold by the addition of a 100,000 x g soluble fraction. The reductase had an opimal pH at 8.0. These results indicate that dolichol is formed from dehydrodolichol in rat liver microsomes. The formation of dolichol from dehydrodolichol was also catalyzed by 10,000 x g supernatant of rat or pig testis homogenates.			SAGAMI, H (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN.							ALLEN CM, 1978, BIOCHEMISTRY-US, V17, P5020, DOI 10.1021/bi00616a025; BELOCOPITOW E, 1982, EUR J BIOCHEM, V125, P167, DOI 10.1111/j.1432-1033.1982.tb06664.x; CHEN Z, 1988, ARCH BIOCHEM BIOPHYS, V266, P98, DOI 10.1016/0003-9861(88)90240-8; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; EKSTROM TJ, 1987, J BIOL CHEM, V262, P4090; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; ROSENWALD AG, 1990, J LIPID RES, V31, P523; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V1002, P218, DOI 10.1016/0005-2760(89)90290-7; SAGAMI H, 1992, J LIPID RES, V33, P1857; SCHER MG, 1984, J BIOL CHEM, V259, P4580; STOLL J, 1988, J BIOL CHEM, V263, P10774; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35	15	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10109	10113						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486680				2022-12-27	WOS:A1993LB80000027
J	SARABIA, VE; CASEY, JR; REITHMEIER, RAF				SARABIA, VE; CASEY, JR; REITHMEIER, RAF			MOLECULAR CHARACTERIZATION OF THE BAND-3 PROTEIN FROM SOUTHEAST-ASIAN OVALOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN-ERYTHROCYTE-MEMBRANE; ANION-TRANSPORT PROTEIN; PAPUA-NEW-GUINEA; MELANESIAN OVALOCYTES; CARBOHYDRATE MOIETY; MALARIA PARASITES; INVASION; RESISTANT; DELETION	Southeast Asian ovalocytosis (SAO) is a hereditary form of elliptocytosis resulting in rigid, oval-shaped erythrocytes resistant to invasion by malaria parasites. The molecular defect is due to deletion of codons 400-408, encoding a 9-amino-acid sequence located at the boundary between the cytosol and the first transmembrane segment in Band 3, the erythrocyte anion transport protein. We have carried out an extensive characterization of Band 3 isolated from SAO erythrocytes which contain about 50% mutant Band 3. A slightly higher proportion of Band 3 in SAO erythrocytes was left associated with the cytoskeleton after extraction of ghost membranes with non-ionic detergents. Size exclusion high performance liquid chromatography analysis showed that SAO Band 3 contained a higher proportion of tetramers relative to dimers (50% tetramer) than normal Band 3 (33% tetramer). The circular dichroism spectrum of Band 3 from SAO erythrocytes was very similar to the spectrum for normal Band 3. Enzymatic deglycosylation and tomato lectin binding showed that SAO Band 3 lacked the polylactosaminyl oligosaccharide found on normal Band 3. SAO Band 3 was unable to bind the anion transport inhibitor 4-benzamido-4'-aminostilbene-2,2'-disulfonate, suggesting a dramatic alteration in the inhibitor binding site. In conclusion, deletion of 9 amino acids from Band 3 on the cytosolic side of the membrane affects the properties (glycosylation and inhibitor binding) of Band 3 on the opposite side of the membrane without dramatic changes in the secondary and quaternary structure of the protein.	UNIV TORONTO, DEPT MED,MRC,MEMBRANE BIOL GRP,RM 7307, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University of Toronto			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				BANNISTER LH, 1990, BLOOD CELLS, V16, P257; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1992, J BIOL CHEM, V267, P11940; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HADLEY T, 1983, J CLIN INVEST, V71, P780, DOI 10.1172/JCI110827; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; KIDSON C, 1981, P NATL ACAD SCI-BIOL, V78, P5829, DOI 10.1073/pnas.78.9.5829; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MOHANDAS N, 1992, J CLIN INVEST, V89, P686, DOI 10.1172/JCI115636; MOHANDAS N, 1984, BLOOD, V63, P1385; MORIYAMA R, 1992, J BIOL CHEM, V267, P25792; MUELLER TJ, 1977, J BIOL CHEM, V252, P6573; PALATNIK M, 1990, HUM GENET, V86, P126, DOI 10.1007/BF00197692; SAUL A, 1984, J CELL BIOL, V98, P1348, DOI 10.1083/jcb.98.4.1348; SCHOFIELD AE, 1992, J MOL BIOL, V223, P949, DOI 10.1016/0022-2836(92)90254-H; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1991, BLOOD, V78, P2785; TILLEY L, 1991, J MEMBRANE BIOL, V121, P59, DOI 10.1007/BF01870651; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	32	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10676	10680						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486716				2022-12-27	WOS:A1993LB80000099
J	TANIGUCHI, H; MANENTI, S				TANIGUCHI, H; MANENTI, S			INTERACTION OF MYRISTOYLATED ALANINE-RICH PROTEIN-KINASE-C SUBSTRATE (MARCKS) WITH MEMBRANE PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; BACTERIAL LIPOPOLYSACCHARIDE; CELLULAR SUBSTRATE; PHORBOL ESTERS; GROWTH-FACTORS; PHOSPHORYLATION; 80-KDA; BRAIN; ACTIVATION; CALMODULIN	A major in vivo substrate of Ca2+-phospholipid-dependent protein kinase (MARCKS) shows phosphorylation-dependent translocation between the cytoplasmic and the membrane fractions. The mechanism of the translocation was studied with purified MARCKS and various membranes. MARCKS was found to bind to pure phospholipid membranes as well as to the synaptic vesicle membranes. Although the interaction of MARCKS with the latter was phosphorylation-dependent, phosphorylation by protein kinase C showed no significant effect on the binding to the phosphatidylcholine liposomes. However, when phosphatidylserine was included in the membranes, the association became phosphorylation-dependent. A synthetic phosphorylation domain peptide showed a similar phosphorylation-dependent interaction with the negatively charged liposomes. Phosphatidylserine but not phosphatidylcholine inhibited phosphorylation of MARCKS by protein kinase C. MARCKS seems to bind to the biomembranes through two binding sites: the N-terminal myristoyl moiety and the basic phosphorylation domain of amphiphilic nature. Phosphorylation of this domain lowers its affinity to phosphatidylserine and makes the whole molecule strongly negatively charged, which causes its dissociation from the membranes.			TANIGUCHI, H (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BURN P, 1988, TRENDS BIOCHEM SCI, V13, P79, DOI 10.1016/0968-0004(88)90043-6; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; JAMES G, 1989, J BIOL CHEM, V264, P20928; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KISH PE, 1989, METHOD ENZYMOL, V174, P10; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIZUTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P1395, DOI 10.1016/0006-291X(92)91888-W; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	29	147	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9960	9963						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486722				2022-12-27	WOS:A1993LB80000007
J	HANSBROUGH, JR; FINE, SM; GORDON, JI				HANSBROUGH, JR; FINE, SM; GORDON, JI			A TRANSGENIC MOUSE MODEL FOR STUDYING THE LINEAGE RELATIONSHIPS AND DIFFERENTIATION PROGRAM OF TYPE-II PNEUMOCYTES AT VARIOUS STAGES OF LUNG DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROENDOCRINE CELL-POPULATIONS; FETAL-RAT LUNG; EPITHELIAL-CELL; SUBEPITHELIAL FIBROBLASTS; DEVELOPING INTESTINE; GENE-EXPRESSION; MAMMALIAN-CELLS; FLOW-CYTOMETRY; MESSENGER-RNA; STEM-CELLS	A pedigree of transgenic mice has been characterized that contains a H2-K(b)/LacZ fusion gene that exhibits integration site-dependent expression from the earliest stages of lung development through adulthood. Histochemical and immunocytochemical studies indicate that the LacZ reporter appears throughout the pulmonary endoderm by embryonic day 11 (E11). A proximal-to-distal wave of extinction of transgene expression occurs during E13-14 that parallels the wave of cytodifferentiation of the pulmonary endoderm. By E16, the LacZ reporter is restricted to the distal portion of epithelial tubules and by birth to scattered cells located in alveoli. Crude epithelial cell suspensions were prepared from lungs harvested from E16 and 14 day postnatal transgenic mice, labeled with the fluorescent LacZ substrate fluorescein di-(beta-galactopyranoside), and the LacZ expressing population isolated by fluorescence-activated cell sorting. Electron microscopic, immunocytochemical and histochemical studies of this purified cell population establish that type II pneumocytes are the only cell lineage that support H2K(b)/LacZ expression in the mature postnatal lung. Fluorescence-activated cell sorting of E16 lung suspensions yielded a homogeneous population of cells that produced surfactant protein A, that could be maintained in cell culture, and that are likely precursors of adult type II pneumocytes. Together these studies indicate that (i) expression of the transgene in this pedigree of mice provides a marker for describing early differentiation of the pulmonary epithelium; (ii) the transgene may be useful as an enhancer trap to isolate cis-acting sequences that regulate gene transcription within this lineage; (iii) the LacZ reporter expression can be used to purify specific embryonic pulmonary epithelial cell populations; and (iv) primary cultures of these embryonic populations represent a potentially useful model system for analyzing the cellular components and signaling pathways necessary to support and complete passage through the type II pneumocyte differentiation program.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	HANSBROUGH, JR (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,BOX 8052,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.				NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESCIO T, 1962, J EXP ZOOL, V150, P83, DOI 10.1002/jez.1401500202; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; BALLARD PL, 1986, BIOCHIM BIOPHYS ACTA, V883, P335, DOI 10.1016/0304-4165(86)90326-0; BATENBURG JJ, 1988, BIOCHIM BIOPHYS ACTA, V960, P441, DOI 10.1016/0005-2760(88)90053-7; BAUSCH JN, 1977, BIOCHEMISTRY-US, V16, P5790, DOI 10.1021/bi00645a023; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; DOBBS LG, 1985, BIOCHIM BIOPHYS ACTA, V846, P155, DOI 10.1016/0167-4889(85)90121-1; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; EVANS MJ, 1989, LUNG CELL BIOL, V41, P1; Gilbert Scott F., 1988, DEV BIOL; GLASSER SW, 1992, AM REV RESPIR DIS, V145, P225; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAFFEN K, 1983, DIFFERENTIATION, V23, P226; Have-Opbroek A. T., 1986, ANAT EMBRYOL, V174, P49; HAVEOPBROEK AAW, 1988, ANAT REC, V221, P846; HAVEOPHBROEK AAW, 1981, AM J ANAT, V162, P201; HOGAN B, 1986, MANIPULATING MOUSE E; Jones KH, 1987, J HISTOCHEM CYTOCHEM, V35, P123, DOI 10.1177/35.1.2432112; KEDINGER M, 1987, CELL DIFFER DEV, V20, P171, DOI 10.1016/0045-6039(87)90431-3; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; KIKKAWA Y, 1974, LAB INVEST, V30, P76; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LEARY JF, 1982, AM REV RESPIR DIS, V125, P326; MARSH MN, 1974, GASTROENTEROLOGY, V67, P636; MARSH MN, 1974, GASTROENTEROLOGY, V67, P622; MASKENS AP, 1979, GUT, V20, P775, DOI 10.1136/gut.20.9.775; MASON RJ, 1977, PULMONARY MACROPHAGE, P280; MASSEY TE, 1987, CAN J PHYSIOL PHARM, V65, P2368, DOI 10.1139/y87-375; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; OOMEN LCJM, 1990, AM J RESP CELL MOL, V3, P325, DOI 10.1165/ajrcmb/3.4.325; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTH KA, 1992, AM J PHYSIOL, V263, pG186, DOI 10.1152/ajpgi.1992.263.2.G186; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; ROTH KA, 1992, AM J PHYSIOL, V263, P174; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHELLHASE DE, 1989, PEDIATR RES, V26, P167, DOI 10.1203/00006450-198909000-00001; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SEVANIAN A, 1981, BIOCHIM BIOPHYS ACTA, V664, P498, DOI 10.1016/0005-2760(81)90128-4; SHANNON JM, 1989, AM REV RESPIR DIS, V139, P255; SIMONASSMANN P, 1989, J CELL BIOL, V109, P1837, DOI 10.1083/jcb.109.4.1837; SIMONASSMANN P, 1990, J CELL BIOL, V110, P849, DOI 10.1083/jcb.110.3.849; SIMONASSMANN P, 1988, DEVELOPMENT, V102, P339; SLAVKIN HC, 1989, DIFFERENTIATION, V41, P223, DOI 10.1111/j.1432-0436.1989.tb00751.x; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; Ten Have-Opbroek A.A., 1991, EXP LUNG RES, V17, P111, DOI DOI 10.3109/01902149109064406; Theiler K., 1972, HOUSE MOUSE; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WEIS J, 1991, J CELL BIOL, V113, P1385, DOI 10.1083/jcb.113.6.1385; WHITSETT JA, 1985, BIOCHIM BIOPHYS ACTA, V828, P162, DOI 10.1016/0167-4838(85)90053-6; WILLIAMS MC, 1990, AM J RESP CELL MOL, V2, P533, DOI 10.1165/ajrcmb/2.6.533; WILSON JS, 1986, CYTOMETRY, V7, P157, DOI 10.1002/cyto.990070206; WOODCOCKMITCHELL J, 1990, AM J RESP CELL MOL, V2, P503, DOI 10.1165/ajrcmb/2.6.503	61	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9762	9770						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486660				2022-12-27	WOS:A1993LA68900089
J	GUIMBAL, C; KILIMANN, MW				GUIMBAL, C; KILIMANN, MW			A NA+-DEPENDENT CREATINE TRANSPORTER IN RABBIT BRAIN, MUSCLE, HEART, AND KIDNEY - CDNA CLONING AND FUNCTIONAL EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEROTONIN TRANSPORTER; RAT-BRAIN; DOPAMINE TRANSPORTER; CULTURED-CELLS; RNA; ANTIDEPRESSANTS; KINASE; DNA	A cDNA has been cloned from rabbit brain that is a new member of the emerging family of Na+-dependent plasma membrane transporters for several neurotransmitters and structurally related compounds. Functional expression of this cDNA in COS-7 cells identifies its product as a Na+- and Cl--dependent creatine transporter with a K(m) of approximately 35 muM. Its creatine transporter activity is efficiently antagonized by 3-guanidinopropionate, a well characterized alternative substrate of creatine transport in several tissues, and by 4-guanidinobutyrate. More distant structural analogues of creatine are much less efficient or inactive as antagonists, indicating a high substrate specificity of the transporter. Northern blot hybridization detects the expression of its mRNA in most tissues tested, most prominently in kidney, heart, and muscle, but not in liver and intestine. A full-length cDNA clone was also isolated from a muscle cDNA library and found to contain the same coding sequence. Substrate affinity and specificity of the cloned transporter are very similar to the endogenous creatine transporter of the COS-7 cells and to the creatine transport activities of several cell types described in the literature. Moreover, its mRNA is most abundant in the tissues known to possess high creatine uptake capacity.	RUHR UNIV BOCHUM,INST PHYSIOL CHEM,UNIV STR 150,W-4630 BOCHUM 1,GERMANY	Ruhr University Bochum								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERLET HH, 1976, BIOCHIM BIOPHYS ACTA, V437, P166, DOI 10.1016/0304-4165(76)90358-5; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DALY MM, 1980, ARCH BIOCHEM BIOPHYS, V203, P317, DOI 10.1016/0003-9861(80)90182-4; FITCH CD, 1968, J BIOL CHEM, V243, P2024; FITCH CD, 1966, J BIOL CHEM, V241, P3611; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARMANN B, 1990, FEBS LETT, V273, P248, DOI 10.1016/0014-5793(90)81096-7; HARMANN B, 1991, J BIOL CHEM, V266, P15631; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KU CP, 1980, BIOCHIM BIOPHYS ACTA, V600, P212, DOI 10.1016/0005-2736(80)90426-5; KURAHASHI M, 1977, AM J PHYSIOL, V233, pE91, DOI 10.1152/ajpendo.1977.233.2.E91; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LIU QR, 1993, FEBS LETT, V315, P114, DOI 10.1016/0014-5793(93)81145-P; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOIKE JD, 1986, AM J PHYSIOL, V251, pC128, DOI 10.1152/ajpcell.1986.251.1.C128; LOIKE JD, 1988, P NATL ACAD SCI USA, V85, P807, DOI 10.1073/pnas.85.3.807; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MAYSER W, 1992, FEBS LETT, V305, P31, DOI 10.1016/0014-5793(92)80649-2; MOLLER A, 1989, J NEUROCHEM, V52, P544, DOI 10.1111/j.1471-4159.1989.tb09154.x; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SYLLMRAPOPORT I, 1981, ACTA BIOL MED GER, V40, P653; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	36	226	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8418	8421						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473283				2022-12-27	WOS:A1993KX81100010
J	SAKAMOTO, A; YANAGISAWA, M; SAWAMURA, T; ENOKI, T; OHTANI, T; SAKURAI, T; NAKAO, K; TOYOOKA, T; MASAKI, T				SAKAMOTO, A; YANAGISAWA, M; SAWAMURA, T; ENOKI, T; OHTANI, T; SAKURAI, T; NAKAO, K; TOYOOKA, T; MASAKI, T			DISTINCT SUBDOMAINS OF HUMAN ENDOTHELIN RECEPTORS DETERMINE THEIR SELECTIVITY TO ENDOTHELIN(A)-SELECTIVE ANTAGONIST AND ENDOTHELIN(B)-SELECTIVE AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA; EXPRESSION; CLONING; EFFICIENT; FAMILY	The endothelin (ET) family of peptides acts via two subtypes of G-protein-coupled heptahelical receptors termed ET(A) and ET(B), which have distinct rank orders of affinity to endothelin receptor agonists and antagonists. To delineate which portions of the receptor molecules determine ligand selectivity, we have constructed a series of chimeras between human ET(A) and ET(B) receptors and characterized the chimeric receptors expressed in heterologous cell lines by competitive radioligand binding analysis and by measuring agonist-induced transients of intracellular Ca2+. We demonstrate that the binding determinant for the ET(B)-selective agonists ET-3, BQ3020, and IRL1620 resides within the region spanning the putative transmembrane helices IV-VI and the adjacent loop regions. In contrast, the transmembrane helices I, II, III, and VII plus the intervening loop regions specify the selectivity for BQ123, an ET(A)-selective antagonist. BQ123 exhibited no detectable agonistic activity in all wild-type and chimeric receptors tested. A chimeric receptor that has the transmembrane helices IV-VI (and adjacent loops) from the ET(B) receptor inserted into the remaining regions from the ET(A) receptor binds both the ET(A)- and ET(B)-selective ligands with high affinities. Moreover, BQ123 competitively inhibits the binding of the amino-terminally truncated ET(B) agonists, I-125-BQ3020 and I-125-IRL1620, to this chimeric receptor, suggesting that BQ123 is a mimic of the carboxyl-terminal linear portion of endothelins. These findings indicate that there are at least two separable ligand interaction subdomains within the endothelin receptors.	KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT INTERNAL MED 2, KYOTO 606, JAPAN; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 2, BUNKYO KU, TOKYO 113, JAPAN	Kyoto University; Kyoto University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo			Sawamura, Tatsuya/E-7103-2010					ADACHI M, 1992, FEBS LETT, V311, P179, DOI 10.1016/0014-5793(92)81393-Z; ANDERSEN NH, 1992, BIOCHEMISTRY-US, V31, P1280, DOI 10.1021/bi00120a003; ATKINSON RA, 1992, FEBS LETT, V296, P1, DOI 10.1016/0014-5793(92)80390-3; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOHERTY AM, 1992, J MED CHEM, V35, P1493, DOI 10.1021/jm00087a001; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FUKURODA T, 1992, LIFE SCI, V50, pPL107, DOI 10.1016/0024-3205(92)90353-Q; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; IHARA M, 1992, LIFE SCI, V51, pPL47, DOI 10.1016/0024-3205(92)90418-O; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1992, J MED CHEM, V35, P2139, DOI 10.1021/jm00089a028; JACKSON T, 1991, PHARMACOL THERAPEUT, V50, P425, DOI 10.1016/0163-7258(91)90052-N; KRYSTEK SR, 1992, FEBS LETT, V299, P255, DOI 10.1016/0014-5793(92)80127-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; NAKAMICHI K, 1992, BIOCHEM BIOPH RES CO, V182, P144, DOI 10.1016/S0006-291X(05)80123-8; REILY MD, 1992, FEBS LETT, V300, P136, DOI 10.1016/0014-5793(92)80181-F; SAIDA K, 1991, J CARDIOVASC PHARM, V17, pS55, DOI 10.1097/00005344-199100177-00015; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEMORI AE, 1992, ANNU REV PHARMACOL, V32, P239, DOI 10.1146/annurev.pa.32.040192.001323; URADE Y, 1992, FEBS LETT, V311, P12, DOI 10.1016/0014-5793(92)81355-P; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WATAKABE T, 1992, BIOCHEM BIOPH RES CO, V185, P867, DOI 10.1016/0006-291X(92)91707-W; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	32	175	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8547	8553						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473300				2022-12-27	WOS:A1993KX81100029
J	STOVER, T; KOHLER, E; FAGIN, U; WENDE, W; WOLFES, H; PINGOUD, A				STOVER, T; KOHLER, E; FAGIN, U; WENDE, W; WOLFES, H; PINGOUD, A			DETERMINATION OF THE DNA BEND ANGLE INDUCED BY THE RESTRICTION ENDONUCLEASE ECORV IN THE PRESENCE OF MG2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATABOLITE ACTIVATOR PROTEIN; GEL-ELECTROPHORESIS; CRYSTAL-STRUCTURE; B-DNA; RECOGNITION; RESOLUTION; SEQUENCE; COMPLEX; CONFORMATION; REFINEMENT	We have used the method of Zinkel and Crothers (Zinkel, S. S., and Crothers, D. M. (1990) Biopolymers 29, 29-38) to determine the degree of bending induced by the binding of the restriction endonuclease EcoRV to its recognition sequence (-GATATC-). A set of four calibration DNA fragments was constructed that contained zero, two, four, or six phased A-tracts in their centers and an EcoRV site at the 5'-end to account for the electrophoretic influence of the bound protein. The mobilities of these calibration molecules complexed with EcoRV were compared to that of a test DNA containing a central EcoRV site also complexed with EcoRV. The EcoRV-induced bend angle was found to be 44-degrees +/- 4-degrees. These experiments were performed with a catalytically inactive EcoRV mutant that still binds DNA specifically in the presence of Mg2+. In the absence of Mg2+, which is necessary for specific binding, there is no difference in the mobilities of the fragments with a peripheral or a central EcoRV site complexed with EcoRV, indicating that nonspecific binding on average does not lead to measurable DNA bending.			STOVER, T (corresponding author), HANNOVER MED SCH,ZENTRUM BIOCHEM,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY.		Wende, Wolfgang/F-6127-2014; Köhler, Eleonore/D-2915-2012	Köhler, Eleonore/0000-0003-1977-9977; Wende, Wolfgang/0000-0001-6577-9535				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AIKEN CR, 1991, J BIOL CHEM, V266, P19063; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DIEKMANN S, 1988, J MOL BIOL, V202, P823, DOI 10.1016/0022-2836(88)90561-X; DOUCRASY S, 1989, NUCLEIC ACIDS RES, V17, P5173, DOI 10.1093/nar/17.13.5173; FREDERICK CA, 1988, J BIOL CHEM, V263, P17872; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; LYUBCHENKO Y, 1991, P NATL ACAD SCI USA, V88, P5331, DOI 10.1073/pnas.88.12.5331; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NERDAL W, 1989, BIOCHEMISTRY-US, V28, P10008, DOI 10.1021/bi00452a020; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; THOMAS GA, 1989, BIOCHEMISTRY-US, V28, P2001, DOI 10.1021/bi00431a007; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WENDE W, 1991, BIOL CHEM H-S, V372, P777; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8645	8650						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473307				2022-12-27	WOS:A1993KX81100042
J	WEITZMAN, JB; PASQUALINI, R; TAKADA, Y; HEMLER, ME				WEITZMAN, JB; PASQUALINI, R; TAKADA, Y; HEMLER, ME			THE FUNCTION AND DISTINCTIVE REGULATION OF THE INTEGRIN VLA-3 IN CELL-ADHESION, SPREADING, AND HOMOTYPIC CELL-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; MEMBRANE GLYCOPROTEIN; T-CELLS; ONCOGENIC TRANSFORMATION; FIBRONECTIN RECEPTOR; COLLAGEN RECEPTOR; DIVALENT-CATIONS; LAMININ RECEPTOR; BINDING-SITE; ALPHA-3-BETA-1	To assess directly the functional role of the integrin VLA-3 (alpha3beta1), we transfected human alpha3 cDNA into erythroleukemia (K562) cells and rhabdomyosarcoma (RD) cells. The resulting transfectants (KA3 and RA3) expressed alpha3beta1 on the cell surface as confirmed using a panel of nine anti-alpha3 monoclonal antibodies. Neither of the transfected cells exhibited increased adhesion to the extracellular matrix proteins fibronectin, laminin, and collagen. However, the KA3 transfectants did bind strongly to the extracellular matrix deposited by epidermal and carcinoma cell lines, allowing the cells to attach and spread. Binding to this cell-deposited ligand, probably containing epiligrin/kalinin, was specific to VLA-3 and could be inhibited by anti-alpha3 antibodies and by EDTA, but not by RGD peptides. In marked contrast to other integrins (VLA-2 and VLA-4), VLA-3 showed high constitutive activity in K562 cells, but was minimally active in RD cells. Also contrasting with other beta1 integrins, VLA-3 was minimally stimulated by the anti-beta1 monoclonal antibody TS/216 under normal conditions. VLA-3-mediated adhesive function was well supported by either Mg2+ or Mn2+, but was almost completely abolished by the presence of 1 mM Ca2+. Surprisingly, this negative Ca2+ effect was completely overcome by the addition of the stimulatory anti-beta1 monoclonal antibody TS2/16. Together, these results point to markedly distinct regulation for VLA-3 function compared to other beta1 integrins. Also, all anti-VLA-3 antibodies were able to induce temperature-dependent homotypic cell aggregation of KA3 cells, but not K562 cells. However, this aggregation did not appear to be directly mediated by VLA-3 since it was not inhibited by EDTA. In addition, no enhancement of heterotypic cell-cell adhesion was observed in alpha3-transfected cells.	Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	WEITZMAN, JB (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.			Weitzman, Jonathan/0000-0001-8445-0102; takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903, R01GM047157, R01GM046526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157, GM38903, GM46526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHOY MY, 1990, J PATHOL, V160, P35, DOI 10.1002/path.1711600109; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MORHENN VB, 1985, J CLIN INVEST, V76, P1978, DOI 10.1172/JCI112197; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; RETTIG WJ, 1989, ANNU REV IMMUNOL, V7, P481, DOI 10.1146/annurev.iy.07.040189.002405; ROUSELLE P, 1992, J CELL BIOL, V114, P567; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAQUET MJ, 1990, EXP CELL RES, V187, P277, DOI 10.1016/0014-4827(90)90092-O; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TSUJI T, 1990, J BIOL CHEM, V265, P7016; TSUJI T, 1991, J BIOCHEM-TOKYO, V109, P659, DOI 10.1093/oxfordjournals.jbchem.a123436; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WATT F M, 1992, Current Biology, V2, P106, DOI 10.1016/0960-9822(92)90236-4; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	62	158	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8651	8657						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473308				2022-12-27	WOS:A1993KX81100043
J	MURGIA, M; HANAU, S; PIZZO, P; RIPPA, M; DIVIRGILIO, F				MURGIA, M; HANAU, S; PIZZO, P; RIPPA, M; DIVIRGILIO, F			OXIDIZED ATP - AN IRREVERSIBLE INHIBITOR OF THE MACROPHAGE PURINERGIC-P2Z RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; PLASMA-MEMBRANE; CELLS; NUCLEOTIDES; MECHANISMS; FLUXES; PC12	The effects of oxidized ATP (oATP) on responses triggered by extracellular adenosine 5'-triphosphate (ATP(e)) were investigated in the mouse macrophage-like cell line J774. ATP(e) induced in this cell line two kinds of responses mediated by two different P2 purinergic receptors: 1) an early permeabilization of the plasma membrane to extracellular hydrophilic markers of M(r) up to 900 mediated by P2Z receptors; and 2) a fast mobilization of Ca2+ from intracellular stores mediated by P2Y receptors. Low oATP concentrations (100 muM) completely blocked the first response without affecting the second. ATP(e)-dependent cell swelling, vacuolization, and lysis were also inhibited. Antagonism developed slowly, as an incubation at 37-degrees-C for at least 2 h in the presence of oATP was needed and was irreversible, thus suggesting that the inhibitory action was due to covalent modification of the receptor. The rate of hydrolysis of exogenous ATP was slightly decreased by oATP, indicating a minor blocking effect of this compound on plasma membrane ecto-ATPases in the concentration range tested. These observations suggest that oATP may be a potentially very useful tool for isolation and characterization of the P2Z purinergic receptor.	UNIV FERRARA, INST GEN PATHOL, VIA BORSARI 46, I-44100 FERRARA, ITALY; UNIV FERRARA, INST BIOCHEM, I-44100 FERRARA, ITALY; UNIV PADUA, NATL RES COUNCIL, STUDY PHYSIOL MITOCHONDRIA UNIT, I-35100 PADUA, ITALY; UNIV PADUA, DEPT EXPTL BIOMED, I-35100 PADUA, ITALY	University of Ferrara; University of Ferrara; University of Padua; University of Padua			Hanau, Stefania/AAG-7534-2021; Pizzo, Paola/T-4874-2018; DI VIRGILIO, Francesco/O-4634-2019; Di Virgilio, Francesco/J-3754-2018	Hanau, Stefania/0000-0002-2817-9941; Pizzo, Paola/0000-0001-6077-3265; DI VIRGILIO, Francesco/0000-0003-3566-1362; Di Virgilio, Francesco/0000-0003-3566-1362	Telethon [187] Funding Source: Medline	Telethon(Fondazione Telethon)		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V3, P118; BURNSTOCK G, 1964, INT J NEUROPHARMACOL, V3, P163, DOI 10.1016/0028-3908(64)90003-6; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COLMAN RF, 1990, ENZYMES, V19, P283; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; DIVIRGILIO F, 1990, IMMUNOL TODAY, V11, P274, DOI 10.1016/0167-5699(90)90111-L; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DIVIRGILIO F, 1993, IN PRESS PROTOCOLS C; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; EASTERBROOKSMITH SB, 1976, EUR J BIOCHEM, V62, P125, DOI 10.1111/j.1432-1033.1976.tb10105.x; FEDAN JS, 1990, ANN NY ACAD SCI, V603, P182; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; MURGIA M, 1992, BIOCHEM J, V288, P897, DOI 10.1042/bj2880897; MURGIA M, 1992, ATLA-ALTERN LAB ANIM, V20, P66; NAKAZAWA K, 1990, BRIT J PHARMACOL, V101, P224, DOI 10.1111/j.1476-5381.1990.tb12117.x; OCONNOR SE, 1992, LIFE SCI, V50, P1657, DOI 10.1016/0024-3205(92)90420-T; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PEARCE PH, 1978, EUR J BIOCHEM, V88, P543, DOI 10.1111/j.1432-1033.1978.tb12480.x; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; STEINBERG TH, 1989, METHOD CELL BIOL, V31, P45; THOMAS SA, 1991, BRIT J PHARMACOL, V103, P1963, DOI 10.1111/j.1476-5381.1991.tb12360.x	28	325	326	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8199	8203						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463330				2022-12-27	WOS:A1993KW97900089
J	CARTAUD, A; STETZKOWSKIMARDEN, F; CARTAUD, J				CARTAUD, A; STETZKOWSKIMARDEN, F; CARTAUD, J			IDENTIFICATION OF DYSTROPHIN-BINDING PROTEIN(S) IN MEMBRANES FROM TORPEDO ELECTROCYTE AND RAT MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; ACETYLCHOLINE-RECEPTOR; ELECTRIC ORGAN; POSTSYNAPTIC MEMBRANE; MARMORATA ELECTROCYTE; GLYCOPROTEIN COMPLEX; PURIFICATION; MICE; LOCALIZATION	Using solubilized dystrophin isolated from torpedo electric tissue and in vitro blot overlay assay, we have identified dystrophin-binding proteins in membranes from Torpedo electrocyte and rat muscle. In acetylcholine receptor-rich membranes from Torpedo marmorata electric tissue, an extrinsic protein of M(r) 52,000, known as the 58-kDa protein (Froehner, S. C. (1984) J. Cell Biol. 99, 88-96), represents the major binding site for dystrophin. When membranes were solubilized by non-ionic detergents, the 52-kDa protein as well as a few proteins of M(r) 200,000, 87,000, and 45,000 coextract and copurify with dystrophin. In rat sarcolemma, a protein doublet of approximately 58-60 kDa also binds dystrophin in vitro, this protein likely being the DAP 59 characterized by Ervasti and Campbell (Ervasti, J. M., and Campbell, K. P. (1991) Cell 66, 1121-1131). We postulate that the 52- and 59-kDa proteins are functional homologs that play the role of ''receptors'' for dystrophin in various specialized membrane domains.	UNIV PARIS 07, CNRS,INST JACQUES MONOD, DEPT BIOL SUPRAMOLEC & CELLULAIRE,2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								Bollag D.M., 1991, PROTEIN METHODS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARTAUD A, 1992, NEUROSCIENCE, V48, P995, DOI 10.1016/0306-4522(92)90288-D; CARTAUD A, 1990, J CELL BIOL, V111, P581, DOI 10.1083/jcb.111.2.581; CARTAUD A, 1992, MOL BIOL CELL, V3, pA366; CARTAUD J, 1978, J CELL SCI, V29, P313; CARTAUD J, 1993, EUR J NEUROSCI, V5, P191, DOI 10.1111/j.1460-9568.1993.tb00485.x; CHANG HW, 1989, J BIOL CHEM, V264, P20831; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FARDEAU M, 1990, CR ACAD SCI III-VIE, V311, P197; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1984, J CELL BIOL, V99, P88, DOI 10.1083/jcb.99.1.88; HAMMONDS RG, 1987, CELL, V51, P1, DOI 10.1016/0092-8674(87)90002-X; HEUSER JE, 1979, J CELL BIOL, V82, P150, DOI 10.1083/jcb.82.1.150; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JASMIN BJ, 1990, P NATL ACAD SCI USA, V87, P3938, DOI 10.1073/pnas.87.10.3938; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KORDELI E, 1986, J CELL BIOL, V102, P748, DOI 10.1083/jcb.102.3.748; KORDELI E, 1989, J CELL BIOL, V108, P127, DOI 10.1083/jcb.108.1.127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHELLE WJ, 1990, J NEUROSCI, V10, P3460; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MUELLER H, 1983, J MOL BIOL, V163, P647, DOI 10.1016/0022-2836(83)90116-X; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; RICHARDSON GP, 1987, CELL TISSUE RES, V247, P651, DOI 10.1007/BF00215760; SATO O, 1992, J BIOCHEM-TOKYO, V112, P631, DOI 10.1093/oxfordjournals.jbchem.a123951; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SHIMIZU T, 1989, BIOMED RES-TOKYO, V10, P405, DOI 10.2220/biomedres.10.405; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13019	13022						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514742				2022-12-27	WOS:A1993LH55300003
J	HEI, YJ; MCNEILL, JH; SANGHERA, JS; DIAMOND, J; BRYERASH, M; PELECH, SL				HEI, YJ; MCNEILL, JH; SANGHERA, JS; DIAMOND, J; BRYERASH, M; PELECH, SL			CHARACTERIZATION OF INSULIN-STIMULATED SERYL THREONYL PROTEIN-KINASES IN RAT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASES; ACTIVATED S6 KINASE; RIBOSOMAL PROTEIN-S6; 3T3 CELLS; XENOPUS EGGS; II ACTIVITY; PHOSPHORYLATION; PURIFICATION; RAF-1	Postinsulin receptor signal transduction is mediated by a cascade of seryl/threonyl protein kinases which includes a family of mitogen-activated protein (MAP) kinases, ribosomal protein S6 kinases, and casein kinase-2. Previous studies have characterized these kinases primarily in cultured or isolated cells. We have demonstrated that intravenous injection of insulin into fasted rats significantly stimulated the activities of MAP kinases and S6 kinases in skeletal muscle, independently of the blood glucose levels in these animals. Anion exchange chromatography on Mono Q afforded the resolution of at least five peaks of insulin-stimulated myelin basic protein kinase activity. By immunological criteria, these myelin basic protein kinases included the p42mapk and p44erk1 as well as other potentially novel 44-kDa MAP kinases. Insulin-activated ribosomal S6 kinases were resolved into two major peaks by Mono Q chromatography, the latter of which contained a 100-kDa isoform of p90rsk as revealed by immunoblotting with an anti-rsk-peptide antibody. A 32-kDa S6 kinase in the earlier peak may represent a novel protein kinase in this tissue. Skeletal muscle casein kinase-2 was not significantly stimulated following insulin injection into rats under our experimental conditions. These results indicate that the intact rat can serve as a useful model system to investigate the mechanisms of insulin signal transduction.	UNIV BRITISH COLUMBIA, FAC PHARMACEUT SCI, DIV PHARMACOL & TOXICOL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, FAC MED, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; KINETEK BIOTECHNOL CORP, RICHMOND V7C 1T6, BC, CANADA	University of British Columbia; University of British Columbia								ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; AVRUCH J, 1991, RECENT ADV INSULIN A, P63; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLENIS J, 1991, CANCER CELL, V3, P1; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CRWW C, 1992, P NATL ACAD SCI USA, V89, P8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GERICH JE, 1988, DIABETES, V37, P1608, DOI 10.2337/diabetes.37.12.1608; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HECHT LB, 1988, BIOCHEM BIOPH RES CO, V152, P1200, DOI 10.1016/S0006-291X(88)80412-1; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAWAKAMI M, 1991, EXP CELL RES, V193, P120, DOI 10.1016/0014-4827(91)90545-6; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KLARLUND JK, 1990, J BIOL CHEM, V265, P227; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, METHOD ENZYMOL, V164, P575; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1991, J BIOL CHEM, V266, P10351; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROTH RA, 1990, INSULIN, P169; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SEGER R, 1992, J BIOL CHEM, V267, P14373; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TABARINI D, 1987, BIOCHEM BIOPH RES CO, V144, P891, DOI 10.1016/S0006-291X(87)80048-7; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1992, J BIOL CHEM, V267, P21089; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	69	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13203	13213						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514759				2022-12-27	WOS:A1993LH55300030
J	BHASKER, CR; BURGIEL, G; NEUPERT, B; EMERYGOODMAN, A; KUHN, LC; MAY, BK				BHASKER, CR; BURGIEL, G; NEUPERT, B; EMERYGOODMAN, A; KUHN, LC; MAY, BK			THE PUTATIVE IRON-RESPONSIVE ELEMENT IN THE HUMAN ERYTHROID 5-AMINOLEVULINATE SYNTHASE MESSENGER-RNA MEDIATES TRANSLATIONAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; UNTRANSLATED REGION; AFFINITY PURIFICATION; REGULATORY REGION; RABBIT LIVER; FERRITIN; SEQUENCE; IDENTIFICATION; REPRESSION; EXPRESSION	The 52-nucleotide 5'-untranslated region of the human erythroid 5-aminolevulinate synthase mRNA contains a 28-nucleotide iron-responsive element-like stem-loop motif. We fused the 5'-untranslated region upstream to the coding sequence of the human growth hormone cDNA. A chimeric construct containing a mutated variant of the presumptive iron-responsive element was similarly synthesized. Translation of the wild type chimeric transcript was markedly repressed (approximately 95%) in rabbit reticulocyte lysates as opposed to the mutant. Both transcripts translated with comparable efficiency in wheat germ extracts. Purified placental iron regulatory factor selectively and markedly inhibited translation of the wild type chimeric transcript (>90%) when tested in wheat germ extracts. By contrast, translations of either the mutant chimeric transcript or other control mRNA species were unaffected. The proximal position of the iron-responsive element relative to the cap site was shown to be important for translational control, in vitro. Our studies suggest that interaction of the iron regulatory factor with the iron-responsive element sterically hinders formation of the preinitiation complex, resulting in translational repression. Thus inactivation of the repressor protein by critical levels of iron or heme would trigger translation of this mRNA in erythroid cells. Consequently, protoporphyrin and heme synthesis would be subtly coordinated with iron supply.	SWISS INST EXPTL CANC RES,GENET UNIT,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research	BHASKER, CR (corresponding author), UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5001,AUSTRALIA.							AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BAWDEN MJ, 1987, NUCLEIC ACIDS RES, V15, P8563, DOI 10.1093/nar/15.20.8563; BOTTOMLEY SS, 1988, SEMIN HEMATOL, V25, P282; BROWN PH, 1989, J BIOL CHEM, V264, P13383; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; MAY BK, 1990, MOL BIOL MED, V7, P405; MOSKAITIS JE, 1990, NUCLEIC ACIDS RES, V18, P2184, DOI 10.1093/nar/18.8.2184; MULLER JP, 1991, DNA CELL BIOL, V10, P571, DOI 10.1089/dna.1991.10.571; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	91	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12699	12705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509404				2022-12-27	WOS:A1993LG65800070
J	CARROLL, MA; BALAZY, M; MARGIOTTA, P; FALCK, JR; MCGIFF, JC				CARROLL, MA; BALAZY, M; MARGIOTTA, P; FALCK, JR; MCGIFF, JC			RENAL VASODILATOR ACTIVITY OF 5,6-EPOXYEICOSATRIENOIC ACID DEPENDS UPON CONVERSION BY CYCLOOXYGENASE AND RELEASE OF PROSTAGLANDINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAM SEMINAL-VESICLES; ARACHIDONIC-ACID; METABOLITES; CELLS; MECHANISM	The 5,6-epoxyeicosatrienoic acid (5,6-EET), a renal vasodilator metabolite of arachidonic acid via cytochrome P450 (P450) requires cyclooxygenase for expression of its vasoactivity as the responses are inhibited by indomethacin and other aspirin-like drugs. We now report on the metabolism of 5,6-EET by rabbit kidneys in order to characterize those metabolites that may account for its vasoactivity. The 5,6-EET was injected close-arterially into the rabbit isolated Krebs-Henseleit perfused kidney, preconstricted with phenylephrine, and the effluent collected throughout the response period. Basal collections, following injection of 100 mul of vehicle, were made at 20-min intervals before each 5,6-EET injection. Prior to acidic extraction, deuterated 6-keto-prostaglandin (PG) F1alpha and PGE2 were added as internal standards. The extracts were separated by TLC and prostaglandins were derivatized for gas chromatography-mass spectrometry analysis using a negative ion chemical ionization mode. Injection of 0.5, 1, 5, 10, and 20 mug of 5,6-EET (n = 4) resulted in dose-related decreases in perfusion pressure of 6 +/- 2, 12 +/- 4, 21 +/- 4, 26 +/- 4, and 27 +/- 7 mm g, respectively. Basal perfusates contained 6-keto-PGF1alpha and PGE2, levels of which were increased by 2-fold or more by 5,6-EET. Perfusates, collected during 5,6-EET administration, also contained 5-hydroxy-PGI1 and 5,6-epoxy-PGE1, cyclooxygenase metabolites of 5,6-EET. This is the first report of the recovery and identification of these 5,6-EET metabolites from an intact organ. Since the responses to 5,6-EET are endothelial-dependent, we also studied the profile of eicosanoids formed following incubation of 5,6-EET with cultured bovine pulmonary endothelial cells. Endothelial cells metabolized 5,6-EET to products with a similar radioactive profile on reverse-phase high pressure liquid chromatography compared to kidney perfusates. We compared the vasodilator activity of 5,6-epoxy-PGE1 and 5-hydroxy-PGI1, chemically synthesized by us from PGE2 and PGF2alpha, respectively, with PGE2 and PGI2 in the rabbit kidney. The 5,6-epoxy-PGE1 was equipotent to PGE2 as a vasodilator. The ED50 values for 5,6-EET, 5,6-epoxy-PGE1, and PGE2 were 4.69, 0.43, and 0.42 nmol, respectively. Although PGI2 was a potent vasodilator (ED50, 0.24 nmol), 5-hydroxy-PGI1 was devoid of activity. Thus, the cyclooxygenase-dependent vasoactivity of 5,6-EET in the rabbit kidney has two components: release of vasodilator prostaglandins, PGE2 and PGI2, and metabolism of 5,6-EET to a prostaglandin analog, 5,6-epoxy-PGE1.	UNIV TEXAS, HLTH SCI CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas	CARROLL, MA (corresponding author), NEW YORK MED COLL, DEPT PHARMACOL, VALHALLA, NY 10595 USA.			Falck, John/0000-0002-9219-7845; Balazy, Ph.D., Michael/0000-0003-0218-8820	NHLBI NIH HHS [HL25394, HL34300] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025394, R37HL025394, P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAZY M, 1991, J BIOL CHEM, V266, P23561; BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; CAPDEVILA JH, 1992, 8TH INT C PROST REL, P5; CARROLL MA, 1992, J PHARMACOL EXP THER, V260, P104; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; CARROLL MA, 1990, CIRC RES, V67, P1082, DOI 10.1161/01.RES.67.5.1082; COREY EJ, 1979, J AM CHEM SOC, V101, P1586, DOI 10.1021/ja00500a035; DOUGLAS JG, 1990, KIDNEY INT, V38, pS43; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; FULTON D, 1993, IN PRESS J AM SOC MA; KARARA A, 1991, J BIOL CHEM, V266, P7561; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; MURRAY RW, 1985, J ORG CHEM, V50, P2847, DOI 10.1021/jo00216a007; OLIW EH, 1984, J BIOL CHEM, V259, P2716; OLIW EH, 1984, FEBS LETT, V172, P279, DOI 10.1016/0014-5793(84)81141-2; OLIW EH, 1984, BIOCHIM BIOPHYS ACTA, V793, P408, DOI 10.1016/0005-2760(84)90256-X; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; Terragno N A, 1978, Clin Sci Mol Med Suppl, V4, p199s; VENTON D, 1990, METHOD ENZYMOL, V187, P245; WONG PYK, 1982, J PHARMACOL EXP THER, V223, P757; ZHANG JY, 1992, BIOCHEM BIOPH RES CO, V183, P138, DOI 10.1016/0006-291X(92)91619-2; ZUSMAN RM, 1977, J BIOL CHEM, V252, P2069	25	105	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12260	12266						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509363				2022-12-27	WOS:A1993LG65800009
J	HOCHMAN, Y; CARMELI, S; CARMELI, C				HOCHMAN, Y; CARMELI, S; CARMELI, C			VANADATE, A TRANSITION-STATE INHIBITOR OF CHLOROPLAST CF(1)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; HEART MITOCHONDRIAL ATPASE; NUCLEOTIDE-BINDING-SITES; ADENOSINE-TRIPHOSPHATASE; H+-ATPASE; MECHANISM; HYDROLYSIS; CATALYSIS; SYNTHASE; ADP	The activity of CF1-ATPase was inhibited by vanadate in an allosteric manner with respect to CaATP as substrate. The cooperative interaction was enhanced by preincubation of the enzyme in the presence of ADP and Ca2+ ions and of free divalent metal ions during assay of the activity. The strongest cooperative interaction with a Hill coefficient of 5.3 +/- 0.1 was found when the reaction was stopped after 30 s, before steady state was reached. Under these conditions, the concentration of an exchangeable ADP, tightly bound to one of the active sites on the enzyme, was shown to be the highest. A K(i) of 12.4 +/- 1.2 muM for vanadate inhibition was determined under these conditions. Direct measurements with the aid of V-51 NMR indicated that vanadate binds to CF1 in the presence of Ca2+ and ADP in a positive cooperative manner with a Hill coefficient of 2.3 +/- 0.2 and an average K(d) of 0.3 +/- 0.04 nM. It was suggested that a formation of pentacovalent vanadyl-ADP at the active site caused the inhibition. Vanadyl-ADP was suggested to be a strong inhibitor, being an analogue of a pentacovalent phosphoryl-ADP, which is proposed to be the transition state intermediate of CF1.	TEL AVIV UNIV,DEPT CHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University	HOCHMAN, Y (corresponding author), TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL.		Carmeli, shmuel/N-1273-2018	Carmeli, shmuel/0000-0002-9641-9943				ABBOTT MS, 1984, J BIOL CHEM, V259, P2271; ANTON GE, 1983, BIOCH BIPHYS ACTA, V723, P358; BINDER A, 1978, J BIOL CHEM, V253, P3094; BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; BOWMAN BJ, 1978, BIOCHIM BIOPHYS ACTA, V512, P13, DOI 10.1016/0005-2736(78)90214-6; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; BRUIST MF, 1982, BIOCHEMISTRY-US, V21, P3370, DOI 10.1021/bi00257a019; CARMELI C, 1981, BIOCHEMISTRY-US, V20, P3940, DOI 10.1021/bi00516a042; CARMELI C, 1992, FEBS LETT, V299, P227, DOI 10.1016/0014-5793(92)80120-6; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; CARMELI C, 1986, J BIOL CHEM, V261, P1669; CARMELI C, 1989, PHYSIOL PLANTARUM, V76, P858; CRANS DC, 1990, J AM CHEM SOC, V112, P427, DOI 10.1021/ja00157a063; DEMASTER EG, 1973, BIOCHEMISTRY-US, V12, P3616, DOI 10.1021/bi00743a007; FARRON F, 1970, BIOCHEMISTRY-US, V9, P3829, DOI 10.1021/bi00821a024; FELDMAN RI, 1982, J BIOL CHEM, V257, P1676; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1020, P187, DOI 10.1016/0005-2728(90)90050-E; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Gresser MJ, 1990, VANADIUM BIOL SYSTEM, P63; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HILLER R, 1985, J BIOL CHEM, V260, P1614; LECKBAND D, 1978, BIOCHEMISTRY-US, V26, P2306; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; MCCARTY RE, 1982, PHOTOSYNTHESIS ENERG, V1, P647; MORONEY JV, 1983, FEBS LETT, V158, P58, DOI 10.1016/0014-5793(83)80676-0; NELSON N, 1972, J BIOL CHEM, V247, P6506; SCHREIER AA, 1974, J MOL BIOL, V86, P601, DOI 10.1016/0022-2836(74)90183-1; SMITH LT, 1983, J BIOL CHEM, V258, P887; STROOP SD, 1985, BIOCHEMISTRY-US, V24, P2304, DOI 10.1021/bi00330a027; WALAAS E, 1958, ACTA CHEM SCAND, V12, P528, DOI 10.3891/acta.chem.scand.12-0528; WEBB MR, 1980, J BIOL CHEM, V255, P1637; ZHIXONG X, 1987, BIOCHEMISTRY-US, V26, P3749; ZHOU JM, 1992, BIOCHEMISTRY-US, V31, P3166, DOI 10.1021/bi00127a017	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12373	12379						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509376				2022-12-27	WOS:A1993LG65800026
J	LI, WWF; ALEXANDRE, S; CAO, XJ; LEE, AS				LI, WWF; ALEXANDRE, S; CAO, XJ; LEE, AS			TRANSACTIVATION OF THE GRP78 PROMOTER BY CA2+ DEPLETION - A COMPARATIVE-ANALYSIS WITH A23187 AND THE ENDOPLASMIC-RETICULUM CA2+-ATPASE INHIBITOR THAPSIGARGIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; IMMUNOGLOBULIN HEAVY-CHAIN; EPIDERMAL GROWTH-FACTOR; C-FOS; BINDING-PROTEIN; HAMSTER FIBROBLASTS; CALCIUM IONOPHORE; MAMMALIAN-CELLS; TUMOR PROMOTER; MESSENGER-RNA	The calcium ionophore A23187 has been shown to induce the expression of a set of glucose-regulated protein (GRP) genes through the depletion of Ca2+ from the intracellular Ca2+ stores. Here we demonstrate that thapsigargin, which inhibits specifically the endoplasmic reticulum Ca2+-ATPase and causes a discharge of the intracellular Ca2+ store, is able to induce the transcription of two grp genes (grp78/BiP and grp94) with kinetics and magnitude similar to that of A23187. The induction of the grp genes by both reagents requires several hours of sustained treatment, in contrast to the rapid induction previously described for c-jun and c-fos. The transactivation of the rat grp78 promoter by A23187 is mediated through sequences spanning -154 to -130 and -99 to -90. Further, simultaneous mutation of two 10-base pair regions, spanning -139 to -130 and -99 to -90, severely reduced the A23187 response. The induction by thapsigargin is also partially mediated through these same promoter elements, without the involvement of the TRE and CRE-like elements of the grp78 promoter. The Ca2+ response elements are further defined by their ability to confer Ca2+ stress inducibility to a heterologous promoter. We show that subdomains of the grp78 promoter are capable of conferring the Ca2+ stress response. In particular, two copies of a 50-base pair region spanning -159 to -110, when cloned in either orientation, can confer a 5- and 9-fold induction by A23187 and thapsigargin, respectively. Our results lend support to the hypothesis that the induction of grp78 by A23187 and thapsigargin following ER Ca2+ discharge acts through a novel pathway in which a Ca2+ signal is transduced through redundant elements containing CCAAT box-like motifs flanked by GC-rich regions.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033; NORRIS CANC CTR,LOS ANGELES,CA 90033	University of Southern California				Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [R37 CA27607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDRE S, 1991, MOL ENDOCRINOL, V5, P1862, DOI 10.1210/mend-5-12-1862; ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CAMPBELL AK, 1983, INTRACELLULAR CALCIU, P23; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CURRAN T, 1987, ONCOGENE, V2, P79; CUTRY AF, 1989, J BIOL CHEM, V264, P19700; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; KIM YK, 1989, GENE, V77, P123, DOI 10.1016/0378-1119(89)90366-1; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1986, J CELL PHYSIOL, V129, P277, DOI 10.1002/jcp.1041290302; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LENORMAND P, 1990, CELL GROWTH DIFFER, V1, P627; LIN AY, 1984, P NATL ACAD SCI-BIOL, V81, P988, DOI 10.1073/pnas.81.4.988; LIU ES, 1992, J BIOL CHEM, V267, P7128; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MELNICK J, 1992, J BIOL CHEM, V267, P21303; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; WOODEN SW, 1991, THESIS U SO CALIFORN	46	225	228	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12003	12009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505325				2022-12-27	WOS:A1993LF28400082
J	PALMER, M; WELLER, U; MESSNER, M; BHAKDI, S				PALMER, M; WELLER, U; MESSNER, M; BHAKDI, S			ALTERED PORE-FORMING PROPERTIES OF PROTEOLYTICALLY NICKED STAPHYLOCOCCAL ALPHA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PORES; MEMBRANE DAMAGE; AUREUS; MECHANISM; FRAGMENT; BINDING; CELLS	Staphylococcal alpha-toxin is a single-chain polypeptide with a molecular weight of 34,000 that hexamerizes in lipid bilayers to form pores of 1-1.5 nm effective diameter in membranes. We demonstrate that limited proteolysis of purified alpha-toxin with proteinase K generates a hemolytically active product that yields one major protein band of 17-18 kDa in SDS-polyacrylamide gel electrophoresis. The 17-18-kDa protein band harbors two major fragments of similar size representing the N- and C-terminal halves, which remain associated with each other in non-denaturing buffers but dissociate in 6 M urea. Dissociation in urea leads to loss of hemolytic activity. In contrast, unnicked alpha-toxin is not inactivated by urea. Nicked, hemolytically active alpha-toxin forms hexamers on erythrocyte membranes and on lymphocytes and monocytes. However, the nicked toxin can only lyse erythrocytes and fails to permeabilize nucleated cells. Osmotic protection experiments indicate that the size of pores generated by the nicked toxin is considerably smaller (0.6-0.9 nm effective diameter) than that generated by native toxin. The collective results do not support a previous proposal that different functions of alpha-toxin are contained in separate domains of the molecule.	UNIV MAINZ,INST MED MICROBIOL,AUGUSTUSPL,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz								BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BHAKDI S, 1988, J EXP MED, V168, P527, DOI 10.1084/jem.168.2.527; BLOMQVIST L, 1987, FEBS LETT, V211, P127, DOI 10.1016/0014-5793(87)81422-9; BLOMQVIST L, 1986, ACTA PATH MICRO IM B, V94, P277; BLOMQVIST L, 1987, INFECT IMMUN, V55, P1906, DOI 10.1128/IAI.55.8.1906-1913.1987; BLOMQVIST L, 1988, MICROB PATHOGENESIS, V4, P223, DOI 10.1016/0882-4010(88)90072-1; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; PALMER M, 1993, J BIOL CHEM, V268, P11959; THELESTAM M, 1975, INFECT IMMUN, V12, P225, DOI 10.1128/IAI.12.2.225-232.1975; THELESTAM M, 1991, BIOCHIM BIOPHYS ACTA, V1062, P245, DOI 10.1016/0005-2736(91)90399-S; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017	18	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11963	11967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505321				2022-12-27	WOS:A1993LF28400076
J	RUSHMORE, TH; PICKETT, CB				RUSHMORE, TH; PICKETT, CB			GLUTATHIONE S-TRANSFERASES, STRUCTURE, REGULATION, AND THERAPEUTIC IMPLICATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; SITE-DIRECTED MUTAGENESIS; PLANAR AROMATIC-COMPOUNDS; AH RECEPTOR COMPLEX; BREAST CANCER-CELLS; RESPONSIVE ELEMENT; PI-GENE; ACTIVE-SITE; TRANSCRIPTIONAL REGULATION				RUSHMORE, TH (corresponding author), MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE H9R 4P8,PQ,CANADA.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; BATIST G, 1986, J BIOL CHEM, V261, P5544; BOYLAND E, 1969, ADV ENZYMOL RAMB, V32, P173; CHANG LH, 1991, BIOCHEM BIOPH RES CO, V180, P323, DOI 10.1016/S0006-291X(05)81295-1; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; DULIK DM, 1987, DRUG METAB DISPOS, V15, P195; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; FAN WM, 1992, P NATL ACAD SCI USA, V89, P6104, DOI 10.1073/pnas.89.13.6104; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; HIRATSUKA A, 1990, J BIOL CHEM, V265, P11973; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KLONE A, 1992, BIOCHEM J, V285, P925; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; KOUITERT L, 1992, NEW DRUGS ASTHMA, V2, P78; LAI HCJ, 1988, J BIOL CHEM, V263, P11389; LI Y, 1992, J BIOL CHEM, V267, P15097; LIU SX, 1992, J BIOL CHEM, V267, P4296; LUNDQVIST G, 1992, BIOCHIM BIOPHYS ACTA, V1159, P103, DOI 10.1016/0167-4838(92)90081-N; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MORGENSTERN R, 1988, GLUTATHIONE CONJUGAT, P157; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MORTON MR, 1990, ARCH BIOCHEM BIOPHYS, V277, P56, DOI 10.1016/0003-9861(90)90549-E; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; NEUBOLD LA, 1989, MOL CELL BIOL, V9, P2378; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NICHOLSON DW, 1992, EUR J BIOCHEM, V209, P725, DOI 10.1111/j.1432-1033.1992.tb17341.x; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; NORRIS JS, 1991, MOL ENDOCRINOL, V5, P979, DOI 10.1210/mend-5-7-979; OGURA K, 1991, BIOCHEM BIOPH RES CO, V182, P1122; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICCI G, 1991, J BIOL CHEM, V266, P21409; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROHRDANZ E, 1992, ARCH BIOCHEM BIOPHYS, V298, P667; ROZEN F, 1992, ARCH BIOCHEM BIOPHYS, V292, P589, DOI 10.1016/0003-9861(92)90035-U; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TAYLOR JB, 1991, BIOCHEM J, V274, P587, DOI 10.1042/bj2740587; TELAKOWSKIHOPKINS CA, 1986, P NATL ACAD SCI USA, V83, P9393, DOI 10.1073/pnas.83.24.9393; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; TSUCHIDA S, 1992, CRC CRIT REV BIOCH M, V27, P3370; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; VANOMMEN B, 1989, EUR J BIOCHEM, V181, P423; VANOMMEN B, 1991, BIOCHEM J, V276, P661, DOI 10.1042/bj2760661; WANG RW, 1992, ARCH BIOCHEM BIOPHYS, V297, P86, DOI 10.1016/0003-9861(92)90644-C; WANG RW, 1992, J BIOL CHEM, V267, P19866; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WIDERSTEN M, 1991, FEBS LETT, V293, P156, DOI 10.1016/0014-5793(91)81175-8; ZHANG PH, 1991, J BIOL CHEM, V266, P19475	91	378	395	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11475	11478						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505281				2022-12-27	WOS:A1993LF28400001
J	SHIPLEY, JM; GRUBB, JH; SLY, WS				SHIPLEY, JM; GRUBB, JH; SLY, WS			THE ROLE OF GLYCOSYLATION AND PHOSPHORYLATION IN THE EXPRESSION OF ACTIVE HUMAN BETA-GLUCURONIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYL PHOSPHODIESTERASE; LYSOSOMAL-ENZYME; DEFICIENCY MUCOPOLYSACCHARIDOSIS; PARTIAL-PURIFICATION; PROTEIN; LIVER; BIOSYNTHESIS; RECOGNITION; CELLS; N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE	Phosphorylation of mannose residues on N-linked oligosaccharide side chains of lysosomal enzymes targets them to lysosomes. We used site-directed mutagenesis to observe the effect of eliminating selective glycosylation sites from human beta-glucuronidase on enzyme sorting. Expression studies allowed us to determine which of four potential sites were glycosylated, preferentially phosphorylated, and required for catalytic activity. All four sites of the human enzyme were glycosylated, whereas in the mouse and rat enzymes, only three of four sites are used. Sites 2 and 3 were preferentially phosphorylated. Elimination of sites 2 and 3 in combination markedly decreased sorting to lysosomes and increased enzyme secretion. Each of the four glycosylation sites could be eliminated individually without drastic reduction in catalytic activity. Activity was progressively lost as combinations of two, three, and four sites were eliminated. Wild-type enzyme produced in the presence of tunicamycin was also inactive, indicating that glycosylation is required for realization of enzyme activity. However, active enzyme could be deglycosylated with only minimal loss of activity. Mutant enzyme completely lacking glycosylation did not form tetramers. Partial restoration of tetramerization was achieved by the co-expression of normal rat enzyme, provided that the normal rat enzyme supplied at least two subunits to the tetramer.	ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BROT FE, 1978, BIOCHEMISTRY-US, V17, P385, DOI 10.1021/bi00596a001; ERICKSON AH, 1983, BIOCHEMISTRY-US, V22, P5201, DOI 10.1021/bi00291a021; GABEL CA, 1987, J CELL BIOL, V105, P1561, DOI 10.1083/jcb.105.4.1561; GLASER JH, 1973, J LAB CLIN MED, V82, P969; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; HALL CW, 1973, ARCH BIOCHEM BIOPHYS, V155, P32, DOI 10.1016/S0003-9861(73)80006-2; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYLE JW, 1992, GUS PROTOCOLS USING, P189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LEARNED RM, 1981, INITIATION DNA REPLI, P555; LUSIS AJ, 1976, J BIOL CHEM, V251, P7753; ONO M, 1988, J BIOL CHEM, V263, P5884; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; POWELL PP, 1988, BIOCHEM J, V250, P547, DOI 10.1042/bj2500547; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; VARKI A, 1981, J BIOL CHEM, V256, P9937; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; WEITZ G, 1992, J BIOL CHEM, V267, P10039	30	80	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12193	12198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505339				2022-12-27	WOS:A1993LF28400107
J	VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB				VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB			GLYCOPROTEIN-BIOSYNTHESIS IN THE ALG3 SACCHAROMYCES-CEREVISIAE MUTANT .1. ROLE OF GLUCOSE IN THE INITIAL GLYCOSYLATION OF INVERTASE IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; LIPID-LINKED OLIGOSACCHARIDE; YEAST EXTERNAL INVERTASE; PROTEIN GLYCOSYLATION; CORE OLIGOSACCHARIDES; GLUCOSYLATION STEPS; 500 MHZ; PATHWAY; IDENTIFICATION; MICROSOMES	Oligosaccharides on invertase restricted to the endoplasmic reticulum (ER) in alg3,sec18 yeast at 37-degrees-C were found to be 20% wild type Man8GlcNAc and 80% Man1alpha-->2Man1alpha-->2Man1alpha-->3(Man1alpha-->6)Man1beta-->4GlcNAc2 (Verostek, M. F., Atkinson, P. H., and Trimble, R. B. (1991) J. Biol. Chem. 266, 5547-5551). These results suggested that alg3 was slightly leaky, but did not address whether the oligosaccharide-lipid Man9GlcNAC2 and Man5GlcNAC2 precursors were glucosylated in alg3 yeast. Therefore, an alg3,sec18,gls1 strain was constructed to delete the GLS1-encoded glucosidase I responsible for trimming the terminal alpha1,2-linked glucose from newly transferred Glc3ManxGlcNAC2 oligosaccharides. Invertase activity was overexpressed 5-10-fold on transforming this strain with a multicopy plasmid (pRB58) carrying the SUC2 gene, and preparative amounts of the ER form of external invertase, derepressed and accumulated at 37-degrees-C, were purified. The N-linked glycans were released by sequential treatment with endo-beta-N-acetylglucosaminidase H (endo H) and peptide-N4-N-acetyl-beta-glucosaminyl asparagine amidase. Oligosaccharide pools were sized separately on Bio-Gel P-4, which showed that endo H released about 17% of the carbohydrate as Glc3Man8GlcNAc, while peptide-N4-N-acetyl-beta-glucosaminyl asparagine amidase released the remainder as Hex8GlcNAC2 and Man5GlcNAc2 in a 1:4 ratio. Glycan structures were assigned by 500-MHz two-dimensional DQF-COSY H-1 NMR spectroscopy, which revealed that the endo H-resistant Hex8GlcNAc2 pool contained Glc3Man5GlcNAc2 and Man8GlcNAc2 in a 6:4 ratio, the latter a different isomer from that formed by the ER alpha1,2-mannosidase (Byrd, J. C., Tarentino, A. L., Maley, F., Atkinson, P. H., and Trimble, R. B. (1982) J. Biol. Chem. 257, 14657-14666). Recovery of Glc3Man8GlcNAc and not the ER form of Man8GlcNAc provided an internal control indicating the absence of glucosidase I, which was confirmed by incubation of [H-3]Glc3[C-14]Man9GlcNAc with solubilized membranes from either alg3,sec18,gls1 or alg3,sec18,GLS1 strains. Chromatographic analysis of the products showed that [H03]Glc was removed only in the presence of the GLS1 gene product. Thus, the vast majority of the N-linked glycosylation in the ER of alg3 yeast (>75%) occurs by transfer of Man5GlcNAc2 without prior addition of the 3 glucoses normally found on the lipid-linked precursor.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES E524, POB 509, ALBANY, NY 12201 USA; SUNY, SCH PUBL HLTH, ALBANY, NY 12201 USA; MINIST AGR & FISHERIES TECHNOL, UPPER HUTT, NEW ZEALAND	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; SUNY Maritime College					NATIONAL CANCER INSTITUTE [R01CA013402, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NCI NIH HHS [CA13402, CA13330] Funding Source: Medline; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; ALVARADO E, 1991, BIOCHEMISTRY-US, V30, P881, DOI 10.1021/bi00218a001; BALLOU L, 1986, P NATL ACAD SCI USA, V83, P3081, DOI 10.1073/pnas.83.10.3081; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6607, DOI 10.1021/bi00526a014; CECCARINI C, 1984, J MOL BIOL, V176, P161, DOI 10.1016/0022-2836(84)90387-5; CHAPMAN A, 1979, CELL, V17, P509, DOI 10.1016/0092-8674(79)90259-9; CHAPMAN A, 1979, J BIOL CHEM, V254, P243; CHU FK, 1978, J BIOL CHEM, V253, P8691; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ESMON B, 1984, J BIOL CHEM, V259, P322; Goldstein A, 1975, Methods Enzymol, V42, P504; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURANDA MJ, 1987, P NATL ACAD SCI USA, V84, P2585, DOI 10.1073/pnas.84.9.2585; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1978, BIOCHIM BIOPHYS ACTA, V539, P218, DOI 10.1016/0304-4165(78)90008-9; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Maurer P H, 1980, Methods Enzymol, V70, P49; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; RAY MK, 1991, J BIOL CHEM, V266, P22818; RUNGE KW, 1984, J BIOL CHEM, V259, P412; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSAI PK, 1984, P NATL ACAD SCI-BIOL, V81, P6340, DOI 10.1073/pnas.81.20.6340; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411; VANHALBEEK H, 1980, FEBS LETT, V121, P71; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12104; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WANG HY, 1977, BIOTECHNOL BIOENG, V19, P69, DOI 10.1002/bit.260190107; WILLIAMS RS, 1985, J BIOL CHEM, V260, P3334; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	48	50	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12095	12103						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505333				2022-12-27	WOS:A1993LF28400095
J	XIAO, H; DONG, ZM; ODONNELL, M				XIAO, H; DONG, ZM; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .4. CHARACTERIZATION OF CHI AND PSI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GAMMA-SUBUNIT; PRIMED TEMPLATE; HOLOENZYME; TAU; MECHANISM; COMPLEX	The gamma complex (gammadeltadelta'chipsi) subassembly of the Escherichia coli replicase initiates processive replication upon assembling the ring-shaped beta subunit around DNA. The beta ring acts as a clamp to hold the replicase down to DNA for highly processive synthesis. In this report we characterize the chi and psi subunits of the gamma complex. Both chi and psi are monomeric, and they associate to form a 1:1 complex. The chi subunit does not form a complex with gamma, but psi binds gamma tightly thereby acting as a bridge to assimilate chi into the gamma complex structure. The psi subunit stimulated the ATPase and replication activities of gamma. The chi subunit only stimulated the activities of gamma when the psi subunit was also present thus reflecting the structure where psi bridges the interaction of chi with gamma.	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1991, DNA REPLICATION, P176; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 1970, HDB BIOCHEMISTRY, pC1; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1993, J BIOL CHEM, V268, P11773	25	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11779	11784						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505305				2022-12-27	WOS:A1993LF28400049
J	FORGE, V; MINTZ, E; GUILLAIN, F				FORGE, V; MINTZ, E; GUILLAIN, F			CA2+ BINDING TO SARCOPLASMIC-RETICULUM ATPASE REVISITED .1. MECHANISM OF AFFINITY AND COOPERATIVITY MODULATION BY H+ AND MG2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CALCIUM-BINDING; CONFORMATIONAL TRANSITION; INORGANIC-PHOSPHATE; CA2+-TRANSPORTING ATPASE; DIRECT FLUORESCENCE; TRANSPORT SITE; STOPPED FLOW; PHOSPHORYLATION; MAGNESIUM	H+ and Mg2+ are known to inhibit Ca2+ binding to the transport sites of sarcoplasmic reticulum-ATPase. Evaluation of the affinity for the Ca2+ binding sites requires measurement of the amount of Ca2+ bound to ATPase as a function of the free Ca2+ concentration imposed by a Ca2+ chelator. The choice of the chelator is crucial as it determines the accuracy of the free Ca2+ concentration. At pH > 7, the EGTA affinity for Ca2+ is higher than that of ATPase, inducing artifacts that alter the shape of the binding curves. Thus, we have used 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), whose affinity is unchanged at pH greater-than-or-equal-to 7. Ca2+ binding was studied at equilibrium, from pH 6 to pH 8 and from 0 to 10 mM Mg2+, using EGTA and/or BAPTA and [Ca-45]Ca2+. Under all conditions, the stoichiometry was 2 Ca2+/ATPase. At variance with previous studies, the Hill coefficient was 1.1-2 and higher at pH 6 than at pH 8. In addition, it decreased in the presence of Mg2+. The Ca2+ binding curves were analyzed according to a model in which they result from a sequential binding of two Ca2+, each binding step being modified by H+ and Mg2+. The effect of H+ is described by two steps involving two H+ and one H+, with pK 7 and 7.9, respectively. At pH 6, ATPase must lose two H+ for the first Ca2+ to bind and a third H+ for the second Ca2+ to bind. At pH 9, both Ca2+ bind without any H+ exchange. Mg2+ can bind to all species, except to that saturated with Ca2+. The species having lost two H+ has a higher affinity for Mg2+ (less-than-or-equal-to mM) than the species having bound three H+ (4 mM). The above model allows us to analyze the effects of H+ and Mg2+ at each Ca2+ binding step and to explain the changes in the apparent affinity and cooperativity.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,CNRS,URA 1290,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	FORGE, V (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,F-91191 GIF SUR YVETTE,FRANCE.							BISHOP JE, 1988, J BIOL CHEM, V263, P1886; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CUENDA A, 1991, FEBS LETT, V283, P273, DOI 10.1016/0014-5793(91)80606-4; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FORGE V, 1993, J BIOL CHEM, V268, P10961; FROUD RJ, 1986, BIOCHEM J, V237, P197, DOI 10.1042/bj2370197; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GIRARDET JL, 1992, FEBS LETT, V296, P103, DOI 10.1016/0014-5793(92)80413-B; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HENAO F, 1992, J BIOL CHEM, V267, P10302; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P3978, DOI 10.1073/pnas.79.13.3978; HOLGUIN JA, 1986, ARCH BIOCHEM BIOPHYS, V251, P9, DOI 10.1016/0003-9861(86)90045-7; IKEMOTO N, 1974, J BIOL CHEM, V249, P649; IMAMURA Y, 1991, J BIOCHEM-TOKYO, V110, P214, DOI 10.1093/oxfordjournals.jbchem.a123559; IMAMURA Y, 1991, J BIOCHEM-TOKYO, V110, P220, DOI 10.1093/oxfordjournals.jbchem.a123560; INESI G, 1982, Z NATURFORSCH C, V37, P685; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LEVY D, 1990, J BIOL CHEM, V265, P19524; LOOMIS CR, 1982, BIOCHEMISTRY-US, V21, P151, DOI 10.1021/bi00530a026; MADEIRA VMC, 1980, ARCH BIOCHEM BIOPHYS, V200, P319, DOI 10.1016/0003-9861(80)90361-6; MAKINOSE M, 1969, EUR J BIOCHEM, V10, P74; MAKINOSE M, 1979, CATION FLUX BIOMEMBR, P89; MARTIN RB, 1992, FEBS LETT, V308, P59, DOI 10.1016/0014-5793(92)81050-V; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MINTZ E, 1990, J BIOL CHEM, V265, P18762; MOUTIN MJ, 1991, J BIOL CHEM, V266, P5580; OGURUSU T, 1991, BIOCHEMISTRY-US, V30, P9966, DOI 10.1021/bi00105a022; PICK U, 1982, J BIOL CHEM, V257, P6120; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WAKABAYASHI S, 1990, J BIOCHEM-TOKYO, V107, P563, DOI 10.1093/oxfordjournals.jbchem.a123087; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526	47	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10953	10960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496159				2022-12-27	WOS:A1993LD46600039
J	VERTEL, BM; WALTERS, LM; FLAY, N; KEARNS, AE; SCHWARTZ, NB				VERTEL, BM; WALTERS, LM; FLAY, N; KEARNS, AE; SCHWARTZ, NB			XYLOSYLATION IS AN ENDOPLASMIC-RETICULUM TO GOLGI EVENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; TERMINAL N-ACETYLGALACTOSAMINE; SEMI-INTACT CELLS; CORE PROTEIN; BREFELDIN-A; SUBCELLULAR-LOCALIZATION; CULTURED CHONDROCYTES; RAT CHONDROSARCOMA; CIS-GOLGI; TRANSPORT	The subcellular site of xylosylation, the first carbohydrate modification of the core protein that initiates glycosaminoglycan chain synthesis, was characterized in situ. Methods were developed to combine electron microscopic (EM) autoradiography and the radiolabeling of semi-intact chondrocytes. In the accompanying paper, Kearns et al. (Kearns, A. E., Vertel, B. M., and Schwartz, N. B. (1993) J. Biol. Chem. 268, 11097-11104) presented biochemical and subcellular fractionation studies that utilized semi-intact chondrocytes and radiolabeled UDP sugars to overcome obstacles to the direct analysis of xylosylation. The results suggested that xylosylation begins in the endoplasmic reticulum (ER) and continues in the Golgi. The site of xylosylation was not specified further due to the limitations of subcellular fractionation techniques. The studies described in this report were undertaken to localize these modifications directly in situ. Semi-intact cell preparations were optimized for ultrastructural preservation by modifications of permeabilization methods utilizing nitrocellulose filter overlays. Biochemical analysis demonstrated the exclusive incorporation of UDP-xylose into the cartilage chondroitin sulfate proteoglycan (aggrecan) core protein and 3'-phosphoadenosine 5'-phosphosulfate (PAPS) into the highly modified proteoglycan monomer. Immunolocalization studies showed the equivalence of cytoplasmic subcompartments in normal and semi-intact chondrocytes at the levels of light and electron microscopy. Once the biochemical and morphological equivalence of intact and semi-intact cells was established, EM autoradiographic studies were pursued using UDP-[H-3]xylose and [S-35]PAPS. Based on both qualitative and quantitative data, silver grains resulting from incorporated sulfate were concentrated in the perinuclear Golgi, while those resulting from incorporated xylose were found at the cis or forming face of the Golgi and in vesicular regions of the peripheral cytoplasm associated with the late ER. These data support the view that xylose addition begins in a late ER compartment and continues in intermediate compartments, perhaps including the cis-Golgi.	UNIV HLTH SCI CHICAGO MED SCH,DEPT PHYS THERAPY,N CHICAGO,IL 60064; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Chicago Medical School; University of Chicago; University of Chicago	VERTEL, BM (corresponding author), UNIV HLTH SCI CHICAGO MED SCH,DEPT CELL BIOL & ANAT,3333 GREEN BAY RD,N CHICAGO,IL 60064, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028433] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-19266] Funding Source: Medline; NICHD NIH HHS [HD-17332] Funding Source: Medline; NIDDK NIH HHS [DK-28433] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BRINKLEY BR, 1967, J CELL BIOL, V35, P279, DOI 10.1083/jcb.35.1.279; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; BUMOL TF, 1982, P NATL ACAD SCI-BIOL, V79, P1245, DOI 10.1073/pnas.79.4.1245; CAHN RD, 1967, METHODS DEVELOPMENTA, P493; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FARQUHAR MG, 1991, INTRACELLULAR TRAFFI, P431; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Hascall V.C., 1991, CELL BIOL EXTRACELLU, P149; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; HORWITZ AL, 1968, J CELL BIOL, V38, P358, DOI 10.1083/jcb.38.2.358; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAO CY, 1992, J CELL BIOL, V17, P701; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MAUNSBACH AB, 1966, J ULTRA MOL STRUCT R, V15, P197, DOI 10.1016/S0022-5320(66)80108-9; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; ODONNELL CM, 1988, J BIOL CHEM, V263, P17749; PACIFICI M, 1983, J CELL BIOL, V97, P1724, DOI 10.1083/jcb.97.6.1724; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; RATCLIFFE A, 1985, J CELL BIOL, V101, P2355, DOI 10.1083/jcb.101.6.2355; RIZZOLO LJ, 1985, J CELL BIOL, V101, P1351, DOI 10.1083/jcb.101.4.1351; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWARTZ NB, 1976, J BIOL CHEM, V251, P3346; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; UPHOLT WB, 1981, ALA J MED SCI, V18, P35; UPHOLT WB, 1979, P NATL ACAD SCI USA, V76, P1261; Vertel B M, 1992, Semin Cell Biol, V3, P325, DOI 10.1016/1043-4682(92)90019-R; VERTEL BM, 1985, EXP CELL RES, V158, P423, DOI 10.1016/0014-4827(85)90466-5; VERTEL BM, 1984, COLLAGEN REL RES, V4, P1; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VERTEL BM, 1987, COLLAGEN REL RES, V7, P57; VERTEL BM, 1985, J CELL BIOCHEM, V27, P215, DOI 10.1002/jcb.240270304; VERTEL BM, 1979, P NATL ACAD SCI USA, V76, P4847; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3	72	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11105	11112						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496173				2022-12-27	WOS:A1993LD46600059
J	REINBOTHE, S; REINBOTHE, C; PARTHIER, B				REINBOTHE, S; REINBOTHE, C; PARTHIER, B			METHYL JASMONATE-REGULATED TRANSLATION OF NUCLEAR-ENCODED CHLOROPLAST PROTEINS IN BARLEY (HORDEUM-VULGARE L CV SALOME)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; TOMATO CELL-CULTURES; HEAT-SHOCK GRANULES; EUGLENA-GRACILIS; LEAF SENESCENCE; MESSENGER-RNAS; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; LEUCYL-TRNA; ACID; LIGHT	The naturally occurring plant growth regulator (-)-jasmonic acid methyl ester (JaMe) induces the formation of novel abundant proteins in excised barley leaf segments. Concomitantly, this substance depresses the translation of most preexisting (''control'') leaf mRNAs, including those for nuclear-encoded chloroplast proteins such as the small subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase (SSU, rbcS gene product) and several light harvesting chlorophyll protein complex apoproteins (LHCPs, cab gene products). The changes in protein synthesis observed for SSU and LHCPs did not correspond to equivalent alterations in the rbcS and cab transcript levels. Analysis of polysome-associated in vitro translatable and hybridizable mRNAs, however, demonstrated a restriction of rbcS and cab transcripts to smaller polysomes in JaMe-exposed leaf tissues, in comparison to water-treated tissues. Since treatment of JaMe-incubated leaf segments with cycloheximide prior to harvest led to a shift of both transcripts toward larger polysomes, a hormone-induced impairment of chain initiation is assumed to lower translation of SSU and LHCP in situ. In contrast, the mRNA for plastid leucyl-tRNA synthetase (LRS1, lrs1 gene product) neither changed its abundance nor its association with polysomes in JaMe-treated leaves and was translated into the corresponding polypeptide. Together, our results highlight a remarkable variability of nuclear gene expression in response to plant growth regulators of the methyl jasmonate type.	INST PLANT BIOCHEM, O-4050 HALLE, GERMANY; CARLSBERG RES CTR, DEPT PHYSIOL, DK-2500 COPENHAGEN, DENMARK	Leibniz Institut fur Pflanzenbiochemie	REINBOTHE, S (corresponding author), SWISS FED INST TECHNOL, INST PLANT SCI, DEPT GENET, UNIV STR 2, CH-8092 ZURICH, SWITZERLAND.		Reinbothe, Steffen/AAW-9893-2021					ANDERSON JM, 1989, PLANT SCI, V62, P45, DOI 10.1016/0168-9452(89)90188-X; ANDRESEN I, 1992, PLANT MOL BIOL, V19, P193, DOI 10.1007/BF00027341; ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; BARTHOLOMEW DM, 1991, PLANT PHYSIOL, V96, P291, DOI 10.1104/pp.96.1.291; BERRY JO, 1990, PLANT CELL, V2, P795, DOI 10.1105/tpc.2.8.795; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; GOLLMER I, 1983, EUR J BIOCHEM, V133, P309, DOI 10.1111/j.1432-1033.1983.tb07463.x; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P10199, DOI 10.1093/nar/15.24.10199; HERMAN EM, 1988, PLANT PHYSIOL, V86, P1027, DOI 10.1104/pp.86.4.1027; ILAN J, 1987, TRANSLATIONAL REGULA; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KRAUSPE R, 1988, BIOCHEM PHYSIOL PFL, V183, P477, DOI 10.1016/S0015-3796(88)80004-0; KRAUSPE R, 1987, J PLANT PHYSIOL, V130, P327, DOI 10.1016/S0176-1617(87)80199-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; MASON HS, 1990, PLANT CELL, V2, P569, DOI 10.1105/tpc.2.6.569; MEDFORD JI, 1989, PLANTA, V179, P309, DOI 10.1007/BF00391075; MEYER A, 1984, J PLANT GROWTH REGUL, V3, P1, DOI 10.1007/BF02041987; MULLERURI F, 1988, PLANTA, V176, P241; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; NOVER L, 1983, MOL CELL BIOL, V3, P1648, DOI 10.1128/MCB.3.9.1648; NOVER L, 1984, EUR J BIOCHEM, V139, P303, DOI 10.1111/j.1432-1033.1984.tb08008.x; NOVER L, 1990, HEAT SHOCK OTHER STR; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARTHIER B, 1990, J PLANT GROWTH REGUL, V9, P57, DOI 10.1007/BF02041942; PARTHIER B, 1991, BOT ACTA, V104, P446, DOI 10.1111/j.1438-8677.1991.tb00257.x; PERLMAN S, 1972, NATURE-NEW BIOL, V238, P143, DOI 10.1038/newbio238143a0; QUATRANO RS, 1983, PLANT MOL BIOL, P343; REINBOTHE S, 1992, PHYSIOL PLANTARUM, V86, P49, DOI 10.1111/j.1399-3054.1992.tb01310.x; REINBOTHE S, 1990, J PLANT PHYSIOL, V137, P81, DOI 10.1016/S0176-1617(11)80015-5; REINBOTHE S, 1992, J PLANT GROWTH REGUL, V11, P7, DOI 10.1007/BF00193837; REINBOTHE S, 1990, PLANTA, V181, P176, DOI 10.1007/BF02411535; REINBOTHE S, 1992, NATO ADV SCI I A-LIF, V226, P43; REINBOTHE S, 1990, FEBS LETT, V265, P7, DOI 10.1016/0014-5793(90)80870-O; Sambrook J, 1989, MOL CLONING LABORATO; SATLER SO, 1981, CR ACAD SCI III-VIE, V293, P735; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; Sembdner G., 1986, Plant growth substances 1985. Proceedings of the 12th international conference on plant growth substances., P139; STASWICK PE, 1990, PLANT CELL, V2, P1, DOI 10.1105/tpc.2.1.1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA J, 1981, Z PFLANZENPHYSIOL, V103, P357, DOI 10.1016/S0044-328X(81)80134-1; UEDA J, 1980, PLANT PHYSIOL, V66, P246, DOI 10.1104/pp.66.2.246; VASSART G, 1971, BIOCHIM BIOPHYS ACTA, V247, P471, DOI 10.1016/0005-2787(71)90034-7; WEIDHASE RA, 1987, PHYSIOL PLANTARUM, V69, P161, DOI 10.1111/j.1399-3054.1987.tb01961.x; WEIDHASE RA, 1987, PLANT SCI, V51, P177, DOI 10.1016/0168-9452(87)90191-9; WILEN RW, 1991, PLANT PHYSIOL, V95, P399, DOI 10.1104/pp.95.2.399	47	79	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10606	10611						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486714				2022-12-27	WOS:A1993LB80000090
J	RANDAZZO, PA; YANG, YC; RULKA, C; KAHN, RA				RANDAZZO, PA; YANG, YC; RULKA, C; KAHN, RA			ACTIVATION OF ADP-RIBOSYLATION FACTOR BY GOLGI MEMBRANES - EVIDENCE FOR A BREFELDIN A-SENSITIVE AND PROTEASE-SENSITIVE ACTIVATING FACTOR ON GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; BOVINE BRAIN; ADENYLATE-CYCLASE; SUCCESSIVE COMPARTMENTS; REGULATORY COMPONENT; GUANINE-NUCLEOTIDES; CHOLERA-TOXIN; PURIFICATION; COFACTOR; ALPHA	Recent evidence has implicated ADP-ribosylation factor (ARF) proteins as critical regulators of the protein secretory pathway, particularly in the endoplasmic reticulum-Golgi pathway. We have examined whether Golgi membranes contain activators of ARF and the consequences of ARF activation and acylation on its membrane association. Two means were used to assess ARF activation. First, guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding to protein was found to be greater when ARF and Golgi were incubated together than when either was incubated alone. These data suggested that ARF . GTPgammaS was formed. This was confirmed by showing that the GTPgammaS-bound protein functioned as a cofactor for cholera toxin-stimulated ADP-ribosylation of G(salpha), a reaction for which activated ARF is a necessary cofactor. Trypsin treatment of Golgi, an inhibitory ARF peptide, and brefeldin A each inhibited Golgi-mediated activation by approximately 70%, demonstrating that a specific protein interaction is required for the majority of the ARF activation. This ARF-activating protein is a strong candidate for the molecular target for brefeldin A. The ubiquitous nature of ARF proteins and their importance in both the exocytic and endocytic pathways may explain the effects of brefeldin A on both exocytic and endocytic membrane traffic in animal cells. A protease-insensitive activation of ARF by Golgi could also be demonstrated and was the dominant activity observed in submicromolar concentrations of magnesium. We believe this to be the lipid-mediated process described previously for purified ARF proteins. ARF activation resulted in tight association of ARF with phospholipid vesicles. Vesicle association required amino-terminal myristoylation of ARF whereas activation did not. These studies indicate that the brefeldin A-sensitive ARF-activating protein and other factors that determine the level of activation of ARF in animal cells are fundamental regulators of membrane traffic in animal cells.	NCI, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, BIOL CHEM LAB,REGULATORY MECHANISMS SECT, BLDG 37, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1988, J BIOL CHEM, V263, P1768; WEISS O, 1989, J BIOL CHEM, V264, P21066	35	126	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9555	9563						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486645				2022-12-27	WOS:A1993LA68900063
J	BOTTALICO, LA; KEESLER, GA; FLESS, GM; TABAS, I				BOTTALICO, LA; KEESLER, GA; FLESS, GM; TABAS, I			CHOLESTEROL LOADING OF MACROPHAGES LEADS TO MARKED ENHANCEMENT OF NATIVE LIPOPROTEIN(A) AND APOPROTEIN(A) INTERNALIZATION AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; ACYL COENZYME-A; ALPHA-2-MACROGLOBULIN RECEPTOR; TRANSFERASE-ACTIVITY; PLASMINOGEN BINDING; HUMAN AORTA; ATHEROSCLEROSIS; PROTEIN; APOLIPOPROTEIN(A)	Lipoprotein(a) levels in the plasma are strongly correlated with atherosclerotic coronary artery disease. Although the mechanism of this effect is not known, the interaction of lipoprotein(a) with macrophages may be important. Previous work has shown that macrophages in culture internalize and degrade native lipoprotein(a) poorly. In the present study, the interaction of Lp(a) with mouse peritoneal and human monocyte-derived macrophages that were cholesterol-loaded, such as occur in atheromata, was investigated. I-125-Lp(a) degradation was increased 4-5-fold in macrophages that had been loaded with cholesterol by incubation with acetyl-LDL for 2-4 days. The enhanced degradation of Lp(a) by foam cells was chloroquine-sensitive and dependent upon the presence of calcium in the extracellular medium. Incubation of the macrophages with acetyl-LDL plus an inhibitor of acyl CoA:cholesterol acyltransferase, which increased the free cholesterol content and decreased the cholesteryl ester content of the cells, resulted in an even greater up-regulation of I-125-Lp(a) degradation (8-23-fold over control macrophages). The interaction of Lp(a) with cholesterol-loaded macrophages involved the apoprotein(a) moiety of Lp(a) since I-125-apoprotein(a), but not I-125-Lp(a-), was degraded to a much greater extent by foam cells compared to control macrophages. The uptake and degradation of Lp(a) in foam cells was not mediated by LDL, scavenger, LDL receptor-related protein (LRP), or plasminogen receptors. Thus, cholesterol loading of macrophages markedly enhances the internalization and lysosomal degradation of Lp(a) and apo(a) by a calcium-dependent receptor activity different from known lipoprotein receptors.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	Columbia University; Columbia University; University of Chicago					NHLBI NIH HHS [HL18577, HL21006, HL39703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, P50HL021006, R01HL039703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BIHAIN BE, 1992, BIOCHEMISTRY-US, V31, P4628, DOI 10.1021/bi00134a013; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FOWLER S, 1980, ACTA MED SCAND, P151; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HABERLAND ME, 1992, J BIOL CHEM, V267, P4143; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1991, J BIOL CHEM, V266, P21232; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KREMPLER F, 1984, J LIPID RES, V25, P283; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; RAPP JH, 1983, J LIPID RES, V24, P1329; ROSS AC, 1984, J BIOL CHEM, V259, P815; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; SNYDER ML, 1992, J BIOL CHEM, V267, P339; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1989, J CLIN INVEST, V84, P1713, DOI 10.1172/JCI114354; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1992, CIRCULATION, V86, P336; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	53	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8569	8573						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473302				2022-12-27	WOS:A1993KX81100032
J	HUSAIN, SS				HUSAIN, SS			FIBRIN AFFINITY OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - EVIDENCE THAT ZN2+ MEDIATES STRONG AND SPECIFIC INTERACTION OF SINGLE-CHAIN UROKINASE WITH FIBRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; AMINO-ACID-SEQUENCE; PRO-UROKINASE; HUMAN-URINE; PROTEOLYTIC CLEAVAGE; ESCHERICHIA-COLI; U937 MONOCYTES; TISSUE; BINDING; PURIFICATION	Interactions of components of the fibrinolytic system with fibrin play a key role in localization and regulation of plasminogen activation at the clot surface. Although interaction of tissue plasminogen activator (tPA) with fibrin is well established, the prevailing view is that urokinase-type plasminogen activator (uPA) does not bind to fibrin. In this report, I show that although there is little or no interaction of single-chain urokinase (Sc-uPA), two-chain urokinase (Tc-uPA), or low molecular weight urokinase (LMW-uPA) with fibrin in the absence of divalent metal cations, Sc-uPA is effectively bound to fibrin in the presence of Zn2+. By comparison, Tc-uPA is poorly bound and LMW-uPA is not bound to fibrin in the presence of the metal ion. The Zn2+-mediated fibrin binding of Sc-uPA is reversible, specific, and saturable. The interaction involves a single class of binding site with dissociation constant of 0.3 muM and stoichiometry of 2.7. Lacking apparent affinity for fibrin, uPA has not been considered to play a role in physiological fibrinolysis. The present study conclusively shows that Sc-uPA possesses a latent affinity for fibrin that is expressed in the presence of Zn2+. These findings raise the possibility that Zn2+ plays a regulatory role in uPA-mediated fibrinolysis by promoting effective localization of Sc-uPA at the clot surface.	HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	HUSAIN, SS (corresponding author), MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114, USA.				NHLBI NIH HHS [HL38178] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038178] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTS RJ, 1989, THROMB HAEMOSTASIS, V62, P699; AKLUGA A, 1975, PLATELETS RECENT ADV, P185; BACHMANN F, 1987, HEMOSTASIS THROMBOSI, P318; BAJPAI A, 1985, BIOCHEM BIOPH RES CO, V133, P475, DOI 10.1016/0006-291X(85)90931-3; BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAWSON RMC, 1986, DATA BIOCH RES, P408; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1989, J BIOL CHEM, V264, P2185; FOLEY B, 1968, P SOC EXP BIOL MED, V128, P265; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; GUREWICH V, 1983, THROMB HAEMOSTASIS, V50, P386; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; HEYNS AD, 1985, BLOOD, V66, P213; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HUSAIN S S, 1990, Fibrinolysis, V4, P121; HUSAIN SS, 1981, P NATL ACAD SCI-BIOL, V78, P4265, DOI 10.1073/pnas.78.7.4265; HUSAIN SS, 1989, BLOOD, V74, P999; HUSAIN SS, 1983, ARCH BIOCHEM BIOPHYS, V220, P31, DOI 10.1016/0003-9861(83)90383-1; HUSAIN SS, 1985, THROMB HAEMOSTASIS, V54, P122; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; KASAI S, 1985, J BIOL CHEM, V260, P2377; KRISTENSEN P, 1984, FEBS LETT, V168, P33, DOI 10.1016/0014-5793(84)80201-X; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1991, J BIOL CHEM, V266, P9408; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; OSSOWSKI L, 1975, PROTEASES BIOL CONTR, P901; PRASAD AS, 1988, J CLIN INVEST, V82, P1202, DOI 10.1172/JCI113717; REICH E, 1978, MOL BASIS BIOL DEGRA, P155; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; STUMP DC, 1986, J BIOL CHEM, V261, P1274; STUMP DC, 1986, J BIOL CHEM, V261, P1267; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; THORSEN S, 1972, THROMB DIATH HAEMOST, V28, P65; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WIMAN B, 1978, NATURE, V272, P54; WINKLER ME, 1985, BIO-TECHNOL, V3, P990, DOI 10.1038/nbt1185-990; WUN TC, 1982, J BIOL CHEM, V257, P7262; ZAIDI STH, 1990, FIBRINOLYSIS, V4, P160	58	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8574	8579						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473303				2022-12-27	WOS:A1993KX81100033
J	MAO, PL; BEAUCHEMIN, M; BEDARD, PA				MAO, PL; BEAUCHEMIN, M; BEDARD, PA			QUIESCENCE-DEPENDENT ACTIVATION OF THE P20K PROMOTER IN GROWTH-ARRESTED CHICKEN-EMBRYO FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; RETINOBLASTOMA GENE-PRODUCT; HEART MESENCHYMAL CELLS; DNA-BINDING; MESSENGER-RNAS; EXPRESSION; PROTEIN; ENHANCER; TRANSCRIPTION; REPRESSION	We described the synthesis of a quiescence-specific p20K protein in quiescent chicken heart mesenchymal cells and contact-inhibited chicken embryo fibroblasts (Bedard, P.-A., Balk, S. D., Gunther, H. S., Morisi, A., and Erikson, R. L. (1987a) Mol. Cell. Biol. 7, 1450-1459). We now report that the expression of p20K is enhanced in cells rendered quiescent by other conditions of growth arrest such as serum starvation or treatment with hydroxyurea. Chicken embryo fibroblasts transformed by the Rous sarcoma virus also expressed p20K upon serum/medium depletion. In all conditions investigated, the synthesis of p20K was correlated with decreased DNA synthesis, indicating that growth arrest regulates the expression of p20K in fibroblasts. The abundance of p20K mRNAs was elevated in quiescent cells, and the p20K gene was more active in nuclear run-on transcription assays in conditions of growth arrest. The p20K gene was isolated, and the promoter region was analyzed in transient expression assays. Serum starvation increased the activity of the promoter, indicating that the expression of p20K is controlled at least in part at the transcriptional level. Deletion analysis revealed that a region of less than 217 base pairs (bp) is sufficient for quiescence-dependent activity of the promoter. Within this region, a segment of 48 bp was essential to basal and quiescence-induced activity of the promoter in dividing and nondividing cells, respectively. The 48-bp region enhanced the activity of a minimal heterologous promoter in quiescent cells but had no effect in conditions of proliferation, indicating that it functions as a quiescence-responsive unit (QRU). Therefore, the transcription of the p20K gene in quiescent fibroblasts is controlled by the one or several growth-regulated elements located in the 48-bp QRU of the promoter.	UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALK SD, 1980, P NATL ACAD SCI-BIOL, V77, P6606, DOI 10.1073/pnas.77.11.6606; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Baserga R., 1976, MULTIPLICATION DIVIS; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DODGSON JB, 1979, CELL, V17, P879, DOI 10.1016/0092-8674(79)90328-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MEDRANO EE, 1980, P NATL ACAD SCI-BIOL, V77, P4123, DOI 10.1073/pnas.77.7.4123; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; PARDEE AB, 1975, P NATL ACAD SCI USA, V72, P4994, DOI 10.1073/pnas.72.12.4994; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; WANG E, 1985, J CELL BIOL, V101, P1695, DOI 10.1083/jcb.101.5.1695; WANG E, 1985, J CELL BIOL, V100, P545, DOI 10.1083/jcb.100.2.545; ZETTERBERG A, 1991, COLD SH Q B, V56, P137	36	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8131	8139						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463325				2022-12-27	WOS:A1993KW97900078
J	BLAXTER, ML				BLAXTER, ML			CUTICLE SURFACE-PROTEINS OF WILD-TYPE AND MUTANT CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT BRUGIA-MALAYI; PARASITIC NEMATODES; ASCARIS-SUUM; PANAGRELLUS-REDIVIVUS; DIROFILARIA-IMMITIS; EXCRETORY SYSTEM; COLLAGEN GENE; GLYCOPROTEIN; ANTIGENS; MEMBRANE	The molecular components of the surface of the free-living nematode Caenorhabditis elegans have been identified by surface-specific radioiodination. Four compartments were defined by fractionation of labeled wild type (N2 strain) adult hermaphrodites. Organic solvents extracted cuticular lipids. Homogenization in detergents released a single, non-collagenous, hydrophobic protein. This is not glycosylated and is a heterodimer of 6.5- and 12-kDa subunits. The third compartment, proteins solubilized by reducing agents, included both the cuticular collagens and the heterodimer. Residual material corresponds to the cuticlin fraction. Larval stages showed a similar pattern, except that the dauer larva had an additional 37-kDa detergent-soluble protein. Other species of rhabditid nematodes displayed similar profiles, and comparison with parasitic species suggests that this simple pattern may be primitive in the Nematoda. A C. elegans strain mutant in cuticular collagen (rol-6) had a pattern identical to that of wild type, but another morphological mutant (dpy-6) and several mutants that differ in surface reactivity to antibody and lectins (srf mutants) also had striking differences in surface labeling patterns.			BLAXTER, ML (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, WELLCOME RES CTR PARASIT INFECT, LONDON SW7 2BB, ENGLAND.		Blaxter, Mark/O-2535-2019; Blaxter, Mark L/B-4113-2010	Blaxter, Mark L/0000-0003-2861-949X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ RM, 1989, MOL BIOCHEM PARASIT, V33, P183, DOI 10.1016/0166-6851(89)90032-7; BACIC A, 1990, EXP PARASITOL, V71, P483, DOI 10.1016/0014-4894(90)90074-M; BAIRD SE, 1993, IN PRESS NEMATOLOGIC; Barrett J., 1981, BIOCH PARASITIC HELM; Barron G.L., 1977, NEMATODE DESTROYING, VI, P144; BEAMES CG, 1964, EXP PARASITOL, V15, P387, DOI 10.1016/0014-4894(64)90033-5; BETSCHART B, 1990, ACTA TROP, V47, P331, DOI 10.1016/0001-706X(90)90034-W; BIRD AF, 1988, J NEMATOL, V20, P493; BIRD AF, 1987, INT J PARASITOL, V17, P1239, DOI 10.1016/0020-7519(87)90088-9; Bird AF, 1991, STRUCTURE NEMATODES; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRENNER S, 1974, GENETICS, V77, P71; Chitwood, 1974, INTRO NEMATOLOGY; COOKSON E, 1992, P NATL ACAD SCI USA, V89, P5837, DOI 10.1073/pnas.89.13.5837; COX GN, 1980, GENETICS, V95, P317; COX GN, 1981, DEV BIOL, V86, P456, DOI 10.1016/0012-1606(81)90204-9; COX GN, 1990, EXP PARASITOL, V70, P175, DOI 10.1016/0014-4894(90)90098-W; COX GN, 1981, J CELL BIOL, V90, P7, DOI 10.1083/jcb.90.1.7; COX GN, 1990, ACTA TROP, V47, P269, DOI 10.1016/0001-706X(90)90028-X; DESPOMMIER DD, 1990, EXP PARASITOL, V71, P27, DOI 10.1016/0014-4894(90)90005-W; ENDO BY, 1992, PROTOPLASMA, V166, P67, DOI 10.1007/BF01320145; Findlay J.B.C., 1990, PROTEIN PURIFICATION, P59; FUJIMOTO D, 1981, BIOCHEM BIOPH RES CO, V99, P637, DOI 10.1016/0006-291X(81)91792-7; FUJIMOTO D, 1973, ARCH BIOCHEM BIOPHYS, V157, P1, DOI 10.1016/0003-9861(73)90382-2; GINGER CD, 1967, S BRIT SOC PARASITOL, V7, P17; GOODAY T, 1951, SOIL FRESHWATER NEMA; HANASH SM, 1991, P NATL ACAD SCI USA, V88, P5709, DOI 10.1073/pnas.88.13.5709; HEMMER RM, 1991, J CELL BIOL, V115, P1237, DOI 10.1083/jcb.115.5.1237; HILL DE, 1990, MOL BIOCHEM PARASIT, V41, P45, DOI 10.1016/0166-6851(90)90095-4; HIMMELHOCH S, 1977, EXP PARASITOL, V41, P118, DOI 10.1016/0014-4894(77)90137-0; HIMMELHOCH S, 1983, EXP PARASITOL, V55, P299, DOI 10.1016/0014-4894(83)90026-7; HO NFH, 1990, MOL BIOCHEM PARASIT, V41, P153, DOI 10.1016/0166-6851(90)90178-O; IBRAHIM MS, 1989, PARASITOLOGY, V99, P89, DOI 10.1017/S0031182000061060; JANSSON HB, 1986, J NEMATOL, V18, P570; JENNINGS AC, 1949, AUST J SCI RES SER B, V2, P408, DOI 10.1071/BI9490408; Jones M. G. K., 1981, Plant parasitic nematodes. Volume III., P255; KENNEDY MW, 1987, MOL BIOCHEM PARASIT, V22, P233, DOI 10.1016/0166-6851(87)90054-5; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KWANLIM GE, 1990, J IMMUNOL, V145, P1912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK CD, 1992, GENETICS, V131, P867; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; Maizels R, 1991, PARASITE ANTIGENS PA; Maizels R. M., 1988, The biology of parasitism. A molecular and immunological approach., P285; MAIZELS RM, 1982, IMMUNOL REV, V61, P109, DOI 10.1111/j.1600-065X.1982.tb00375.x; MAIZELS RM, 1989, MOL BIOCHEM PARASIT, V32, P213, DOI 10.1016/0166-6851(89)90072-8; MALONEY MD, 1991, PARASITOL RES, V77, P294, DOI 10.1007/BF00930904; MARSHALL E, 1986, MOL BIOCHEM PARASIT, V18, P17, DOI 10.1016/0166-6851(86)90046-0; MARSHALL E, 1985, MOL BIOCHEM PARASIT, V15, P295, DOI 10.1016/0166-6851(85)90091-X; MCCLURE MA, 1991, PARASITOLOGY, V103, P421, DOI 10.1017/S0031182000059941; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; PAGE AP, 1992, EXP PARASITOL, V75, P72, DOI 10.1016/0014-4894(92)90123-R; PAGE AP, 1992, PARASITOLOGY, V105, P285, DOI 10.1017/S0031182000074217; PHILIPP M, 1980, NATURE, V287, P538, DOI 10.1038/287538a0; POLITZ SM, 1990, P NATL ACAD SCI USA, V87, P2901, DOI 10.1073/pnas.87.8.2901; POLITZ SM, 1992, PARASITOL TODAY, V8, P6, DOI 10.1016/0169-4758(92)90302-I; POLITZ SM, 1987, GENETICS, V117, P467; PREMACHANDRAN D, 1988, J NEMATOL, V20, P70; PRITCHARD DI, 1985, PARASITE IMMUNOL, V7, P575, DOI 10.1111/j.1365-3024.1985.tb00101.x; Proudfoot L., 1991, P1; PROUDFOOT L, 1990, ACTA TROP, V47, P323, DOI 10.1016/0001-706X(90)90033-V; ROSENZWEIG WD, 1985, CAN J MICROBIOL, V31, P693, DOI 10.1139/m85-131; ROTHSTEIN M, 1963, COMP BIOCHEM PHYSIOL, V9, P51, DOI 10.1016/0010-406X(63)90028-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLAGER SI, 1979, J IMMUNOL, V123, P2108; SCOTT AL, 1990, ACTA TROP, V47, P339, DOI 10.1016/0001-706X(90)90035-X; SCOTT AL, 1988, EXP PARASITOL, V67, P307, DOI 10.1016/0014-4894(88)90078-1; SEBASTIANO M, 1991, DEV BIOL, V146, P519, DOI 10.1016/0012-1606(91)90253-Y; Selkirk M.E., 1991, P27; SELKIRK ME, 1990, MOL BIOCHEM PARASIT, V42, P31, DOI 10.1016/0166-6851(90)90110-8; SELKIRK ME, 1989, MOL BIOCHEM PARASIT, V32, P229, DOI 10.1016/0166-6851(89)90073-X; Skipski V.P., 1969, METHOD ENZYMOL, V14, P530; Vanfleteren J.R., 1980, P47; Ward S., 1988, MBL (Marine Biology Laboratory) Lectures in Biology, V9, P503; WHARTON DA, 1990, PARASITOLOGY, V101, P101, DOI 10.1017/S0031182000079804; Wood WB, 1988, NEMATODE CAENORHABDI; WRIGHT KA, 1987, J PARASITOL, V73, P1077, DOI 10.2307/3282284; ZUCKERMAN BM, 1979, EXP PARASITOL, V47, P419, DOI 10.1016/0014-4894(79)90095-X	79	52	57	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6600	6609						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8503957				2022-12-27	WOS:A1993KT36800076
J	NUTTALL, FQ; GANNON, MC				NUTTALL, FQ; GANNON, MC			ALLOSTERIC REGULATION OF GLYCOGEN-SYNTHASE IN LIVER - A PHYSIOLOGICAL DILEMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY FRUCTOSE INTOLERANCE; FASTED RATS; GLUCOSE; DEGRADATION; ADULT	Glycogen synthase catalyzes the transfer of the glucosyl moiety from UDP-glucose to the terminal branch of the glycogen molecule and is considered to be the rate-limiting enzyme for glycogen synthesis. However, under ideal assay conditions, i.e. 37-degrees-C with saturating concentrations of UDP-glucose and the activator, glucose-6-P, the maximal catalytic activity of glycogen synthase was only 78% of the in vivo glycogen synthetic rate. Using concentrations of UDP-glucose and glucose-6-P likely to be present in vivo, the rate was only approximately 30%. This prompted us to reassess a possible role of allosteric effectors on synthase activity. Glycogen synthase was assayed at 37-degrees-C using dilute, pH 7.0, buffered extracts, initial rate conditions, and UDPglucose and glucose-6-P concentrations, which approximate those calculated to be present in total liver cell water. Several allosteric effectors were tested. Magnesium and AMP had little effect on activity. P(i), ADP, ATP, and UTP inhibited activity. When a combination of effectors were added at concentrations approximating those present in cell water, synthase activity could account for only 2% of the glycogen synthetic rate. Thus, although allosteric effectors are likely to be playing a major role in regulating synthase enzymic activity in liver cells, to date, a metabolite that can stimulate activity and/or overcome nucleotide inhibition has yet to be identified. If such a metabolite cannot be identified, an additional or alternative pathway for glycogen synthesis must be considered.	UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities	NUTTALL, FQ (corresponding author), VET ADM MED CTR, ENDOCRINOL METAB & NUTR SECT, 1 VET DR, MINNEAPOLIS, MN 55417 USA.		Gannon, Mary Carol/L-7092-2016	Gannon, Mary Carol/0000-0001-5460-2478	NIDDK NIH HHS [DK 43018-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA T, 1978, CELL MOL BIOL, V23, P155; BURCH HB, 1969, BIOCHEM BIOPH RES CO, V34, P619, DOI 10.1016/0006-291X(69)90783-9; BURMEISTER LA, 1991, ARCH INTERN MED, V151, P773, DOI 10.1001/archinte.151.4.773; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; DEWULF H, 1968, EUR J BIOCHEM, V6, P545; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; GANNON MC, 1987, DIABETES, V36, P52, DOI 10.2337/diabetes.36.1.52; GILBOE DP, 1973, BIOCHEM BIOPH RES CO, V53, P164, DOI 10.1016/0006-291X(73)91415-0; GOLD AH, 1970, BIOCHEMISTRY-US, V9, P946, DOI 10.1021/bi00806a034; GOLD AH, 1968, BIOCHEM BIOPH RES CO, V31, P361, DOI 10.1016/0006-291X(68)90484-1; GOLD AH, 1967, ARCH BIOCHEM BIOPHYS, V120, P359, DOI 10.1016/0003-9861(67)90251-2; HAVERSTICK DM, 1980, J BIOL CHEM, V255, P1351; HETENYI G, 1969, CAN J PHYSIOL PHARM, V47, P361, DOI 10.1139/y69-064; HIZUKURI S, 1964, BIOCHEMISTRY-US, V3, P1783, DOI 10.1021/bi00899a034; LANE RD, 1989, BIOCHEM INT, V18, P961; MERSMANN HJ, 1967, P NATL ACAD SCI USA, V58, P1688, DOI 10.1073/pnas.58.4.1688; NIEWOEHNER CB, 1984, AM J PHYSIOL, V247, pE505, DOI 10.1152/ajpendo.1984.247.4.E505; NIEWOEHNER CB, 1988, DIABETES, V37, P1559, DOI 10.2337/diabetes.37.11.1559; NIEWOEHNER CB, 1986, DIABETES, V35, P705, DOI 10.2337/diabetes.35.6.705; NIEWOEHNER CB, 1984, AM J PHYSIOL, V246, pE89, DOI 10.1152/ajpendo.1984.246.1.E89; NUTTALL FQ, 1989, ANAL BIOCHEM, V178, P311, DOI 10.1016/0003-2697(89)90644-1; NUTTALL FQ, 1988, AM J MED, V85, P77, DOI 10.1016/0002-9343(88)90400-7; PIRAS R, 1968, BIOCHEMISTRY-US, V7, P56, DOI 10.1021/bi00841a009; PIRAS R, 1969, BIOCHEMISTRY-US, V8, P2153, DOI 10.1021/bi00833a056; ROACH PJ, 1976, J BIOL CHEM, V251, P1920; TAN AWH, 1976, BIOCHIM BIOPHYS ACTA, V445, P118, DOI 10.1016/0005-2744(76)90165-0; TAN AWH, 1979, BIOCHIM BIOPHYS ACTA, V582, P543, DOI 10.1016/0304-4165(79)90146-6; VANDENBERGHE G, 1973, BIOCHEM J, V134, P637; WILLIAMSON DH, 1981, CONCENTRATIONS METAB, V4, P2266; YOUN JH, 1987, J BIOL CHEM, V262, P11470	30	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13286	13290						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514767				2022-12-27	WOS:A1993LH55300042
J	IZBAN, MG; LUSE, DS				IZBAN, MG; LUSE, DS			THE INCREMENT OF SII-FACILITATED TRANSCRIPT CLEAVAGE VARIES DRAMATICALLY BETWEEN ELONGATION COMPETENT AND INCOMPETENT RNA POLYMERASE-II TERNARY COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TERMINATION SITES; INVITRO; GENE; PURIFICATION; SEQUENCES; MECHANISM; SUBUNIT; TFIIS	Elongation factor SII is required to increase the efficiency of transcription by RNA polymerase II through intrinsic arrest sites. RNA polymerase II ternary complexes exhibit a ribonuclease activity in the presence of SII, truncating nascent transcripts in a 3' --> 5' direction. We show here that transcript cleavage is an obligatory step in re-establishing the elongation competency of complexes that have become blocked in elongation at an intrinsic arrest site. SII-facilitated transcript cleavage by these arrested complexes released 7-14 nucleotide RNA fragments. In contrast, SII-facilitated transcript cleavage by elongation competent complexes, which are stalled because of the absence of a nucleoside triphosphate from the reaction mixture, occurred primarily in dinucleotide increments. We can partially recreate the arrested phenotype and the preference for the large cleavage increment by stalling ternary complexes such that the 3'-end of the transcript contains consecutive U residues, which mimics the sequence of the 3'-ends of transcripts in arrested complexes.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM 29487, GM 14111] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487, F32GM014111] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FLORES O, 1990, J BIOL CHEM, V265, P5629; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE DN, 1990, J BIOL CHEM, V265, P15145; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; MI H, 1983, EUR J BIOCHEM, V131, P113; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1989, J BIOL CHEM, V264, P9953; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STEVENS A, 1969, J BIOL CHEM, V244, P425; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	34	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12874	12885						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509421				2022-12-27	WOS:A1993LG65800094
J	PAGLIN, S; ROY, R; POLGAR, P				PAGLIN, S; ROY, R; POLGAR, P			CHARACTERIZATION OF HORMONALLY REGULATED AND PARTICULATE-ASSOCIATED PHOSPHOLIPASE-A(2) FROM BOVINE ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; PLATELET-ACTIVATING FACTOR; SMOOTH-MUSCLE CELLS; PULMONARY-ARTERY; CALCIUM; PURIFICATION; BRADYKININ; LINE	Hormonally regulated and particulate-associated phospholipase A2 (PLA2) was detected in endothelial cells from bovine pulmonary artery. The enzyme was solubilized and subjected to initial characterization. PLA2 activity was determined in subcellular fractions from bradykinin (BK)-stimulated and nonstimulated cells by following the release of arachidonic acid (AA) from exogenously added 1-palmitoyl-2-[C-14]arachidonoyl-phosphatidylcholine. Stimulation of cells with BK led to increased PLA2 activity in a particulate fraction (the 92,000 x g pellet of the postnuclear supernatant). The activity in the cytosolic fractions from BK-stimulated and nonstimulated cells was the same. The association of the hormonally regulated PLA2 (HR-PLA2) activity with the particulate fraction was not affected by decreasing the Ca2+ concentrations in the homogenate from 7 muM to 33 nM and therefore was not induced during homogenization by the presence of Ca2+ in the homogenate. The HR-PLA2 activity was Ca2+-dependent and was maximal at submicromolar concentrations of Ca2+. Incubation of the particulate fraction obtained from BK-stimulated and nonstimulated cells with 10 mM n-octyl-beta-D-glucopyranoside resulted in a differential solubilization of the HR-PLA2 activity. Its isoelectric point was determined to be 5.7. HR-PLA2 activity in the octyl glucoside extract of the particulate fraction from stimulated cells co-sedimented in sucrose gradients with the cytosolic PLA2. Their molecular mass was estimated to be 103,000 Da. The extracted enzyme from BK-stimulated cells retained its increased activity toward 1-palmitoyl-2-[1-C-14]arachidonoyl-phosphatidylcholine. However, its activity toward 1-palmitoyl-2-[1-C-14]oleoyl-phosphatidylcholine was equal to the PLA2 activity extracted from nonstimulated cells. Treatment of the cells with 100 nM 12-O-tetradecanoylphorbol-13-acetate resulted in a 20 +/-1.2% (mean +/- S.E., p < 0.01, n = 4) increase in the PLA2 activity in the cytosol but failed to increase PLA2 activity in the particulate fraction. In contrast, addition of 7 muM Ca2+ ionophore A23187 resulted in a 21 +/-0.55% (mean +/- S.E., p < 0.01, n = 5) decrease in the cytosolic activity and a concomitant increase of 68 +/-9.6% (mean +/- S.E., p < 0.05, n = 5) in the particulate-associated activity. We conclude that stimulation of endothelial cells with BK increases the activity of a Ca2+-sensitive high molecular weight isoform of PLA2 which is associated with the particulate fraction. Possible mechanisms of activation are discussed.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Polgar, Peter/0000-0002-9112-1101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25776] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, FEBS LETT, V234, P283; BUCHAN KW, 1991, BRIT J PHARMACOL, V102, P35, DOI 10.1111/j.1476-5381.1991.tb12128.x; BURCH RM, 1988, P NATL ACAD SCI USA, V85, P6306, DOI 10.1073/pnas.85.17.6306; BURCH RM, 1989, MOL NEUROBIOL, V3, P155, DOI 10.1007/BF02935629; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAKRABORTI S, 1991, FEBS LETT, V285, P104, DOI 10.1016/0014-5793(91)80735-L; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHERRY PD, 1982, P NATL ACAD SCI-BIOL, V79, P2106, DOI 10.1073/pnas.79.6.2106; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1986, J BIOL CHEM, V261, P713; Colton T., 1974, STAT MED, V1; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Dennis EA, 1983, ENZYMES, P307; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FARMER SG, 1991, AM J PHARM, V190, P159; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HONG SL, 1982, J BIOL CHEM, V257, P7151; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LOEB GI, 1957, J PHYS CHEM-US, V60, P1633, DOI 10.1021/j150546a009; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MENCONI M, 1984, J CELL PHYSIOL, V120, P163, DOI 10.1002/jcp.1041200209; MENNON NK, 1990, LIFE SCI, V47, P1941; MONCADA S, 1980, PHARMACOL BASIS THER, P668; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PRENTKI M, 1982, J BIOL CHEM, V258, P7597; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RAAFLAUB J, 1956, METHOD BIOCHEM ANAL, V3, P301; RICCUPERO D, 1992, MED INFLAMMATION, V1, P130; SAGE SO, 1989, J BIOL CHEM, V264, P6; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHEELE GA, 1975, J BIOL CHEM, V250, P5375; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SIMON W, 1978, ANN NY ACAD SCI, V307, P52; SUNDARAM GS, 1978, J BIOL CHEM, V253, P7703; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11697	11702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505299				2022-12-27	WOS:A1993LF28400038
J	PASCAL, S; TATON, M; RAHIER, A				PASCAL, S; TATON, M; RAHIER, A			PLANT STEROL BIOSYNTHESIS - IDENTIFICATION AND CHARACTERIZATION OF 2 DISTINCT MICROSOMAL OXIDATIVE ENZYMATIC SYSTEMS INVOLVED IN STEROL C4-DEMETHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-ENERGY INTERMEDIATE; STRUCTURAL REQUIREMENTS; CONFORMATIONAL-ANALYSIS; OBTUSIFOLIOL; CYCLOARTENOL; INHIBITION; CLEAVAGE; ANALOGS; CYCLOEUCALENOL; DERIVATIVES	Membrane-bound enzymatic systems obtained from maize embryos that catalyze the oxidative C4-mono-demethylation of 4,4-dimethyl- and 4alpha-methylsterols have been investigated. Enzymatic assay conditions have been developed for the first time to detect the C4-monodemethylated products formed. The properties of the microsomal systems have been established for cofactor requirements and kinetics. The demethylation process has been interrupted to demonstrate the formation of stable, oxygenated intermediates. In addition to the 3-keto and 3beta-hydroxy-4-monodemethylated products formed, three new sterols have been identified. 3Beta-hydroxy-4beta,14alpha-dimethyl-5alpha-ergosta-9beta,19-cyclo-24(24(1))-en-4alpha-hydroxy methyl was identified for the first time as the immediate metabolite of 24-methylenecycloartanol by 4alpha-methyl oxidase in addition to 3beta-hydroxy-4beta,14alpha-dimethyl-5alpha-ergosta-9beta, 19-cyclo-24(24(1))-en-4alpha-carboxylic-acid and 3beta-hydroxy-5alpha-stigmasta-7,24(24(1))-dien-4alpha-carboxylic-acid, intermediates involved respectively in the oxidative demethylation of 24-methylenecycloartanol and 24-ethylidenelophenol. Proton nuclear magnetic resonance studies of enzymatically produced 3beta-hydroxy-4beta,14alpha-dimethyl-5alpha-ergosta-9beta,19-cyclo-24(24(1))en-4alpha-carboxylic acid indicate that the 4alpha-methyl group of 24-methylenecycloartanol is oxidized and subsequently removed during its enzymatic conversion to cycloeucalenol. From a series of incubations with 25 natural or synthetic 4,4-dimethyl and 4alpha-methylsterols, a high degree of substrate specificity for the oxidation at C4 of 4,4-dimethyl- and 4alpha-methylsterols was determined. Our results indicate that oxidation of the 4alpha-methyl group of the 4,4-geminal dimethylsterols requires the more flexible and presumably bent conformation of 9beta,19-cyclopropylsterols and the absence of a DELTA24(25) unsaturation, whereas the rigid planar conformation of DELTA7-unsaturated sterols favors oxidation of 4alpha-methylsterols. Distinct strict structural requirements for the oxidation of 4,4-dimethyl- and 4alpha-methylsterols and different sensitivity toward cyanide ions and 3beta,5alpha,6alpha-stigmastatriol, a novel inhibitor of 4alpha-methylsterol C4 oxidase activity, are consistent with the conclusion that two distinct oxidative systems are involved in the removal of the first and second C4-methyl group of phytosterol precursors. Moreover, the present study directly establishes that during the conversion of cycloartenol to phytosterol one C4 dealkylation occurs before the removal of the 14alpha-methyl group.	INST BOT,CNRS,UPR 406,DEPT ENZYMOL CELLULAIRE & MOLEC,INST BIOL MOLEC PLANTES,28 RUE GOETHE,F-67083 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BENVENISTE P, 1986, ANNU REV PLANT PHYS, V37, P275, DOI 10.1146/annurev.pp.37.060186.001423; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; CATTEL L, 1979, J AM OIL CHEM SOC, V56, P6, DOI 10.1007/BF02671752; FONTENEAU P, 1977, PLANT SCI LETT, V10, P147, DOI 10.1016/0304-4211(77)90122-5; GHISALBERTI EL, 1969, J CHEM SOC CHEM COMM, P1403, DOI 10.1039/c29690001403; GUILHEM J, 1975, Tetrahedron Letters, V34, P2937; HEINTZ R, 1974, J BIOL CHEM, V249, P4267; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HOSODA H, 1973, J ORG CHEM, V38, P4209, DOI 10.1021/jo00963a028; KNAPP FF, 1970, J CHEM SOC CHEM COMM, P399, DOI 10.1039/c29700000399; KNAPP FF, 1971, PHYTOCHEMISTRY, V10, P97, DOI 10.1016/S0031-9422(00)90255-3; LENTON JR, 1975, PHYTOCHEMISTRY, V14, P1523, DOI 10.1016/0031-9422(75)85344-1; MAILLOTVERNIER P, 1991, MOL GEN GENET, V231, P33, DOI 10.1007/BF00293818; MILLER WL, 1970, J BIOL CHEM, V245, P5375; MILLER WL, 1971, J BIOL CHEM, V246, P2494; MILON A, 1989, HELV CHIM ACTA, V72, P1, DOI 10.1002/hlca.19890720102; NARULA AS, 1971, TETRAHEDRON, V27, P1119, DOI 10.1016/S0040-4020(01)90859-2; NELSON JA, 1975, BIOORG CHEM, V4, P363, DOI 10.1016/0045-2068(75)90047-4; NES WD, 1988, P NATL ACAD SCI USA, V85, P5759, DOI 10.1073/pnas.85.16.5759; OMURA T, 1964, J BIOL CHEM, V239, P2379; PASCAL S, 1990, BIOCHEM BIOPH RES CO, V172, P98, DOI 10.1016/S0006-291X(05)80178-0; QIN GW, 1989, YOUJI HUAXAE, V9, P263; RAHIER A, 1977, PHYTOCHEMISTRY, V16, P1187, DOI 10.1016/S0031-9422(00)94357-7; RAHIER A, 1986, BIOCHEM BIOPH RES CO, V140, P1064, DOI 10.1016/0006-291X(86)90743-6; RAHIER A, 1984, J BIOL CHEM, V259, P5215; RAHIER A, 1989, EUR J BIOCHEM, V181, P615, DOI 10.1111/j.1432-1033.1989.tb14768.x; RAHIER A, 1986, LIPIDS, V21, P52, DOI 10.1007/BF02534303; RAHMAN R, 1970, J BIOL CHEM, V245, P2667; SANGARE M, 1975, Tetrahedron Letters, V22/23, P1791; SCALLEN TJ, 1971, J BIOL CHEM, V246, P3168; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SHARPLESS KB, 1969, J AM CHEM SOC, V91, P3394, DOI 10.1021/ja01040a065; SHARPLESS KB, 1968, J AM CHEM SOC, V90, P6874, DOI 10.1021/ja01026a073; TATON M, 1987, PESTIC SCI, V21, P269, DOI 10.1002/ps.2780210404; TATON M, 1991, BIOCHEM BIOPH RES CO, V181, P465, DOI 10.1016/S0006-291X(05)81442-1; TATON M, 1986, BIOCHEM BIOPH RES CO, V138, P764, DOI 10.1016/S0006-291X(86)80562-9; TATON M, 1989, EUR J BIOCHEM, V185, P605, DOI 10.1111/j.1432-1033.1989.tb15156.x; TATON M, 1991, BIOCHEM J, V277, P483, DOI 10.1042/bj2770483; TATON M, 1988, PESTIC BIOCHEM PHYS, V30, P178, DOI 10.1016/0048-3575(88)90051-X; TRZASKOS JM, 1985, ENZYMES BIOL MEMBR, V2, P177; YOSHIDA K, 1989, AGR BIOL CHEM TOKYO, V53, P1901, DOI 10.1080/00021369.1989.10869552; 1989, EUR J BIOCHEM, V186, P429	42	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11639	11654						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505296				2022-12-27	WOS:A1993LF28400031
J	SHAW, LM; LOTZ, MM; MERCURIO, AM				SHAW, LM; LOTZ, MM; MERCURIO, AM			INSIDE-OUT INTEGRIN SIGNALING IN MACROPHAGES - ANALYSIS OF THE ROLE OF THE ALPHA-6A-BETA-1 AND ALPHA-6B-BETA-1 INTEGRIN VARIANTS IN LAMININ ADHESION BY CDNA EXPRESSION IN AN ALPHA-6 INTEGRIN-DEFICIENT MACROPHAGE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-35 MAC-2; CYTOPLASMIC DOMAIN; RECEPTOR; SUBUNIT; PHOSPHORYLATION; ACTIVATION; ADHERENCE; BETA-1; LEUKOCYTES; PLATELETS	Leukocytes use the alpha6beta1 integrin to adhere to laminin based on mAb inhibition and affinity chromatography studies. This adhesion requires leukocyte stimulation with either PMA or specific cytokines, a process that has been termed ''inside-out'' integrin signaling. In the present study, the involvement of alpha6 integrin structural variants in this regulated adhesion was examined using mouse macrophages. The two known alpha6 structural variants, alpha6A and alpha6B, differ only in their cytoplasmic domain sequences. Using reverse transcriptase-polymerase chain reaction, we observed that macrophages express only the alpha6A structural variant, in contrast to most cell types which express both alpha6A and alpha6B variants. The role of this integrin subunit in macrophage adhesion was assessed by cDNA transfection of P388D1 cells. We found that this mouse macrophage cell line does not adhere to laminin even in response to phorbol 12-myristate 13-acetate (PMA) stimulation, though it does adhere normally to fibronectin and tissue culture plastic. Subsequent analysis employing reverse transcriptase-polymerase chain reaction and immunoprecipitation of surface labeled cells revealed that this cell line expresses neither the alpha6A nor alpha6B integrin subunits. Stable transfection of either the chick or human alpha6A cDNAs into P388D1 cells resulted in chimeric alpha6Abeta1 surface expression. The alpha6A transfectants exhibited inside-out integrin signaling because PMA stimulation markedly increased their ability to adhere to laminin but it did not increase alpha6Abeta1 surface expression. Similar results were obtained after transfection of the human alpha6B cDNA. Analysis of the human transfectants was facilitated by the generation of a monoclonal antibody, 2B7, that is specific for the human alpha6 integrin subunit. These observations demonstrate that both alpha6Abeta1 and alpha6Bbeta1 can be regulated by inside-out signaling pathways in macrophages, even though this cell type expresses only alpha6Abeta1. The data presented also demonstrate clearly that the alpha6A and alpha6B cytoplasmic domains do not differ in their ability to be regulated by PMA.	HARVARD UNIV,DEACONESS HOSP,SCH MED,CANC BIOL LAB,50 BINNEY ST,BOSTON,MA 02215; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA42276] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042276] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P2; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; EVANS R, 1990, BIOTECHNIQUES, V8, P357; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HO MK, 1983, J BIOL CHEM, V258, P2766; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOREN HS, 1975, J IMMUNOL, V114, P894; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; MERCURIO AM, 1991, BIOESSAYS, V13, P469, DOI 10.1002/bies.950130907; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHAW L M, 1991, Journal of Cell Biology, V115, p131A; SHAW LM, 1989, J EXP MED, V169, P303, DOI 10.1084/jem.169.1.303; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; WOO HJ, 1990, J BIOL CHEM, V265, P7097; WOO HJ, 1991, J BIOL CHEM, V266, P18419; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	43	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11401	11408						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496190				2022-12-27	WOS:A1993LD46600099
J	SORIMACHI, H; TOYAMASORIMACHI, N; SAIDO, TC; KAWASAKI, H; SUGITA, H; MIYASAKA, M; ARAHATA, K; ISHIURA, S; SUZUKI, K				SORIMACHI, H; TOYAMASORIMACHI, N; SAIDO, TC; KAWASAKI, H; SUGITA, H; MIYASAKA, M; ARAHATA, K; ISHIURA, S; SUZUKI, K			MUSCLE-SPECIFIC CALPAIN, P94, IS DEGRADED BY AUTOLYSIS IMMEDIATELY AFTER TRANSLATION, RESULTING IN DISAPPEARANCE FROM MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; ACTIVATED NEUTRAL PROTEASE; MOLECULAR-CLONING; CDNA CLONES; SEQUENCE-ANALYSIS; SKELETAL-MUSCLE; LARGE SUBUNIT; KINASE-C; NUCLEOTIDE-SEQUENCE; BINDING PROTEIN	We previously identified a third type of the calpain large subunit named p94 as a cDNA whose mRNA is expressed exclusively in skeletal muscle at levels approximately 10-fold more abundant than those of the conventional calpain subunit. Rat skeletal muscle fractions were screened by two anti-peptide antibodies raised against two specific sequences in p94, but the p94 protein could not be found. To examine this apparent discrepancy between the amounts of mRNA and protein, wild-type p94 was expressed in COS cells. Although p94 mRNA was expressed normally in COS cells, only very small amounts of the protein and its presumed degradation products were detected by the antibodies described above. A series of COOH-terminal deletion mutants was constructed and expressed in COS cells and L8 cells, a rat myoblast cell line. When IS2, one of the specific regions of p94, was completely eliminated, the truncated p94 proteins were expressed normally, and the amount of the expressed proteins was at least 100-fold higher than with wild-type p94. Moreover, when site-directed mutagenesis was introduced to change the presumed active-site cysteine of p94 to serine or alanine, the mutated p94 proteins were highly expressed like the IS2-deleted mutants. These results indicate the following. 1) The mRNA for p94 is normally transcribed in COS, L8, and muscle cells; 2) the p94 protein becomes active in the cytosol immediately after translation; 3) the p94 protein virtually disappears from cells by autocatalytic degradation; and 4) the p94-specific IS2 region plays an important role in this degradation. In vitro translation experiments support this idea. Furthermore, p94 shows nuclear localization when expressed in COS cells. The physiological function of p94 in muscle is discussed on the basis of the analysis of these transfectants.	NATL INST NEUROSCI, DIV NEUROMUSCULAR RES, KODAIRA, TOKYO 187, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN	National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	SORIMACHI, H (corresponding author), UNIV TOKYO, INST APPL MICROBIOL, TOKYO 113, JAPAN.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Sorimachi, Hiroyuki/C-6448-2009; Kawasaki, Hiroshi/C-3048-2011; Miyasaka, Masayuki/AAM-6343-2020	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Sorimachi, Hiroyuki/0000-0001-9509-6727; Kawasaki, Hiroshi/0000-0002-2517-159X; 				ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DAYTON WR, 1982, BIOCHIM BIOPHYS ACTA, V709, P166, DOI 10.1016/0167-4838(82)90457-5; EMORI Y, 1986, FEBS LETT, V194, P249, DOI 10.1016/0014-5793(86)80094-1; EMORI Y, 1986, J BIOL CHEM, V261, P9465; EMORI Y, 1986, J BIOL CHEM, V261, P9472; FRIEDRICH P, 1990, NEUROSCIENCE, V35, P1, DOI 10.1016/0306-4522(90)90115-K; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MURACHI T, 1989, BIOCHEM INT, V18, P263; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHNO S, 1986, NUCLEIC ACIDS RES, V14, P5559; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; SORIMACHI H, 1990, BIOL CHEM H-S, V371, P171; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SUZUKI K, 1979, FEBS LETT, V104, P355, DOI 10.1016/0014-5793(79)80851-0; SUZUKI K, 1991, BIOMED BIOCHIM ACTA, V50, P483; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V8, P167; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOLFE FH, 1989, BIOCHIM BIOPHYS ACTA, V998, P236, DOI 10.1016/0167-4838(89)90280-X; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68	52	235	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10593	10605						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486713				2022-12-27	WOS:A1993LB80000089
J	SVOBODA, DL; SMITH, CA; TAYLOR, JSA; SANCAR, A				SVOBODA, DL; SMITH, CA; TAYLOR, JSA; SANCAR, A			EFFECT OF SEQUENCE, ADDUCT TYPE, AND OPPOSING LESIONS ON THE BINDING AND REPAIR OF ULTRAVIOLET PHOTODAMAGE BY DNA PHOTOLYASE AND (A)BC EXCINUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; UV-INDUCED MUTATION; SYN THYMINE DIMER; ESCHERICHIA-COLI; ACTION MECHANISM; CROSS-LINKS; CIS-SYN; EXCISION NUCLEASE; 6-4 PHOTOPRODUCT; POLYMERASE-I	The cis,syn and (6-4) products of dipyrimidine sites are the major mutagenic and lethal UV photoproducts in DNA. To investigate their relative susceptibilities to repair and other factors such as sequence context and lesions in the complementary strand that might influence repair efficiencies, we constructed 49-mer duplexes containing site-specific photoproducts of thymidylyl(3',5')thymidine sites at central locations. Using these substrates, we measured the binding of Escherichia coli DNA photolyase to cis,syn dimers in four sequence contexts and to two cis,syn dimers in close proximity and on opposing strands. We found that the sequence within a 10-base pair region had little effect on binding and that two enzyme molecules bound to substrate containing two dimers in the 5'-staggered orientation, but not in the 3'-staggered one. Similarly, the excision of a cis,syn dimer by (A)BC excinuclease was not influenced by the sequence in the immediate vicinity of the dimer, and the enzyme was active on 5'-staggered cis,syn dimers, but not on 3'-staggered ones. Of special significance, we found that (A)BC excinuclease removed the cis,syn, trans,syn-I, (6-4), and Dewar photoproducts at vastly differing relative rates of 1:6:9:9, respectively.	WASHINGTON UNIV, DEPT CHEM, ST LOUIS, MO 63130 USA	Washington University (WUSTL)	SVOBODA, DL (corresponding author), UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.		Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257; Smith, Colin/0000-0001-5652-0855				BAER M, 1989, MOL CELL BIOL, V9, P4777, DOI 10.1128/MCB.9.11.4777; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BENHUR E, 1968, BIOCHIM BIOPHYS ACTA, V166, P9, DOI 10.1016/0005-2787(68)90485-1; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BOYCE RP, 1964, Z VEREBUNGSL, V95, P345, DOI 10.1007/BF01268667; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; CHENG S, 1988, J BIOL CHEM, V263, P1510; COLE RS, 1976, J MOL BIOL, V103, P39, DOI 10.1016/0022-2836(76)90051-6; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FRANKLIN WA, 1986, MUTAT RES, V165, P1, DOI 10.1016/0167-8817(86)90002-7; FRANKLIN WA, 1981, P NATL ACAD SCI USA, V81, P32821; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; KIENER A, 1989, J BIOL CHEM, V264, P13880; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KOEHLER DR, 1991, J BIOL CHEM, V266, P11766; LAM LH, 1987, MUTAT RES, V178, P167, DOI 10.1016/0027-5107(87)90266-1; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; MITCHELL DL, 1988, MUTAT RES, V194, P227, DOI 10.1016/0167-8817(88)90024-7; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PAGE JD, 1990, BIOCHEMISTRY-US, V29, P1016, DOI 10.1021/bi00456a026; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; RYCYNA RE, 1985, NUCLEIC ACIDS RES, V13, P5949, DOI 10.1093/nar/13.16.5949; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SANCAR GB, 1987, J BIOL CHEM, V262, P478; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; SMITH CA, 1992, BIOCHEMISTRY-US, V31, P2208; SVOBODA DL, 1991, THESIS WASHINGTON U; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; TAYLOR JS, 1987, J AM CHEM SOC, V109, P2834, DOI 10.1021/ja00243a052; TAYLOR JS, 1988, NUCLEIC ACIDS RES, V16, P5123, DOI 10.1093/nar/16.11.5123; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; Wang S.Y., 1976, PHOTOCHEM PHOTOBIOL, P295; WOOD RD, 1985, J MOL BIOL, V184, P577, DOI 10.1016/0022-2836(85)90304-3; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005	57	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10694	10700						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486719				2022-12-27	WOS:A1993LB80000102
J	WHITE, HD; BELKNAP, B; JIANG, W				WHITE, HD; BELKNAP, B; JIANG, W			KINETICS OF BINDING AND HYDROLYSIS OF A SERIES OF NUCLEOSIDE TRIPHOSPHATES BY ACTOMYOSIN-S1 - RELATIONSHIP BETWEEN SOLUTION RATE CONSTANTS AND PROPERTIES OF MUSCLE-FIBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; SHORTENING VELOCITY; FORCE GENERATION; MECHANISM; MYOSIN; SUBFRAGMENT-1; CONTRACTION; ACTIN; NUCLEOTIDE	We have measured the steady state kinetics of hydrolysis and presteady state kinetics of binding of the nucleoside triphosphates GTP, CTP, aza-ATP (1-N6-etheno-2-aza-ATP), and ATP by rabbit skeletal actomyosin-S1. The maximum rates of steady state hydrolysis at 10-degrees-C at low ionic strength are: CTP, 1.9 s-1 > ATP, 1.3 s-1 > aza-ATP, 0.19 s-1 > GTP, 0.03 s-1. A similar dependence of the rate of steady state hydrolysis upon nucleotide structure has been observed in isometrically contracting muscle fibers in the accompanying paper (Pate, E., Franks-Skiba, K., White, H., and Cooke, R. (1993) J. Biol. Chem. 268, 10046-10053) which strongly suggests that the same biochemical step that limits the maximum rate of hydrolysis of nucleoside triphosphates by actomyosin-Sl in solution also limits the rate of hydrolysis by isometrically contracting muscle fibers. The apparent second order rate constants for the dissociation of actomyosin-S1 by nucleoside triphosphates at 10-degrees-C are: ATP, 2.7 x 10(6) M-1 s-1 > aza-ATP, 3.4 x 10(5) M-1 s-1 > GTP, 2.5 x 10(5) M-1 s-1 > CTP, 1.4 x 10(5) M-1 s-1. There is an excellent correlation between the second order rate constant for the dissociation of actomyosin-SI in solution and the dependence of shortening velocity in glycerinated muscle fibers upon the concentration for ATP, aza-ATP, and CTP (as per accompanying article; Pate et al., 1993). We have used the second order rate constants obtained in solution for the dissociation of actomyosin-S1 by these nucleotides and shortening velocity data obtained with the same nucleoside triphosphates in glycerinated psoas fibers in the accompanying article (Pate et al., 1993) to determine the average distance over which cross-bridges remain attached during unloaded shortening to be 5-12 nm.			WHITE, HD (corresponding author), EASTERN VIRGINIA MED SCH,DEPT BIOCHEM,NORFOLK,VA 23501, USA.				NHLBI NIH HHS [HL41776] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041776] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELKNAP B, 1992, Biophysical Journal, V61, pA440; BURTON K, 1987, BIOPHYS J, V51, pA6; CHALOVICH JM, 1984, BIOCHEMISTRY-US, V23, P4885, DOI 10.1021/bi00316a011; CHALOVITCH J, 1983, J BIOL CHEM, V257, P2432; COOKE R, 1979, BIOPHYS J, V28, P241, DOI 10.1016/S0006-3495(79)85174-7; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CRAIG R, 1985, P NATL ACAD SCI USA, V82, P3247, DOI 10.1073/pnas.82.10.3247; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; DYSON RD, 1971, BIOCHEMISTRY-US, V10, P3233, DOI 10.1021/bi00793a012; ECCLESTON JF, 1979, BIOCHEMISTRY-US, V18, P2896, DOI 10.1021/bi00580a034; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FERENCZI MA, 1984, J PHYSIOL-LONDON, V350, P519, DOI 10.1113/jphysiol.1984.sp015216; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOMSHER E, 1981, J PHYSIOL-LONDON, V321, P423, DOI 10.1113/jphysiol.1981.sp013994; HOUADJETO M, 1992, BIOCHEMISTRY-US, V31, P1564, DOI 10.1021/bi00120a038; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KAWAI M, 1989, BIOPHYS J, V55, P595, DOI 10.1016/S0006-3495(89)82857-7; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARSTON S, 1978, FEBS LETT, V92, P147, DOI 10.1016/0014-5793(78)80741-8; MCDOWELL J, 1989, BIOPHYS SOC, V55, pA269; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; PATE E, 1993, J BIOL CHEM, V268, P10046; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; Simmons RM, 1974, RECENT ADV PHYSIOL, V31, P87; SMITH SJ, 1985, J BIOL CHEM, V260, P5156; STEIN LA, 1984, BIOCHEMISTRY-US, V23, P1555, DOI 10.1021/bi00302a033; TONOMURA Y, 1973, MUSCLE PROTEINS MUSC, P259; WALKER JW, 1992, J BIOL CHEM, V267, P2459; WEBER A, 1969, J GEN PHYSIOL, V53, P781, DOI 10.1085/jgp.53.6.781; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITE HD, 1982, METHOD ENZYMOL, V85, P698	38	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10039	10045						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486675				2022-12-27	WOS:A1993LB80000018
J	BELCOURT, DR; LAZURE, C; BENNETT, HPJ				BELCOURT, DR; LAZURE, C; BENNETT, HPJ			ISOLATION AND PRIMARY STRUCTURE OF THE 3 MAJOR FORMS OF GRANULIN-LIKE PEPTIDES FROM HEMATOPOIETIC TISSUES OF A TELEOST FISH (CYPRINUS-CARPIO)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE LIQUID-CHROMATOGRAPHY; LEUKOCYTES; PROTEINS; SYSTEM	Granulins are cysteine-rich polypeptides purified from human and rat hematopoietic cells and structurally related to the epithelin family of growth modulatory factors. A prototypic form of granulin was isolated from the hematopoietic organs of teleost fish (Belcourt, D., and Bennett, H. P. J. (1988) J. Cell Biol. 107, 629 (abstr.)). This study reports the structure of three granulins purified from the spleen and head kidney of the carp (Cyprinus carpio). Ion-spray mass spectrometric analysis of granulin-1, -2, and -3 corroborated the observed primary structures and demonstrated that each 57-residue-peptide was monomeric in nature with all cysteines linked via intramolecular disulfide bridges. A comparison of the carp granulin sequences demonstrates that granulins 2 and 3 are most closely related with sequence variations occurring primarily toward the amino terminus. A rabbit polyclonal antibody was raised against carp granulin-1 to develop a radioimmunoassay for this peptide, which showed no significant cross-reactivity with granulin-2 and -3. The distribution of carp granulin-1 was studied by screening purified tissue extracts for immunoreactivity using reversed-phase high performance liquid chromatography. A single form of immunoreactive granulin-1 was identified in all carp tissues studied including spleen, head kidney, heart, skin, gills, and gut. These studies have established that members of the granulin/epithelin family are found in a lower vertebrate and may serve important growth modulatory functions throughout the vertebrate kingdom.	ROYAL VICTORIA HOSP, ENDOCRINE LAB, RM L205, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3A 1A1, QUEBEC, CANADA; INST RECH CLIN MONTREAL, NEUROPEPTIDE STRUCT & METAB LAB, MONTREAL H2W 1R7, QUEBEC, CANADA	McGill University; Royal Victoria Hospital; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								Agius C., 1985, P85; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BELCOURT D, 1992, REGUL PEPTIDES, V40, P87, DOI 10.1016/0167-0115(92)90086-A; BELCOURT D R, 1988, Journal of Cell Biology, V107, P629; BENNETT HPJ, 1989, ANAL BIOCHEM, V179, P222, DOI 10.1016/0003-2697(89)90119-X; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BROCKES JP, 1975, BIOCHEMISTRY-US, V14, P2100, DOI 10.1021/bi00681a009; BROWNE CA, 1982, ANAL BIOCHEM, V124, P201, DOI 10.1016/0003-2697(82)90238-X; CARRIERE PD, 1989, PEPTIDES, V10, P485, DOI 10.1016/0196-9781(89)90063-6; COHEN A, 1990, BRAIN RES, V537, P24, DOI 10.1016/0006-8993(90)90335-9; COUTO MA, 1992, INFECT IMMUN, V60, P3065, DOI 10.1128/IAI.60.8.3065-3071.1992; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DENTON TE, 1973, FISH CHROMOSOME METH, P129; ELLIS AE, 1977, J FISH BIOL, V11, P453, DOI 10.1111/j.1095-8649.1977.tb04140.x; ELLIS AE, 1976, J FISH BIOL, V8, P67, DOI 10.1111/j.1095-8649.1976.tb03908.x; IGER Y, 1990, J FISH BIOL, V36, P421, DOI 10.1111/j.1095-8649.1990.tb05622.x; LAZURE C, 1989, INT J PEPT PROT RES, V33, P46; LOTAN M, 1992, J NEUROCHEM, V58, P1637, DOI 10.1111/j.1471-4159.1992.tb10035.x; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; OZOLS J, 1990, J BIOL CHEM, V265, P10289; Ozols J., 1990, METHOD ENZYMOL, P587; PENKE B, 1974, ANAL BIOCHEM, V60, P45, DOI 10.1016/0003-2697(74)90129-8; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912	27	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9230	9237						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486624				2022-12-27	WOS:A1993LA68900016
J	TOBIN, AB; NAHORSKI, SR				TOBIN, AB; NAHORSKI, SR			RAPID AGONIST-MEDIATED PHOSPHORYLATION OF M3-MUSCARINIC-RECEPTORS REVEALED BY IMMUNOPRECIPITATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MUSCARINIC ACETYLCHOLINE-RECEPTOR; INHIBITS PHOSPHOINOSITIDE HYDROLYSIS; NEURO-BLASTOMA CELLS; CHOLINERGIC RECEPTORS; CHICK HEART; TUMOR PROMOTER; DESENSITIZATION; BINDING; ACTIVATION	A specific antiserum against the human m3-muscarinic receptor subtype was made by subcloning a variant region of the third intracellular loop of the m3-receptor (Ser345-Leu463) into a bacterial expression plasmid that produced a fusion protein with glutathione S-transferase. In immunoblot studies this antiserum identified the human m3-receptor expressed in transfected Chinese hamster ovary (CHO) cells (CHO-m3 cells, 1343 fmol/mg protein) as a diffuse band at approximately 97-110 kDa. In vivo labeling of the ATP pool in CHO-m3 cells with [P-32]orthophosphate followed by immunoprecipitation of solubilized m3-receptors revealed that the unstimulated receptor existed in a phosphorylated form. Incubation of CHO-m3 cells with the cholinergic agonist carbachol (1 mM) increased the phosphorylated state of the receptor dramatically, primarily at serine. The time course for agonist-dependent phosphorylation was very rapid occurring within seconds of agonist addition and was maintained for at least 30 min. The muscarinic antagonist atropine (10 muM) inhibited agonist-stimulated phosphorylation. Neither forskolin (10 muM) nor the calcium ionophore, ionomycin (1 muM), had any effect on the state of phosphorylation of the m3-receptor, eliminating a role for cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in the agonist-dependent phosphorylation of m3-receptors. 4Beta-phorbol 12beta-myristate 13alpha-acetate (100 nM) did increase m3-receptor phosphorylation, an effect that was inhibited by the selective protein kinase C inhibitor RO-318220 (10 muM). However, agonist-stimulated m3-receptor phosphorylation was not inhibited by RO-318220 indicating that protein kinase C was not involved in agonist-induced m3-receptor phosphorylation. In conclusion the phosphorylation of m3-receptors, in vivo, was increased following the application of muscarinic agonist or PMA. The response to agonist was mediated via a kinase distinct from protein kinase C, protein kinase A and Ca2+/calmodulin dependent protein kinase, whereas the effect of 4beta-phorbol 12beta-myristate 13alpha-acetate was mediated by protein kinase C.			TOBIN, AB (corresponding author), UNIV LEICESTER,DEPT PHARMACOL & THERAPEUT,POB 138,MED SCI BLDG,UNIV RD,LEICESTER LE1 9HN,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK MA, 1990, BIOCHEM BIOPH RES CO, V173, P666, DOI 10.1016/S0006-291X(05)80087-7; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BURGOYNE RD, 1981, FEBS LETT, V127, P144, DOI 10.1016/0014-5793(81)80361-4; BURGOYNE RD, 1980, FEBS LETT, V122, P288, DOI 10.1016/0014-5793(80)80458-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P383; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FISHER SK, 1988, J NEUROCHEM, V50, P984, DOI 10.1111/j.1471-4159.1988.tb03008.x; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HARLOW E, 1984, ANTIBODIES LABORATOR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HO AKS, 1985, BIOCHEM BIOPH RES CO, V133, P1193, DOI 10.1016/0006-291X(85)91263-X; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KOPP R, 1990, BIOCHEM J, V269, P73, DOI 10.1042/bj2690073; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LILES WC, 1986, J BIOL CHEM, V261, P5307; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; ROSENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183, DOI 10.1021/bi00399a024; SERRA M, 1986, BIOCHEM BIOPH RES CO, V140, P160, DOI 10.1016/0006-291X(86)91071-5; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; THOMPSON AK, 1991, J BIOL CHEM, V266, P5004; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; VICENTINI LM, 1985, BIOCHEM BIOPH RES CO, V127, P310, DOI 10.1016/S0006-291X(85)80160-1; WALL SJ, 1991, MOL PHARMACOL, V40, P783	36	121	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9817	9823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486662				2022-12-27	WOS:A1993LA68900096
J	GAO, BC; EMOTO, Y; GREENE, L; EISENBERG, E				GAO, BC; EMOTO, Y; GREENE, L; EISENBERG, E			NUCLEOTIDE BINDING-PROPERTIES OF BOVINE BRAIN UNCOATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; PEPTIDE BINDING; COATED VESICLES; CLATHRIN COATS; PROTEINS; HSP70; TRANSLOCATION; DISSOCIATION; SUBFAMILY; ACTIN	Many functions of the 70-kDa heat-shock proteins (hsp70s) appear to be regulated by bound nucleotide. In this study we examined the nucleotide binding properties of purified bovine brain uncoating ATPase, one of the constitutively expressed members of the hsp70 family. We found that uncoating ATPase purified by ATP-agarose column chromatography retained one ADP molecule bound per enzyme molecule which could not be removed by extensive dialysis. Since this bound ADP exchanged rapidly with free ADP or ATP, the inability to remove the bound nucleotide was not due to slow dissociation but rather to strong binding of the nucleotide to the uncoating ATPase. In confirmation of this view, equilibrium dialysis experiments suggested that the dissociation constants for both ADP and ATP were less than 0.1 muM. Schmid et al. (Schmid, S. L., Braell, W. A., and Rothman, J. E. (1985) J. Biol. Chem 260, 10057-10062) suggested that the uncoating ATPase had two sites for bound nucleotide, one specific for ATP and one binding both ATP and ATP analogues but not ADP. In contrast, we found that enzyme with bound ADP did not bind further adenosine 5'-(beta,gamma-imino)triphosphate or dATP, nor did more than one ATP molecule bind per enzyme even in 200 muM free ATP. These results strongly suggest that the enzyme has only one binding site for nucleotide. During steady-state ATP hydrolysis, 85% of the bound nucleotide at this site was determined to be ATP and 15% ADP; this is consistent with the rate of ADP release determined in the exchange experiments noted above, where ADP release was found to be six times faster than the overall rate of ATP hydrolysis.	MED COLL OITA,DEPT PHYSIOL,OITA 87956,JAPAN	Oita University	GAO, BC (corresponding author), NHLBI,CELL BIOL LAB,BLDG 3,RM B1-23,BETHESDA,MD 20892, USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAO B, 1992, MOL BIOL CELL, V3, pA58; GAO BC, 1991, J BIOL CHEM, V266, P19565; GREENE LE, 1990, J BIOL CHEM, V265, P6682; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; NOVER L, 1991, HEAT SHOCK RESPONSE, P41; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; WANG N M, 1991, Journal of Cell Biology, V115, p255A; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568	23	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8507	8513						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473294				2022-12-27	WOS:A1993KX81100023
J	SIMONIN, F; POCH, O; DELARUE, M; DEMURCIA, G				SIMONIN, F; POCH, O; DELARUE, M; DEMURCIA, G			IDENTIFICATION OF POTENTIAL ACTIVE-SITE RESIDUES IN THE HUMAN POLY(ADP-RIBOSE) POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBOSE) POLYMERASE; ADP-RIBOSYLATION; CDNA SEQUENCE; DNA; EXPRESSION; PROTEIN; DOMAIN; SYNTHETASE; INVITRO	The carboxyl-terminal catalytic domain of the human poly(ADP-ribose) polymerase (PARP) exhibits sequence homology with the NAD(P)+-dependent leucine and glutamate dehydrogenases. To clarify the role played by some conserved residues between PARP and NAD(P)+-dependent dehydrogenases, point mutations were introduced into the whole enzyme context. Non-conservative mutations of Lys-893 (K893I) and Asp-993 (D993A) completely inactivate human PARP, whereas conservative and nonconservative mutations of Asp-914 (D914E and D914A, respectively) and Lys-953 (K953R and K953I, respectively) partially alter PARP activity. The consequences of conservative substitution of Lys-893 and Asp-993 on the kinetic properties of human poly(ADP-ribose) polymerase enzyme and the polymer it synthesizes suggest that these 2 amino acids are directly involved in the covalent attachment of the first ADP-ribosyl residue from NAD+ onto the acceptor amino acid. In addition, the recent resolution of the three-dimensional structure of the NAD+-linked glutamate dehydrogenase from Clostridium symbiosum (Baker, P. J., Britton, K. L., Engel, P.C., Farrants, G. W., Lilley, K. S., Rice, D. W., and Stillman, T. J. (1992) Proteins 12, 75-86) strongly supports our alignment with leucine and glutamate dehydrogenases and provides an interesting structural framework for the analysis of our results of site-directed mutagenesis.	CNRS,INST BIOL MOLEC & CELLULAIRE,UNITE PROPRE RECH CANCEROGENESE & MUTAGENESE MOLEC & STRUCT,F-67084 STRASBOURG,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,DIV CELLULAIRE & DEV,UNITE PROPRE RECH MECAN,F-67084 STRASBOURG,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,UNITE PROPRE RECH BIOL STRUCT,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ATANASSOV C, 1991, CLIN EXP IMMUNOL, V86, P124; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HERZOG H, 1989, P NATL ACAD SCI USA, V86, P3514, DOI 10.1073/pnas.86.10.3514; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KEITH G, 1990, ANAL BIOCHEM, V157, P4350; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARSISCHKY GT, 1992, ADP RIBOSYLATION REA, P47; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MIWA M, 1982, ADP RIBOSYLATION REA, P43; NIEDERGANG C, 1979, EUR J BIOCHEM, V102, P43, DOI 10.1111/j.1432-1033.1979.tb06261.x; OGATA N, 1980, J BIOL CHEM, V255, P7616; RIQUELME PT, 1979, J BIOL CHEM, V254, P3018; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; SIMONIN F, 1991, ANAL BIOCHEM, V195, P226, DOI 10.1016/0003-2697(91)90321-J; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; STILLMAN TJ, 1992, J MOL BIOL, V224, P1181, DOI 10.1016/0022-2836(92)90481-X; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; USHIRO H, 1987, J BIOL CHEM, V262, P2352; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	38	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8529	8535						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473297				2022-12-27	WOS:A1993KX81100026
J	KOCH, WJ; INGLESE, J; STONE, WC; LEFKOWITZ, RJ				KOCH, WJ; INGLESE, J; STONE, WC; LEFKOWITZ, RJ			THE BINDING-SITE FOR THE BETA-GAMMA-SUBUNITS OF HETEROTRIMERIC G-PROTEINS ON THE BETA-ADRENERGIC-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; BOVINE; FAMILY; PHOSPHOLIPASE-A2; ALPHA	The betagamma subunits of heterotrimeric G proteins play important roles in regulating receptor-stimulated signal transduction processes. Recently appreciated among these is their role in the signaling events that lead to the phosphorylation and subsequent desensitization of muscarinic cholinergic (Haga, K., and Haga, T. (1992) J. Biol. Chem. 267, 2222-2227) and beta-adrenergic (Pitcher, J. A., Inglese, J., Higgins, J. B., Arriza, J. L., Casey, P. J., Kim, C., Benovic, J. L., Kwatra, M. M., Caron, M. G., and Lefkowitz, R. J. (1992) Science 257, 1264-1267) receptors. Betagamma mediates the membrane targeting of the beta-adrenergic receptor kinase (betaARK), in response to receptor activation, through a specific betaARK-betagamma interaction. This process utilizes the membrane-anchoring properties of the isoprenylated gamma subunit of betagamma. In the present study, we have employed three distinct approaches to identify the region within the carboxyl terminus of betaARK which binds betagamma and thereby results in membrane translocation. We studied the ability of betagamma to enhance the enzymatic activity of a series of truncated mutants of bovine betaARK1, the ability of glutathione S-transferase fusion proteins containing various lengths of the carboxyl terminus of betaARK to bind betagamma subunits, and the ability of synthetic peptides comprised of betaARK sequences to inhibit betagamma activation of betaARK1. We find that the minimal betagamma binding domain of betaARK is localized to a 125-amino acid residue stretch, the distal end of which is located 19 residues from the carboxyl terminus. A single 28-mer peptide (Trp643 to Ser670) derived from this sequence effectively inhibited betagamma activation of betaARK1, with an IC50 of 76 muM. The identification of this ''betagamma binding domain'' on betaARK and the development of peptide inhibitors provide important tools for the study of G protein-coupled receptor desensitization, as well as for the investigation of betagamma activation of other G protein-effector systems.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,BOX 3821,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [4R37-HL16039] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CULLEN B, 1987, METHOD ENZYMOL, V152, P687; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P6678, DOI 10.1021/bi00480a018; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WHITEWAY M, 1988, COLD SPRING HARB SYM, V53, P585, DOI 10.1101/SQB.1988.053.01.067	30	448	452	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8256	8260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463335				2022-12-27	WOS:A1993KW97900097
J	WARE, J; RUSSELL, SR; MARCHESE, P; RUGGERI, ZM				WARE, J; RUSSELL, SR; MARCHESE, P; RUGGERI, ZM			EXPRESSION OF HUMAN PLATELET GLYCOPROTEIN-IB-ALPHA IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID-SEQUENCE; MEMBRANE; PROTEINS; COMPLEX; FIBRINOGEN; DOMAIN; GENE; DNA; IX	Platelets are cytoplasmic fragments of megakaryocytes and, therefore, their membrane proteins cannot be manipulated by expression methods in culture. To overcome this limitation, we have expressed human glycoprotein (GP) Ibalpha in transgenic mouse megakaryocytes and found that it was present on the surface of platelets associated with the mouse GP Ibbeta subunit. This finding demonstrates that assembly of the heterooligomeric GP Ib complex occurs through mechanisms conserved across species. In contrast, the receptor function of GP Ib exhibited restricted species specificity, since only the chimeric complex containing human GP Ibalpha bound human von Willebrand factor and supported platelet aggregation mediated by ristocetin. These studies demonstrate the transgenic engineering of a platelet adhesion receptor under control of the human GP Ibalpha promoter and illustrate a new approach to manipulate platelet receptors and study structure-function relationships in hemostasis and thrombosis.	SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-42846, R01 HL050545, R01 HL050545-06, HL-31950] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R37HL042846, R01HL050545, R01HL042846] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRINKHOUS KM, 1983, P NATL ACAD SCI-BIOL, V80, P1463, DOI 10.1073/pnas.80.5.1463; COLLER BS, 1983, BLOOD, V61, P99; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DU XP, 1987, BLOOD, V69, P1524; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HANDA M, 1986, J BIOL CHEM, V261, P2579; HARLOW E, 1988, ANTIBODIES LAB MANUA, P319; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; ISHIDA F, 1991, BLOOD, V78, P1722; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; MURATA M, 1991, J BIOL CHEM, V266, P15474; NIIYA K, 1987, BLOOD, V70, P475; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; PLOW EF, 1985, BLOOD, V66, P724; RAJAGOPALAN V, 1992, BLOOD, V80, P153; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; RUGGERI ZM, 1992, THROMB HAEMOSTASIS, V67, P594; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; RUGGERI ZM, 1987, BLOOD, V70, P895; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SHIMOMURA T, 1990, BLOOD, V75, P2349; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WENGER RH, 1989, GENE, V85, P517, DOI 10.1016/0378-1119(89)90446-0; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; [No title captured]	51	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8376	8382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463345				2022-12-27	WOS:A1993KW97900112
J	YURCHENCO, PD; SUNG, U; WARD, MD; YAMADA, Y; OREAR, JJ				YURCHENCO, PD; SUNG, U; WARD, MD; YAMADA, Y; OREAR, JJ			RECOMBINANT LAMININ-G DOMAIN MEDIATES MYOBLAST ADHESION AND HEPARIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; GLOBULAR DOMAIN; CELL-ADHESION; B-CHAINS; A-CHAIN; INTEGRIN; IDENTIFICATION; SUBUNIT; PROTEIN; POLYMERIZATION	A recombinant mouse cDNA fragment encoding the G domain of the basement membrane laminin A chain was inserted into the eukaryotic baculovirus expression vector pVL1392 modified to produce fusion proteins carrying the rat fibronectin signal. G domain, expressed and secreted as a soluble glycoprotein (rG), was purified to near homogeneity without denaturing conditions. By electron microscopy rG possessed the same globular morphology as found in laminin. rG was cleaved with elastase into two fragments, rG70 and rG50. The latter fragment possessed the identical N terminus as laminin fragment E3 and both shared the same secondary structure by circular dichroism. rG, and rG containing a deletion (residues 2980-3028) rich in basic residues bound to heparin with similar avidity. rG also promoted mouse C2 myoblast cell adhesion and spreading, and evaluation of myoblasts on rG70 and rG50 further revealed that cell spreading was an activity confined to the more proximal sequence of rG70. Antibody specific for rG70 completely blocked cell adhesion to intact laminin in contrast to antibody specific for E3. Finally rG did not inhibit laminin polymerization. These data support the role of G domain in cell and heparin binding, but not laminin self-assembly, and the approach provides a means to further characterize these functions.	ROBERT WOOD JOHNSON MED SCH,DEPT MICROBIOL & MOLEC GENET,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854; NIDR,BETHESDA,MD 20892	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425, R01DK036425] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36425] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CHARKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; CHEN WY, 1991, J BIOL CHEM, V266, P4081; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; DEAN JW, 1990, J BIOL CHEM, V265, P12553; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; Summers MD, 1987, TEXAS AGR EXPT STATI; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSAO T, 1990, J BIOL CHEM, V265, P5188; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	38	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8356	8365						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463343				2022-12-27	WOS:A1993KW97900110
J	WELLSKNECHT, MC; HUGGINS, TG; DYER, DG; THORPE, SR; BAYNES, JW				WELLSKNECHT, MC; HUGGINS, TG; DYER, DG; THORPE, SR; BAYNES, JW			OXIDIZED AMINO-ACIDS IN LENS PROTEIN WITH AGE - MEASUREMENT OF O-TYROSINE AND DITYROSINE IN THE AGING HUMAN LENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-TRYPTOPHAN FLUORESCENCE; DEPENDENT ACCUMULATION; N-EPSILON-(CARBOXYMETHYL)LYSINE; IDENTIFICATION; COLLAGEN; INVIVO	The concentrations of ortho-tyrosine (o-Tyr) and dityrosine (DT) were measured in noncataractous human lenses in order to assess the role of protein oxidation reactions in the aging of lens proteins. The measurements were conducted by selected ion monitoring-gas chromatography/mass spectrometry using deuterium-labeled internal standards, which provided both high sensitivity and specificity for the quantitation of o-Tyr and DT. Between ages 1 and 78 years, the o-Tyr concentration in lens proteins varied from 0.3 to 0.9 mmol of o-Tyr/mol of Phe (n = 19), while DT ranged from 1 to 3 mumol of DT/mol of Tyr (n = 30). There were no significant changes in levels of o-Tyr with lens age. There was a statistically significant, but only slight, increase in DT in lens proteins with age (approximately 33% increases between ages 1 and 78, r = 0.5, p < 0.01). At the same time, total protein fluorescence, measured at DT wavelengths (E(x) = 317 nm, E(m) = 407 nm), increased 11-fold between ages 1 and 78 and correlated strongly with age (r = 0.82, p < 0.0001). Although the fluorescence maxima of lens proteins were similar to those of DT, DT accounted for less than 1% of the DT-like fluorescence in lens protein at all ages. These observations indicate that oxidation of Phe and Tyr plays a limited role in the normal aging of lens proteins in vivo.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NIDDK NIH HHS [DK25373, DK19971] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025373, R01DK019971, R37DK019971] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BOGUTA G, 1983, INT J RADIAT BIOL, V43, P249, DOI 10.1080/09553008314550301; DILLON J, 1976, NATURE, V259, P422, DOI 10.1038/259422a0; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYER DG, 1991, Z ERNAHRUNGSWISS, V30, P29, DOI 10.1007/BF01910730; GARCIACASTINEIRAS S, 1978, EXP EYE RES, V26, P461, DOI 10.1016/0014-4835(78)90132-X; GARCIACASTINEIRAS S, 1978, SCIENCE, V199, P897, DOI 10.1126/science.622574; GUPTASARMA P, 1992, CURR EYE RES, V11, P1121, DOI 10.3109/02713689209015084; Harding JJ, 1984, EYE B, V1b, P207; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; LAYNE E, 1957, METHOD ENZYMOL, V3, P450; MCNAMARA MK, 1980, EXP EYE RES, V30, P319, DOI 10.1016/0014-4835(80)90014-7; SATOH K, 1973, EXP EYE RES, V16, P167, DOI 10.1016/0014-4835(73)90311-4; SPECTOR A, 1975, EXP EYE RES, V21, P9, DOI 10.1016/0014-4835(75)90053-6; ZIGLER JS, 1981, TRENDS BIOCHEM SCI, V6, P133	17	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12348	12352						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509374				2022-12-27	WOS:A1993LG65800022
J	COX, AD; GRAHAM, SM; SOLSKI, PA; BUSS, JE; DER, CJ				COX, AD; GRAHAM, SM; SOLSKI, PA; BUSS, JE; DER, CJ			THE CARBOXYL-TERMINAL CXXX SEQUENCE OF GI-ALPHA, BUT NOT RAB5 OR RAB11, SUPPORTS RAS PROCESSING AND TRANSFORMING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; POSTTRANSLATIONAL MODIFICATION; VESICULAR TRANSPORT; GAMMA-SUBUNITS; FARNESYLTRANSFERASE; ISOPRENYLATION; FARNESYL; P21RAS; CELLS; MOTIF	Although the heterotrimeric G(i)alpha subunit terminates in an apparent CXXX prenylation signal (CGLF), it is not modified by isoprenylation. To determine if the G(i)alpha CXXX sequence can signal prenylation when placed at the carboxyl termini of normally prenylated proteins, we have characterized the processing and biological activity of chimeric oncogenic Ras proteins that terminate in the G(i)alpha CXXX sequence (Ras/G(i)alpha). Surprisingly, these chimeras were prenylated both in vivo and in vitro, demonstrated significant membrane association, exhibited transforming activity, and induced transcriptional transactivation from Ras-responsive elements. We then extended these studies to determine if, unlike the CC or CXC carboxyl-terminal sequences of other Rab proteins, the carboxyl-terminal CXXX sequences of the Ras-related Rab5 and Rab11 proteins represent conventional CXXX prenylation signals that can support Ras processing and transforming activity. Unexpectedly, these Ras/Rab chimeras were nonprenylated, were cytosolic, and lacked detectable transforming or transcriptional transactivation activity. Taken together, these results suggest that the context within which a CXXX sequence occurs may also critically control the modification of a protein by prenylation, and that the Rab5 and Rab11 carboxyl termini do not possess conventional CXXX sequences. Instead, their CCXX and CCXXX motifs may represent additional classes of protein prenylation signals.	UNIV N CAROLINA,CURRICULUM GENET,CHAPEL HILL,NC 27599; IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	University of North Carolina; University of North Carolina Chapel Hill; Iowa State University	COX, AD (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA55008, CA52072, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978, R01CA055008, R01CA052072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P469; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4446; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JONES TLZ, 1990, J BIOL CHEM, V265, P19389; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	39	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11548	11552						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505289				2022-12-27	WOS:A1993LF28400017
J	DELAHUNTY, MD; STAFFORD, FJ; YUAN, LC; SHAZ, D; BONIFACINO, JS				DELAHUNTY, MD; STAFFORD, FJ; YUAN, LC; SHAZ, D; BONIFACINO, JS			UNCLEAVED SIGNALS FOR GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORING CAUSE RETENTION OF PRECURSOR PROTEINS IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; SITE-SPECIFIC MUTAGENESIS; CLEAVAGE ATTACHMENT SITE; CELL ANTIGEN RECEPTOR; QA-2 ANTIGEN; THY-1 GLYCOPROTEIN; MOLECULAR-CLONING; PHOSPHOLIPASE-C	Glycosylphosphatidylinositol (GPI)-anchored proteins are generally absent from the surface of cells that are defective in GPI biosynthesis. The current study was undertaken to: (a) examine in detail the intracellular localization and fate of precursors of GPI-anchored proteins in cells that fail to add GPI groups and (b) define structural characteristics of the precursor proteins that determine their intracellular localization. By examining GPI-deficient cells, we show that the uncleaved precursor of the GPI-anchored protein, Q7b, is retained in the cisternae of the endoplasmic reticulum (ER) and is largely lost intracellularly with a half-time of 2-4 h. Only a small amount (1-10%) of a proteolytically cleaved form of the protein is secreted into the medium. In cells competent for GPI anchor addition, mutation of the putative cleavage/attachment site for GPI addition in Q7b results in a similar phenotype of ER retention of the uncleaved precursor. An aspartic acid residue (Asp316) within the Q7b GPI anchoring signal, previously found to be essential for GPI anchor addition (Waneck, G. L., Stein, M. E., and Flavell, R. A. (1988) Science 241, 697-699), is also shown to be critical for ER retention. Information leading to ER retention is transferable to another protein by fusion of the GPI anchoring signals from either Q7b or the GPI-anchored form of the IgG Fc receptor type III. Analysis by sedimentation on sucrose gradients shows that Q7b species retained in the ER are multimeric, whereas species that exit the ER are monomeric. This correlation suggests that the presence of an uncleaved signal for GPI anchoring induces changes in the aggregation state of the precursor proteins, which may lead to their retention in the ER.			DELAHUNTY, MD (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Bonifacino, Juan S./0000-0002-5673-6370				BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLAHERTY L, 1976, IMMUNOGENETICS, V3, P533, DOI 10.1007/BF01576983; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANSCH GM, 1988, BLOOD, V72, P1089; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; JOST CR, 1991, BLOOD, V78, P3030; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MAHONEY JF, 1992, BLOOD, V79, P1400; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MICHAELSON J, 1981, IMMUNOGENETICS, V14, P129, DOI 10.1007/BF00344306; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SHARROW SO, 1989, J IMMUNOL, V142, P3495; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STROYNOWSKI I, 1987, CELL, V50, P759, DOI 10.1016/0092-8674(87)90334-5; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAMI N, 1992, J BIOL CHEM, V267, P1042; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; WADA I, 1991, J BIOL CHEM, V266, P19599; WANECK GL, 1987, J EXP MED, V165, P1358, DOI 10.1084/jem.165.5.1358; WANECK GL, 1988, P NATL ACAD SCI USA, V85, P577, DOI 10.1073/pnas.85.2.577; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WIENANDS J, 1992, NATURE, V356, P246, DOI 10.1038/356246a0; WILCOX LA, 1991, BLOOD, V78, P820, DOI 10.1182/blood.V78.3.820.bloodjournal783820; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	65	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12017	12027						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505326				2022-12-27	WOS:A1993LF28400084
J	DONG, ZM; ONRUST, R; SKANGALIS, M; ODONNELL, M				DONG, ZM; ONRUST, R; SKANGALIS, M; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .1. HOLA AND HOLB ENCODING DELTA AND DELTA'	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; GAMMA-SUBUNIT; READING FRAME; HOLOENZYME; SEQUENCE; REPLICATION; BINDING; GENES; QUANTITIES; MECHANISM	The genes encoding the delta and delta' subunits of the 10-subunit Escherichia coli replicase, DNA polymerase III holoenzyme, have been identified and sequenced. The holA gene encoding delta is located downstream of rlpB at 15.2 min and predicts a 38.7 kda protein. The holB gene encoding delta' is located at 24.3 min and predicts a 36.9-kDa protein. Hence the delta and delta' subunits are unrelated proteins encoded by separate genes. The genes have been used to express and purify delta and delta' in quantity. The predicted amino acid sequence of delta' is homologous to the sequences of the tau and gamma subunits revealing a large amount of structural redundancy within the holoenzyme.	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KONIGSBERG W, 1983, P NATL ACAD SCI-BIOL, V80, P687, DOI 10.1073/pnas.80.3.687; KORNBERG A, 1991, DNA REPLICATION, P176; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; Maniatis T., 1982, MOL CLONING LABORATO, P76; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCHENRY C, 1981, ENZYMES, V14, P39; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROWEN L, 1979, J BIOL CHEM, V253, P758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAKASE I, 1987, J BACTERIOL, V169, P5692, DOI 10.1128/jb.169.12.5692-5699.1987; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER W, 1974, J BIOL CHEM, V249, P6244; YIN KC, 1986, NUCLEIC ACIDS RES, V14, P6541, DOI 10.1093/nar/14.16.6541	42	69	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11758	11765						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505303				2022-12-27	WOS:A1993LF28400046
J	KESTI, T; FRANTTI, H; SYVAOJA, JE				KESTI, T; FRANTTI, H; SYVAOJA, JE			MOLECULAR-CLONING OF THE CDNA FOR THE CATALYTIC SUBUNIT OF HUMAN DNA-POLYMERASE EPSILON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE CDC2 GENE; CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; CALF THYMUS; NUCLEOTIDE-SEQUENCE; STRAND SYNTHESIS; ALPHA-GENE; HELA-CELLS; 2 FORMS; DELTA	The cDNA encoding the catalytic polypeptide of human DNA polymerase epsilon was cloned. The deduced amino acid sequence reveals that the catalytic polypeptide is 2257 amino acids in length and its calculated molecular mass is 258 kDa. A single RNA message of 7.5 kilobases was recognized by isolated cDNA clones. The identity of the cDNA was verified by direct amino acid sequencing of tryptic fragments derived from the catalytic polypeptide of the HeLa DNA polymerase epsilon. The primary structure comparison with multiple DNA polymerases indicates that human DNA polymerase epsilon catalytic polypeptide is a homolog of the yeast Saccharomyces cerevisiae DNA polymerase II catalytic polypeptide. The proteins are 39% identical. In the region containing known DNA polymerase consensus motifs, the identity is 63%. The expression of the mRNA encoding DNA polymerase epsilon is strongly dependent on cell proliferation.	UNIV OULU, DEPT BIOCHEM, LINNANMAA, SF-90570 OULU, FINLAND	Finland National Institute for Health & Welfare; University of Oulu								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALESTROM P, 1982, J BIOL CHEM, V257, P13492; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BLANK A, 1991, BIOCHEMISTRY-US, V30, P8092, DOI 10.1021/bi00246a030; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; Burgers P M, 1989, Prog Nucleic Acid Res Mol Biol, V37, P235; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; KESTI T, 1991, J BIOL CHEM, V266, P6336; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MORRISON A, 1992, NUCLEIC ACIDS RES, V20, P375, DOI 10.1093/nar/20.2.375; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1993, IN PRESS PROG NUCLEI, V46; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Sambrook J, 1989, MOL CLONING LABORATO; SAVILAHTI H, 1986, GENE, V49, P199, DOI 10.1016/0378-1119(86)90280-5; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STRAUSS PR, 1990, EUKARYOTIC NUCLEUS M, V1; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; SYVAOJA JE, 1990, BIOESSAYS, V12, P533, DOI 10.1002/bies.950121106; TAKAHASHI Y, 1985, P NATL ACAD SCI USA, V82, P1931, DOI 10.1073/pnas.82.7.1931; TAN CK, 1986, J BIOL CHEM, V261, P2310; THOMMES P, 1990, EUR J BIOCHEM, V194, P699, DOI 10.1111/j.1432-1033.1990.tb19460.x; TOMALSKI MD, 1988, VIROLOGY, V167, P591, DOI 10.1016/S0042-6822(88)90122-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG BY, 1989, MOL CELL BIOL, V9, P1940, DOI 10.1128/MCB.9.5.1940; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WEISER T, 1991, J BIOL CHEM, V266, P10420; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; WONG SW, 1989, J BIOL CHEM, V264, P5924; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; YOSHIKAWA H, 1982, GENE, V17, P323; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002	71	72	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10238	10245						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486689				2022-12-27	WOS:A1993LB80000044
J	WANG, ZY; LIN, XH; NOBUYOSHI, M; DEUEL, TF				WANG, ZY; LIN, XH; NOBUYOSHI, M; DEUEL, TF			IDENTIFICATION OF A SINGLE-STRANDED DNA-BINDING PROTEIN THAT INTERACTS WITH AN S1 NUCLEASE-SENSITIVE REGION IN THE PLATELET-DERIVED GROWTH-FACTOR A-CHAIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; CARDIAC ACTIN; CODING STRAND; TRANSCRIPTION; SEQUENCES; CONFORMATION; ELEMENTS; ROLES	We previously observed that transcription of the platelet-derived growth factor (PDGF) A-chain gene is enhanced in cells stimulated by PDGF through a serum response element (SRE) in its 5'-flanking sequence. We now show that the region of the SRE is sensitive to S1 nuclease in vitro. We also identify a single-stranded DNA-binding protein in HeLa cell nuclear extracts that binds to the noncoding strand of the PDGF A-chain SRE but not to its double-stranded counterpart or to the single-stranded coding sequence. Competition assays using oligonucleotides with sequence-specific mutations that diminished or eliminated detectable complex formation were used to establish the specificity of this protein/DNA interaction. Remarkably, the sequence-specific single-stranded binding protein binds to this region only when it is highly supercoiled. The data suggest that the single-stranded DNA-binding protein specifically interacts with a highly supercoiled region of the PDGF A-chain promoter and that this interaction may have a role in the transcriptional regulation of this gene.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)								BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAILLARD C, 1988, J VIROL, V62, P2380, DOI 10.1128/JVI.62.7.2380-2385.1988; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; GRAYHACK ZJ, 1992, MOL CELL BIOL, V12, P3573; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LIN XH, 1992, J BIOL CHEM, V267, P25614; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; SAMBROOK T, 1989, MOL CLONING LABORATO; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WALSH K, 1987, J BIOL CHEM, V262, P9429; WANG ZY, 1992, J BIOL CHEM, V267, P13669; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1991, T ASSOC AM PHYSICIAN, V14, P1; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YAN WA, 1989, EMBO J, V8, P1785; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	35	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10681	10685						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486717				2022-12-27	WOS:A1993LB80000100
J	YAVER, DS; NELSON, H; NELSON, N; KLIONSKY, DJ				YAVER, DS; NELSON, H; NELSON, N; KLIONSKY, DJ			VACUOLAR ATPASE MUTANTS ACCUMULATE PRECURSOR PROTEINS IN A PRE-VACUOLAR COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; H+-ATPASE; YEAST MUTANTS; ALPHA-FACTOR; CARBOXYPEPTIDASE-Y; SECRETORY PATHWAY; PLASMA-MEMBRANE; TRANSPORT; GENE; ACIDIFICATION	The vacuole of the yeast Saccharomyces cerevisiae contains a proton-translocating ATPase that acidifies the vacuolar lumen and generates an electrochemical potential across the vacuole membrane. Strains with chromosomal disruptions of the genes encoding the A, B, and c subunits of the vacuolar ATPase accumulate precursor forms of the vacuolar membrane protein alkaline phosphatase, and the soluble vacuolar hydrolases carboxypeptidase Y and proteinase A. We have found that the intracellular precursors in DELTAvat strains accumulate within the secretory pathway at some point before delivery to the vacuole but after transit to the Golgi complex. Purified vacuoles from DELTAvat cells do not contain the precursor forms of carboxypeptidase Y or alkaline phosphatase. In addition, vacuolar hydrolase-invertase hybrid proteins are inefficiently delivered to the vacuole in DELTAvat strains as demonstrated by vacuole isolation. Further subcellular fractionation to separate organelles indicate that significant amounts of the carboxypeptidase Y-invertase and alkaline phosphatase-invertase hybrid proteins are located in the late Golgi complex and/or post Golgi compartments.	UNIV CALIF DAVIS, DEPT MICROBIOL, DAVIS, CA 95616 USA; ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	University of California System; University of California Davis; Roche Holding				Yaver, Debbie/0000-0003-4150-6756	NIDDK NIH HHS [DK43684] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043684] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P7080, DOI 10.1073/pnas.80.23.7080; FOURY F, 1990, J BIOL CHEM, V265, P18554; Goldstein A, 1975, Methods Enzymol, V42, P504; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HALVORSON H, 1958, BIOCHIM BIOPHYS ACTA, V30, P28, DOI 10.1016/0006-3002(58)90237-3; HIRATA R, 1990, J BIOL CHEM, V265, P6726; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KANE PM, 1989, J BIOL CHEM, V264, P19236; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; PRESTON RA, 1992, GENETICS, V131, P551; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, J CELL BIOL, V109, P93, DOI 10.1083/jcb.109.1.93; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418	46	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10564	10572						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486710				2022-12-27	WOS:A1993LB80000085
J	KANAMOTO, R; KAMEJI, T; IWASHITA, S; IGARASHI, K; HAYASHI, S				KANAMOTO, R; KAMEJI, T; IWASHITA, S; IGARASHI, K; HAYASHI, S			SPERMIDINE-INDUCED DESTABILIZATION OF ORNITHINE DECARBOXYLASE (ODC) IS MEDIATED BY ACCUMULATION OF ANTIZYME IN ODC-OVERPRODUCING VARIANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED-HEPATOCYTES; RAT-LIVER; ALPHA-DIFLUOROMETHYLORNITHINE; ERYTHROLEUKEMIA-CELLS; CASEIN KINASE; PHOSPHORYLATION; DEGRADATION; PUTRESCINE; POLYAMINES; STABILIZATION	The mechanism of spermidine-induced destabilization of ornithine decarboxylase (ODC) was examined in newly isolated ODC-overproducing variant cells by use of an in vitro ODC degrading system. The cells accumulated ODC protein at a level of 2-4% of the total cytosolic protein in the presence of alpha-difluoromethylornithine. Addition of spermidine to the medium accelerated degradation of ODC protein concomitantly with induction of antizyme, a regulatory protein that binds to ODC, inhibiting its activity. Both the acceleration of ODC degradation and the induction of antizyme were inhibited by cycloheximide, but not by actinomycin D. ODC was degraded rapidly in extracts from spermidine-treated cells. The rate of ODC degradation correlated with the amount of antizyme in the extracts, and the degradation activity was abolished by treatment of the extracts with anti-antizyme antibody. Thus, antizyme induced by spermidine was essential for the accelerated degradation of ODC in the cells. ODC was phosphorylated in the cells, probably at serine residue 303 in the first internal PEST region. ODC phosphorylation occurred even when its new synthesis was inhibited by cycloheximide. Antizyme accelerated the degradations of both dephosphorylated ODC and native ODC.	MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; CHIBA UNIV, FAC PHARMACEUT SCI, YAYOI, CHIBA 260, JAPAN	Chiba University	KANAMOTO, R (corresponding author), JIKEI UNIV SCH MED, DEPT NUTR, MINATO KU, TOKYO 105, JAPAN.			Iwashita, Shintaro/0000-0001-8086-9192; Igarashi, Kazuei/0000-0003-3751-3187				AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Canellakis E S, 1979, Curr Top Cell Regul, V15, P155; FLAMIGNI F, 1990, BIOCHIM BIOPHYS ACTA, V1052, P345, DOI 10.1016/0167-4889(90)90232-3; FLAMIGNI F, 1989, BIOCHEM BIOPH RES CO, V163, P1217, DOI 10.1016/0006-291X(89)91107-8; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Hayashi S., 1989, ORNITHINE DECARBOXYL, P35; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HOGAN BLM, 1974, J CELL PHYSIOL, V83, P345, DOI 10.1002/jcp.1040830304; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; KAMEJI T, 1993, BIOCHEM J, V289, P581, DOI 10.1042/bj2890581; KAMEJI T, 1982, BIOCHIM BIOPHYS ACTA, V717, P111, DOI 10.1016/0304-4165(82)90387-7; KANAMOTO R, 1991, ARCH BIOCHEM BIOPHYS, V291, P247, DOI 10.1016/0003-9861(91)90130-B; KANAMOTO R, 1987, J BIOL CHEM, V262, P14801; KANAMOTO R, 1986, EUR J BIOCHEM, V154, P539, DOI 10.1111/j.1432-1033.1986.tb09432.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MATSUFUJI S, 1984, J BIOCHEM-TOKYO, V96, P1525, DOI 10.1093/oxfordjournals.jbchem.a134981; MEGGIO F, 1987, BIOCHIM BIOPHYS ACTA, V929, P114, DOI 10.1016/0167-4889(87)90246-1; MEGGIO F, 1984, BIOCHEM BIOPH RES CO, V122, P997, DOI 10.1016/0006-291X(84)91190-2; MITCHELL JLA, 1991, ARCH BIOCHEM BIOPHYS, V290, P143, DOI 10.1016/0003-9861(91)90600-N; MITSUI K, 1990, FEBS LETT, V268, P157, DOI 10.1016/0014-5793(90)80997-W; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1989, EUR J BIOCHEM, V180, P181, DOI 10.1111/j.1432-1033.1989.tb14630.x; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; NISHIYAMA M, 1988, PREP BIOCHEM, V18, P227, DOI 10.1080/00327488808062524; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PENG T, 1988, BIOCHEM BIOPH RES CO, V153, P135, DOI 10.1016/S0006-291X(88)81199-9; POULIN R, 1990, J BIOL CHEM, V265, P4025; PROUTY WF, 1976, J CELL PHYSIOL, V89, P65, DOI 10.1002/jcp.1040890107; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V197, P419, DOI 10.1111/j.1432-1033.1991.tb15927.x; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOHYAMA Y, 1991, EUR J BIOCHEM, V202, P1327, DOI 10.1111/j.1432-1033.1991.tb16507.x; UTSUNOMIYA K, 1985, Jikeikai Medical Journal, V32, P575; VICEPSMADORE D, 1982, BIOCHIM BIOPHYS ACTA, V717, P305, DOI 10.1016/0304-4165(82)90184-2	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9393	9399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486633				2022-12-27	WOS:A1993LA68900039
J	REICH, NO; MASHHOON, N				REICH, NO; MASHHOON, N			PRESTEADY STATE KINETICS OF AN S-ADENOSYLMETHIONINE-DEPENDENT ENZYME - EVIDENCE FOR A UNIQUE BINDING ORIENTATION REQUIREMENT FOR ECORI DNA METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							METHYLASE	We present the first presteady state kinetic analysis of an S-adenosylmethionine-dependent enzyme. The target enzyme is the bacterial EcoRI DNA methyltransferase, which transfers the methyl group to the second adenine in the DNA sequence GAATTC. The rate constant for conversion of the central complex (enzyme-DNA-S-adenosylmethionine) to products (enzyme-methylated DNA-S-adenosylhomocysteine) (41 +/- 7 s-1) is over 300-fold faster than k(cat), consistent with our demonstration that steps after methyl transfer are rate-limiting (Reich, N. O., and Mashhoon, N. (1991) Biochemistry 30,2933-2939). Methyl transfer at the N6 amino moiety of adenine on each strand requires a single binding orientation.			REICH, NO (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106, USA.							BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9293, DOI 10.1021/bi00450a009; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; Modrich P., 1982, NUCLEASES, P109; RAZIN A, 1984, DNA METHYLATION BIOC; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1991, NUCLEIC ACIDS RES, V19, P6587, DOI 10.1093/nar/19.23.6587; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REICH NO, 1992, BIOCHEMISTRY-US, V31, P1937, DOI 10.1021/bi00122a006; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0	13	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9191	9193						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486619				2022-12-27	WOS:A1993LA68900010
J	BRACH, MA; GRUSS, HJ; KAISHO, T; ASANO, Y; HIRANO, T; HERRMANN, F				BRACH, MA; GRUSS, HJ; KAISHO, T; ASANO, Y; HIRANO, T; HERRMANN, F			IONIZING-RADIATION INDUCES EXPRESSION OF INTERLEUKIN-6 BY HUMAN FIBROBLASTS INVOLVING ACTIVATION OF NUCLEAR FACTOR-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; DNA DAMAGE; MAMMALIAN-CELLS; MESSENGER-RNA; C-FOS; METALLOTHIONEIN; IRRADIATION; INDUCTION; ELEMENT	We here report that human lung fibroblasts respond to x-ray treatment (XRT) with release of interleukin (IL)-6. Synthesis of IL-6 upon ionizing radiation is preceded by an increase of IL-6 transcript levels resulting from transcriptional activation of the IL-6 gene. Analysis of deleted fragments of the IL-6 promoter indicated that transcriptional activation of the IL-6 promoter was due to enhanced binding activity of the transcription factor nuclear factor (NF)-kappaB. Although AP-1 did not participate in the rapid induction of the IL-6 promoter, its binding activity was also enhanced by XRT. In contrast to binding kinetics observed with NF-kappaB, AP-1 binding following XRT was biphasic with the second peak being dependent on de novo protein synthesis. In contrast, however, NF-IL-6 activity was not enhanced by XRT in fibroblasts. The introduction of both the NF-kappaB- and the AP-1 recognition sequence conferred inducibility by XRT to a heterologous promoter, with reporter gene activity being maximal 24 or 48 h following XRT, respectively. Sequential activation of two distinct transcription factors might thus contribute to synchronize transcriptional activation of different genes participating in the x-ray response.	FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,DEPT MED ONCOL & APPL MOLEC BIOL,ROBERT ROSSLE KLIN,W-1115 BERLIN,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,W-1115 BERLIN,GERMANY; UNIV FREIBURG KLINIKUM,DEPT HEMATOL & ONCOL,W-7800 FREIBURG,GERMANY; OSAKA UNIV,SCH MED,DIV MOLEC ONCOL,SUITA,OSAKA 565,JAPAN	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Freiburg; Osaka University			Hirano, Toshio/C-8194-2009; Kaisho, Tsuneyasu/B-4130-2012					ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BRACH MA, 1992, BLOOD, V79, P728; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRACH MA, 1992, INT J CLIN LAB RES, V22, P143, DOI 10.1007/BF02591414; Bradford MM, 1976, ANAL BIOCHEM, V72, P234; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HALAZONETIS T, 1988, CELL, V55, P924; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HIRANO T, 1991, INT J CELL CLONING, V9, P166, DOI 10.1002/stem.5530090303; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Law MP., 1981, ADV RADIAT BIOL, P37; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; MANTOVANI L, 1990, FEBS LETT, V270, P152, DOI 10.1016/0014-5793(90)81256-N; PHILLIPS TL, 1972, FRONTIERS RADIATION, V6, P21; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WALTHER Z, 1988, J IMMUNOL, V140, P974; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x	33	134	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8466	8472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473290				2022-12-27	WOS:A1993KX81100017
J	INMAN, RS; WESSLINGRESNICK, M				INMAN, RS; WESSLINGRESNICK, M			CHARACTERIZATION OF TRANSFERRIN-INDEPENDENT IRON TRANSPORT IN K562 CELLS - UNIQUE PROPERTIES PROVIDE EVIDENCE FOR MULTIPLE PATHWAYS OF IRON UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; CADMIUM UPTAKE; SACCHAROMYCES-CEREVISIAE; BOUND IRON; RAT-LIVER; SYSTEM; GROWTH; RETICULOCYTES; HEPATOCYTES; REDUCTION	The present study characterizes the transport of nontransferrin (non-Tf) iron by K562 cells. Accumulation of radiolabel by cells incubated with Fe-55-nitrilotriacetate (NTA) is a saturable process that is time and temperature dependent (Ea approximately 20 kcal/mol). Initial rate analysis of iron influx yields values of V(max) = 855 fmol/min/10(6) cells and apparent K(m) = 0.54 muM. NHCl4 and chloroquine, agents that block cellular acquisition of iron from Tf, do not interfere with assimilation from FeNTA, demonstrating that uptake is truly independent of the Tf-mediated pathway. Furthermore, the inactivation of this transport mechanism by limited proteolytic digestion on ice indicates that specific cell surface proteins are involved. The extent of radiolabel incorporation into heme and ferritin is the same regardless of whether K562 cells acquire iron from Fe-55NTA via the cell surface mechanism or from Fe-55-Tf via receptor-mediated endocytosis. Unlike other Tf-independent iron transport pathways that have been described, the K562 cell transport mechanism is not inhibited by divalent cations such as Ni2+, Co2+, or Mn2+. Uptake from Fe-55NTA can be blocked by Cu2+ but at concentrations >1500-fold molar excess. However, Cd2+ is a fairly specific inhibitor of Fe-55 uptake by K562 cells (IC50 approximately 50 muM). Additionally, the K562 cell transport mechanism is not Ca+2 dependent and does not appear to be regulated by extracellular iron salts, in contrast to features noted for non-Tf iron uptake by fibroblasts (Sturrock, A., Alexander, J., Lamb, J., Craven, C. M., and Kaptan, J. (1991) J. Biol. Chem. 265, 3139-3145; Kaplan, J., Jordan, I., and Sturrock, A. (1991) J. Biol. Chem. 266, 2997-3004). These unique characteristics of the K562 cell uptake mechanism suggest that multiple transport systems function in Tf-independent iron assimilation.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health								BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BASSET P, 1986, CANCER RES, V46, P1644; BOTTOMLEY SS, 1985, J BIOL CHEM, V260, P6811; COX TM, 1990, IRON TRANSPORT STORA, P263; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; FOULKES EC, 1985, TOXICOLOGY, V37, P117, DOI 10.1016/0300-483X(85)90118-0; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; GARTY M, 1986, TOXICOLOGY, V42, P111, DOI 10.1016/0300-483X(86)90002-8; GREBING C, 1984, J BIOENERG BIOMEMBR, V16, P517, DOI 10.1007/BF00743243; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KLUG S, 1988, HUM TOXICOL, V7, P545, DOI 10.1177/096032718800700605; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OKABE T, 1984, P NATL ACAD SCI-BIOL, V81, P453, DOI 10.1073/pnas.81.2.453; STEIN BS, 1986, J BIOL CHEM, V261, P319; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TEICHMANN R, 1990, J CLIN INVEST, V86, P2145, DOI 10.1172/JCI114953; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; TITEUX M, 1984, J CELL PHYSIOL, V121, P251, DOI 10.1002/jcp.1041210131; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P690; WRIGHT TL, 1986, J BIOL CHEM, V261, P909	30	125	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8521	8528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473296				2022-12-27	WOS:A1993KX81100025
J	OCONNOR, TR; GRAVES, RJ; DEMURCIA, G; CASTAING, B; LAVAL, J				OCONNOR, TR; GRAVES, RJ; DEMURCIA, G; CASTAING, B; LAVAL, J			FPG PROTEIN OF ESCHERICHIA-COLI IS A ZINC FINGER PROTEIN WHOSE CYSTEINE RESIDUES HAVE A STRUCTURAL AND OR FUNCTIONAL-ROLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; TRANSCRIPTION FACTOR-IIIA; BINDING DOMAINS; GENE; REPAIR; POLY(ADP-RIBOSE)POLYMERASE; RECOGNITION; MUTAGENESIS; NICKING	The Fpg protein of Escherichia coli is a DNA repair enzyme with DNA glycosylase, abasic site nicking, and deoxyribose excising activities. Analysis of the amino acid sequence of this protein suggests that the Fpg protein is a zinc finger protein with a Cys-X2-Cys-X16-Cys-X2-Cys motif. Competition experiments show that the Fpg protein substitutes Cu(II), Cd(II), and Hg(II), metal ions classically associated with substitutions in zinc finger proteins. The Fpg protein activities are inhibited following the reaction with a Cys-specific reagent at low protein:reagent ratios, suggesting that these residues are important for the enzymatic activities. Site-directed mutagenesis was used to produce 6 mutant Fpg proteins with Cys --> Gly mutations. Substitution of the zinc in these proteins by Zn-65(II) indicates that all the proteins bind zinc, but the Zn(II) is not retained as strongly in the zinc finger mutants. The mutations in the Fpg protein outside the zinc finger consensus sequence do not eliminate the Fapy-DNA glycosylase and abasic site nicking. One of the Fpg mutant proteins outside the zinc finger has a reduced capacity to release deoxyribose from abasic sites. Cys --> Gly mutations in the zinc finger consensus sequence reduce all three aforementioned activities substantially. The purified Fpg proteins with Cys --> Gly mutations in the zinc finger consensus sequence do not incise DNA at abasic sites with the same efficiency nor mechanism as the native Fpg protein. The wild type Fpg protein and the Fpg proteins mutated outside the zinc finger sequence bind an oligonucleotide with a unique chemically reduced abasic site in a defined sequence as assayed by retention on nitrocellulose filters, whereas the mutant Fpg proteins within the zinc finger sequence do not bind to the same oligonucleotide. Therefore, the disruption of zinc coordination in the zinc finger of the Fpg protein is associated with decreased binding capacity to DNA as well as decreased enzymatic activities.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,UPR 9003,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	OCONNOR, TR (corresponding author), INST GUSTAVE ROUSSY,REPARAT LESIONS RADIO & CHIMIOINDUITES GRP,CNRS,URA 147,INSERM,F-94805 VILLEJUIF,FRANCE.			Castaing, Bertrand/0000-0001-5077-8978; O'Connor, Timothy/0000-0001-5848-3592				ANGULO JF, 1991, NUCLEIC ACIDS RES, V19, P5117, DOI 10.1093/nar/19.19.5117; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; INAOKA T, 1989, J BIOL CHEM, V264, P2609; IVEY DM, 1990, NUCLEIC ACIDS RES, V18, P5882, DOI 10.1093/nar/18.19.5882; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; LAVAL J, 1990, J CELL BIOCH SA, V14, P24; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MULLER E, 1990, NUCLEIC ACIDS RES, V18, P5969, DOI 10.1093/nar/18.20.5969; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; O'Connor T R, 1989, Ann Ist Super Sanita, V25, P27; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Sambrook J, 1989, MOL CLONING LABORATO; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857	35	129	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9063	9070						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473347				2022-12-27	WOS:A1993KX81100097
J	THEUNISSEN, HJM; DIJKEMA, R; GROOTENHUIS, PDJ; SWINKELS, JC; DEPOORTER, TL; CARATI, P; VISSER, A				THEUNISSEN, HJM; DIJKEMA, R; GROOTENHUIS, PDJ; SWINKELS, JC; DEPOORTER, TL; CARATI, P; VISSER, A			DISSOCIATION OF HEPARIN-DEPENDENT THROMBIN AND FACTOR-XA INHIBITORY ACTIVITIES OF ANTITHROMBIN-III BY MUTATIONS IN THE REACTIVE SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-THROMBIN; ALPHA-1-ANTITRYPSIN; MECHANISM; KINETICS; SERPINS; CELLS	Antithrombin-III (AT-III) is a heparin-dependent inhibitor of thrombin and Factor Xa, two serine proteases that are crucial for blood coagulation. In order to assess whether it would be possible to target AT-III only towards Factor Xa, we replaced parts of the reactive site, or P region, of AT-III by sequences present in prothrombin, a substrate of Factor Xa in the coagulation cascade. We show that replacement of the P3 to P3' region generates the hypothesized phenotype. In fact, point mutation of the P1' site from Ser (present in AT-III) to Ile (present in prothrombin) is sufficient to dissociate heparin-dependent thrombin and Factor Xa inhibitory activities. Interestingly, a combined mutation at P3 and P3' brings about the same dissociation. We show that besides Ile, other amino acids at P1' can lead to the dissociation in inhibitory activity. Amino acids with small side chains (Gly, Ser, Ala, and Thr) have only a marginal effect on the inhibitory activity against either protease. However, larger residues at the P1' position abolish the heparin-dependent antithrombin activity, whereas the heparin-dependent anti-Factor Xa activity is not at all or only moderately affected. These results can be rationalized by a comparison of the x-ray structure and a three-dimensional model of the S1' binding pockets of thrombin and Factor Xa, respectively. It appears that the S1' pocket of Factor Xa leaves much more space for the P1' residue of AT-III than the S1' pocket of thrombin.	ORGANON INT BV, DEPT VASC PHARMACOL, 5340 BH OSS, NETHERLANDS; ORGANON INT BV, DEPT COMP MEDICINAL CHEM, ORGANON SCI DEV GRP, 5340 BH OSS, NETHERLANDS		THEUNISSEN, HJM (corresponding author), ORGANON INT BV, DEPT BIOTECHNOL & BIOCHEM, POB 20, 5340 BH OSS, NETHERLANDS.							BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; Carrell R. W., 1987, THROMB DIATH HAEMO, P1; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IRELAND H, 1991, BRIT J HAEMATOL, V79, P70, DOI 10.1111/j.1365-2141.1991.tb08009.x; JORDAN RE, 1980, J BIOL CHEM, V255, P81; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KOYMANS LMH, 1992, IN PRESS RECL TRAV C; LANE DA, 1991, THROMB HAEMOSTASIS, V66, P657; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Muszbek L, 1984, THROMBIN, P83; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1991, THROMB HAEMOSTASIS, V65, P670; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J, 1989, MOL CLONING LABORATO; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; ZETTLMEISSL G, 1989, J BIOL CHEM, V264, P21153	37	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9035	9040						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473344				2022-12-27	WOS:A1993KX81100093
J	CUNNIFF, NFA; MORGAN, WD				CUNNIFF, NFA; MORGAN, WD			ANALYSIS OF HEAT-SHOCK ELEMENT RECOGNITION BY SATURATION MUTAGENESIS OF THE HUMAN HSP70.1 GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; RAT HEME OXYGENASE; TRANSCRIPTION FACTOR; REGULATORY PROTEINS; GEL-ELECTROPHORESIS; MOLECULAR-CLONING; EXPRESSION; SEQUENCE; CELLS; SITES	We analyzed the human HSP70.1 gene promoter heat shock element by saturation point mutagenesis and performed quantitative assays of in vitro heat shock factor binding and of in vivo transcription activity in HeLa cells with this extensive set of mutants. These results showed a significant correlation between measurements of heat shock factor binding and heat-inducible expression and provided a detailed thermodynamic description of the preferred recognition consensus sequence. In particular, this work demonstrated that outer positions 1 and 5 of the 5-base pair motif NGAAN, in addition to the most conserved triplet in the center, can have a strong influence on activity. Optimal activity occurred with the sequence AGAAC, and the levels of activity for all single base substitution variants were established. This analysis should be useful both for predicting the activity of potential heat shock element sequences near mammalian promoters and for interpreting structural features of protein-nucleic acid interactions in this system.	MCGILL UNIV,DEPT BIOL,1205 AVE DOCTEUR PENFIELD,MONTREAL H3A 1B1,QUEBEC,CANADA; MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3A 1B1,QUEBEC,CANADA	McGill University; McGill University								ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; BERG OG, 1988, TRENDS BIOCHEM SCI, V13, P207, DOI 10.1016/0968-0004(88)90085-0; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; CANN JR, 1989, J BIOL CHEM, V264, P17032; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CUNNIFF NFA, 1991, MOL CELL BIOL, V11, P3504, DOI 10.1128/MCB.11.7.3504; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lis J.T., 1990, STRESS PROTEINS BIOL, P411; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MULLER RM, 1987, J BIOL CHEM, V262, P6795; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SORGER P, 1989, CELL, V54, P807; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; VOELLMY R, 1985, P NATL ACAD SCI USA, V82, P4949, DOI 10.1073/pnas.82.15.4949; WEIDERRECHT G, 1988, CELL, V54, P841; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	38	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8317	8324						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463341				2022-12-27	WOS:A1993KW97900105
J	MUSZBEK, L; LAPOSATA, M				MUSZBEK, L; LAPOSATA, M			MYRISTOYLATION OF PROTEINS IN PLATELETS OCCURS PREDOMINANTLY THROUGH THIOESTER LINKAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ACYLATION; N-MYRISTOYLTRANSFERASE; COVALENT MODIFICATION; EUKARYOTIC PROTEINS; CELLULAR PROTEINS; PLASMA-MEMBRANE; COA; SPECIFICITY; RECEPTOR; PEPTIDE	We have demonstrated by several lines of evidence that in platelets myristate is linked to proteins predominantly via thioester bonds as is palmitate, and the covalent binding of the two long chain saturated fatty acids to proteins involves the same mechanisms. The first piece of evidence to support the thioester linkage between myristate and proteins is that [H-3]myristate could be removed from proteins via alkaline methanolysis, which disrupts ester bonds but not amide bonds. The second piece of evidence is that unlabeled palmitate, which can form only thioester bonds in physiologic concentrations, competitively inhibits the formation of alkaline methanolysis-sensitive covalent bonds between [H-3]myristate and proteins. Third, by SDS-polyacrylamide gel electrophoresis and fluorography, the patterns of labeled proteins from [H-3]myristate- and [H-3]palmitate-labeled platelets are identical. Fourth, [H-3]myristate-labeled proteins, like [H-3]palmitate-labeled proteins, both release their fatty acid moieties when exposed to hydroxylamine at neutral pH, which disrupts thioester but not hydroxyester bonds. These findings indicate that although the covalent binding of palmitate to proteins was found to occur at a faster rate than that of myristate, protein S fatty acid acylation that occurs posttranslationally is not specific for palmitate.	MASSACHUSETTS GEN HOSP,DEPT PATHOL,CLIN LABS,RM 249,GRAY BLDG,BOSTON,MA 02114; DEBRECEN UNIV MED,SCH MED,DEPT CLIN CHEM,H-4012 DEBRECEN,HUNGARY; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; University of Debrecen; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK43159] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043159] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER M, 1984, J BIOL CHEM, V259, P7245; BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; BOOYSE FM, 1967, BIOCHIM BIOPHYS ACTA, V145, P188, DOI 10.1016/0005-2787(67)90673-9; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HENNES AR, 1966, NATURE, V210, P839, DOI 10.1038/210839a0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JEMMERSON R, 1987, BIOCHEMISTRY-US, V26, P5703, DOI 10.1021/bi00392a019; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KIEFFER N, 1987, EUR J BIOCHEM, V164, P189, DOI 10.1111/j.1432-1033.1987.tb11010.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1987, BIOCHEM J, V244, P1; MAGEE AI, 1990, J CELL SCI, V97, P581; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; MUSZBEK L, 1989, BLOOD, V74, P1339; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; NEUFELD EJ, 1983, J CLIN INVEST, V72, P214, DOI 10.1172/JCI110959; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OLSON EN, 1985, J BIOL CHEM, V260, P3784; OMARY MB, 1981, J BIOL CHEM, V256, P4715; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WILCOX CA, 1987, BIOCHEMISTRY-US, V26, P1029, DOI 10.1021/bi00378a008	32	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8251	8255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463334				2022-12-27	WOS:A1993KW97900096
J	OCONNOR, PM; FERRIS, DK; PAGANO, M; DRAETTA, G; PINES, J; HUNTER, T; LONGO, DL; KOHN, KW				OCONNOR, PM; FERRIS, DK; PAGANO, M; DRAETTA, G; PINES, J; HUNTER, T; LONGO, DL; KOHN, KW			G2 DELAY INDUCED BY NITROGEN-MUSTARD IN HUMAN-CELLS AFFECTS CYCLIN A/CDK2 AND CYCLIN-B1 CDC2-KINASE COMPLEXES DIFFERENTLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; HAMSTER OVARY CELLS; DNA DAMAGE; SACCHAROMYCES-CEREVISIAE; REGULATORY PHOSPHORYLATION; ALKYLATING-AGENTS; MAMMALIAN-CELLS; HELA-CELLS; RAD9 GENE; MITOSIS	We investigated the temporal regulation of cyclin A- and B1-dependent kinases in human lymphoma cells treated with nitrogen mustard (HN2) and pentoxifylline, to determine whether the activity of these complexes correlated with cell cycle arrest induced by DNA damage. Cells were synchronized in G1/S, treated with HN2, and then postincubated with pentoxifylline. HN2-induced a protracted delay in G2 phase. This delay correlated with suppression of cyclin B1- and cdc2-kinase activities, and stabilization of hyperphosphorylated-cdc2 in the presence of similar cyclin B1 levels to those found in mitosis. HN2 had no discernible effect on the S phase activity of cyclin A- or cdk2-immune complexes. Entry of control cells into mitosis correlated with destruction of cyclin A, disappearance of cyclin A-bound cdk2 and decreased cdk2 kinase activity. G2 delay induced by HN2 was associated with stabilization of cyclin A, increased abundance of cyclin A-bound cdk2, and increased cdk2 activity. Cyclin A was also associated with cdc2, which, contrary to complexes containing cdk2, were only activated upon entry into mitosis. Pentoxifylline abrogated cell cycle arrest induced by aphidicolin and HN2 in human lymphoma cells. Pentoxifylline also reverted the activity of cyclin A- and B1-kinases in HN2-treated cells to approximately that observed in controls. Our findings suggest that delayed entry into mitosis following DNA damage correlates with suppression of cyclin B1/cdc2 and cyclin A/cdc2 complexes, while maintaining cyclin A/cdk2 complexes in an active state. Furthermore, we found that pentoxifylline disrupts the signal transduction pathway that regulates these complexes when damaged DNA is present, resulting in abrogation of cell cycle arrest.	PROGRAM RESOURCES INC DYN CORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD; NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,W-6900 HEIDELBERG,GERMANY; WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; European Molecular Biology Laboratory (EMBL); Salk Institute	OCONNOR, PM (corresponding author), NCI,DIV CANC TREATMENT,MOLEC PHARMACOL LAB,DEV THERAPEUT PROGRAM,RM 5C-19,BLDG 37,BETHESDA,MD 20892, USA.		Longo, Dan L./F-6022-2011	Pines, Jonathon/0000-0002-5227-6004; pagano, michele/0000-0003-3210-2442	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENDIA B, 1991, COLD SPRING HARB SYM, V56, P523; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; DAS SK, 1982, CANCER RES, V42, P4499; DEZUBE BJ, 1990, CANCER RES, V50, P6806; DOWNES CS, 1990, J CELL BIOL, V110, P1855, DOI 10.1083/jcb.110.6.1855; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; FERRIS DK, 1991, CELL GROWTH DIFFER, V2, P343; FINGERT HJ, 1988, CANCER RES, V48, P4375; FINGERT HJ, 1986, CANCER RES, V46, P2463; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KONOPA J, 1988, BIOCHEM PHARMACOL, V37, P2303, DOI 10.1016/0006-2952(88)90355-3; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1990, CANCER RES, V50, P3767; LOCK RB, 1992, CANCER RES, V52, P1817; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LUNDGREN K, 1991, CELL, V64, P111; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORIA AO, 1989, CELL, V58, P193; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Connor P M, 1992, Semin Cancer Biol, V3, P409; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OCONNOR PM, 1991, CANCER RES, V51, P6550; OCONNOR PM, 1989, J BIOL CHEM, V264, P6391; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO PN, 1980, MOL CELL BIOCHEM, V29, P47; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAO YP, 1992, CANCER RES, V52, P1823; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554	74	162	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8298	8308						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463339				2022-12-27	WOS:A1993KW97900103
J	HUPP, TR; KAGUNI, JM				HUPP, TR; KAGUNI, JM			ACTIVATION OF MUTANT FORMS OF DNAA PROTEIN OF ESCHERICHIA-COLI BY DNAK AND GRPE PROTEINS OCCURS PRIOR TO DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; HEAT-SHOCK PROTEINS; BACTERIOPHAGE-LAMBDA; CHROMOSOMAL ORIGIN; INITIATION PROTEIN; GENE-PRODUCT; ENZYMATIC REPLICATION; GROWTH; PURIFICATION; TEMPERATURES	Mutant forms of DnaA protein, inert in a replication system composed of other purified proteins, are ''activated'' by DnaK and GrpE heat shock proteins (Hupp, T. R., and Kaguni, J. M. (1993) J. Biol. Chem. 268, 13137-13142). The effect of these heat shock proteins on DnaA5 and DnaA46 protein was separated from the event of DNA synthesis by incubation in two stages. Components necessary during the first stage for ''activation'' included GrpE and DnaK proteins, ATP at 0.2 mm or greater, and polyvinyl alcohol (8%) or glycerol, optimal at concentrations between 20 and 30%. An ATP regenerating system provided by creatine kinase and creatine phosphate was stimulatory. Addition of the activated form of DnaA5 or DnaA46 protein to a reconstituted system containing other purified replication proteins during the second stage of incubation resulted in DNA replication. Activation of DnaA5 or DnaA46 protein by heat shock proteins was thermolabile, suggesting that the temperature sensitivity of dnaA5 and dnaA46 mutants is related to this thermolabile interaction. A third heat shock protein, DnaJ protein, interfered with the activation of DnaA5 protein if present during the first stage of incubation. This inhibitory effect was less striking if included during the second stage of incubation. These results suggest a mechanism for regulation of the activity of DnaA protein.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1988, NUCLEIC ACIDS RES, V16, P9611, DOI 10.1093/nar/16.20.9611; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANG D, 1991, J BIOL CHEM, V266, P24233; ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BOCHNER BR, 1986, J BACTERIOL, V168, P931, DOI 10.1128/jb.168.2.931-935.1986; BOYE E, 1988, BIOCHIM BIOPHYS ACTA, V951, P359, DOI 10.1016/0167-4781(88)90107-8; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; CHAKRABORTY T, 1982, EMBO J, V1, P1545, DOI 10.1002/j.1460-2075.1982.tb01353.x; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FULLER RS, 1986, CELL, V38, P5616; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; GOMES SL, 1990, J BACTERIOL, V172, P3051, DOI 10.1128/jb.172.6.3051-3059.1990; HANSEN EB, 1984, MOL GEN GENET, V196, P387, DOI 10.1007/BF00436184; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWANG DS, 1990, J BIOL CHEM, V265, P19244; HWANG DS, 1988, J BIOL CHEM, V263, P10625; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; OHKI M, 1989, NUCLEIC ACIDS RES, V17, P3479, DOI 10.1093/nar/17.9.3479; PIERUCCI O, 1989, J BACTERIOL, V171, P3760, DOI 10.1128/jb.171.7.3760-3766.1989; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SAITO H, 1978, MOL GEN GENET, V164, P1, DOI 10.1007/BF00267592; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WANG QP, 1989, J BIOL CHEM, V264, P7338; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; ZIMMERMAN SB, 1988, NUCLEIC ACIDS RES, V16, P6309, DOI 10.1093/nar/16.14.6309; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	63	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13143	13150						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514753				2022-12-27	WOS:A1993LH55300022
J	OGISO, M; IRIE, A; KUBO, H; KOMOTO, M; MATSUNO, T; KOIDE, Y; HOSHI, M				OGISO, M; IRIE, A; KUBO, H; KOMOTO, M; MATSUNO, T; KOIDE, Y; HOSHI, M			CHARACTERIZATION OF NEUTRAL GLYCOSPHINGOLIPIDS IN HUMAN CATARACTOUS LENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SENILE CATARACTS; N-FUCOPENTAOSE-III; SIALIC ACIDS; GANGLIOSIDES; CELLS; ACETYLGLUCOSAMINE; LACTOSYLCERAMIDE; PURIFICATION; RECOGNITION; CERAMIDE	Neutral glycosphingolipids were purified from human senile cataractous lenses by a combination of solvent extraction, Folch's partition, acetylation, and column chromatography using DEAE-Sephadex and Iatrobeads. Six major glycosphingolipids (A-F) from monohexosylceramide to pentahexosylceramide were identified by sugar composition analysis, methylation analysis, secondary ion-mass spectrometry, glycosidase digestion, and chromium trioxide oxidation. Their structures suggested that they were closely related in their metabolism: their sugar chains were in sequence and their ceramide moieties were similarly composed, namely C16:0 and C24:1 constituted most of the fatty acids, and long-chain base components were mostly C18-dihydrosphingosine with a small portion of C18-sphingosine. The sugar chains implied two pathways branching from lactosylceramide: one to globotriaosylceramide and the other to lactotriaosylceramide, which leads to the production of Le(x) glycolipid via neolacto type 2 core chain.	TOHO UNIV, SCH MED, DEPT OPHTHALMOL, TOKYO 143, JAPAN; TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 227, JAPAN; ZENYAKU KOGYO CO LTD, RES LAB, TOKYO 178, JAPAN	Toho University; Tokyo Institute of Technology	OGISO, M (corresponding author), TOHO UNIV, SCH MED, DEPT PHYSIOL, 5-21-16 OHMORI NISHI, OHTA KU, TOKYO 143, JAPAN.							[Anonymous], 1977, Lipids, V12, P455; [Anonymous], 1981, MOL CELLULAR BIOL EY; BASU S, 1970, Federation Proceedings, V29, P410; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; Dickson D.H., 1975, CATARACT ABNORMALITI, P49; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FELDMAN GERALD L., 1965, INVEST OPHTHAL MOL, V4, P162; FELDMAN GL, 1966, LIPIDS, V1, P21, DOI 10.1007/BF02668120; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P294, DOI 10.1007/BF02540132; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; IRIE A, 1990, J BIOCHEM-TOKYO, V108, P531, DOI 10.1093/oxfordjournals.jbchem.a123237; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; KOJIMA N, 1991, Glycobiology, V1, P623, DOI 10.1093/glycob/1.6.623; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; LAINE RA, 1975, J LIPID RES, V16, P102; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; OGISO M, 1990, EXP EYE RES, V50, P51, DOI 10.1016/0014-4835(90)90010-R; OGISO M, 1990, INVEST OPHTH VIS SCI, V31, P2171; OGISO M, 1992, J BIOL CHEM, V267, P6467; SARKAR CP, 1982, BIOCHIM BIOPHYS ACTA, V711, P503, DOI 10.1016/0005-2760(82)90065-0; STEIGERWALD JC, 1975, J BIOL CHEM, V250, P6727; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SWANSON AA, 1978, INTERDISCPL TOPICS G, V12, P241; SWINDELL RT, 1987, CURR EYE RES, V6, P451, DOI 10.3109/02713688709025201; SWINDELL RT, 1988, OPHTHALMIC RES, V20, P232, DOI 10.1159/000266650; TAKI T, 1979, BIOCHIM BIOPHYS ACTA, V572, P113; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; TAO RVP, 1986, CURR EYE RES, V5, P167, DOI 10.3109/02713688609015105; TAO RVP, 1982, CURR EYE RES, V2, P427, DOI 10.3109/02713688208996345; TAO RVP, 1983, BIOCHIM BIOPHYS ACTA, V753, P89, DOI 10.1016/0005-2760(83)90102-9; WINDELER AS, 1970, BIOCHIM BIOPHYS ACTA, V202, P361, DOI 10.1016/0005-2760(70)90199-2; YANG HJ, 1971, J BIOL CHEM, V246, P1192; ZIELENSKI J, 1982, EUR J BIOCHEM, V125, P323, DOI 10.1111/j.1432-1033.1982.tb06686.x	38	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13242	13247						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514762				2022-12-27	WOS:A1993LH55300035
J	BERNARDO, MM; DAY, DE; HALVORSON, HR; OLSON, ST; SHORE, JD				BERNARDO, MM; DAY, DE; HALVORSON, HR; OLSON, ST; SHORE, JD			SURFACE-INDEPENDENT ACCELERATION OF FACTOR-XII ACTIVATION BY ZINC IONS .2. DIRECT BINDING AND FLUORESCENCE STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; COAGULATION FACTOR-XII; HIGH-MR KININOGEN; WASHED HUMAN-PLATELETS; HAGEMAN-FACTOR; BLOOD-COAGULATION; MEDIATED ACTIVATION; CONTACT ACTIVATION; DEPENDENT ACTIVATION; ENDOTHELIAL-CELLS	To determine the role of Zn(II)-factor XII interactions in the rate-enhancing effect of Zn(II) on factor XII activation demonstrated in the preceding paper, equilibrium binding of zinc ions to factor XII, and the spectroscopic changes accompanying this binding were investigated. Equilibrium dialysis provided direct evidence for the binding of Zn(II) to factor XII. The binding data were consistent with 7.8 +/- 0.3 zinc ions binding with an indistinguishable K(d) of 91 +/- 6 muM. Binding of Zn(II) was accompanied by a 10% quenching of the intrinsic protein fluorescence and a 2-nm red shift of the wavelength of maximum emission. These spectroscopic changes were specific for factor XII and were not observed with factor XIIa. The Zn(II) concentration dependence of factor XII fluorescence quenching was sigmoid and paralleled the Zn(II)-accelerating effect on factor XII activation by kallikrein and factor XIIa, indicating that the spectral change was reporting Zn(II)-factor XII interactions responsible for the enhanced activation rate. The apparent cooperativity of Zn(II) effects on factor XII fluorescence quenching and activation kinetics, and the apparent noncooperativity in Zn(II) binding to factor XII measured by equilibrium dialysis could be explained by a two-state model in which Zn(II) binding is linked to a conformational change in the protein. The Zn(II)-induced quenching of factor XII fluorescence exhibited a pH dependence consistent with the involvement of histidine residues in the binding of Zn(II). Dynamic quenching of factor XII protein fluorescence by iodide or acrylamide, in the absence and presence of Zn(II), revealed heterogeneity in the environment of the 13 tryptophan residues of factor XII that was markedly reduced by metal ion binding. Together, these results indicate that cooperative interactions of Zn(II) with factor XII induce structural changes in the zymogen that facilitate its proteolytic cleavage and activation.	HENRY FORD HOSP,DIV BIOCHEM RES,EDUC & RES BLDG,RM 3126,2799 W GRAND BLVD,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								BERNARDO MM, 1993, J BIOL CHEM, V268, P12468; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOCK PE, 1981, BIOCHEMISTRY-US, V20, P7258, DOI 10.1021/bi00528a032; BOUMA BN, 1986, NEW COMPREHENSIVE BI, V13, P103; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COOL DE, 1987, J BIOL CHEM, V262, P13662; CORNISHBOWDEN A, 1975, J MOL BIOL, V95, P201, DOI 10.1016/0022-2836(75)90390-3; DIXON M, 1964, ENZYMES, P84; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ESPANA F, 1983, J LAB CLIN MED, V102, P487; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIEP MA, 1986, BIOCHEMISTRY-US, V25, P6688, DOI 10.1021/bi00369a054; GRIFFIN JH, 1978, P NATL ACAD SCI USA, V75, P1998, DOI 10.1073/pnas.75.4.1998; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; KAPLAN AP, 1987, BLOOD, V70, P1; KOZIN F, 1988, INFLAMMATION BASIC P, P101; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P379; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MCMILLIN CR, 1974, J CLIN INVEST, V54, P1312, DOI 10.1172/JCI107877; MOOZ ED, 1989, PRACTICAL HDB BIOCH, P34; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; NUIGENS JH, 1989, J BIOL CHEM, V264, P12941; ROSING J, 1985, EUR J BIOCHEM, V151, P531, DOI 10.1111/j.1432-1033.1985.tb09135.x; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHOUSBOE I, 1990, EUR J BIOCHEM, V193, P495, DOI 10.1111/j.1432-1033.1990.tb19364.x; SCHOUSBOE I, 1991, EUR J BIOCHEM, V197, P309, DOI 10.1111/j.1432-1033.1991.tb15912.x; SHIMADA T, 1985, J BIOCHEM-TOKYO, V97, P429, DOI 10.1093/oxfordjournals.jbchem.a135077; SHIMADA T, 1987, J BIOCHEM-TOKYO, V102, P913, DOI 10.1093/oxfordjournals.jbchem.a122132; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SHORE JD, 1989, THROMB HAEMOSTASIS, V62, P15; SILVERBERG M, 1987, BIOCHEM J, V248, P715, DOI 10.1042/bj2480715; SUGO T, 1985, EUR J BIOCHEM, V146, P43, DOI 10.1111/j.1432-1033.1985.tb08617.x; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; TANS G, 1986, NEW COMPREHENSIVE BI, V13, P59; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WOO J, 1984, CLIN DIAGNOSIS MANAG, P161	42	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12477	12483						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509387				2022-12-27	WOS:A1993LG65800039
J	CHOW, CM; RAJBHANDARY, UL				CHOW, CM; RAJBHANDARY, UL			SACCHAROMYCES-CEREVISIAE CYTOPLASMIC TYROSYL-TRANSFER RNA-SYNTHETASE GENE - ISOLATION BY COMPLEMENTATION OF A MUTANT ESCHERICHIA-COLI SUPPRESSOR TRANSFER-RNA DEFECTIVE IN AMINOACYLATION AND SEQUENCE-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA-CRASSA; YEAST; RECOGNITION; AMBER; CONSTRUCTION; PARAMETERS; RESOLUTION; ANTICODON; MUTATIONS; PROTEINS	Exploiting differences in tRNA recognition between prokaryotic and eukaryotic tyrosyl-tRNA synthetases (TyrRSs), we have isolated the gene for the cytoplasmic TyrRS of Saccharomyces cerevisiae by functional complementation in Escherichia coli of a mutant E. coli tRNA. The tRNA, derived from the E. coli initiator tRNA with changes to allow suppression of amber termination codons, is poorly aminoacylated in E. coli and hence, is only a weak amber suppressor. The same tRNA functions as a good suppressor in S. cerevisiae and is aminoacylated with tyrosine by yeast extracts. We expressed a yeast cDNA library in an E. coli strain carrying the mutant tRNA gene and several genes with amber mutations. cDNA clones were isolated which increased suppression and levels of amino-acylation of the mutant tRNA. Characterization of the gene identified a methionine-initiated open reading frame encoding a protein of 394 amino acids. Expression of this protein in E. coli demonstrated that tyrosine was incorporated during suppression and that yeast cytoplasmic TyrRS activity was produced. Yeast cytoplasmic TyrRS has sequences typical of class I aminoacyl-tRNA synthetases, but only weak overall sequence similarity to the corresponding eubacterial and mitochondrial TyrRSs. However, many of the residues known to line the tyrosyl-adenylate-binding pocket of the Bacillus stearothermophilus enzyme can be aligned in the yeast sequence. These include the aspartic acid and tyrosine residues thought to contact the tyrosine side chain to provide substrate specificity.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017151, R01GM017151, F32GM017151] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARE LA, 1986, BIOCHEMISTRY-US, V25, P5825, DOI 10.1021/bi00367a072; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BEDOUELLE H, 1990, J BACTERIOL, V172, P3940, DOI 10.1128/jb.172.7.3940-3945.1990; BEIKIRCH H, 1972, EUR J BIOCHEM, V26, P182, DOI 10.1111/j.1432-1033.1972.tb01755.x; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CAPONE JP, 1986, MOL CELL BIOL, V6, P3059, DOI 10.1128/MCB.6.9.3059; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOW CM, 1989, MOL CELL BIOL, V9, P4631, DOI 10.1128/MCB.9.11.4631; CUDNY H, 1986, J BIOL CHEM, V261, P6450; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; EDWARDS H, 1991, P NATL ACAD SCI USA, V88, P1153, DOI 10.1073/pnas.88.4.1153; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FRANCKLYN C, 1992, EUR J BIOCHEM, V206, P315, DOI 10.1111/j.1432-1033.1992.tb16929.x; HECKMAN JE, 1979, P NATL ACAD SCI USA, V76, P717, DOI 10.1073/pnas.76.2.717; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; LEE CP, 1991, P NATL ACAD SCI USA, V88, P11378, DOI 10.1073/pnas.88.24.11378; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8121, DOI 10.1073/pnas.88.18.8121; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PLOHL M, 1988, BIOCHIMIE, V70, P637, DOI 10.1016/0300-9084(88)90247-7; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SEONG BL, 1989, J BIOL CHEM, V246, P6504; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P1547, DOI 10.1093/nar/20.7.1547; SMITH JD, 1973, NATURE-NEW BIOL, V243, P66; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1992, J BACTERIOL, V174, P7819, DOI 10.1128/JB.174.23.7819-7826.1992	43	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12855	12863						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509419				2022-12-27	WOS:A1993LG65800092
J	GLANTZ, SB; LI, Y; RUBIN, CS				GLANTZ, SB; LI, Y; RUBIN, CS			CHARACTERIZATION OF DISTINCT TETHERING AND INTRACELLULAR TARGETING DOMAINS IN AKAP75, A PROTEIN THAT LINKS CAMP-DEPENDENT PROTEIN KINASE-II-BETA TO THE CYTOSKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT; BRAIN; DNA; RII; PHOSPHORYLATION; EXPRESSION; ASSAY; CELLS; SITE	Cyclic AMP-dependent protein kinase IIbeta (PKAIIbeta) is the principal mediator of cAMP action in neurons. A Kinase Anchor Proteins (AKAPs) are enriched in forebrain neurons and have distinct high affinity binding domains for the regulatory subunit (RIIbeta) of PKAIIbeta and components of the dendritic cytoskeleton. The selective accumulation of AKAP.RIIbeta complexes near dendritic microtubules tethers PKAIIbeta in proximity with adenylate cyclase in the synaptic plasma membrane and cytoskeletal proteins that are substrates for the kinase, thereby creating intraneuronal target sites for signals carried by cAMP. We have characterized the targeting (anchoring) and tethering (RIIbeta binding) domains of a prototypic anchor protein AKAP75. Deletion of N-terminal residues 27-48 generated a truncated RIIbeta-binding protein that partitions equally between the cytosol and detergent-insoluble fractions of HEK293 cells. Further removal of a non-adjacent sequence (residues 77-91) produced a cytosolic protein with unimpaired RIIbeta binding activity. Thus, two noncontiguous domains mediate the intracellular localization of AKAP75. Boundaries for the RIIbeta tethering domain were mapped to residues 392-413 by scanning mutagenesis. Residues containing long aliphatic side chains are essential for the high affinity binding of RIIbeta by AKAP75. Contributions of hydrophobic amino acids to tethering activity also depend on the position of the residue in the sequence. Certain conservative mutations that should not alter significantly the overall hydrophobicity or helicity of the tethering region (e.g. replacement of Leu with Ala) diminish the RIIbeta binding activity of AKAP75.			GLANTZ, SB (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,ATRAN LABS,BRONX,NY 10461, USA.				NIGMS NIH HHS [GM07260, GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792, T32GM007260] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI I, 1991, J BIOL CHEM, V267, P3024; BEEBE SJ, 1986, ENZYMES, V17, P44; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; DUMUIS A, 1988, MOL PHARMACOL, V34, P880; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P11; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HEMMINGS HC, 1987, TRENDS NEUROSCI, V10, P377, DOI 10.1016/0166-2236(87)90075-0; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFFMANN A, 1990, NUCLEIC ACIDS RES, V22, P6337; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEISER M, 1986, J BIOL CHEM, V261, P1904; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MCGEER PL, 1987, MOL NEUROBIOLOGY MAM, P162; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; STEIN JC, 1987, J BIOL CHEM, V262, P3002	34	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12796	12804						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509414				2022-12-27	WOS:A1993LG65800084
J	ONRUST, R; ODONNELL, M				ONRUST, R; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .2. CHARACTERIZATION OF DELTA AND DELTA'	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOLOENZYME; TAU; MECHANISM; TEMPLATE; SUBUNITS; GAMMA	The gamma complex subassembly (gammadeltadelta'chipsi) of DNA polymerase III holoenzyme couples ATP to assemble the ring-shaped beta subunit around DNA forming a DNA sliding clamp. This beta clamp is needed for highly processive synthesis by the holoenzyme. Here, the delta and delta' subunits of the gamma complex are studied for their structural and functional interaction with each other and with the gamma subunit. Both delta and delta' are monomeric in their native state, and they bind each other tightly to form a 1:1 complex. Neither delta nor delta' alone binds tightly to the gamma subunit. However, as a complex, deltadelta' binds gamma tightly to form a gammadeltadelta' complex. The fact that all three subunits, gamma, delta, and delta' are needed to form a tight complex correlates well with activity assays which show that gamma and delta are capable but inefficient in assembly of the beta ring onto DNA and delta' is needed for an efficient reaction.	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1991, DNA REPLICATION, P176; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1991, J BIOL CHEM, V266, P21681; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 1970, HDB BIOCHEMISTRY, pC1; STUDWELL PS, 1990, UCLA SYM BI, V127, P153; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1993, J BIOL CHEM, V268, P11779	23	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11766	11772						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505304				2022-12-27	WOS:A1993LF28400047
J	REDDIGARI, SR; SHIBAYAMA, Y; BRUNNEE, T; KAPLAN, AP				REDDIGARI, SR; SHIBAYAMA, Y; BRUNNEE, T; KAPLAN, AP			HUMAN HAGEMAN-FACTOR (FACTOR-XII) AND HIGH-MOLECULAR-WEIGHT KININOGEN COMPETE FOR THE SAME BINDING-SITE ON HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MR KININOGEN; RELAXING FACTOR; ZINC IONS; ACTIVATION; BRADYKININ; RADIOIMMUNOASSAY; PREKALLIKREIN; ACID	Factor XII (FXII, plasma concentration 375 nM) is a critical member of the plasma contact activation system and is the zymogen form of FXII(a), a serine protease involved in intrinsic coagulation, complement activation, activation of factor VII, and generation of the vasoactive peptide bradykinin. As such its interaction with cells involved in inflammatory pathways can be of physiologic and pathologic significance. We have studied the binding of FXII to cultured human umbilical vein endothelial cells (HUVEC). HUVEC were incubated with I-125-FXII, and cell-bound factor FXII was measured. FXII bound to HUVEC saturably in a zinc-dependent manner. The optimal zinc concentration was 50-60 muM. Binding of labeled FXII was drastically reduced when a 200-fold molar excess of unlabeled FXII was included in the incubation mixture at time zero or when added at 60 min during a 150-min time course experiment. Quantitative binding experiments indicated a dissociation constant of 144 nM with 10-12 million binding sites/endothelial cell. Unlabeled high molecular weight kininogen (HK) inhibited the binding of labeled FXII with a K(i) of 98 nM, whereas unlabeled FXII inhibited the binding of labeled HK to HUVEC with a K(i) of 152 nM. SDS-polyacrylamide gel electrophoresis and autoradiography of cell-bound I-125-FXII showed that factor XII underwent limited proteolysis and the molecular weights of the fragments were similar in size to activated FXII. The cell-bound activated factor XII was also able to activate prekallikrein. These data suggest that (i) FXII binds to HUVEC specifically, saturably, and reversibly in a zinc-dependent manner, (ii) HK and FXII may compete with each other for the same cell-surface receptor/s, and (iii) cell-bound FXII is capable of undergoing activation to FXII(a).	NIPPON ZOKI PHARMACEUT CO LTD,INST BIOACT SCI,DIV NAT PROD 1,HYOGO,JAPAN		REDDIGARI, SR (corresponding author), SUNY,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,STONY BROOK,NY 11794, USA.							ADAM A, 1985, CLIN CHEM, V31, P423; ARMSTRONG D, 1970, HDB EXPERIMENTAL PHA, V25, P434; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BHARTHA K, 1989, BIOCHEM J, V263, P149; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOGLE RG, 1991, BIOCHEM BIOPH RES CO, V180, P926, DOI 10.1016/S0006-291X(05)81154-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GINSBERG MH, 1980, J LAB CLIN MED, V95, P497; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; JAFFE EA, 1980, TRANSPL P, V12, P49; KAPLAN AP, 1987, BLOOD, V70, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCEAU F, 1983, GEN PHARMACOL, V14, P209, DOI 10.1016/0306-3623(83)90001-0; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MELONI FJ, 1992, BLOOD, V79, P1233; MORRISON DC, 1974, J EXP MED, V140, P797, DOI 10.1084/jem.140.3.797; MULLER R, 1983, METHOD ENZYMOL, V92, P589; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIKAWA K, 1992, BLOOD, V80, P1980; PASKHINA TS, 1979, HDB EXPT PHARM, P609; PLOW EF, 1985, BLOOD, V66, P724; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; REVAK SD, 1974, J CLIN INVEST, V54, P619, DOI 10.1172/JCI107799; SAMUEL M, 1992, J BIOL CHEM, V267, P19691; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHMEIDLERSAPIRO KT, 1991, P NATL ACAD SCI USA, V88, P4382, DOI 10.1073/pnas.88.10.4382; SCHOUSBOE I, 1990, EUR J BIOCHEM, V193, P495, DOI 10.1111/j.1432-1033.1990.tb19364.x; SCHOUSBOE I, 1991, EUR J BIOCHEM, V197, P309, DOI 10.1111/j.1432-1033.1991.tb15912.x; SHIMADA T, 1985, J BIOCHEM-TOKYO, V97, P429, DOI 10.1093/oxfordjournals.jbchem.a135077; SILVERBERG M, 1987, BIOCHEM J, V248, P715, DOI 10.1042/bj2480715; SIMIONESCU M, 1988, RECEPTOR MEDIATED TR, P69; SPRAGG J, 1973, ANN NY ACAD SCI, V209, P372, DOI 10.1111/j.1749-6632.1973.tb47541.x; Stewart J.M., 1980, BRADYKININ KALLIDIN, P227; STOLPEN AH, 1986, AM J PATHOL, V123, P16; TOLINS JP, 1991, HYPERTENSION, V17, P909, DOI 10.1161/01.HYP.17.6.909; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WIGGINS RC, 1980, J CLIN INVEST, V65, P197, DOI 10.1172/JCI109651	39	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11982	11987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505323				2022-12-27	WOS:A1993LF28400079
J	SUGIMOTO, M; DENT, J; MCCLINTOCK, R; WARE, J; RUGGERI, ZM				SUGIMOTO, M; DENT, J; MCCLINTOCK, R; WARE, J; RUGGERI, ZM			ANALYSIS OF STRUCTURE-FUNCTION-RELATIONSHIPS IN THE PLATELET MEMBRANE GLYCOPROTEIN IB-BINDING DOMAIN OF VONWILLEBRAND-FACTOR BY EXPRESSION OF DELETION MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; PROTEIN-A; DISEASE; IDENTIFICATION; SEQUENCES; BOTROCETIN; FRAGMENT; SITE; IIB; THROMBOSIS	We have used a series of Escherichia coli-expressed deletion mutants of the glycoprotein (GP) Ib-binding domain of von Willebrand factor (vWF) to study the structural basis of its function. In addition to the prototypic molecule (rvWF441-733), we constructed 11 mutants; seven had deletions of sequence on the amino and/or carboxyl-terminal side of the Cys509-Cys695 intrachain disulfide loop, and four had limited deletions inside the loop. Other cysteine residues in addition to 509 and 695, when present in the corresponding native sequence, were mutated to glycine; all molecules were purified in the oxidized as well as reduced and alkylated state. The smallest species retaining the ability to interact with GP Ib in the absence of modulators was the oxidized rvWF508-696; the latter, as well as rvWF441-696, became inactive after reduction and alkylation. In contrast, all the other fragments with deletions outside of the loop, but extending at least to residue 700, showed better binding to platelets after reduction and alkylation than when the Cys509-Cys695 disulfide bond was oxidized. Any limited deletion of sequence inside the loop caused complete loss of GP Ib-binding function both in the absence or in the presence of botrocetin, and this persisted even after reduction and alkylation. In contrast, all mutants with intact sequence between residues 509 and 695 bound to GP Ib in the presence of botrocetin, regardless of whether the 2 cysteine residues were oxidized or reduced and alkylated. Ristocetin, unlike botrocetin, appeared to have no effect in modulating the binding of any of the expressed fragments to platelets. Our findings suggest that the GP Ib-binding domain of vWF contains multiple interaction sites, but integrity of the sequence 509-695 is important for function.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEVRIADOU RB, 1993, BLOOD, V81, P1263; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1993, J BIOL CHEM, V268, P2821; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BERNDT MC, 1992, BIOCHEMISTRY-US, V31, P11144, DOI 10.1021/bi00160a027; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; FUJIMURA Y, 1987, BLOOD, V70, P985; FUSTER V, 1978, J CLIN INVEST, V61, P722, DOI 10.1172/JCI108985; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; GRALNICK HR, 1992, P NATL ACAD SCI USA, V89, P7880, DOI 10.1073/pnas.89.17.7880; HANDA M, 1986, J BIOL CHEM, V261, P2579; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NICHOLS TC, 1986, CIRC RES, V59, P15, DOI 10.1161/01.RES.59.1.15; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUGGERI ZM, 1987, BLOOD, V70, P895; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946	41	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12185	12192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505338				2022-12-27	WOS:A1993LF28400106
J	WEBSTER, MK; GOYA, L; FIRESTONE, GL				WEBSTER, MK; GOYA, L; FIRESTONE, GL			IMMEDIATE-EARLY TRANSCRIPTIONAL REGULATION AND RAPID MESSENGER-RNA TURNOVER OF A PUTATIVE SERINE THREONINE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; CELL-CYCLE; 3T3 CELLS; C-FOS; MOUSE FIBROBLASTS; GENE-EXPRESSION; RAT FIBROBLASTS; ONCOGENE; JUN; SEQUENCE	Serine/threonine protein kinases are important regulators of diverse cellular processes including metabolism, proliferation, and differentiation. We have previously identified the cDNA for a 49-kDa serine/threonine kinase, designated sgk, which is transcriptionally responsive to glucocorticoid hormones and serum in epithelial cells. We report here that sgk expression is also rapidly induced by dexamethasone or serum in Rat2 fibroblasts. Nuclear run-on and Northern blot analysis revealed that the induction of sgk mRNA is an immediate-early transcriptional response to serum stimulation of quiescent fibroblasts, which occurs just after the peak in c-jun transcription. In contrast to the glucocorticoid-stimulated sgk expression in Rat2 fibroblasts, the transcriptional induction of sgk by serum was transient and sgk transcripts decayed with a particularly rapid half-life of 20 min. The rapid turnover of sgk, in combination with its immediate-early transcriptional response to serum, suggests a novel mechanism for responding to mitogenic signals during G(o), to S transition and entry into the cell cycle.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BOX 591 LSA, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Goya, Luis/H-5735-2012	Goya, Luis/0000-0001-9449-6200	NCI NIH HHS [CA-05388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; COOK PW, 1988, J BIOL CHEM, V263, P19296; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LACY J, 1989, EMBO J, V8, P1973, DOI 10.1002/j.1460-2075.1989.tb03603.x; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; Witters LA, 1990, CURR OPIN CELL BIOL, V2, P212, DOI 10.1016/0955-0674(90)90009-4	20	152	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11482	11485						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505283				2022-12-27	WOS:A1993LF28400003
J	BIDEN, TJ; DAVISON, AGM; PRUGUE, ML				BIDEN, TJ; DAVISON, AGM; PRUGUE, ML			REGULATION BY MEMBRANE-POTENTIAL OF PHOSPHATIDYLINOSITOL HYDROLYSIS IN PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INOSITOL 1,4,5-TRISPHOSPHATE; INSULIN-SECRETION; B-CELLS; SIGNAL TRANSDUCTION; GLUCOSE; CA-2+; K+; TRISPHOSPHATE; PHOSPHATES	In pancreatic islets stimulated with carbamylcholine (carbachol), hydrolysis of both phosphatidylinositol (PtdIns) and phosphatidylinositol bisphosphate (PtdInsP2) occurs and can be measured as the inositol monophosphates Ins(1)P1, or Ins(4)P1, respectively (Biden, T. J., Prugue, M. L., and Davison, A. G. M. (1992) Biochem. J. 285, 541-549). Our current aim was to establish whether these two events were independently regulated. Rat islets were labeled with either [H-3]inositol or [H-3]arachidonic acid for measurement of InsP1s by high performance liquid chromatography or diacylglycerol by TLC, respectively. The rise in Ins(1)P1 due to carbachol (1 min) was inhibited by 50% by concomitantly raising extracellular KCl ([K+]e) from 6 to 30 mM, thereby depolarizing the islets. Similiar results, obtained in the absence of extracellular Ca2+, exclude the involvement of voltage-gated Ca2+ channels. Conversely, hyperpolarization, by lowering [K+]e to 3 mM, increased by 30% the rise in Ins(1)P1. In fact, over the [K+]e range of 3 to 48 mM, stimulated Ins(1)P1 accumulation was directly proportional to the calculated membrane potential. In contrast, raising [K+]e from 6 to 48 mM exerted no significant effect on carbachol-stimulated Ins(4)P1 levels, and both Ins(1)P1 and Ins(4)P1 were unaffected in the absence of carbachol. rhe rises in Ins(1)P1 (but not Ins(4)P1) were also inhibited by depolarization with the sodium pump inhibitor, ouabain, or the K+ channel blocker, tolbutamide. Stimulated diacylglycerol accumulation and insulin secretion (20 min) showed a biphasic dependency on [K+]e, being less pronounced at 6 mM than at either 3 or 30 mM KCl. This reflects a selective potentiation of PtdIns and PtdInSP2 hydrolysis, due, respectively, to hyperpolarization and the gating of voltage-dependent Ca2+ channels. The differential regulation of these two hydrolytic events is probably important for independent control of the activation of protein kinase C and Ca2+ mobilization and might play a role in modulating the secretory response in vivo.			BIDEN, TJ (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA.		Biden, Trevor/AAW-2829-2021; Davison, Aidan GM/N-3863-2013	Davison, Aidan GM/0000-0002-5618-7068; Biden, Trevor/0000-0001-5211-0234				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIDEN TJ, 1992, BIOCHEM J, V285, P541, DOI 10.1042/bj2850541; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; CAPIOD T, 1987, FEBS LETT, V217, P247, DOI 10.1016/0014-5793(87)80672-5; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; EASOM RA, 1990, J BIOL CHEM, V265, P14938; EBERHARD DA, 1987, J NEUROCHEM, V49, P1634, DOI 10.1111/j.1471-4159.1987.tb01037.x; FISHER SK, 1990, MOL PHARMACOL, V38, P54; HENQUIN JC, 1982, J PHYSIOL-LONDON, V332, P529, DOI 10.1113/jphysiol.1982.sp014429; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HERMANS MP, 1989, DIABETES, V38, P198, DOI 10.2337/diabetes.38.2.198; HIGASHIDA H, 1986, NATURE, V323, P333, DOI 10.1038/323333a0; HUGHES AR, 1989, J BIOL CHEM, V264, P9400; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MEISSNER HP, 1978, FEBS LETT, V94, P87, DOI 10.1016/0014-5793(78)80912-0; MORGAN NG, 1985, BIOCHEM J, V228, P713, DOI 10.1042/bj2280713; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PITTET D, 1990, J BIOL CHEM, V265, P14256; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANA RS, 1986, J BIOL CHEM, V261, P5237; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; TAKUWA Y, 1986, J BIOL CHEM, V261, P4670; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANDONGEN CJ, 1985, ANAL BIOCHEM, V144, P104, DOI 10.1016/0003-2697(85)90090-9; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLF BA, 1988, J BIOL CHEM, V263, P3565; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; WOLLHEIM CB, 1980, ENDOCRINOLOGY, V107, P924, DOI 10.1210/endo-107-4-924	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11065	11072						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496168				2022-12-27	WOS:A1993LD46600053
J	SHAW, JP; REKIK, M; SCHWAGER, F; HARAYAMA, S				SHAW, JP; REKIK, M; SCHWAGER, F; HARAYAMA, S			KINETIC-STUDIES ON BENZYL ALCOHOL-DEHYDROGENASE ENCODED BY TOL PLASMID-PWWO - A MEMBER OF THE ZINC-CONTAINING LONG-CHAIN ALCOHOL-DEHYDROGENASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPPER-PATHWAY OPERON; PSEUDOMONAS-PUTIDA; ACINETOBACTER-CALCOACETICUS; BENZALDEHYDE DEHYDROGENASE; POLYOL DEHYDROGENASES; SIMILARITY SEARCHES; TERNARY COMPLEX; LIVER; PURIFICATION; BINDING	The nucleotide sequence of the structural gene for benzyl alcohol dehydrogenase encoded by TOL plasmid pWWO of Pseudomonas putida has been determined. Benzyl alcohol dehydrogenase is a member of the long-chain zinc alcohol dehydrogenase family and, like other alcohol dehydrogenases of this family, contains two zinc atoms per subunit. Benzyl alcohol dehydrogenase, while sharing 31% identical residues with horse liver alcohol dehydrogenase, contains several amino acid substitutions near the active site, some of which may be responsible for the substrate specificity of benzyl alcohol dehydrogenase, which oxidizes exclusively aromatic substrates. Benzyl alcohol dehydrogenase also notably lacks the His51 residue of horse liver alcohol dehydrogenase. Contrary to the results obtained with a mutant human liver alcohol dehydrogenase lacking this residue, the concentration and pK(a) of solvent proton acceptors had no effect on the catalytic efficiency of benzyl alcohol dehydrogenase. The electronic nature of substituents on the aromatic ring of the substrate influenced the k(cat) of the enzyme in low concentrations of external proton acceptor, but not in high concentrations. Product inhibition studies demonstrated that benzyl alcohol dehydrogenase followed a general Ordered Bi Bi kinetic mechanism in low proton acceptor conditions, while following a Theorell-Chance kinetic mechanism at high proton acceptor conditions.	CTR MED UNIV GENEVA,DEPT BIOCHIM MED,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva				Harayama, Shigeaki/0000-0003-2103-7796				BORRAS T, 1989, BIOCHEMISTRY-US, V28, P6133, DOI 10.1021/bi00441a001; Branden C.-I., 1975, ENZYMES, V11, P103; CHALMERS RM, 1991, BIOCHEM J, V273, P99, DOI 10.1042/bj2730099; CHALMERS RM, 1990, J GEN MICROBIOL, V136, P637, DOI 10.1099/00221287-136-4-637; CHALMERS RM, 1989, BIOCHEM J, V263, P913, DOI 10.1042/bj2630913; Cleland W. W, 1970, ENZYMES, V2, P1; DEPOUPLANA LR, 1991, BIOCHEM J, V276, P433, DOI 10.1042/bj2760433; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; EKLUND H, 1990, EUR J BIOCHEM, V193, P303, DOI 10.1111/j.1432-1033.1990.tb19337.x; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; EKLUND H, 1982, BIOCHEMISTRY-US, V21, P4858, DOI 10.1021/bi00263a005; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; GOULD RM, 1990, BIOCHEMISTRY-US, V29, P5463, DOI 10.1021/bi00475a009; HAMMETT LP, 1940, PHYSICAL ORGANIC CHE; HARAYAMA S, 1986, J BACTERIOL, V167, P455, DOI 10.1128/jb.167.2.455-461.1986; HARAYAMA S, 1989, J BACTERIOL, V171, P5048, DOI 10.1128/jb.171.9.5048-5055.1989; HARAYAMA S, 1990, MOL GEN GENET, V221, P113, DOI 10.1007/BF00280375; HIGGINS DG, 1988, GENE AMST, V73, P351; HURLEY TD, 1990, ENZYMOLOGY MOL BIOL; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARCH J, 1985, ADV ORG CHEM, P242; NIEDLE E, 1992, EUR J BIOCHEM, V204, P113; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; PLAPP BV, 1978, J MOL BIOL, V122, P23, DOI 10.1016/0022-2836(78)90105-5; PLAPP BV, 1990, ENZYMOLOGY MOL BIOL, V3, P76; RUDOLPH FB, 1980, METHOD ENZYMOL, V63, P411; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOPES RK, 1983, FEBS LETT, V156, P303, DOI 10.1016/0014-5793(83)80517-1; Segel I.H., 1975, ENZYME KINETICS; SHAW JP, 1990, EUR J BIOCHEM, V191, P705, DOI 10.1111/j.1432-1033.1990.tb19179.x; SHAW JP, 1992, BIOCHEM J, V283, P789, DOI 10.1042/bj2830789; SHAW JP, 1992, EUR J BIOCHEM, V209, P51, DOI 10.1111/j.1432-1033.1992.tb17260.x; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; THEORELL H, 1951, ACTA CHEM SCAND, V5, P1127, DOI 10.3891/acta.chem.scand.05-1127; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; WRATTEN CC, 1965, BIOCHEMISTRY-US, V4, P2442, DOI 10.1021/bi00887a025; YIN SJ, 1984, BIOCHEMISTRY-US, V23, P5847, DOI 10.1021/bi00319a026; YOU KS, 1985, CRC CR REV BIOCH MOL, V17, P313, DOI 10.3109/10409238509113625	44	41	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10842	10850						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496150				2022-12-27	WOS:A1993LD46600023
J	WU, SY; GUPTA, S; CHATTERJEE, N; HILEMAN, RE; KINZY, TG; DENSLOW, ND; MERRICK, WC; CHAKRABARTI, D; OSTERMAN, JC; GUPTA, NK				WU, SY; GUPTA, S; CHATTERJEE, N; HILEMAN, RE; KINZY, TG; DENSLOW, ND; MERRICK, WC; CHAKRABARTI, D; OSTERMAN, JC; GUPTA, NK			CLONING AND CHARACTERIZATION OF COMPLEMENTARY-DNA ENCODING THE EUKARYOTIC INITIATION FACTOR-2-ASSOCIATED 67-KDA PROTEIN (P(67))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; FACTOR-II; PHOSPHORYLATION; POLYPEPTIDE; INHIBITION; SEQUENCE; KINASE	The eukaryotic initiation factor 2 (eIF-2)-associated 67-kDa glycoprotein (p67) protects eIF-2 alpha-subunit from inhibitory phosphorylation by eIF-2 kinases, such as heme-regulated inhibitor and double-stranded RNA-activated inhibitor. This promotes protein synthesis in the presence of eIF-2 kinases present in animal cells (Ray, M. K., Datta, B., Chakraborty, A., Chattopadhyay, A., Meza-Keuthen, S., and Gupta, N. K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 539-543). In this study, the primary structure of rat p67 is determined by cDNA cloning. Based on the partial amino acid sequences of overlapping tryptic and cyanogen bromide cleaved fragments, degenerate oligonucleotides were synthesized and used as primers for the polymerase chain reaction to amplify the corresponding p67 cDNA fragment from rat liver first strand cDNA. The amplified DNA was then used as a probe to screen a rat tumor hepatoma (KRC-7) cDNA library, and a positive clone covering the entire coding region was obtained. From the cDNA sequence, an open reading frame that encodes p67 as a 480-amino acid protein with a molecular mass of 53 kilodaltons was predicted for the unglycosylated protein. The cloned cDNA was further characterized by in vitro transcription-coupled translation in micrococcal nuclease-treated reticulocyte lysate. The translated product migrated similarly to p67 in SDS-polyacrylamide gel electrophoresis and was precipitated with antibodies against p67. Northern blot analysis of rat liver poly(A)+ RNA showed a single size class (approximately 2 kilobases) of mRNA. The deduced amino acid sequence of the protein showed a highly charged N-terminal region composed of two basic polylysine blocks and an acidic aspartic acid block. The protein also exhibits significant sequence identity in the N-terminal region with human eIF-2 beta-subunit.	UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588; UNIV NEBRASKA,SCH BIOL SCI,LINCOLN,NE 68588; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; UNIV FLORIDA,DEPT INFECT DIS,GAINESVILLE,FL 32611; UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,GAINESVILLE,FL 32611	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Case Western Reserve University; State University System of Florida; University of Florida; State University System of Florida; University of Florida			Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022079, R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26796, GM22079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V281, P157; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DENSLOW ND, 1992, 6TH S PROTE SOC SAN, P61; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; GUPTA NK, 1991, 15TH INT C BIOCH JER, P146; GUPTA NK, 1987, TRANSLATIONAL REGULA, P287; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; RANSONE LJ, 1988, J VIROL, V62, P3551, DOI 10.1128/JVI.62.10.3551-3557.1988; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER RJ, 1985, P NATL ACAD SCI USA, V82, P4321, DOI 10.1073/pnas.82.13.4321; SCOTT MG, 1988, BIOCHEM BIOPH RES CO, V155, P1353, DOI 10.1016/S0006-291X(88)81290-7; SIEKIERKA J, 1985, P NATL ACAD SCI USA, V82, P1259	24	57	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10796	10801						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496145				2022-12-27	WOS:A1993LD46600016
J	BUTOR, C; DIAZ, S; VARKI, A				BUTOR, C; DIAZ, S; VARKI, A			HIGH-LEVEL O-ACETYLATION OF SIALIC ACIDS ON N-LINKED OLIGOSACCHARIDES OF RAT-LIVER MEMBRANES - DIFFERENTIAL SUBCELLULAR-DISTRIBUTION OF 7-O-ACETYL AND 9-O-ACETYL GROUPS AND OF ENZYMES INVOLVED IN THEIR REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-ORTHO-ACETYLATION; BOMBARDMENT MASS-SPECTROMETRY; HEPATIC GOLGI FRACTIONS; HUMAN-MELANOMA CELLS; GANGLIOSIDE 9-O-ACETYL-GD3; LIQUID-CHROMATOGRAPHY; ACETYLNEURAMINIC ACID; PURIFICATION; GLYCOPROTEIN; RESIDUES	O-Acetylation of sialic acids has previously been considered an uncommon modification found on certain salivary mucins and neural gangliosides. We show here that glycosidically bound sialic acids from total membranes of rat liver have surprisingly high levels (approximately 20%) of O-acetylation at the 7- or 9-position. This O-acetylation is further enriched in N-linked oligosaccharides but is barely detectable in ganglioside fractions from the same tissue. The position of O-acetylation on the sialic acid side chain varies between different subcellular fractions. In particular, 7-O-acetylation was enriched in lysosomal membranes and 9-O-acetylation in plasma membranes, whereas Golgi membranes contained both types. This distribution fits with the ability of the rat liver sialate:O-acetyltransferase(s) to synthesize both 7- and 9-O-acetyl esters (Diaz, S., Higa, H. H., Hayes, B. K., and Varki, A. (1989) J. Biol. Chem. 264, 19416-19426) and the fact that 7-O-acetyl esters can migrate to the 9-position at physiological temperature but only under neutral or mildly alkaline conditions. Subcellular fractionation shows that sialate:O-acetyltransferase activity directed toward endogenous acceptors is enriched in Golgi fractions, whereas an intralumenal sialic acid-specific O-acetylesterase activity is not. The O-acetyltransferase is labile and difficult to solubilize in the intact state and cannot be assayed with exogenous acceptors. However, a prelabeled [H-3]acetyl intermediate can be solubilized from Golgi membranes with Triton X-100 and is stable for a prolonged time in the cold. In contrast to the transferase, the lumenal esterase is easily released in a stable and water-soluble form from membrane fractions by saponin permeabilization or repeated freeze-thaw. In keeping with this finding, differential subcellular fractionation and continuous sucrose gradients indicate that this enzyme is enriched in lysosomal fractions (see also the accompanying paper (Butor, C., Higa, H. H., and Varki, A. (1993) J. Biol. Chem. 268, 10207-10213). Based upon findings reported in this and previous studies, a model is proposed for the biosynthesis, maturation, and turnover of 7- and 9-O-acetyl esters on the sialic acids of N-linked oligosaccharides that are attached to membrane-bound proteins in the rat liver.	UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; SAN DIEGO VET AFFAIRS MED CTR, SAN DIEGO, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARMSTRONG JM, 1985, ARCH BIOCHEM BIOPHYS, V238, P619, DOI 10.1016/0003-9861(85)90207-3; BAME KJ, 1986, J BIOL CHEM, V261, P127; BERGERON JJM, 1985, BIOCHIM BIOPHYS ACTA, V821, P393, DOI 10.1016/0005-2736(85)90043-4; BONAFEDE DM, 1989, LIPIDS, V24, P680, DOI 10.1007/BF02535204; BRETZ R, 1980, J CELL BIOL, V84, P87, DOI 10.1083/jcb.84.1.87; BUTOR C, 1993, J BIOL CHEM, V268, P10207; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CORFIELD AP, 1981, BIOCHEM J, V197, P293, DOI 10.1042/bj1970293; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; HANAOKA K, 1989, J BIOL CHEM, V264, P9842; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HIGA HH, 1989, J BIOL CHEM, V264, P19435; HIGA HH, 1987, BIOCHEM BIOPH RES CO, V144, P1099, DOI 10.1016/0006-291X(87)91425-2; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIGA HH, 1989, METHOD ENZYMOL, V179, P409; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MANZI AE, 1990, J BIOL CHEM, V265, P13091; NEUBERGER A, 1973, BIOCHEM J, V133, P623, DOI 10.1042/bj1330623; NEUBERGER A, 1972, BIOCHEM J, V129, P683, DOI 10.1042/bj1290683; OHSUMI Y, 1983, J BIOCHEM, V93, P547; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; REUTER G, 1983, EUR J BIOCHEM, V134, P139, DOI 10.1111/j.1432-1033.1983.tb07542.x; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; ROUX L, 1988, J BIOL CHEM, V263, P8879; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SANDERWEWER M, 1982, ADV EXP MED BIOL, V152, P215; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1989, J BIOCHEM-TOKYO, V106, P143, DOI 10.1093/oxfordjournals.jbchem.a122804; SCHAUER R, 1970, H-S Z PHYSIOL CHEM, V351, P749, DOI 10.1515/bchm2.1970.351.1.749; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SONNINO S, 1982, ADV EXP MED BIOL, V152, P55; TABAS I, 1979, J BIOL CHEM, V254, P1655; THURIN J, 1985, J BIOL CHEM, V260, P4556; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1986, P NATL ACAD SCI USA, V83, P882, DOI 10.1073/pnas.83.4.882; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1983, J BIOL CHEM, V258, P2465; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WARREN L, 1959, J BIOL CHEM, V234, P1971; WARREN L, 1966, METHOD ENZYMOL, V8, P131	58	80	80	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10197	10206						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486687				2022-12-27	WOS:A1993LB80000039
J	PAREEK, S; SUTER, U; SNIPES, GJ; WELCHER, AA; SHOOTER, EM; MURPHY, RA				PAREEK, S; SUTER, U; SNIPES, GJ; WELCHER, AA; SHOOTER, EM; MURPHY, RA			DETECTION AND PROCESSING OF PERIPHERAL MYELIN PROTEIN PMP22 IN CULTURED SCHWANN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOOTH DISEASE TYPE-1A; NERVOUS-SYSTEM MYELIN; ARREST-SPECIFIC GENE; SCIATIC-NERVE; GROWTH ARREST; CYCLIC-AMP; EXPRESSION; GLYCOPROTEIN; RECEPTOR; INVITRO	Peripheral myelin protein, 22 kDa (PMP22), is a myelin molecule associated with Schwann cells in peripheral nerves (Snipes, G. J., Suter, U., Welcher, A. A., and Shooter, E. M. (1992) J. Cell Biol. 117, 225-238). Mutations affecting the PMP22 gene have been implicated in the trembler mutation in mice (Suter, U., Welcher, A. A., Ozcelik, T., Snipes, G. J., Kosaras, B., Francke, U., Billings-Gagliardi, S., Sidman, R. L., and Shooter, E. M. (1992) Nature 356, 241-244; Suter, U., Moskow, J. J., Welcher, A. A., Snipes, G. J., Kosaras, B., Sidman, R. L., Buchberg, A. M., and Shooter, E. M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4382-4386) and Charcot-Marie-Tooth Disease in humans (Patel, P. I., Roa, B. B., Welcher, A. A., Schoener-Scott, R., Trask, B. J., Pentao, L., Snipes, G. J., Garcia, C. A., Francke, U., Shooter, E. M., Lupski, J. R., and Suter, U. (1992) Nature genet. 1, 159-165). In this report, we have studied PMP22 production in cultured rat Schwann cells. Schwann cells contain a 1.8-kilobase mRNA transcript coding for PMP22, and its production is up-regulated in vitro by forskolin. Metabolic labeling combined with immunoprecipitation methods using antibodies raised against synthetic peptides of PMP22 reveal that Schwann cells generate the protein from an 18-kDa precursor form which is post-translationally modified by N-linked glycosylation. A second molecule (molecular mass, 48 kDa) that reacted with PMP22 antibodies was also detected in Schwann cells but is not related chemically to PMP22 as determined by pulse-chase labeling. Metabolic labeling of rat sciatic nerve and Western blot analyses of purified rat sciatic nerve myelin reveal that deglycosylation of PMP22 gives rise to an 18-kDa protein similar in size to that in Schwann cells. These results indicate that cultured Schwann cells may provide a good model in which to investigate the production and function of PMP22 and to establish the cellular basis for the protein's involvement in inherited peripheral neuropathies.	MCGILL UNIV,MONTREAL NEUROL INST,3801 UNIV AVE,MONTREAL H3A 2B4,QUEBEC,CANADA; MCGILL UNIV,FAC MED,MONTREAL H3A 2B4,QUEBEC,CANADA; SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305	McGill University; McGill University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Stanford University; Stanford University			Suter, Ueli/A-1624-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRAWAL HC, 1983, J BIOL CHEM, V258, P6556; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BARONVANEVERCOOREN A, 1986, DEV NEUROSCI-BASEL, V8, P182, DOI 10.1159/000112252; BROCKES JP, 1980, J NEUROCYTOL, V9, P67, DOI 10.1007/BF01205227; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVISON AN, 1961, BIOCHEM J, V78, P272, DOI 10.1042/bj0780272; DELEON M, 1991, J NEUROSCI RES, V29, P437; EVERLY JL, 1973, J NEUROCHEM, V21, P329, DOI 10.1111/j.1471-4159.1973.tb04253.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; GOULD RM, 1977, J CELL BIOL, V75, P326, DOI 10.1083/jcb.75.2.326; HOOGENDIJK JE, 1991, HUM GENET, V88, P215, DOI 10.1007/BF00206075; IKENAKA K, 1992, J NEUROCHEM, V58, P2248, DOI 10.1111/j.1471-4159.1992.tb10970.x; KITAMURA K, 1981, GLYCOCONJUGATES, P273; LEBLANC AC, 1987, MOL BRAIN RES, V2, P57, DOI 10.1016/0169-328X(87)90021-0; Lees M., 1984, MYELIN, P197; LEMKE G, 1988, DEVELOPMENT, V102, P499; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATA M, 1990, J NEUROCYTOL, V19, P432, DOI 10.1007/BF01188409; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MATTHIEU JM, 1975, BIOCHIM BIOPHYS ACTA, V392, P167, DOI 10.1016/0304-4165(75)90177-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIRSKY R, 1990, DEVELOPMENT, V109, P105; MIRSKY R, 1980, J CELL BIOL, V84, P483, DOI 10.1083/jcb.84.3.483; MITCHELL LS, 1990, J NEUROSCI RES, V27, P125, DOI 10.1002/jnr.490270202; MORELL P, 1989, BASIC NEUROCHEMISTRY, P109; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MORRISON S, 1991, J NEUROCYTOL, V20, P769, DOI 10.1007/BF01187850; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; SAMBROOK J, 1989, MOL CLONING LABORTOR; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHUMAN S, 1988, J NEUROCHEM, V50, P190, DOI 10.1111/j.1471-4159.1988.tb13248.x; SINGH H, 1976, BIOCHIM BIOPHYS ACTA, V448, P325, DOI 10.1016/0005-2736(76)90246-7; SKRE H, 1974, CLIN GENET, V6, P98; SMITH ME, 1982, J NEUROCHEM, V38, P1044, DOI 10.1111/j.1471-4159.1982.tb05346.x; SMITH ME, 1986, J NEUROCHEM, V47, P924; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SOBUE G, 1986, BRAIN RES, V362, P23, DOI 10.1016/0006-8993(86)91394-6; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; STEFANSSON K, 1982, BRAIN RES, V234, P309, DOI 10.1016/0006-8993(82)90871-X; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; TIMSIT SG, 1992, J NEUROCHEM, V58, P1172, DOI 10.1111/j.1471-4159.1992.tb09378.x; TOMA JG, 1992, J NEUROSCI, V12, P2504; TRAPP BD, 1988, J NEUROSCI, V8, P3515; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WIGGINS RC, 1980, J NEUROCHEM, V34, P627, DOI 10.1111/j.1471-4159.1980.tb11190.x; WOOD JG, 1974, J NEUROCHEM, V22, P627, DOI 10.1111/j.1471-4159.1974.tb04273.x; YAZAKI T, 1992, FEBS LETT, V307, P361, DOI 10.1016/0014-5793(92)80713-Q	56	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10372	10379						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486695				2022-12-27	WOS:A1993LB80000060
J	SJOBERG, ER; VARKI, A				SJOBERG, ER; VARKI, A			KINETIC AND SPATIAL INTERRELATIONSHIPS BETWEEN GANGLIOSIDE GLYCOSYLTRANSFERASES AND O-ACETYLTRANSFERASE(S) IN HUMAN-MELANOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GOLGI; DE-ORTHO-ACETYLATION; ASPARAGINE-LINKED OLIGOSACCHARIDES; BREFELDIN-A; SIALIC-ACID; O-ACETYLATION; CARBOHYDRATE LIGAND; GD3 GANGLIOSIDE; GERMINAL CELLS; UDP-GALACTOSE	The melanoma-associated disialogangliosides 9(7)-O-acetyl-G(D3) and 9(7)-O-acetyl-G(D2) have been structurally well characterized. However, the compartmentalization and sequence of action of the biosynthetic activities responsible for synthesizing these molecules remain obscure. Here, we have studied the spatial and temporal interrelationships among the activities responsible for the later stages of ganglioside biosynthesis and those for O-acetylation in cultured human melanoma cells. First, brefeldin A treatment was used to separate biosynthetic steps into compartments distal or proximal to the transport block imposed by the drug. In keeping with prior reports, G(M2)/G(D2) synthase was consistently rendered inaccessible to its acceptors G(M3) and G(D3). In contrast, the effect on G(D3) biosynthesis was cell line-specific. Synthesis of G(D3) was nearly abrogated in two lines, while it accumulated in a third line. This indicates that the spatial organization of ganglioside processing activities can vary even between similar cell lines. However, in all cell lines studied, the ratio of 9(7)-O-acetyl-G(D3) to G(D3) was not changed by brefeldin A, indicating that the majority of ganglioside O-acetyltransferase activity is co-localized with G(D3) biosynthetic activity in the same Golgi subcompartment(s). As an alternative approach, Golgi-enriched fractions from melanoma cells were incubated with radiolabeled and nonlabeled nucleotide sugars or acetyl-CoA. In these preparations, biosynthesis is dependent upon the co-localization of appropriate sugar nucleotide transporters, glycosyltransferases, and acceptors that are endogenously present within intact topologically correct compartments. Incubations with CMP-Neu5Ac and acetyl-CoA corroborated the results with brefeldin A, co-localizing ganglioside O-acetyltransferase activity in compartments where G(D3) biosynthesis takes place. Analyses with CMP-Neu5Ac and UDP-GalNAc showed that G(D2) and G(D3) synthesis occur in partially overlapping compartments. Labeling with acetyl-CoA and UDP-GalNAc indicated that although labeled acetate can be transferred from acetyl-CoA directly to G(D2), ganglioside O-acetyltransferase activity does not substantially overlap with the biosynthetic compartment(s) for G(D2). Instead, O-acetyl-G(D3) appears to be co-localized with the compartment of G(D2) biosynthesis and serves as an acceptor for G(D2) synthase. Thus, both 9-O-acetyl-G(D3) and G(D2) can be precursors of 9-O-acetyl-G(D2), but apparently in distinct compartments.	UNIV CALIF SAN DIEGO, SCH MED, CTR CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU M, 1991, CARBOHYD RES, V209, P261, DOI 10.1016/0008-6215(91)80162-G; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; BEYER TA, 1979, J BIOL CHEM, V254, P2531; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BRETZ R, 1980, J CELL BIOL, V84, P87, DOI 10.1083/jcb.84.1.87; BUSAM K, 1986, EUR J BIOCHEM, V160, P23, DOI 10.1111/j.1432-1033.1986.tb09934.x; CACAN R, 1984, BIOCHEM J, V224, P277, DOI 10.1042/bj2240277; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DAWSON G, 1990, CANCER CELL-MON REV, V2, P327; DAWSON G, 1986, CHEM PHYS LIPIDS, V42, P105, DOI 10.1016/0009-3084(86)90046-0; DAWSON G, 1978, GLYCOCONJUGATES, P287; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DIXON SJ, 1987, J CELL BIOL, V105, P1153, DOI 10.1083/jcb.105.3.1153; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1983, METHOD ENZYMOL, V98, P1; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FLEISCHER B, 1989, METHOD ENZYMOL, V174, P173; Ghidoni R, 1984, Adv Exp Med Biol, V174, P307; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANAI N, 1988, J BIOL CHEM, V263, P6296; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HENDRICKS LC, 1992, EUR J CELL BIOL, V58, P202; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IBER H, 1992, GLYCOBIOLOGY, V2, P137, DOI 10.1093/glycob/2.2.137; IBER H, 1992, J NEUROCHEM, V58, P1533, DOI 10.1111/j.1471-4159.1992.tb11375.x; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JOHNSTONE SR, 1988, J NEUROCHEM, V51, P1655, DOI 10.1111/j.1471-4159.1988.tb01138.x; KAIN SR, 1992, J BIOL CHEM, V267, P8128; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLEIN D, 1987, BIOL CHEM H-S, V368, P1495, DOI 10.1515/bchm3.1987.368.2.1495; KLEIN D, 1987, EUR J BIOCHEM, V167, P417, DOI 10.1111/j.1432-1033.1987.tb13354.x; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LADISCH S, 1984, J CLIN INVEST, V74, P2074, DOI 10.1172/JCI111631; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LEVINE JM, 1984, J NEUROSCI, V4, P820; LIESER M, 1989, BIOCHEM J, V260, P69, DOI 10.1042/bj2600069; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARCUS DM, 1984, MOL IMMUNOL, V21, P1083, DOI 10.1016/0161-5890(84)90118-4; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PATON MC, 1986, NATURE, V324, P459; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PODRAZA HM, 1982, BIOCHEMISTRY-US, V21, P3260; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REN S, 1989, CANCER RES, V49, P7051; REN SL, 1992, J BIOL CHEM, V267, P12632; RIBONI L, 1984, J BIOCHEM-TOKYO, V96, P1943, DOI 10.1093/oxfordjournals.jbchem.a135030; RITTER G, 1990, IMMUNOBIOLOGY, V182, P32, DOI 10.1016/S0171-2985(11)80581-4; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUAN S, 1992, CANCER RES, V52, P5725; SAITO M, 1979, J BIOL CHEM, V254, P7845; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHACHTER H, 1983, METHOD ENZYMOL, V98, P98; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P1; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; SONNINO S, 1982, ADV EXP MED BIOL, V152, P55; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; TAATJES DJ, 1991, INT REV CYTOL, V126, P135; TAATJES DJ, 1987, EUR J CELL BIOL, V44, P187; THURIN J, 1985, J BIOL CHEM, V260, P4556; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YUSUF HKM, 1983, P NATL ACAD SCI-BIOL, V80, P7075, DOI 10.1073/pnas.80.23.7075	104	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10185	10196						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486686				2022-12-27	WOS:A1993LB80000038
J	KIKUTA, Y; KUSUNOSE, E; ENDO, K; YAMAMOTO, S; SOGAWA, K; FUJIIKURIYAMA, Y; KUSUNOSE, M				KIKUTA, Y; KUSUNOSE, E; ENDO, K; YAMAMOTO, S; SOGAWA, K; FUJIIKURIYAMA, Y; KUSUNOSE, M			A NOVEL FORM OF CYTOCHROME-P-450 FAMILY-4 IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES - CDNA CLONING AND EXPRESSION OF LEUKOTRIENE-B4 OMEGA-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY CORTEX MICROSOMES; NUCLEOTIDE-SEQUENCE; PROSTAGLANDIN-A; MESSENGER-RNA; 2 FORMS; MOLECULAR-CLONING; COMPLEMENTARY-DNA; GENE STRUCTURE; FATTY-ACIDS; PURIFICATION	Isolation of cDNA clones for human leukotriene B4 (LTB4) omega-hydroxylase clearly demonstrates that the hydroxylase is a member of the cytochrome P-450 (CYP) superfamily. cDNA clones isolated from a human leukocyte cDNA library with CYP4A4 cDNA as a probe encode a protein of 520 amino acids with a molecular weight of 59,805. The deduced amino acid sequence contains an invariant cysteine in the conserved heme-binding domain near the C terminus, characteristic of the P-450 superfamily. The microsomes from yeast cells transfected with an expression vector pAAH5 carrying isolated cDNA catalyzed the omega-hydroxylation of LTB4 with a K(m) value of 0.71 muM, and its activity was significantly inhibited by carbon monoxide and by antisera against CYP4A4, consistent with the properties previously reported with LTB4 omega-hydroxylase in human polymorphonuclear leukocytes. The amino acid sequence of LTB4 omega-hydroxylase (P-450LTBomega) shows 31-44% similarity to those of CYP4A, CYP4B, and CYP4C, whereas less than 25% similarity was observed with any of the other P-450 families. According to the systematic classification of the P-450 superfamily, P-450LTBomega is classified into the CYP4 family but does not belong to any of the known CYP4 subfamilies. This P-450 composes a new subfamily of CYP4. RNA blot analysis indicated that mRNA hybridized to the cDNA was expressed in the polymorphonuclear leukocytes as well as leukocytes from four individuals. Isolation of the cDNA opens the way to investigate the physiological role and to regulation of the hydroxylase in the inflammation process.	FUKUYAMA UNIV,FAC ENGN,DEPT FOOD SCI & TECHNOL,FUKUYAMA,HIROSHIMA 72902,JAPAN; OSAKA CITY UNIV,SCH MED,TONEYAMA INST TB RES,TOYONAKA,OSAKA 560,JAPAN; TOHOKU UNIV,FAC SCI,DEPT CHEM,SENDAI,MIYAGI 980,JAPAN	Fukuyama University; Osaka Metropolitan University; Tohoku University								AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEAUNE PH, 1986, P NATL ACAD SCI USA, V83, P8064, DOI 10.1073/pnas.83.21.8064; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFIELD JY, 1991, P NATL ACAD SCI USA, V88, P4558, DOI 10.1073/pnas.88.10.4558; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; FURUYA H, 1989, BIOCHEM BIOPH RES CO, V160, P669, DOI 10.1016/0006-291X(89)92485-6; GOTOH O, 1983, J BIOCHEM, V93, P807, DOI 10.1093/jb/93.3.807; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; IMAI Y, 1988, J BIOCHEM-TOKYO, V103, P143, DOI 10.1093/oxfordjournals.jbchem.a122220; KAWAJIRI K, 1986, EUR J BIOCHEM, V159, P219, DOI 10.1111/j.1432-1033.1986.tb09857.x; KAWASHIMA H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P156, DOI 10.1016/0005-2760(92)90106-6; KIKUTA Y, 1990, J BIOCHEM, V107, P280, DOI 10.1093/oxfordjournals.jbchem.a123039; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; KUSUNOSE E, 1989, J BIOCHEM-TOKYO, V106, P194, DOI 10.1093/oxfordjournals.jbchem.a122831; MATSUBARA S, 1987, J BIOL CHEM, V262, P13366; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V102, P559, DOI 10.1093/oxfordjournals.jbchem.a122089; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; POWELL WS, 1984, J BIOL CHEM, V259, P3082; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SHAK S, 1984, J BIOL CHEM, V259, P181; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SUMIMOTO H, 1988, EUR J BIOCHEM, V172, P315, DOI 10.1111/j.1432-1033.1988.tb13889.x; SUMIMOTO H, 1990, BIOCHEM INT, V20, P381; TANIGUCHI H, 1979, BIOCHIM BIOPHYS ACTA, V550, P341, DOI 10.1016/0005-2736(79)90220-7; UNGER BP, 1986, J BIOL CHEM, V261, P1158; YAMAMOTO S, 1984, J BIOCHEM, V96, P593, DOI 10.1093/oxfordjournals.jbchem.a134874; YOKOTANI N, 1990, EUR J BIOCHEM, V187, P23, DOI 10.1111/j.1432-1033.1990.tb15273.x; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665; YOKOTANI N, 1991, EUR J BIOCHEM, V196, P531, DOI 10.1111/j.1432-1033.1991.tb15846.x; YOSHIMURA R, 1990, J BIOCHEM, V108, P544, DOI 10.1093/oxfordjournals.jbchem.a123239	41	121	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9376	9380						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486631				2022-12-27	WOS:A1993LA68900036
J	BARDELLE, C; FURIE, B; FURIE, BC; GILBERT, GE				BARDELLE, C; FURIE, B; FURIE, BC; GILBERT, GE			MEMBRANE-BINDING KINETICS OF FACTOR-VIII INDICATE A COMPLEX BINDING PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; COAGULATION FACTOR-VA; PROTEIN-KINASE-C; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; ENZYME COMPLEXES; HUMAN-PLATELETS; MOLECULAR-BASIS; LIGHT CHAIN; SEQUENCES	Factor VIII functions as a component of the tenase enzyme complex upon phospholipid membranes. Factor VIII binds to phosphatidylserine-containing membranes and apparently provides high affinity binding sites for factor IXa upon these membranes. We have characterized the binding kinetics of human factor VIII with phosphatidylserine-containing membranes and directly compared the measured properties with those of factor V. The initial phase of association was evaluated in a stopped-flow apparatus by fluorescence energy transfer from aromatic residues in the protein to dansyl-labeled phosphatidylethanolamine in the vesicles. Association proceeded at an apparent second-order rate of 0.12 muM-1 s-1 for extruded phospholipid vesicles and 0.42 muM-1 s-1 for sonicated vesicles under pseudo-first-order conditions in which the phospholipid concentration determined the rate. Increased temperature resulted in more rapid association, and the effect decreased in the order extruded vesicles > sonicated vesicles > extruded vesicles of dioleoylphospholipids, indicating that the structure of the phospholipid membrane contributes to the activation energy of binding. The binding of fluorescein-labeled factor VIII to membranes supported on glass microspheres (lipospheres) was monitored by flow cytometry. Under conditions in which the factor VIII concentration determined the rate there was rapid initial association at 6.9 muM-1 s-1, accounting for half of the bound factor VIII, and a slower component of 0.87 muM-1 s-1, accounting for the other half. Likewise, the dissociation of factor VIII from liposphere membranes was biphasic with a faster component of 0.010 s-1 and a slower component of 0.0012 s-1. Rates of association and dissociation for factor V were similar to those for factor VIII and were biphasic. These results allow estimation of the size of the phospholipid sites that interact with factors VIII and V and suggest that both proteins bind to membranes via a multistep process in which rapid association is followed by a slower step yielding higher affinity binding.	VET ADM MED CTR W ROXBURY,DEPT MED,1400 VFW PKWY,BOSTON,MA 02132; NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Tufts Medical Center; Tufts University; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BENTAL O, 1991, BLOOD, V78, P180; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN SSH, 1982, J CHROMATOGR, V227, P25, DOI 10.1016/S0378-4347(00)80352-7; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FOSTER PA, 1990, BLOOD, V75, P1999; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KANE WH, 1988, BLOOD, V71, P539; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; SHEETZ M, 1972, BIOCHEMISTRY-US, V24, P4573; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0	37	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8815	8824						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473326				2022-12-27	WOS:A1993KX81100066
J	MORRIS, DP; SOUTE, BAM; VERMEER, C; STAFFORD, DW				MORRIS, DP; SOUTE, BAM; VERMEER, C; STAFFORD, DW			CHARACTERIZATION OF THE PURIFIED VITAMIN-K-DEPENDENT GAMMA-GLUTAMYL CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; BONE GLA-PROTEIN; CARBOXYGLUTAMIC ACID; REDUCTASE ACTIVITIES; PROTHROMBIN; WARFARIN; SUBSTRATE; IDENTIFICATION; PROPEPTIDE; INHIBITION	Vitamin K-dependent carboxylase, purified from bovine liver, has properties similar to those reported for the carboxylase activity present in crude, solubilized microsomes. The purified carboxylase was found to possess the vitamin K epoxidase activity, believed to be essential for vitamin K-dependent carboxylation, but did not contain vitamin K epoxide reductase activity. Kinetic studies of the carboxylase done under defined conditions were complicated by the non-Michaelis-Menten kinetic behavior observed for reactions with two of the enzymes substrates, FLEEL and vitamin K1 hydroquinone. Initial rate experiments with the substrate FLEEL demonstrated behavior consistent with substrate inhibition and gave half-maximal activity at 1 mM FLEEL. Experiments with the substrate vitamin K1 hydroquinone also displayed non-Michaelis-Menten kinetics, as maximal activity was reached prematurely in relation to behavior at lower concentrations. Half-maximal activity was observed at 35 mum vitamin K1 hydroquinone. Initial rate experiments with varying (NaHCO3)-C-14 concentration displayed Michaelis-Menten kinetics and gave a K(m(app)) of 0.29 mM. At cosubstrate concentrations chosen to obtain near-maximal activity, initial rate studies with varying (NaHCO3)-C-14 concentration indicated a k(cat) near 1.0 s-1. Removal of the fourth substrate, oxygen, resulted in the loss of more than 99% of carboxylase activity. The sulfhydryl reagent N-ethylmaleimide inhibited carboxylase irreversibly, as did the anticoagulant warfarin.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV LIMBURG,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Hasselt University; Maastricht University				Vermeer, Cees/0000-0002-2300-8561	NHLBI NIH HHS [HL06350-30, HL48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKNER KL, 1992, P NATL ACAD SCI USA, V89, P6242, DOI 10.1073/pnas.89.14.6242; BUITENHUIS HC, 1990, BIOCHIM BIOPHYS ACTA, V1034, P170, DOI 10.1016/0304-4165(90)90072-5; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; DEMETZ M, 1981, J BIOL CHEM, V256, P843; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FASCO MJ, 1982, J BIOL CHEM, V257, P4894; FIESER L. F., 1939, Journal of the American Chemical Society, V61, P3467, DOI 10.1021/ja01267a072; FRIEDMAN PA, 1976, BIOCHEM BIOPH RES CO, V70, P647, DOI 10.1016/0006-291X(76)91096-2; FURIE B, 1990, BLOOD, V75, P1753; GIRARDOT JM, 1982, ANAL BIOCHEM, V121, P315, DOI 10.1016/0003-2697(82)90486-9; HALL AL, 1982, ARCH BIOCHEM BIOPHYS, V214, P45, DOI 10.1016/0003-9861(82)90006-6; HELGELAND L, 1977, BIOCHIM BIOPHYS ACTA, V499, P181, DOI 10.1016/0304-4165(77)90001-0; HILDEBRANDT EF, 1982, BIOCHEMISTRY-US, V21, P2406, DOI 10.1021/bi00539a020; JONES JP, 1977, J BIOL CHEM, V252, P7738; JONES JP, 1976, BIOCHEM BIOPH RES CO, V72, P589, DOI 10.1016/S0006-291X(76)80081-2; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; LARSON AE, 1981, J BIOL CHEM, V256, P1032; LARSON AE, 1980, FEBS LETT, V118, P95, DOI 10.1016/0014-5793(80)81226-9; MACK DO, 1976, J BIOL CHEM, V251, P3269; MAGNUSSO.S, 1974, FEBS LETT, V44, P189, DOI 10.1016/0014-5793(74)80723-4; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; OLSON RE, 1987, HEMOSTASIS THROMBOSI, P846; PACKER L, 1980, METHOD ENZYMOL, V69, P625; SEGEL EH, 1975, ENZYME KINETICS, P619; SOUTE BAM, 1990, BIOCHIM BIOPHYS ACTA, V1034, P11, DOI 10.1016/0304-4165(90)90146-N; SOUTE BAM, 1992, THROMB HAEMOSTASIS, V68, P521; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUTTIE J W, 1988, Biofactors, V1, P55; SUTTIE JW, 1986, BIOCHEM PHARMACOL, V35, P2429, DOI 10.1016/0006-2952(86)90472-7; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469; SUTTIE JW, 1979, BIOCHEM BIOPH RES CO, V86, P500, DOI 10.1016/0006-291X(79)91742-X; THIJSSEN HHW, 1987, BIOCHEM PHARMACOL, V36, P2753, DOI 10.1016/0006-2952(87)90260-7; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; UOTILA L, 1982, BIOCHEM J, V201, P249, DOI 10.1042/bj2010249; UOTILA L, 1988, ARCH BIOCHEM BIOPHYS, V264, P135, DOI 10.1016/0003-9861(88)90578-4; VERMEER C, 1982, BIOCHIM BIOPHYS ACTA, V714, P361, DOI 10.1016/0304-4165(82)90346-4; VERMEER C, 1984, FEBS LETT, V165, P16, DOI 10.1016/0014-5793(84)80005-8; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WU SM, 1990, J BIOL CHEM, V265, P13124; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; 1981, BIORAD PROTEIN ASSAY, V1069, P2	45	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8735	8742						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473318				2022-12-27	WOS:A1993KX81100055
J	BIETLOT, HP; SCHERNTHANER, JP; MILNE, RE; CLAIRMONT, FR; BHELLA, RS; KAPLAN, H				BIETLOT, HP; SCHERNTHANER, JP; MILNE, RE; CLAIRMONT, FR; BHELLA, RS; KAPLAN, H			EVIDENCE THAT THE CRYIA CRYSTAL PROTEIN FROM BACILLUS-THURINGIENSIS IS ASSOCIATED WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; DELTA-ENDOTOXIN; KURSTAKI; TOXINS; ASSAY	Toxin generated by activation of the Bacillus thuringiensis CryIA(c) crystal protein (protoxin) with bovine trypsin was separated into two components by anion-exchange chromatography. One component (T2) was DNA-associated toxin, and the other was the DNA-free toxin (T1). Only one major protoxin component was observed, and it was found to be associated with DNA. The DNA from the T2 toxin varied in size from 100 to 300 base pairs, whereas the crystal and the solubilized protoxin contained 20-kilobase DNA as the major DNA component. DNase treatment converted the T2 toxin to the DNA-free T1 toxin. In contrast, the DNA in the crystal and the solubilized protoxin was resistant to DNase digestion and was not dissociated from the protein by 1.5 M NaCl. The protoxin and DNA appeared to elute as a complex with a molecular mass of >2 x 10(6) Da on gel-filtration chromatography. No toxin was generated from the protoxin with trypsin after extensive digestion of the protoxin with DNase or dissociation of the DNA by succinylation of the lysine residues. It is proposed that DNA binds to the COOH-terminal half of the crystal protein and is essential for maintaining the conformational integrity required for crystal formation and generation of toxin.	UNIV OTTAWA,DEPT CHEM,140 LOUIS PASTEUR,OTTAWA K1N 6N5,ONTARIO,CANADA	University of Ottawa								ANDREWS RE, 1987, CRC CR REV BIOTECHN, V6, P163, DOI 10.3109/07388558709113596; ARONSON AI, 1986, MICROBIOL REV, V50, P1; BIETLOT H, 1989, BIOCHEM J, V260, P87, DOI 10.1042/bj2600087; BIETLOT HPL, 1990, BIOCHEM J, V267, P309, DOI 10.1042/bj2670309; BULLA LA, 1977, J BACTERIOL, V130, P375, DOI 10.1128/JB.130.1.375-383.1977; BULLA LA, 1980, CRC CR REV MICROBIOL, V8, P147, DOI 10.3109/10408418009081124; CAREY PR, 1986, BIOCHIM BIOPHYS ACTA, V872, P169, DOI 10.1016/0167-4838(86)90268-2; CHESTUKHINA GG, 1982, ARCH MICROBIOL, V132, P159, DOI 10.1007/BF00508723; CHOMA CT, 1992, J INVERTEBR PATHOL, V59, P75, DOI 10.1016/0022-2011(92)90114-J; CHOMA CT, 1990, EUR J BIOCHEM, V189, P523, DOI 10.1111/j.1432-1033.1990.tb15518.x; Dulmage H.T., 1981, MICROBIAL CONTROL PE, P193; Fast PG, 1981, MICROBIAL CONTROL PE, p[223, 949]; GRINGORTEN JL, 1990, J INVERTEBR PATHOL, V56, P237, DOI 10.1016/0022-2011(90)90106-G; HOFTE H, 1989, MICROBIOL REV, V53, P242; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Mattes O., 1927, GESELL BEFORD GES NA, V62, P381; NICKERSON KW, 1980, BIOTECHNOL BIOENG, V12, P1305; OHLENBUSCH HH, 1967, J MOL BIOL, V25, P299, DOI 10.1016/0022-2836(67)90143-X; YAMAMOTO T, 1983, ARCH BIOCHEM BIOPHYS, V227, P233, DOI 10.1016/0003-9861(83)90366-1	20	26	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8240	8245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463332				2022-12-27	WOS:A1993KW97900094
J	MIYAZAWA, H; IZUMI, M; TADA, S; TAKADA, R; MASUTANI, M; UI, M; HANAOKA, F				MIYAZAWA, H; IZUMI, M; TADA, S; TAKADA, R; MASUTANI, M; UI, M; HANAOKA, F			MOLECULAR-CLONING OF THE CDNAS FOR THE 4 SUBUNITS OF MOUSE DNA-POLYMERASE ALPHA-PRIMASE COMPLEX AND THEIR GENE-EXPRESSION DURING CELL-PROLIFERATION AND THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; SINGLE ESSENTIAL GENE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; HEAT-LABILE; TSFT20 STRAIN; AMINO-ACID; ENZYMOLOGICAL CHARACTERIZATION; DROSOPHILA-MELANOGASTER; MONOCLONAL-ANTIBODIES	The DNA polymerase alpha-primase complex purified from mouse FM3A cells is composed of four polypeptides with molecular masses of 180, 68, 54, and 46 kDa. The largest subunit has DNA polymerase activity, the two smallest subunits have DNA primase activity, and the function of the 68-kDa subunit is unknown. We have isolated the cDNAs of the four subunits by low stringency hybridization and reverse transcription polymerase chain reaction and determined their nucleotide sequences. The predicted amino acid sequence of the 180-kDa subunit shows 88, 38, 34, and 32% identity to those of the catalytic subunits of human, Drosophila melanogaster, Schizosaccharomyces pombe, and Saccharomyces cerevisiae DNA polymerase alpha, respectively, and contains seven regions whose orders and sequences are highly conserved among viral and other eukaryotic DNA polymerases. The deduced amino acid sequence of the 68-kDa subunit shows 25% identity to that of the 73-kDa subunit of D. melanogaster DNA polymerase alpha-primase, shows no significant sequence similarity to any other protein in the data bases, but contains a potential phosphorylation site(s) for cdc2 kinase. The amino acid sequence of the 54-kDa subunit shows 32% identity to that of the large subunit of S. cerevisiae DNA primase. During activation of quiescent Swiss mouse 3T3 cells to proliferate, the levels of mRNA of the four subunits of the DNA polymerase alpha-primase complex increased before DNA synthesis. In growing mouse FM3A cells, the transcripts of the four subunits are present throughout the cell cycle and increase slightly prior to the S phase.	INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,BIODESIGN RES GRP,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; RIKEN; University of Tokyo				Takada, Ritsuko/0000-0002-1615-056X				ADLER DA, 1991, GENOMICS, V9, P642, DOI 10.1016/0888-7543(91)90357-K; ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; BROOKE RG, 1991, J BIOL CHEM, V266, P10093; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COTTERILL S, 1992, NUCLEIC ACIDS RES, V20, P4325, DOI 10.1093/nar/20.16.4325; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; DDDORNREITER I, 1992, EMBO J, V11, P769; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; EKI T, 1988, ARCH BIOCHEM BIOPHYS, V260, P552, DOI 10.1016/0003-9861(88)90481-X; EKI T, 1987, EXP CELL RES, V171, P24, DOI 10.1016/0014-4827(87)90248-5; EKI T, 1986, J BIOL CHEM, V261, P8888; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FOIANI M, 1989, J BIOL CHEM, V264, P2189; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; JOHNSTON LH, 1990, MOL GEN GENET, V221, P44, DOI 10.1007/BF00280366; KACZMAREK L, 1986, J BIOL CHEM, V261, P802; Kornberg A., 1992, DNA REPLICATION; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; MCCONKEY EH, METHODS ENZYMOL A, V12, P620; MILLER MA, 1988, NUCLEIC ACIDS RES, V16, P7961, DOI 10.1093/nar/16.16.7961; MILLER MR, 1985, J BIOL CHEM, V260, P134; MIYAZAWA H, 1986, BIOCHEM BIOPH RES CO, V139, P637, DOI 10.1016/S0006-291X(86)80038-9; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURAKAMI Y, 1986, EXP CELL RES, V163, P135, DOI 10.1016/0014-4827(86)90565-3; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; OHTSUKA E, 1985, J BIOL CHEM, V260, P2605; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROTH YF, 1987, EUR J BIOCHEM, V165, P473, DOI 10.1111/j.1432-1033.1987.tb11463.x; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TAKADATAKAYAMA R, 1990, BIOCHEM BIOPH RES CO, V170, P589, DOI 10.1016/0006-291X(90)92132-J; TAKADATAKAYAMA R, 1990, FEBS LETT, V273, P27, DOI 10.1016/0014-5793(90)81043-N; TAKADATAKAYAMA R, 1991, J BIOL CHEM, V266, P15716; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TSENG BY, 1989, MOL CELL BIOL, V9, P1940, DOI 10.1128/MCB.9.5.1940; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; VERMA R, 1991, P NATL ACAD SCI USA, V88, P7155, DOI 10.1073/pnas.88.16.7155; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1986, J BIOL CHEM, V261, P7958; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YAMAGUCHI M, 1991, NUCLEIC ACIDS RES, V19, P2403, DOI 10.1093/nar/19.9.2403	73	77	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8111	8122						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463324				2022-12-27	WOS:A1993KW97900076
J	DIVITA, G; GOODY, RS; GAUTHERON, DC; DIPIETRO, A				DIVITA, G; GOODY, RS; GAUTHERON, DC; DIPIETRO, A			STRUCTURAL MAPPING OF CATALYTIC SITE WITH RESPECT TO ALPHA-SUBUNIT AND NONCATALYTIC SITE IN YEAST MITOCHONDRIAL F1-ATPASE USING FLUORESCENCE RESONANCE ENERGY-TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; CHLOROPLAST COUPLING FACTOR; APPARENT NEGATIVE COOPERATIVITY; ESCHERICHIA-COLI F1-ATPASE; ISOLATED BETA-SUBUNIT; ATP SYNTHASE; ADENOSINE 5'-TRIPHOSPHATE; RAT-LIVER; FACTOR-I; SCHIZOSACCHAROMYCES-POMBE	The intrinsic tryptophan fluorescence of Schizosaccharomyces pombe mitochondrial F1 is a very sensitive probe to differentiate nucleotide binding to catalytic and noncatalytic sites (Divita, G., Di Pietro, A., Roux, B., and Gautheron, D. C. (1992) Biochemistry 31, 5791-5798), the catalytic site saturation producing quenching of Trp-257 fluorescence (Divita, G., Jault, J.-M., Gautheron, D. C., and Di Pietro, A. (1993) Biochemistry 32, 1017-1024). The present results indicate that two types of fluorescent nucleotide analogues, bearing either 2'(3')N-methylanthraniloyl (mant) or 2',3'-O-(2,4,6-trinitrophenyl) (TNP) group, exhibit high-affinity binding and behave similarly to the corresponding unmodified nucleotides. Selective binding of mant GDP to the catalytic site produces a marked quenching of intrinsic fluorescence which is due to resonance energy transfer between Trp-257 and the mant group. The high efficiency of the transfer allows the determination of a short distance, 10.5 angstrom, indicating the close proximity of catalytic site and alpha-subunit Trp-257. Selective saturation of the noncatalytic site by TNP-ADP produces a marked quenching of the extrinsic fluorescence of mant GDP bound to the catalytic site, which is correlated to an important resonance energy transfer between the two fluorescent groups. A rather short distance of 17.5 angstrom is calculated, indicating vicinity of catalytic and noncatalytic sites.	UNIV CLAUDE BERNARD LYON 1, INST BIOL CHIM PROT,CNRS,UPR 412, 7 PASSAGE VERCORS, F-69367 LYON 07, FRANCE; MAX PLANCK INST MED RES, BIOPHYS ABT, W-6900 HEIDELBERG 1, GERMANY; UNIV LYON 1, BIOL & TECHNOL MEMBRANES & SYST INTEGRES LAB, F-69622 VILLEURBANNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Max Planck Society; UDICE-French Research Universities; Universite Claude Bernard Lyon 1			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERMAN MC, 1986, J BIOL CHEM, V261, P6494; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; CARLIER MF, 1979, BIOCHEMISTRY-US, V18, P3452, DOI 10.1021/bi00583a003; CERIONE RA, 1982, BIOCHEMISTRY-US, V21, P745, DOI 10.1021/bi00533a026; CHEN R F, 1967, Analytical Letters, V1, P35; COLVERT KK, 1992, BIOCHEMISTRY-US, V31, P3930, DOI 10.1021/bi00131a006; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DIPIETRO A, 1988, BIOCHEM BIOPH RES CO, V152, P1319, DOI 10.1016/S0006-291X(88)80429-7; DIVITA G, 1991, BIOCHEMISTRY-US, V30, P3256, DOI 10.1021/bi00227a013; DIVITA G, 1992, BIOCHEMISTRY-US, V31, P5791, DOI 10.1021/bi00140a015; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P1017, DOI 10.1021/bi00055a004; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; Fairclough R H, 1978, Methods Enzymol, V48, P347; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FALSON P, 1989, BIOCHIM BIOPHYS ACTA, V975, P119, DOI 10.1016/S0005-2728(89)80209-9; FALSON P, 1991, J BIOL CHEM, V266, P287; FALSON P, 1986, J BIOL CHEM, V261, P7151; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HISABORI T, 1992, J BIOL CHEM, V267, P4551; JACOBSON MA, 1983, BIOCHEMISTRY-US, V22, P4247, DOI 10.1021/bi00287a014; JAULT JM, 1991, J BIOL CHEM, V266, P8073; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KORMER ZS, 1982, EUR J BIOCHEM, V121, P451, DOI 10.1111/j.1432-1033.1982.tb05808.x; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEE JH, 1990, J BIOL CHEM, V265, P4664; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MORADIAMELI M, 1989, J BIOL CHEM, V264, P1361; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; RAO R, 1988, J BIOL CHEM, V263, P5569; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SCHAFER HJ, 1984, J BIOL CHEM, V259, P5301; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; VASAK M, 1979, BIOCHEMISTRY-US, V18, P5050, DOI 10.1021/bi00590a004; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; WU JC, 1986, BIOCHEMISTRY-US, V25, P7991, DOI 10.1021/bi00372a030; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	63	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13178	13186						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514756				2022-12-27	WOS:A1993LH55300027
J	MARIANI, M; MARETZKI, D; LUTZ, HU				MARIANI, M; MARETZKI, D; LUTZ, HU			A TIGHTLY MEMBRANE-ASSOCIATED SUBPOPULATION OF SPECTRIN IS H-3 PALMITOYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURALLY-OCCURRING AUTOANTIBODIES; RED-BLOOD-CELLS; ERYTHROCYTE-MEMBRANE; SKELETAL PROTEINS; PHOSPHORYLATION; ANKYRIN; ACYLATION; VESICLES; BINDING; IDENTIFICATION	A tightly membrane-associated form of spectrin (TMA-spectrin) was labeled when human red blood cells were incubated with [H-3]palmitic acid. About 90% of spectrin was not fatty acid-acylated and was extracted from membranes by low salt buffers. The H-3-palmitoylated TMA-spectrin, however, resisted low and even high salt extraction and remained associated with inside-out vesicles that were generated in the process of spectrin-actin extraction from membranes. TMA-spectrin was preferentially extracted from KCl-stripped vesicles by 5 M urea at low ionic strength. TMA-spectrin was purified by gel filtration and by ion exchange chromatography in the presence of urea and a non-ionic detergent. Purified TMA-spectrin was H-3-palmitoylated exclusively in the beta subunit to 0.28 mol/mol after a 12-h incubation of red cells. The labeled palmitate may be bound as an ester or thioester, since hydroxylamine (1 M, pH 7.5) released the label completely. Peptide maps of H-3-palmitoylated TMA-spectrin showed three or two labeled peptides from the beta subunit, when generated by V8 protease and trypsin, respectively. Two types of antibodies to spectrin reacted with purified TMA-spectrin, and TMA-spectrin contained the same antigenic peptides as low salt-extractable spectrin. Rabbit anti-ankyrin antibodies did not bind to TMA-spectrin. The substoichiometric incorporation of [H-3]palmitic acid into TMA-spectrin could result from the slow turnover of endogenously bound fatty acids. Generation of the tightly membrane-associated and H-3-palmitoylated subpopulation of spectrin cannot be due to entrapment of an unmodified residual fraction of spectrin in right-side-out vesicles. Instead, the data suggest the existence of a subpopulation of spectrin molecules that undergo a covalent fatty acid modification and thereby alter their binding properties. This may offer a new, metabolically dependent mechanism for dynamic interactions between spectrin and the membrane lipid bilayer.	SWISS FED INST TECHNOL, BIOCHEM LAB, CH-8092 ZURICH, SWITZERLAND; HUMBOLDT UNIV BERLIN, BEREICH MED CHARITE, INST MED PHYS & BIOPHYS, O-1040 BERLIN, GERMANY	ETH Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								ALLAN D, 1976, NATURE, V261, P58, DOI 10.1038/261058a0; ANDERSON JM, 1980, J BIOL CHEM, V255, P1259; BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BOIVIN P, 1988, BIOCHEM J, V256, P689, DOI 10.1042/bj2560689; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CIANCI CD, 1988, J CELL BIOCHEM, V37, P301, DOI 10.1002/jcb.240370305; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FAIRBANKS G, 1981, SCAND J CLIN LAB INV, V41, P139, DOI 10.3109/00365518109097446; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HAEST CWM, 1982, BIOCHIM BIOPHYS ACTA, V694, P331, DOI 10.1016/0304-4157(82)90001-6; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAMOUN PP, 1988, TRENDS BIOCHEM SCI, V13, P424, DOI 10.1016/0968-0004(88)90211-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU PW, 1985, J BIOL CHEM, V260, P4958; LUTZ HU, 1986, J CARDIOVASC PHARM, V8, pS76, DOI 10.1097/00005344-198600088-00016; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1977, J CELL BIOL, V73, P548, DOI 10.1083/jcb.73.3.548; LUTZ HU, 1984, J IMMUNOL, V133, P2610; LUTZ HU, 1982, J IMMUNOL, V128, P1695; LUTZ HU, 1984, FEBS LETT, V169, P323, DOI 10.1016/0014-5793(84)80343-9; LUZ HU, 1989, SPRINGER SERIES BIOP, V3, P328; MARCHESI VT, 1983, BLOOD, V61, P1; MARETZKI D, 1986, ARCH BIOCHEM BIOPHYS, V246, P469, DOI 10.1016/0003-9861(86)90493-5; MARETZKI D, 1990, FEBS LETT, V259, P305, DOI 10.1016/0014-5793(90)80033-F; MOMBERS C, 1980, BIOCHIM BIOPHYS ACTA, V603, P52, DOI 10.1016/0005-2736(80)90390-9; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PALEK J, 1992, BLOOD, V80, P308; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; RYBICKI AC, 1988, J CLIN INVEST, V81, P255, DOI 10.1172/JCI113303; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; ZIPARO E, 1978, J CELL SCI, V34, P91	44	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12996	13001						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509431				2022-12-27	WOS:A1993LG65800111
J	YULE, DI; WU, D; ESSINGTON, TE; SHAYMAN, JA; WILLIAMS, JA				YULE, DI; WU, D; ESSINGTON, TE; SHAYMAN, JA; WILLIAMS, JA			SPHINGOSINE METABOLISM INDUCES CA2+ OSCILLATIONS IN RAT PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; NECROSIS-FACTOR-ALPHA; POLYMORPHONUCLEAR NEUTROPHILS; CALCIUM; HYDROLYSIS; RECEPTORS; SPHINGOSINE-1-PHOSPHATE; PHOSPHATIDYLINOSITOL; CHOLECYSTOKININ; MOBILIZATION	The possibility that sphingosine or a related metabolite could mediate inositol-1,4,5-trisphospate (1,4,5-IP3)-independent Ca2+ release in pancreatic acinar cells was investigated. In intact rat pancreatic acini superfused at 37-degrees-C, sphingosine (10-100 muM) evoked, after a delay of several minutes, an increase in the cytosolic [Ca2+]i which was oscillatory below concentrations of 50 muM. At room temperature no increase in [Ca2+]i was observed. The increase in [Ca2+]i evoked by sphingosine was not inhibited by U73122, and thus was unlikely to be due to phosphatidylinositol (PI) hydrolysis. Furthermore, no PI hydrolysis or 1,4,5-IP3 production was detected on incubation with sphingosine. As metabolism of sphingosine could explain the temperature-dependent action, the effects of sphingosine and related sphingoid bases were tested in permeabilized cells. After a delay of 30 s at 37-degrees-C, sphingosine evoked a slow increase in [Ca2+] into the medium. In contrast, addition of sphingosylphosphorylcholine (SPC) resulted in a rapid increase in [Ca2+]. This response was mimicked by 1,4,5-IP3 but not by addition of sphingosine phosphate 1-10 muM), ceramide (30 muM), or sphingomyelin (50 mug/ml). SPC appeared to induce release of Ca2+ from the same store as 1,4,5-IP3, as SPC failed to evoke any further increase in Ca2+ from cells previously depleted by addition of a maximal concentration of 2,4,5-IP3 or thapsigargin. 1,4,5-IP3 but not SPC-induced Ca2+ release was blocked by heparin, indicating that SPC-induced Ca2+ release was not mediated through the IP3 receptor-channel complex. This study demonstrates that SPC, a sphingosine metabolite, could be responsible for IP3-independent Ca2+ oscillations previously seen in pancreatic acinar cells.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	YULE, DI (corresponding author), UNIV MICHIGAN,DEPT PHYSIOL,7737 MED SCI 2,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [DK41225, DK41487] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041225, R01DK041487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, IN PRESS EUR J BIOCH; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GALLONE A, 1991, SCIENCE, V253, P1143; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MATOZAKI T, 1991, AM J PHYSIOL, V260, pG858, DOI 10.1152/ajpgi.1991.260.6.G858; METZ DC, 1992, J BIOL CHEM, V267, P20620; OKASAKI T, 1990, J BIOL CHEM, V265, P15823; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG665; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SHAYMAN JA, 1990, AM J PHYSIOL, V258, pF1282; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	38	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12353	12358						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509375				2022-12-27	WOS:A1993LG65800023
J	GAUSSEM, P; GRAILHE, P; ANGLESCANO, E				GAUSSEM, P; GRAILHE, P; ANGLESCANO, E			SODIUM DODECYL SULFATE-INDUCED DISSOCIATION OF COMPLEXES BETWEEN HUMAN TISSUE-PLASMINOGEN ACTIVATOR AND ITS SPECIFIC INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROTEIN; MECHANISM; PLASMA; FLUIDS; CELLS; ASSAY	The stability of complexes between serine proteinases and their inhibitors after sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis has been claimed to indicate covalent bond formation. In this work we have investigated the effects of SDS on the stability of complexes between single-chain or two-chain tissue plasminogen activator (t-PA) and its inhibitor (PAI-1). Complexes formed by incubation of t-PA with PAI-1 for 15 min at 22-degrees-C were further incubated with various amounts of SDS before being subjected to SDS-polyacrylamide gel electrophoresis. The molecular species in the gels were identified both by zymography or by autoradiography after immunoblotting with antibodies directed against either t-PA or PAI-1. It was demonstrated that the interaction of SDS with t-PA.PAI-1 complexes before electrophoresis resulted in a transition from the complexed state to the free forms of t-PA and PAI-1 in a time- and dose-dependent manner. The first-order dissociation rate constant in the presence of 35 mm SDS at 22-degrees-C had a k(off) value of 1.4 x 10(-2) min-1, which corresponds to a half-life of 49.5 min. The t-PA released from the complexes was fibrinolytically active, whereas the released PAI-1 inhibited activator-dependent fibrinolysis. In a similar fashion, the well characterized non-acylated pair alpha1-proteinase inhibitor-elastase was dissociated by SDS treatment, confirming the validity of our experimental approach to demonstrate the reversibility of t-PA.PAI-1 complexes. These results demonstrate that SDS-polyacrylamide gel electrophoresis traps the molecular species in the state in which the proteins existed prior to the analysis, and they suggest that under the conditions used, the interaction of t-PA with PAI-1 results in the formation of nonacylated reversible complexes. This phenomenon may be relevant to the pathophysiology of fibrinolysis and to the general mechanism of serine proteinase-inhibitor complex formation.	CHU BICETRE, INSERM, U143, F-94275 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Gaussem, Pascale/AGY-9723-2022; ANGLES-CANO, Eduardo/ABA-1739-2020; ANGLES-CANO, Eduardo/G-2311-2012; Gaussem, P./ABA-1222-2020; Gaussem, Pascale/ABA-2228-2020	ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975; Gaussem, P./0000-0002-9139-2147; 				ANGLESCANO E, 1986, ANAL BIOCHEM, V153, P201, DOI 10.1016/0003-2697(86)90082-5; DECLERCK PJ, 1988, BLOOD, V71, P220; ERICKSON LA, 1984, ANAL BIOCHEM, V137, P454, DOI 10.1016/0003-2697(84)90113-1; FAY WP, 1989, BIOCHEMISTRY-US, V28, P5773, DOI 10.1021/bi00440a011; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GAUSSEM P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P321, DOI 10.1016/0167-4838(91)90076-C; GRAILHE P, 1993, FIBRINOLYSIS, V7, P123, DOI 10.1016/0268-9499(93)90033-R; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1983, P NATL ACAD SCI-BIOL, V80, P6804, DOI 10.1073/pnas.80.22.6804; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; LONGSTAFF C, 1992, BLOOD COAGUL FIBRIN, V3, P89, DOI 10.1097/00001721-199202000-00013; MASSON C, 1988, BIOCHEM J, V256, P237, DOI 10.1042/bj2560237; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; NIELSEN LS, 1986, FEBS LETT, V196, P269, DOI 10.1016/0014-5793(86)80261-7; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; SANZO MA, 1987, BIOCHEMISTRY-US, V26, P7443, DOI 10.1021/bi00397a037; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SPRENGERS ED, 1987, BLOOD, V69, P381; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; WAEHNELDT TV, 1975, BIOSYSTEMS, V6, P176, DOI 10.1016/0303-2647(75)90025-8; WAGNER OF, 1986, J BIOL CHEM, V261, P4474; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; WIMAN B, 1984, J BIOL CHEM, V259, P3644	28	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12150	12155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505335				2022-12-27	WOS:A1993LF28400102
J	UCHIDA, T; MATOZAKI, T; MATSUDA, K; SUZUKI, T; MATOZAKI, S; NAKANO, O; WADA, K; KONDA, Y; SAKAMOTO, C; KASUGA, M				UCHIDA, T; MATOZAKI, T; MATSUDA, K; SUZUKI, T; MATOZAKI, S; NAKANO, O; WADA, K; KONDA, Y; SAKAMOTO, C; KASUGA, M			PHORBOL ESTER STIMULATES THE ACTIVITY OF A PROTEIN-TYROSINE-PHOSPHATASE CONTAINING SH(2) DOMAINS (PTP1C) IN HL-60 LEUKEMIA-CELLS BY INCREASING GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTIC DIFFERENTIATION; SIGNAL TRANSDUCTION; SEQUENCE SIMILARITY; INDUCTION; ONCOGENE; KINASES; CD45; SH2; LAR	The affinity-purified antibody to a protein tyrosine phosphatase (PTP) containing two src homology 2 domains (PTP1C) was generated. The antibody recognized two types of PTP1C (PTP1C-alpha and -beta) of which the molecular sizes were 66 (alpha) and 62 kDa (beta), respectively, and these two types were expressed differentially in various cell types. The immune complex phosphatase assay using the antibody demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) and a vitamin D metabolite increased the PTP activity of immunoprecipitated PTP1C to 230 and 150% of control, respectively. By contrast, neither dimethyl sulfoxide nor retinoic acid significantly affected the PTP activity of PTP1C in HL-60 cells. The time course increment by TPA of PTP1C activity was closely correlated with that of the acquisition by HL-60 cells of a macrophage-like phenotype. In addition, TPA increased the amount of PTP1C detected by immunoblotting and immunoprecipitation and raised the level of expression of PTP1C mRNA in HL-60 cells. The increase of PTP1C mRNA induced by TPA treatment was inhibited by cycloheximide, suggesting that new protein synthesis is required for the increase by TPA of PTP1C mRNA expression. Furthermore, TPA increased the rate of transcription of the PTP1C gene without affecting the stability of PTP1C mRNA. These results suggest that (i) two subtypes of PTP1C may exist and function in various cell types, and (ii) TPA stimulates the PTP activity of PTP1C by increasing the transcription rate of PTP1C gene expression. The possible role of PTP1C in the macrophage differentiation will be also discussed.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN; HYOGO MED CTR ADULTS,KITAOHJI,AKASHI 673,JAPAN	Kobe University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P62; FISHER EH, 1991, SCIENCE, V253, P401; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANK DA, 1986, BIOCHEM BIOPH RES CO, V140, P440, DOI 10.1016/0006-291X(86)91110-1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATOZAKI T, 1992, BIOCHEM BIOPH RES CO, V182, P215, DOI 10.1016/S0006-291X(05)80133-0; MATOZAKI T, 1992, CANCER RES, V352, P1; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1991, J BIOL CHEM, V266, P19688; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; Sambrook J, 1989, MOL CLONING LABORATO; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAETLE R, 1991, LEUKEMIA, V5, P309; TAETLE R, 1987, BLOOD, V70, P852; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATANABE T, 1985, BIOCHEM BIOPH RES CO, V126, P999, DOI 10.1016/0006-291X(85)90284-0; YAM LT, 1971, AM J CLIN PATHOL, V55, P213; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11845	11850						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505313				2022-12-27	WOS:A1993LF28400059
J	DVIR, A; STEIN, LY; CALORE, BL; DYNAN, WS				DVIR, A; STEIN, LY; CALORE, BL; DYNAN, WS			PURIFICATION AND CHARACTERIZATION OF A TEMPLATE-ASSOCIATED PROTEIN-KINASE THAT PHOSPHORYLATES RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; REPEAT DOMAIN; DNA; INVITRO; IDENTIFICATION; REQUIREMENT; PROMOTER; INVIVO	We have recently shown that a template-associated protein kinase, which phosphorylates the carboxyl-terminal domain (CTD) of RNA polymerase II, is a two-component system. We describe here the purification of these two components to apparent homogeneity from human (HeLa) cell nuclear extract. Kinase component A has a 340-kDa native molecular mass, consists of a single large polypeptide, and contains the kinase active site. Kinase component B, which is identical to the Ku autoantigen, has a 180-kDa native molecular mass, and consists of apparently equimolar 67- and 83-kDa polypeptides. Component B stimulates the activity of component A, and under some conditions, confers DNA dependence on the reaction. The purified kinase converts the CTD to the multiply phosphorylated CTD0 form. Conversion occurs processively, and this processivity is an inherent property of component A. The in vitro phosphorylated CTD0 form contains approximately equimolar phosphoserine and phosphothreonine, but no detectable phosphotyrosine.	UNIV COLORADO,DEPT CHEM & BIOCHEM,CAMPUS BOX 215,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder			Stein, Lisa Y./E-6374-2016	Stein, Lisa Y./0000-0001-5095-5022; Dynan, William/0000-0002-4045-5662	NIGMS NIH HHS [GM 35866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAO DM, 1991, GENE EXPRESSION, V1, P1; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GUILFOYLE TJ, 1989, PLANT CELL, V1, P827, DOI 10.1105/tpc.1.8.827; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LU H, 1991, P NATL ACAD SCI USA, V88, P1004; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STONE N, 1992, J BIOL CHEM, V267, P6353; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WINTZERITH M, 1992, NUCLEIC ACIDS RES, V20, P910, DOI 10.1093/nar/20.4.910; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290; ZHANG J, 1991, J BIOL CHEM, V266, P2297	48	169	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10440	10447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486698				2022-12-27	WOS:A1993LB80000068
J	BEAVAN, LA; QUENTINHOFFMANN, E; SCHONHERR, E; SNIGULA, F; LEROY, JG; KRESSE, H				BEAVAN, LA; QUENTINHOFFMANN, E; SCHONHERR, E; SNIGULA, F; LEROY, JG; KRESSE, H			DEFICIENT EXPRESSION OF DECORIN IN INFANTILE PROGEROID PATIENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; GROWTH-FACTOR-BETA; CORE PROTEIN; MARFAN-SYNDROME; PROTEODERMATAN SULFATE; FIBRILLAR COLLAGEN; HUMAN-FIBROBLASTS; HUMAN-SKIN; LOCALIZATION; BIOSYNTHESIS	Fibroblasts from young patients exhibiting clinical features of progeroidal syndromes showed decreased biosynthesis of the small proteoglycan decorin. Cells in culture were metabolically labeled, and proteoglycans secreted into the medium were analyzed electrophoretically after immunoprecipitation with antibodies raised against decorin and biglycan. Fluorograms showed regularly a reduction to 15-30% of the normal amount of mature decorin and its core protein after chondroitin ABC lyase treatment. The size of the glycosaminoglycan chains was increased, but there was no obvious anomaly in the secretion kinetics of the mature proteoglycan. In addition, the patients' fibroblasts synthesized an increased amount of biglycan compared to control cells from healthy donors. Northern blot analysis clearly demonstrated a reduction by 85-94% in decorin mRNA, but biglycan mRNA was concomitantly increased, indicating that these alterations occur at the transcriptional level of protein expression. Transcription of decorin in fibroblasts from one of the patients was stimulated up to 3-fold by treatment with interleukin-1beta. No response to interleukin-1beta and transforming growth factor-beta was observed in the cells from another patient. In situ hybridization of cultured cells with an antisense decorin probe showed that decorin levels were reduced throughout the cell population. Surprisingly, subsequent examination of cells from one of the patients, now in mid-teenage, revealed a return to normal levels of decorin expression compared to age-matched controls. These studies suggest that, as in Marfan's syndrome where the primary defect concerns the fibrillin gene, reduced decorin expression contributes to the formation of an abnormal matrix and the pathogenesis of these disorders. They also indicate that this abnormality is likely to represent a secondary phenomenon which leads to a fault in the regulation of decorin gene transcription.	UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, WALDEYERSTR 15, W-4400 MUNSTER, GERMANY	University of Munster								BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; BYERS PH, 1989, METABOLIC BASIS INHE, P2805; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DEVOS EA, 1981, EUR J PEDIATR, V136, P245, DOI 10.1007/BF00442991; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; FEDARKO NS, 1992, J CELL PHYSIOL, V151, P215, DOI 10.1002/jcp.1041510202; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FUSHIMI H, 1989, J INTERN MED, V226, P409, DOI 10.1111/j.1365-2796.1989.tb01416.x; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GREVE H, 1990, BIOCHEM J, V269, P149, DOI 10.1042/bj2690149; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARPER RA, 1979, SCIENCE, V204, P526, DOI 10.1126/science.432659; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRESSE H, 1987, AM J HUM GENET, V41, P436; KRESSE H, 1993, IN PRESS EXPRIENTIA; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; Maniatis T, 1989, MOL CLONING; MCBRIDE OW, 1990, GENOMICS, V6, P219, DOI 10.1016/0888-7543(90)90560-H; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; MOOS M, 1983, EMBO J, V2, P757, DOI 10.1002/j.1460-2075.1983.tb01496.x; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; PULKKINEN L, 1990, J BIOL CHEM, V265, P17780; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; RAUTENSTRAUCH T, 1977, EUR J PEDIATR, V124, P101, DOI 10.1007/BF00477545; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONHERR E, 1993, IN PRESS BIOCH J; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SUPERTIFURGA A, 1992, J MED GENET, V29, P875, DOI 10.1136/jmg.29.12.875; VOGEL KG, 1989, EUR J CELL BIOL, V49, P236; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WESTERGRENTHORSSON G, 1991, MATRIX, V11, P177, DOI 10.1016/S0934-8832(11)80156-3; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	52	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9856	9862						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486665				2022-12-27	WOS:A1993LA68900100
J	DOERING, TL; PESSIN, MS; HOFF, EF; HART, GW; RABEN, DM; ENGLUND, PT				DOERING, TL; PESSIN, MS; HOFF, EF; HART, GW; RABEN, DM; ENGLUND, PT			TRYPANOSOME METABOLISM OF MYRISTATE, THE FATTY-ACID REQUIRED FOR THE VARIANT SURFACE GLYCOPROTEIN MEMBRANE ANCHOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; AFRICAN TRYPANOSOMES; CULTURED FIBROBLASTS; ALPHA-THROMBIN; BRUCEI; BIOSYNTHESIS; PURIFICATION; PROTEIN; IDENTIFICATION; FORM	The trypanosome variant surface glycoprotein (VSG) is anchored to the outer leaflet of the parasite plasma membrane by a glycosyl phosphatidylinositol (GPI). The VSG anchor is unique among GPIs in containing exclusively dimyristoylglycerol as its lipid moiety. Myristate is incorporated into the anchor precursor by sequential deacylation and specific reacylation with myristate. Although myristate is required for the VSG anchor, trypanosomes cannot synthesize this fatty acid and must import their entire supply from the host bloodstream, where it exists in low abundance. Chemical analysis of these parasites reveals that most of their myristate is in VSG protein, with no major lipid storage form. Unexpectedly, when these cells are radiolabeled with [H-3]myristate in culture, most of the label is incorporated into phospholipids, with little into VSG. This apparent contradiction is explained by the fact that trypanosomes in culture medium elongate much of the [H-3]myristate into palmitate and stearate, probably because the medium (with only 5% serum) contains limiting amounts of these fatty acids. In contrast, trypanosomes radiolabeled in whole blood (with higher concentrations of palmitate and stearate) do not modify most of the [H-3]myristate, and instead utilize the major portion of it for GPI synthesis. Our studies suggest that bloodstream trypanosomes have evolved highly efficient means of directing myristate into the GPI biosynthetic pathway.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University				Pessin, Melissa/0000-0003-3990-6494	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39086] Funding Source: Medline; NIAID NIH HHS [AI21334] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES BN, 1960, J BIOL CHEM, V235, P769; BALDASSARE JJ, 1977, J BIOL CHEM, V252, P8797; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BULOW R, 1986, J BIOL CHEM, V261, P1918; CARAS IW, 1991, CELL BIOL INT REP, V15, P815, DOI 10.1016/0309-1651(91)90035-H; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DETHLOFF LA, 1986, J CHROMATOGR, V382, P79, DOI 10.1016/S0378-4347(00)83506-9; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING T L, 1990, Methods (Orlando), V1, P288, DOI 10.1016/S1046-2023(05)80330-5; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; DOERING TL, 1993, CELL SURFACE EXTRACE; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1988, SCIENCE, V239, P75; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FIELD MC, 1990, METHODS, V1, P297; FOX JA, 1986, J BIOL CHEM, V261, P5767; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HERELD D, 1986, J BIOL CHEM, V261, P3813; KORN ED, 1965, J LIPID RES, V6, P43; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MYHER JJ, 1988, J CHROMATOGR, V452, P93, DOI 10.1016/S0021-9673(01)81440-0; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; SILBERT DF, 1973, BIOCHIM BIOPHYS ACTA, V311, P349, DOI 10.1016/0005-2736(73)90315-5; Spector A A, 1980, Prog Lipid Res, V19, P155; STOLL LL, 1984, IN VITRO CELL DEV B, V20, P732; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TURNER MJ, 1985, CURR TOP MICROBIOL, V117, P23; UDENFRIEND S, 1991, CELL BIOL INT REP, V15, P739, DOI 10.1016/0309-1651(91)90030-M; VISCARDI RM, 1991, LAB INVEST, V65, P250; WANG LX, 1991, J BIOL CHEM, V266, P13883; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	46	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9215	9222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486622				2022-12-27	WOS:A1993LA68900014
J	KOWALSKI, RJ; WILLIAMS, RC				KOWALSKI, RJ; WILLIAMS, RC			MICROTUBULE-ASSOCIATED PROTEIN 2 ALTERS THE DYNAMIC PROPERTIES OF MICROTUBULE ASSEMBLY AND DISASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIDEO LIGHT-MICROSCOPY; INDIVIDUAL MICROTUBULES; TUBULIN POLYMERIZATION; LIVING CELLS; INSTABILITY; INVITRO; BINDING; ELONGATION; BRAIN; PURIFICATION	The influence of microtubule-associated protein 2 (MAP2) on the dynamics of microtubule assembly and disassembly from axonemal fragments was characterized in vitro in solutions of pure tubulin and varying concentrations of MAP2. A mechanistic description of interactions between MAP2 and individual microtubules was developed from analysis of recorded images obtained by video-enhanced differential-interference-contrast light microscopy. MAP2 decreased the rates and lengths of shortening events and decreased the frequency of transitions between growth and shortening over a wide range of concentrations, thereby producing the increases in net microtubule growth previously described by light-scattering techniques. Increases in rates and lengths of elongation phases, as well as rescue frequencies (i.e. transition from shortening to growth), were observed under conditions in which microtubules are expected to be saturated with MAP2. During early stages of nucleated assembly, MAP2 greatly increased the number of microtubules growing from a given axoneme and caused elongation of ''curved'' structures which may be sheet-like microtubules.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA	Vanderbilt University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025638, T32GM008320] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08320, GM25638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL CW, 1982, METHOD CELL BIOL, V24, P373; BERG HC, 1984, J GEN MICROBIOL, V130, P2915; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES A, 1984, J NEUROSCI, V4, P394; CAPLOW M, 1988, J BIOL CHEM, V263, P10344; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DETRICH HW, 1985, J BIOL CHEM, V260, P9479; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; PRYER NK, 1992, J CELL SCI, V103, P965; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; SIMON JR, 1990, J CELL SCI, V96, P571; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VALLEE RB, 1977, J BIOL CHEM, V252, P377; VOTER WA, 1984, J BIOL CHEM, V259, P430; WALKER RA, 1991, J CELL BIOL, V114, P73, DOI 10.1083/jcb.114.1.73; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WILLIAMS R C JR, 1992, P151	42	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9847	9855						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486664				2022-12-27	WOS:A1993LA68900099
J	RANDOLPH, RK; SIMON, M				RANDOLPH, RK; SIMON, M			CHARACTERIZATION OF RETINOL METABOLISM IN CULTURED HUMAN EPIDERMAL-KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND MICROSOMES; BINDING-PROTEIN; VITAMIN-A; HUMAN-SKIN; ACYL-COA; TERMINAL DIFFERENTIATION; ACYLTRANSFERASE ACTIVITY; SMALL-INTESTINE; CELL-CULTURE; RAT-LIVER	Retinoids present in cultured human epidermal keratinocytes maintained in medium containing 25 nM retinol were identified and quantitated utilizing reverse-phase gradient high performance liquid chromatography. Total cell retinoid mass and composition averaged 12.59 pmol/mg cell protein +/- 1.86, (mean +/-S.D., n = 5) between strains and was constant with culture age. Long chain fatty acid esters of retinol and 3,4-didehydroretinol comprised greater than 95% of total retinoid, each contributing 77 and 23% of total esters, respectively. In mature stratified cultures, less abundant retinoids included unesterified retinol, 1%, and 3,4-didehydroretinol, 0.5%, retinoic acid, 0.5%, and a retinoid not previously reported in mammalian cells, 3,4-didehydroretinoic acid, 0.3%. This absolute and relative retinoid composition was essentially constant with culture age except that 3,4-didehydroretinoic acid was not detected in 3-4-day-old cultures (16-32 cell colonies), suggesting that keratinocyte differentiation may be related to endogenous changes in production of ''active'' retinoids. Separate pools of retinyl and 3,4-didehydroretinyl esters served as predominant sources of substrate for production of retinoic and 3,4-didehydroretinoic acids, respectively, suggesting that their production may be regulated in dependently.	SUNY STONY BROOK HOSP, SCH DENT MED, LIVING SKIN BANK, STONY BROOK, NY 11794 USA; SUNY, SCH DENT MED, DEPT ORAL BIOL & PATHOL, STONY BROOK, NY 11794 USA; SUNY, SCH MED, DEPT FOOD TECHNOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College								ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; BARUA AB, 1990, METHOD ENZYMOL, V189, P136; Bloch CE, 1921, J HYG-CAMBRIDGE, V19, P283, DOI 10.1017/S0022172400007865; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; Darmon M., 1991, SEMINARS DEV BIOL, V2, P219; DIAMOND L, 1978, LIFE SCI, V23, P1979, DOI 10.1016/0024-3205(78)90229-1; FELL HB, 1953, J PHYSIOL-LONDON, V119, P470, DOI 10.1113/jphysiol.1953.sp004860; FRAZIER G. N., 1931, Archives of Internal Medicine, V48, P507, DOI 10.1001/archinte.1931.00150030158012; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FURR HC, 1990, METHOD ENZYMOL, V189, P85; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Goodman DS, 1984, RETINOIDS, V2, P42; Goodwin GP, 1934, BRIT MED J, V1934, P113, DOI 10.1136/bmj.2.3837.113; Hatch F T, 1968, Adv Lipid Res, V6, P1; HELGERUD P, 1983, J CLIN INVEST, V71, P747, DOI 10.1172/JCI110822; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODAM JR, 1991, J INVEST DERMATOL, V97, P298, DOI 10.1111/1523-1747.ep12480562; HUANG HS, 1965, J BIOL CHEM, V240, P2839; KARASEK M A, 1970, Journal of the Society of Cosmetic Chemists, V21, P925; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; ONG DE, 1987, J BIOL CHEM, V262, P2729; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROSS AC, 1986, METHOD ENZYMOL, V123, P68, DOI 10.1016/S0076-6879(86)23010-4; ROSS AC, 1982, J LIPID RES, V23, P133; ROSS AC, 1978, J BIOL CHEM, V253, P6591; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SIEGENTHALER G, 1988, EXP CELL RES, V178, P114, DOI 10.1016/0014-4827(88)90383-7; SIEGENTHALER G, 1984, BRIT J DERMATOL, V111, P647, DOI 10.1111/j.1365-2133.1984.tb14147.x; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; STOFFEL W, 1959, ANAL CHEM, V31, P307, DOI 10.1021/ac60146a047; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; TORMA H, 1990, J INVEST DERMATOL, V94, P132, DOI 10.1111/1523-1747.ep12873990; UBELS JL, 1990, INVEST OPHTH VIS SCI, V31, P582; VAHLQUIST A, 1988, INT J DERMATOL, V27, P81, DOI 10.1111/j.1365-4362.1988.tb01278.x; VAHLQUIST A, 1982, J INVEST DERMATOL, V79, P94, DOI 10.1111/1523-1747.ep12500033; VAHLQUIST A, 1982, J INVEST DERMATOL, V79, P89, DOI 10.1111/1523-1747.ep12500032; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YOST RW, 1988, J BIOL CHEM, V263, P18693	46	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9198	9205						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486621				2022-12-27	WOS:A1993LA68900012
J	LOEWY, AG; SANTER, UV; WIECZOREK, M; BLODGETT, JK; JONES, SW; CHERONIS, JC				LOEWY, AG; SANTER, UV; WIECZOREK, M; BLODGETT, JK; JONES, SW; CHERONIS, JC			PURIFICATION AND CHARACTERIZATION OF A NOVEL ZINC-PROTEINASE FROM CULTURES OF AEROMONAS-HYDROPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; BITIS-ARIETANS; GAMMA-CHAIN; D-DIMER; SEQUENCE; FIBRIN; VENOM; CLEAVAGE; FRAGMENTS	While searching for an enzyme capable of breaking epsilon-(gamma-Glu)-Lys isopeptide bonds cross-linking protein chains, we purified a metallo-proteinase which mimics the action of an isopeptidase on the gamma-chain dimers of cross-linked fibrin. The enzyme is present in the growth medium of the bacterium Aeromonas hydrophila, isolated from the intestinal tract of the leech Hirudo medicinalis. It is a 19-kDa protein which specifically hydrolyzes the Gly-Ala peptide bond within the Gly-Gly-Ala sequence, located near the cross-link site in the gamma-chain dimer of fibrin. Substrate specificity studies with a number of synthetic peptides suggest that the enzyme prefers Gly-Gly or acetyl-Gly in the P2 and P1 positions, respectively (Schecter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157-162). Nonpolar amino acid residues seem to be favored in the P1' and P2' positions. The enzyme contains one atom of zinc and is inhibited by 1,10-phenanthroline, but not by EDTA. Iodoacetate, leupeptin, diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, pepstatin, and alpha2-macroglobulin have no effect on enzyme activity. Disulfide reducing reagents, such as dithiothreitol or 2-mereaptoethanol, inactivate the enzyme completely. The partial amino-terminal sequence shows 46% identity with a zinc metallo-proteinase from a strain of Lysobacter enzymogenes and 69% identity with the LasA protein from Pseudomonas aeruginosa.	CORTECH INC, DENVER, CO 80221 USA		LOEWY, AG (corresponding author), HAVERFORD COLL, DEPT BIOL, HAVERFORD, PA 19041 USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM034503] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 34503] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BASKOVA I P, 1990, Biokhimiya, V55, P674; BASKOVA I P, 1985, Biokhimiya, V50, P424; BASKOVA I P, 1990, Biokhimiya, V55, P771; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BEYNON RJ, 1989, PROTEOLYTIC ENZYMES, P246; CRUSE WBT, 1976, J MOL BIOL, V102, P173, DOI 10.1016/0022-2836(76)90081-4; DAMAGLOU AP, 1976, ATLAS PROTEIN SEQ S2, V5, P98; DARZINS A, 1990, NUCLEIC ACIDS RES, V18, P6444, DOI 10.1093/nar/18.21.6444; DONOVAN JW, 1985, BIOCHEMISTRY-US, V24, P3434, DOI 10.1021/bi00335a007; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1703, DOI 10.1021/bi00627a028; EGEN NB, 1984, TOXICON, V22, P653, DOI 10.1016/0041-0101(84)90005-9; FRANCIS CW, 1988, BLOOD, V71, P1361; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HARSFALVI J, 1991, BIOCHIM BIOPHYS ACTA, V1073, P268, DOI 10.1016/0304-4165(91)90131-Y; HOFMANN T, 1982, BIOCHEM J, V203, P603, DOI 10.1042/bj2030603; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWY AG, 1991, 15TH INT C BIOCH JER, P61; LOEWY AG, 1990, INT S PEPTIDE INHIBI; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; North M, 1989, PROTEOLYTIC ENZYMES, P105; OZA NB, 1973, INT J PEPT PROT RES, V5, P365; PETERS JE, 1990, J BACTERIOL, V172, P2236, DOI 10.1128/jb.172.5.2236-2240.1990; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; PURVES LR, 1986, S AFR J SCI, V82, P30; PURVES M, 1989, S AFR J SCI, V85, P519; RIGBI M, 1987, COMP BIOCHEM PHYS B, V87, P567, DOI 10.1016/0305-0491(87)90053-8; ROWBOTHAM B, 1985, Australian and New Zealand Journal of Medicine, V15, P110; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SANTER UV, 1984, CANCER RES, V44, P3730; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHEEHAN JC, 1973, J AM CHEM SOC, V95, P875, DOI 10.1021/ja00784a041; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P276; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STEWART JM, 1984, LABORATORY TECNIQUES, P85; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001	40	37	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9071	9078						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473348				2022-12-27	WOS:A1993KX81100098
J	PRABAKARAN, D; KIM, P; KIM, KR; ARVAN, P				PRABAKARAN, D; KIM, P; KIM, KR; ARVAN, P			POLARIZED SECRETION OF THROMBOSPONDIN IS OPPOSITE TO THYROGLOBULIN IN THYROID EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SUSPENSION-CULTURE; PROTEINS; FOLLICLES; MEMBRANE; GLYCOPROTEIN; EXOCYTOSIS; COMPONENTS; OCCURS	In addition to thyroglobulin, primary thyrocytes secrete into the culture medium significant quantities of p500, a protein so named because of its M(r) greater-than-or-equal-to 500,000. Epithelial monolayers cultured on porous filters serve as a useful model system in which to study protein secretion. From these monolayers, thyroglobulin, the precursor in thyroid hormonogenesis, was released with apical predominance, while p500 was found mostly in the basolateral medium. Thyrocyte exposure to thyrotropin augmented selectively thyroglobulin but not p500 production. By contrast, exposure to cycloheximide actually augmented p500 production, a response observed for immediate-early proto-oncogenes. Using thyrocyte conditioned medium, the p500 protein was purified to homogeneity. Peptide sequencing of tryptic fragments of purified p500 showed identity to thrombospondin. Immunoprecipitation of thrombospondin from media bathing primary thyrocytes and the FRTL5 cell line quantitatively recovered p500, confirming its identity and indicating an epithelial origin. Gel filtration of secreted thrombospondin eluted at a high molecular weight, suggesting complexation with components of the extracellular matrix. Further, immunofluorescence showed cellular codistribution of thrombospondin and thyroglobulin, although thrombospondin exhibited predominantly an extracellular, basolateral deposition. It seems likely that thrombospondin production by thyrocytes plays a role in the growth or development of the thyroid epithelium.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, CELL & DEV BIOL PROGRAM, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK40344] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK040344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BERG G, 1975, BIOCHIM BIOPHYS ACTA, V405, P11, DOI 10.1016/0005-2795(75)90309-8; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHAMBARD M, 1984, BIOL CELL, V51, P315, DOI 10.1111/j.1768-322X.1984.tb00310.x; CHAMBARD M, 1990, J MOL ENDOCRINOL, V4, P193, DOI 10.1677/jme.0.0040193; CHANG A, 1989, HDB PHYSL GASTROINTE, V3, P531; DIXIT VM, 1986, P NATL ACAD SCI USA, V83, P5449, DOI 10.1073/pnas.83.15.5449; ERICSON LE, 1981, MOL CELL ENDOCRINOL, V22, P1, DOI 10.1016/0303-7207(81)90098-8; FAYET G, 1982, J CELL BIOL, V93, P479, DOI 10.1083/jcb.93.2.479; FAYET G, 1980, BIOCHIMIE, V62, P27, DOI 10.1016/S0300-9084(80)80367-1; FRATI L, 1974, ARCH BIOCHEM BIOPHYS, V162, P126, DOI 10.1016/0003-9861(74)90111-8; FRAUMAN AG, 1990, ENDOCRIN METAB CLIN, V19, P479, DOI 10.1016/S0889-8529(18)30306-2; GARBI C, 1982, J CELL BIOL, V94, P489, DOI 10.1083/jcb.94.2.489; GARBI C, 1988, J CELL PHYSIOL, V135, P39, DOI 10.1002/jcp.1041350106; GROLLMAN EF, 1992, J CLIN ENDOCR METAB, V74, P43, DOI 10.1210/jc.74.1.43; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MARRIQ C, 1977, EUR J BIOCHEM, V79, P143, DOI 10.1111/j.1432-1033.1977.tb11792.x; MAUCHAMP J, 1987, ACTA ENDOCRINOL-COP, V115, P220; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUMBY SM, 1984, J CELL PHYSIOL, V120, P280, DOI 10.1002/jcp.1041200304; NADLER NJ, 1964, ENDOCRINOLOGY, V74, P333, DOI 10.1210/endo-74-3-333; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; RING P, 1987, CELL TISSUE RES, V247, P505, DOI 10.1007/BF00215743; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1983, BIOCHEMISTRY-US, V22, P2148, DOI 10.1021/bi00278a015; SHIFRIN S, 1982, J BIOL CHEM, V257, P9539; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SMEDS S, 1970, BIOCHEM BIOPH RES CO, V38, P1168, DOI 10.1016/0006-291X(70)90362-1; SPRAY DC, 1987, J CELL BIOL, V105, P541, DOI 10.1083/jcb.105.1.541; STEELE RE, 1986, AM J PHYSIOL, V251, pC136, DOI 10.1152/ajpcell.1986.251.1.C136; STUDER H, 1989, ENDOCR REV, V10, P125, DOI 10.1210/edrv-10-2-125; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TACCHETTI C, 1986, J CELL PHYSIOL, V126, P93, DOI 10.1002/jcp.1041260113; TUSZYNSKI GP, 1987, SCIENCE, V236, P1570, DOI 10.1126/science.2438772; WADELEUX P, 1985, BIOCHIM BIOPHYS ACTA, V846, P257, DOI 10.1016/0167-4889(85)90073-4	55	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9041	9048						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473345				2022-12-27	WOS:A1993KX81100094
J	CHUANG, JL; COX, RP; CHUANG, DT				CHUANG, JL; COX, RP; CHUANG, DT			CHARACTERIZATION OF THE PROMOTER-REGULATORY REGION AND STRUCTURAL ORGANIZATION OF E1-ALPHA GENE (BCKDHA) OF HUMAN BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP-URINE-DISEASE; MESSENGER-RNA; 5'-FLANKING SEQUENCES; TRANSCRIPTION FACTOR; E1-BETA SUBUNIT; Y393N MUTATION; BOVINE KIDNEY; EXPRESSION; IDENTIFICATION; PURIFICATION	We have isolated genomic clones containing the complete exon 1 and the promoter-regulatory region of the E1alpha gene (BCKDHA) of human branched-chain alpha-keto acid dehydrogenase complex. The cloning was achieved by amplification of a genomic library in the SRB (P2) host strain that allowed the replication of nonstandard DNA structures. The results of this and previous (Dariush, N., Fisher, C. W., Cox, R. P., and Chuang, D. T. (1991) FEBS Lett. 284, 34-38) studies showed that the human E1alpha gene contains 9 exons, and spans at least 55 kilobases (kb). Exon 1 is 135 bp in length, and contains multiple transcription initiation sites at bases +1, +18, and +22. The complete human E1alpha cDNA is, therefore, 1,758 bp in length excluding the poly(A)+ tail, and has 27 nucleotides in the 5'-untranslated region. Sequencing of the 5'-flanking region disclosed the absence of a canonical TATA-box in the vicinity of base -30. Several sets of ''CAAT'' box-like sequences and Spl binding-sites are present. Also present are copies of potential AP-2 binding, fat-specific element 1, fat-specific element 2, glucocorticoid-responsive element, and cAMP-responsive element sequences, as well as multiple sets of direct and inverted repeats. The promoter-regulatory region was characterized using deletion constructs and the luciferase reporter assay. The human hepatoma cells (Hep-G2) and Chinese hamster ovary (CHO) cell lines were used as hosts. The results obtained with Hep-G2 cells indicate that the region for high level transcription is located between bases -320 and -115. Extension of the 5'-end of the insert to beyond base -320 markedly reduces promoter activity. The results strongly suggest the presence of inhibitory elements in the region upstream of base -320. Assays in CHO cells show that the region for high level transcription lies between bases -909 and -115. The variation in the region for high level transcription in Hep-G2 and CHO cells may represent cell-type specific differences in the E1alpha gene promoter function.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	CHUANG, JL (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.				NIDDK NIH HHS [DK-26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Battey, 1986, BASIC METHODS MOL BI; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHUANG DT, 1983, BIOCHEM J, V214, P177, DOI 10.1042/bj2140177; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DANCIS J, 1960, BIOCHIM BIOPHYS ACTA, V43, P342, DOI 10.1016/0006-3002(60)90448-0; Danner DJ, 1989, METABOLIC BASIS INHE, P671; DARIUSH N, 1991, FEBS LETT, V284, P34, DOI 10.1016/0014-5793(91)80755-R; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FATANIA HR, 1983, FEBS LETT, V158, P234, DOI 10.1016/0014-5793(83)80585-7; FEKETE G, 1989, CYTOGENET CELL GENET, V50, P236, DOI 10.1159/000132768; FISHER CR, 1991, J CLIN INVEST, V88, P1034, DOI 10.1172/JCI115363; FISHER CR, 1991, AM J HUM GENET, V49, P429; FISHER CW, 1989, J BIOL CHEM, V264, P3448; FISHER CW, 1993, AM J HUM GENET, V52, P414; FISHER CW, 1991, BIOCHEM BIOPH RES CO, V174, P804, DOI 10.1016/0006-291X(91)91489-Y; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HEFFELFINGER SC, 1983, BIOCHEMISTRY-US, V22, P5519, DOI 10.1021/bi00293a011; HERRING WJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P236, DOI 10.1016/0925-4439(92)90043-M; HIPSKIND RA, 1983, CELL, V34, P881, DOI 10.1016/0092-8674(83)90545-7; HU CWC, 1988, J BIOL CHEM, V263, P9007; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LAU KS, 1992, J BIOL CHEM, V267, P24090; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LEACH DRF, 1983, NATURE, V305, P448, DOI 10.1038/305448a0; MARTINI G, 1986, EMBO J, V5, P1849, DOI 10.1002/j.1460-2075.1986.tb04436.x; MATSUDA I, 1990, BIOCHEM BIOPH RES CO, V172, P646, DOI 10.1016/0006-291X(90)90723-Z; MCKEAN MC, 1992, BIOCHIM BIOPHYS ACTA, V1171, P109, DOI 10.1016/0167-4781(92)90149-T; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITSUBUCHI H, 1991, J BIOL CHEM, V266, P14686; NOBUKUNI Y, 1991, J CLIN INVEST, V87, P1862, DOI 10.1172/JCI115209; ODESSEY R, 1982, BIOCHEM J, V204, P353, DOI 10.1042/bj2040353; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; REED LJ, 1980, ENZYME REGULATION ME, P47; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TANOUE A, 1990, J BIOL CHEM, V265, P11306; WYMAN AR, 1985, P NATL ACAD SCI USA, V82, P2880, DOI 10.1073/pnas.82.9.2880; YOGANATHAN T, 1992, BIOCHEM J, V285, P721, DOI 10.1042/bj2850721; ZHANG B, 1989, J CLIN INVEST, V83, P1425, DOI 10.1172/JCI114033; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	59	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8309	8316						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463340				2022-12-27	WOS:A1993KW97900104
J	DEPRE, C; RIDER, MH; VEITCH, K; HUE, L				DEPRE, C; RIDER, MH; VEITCH, K; HUE, L			ROLE OF FRUCTOSE 2,6-BISPHOSPHATE IN THE CONTROL OF HEART GLYCOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PERFUSED RAT-HEART; MYOCARDIAL FRUCTOSE-6-PHOSPHATE,2-KINASE; FRUCTOSE-2,6-BISPHOSPHATE CONTENT; GLUCOSE; INSULIN; PURIFICATION; HEPATOCYTES; MUSCLE; WORK	The aim of this work was to study whether changes in fructose 2,6-bisphosphate concentration are correlated with variations of the glycolytic flux in the isolated working rat heart. Glycolysis was stimulated to different extents by increasing the concentration of glucose, increasing the workload, or by the addition of insulin. The glycolytic flux was measured by the rate of detritiation of [2-H-3]- and [3-H-3]glucose. Under all the conditions tested, an increase in fructose 2,6-bisphosphate content was observed. The glucose- or insulin-induced increase in fructose 2,6-bisphosphate content was related to an increase in the concentration of fructose 6-phosphate, the substrate of 6-phosphofructo-2-kinase. An increase in the workload correlated with a 50% decrease in the K(m) of 6-phosphofructo-2-kinase for fructose 6-phosphate. Similar changes in K(m) have been observed when purified heart 6-phosphofructo-2-kinase was phosphorylated in vitro by the cyclic AMP-dependent protein kinase or by the calcium/calmodulin-dependent protein kinase. Since the concentration of cyclic AMP was not affected by increasing the workload, it is possible that the change in K(m) of 6-phosphofructo-2-kinase, which was found in hearts submitted to a high load, resulted from phosphorylation by calcium/calmodulin protein kinase; other possibilities are not excluded. Anoxia decreased the external work developed by the heart, stimulated glycolysis and glycogenolysis, but did not increase fructose 2,6-bisphosphate.	UNIV CATHOLIQUE LOUVAIN, SCH MED, INT INST CELLULAR & MOLEC PATHOL, HORMONE & METAB RES UNIT, B-1200 BRUSSELS, BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRGMEYER HU, 1984, METHODS ENZYMATIC AN, V6; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; HUE L, 1982, BIOCHEM J, V206, P359, DOI 10.1042/bj2060359; HUE L, 1982, J BIOL CHEM, V257, P4308; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1974, BIOCHEM BIOPH RES CO, V58, P532, DOI 10.1016/S0006-291X(74)80453-5; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; HUE L, 1988, BIOCHEM J, V251, P541, DOI 10.1042/bj2510541; JOOST HG, 1989, DIABETOLOGIA, V32, P831, DOI 10.1007/BF00297447; JUNCO M, 1990, FEBS LETT, V263, P169, DOI 10.1016/0014-5793(90)80731-W; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITAMURA K, 1988, J BIOL CHEM, V263, P9027; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; KURET J, 1984, BIOCHEMISTRY-US, V23, P5495, DOI 10.1021/bi00318a018; LAWSON JWR, 1987, J BIOL CHEM, V262, P3165; MARBAN E, 1980, NATURE, V286, P845, DOI 10.1038/286845a0; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MINATOGAWA Y, 1984, BIOCHEM J, V223, P73, DOI 10.1042/bj2230073; MORGAN HE, 1959, BIOCHEM J, V73, P573, DOI 10.1042/bj0730573; NARABAYASHI H, 1985, J BIOL CHEM, V260, P9750; NEELY JR, 1967, AM J PHYSIOL, V212, P815; NEELY JR, 1972, BIOCHEM J, V128, P147, DOI 10.1042/bj1280147; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; OPIE LH, 1971, BIOCHEM J, V124, P475, DOI 10.1042/bj1240475; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1992, FEBS LETT, V310, P139, DOI 10.1016/0014-5793(92)81315-D; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; RIDER MH, 1986, BIOCHEM SOC T, V14, P321, DOI 10.1042/bst0140321; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROVETTO MJ, 1973, CIRC RES, V32, P699, DOI 10.1161/01.RES.32.6.699; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; WATSON PA, 1989, J BIOL CHEM, V264, P14735	38	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13274	13279						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514765				2022-12-27	WOS:A1993LH55300040
J	ROSENTHAL, W; ANTARAMIAN, A; GILBERT, S; BIRNBAUMER, M				ROSENTHAL, W; ANTARAMIAN, A; GILBERT, S; BIRNBAUMER, M			NEPHROGENIC DIABETES-INSIPIDUS - A V2 VASOPRESSIN RECEPTOR UNABLE TO STIMULATE ADENYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DOMINANT RETINITIS-PIGMENTOSA; DIRECTED MUTAGENESIS; DNA; RHODOPSIN; GENE	The coding region of the human vasopressin type 2 receptor gene bears mutations in the individuals affected with congenital nephrogenic diabetes insipidus, a disease characterized by the inability of the kidney to concentrate urine in response to vasopressin. Although it is assumed that the mutations result in loss of receptor function, proof of this hypothesis is lacking. We introduced one of these naturally occurring point mutations leading to a single amino acid change (Arg137 --> His) into wild type cDNA. The mutant protein was expressed, and the functional properties of the receptor were examined. The mutant receptor exhibited an unaltered binding affinity for vasopressin compared to the wild type but failed to stimulate the G(s)/adenylyl cyclase system. These data provide biochemical proof that the mutant receptor is the cause of the disease.	BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIDDK NIH HHS [DK 21-244] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHET DG, 1992, AM J HUM GENET, V51, P1089; BICHET DG, 1993, IN PRESS J CLIN INVE; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; BIRNBAUMER M, 1992, J BIOL CHEM, V267, P11783; CULPEPPER RM, 1989, METABOLIC BASES INHE, P1867; DAVIES K, 1992, NAT GENET, V2, P103; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRASER CM, 1988, P NATL ACAD SCI USA, V85, P5478, DOI 10.1073/pnas.85.15.5478; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KAMBOURIS M, 1988, AM J MED GENET, V29, P239, DOI 10.1002/ajmg.1320290138; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99	31	137	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13030	13033						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514744				2022-12-27	WOS:A1993LH55300006
J	XIE, HY; CLARKE, S				XIE, HY; CLARKE, S			METHYL ESTERIFICATION OF C-TERMINAL LEUCINE RESIDUES IN CYTOSOLIC 36-KDA POLYPEPTIDES OF BOVINE BRAIN - A NOVEL EUKARYOTIC PROTEIN CARBOXYL METHYLATION REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ISOASPARTYL PEPTIDES; CHEB METHYLESTERASE; MEMBRANE-PROTEINS; EUKARYOTIC CELLS; ESCHERICHIA-COLI; RAS2 PROTEIN; METHYLTRANSFERASE; REPAIR; ASPARTYL	Incubation of cytosolic extracts of bovine brain with S-adenosyl[methyl-H-3]methionine results in the predominant [H-3]methyl esterification of a 36-kDa polypeptide. This reaction appears to be distinct from any of the three known types of protein carboxyl methylation reactions previously established. We show here that the methylated 36-kDa polypeptide is a component of a cytosolic protein with a native molecular mass estimated at 178 kDa by gel filtration chromatography. The methyl group is not stable on the protein and is lost as [H-3]methanol with a half-life of about 180 min at pH 7.0, 37-degrees-C. The methyltransferase responsible for this reaction is a cytosolic protein with a native molecular mass of about 40 kDa that is readily separated from the well described protein-L-isoaspartate (D-aspartate) O-methyltransferase (EC 2.1.1.77). The methyl ester linkage is cleaved by carboxypeptidase Y, suggesting that the 36-kDa polypeptide is methylated on its C-terminal carboxyl group. Extensive digestion of gel-purified H-3-methylated 36-kDa polypeptide with trypsin and leucine aminopeptidase results in a radioactive product that co-chromatographs with authentic L-leucine methyl ester in reverse phase high performance liquid chromatography (HPLC), thin layer chromatography, thin layer electrophoresis, and high resolution-sulfonated polystyrene cation-exchange chromatography. Additionally, the o-phthalaldehyde/beta-mercaptoethanol-derived isoindole derivative of the H-3 digestion product co-migrates on HPLC with the corresponding isoindole for L-leucine methyl ester. We demonstrate that a similar methylation system is present in yeast Saccharomyces cerevisiae but not in the bacterium Escherichia coli. These results provide evidence for a new type of reversible posttranslational modification reaction that may function to modulate the activities of its methyl-accepting substrates.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	XIE, HY (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA.				NIGMS NIH HHS [GM 26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BARTEN DM, 1990, LIFE SCI, V47, P181, DOI 10.1016/0024-3205(90)90319-M; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; GALLETTI P, 1981, FEBS LETT, V126, P236, DOI 10.1016/0014-5793(81)80250-5; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KLEENE SJ, 1977, J BIOL CHEM, V252, P3214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LOWENSON JD, 1991, GERONTOLOGY, V37, P128; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; NAJBAUER J, 1991, ANAL BIOCHEM, V197, P412, DOI 10.1016/0003-2697(91)90413-N; OCONNOR CM, 1984, J BIOL CHEM, V259, P2570; OTA IM, 1990, PROTEIN METHYLATION, P179; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; SAMBROOK J, 1989, MOL CLONING LABORATO, pE37; SIEGEL FL, 1985, ARCH BIOCHEM BIOPHYS, V237, P347, DOI 10.1016/0003-9861(85)90286-3; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; STOCK JB, 1992, J BIOL CHEM, V267, P19753; TAN EW, 1991, J BIOL CHEM, V266, P10719; TAN EW, 1992, BIOCHEMISTRY-US, V31, P5572, DOI 10.1021/bi00139a021; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7	50	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13364	13371						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514774				2022-12-27	WOS:A1993LH55300052
J	STAMELLOS, KD; SHACKELFORD, JE; SHECHTER, I; JIANG, GJ; CONRAD, D; KELLER, GA; KRISANS, SK				STAMELLOS, KD; SHACKELFORD, JE; SHECHTER, I; JIANG, GJ; CONRAD, D; KELLER, GA; KRISANS, SK			SUBCELLULAR-LOCALIZATION OF SQUALENE SYNTHASE IN RAT HEPATIC CELLS - BIOCHEMICAL AND IMMUNOCHEMICAL EVIDENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; LIVER PEROXISOMES; CHOLESTEROL-SYNTHESIS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ACETOACETYL-COA; ACETYL-COA; MICROSOMES; SYNTHETASE; HEPATOCYTES; SECTIONS	In the present study we investigated the subcellular localization of squalene synthase (farnesyl-diphosphate: farnesyl-diphosphate farnesyltransferase, EC 2.5.1.21). Squalene synthase catalyzes the formation of squalene from trans-farnesyl diphosphate in two distinct steps and is the first committed enzyme for the biosynthesis of cholesterol. Recently, a truncated form of the enzyme from rat hepatocytes was purified, and monospecific antibodies for squalene synthase were produced. This enabled the subcellular localization of squalene synthase by three different methods: (i) analytical subcellular fractionation and measurements of enzyme activities; (ii) immunodeterminations of squalene synthase in the isolated subcellular fractions with a monospecific antibody; and (iii) immunoelectron microscopy. All three methods gave consistent results. The data clearly illustrate that squalene synthase enzymatic activity and squalene synthase are exclusively localized in the endoplasmic reticulum. In rat hepatic peroxisomes we were not able to detect any squalene synthase. In addition, we also demonstrated that squalene synthase in the microsomal fraction is dramatically regulated by a number of hypolipidemic drugs and dietary treatments.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; ELEANOR ROOSEVELT INST, DENVER, CO 80206 USA; GENENTECH INC, DEPT PRECLIN PHARMACOL, S SAN FRANCISCO, CA 94080 USA	California State University System; San Diego State University; Roche Holding; Genentech					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGNEW WS, 1978, J BIOL CHEM, V253, P4574; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V1; COHEN LH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P114, DOI 10.1016/0005-2760(92)90224-J; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; HOVIK R, 1991, J LIPID RES, V32, P993; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; PARKER RA, 1989, J BIOL CHEM, V264, P4877; POPJAK G, 1979, MOL CELL BIOCHEM, V27, P97; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105	33	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12825	12836						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509416				2022-12-27	WOS:A1993LG65800088
J	TENG, Q; SCARLATA, S				TENG, Q; SCARLATA, S			EFFECT OF HIGH-PRESSURE ON THE ASSOCIATION OF MELITTIN TO MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-RESOLUTION H-1-NMR; SELF-ASSOCIATION; PHOSPHOLIPID-MEMBRANES; FRICTIONAL RESISTANCE; THERMAL COEFFICIENT; MONOMERIC MELITTIN; AGGREGATION STATE; AQUEOUS-SOLUTION; ENERGY-TRANSFER; LIPID BILAYERS	To determine the underlying basis for the sensitivity of peripheral peptides to lipid packing, we monitored the change in association of melittin to different membranes under hydrostatic pressure by fluorescence polarization and by fluorescence intensity in the presence of aqueous quenchers. Association to lysophosphatidylcholine micelles or to membranes composed of dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, palmitoyloleoylphosphatidylcholine, or dioleoylphosphatidylcholine was found to be stable from 1 to 2000 atm. Similar results were obtained using multilamellar vesicles, small unilamellar vesicles, or large unilamellar vesicles. Thus, the increase in lipid chain packing induced by pressure does not alter the association of bound complexes. This result indicates similar compressibilities of the peptide and the head group binding region. Increasing the ionic strength to increase the charge of the free peptide also resulted in a pressure-insensitive complex showing that the hydration does not change upon binding. This conclusion is substantiated by a lack of van't Hoff DELTAH to dioleoylphosphatidylcholine large unilamellar vesicles. To gain a more molecular picture of these associations, the rotational properties of the tryptophan side chain of bound melittin as a function of lipid packing was also studied. These data indicate subtle differences in peptide orientation in different lipids.	SUNY,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College					NIGMS NIH HHS [GM38824] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLO J, 1982, BIOCHEMISTRY-US, V21, P461, DOI 10.1021/bi00532a007; BESCHIASCHVILI G, 1991, BIOCHIM BIOPHYS ACTA, V1068, P195, DOI 10.1016/0005-2736(91)90210-Y; BRADRICK TD, 1989, BIOCHIM BIOPHYS ACTA, V982, P94, DOI 10.1016/0005-2736(89)90179-X; BRIDGEMAN PW, 1970, PHYSICS HIGH PRESSUR, P346; BROWN LR, 1980, BIOCHIM BIOPHYS ACTA, V622, P231, DOI 10.1016/0005-2795(80)90034-3; DECKMANN M, 1986, BIOCHIM BIOPHYS ACTA, V821, P334; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUFOURC E, 1986, FEBS LETT, V101, P205; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; FAUCON JF, 1979, FEBS LETT, V101, P187; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAMANN SD, 1980, REV PHYS CHEM JPN, V50, P147; HERMETTER A, 1986, J BIOL CHEM, V261, P8243; JOHN E, 1991, BIOPHYS J, V60, P319, DOI 10.1016/S0006-3495(91)82056-2; KASZYCKI P, 1990, BIOCHIM BIOPHYS ACTA, V1040, P337, DOI 10.1016/0167-4838(90)90131-X; KITCHEN DB, 1992, BIOCHEMISTRY-US, V31, P10083, DOI 10.1021/bi00156a031; KUCHINKA E, 1989, BIOCHEMISTRY-US, V28, P4216, DOI 10.1021/bi00436a014; LAUTERWEIN J, 1980, BIOCHIM BIOPHYS ACTA, V622, P219, DOI 10.1016/0005-2795(80)90033-1; LESTER DS, 1989, J NEUROCHEM, V52, P1950, DOI 10.1111/j.1471-4159.1989.tb07284.x; MATHIAS RT, 1991, ELECTRIFIED INTERFAC; MILLERO FJ, 1974, J PHYS CHEM-US, V78, P1636, DOI 10.1021/j100609a008; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; PARASASSI T, 1990, BIOPHYS J, V57, P1179, DOI 10.1016/S0006-3495(90)82637-0; PLAGER DA, 1992, PROTEIN SCI, V1, P530; QUAY SC, 1983, BIOCHEMISTRY-US, V22, P695, DOI 10.1021/bi00272a026; SCARLATA S, 1984, BIOCHEMISTRY-US, V23, P6789, DOI 10.1021/bi00321a078; SCARLATA S, 1992, IN PRESS LIFE SCI AD; SCARLATA SF, 1989, BIOPHYS J, V55, P1215, DOI 10.1016/S0006-3495(89)82917-0; SCARLATA SF, 1991, BIOCHEMISTRY-US, V30, P9853, DOI 10.1021/bi00105a007; SCARLATA SF, 1991, BIOPHYS J, V60, P334, DOI 10.1016/S0006-3495(91)82058-6; SCARLATA SF, 1990, BIOCHEMISTRY-US, V29, P10233, DOI 10.1021/bi00496a012; SCARLATA SF, 1993, BIOPHYS J, V64, pA124; SCHUBERT D, 1985, BIOPHYS J, V48, P327, DOI 10.1016/S0006-3495(85)83786-3; SCHWARZ G, 1989, BIOCHIM BIOPHYS ACTA, V979, P82, DOI 10.1016/0005-2736(89)90526-9; STANKOWSKI S, 1990, BIOCHIM BIOPHYS ACTA, V1025, P164, DOI 10.1016/0005-2736(90)90094-5; SUNKARAM M, 1990, BIOCHEMISTRY-US, V29, P10676; TALBOT JC, 1979, FEBS LETT, V102, P191, DOI 10.1016/0014-5793(79)80957-6; TALBOT JC, 1987, EUR BIOPHYS J BIOPHY, V15, P147, DOI 10.1007/BF00263679; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; THOMPSON RB, 1984, BIOCHEMISTRY-US, V23, P3411, DOI 10.1021/bi00310a005; TORGERSON PM, 1979, BIOCHEMISTRY-US, V18, P3079, DOI 10.1021/bi00581a026; VOGEL H, 1981, FEBS LETT, V134, P37, DOI 10.1016/0014-5793(81)80545-5; WEBER G, 1984, BIOCHEMISTRY-US, V23, P6785, DOI 10.1021/bi00321a077; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WONG PTT, 1982, J CHEM PHYS, V76, P5230, DOI 10.1063/1.442918; WONG PTT, 1988, BIOPHYS J, V54, P781, DOI 10.1016/S0006-3495(88)83016-9; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	48	7	7	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12434	12442						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509383				2022-12-27	WOS:A1993LG65800034
J	ABDELGHANY, M; ELSEBAE, AK; SHALLOWAY, D				ABDELGHANY, M; ELSEBAE, AK; SHALLOWAY, D			ALUMINUM-INDUCED NONENZYMATIC PHOSPHO-INCORPORATION INTO HUMAN-TAU AND OTHER PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL NEUROFIBRILLARY DEGENERATION; MICROTUBULE-ASSOCIATED PROTEIN-2; BRAIN CYTOSKELETAL PROTEINS; HUMAN NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; DEPENDENT PHOSPHORYLATION; DIALYSIS ENCEPHALOPATHY; CHEMICAL-PROPERTIES; GAMMA-PHOSPHATE; ACTIN-FILAMENTS	Incubation of purified recombinant human tau protein with aluminum salts at concentrations greater-than-or-equal-to 100 muM induces aggregation of tau that prevents its entry into SDS-polyacrylamide gels and filtration through nylon membranes. This effect is noncovalent and can be reversed by addition of EDTA. However, when incubated along with ATP, GTP, or CTP, aluminum catalyzes a covalent linkage that results in incorporation of the alpha- and gamma-phosphates into the tau protein (phospho-incorporation). The sensitivity to phosphatases and partial hydrolysis and the labeling observed with ATP containing radioisotopes at different positions suggest a novel reaction in which the entire triphosphate moiety is transferred from ATP and linked to tau via an O-linkage to the alpha-phosphate. The aggregation and triphosphorylation phenomena were not catalyzed by divalent or quadrivalent cations, but similar effects were observed with some other trivalent cations. They occurred at aluminum concentrations similar to those found in human brains with Alzheimer's disease, suggesting the possibility that related reactions may have physiological significance in vivo.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University								ABDELGHANY M, 1988, P NATL ACAD SCI USA, V85, P1408, DOI 10.1073/pnas.85.5.1408; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIZZI A, 1986, ACTA NEUROPATHOL, V71, P154, DOI 10.1007/BF00687978; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CRAPPER DR, 1973, SCIENCE, V180, P511, DOI 10.1126/science.180.4085.511; DIAZNIDO J, 1990, NEUROSCI LETT, V110, P221, DOI 10.1016/0304-3940(90)90815-Q; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FATEMI SJA, 1991, BIOCHEM J, V280, P527, DOI 10.1042/bj2800527; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUY SP, 1991, NEUROSCI LETT, V121, P166, DOI 10.1016/0304-3940(91)90676-K; HEWITT CD, 1991, NEUROPATH APPL NEURO, V17, P47, DOI 10.1111/j.1365-2990.1991.tb00693.x; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; JOHNSON GVW, 1988, BRAIN RES, V456, P95, DOI 10.1016/0006-8993(88)90350-2; JULIEN JP, 1982, J BIOL CHEM, V257, P467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; LANGUI D, 1988, BRAIN RES, V438, P67, DOI 10.1016/0006-8993(88)91324-8; LANGUI D, 1990, ACTA NEUROPATHOL, V80, P649, DOI 10.1007/BF00307634; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LISS L, 1989, ENV CHEM TOXICOLOGY, P317; MACDONALD TL, 1987, SCIENCE, V236, P183, DOI 10.1126/science.3105058; MARKESBERY WR, 1981, ANN NEUROL, V10, P511; Martell A.E., 1989, ENV CHEM TOXICOLOGY, P4; MARTIN RB, 1986, CLIN CHEM, V32, P1797; MARTYN CN, 1989, LANCET, V1, P59; Mason B., 1952, PRINCIPLES GEOCHEMIS; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MCDERMOTT JR, 1978, LANCET, V1, P901, DOI 10.1016/S0140-6736(78)90681-5; MCDERMOTT JR, 1979, NEUROLOGY, V29, P809, DOI 10.1212/WNL.29.6.809; MCLACHLAN DRC, 1986, NEUROBIOL AGING, V7, P525; MESCO ER, 1991, MOL CHEM NEUROPATHOL, V14, P199, DOI 10.1007/BF03159936; MUMA NA, 1988, MOL BRAIN RES, V3, P115, DOI 10.1016/0169-328X(88)90056-3; NISHIDA E, 1981, J BIOCHEM-TOKYO, V90, P575, DOI 10.1093/oxfordjournals.jbchem.a133510; NIXON RA, 1990, J NEUROCHEM, V55, P1950, DOI 10.1111/j.1471-4159.1990.tb05781.x; PERL DP, 1988, MET IONS BIOL SYST, V24, P259; PERL DP, 1982, SCIENCE, V217, P1053, DOI 10.1126/science.7112111; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; SAYRE LM, 1985, BRAIN RES REV, V10, P69, DOI 10.1016/0165-0173(85)90008-6; SCHIEVEN G, 1988, J BIOL CHEM, V263, P15590; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SELKOE DJ, 1979, BRAIN RES, V163, P235, DOI 10.1016/0006-8993(79)90352-4; SHEA TB, 1992, J NEUROCHEM, V58, P542, DOI 10.1111/j.1471-4159.1992.tb09753.x; SHEA TB, 1991, NEUROSCI RES COMMUN, V9, P21; Sigel H., 1988, MET IONS BIOL SYST, V24; STERN AJ, 1986, J NEUROPATH EXP NEUR, V45, P361, DOI 10.1097/00005072-198605000-00140; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TRONCOSO JC, 1986, BRAIN RES, V364, P295, DOI 10.1016/0006-8993(86)90842-5; USUKI K, 1991, J BIOL CHEM, V237, P841; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLS MR, 1983, LANCET, V2, P29; WISNIEWSKI HM, 1986, NEUROBIOL AGING, V7, P532, DOI 10.1016/0197-4580(86)90103-X; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YAMAMOTO H, 1990, J NEUROCHEM, V55, P683, DOI 10.1111/j.1471-4159.1990.tb04187.x; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	66	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11976	11981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505322				2022-12-27	WOS:A1993LF28400078
J	FUKAMIZU, A; SUGIMURA, K; TAKIMOTO, E; SUGIYAMA, F; SEO, MS; TAKAHASHI, S; HATAE, T; KAJIWARA, N; YAGAMI, K; MURAKAMI, K				FUKAMIZU, A; SUGIMURA, K; TAKIMOTO, E; SUGIYAMA, F; SEO, MS; TAKAHASHI, S; HATAE, T; KAJIWARA, N; YAGAMI, K; MURAKAMI, K			CHIMERIC RENIN-ANGIOTENSIN SYSTEM DEMONSTRATES SUSTAINED INCREASE IN BLOOD-PRESSURE OF TRANSGENIC MICE CARRYING BOTH HUMAN RENIN AND HUMAN ANGIOTENSINOGEN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RAT; FRAGMENT-LENGTH-POLYMORPHISMS; EXPRESSION; CELLS	A reaction between enzyme renin and its only natural substrate angiotensinogen is the initial and rate-limiting step for producing a potent vasoconstrictor angiotensin II as the final product of the renin-angiotensin system, a contributory factor in the pathogenesis of hypertension. In order to assess the role of the interaction of human renin with human angiotensinogen in the development of high blood pressure, we have constructed the chimeric renin-angiotensin cascade in mice comprising both human renin and human angiotensinogen as well as the endogenous angiotensin-converting enzyme and angiotensin II receptor by cross-mating separate lines of transgenic mice carrying either the human renin or human angiotensinogen genes. Although each single gene carrier did not develop hypertension despite the observed normal tissue-specific expression of the transgenes, dual gene strains exhibited a chronically sustained increase in blood pressure. Administration of a human renin-specific inhibitor (ES-8891) was effective in reducing the elevated blood pressure only against the cross-mated hybrid mice, but treatment of an angiotensin-converting enzyme inhibitor (captopril) and a selective antagonist (DuP 753) directed at the angiotensin II receptor decreased the basal level of blood pressure even in single gene carriers as well as in dual gene mice. These results clearly demonstrated that the sustained increase in blood pressure of the hybrid mice was initiated by the interaction between the products of the two human genes.	UNIV TSUKUBA, LAB ANIM RES CTR, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	FUKAMIZU, A (corresponding author), UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN.		fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				CORNETTE JC, 1987, ANAL BIOCHEM, V163, P93, DOI 10.1016/0003-2697(87)90097-2; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; DESSIFULGHERI P, 1987, CLIN EXP HYPERTENS A, V9, P1383, DOI 10.3109/10641968709158991; FUKAMIZU A, 1991, BIOCHEM J, V278, P601, DOI 10.1042/bj2780601; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; GARDES J, 1982, HYPERTENSION, V4, P185, DOI 10.1161/01.HYP.4.2.185; HATAE T, 1992, BIOMED RES-TOKYO, V13, P381, DOI 10.2220/biomedres.13.381; HIGAKI J, 1988, CLIN SCI, V75, P669, DOI 10.1042/cs0750669; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIM S, 1992, HYPERTENSION, V20, P280, DOI 10.1161/01.HYP.20.3.280; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOKUBU T, 1990, HYPERTENSION, V15, P909, DOI 10.1161/01.HYP.15.6.909; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; MCCAA RE, 1978, CIRC RES, V43, pI32; MENARD J, 1985, J HYPERTENS, V3, pS275; MOORE TJ, 1981, HYPERTENSION, V3, P168, DOI 10.1161/01.HYP.3.2.168; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; NAFTILAN AJ, 1989, HYPERTENSION, V14, P614, DOI 10.1161/01.HYP.14.6.614; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; OLIVER WJ, 1966, P SOC EXP BIOL MED, V122, P923; OPARIL S, 1974, NEW ENGL J MED, V291, P389, DOI 10.1056/NEJM197408222910805; PRINTZ MP, 1977, J BIOL CHEM, V252, P1654; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RHALEB NE, 1991, HYPERTENSION, V17, P480, DOI 10.1161/01.HYP.17.4.480; SIMON D, 1987, CLIN EXP HYPERTENS A, V9, P1333, DOI 10.3109/10641968709158987; SOUBRIER F, 1990, HYPERTENSION, V16, P712, DOI 10.1161/01.HYP.16.6.712; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; WARD R, 1990, HYPERTENSION PATHOPH, P81	35	236	242	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11617	11621						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505294				2022-12-27	WOS:A1993LF28400028
J	KUHNE, MR; PAWSON, T; LIENHARD, GE; FENG, GS				KUHNE, MR; PAWSON, T; LIENHARD, GE; FENG, GS			THE INSULIN-RECEPTOR SUBSTRATE-1 ASSOCIATES WITH THE SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN; KINASE	The insulin receptor substrate 1 (IRS1) is a protein that is rapidly phosphorylated on tyrosine by the activated insulin receptor. Syp is a recently discovered, broadly expressed phosphotyrosine (Tyr(P)) phosphatase that contains two Src homology 2 (SH2) domains. We have found that insulin treatment of 3T3-L1 adipocytes leads to complex formation between IRS1 and Syp. Syp was detected in immunoadsorbates of IRS1 from extracts of insulin-treated but not basal cells by both immunoblotting and Tyr(P) phosphatase activity. The association of Syp with IRS1 apparently occurs between the SH2 domains of Syp and Tyr(P)-containing sequences of IRS1, since a fusion protein containing only the SH2 domains of Syp bound the Tyr(P) form of IRS1. Unlike the receptors for epidermal and platelet-derived growth factors, which in their activated state bind to the SH2 domains of Syp and elicit phosphorylation of Syp on tyrosine in intact cells, the Tyr(P) form of the insulin receptor did not bind to the SH2 domains of Syp, and no phosphorylation of Syp on tyrosine was detected in insulin-treated 3T3-L1 adipocytes. In combination with other findings these results indicate that IRS1 functions as a docking protein for SH2 domain-containing proteins participating in signaling from the insulin receptor.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1AB, ON, CANADA	Dartmouth College; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FORMISANO P, 1991, ENDOCRINOLOGY, V128, P2949, DOI 10.1210/endo-128-6-2949; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FROST SC, 1985, J BIOL CHEM, V260, P2646; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MOONEY RA, 1992, J BIOL CHEM, V267, P14054; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	21	375	383	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11479	11481						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505282				2022-12-27	WOS:A1993LF28400002
J	MADURA, K; DOHMEN, RJ; VARSHAVSKY, A				MADURA, K; DOHMEN, RJ; VARSHAVSKY, A			N-RECOGNIN/UBC2 INTERACTIONS IN THE N-END RULE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; REPAIR GENE RAD6; YEAST SACCHAROMYCES-CEREVISIAE; RNA-PROTEIN TRANSFERASE; SHORT-LIVED PROTEIN; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; CELL-CYCLE; DEGRADATION; TRANSFORMATION	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. In the yeast Saccharomyces cerevisiae, substrates of the N-end rule pathway are targeted for degradation by a complex that includes the 225-kDa N-recognin, encoded by UBR1, and the 20-kDa ubiquitin-conjugating enzyme encoded by UBC2. We report that both physical stability and functional activity of the N-recognin . Ubc2 complex require the presence of a highly acidic 23-residue region at the C terminus of Ubc2. Ubc2-C88A, an inactive variant of Ubc2 in which the active-site Cys-88 has been replaced by Ala, is shown to retain the affinity for N-recognin. Expression of Ubc2-C88A inhibits the N-end rule pathway, apparently as a result of competition between Ubc2 and Ubc2-C88A for binding to N-recognin. The two-hybrid (interaction cloning) technique was used to identify a approximately 170-residue C-terminal fragment of the 1,950-residue N-recognin as a Ubc2-interacting domain. We also show that the level of UBR1 mRNA decreases upon overexpression of UBC2. This effect of UBC2 is observed with cells whose UBR1 is expressed from an unrelated promoter but is not observed if UBR1 contains a frameshift mutation, or if the Ubc2 protein lacks its C-terminal acidic region. The N-recognin . Ubc2 complex appears to regulate the expression of N-recognin through changes in the metabolic stability of its mRNA.	CALTECH,DIV BIOL,147-75,PASADENA,CA 91125	California Institute of Technology			Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780	NIA NIH HHS [AG08991] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008991] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel FM, 1988, MOL REPROD DEV; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BALZI E, 1990, J BIOL CHEM, V265, P7464; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BORTS RH, 1986, GENETICS, V113, P551; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CIECHANOVER A, 1988, J BIOL CHEM, V263, P11155; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KANG X, 1991, GENETICS, V130, P285; KOKEN M, 1991, P NATL ACAD SCI USA, V88, P3832, DOI 10.1073/pnas.88.9.3832; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MADURA K, 1990, NUCLEIC ACIDS RES, V18, P771, DOI 10.1093/nar/18.4.771; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; NICOLET CM, 1987, YEAST, V3, P149, DOI 10.1002/yea.320030303; PHILLIPS JD, 1993, IN PRESS YEAST; PICKART CM, 1988, UBIQUITIN, P77; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1988, J BIOL CHEM, V263, P2693; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Sherman F., 1986, METHODS YEAST GENETI; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SILVERMAN SJ, 1987, ANAL BIOCHEM, V164, P271, DOI 10.1016/0003-2697(87)90492-1; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; WING SS, 1992, J BIOL CHEM, V267, P6495; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382	67	76	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12046	12054						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505328				2022-12-27	WOS:A1993LF28400088
J	CLARK, AC; SINCLAIR, JF; BALDWIN, TO				CLARK, AC; SINCLAIR, JF; BALDWIN, TO			FOLDING OF BACTERIAL LUCIFERASE INVOLVES A NONNATIVE HETERODIMERIC INTERMEDIATE IN EQUILIBRIUM WITH THE NATIVE ENZYME AND THE UNFOLDED SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOLTEN GLOBULE STATE; AMINO-ACID SEQUENCE; VIBRIO-HARVEYI; ESCHERICHIA-COLI; ALPHA-SUBUNIT; NUCLEOTIDE-SEQUENCE; BETA-SUBUNIT; LUXB GENE; PROTEIN	Bacterial luciferase is a heterodimeric enzyme that catalyzes the reaction of reduced FMN, O2 and an aliphatic aldehyde to yield the carboxylic acid and an excited flavin that emits blue-green light upon return to ground state. The two subunits of the luciferase from Vibrio harveyi, alpha and beta, have molecular weights of 40,108 and 36,349, respectively; the single active center resides primarily, if not exclusively, on the alpha subunit. We have found that bacterial luciferase can be unfolded in urea-containing 50 mM phosphate buffer, pH 7.0, and refolded by dilution of the urea with final luciferase concentrations of 5-25 mug/ml. We have analyzed the urea-induced equilibrium unfolding of bacterial luciferase by monitoring changes in both the far ultraviolet circular dichroism (predominantly secondary structure) and intrinsic fluorescence emission (predominantly tertiary structure) resulting from incubation in various concentrations of urea at 18-degrees-C for 18-24 h. Both spectral methods indicated a biphasic unfolding transition; the first phase was protein concentration-independent, whereas the second phase was protein concentration-dependent. Equilibrium unfolding curves showed an increase in fluorescence up to 2 M urea followed by a decrease in intensity and red shift of the emission maximum. The ratio of the fluorescence emission in the presence of 2 M urea relative to that in the absence of urea was greater when fluorescence was excited at 295 nm than at 280 nm. The fluorescence increase in the 0-2 M urea range corresponded to the first phase of the biphasic unfolding process. The urea-induced loss of luciferase enzymatic activity appeared to correspond to the first transition observed with the spectroscopic methods, and likewise to be protein concentration-independent. These observations suggested a three-state unfolding mechanism in which the native heterodimeric enzyme rearranges to an inactive heterodimeric species that is well populated, followed by dissociation and unfolding of the alpha and beta subunits. The data were fit to a three-state mechanism using a nonlinear least squares method. At 18-degrees-C in 50 mM phosphate, pH 7.0, the free energy change for the interconversion of the active heterodimer and the inactive heterodimeric species was estimated to be 4.52 +/- 0.30 kcal/mol; the free energy change for the interconversion of the inactive heterodimer and the individual subunits was 19.7 +/- 0.2 kcal/mol. These measurements demonstrate that the equilibrium unfolding of bacterial luciferase proceeds through a well populated inactive heterodimeric species that appears to be partially unfolded and are consistent with the observation (Ziegler, M. M., Goldberg, M. E., Chaffotte, A. F., and Baldwin, T. O. (1993) J. Biol. Chem. 268, 10760-10765) of an inactive heterodimeric intermediate that forms from the individual subunits and precedes the active heterodimeric enzyme on the refolding pathway.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843; TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,CTR MACROMOLEC DESIGN,COLL STN,TX 77843; TEXAS A&M UNIV SYST,DEPT CHEM,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station								BALDWIN TO, 1993, J BIOL CHEM, V268, P10766; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BELAS R, 1982, SCIENCE, V218, P791, DOI 10.1126/science.10636771; BORDEN KLB, 1990, BIOCHEMISTRY-US, V29, P3071, DOI 10.1021/bi00464a025; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P685, DOI 10.1021/bi00428a041; CHEN LH, 1989, BIOCHEMISTRY-US, V28, P2684, DOI 10.1021/bi00432a048; CHLUMSKY LJ, 1991, FLAVINS AND FLAVOPROTEINS 1990, P261; COHN DH, 1985, J BIOL CHEM, V260, P6139; COHN DH, 1983, P NATL ACAD SCI-BIOL, V80, P120, DOI 10.1073/pnas.80.1.120; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FUCHS AF, 1991, BIOCHEMISTRY-US, V29, P6598; HASTINGS JW, 1966, BIOLUMINESCENCE PROG, P151; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; HURLE MR, 1987, PROTEINS, V2, P54, DOI 10.1002/prot.340020107; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PACE CN, 1991, ANGEW CHEM INT EDIT, V30, P343, DOI 10.1002/anie.199103433; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SINCLAIR JF, 1993, IN PRESS BIOCHEMISTR, V32; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TANDON S, 1986, J BIOL CHEM, V261, P5615; THOMSON JA, 1989, J BIOL CHEM, V264, P11614; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wetlaufer D B, 1981, Adv Protein Chem, V34, P61, DOI 10.1016/S0065-3233(08)60518-5; ZETINA CR, 1980, J MOL BIOL, V137, P401, DOI 10.1016/0022-2836(80)90165-5; ZIEGLER MM, 1981, CURR TOP BIOENERG, V12, P65; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760	45	88	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10773	10779						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496144				2022-12-27	WOS:A1993LD46600013
J	FORGE, V; MINTZ, E; GUILLAIN, F				FORGE, V; MINTZ, E; GUILLAIN, F			CA2+ BINDING TO SARCOPLASMIC-RETICULUM ATPASE REVISITED .2. EQUILIBRIUM AND KINETIC EVIDENCE FOR A 2-ROUTE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL TRANSITION; STOPPED FLOW; PHOSPHORYLATION; MAGNESIUM; VESICLES; IONS; CA-2+; DISSOCIATION; PHOSPHATE	The experiments reported in the present paper were designed to check the model proposed for Ca2+ binding in the preceding paper (Forge, V., Mintz, E., and Guillain, F. (1993) J. Biol. Chem. 268,10953-10960). The pH dependence of the Mg2+-induced variation of the intrinsic fluorescence, as well as that of the phosphorylation by P(i), confirmed that there are several species of Ca2+-deprived ATPase. Kinetics of Ca2+ binding as a function of pH suggested that the deprotonated form of the ATPase binds Ca2+ rapidly (k > 50 s-1), whereas the protonated forms bind Ca2+ slowly (1.3-2.7 s-1). At variance with other models which are linear, slow and rapid Ca2+ binding take two different routes, and intermediate pH values and Mg2+, which favors the deprotonated forms, result in biphasic kinetics. Mg2+ binds to all Ca2+-deprived species and to species having one bound Ca2+ but does not bind to ECa2. This is the reason why Mg2+ inhibits Ca2+ binding, and this inhibition is removed in the presence of adenosine-5'-O-(3-thiotriphosphate) which drives Mg2+ into the catalytic site.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE,CNRS,URA 1290,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	FORGE, V (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,F-91191 GIF SUR YVETTE,FRANCE.							CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CUENDA A, 1991, FEBS LETT, V283, P273, DOI 10.1016/0014-5793(91)80606-4; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; FORGE V, 1993, J BIOL CHEM, V268, P10953; FROUD RJ, 1986, BIOCHEM J, V237, P197, DOI 10.1042/bj2370197; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1987, J BIOL CHEM, V262, P3025; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LEVY D, 1990, J BIOL CHEM, V265, P19524; MADEIRA VMC, 1980, ARCH BIOCHEM BIOPHYS, V200, P319, DOI 10.1016/0003-9861(80)90361-6; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEISSNER G, 1981, J BIOL CHEM, V256, P636; MOUTIN MJ, 1990, J BIOL CHEM, V266, P5580; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1982, J BIOL CHEM, V257, P6120; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526; YASUOKA K, 1982, J BIOCHEM-TOKYO, V91, P1629, DOI 10.1093/oxfordjournals.jbchem.a133854	32	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10961	10968						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496160				2022-12-27	WOS:A1993LD46600040
J	KWON, YG; MENDELOW, M; SRINIVASAN, J; LEE, TR; PLUSKEY, S; SALERNO, A; LAWRENCE, DS				KWON, YG; MENDELOW, M; SRINIVASAN, J; LEE, TR; PLUSKEY, S; SALERNO, A; LAWRENCE, DS			THE ACTIVE-SITE SUBSTRATE-SPECIFICITY OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYMER-BOUND OXIME; BOVINE CARDIAC-MUSCLE; APOLIPOPROTEIN-A-I; CATALYTIC SUBUNIT; BASIC RESIDUES; PEPTIDE MODEL; SEQUENCE; REQUIREMENTS; INHIBITOR; SEGMENTS	cAMP-dependent protein kinase substrates have been synthesized employing an unusually efficient method that allows the alcohol-bearing residue to be incorporated into the peptide after solid phase peptide synthesis. These peptide substrates have been utilized to map the active site substrate specificity of the protein kinase. Only alpha- or beta-substituted alcohol-bearing residues containing the proper absolute configuration are phosphorylated by the enzyme. However, the cAMP-dependent protein kinase will phosphorylate achiral residues. The implications of the observed protein kinase substrate specificity with respect to inhibitor design are discussed.	SUNY Buffalo, DEPT CHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIGMS NIH HHS [GM45989] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; DEGRADO WF, 1982, J ORG CHEM, V47, P3258, DOI 10.1021/jo00138a011; DEGRADO WF, 1980, J ORG CHEM, V45, P1295, DOI 10.1021/jo01295a026; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FERAMISCO JR, 1979, J BIOL CHEM, V254, P6987; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAISER ET, 1989, ACCOUNTS CHEM RES, V22, P47, DOI 10.1021/ar00158a001; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; NAKAGAWA SH, 1983, J ORG CHEM, V48, P678, DOI 10.1021/jo00153a012; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; PROROK M, 1989, J BIOL CHEM, V264, P17727; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025	17	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10713	10716						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496138				2022-12-27	WOS:A1993LD46600004
J	SMITH, CA; TAYLOR, JS				SMITH, CA; TAYLOR, JS			PREPARATION AND CHARACTERIZATION OF A SET OF DEOXYOLIGONUCLEOTIDE 49-MERS CONTAINING SITE-SPECIFIC CIS-SYN, TRANS-SYN-I, (6-4), AND DEWAR PHOTOPRODUCTS OF THYMIDYLYL(3'-]5')-THYMIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; SOLID-PHASE SYNTHESIS; THYMINE DIMER; NUCLEIC-ACIDS; ULTRAVIOLET-RADIATION; ESCHERICHIA-COLI; BUILDING BLOCK; ENDONUCLEASE-V; SKIN-CANCER; DNA	Deoxyoligonucleotide 49-mers containing a central cis-syn, trans-syn-I, (6-4), or Dewar photoproduct of TpT were constructed for use in repair and replication studies by ligation of shorter photoproduct-containing oligonucleotides. A (6-4) product-containing 6-mer was prepared in 3.4% yield by 254 nm irradiation of d(AATTAA) and converted in nearly quantitative yield to the Dewar isomer by irradiation with Pyrex- and Mylar-filtered medium-pressure mercury arc light. d(CGAATTAAGC) containing a site-specific cis-syn or trans-syn-I dimer was prepared via automated solid-phase DNA synthesis utilizing photoproduct building blocks. The photoproduct-containing 49-mers were characterized by their susceptibility to base cleavage and a number of enzymes routinely used to map the sites of DNA photoproduct formation. 1 M piperidine at 90-degrees-C cleaved the Dewar product faster than the (6-4) product, but did not cleave the cyclobutane dimers. The 3' --> 5' exonuclease activity of T4 DNA polymerase was completely blocked by all the lesions except the (6-4) product, which it slowly bypassed. T4 endonuclease V did not cleave the (6-4) or Dewar photoproduct, but unexpectedly cleaved the trans-syn-I dimer at most 1 % the rate of the cis-syn dimer in double-stranded DNA. The trans-syn-I dimer was cleaved at a 50-fold higher rate in double- than in single-stranded DNA. Escherichia coli photolyase was found to be specific for the cis-syn dimer at low concentrations. Implications of this work to methodology for mapping and quantifying DNA photoproducts are also discussed.	WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110	Washington University (WUSTL)				Smith, Colin/0000-0001-5652-0855; Taylor, John-Stephen/0000-0002-8615-7257	NATIONAL CANCER INSTITUTE [R01CA040463] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA40463] Funding Source: Medline; NCRR NIH HHS [1 S10 RR02004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BOSE SN, 1983, SCIENCE, V220, P723, DOI 10.1126/science.6836308; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRASH DE, 1985, J BIOL CHEM, V260, P1438; BUTZOW JJ, 1971, BIOCHEMISTRY-US, V10, P2019, DOI 10.1021/bi00787a009; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; CHAN GL, 1985, BIOCHEMISTRY-US, V24, P5723, DOI 10.1021/bi00342a006; CHAN GL, 1986, INT J RADIAT BIOL, V50, P641, DOI 10.1080/09553008614551041; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOETSCH PW, 1985, NUCLEIC ACIDS RES, V13, P3285, DOI 10.1093/nar/13.9.3285; Fasman G.D, 1975, HDB BIOCH MOL BIOL N, V1; GORDON LK, 1980, J BIOL CHEM, V255, P2047; HAMILTON KK, 1992, NATURE, V356, P725, DOI 10.1038/356725a0; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; JOHNS HE, 1964, J MOL BIOL, V9, P503, DOI 10.1016/S0022-2836(64)80223-0; KEMMINK J, 1987, EUR J BIOCHEM, V162, P37, DOI 10.1111/j.1432-1033.1987.tb10538.x; KONING TMG, 1990, NUCLEIC ACIDS RES, V18, P277, DOI 10.1093/nar/18.2.277; KUMAR S, 1991, NUCLEIC ACIDS RES, V19, P2841, DOI 10.1093/nar/19.11.2841; KUMAR S, 1987, NUCLEIC ACIDS RES, V15, P1199, DOI 10.1093/nar/15.3.1199; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LIU FT, 1978, BIOCHEMISTRY-US, V17, P4865, DOI 10.1021/bi00616a003; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; RYCYNA RE, 1985, NUCLEIC ACIDS RES, V13, P5949, DOI 10.1093/nar/13.16.5949; RYCYNA RE, 1988, BIOCHEMISTRY-US, V27, P3152, DOI 10.1021/bi00409a006; TAYLOR JS, 1990, PHOTOCHEM PHOTOBIOL, V51, P161, DOI 10.1111/j.1751-1097.1990.tb01698.x; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1990, J CHEM EDUC, V67, P835, DOI 10.1021/ed067p835; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; TAYLOR JS, 1987, J AM CHEM SOC, V109, P2834, DOI 10.1021/ja00243a052; TAYLOR JS, 1988, NUCLEIC ACIDS RES, V16, P5123, DOI 10.1093/nar/16.11.5123; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; Wang, 1976, PHOTOCHEM PHOTOBIOL, VTwo; Wang, 1976, PHOTOCHEM PHOTOBIOL	41	119	121	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11143	11151						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496175				2022-12-27	WOS:A1993LD46600064
J	VANADELSBERG, JS; EDWARDS, JC; ALAWQATI, Q				VANADELSBERG, JS; EDWARDS, JC; ALAWQATI, Q			THE APICAL CL/HCO3 EXCHANGER OF BETA-INTERCALATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CYTOSKELETAL COMPLEX; KIDNEY EPITHELIAL-CELLS; COLLECTING DUCT; RAT-KIDNEY; ANION-EXCHANGER; MDCK CELLS; H+-ATPASE; BAND-3; ANKYRIN; PROTEIN	There are two types of intercalated cells of the renal collecting duct; one secretes H+ and the other secretes HCO3-. The H+-secreting form has an apical vacuolar H+-ATPase and a basolateral Cl/HCO3 exchanger that cross-reacts with antibodies to band 3, the product of the AE1 gene. The HCO3--secreting form has a basolateral vacuolar H+-ATPase and an apical Cl/HCO3 exchanger, whose identity has not been established previously. Apical membrane vesicles of beta intercalated cells purified from rabbit kidney cortex contain both an electroneutral Cl/HCO3 exchange activity and polypeptides that react with antibodies to band 3 on Western blots. Furthermore, both primary cultures of HCO3--secreting intercalated cells and an immortalized cell line derived from these cells express AE1 and have an apical Cl/HCO3 exchanger. Apical membranes purified from these cells contain a 100-kDa polypeptide that cross-reacts with antibody to the cytoplasmic domain of band 3. These data suggest that the apical Cl/HCO3 exchanger of HCO3--secreting intercalated cells is band 3.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University			Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NIDDK NIH HHS [DK-01869, DK-20999] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020999, K08DK001869, R01DK020999] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BARTLES JR, 1984, ANAL BIOCHEM, V140, P284, DOI 10.1016/0003-2697(84)90166-0; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CHASE HS, 1988, AM J PHYSIOL, V254, pF374, DOI 10.1152/ajprenal.1988.254.3.F374; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; EDWARDS JC, 1992, AM J PHYSIOL, V263, pC521, DOI 10.1152/ajpcell.1992.263.2.C521; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; KOHN OF, 1990, AM J PHYSIOL, V258, pF9, DOI 10.1152/ajprenal.1990.258.1.F9; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LEHIR M, 1982, AM J PHYSIOL, V242, pC117, DOI 10.1152/ajpcell.1982.242.1.C117; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOW PS, 1987, J BIOL CHEM, V262, P4592; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OKUBO K, 1991, J BIOL CHEM, V266, P16420; OSTEDGAARD LS, 1991, P NATL ACAD SCI USA, V88, P981, DOI 10.1073/pnas.88.3.981; SAMBUY Y, 1988, P NATL ACAD SCI USA, V85, P1529, DOI 10.1073/pnas.85.5.1529; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SCHUSTER VL, 1985, J CLIN INVEST, V75, P2056, DOI 10.1172/JCI111925; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THORENS B, 1990, AM J PHYSIOL, V259, pC286; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANADELSBERG J, 1989, AM J PHYSIOL, V256, pC1004, DOI 10.1152/ajpcell.1989.256.5.C1004; VANADELSBERG J, 1989, METHOD ENZYMOL, V172, P85; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213	35	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11283	11289						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496183				2022-12-27	WOS:A1993LD46600083
J	ZHANG, JZ; KUDRYK, B; REDMAN, CM				ZHANG, JZ; KUDRYK, B; REDMAN, CM			SYMMETRICAL DISULFIDE BONDS ARE NOT NECESSARY FOR ASSEMBLY AND SECRETION OF HUMAN FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTION; CHAINS; CELLS	Human fibrinogen is a dimer, and each half-molecule is composed of three different polypeptides (Aalpha, Bbeta, and gamma). The two half-molecules are joined together at the amino-terminal ends by three symmetrical disulfide bonds between adjacent Aalpha chains, at position 28, and between adjacent gamma chains at gamma8 and 9. To determine the role of these disulfide bonds in fibrinogen assembly and secretion, site-directed mutagenesis was used to change cysteines of Aalpha28 and gamma8 and 9 to serine, the mutant chains were coexpressed with normal fibrinogen chains in COS cells, and assembly and secretion of fibrinogen were measured. Elimination of the symmetrical disulfide bonds did not affect assembly of tbe chains and dimeric fibrinogen was secreted. Analysis by plasmin digestion indicated that the secreted mutant fibrinogens have a similar structure to normal fibrinogen. Our results indicate that other domains of fibrinogen participate in dimer formation and that the three symmetrical disulfide bonds are not crucial for assembly and secretion of fibrinogen.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,310 E 67 ST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FERGUSON EW, 1975, J BIOL CHEM, V250, P7210; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAEKAWA H, 1991, J BIOL CHEM, V266, P11575; MAEKAWA H, 1992, J CLIN INVEST, V90, P67, DOI 10.1172/JCI115857; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NIEUWENHUIZEN W, 1983, ANN NY ACAD SCI, V408, P92, DOI 10.1111/j.1749-6632.1983.tb23236.x; NUSSENZWEIG V, 1961, ANN I PASTEUR PARIS, V100, P377; PROCYK R, 1992, BIOCHEMISTRY-US, V31, P2273, DOI 10.1021/bi00123a009; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; YAMAZUMI K, 1989, J CLIN INVEST, V83, P1590, DOI 10.1172/JCI114056; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665; ZHANG JZ, 1992, J BIOL CHEM, V267, P21272; ZHANG JZ, 1992, MOL BIOL CELL, V3, P113	30	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11278	11282						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496182				2022-12-27	WOS:A1993LD46600082
J	ZHOU, J; GAO, G; CRABB, JW; SERRERO, G				ZHOU, J; GAO, G; CRABB, JW; SERRERO, G			PURIFICATION OF AN AUTOCRINE GROWTH-FACTOR HOMOLOGOUS WITH MOUSE EPITHELIN PRECURSOR FROM A HIGHLY TUMORIGENIC CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RELATED FACTOR; PROTEINS; DIFFERENTIATION; BINDING; 1246-3A	PC cell line is a highly tumorigenic insulin-independent variant from the teratoma-derived adipogenic cell line 1246. Culture medium of PC cells contains a growth promoting activity for 3T3 cells and producer cells. PC cell-derived growth factor (PCDGF) was purified to homogeneity from PC cell-conditioned medium as an apparent 88-kDa protein by chromatography on heparin-Sepharose, Sephacryl S-200, and phenyl-Sepharose. Digestion with peptide-N-glycosidase F yielded an apparent 68-kDa protein component indicating that PCDGF is a glycoprotein containing about 20 kDa of carbohydrate. Partial sequence from Edman degradation of peptide fragments obtained by digestion of PCDGF with cyanogen bromide and trypsin demonstrates that PCDGF contains regions of sequence identity to that deduced from the granulin or epithelin precursor cDNAs. Granulins are small polypeptides purified from granulocyte extracts with no apparent biological functions. Epithelins are cell growth modulators purified as small molecular mass 6-kDa polypeptides from kidney extracts. The existence of a large molecular mass precursor for granulin or epithelin has been predicted based upon recently cloned cDNAs encoding these biomolecules within a 63.5-kDa protein with putative glycosylation sites. No biological activity has previously been attributed to the precursor. The present results indicate that PCDGF is a potential precursor for epithelin and/or granulin, that this 88-kDa protein is secreted and glycosylated, and that it can function as a mitogen for 3T3 cells as well as an autocrine growth factor for PC cells.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639] Funding Source: NIH RePORTER; NCI NIH HHS [CA37589] Funding Source: Medline; NIDDK NIH HHS [DK38639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; CRABB JW, 1988, J BIOL CHEM, V263, P18678; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; SERRERO G, 1985, IN VITRO CELL DEV B, V21, P537, DOI 10.1007/BF02620848; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SERRERO G, 1991, J CELL PHYSIOL, V149, P503, DOI 10.1002/jcp.1041490321; SERRERO G, 1982, ANAL BIOCHEM, V120, P351, DOI 10.1016/0003-2697(82)90357-8; SERRERO G, 1991, CELL GROWTH DIFFER, V2, P173; SERRERO G, 1982, COLD SPRING HARBOR C, V9, P943; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; TARR GE, 1983, ANAL BIOCHEM, V131, P99, DOI 10.1016/0003-2697(83)90140-9; WEST KA, 1992, TECHNIQUES PROTEIN C, V3, P233; YAMADA Y, 1989, J CELL PHYSIOL, V140, P254, DOI 10.1002/jcp.1041400210; YAMADA Y, 1988, P NATL ACAD SCI USA, V85, P5936, DOI 10.1073/pnas.85.16.5936; YAMADA Y, 1987, J BIOL CHEM, V262, P209	19	179	205	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10863	10869						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496151				2022-12-27	WOS:A1993LD46600025
J	KELLY, WG; DAHMUS, ME; HART, GW				KELLY, WG; DAHMUS, ME; HART, GW			RNA POLYMERASE-II IS A GLYCOPROTEIN - MODIFICATION OF THE COOH-TERMINAL DOMAIN BY O-GLCNAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; LARGEST SUBUNIT; NUCLEAR-PORE; WHEAT-GERM; CALF THYMUS; CYTOPLASMIC GLYCOPROTEINS; TRANSCRIPTION FACTORS; PROTEIN-KINASE; PHOSPHORYLATION; IDENTIFICATION	The largest subunit of mammalian RNA polymerase II (RNAP II) contains at its carboxyl terminus an unusual domain consisting of 52 tandem repeats of the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. This domain, designated the COOH-terminal domain (CTD), is essential for viability and is extensively phosphorylated during the transition from preinitiation complex assembly to elongation (1). Indeed, phosphorylation of the CTD may play an important regulatory role in this transition. We show here that the CTD is also modified by a novel form of protein glycosylation, O-GlcNAc. This modification has been found on numerous transcription factors and other nuclear and cytosolic proteins (2). Glycopeptides obtained by proteolytic digestion of the CTD were purified by reverse-phase high performance liquid chromatography and sequenced. Results from such experiments suggest that glycosylation occurs at multiple sites throughout the CTD, similar to the phosphorylation of this domain. The carbohydrate, however, is not detectable on the phosphorylated form of the enzyme. This observation is consistent with the idea that phosphorylation and glycosylation are mutually exclusive modifications. The CTD of RNAP II, therefore, appears to exist in three distinct conformational states: unmodified, phosphorylated, and glycosylated. The differential modification of the CTD may play an important role in the regulated expression of genes transcribed by RNA polymerase II.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; UNIV CALIF DAVIS,DEPT BIOCHEM & BIOPHYS,DAVIS,CA 95616	Johns Hopkins University; University of California System; University of California Davis					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD013563, R01HD013563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42486] Funding Source: Medline; NICHD NIH HHS [HD 13563] Funding Source: Medline; NIGMS NIH HHS [GM 33300] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1988, P NATL ACAD SCI USA, V85, P1010, DOI 10.1073/pnas.85.4.1010; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BENKO DM, 1988, P NATL ACAD SCI USA, V85, P2573, DOI 10.1073/pnas.85.8.2573; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAILLETBOUDIN ML, 1989, EUR J BIOCHEM, V184, P205, DOI 10.1111/j.1432-1033.1989.tb15008.x; CAPASSO JM, 1988, J BIOL CHEM, V263, P19778; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DONG LYD, 1991, GLYCOCONJUGATE J, V8, P211; DONOFRIO M, 1988, P NATL ACAD SCI USA, V85, P9595, DOI 10.1073/pnas.85.24.9595; FACY P, 1990, EXP CELL RES, V190, P151, DOI 10.1016/0014-4827(90)90179-E; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUILFOYLE TJ, 1989, PLANT CELL, V1, P827, DOI 10.1105/tpc.1.8.827; HAGMANN J, 1992, J BIOL CHEM, V267, P14424; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1988, CELL, V57, P243; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1988, J BIOL CHEM, V263, P18880; KING IA, 1989, J BIOL CHEM, V264, P14022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MEIKRANTZ W, 1991, J CELL SCI, V98, P303; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SEVE AP, 1985, EXP CELL RES, V157, P533, DOI 10.1016/0014-4827(85)90138-7; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; STONE N, 1992, J BIOL CHEM, V267, P6353; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TORRES CR, 1984, J BIOL CHEM, V259, P3308; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; ZHANG J, 1991, J BIOL CHEM, V266, P2290; ZHERING WA, 1988, P NATL ACAD SCI USA, V85, P3698	72	346	364	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10416	10424						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486697				2022-12-27	WOS:A1993LB80000065
J	ATTAASAFOADJEI, E; LAWTON, MP; PHILPOT, RM				ATTAASAFOADJEI, E; LAWTON, MP; PHILPOT, RM			CLONING, SEQUENCING, DISTRIBUTION, AND EXPRESSION IN ESCHERICHIA-COLI OF FLAVIN-CONTAINING MONOOXYGENASE 1C1 - EVIDENCE FOR A 3RD GENE SUBFAMILY IN RABBITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION AMINE OXIDASE; PIG-LIVER-MICROSOMES; MULTIPLE FORMS; GEL-ELECTROPHORESIS; PRIMARY ALKYLAMINES; COVALENT STRUCTURE; RIBONUCLEIC-ACID; DNA; PURIFICATION; MOUSE	Two full-length cDNA clones (2.2 kilobases) encoding a newly recognized form of mammalian flavin-containing monooxygenase (FMO) have been isolated from independent libraries constructed with mRNA from different rabbits. The cDNAs encode a polypeptide of 533 amino acids which contains two putative pyrophosphate binding domains and a hydrophobic carboxyl terminus characteristic of FMOs. This sequence is 52 and 57% identical to sequences of the rabbit ''hepatic'' and ''pulmonary'' FMOs, respectively, and 55% identical to the sequence of ''liver form 2'' published recently by Ozols (Ozols, J. (1991) Arch. Biochem. Biophys. 290, 103-115). cDNA for the new FMO (FMO 1C1) hybridizes with two species of mRNA, one of 2.6 kilobases and one of about 5.4 kilobases, from liver or kidney, but not lung. Guinea pig, hamster, rat, and mouse all express this form of FMO in liver, kidney, and lung. FMO 1C1 has been tentatively characterized following expression in Escherichia coli. It is inactive with methimazole as substrate but highly active with n-octylamine. The temperature lability, responses to ions and detergent, and pH optimum of FMO 1C1 are similar to values reported for hepatic FMO. Sequence comparisons and analysis of rabbit and human genomic DNA indicate that FMO 1C1, as well as the pulmonary and hepatic FMOs, comprise a single gene family made up of distinct gene subfamilies (A, B,C, D,...N), each appearing to contain a single gene. A nomenclature, based on these interrelationships and following the same designations used for classifying cytochromes P-450, is proposed.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,POB 12233,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BELANGER PM, 1981, ANAL BIOCHEM, V118, P47, DOI 10.1016/0003-2697(81)90154-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANNAN GA, 1982, MOL PHARMACOL, V22, P787; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEKMANN H, 1991, N OXIDATION DRUGS BI, P134; DIXIT A, 1984, ARCH BIOCHEM BIOPHYS, V233, P50, DOI 10.1016/0003-9861(84)90600-3; DOLPHIN C, 1991, J BIOL CHEM, V266, P12379; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSER R, 1990, BIOCHEMISTRY-US, V29, P119, DOI 10.1021/bi00453a014; GASSER R, 1988, MOL PHARMACOL, V32, P22; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HASTINGS JW, 1973, P NATL ACAD SCI USA, V70, P3468, DOI 10.1073/pnas.70.12.3468; HERRERO M, 1988, J BACTERIOL, V170, P56, DOI 10.1128/jb.170.1.56-64.1988; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; KIMURA T, 1983, BIOCHEM BIOPH RES CO, V110, P640, DOI 10.1016/0006-291X(83)91197-X; KRAUTHSIEGEL RL, 1982, EUR J BIOCHEM, V121, P259, DOI 10.1111/j.1432-1033.1982.tb05780.x; KYLE J, 1982, J MOL BIOL, V157, P105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWTON MP, 1991, MOL PHARMACOL, V40, P692; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; NIKBAKHT KN, 1992, PHARMACOGENETICS, V2, P207, DOI 10.1097/00008571-199210000-00003; OZOLS J, 1990, J BIOL CHEM, V265, P10289; OZOLS J, 1991, ARCH BIOCHEM BIOPHYS, V290, P103, DOI 10.1016/0003-9861(91)90596-B; OZOLS J, 1989, BIOCHEM BIOPH RES CO, V163, P49, DOI 10.1016/0006-291X(89)92097-4; POULSEN LL, 1986, MOL PHARMACOL, V30, P680; POULSEN LL, 1979, J BIOL CHEM, V254, P6449; PRESSWOOD RP, 1976, FLAVINS FLAVOPROTEIN, P145; SABOURIN PJ, 1984, INT J BIOCHEM, V16, P713, DOI 10.1016/0020-711X(84)90180-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYSER BP, 1985, BIOCHEM PHARMACOL, V34, P1145, DOI 10.1016/0006-2952(85)90487-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRICKLAND S, 1973, J BIOL CHEM, V248, P2953; TYNES RE, 1986, ARCH BIOCHEM BIOPHYS, V251, P654, DOI 10.1016/0003-9861(86)90375-9; TYNES RE, 1985, BIOCHEM BIOPH RES CO, V126, P1069, DOI 10.1016/0006-291X(85)90294-3; TYNES RE, 1987, MOL PHARMACOL, V31, P569; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WILLIAMS DE, 1984, BIOCHEM BIOPH RES CO, V125, P116, DOI 10.1016/S0006-291X(84)80342-3; YAMADA H, 1990, ARCH BIOCHEM BIOPHYS, V280, P305, DOI 10.1016/0003-9861(90)90334-U; YAMADA T, 1985, P NATL ACAD SCI USA, V82, P6522, DOI 10.1073/pnas.82.19.6522; Ziegler D. M., 1988, DRUG METAB REV, V6, P1; ZIEGLER DM, 1972, ARCH BIOCHEM BIOPHYS, V150, P116, DOI 10.1016/0003-9861(72)90017-3	50	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9681	9689						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486656				2022-12-27	WOS:A1993LA68900079
J	DAVID, V; HOCHSTENBACH, F; RAJAGOPALAN, S; BRENNER, MB				DAVID, V; HOCHSTENBACH, F; RAJAGOPALAN, S; BRENNER, MB			INTERACTION WITH NEWLY SYNTHESIZED AND RETAINED PROTEINS IN THE ENDOPLASMIC-RETICULUM SUGGESTS A CHAPERONE FUNCTION FOR HUMAN INTEGRAL MEMBRANE-PROTEIN IP90 (CALNEXIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL SEQUENCE RECEPTOR; TRANSMEMBRANE PROTEINS; HEAT-SHOCK; DEGRADATION; COMPLEX; TRANSLOCATION; ALPHA; CALRETICULIN; RETENTION	A cDNA clone encoding the human endoplasmic reticulum (ER) resident protein IP90 was isolated and sequenced. It predicts a transmembrane protein with a large ER luminal region showing sequence similarity to calreticulin and a short cytoplasmic domain containing a COOH-terminal RKPRRE sequence that may be relevant to its retention in the ER. It is 95% homologous to the canine ER membrane phosphoprotein called pp90 or calnexin (Wada, I., Rindress, D., Cameron, P. H., Ou, W.-J., Doherty, J. J., II, Louvard, D., Bell, A. W., Dignard, D., Thomas, D. Y., and Bergeron, J. J. M. (1991) J. Biol. Chem. 266, 19599-19610). Previously, in lymphocytes, we have characterized IP90 as a protein associated with partially assembled multi-chain proteins including the T cell receptor, the membrane immunoglobulin, and the heavy chain of the major histocompatibility complex class I molecules (Hochstenbach, F., David, V., Watkins, S., and Brenner, M. B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4734-4738). Here, we show that within a short metabolic labeling period, IP90 associates transiently with many different newly synthesized proteins. However, in a T cell line that cannot assemble a complete T cell receptor because it lacks the a subunit, the unassembled T cell receptor beta chains, which are retained in the ER, remain associated with IP90 throughout a prolonged chase time period. Together, these data offer further evidence suggesting that IP90 may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits.			DAVID, V (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.		Hochstenbach, Frans/B-5232-2008; david, violaine/E-3892-2019	david, violaine/0000-0003-0127-1200				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALARCON B, 1988, J BIOL CHEM, V263, P2953; BRENNER MB, 1987, J IMMUNOL, V138, P1502; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUYNH TV, 1985, DNA CLONING, V1; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROKEACH LA, 1991, J IMMUNOL, V147, P3031; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	38	197	205	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9585	9592						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486646				2022-12-27	WOS:A1993LA68900067
J	GELLER, B; ZHU, HY; CHENG, SY; KUHN, A; DALBEY, RE				GELLER, B; ZHU, HY; CHENG, SY; KUHN, A; DALBEY, RE			CHARGED RESIDUES RENDER PRO-OMPA POTENTIAL-DEPENDENT FOR INITIATION OF MEMBRANE TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; SIGNAL-SEQUENCE; CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; INNER MEMBRANE; AMINO TERMINUS; OUTER-MEMBRANE; SECA PROTEIN	We have examined the effects of positively and negatively charged residues on the translocation of outer membrane protein A precursor (pro-OmpA) across the bacterial inner membrane. Pro-OmpA does not translocate across the membrane when 2 positively charged residues are inserted immediately after the leader peptide, whereas it does insert when 2 neutral or negatively charged residues are introduced. Using a cell-free translocation system, we show that the membrane potential stimulated the rate of initial insertion of pro-OmpA with negatively charged residues, inhibited pro-OmpA with positively charged residues, and had no effect on neutral pro-OmpA. Thus, acidic residues render pro-OmpA potential-dependent for loop formation, which then initiates the translocation process.	OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210; UNIV KARLSRUHE,DEPT APPL MICROBIOL,W-7500 KARLSRUHE,GERMANY; OREGON STATE UNIV,DEPT MICROBIOL,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR GENE RES & BIOTECHNOL,CORVALLIS,OR 97331	University System of Ohio; Ohio State University; Helmholtz Association; Karlsruhe Institute of Technology; Oregon State University; Oregon State University								ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BANKAITIS VA, 1985, CURR TOP MEMBR TRANS, V24, P105; BASSFORD PJ, 1979, J BACTERIOL, V139, P19, DOI 10.1128/JB.139.1.19-31.1979; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GELLER BL, 1989, J BIOL CHEM, V264, P16465; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GOLD LM, 1971, METHOD ENZYMOL, V20, P537; ITO K, 1980, J BIOL CHEM, V255, P2123; KATO M, 1992, J BIOL CHEM, V267, P413; KLIONSKY DJ, 1983, J BIOL CHEM, V258, P136; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LU HM, 1991, J BIOL CHEM, V266, P9977; MACINTYRE S, 1990, MOL GEN GENET, V221, P466; Maniatis T., 1982, MOL CLONING; MICHAELIS S, 1982, ANNU REV MICROBIOL, V36, P435, DOI 10.1146/annurev.mi.36.100182.002251; Miller J.H., 1972, EXPT MOL GENETICS; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SILHAVY TJ, 1977, P NATL ACAD SCI USA, V74, P5411, DOI 10.1073/pnas.74.12.5411; SUMMERS RG, 1989, J BIOL CHEM, V264, P20074; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; TANI K, 1989, J BIOL CHEM, V264, P18582; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YAMANE K, 1988, J BIOL CHEM, V263, P19690; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	44	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9442	9447						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486637				2022-12-27	WOS:A1993LA68900047
J	WANG, ZY; QIU, QQ; DEUEL, TF				WANG, ZY; QIU, QQ; DEUEL, TF			THE WILMS-TUMOR GENE-PRODUCT WT1 ACTIVATES OR SUPPRESSES TRANSCRIPTION THROUGH SEPARATE FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-GROWTH; DELETION; EXPRESSION	We recently reported that the putative tumor suppressor gene product WT1 interacts with a 5'-flanking DNA sequence 5'-GCGGGGGCG-3' within the platelet-derived growth factor A-chain gene and abolishes its promoter activity, suggesting that WT1 functions as a transcriptional suppressor of the platelet-derived growth factor A-chain gene. We now show that WT1 functions also as a transcriptional activator. Using chimeric reporter plasmids, we demonstrated that WT1 requires both 5' and 3' binding sites relative to transcription start site for transcriptional repression; however, when WT1 binds to either the 5' or the 3' site alone, WT1 functions to activate transcription. We truncated the wt1 gene and established that amino acid residues 84-179 are required for transcriptional suppression, whereas amino acid residues 180-294 contain a domain that mediates transcriptional activation. These results establish that WT1 has regulatory domains that function either to activate or suppress transcription and suggest the possibility that WT1 functions as an activator and not as a suppressor of selected gene transcription.	WASHINGTON UNIV,SCH MED,DEPT MED,216 S KINGSHIGHWAY,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL031102, R01HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL31102, HL14147] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSSLER M, 1990, NATURE, V343, P774; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1992, NEW BIOL, V4, P97; HUFF V, 1991, AM J HUM GENET, V48, P997; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIN XH, 1992, J BIOL CHEM, V267, P25614; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; RAUSCHER FJ, 1990, SCIENCE, V250, P1257; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1992, J BIOL CHEM, V267, P21999	23	185	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9172	9175						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486616				2022-12-27	WOS:A1993LA68900005
J	HATA, A; RIDINGER, DN; SUTHERLAND, S; EMI, M; ZHANG, SH; MYERS, RL; REN, KS; CHENG, T; INOUE, I; WILSON, DE; IVERIUS, PH; LALOUEL, JM				HATA, A; RIDINGER, DN; SUTHERLAND, S; EMI, M; ZHANG, SH; MYERS, RL; REN, KS; CHENG, T; INOUE, I; WILSON, DE; IVERIUS, PH; LALOUEL, JM			BINDING OF LIPOPROTEIN-LIPASE TO HEPARIN - IDENTIFICATION OF 5 CRITICAL RESIDUES IN 2 DISTINCT SEGMENTS OF THE AMINO-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC TRIGLYCERIDE LIPASE; HUMAN POSTHEPARIN PLASMA; RADIATION INACTIVATION; MOLECULAR-PROPERTIES; ADIPOSE-TISSUE; BOVINE-MILK; SECONDARY-STRUCTURE; KINETIC-PROPERTIES; PANCREATIC LIPASE; CDNA SEQUENCE	Binding to heparan sulfate governs many aspects of the physiological action and regulation of the lipolytic enzyme, lipoprotein lipase (LPL). In an attempt to identify the structural determinants which mediate this interaction, basic residues in three segments of the primary sequence of human LPL (residues 147-151, 279-282, and 292-304) were replaced with alanine, either singly or in various combinations, and variant proteins were subjected to affinity chromatography on heparin-Superose. Five basic residues in two distinct segments of the primary sequence were critical determinants of the high affinity for heparin manifested by the active enzyme (R279, K280, R282, K296, R297). By contrast, no such evidence could be detected for basic residues in the first cluster (K147, K148) or for other basic residues in the third cluster (K292, R294, K304), while the evidence for K300 was unresolved. The conformation of this heparin-binding domain can be inferred by reference to the three-dimensional structure of the homologous enzyme, pancreatic lipase (Winkler, F. K., D'Arcy, A., and Hunziker, W. (1990) Nature 343, 771-774). Affinity of the active enzyme for heparin could not be reduced below a threshold, suggesting that other heparin-binding determinants exist elsewhere in the molecule, as supported by recently published evidence (Davis, R. C., Wong, H., Nikazy, J., Wang, K., Han, Q., and Schotz, M. C. (1992) J. Biol. Chem. 267, 21499-21504).	UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, DIV SOCIAL MED, SALT LAKE CITY, UT 84132 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL39593, HL45753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL145753, R01HL045753, R01HL039593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHBY P, 1978, BIOCHEM J, V171, P305, DOI 10.1042/bj1710305; ATKINS EDT, 1976, HEPARIN CHEM CLIN US, P21; AUGUSTIN J, 1978, J BIOL CHEM, V253, P2912; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSON G, 1981, EUR J BIOCHEM, V113, P547, DOI 10.1111/j.1432-1033.1981.tb05097.x; BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; BENGTSSON G, 1979, BIOCHIM BIOPHYS ACTA, V575, P471, DOI 10.1016/0005-2760(79)90118-8; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; BENSADOU.A, 1974, J BIOL CHEM, V249, P2220; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CHOAY J, 1989, ANN NY ACAD SCI, V556, P61; CHOAY J, 1980, THROMB RES, V18, P573, DOI 10.1016/0049-3848(80)90356-4; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CLARKE AR, 1983, BIOCHIM BIOPHYS ACTA, V747, P130, DOI 10.1016/0167-4838(83)90131-0; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; EGELRUD T, 1972, J BIOL CHEM, V247, P6212; EHNHOLM C, 1974, BIOCHIM BIOPHYS ACTA, V360, P68, DOI 10.1016/0005-2760(74)90180-5; EMI M, 1990, J BIOL CHEM, V265, P5910; GARFINKEL AS, 1972, J LIPID RES, V13, P63; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; HATA A, 1992, J BIOL CHEM, V267, P20132; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IKEDA Y, 1989, BIOCHIM BIOPHYS ACTA, V1003, P254, DOI 10.1016/0005-2760(89)90231-2; Iverius P H, 1986, Methods Enzymol, V129, P691; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KEMPNER ES, 1991, METHOD ENZYMOL, V197, P280; Kinnunen P.K.J., 1984, P307; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; OLIVECRONA T, 1971, BIOCHEM BIOPH RES CO, V43, P524, DOI 10.1016/0006-291X(71)90645-0; OLIVECRONA T, 1982, EUR J BIOCHEM, V124, P629, DOI 10.1111/j.1432-1033.1982.tb06640.x; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1467; QUINN D, 1983, PROG LIPID RES, V22, P35, DOI 10.1016/0163-7827(83)90003-6; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; Smith L.C., 1984, P263; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; VANNIER C, 1989, J BIOL CHEM, V264, P13199; WALLINDER L, 1982, BIOCHIM BIOPHYS ACTA, V711, P107, DOI 10.1016/0005-2760(82)90015-7; WANG CS, 1983, BIOCHIM BIOPHYS ACTA, V754, P142, DOI 10.1016/0005-2760(83)90155-8; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YANG CY, 1989, J BIOL CHEM, V264, P16822	64	105	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8447	8457						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473288				2022-12-27	WOS:A1993KX81100015
J	JACKSON, DG; WINDLE, HJ; VOORHEIS, HP				JACKSON, DG; WINDLE, HJ; VOORHEIS, HP			THE IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF 2 INVARIANT SURFACE GLYCOPROTEINS LOCATED BENEATH THE SURFACE-COAT BARRIER OF BLOOD-STREAM FORMS OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; GENE-EXPRESSION SITE; DISTINCT ACID-PHOSPHATASES; POLYACRYLAMIDE GELS; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; T-BRUCEI; AFRICAN TRYPANOSOMES; LEISHMANIA-DONOVANI; ANTIGENIC VARIATION	Two new polypeptides, termed ISG70 and ISG64, have been found in Trypanosoma brucei, using enzyme-catalyzed radioiodination techniques. Both are externally disposed integral membrane glycoproteins, containing N-linked carbohydrate chains. No structural homology was detected between ISG70, ISG64, or the variant surface glycoprotein (VSG) when assessed by 1) comparative peptide mapping, 2) immunoprecipitation analysis, and 3) lectin affinity chromatography. ISG70 occurred in 5.1 x 10(4) copies/cell and has been purified 880-fold from detergent extracts of plasma membranes by a procedure that includes gel filtration, lectin affinity chromatography, and preparative SDS-polyacrylamide gel electrophoresis. ISG70 Was present only in bloodstream forms and was specifically detected in six different cloned variants from the Molteno Institute trypanosomal antigen type (MITat) serodeme of T. brucei and from the single cloned variant of the International Laboratory for Research on Animal Diseases trypanosomal antigen type (ILTat) serodeme that was examined. Rabbits with chronic infections of T. brucei displayed circulating antibodies against ISG70. Both the immunogenicity of ISG70 and its invariant nature suggest that it may be useful in the development of an effective serodiagnostic test. Furthermore, its stage-specific location combined with its invariant nature implies that its function is strictly related to a physiological role required for the parasite's residence in its mammalian host.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND	Trinity College Dublin				, david/0000-0002-4133-9364				ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; AUFFRET CA, 1981, BIOCHEM J, V193, P647, DOI 10.1042/bj1930647; BEAT DA, 1984, J PROTOZOOL, V31, P541, DOI 10.1111/j.1550-7408.1984.tb05499.x; BERBEROF M, 1991, MOL CELL BIOL, V11, P1473, DOI 10.1128/MCB.11.3.1473; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BRUN R, 1981, Z PARASITENKD, V66, P17, DOI 10.1007/BF00941941; BULOW R, 1986, J BIOL CHEM, V261, P1918; BURGESS DE, 1985, INFECT IMMUN, V50, P893, DOI 10.1128/IAI.50.3.893-899.1985; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; CULLY DF, 1986, MOL BIOCHEM PARASIT, V21, P189, DOI 10.1016/0166-6851(86)90022-8; DONELSON JE, 1985, MICROBIOL REV, V49, P107, DOI 10.1128/MMBR.49.2.107-125.1985; FAHEY JL, 1978, HDB EXPT IMMUNOLOGY; FOX JA, 1986, J BIOL CHEM, V261, P5767; GIBBS CP, 1988, MOL BIOCHEM PARASIT, V28, P197, DOI 10.1016/0166-6851(88)90004-7; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; GOTTLIEB M, 1981, EXP PARASITOL, V52, P117, DOI 10.1016/0014-4894(81)90067-9; GRAB DJ, 1987, J CELL BIOL, V105, P737, DOI 10.1083/jcb.105.2.737; HAND ES, 1962, J AM CHEM SOC, V84, P3505, DOI 10.1021/ja00877a017; HASSAN HF, 1987, MOL BIOCHEM PARASIT, V23, P285, DOI 10.1016/0166-6851(87)90035-1; HERELD D, 1986, J BIOL CHEM, V261, P3813; HIDE G, 1989, MOL BIOCHEM PARASIT, V36, P51, DOI 10.1016/0166-6851(89)90199-0; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; JACKSON DG, 1985, BIOCHEM J, V230, P195, DOI 10.1042/bj2300195; JACKSON DG, 1990, BIOCHEM SOC T, V18, P1032, DOI 10.1042/bst0181032; JACKSON DG, 1984, J BIOL CHEM, V260, P5179; JOHNSON JG, 1977, J PROTOZOOL, V24, P587, DOI 10.1111/j.1550-7408.1977.tb01020.x; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOOTER JM, 1988, GENE, V69, P1, DOI 10.1016/0378-1119(88)90372-1; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MANCINI PE, 1982, BIOCHIM BIOPHYS ACTA, V688, P399, DOI 10.1016/0005-2736(82)90351-0; Markwell M. A. K., 1978, ANAL BIOCHEM, V87, P207; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MCLAUGHLIN J, 1986, MOL CELL BIOCHEM, V70, P177, DOI 10.1007/BF00229432; MCLAUGHLIN J, 1987, EXP PARASITOL, V64, P1, DOI 10.1016/0014-4894(87)90002-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY NB, 1987, MOL STRATEGIES PARAS, P449; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OWEN P, 1985, ENTEROBACTERIAL SURF, P237; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; REINWALD E, 1981, BIOCHIM BIOPHYS ACTA, V668, P119, DOI 10.1016/0005-2795(81)90155-0; REMALEY AT, 1985, J BIOL CHEM, V260, P880; REVELARD P, 1990, NUCLEIC ACIDS RES, V18, P7299, DOI 10.1093/nar/18.24.7299; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; ROVIS L, 1984, ACTA TROP, V41, P227; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1990, FEBS LETT, V271, P67, DOI 10.1016/0014-5793(90)80373-Q; SIEGEL MB, 1983, METHOD ENZYMOL, V93, P3; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; SON HJ, 1989, MOL BIOCHEM PARASIT, V33, P59, DOI 10.1016/0166-6851(89)90042-X; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; TACK LO, 1977, BIOCHEMISTRY-US, V16, P3746, DOI 10.1021/bi00636a003; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TAYLOR DW, 1977, PARASITOLOGY, V74, P47, DOI 10.1017/S0031182000047521; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOORHEIS HP, 1977, BIOCHEM J, V164, P15, DOI 10.1042/bj1640015; VOORHEIS HP, 1979, BIOCHEM J, V180, P11, DOI 10.1042/bj1800011; VOORHEIS HP, 1980, EUR J BIOCHEM, V113, P223, DOI 10.1111/j.1432-1033.1980.tb06160.x; VOORHEIS HP, 1982, J BIOL CHEM, V257, P2300; WILLIAMS AF, 1988, ANN REV BIOCH, V57, P285; WYNS L, 1978, NUCLEIC ACIDS RES, V5, P2345, DOI 10.1093/nar/5.7.2345; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	69	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8085	8095						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463323				2022-12-27	WOS:A1993KW97900073
J	REICH, Z; FRIEDMAN, P; LEVINZAIDMAN, S; MINSKY, A				REICH, Z; FRIEDMAN, P; LEVINZAIDMAN, S; MINSKY, A			EFFECTS OF ADENINE TRACTS ON THE B-Z TRANSITION - FINE TUNING OF DNA CONFORMATIONAL TRANSITION PROCESSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-HANDED DNA; HIGH-SALT; BASE-PAIRS; Z JUNCTION; Z-HELIX; METHYLATION; POLY(DG-DC); DODECAMER; PLASMID; DUPLEX	The effects exerted by short runs of adenines (A-tracts), alternating (AT)n segments, and single-stranded DNA upon the right- to left-handed DNA transition, as well as upon the energetic and structural parameters of the B/Z junctions, were investigated by using synthetic segments in which these motifs are coupled to a potentially Z-forming core. UV, CD, and P-31 NMR studies of the salt-induced B to Z transition occurring in the various segments indicate that the transition is composed of two phases: a slow rate-determining induction of an initial structural deformation followed by a cooperative propagation of this ''nucleus'' in the form of a left-handed Z-DNA. The first phase is found to be crucially affected by the nature of the sequences coupled to the potentially Z-forming core. Thus, a higher rigidity of the flanking segments, such as that characterizing adenine tracts, is associated with higher energy values required for the induction of the initial conformational deformation, as well as with more defined structural parameters of the ultimate B/Z junctions. The second phase is affected mainly by the composition and sequence of the Z-forming segment. The observations that DNA conformational changes can be finely tuned and modulated by parameters pertaining to both the segment which undergoes the transition and the flanking sequences support the notion that DNA secondary motifs, such as the Z form and A-tracts, might be involved in the regulation of cellular processes.	WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DAI ZG, 1992, J BIOMOL STRUCT DYN, V9, P1155, DOI 10.1080/07391102.1992.10507985; DANG LX, 1990, P NATL ACAD SCI USA, V87, P4630, DOI 10.1073/pnas.87.12.4630; DOKTYCZ MJ, 1990, J MOL BIOL, V212, P3, DOI 10.1016/0022-2836(90)90297-Y; DREW H, 1980, NATURE, V286, P567, DOI 10.1038/286567a0; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; GORENSTEIN DG, 1982, BIOCHEMISTRY-US, V21, P580, DOI 10.1021/bi00532a026; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JOVIN TM, 1987, ANNU REV PHYS CHEM, V38, P521, DOI 10.1146/annurev.pc.38.100187.002513; KLYSIK J, 1981, NATURE, V290, P672, DOI 10.1038/290672a0; KMIEC EB, 1985, CELL, V40, P139, DOI 10.1016/0092-8674(85)90317-4; LESLIE AGW, 1980, J MOL BIOL, V143, P47; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; PATEL DJ, 1979, P NATL ACAD SCI USA, V76, P2508, DOI 10.1073/pnas.76.6.2508; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; RAMSTEIN J, 1980, NATURE, V288, P413, DOI 10.1038/288413a0; REICH Z, 1992, J BIOMOL STRUCT DYN, V9, P1097, DOI 10.1080/07391102.1992.10507981; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; Saenger W., 1984, PRINCIPLES NUCLEIC A, P253; SHATZKYSCHWARTZ M, 1992, BIOCHEMISTRY-US, V31, P2339, DOI 10.1021/bi00123a019; SHEARDY RD, 1989, BIOCHEMISTRY-US, V28, P720, DOI 10.1021/bi00428a046; SOUMPASIS DM, 1984, P NATL ACAD SCI-BIOL, V81, P5116, DOI 10.1073/pnas.81.16.5116; STIRDIVANT SM, 1982, J BIOL CHEM, V257, P159; Sundaralingam M., 1988, STRUCTURE EXPRESSION, P191; TOPAL MD, 1976, BIOPOLYMERS, V15, P1775, DOI 10.1002/bip.1976.360150912; VANDESANDE JH, 1982, EMBO J, V1, P115, DOI 10.1002/j.1460-2075.1982.tb01133.x; WANG AHJ, 1981, SCIENCE, V211, P171, DOI 10.1126/science.7444458; ZACHARIAS W, 1988, BIOCHEMISTRY-US, V27, P2970, DOI 10.1021/bi00408a046	31	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8261	8266						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463336				2022-12-27	WOS:A1993KW97900098
J	DRYDEN, DTF; COOPER, LP; MURRAY, NE				DRYDEN, DTF; COOPER, LP; MURRAY, NE			PURIFICATION AND CHARACTERIZATION OF THE METHYLTRANSFERASE FROM THE TYPE-1 RESTRICTION AND MODIFICATION SYSTEM OF ESCHERICHIA-COLI K12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA RECOGNITION DOMAINS; DEOXYRIBONUCLEIC ACID MODIFICATION; I RESTRICTION; CATALYTIC PROPERTIES; SPECIFICITY POLYPEPTIDES; MODIFICATION ENZYMES; SUBUNIT STRUCTURE; SEQUENCE; ENDONUCLEASE; ORGANIZATION	The DNA methyltransferase component of the type I restriction and modification enzyme of Escherichia coli K12 has been purified. The active component, a trimer of molecular mass 170 kDa consisting of one DNA recognition subunit (S) and two modification subunits (M), showed the expected preference for modifying a hemimethylated substrate rather than an unmethylated one. Small amounts of the dimers M2 and M1S1 were also isolated. Subunit rearrangements of the three protein species occurred on ion exchange and heparin-agarose chromatography. Denaturation of the trimer gave folding intermediates, and these and the dimer forms isolated during purification may reflect the assembly of the protein in vivo. Enzyme activity was recovered on refolding the denatured protein by dilution of the denaturant. A comparison of the predicted isoelectric points of all known S subunits of type I restriction and modification enzymes revealed values that correlated with the arrangement of type I systems in several families. Electrostatic interactions may explain the different subunit stoichiometries observed during purification of type I enzymes and the differing preferences for hemimethylated DNA displayed by the three type I families.			DRYDEN, DTF (corresponding author), UNIV EDINBURGH, INST CELL & MOLEC BIOL, EDINBURGH EH9 3JR, MIDLOTHIAN, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BICKLE TA, 1978, P NATL ACAD SCI USA, V75, P3099, DOI 10.1073/pnas.75.7.3099; BICKLE TA, 1987, ESCHERICHIA COLI SAL, P692; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BURCKHARDT J, 1981, J MOL BIOL, V153, P425, DOI 10.1016/0022-2836(81)90287-4; Cantor, 1980, BIOPHYS CHEM; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; COWAN GM, 1989, CELL, V56, P103, DOI 10.1016/0092-8674(89)90988-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESKIN B, 1972, J BIOL CHEM, V247, P6183; FULLERPACE FV, 1986, P NATL ACAD SCI USA, V83, P9368, DOI 10.1073/pnas.83.24.9368; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GANN AAF, 1987, MOL MICROBIOL, V1, P13, DOI 10.1111/j.1365-2958.1987.tb00521.x; GIANAZZA E, 1980, J CHROMATOGR, V193, P1, DOI 10.1016/S0021-9673(00)81438-7; GORBALENYA AE, 1991, FEBS LETT, V291, P277, DOI 10.1016/0014-5793(91)81301-N; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KANNAN P, 1989, J MOL BIOL, V209, P335, DOI 10.1016/0022-2836(89)90001-6; KARLIN S, 1990, METHOD ENZYMOL, V183, P388; KELLEHER JE, 1991, J MOL BIOL, V221, P431, DOI 10.1016/0022-2836(91)80064-2; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KUSIAK M, 1992, MOL MICROBIOL, V6, P3251, DOI 10.1111/j.1365-2958.1992.tb01779.x; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAUTENBERGER JA, 1972, J BIOL CHEM, V247, P6176; LEATHERBARROW RJ, 1990, GRAFT VERSION 2 0; LOENEN WAM, 1987, J MOL BIOL, V198, P159, DOI 10.1016/0022-2836(87)90303-2; MATHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MURRAY NE, 1982, EMBO J, V1, P535, DOI 10.1002/j.1460-2075.1982.tb01205.x; Pace C N, 1986, Methods Enzymol, V131, P266; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PATEL J, 1992, GENE, V112, P21, DOI 10.1016/0378-1119(92)90298-4; PRICE C, 1989, J MOL BIOL, V205, P115, DOI 10.1016/0022-2836(89)90369-0; PRICE C, 1987, EUR J BIOCHEM, V167, P111, DOI 10.1111/j.1432-1033.1987.tb13310.x; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; SAIN B, 1980, MOL GEN GENET, V180, P35, DOI 10.1007/BF00267350; Sambrook J, 1989, MOL CLONING LABORATO; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SHARP PM, 1992, P NATL ACAD SCI USA, V89, P9836, DOI 10.1073/pnas.89.20.9836; SOBER HA, 1970, HDB BIOCH, pB75; SURI B, 1984, EMBO J, V3, P575, DOI 10.1002/j.1460-2075.1984.tb01850.x; SURI B, 1985, J MOL BIOL, V186, P77, DOI 10.1016/0022-2836(85)90258-X; TAYLOR I, 1992, NUCLEIC ACIDS RES, V20, P179, DOI 10.1093/nar/20.2.179; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441	47	87	87	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13228	13236						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514761				2022-12-27	WOS:A1993LH55300033
J	WULFF, BS; JOHANSEN, TE; DALBOGE, H; OHARE, MMT; SCHWARTZ, TW				WULFF, BS; JOHANSEN, TE; DALBOGE, H; OHARE, MMT; SCHWARTZ, TW			PROCESSING OF 2 HOMOLOGOUS PRECURSORS, PRO-NEUROPEPTIDE-Y AND PRO-PANCREATIC POLYPEPTIDE, IN TRANSFECTED CELL-LINES EXPRESSING DIFFERENT PRECURSOR CONVERTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA; COMMON PRECURSOR; MAMMALIAN-CELLS; CHO CELLS; CDNA; IDENTIFICATION; PHEOCHROMOCYTOMA; SECRETION; HORMONE; PEPTIDE	The processing of two homologous precursors, pro-neuropeptide Y (pro-NPY) and pro-pancreatic polypeptide (pro-PP), was studied in four neuroendocrine cell lines after transfection: CA-77 medullary thyroid carcinoma cells, AtT-20 corticotrope pituitary cells, RIN2A- 19 pancreatic endocrine cells, and NB1 neuroblastoma cells. Northern blot analysis indicated that the AtT-20 cells only expressed precursor convertase 3; in contrast, NB1 cells only expressed precursor convertase 2, whereas the RIN2A-19 and CA-77 cells expressed both enzymes. Despite these differences in expression pattern of precursor convertases the four cell lines were, surprisingly, indistinguishable in respect to their processing of pro-PP and pro-NPY. In all four cell lines, pro-NPY was almost completely converted to NPY, and, in all four cell lines, only around 50% of the PP precursor was converted to PP. The relatively poor processing efficiency of pro-PP was rather similar to the processing efficiency of the endogenously produced precursors in the respective cell lines, pro-calcitonin (CA-77), proopiomelanocortin (AtT-20), proinsulin (RIN2A-19), and pro-vasoactive intestinal polypeptide (NB1). At least in the CA-77 cells, NPY and PP were apparently sorted to the regulated secretory pathway, as upon stimulation with secretagogue the release of the transfected peptides increased in parallel with the endogenously expressed peptide, calcitonin gene-related peptide. Mutagenesis studies showed that on the N-terminal side of the dibasic processing site, the otherwise important difference in structure between PP and NPY, a proline for glutamine in position 34, was not responsible for the difference in processing efficiency. On the C-terminal side of the processing site, the efficient processing of pro-NPY could not be transferred to pro-PP by exchanging the whole C-terminal domains of the precursors. It is concluded that pro-NPY is processed more efficiently than pro-PP in all neuroendocrine cell lines tested independent on their expression of the two main precursor convertases and that mutagenesis data indicate that the structural element responsible for the efficient processing of pro-NPY is not located on the N-terminal side of the dibasic processing site.	UNIV COPENHAGEN, RIGSHOSP 6321, DEPT CLIN CHEM, MOLEC ENDOCRINOL LAB, DK-2100 COPENHAGEN, DENMARK; NOVO NORD AS, DK-2880 BAGSVAERD, DENMARK	Rigshospitalet; University of Copenhagen; Novo Nordisk				Schwartz, Thue W./0000-0002-0261-6904				BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BIRNBAUM RS, 1984, J BIOL CHEM, V259, P2870; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOEL E, 1984, EMBO J, V3, P909, DOI 10.1002/j.1460-2075.1984.tb01904.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; DIKCERSON IM, 1990, J BIOL CHEM, V265, P242; FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463; FUHLENDORFF J, 1990, J BIOL CHEM, V265, P11706; GLOVER I, 1983, BIOPOLYMERS, V22, P293, DOI 10.1002/bip.360220138; GLOVER ID, 1984, EUR J BIOCHEM, V142, P379, DOI 10.1111/j.1432-1033.1984.tb08298.x; HOSHINO M, 1984, PEPTIDES, V5, P155, DOI 10.1016/0196-9781(84)90199-2; JOHANSEN TE, 1990, BIOCHEM BIOPH RES CO, V172, P1384, DOI 10.1016/0006-291X(90)91603-P; JOHANSEN TE, 1991, MOL CELL ENDOCRINOL, V82, P51, DOI 10.1016/0303-7207(91)90008-G; LAPPS W, 1988, J BIOL CHEM, V263, P13456; LI X, 1992, BIOCHEMISTRY-US, V31, P1245, DOI 10.1021/bi00119a038; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; OHARE MMT, 1985, CANCER, V55, P1895, DOI 10.1002/1097-0142(19850501)55:9<1895::AID-CNCR2820550910>3.0.CO;2-S; OHARE MMT, 1989, CANCER RES, V49, P7015; OHARE MMT, 1989, CANCER RES, V49, P7010; SCHWARTZ TW, 1987, J BIOL CHEM, V262, P5093; SCHWARTZ TW, 1978, J CLIN INVEST, V61, P781, DOI 10.1172/JCI108992; SCHWARTZ TW, 1987, FEBS LETT, V225, P209, DOI 10.1016/0014-5793(87)81159-6; SCHWARTZ TW, 1981, NATURE, V294, P589, DOI 10.1038/294589a0; SCHWARTZ TW, 1980, J BIOL CHEM, V255, P1494; SCHWARTZ TW, 1989, NEUROPEPTIDE Y, P143; SCHWARTZ TW, 1990, ANN NY ACAD SCI, V611, P35; Schwartz TW, 1990, MOL BIOL ISLETS LANG, P153; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKEUCHI T, 1991, J BIOL CHEM, V266, P17409; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WULFF BS, 1990, FEBS LETT, V261, P101, DOI 10.1016/0014-5793(90)80646-Z	41	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13327	13335						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514771				2022-12-27	WOS:A1993LH55300047
J	BOLL, W; SCHMIDCHANDA, T; SEMENZA, G; MANTEI, N				BOLL, W; SCHMIDCHANDA, T; SEMENZA, G; MANTEI, N			MESSENGER-RNAS EXPRESSED IN INTESTINE OF ADULT BUT NOT BABY RABBITS - ISOLATION OF COGNATE CDNAS AND CHARACTERIZATION OF A NOVEL BRUSH-BORDER PROTEIN WITH ESTERASE AND PHOSPHOLIPASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; HORMONE FUSION GENES; LACTASE-PHLORIZIN HYDROLASE; GLUTATHIONE S-TRANSFERASES; SUCRASE-ISOMALTASE; TRANSGENIC MICE; NUCLEOTIDE-SEQUENCE; MEMBRANE; DNA; PURIFICATION	Using a subtractive hybridization method, we have cloned cDNAs corresponding to 10 different mRNAs which share the property of being expressed in the intestine of adult but not baby rabbits. Four could be identified as coding for previously known gene products (sucrase-isomaltase, a glutathione S-transferase, a cytochrome P450, and a long form of ferritin mRNA), while six code for previously unknown proteins. One clone, AdRab-B, codes for a protein of 1458 amino acids, including (i) a putative signal sequence at the NH2 terminus, (ii) four internal repeats, 308-346 amino acids in length, (iii) a hydrophobic stretch near the COOH terminus, which represents a potential membrane anchor, and (iv) a short hydrophilic stretch at the very COOH terminus. The corresponding protein was studied with the aid of antibodies prepared against polypeptides expressed from segments of the cDNA in Escherichia coli. The protein was shown to be proteolytically processed in the intestine (but not when expressed in COS cells) and to be targeted to the brush border membrane of the enterocytes. Finally, the protein was found to have esterase and phospholipase A/lysophospholipase activity.	SWISS FED INST TECHNOL, DEPT BIOCHEM, CH-8092 ZURICH, SWITZERLAND; UNIV ZURICH, DEPT ANAT, CH-8057 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich								AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; [Anonymous], 1972, ENZYMES; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLANK ML, 1991, METHOD ENZYMOL, V197, P158; BOARD PG, 1987, P NATL ACAD SCI USA, V84, P2377, DOI 10.1073/pnas.84.8.2377; Brockerhoff H, 1975, Methods Enzymol, V35, P315, DOI 10.1016/0076-6879(75)35171-9; Challberg M D, 1980, Methods Enzymol, V65, P39; COHN SM, 1991, P NATL ACAD SCI USA, V88, P1034, DOI 10.1073/pnas.88.3.1034; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOELL RG, 1962, BIOCHIM BIOPHYS ACTA, V62, P353, DOI 10.1016/0006-3002(62)90097-5; DUGUID JR, 1990, NUCLEIC ACIDS RES, V18, P2789, DOI 10.1093/nar/18.9.2789; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; HENNING SJ, 1985, ANNU REV PHYSIOL, V47, P231; HERBST JJ, 1969, PEDIATR RES, V3, P27, DOI 10.1203/00006450-196901000-00004; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KO MSH, 1990, NUCLEIC ACIDS RES, V18, P4293, DOI 10.1093/nar/18.14.4293; KOLDOVSK.O, 1966, NATURE, V212, P1389, DOI 10.1038/2121389a0; KOLDOVSKY O, 1972, COMP BIOCHEM PHYSIOL, V43, P1, DOI 10.1016/0305-0491(72)90193-9; Krisch K., 1971, ENZYMES            A, V5, P43; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESE HJ, 1973, J BIOL CHEM, V248, P8170; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; NAIM HY, 1991, J BIOL CHEM, V266, P12313; PICKETT CB, 1984, J BIOL CHEM, V259, P5182; PIND S, 1988, BIOCHIM BIOPHYS ACTA, V938, P211, DOI 10.1016/0005-2736(88)90160-5; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; POLLACK JD, 1971, J LIPID RES, V12, P563; POTENZA CL, 1989, J BIOL CHEM, V264, P16222; Rhoades D.F., 1979, HERBIVORES THEIR INT, P1; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; ROTH KA, 1991, J BIOL CHEM, V266, P5949; RUF J, 1990, J BIOL CHEM, V265, P15034; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBASTIO G, 1987, BIOCHEM BIOPH RES CO, V149, P830, DOI 10.1016/0006-291X(87)90442-6; SEBASTIO G, 1986, FEBS LETT, V208, P460, DOI 10.1016/0014-5793(86)81069-9; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SMITH MW, 1987, BIOCHIM BIOPHYS ACTA, V905, P503, DOI 10.1016/0005-2736(87)90481-0; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; THURNHOFER H, 1990, BIOCHIM BIOPHYS ACTA, V1024, P249, DOI 10.1016/0005-2736(90)90351-N; TU CPD, 1987, BIOCHEM SOC T, V15, P734, DOI 10.1042/bst0150734; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WACHTER L, 1986, NUCLEIC ACIDS RES, V14, P7985, DOI 10.1093/nar/14.20.7985; WACKER H, 1992, J BIOL CHEM, V267, P18744; WU GD, 1992, J BIOL CHEM, V267, P7863	60	49	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12901	12911						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509424				2022-12-27	WOS:A1993LG65800097
J	LANE, BG; DUNWELL, JM; RAY, JA; SCHMITT, MR; CUMING, AC				LANE, BG; DUNWELL, JM; RAY, JA; SCHMITT, MR; CUMING, AC			GERMIN, A PROTEIN MARKER OF EARLY PLANT DEVELOPMENT, IS AN OXALATE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHYSARUM-POLYCEPHALUM; MESSENGER-RNA; CELL-WALLS; WHEAT; GROWTH; PURIFICATION; STIMULATION; PEROXIDASE; SEEDLINGS; EMBRYOS	Germin is a homopentameric glycoprotein, the synthesis of which coincides with the onset of growth in germinating wheat embryos. There have been detailed studies of germin structure, biosynthesis, homology with other proteins, and of its value as a marker of wheat development. Germin isoforms associated with the apoplast have been speculated to have a role in embryo hydration during maturation and germination. Antigenically related isoforms of germin are present during germination in all of the economically important cereals studied, and the amounts of germin-like proteins and coding elements have been found to undergo conspicuous change when salt-tolerant higher plants are subjected to salt stress. In this report, we describe how circumstantial evidence arising from unrelated studies of barley oxalate oxidase and its coding elements have led to definitive evidence that the germin isoform made during wheat germination is an oxalate oxidase. Establishment of links between oxalate degradation, cereal germination, and salt tolerance has significant implications for a broad range of studies related to development and adaptation in higher plants. Roles for germin in cell wall biochemistry and tissue remodeling are discussed, with special emphasis on the generation of hydrogen peroxide during germin-induced oxidation of oxalate.	ZENECA SEEDS,JEALOTTS HILL RES STN,BRACKNELL RG12 6EY,BERKS,ENGLAND; ENICHEM AMER INC,MONMOUTH JCT,NJ 08852; UNIV LEEDS,DEPT GENET,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds	LANE, BG (corresponding author), UNIV TORONTO,FAC MED,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA.		Dunwell, Jim/AAS-6217-2020	Dunwell, Jim/0000-0003-2147-665X				ANDREWS JC, 1951, FOOD RES, V16, P306; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; BERNIER F, 1987, GENE, V59, P265, DOI 10.1016/0378-1119(87)90334-9; BERNIER F, 1986, BIOCHEM CELL BIOL, V64, P337, DOI 10.1139/o86-047; Carpita N. C., 1988, Current Topics in Plant Biochemistry and Physiology, V7, P112; Carpita N. C., 1987, PHYSL CELL EXPANSION, P28; CARPITA NC, 1986, PLANT PHYSIOL, V80, P660, DOI 10.1104/pp.80.3.660; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CORNISHBOWDEN A, 1983, METHOD ENZYMOL, V91, P60; DARVILL JE, 1980, PLANT PHYSIOL, V66, P1135, DOI 10.1104/pp.66.6.1135; DRATEWKAKOS E, 1989, J BIOL CHEM, V264, P4896; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; GIBEAUT DM, 1991, PLANT PHYSIOL, V97, P551, DOI 10.1104/pp.97.2.551; GRZELCZAK ZF, 1983, CAN J BIOCHEM CELL B, V61, P1233, DOI 10.1139/o83-159; GRZELCZAK ZF, 1985, CAN J BIOCHEM CELL B, V63, P1003, DOI 10.1139/o85-125; GRZELCZAK ZF, 1984, CAN J BIOCHEM CELL B, V62, P1351, DOI 10.1139/o84-172; HALLIWELL B, 1978, PLANTA, V140, P81, DOI 10.1007/BF00389384; HURKMAN WJ, 1991, PLANT PHYSIOL, V97, P366, DOI 10.1104/pp.97.1.366; JAIKARAN ASI, 1990, J BIOL CHEM, V265, P12503; JOHNSTON FB, 1957, NATURE, V179, P160, DOI 10.1038/179160b0; KARIMI SH, 1986, BOT GAZ, V147, P65, DOI 10.1086/337569; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE B, 1987, BIOCHEM CELL BIOL, V65, P354, DOI 10.1139/o87-045; LANE BG, 1992, EUR J BIOCHEM, V209, P961, DOI 10.1111/j.1432-1033.1992.tb17369.x; LANE BG, 1988, ROOTS OF MODERN BIOCHEMISTRY, P457; LANE BG, 1991, J BIOL CHEM, V266, P10461; LANE BG, 1991, FASEB J, V5, P2893, DOI 10.1096/fasebj.5.14.1752357; LUTTRELL BM, 1993, J BIOL CHEM, V268, P1521; MCCUBBIN WC, 1987, BIOCHEM CELL BIOL, V65, P1039, DOI 10.1139/o87-136; MICHALOWSKI CB, 1992, PLANT PHYSIOL, V100, P537, DOI 10.1104/pp.100.1.537; Sambrook J, 1989, MOL CLONING LABORATO; SCALBERT A, 1985, PHYTOCHEMISTRY, V24, P1359, DOI 10.1016/S0031-9422(00)81133-4; SCHMITT M R, 1991, Plant Physiology (Rockville), V96, P85; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; SMITH FW, 1972, AUST J AGR RES, V23, P969, DOI 10.1071/AR9720969; SUGIURA M, 1979, CHEM PHARM BULL, V27, P2003; THOMPSON EW, 1980, J BIOL CHEM, V255, P5965; VANHUYSTEE RB, 1980, BOT REV, V46, P429, DOI 10.1007/BF02860533; VARNER JE, 1993, J CELL BIOCH S, V17, P2; WILLIAMS RF, 1972, SHOOT APEX LEAF GROW, P9; [No title captured]	41	277	301	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12239	12242						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509360				2022-12-27	WOS:A1993LG65800003
J	SALT, DE; WAGNER, GJ				SALT, DE; WAGNER, GJ			CADMIUM TRANSPORT ACROSS TONOPLAST OF VESICLES FROM OAT ROOTS - EVIDENCE FOR A CD2+/H+ ANTIPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-PUMPING ATPASE; BETA-VULGARIS L; MEMBRANE-VESICLES; CALCIUM-TRANSPORT; CA2+/H+ ANTIPORT; SUSPENSION CELLS; ACRIDINE-ORANGE; SYSTEM DRIVEN; BINDING; TOBACCO	Cadmium accumulates in the vacuole of plant cells, but the mechanism driving its transport across the vacuole membrane is not understood. Here we present evidence for Cd2+ transport via a Cd2+/H+ antiport activity into tonoplast-enriched vesicles isolated from oat roots. Experimentally, accumulation of Cd2+ into vesicles could be driven by DELTApH generated by either V-type ATPase or artificially using nigericin to exchange K+ and H+ in K+-loaded vesicles. When tonoplast-enriched vesicles were separated on a linear sucrose gradient, NO3--sensitive ATPase, total MgATPase, and DELTApH-dependent Cd2+ transport equilibrated at 1.11 g/ml, the density of tonoplast membrane. Cd2+ accumulation in vesicles was accompanied by efflux of protons in a Cd2+ concentration-dependent manner characteristic of an antiport activity. The DELTApH-dependent Cd2+ accumulation process showed saturation kinetics with a K(m(app)) of 5.5 muM. Thus the process is a candidate for transport of Cd2+ from the cytoplasm to the vacuolar sap under conditions of low as well as high Cd2+ exposure.	UNIV KENTUCKY,DEPT AGRON,PLANT PHYSIOL,BIOCHEM MOLEC BIOL PROGRAM,N212F,AGR SCI BLDG N,LEXINGTON,KY 40546	University of Kentucky			Salt, David E/B-3864-2009					BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BHATTACHARYYA MH, 1988, P NATL ACAD SCI USA, V85, P8761, DOI 10.1073/pnas.85.22.8761; BLACKFORD S, 1990, J BIOL CHEM, V265, P9617; BLUMWALD E, 1986, PLANT PHYSIOL, V80, P727, DOI 10.1104/pp.80.3.727; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH DR, 1986, PLANT PHYSIOL, V80, P549, DOI 10.1104/pp.80.2.549; CATALDO DA, 1981, PLANT PHYSIOL, V68, P835, DOI 10.1104/pp.68.4.835; CHANSON A, 1991, J PLANT PHYSIOL, V137, P471, DOI 10.1016/S0176-1617(11)80319-6; CHURCHILL KA, 1984, PLANT PHYSIOL, V76, P490, DOI 10.1104/pp.76.2.490; CHURCHILL KA, 1983, PLANT PHYSIOL, V71, P610, DOI 10.1104/pp.71.3.610; CHURCHILL KA, 1983, PLANT PHYSIOL, V73, P921, DOI 10.1104/pp.73.4.921; DABIN P, 1978, PLANT SOIL, V50, P329, DOI 10.1007/BF02107182; DUPONT FM, 1990, PLANT PHYSIOL, V94, P179, DOI 10.1104/pp.94.1.179; GIANNINI JL, 1991, PLANT SCI, V74, P203, DOI 10.1016/0168-9452(91)90047-C; GOGARTENBOEKELS M, 1985, J PLANT PHYSIOL, V118, P309, DOI 10.1016/S0176-1617(85)80190-5; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; HOPPS H, 1974, GEOCHEMISTRY ENV, V1, P6; JOYCE DC, 1988, PLANT PHYSIOL, V88, P1097, DOI 10.1104/pp.88.4.1097; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KAREZ CS, 1990, PLANT CELL ENVIRON, V13, P483, DOI 10.1111/j.1365-3040.1990.tb01326.x; KROTZ RM, 1989, PLANT PHYSIOL, V91, P780, DOI 10.1104/pp.91.2.780; LEIGH RA, 1980, PLANTA, V150, P222, DOI 10.1007/BF00390830; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; PEEREBOOMSTEGEMAN JHJC, 1989, ECOTOX ENVIRON SAFE, V18, P93, DOI 10.1016/0147-6513(89)90095-X; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; RANDALL SK, 1987, METHOD ENZYMOL, V148, P123; RYAN JA, 1982, ENVIRON RES, V28, P251, DOI 10.1016/0013-9351(82)90128-1; SCHUMAKER KS, 1986, J BIOL CHEM, V261, P2172; SCHUMAKER KS, 1985, PLANT PHYSIOL, V79, P1111, DOI 10.1104/pp.79.4.1111; SZE H, 1982, PLANT PHYSIOL, V70, P498, DOI 10.1104/pp.70.2.498; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; SZE H, 1981, P NATL ACAD SCI-BIOL, V78, P5578, DOI 10.1073/pnas.78.9.5578; TUKENDORF A, 1990, PLANT SCI, V70, P155, DOI 10.1016/0168-9452(90)90129-C; VOGELILANGE R, 1990, PLANT PHYSIOL, V92, P1086, DOI 10.1104/pp.92.4.1086; WAGNER GJ, 1986, PLANT PHYSIOL, V82, P274, DOI 10.1104/pp.82.1.274; WAGNER GJ, 1983, BIOCHIM BIOPHYS ACTA, V728, P267, DOI 10.1016/0005-2736(83)90479-0; WAGNER GJ, 1989, UCLA S MOL CELL BIOL, V98, P325; WANG YZ, 1985, J BIOL CHEM, V260, P434	38	168	185	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12297	12302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509367				2022-12-27	WOS:A1993LG65800014
J	VENISSE, A; BERJEAUD, JM; CHAURAND, P; GILLERON, M; PUZO, G				VENISSE, A; BERJEAUD, JM; CHAURAND, P; GILLERON, M; PUZO, G			STRUCTURAL FEATURES OF LIPOARABINOMANNAN FROM MYCOBACTERIUM-BOVIS BCG - DETERMINATION OF MOLECULAR-MASS BY LASER-DESORPTION MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; TUMOR-NECROSIS-FACTOR; FAST-ATOM-BOMBARDMENT; T-CELL PROLIFERATION; MULTIPLE QUANTUM NMR; POLYACRYLAMIDE GELS; TUBERCULOSIS; ARABINOMANNAN; SPECTROSCOPY; C-13	It was recently shown that mycobacterial lipoarabinomannan (LAM) can be classified into two types (Chatterjee, D., Lowell, K., Rivoire B., McNeil M. R., and Brennan, P. J. (1992) J. Biol. Chem. 267, 6234-6239) according to the presence or absence of mannosyl residues (Manp) located at the nonreducing end of the oligoarabinosyl side chains. These two types of LAM were found in a pathogenic Mycobacterium tuberculosis strain and in an avirulent M. tuberculosis strain, respectively, suggesting that LAM with Manp characterizes virulent and ''disease-inducing strains.'' We now report the structure of the LAM from Mycobacterium bovis Bacille Calmette-Guerin (BCG) strain Pasteur, largely used throughout the world as vaccine against tuberculosis. Using an up-to-date analytical approach, we found that the LAM of M. bovis BCG belongs to the class of LAMs capped with Manp. By means of two-dimensional homonuclear and heteronuclear scalar coupling NMR analysis and methylation data, the sugar spin system assignments were partially established, revealing that the LAM contained two types of terminal Manp and 2-O-linked Manp. From the following four-step process: (i) partial hydrolysis of deacylated LAM (dLAM), (ii) oligosaccharide derivatization with aminobenzoic ethyl ester, (iii) HPLC purification, (iv) FAB/MS-MS analysis; it was shown that the dimannosyl unit alpha-D-Manp-(1-->2)-alpha-D-Manp. Manp is the major residue capping the termini of the arabinan of the LAM. In this report, LAM molecular mass determination was established using matrix-assisted UV-laser desorption/ionization mass spectrometry which reveals that the LAM molecular mass is around 17.4 kDa. The similarity of the LAM structures between M. bovis BCG and M. tuberculosis H37Rv is discussed in regard to their function in the immunopathology of mycobacterial infection.	CNRS,DEPT GLYCOCONJUGUES & BIOMEMBRANES,PHARMACOL & TOXICOL LAB,F-31062 TOULOUSE,FRANCE; CNRS,DEPT BIOL STRUCT & INGN PROT,PHARMACOL & TOXICOL FONDAMENTALES LAB,F-31062 TOULOUSE,FRANCE; INST PHYS NUCL LYON,F-91406 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Berjeaud, Jean-Marc/ABF-9966-2021; Berjeaud, Jean-Marc/GOP-0237-2022	Berjeaud, Jean-Marc/0000-0001-9013-8430; GILLERON, Martine/0000-0002-2581-3302				ABEYGUNAWARDANA C, 1990, BIOCHEMISTRY-US, V30, P378; ANSORGE W, 1983, ELECTROPHORESIS 82, P235; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; AZUMA I, 1970, Infection and Immunity, V2, P347; BARNES PF, 1990, J IMMUNOL, V145, P149; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BERMUDEZ LE, 1988, J IMMUNOL, V145, P3006; BRENNAN PJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P55; CAROFF M, 1990, J BACTERIOL, V172, P1121, DOI 10.1128/jb.172.2.1121-1128.1990; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DANIEL TM, 1984, MYCOBACTERIA SOURCE, P417; DENIS M, 1990, IMMUNOLOGY, V71, P139; DUPENHOAT CH, 1987, CARBOHYD RES, V165, P31, DOI 10.1016/0008-6215(87)80075-7; EGGE H, 1991, PURE APPL CHEM, V63, P491, DOI 10.1351/pac199163040491; ELLNER JJ, 1979, CLIN EXP IMMUNOL, V35, P250; GAYLORD H, 1987, INFECT IMMUN, V55, P2860, DOI 10.1128/IAI.55.11.2860-2863.1987; Gorin P. A. J., 1981, ADV CARBOHYD CHEM BI, VV38, P13, DOI DOI 10.1016/S0065-2318(08)60309-1; GORIN PAJ, 1976, CARBOHYD RES, V48, P171, DOI 10.1016/S0008-6215(00)83213-9; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; KAPLAN G, 1987, J IMMUNOL, V138, P3028; KARAS M, 1989, BIOMED ENVIRON MASS, V18, P841, DOI 10.1002/bms.1200180931; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; KINDLER V, 1989, CELL, V56, P994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MISAKI A, 1977, J BIOCHEM-TOKYO, V82, P1759, DOI 10.1093/oxfordjournals.jbchem.a131874; MIZUTANI K, 1908, CARBOHYD RES, V185, P27; MOCK KK, 1991, BIOCHEM BIOPH RES CO, V177, P644, DOI 10.1016/0006-291X(91)91837-3; MORENO C, 1989, CLIN EXP IMMUNOL, V76, P240; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; OHASHI M, 1970, JPN J EXP MED, V40, P1; ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O; SCHNITTMAN S, 1988, J CLIN IMMUNOL, V8, P234, DOI 10.1007/BF00916551; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SIBLEY LD, 1990, CLIN EXP IMMUNOL, V80, P141; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; STAHL B, 1991, ANAL CHEM, V63, P1463, DOI 10.1021/ac00014a022; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUGDEN EA, 1987, INFECT IMMUN, V55, P762, DOI 10.1128/IAI.55.3.762-770.1987; SWEET DP, 1975, CARBOHYD RES, V40, P217, DOI 10.1016/S0008-6215(00)82604-X; THOMASOATES JE, 1989, BIOCHEM SOC T, V17, P243, DOI 10.1042/bst0170243; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; WEBB JW, 1988, ANAL BIOCHEM, V169, P337, DOI 10.1016/0003-2697(88)90293-X; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3; WHITEHOUSE CM, 1985, ANAL CHEM, V57, P675, DOI 10.1021/ac00280a023	55	114	117	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12401	12411						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509380				2022-12-27	WOS:A1993LG65800030
J	ROTTMAN, JN; GORDON, JI				ROTTMAN, JN; GORDON, JI			COMPARISON OF THE PATTERNS OF EXPRESSION OF RAT INTESTINAL FATTY-ACID BINDING-PROTEIN HUMAN GROWTH-HORMONE FUSION GENES IN CULTURED INTESTINAL EPITHELIAL-CELL LINES AND IN THE GUT EPITHELIUM OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; MOUSE SMALL-INTESTINE; A-I GENE; TRANSCRIPTION FACTORS; SEQUENCE-ANALYSIS; DIFFERENTIATION; DNA; LOCALIZATION; CACO-2; MEMBER	The intestinal fatty acid binding protein gene (Fabpi) provides a good model system for studying how gene transcription is regulated in enterocytes as a function of their differentiation program and location along the duodenal-to-colonic axis. We have compared and contrasted the transcriptional activity of four fusion genes composed of elements from the 5'-nontranscribed domain of rat Fabpi linked to the human growth hormone gene (I-FABP/hGH) in transgenic mice and in five primate epithelial cell lines derived from intestine, liver, kidney, and cervix. Nucleotides -103 to +28 of rat Fabpi are able to direct appropriate lineage-specific and geographic patterns of hGH expression in transgenic mice. I-FABP-103 to +28/hGH is preferentially expressed in Caco-2 cells, which emulate some of the features of differentiated small intestinal enterocytes after they reach confluence. However, other I-FABP/hGH fusion genes that exhibit differentiation-dependent changes in their expression along the crypt-to-villus axis do not manifest the same pattern of differentiation-dependent change in activity in this cell line. Correlation of their patterns of expression in vivo and ex vivo suggest that nonproliferating Caco-2 cells mimic some of the features of the transcriptional regulatory environment of enterocytes located in the upper crypt. Nucleotides -103 to +28 of rat Fabpi contain one copy of a repeated 14-base pair element that is conserved in the orthologous mouse and human genes and represented in several other homologous and nonhomologous genes, which are expressed in villus-associated enterocytes. This element binds to two members of the steroid hormone receptor superfamily of transcription factors produced in enterocytes and Caco-2 cells: hepatic nuclear factor-4 (HNF-4) and apolipoprotein regulatory protein-1 (ARP-1). Co-transfection studies performed in Caco-2 cells and in a monkey kidney cell line (CV-1) that lacks endogenous pools of ARP-1 and HNF-4 suggest that ARP-1 and HNF-4 can function to activate I-FABP-103 to +28/hGH+3 through their interactions with the 14-base pair element. This activation appears to be affected by elements located between nucleotides -277 and -104 and other transcription factors.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P51, DOI 10.1007/BF02932850; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS GS, 1992, J CELL SCI, V101, P219; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FORMAN B M, 1990, New Biologist, V2, P587; GEY GO, 1952, CANCER RES, V12, P264; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSET E, 1984, AM J PHYSIOL, V247, pC260, DOI 10.1152/ajpcell.1984.247.3.C260; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KUO CF, 1990, DEVELOPMENT, V109, P473; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; PINTO M, 1983, BIOL CELL, V47, P323; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHIELDS HM, 1986, J LIPID RES, V27, P549; SIMON TC, 1993, IN PRESS J BIOL CHEM; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	61	76	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11994	12002						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505324				2022-12-27	WOS:A1993LF28400081
J	ROBINE, S; SAHUQUILLOMERINO, C; LOUVARD, D; PRINGAULT, E				ROBINE, S; SAHUQUILLOMERINO, C; LOUVARD, D; PRINGAULT, E			REGULATORY SEQUENCES ON THE HUMAN VILLIN GENE TRIGGER THE EXPRESSION OF A REPORTER GENE IN A DIFFERENTIATING HT29 INTESTINAL-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE GENE; TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; CYTOSKELETAL PROTEIN; EPITHELIAL-CELLS; BRUSH-BORDER; VISCERAL ENDODERM; MAMMALIAN-CELLS; CARCINOMA-CELLS; TRANSCRIPTION	To develop a molecular tool for tissue-specific targeting of gene expression in immature and differentiated epithelial cells of the small and large intestinal mucosa, we have isolated the 2-kb 5'-flanking region of the human villin gene. This region contains numerous short sequences that are conserved among other tissue-specific promoters of genes expressed in differentiated enterocytes. This DNA fragment promotes the transcription and expression of the luciferase reporter gene in villin-positive intestinal, renal, and hepatoma cell lines but not in a villin-negative keratinocyte cell line. The pattern of expression corresponds that of the endogenous gene, indicating that this sequence can direct intestine-specific transcription. In the differentiating HT29 intestinal cell line, expression of the reporter gene is already detectable in undifferentiated cells, and dramatically increases when terminal differentiation is induced. Thus, as previously reported for the endogenous gene the isolated 5'-flanking region of the villin gene responds positively to conditions known to stimulate terminal differentiation of these cultured epithelial intestinal cells. The reported results indicate that this genomic fragment contains sufficient regulatory elements to recapitulate the expression pattern of the villin promoter during intestinal differentiation.	INST PASTEUR,DEPT BIOL MOLEC,CNRS,URA 1149,25 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BACCHI CE, 1991, LAB INVEST, V64, P418; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; CARBONI JM, 1987, AM J PATHOL, V129, P589; CARTIER N, 1992, ONCOGENE, V7, P1413; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALEMANS W, 1990, BIOLOGICALS, V18, P191, DOI 10.1016/1045-1056(90)90006-L; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; DUDOUET B, 1987, J CELL BIOL, V105, P365; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; ELSASSER HP, 1991, HISTOCHEMISTRY, V95, P383, DOI 10.1007/BF00266966; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; GRONE HJ, 1986, AM J PATHOL, V124, P294; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HENTHORN PS, 1988, J BIOL CHEM, V263, P12011; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; LOKER J, 1990, J DNA SEQUENCING MAP, V1, P3; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MAUNOURY R, 1992, DEVELOPMENT, V115, P717; MEZGER V, 1987, DEV BIOL, V124, P544, DOI 10.1016/0012-1606(87)90507-0; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MILLAN JL, 1987, NUCLEIC ACIDS RES, V15, P10599, DOI 10.1093/nar/15.24.10599; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOLL R, 1987, VIRCHOWS ARCH B, V54, P155, DOI 10.1007/BF02899208; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; OLSEN J, 1991, J BIOL CHEM, V266, P18089; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; PINTO M, 1983, BIOL CELL, V47, P323; PINTO M, 1982, BIOL CELL, V44, P193; PRINGAULT E, 1991, P NATL ACAD SCI USA, V88, P10811, DOI 10.1073/pnas.88.23.10811; PRINGAULT E, 1986, EMBO J, V5, P3119, DOI 10.1002/j.1460-2075.1986.tb04618.x; PRINGAULT E, 1990, ANN I PASTEUR, V2, P120; RABITO CA, 1984, J BIOL CHEM, V259, P574; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; ROUSSEAUMERCK MF, 1988, HUM GENET, V78, P130, DOI 10.1007/BF00278181; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIFERS RN, 1989, J BIOL CHEM, V264, P15696; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1977, NUCLEIC ACIDS RES, V4, P4037, DOI 10.1093/nar/4.11.4037; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; SWIFT GH, 1984, CELL, V38, P639, DOI 10.1016/0092-8674(84)90258-7; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; WEISS MJ, 1988, J BIOL CHEM, V263, P12002; WEST AB, 1988, GASTROENTEROLOGY, V94, P343, DOI 10.1016/0016-5085(88)90421-0; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WU GD, 1992, J BIOL CHEM, V267, P7863	76	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11426	11434						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496191				2022-12-27	WOS:A1993LD46600102
J	SCHAEFER, A; STOCKER, U; MARQUARDT, H				SCHAEFER, A; STOCKER, U; MARQUARDT, H			CALCIUM IONOPHORE-INDUCED TRANSIENT DOWN-REGULATION OF C-MYB MESSENGER-RNA LEVELS IN FRIEND-ERYTHROLEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION; DIMETHYL SULFOXIDE; GENE-EXPRESSION; GLOBIN GENES; MURINE; COMMITMENT; DIMETHYLSULFOXIDE; ERYTHROPOIETIN; HEMOGLOBIN; FRAGMENTS	The effects of calcium ionophores A23187 and ionomycin on the c-myb and c-myc mRNA levels have been investigated in the Friend erythroleukemia cell line F4-6 using Northern blot analysis. Treatment of the cells with 0.5-4 muM A23187 or 1-4 muM ionomycin induced a concentration-dependent decrease in c-myb mRNA; this decrease was abolished by EGTA. c-myc mRNA levels were only moderately affected. After 12-24 h of calcium ionophore exposure, c-myb mRNA returned to pretreatment levels. No similar decrease in c-myb mRNA was seen with the sodium ionophore monensin (up to 16 muM). The dimethyl sulfoxide-induced suppression of c-myb and also of c-myc mRNA levels was not prevented in Ca2+-free medium and thus appeared Ca2+-independent. A23187 and ionomycin were capable of inducing beta-globin mRNA synthesis in F4-6 cells. Prolonged calcium ionophore exposure, however, strongly reduced cell viability and resulted only in a slight hemoglobin increase at lower concentrations. These results suggest that a rise in [Ca2+]i may be a signal leading to a transient decrease in c-myb mRNA and the initiation of erythroid differentiation in Friend cells. The transient suppression of c-myb mRNA levels represents a common feature of the action of dimethyl sulfoxide and calcium ionophores.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,W-2000 HAMBURG 13,GERMANY	Fraunhofer Gesellschaft	SCHAEFER, A (corresponding author), UNIV HAMBURG,SCH MED,DEPT TOXICOL,GRINDELALLEE 117,W-2000 HAMBURG 13,GERMANY.							BRIDGES K, 1981, J CELL BIOL, V90, P542, DOI 10.1083/jcb.90.2.542; BUSFIELD SJ, 1992, BLOOD, V80, P412; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DANISH R, 1992, ONCOGENE, V7, P901; FALETTO DL, 1985, J BIOL CHEM, V260, P4884; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; HENSOLD JO, 1991, BLOOD, V77, P1362; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; LACHMAN HM, 1984, NATURE, V310, P249; LACHMAN HM, 1985, P NATL ACAD SCI USA, V82, P5223; LANNIGAN DA, 1985, J BIOL CHEM, V260, P7322; LEVENSON R, 1980, P NATL ACAD SCI-BIOL, V77, P5948, DOI 10.1073/pnas.77.10.5948; LEVENSON R, 1983, J CELL BIOCHEM, V21, P1, DOI 10.1002/jcb.240210102; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; OSTERTAG W, 1972, NATURE-NEW BIOL, V239, P231, DOI 10.1038/newbio239231a0; PATEL HR, 1992, J BIOL CHEM, V267, P21300; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REUBEN RC, 1980, BIOCHIM BIOPHYS ACTA, V605, P325, DOI 10.1016/0304-419X(80)90015-3; SCHAEFER A, 1984, J CELL PHYSIOL, V119, P335, DOI 10.1002/jcp.1041190312; SCHAEFER A, 1992, LEUKEMIA, V6, P828; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMITH RL, 1982, J BIOL CHEM, V257, P773; SPIVAK JL, 1992, EXP HEMATOL, V20, P283; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIEMEIER DC, 1978, CELL, V14, P237, DOI 10.1016/0092-8674(78)90110-1; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TSIFTSOGLOU AS, 1981, J CELL PHYSIOL, V108, P327, DOI 10.1002/jcp.1041080306; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; YEH LA, 1983, J BIOL CHEM, V258, P6567	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10876	10880						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496152				2022-12-27	WOS:A1993LD46600027
J	ANIENTO, F; ROCHE, E; CUERVO, AM; KNECHT, E				ANIENTO, F; ROCHE, E; CUERVO, AM; KNECHT, E			UPTAKE AND DEGRADATION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE BY RAT-LIVER LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; MICROSCOPIC LOCALIZATION; POLYACRYLAMIDE GELS; CYTOSOLIC PROTEINS; UBIQUITIN; PROTEOLYSIS; PATHWAY; CELLS; INHIBITORS; SYSTEM	The molecular mechanisms involved in the degradation of individual cellular proteins are probably unique and characteristic. We have investigated in rat liver the degradation of glyceraldehyde-3-phosphate dehydrogenase, an abundant cytosolic enzyme of the glycolytic pathway. Immunoblot analysis of isolated liver lysosomes from rats treated with lysosomal inhibitors show that this protein is degraded, at least in part, by a lysosomal pathway. This pathway was further investigated by incubating the enzyme with lysosomes in a cell-free system, followed by proteolysis measurements, sodium dodecyl sulfate-polyacrylamide gel electrophoresis of lysosomes, and electron microscopic immunocytochemistry. We postulate that the degradative mechanism of glyceraldehyde-3-phosphate dehydrogenase includes a temperature-dependent lysosomal pathway, different from classical nonspecific macroautophagy. The postulated pathway involves: binding of the enzyme to the lysosomal membrane, entry into the lysosomal matrix, and degradation. This cell-free system, which can also incorporate in vitro synthesized proteins, should allow further advances toward clarifying the complex signals that regulate protein degradation as well as its close interrelationship with protein synthesis.	INST INVEST CITOLOGICAL CAJA AHORROS VALENCIA, AMADEO SABOYA 4, E-46010 VALENCIA, SPAIN				Knecht, Erwin/A-9366-2014; Roche, Enrique/V-5738-2017; Company, Fernando Aniento/G-9781-2015; Knecht, Erwin/K-2432-2014	Roche, Enrique/0000-0001-5128-1672; Company, Fernando Aniento/0000-0003-3553-585X; Knecht, Erwin/0000-0002-7208-3832; Cuervo, Ana Maria/0000-0002-0771-700X				AHLBERG J, 1982, LAB INVEST, V47, P523; AHLBERG J, 1985, EXP MOL PATHOL, V42, P78, DOI 10.1016/0014-4800(85)90020-6; BENDAYAN M, 1989, COLLOIDAL GOLD PRINC, V1, P33; Bergmeyer HU, 1974, METHOD ENZYMAT AN, P466; Beynon R.J., 1989, PROTEOLYTIC ENZYMES, P241; BOHLEY P, 1987, NEW COMPR BIOCH, V16, P307; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BONNER WD, 1955, METHOD ENZYMOL, V1, P722, DOI 10.1016/0076-6879(55)01126-9; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOWERS WE, 1967, J CELL BIOL, V32, P325, DOI 10.1083/jcb.32.2.325; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FINDLAY J, 1958, BIOCHEM J, V69, P467, DOI 10.1042/bj0690467; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROPPER R, 1991, J BIOL CHEM, V266, P3602; Harrison J., 1976, P1; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; KNECHT E, 1986, FEBS LETT, V206, P339, DOI 10.1016/0014-5793(86)81008-0; KNECHT E, 1978, CELL TISSUE RES, V193, P473; KNECHT E, 1986, J HISTOCHEM CYTOCHEM, V34, P913, DOI 10.1177/34.7.3519755; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Kun E, 1979, Methods Enzymol, V55, P115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; MARZELLA L, 1980, EXP CELL RES, V129, P460, DOI 10.1016/0014-4827(80)90515-7; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; Nuzum CT, 1976, UREA CYCLE, P325; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Rivett A.J., 1990, Essays in Biochemistry, V25, P39; ROCHE E, 1987, FEBS LETT, V221, P231, DOI 10.1016/0014-5793(87)80931-6; ROCHE E, 1987, BIOCHEM BIOPH RES CO, V142, P680, DOI 10.1016/0006-291X(87)91468-9; ROCHE E, 1989, CURRENT TRENDS STUDY, V2, P285; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STEER CJ, 1991, INTRACELLULAR TRAFFI; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umezawa H, 1976, Methods Enzymol, V45, P678; VARGAS JL, 1990, EUR J BIOCHEM, V188, P99, DOI 10.1111/j.1432-1033.1990.tb15376.x; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WINKLER JR, 1984, J BIOL CHEM, V259, P5369; WOLF DH, 1992, EXPERIENTIA, V48, P117, DOI 10.1007/BF01923505; YAMAZAKI K, 1989, HEPATOLOGY, V10, P877, DOI 10.1002/hep.1840100522	56	126	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10463	10470						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486700				2022-12-27	WOS:A1993LB80000071
J	SCUDDER, P; DOOM, JP; CHUENKOVA, M; MANGER, ID; PEREIRA, MEA				SCUDDER, P; DOOM, JP; CHUENKOVA, M; MANGER, ID; PEREIRA, MEA			ENZYMATIC CHARACTERIZATION OF BETA-D-GALACTOSIDE ALPHA-2,3-TRANS-SIALIDASE FROM TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID; ALPHA-2->6 SIALYLTRANSFERASE; INFECTION INVITRO; NEURAMINIDASE; SURFACE; OLIGOSACCHARIDES; TRYPOMASTIGOTES; CELLS; GLYCOPROTEIN; COLOSTRUM	The substrate specificity, physico-chemical, and kinetic properties of the trans-sialidase from Trypanosoma cruzi have been investigated. The enzyme demonstrates activity towards a wide range of saccharide, glycolipid, and glycoprotein acceptors which terminate with a beta-linked galactose residue, and synthesizes exclusively an alpha2-3 sialosidic linkage. Oligosaccharides which terminate in Galbeta1-4(Fucalpha1-3)GlcNAc, Galbeta1-3(Fucalpha1-4)GlcNAc, or Galalpha1- are not acceptor-substrates. The enzyme utilizes alpha2,3-linked sialic acid when the donor species is an oligosaccharide and can also transfer, at a low rate, sialic acid from synthetic alpha-sialosides such as p-nitrophenyl-alpha-N-acetylneuraminic acid, but NeuAcalpha2-3Galbeta1-4(Fucalpha1-3)Glc is not a donor-substrate. The trans-sialidase has an apparent pH optimum of 7.9 and a temperature optimum of 13-degrees-C. The kinetic properties of the enzyme suggest that the trans-sialylation reaction may occur via a rapid equilibrium random or steady-state ordered mechanism. A method for immobilizing the enzyme is described together with examples of its use for the synthesis of oligosaccharide and glycoprotein precursors of sialyl-Lewis(a) and sialyl-Lewis(x).	MONSANTO CO,CTR PHYS SCI,ST LOUIS,MO 63198; NEW ENGLAND MED CTR,DEPT MED,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111	Monsanto; Tufts Medical Center	SCUDDER, P (corresponding author), MONSANTO CO,DIV PROT BIOCHEM,GLYCOSCI GRP,800 N LINDBERGH BLVD,ST LOUIS,MO 63167, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; CAVALLESCO R, 1988, J IMMUNOL, V140, P617; DONALD ASR, 1988, CARBOHYD RES, V178, P79, DOI 10.1016/0008-6215(88)80103-4; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HANFLAND P, 1975, CHEM PHYS LIPIDS, V15, P105, DOI 10.1016/0009-3084(75)90035-3; LIBBY P, 1986, J CLIN INVEST, V77, P127, DOI 10.1172/JCI112266; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGER ID, 1992, BIOCHEMISTRY-US, V31, P10724, DOI 10.1021/bi00159a012; PARDI AJ, 1992, EMBO J, V11, P1705; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; PRIOLI RP, 1992, MOL BIOCHEM PARASIT, V52, P85, DOI 10.1016/0166-6851(92)90038-L; REARICK JI, 1979, J BIOL CHEM, V254, P4444; ROSENBERG I, 1991, MOL BIOCHEM PARASIT, V46, P303, DOI 10.1016/0166-6851(91)90054-A; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; SCUDDER P, 1987, EUR J BIOCHEM, V168, P585, DOI 10.1111/j.1432-1033.1987.tb13457.x; SCUDDER P, 1990, J BIOL CHEM, V265, P16472; Smith D F, 1978, Methods Enzymol, V50, P169; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; VEH RW, 1981, J CHROMATOGR, V212, P313, DOI 10.1016/S0021-9673(01)84044-9; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845	28	108	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9886	9891						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486668				2022-12-27	WOS:A1993LA68900104
J	ABBAS, A; LABBEBOIS, R				ABBAS, A; LABBEBOIS, R			STRUCTURE-FUNCTION STUDIES OF YEAST FERROCHELATASE - IDENTIFICATION AND FUNCTIONAL-ANALYSIS OF AMINO-ACID SUBSTITUTIONS THAT INCREASE V(MAX) AND THE K(M) FOR BOTH SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; SACCHAROMYCES-CEREVISIAE; ERYTHROPOIETIC PROTOPORPHYRIA; COPROPORPHYRINOGEN OXIDASE; MOUSE FERROCHELATASE; LIVER-FERROCHELATASE; MITOCHONDRIAL IRON; HEME-BIOSYNTHESIS; MOLECULAR-CLONING; INHIBITION	The molecular basis of the ferrochelatase defects was investigated in two ''protoporphyric'' and partially heme-deficient yeast mutants. Ferrochelatase, a mitochondrial inner membrane-bound enzyme, catalyzes the incorporation of ferrous iron into protoporphyrin, the last step in protoheme biosynthesis. The mutant cells made normal amounts of normal-sized ferrochelatase, as detected by immunoblotting. The mutations were identified by sequencing the mutant hem15 alleles amplified in vitro from mutant strains genomic DNA. A single nucleotide change, causing an amino acid substitution, was found in each mutant. Substitution of the conserved Ser-169 by Phe caused a 10-fold increase in V(max) and a 45- and 35-fold increase in the K(M) for protoporphyrin and metal, respectively. Replacement of Ser-174 by Pro produced the same effects, but to a lesser degree. There was a good correlation between the ferrochelatase defects measured in vitro and the heme synthesis deficiencies estimated in vivo. The decreased in vivo heme synthesis is probably due to the lower affinity of the mutant enzymes for iron. We propose that the region identified by the two close mutations contributes to the binding domains of metal and protoporphyrin.	UNIV PARIS 07,INST JACQUES MONOD,BIOCHIM PORPHYRINES LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite								ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; BLOM C, 1990, BIOCHIM BIOPHYS ACTA, V1039, P339, DOI 10.1016/0167-4838(90)90268-K; BLOOMER JR, 1987, J BIOL CHEM, V262, P667; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1981, BIOCHIMIE, V63, P463, DOI 10.1016/S0300-9084(81)80022-3; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1989, BIOCHIM BIOPHYS ACTA, V999, P7, DOI 10.1016/0167-4838(89)90021-6; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DEMATTEIS F, 1985, BIOCHEM J, V226, P537, DOI 10.1042/bj2260537; EIDE D, 1992, J BIOL CHEM, V267, P20774; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; HONEYBOURNE CL, 1979, FEBS LETT, V98, P207, DOI 10.1016/0014-5793(79)80185-4; KENG T, 1987, P NATL ACAD SCI USA, V84, P9113, DOI 10.1073/pnas.84.24.9113; KURLANDZKA A, 1985, J GEN MICROBIOL, V131, P2909; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; MCCLUSKEY SA, 1989, MOL PHARMACOL, V36, P608; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MOODY MD, 1985, J BACTERIOL, V161, P1074, DOI 10.1128/JB.161.3.1074-1079.1985; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; RYTKA J, 1984, BIOCHEM J, V218, P405, DOI 10.1042/bj2180405; SHERMAN F, 1986, LABORATORY COURSE MA; STRAKA JG, 1991, AM J HUM GENET, V48, P72; TAKETANI S, 1982, EUR J BIOCHEM, V127, P443; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; TANGERAS A, 1985, BIOCHIM BIOPHYS ACTA, V843, P199, DOI 10.1016/0304-4165(85)90140-0; TANGERAS A, 1986, BIOCHIM BIOPHYS ACTA, V882, P77, DOI 10.1016/0304-4165(86)90058-9; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; URBANGRIMAL D, 1981, MOL GEN GENET, V183, P85, DOI 10.1007/BF00270144; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	39	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8541	8546						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473299				2022-12-27	WOS:A1993KX81100028
J	GHIVIZZANI, SC; MADSEN, CS; HAUSWIRTH, WW				GHIVIZZANI, SC; MADSEN, CS; HAUSWIRTH, WW			INORGANELLO FOOTPRINTING - ANALYSIS OF PROTEIN-BINDING AT REGULATORY REGIONS IN BOVINE MITOCHONDRIAL-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; TRANSCRIPTION FACTOR-I; LIGHT-STRAND PROMOTER; MOUSE L-CELLS; HEAVY-STRAND; ACCURATE INITIATION; PRECISE ASSIGNMENT; GENE-EXPRESSION; REPLICATION; RNA	Detailed study of mammalian mitochondrial transcriptional and replicative mechanisms is currently limited to in vitro analyses, requiring isolation and reassembly of functional components to mimic the in vivo process. To complement these studies and begin understanding the intracellular function of mitochondrial DNA (mtDNA) regulatory regions, we developed in organello footprinting to investigate protein-DNA interactions within the mitochondrion. Using a methylation protection technique and mitochondria isolated from bovine brain tissue, we analyzed five domains believed critical for regulating mtDNA function. Near equivalent protein-DNA interactions were seen upstream of both light and heavy strand RNA start sites at positions consistent with those observed for human mitochondrial transcription factor 1 DNA binding in vitro. Downstream of the 16 S rRNA gene, a high level of protein occupancy was detected within the bovine homologue of the human tridecamer sequence required for attenuation of transcription in vitro. Immediately upstream of the origin of heavy strand replication, a novel site of protein-mtDNA interaction was observed within conserved sequence block 1, suggesting its potential as a regulatory element involved in initiation of heavy strand DNA synthesis. Unlike regions associated with the origin of heavy strand replication, protein-mtDNA interaction was not detected at the origin of light strand replication or within flanking tRNA genes.	UNIV FLORIDA,COLL MED,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIGMS NIH HHS [GM34825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ANNEX BH, 1990, MOL CELL BIOL, V10, P5671, DOI 10.1128/MCB.10.11.5671; ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BARATGUERIDE M, 1989, EUR J BIOCHEM, V183, P297, DOI 10.1111/j.1432-1033.1989.tb14928.x; BECKWITH B, 1985, WOMEN HEALTH, V10, P1, DOI 10.1300/J013v10n01_01; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BERK AJ, 1976, J MOL BIOL, V100, P85, DOI 10.1016/S0022-2836(76)80036-8; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANG DD, 1986, MOL CELL BIOL, V6, P3262, DOI 10.1128/MCB.6.9.3262; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1986, MOL CELL BIOL, V6, P3253, DOI 10.1128/MCB.6.9.3253; CHAPPELL JB, 1963, BIOCHEM SOC S, V23, P39; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GELFAND R, 1981, MOL CELL BIOL, V4, P1605; GHIVIZZANI SC, 1993, IN PRESS J MOL EVOL; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; HEHMAN GL, 1992, P NATL ACAD SCI USA, V89, P8562, DOI 10.1073/pnas.89.18.8562; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HIXSON JE, 1986, J BIOL CHEM, V261, P2384; HUIE MA, 1992, MOL CELL BIOL, V12, P2690, DOI 10.1128/MCB.12.6.2690; JACKSON KL, 1956, J GEN PHYSIOL, V40, P47, DOI 10.1085/jgp.40.1.47; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KING TC, 1987, J BIOL CHEM, V262, P6204; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; MARTENS PA, 1979, J MOL BIOL, V135, P327, DOI 10.1016/0022-2836(79)90440-6; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIGNOTTE F, 1990, EUR J BIOCHEM, V194, P561, DOI 10.1111/j.1432-1033.1990.tb15653.x; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NICK H, 1985, NATURE, V313, P795, DOI 10.1038/313795a0; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; SACCONE C, 1991, J MOL EVOL, V33, P83, DOI 10.1007/BF02100199; Sambrook J, 1989, MOL CLONING LABORATO; SEKIYA T, 1980, GENE, V11, P53; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TAPPER DP, 1982, J MOL BIOL, V162, P1, DOI 10.1016/0022-2836(82)90159-0; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WONG TW, 1985, J BIOL CHEM, V260, P1530; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0	65	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8675	8682						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473311				2022-12-27	WOS:A1993KX81100047
J	PAIGE, LA; NADLER, MJS; HARRISON, ML; CASSADY, JM; GEAHLEN, RL				PAIGE, LA; NADLER, MJS; HARRISON, ML; CASSADY, JM; GEAHLEN, RL			REVERSIBLE PALMITOYLATION OF THE PROTEIN-TYROSINE KINASE P56(LCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; FATTY-ACID ACYLATION; CYTOPLASMIC DOMAINS; PALMITIC ACID; POSTTRANSLATIONAL MODIFICATION; VIRUS GLYCOPROTEINS; CELLULAR PROTEINS; CYSTEINE MOTIFS; LYMPHOCYTES-T; RAS PROTEINS	The myristoylated protein-tyrosine kinase, p56lck, is expressed predominantly in T cells where it is believed to play a role in T cell activation. We observed a 56-kDa protein that became metabolically labeled in intact T lymphoid cells that were incubated with either [H-3] myristate or [H-3]palmitate. This protein was identified as p56lck based on its specific immunoprecipitation with polyclonal antisera to p56lck, by induction of a shift in its electrophoretic mobility following treatment of cells with 12-O-tetradecanoylphorbol-13-acetate and by co-chromatography with p56lck on protamine-agarose. Characterization of the two acylation events revealed that, in contrast to the p56lck-associated radioactivity from [H-3]myristate-labeled cells, the p56lck-associated radioactivity from [H-3]palmitate-labeled cells was susceptible to cleavage by neutral hydroxylamine and was not blocked by inhibitors of protein synthesis. Pulse-chase analyses revealed that the labeling of p56lck with [H-3]palmitate, but not [H-3]myristate, was reversible. The presence of covalently attached palmitate on p56lck from [H-3]palmitate-labeled cells was verified by thin-layer chromatography following acid hydrolysis of the acylated protein. 2-Hydroxymyristate, which is metabolically activated to form a potent inhibitor of protein myristoylation, specifically inhibited the acylation of p56lck with [H-3]myristate without affecting its labeling with [H-3]palmitate. These studies indicate that p56lck is both a cotranslationally myristoylated and post-translationally palmitoylated protein.	PURDUE UNIV,DEPT MEDICINAL CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907; OHIO STATE UNIV,COLL PHARM,COLUMBUS,OH 43210	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University System of Ohio; Ohio State University				Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R55CA045667, R01CA045667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008298, R01GM048099] Funding Source: NIH RePORTER; NCI NIH HHS [CA45667] Funding Source: Medline; NIGMS NIH HHS [GM48099, 5 T32 GM08298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ADAM M, 1988, ARCH BIOCHEM BIOPHYS, V264, P553, DOI 10.1016/0003-9861(88)90321-9; ALVEREZ E, 1990, J BIOL CHEM, V265, P16644; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9859; CHEN RF, 1967, J BIOL CHEM, V242, P173; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CRISE B, 1992, J BIOL CHEM, V267, P13593; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; GLYNN JP, 1964, CANCER RES, V24, P502; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HURLEY TR, 1989, ONCOGENE, V4, P265; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGEE AI, 1988, J CELL BIOCHEM, V37, P347, DOI 10.1002/jcb.240370403; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1989, J IMMUNOL, V142, P2430; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1985, J BIOL CHEM, V260, P3784; OMARY MB, 1981, J BIOL CHEM, V256, P4715; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SCHMIDT MFG, 1982, VIROLOGY, V116, P327, DOI 10.1016/0042-6822(82)90424-X; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SPECTOR AA, 1986, METHOD ENZYMOL, V128, P320; SPECTOR AA, 1969, ANAL BIOCHEM, V32, P297, DOI 10.1016/0003-2697(69)90089-X; TAMANOI F, 1988, J CELL BIOCHEM, V36, P261, DOI 10.1002/jcb.240360307; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	47	141	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8669	8674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473310				2022-12-27	WOS:A1993KX81100046
J	WEBBER, AN; GIBBS, PB; WARD, JB; BINGHAM, SE				WEBBER, AN; GIBBS, PB; WARD, JB; BINGHAM, SE			SITE-DIRECTED MUTAGENESIS OF THE PHOTOSYSTEM-I REACTION-CENTER IN CHLOROPLASTS - THE PROLINE-CYSTEINE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; CHLAMYDOMONAS-REINHARDTII; TRANSFORMATION; MUTATIONS; POLYPEPTIDES; PROTEINS; LOCI	Site-directed mutagenesis has been used to introduce specific amino acid changes into the photosystem I reaction center in the green alga Chlamydomonas reinhardtii. Plasmids containing mutated copies of the chloroplast psaB gene, encoding a polypeptide of the photosystem I reaction center heterodimer, were introduced into the chloroplast genome by particle bombardment. Successful transformants were selected by two procedures. The first involved complementation of a nonphotosynthetic mutant of Chlamydomonas, CC-2341 (ac-u-g-2.3), which has a frameshift mutation in the psaB gene, and selection of photosynthetic transformants on minimal medium. The second procedure utilized a co-transformation procedure with a plasmid containing a rRNA gene that confers spectinomycin resistance. Homologous replacement of the psaB gene was confirmed by screening for a unique restriction enzyme site within the transforming psaB sequences. These procedures have been used to specifically mutate a highly conserved proline-cysteine motif suggested to be important in coordinating the [4Fe-4S] iron-sulfur center F(x). Our results show that the cysteine is essential for assembly of the photosystem I reaction center although the adjacent proline fulfills no identifiable function. The approach described in this paper will be of value to future studies of the structure, function, and assembly of photosystem I.	ARIZONA STATE UNIV, CTR STUDY EARLY EVENTS PHOTOSYNTH, TEMPE, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	WEBBER, AN (corresponding author), ARIZONA STATE UNIV, DEPT BOT, TEMPE, AZ 85287 USA.							ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; ARMSTRONG FA, 1989, BIOCHH J, V264, P275; BINGHAM SE, 1991, FEBS LETT, V292, P17; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; CANOVER RC, 1990, J BIOL CHEM, V265, P8533; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; FISH LE, 1985, MOL BIOL PHOTOSYNTHE, P111; FUJII T, 1990, BIOCHIM BIOPHYS ACTA, V1015, P41, DOI 10.1016/0005-2728(90)90213-N; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARRIS EH, 1989, GENETICS, V123, P281; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; KOSSEL H, 1990, PLANT MOL BIOL, V15, P497, DOI 10.1007/BF00019166; LEIBEL U, 1992, CURRENT RES PHOTOSYN, V2, P595; LIN S, 1991, PHOTOSYNTH RES, V27, P157, DOI 10.1007/BF00035837; NEWMAN SM, 1990, GENETICS, V126, P875; SAKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SHEPHERD HS, 1979, P NATL ACAD SCI USA, V76, P1353, DOI 10.1073/pnas.76.3.1353; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TROST JT, 1992, PHOTOSYNTH RES, V32, P11, DOI 10.1007/BF00028794; WEBBER AN, 1990, FEBS LETT, V264, P1, DOI 10.1016/0014-5793(90)80749-9; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001	29	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12990	12995						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509430				2022-12-27	WOS:A1993LG65800110
J	BOHINSKI, RJ; HUFFMAN, JA; WHITSETT, JA; LATTIER, DL				BOHINSKI, RJ; HUFFMAN, JA; WHITSETT, JA; LATTIER, DL			CIS-ACTIVE ELEMENTS CONTROLLING LUNG CELL-SPECIFIC EXPRESSION OF HUMAN PULMONARY SURFACTANT PROTEIN-B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ENHANCER; TRANSGENIC MICE; FETAL LUNG; CHROMATIN; RECEPTOR; LOCUS; LIVER; ORGANIZATION; INITIATOR; INTERACT	Human surfactant protein B (SPB) is a 79-aminoacid hydrophobic protein that enhances the surface active properties of pulmonary surfactant. SPB is expressed in nonciliated bronchiolar and alveolar type II cells of the respiratory epithelium, and its expression increases markedly late in gestation. In the present study, a human pulmonary adenocarcinoma cell line, H441, was used in both functional and biochemical assays to identify DNA sequences controlling lung cell-specific expression of the SPB gene. DNase I hypersensitive studies demonstrated two distinct regions of lung cell-specific hypersensitivity located proximal to the SPB promoter and within the eighth intron of the gene. To functionally define these DNA sequences, a series of plasmid vectors were constructed in which segments of the human SPB gene and 5'-flanking sequence were linked to a CAT reporter gene and assayed for expression in lung and nonlung cell lines. Whereas far upstream and intronic sequences did not contain enhancer-like elements, a 259-base pair DNA segment (base pair -218 to +41) was sufficient to support lung cell-specific expression. DNase I footprinting demonstrated that this pulmonary epithelial cell-specific promoter fragment contained five nuclear protein-binding sites, two of which bound lung cell-specific nuclear protein complexes. These results suggest that the pulmonary epithelial cell-specific expression of SPB is determined, in part, by both ubiquitous and cell type-specific protein-DNA interactions within the proximal promoter region.	CHILDRENS HOSP MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD011725] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038859, P01HL041496, R01HL038859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38859, HL41496] Funding Source: Medline; NICHD NIH HHS [HD11725] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALAM J, 1991, BIOTECHNIQUES, V10, P423; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BAATZ JE, 1990, BIOCHEMISTRY-US, V29, P6714, DOI 10.1021/bi00480a022; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; COCHRANE CG, 1991, SCIENCE, V254, P566, DOI 10.1126/science.1948032; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EISSENBERG JC, 1985, ANNU REV GENET, V19, P485, DOI 10.1146/annurev.genet.19.1.485; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAZDAR AF, 1990, CANCER RES, V50, P5481; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGWOOD S, 1991, ANNU REV PHYSIOL, V53, P375; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; JACOB GA, 1991, J BIOL CHEM, V266, P22537; KAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T, 1989, DECONTAMINATION DILU; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; Miller J. H, 1972, EXPT MOL GENETICS; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MOON AM, 1991, BLOOD, V77, P2272; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V970, P194, DOI 10.1016/0167-4889(88)90179-6; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; OREILLY MA, 1991, AM J PHYSIOL, V260, pL37, DOI 10.1152/ajplung.1991.260.2.L37; OREILLY MA, 1989, AM J PHYSIOL, V257, pL385, DOI 10.1152/ajplung.1989.257.6.L385; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; PILOTMATIAS TJ, 1989, DNA-J MOLEC CELL BIO, V8, P75, DOI 10.1089/dna.1.1989.8.75; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RISSE G, 1989, EMBO J, V8, P2825; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STAHLMAN MT, 1992, J HISTOCHEM CYTOCHEM, V40, P1471, DOI 10.1177/40.10.1527371; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WERT SE, 1993, IN PRESS DEV BIOL; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	52	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11160	11166						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496176				2022-12-27	WOS:A1993LD46600066
J	DIECI, G; DUIMIO, L; CODAZABETTA, F; SPRAGUE, KU; OTTONELLO, S				DIECI, G; DUIMIO, L; CODAZABETTA, F; SPRAGUE, KU; OTTONELLO, S			A NOVEL RNA POLYMERASE-III TRANSCRIPTION FACTOR FRACTION THAT IS NOT REQUIRED FOR TEMPLATE COMMITMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TRANSFER-RNA; GENE-TRANSCRIPTION; FACTOR-TFIIIB; COMPLEXES; BINDING; DNA; POLYPEPTIDE; COMPONENTS; INITIATION; PURIFICATION	We have identified and partially characterized a novel class III transcription factor fraction (TFIIIE) from yeast nuclear extracts. TFIIIE is functionally distinct from the standard yeast transcription factor fractions, TFIIIB and TFIIIC. It is also different from either of the TFIIIB subfractions, B' and B''. TFIIIE is essential for specific transcription of both tRNA and 5 S RNA genes, its activity is sensitive to proteinase K, and it exhibits an apparent sedimentation coefficient of 4.0 S when analyzed on glycerol gradients. In the case of a tRNA gene, TFIIIE does not play a role in the formation of stable preinitiation complexes containing TFIIIB and TFIIIC. It is required for single as well as multiple rounds of transcription, however. Thus, TFIIIE is involved in the utilization of stable transcription complexes, but its action is not restricted to reinitiation events.	UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Parma; University of Oregon			Dieci, Giorgio/B-3434-2012	Dieci, Giorgio/0000-0002-8792-3961	NIGMS NIH HHS [GM25388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; FLORES O, 1992, J BIOL CHEM, V267, P2786; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; HUIBREGTSE JM, 1987, MOL CELL BIOL, V7, P3212, DOI 10.1128/MCB.7.9.3212; JOHNSON DL, 1989, MOL CELL BIOL, V9, P2018, DOI 10.1128/MCB.9.5.2018; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KLEKAMP MS, 1987, J BIOL CHEM, V262, P7878; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; OEI SL, 1990, J BIOL CHEM, V265, P7485; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; RAYMOND GJ, 1983, NUCLEIC ACIDS RES, V11, P5969, DOI 10.1093/nar/11.17.5969; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; SCHULTZ LD, 1976, P NATL ACAD SCI USA, V73, P1029, DOI 10.1073/pnas.73.4.1029; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Sentenac A, 1982, MOL BIOL YEAST SACCH, P561; Shoyab M, 1979, Methods Enzymol, V68, P199; STILMAN DJ, 1985, J MOL BIOL, V815, P451; WANG CK, 1989, J BIOL CHEM, V264, P1092; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOUNG LS, 1991, MOL CELL BIOL, V11, P1382, DOI 10.1128/MCB.11.3.1382; YOUNG LS, 1991, SCIENCE, V252, P542, DOI 10.1126/science.1708526	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11199	11207						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496177				2022-12-27	WOS:A1993LD46600072
J	MILNE, CA; SEGALL, J				MILNE, CA; SEGALL, J			MAPPING REGIONS OF YEAST TRANSCRIPTION FACTOR-IIIA REQUIRED FOR DNA-BINDING, INTERACTION WITH TRANSCRIPTION FACTOR-IIIC, AND TRANSCRIPTION ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; 5-S RNA GENE; XENOPUS 5S-RNA GENE; SINGLE ZINC FINGER; 5S RNA; POLYMERASE-III; FACTOR-TAU; DELETION MUTANTS; FACTOR TFIIIA; PROTEIN	TFIIIA, a site-specific DNA-binding protein containing nine zinc finger motifs, is an RNA polymerase III transcription factor responsible for the assembly of a transcription complex on the 5 S RNA gene. We have analyzed the effect of deleting various regions of yeast TFIIIA on its ability to bind to the internal control region of the yeast 5 S RNA gene, to recruit TFIIIC into the TFIIIA.DNA complex and to promote in vitro transcription of the 5 S RNA gene. A truncated polypeptide containing only the three amino-terminal zinc fingers retained the ability to bind specifically to the internal control region of the 5 S RNA gene. The TFIIIA.DNA complex formed with this three zinc finger module was able to recruit TFIIIC but could not promote transcription. An 81-amino acid domain, which interrupts the repeating zinc finger motifs between fingers 8 and 9, was found to be essential for the transcription activity of the protein. Removal of the carboxyl-terminal region of yeast TFIIIA that extends beyond the ninth zinc finger motif had no effect on the in vitro activities of the protein. Extending the carboxyl-terminal deletion to include the ninth zinc finger led to reduced transcription activity. We speculate that the ninth zinc finger serves to anchor the carboxyl-terminal portion of TFIIIA on the 5 S RNA gene, correctly orienting the 81-amino acid domain to serve its role in promoting transcription. Removal of the region of the protein amino-terminal to the first zinc finger motif was without effect. Extending the amino-terminal deletion to include the first zinc finger appeared to decrease the affinity of TFIIIA for DNA without affecting the specificity of the protein-DNA interaction. The resultant TFIIIA.DNA complex was defective in recruiting TFIIIC and did not support transcription.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto								ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P1607; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HANAS JS, 1989, NUCLEIC ACIDS RES, V17, P9861, DOI 10.1093/nar/17.23.9861; HAYES J, 1989, J BIOL CHEM, V264, P6009; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON DL, 1989, MOL CELL BIOL, V9, P2018, DOI 10.1128/MCB.9.5.2018; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KELLER HJ, 1992, J BIOL CHEM, V267, P18190; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SEGALL J, 1986, J BIOL CHEM, V261, P1578; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG CK, 1989, J BIOL CHEM, V264, P1092; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; WOYCHIK NA, 1992, P NATL ACAD SCI USA, V89, P3999, DOI 10.1073/pnas.89.9.3999; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	69	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11364	11371						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496187				2022-12-27	WOS:A1993LD46600094
J	OH, BH; PANDIT, J; KANG, CH; NIKAIDO, K; GOKCEN, S; AMES, GFL; KIM, SH				OH, BH; PANDIT, J; KANG, CH; NIKAIDO, K; GOKCEN, S; AMES, GFL; KIM, SH			3-DIMENSIONAL STRUCTURES OF THE PERIPLASMIC LYSINE ARGININE ORNITHINE-BINDING PROTEIN WITH AND WITHOUT A LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; RESOLUTION STRUCTURE; HISTIDINE PERMEASE; ACTIVE-TRANSPORT; X-RAY; COMPLEX; SYSTEM; CRYSTALLIZATION; CHEMOTAXIS	Many proteins exhibit a large-scale movement of rigid globular domains. Among these, bacterial periplasmic binding proteins involved in substrate transport, or transport and chemotaxis, can be used as prototypes for understanding the mechanism of the movement. Such movements have been found to be associated with specific functions, such as substrate binding, catalysis, and recognition by other biomolecules. We have determined the three-dimensional structures of the lysine/arginine/ornithine-binding protein (LAO) from Salmonella typhimurium with and without lysine by x-ray crystallographic methods at 1.8- and 1.9-angstrom resolution, respectively. The structures are composed of two lobes held together by two short connecting strands. The two lobes are far apart in the unliganded structure, but in contact with each other in the lysine-liganded structure. The large movement of the lobes is a consequence of a 52-degrees rotation of a single backbone torsion angle in the first connecting strand and of distributed smaller changes of three backbone torsion angles of the second connecting strand. The absence of contact between the lysine and the connecting strands suggests that the ligand does not induce the conformational change directly. We instead propose that the unliganded protein undergoes a dynamic change between an ''open'' and a ''closed'' conformation and that the role of the ligand is to stabilize the closed conformation. We discuss the nature of a surface area which might be recognized by the membrane-bound complex of these amino acids transport systems.	LAWRENCE BERKELEY LAB, DEPT CHEM & STRUCT BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley			Oh, Byung-Ha/C-2061-2011	Pandit, Jayvardhan/0000-0001-6128-7779	NIAID NIH HHS [AI30725] Funding Source: Medline; NIDDK NIH HHS [DK43747, DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R01DK043747, R37DK012121] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Brtinger A. T., 1990, X PLOR VERSION 2 1; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; HIGGINS CF, 1981, P NATL ACAD SCI-BIOL, V78, P6038, DOI 10.1073/pnas.78.10.6038; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KANG CH, 1991, J BIOL CHEM, V266, P23893; KANG CH, 1989, J MOL BIOL, V207, P643, DOI 10.1016/0022-2836(89)90475-0; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Mowbray S L, 1990, Receptor, V1, P41; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; NWECOMER ME, 1901, J BIOL CHEM, V256, P13218; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1977, J BIOL CHEM, V252, P5142; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; ROSEN BP, 1971, J BIOL CHEM, V246, P3653; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEIGEMANN W, 1982, PROTEIN PACKAGE CRYS; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	39	286	289	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11348	11355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496186				2022-12-27	WOS:A1993LD46600092
J	PROSPERI, MT; FERBUS, D; KARCZINSKI, I; GOUBIN, G				PROSPERI, MT; FERBUS, D; KARCZINSKI, I; GOUBIN, G			A HUMAN CDNA CORRESPONDING TO A GENE OVEREXPRESSED DURING CELL-PROLIFERATION ENCODES A PRODUCT SHARING HOMOLOGY WITH AMEBIC AND BACTERIAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; HEAT-SHOCK PROTEIN; HELICOBACTER-PYLORI; PLATELET PROTEIN; MESSENGER-RNA; RAS ONCOGENE; SEQUENCE; EXPRESSION; FIBROBLASTS; DIFFERENTIATION	A clone, designated pag, was isolated by differential screening of cDNA libraries made from the untransformed and ras-transformed human mammary epithelial cell line HBL100. This cDNA corresponds to a gene constitutively expressed in most human cells which is induced to higher levels upon serum stimulation in untransformed and ras-transformed HBL100 cells. However, the abundance of the pag transcript is approximately 3-fold higher in transformed as compared to untransformed cells after 7-15 h of serum stimulation. In the promyelocytic leukemia cell line HL60 induced to differentiate the level of pag mRNA starts to decrease between 48 and 72 h following induction. During this period, which represents the commitment phase of differentiation, HL60 cells cease to proliferate. Therefore, in HBL100 and HL60 cells, higher levels of pag gene expression are correlated with cell proliferation. The pag cDNA codes for a 22-kDa protein, devoid of known consensus motifs, and shares 66% homology with a murine gene product (MER5) that is preferentially expressed in erythroleukemia cells during the early period of cell differentiation. In addition, the pag gene product shares approximately 50% identity with a 29-kDa surface antigen of Entamoeba histolytica and a 26-kDa antigen of Helicobacter pylori. Distant relationship was also found with other prokaryotic proteins. The pag cDNA hybridizes to multiple sequences within human and other mammalian genomes and to fewer sequences in chicken and Saccharomyces cerevisiae. Although a true relationship between eukaryotic and prokaryotic genes is difficult to establish, the conservation of pag gene sequences throughout Eukaryotae rather suggests that the pag locus belongs to a new class of genes encoding highly conserved proteins.	INST CURIE,ONCOGENESE LAB,26 RUE ULM,F-75005 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								Adams S. M., 1992, Human Molecular Genetics, V1, P91, DOI 10.1093/hmg/1.2.91; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BOS JL, 1989, CANCER RES, V49, P4682; CHEN L, 1990, ONCOGENE, V5, P1391; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P679; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FIBACH E, 1982, J CELL PHYSIOL, V113, P152, DOI 10.1002/jcp.1041130124; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; HARLOW E, 1988, ANTIBODIES LABORATOR; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGH KA, 1987, J CLIN INVEST, V79, P93, DOI 10.1172/JCI112814; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; LEBEAU J, 1991, ONCOGENE, V6, P1125; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NEMOTO Y, 1990, GENE, V91, P261, DOI 10.1016/0378-1119(90)90097-B; OTOOLE PW, 1991, J BACTERIOL, V173, P505, DOI 10.1128/jb.173.2.505-513.1991; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P1905; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TORIAN BE, 1990, P NATL ACAD SCI USA, V87, P6358, DOI 10.1073/pnas.87.16.6358; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; XU XM, 1991, J BIOCHEM-TOKYO, V109, P678, DOI 10.1093/oxfordjournals.jbchem.a123440; YAMAMOTO T, 1989, GENE, V80, P337; YEN A, 1985, EXP CELL RES, V156, P198, DOI 10.1016/0014-4827(85)90274-5	37	177	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11050	11056						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496166				2022-12-27	WOS:A1993LD46600051
J	SMITH, MT; EMERICH, DW				SMITH, MT; EMERICH, DW			ALANINE DEHYDROGENASE FROM SOYBEAN NODULE BACTEROIDS - KINETIC MECHANISM AND PH STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSEUDOMONAS-CAPSULATA	The kinetic mechanism of alanine dehydrogenase from soybean nodule bacteroids was studied by initial velocity experiments with or without product inhibitors, dead-end inhibitors, or alternate substrates. Without inhibitors, double-reciprocal plots of initial velocity experiments showed intersecting lines, indicating a sequential mechanism. These initial velocity experiments also revealed rapid-equilibrium ordered binding of NH4+ prior to pyruvate. When NAD was varied at changing-fixed concentrations of L-alanine, a nonlinear, concave down double-reciprocal plot was obtained. Substrate inhibition by pyruvate or L-alanine with cosubstrates varied was uncompetitive giving further support to an ordered mechanism. Product inhibition studies showed that both NAD and NADH and pyruvate and L-alanine were competitive. This suggested a Theorell-Chance mechanism. When product inhibition by L-alanine was studied with NH4+ varied in a series of experiments at increasing concentrations of pyruvate, the inhibition was eliminated, as expected for a Theorell-Chance mechanism. Furthermore, when NADH, NH4+, and pyruvate were varied simultaneously, maintaining their concentrations at a constant ratio to each other, an infinite V(max) was obtained. pH studies of the kinetic parameters indicated that NH4+, rather than NH3, was the true substrate that binds to a residue on the enzyme with a pK of 8.1. In conclusion, the kinetic mechanism at pH 8.5 was determined to be a Ter-Bi Theorell-Chance. In the amination direction, the substrates add in the order: NADH, NH4+, pyruvate, with NH4+ binding in rapid-equilibrium. In the reverse direction, NAD adds first, followed by L-alanine.	UNIV MISSOURI,DEPT BIOCHEM,117 SCHWEITZER HALL,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia								CABALLERO FJ, 1985, J BACTERIOL, V162, P804, DOI 10.1128/JB.162.2.804-809.1985; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W. W, 1970, ENZYMES, V2, P1; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; CROW VL, 1987, APPL ENVIRON MICROB, V53, P1885, DOI 10.1128/AEM.53.8.1885-1892.1987; DUNN SD, 1973, CAN J MICROBIOL, V19, P1493, DOI 10.1139/m73-243; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3820, DOI 10.1021/bi00410a045; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3826, DOI 10.1021/bi00410a046; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3834, DOI 10.1021/bi00410a047; GOLDMAN DS, 1959, BIOCHIM BIOPHYS ACTA, V34, P527, DOI 10.1016/0006-3002(59)90305-1; GRIMSHAW CE, 1981, BIOCHEMISTRY-US, V20, P5655, DOI 10.1021/bi00523a003; GRIMSHAW CE, 1981, BIOCHEMISTRY-US, V20, P5650, DOI 10.1021/bi00523a002; MCCOWEN SM, 1974, J BACTERIOL, V118, P590, DOI 10.1128/JB.118.2.590-597.1974; MULLER P, 1982, Z NATURFORSCH C, V37, P927; MURRELL JC, J GEN MICROBIOL, V129, P1197; Neet K E, 1980, Methods Enzymol, V64, P139; OHASHIMA T, 1979, EUR J BIOCHEM, V100, P29, DOI 10.1111/j.1432-1033.1979.tb02030.x; ROWELL P, 1976, ARCH MICROBIOL, V107, P115, DOI 10.1007/BF00446830; SCHIMERLIK MI, 1977, BIOCHEMISTRY-US, V16, P571, DOI 10.1021/bi00623a002; SMITH MT, 1991, THESIS U MISSOURI; TOLXDORFFNEUTZLING R, 1982, FEMS MICROBIOL LETT, V13, P155; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	22	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10746	10753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496141				2022-12-27	WOS:A1993LD46600009
J	WU, YN; MIKULSKI, SM; ARDELT, W; RYBAK, SM; YOULE, RJ				WU, YN; MIKULSKI, SM; ARDELT, W; RYBAK, SM; YOULE, RJ			A CYTOTOXIC RIBONUCLEASE - STUDY OF THE MECHANISM OF ONCONASE CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN PLACENTAL RIBONUCLEASE; TOXIC LECTINS ABRIN; DIPHTHERIA-TOXIN; RANA-CATESBEIANA; P-30 PROTEIN; TUMOR-CELLS; RICIN; INHIBITOR; JAPONICA	Onconase, or P-30, is a protein initially purified from extracts of Rana pipiens oocytes and early embryos based upon its anticancer activity both in vitro and in vivo. It is a basic single-chain protein with an apparent molecular mass of 12,000 daltons and is homologous to RNase A. In cultured 9L glioma cells, onconase inhibits protein synthesis with an IC50 of about 10(-7) M. The inhibition of protein synthesis correlates with cell death determined by clonogenic assays. I-125-Labeled onconase binds to specific sites on cultured 9L glioma cells. Scatchard analysis of the binding data shows that onconase appears to bind to cells with two different affinities, one with a K(d) of 6.2 x 10(-8) and another of 2.5 x 10(-7) M. Each cell could bind about 3 x 10(5) molecules of onconase at each of the two affinity sites. The low affinity K(d) is similar to the IC50 for onconase toxicity. Onconase also demonstrates a saturability of cytotoxicity at a concentration that would saturate the low affinity binding site. Incubation at 4-degrees-C increased the binding of onconase to cells relative to 37-degrees-C binding and also increased the sensitivity of cells to onconase toxicity, indicating that receptor binding may be an initial step in cell toxicity. Onconase cytotoxicity can be blocked by metabolic inhibitors, NaN3 and 2-deoxyglucose, and cytotoxicity is potentiated 10-fold by monensin. Ribonuclease activity appears necessary for onconase toxicity because alkylated onconase, which only retains 2% of the ribonuclease activity, was at least 100-fold less potent in inhibiting protein synthesis in cells. Onconase inhibition of protein synthesis in 9L cells coincides with the degradation of cellular 28 S and 18 S rRNA. In contrast to RNase A, onconase is resistant to two RNase inhibitors, placental ribonuclease inhibitor and Inhibit-Ace(TM). Northern hybridization with placental ribonuclease inhibitor cDNA probe indicates that 9L glioma cells contain endogenous placental ribonuclease inhibitor mRNA. Based on these results, we propose that onconase toxicity results from onconase binding to cell surface receptors, internalization to the cell cytosol where it degrades ribosomal RNA, inhibiting protein synthesis and causing cell death.	ALFACELL CORP,BLOOMFIELD,NJ 07003		WU, YN (corresponding author), NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892, USA.							ANFINSEN CB, 1954, J BIOL CHEM, V207, P201; ARDELT W, 1991, J BIOL CHEM, V266, P245; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BLANK A, 1981, BIOCHEMISTRY-US, V20, P2261, DOI 10.1021/bi00511a030; BREGNI M, 1986, CANCER RES, V46, P1208; COLLIER RJ, 1988, IMMUNOTOXINS, P25; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; DIJKSTRA J, 1978, BIOCHIM BIOPHYS ACTA, V521, P363, DOI 10.1016/0005-2787(78)90278-2; ENDO Y, 1987, J BIOL CHEM, V262, P5908; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HONJO T, 1968, J BIOL CHEM, V243, P3553; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; JOHNSON EA, 1961, BIOMETRICS, V17, P79, DOI 10.2307/2527497; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KAMIYA Y, 1990, J BIOCHEM-TOKYO, V108, P139, DOI 10.1093/oxfordjournals.jbchem.a123153; KAWANOMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P335, DOI 10.1016/0167-4781(92)90513-Y; KIM K, 1965, J BACTERIOL, V90, P1557, DOI 10.1128/JB.90.6.1557-1562.1965; KRAFT N, 1970, BIOCHIM BIOPHYS ACTA, V217, P164, DOI 10.1016/0005-2787(70)90133-4; KYNER D, 1979, EUR J BIOCHEM, V99, P395, DOI 10.1111/j.1432-1033.1979.tb13268.x; LACCETTI P, 1992, CANCER RES, V52, P4582; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEWIS M T, 1989, Protein Sequences and Data Analysis, V2, P101; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; MIKULSKI SM, 1990, CELL TISSUE KINET, V23, P237, DOI 10.1111/j.1365-2184.1990.tb01119.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; NITTA K, 1987, CANCER RES, V47, P4877; OKABE Y, 1991, J BIOCHEM-TOKYO, V109, P786, DOI 10.1093/oxfordjournals.jbchem.a123457; OLSNES S, 1976, J BIOL CHEM, V251, P3985; OLSNES S, 1974, NATURE, V249, P627, DOI 10.1038/249627a0; ROTH JS, 1962, BIOCHIM BIOPHYS ACTA, V61, P903, DOI 10.1016/0926-6550(62)90007-5; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAKAKIBARA F, 1979, CANCER RES, V39, P1347; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018; UCHIDA T, 1973, J BIOL CHEM, V248, P3845; VANTIELMENKVELD GJ, 1982, J BACTERIOL, V150, P490, DOI 10.1128/JB.150.2.490-497.1982; WATSON DH, 1979, NATURE, V278, P278; YOULE RJ, 1993, IN PRESS CRIT REV TH	46	235	247	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10686	10693						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486718				2022-12-27	WOS:A1993LB80000101
J	COUGHLIN, PB; TETAZ, T; SALEM, HH				COUGHLIN, PB; TETAZ, T; SALEM, HH			IDENTIFICATION AND PURIFICATION OF A NOVEL SERINE PROTEINASE-INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-THROMBIN-III; ALPHA-1-PROTEINASE INHIBITOR; ALPHA-1-ANTITRYPSIN; INACTIVATION; ANTITHROMBIN; SUPERFAMILY; EXPRESSION; OVALBUMIN; CLONING	We report the identification, purification, and partial amino acid sequence of a novel serine proteinase inhibitor which is present in extracts from human placentas and in the cytosolic fraction of the leukemic line K562. Extracts from these tissues exhibited time-dependent inhibition of the serine proteinase thrombin. This activity was not accelerated by heparin and corresponded to a protein which formed a 67-kDa complex with I-125-thrombin. The complex was stable on reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A cleaved and functionally inactive form of the protein was purified from placental tissue by chromatography on DEAE-Sepharose, followed by affinity chromatography on thrombin-Sepharose. Antibodies raised against the placental protein recognized the inhibitor from K562 cells and placental extract. Western blotting experiments using the antibody showed that the uncleaved inhibitor has a molecular mass of 38 kDa. Amino acid sequencing was performed on the purified protein. Sequences of peptides resulting from digestion with cyanogen bromide followed by Endoproteinase Lys-c confirmed that this is a novel inhibitor with significant homology to the serpin family.	BAKER MED RES INST,PRAHRAN,VIC 3181,AUSTRALIA	Baker Heart and Diabetes Institute	COUGHLIN, PB (corresponding author), BOX HILL HOSP,MONASH MED SCH,DEPT MED,NELSON RD,BOX HILL,MELBOURNE,VIC 3128,AUSTRALIA.							BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; BOLLEN A, 1983, DNA-J MOLEC CELL BIO, V2, P255, DOI 10.1089/dna.1983.2.255; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; DESROCHERS PE, 1988, J CLIN INVEST, V81, P1646, DOI 10.1172/JCI113500; DUBIN A, 1992, J BIOL CHEM, V267, P6576; FENTON JW, 1977, CHEM BIOL THROMBIN, P43; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAST AE, 1991, J BIOL CHEM, V266, P15810; POTEMPA J, 1988, J BIOL CHEM, V263, P7364; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; STONE KL, 1989, PRACTICAL GUIDE PROT, P33; TETAZ T, 1993, TECHNIQUES PROTEIN C, V4; THOMPSON EA, 1988, THROMB HAEMOSTASIS, V59, P415; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; YE RD, 1989, J BIOL CHEM, V264, P5495	20	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9541	9547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486644				2022-12-27	WOS:A1993LA68900061
J	HOLNESS, CL; DASILVA, RP; FAWCETT, J; GORDON, S; SIMMONS, DL				HOLNESS, CL; DASILVA, RP; FAWCETT, J; GORDON, S; SIMMONS, DL			MACROSIALIN, A MOUSE MACROPHAGE-RESTRICTED GLYCOPROTEIN, IS A MEMBER OF THE LAMP/LGP FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; O-LINKED GLYCOSYLATION; DIFFERENTIAL EXPRESSION; ADHESION MOLECULES; SEQUENCE-ANALYSIS; PROTEIN-SEQUENCE; PLASMA-MEMBRANE; ANTIGEN; CDNA; ACID	Macrosialin is a heavily glycosylated transmembrane protein of 87-115 kDa, highly and specifically expressed by mouse tissue macrophages, and to a lesser extent by dendritic cells. We have isolated cDNA clones encoding macrosialin from a thioglycollate-elicited peritoneal macrophage cDNA library by transient expression in COS cells and panning with the anti-macrosialin monoclonal antibody FA/11. A single 1.3-kilobase macrosialin transcript was detected in both untreated and phorbol 12-myristate 13-acetate-stimulated RAW cells. The cDNA sequence predicts a type I integral membrane protein of 326 residues with a heavily glycosylated extracellular domain of 306 residues containing nine potential N-linked glycosylation sites and numerous potential O-linked glycosylation sites. The extracellular domain consists of two distinct regions, separated by an extended 12 residue proline-rich hinge; a membrane-distal mucin-like domain of 89 residues containing short peptide repeats and consisting of 44% serine and threonine residues; and a membrane proximal domain of 170 residues, which has significant sequence homology to a family of lysosomal associated glycoproteins known as the lamp-1 group. Macrosialin is the murine homologue of the human macrophage glycoprotein CD68 (72% identity, 80% similarity). Both proteins are preferentially expressed by macrophages and share the same bipartite structure having a mucin-like domain and a domain common to the lamp family. Macrosialin and CD68 are the first examples of a lamp family protein with a restricted cell-type-specific expression. They may have evolved from the lamps to carry out specialized functions in dedicated phagocytic cells.	JOHN RADCLIFFE HOSP, IMPERIAL CANC RES FUND, INST MOLEC MED, CELL ADHES LAB, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND	University of Oxford; University of Oxford					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTERBURN LM, 1990, J BIOL CHEM, V265, P7419; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CARLSSON SR, 1989, J BIOL CHEM, V264, P20526; CHA Y, 1990, J BIOL CHEM, V265, P5008; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GORDON S, 1986, J CELL SCI, P267, DOI 10.1242/jcs.1986.Supplement_4.16; GORDON S, 1992, CURR OPIN IMMUNOL, V4, P25, DOI 10.1016/0952-7915(92)90119-Y; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KILLEEN N, 1987, EMBO J, V6, P4029, DOI 10.1002/j.1460-2075.1987.tb02747.x; KNAPP W, 1991, LEUKOCYTE TYPING, V4; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MCMICHAEL AJ, 1991, LEUKOCYTE TYPING, V3; MICKLEM K, 1989, BRIT J HAEMATOL, V73, P6, DOI 10.1111/j.1365-2141.1989.tb00210.x; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; PARWARESCH MR, 1986, AM J PATHOL, V125, P141; PULFORD KAF, 1990, INT IMMUNOL, V2, P973, DOI 10.1093/intimm/2.10.973; RABINOWITZ S, 1989, J CELL SCI, V93, P623; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SAITO N, 1991, AM J PATHOL, V139, P1053; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2889; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SMITH MEF, 1991, AM J SURG PATHOL, V15, P757, DOI 10.1097/00000478-199108000-00005; SMITH MJ, 1987, J CELL SCI, V87, P113; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUTHERLAND DR, 1988, LEUKEMIA, V2, P793; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARNKE RA, 1989, AM J PATHOL, V135, P1089; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; ZOT AS, 1990, J BIOL CHEM, V265, P20988	48	169	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9661	9666						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486654				2022-12-27	WOS:A1993LA68900076
J	GIULIVI, C; DAVIES, KJA				GIULIVI, C; DAVIES, KJA			DITYROSINE AND TYROSINE OXIDATION-PRODUCTS ARE ENDOGENOUS MARKERS FOR THE SELECTIVE PROTEOLYSIS OF OXIDATIVELY MODIFIED RED-BLOOD-CELL HEMOGLOBIN BY (THE 19-S) PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; COLI GLUTAMINE-SYNTHETASE; MIXED-FUNCTION OXIDATION; OXYGEN RADICALS; ESCHERICHIA-COLI; DENATURED PROTEINS; MULTICATALYTIC PROTEASE; HORSERADISH-PEROXIDASE; MAMMALIAN-CELLS; SKELETAL-MUSCLE	Cells exposed to oxidative stress have been shown previously to exhibit both protein oxidation and increased proteolysis. Experiments conducted with purified proteins in vitro have indicated that oxidatively modified proteins may be selectively degraded by intracellular proteases, but a definitive cause-and-effect relationship has not been demonstrated previously in intact cells. Several investigators have proposed that oxidatively modified proteins are selectively degraded within cells, but the possibility that oxidants may activate intracellular proteases (directly or indirectly) to catalyze the indiscriminate degradation of undamaged proteins has not been discounted. Armed with the knowledge that dityrosine is a specific product of protein oxidation, we undertook a series of experiments to test the hypothesis that oxidized proteins undergo selective intracellular degradation. Our results demonstrate that dityrosine is produced in the hemoglobin molecule when red blood cells are exposed to a continuous flux of hydrogen peroxide (H2O2). The dityrosine so produced is only released from the hemoglobin by proteolysis and is stable to prolonged incubation with cell extracts. Inhibitors of proteolysis have no effect on dityrosine production but do effectively prevent dityrosine release. Proteasome (the 670-kDa multicatalytic proteinase complex, that we have previously called macroxyproteinase or MOP (Pacifici, R. E., Salo, D. C., and Davies, K. J. A. (1989) Free Radical Biol. & Med. 7, 521-526; Salo, D. C., Pacifici, R. E., Lin, S. W., Giulivi, C., and Davies, K. J. A. (1990) J. Biol. Chem. 265, 11919-11927; Pacifici, R. E., and Davies, K. J. A. (1991) Gerontology 37, 166-180) appears responsible for dityrosine release during the selective degradation of oxidatively modified proteins in red blood cells and red cell extracts. We conclude that the elevated rates of proteolysis observed in response to oxidative stress do, indeed, reflect selective degradation of oxidatively modified (damaged) proteins. Despite a relatively low production rate, dityrosine has a high fluorometric quantum yield and is, of course, a specific product of protein oxidation. As an apparently stable metabolic end product, dityrosine may prove to be an extremely valuable (cellular or urinary) marker or index of organismal oxidative stress.	ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,47 NEW SCOTLAND AVE,ALBANY,NY 12208; UNIV SO CALIF,INST TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,DEPT BIOCHEM,LOS ANGELES,CA 90033	Albany Medical College; University of Southern California; University of Southern California			Giulivi, Cecilia/ABB-7809-2020	Giulivi, Cecilia/0000-0003-1033-7435; Davies, Kelvin/0000-0001-7790-3003	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R56ES003598, R23ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKHAYAT O, 1987, P NATL ACAD SCI USA, V84, P1595, DOI 10.1073/pnas.84.6.1595; ANDERSEN SO, 1964, BIOCHIM BIOPHYS ACTA, V93, P213, DOI 10.1016/0304-4165(64)90289-2; ARMON T, 1990, J BIOL CHEM, V265, P20723; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BOGUTA G, 1983, INT J RADIAT BIOL, V43, P249, DOI 10.1080/09553008314550301; BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DAHLMANN B, 1983, FEBS LETT, V160, P243, DOI 10.1016/0014-5793(83)80975-2; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P225, DOI 10.1016/0891-5849(88)90016-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DAVIES KJA, 1988, INT COMMITTEE PROTEO, P3; DAVIES KJA, 1990, CELLULAR ANTIOXIDANT, P123; DAVIES KJA, 1985, CELLULAR MOL ASPECTS, P15; DAVIES KJA, 1988, LIPID PEROXIDATION B, P101; DAVIES KJA, 1981, OXIDATIVE DAMAGE REP; DAVIES KJA, 1988, ROLE OXYGEN RADICALS, P169; DEAN RT, 1985, BIOCHEM BIOPH RES CO, V126, P1082, DOI 10.1016/0006-291X(85)90296-7; DEAN RT, 1986, BIOCHEM J, V240, P489, DOI 10.1042/bj2400489; Di Iorio E E, 1981, Methods Enzymol, V76, P57; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GARCIACASTINEIRAS S, 1978, SCIENCE, V199, P897, DOI 10.1126/science.622574; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1988, INT COMMITTEE PROTEO, P4; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; KIKUGAWA K, 1991, LIPIDS, V26, P922, DOI 10.1007/BF02535978; LABELLA F, 1967, BIOCHEM BIOPH RES CO, V26, P748, DOI 10.1016/S0006-291X(67)80137-2; LABELLA F, 1968, BIOCHEM BIOPH RES CO, V30, P333, DOI 10.1016/0006-291X(68)90746-8; LEHRER SS, 1967, BIOCHEMISTRY-US, V6, P757, DOI 10.1021/bi00855a017; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARCILLAT O, 1988, BIOCHEM J, V254, P677, DOI 10.1042/bj2540677; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MISRA HP, 1972, J BIOL CHEM, V247, P6960; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; ORLOWSKI M, 1988, BIOCHEM J, V255, P751; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PACIFICI RE, 1988, FASEB J, V2, pA1007; PACIFICI RE, 1991, OXIDATIVE DAMAGE & REPAIR, P364; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PENNELL RB, 1964, RED BLOOD CELL, P53; PRTZ WA, 1983, INT J RADIAT BIOL, V44, P183; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIVETT AJ, 1989, BIOCHEM J, V263, P625, DOI 10.1042/bj2630625; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; RYTER SW, 1990, BIOL OXIDATION SYSTE, V2, P929; SALO DC, 1990, J BIOL CHEM, V265, P11919; SALO DC, 1988, FREE RADICAL BIO MED, V5, P335, DOI 10.1016/0891-5849(88)90105-0; STADTMAN ER, 1985, ARCH BIOCHEM BIOPHYS, V239, P379, DOI 10.1016/0003-9861(85)90703-9; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; TEW D, 1988, J BIOL CHEM, V263, P17880; URSINI F, 1990, PROTEIN METABOLISM A, P373; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	76	179	189	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8752	8759						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473319				2022-12-27	WOS:A1993KX81100057
J	HU, NM; MILLS, DA; HUCHZERMEYER, B; RICHTER, ML				HU, NM; MILLS, DA; HUCHZERMEYER, B; RICHTER, ML			INHIBITION BY TENTOXIN OF COOPERATIVITY AMONG NUCLEOTIDE BINDING-SITES ON CHLOROPLAST COUPLING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI F1-ATPASE; FACTOR-I; BETA-SUBUNIT; EPSILON-SUBUNIT; ATP SYNTHASE; CONFORMATION; HYDROLYSIS; ACTIVATION; MECHANISM	Tentoxin, a cyclic tetrapeptide produced by the fungus Alternaria tenuis, is a potent inhibitor of the chloroplast coupling factor 1 from certain sensitive species of plants. We have shown that the beta subunit is at least partly responsible for conferring sensitivity to the toxin. This was confirmed by Avni et al. (Avni, A., Anderson, J. D., Holland, N., Rochaix, J-D., Gromet-Elhanan, Z., and Edelman, M. (1992) Science 257, 1245-1247) who demonstrated the importance for tentoxin sensitivity of an acidic amino acid residue at position 83 in the beta subunit sequence. In this paper we show that the Ca2+-ATPase and Mg2+-ATPase activities of CF1 lacking the delta and epsilon subunits, CF1(-deltaepsilon), were fully sensitive to tentoxin, even after the gamma subunit is cleaved by trypsin into several smaller fragments. We also show that the isolated reconstitutively active beta subunit of CF1 does not effectively compete with CF1(-deltaepsilon) for tentoxin binding. The results suggest that tight tentoxin binding requires the presence of at least the alpha and beta subunits but is independent of the delta and epsilon subunits. Tentoxin inhibited the release of a tightly bound molecule of ADP from CF1, which was induced by the binding of the ATP analogue adenylyl-beta,gamma-imidodiphosphate (AMP-PNP). AMP-PNP was shown previously (Shapiro, A. B., and McCarty, R. E. (1990) J. Biol. Chem. 265, 4340-4347) to cause two adenine nucleotide binding sites on CF1, sites 1 and 3, to switch their properties, possibly as part of an alternating site catalytic cooperativity mechanism (Boyer, P. D. (1989) FASEB J. 3, 2164-2178). It is proposed that the effect of tentoxin on catalytic cooperativity in CF1 results from tentoxin binding at an interface between alpha and beta subunits, preventing transfer of information between different nucleotide binding sites on the enzyme.	UNIV KANSAS,DEPT BIOCHEM,LAWRENCE,KS 66045; HANNOVER SCH VET MED,INST BOT,W-3000 HANNOVER 1,GERMANY	University of Kansas; University of Veterinary Medicine Hannover, Foundation			Huchzermeyer, Bernhard/AAF-5071-2020					ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ANTHON GE, 1983, BIOCHIM BIOPHYS ACTA, V723, P358, DOI 10.1016/0005-2728(83)90041-5; ARANA JL, 1982, J BIOL CHEM, V257, P1125; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BAIRD BA, 1976, J BIOL CHEM, V251, P6953; BARZVI D, 1983, FEBS LETT, V160, P233, DOI 10.1016/0014-5793(83)80973-9; BARZVI D, 1984, BIOCHIM BIOPHYS ACTA, V765, P340, DOI 10.1016/0005-2728(84)90174-9; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CERIONE RA, 1981, BIOCHEMISTRY-US, V20, P3359, DOI 10.1021/bi00515a008; COLVERT KK, 1992, BIOCHEMISTRY-US, V31, P3930, DOI 10.1021/bi00131a006; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; FROMME P, 1992, Z NATURFORSCH C, V47, P239; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GROMETELHANAN G, 1992, BIOCHIM BIOPHYS ACTA, V1102, P379; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P67, DOI 10.1016/S0005-2728(89)80404-9; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MILLS DA, 1990, CURRENT PROGR PHOTOS, V3, P6; MITRA B, 1990, BIOCHEMISTRY-US, V29, P9879, DOI 10.1021/bi00494a018; NALIN CM, 1977, BIOCHEMISTRY-US, V24, P2318; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; RICHTER ML, 1987, PROGR PHOTOSYNTHESIS, V3, P53; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SHOSHAN V, 1979, J BIOL CHEM, V254, P8808; SNYDER B, 1985, BIOCHEMISTRY-US, V24, P2324, DOI 10.1021/bi00330a030; SNYDER B, 1984, BIOCHEMISTRY-US, V23, P5787, DOI 10.1021/bi00319a018; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; STEELE JA, 1977, BIOCHIM BIOPHYS ACTA, V459, P347, DOI 10.1016/0005-2728(77)90036-6; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; YU F, 1985, ARCH BIOCHEM BIOPHYS, V238, P61, DOI 10.1016/0003-9861(85)90140-7	51	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8536	8540						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473298				2022-12-27	WOS:A1993KX81100027
J	JONES, DA; CARLTON, DP; MCINTYRE, TM; ZIMMERMAN, GA; PRESCOTT, SM				JONES, DA; CARLTON, DP; MCINTYRE, TM; ZIMMERMAN, GA; PRESCOTT, SM			MOLECULAR-CLONING OF HUMAN PROSTAGLANDIN ENDOPEROXIDE SYNTHASE TYPE-II AND DEMONSTRATION OF EXPRESSION IN RESPONSE TO CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; MESSENGER-RNA; PROSTACYCLIN SYNTHESIS; PHORBOL ESTER; G/H SYNTHASE; HEME-BINDING; CYCLOOXYGENASE; GENE; STIMULATION; ENCODES	Prostaglandin endoperoxide synthase (PHS) catalyzes the committed step in the biosynthesis of prostaglandins and thromboxane. We recently observed dissociation of PHS activity and enzyme mass measured in an immunoassay of endothelial cells exposed to tumor necrosis factor. These data and observations by others suggested that endothelial cells express an alternate PHS. We now report the molecular cloning of human PHS type II from an endothelial cell cDNA library. The protein encoded by this cDNA shares 61% identity with the human PHS I. Southern analysis demonstrated a single copy of PHS II and we found a polymorphism in approximately 5% of the population. PHS II mapped to chromosome 1, in contrast to PHS I, which is on chromosome 9. The PHS II cDNA hybridized strongly to a 4.3-kilobase (kb) message from endothelial cells. Stimulation of the cells with tumor necrosis factor, phorbol 12-myristate 13-acetate, lipopolysaccharide, or interleukin-1 increased mRNA levels for PHS II, and this change correlated well with increased prostacyclin biosynthesis. Cycloheximide induced PHS II mRNA without a corresponding activity increase demonstrating that translation of the 4.3-kb message is required for increased prostacyclin biosynthesis. We conclude that expression of PHS II may have important pathophysiological effects in the vasculature.			JONES, DA (corresponding author), UNIV UTAH, NORA ECCLES HARRISON CARDIOVASC RES TRAINING INST, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA.				NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034127, R01HL044525, R37HL044525] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA42014] Funding Source: Medline; NHLBI NIH HHS [HL34127, HL44525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; CARLTON DP, 1992, CLIN RES, V40, pA193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Fourney R.M., 1988, FOCUS, V10, P5; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INGERMANWOJENSKI CM, 1988, PROSTAGLANDINS, V36, P127, DOI 10.1016/0090-6980(88)90300-0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TAGGART RT, 1985, P NATL ACAD SCI USA, V82, P6240, DOI 10.1073/pnas.82.18.6240; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	36	700	724	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9049	9054						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473346				2022-12-27	WOS:A1993KX81100095
J	LI, KH; TAMAI, K; TAN, EML; UITTO, J				LI, KH; TAMAI, K; TAN, EML; UITTO, J			CLONING OF TYPE-XVII COLLAGEN - COMPLEMENTARY AND GENOMIC DNA-SEQUENCES OF MOUSE 180-KILODALTON BULLOUS PEMPHIGOID ANTIGEN (BPAG2) PREDICT AN INTERRUPTED COLLAGENOUS DOMAIN, A TRANSMEMBRANE SEGMENT, AND UNUSUAL FEATURES IN THE 5'END OF THE GENE AND THE 3'-UNTRANSLATED REGION OF THE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONING; EXPRESSION; AUTOANTIGEN; CHAIN; SKIN	Thus far, 16 distinct vertebrate collagens (types I-XVI) have been delineated. In this study, we have cloned a mouse collagenous protein, the 180-kDa bullous pemphigoid antigen (BPAG2). Isolation of overlapping clones, together with 5' and 3' rapid amplification of cDNA ends, allowed delineation of the entire coding sequence. The 5' and 3' ends of the mRNA transcripts were confirmed by primer extension and anchored reverse transcription polymerase chain reaction analyses. The deduced polypeptide contained 1,433 amino acids, including a collagenous domain that consisted of 13 separate segments. Computer analysis of the deduced amino acid sequence demonstrated the presence of a membrane-associated segment. Examination of the 5' end of the BPAG2 gene revealed that the 295-base pair (bp) exon 1 contained two segments of (T)13AA and TT(A)11, whereas exon 2 was shown to contain the translation initiation codon. The 3' end of the mRNA transcript identified two 6-bp inverted repeat sequences that could form a stem for a 30-bp hairpin loop followed by a series of U residues. Comparison of mouse and human BPAG2 sequences demonstrated 86% homology and the unit of evolutionary period of 4.2 million years. In summary, we have cloned full-length mouse BPAG2 cDNA sequences that encode a collagenous polypeptide. We propose that this polypeptide be designated as the alpha1-chain of type XVII collagen.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,233 S 10TH ST,RM 450,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923, T32AR007561] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1990, J INVEST DERMATOL, V95, P252, DOI 10.1111/1523-1747.ep12484863; BERNARD P, 1992, J INVEST DERMATOL, V99, P174, DOI 10.1111/1523-1747.ep12616797; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTIANO AM, 1992, HUM MOL GENET, V1, P475, DOI 10.1093/hmg/1.7.475; Chu Mon-Li, 1993, P149; COPELAND NG, 1993, GENOMICS, V15, P180, DOI 10.1006/geno.1993.1027; DENG G, 1981, NUCLEIC ACIDS RES, V9, P4173, DOI 10.1093/nar/9.16.4173; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; FAZIO MJ, 1988, LAB INVEST, V58, P270; Frohman MA, 1990, PCR PROTOCOLS GUIDE; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GIUDICE GJ, 1991, CLIN RES, V39, P478; HART GW, 1979, J BIOL CHEM, V254, P9747; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KIVIRIKKO KI, 1985, ANN NY ACAD SCI, V460, P187, DOI 10.1111/j.1749-6632.1985.tb51167.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABIB RS, 1986, J IMMUNOL, V136, P1231; LI K, 1991, J BIOL CHEM, V266, P24064; LI K, J INVEST DERMATOL, V99, P258; MARCHANT JK, 1991, P NATL ACAD SCI USA, V88, P1560, DOI 10.1073/pnas.88.4.1560; MORRISON LH, 1988, J CLIN INVEST, V81, P2023, DOI 10.1172/JCI113554; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Piez K.A., 1976, BIOCH COLLAGENS, P1; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1992, NEW ENGL J MED, V326, P540; RYYNANEN J, 1991, J INVEST DERMATOL, V97, P562, DOI 10.1111/1523-1747.ep12481896; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1992, J INVEST DERMATOL, V98, P942; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; UITTO J, 1992, J INVEST DERMATOL, V98, P391, DOI 10.1111/1523-1747.ep12499822; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	46	173	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8825	8834						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473327				2022-12-27	WOS:A1993KX81100067
J	NACHTIGAL, MW; NICKEL, BE; CATTINI, PA				NACHTIGAL, MW; NICKEL, BE; CATTINI, PA			PITUITARY-SPECIFIC REPRESSION OF PLACENTAL MEMBERS OF THE HUMAN GROWTH-HORMONE GENE FAMILY - A POSSIBLE MECHANISM FOR LOCUS REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC SOMATOMAMMOTROPIN; 5'-FLANKING REGION; HUMAN-PROLACTIN; TUMOR-CELLS; EXPRESSION; BINDING; TRANSCRIPTION; ACTIVATION; SEQUENCES; EVOLUTION	Five members of the human growth hormone (GH) gene family are located at a single locus on chromosome 17. Growth hormone is expressed in the pituitary under the control of the tissue-specific factor Pit 1/GHF-1, and chorionic somatomammotropin (CS) -A, -B, and -L, as well as placental GH variant, are expressed specifically in the placental syncytiotrophoblast. Despite this specificity in vivo, the CS-A promoter can bind Pit 1/GHF-1 and allow CS-A promoter activity in pituitary tumor cells after gene transfer. We have identified and characterized PSF sequences associated with only the placental members in the GH/CS locus which repress placental promoter activity >90% in transfected pituitary cells. These sequences do not significantly affect promoter function in placental cells after gene transfer. Repressor activity correlates with binding of protein at two sites (PSF-A and PSF-B) with pituitary, but not placental, nuclear extracts. Competition studies suggest an interaction between PSF and Pit 1/GHF-1 proteins. These results indicate that PSF protein can repress CS-A promoter activity in a tissue-specific manner in vitro and provide a possible mechanism by which expression of placental members of the GH family are inhibited in the pituitary in vivo.	UNIV MANITOBA,DEPT PHYSIOL,770 BANNATYNE AVE,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Manitoba				Nachtigal, Mark/0000-0003-3291-8628				BALDWIN AS, 1990, DNA PROTEIN ENG TECH, V2, P73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTINI PA, 1986, DNA-J MOLEC CELL BIO, V5, P503, DOI 10.1089/dna.1.1986.5.503; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DAVIDSON RL, 1966, P NATL ACAD SCI USA, V56, P1437, DOI 10.1073/pnas.56.5.1437; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; DUCKWORTH ML, 1993, IN PRESS TROPHOBLAST; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; HJELLE BL, 1982, NUCLEIC ACIDS RES, V10, P3459, DOI 10.1093/nar/10.11.3459; IMMONS DM, 1990, GENE DEV, V4, P695; JACKSONGRUSBY LL, 1988, ENDOCRINOLOGY, V122, P2462, DOI 10.1210/endo-122-6-2462; JONES BK, 1992, 74TH M END SOC SAN A; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LEMAIGRE FP, 1989, DNA-J MOLEC CELL BIO, V8, P149, DOI 10.1089/dna.1.1989.8.149; LEW AM, 1991, NUCLEIC ACIDS RES, V19, P6329, DOI 10.1093/nar/19.22.6329; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NACHTIGAL MW, 1993, IN PRESS TROPHOBLAST; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKEL BE, 1990, BIOCHEM J, V267, P653, DOI 10.1042/bj2670653; NICKEL BE, 1991, MOL CELL BIOCHEM, V106, P181; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	35	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8473	8479						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473291				2022-12-27	WOS:A1993KX81100018
J	REICHARD, P				REICHARD, P			THE ANAEROBIC RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRIPHOSPHATE REDUCTASE; OXYGEN				REICHARD, P (corresponding author), KAROLINSKA INST, MED NOBEL INST, DEPT BIOCHEM, S-10401 STOCKHOLM 60, SWEDEN.							BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BIANCHI V, 1993, IN PRESS J BACTERIOL; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; Frey P A, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P1; HANTKE K, 1988, ARCH MICROBIOL, V149, P344, DOI 10.1007/BF00411654; HARDER J, 1992, J BIOL CHEM, V267, P25548; HOGENKAMP HPC, 1987, FEBS LETT, V219, P197, DOI 10.1016/0014-5793(87)81215-2; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JAMISON CS, 1987, J BACTERIOL, V169, P5087, DOI 10.1128/jb.169.11.5087-5094.1987; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; PANAGOU D, 1972, BIOCHEMISTRY-US, V11, P2378, DOI 10.1021/bi00762a025; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; PONTIS E, 1991, BIOCHEM BIOPH RES CO, V180, P1222, DOI 10.1016/S0006-291X(05)81326-9; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1993, IN PRESS SCIENCE; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996	25	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8383	8386						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473279				2022-12-27	WOS:A1993KX81100001
J	JI, H; BALDWIN, GS; BURGESS, AW; MORITZ, RL; WARD, LD; SIMPSON, RJ				JI, H; BALDWIN, GS; BURGESS, AW; MORITZ, RL; WARD, LD; SIMPSON, RJ			EPIDERMAL GROWTH-FACTOR INDUCES SERINE PHOSPHORYLATION OF STATHMIN IN A HUMAN COLON-CARCINOMA CELL-LINE (LIM-1215)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; RECEPTOR TYROSINE KINASES; PROTEIN-KINASE; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; EGF RECEPTOR; FACTOR-ALPHA; A431 CELLS; IDENTIFICATION; ACTIVATION	Changes in protein phosphorylation in the human colon carcinoma cell line LIM 1215 after stimulation with epidermal growth factor (EGF) have been analyzed by two-dimensional gel electrophoresis and phosphoamino acid analysis. In addition to a number of tyrosine-phosphorylated proteins, a family of small proteins (M(r) 19,000-20,000) is maximally phosphorylated on serine within 5 min of EGF stimulation. One member of the family has been purified by a combination of two-dimensional electrophoresis and reversed-phase high performance liquid chromatography and identified by amino acid sequence analysis as stathmin. Although phosphorylation of stathmin has been reported previously in leukemia cells and following stimulation of hemopoietic or lymphoid cells with several mitogenic agents, this is the first report of stathmin phosphorylation in response to EGF.	LUDWIG INST CANC RES, JOINT PROT STRUCT LAB, PO ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute			Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796; Baldwin, Graham/0000-0002-0944-8747				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BALDWIN GS, 1992, CANCER RES, V52, P2261; BARNES D, 1987, METHOD ENZYMOL, V146, P88; BEGG GS, 1989, TECHNIQUES PROTEIN C, P79; BERETTA L, 1989, J BIOL CHEM, V264, P9932; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER HL, 1990, J IMMUNOL, V145, P1205; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GIUGNI TD, 1988, J BIOL CHEM, V263, P18988; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GREENE LA, 1982, ADV CELL NEUROBIOL, V3, P374; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LAYTON JE, 1991, J BIOL CHEM, V266, P23815; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEYRON JF, 1989, BIOCHEM J, V258, P505, DOI 10.1042/bj2580505; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SEGER R, 1992, J BIOL CHEM, V267, P14373; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; SIMPSON RJ, 1987, FEBS LETT, V224, P128, DOI 10.1016/0014-5793(87)80435-0; SIMPSON RJ, 1988, EUR J BIOCHEM, V176, P187, DOI 10.1111/j.1432-1033.1988.tb14267.x; SIZELAND AM, 1991, MOL CELL BIOL, V11, P4005, DOI 10.1128/MCB.11.8.4005; Sizeland A, 1991, GROWTH FACTORS, V4, P129, DOI 10.3109/08977199109000264; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WARD L D, 1991, Peptide Research, V4, P187; WARD LD, 1990, ELECTROPHORESIS, V11, P883, DOI 10.1002/elps.1150111019; WHITEHEAD RH, 1990, INT J CANCER, V46, P858, DOI 10.1002/ijc.2910460518; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHU XX, 1989, J BIOL CHEM, V264, P14556	66	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13396	13405						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514777				2022-12-27	WOS:A1993LH55300056
J	MARSHALL, ICB; TAYLOR, CW				MARSHALL, ICB; TAYLOR, CW			BIPHASIC EFFECTS OF CYTOSOLIC CA2+ ON INS(1,4,5)P3-STIMULATED CA2+ MOBILIZATION IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INDUCED CALCIUM RELEASE; PIG TAENIA CECI; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; XENOPUS OOCYTES; CA-2+; OSCILLATIONS; CELLS; TRISPHOSPHATE	The increase in cytosolic free Ca2+ concentration that follows mobilization of intracellular Ca2+ stores by inositol 1,4,5-trisphosphate Ins(1,4,5)P3 has been reported to modulate the sensitivity of Ins(1,4,5)P3 receptors. We have examined the effects of cytosolic Ca2+ on Ins(1,4,5)P3-Stimulated Ca2+ mobilization in permeabilized hepatocytes. Increasing the free Ca2+ concentration in the medium ([Ca2+]m) caused a concentration-dependent increase in the sensitivity of the stores to Ins(1,4,5)P3; the concentration of Ins(1,4,5)P3 that caused half-maximal Ca2+ mobilization (EC50) decreased from 261 +/- 11 nM (n = 3) to 50 +/- 4 nM (n = 8) as [Ca2+]m was increased from approximately 7 nM to 1.6 muM. The EC50 for this effect of Ca2+ was -250 nm. In addition, higher [Ca2+]m (>600 nM) reduced the extent of Ca2+ release induced by a maximal concentration of Ins(1,4,5)P3; elevating [Ca2+]m to 2.6 muM reduced the proportion of Ca2+ releasable by Ins(1,4,5)P3 by 94 +/- 8% (n = 3). Both effects of Ca2+ were independent of Ca2+-stimulated Ins(1,4,5)P3 formation. When elevated [Ca2+]m was returned to control levels, the sensitization of Ins()1,4,5)P3-mediated Ca2+ mobilization reversed completely, whereas the reduction in the size of the Ins(1,4,5)P3-sensitive Ca2+ pool was reversed by only 59 +/- 12% (n = 5) after 20 s and was not further reversed after 100 s. The two distinct effects of Ca2+ on Ins(1,4,5)P3-mediated Ca2+ release combined to control the amount of Ca2+ released by a submaximal concentration of Ins(1,4,5)P3 in a biphasic manner.	DEPT PHARMACOL, TENNIS COURT RD, CAMBRIDGE CB2 1QJ, ENGLAND				Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BURGESS GM, 1984, BIOCHEM J, V224, P741, DOI 10.1042/bj2240741; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1987, BIOCHEM BIOPH RES CO, V142, P47, DOI 10.1016/0006-291X(87)90449-9; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1992, J BIOL CHEM, V267, P16312; ORON Y, 1985, NATURE, V313, P141, DOI 10.1038/313141a0; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; PIETRI F, 1990, J BIOL CHEM, V265, P17478; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1986, BIOCHEM J, V238, P765, DOI 10.1042/bj2380765; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	40	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13214	13220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514760				2022-12-27	WOS:A1993LH55300031
J	NORDSTROM, LA; DEAN, DM; SANDERS, MM				NORDSTROM, LA; DEAN, DM; SANDERS, MM			A COMPLEX ARRAY OF DOUBLE-STRANDED AND SINGLE-STRANDED DNA-BINDING PROTEINS MEDIATES INDUCTION OF THE OVALBUMIN GENE BY STEROID-HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE ELEMENTS; DEPENDENT REGULATORY ELEMENT; EGG-WHITE GENES; NF-KAPPA-B; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REGULATION; CHICK OVIDUCT; TATA BOX; C-MYC; PROMOTER	The transcriptional induction of the chicken ovalbumin gene by steroid hormones is abolished by inhibitors of protein synthesis such as cycloheximide, suggesting that a labile protein mediates this process. A steroid-dependent regulatory element (SDRE) has been identified in the 5'-flanking region of the gene between -900 and -780 that is required for induction by steroids. Additional transfection experiments limit the 5'-border of the SDRE to the region between -892 and -864. To investigate whether any of the proteins binding to the SDRE are affected by estrogen or cycloheximide, protein binding was investigated using DNase I and exonuclease III footprinting and gel mobility shift assays. These experiments demonstrate that labile proteins bind to the sequences between -900 and -860 and between -810 and -820. Four oviduct nuclear proteins, including one of the labile proteins, binding to the SDRE prefer single-stranded DNA (ssDNA) in a sequence-specific manner. The binding activity of three of these ssDNA-binding proteins is increased in oviduct nuclear protein extracts from estrogen-treated chicks. These data suggest that induction of the ovalbumin gene is mediated by a complex collection of ssDNA- and double-stranded DNA-binding proteins whose activities are in turn regulated by their short half-lives or by estrogen.			NORDSTROM, LA (corresponding author), UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040082] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29DK40082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCHER T, 1992, SCIENCE, V255, P573; ASHBURNER M, 1972, CHROMOSOMA, V38, P255, DOI 10.1007/BF00290925; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COMPERE SJ, 1981, J BIOL CHEM, V256, P6341; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS MI, 1984, ENDOCRINOLOGY, V115, P368, DOI 10.1210/endo-115-1-368; FAN WM, 1992, P NATL ACAD SCI USA, V89, P6104, DOI 10.1073/pnas.89.13.6104; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HESS P, 1990, P NATL ACAD SCI USA, V87, P2564, DOI 10.1073/pnas.87.7.2564; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HUMPHRIES P, 1977, NUCLEIC ACIDS RES, V4, P2389, DOI 10.1093/nar/4.7.2389; ISOMAA VV, 1983, J BIOL CHEM, V258, P6735; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JUMP DB, 1987, J BIOL CHEM, V262, P778; KAYE JS, 1984, EMBO J, V3, P1137, DOI 10.1002/j.1460-2075.1984.tb01942.x; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT G, 1976, PROGR DIFFERENTIATIO, P437; MCKNIGHT GS, 1980, CELL, V22, P469; MCKNIGHT GS, 1978, CELL, V14, P403; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NELMS K, 1990, NUCLEIC ACIDS RES, V18, P1037; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PAN WT, 1990, J BIOL CHEM, V265, P7022; PARKER MG, 1991, NUCLEAR HORMONE RECE; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RORIES C, 1989, ANNU REV PHYSIOL, V51, P653, DOI 10.1146/annurev.physiol.51.1.653; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SANDERS MM, 1985, ENDOCRINOLOGY, V116, P398, DOI 10.1210/endo-116-1-398; SANDERS MM, 1986, MOL GENETICS MAMMALI, P183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SCHWEERS LA, 1991, J BIOL CHEM, V266, P10490; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	51	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13193	13202						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514758				2022-12-27	WOS:A1993LH55300029
J	GAO, PQ; SIMS, SH; CHANG, DC; DEISSEROTH, AB				GAO, PQ; SIMS, SH; CHANG, DC; DEISSEROTH, AB			INTERFERON-GAMMA PRIMING EFFECTS IN THE ACTIVATION AND DEACTIVATION OF ISGF3 IN K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC PROGENITOR CELLS; INDUCED NUCLEAR FACTORS; DOUBLE-STRANDED-RNA; ALPHA-INTERFERON; SYNTHETASE GENE; TRANSCRIPTIONAL ACTIVATOR; STIMULATED TRANSCRIPTION; PROMOTER ELEMENT; RESPONSE ELEMENT	ISGF3 is a major protein factor which mediates the transcriptional activation of interferon-inducible genes. ISGF3 is composed of two subunits, ISGF3gamma and ISGF3alpha, which are stimulated by interferon-gamma (IFN-gamma) and interferon-alpha (IFN-alpha), respectively. In this paper, the effect of pretreatment of IFN-gamma on the response of K562 cells to IFN-alpha, termed ''gamma-priming,'' is examined. Using techniques of gene transfection and mobility shift assay, we studied the gamma-priming effects on the kinetics of appearance and disappearance of (i) the protein product of a luciferase reporter gene driven by an IFN-inducible promoter and (ii) the binding of ISGF3 to the interferon-stimulated response element. We found that exposure of cells to IFN-gamma prior to IFN-alpha greatly increased both the levels and the rate of ISGF3 binding activity during the early phase of IFN-alpha treatment and caused the amount of ISGF3 bound to the interferon-stimulated response element to decrease more rapidly with time during the later phase. Such effects were reflected also on the kinetics of expression of the interferon-inducible luciferase gene induced by IFN-alpha. In order to understand the basis of these gamma-priming effects, we use an in vitro reconstitution method to examine the kinetics of the subcomponents of ISGF3 in response to different IFN treatments in K562 cells. It was found that gamma-priming not only increased the levels of ISGF3gamma, but it also stimulated both the rates of rise and fall of the activated alpha-component of ISGF3. A molecular model is proposed to explain these findings.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; GENOSYS BIOTECHNOL INC,THE WOODLANDS,TX 77381; HONG KONG UNIV SCI & TECHNOL,DEPT BIOL,HONG KONG,HONG KONG	University of Texas System; UTMD Anderson Cancer Center; Hong Kong University of Science & Technology			Chang, Donald/AAV-7180-2021		NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49639-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON P, 1982, J BIOL CHEM, V257, P1301; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BRANCA AA, 1982, J BIOL CHEM, V257, P13291; BROXMEYER HE, 1985, J IMMUNOL, V135, P2502; CARLOSTELLA C, 1988, BLOOD, V72, P1293; CHANG DC, 1989, BIOPHYS J, V56, P641, DOI 10.1016/S0006-3495(89)82711-0; CHANG DC, 1988, B AM PHYS SOC, V33, P297; CHANG DC, 1989, ELECTROPORATION ELEC, P215; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; CZARNIECKI CW, 1984, J VIROL, V49, P490, DOI 10.1128/JVI.49.2.490-496.1984; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GOETSCHY JF, 1989, J VIROL, V63, P2616, DOI 10.1128/JVI.63.6.2616-2622.1989; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HORISBERGER MA, 1987, J INTERFERON RES, V7, P331, DOI 10.1089/jir.1987.7.331; HUBBELL HR, 1987, J BIOL RESP MODIF, V6, P141; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KURZROCK R, 1987, BLOOD, V70, P943; KUSARI J, 1986, MOL CELL BIOL, V6, P2062, DOI 10.1128/MCB.6.6.2062; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1986, J BIOL CHEM, V261, P453; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PINE R, 1989, MOL CELL BIOL, V9, P3533, DOI 10.1128/MCB.9.8.3533; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RAEFSKY EL, 1985, J IMMUNOL, V135, P2507; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STRIFE A, 1990, CHRONIC MYELOGENOUS; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; VAIMAN D, 1990, FEBS LETT, V265, P12, DOI 10.1016/0014-5793(90)80871-F; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VISANI G, 1988, BLUT, V57, P41, DOI 10.1007/BF00320633	53	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12380	12387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509377				2022-12-27	WOS:A1993LG65800027
J	NAKAMURA, S; TAKASAKI, H; KOBAYASHI, K; KATO, A				NAKAMURA, S; TAKASAKI, H; KOBAYASHI, K; KATO, A			HYPERGLYCOSYLATION OF HEN EGG-WHITE LYSOZYME IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE CHAINS; PROTEIN GLYCOSYLATION; CARBOXYPEPTIDASE-Y; ACID-PHOSPHATASE; GLYCOPROTEINS; INHIBITORS	The large molecular size of N-glycosylated lysozyme with a polymannose chain was predominantly expressed in the yeast carrying the lysozyme expression plasmid in 9-fold greater secretion compared with the wild type. Complementary DNA encoding hen egg white lysozyme was subjected to site-directed mutagenesis to obtain the Asn-X-Ser/Thr sequence that is the signal for asparagine-linked (N-linked) glycosylation. At positions 49, 67, 70, and 103, the signal for N-linked glycosylation was created. Only the mutant lysozyme whose glycine 49 was substituted with asparagine was expressed in the two types of glycosylated forms, a small oligomannose chain (Man18GlcNAc2)-linked form and a large polymannose chain (Man310GlcNAc2)-linked form, whereas other mutants were not glycosylated. The secreted amount of polymannosyl lysozyme was much higher than that of the oligomannosyl lysozyme. Both types of glycosylated lysozymes were susceptible to endo-beta-N-acetyl-glucosaminidase cleavage of their carbohydrate chains. The average molecular masses of oligomannosyl and polymannosyl lysozymes were 18 and 71 kDa, respectively. The length of the polymannose chain was found to be 200-350 residues/molecule of lysozyme according to the estimation of the molecular mass distribution by low angle laser light scattering measurements. The protein conformation estimated by CD analysis was completely conserved in these glycosylated lysozymes. The enzymatic activities of oligomannosyl and polymannosyl lysozymes were 100 and 91%, respectively, of wild-type protein when glycol chitin was used as a substrate. In addition, the polymannosyl lysozyme revealed remarkable heat stability in that no coagulation was observed under conditions in which the wild-type lysozyme coagulated. Thus, this novel glycoprotein can be used as a reporter in studies of the processing and sorting of glycoproteins and as a model of the expression of foreign genes in yeast for the construction of stable enzymes.	YAMAGUCHI UNIV,DEPT BIOCHEM,YAMAGUCHI 753,JAPAN; UBE COLL,DEPT FOOD & NUTR,YAMAGUCHI 755,JAPAN	Yamaguchi University								BALLOU CE, 1974, SCIENCE, V184, P127, DOI 10.1126/science.184.4133.127; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BARBARIC S, 1984, ARCH BIOCHEM BIOPHYS, V234, P567, DOI 10.1016/0003-9861(84)90305-9; CHU FK, 1985, BIOCHEMISTRY-US, V24, P6125, DOI 10.1021/bi00343a014; CHU FK, 1982, ARCH BIOCHEM BIOPHYS, V214, P134, DOI 10.1016/0003-9861(82)90015-7; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; ITOH H, 1983, J BACTERIOL, V153, P163; KATO A, 1992, BIOSCI BIOTECH BIOCH, V56, P1424, DOI 10.1271/bbb.56.1424; KATO A, 1992, BIOCHIM BIOPHYS ACTA, V1159, P22, DOI 10.1016/0167-4838(92)90070-T; KUKAGAI I, 1989, J BIOCH, V105, P946; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; MIZUNAGA T, 1982, J BIOCHEM, V91, P191, DOI 10.1093/oxfordjournals.jbchem.a133676; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; PARRY RM, 1965, P SOC EXP BIOL MED, V119, P384; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; SMITH WL, 1974, BIOCHEMISTRY-US, V13, P355, DOI 10.1021/bi00699a021; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TOHE A, 1981, J BACTERIOL, V145, P1421, DOI 10.1128/JB.145.3.1421-1424.1981; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	27	64	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12706	12712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509405				2022-12-27	WOS:A1993LG65800071
J	THORVALDSEN, JL; SEWELL, AK; MCCOWEN, CL; WINGE, DR				THORVALDSEN, JL; SEWELL, AK; MCCOWEN, CL; WINGE, DR			REGULATION OF METALLOTHIONEIN GENES BY THE ACE1 AND AMT1 TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM ACTIVATION SEQUENCES; SUPEROXIDE-DISMUTASE GENE; DNA-BINDING PROTEIN; YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; CANDIDA-GLABRATA; COPPER RESISTANCE; SHUTTLE VECTORS; EXPRESSION; CLONING	The AMT1 metalloregulatory trans-acting factor from Candida glabrata was found to functionally mimic the ACE1 metalloregulatory trans-acting factor from Saccharomyces cerevisiae in the copper-induced expression of the chromosomal S. cerevisiae metallothionein gene. Plasmid constructs with promoters of various metal-inducible genes fused to the bacterial beta-galactosidase (lacZ) reporter gene were used in S. cerevisiae to evaluate the roles of ACE1 and AMT1 in mediating metal-stimulated expression. Promoters from the S. cerevisiae CUP1 gene and Cu,Zn-superoxide dismutase (SOD1) and from the C. glabrata MT genes MTI, MTIIa, and MTIIb were used. The ACE1 factor was effective in the metalloregulation of the two S. cerevisiae promoters, CUP1 and SOD1, but of only one C. glabrata promoter, MTI. AMT1 was found to be effective in the metalloregulation of all three C. glabrata MT promoters and the two S. cerevisiae promoters tested. The regulation mediated by both ACE1 and AMT1 was copper-dependent and copper-specific. Episomally expressed SWI5, a distinct trans-acting factor of S. cerevisiae, enhanced only the basal expression from promoters. The SWI5 enhancement was not metal dependent. In conclusion, AMT1 and ACE1 are functionally homologous in metal-specific regulation, AMT1 appears to be more promiscuous than ACE1 in this function.	UNIV UTAH,MED CTR,DEPT BIOCHEM,SALT LAKE CITY,UT 84132; UNIV UTAH,MED CTR,DEPT MED,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Sewell, Andrew/GPT-4220-2022	Sewell, Andrew/0000-0003-3194-3135	NCI NIH HHS [T32 CA 09602] Funding Source: Medline; NIEHS NIH HHS [ES 03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CULOTTA VC, 1989, P NATL ACAD SCI USA, V86, P8377, DOI 10.1073/pnas.86.21.8377; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; EVANS CF, 1990, MOL CELL BIOL, V10, P426, DOI 10.1128/MCB.10.1.426; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GORMAN JA, 1986, GENE, V48, P13, DOI 10.1016/0378-1119(86)90347-1; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HU S, 1990, New Biologist, V2, P544; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; JEYAPRAKASH A, 1991, MOL GEN GENET, V225, P363, DOI 10.1007/BF00261675; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; MANTIATIS T, 1982, MOL CLONING LABORATO; MEHRA RK, 1992, GENE, V113, P119, DOI 10.1016/0378-1119(92)90678-I; MEHRA RK, 1991, J CELL BIOCHEM, V45, P30, DOI 10.1002/jcb.240450109; MEHRA RK, 1992, GENE, V114, P75, DOI 10.1016/0378-1119(92)90709-X; MEHRA RK, 1990, J BIOL CHEM, V265, P6369; MEHRA RK, 1989, J BIOL CHEM, V264, P19747; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; THIELE DJ, 1986, MOL CELL BIOL, V6, P1158, DOI 10.1128/MCB.6.4.1158; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	40	55	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12512	12518						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509391				2022-12-27	WOS:A1993LG65800044
J	JONES, LR; FIELD, LJ				JONES, LR; FIELD, LJ			RESIDUES 2-25 OF PHOSPHOLAMBAN ARE INSUFFICIENT TO INHIBIT CA2+ TRANSPORT ATPASE OF CARDIAC SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC STIMULATION; CA-2+ PUMP; PHOSPHORYLATION; VESICLES; CA-2+-ATPASE; VENTRICLES; RESOLUTION; PROTEIN; SITE; MICE	We have used sarcoplasmic reticulum (SR) vesicles isolated from AT-1 cardiomyocytes to examine the mechanism of phospholamban (PLB) inhibition of the Ca2+ pump of cardiac SR. By immunoblotting with monoclonal antibodies, we observed that these SR vesicles contained a normal amount of the cardiac isoform of the Ca2+ pump (SERCA 2) but only a trace level of PLB. A monoclonal antibody that recognized amino acid residues 9-17 of PLB had no significant effect on Ca2+ transport by AT-1 SR vesicles, but it increased Ca2+ transport into mouse ventricular SR vesicles greater than 10-fold by reversing PLB inhibition of SERCA 2 at low ionized Ca2+ concentration. To further explore the domains of PLB responsible for SERCA 2 inhibition, we examined the effect of a PLB synthetic peptide consisting of amino acid residues 2-25 on Ca2+ uptake by AT-1 SR vesicles. Even at concentrations as high as 0.44 mM, no significant effect of the peptide was observed. Based on these results, we conclude that the cytoplasmic domain of PLB, containing the phosphorylation sites, by itself is insufficient to inhibit the Ca2+ pump and that the transmembrane region, which stabilizes the pentamer, is also essential for Ca2+ transport regulation.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	JONES, LR (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045453, R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06308, HL28556, HL45453] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHIESI M, 1989, FEBS LETT, V244, P240; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1985, J BIOL CHEM, V260, P7721; JONES LR, 1981, J BIOL CHEM, V256, P1809; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIMURA Y, 1991, J MOL CELL CARDIOL, V23, P1223, DOI 10.1016/0022-2828(91)90080-6; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1989, BIOCHIM BIOPHYS ACTA, V997, P322, DOI 10.1016/0167-4838(89)90203-3; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WEGENER AD, 1986, J BIOL CHEM, V261, P5154; XU ZC, 1989, J BIOL CHEM, V264, P16644	27	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11486	11488						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505284				2022-12-27	WOS:A1993LF28400004
J	TSAI, SC; ADAMIK, R; HAUN, RS; MOSS, J; VAUGHAN, M				TSAI, SC; ADAMIK, R; HAUN, RS; MOSS, J; VAUGHAN, M			EFFECTS OF BREFELDIN-A AND ACCESSORY PROTEINS ON ASSOCIATION OF ADP-RIBOSYLATION FACTOR-I, FACTOR-III, AND FACTOR-5 WITH GOLGI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; NUCLEOTIDE-BINDING; CHOLERA-TOXIN; BOVINE BRAIN; ACTIVATOR; STIMULATION; EXPRESSION; VESICLES; MEMBRANE; CELLS	ADP-ribosylation factors (ARFs) are approximately 20-kDa guanine nucleotide-binding proteins initially identified by their ability to enhance in vitro cholera toxin-catalyzed ADP-ribosylation and subsequently shown to participate in vesicular transport in the Golgi and other cellular compartments. By cDNA and genomic cloning, at least six mammalian ARFs were identified. Brefeldin A (BFA) disrupts Golgi membranes and inhibits binding of soluble high molecular weight proteins to Golgi fractions. We examined the effects of BFA on binding of ARF1, -3, and -5 to a Golgi fraction in the presence of an ATP-regenerating system and a fraction of soluble, high molecular weight, accessory proteins (SAP), presumably containing complexes identified by others as coatomers that are involved in vesicular transport. ARF binding in all instances was dependent on guanosine 5'-O-(3-thiotriphosphate) and increased by the ATP-regenerating system. Binding of ARF1 and -3, but not ARF5, was enhanced by SAP. BFA inhibited the SAP-dependent, but not the SAP-independent, binding of ARF1 and -3. It had no effect on the increment in binding produced by an ATP-regenerating system. B36, an inactive derivative of BFA, did not inhibit SAP-dependent binding of ARF1 and -3. Binding of ARF5, which was SAP-independent, was not affected by BFA. These observations are consistent with the conclusion that mammalian ARFs differ in their dependence on accessory proteins for interaction with Golgi and, perhaps, other cellular membranes and that BFA specifically inhibits SAP-dependent ARF binding.			TSAI, SC (corresponding author), NHLBI,CELLULAR METAB LAB,RM 5N-307,BLDG 10,BETHESDA,MD 20892, USA.							BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FLEISCHER B, 1974, METHOD ENZYMOL, V31, P181; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUNZ BC, 1990, FASEB J, V4, P167; LEE CM, 1992, J BIOL CHEM, V267, P9028; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	38	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10820	10825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496147				2022-12-27	WOS:A1993LD46600020
J	BIRKENMEIER, CS; WHITE, RA; PETERS, LL; HALL, EJ; LUX, SE; BARKER, JE				BIRKENMEIER, CS; WHITE, RA; PETERS, LL; HALL, EJ; LUX, SE; BARKER, JE			COMPLEX PATTERNS OF SEQUENCE VARIATION AND MULTIPLE 5' AND 3' ENDS ARE FOUND AMONG TRANSCRIPTS OF THE ERYTHROID ANKYRIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN MESSENGER-RNA; CYTOPLASMIC DOMAIN; MEMBRANE SKELETON; BRAIN ANKYRIN; CDNA SEQUENCE; SPECTRIN; PROTEIN; PURIFICATION; CELLS; DNA	The structural protein ankyrin functions in red blood cells to link the spectrin-based membrane skeleton to the plasma membrane. Ankyrin proteins are now known to occur in most cell types, and two distinct ankyrin genes have been identified (erythroid (Ank-1) and brain (Ank-2)). We have characterized transcripts of the mouse erythroid ankyrin gene by cDNA cloning and DNA sequencing. Ank-1 transcripts of 7.5 and 9.0 kilobases are found in erythroid tissues, and a 9.0-kilobase transcript is found in cerebellum. RNA hybridization blot analysis of 13 additional mouse tissues has detected four novel Ank-1 transcripts (5.0, 3.5, 2.0, and 1.6 kilobases in size). Sequencing of Ank-1 cDNA clones isolated from mouse reticulocyte, spleen, and cerebellar libraries has identified (i) multiple 5' ends that indicate possible multiple promoters; (ii) alternative polyadenylation sites that probably account for the 7.5- and 9.0-kilobase size difference; (iii) a variety of small insertions and deletions that could produce transcripts (and ultimately proteins) of nearly identical size, but different functions; and (iv) clones with large deletions of coding sequence that account for the smaller transcripts seen in spleen, skeletal muscle, and heart.	CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	BIRKENMEIER, CS (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.			Peters, Luanne/0000-0002-0784-0534	NHLBI NIH HHS [HL29305, HL15157] Funding Source: Medline; NIDDK NIH HHS [DK27726] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157, R01HL029305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027726] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; CHUI DHK, 1980, BRIT J HAEMATOL, V44, P431, DOI 10.1111/j.1365-2141.1980.tb05913.x; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LUNA EJ, 1979, J BIOL CHEM, V254, P2526; LUX SE, 1990, NATURE, V345, P736, DOI 10.1038/345736a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Lyon M., 1989, GENETIC VARIANTS STR; Maniatis T., 1982, MOL CLONING; MOON RT, 1985, J CELL BIOL, V100, P152, DOI 10.1083/jcb.100.1.152; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1991, J CELL BIOL, V114, P1233, DOI 10.1083/jcb.114.6.1233; PETERS LL, 1993, IN PRESS SEMIN HEMAT; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIVAK JL, 1972, J LAB CLIN MED, V79, P526; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; THURSTON SJ, 1989, ANAL BIOCHEM, V178, P41, DOI 10.1016/0003-2697(89)90353-9; TSE WT, 1991, GENOMICS, V10, P858, DOI 10.1016/0888-7543(91)90173-C; TSE WT, 1990, THESIS YALE U; WHITE RA, 1992, MAMM GENOME, V3, P281, DOI 10.1007/BF00292156; WHITE RA, 1990, P NATL ACAD SCI USA, V87, P3117, DOI 10.1073/pnas.87.8.3117; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3	47	55	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9533	9540						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486643				2022-12-27	WOS:A1993LA68900060
J	OLSON, AL; LIU, ML; MOYEROWLEY, WS; BUSE, JB; BELL, GI; PESSIN, JE				OLSON, AL; LIU, ML; MOYEROWLEY, WS; BUSE, JB; BELL, GI; PESSIN, JE			HORMONAL METABOLIC-REGULATION OF THE HUMAN GLUT4/MUSCLE-FAT FACILITATIVE GLUCOSE TRANSPORTER GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSIVE TISSUES; SKELETAL-MUSCLE; MESSENGER-RNA; DIFFERENTIAL REGULATION; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; DIABETIC RATS; EXPRESSION; PROTEIN; GLUT4	To examine the hormonal/metabolic as well as tissue-specific expression of the GLUT4/muscle-fat facilitative glucose transporter gene, we have generated several transgenic mouse lines expressing a human GLUT4 mini-gene which extends 5.3 kilobases (kb) upstream of transcription start and terminates within exon 10. This construct (hGLUT4-11.5) was expressed in a tissue-specific pattern identical to the endogenous mouse GLUT4 gene. The transcription initiation sites of the transgenic construct were similar to the GLUT4 gene expressed in human tissues. To investigate the hormonal/metabolic-dependent regulation of GLUT4, the transgenic animals were made insulin-deficient by streptozotocin (STZ) treatment. In these animals, STZ-induced diabetes resulted in a parallel decrease in endogenous mouse GLUT4 mRNA and the transgenic human GLUT4 mRNA in white adipose tissue, brown adipose tissue, and cardiac muscle. Similarly, insulin treatment of the STZ-diabetic animals restored both the endogenous mouse and transgenic human GLUT4 mRNA levels. To further define cis-regulatory regions responsible for this hormonal/metabolic regulation, the same analysis was performed on transgenic animals which carry 2.4 kb of the human GLUT4 5'-flanking region fused to a CAT reporter gene (hGLUT4[2.4]-CAT). This reporter construct responded similarly to the human GLUT4 mini-gene demonstrating that the element(s) controlling hormonal/metabolic regulation and tissue specificity all reside exclusively within 2.4 kb of the transcriptional initiation site.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Iowa; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago			Buse, John Bernard/J-9742-2019; Moye-Rowley, Scott/AFL-7135-2022	Buse, John Bernard/0000-0002-9723-3876; Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044612, R01DK042452] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44612, DK42452, DK25925] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; BUSE JB, 1992, DIABETES, V41, P1436, DOI 10.2337/diabetes.41.11.1436; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GERRITS PM, 1993, J BIOL CHEM, V268, P640; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; LEMARCHANDBRUSTEL Y, 1990, ENDOCRINOLOGY, V127, P2687; LIU ML, 1992, J BIOL CHEM, V267, P11673; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; OLSON AL, 1990, PEDIATR RES, V28, P183, DOI 10.1203/00006450-199009000-00001; OLSON AL, 1992, DIABETES S, V41, pA88; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	31	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9839	9846						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486663				2022-12-27	WOS:A1993LA68900098
J	CHANDRA, R; SALMON, ED; ERICKSON, HP; LOCKHART, A; ENDOW, SA				CHANDRA, R; SALMON, ED; ERICKSON, HP; LOCKHART, A; ENDOW, SA			STRUCTURAL AND FUNCTIONAL DOMAINS OF THE DROSOPHILA NCD MICROTUBULE MOTOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN HEAVY-CHAIN; CHROMOSOME SEGREGATION; ELECTRON-MICROSCOPY; LEUCINE ZIPPER; BINDING; ATPASE; IDENTIFICATION; POLYPEPTIDES; CLEAVAGE	Nonclaret disjunctional (ncd) is a kinesin-related microtubule motor protein that is required for proper chromosome distribution in Drosophila. Despite its sequence similarity to kinesin heavy chain, ncd translocates with the opposite polarity as kinesin, toward microtubule minus ends. We have expressed different regions of the protein in bacteria and analyzed the proteins for function. Results indicate that ncd consists of three domains: a basic, proline-rich N-terminal ''tail,'' a central alpha-helical coiled-coil stalk, and a C-terminal motor domain. The ncd N terminus proteins bundle microtubules in motility assays and show ATP-independent binding to microtubules in solution. Truncated proteins, lacking the tail but containing the predicted motor domain and differing lengths of the stalk, did not support microtubule gliding in in vitro assays but showed microtubule-stimulated MgATPase activity in solution. Addition of a nonspecific N terminus to two of the truncated proteins restored directional gliding and rotation of microtubules in motility assays, demonstrating that these properties map to the predicted mechanochemical domain of ncd. Physical properties of the C terminus proteins indicate that the stalk region is important for dimerization and that the ncd protein probably exists and functions as a dimer.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; MARIE CURIE INST, SURREY RH8 0TL, ENGLAND	University of North Carolina; University of North Carolina Chapel Hill; Duke University	CHANDRA, R (corresponding author), DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA.			Endow, Sharyn A./0000-0002-0907-8889	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046225] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHANDRA R, 1993, IN PRESS METHODS CEL, V69; CHANDRA R, 1993, IN PRESS J CELL SCI, V104; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; DAVIS DG, 1969, GENETICS, V61, P577; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HATSUMI M, 1992, J CELL SCI, V103, P1013; HATSUMI M, 1992, J CELL SCI, V101, P547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; KIMBLE M, 1983, J CELL SCI, V62, P301; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEWIS EB, 1952, GENETICS, V37, P600; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sturtevant AH, 1929, Z WISS ZOOL ABT A, V135, P323; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; Wald H, 1936, GENETICS, V21, P264; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YAMAMOTO AH, 1989, EMBO J, V8, P3543, DOI 10.1002/j.1460-2075.1989.tb08526.x; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	48	154	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9005	9013						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473343				2022-12-27	WOS:A1993KX81100090
J	HAMAMOTO, T; YAMAMOTO, M; NORDFANG, O; PETERSEN, JGL; FOSTER, DC; KISIEL, W				HAMAMOTO, T; YAMAMOTO, M; NORDFANG, O; PETERSEN, JGL; FOSTER, DC; KISIEL, W			INHIBITORY PROPERTIES OF FULL-LENGTH AND TRUNCATED RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - EVIDENCE THAT THE 3RD KUNITZ-TYPE DOMAIN OF TFPI IS NOT ESSENTIAL FOR THE INHIBITION OF FACTOR-VIIA-TISSUE FACTOR COMPLEXES ON CELL-SURFACES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION INHIBITOR; EXTRINSIC PATHWAY; BLOOD-COAGULATION; FACTOR-XA; DIRECTED MUTAGENESIS; PURIFICATION; PLASMA; INITIATION; MECHANISM; BINDING	Human tissue factor pathway inhibitor (TFPI) is a plasma protease inhibitor that consists of three tandem Kunitz-type inhibitor domains flanked by a negatively charged NH2 terminus and a positively charged COOH-terminal tail. Previous studies have shown that the first and second Kunitz-type domains in TFPI are involved in the inhibition of factor VIIa and factor Xa activity, respectively. In the present study, we have compared the inhibitory properties of full-length recombinant TFPI and a truncated form of TFPI lacking the third Kunitz-type domain and COOH-terminal tail (TFPI1-161) with respect to inhibition of factor VIIa-tissue factor complexes on the surface of a human bladder carcinoma cell line J82. Full-length TFPI and TFPI1-161 were kinetically indistinguishable with respect to neutralization of the proteolytic activity of preformed complexes of factor VIIa-tissue factor on the J82 cell surface in the absence of factor Xa. Equimolar amounts of factor Xa augmented the anticoagulant activity of both preparations of TFPI to the same extent, and both preparations of TFPI were equally effective in inhibiting factor VIIa-tissue factor amidolytic activity in solution phase. In addition, plasma concentrations of both forms of TFPI, in stoichiometric complex with factor Xa, inhibited cell surface factor VIIa-tissue factor proteolytic activity markedly faster than plasma levels of antithrombin III, even in the presence of 1 unit/ml heparin. The results of displacement studies suggested slight differences in the affinity of the two TFPI molecules for the cell surface in that approximately 5% of a VIIa.TF.Xa.TFPI1-161 quaternary complex on J82 cells was displaceable from the cell surface by high concentrations of factor VIIa (10-100 nM), whereas only 1-2% of a VIIa.TF.Xa.TFPI complex was displaceable under comparable conditions. Pretreatment of the cells with TFPI/Xa alone or together with R152E factor VII, followed by factor VIIa treatment, revealed significant differences in the two TFPI forms with respect to the degree with which offered factor VIIa could restore factor X activation on the cell surface. These differences notwithstanding, our collective findings indicate that the third Kunitz-type domain and/or COOH-terminal tail of TFPI is not essential for the inhibition of cell surface factor VIIa-tissue factor complexes and suggests that TFPI1-161 may be a useful therapeutic agent in the treatment of thromboembolic episodes.	UNIV NEW MEXICO, SCH MED, DEPT PATHOL, BLOOD SYST RES FDN LAB, ALBUQUERQUE, NM 87131 USA; NOVO NORDISK AS, GENTOFTE, DENMARK; ZYMOGENET INC, SEATTLE, WA 98105 USA	University of New Mexico; Novo Nordisk; Zymogenet Inc.					NHLBI NIH HHS [HL35246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BROZE GJ, 1988, BLOOD, V71, P335; BUSBY SJ, 1988, CURRENT ADV VITAMIN, P173; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Engvall E, 1980, Methods Enzymol, V70, P419; FOSTER DC, 1991, BIOCHEMISTRY-US, V30, P367, DOI 10.1021/bi00216a009; GEMMELL CH, 1990, BLOOD, V76, P2266; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEDNER U, 1983, J CLIN INVEST, V71, P1836, DOI 10.1172/JCI110939; HEDNER U, 1988, LANCET, V2, P1193; KAZAMA Y, 1993, BLOOD, V81, P676; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONDO S, 1987, BLOOD, V70, P1947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIK BG, 1989, AM J HEMATOL, V32, P232, DOI 10.1002/ajh.2830320315; MAHONEY WC, 1980, EUR J BIOCHEM, V105, P545, DOI 10.1111/j.1432-1033.1980.tb04531.x; Maniatis T., 1982, MOL CLONING; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; NOVOTNY WF, 1989, J BIOL CHEM, V264, P18832; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAPAPORT SI, 1989, BLOOD, V73, P359; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SANDERS NL, 1985, BLOOD, V66, P204; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; WARNCRAMER BJ, 1988, THROMB HAEMOSTASIS, V60, P453; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1992, CIRCULATION, V86, P815; WUN TC, 1988, J BIOL CHEM, V263, P6001; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	39	76	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8704	8710						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473315				2022-12-27	WOS:A1993KX81100051
J	HARROCH, S; GOTHELF, Y; WATANABE, N; REVEL, M; CHEBATH, J				HARROCH, S; GOTHELF, Y; WATANABE, N; REVEL, M; CHEBATH, J			INTERLEUKIN-6 ACTIVATES AND REGULATES TRANSCRIPTION FACTORS OF THE INTERFERON REGULATORY FACTOR FAMILY IN M1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; IMMEDIATE EARLY RESPONSE; TERMINAL DIFFERENTIATION; INDUCIBLE ENHANCER; SYNTHETASE GENE; NUCLEAR FACTOR; GROWTH ARREST; IRF-1; IFN; ELEMENTS	Activation of (2'-5') A synthetase gene expression in interleukin-6 (IL-6)-treated myeloleukemic M1 cells correlates with protein binding to the interferon response sequence enhancer (IRS). A new interferon response sequence complex, F6, is induced by IL-6 independently of interferon and is identified here as comprising the interferon regulatory factor-1 (IRF-1) and IRF-2, by use of specific antibodies in DNA mobility shift assays with probes containing IRF binding sites. IRF-1 and IRF-2 have, respectively, positive and negative transcriptional effects on interferon-beta and interferon-inducible genes. In the IL-6-treated M1 or cells, IRF-1 binding is activated early and maximally at 1 h, whereas the onset of IRF-2 binding is delayed. In a cell variant M1res, where (2'-5') A synthetase is no more induced, IRF-2 binding is constitutive, and IRF-1 binding is not seen before or after IL-6 treatment. In sensitive M1or cells, IL-6 rapidly induces IRF-1 mRNA, but in M1res cells, IRF-1 mRNA is constitutively high and not changed by IL-6. IRF-2 mRNA levels are also constitutive and not inducible by IL-6 even in M1or cells. The dissociation between induction of mRNAs and of protein binding observed suggests that the activity of the IRF proteins is regulated by IL-6. Transcripts of a third member of the IRF gene family, ICSBP, encoding a protein known to act as repressor, were found to be strongly down-regulated by IL-6. The rapid activation of IRF-1 and the modulation of the other transcription factors of this family may play a role in the early phase of IL-6 action on the M1 cells.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Chebath, Judith/0000-0002-8151-7428				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BICKEL M, 1990, Cytokine, V2, P238, DOI 10.1016/1043-4666(90)90023-M; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHIU CP, 1989, J IMMUNOL, V142, P1909; COHEN B, 1991, CYTOKINE, V3, P83, DOI 10.1016/1043-4666(91)90027-B; COHEN B, 1989, NUCLEIC ACIDS RES, V17, P1679, DOI 10.1093/nar/17.4.1679; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GIVON T, 1992, BLOOD, V79, P2392; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GOTHELF Y, 1991, LYMPHOKINE CYTOK RES, V10, P369; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LEVY D, 1990, New Biologist, V2, P923; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MAEKAWA T, 1990, INT J CANCER, V45, P353, DOI 10.1002/ijc.2910450224; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; NATSUKA S, 1992, BLOOD, V79, P460; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; ONOZAKI K, 1989, CANCER RES, V49, P3602; PIEN R, 1992, J VIROL, V66, P4470; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAMJI DP, 1992, IL6 PHYSIOPATHOLOGY, P55; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; REVEL M, 1989, ANN NY ACAD SCI, V557, P144; REVEL M, 1989, EXPERIENTIA, V45, P549, DOI 10.1007/BF01990505; SAMAL B, 1990, LEUKEMIA RES, V14, P575, DOI 10.1016/0145-2126(90)90010-7; SHABO Y, 1990, LEUKEMIA, V4, P797; SHABO Y, 1988, BLOOD, V72, P2070; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WEISZ A, 1992, J BIOL CHEM, V267, P25589	40	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9092	9097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473349				2022-12-27	WOS:A1993KX81100100
J	HATA, A; AKITA, Y; SUZUKI, K; OHNO, S				HATA, A; AKITA, Y; SUZUKI, K; OHNO, S			FUNCTIONAL DIVERGENCE OF PROTEIN-KINASE-C (PKC) FAMILY MEMBERS - PKC-GAMMA DIFFERS FROM PKC-ALPHA AND PKC-BETA-II AND NPKC-EPSILON IN ITS COMPETENCE TO MEDIATE-12-O-TETRADECANOYL PHORBOL 13-ACETATE (TPA)-RESPONSIVE TRANSCRIPTIONAL ACTIVATION THROUGH A TPA-RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; FOS GENE; DISTINCT FORMS; SERUM FACTORS; RAT-BRAIN; EXPRESSION; JUN; RECEPTOR; ONCOGENE; AP-1	We have established an assay system where overexpression of a specific protein kinase C (PKC) type caused by introduction of the respective cDNA results in the enhancement of a cell response: the transcriptional activation of a set of genes in response to PKC activators such as 12-O-tetradecanoylphorbol 13-acetate (TPA). When monitored by the expression of a reporter gene containing the chloramphenicol acetyltransferase gene fused downstream of a synthetic TPA response element (TRE) or a serum response element (SRE), the overexpression of cPKCalpha and betaII or nPKCepsilon all resulted in the enhancement of transcriptional activation through both TRE and SRE. On the other hand, PKCgamma activates TRE only very weakly, although it activates SRE in a similar manner to the other PKC members examined. The overexpression of cPKCalpha and -betaII or nPKCepsilon, but not cPKCgamma, resulted in the enhanced expression of the endogenous c-jun gene, which contains TRE in the 5'-upstream, promoter region. The gel mobility shift assay showed that the activation of PKCgamma, as well as PKCalpha and -betaII and nPKCepsilon, causes the increase in TRE-binding proteins, suggesting that transcriptional activation through TRE requires an additional step, which is not activated by PKCgamma, such as a qualitative change in TRE-binding or in TRE-associating proteins. This finding provides not only a rationale to explain the presence of multiple PKC family members, but also permits the dissection of the complex cellular signaling cascade involving PKC family members.	TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269				AKITA Y, 1990, J BIOL CHEM, V265, P354; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HATA A, 1989, J BIOL CHEM, V264, P6404; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SAKAI M, 1989, CANCER RES, V49, P5633; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	57	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9122	9129						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473351				2022-12-27	WOS:A1993KX81100105
J	SILBERSTEIN, DS; MCDONOUGH, S; MINKOFF, MS; BALCEWICZSABLINSKA, MK				SILBERSTEIN, DS; MCDONOUGH, S; MINKOFF, MS; BALCEWICZSABLINSKA, MK			HUMAN EOSINOPHIL CYTOTOXICITY-ENHANCING FACTOR - EOSINOPHIL-STIMULATING AND DITHIOL REDUCTASE ACTIVITIES OF BIOSYNTHETIC (RECOMBINANT) SPECIES WITH COOH-TERMINAL DELETIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; AMINO-ACID SEQUENCE; SCHISTOSOMA-MANSONI; U937 CELLS; FACTOR ADF; PURIFICATION; THIOREDOXIN; CLEAVAGE; NEUTROPHILS; MONOKINES	U937 cells produce eosinophil cytotoxicity-enhancing factor (ECEF) polypeptides of 14 and 10 kDa that have identical NH2-terminal amino acid sequences. The 10-kDa form has greater eosinophil-stimulating activity (half-maximal at >20-fold lower concentration). We considered the hypothesis that there is a precursor-product relationship between the 14- and 10-kDa species. Recombinant 14-kDa 104-amino acid ECEF (rECEF-104) had a slight stimulatory effect on eosinophil cytotoxic function at concentrations of 160 nm and above. In contrast, two species, rECEF-80 and rECEF-84, representing cleavage products of approximately 10 kDa had substantial statistically significant cytotoxicity-enhancing activity at concentrations as low as 10 pm. This evidence demonstrates the potential to generate the high-activity ECEF species by proteolytic cleavage of the 104-amino acid species. Another feature of this cytokine is the sequence from amino acids 31 to 34, which constitutes the conserved and active site of the enzyme thioredoxin. When tested for dithiol reductase enzymatic activity, rECEF-104 was active in a dose- and time-dependent manner, whereas the truncated forms of the molecule had no dithiol reductase activity. Thus the eosinophil-stimulating functions of the molecule do not correlate with its enzymatic activity. The evidence shows that the enzymatic activity is not essential for the initial interaction of ECEF with the eosinophil, and it suggests that the ECEF molecule functions by means of two discrete mechanisms.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028525, R01AI022532] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28525, AI-22532] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALCEWICZSABLINSKA MK, 1991, J IMMUNOL, V147, P2170; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; DESSEIN AJ, 1986, J IMMUNOL, V136, P3829; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECH K, 1990, CURRENT PROTOCOLS MO; LENZI HL, 1985, CELL IMMUNOL, V94, P333, DOI 10.1016/0008-8749(85)90257-6; LINSLEY PS, 1990, MOL CELL BIOL, V10, P1882, DOI 10.1128/MCB.10.5.1882; MATSUDA M, 1991, J IMMUNOL, V147, P3837; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; RAMALHOPINTO FJ, 1974, EXP PARASITOL, V36, P360, DOI 10.1016/0014-4894(74)90076-9; RIMSKY L, 1986, J IMMUNOL, V136, P3304; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILBERSTEIN DS, 1990, HYBRIDOMA, V9, P237, DOI 10.1089/hyb.1990.9.237; SILBERSTEIN DS, 1987, J IMMUNOL, V138, P3042; SILBERSTEIN DS, 1989, J IMMUNOL, V143, P979; TAGAYA Y, 1988, J IMMUNOL, V140, P2614; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; VADAS MA, 1979, J IMMUNOL, V122, P1228; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506	21	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9138	9142						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473353				2022-12-27	WOS:A1993KX81100107
J	SIRAWARAPORN, W; CAO, M; SANTI, DV; EDMAN, JC				SIRAWARAPORN, W; CAO, M; SANTI, DV; EDMAN, JC			CLONING, EXPRESSION, AND CHARACTERIZATION OF CRYPTOCOCCUS-NEOFORMANS DIHYDROFOLATE-REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIS3 REGULATORY SEQUENCES; ACID BIOSYNTHETIC GENES; X-RAY STRUCTURE; SACCHAROMYCES-CEREVISIAE; PNEUMOCYSTIS-CARINII; SYNTHESIZED INVITRO; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; GCN4 PROTEIN; METHOTREXATE	The Cryptococcus neoformans dihydrofolate reductase (DHFR) gene has been isolated from cDNA and genomic DNA libraries. The 690-base pair coding sequence codes for a 25,152-Da protein, which is the largest monofunctional DHFR yet reported. The gene contains two introns, and several putative regulatory sequences have been identified. The coding sequence was placed in a pUC-based expression vector, which expresses C. neoformans DHFR in Escherichia coli at a level of about 5% of the total soluble extract. The expressed DHFR was purified to homogeneity by methotrexate-Sepharose affinity chromatography, followed by anion exchange chromatography on Q-Sepharose. On SDS-polyacrylamide gel electrophoresis, the purified enzyme migrates as a single protein with apparent mass of 28 kDa. The molecular weight, as determined by electrospray mass spectral analysis, and the amino-terminal sequence are in accord with what was predicted from the DNA sequence. Steady state kinetic parameters, effects of pH, salts, and inhibition constants of several anti-folates have been determined.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HORMONE RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; MAHIDOL UNIV,FAC SCI,DEPT BIOCHEM,BANGKOK 10400,THAILAND	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Mahidol University					NIAID NIH HHS [AI 29312, AI 30261] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029312] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHRWEILER PM, 1988, J BACTERIOL, V170, P3301, DOI 10.1128/jb.170.7.3301-3304.1988; Armstrong D, 1988, Ann N Y Acad Sci, V544, P443, DOI 10.1111/j.1749-6632.1988.tb40442.x; BACCANARI DP, 1989, J BIOL CHEM, V264, P1100; BARCLAY BJ, 1988, GENE, V63, P175, DOI 10.1016/0378-1119(88)90523-9; BENNETT JE, 1979, NEW ENGL J MED, V301, P126, DOI 10.1056/NEJM197907193010303; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; Bodey G P, 1988, Ann N Y Acad Sci, V544, P431, DOI 10.1111/j.1749-6632.1988.tb40441.x; BURCHALL JJ, 1983, INHIBITION FOLATE ME, P55; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; EDMAN JC, 1989, P NATL ACAD SCI USA, V86, P8625, DOI 10.1073/pnas.86.22.8625; FLING ME, 1988, GENE, V63, P165, DOI 10.1016/0378-1119(88)90522-7; FUTTERMAN S, 1957, J BIOL CHEM, V228, P1031; GRANT IH, 1986, AM J MED, V81, P59, DOI 10.1016/0002-9343(86)90515-2; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; KOZAK M, 1983, MICROBIOL REV, V47, P1; KWONCHUNG KJ, 1978, 4TH P INT C MYC, P204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS DA, 1978, J BIOL CHEM, V253, P6946; MATTHEWS DA, 1977, SCIENCE, V197, P452, DOI 10.1126/science.17920; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; Parker R, 1987, MOL BIOL RNA NEW PER, P133; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; RHODES JC, 1985, SABOURAUDIA, V23, P77; Rippon J. W., 1988, MED MYCOLOGY; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Sirawaraporn W, 1991, Protein Expr Purif, V2, P313, DOI 10.1016/1046-5928(91)90088-Z; SIRAWARAPORN W, 1988, MOL BIOCHEM PARASIT, V31, P79, DOI 10.1016/0166-6851(88)90147-8; WILLIAMS JW, 1981, BIOCHEMISTRY-US, V20, P6024, DOI 10.1021/bi00524a016; 1908, LANCET, V8600, P1434	32	13	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8888	8892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473332				2022-12-27	WOS:A1993KX81100075
J	SUN, WL; GODSON, GN				SUN, WL; GODSON, GN			BINDING AND PHASING OF ESCHERICHIA-COLI SINGLE-STRANDED DNA-BINDING PROTEIN BY THE SECONDARY STRUCTURE OF PHAGE-G4 ORIGIN OF COMPLEMENTARY-DNA STRAND SYNTHESIS (G4ORIC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; NUCLEOTIDE-SEQUENCES; MUTATIONAL ANALYSIS; BACTERIOPHAGE-G4 ORIGIN; DEOXYRIBONUCLEIC-ACID; RNA-POLYMERASE; G4 ORIGIN; COMPLEXES; MUTANTS; PRIMASE	The origin of phage G4 DNA complementary strand synthesis (G4ori(c)) consists of three stem-loop structures (stem loops I, II, and III) that have been proposed as a recognition site for primase during primer RNA (pRNA) synthesis (Godson, G. N., Barrell, B. G., Staden, R., and Fiddes, J. C. (1978) Nat. New Biol. 276, 236-247; Fiddes, J. C., Barrell, B. G., and Godson, G. N. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 1081-1085; Sims, J., Capon, D., and Dressler, D. (1979) J. Biol. Chem. 254, 12615-12628). It is generally considered that the double-stranded DNA stem-loop structure is not coated with Escherichia coli single-stranded DNA-binding protein (SSB), but is recognized by primase as naked DNA (Kornberg, A., and Baker, J. (1992) DNA Replication, 2nd Ed., p. 280, W. H. Freeman & Co., New York). Using small G4ori(c) single-stranded DNA fragments of various sizes (302, 278, 149, and 100 nucleotides) consisting of the core 100-nucleotide stem-loop region plus differing lengths of 3'- and 5'-flanking sequence as substrates for gel retardation and DNase I and micrococcal nuclease digestion, we show that under conditions of pRNA synthesis, two SSB tetramers bind to the stem-loop structure. With increasing lengths of 5'- and 3'-flanking sequence, more SSB tetramers are added. Regardless of the number of SSB tetramers bound, however, the region of DNA containing the pRNA initiation site is always left accessible to nuclease digestion. In situ copper-phenanthroline footprinting of individual gel shift assembly intermediates shows that on the 302-nucleotide G4ori(c), the first two SSB tetramers assemble at random, but the addition of more SSB tetramers results in formation of a unique structure. In this structure, SSB tetramers protect both sides of stem loop III plus the intervening region between stem loops III and I, but leave most of stem loop I and the CTG pRNA initiation site accessible to copper-phenanthroline. Primase can only synthesize pRNA when the stem-loop structure is saturated with SSB and presumably in the unique configuration. The G4ori(c) stem-loop structure therefore appears to dictate the phasing of SSB to leave a primase recognition site as free DNA.	NYU MED CTR,DEPT BIOCHEM,550 1ST AVE,NEW YORK,NY 10016	New York University					NIGMS NIH HHS [GM 32898] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; BUJALOWSKI W, 1987, J MOL BIOL, V195, P897, DOI 10.1016/0022-2836(87)90493-1; CHASE JW, 1984, J BIOL CHEM, V259, P805; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; FIDDES JC, 1978, P NATL ACAD SCI USA, V75, P1081, DOI 10.1073/pnas.75.3.1081; GODSON GN, 1978, NATURE, V276, P236, DOI 10.1038/276236a0; GODSON GN, 1990, GENE AMST, V100, P59; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HIASA H, 1989, GENE, V84, P17, DOI 10.1016/0378-1119(89)90134-0; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; HIRAO I, 1989, NUCLEIC ACIDS RES, V17, P2223, DOI 10.1093/nar/17.6.2223; HIRAO I, 1990, BIOCHIM BIOPHYS ACTA, V1087, P199, DOI 10.1016/0167-4781(90)90205-G; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; KODAIRA K, 1989, BIOCHIM BIOPHYS ACTA, V1007, P359, DOI 10.1016/0167-4781(89)90160-7; KODAIRA KI, 1990, MOL GEN GENET, V220, P240; KORNBERG A, 1992, DNA REPLICATION, P280; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAMBERT PF, 1987, GENE, V53, P257, DOI 10.1016/0378-1119(87)90014-X; LAMBERT PF, 1986, J VIROL, V58, P450, DOI 10.1128/JVI.58.2.450-458.1986; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MARSHALL LE, 1981, BIOCHEMISTRY-US, V20, P244, DOI 10.1021/bi00505a003; MASAI H, 1990, J BIOL CHEM, V265, P15124; MASAI H, 1990, J BIOL CHEM, V265, P15134; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; NAKANO K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P43, DOI 10.1016/0167-4781(90)90020-3; SAKAI H, 1988, GENE, V71, P323; SAKAI H, 1987, GENE, V53, P265; SAKAI H, 1985, BIOCHIM BIOPHYS ACTA, V826, P30, DOI 10.1016/S0167-4781(85)80005-1; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; SIMS J, 1980, P NATL ACAD SCI-BIOL, V77, P900, DOI 10.1073/pnas.77.2.900; SIMS J, 1979, J BIOL CHEM, V254, P2615; SMITH DW, 1989, CHROMOSOMES EUCARYOT, V2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; UEDA K, 1985, J BIOL CHEM, V260, P5804; UEDA K, 1992, BIOSCI BIOTECH BIOCH, V56, P394, DOI 10.1271/bbb.56.394; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZECHEL K, 1975, J BIOL CHEM, V250, P4684	44	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8026	8039						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463320				2022-12-27	WOS:A1993KW97900066
J	MARTIN, DW; MUNOZ, RM; SUBLER, MA; DEB, S				MARTIN, DW; MUNOZ, RM; SUBLER, MA; DEB, S			P53 BINDS TO THE TATA-BINDING PROTEIN-TATA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE-II TRANSCRIPTION; CELLULAR TUMOR-ANTIGEN; LARGE T-ANTIGEN; WILD-TYPE P53; HUMAN U6 GENE; MAMMALIAN-CELLS; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; ACTIVATION DOMAIN	Earlier reports show that p53, both wild type and mutants, may affect transcription. Wild-type p53 activates promoters with p53-binding sites while inhibiting promoters without binding sites. Mutant p53, on the other hand, has been shown to activate transcription from specific promoters. These observations suggest that both wild-type and mutant p53 may interact with a general transcription factor(s). In this report, we have shown that the cloned TATA-binding protein (TBP) from human and yeast interacts with human p53. TBP coimmunoprecipitates with wild-type or mutant human p53 when incubated with the p53-specific monoclonal antibody and Protein A-agarose. Wild-type murine p53 has also been found to interact with human TBP. Protein blot assays have demonstrated that the interaction between p53 and human TBP is direct. By gel retention analysis, we have shown that the complex of TBP and p53 (both wild type and mutant) can bind to the TATA box. The similar qualitative binding capability of wild-type and mutant p53 with human TBP and the similarity of the two complexes in binding to the TATA box suggest that the functional discrimination between wild-type and mutant p53 may not lie in their ability to bind TBP. The nature of the p53.TBP or p53.TBP.TATA complex may determine the success of transcription.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007271] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07271-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREEN MR, 1992, NATURE, V357, P364, DOI 10.1038/357364d0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, NATURE, V341, P299; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; INOSTROZA JA, 1992, CELL, V70, P477; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1954; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7305; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	84	119	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13062	13067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514746				2022-12-27	WOS:A1993LH55300011
J	ELDAR, H; BENAV, P; SCHMIDT, US; LIVNEH, E; LISCOVITCH, M				ELDAR, H; BENAV, P; SCHMIDT, US; LIVNEH, E; LISCOVITCH, M			UP-REGULATION OF PHOSPHOLIPASE-D ACTIVITY-INDUCED BY OVEREXPRESSION OF PROTEIN-KINASE C-ALPHA - STUDIES IN INTACT SWISS/3T3 CELLS AND IN DETERGENT-SOLUBILIZED MEMBRANES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE BREAKDOWN; GROWTH-FACTOR; SIGNAL TRANSDUCTION; COMMON MECHANISM; 3T3 FIBROBLASTS; HYDROLYSIS; DIACYLGLYCEROL; ACTIVATION; PHOSPHATIDYLETHANOLAMINE; GENERATION	The role of protein kinase C in the mechanism of phospholipase D activation by platelet-derived growth factor and 12-O-tetradecanoylphorbol-13-acetate was studied in Swiss/3T3 fibroblasts that overexpress protein kinase C-alpha. Production of [H-3]phosphatidylpropanol (specific product of the phospholipase D-catalyzed transphosphatidylation reaction) was determined in cells which were prelabeled with [H-3]oleic acid. Accumulation of [H-3]phosphatidylpropanol in response to platelet-derived growth factor and 12-O-tetradecanoylphorbol-13-acetate was 2-3-fold greater in protein kinase C-alpha-overexpressing SF1.4 cells compared with the vector control cells, SC1. Basal [H-3] phosphatidylpropanol production also was 2-fold higher in SF1.4 cells than in SC1 cells. Hence, -fold stimulation of basal phospholipase D activity by platelet-derived growth factor and 12-O-tetradecanoyl-phorbol-13-acetate was comparable in the two cell lines and was not significantly altered by the overexpression of protein kinase C-alpha. Similarly, overexpression of protein kinase C-alpha did not affect either the kinetics of phospholipase D activation nor its dependence on platelet-derived growth factor or 12-O-tetradecanoylphorbol-13-acetate concentration. In vitro assay of phospholipase D activity in membranes isolated from the cells, utilizing exogenous [H-3]phosphatidylcholine as a substrate, revealed nearly 2-fold higher phospholipase D activity in SF1.4 cell membranes. Kinetic analysis of detergent-solubilized phospholipase D activity indicated that the apparent V(max) and K(m) of phospholipase D derived from SF1.4 and SF3.2 (protein kinase C-alpha-overexpressing) cells are significantly higher than those of phospholipase D from control cells. These results indicate that in Swiss/3T3 cells overexpression of protein kinase C-alpha elevates basal and agonist-stimulated phospholipase D activity in intact cells as well as phospholipase D activity in vitro. These data are consistent with the hypothesis that overexpression of protein kinase C-alpha up-regulates phospholipase D, leading to a constitutive higher level of enzyme activity. Thus, protein kinase C-alpha may play a role in regulating phospholipase D expression.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT HORMONE RES,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Eldar-Finkelman, Hagit/AAF-8329-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686				BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1990, BIOCHEM SOC T, V18, P484, DOI 10.1042/bst0180484; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DANIN M, 1993, LIPID METABOLISM SIG; ELDAR H, 1990, J BIOL CHEM, V265, P13290; EXTON JH, 1990, J BIOL CHEM, V265, P1; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1989, J BIOL CHEM, V264, P1483; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; Raber J, 1991, Eur Cytokine Netw, V2, P281; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; WAKELAM MJO, 1991, BIOCHEM SOC T, V19, P321, DOI 10.1042/bst0190321; WARTMANN M, 1991, CELL REGUL, V2, P491, DOI 10.1091/mbc.2.6.491	28	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12560	12564						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509396				2022-12-27	WOS:A1993LG65800051
J	BUHR, A; ERNI, B				BUHR, A; ERNI, B			MEMBRANE TOPOLOGY OF THE GLUCOSE TRANSPORTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVELY CHARGED RESIDUES; BACTERIAL PHOSPHOTRANSFERASE SYSTEM; SALMONELLA-TYPHIMURIUM; ALKALINE-PHOSPHATASE; PROTEIN TOPOLOGY; ENZYME-II; PHOSPHOENOLPYRUVATE; PERMEASE; SEQUENCE; IIIGLC	The glucose transporter of the bacterial phosphotransferase system couples translocation with phosphorylation of the substrate in a 1:1 stoichiometry. It consists of a transmembrane subunit (IIBC(Glc)) and a hydrophilic subunit (IIA(Glc)). Both subunits are transiently phosphorylated. The IIBC(Glc) subunit is 477 residues long and consists of two domains. The amino-terminal hydrophobic domain is involved in glucose binding and translocation, the carboxyl-terminal domain contains the phosphorylation site (Cys421). Protein fusions between IIBC(Glc) and beta-galactosidase (LacZ) as well as alkaline phosphatase (PhoA) were analyzed to determine the membrane topology of the IIBC(Glc) subunit. The protein fusions were generated by progressively deleting ptsG from its 3' end and ligating the truncated gene to lacZ and 'phoA lacking promoter and leader sequences. LacZ fusions of high activity (32 out of 54) occur at the amino and carboxyl termini and three internal clusters, and 41 active PhoA fusions occur in four internal clusters. Accordingly the hydrophobic domain of IIC(Glc) (residues 19-336) is suggested to contains eight membrane-spanning segments, with the amino terminus and the COOH-terminal hydrophilic domain (IIB(Glc)) located on the cytoplasmic face of the membrane. A sequence comparison of IIBC(Glc) with three related proteins indicates that the periplasmic loops differ in size and sequence while the cytoplasmic loops are better conserved.	UNIV BERN,INST BIOCHEM,CH-3012 BERN,SWITZERLAND	University of Bern								BUHR A, 1992, J BIOL CHEM, V267, P3847; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1986, J BIOL CHEM, V261, P6398; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; FAIRBROTHER WJ, 1992, BIOCHEMISTRY-US, V31, P4413, DOI 10.1021/bi00133a005; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HUMMEL U, 1992, PROTEIN SCI, V1, P356; LENGELER JW, 1990, PHILOS T ROY SOC B, V326, P489, DOI 10.1098/rstb.1990.0027; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; Maniatis T., 1982, MOL CLONING; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; MEINS N, 1993, J BIOL CHEM, V268, P11604; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PERI KG, 1988, BIOCHEMISTRY-US, V27, P6054, DOI 10.1021/bi00416a034; Postma P.W., 1987, ESCHERICHIA COLI SAL, P127; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; PRIOR TI, 1988, J GEN MICROBIOL, V134, P2757; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843, DOI 10.1128/JB.174.9.2843-2850.1992; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1988, J BACTERIOL, V170, P2296, DOI 10.1128/jb.170.5.2296-2300.1988; SCHOLTE BJ, 1981, J BACTERIOL, V148, P257, DOI 10.1128/JB.148.1.257-264.1981; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; ZAGOREC M, 1992, MOL GEN GENET, V234, P325, DOI 10.1007/BF00283853	41	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11599	11603						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505291				2022-12-27	WOS:A1993LF28400025
J	FEENER, EP; BACKER, JM; KING, GL; WILDEN, PA; SUN, XJ; KAHN, CR; WHITE, MF				FEENER, EP; BACKER, JM; KING, GL; WILDEN, PA; SUN, XJ; KAHN, CR; WHITE, MF			INSULIN STIMULATES SERINE AND TYROSINE PHOSPHORYLATION IN THE JUXTAMEMBRANE REGION OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVITY; BETA-SUBUNIT; THREONINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; HEPATOMA-CELLS; AMINO-ACIDS; AUTOPHOSPHORYLATION; IDENTIFICATION; RESIDUES; DOMAIN	Insulin-stimulated autophosphorylation of the cytoplasmic juxtamembrane region of the human insulin receptor was examined by Tricine/SDS-PAGE. Various mutant receptor molecules were used to identify two tryptic phosphopeptides associated with the juxtamembrane region which accounts for 15% of the autophosphorylation of partially purified insulin receptor. These phosphopeptides were immunoprecipitated with an antipeptide antibody against the juxtamembrane sequence and were phosphorylated exclusively on tyrosine. Substitution of both Tyr960 and Tyr953 with alanine eliminated insulin-stimulated phosphorylation of the juxtamembrane region without affecting tyrosine autophosphorylation in the C terminus or regulatory regions. Monosubstitution of Tyr960 with phenylalanine or alanine reduced phosphorylation in the juxtamembrane region by more than 50%, and manual Edman degradation indicated that Tyr960 was phosphorylated in wild-type receptor. In vivo, phosphorylation of the juxtamembrane region accounts for one-third of the insulin receptor phosphorylation and contains both phosphoserine and phosphotyrosine. Deletion of Tyr960 and 11 adjacent amino acids eliminated insulin-stimulated phosphorylation of the juxtamembrane region. Substitution of Tyr960 reduced this phosphorylation by more than 50%. The insulin receptor also undergoes serine phosphorylation outside of the juxtamembrane region which depends on the presence of Tyr1151. Together with our previous studies, this report suggests that phosphorylation of Tyr960 may play an important role in signal transduction by the insulin receptor.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	FEENER, EP (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036433, R55DK038712, R01DK033201, R29DK038712, R01DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, DK 38712, DK 36433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HERRERA R, 1985, P NATL ACAD SCI USA, V82, P7899, DOI 10.1073/pnas.82.23.7899; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1991, J BIOL CHEM, V266, P10616; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	41	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11256	11264						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496180				2022-12-27	WOS:A1993LD46600079
J	FERNANDEZCHECA, JC; OOKHTENS, M; KAPLOWITZ, N				FERNANDEZCHECA, JC; OOKHTENS, M; KAPLOWITZ, N			SELECTIVE INDUCTION BY PHENOBARBITAL OF THE ELECTROGENIC TRANSPORT OF GLUTATHIONE AND ORGANIC-ANIONS IN RAT-LIVER CANALICULAR MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOBILIARY TRANSPORT; HEPATIC GLUTATHIONE; MUTANT RATS; EFFLUX; HEPATOCYTES; INHIBITION; CONJUGATE; HYPERBILIRUBINEMIA; METHIONINE; KINETICS	Glutathione is excreted into bile via a low affinity, electrogenic, ATP-independent transport system which is cis-inhibited and trans-stimulated by certain organic anions (Fernandez-Checa, J. C., Takikawa, H., Horie, T., Ookhtens, M., and Kaplowitz N. (1992) J. Biol. Chem. 267, 1667-1673). This transport system differs from the sinusoidal carrier in several respects, such as affinity for transport and inhibitor specificity. Another differential aspect is the selective increase by phenobarbital pretreatment of GSH excretion into bile without changing the sinusoidal release into blood. To determine if phenobarbital induces the GSH transporter in the canalicular membrane and if this is reflected in the induction of organic anion transport, we have used rat liver canalicular (cLPM) and sinusoidal (bLPM) enriched membrane vesicles from liver of control (saline) and phenobarbital-treated rats. cLPM vesicles prepared from phenobarbital-pretreated rats exhibited a significant, 46% increase in V(max) for transport (9.02 +/- 0.3 versus 6.17 +/- 0.5 nmol/mg/15 s) without a change in the K(m) for GSH transport (14.0 +/- 1.1 versus 16.7 +/- 2.7 mM, respectively). Kinetic parameters for GSH transport in bLPM vesicles remained unchanged after phenobarbital treatment versus control (V(max), 4.67 +/- 0.2 versus 4.77 +/- 0.2 nmol/mg/15 s; K(m), 7.79 +/- 0.8 versus 6.95 +/- 0.8 mM, respectively). Phenobarbital treatment increased the electrogenic transport of [S-35]sulfobromophthalein (BSP) (5 and 50 muM) but not the electrogenic uptake of [C-14] glycocholic acid (10 and 200 muM). In addition, the ATP-dependent transport of [S-35]BSP, [H-3]leukotriene C4, and [C-14]glycocholic acid into cLPM vesicles was not altered by phenobarbital treatment. The ATP-independent transport of [S-35]BSP in cLPM was cis-inhibited and trans-stimulated by GSH, supporting the view that BSP and GSH share a common multispecific transporter. Thus, among the various canalicular transport systems, the multispecific electrogenic organic anion and GSH transport system is selectively induced by phenobarbital treatment.	UNIV SO CALIF,SCH MED,DEPT MED,DIV GASTROINTESTINAL & LIVER DIS,LOS ANGELES,CA 90033	University of Southern California	FERNANDEZCHECA, JC (corresponding author), UNIV BARCELONA,HOSP CLIN & PROV,SERV BIOQUIM,UNIDAD HIGADO,VILLARROEL 170,E-08036 BARCELONA,SPAIN.		Fernández-Checa, José Carlos/L-8342-2014	Fernández-Checa, José Carlos/0000-0003-3422-2990	NIDDK NIH HHS [DK 30312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030312, R37DK030312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1986, AM J PHYSIOL, V250, pG236, DOI 10.1152/ajpgi.1986.250.2.G236; AW TY, 1987, BIOCHEM BIOPH RES CO, V143, P377, DOI 10.1016/0006-291X(87)90676-0; AW TY, 1984, J BIOL CHEM, V259, P9355; AWASTHI YC, 1981, BLOOD, V58, P733; BALATORI N, 1989, AM J PHYSIOL, V256, pG22; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; Fiske CH, 1925, J BIOL CHEM, V66, P375; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; Hatefi Y, 1978, Methods Enzymol, V53, P21; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JANSEN PLM, 1987, GASTROENTEROLOGY, V93, P1094, DOI 10.1016/0016-5085(87)90574-9; KAPLOWITZ N, 1983, J PHARMACOL EXP THER, V224, P141; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; NISHIDA T, 1992, HEPATOLOGY, V16, P149; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; OOKHTENS M, 1985, J CLIN INVEST, V75, P258, DOI 10.1172/JCI111682; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067	30	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10836	10841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496149				2022-12-27	WOS:A1993LD46600022
J	HOLMBERGBETSHOLTZ, I; LUND, E; BJORKHEM, I; WIKVALL, K				HOLMBERGBETSHOLTZ, I; LUND, E; BJORKHEM, I; WIKVALL, K			STEROL 27-HYDROXYLASE IN BILE-ACID BIOSYNTHESIS - MECHANISM OF OXIDATION OF 5-BETA-CHOLESTANE-3-ALPHA,7-ALPHA,12-ALPHA,27-TETROL INTO 3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLESTANOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER-MITOCHONDRIA; ALCOHOL-DEHYDROGENASE; CYTOCHROME-P-450; 5-BETA-CHOLESTANE-3-ALPHA; 7-ALPHA; 26-HYDROXYLATION; 12-ALPHA-TRIOL; HYDROXYLASES; ADRENODOXIN; CONVERSION	The sequence of reactions catalyzed by sterol 27-hydroxylase (CYP27) in the oxidation of 5beta-cholestane-3alpha,7alpha,12alpha,27-tetrol into 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid was studied with apparently homogeneous preparations of the cytochrome P-450 from rabbit liver mitochondria. Conditions are described for the formation and characterization of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-27-al as an enzymatically generated intermediate in the oxidation process. Incubation of 5beta-cholestane-3alpha,7alpha,12alpha-triol or 5beta-cholestane-3alpha,7alpha,12alpha,27-tetrol with sterol 27-hydroxylase in (O2)-O-18 atmosphere resulted in the incorporation of one or two (O2)-O-18 atoms in the carboxyl group of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid. Similar incubations with 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-27-al resulted in the incorporation of one O-18 atom in the 27-carboxyl group. The results strongly indicate that the sterol 27-hydroxylase performs multiple monooxygenations in the conversion of 5beta-cholestane-3alpha,7alpha,12alpha-triol into 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid. The following reaction sequence (Reaction 1) at carbon 27 is proposed.	KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet	HOLMBERGBETSHOLTZ, I (corresponding author), UNIV UPPSALA,DEPT PHARMACEUT BIOCHEM,S-75123 UPPSALA,SWEDEN.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXEN E, 1992, BIOCHEM J, V287, P725, DOI 10.1042/bj2870725; BATTA AK, 1983, J LIPID RES, V24, P94; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1974, BIOCHEM BIOPH RES CO, V57, P870, DOI 10.1016/0006-291X(74)90627-5; BJORKHEM I, 1985, NEW COMPREHENSIVE BI, V12, P231; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CHU JW, 1973, J BIOL CHEM, V248, P2089; CRONHOLM T, 1970, EUR J BIOCHEM, V16, P373, DOI 10.1111/j.1432-1033.1970.tb01091.x; DAHLBACK H, 1990, BIOCHEM BIOPH RES CO, V167, P391, DOI 10.1016/0006-291X(90)92034-W; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V157, P30, DOI 10.1016/S0006-291X(88)80006-8; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V153, P267, DOI 10.1016/S0006-291X(88)81217-8; DEMONTELLANO PRO, 1989, TRENDS PHARMACOL SCI, V10, P354, DOI 10.1016/0165-6147(89)90007-2; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; HANSON RF, 1980, J BIOL CHEM, V255, P1483; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; HUME R, 1984, EUR J BIOCHEM, V140, P583, DOI 10.1111/j.1432-1033.1984.tb08142.x; JONSSON KH, 1990, CHEM-BIOL INTERACT, V75, P267, DOI 10.1016/0009-2797(90)90070-4; KELLIS JT, 1987, J BIOL CHEM, V262, P8840; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OKUDA A, 1983, J BIOL CHEM, V258, P2899; OKUDA K, 1988, J BIOL CHEM, V263, P18138; OKUDA K, 1968, BIOCHEM BIOPH RES CO, V33, P788, DOI 10.1016/0006-291X(68)90229-5; OKUDA K, 1970, BIOCHIM BIOPHYS ACTA, V222, P141; OMURA T, 1964, J BIOL CHEM, V239, P2379; SJOVALL J, 1985, BIOCHIM BIOPHYS ACTA, V836, P8, DOI 10.1016/0005-2760(85)90213-9; WAHLEN E, 1989, J LIPID RES, V30, P1847; WIKVALL K, 1984, J BIOL CHEM, V259, P3800; WOOD AW, 1988, J BIOL CHEM, V263, P17322	30	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11079	11085						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496170				2022-12-27	WOS:A1993LD46600055
J	TANAKA, S; SAITO, K; REED, JC				TANAKA, S; SAITO, K; REED, JC			STRUCTURE-FUNCTION ANALYSIS OF THE BCL-2 ONCOPROTEIN - ADDITION OF A HETEROLOGOUS TRANSMEMBRANE DOMAIN TO PORTIONS OF THE BCL-2-BETA PROTEIN RESTORES FUNCTION AS A REGULATOR OF CELL-SURVIVAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FOLLICULAR LYMPHOMA; MONOCLONAL-ANTIBODY; MEMBRANE PROTEIN; GENE; EXPRESSION; DEATH; MITOCHONDRIAL; APOPTOSIS; GROWTH; LINES	The bcl-2 gene can potentially encode 26-and 22-kDa proteins that differ only in their carboxyl tails because of an alternative splicing mechanism. The larger of these proteins contains a hydrophobic transmembrane domain within its carboxyl terminus, resides (at least in part) in mitochondrial membranes and has been shown to prolong cell survival by blocking programmed cell death (also termed ''apoptosis''). To explore the function of the shorter 22-kDa Bcl-2 protein that lacks a transmembrane domain, DNAs encoding p26-Bcl-2-alpha or p22-Bcl-2-beta were expressed in an interleukin-3 (IL-3)-dependent hematopoietic cell line 32D. In contrast to p26-Bcl-2alpha that markedly prolonged cell survival, p22-Bcl-2-beta did not extend the survival of 32D cells when cultured in the absence of IL-3. Expression in 32D cells of a chimeric DNA that fused portions of the open reading frame common to Bcl-2-alpha and Bcl-2-beta (amino-acids 1-195) with sequences encoding the transmembrane and cytosolic domains of the IL-2 receptor-a protein resulted in production of a Bcl-2/IL-2R fusion protein that was capable of prolonging 32D cell survival in the setting of IL-3 withdrawal. Based on fractionation of cells to produce crude heavy membrane, light membrane, nuclei, and cytosolic preparations, much of the p22-Bcl-2-beta protein appeared to reside in the cytosol, whereas Bcl-2-alpha and the Bcl-2/IL-2R chimeric proteins were found exclusively in fractions that also contained the inner mitochondrial membrane protein F1-beta-ATPase. Taken together, these findings demonstrate the importance of membrane association for the function and intracellular targeting of the apoptosis-blocking Bcl-2 protein. Furthermore, despite the strong evolutionary conservation of the carboxyl regions of Bcl-2-alpha proteins observed previously for mammalian and avian species, these data suggest that a heterologous transmembrane domain can be substituted without loss of function.	LA JOLLA CANC RES FDN, CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN Y, 1991, J HISTOCHEM CYTOCHEM, V39, P635, DOI 10.1177/39.5.2016513; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKLEWIS I, 1985, EXP HEMATOL, V13, P304; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVANS WH, 1987, BIOL MEMBRANES PRACT, P1; FUJII J, 1989, J BIOL CHEM, V264, P12950; HAMILTON MS, 1991, LEUKEMIA, V5, P768; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORTON R, 1989, GENE, V27, P61; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KUO LM, 1986, BIOCHIM BIOPHYS ACTA, V848, P247, DOI 10.1016/0005-2728(86)90047-2; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MAVILIO F, 1989, ONCOGENE, V4, P301; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NUNEZ G, 1990, J IMMUNOL, V144, P3602; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANHAESEBROECK B, 1993, IN PRESS ONCOGENE; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	43	184	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10920	10926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496157				2022-12-27	WOS:A1993LD46600034
J	CISNEROS, RJ; ZAPF, JW; DUNLAP, RB				CISNEROS, RJ; ZAPF, JW; DUNLAP, RB			STUDIES OF 5-FLUORODEOXYURIDINE-5'-MONOPHOSPHATE BINDING TO CARBOXYPEPTIDASE A-INACTIVATED THYMIDYLATE SYNTHASE FROM LACTOBACILLUS-CASEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX; SYNTHETASE; COVALENT; 5-FLUORO-2'-DEOXYURIDYLATE; SITE	The binding of 5-fluorodeoxyuridylate (FdUMP) to carboxypeptidase-inactivated thymidylate synthase obtained from methotrexate-resistant Lactobacillus casei was investigated using [H-3]FdUMP in a trichloroacetic acid precipitation assay and by F-19 nuclear magnetic resonance spectroscopy. The cleavage of 1 valine residue from the carboxyl terminus of one of the identical subunits of the enzyme dimer correlates with complete loss of thymidylate synthesis (Aull, J. L., Loeble, R. B., and Dunlap, R. B. (1974) J. Biol. Chem. 249, 1167-1172). We have further investigated the phenomenon of carboxypeptidase A-dependent inactivation of thymidylate synthase by employing immobilized carboxypeptidase A in order to facilitate the isolation and characterization of the inactivated enzyme. The time course of carboxypeptidase treatment of thymidylate synthase has been profiled by the spectrophotometric assay, tritium release assay, trichloroacetic acid precipitation assay (covalent adduct analysis), F-19 nuclear magnetic resonance spectroscopy, and amino acid analysis. The techniques utilized in this study yielded results which showed that the completely inactivated enzyme (failure to catalyze thymidylate formation) continued to catalyze both covalent FdUMP-enzyme interactions and the formation of the covalent inhibitory ternary complex with the cofactor, 5,10-methylenetetrahydrofolate, although to a reduced extent, thus effectively uncoupling these processes from thymidylate synthesis activity.	UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL CANCER INSTITUTE [R01CA015645] Funding Source: NIH RePORTER; NCI NIH HHS [CA 15645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AULL JL, 1974, J BIOL CHEM, V249, P1167; AULL JL, 1974, MICROCHEM J, V19, P210, DOI 10.1016/0026-265X(74)90076-9; BYRD RA, 1978, J AM CHEM SOC, V100, P7478, DOI 10.1021/ja00492a007; CISNEROS R J, 1988, Drugs of the Future, V13, P859; CISNEROS RJ, 1990, ANAL BIOCHEM, V186, P202, DOI 10.1016/0003-2697(90)90067-J; CROMWELL LD, 1969, BIOCHEMISTRY-US, V8, P4735, DOI 10.1021/bi00840a012; DRECHSLER ER, 1959, J BIOL CHEM, V234, P2627; DUNLAP RB, 1971, BIOCHEMISTRY-US, V10, P88, DOI 10.1021/bi00777a014; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; FOLK JE, 1963, J BIOL CHEM, V238, P3895; FOLK JE, 1963, J BIOL CHEM, V238, P3884; GALIVAN J, 1977, ARCH BIOCHEM BIOPHYS, V184, P346, DOI 10.1016/0003-9861(77)90361-7; GALIVAN JH, 1976, BIOCHEM BIOPH RES CO, V71, P527, DOI 10.1016/0006-291X(76)90819-6; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HATEFI Y, 1960, BIOCHEM PREP, V7, P89; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KUMEL G, 1979, J CHROMATOGR, V172, P221, DOI 10.1016/S0021-9673(00)90957-9; LEWIS CA, 1980, BIOCHEMISTRY-US, V19, P116, DOI 10.1021/bi00542a018; LEWIS CA, 1981, TOPICS MOL PHARM, P160; LOMAX MIS, 1967, J BIOL CHEM, V242, P109; LYON JA, 1975, CANCER BIOCHEM BIOPH, V1, P121; MALEY GF, 1979, J BIOL CHEM, V254, P1288; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MCFADDEN BA, 1968, BIOCHEMISTRY-US, V7, P3574, DOI 10.1021/bi00850a035; MOFFAT K, 1973, J BIOL CHEM, V248, P6387; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MOORE MA, 1986, J BIOL CHEM, V261, P2745; MOORE MA, 1986, BIOCHEMISTRY-US, V25, P3311, DOI 10.1021/bi00359a034; RUTTER WJ, 1961, J BIOL CHEM, V236, P3193; SANTI DV, 1984, FOLATES PTERINS, P345; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; Zakrzewski S F, 1980, Methods Enzymol, V66, P529	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10102	10108						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486679				2022-12-27	WOS:A1993LB80000026
J	KATAYAMA, K; ARMENDARIZBORUNDA, J; RAGHOW, R; KANG, AH; SEYER, JM				KATAYAMA, K; ARMENDARIZBORUNDA, J; RAGHOW, R; KANG, AH; SEYER, JM			A PENTAPEPTIDE FROM TYPE-I PROCOLLAGEN PROMOTES EXTRACELLULAR-MATRIX PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLLAGEN GENE-EXPRESSION; GROWTH-FACTOR-BETA; MESSENGER-RNA LEVELS; FIBROBLAST-CULTURES; LUNG FIBROBLASTS; CELL-DENSITY; BIOSYNTHESIS; PROPEPTIDE; FIBROSIS; REPAIR	The NH2 and COOH propieces of fibril-forming collagens are cleaved off extracellularly and have been implicated in feedback regulation of their own synthesis. Recently, we showed that a subfragment of the carboxyl-terminal propeptide of type I collagen (residues 197-241) dramatically augments extracellular matrix production in subconfluent fibroblasts. This stimulation of type I collagen, type III collagen, and fibronectin production occurred in a dose- and time-dependent manner with no effect on total protein synthesis or on the ratio of secreted proteins to cell-associated proteins (Katayama, K., Seyer, J. M., Raghow, R., and Kang, A. H. (1991) Biochemistry 30, 7097-7104). In the present report, we have extensively dissected this subfragment of the propeptide and found that the pentapeptide Lys-Thr-Thr-Lys-Ser (residues 212-216) is the minimum sequence necessary for potent stimulation of collagen and fibronectin production in a variety of mesenchymal cells. We postulate that the extracellular matrix production in fibroblasts may be subject to either positive or negative feedback regulation depending on the repertoire of specific proteases during postinflammatory tissue regeneration and fibrosis.	VET ADM MED CTR, MEMPHIS, TN 38104 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT MED, MEMPHIS, TN 38104 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT PHARMACOL, MEMPHIS, TN 38104 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Armendáriz-Borunda, Juan/AAU-1471-2021					AUMAILLEY M, 1982, BIOCHEM J, V206, P505, DOI 10.1042/bj2060505; AYCOCK RS, 1986, J BIOL CHEM, V261, P14355; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BREUL SD, 1980, J BIOL CHEM, V255, P5250; FOUSER L, 1991, P NATL ACAD SCI USA, V88, P10158, DOI 10.1073/pnas.88.22.10158; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; HATAMOCHI A, 1989, J BIOL CHEM, V264, P3494; KATAYAMA K, 1991, BIOCHEMISTRY-US, V30, P7097, DOI 10.1021/bi00243a009; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MILLER EJ, 1988, COLLAGEN BIOCH, V1, P136; PAGLIA LM, 1981, BIOCHEMISTRY-US, V18, P5030; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PETERKOF.B, 1972, ARCH BIOCHEM BIOPHYS, V152, P318, DOI 10.1016/0003-9861(72)90221-4; PRIEST RE, 1969, LAB INVEST, V21, P138; QUINONES SR, 1986, BIOCHEM J, V239, P179, DOI 10.1042/bj2390179; RAGHOW R, 1991, CHEST, V99, pS61, DOI 10.1378/chest.99.3_Supplement.61S; RAGHOW R, 1989, MOL CELL BIOCHEM, V86, P5; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; SCHLUMBERGER W, 1988, EUR J CELL BIOL, V46, P244; SEYER JM, 1988, TXB RHEUMATOLOGY, P211; TENDIJKE P, 1989, BIO-TECHNOL, V7, P793, DOI 10.1038/nbt0889-793; TOLSTOSHEV P, 1981, J BIOL CHEM, V256, P3135; VOSS T, 1986, EUR J BIOCHEM, V157, P433, DOI 10.1111/j.1432-1033.1986.tb09686.x; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; WU CH, 1986, J BIOL CHEM, V261, P482	28	112	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9941	9944						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486721				2022-12-27	WOS:A1993LB80000002
J	HUSTEN, EJ; TAUSK, FA; KEUTMANN, HT; EIPPER, BA				HUSTEN, EJ; TAUSK, FA; KEUTMANN, HT; EIPPER, BA			USE OF ENDOPROTEASES TO IDENTIFY CATALYTIC DOMAINS, LINKER REGIONS, AND FUNCTIONAL INTERACTIONS IN SOLUBLE PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE AMIDATION; MESSENGER-RNA; ENZYME; CELLS; PURIFICATION; EXPRESSION; PITUITARY; SEQUENCE; INTERMEDIATE; BIOSYNTHESIS	The production of alpha-amidated peptides is accomplished through the sequential action of two enzymes, peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL), that are contained within the bifunctional peptidylglycine alpha-amidating monooxygenase (PAM) protein. Tissue-specific alternative splicing and endoproteolysis are known to generate both soluble and integral membrane mono- and bifunctional PAM proteins. In order to investigate the functional consequences of these differences we purified PAM-3, a soluble 95-kDa bifunctional form of the enzyme, from the spent medium of stably transfected hEK-293 cells. Using NH2-terminal sequence analysis of products of limited endoproteolysis and antibody cross-reactivity we identified protease-sensitive regions at the NH2 terminus, between the 35-kDa PHM and 42-kDa PAL domains and at the COOH terminus of the protein. Endoproteolytic removal of the COOH-terminal region from the bifunctional PAM-3 protein shifted the pH optimum of PHM to a more alkaline pH, increased the turnover number (k(cat)) of PHM and decreased its K(M) for alpha-N-acetyl-Tyr-Val-Gly; the catalytic properties of PAL were not altered. Since peptide amidation can be a rate-limiting step in the biosynthesis of neuropeptides, similar increases in PHM activity in vivo may play an important role in regulating the extent of peptide alpha-amidation.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,WOOD BASIC SCI BLDG,RM 907,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT DERMATOL,BALTIMORE,MD 21205; MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114	Johns Hopkins University; Johns Hopkins University; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R37DK032949, R01DK032949, F32DK008504] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 00098] Funding Source: Medline; NIDDK NIH HHS [DK 32949, DK 08504] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUDRY GA, 1990, J BIOL CHEM, V265, P17694; BERTELSEN AH, 1990, ARCH BIOCHEM BIOPHYS, V279, P87, DOI 10.1016/0003-9861(90)90466-C; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; DUNCAN K, 1987, BIOCHEM J, V246, P375, DOI 10.1042/bj2460375; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; GLAUDER J, 1990, BIOCHEM BIOPH RES CO, V169, P551, DOI 10.1016/0006-291X(90)90366-U; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; KIM HS, 1992, J BIOL CHEM, V267, P7177; MAINS RE, 1991, MOL ENDOCRINOL, V5, P187, DOI 10.1210/mend-5-2-187; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; MEHTA NM, 1988, ARCH BIOCHEM BIOPHYS, V261, P44, DOI 10.1016/0003-9861(88)90102-6; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MURTHY ASN, 1986, J BIOL CHEM, V261, P1815; NOGUCHI M, 1992, BIOCHEM J, V283, P883, DOI 10.1042/bj2830883; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; OUAFIK L, 1992, MOL ENDOCRINOL, V6, P1571, DOI 10.1210/me.6.10.1571; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAMBURINI PP, 1990, INT J PEPT PROT RES, V35, P153; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; ZABRISKIE TM, 1991, J CHEM SOC CHEM COMM, V114, P571	38	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9709	9717						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486658				2022-12-27	WOS:A1993LA68900082
J	XUE, H; SHEN, WY; GIEGE, R; WONG, JTF				XUE, H; SHEN, WY; GIEGE, R; WONG, JTF			IDENTITY ELEMENTS OF TRANSFER RNA(TRP) - IDENTIFICATION AND EVOLUTIONARY CONSERVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; NUCLEOTIDES; SEQUENCE; GENES	In this study, the varying reactivities of Bacillus subtilis tryptophanyl-tRNA synthetase toward prokaryotic, eukaryotic, and halophile tRNAs were employed to define the potential identity elements on tRNA(TrP). On this basis mutagenesis was performed to obtain, through in vivo heterologous expression in Escherichia coli and in vitro transcription with T7 RNA polymerase, mutant B. subtilis tRNA(Trp) for comparison with the wild-type. These comparisons served to establish G73 and the anticodon as major identity elements, and A1-U72, G5-C68, and A9 as minor identity elements. While the tryptophanyl-tRNA synthetase from B. subtilis and E. coli require G73 to function, replacement of G73 by A73 favors the enzyme from yeast. This change points to the variation of the identity elements for the same amino acid among different organisms. The similarity in these elements between B. subtilis and E. coli tryptophanyl-tRNA synthetase, however, suggests that identity elements on tRNA, like the active centers on enzymes, undergo evolutionary change at slower rates than less essential portions of the macromolecule.	CNRS, INST BIOL MOLEC & CELLULAIRE, STRASBOURG, FRANCE; HONG KONG UNIV SCI & TECHNOL, DEPT BIOCHEM, KOWLOON, HONG KONG	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Hong Kong University of Science & Technology	XUE, H (corresponding author), UNIV TORONTO, DEPT BIOCHEM, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA.			Xue, Hong/0000-0002-8133-9828; Wong, J. Tze-Fei/0000-0001-8539-8537				CHOW KC, 1992, J BIOL CHEM, V267, P9146; CHOW KC, 1988, GENE, V73, P537; FOWDEN L, 1967, ADV ENZYMOL RAMB, V29, P89; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; KWOK Y, 1980, CAN J BIOCHEM CELL B, V58, P213, DOI 10.1139/o80-029; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; NAZARENKO IA, 1992, NUCLEIC ACIDS RES, V20, P475, DOI 10.1093/nar/20.3.475; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; RICHMOND MH, 1962, BACTERIOL REV, V26, P398, DOI 10.1128/MMBR.26.4.398-420.1962; ROGERS MJ, 1992, P NATL ACAD SCI USA, V89, P3463, DOI 10.1073/pnas.89.8.3463; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SHEN W, 1991, 14TH INT TRNA WORKSH, P219; SHI W, 1990, BIOCHEM CELL BIOL, V68, P492, DOI 10.1139/o90-069; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; WANG QS, 1983, ANAL BIOCHEM, V131, P360, DOI 10.1016/0003-2697(83)90184-7; WAWROUSEK EF, 1984, J BIOL CHEM, V259, P3694; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WONG JTF, 1983, P NATL ACAD SCI-BIOL, V80, P6303, DOI 10.1073/pnas.80.20.6303; XU ZJ, 1989, J BIOL CHEM, V264, P4304; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391; ZEFF RA, 1987, FOCUS, V9, P1; ZHANG SB, 1986, J CHROMATOGR, V360, P282, DOI 10.1016/S0021-9673(00)91676-5	26	48	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9316	9322						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486627				2022-12-27	WOS:A1993LA68900028
J	BALDARI, CT; HEGUY, A; TELFORD, JL				BALDARI, CT; HEGUY, A; TELFORD, JL			CALCIUM-DEPENDENT CYCLOSPORINE-A-SENSITIVE ACTIVATION OF THE INTERLEUKIN-2 PROMOTER BY P56(LCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE PROTEIN-KINASE; T-CELL RECEPTOR; CD4; EXPRESSION; COMPLEX; ANTIGEN; PHOSPHORYLATION; P56LCK	T-cell antigen receptor engagement results in suboptimal activation of protein kinase C and a prolonged increase in intracellular free calcium concentration. These signals, in combination with stimulation via accessory molecules usually supplied by the antigen presenting cell, activate expression of interleukin-2 (IL-2) and initiate autocrine growth. The lymphocyte-specific tyrosine kinase p56lck is physically associated with CD4 and is brought into close proximity of the intracellular domain of the antigen receptor by CD4 recognition of the major histocompatibility complex during antigen presentation. p56lck activation enhances and may be essential for antigen receptor signaling. We report that a constitutively active form of p56lck delivers a signal which contributes to IL-2 promoter activation. The signal substituted for a calcium-mobilizing signal in a Jurkat cell model of T-cell activation. The activation was sensitive to EGTA and cyclosporin A, indicating that p56lck functions at an early stage of the calcium-mediated pathway. The transcription factor NF-AT mediated, at least in part, the p56lck activation of IL-2 expression. In addition, activated p56lck synergized with constitutively active p21Ha-ras, which can replace protein kinase C activation, resulting in activation of NF-AT in the absence of external signals.	IMMUNOBIOL RES INST SIENA,VIA FIORENTINA 1,I-53100 SIENA,ITALY; UNIV SIENA,DEPT EVOLUT BIOL,I-53100 SIENA,ITALY	University of Siena			Telford, John Laird/ABG-8144-2020	Baldari, Cosima/0000-0002-4414-6744				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BALDARI CT, 1992, J BIOL CHEM, V267, P4289; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GLEICHENHAUS N, 1991, CELL, V64, P511; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SEFTON BM, 1991, ONCOGENE, V6, P683; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0	31	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8406	8409						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473282				2022-12-27	WOS:A1993KX81100007
J	BROWN, ED; WOOD, JM				BROWN, ED; WOOD, JM			CONFORMATIONAL CHANGE AND MEMBRANE ASSOCIATION OF THE PUTA PROTEIN ARE COINCIDENT WITH REDUCTION OF ITS FAD COFACTOR BY PROLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PYRUVATE OXIDASE; SALMONELLA-TYPHIMURIUM; OXIDATION-REDUCTION; DEHYDROGENASE; BINDING; ENZYME; FLAVOPROTEINS; PURIFICATION; ACTIVATION	The PutA protein is both the put repressor and a membrane-bound enzyme with proline and DELTA1-pyrroline-5-carboxylate dehydrogenase activities. The conditions required for association of purified PutA protein with membrane vesicles suggested that a redox switching mechanism might determine the proportion of PutA protein functioning as a dehydrogenase (Wood, J. M. (1987) Proc. Natl. Acad. Sci. USA 84,373-377). The FAD cofactor was released from the PutA protein with 1 M KBr at neutral pH. The apoprotein retained DELTA1-pyrroline-5-carboxylate dehydrogenase and DNA binding but not proline dehydrogenase activity. Reconstitution with FAD fully restored proline dehydrogenase activity. Proline at a concentration of 0.11 mm caused half-maximal bleaching of the FAD in PutA. Chymotryptic digestion of the PutA protein in the presence and absence of proline demonstrated that the persistence of a 119-kDa protein fragment was characteristic of the reduced protein. Identical digestion patterns were obtained from the apoprotein in the presence and absence of proline. The quantity of the 119-kDa fragment produced varied with proline concentration, yielding a midpoint of 0.056 mm proline. The fraction of PutA protein associated with membrane vesicles was also a function of proline concentration, yielding a titration midpoint of 0.10 mm proline. Membrane binding was thus coincident with both flavin reduction and a change in protein conformation.	UNIV GUELPH, GUELPH WATERLOO CTR GRAD WORK CHEM, DEPT MICROBIOL, GUELPH N1G 2W1, ONTARIO, CANADA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry								ABRAHAMSON JLA, 1983, EUR J BIOCHEM, V134, P77, DOI 10.1111/j.1432-1033.1983.tb07533.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN ED, 1992, J BIOL CHEM, V267, P13086; BUCHANAN BB, 1983, FUNCTIONS GLUTATHION, P231; DENDINGER S, 1970, J BACTERIOL, V103, P144, DOI 10.1128/JB.103.1.144-152.1970; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1986, BIOCHEM J, V239, P1; GRAHAM SB, 1984, J BIOL CHEM, V259, P2656; Husain M, 1978, Methods Enzymol, V53, P429; Kierkegaard P., 1971, FLAVINS FLAVOPROTEIN, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALOY SR, 1987, ESCHERICHIA COLI SAL, V1, P1513; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASSEY V, 1966, J BIOL CHEM, V241, P3417; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MENZEL R, 1981, J BIOL CHEM, V256, P9755; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P262; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PUST S, 1989, BIOCHEMISTRY-US, V28, P516, DOI 10.1021/bi00428a016; RUSSELL P, 1977, J BIOL CHEM, V252, P7877; SANNER C, 1991, EUR J BIOCHEM, V196, P663, DOI 10.1111/j.1432-1033.1991.tb15863.x; SCARPULLA RC, 1978, J BIOL CHEM, V253, P5997; SCHROCK HL, 1977, J BIOL CHEM, V252, P5990; SCHROCK HL, 1980, BIOCHIM BIOPHYS ACTA, V614, P215, DOI 10.1016/0005-2744(80)90182-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P6789, DOI 10.1021/bi00370a010; WEIMAR W R, 1975, P1; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2; WOOD JM, 1987, P NATL ACAD SCI USA, V84, P373, DOI 10.1073/pnas.84.2.373; WOOD JM, 1987, BIOCHEM CELL BIOL, V65, P507, DOI 10.1139/o87-065; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	37	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8972	8979						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473341				2022-12-27	WOS:A1993KX81100086
J	KINOSIAN, HJ; SELDEN, LA; ESTES, JE; GERSHMAN, LC				KINOSIAN, HJ; SELDEN, LA; ESTES, JE; GERSHMAN, LC			NUCLEOTIDE BINDING TO ACTIN - CATION DEPENDENCE OF NUCLEOTIDE DISSOCIATION AND EXCHANGE-RATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT METAL-ION; MONOMERIC ACTIN; ADENOSINE 5'-TRIPHOSPHATE; ATP-ACTIN; ADP-ACTIN; KINETICS; AFFINITY; POLYMERIZATION; FLUORESCENCE; MECHANISM	We have reinvestigated nucleotide binding to actin in order to resolve conflicts regarding the mechanism of nucleotide dissociation and exchange. We present evidence that supports a mechanism for nucleotide binding to actin in which the tightly bound divalent cation (Ca2+ or Mg+) directly interacts with the bound nucleotide. The dissociation rates of ATP or ADP from actin are limited by the dissociation of the high affinity divalent cation from actin and vary inversely with free Ca2+ or free Mg2+ concentration. The divalent cation concentration range over which attenuation of the ATP dissociation takes place is about 100-fold greater for Mg2+ than that for Ca2+ due to the much slower association rate constant for Mg2+ compared with Ca2+. The relative affinity for ATP versus ADP is 200:1 for Ca-actin in 100 muM free [Ca2+], and 4:1 for Mg-actin in 100 muM free [Mg2+]. Actin without a tightly bound divalent cation has about a 3-fold greater affinity for ATP than ADP. At constant free divalent cation concentration, the rate of nucleotide exchange on actin is described by competitive binding kinetics.	VET AFFAIRS SAMUEL S STRATTON MED CTR,RES SERV,151-B,HOLLAND AVE,ALBANY,NY 12208; VET AFFAIRS SAMUEL S STRATTON MED CTR,MED SERV,ALBANY,NY 12208; ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208; ALBANY MED COLL,DEPT MED,ALBANY,NY 12208	Albany Medical College; Albany Medical College					NIGMS NIH HHS [GM 32007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BREMER A, 1992, Current Opinion in Cell Biology, V4, P20, DOI 10.1016/0955-0674(92)90054-G; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; ESTES JE, 1987, J BIOL CHEM, V262, P4952; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; GERSHMAN LC, 1991, J BIOL CHEM, V266, P76; GERSHMAN LC, 1989, BIOCHIM BIOPHYS ACTA, V995, P109, DOI 10.1016/0167-4838(89)90068-X; GERSHMAN LC, 1986, BIOCHEM BIOPH RES CO, V135, P607, DOI 10.1016/0006-291X(86)90036-7; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KINOSIAN HJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P151, DOI 10.1016/0167-4838(91)90052-2; KUEHL WM, 1969, J BIOL CHEM, V244, P4720; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; MANNHERZ HG, 1992, J BIOL CHEM, V267, P11661; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NEIDL C, 1979, EUR J BIOCHEM, V101, P163; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P8613, DOI 10.1021/bi00423a016; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; SELDEN LA, 1986, J MUSCLE RES CELL M, V7, P215, DOI 10.1007/BF01753554; SELDEN LA, 1987, FEBS LETT, V217, P89, DOI 10.1016/0014-5793(87)81249-8; STRAUB FB, 1950, BIOCHIM BIOPHYS ACTA, V4, P455, DOI 10.1016/0006-3002(50)90052-7; STROHMAN RC, 1962, J BIOL CHEM, V237, P363; STRZELECKAGOLASZEWSKA H, 1985, EUR J BIOCHEM, V147, P331, DOI 10.1111/j.1432-1033.1985.tb08754.x; SZENTGYORGYI A, 1951, CHEM MUSCULAR CONTRA, P146; THAMES KE, 1974, BIOCHEM BIOPH RES CO, V60, P1252, DOI 10.1016/0006-291X(74)90333-7; UE K, 1992, EUR J BIOCHEM, V203, P493, DOI 10.1111/j.1432-1033.1992.tb16574.x; VALENTINRANC C, 1991, J BIOL CHEM, V266, P7668; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; WAECHTER F, 1977, EUR J BIOCHEM, V74, P227, DOI 10.1111/j.1432-1033.1977.tb11385.x; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; WANGER M, 1983, FEBS LETT, V162, P112, DOI 10.1016/0014-5793(83)81059-X; WEST JJ, 1971, BIOCHEMISTRY-US, V10, P3547, DOI 10.1021/bi00795a009	39	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8683	8691						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473312				2022-12-27	WOS:A1993KX81100048
J	MUKAI, K; IMAI, M; SHIMADA, H; ISHIMURA, Y				MUKAI, K; IMAI, M; SHIMADA, H; ISHIMURA, Y			ISOLATION AND CHARACTERIZATION OF RAT CYP11B GENES INVOLVED IN LATE STEPS OF MINERALOCORTICOID AND GLUCOCORTICOID SYNTHESES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSTERONE SYNTHASE CYTOCHROME-P-450; BOVINE ADRENOCORTICAL MITOCHONDRIA; MOUSE STEROID 11-BETA-HYDROXYLASE; ADRENAL-CORTEX; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; P-450(11-BETA) GENES; MAMMALIAN-CELLS; PROMOTER REGION; EXPRESSION	We isolated and characterized four forms of ra CYP11B genes, which were tentatively name CYP11B1,-B2,-B3, and-B4. Genomic Southern analyses indicated that the members of the rat CYP11 gene subfamily were confined to these four genes; among them, CYP11B1 and -B2 encoded steroid 11beta-hydroxylase and aldosterone synthase, respectively, while CYP11B3 was a gene highly homologous to CYP11B1 without a known expression product. By being devoid of a region spanning two exons conserved in the other three, CYP11B4 was presumably a pseudogene. In the nucleotide sequences, CYP11B1, -B3, and -B4 showed 95-96 and 93-100% identities in the coding and 0.5-kilobase 5'-flanking regions, respectively. However, the homology between the nucleotide sequences of one of the three and CYP11B2 was rather low, about 90 and 50% in the coding and 0.5-kilobase 5'-flanking regions, respectively. As a whole, CYP11B2 rather than CYP11B1, -B3, or -B4 was more homologous to CYP11B genes of other animals such as cow and human. In transient transfection experiments using mouse adrenocortical Y1 cells and chloramphenicol acetyltransferase gene constructs, the 0.5-kilobase 5'-flanking region of CYP11B1 had a 4- and 10-fold higher promoter activity than the corresponding regions of CYP11B2 and-B3, respectively. The possible presence of a suppressive element(s) was noted in the upstream of the 0.5-kilobase region of CYP11B1. Although a variant of cAMP-responsive element, which was present in rat CYP11B2 and all known CYP11B genes of other animals, was modified in rat CYP11B1 and -B3 genes, dibutyryl cAMP stimulated all the promoter activities of the 5'-flanking regions of the rat genes by 3-fold.	KEIO UNIV, SCH MED,DEPT BIOCHEM,35 SHINANOMACHI,SHINJUKU KU, TOKYO 160, JAPAN	Keio University				Mukai, Kuniaki/0000-0002-9590-5077				BIGLIERI EG, 1987, ANN NY ACAD SCI, V512, P426, DOI 10.1111/j.1749-6632.1987.tb24978.x; BOGERD AM, 1990, MOL ENDOCRINOL, V4, P845, DOI 10.1210/mend-4-6-845; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; DUSH MK, 1985, P NATL ACAD SCI USA, V82, P2731, DOI 10.1073/pnas.82.9.2731; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMAINABA H, 1987, CELL STRUCT FUNCT, V12, P173, DOI 10.1247/csf.12.173; HASHIMOTO T, 1989, J BIOCHEM-TOKYO, V105, P676, DOI 10.1093/oxfordjournals.jbchem.a122725; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; IKUSHIRO SI, 1992, J BIOL CHEM, V267, P1464; IMAI M, 1990, FEBS LETT, V263, P299, DOI 10.1016/0014-5793(90)81398-8; IMAI M, 1992, J BIOCHEM-TOKYO, V111, P440, DOI 10.1093/oxfordjournals.jbchem.a123776; KAWAMOTO T, 1990, FEBS LETT, V269, P345, DOI 10.1016/0014-5793(90)81190-Y; KAWAMOTO T, 1990, BIOCHEM BIOPH RES CO, V173, P309, DOI 10.1016/S0006-291X(05)81058-7; KAWAMOTO T, 1992, P NATL ACAD SCI USA, V89, P1458, DOI 10.1073/pnas.89.4.1458; KIRITA S, 1990, J BIOCHEM, V108, P1030, DOI 10.1093/oxfordjournals.jbchem.a123302; KIRITA S, 1988, J BIOCHEM-TOKYO, V104, P683, DOI 10.1093/oxfordjournals.jbchem.a122533; LAUBER M, 1987, J STEROID BIOCHEM, V26, P693, DOI 10.1016/0022-4731(87)91041-7; LAUBER M, 1989, ARCH BIOCHEM BIOPHYS, V274, P109, DOI 10.1016/0003-9861(89)90421-9; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MALEE MP, 1991, P NATL ACAD SCI USA, V88, P4731, DOI 10.1073/pnas.88.11.4731; MATSUKAWA N, 1990, BIOCHEM BIOPH RES CO, V169, P245, DOI 10.1016/0006-291X(90)91460-A; MORNET E, 1989, J BIOL CHEM, V264, P20961; MOROHASHI K, 1990, J BIOCHEM, V107, P635, DOI 10.1093/oxfordjournals.jbchem.a123099; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V102, P559, DOI 10.1093/oxfordjournals.jbchem.a122089; MOROHASHI KI, 1990, J BIOCHEM-TOKYO, V108, P1050, DOI 10.1093/oxfordjournals.jbchem.a123304; MOUW AR, 1989, J BIOL CHEM, V264, P1305; MUKAI K, 1991, BIOCHEM BIOPH RES CO, V180, P1187, DOI 10.1016/S0006-291X(05)81321-X; Muller J., 1988, REGULATION ALDOSTERO; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; NONAKA Y, 1991, EUR J BIOCHEM, V202, P897, DOI 10.1111/j.1432-1033.1991.tb16449.x; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OGISHIMA T, 1989, J BIOCHEM-TOKYO, V105, P497, DOI 10.1093/oxfordjournals.jbchem.a122694; QUINN SJ, 1988, ANNU REV PHYSIOL, V50, P409, DOI 10.1146/annurev.ph.50.030188.002205; RICE DA, 1989, J BIOL CHEM, V264, P14011; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SHIBATA H, 1991, ENDOCRINOLOGY, V128, P2534, DOI 10.1210/endo-128-5-2534; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; WADA A, 1985, J BIOCHEM-TOKYO, V98, P245, DOI 10.1093/oxfordjournals.jbchem.a135264; YABU M, 1991, HISTOCHEMISTRY, V96, P391, DOI 10.1007/BF00315995; YANAGIBASHI K, 1986, J BIOL CHEM, V261, P3556; YANAGIBASHI K, 1988, J STEROID BIOCHEM, V29, P665	51	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9130	9137						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473352				2022-12-27	WOS:A1993KX81100106
J	COLLEN, D; SCHLOTT, B; ENGELBORGHS, Y; VANHOEF, B; HARTMANN, M; LIJNEN, HR; BEHNKE, D				COLLEN, D; SCHLOTT, B; ENGELBORGHS, Y; VANHOEF, B; HARTMANN, M; LIJNEN, HR; BEHNKE, D			ON THE MECHANISM OF THE ACTIVATION OF HUMAN PLASMINOGEN BY RECOMBINANT STAPHYLOKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE MUTAGENIZED PLASMINOGEN; T-PA; PURIFICATION; EXPRESSION; PROTEIN	The mechanism of activation of human plasminogen by recombinant staphylokinase (STAR) was studied using the active site titrant p-nitrophenyl-p'-guanidinobenzoate (NPGB). NPGB prevented active site exposure in equimolar mixtures of plasminogen and STAR but reacted stoichiometrically with mixtures preincubated in the absence of titrant. Active site generation occurred progressively, with a marked initial lag phase followed by an exponential growth phase, and was associated with the conversion of single-chain plasminogen to two-chain plasmin. Incubation of mixtures of plasminogen and STAR with catalytic amounts (<0.2% molar ratio) of preformed plasmin.STAR complex or of urokinase shortened the lag hase, whereas catalytic amounts (5% molar ratio) of the plasmin inhibitor alpha2-antiplasmin delayed active site generation. The following kinetic model for the activation of plasminogen (P) by STAR (S) fits the experimental data, [GRAPHICS] and is described by [GRAPHICS] or [GRAPHICS] In this model, plasminogen and STAR produce an inactive complex (P.S), in which active plasmin.STAR (p.S) is generated in a rate limiting step, which is accelerated by plasminogen activators and delayed by plasmin inhibitors. At room temperature in a 0.1 M Veronal buffer, pH 8.3, containing 0.1 M arginine, the data are adequately fitted by the integrated equation with k1 = 4.0 x 10(-7) s-1 and k2 = 1.3 x 10(-2) muM-1 s-1. The k1 value could be explained by contamination of the plasminogen preparation with 3 ppm plasmin, converted by S to p.S. It is concluded that STAR activates plasminogen via a mechanism which differs in several essential aspects from that of streptokinase.	CATHOLIC UNIV LEUVEN,PHYS BIOCHEM LAB,B-3000 LOUVAIN,BELGIUM; INST MOLEC BIOTECHNOL,O-6900 JENA,GERMANY	KU Leuven	COLLEN, D (corresponding author), CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,CAMPUS GASTHUISBERG,O&N,HERESTR 49,B-3000 LOUVAIN,BELGIUM.		Lijnen, Roger/AAA-4085-2020					BEHNKE D, 1987, MOL GEN GENET, V210, P528, DOI 10.1007/BF00327208; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1992, FIBRINOLYSIS, V6, P232, DOI 10.1016/0268-9499(92)90076-T; COLLEN D, 1992, IN PRESS CIRCULATION; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ERICSON R, 1977, CHEM ABSTR, V86, P202; GAFFNEY PJ, 1985, THROMB HAEMOSTASIS, V53, P134; GERLACH D, 1988, ZBL BAKT-INT J MED M, V269, P314; KANAI K, 1986, BIOL ABSTR, V81, P748; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LEWIS JH, 1964, AM J PHYSIOL, V207, P1049, DOI 10.1152/ajplegacy.1964.207.5.1049; LEWIS JH, 1964, AM J PHYSIOL, V207, P1044, DOI 10.1152/ajplegacy.1964.207.5.1044; LEWIS JH, 1951, AM J PHYSIOL, V166, P594, DOI 10.1152/ajplegacy.1951.166.3.594; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P214, DOI 10.1016/0268-9499(92)90074-R; LIJNEN HR, 1990, THROMB HAEMOSTASIS, V64, P61; MATSUO O, 1990, BLOOD, V76, P925; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NELLES L, 1987, J BIOL CHEM, V262, P10855; SWEET B, 1965, CLIN SCI, V29, P375; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	26	93	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8284	8289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463338				2022-12-27	WOS:A1993KW97900101
J	KOYAMA, N; HARADA, K; YAMAMOTO, A; MORISAKI, N; SAITO, Y; YOSHIDA, S				KOYAMA, N; HARADA, K; YAMAMOTO, A; MORISAKI, N; SAITO, Y; YOSHIDA, S			PURIFICATION AND CHARACTERIZATION OF AN AUTOCRINE MIGRATION FACTOR FOR VASCULAR SMOOTH-MUSCLE CELLS (SMC), SMC-DERIVED MIGRATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; CANCER-PATIENT FIBROBLASTS; STIMULATING FACTOR; MOTILITY FACTOR; SCATTER FACTOR; FACTOR-BETA; INHIBITION; ATHEROSCLEROSIS; FACTOR-BETA-1; PATHOGENESIS	Migration of medial smooth muscle cells (SMC) into the intima is a key step in intimal thickening of atherosclerotic tissues. We previously reported that cultured SMC secrete a potent migration factor for SMC, named SMC-derived migration factor (SDMF). We purified this factor to homogeneity from 20 liters of serum-free conditioned medium of cultured rat aortic SMC by sequential heparin-Sepharose column, red-Sepharose column, TSK-heparin high performance liquid chromatography (HPLC) column, and Superose 6 HPLC column chromatographies. SDMF was found to be a 58-kDa polypeptide by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Reduction by mercaptoethanol caused only a slight decrease in its molecular mass to 53 kDa. Preparative isoelectric focusing revealed that SDMF is a basic protein with a pI of approximately 10. Purified SDMF enhanced the migration of rat SMC dose dependently, its maximal activity being 4 times that of platelet-derived growth factor-BB. In contrast, SDMF did not enhance the migration of endothelial cells from either human umbilical cord vein or rabbit retinal tissue. SDMF had no effect on the proliferation of SMC. These findings suggest that SDMF enhances SMC migration in vascular walls and that the autocrine system of SMC migration contributes to the formation of intimal thickening in atheroma formation.	CHIBA UNIV, SCH MED,DEPT INTERNAL MED 2,1-8-1 INOHANA,CHUO KU, CHIBA 260, JAPAN; TERUMO CO LTD, CTR RED & DEV, NAKAI, KANAGAWA 25901, JAPAN	Chiba University; Terumo Corporation				Koyama, Noriyuki/0000-0002-7509-6583				AUTIO I, 1990, FEBS LETT, V277, P247, DOI 10.1016/0014-5793(90)80857-F; BOWENPOPE DF, 1984, BLOOD, V64, P458; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P378; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FISCHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KOYAMA N, 1991, ATHEROSCLEROSIS, V86, P219, DOI 10.1016/0021-9150(91)90218-R; KOYAMA N, 1990, BIOCHEM BIOPH RES CO, V169, P725, DOI 10.1016/0006-291X(90)90391-Y; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; NAITO M, 1991, EXP CELL RES, V194, P154, DOI 10.1016/0014-4827(91)90145-K; NAITO M, 1989, FEBS LETT, V247, P358, DOI 10.1016/0014-5793(89)81370-5; NOMOTO A, 1988, ATHEROSCLEROSIS, V72, P213, DOI 10.1016/0021-9150(88)90083-4; OOYAMA T, 1987, ARTERIOSCLEROSIS, V7, P593, DOI 10.1161/01.ATV.7.6.593; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SCHOR SL, 1988, J CELL SCI, V90, P391; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; WATANABE H, 1991, J BIOL CHEM, V266, P13442; WATANABE S, 1992, PREVENTION TREATMENT, P361	42	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13301	13308						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514768				2022-12-27	WOS:A1993LH55300044
J	BLONDELGUINDI, S; FOURIE, AM; SAMBROOK, JF; GETHING, MJH				BLONDELGUINDI, S; FOURIE, AM; SAMBROOK, JF; GETHING, MJH			PEPTIDE-DEPENDENT STIMULATION OF THE ATPASE ACTIVITY OF THE MOLECULAR CHAPERONE BIP IS THE RESULT OF CONVERSION OF OLIGOMERS TO ACTIVE MONOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BINDING-PROTEIN; GLUCOSE-REGULATED PROTEIN; SHOCK COGNATE PROTEIN; ENDOPLASMIC-RETICULUM; HEAT-SHOCK; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SECRETORY PROTEINS; MAMMALIAN-CELLS; HEMAGGLUTININ	The molecular chaperone BiP purified from bovine liver (bBiP) exhibits a low basal level of ATPase activity that can be stimulated 3-6-fold by synthetic peptides (Flynn, G. C., Chappell, T. G., and Rothman, J. E. (1989) Science 245, 385-390). By contrast, recombinant murine BiP (rBiP) purified to homogeneity following expression in Escherichia coli exhibits a higher basal level of ATPase activity and is much less stimulated by synthetic peptides. Nondenaturing gel electrophoresis showed that rBiP is predominantly monomeric, while bBiP exists in multiple forms probably corresponding to differentially modified monomeric, dimeric, and higher oligomeric species. Some, but not all, synthetic peptides cause conversion of the oligomeric and modified species of bBiP to a monomeric form. We propose that the peptide-dependent ATPase stimulation observed for BiP reflects the conversion of inactive oligomeric and/or modified species into active monomers.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KIM PS, 1991, J BIOL CHEM, V266, P12412; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1989, J CELL SCI, P115; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIN AY, 1984, P NATL ACAD SCI-BIOL, V81, P988, DOI 10.1073/pnas.81.4.988; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MORRISON SL, 1975, J IMMUNOL, V114, P655; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEU HC, 1965, J BIOL CHEM, V240, P3685; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHONBERGER O, 1991, MOL MICROBIOL, V5, P2663, DOI 10.1111/j.1365-2958.1991.tb01975.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	44	147	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12730	12735						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509407				2022-12-27	WOS:A1993LG65800075
J	FAUX, MC; PEARSON, RB; MITCHELHILL, KI; KEMP, BE				FAUX, MC; PEARSON, RB; MITCHELHILL, KI; KEMP, BE			ROLE OF THE PSEUDOSUBSTRATE SEQUENCE IN SMOOTH-MUSCLE MYOSIN LIGHT-CHAIN KINASE THERMAL-STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALMODULIN-BINDING DOMAIN; CATALYTIC SUBUNIT; BASIC RESIDUES; IDENTIFICATION; PHOSPHORYLATION; CLEAVAGE; GIZZARD; CDNA	Smooth muscle myosin light chain kinase (MLCK) is stable in the presence of Ca2+/calmodulin and does not undergo inactivation as reported for skeletal muscle MLCK (Kennelly, P. J., Starovasnik, M. A., Edelman, A. M., and Krebs, E. G. (1990) J. Biol. Chem. 265, 1742-1749). The 61-kDa tryptic fragment of smMLCK-(283-779) with the pseudosubstrate/calmodulin binding sequence deleted undergoes rapid inactivation (t1/2 = 5 min at 25-degrees-C). Thermal inactivation renders the 61-kDa fragment more susceptible to cleavage by trypsin. The pseudosubstrate sequence, smMLCK-(787-807) prevents inactivation with high potency (half-maximal protective concentration, PC0.5 = 102 +/- 9 nM). The hexapeptide smMLCK-(797-802), Arg-Arg-Lys-Trp800-Gln-Lys, protected with a similar potency (PC0.5 = 73 +/- 14 nM). The four basic residues as well as Trp were important for maintaining protection by the hexapeptide smMLCK-(797-802). Substitution of Trp800 with Ala or Leu increased the PC0.5 to 500 nM. However, substitution of both aromatic residues Tyr794 and Trp800 in the longer pseudosubstrate peptide-(787-807) had little effect, indicating that with the longer peptide other multiple interactions were sufficient to stabilize the enzyme. The peptide substrate MLC-(11-23) A14,15 was also protective (PC0.5 = 380 nM) as was Mg2+-ATP, Mg2+-ADP, and Mg2+ plus adenosine. The results demonstrate that the sequence extending from 787-815 encoding the previously identified overlapping pseudosubstrate and calmodulin binding sequences also contains residues that are essential for maintaining thermal stability but these exhibit distinct structure/function relationships.			FAUX, MC (corresponding author), ST VINCENTS INST MED RES, 41 VICTORIA PARADE, FITZROY, VIC 3065, AUSTRALIA.		Pearson, Richard Bruce/I-1451-2013; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Pearson, Richard Bruce/0000-0001-5919-5090; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; IKEBE M, 1987, J BIOL CHEM, V262, P13828; ITO M, 1989, J BIOL CHEM, V264, P13971; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KENNELLY PJ, 1990, J BIOL CHEM, V265, P1742; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARS CJ, 1991, EUR J BIOCHEM, V194, P189; PEARSON R B, 1991, Peptide Research, V4, P147; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PEARSON RB, 1991, EUR J BIOCHEM, V200, P723, DOI 10.1111/j.1432-1033.1991.tb16237.x; ROUSH CL, 1988, J BIOL CHEM, V263, P10510; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TAN JL, 1991, J BIOL CHEM, V266, P16044	28	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12484	12491						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509388				2022-12-27	WOS:A1993LG65800040
J	FELDMANN, H; WINNACKER, EL				FELDMANN, H; WINNACKER, EL			A PUTATIVE HOMOLOG OF THE HUMAN AUTOANTIGEN KU FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COMPLEX; DNA; SEQUENCE; YEAST; AUTOANTIBODIES; PURIFICATION; MECHANISM; OVERLAP; SUBUNIT; ANTIGEN	We have identified and purified a new DNA binding protein, designated HDF (high affinity DNA-binding factor) from Saccharomyces cerevisiae. HDF binds in a sequence-independent manner to the ends of double-stranded DNA. The protein appears as a stable heterodimer of two polypeptides with molecular masses of 70 and 85 kDa. We have cloned and sequenced the 70-kDa subunit of the HDF protein. The amino acid sequence shows a weak but significant homology with the p70 subunit of the human Ku autoantigen, a protein that also binds to the ends of double-stranded DNA. Hdf- strains generated by one-step gene disruption show a temperature-sensitive phenotype for growth at 37-degrees-C. Cells arrest growth at 37-degrees-C and after several hours appear as enlarged single-budded cells with abnormally high DNA content indicating a defect in the regulation of DNA replication coupled with or causing a cell cycle arrest in G2 or mitosis.	UNIV MUNICH, MAX PLANCK INST BIOCHEM, INST BIOCHEM, KLOPFERSPITZ, W-8033 MARTINSRIED, GERMANY	Max Planck Society; University of Munich								Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; DAVIS TN, 1992, J CELL BIOL, V118, P607, DOI 10.1083/jcb.118.3.607; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; TUITE MF, 1982, EMBO J, V1, P603, DOI 10.1002/j.1460-2075.1982.tb01215.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407	25	150	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12895	12900						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509423				2022-12-27	WOS:A1993LG65800096
J	IZBAN, MG; LUSE, DS				IZBAN, MG; LUSE, DS			SII-FACILITATED TRANSCRIPT CLEAVAGE IN RNA POLYMERASE-II COMPLEXES STALLED EARLY AFTER INITIATION OCCURS IN PRIMARILY DINUCLEOTIDE INCREMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; S-II; GENE; SEQUENCE; TERMINATION; TFIIS; STIMULATION; EXPRESSION; INVITRO	RNA polymerase II ternary complex cleaves its nascent transcript in a 3' --> 5' direction in the presence of elongation factor SII (Izban, M. G., and Luse, D. S. (1992) Genes & Dev. 6, 1342-1356; Reines, D. (1992) J. Biol. Chem. 267, 3795-3800). We have characterized the cleavage products generated during the truncation process with a variety of stalled RNA polymerase II ternary complexes containing uniformly labeled transcripts. These complexes, which remain elongation competent, had stopped transcription because one nucleoside triphosphate was missing from the reaction mixture. Using a novel assay system, we demonstrate that cleavage occurs in predominantly dinucleotide increments, liberating 5'-phosphodinucleotides (pNpNs). In one instance with a particular C20 complex, the first cleavage event was equally partitioned between either a di- or trinucleotide increment with all subsequent truncations occurring by the preferred dinucleotide step. Our data indicate that both the kinetics and the exact increment of SII-facilitated transcript cleavage are influenced by transcript sequence.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM14111, GM-29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014111, R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; MAITRA U, 1967, J BIOL CHEM, V242, P4897; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RUSHIZKY GW, 1963, BIOCHEMISTRY-US, V2, P787, DOI 10.1021/bi00904a028; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SOPTA M, 1985, J BIOL CHEM, V260, P353; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; SPARKOWSKI J, 1992, GENETICS, V130, P411; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WIEST DK, 1992, J BIOL CHEM, V267, P7733; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	33	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12864	12873						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509420				2022-12-27	WOS:A1993LG65800093
J	EHRIG, T; MUHOBERAC, BB; BREMS, D; BOSRON, WF				EHRIG, T; MUHOBERAC, BB; BREMS, D; BOSRON, WF			MONOMERS OF HUMAN BETA(1)BETA(1) ALCOHOL-DEHYDROGENASE EXHIBIT ACTIVITY THAT DIFFERS FROM THE DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; KINETIC CHARACTERIZATION; ESCHERICHIA-COLI; DISSOCIATION; ISOENZYMES; OXIDATION; PHOSPHOFRUCTOKINASE; SUBSTITUTIONS; PURIFICATION; ISOZYMES	A previously unreported enzymatic activity is described for monomers of the beta1beta1 isoenzyme of human alcohol dehydrogenase that were prepared from dimeric enzyme by freeze-thaw in liquid nitrogen. Whereas the dimeric enzyme has optimal activity at low substrate concentrations (2.5 mM ethanol, 50 muM NAD+; ''low K(m)'' activity), the monomer has its highest activity at high substrate concentrations (1.5 M ethanol, 2.5 mM NAD+; ''high K(m)'' activity). While the activity of the monomer does not appear to be saturated at 1.5 M ethanol, its maximal activity at this high ethanol concentration exceeds the V(max) of the dimer by about 3-fold. The apparent K(m) of NAD+ with monomers is 270 muM, and no activity could be detected with nicotinamide mononucleotide as cofactor. During gel filtration the high K(m) activity elutes at a lower apparent molecular weight position than the dimer. The kinetics of monomer-to-dimer reassociation are consistent with a second-order process with a rate constant of 240 M-1 s-1. The reassociation rate is markedly enhanced by the presence of NAD+. During refolding of beta1beta1 following denaturation in 6 M guanidine hydrochloride, an enzyme species with high K(m) activity and spectral properties similar to the freeze-thaw monomer is observed, indicating that a catalytically active monomer is an intermediate in the refolding pathway. The enzymatic activity of the monomers implies that the intersubunit contacts of beta1beta1 are not crucial in establishing a catalytically competent enzyme. However, the differences in specific activity and K(m) between monomer and dimer suggest that dimerization may serve to modulate the catalytic properties.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MED SCI BLDG 405,635 BARNHILL DR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285; INDIANA UNIV PURDUE UNIV,PURDUE UNIV SCI,DEPT CHEM,INDIANAPOLIS,IN 46205	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis					NIAAA NIH HHS [R37 AA07117] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA007117] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSSON L, 1979, EUR J BIOCHEM, V94, P557, DOI 10.1111/j.1432-1033.1979.tb12925.x; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; Branden C.-I., 1975, ENZYMES, V11, P103; BRIGANTI F, 1989, BIOCHEMISTRY-US, V28, P5374, DOI 10.1021/bi00439a009; BROMBERG JP, 1984, PHYSICAL CHEM, P889; BUHLER R, 1982, FEBS LETT, V144, P135, DOI 10.1016/0014-5793(82)80586-3; BURNS DL, 1982, J BIOL CHEM, V257, P8638; DEVILLEBONNE D, 1989, BIOCHEMISTRY-US, V28, P1917, DOI 10.1021/bi00430a073; EHRIG T, 1992, FEBS LETT, V300, P283, DOI 10.1016/0014-5793(92)80864-D; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; FONG WP, 1987, BIOCHEMISTRY-US, V26, P5733, DOI 10.1021/bi00392a023; GERSCHITZ J, 1978, EUR J BIOCHEM, V87, P591, DOI 10.1111/j.1432-1033.1978.tb12411.x; GHELIS C, 1982, PROTEIN FOLDING, P470; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JORNVALL H, 1987, ENZYME, V37, P5; KAPLAN NO, 1960, ENZYMES, V3, P147; LEBRAS G, 1989, BIOCHEMISTRY-US, V28, P6836, DOI 10.1021/bi00443a009; MARDH G, 1986, P NATL ACAD SCI USA, V83, P2836; MARSH EN, 1989, BIOCHEM J, V260, P353, DOI 10.1042/bj2600353; PIETRUSZKO R, 1972, ARCH BIOCHEM BIOPHYS, V153, P279, DOI 10.1016/0003-9861(72)90446-8; SHORE JD, 1966, ARCH BIOCHEM BIOPHYS, V117, P375, DOI 10.1016/0003-9861(66)90425-5; STONE CL, 1989, J BIOL CHEM, V264, P11112; STONE CL, 1993, J BIOL CHEM, V268, P892; YIN SJ, 1984, BIOCHEMISTRY-US, V23, P5847, DOI 10.1021/bi00319a026	26	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11721	11726						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505301				2022-12-27	WOS:A1993LF28400041
J	GUREVICH, VV; BENOVIC, JL				GUREVICH, VV; BENOVIC, JL			VISUAL ARRESTIN INTERACTION WITH RHODOPSIN - SEQUENTIAL MULTISITE BINDING ENSURES STRICT SELECTIVITY TOWARD LIGHT-ACTIVATED PHOSPHORYLATED RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL S-ANTIGEN; BETA-ADRENERGIC-RECEPTOR; ROD OUTER SEGMENTS; 48-KDA PROTEIN; PHOTORECEPTOR-MEMBRANES; PHOTOEXCITED RHODOPSIN; ALPHA-TRANSDUCIN; BOVINE RETINA; MESSENGER-RNA; INVITRO	Visual arrestin plays an important role in regulating light responsiveness via its ability to specifically bind to the phosphorylated and light-activated form of rhodopsin. Previously, we utilized an in vitro translation system to express and characterize the full-length (404 amino acids) and two truncated forms of visual arrestin. Here we have extended these studies to include a total of 33 different truncation and deletion mutants of arrestin, ranging from 69 to 391 amino acids in length. Mutants were produced by cutting within the open reading frame of the bovine arrestin cDNA with selective restriction enzymes followed by in vitro translation of the transcribed truncated mRNAs. Mutant arrestin binding to dark, light-activated, dark phosphorylated, and light-activated phosphorylated rhodopsin as well as to opsin, phosphoopsin, and truncated rhodopsin was then extensively characterized. In addition, the sensitivity of arrestin/rhodopsin interactions to conditions of increasing ionic strength was measured. These studies suggest the localization of multiple functional domains within the arrestin molecule that include: 1) a ''phosphorylation recognition'' domain, which interacts with the phosphorylated carboxyl terminus of rhodopsin, was localized predominately between residues 158-185; 2) an ''activation recognition'' domain, which interacts with those portions of the rhodopsin molecule that change conformation upon light activation, was found to consist of at least three regions within the first 191 residues of the arrestin molecule; 3) a hydrophobic interaction domain, localized between residues 191 and 365, appears to be mobilized upon binding of arrestin to activated phosphorylated rhodopsin; 4) a regulatory domain, localized in the COOH-terminal region of arrestin (residues 365-391), was found to play a role in controlling the conformational change in arrestin necessary for mobilization of the hydrophobic interaction domain; and 5) The NH2 terminus of arrestin (residues 2-16) was found to be important for interacting with the regulatory COOH-terminal region as well as maintaining the conformation of the NH2-terminal half of arrestin. A mechanism which ensures strict arrestin binding selectivity toward phosphorylated light-activated rhodopsin is proposed.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE T, 1989, FEBS LETT, V247, P307, DOI 10.1016/0014-5793(89)81358-4; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; CHEN CY, 1993, J BIOL CHEM, V268, P7825; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GEIGER T, 1988, EUR J BIOCHEM, V175, P181, DOI 10.1111/j.1432-1033.1988.tb14181.x; GUREVICH VV, 1989, BIOL MEMBRANY, V6, P647; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN P A, 1989, Investigative Ophthalmology and Visual Science, V30, P170; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; OLATE J, 1988, J BIOL CHEM, V263, P10394; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P4201; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; POGOZHEVA ID, 1989, BIOL MEMBRANY, V6, P1248; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1988, FEBS LETT, V234, P39, DOI 10.1016/0014-5793(88)81298-5; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453; ZOZULYA SA, 1989, Patent No. 1547313	53	264	267	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11628	11638						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505295				2022-12-27	WOS:A1993LF28400030
J	DEYEBRA, L; BALLESCA, JL; VANRELL, JA; BASSAS, L; OLIVA, R				DEYEBRA, L; BALLESCA, JL; VANRELL, JA; BASSAS, L; OLIVA, R			COMPLETE SELECTIVE ABSENCE OF PROTAMINE-P2 IN HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR BASIC-PROTEINS; HUMAN-SPERM; NUCLEOTIDE-SEQUENCE; HUMAN-SPERMATOZOA; INFERTILE MEN; HISTONE HYPERACETYLATION; MOUSE; GENE; INVITRO	Male sterility due to abnormal sperm morphology or motion has been widely reported, although relatively little has been published on the sperm nuclear protein abnormalities. We report the first cases worldwide of infertile patients having a complete selective absence of protamine P2 in the sperm nucleus. This provides a selective phenotype that will aid understanding of the mechanisms of synthesis, processing, or function of the P2 protamines. In addition, it is of marked immediate relevance to medicine as it allows the diagnosis of this type of human male sterility and the opportunity to understand the basis of this defect.	UNIV BARCELONA, FAC MED, MOLEC GENET RES GRP, DIAGONAL 643, E-08028 BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, PUIGVERT FDN, E-08025 BARCELONA, SPAIN; HOSP CLIN BARCELONA, OBSTET & GYNECOL UNIT, E-08036 BARCELONA, SPAIN	University of Barcelona; Fundacio Puigvert; University of Barcelona; Hospital Clinic de Barcelona			Oliva, Rafael/C-9741-2009	Oliva, Rafael/0000-0003-4876-2410				ADROER R, 1992, NUCLEIC ACIDS RES, V20, P609, DOI 10.1093/nar/20.3.609; AIMAN J, 1979, NEW ENGL J MED, V300, P223, DOI 10.1056/NEJM197902013000503; ARKHIS A, 1991, EUR J BIOCHEM, V200, P387, DOI 10.1111/j.1432-1033.1991.tb16196.x; AUGER J, 1990, INT J ANDROL, V13, P452, DOI 10.1111/j.1365-2605.1990.tb01052.x; BACH O, 1990, ANDROLOGIA, V22, P217; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; BALHORN R, 1988, EXPERIENTIA, V44, P52, DOI 10.1007/BF01960243; BALHORN R, 1992, ARCH BIOCHEM BIOPHYS, V296, P384, DOI 10.1016/0003-9861(92)90588-N; Balhorn R., 1989, P366; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; BELLVE AR, 1988, BIOCHEMISTRY-US, V27, P2890, DOI 10.1021/bi00408a034; BELOKOPYTOVA IA, 1993, MOL REPROD DEV, V34, P53, DOI 10.1002/mrd.1080340109; BIANCHI F, 1992, BIOCHEM BIOPH RES CO, V182, P540, DOI 10.1016/0006-291X(92)91766-J; BIBBINS PE, 1992, FERTIL STERIL, V57, P402; BLANCHARD Y, 1990, ANDROLOGIA, V22, P549; BOWER PA, 1987, BIOL REPROD, V37, P479, DOI 10.1095/biolreprod37.2.479; BROWN DB, 1992, YALE J BIOL MED, V65, P29; BUNICK D, 1990, EXP CELL RES, V188, P147, DOI 10.1016/0014-4827(90)90290-Q; BUSTOSOBREGON E, 1983, ANDROLOGIA, V15, P468; CANTU JM, 1981, HUM GENET, V59, P380, DOI 10.1007/BF00295476; CHAGANTI RSK, 1980, AM J HUM GENET, V32, P833; CHAUVIERE M, 1992, EUR J BIOCHEM, V204, P759, DOI 10.1111/j.1432-1033.1992.tb16691.x; CHEVAILLIER P, 1987, LANCET, V2, P806; COLLEU D, 1988, ARCH ANDROLOGY, V21, P155, DOI 10.3109/01485018808986737; DADOUNE JP, 1988, ANDROLOGIA, V19, P433; DEBRAEKELEER M, 1991, HUM REPROD, V6, P245, DOI 10.1093/oxfordjournals.humrep.a137315; DEYEBRA L, 1993, ANAL BIOCHEM, V209, P201, DOI 10.1006/abio.1993.1104; DOMENJOUD L, 1988, NUCLEIC ACIDS RES, V16, P7733, DOI 10.1093/nar/16.15.7733; DOMENJOUD L, 1990, GENOMICS, V8, P127, DOI 10.1016/0888-7543(90)90234-L; DOMENJOUD L, 1991, ANDROLOGIA, V23, P333; ELSEVIER SM, 1991, EUR J BIOCHEM, V196, P167, DOI 10.1111/j.1432-1033.1991.tb15800.x; EVENSON DP, 1980, SCIENCE, V210, P1131, DOI 10.1126/science.7444440; FLORKEGERLOFF S, 1984, ANDROLOGIA, V16, P187; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; GUSSE M, 1986, BIOCHIM BIOPHYS ACTA, V884, P124, DOI 10.1016/0304-4165(86)90235-7; Hecht N.B., 1989, P396; HURET JL, 1986, ARCH ANDROLOGY, V16, P97, DOI 10.3109/01485018608986928; JAGER S, 1990, ARCH ANDROLOGY, V25, P253, DOI 10.3109/01485019008987614; JEGOU B, 1991, P NATL ACAD SCI USA, V88, P8710, DOI 10.1073/pnas.88.19.8710; Kasinsky H. E., 1989, HISTONES OTHER BASIC, P73; KREMLING H, 1992, BIOCHIM BIOPHYS ACTA, V1132, P133, DOI 10.1016/0167-4781(92)90003-I; LEE C, 1991, MOL REPROD DEV, V30, P154, DOI 10.1002/mrd.1080300212; LEE CH, 1987, NUCLEIC ACIDS RES, V15, P7639, DOI 10.1093/nar/15.18.7639; LESCOAT D, 1988, ARCH ANDROLOGY, V20, P35, DOI 10.3109/01485018808987050; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUERSSEN H, 1990, GENOMICS, V8, P324, DOI 10.1016/0888-7543(90)90289-7; MAIER WM, 1990, NUCLEIC ACIDS RES, V18, P1249, DOI 10.1093/nar/18.5.1249; MCKAY DJ, 1986, EUR J BIOCHEM, V156, P5, DOI 10.1111/j.1432-1033.1986.tb09540.x; MCKAY DJ, 1985, BIOSCIENCE REP, V5, P383, DOI 10.1007/BF01116555; MEYER JM, 1992, HISTOPATHOLOGY, V21, P25; MEZQUITA C, 1985, CHROMOSOMAL PROTEINS, P315; NAVARRO J, 1990, HUM REPROD, V5, P227, DOI 10.1093/oxfordjournals.humrep.a137076; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; OLIVA R, 1989, J BIOL CHEM, V264, P12472; OLIVA R, 1989, J BIOL CHEM, V264, P17627; OLIVA R, 1987, J BIOL CHEM, V262, P17016; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PASTEUR X, 1992, ANAL QUANT CYTOL, V14, P96; PAVLOU SN, 1991, J CLIN ENDOCR METAB, V73, P1360, DOI 10.1210/jcem-73-6-1360; PIRHONEN A, 1990, BIOCHIM BIOPHYS ACTA, V1039, P177, DOI 10.1016/0167-4838(90)90183-G; POCCIA D, 1986, INT REV CYTOL, V105, P1, DOI 10.1016/S0074-7696(08)61061-X; QUERALT R, 1991, NUCLEIC ACIDS RES, V19, P5786, DOI 10.1093/nar/19.20.5786; RETIEF JD, 1993, IN PRESS J MOL EVOL, V36; SAUTIERE P, 1988, J BIOL CHEM, V263, P11059; SAUTIERE P, 1984, EUR J BIOCHEM, V144, P121, DOI 10.1111/j.1432-1033.1984.tb08439.x; SCAGLIA HE, 1991, J ANDROL, V12, P273; SCHILL WB, 1991, HUM REPROD, V6, P969, DOI 10.1093/oxfordjournals.humrep.a137471; SCHLEGEL PN, 1991, FERTIL STERIL, V55, P235; SCHLUTER G, 1992, GENOMICS, V14, P377, DOI 10.1016/S0888-7543(05)80229-0; SNYDER PJ, 1990, NEW ENGL J MED, V323, P54; STANKER LH, 1992, MOL REPROD DEV, V33, P481, DOI 10.1002/mrd.1080330415; TANHAUSER SM, 1989, NUCLEIC ACIDS RES, V17, P4395, DOI 10.1093/nar/17.11.4395; TOBITA T, 1983, BIOCHIM BIOPHYS ACTA, V744, P141, DOI 10.1016/0167-4838(83)90083-3; UEDA H, 1991, ARCH HISTOL CYTOL, V54, P401, DOI 10.1679/aohc.54.401; VANBEEK MEAB, 1992, J REPROD FERTIL, V94, P327, DOI 10.1530/jrf.0.0940327; WINKFEIN R J, 1991, Journal of Cell Biology, V115, p89A	76	159	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10553	10557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486708				2022-12-27	WOS:A1993LB80000083
J	FENSTERMAKER, RA; POPTIC, E; BONFIELD, TL; KNAUSS, TC; CORSILLO, L; PISKURICH, JF; KAETZEL, CS; JENTOFT, JE; GELFAND, C; DICORLETO, PE; KAETZEL, DM				FENSTERMAKER, RA; POPTIC, E; BONFIELD, TL; KNAUSS, TC; CORSILLO, L; PISKURICH, JF; KAETZEL, CS; JENTOFT, JE; GELFAND, C; DICORLETO, PE; KAETZEL, DM			A CATIONIC REGION OF THE PLATELET-DERIVED GROWTH-FACTOR (PDGF) A-CHAIN (ARG(159)-LYS(160)-LYS(161)) IS REQUIRED FOR RECEPTOR-BINDING AND MITOGENIC ACTIVITY OF THE PDGF-AA HOMODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; BOVINE LUTEINIZING-HORMONE; HAMSTER OVARY CELLS; MESANGIAL CELLS; MESSENGER-RNAS; BETA GENES; ONC GENE; B-CHAIN; V-SIS; DIMERIZATION	Platelet-derived growth factor-AA and -BB homodimers and -AB heterodimers bind with high affinity to the platelet-derived growth factor (PDGF) alpha-receptor. Basic polypeptides such as polylysine and protamine sulfate compete with PDGF for receptor binding, suggesting a role for ligand positive charge in the binding interaction. A pentapeptide amino acid sequence with a cationic tripeptide core is perfectly conserved between the A- and B-chains (Val158-Arg159-Lys160-Lys161-Pro162) and was therefore considered as a possible alpha-receptor-binding domain. We have investigated the functional importance of positive charge within this region of the PDGF A-chain by using site-directed mutagenesis to convert the cationic core amino acids to the acidic sequence triglutamic acid. cDNAs encoding wild-type (PDGF-AA(wt) and charge mutant (PDGF-AA(cm)) proteins were expressed following stable transfection of Chinese hamster ovary cells. Proper assembly and secretion of PDGF-AA(cm) was verified by metabolic labeling with [S-35]cysteine, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis analysis under nonreducing and reducing conditions. PDGF-AA(cm) was secreted as two major species of disulfide-linked A-chain homodimers identical in molecular mass to those observed for PDGF-AA(wt) (32 and 35 kDa). Secreted PDGF-AA(wt) and PDGF-AA(cm) proteins were purified to homogeneity and subjected to structural and functional analyses. Compared to purified PDGF-AA(wt), PDGF-AA(cm) displayed a marked reduction in both binding affinity for PDGF alpha-receptors and mitogenic activity in Swiss 3T3 cells. Large reductions were also observed in the ability of semi-purified PDGF-AA(cm) to stimulate calcium influx and the production of inositol phosphates. Measurement of circular dichroism spectra of highly purified PDGF-AA(cm) and PDGF-AA(wt) revealed no significant difference in secondary structure. Collectively, these results indicate that the cationic Arg159-Lys160-Lys161 region plays a critical role in the biological activity of PDGF-AA by direct participation in ligand binding to the PDGF alpha-receptor.	DEPT VET AFFAIRS MED CTR,DIV RES,10701 E BLVD,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT NEUROSURG,CLEVELAND,OH 44106; CLEVELAND CLIN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation				Kaetzel, Charlotte/0000-0001-7546-0085				BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; DALLAFAVERA R, 1982, SCIENCE, V218, P686, DOI 10.1126/science.6291150; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ENGSTROM J, 1992, J BIOL CHEM, V267, P16581; GANZ MB, 1988, AM J PHYSIOL, V255, pF898, DOI 10.1152/ajprenal.1988.255.5.F898; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HASSID A, 1986, AM J PHYSIOL, V251, pF1018; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG JS, 1982, J BIOL CHEM, V257, P8130; JAUMANN M, 1991, BIOCHEMISTRY-US, V30, P3303, DOI 10.1021/bi00227a019; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KAETZEL DM, 1988, J BIOL CHEM, V263, P6344; KAETZEL DM, 1985, P NATL ACAD SCI USA, V82, P7280, DOI 10.1073/pnas.82.21.7280; KAETZEL DM, 1989, MOL ENDOCRINOL, V3, P1765, DOI 10.1210/mend-3-11-1765; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; NILSON JH, 1983, J BIOL CHEM, V258, P2087; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PINZANI M, 1991, AM J PHYSIOL, V260, pC485, DOI 10.1152/ajpcell.1991.260.3.C485; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1986, ACTA MED SCAND S, V715, P33; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VOGEL S, 1989, BIOCHEMISTRY-US, V28, P2961, DOI 10.1021/bi00433a033; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1986, ACTA MED SCAND S, V715, P19	47	26	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10482	10489						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486701				2022-12-27	WOS:A1993LB80000073
J	HOLMSKOV, U; TEISNER, B; WILLIS, AC; REID, KBM; JENSENIUS, JC				HOLMSKOV, U; TEISNER, B; WILLIS, AC; REID, KBM; JENSENIUS, JC			PURIFICATION AND CHARACTERIZATION OF A BOVINE SERUM LECTIN (CL-43) WITH STRUCTURAL HOMOLOGY TO CONGLUTININ AND SP-D AND CARBOHYDRATE SPECIFICITY SIMILAR TO MANNAN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT APOPROTEIN; RECOGNITION DOMAINS; CLASSICAL PATHWAY; MANNOSE; COMPLEMENT; CLQ	A previously undescribed bovine serum lectin (designated CL-43) was identified by its Ca2+-dependent binding to mannan and by its molecular mass of 43 kDa under reducing conditions on SDS-PAGE. The lectin was isolated by polyethylene glycol precipitation, affinity chromatography on mannan-Sepharose (followed by elution with EDTA), and absorption on Sepharose-4B-coupled rabbit anti-bovine Ig (to remove anti-mannan antibodies). Fractions containing the lectin were reapplied to mannan-Sepharose. Bound conglutinin was eluted with GlcNAc, and then the 43-kDa lectin, together with mannan-binding protein (MBP), was eluted with mannose. The 43-kDa lectin was separated from MBP by ion exchange chromatography on Mono-Q. On SDS-PAGE under nonreducing conditions the lectin showed a molecular mass of 120 kDa. On gel chromatography under nondissociating conditions the protein was eluted at a volume corresponding to a molecular mass of approximately 750 kDa. Amino acid analysis showed the presence of hydroxyproline and hydroxylysine and a high content of glycine (24.3%) indicating the presence of a collagen-like structure. This was supported by the susceptibility of the protein to collagenase digestion. The designation CL-43 was chosen since this molecule appears to belong to the collectins, i.e. proteins with collagen structure and lectin activity. The N-terminal sequence (27 amino acids) showed 56% identity with bovine SP-D and 44% identity to bovine conglutinin. An inhibition assay with biotinylated CL-43, using solid-phase mannan as ligand, revealed the following carbohydrate inhibition pattern: mannose and ManNAc > fucose > GlcNAc > glucose and maltose > galactose > lactose >> GalNAc. We conclude that CL-43 is a circulating lectin, with structural similarities to bovine conglutinin and SP-D, and a ligand binding profile resembling that of MBP.	STATE SERUM INST,DIV IMMUNOL,DK-2300 COPENHAGEN S,DENMARK; UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND; AARHUS UNIV,INST MED MICROBIOL,DEPT IMMUNOL,DK-8000 AARHUS,DENMARK	Statens Serum Institut; University of Oxford; Aarhus University	HOLMSKOV, U (corresponding author), UNIV ODENSE,INST MED BIOL,DEPT MED MICROBIOL,DK-5000 ODENSE C,DENMARK.		Holmskov, Uffe/AAA-3056-2022	Holmskov, Uffe/0000-0002-2391-9445				BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; Bordet J, 1909, ZENTR BAKTERIOL PARA, V49, P260; Bordet J., 1906, ANN I PASTEUR PARIS, V20, P467; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; DAVIS AE, 1984, BIOCHEMISTRY-US, V23, P2139, DOI 10.1021/bi00305a006; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Erb K, 1991, Hum Antibodies Hybridomas, V2, P215; FRIISCHRISTIANSEN P, 1990, SCAND J IMMUNOL, V31, P453, DOI 10.1111/j.1365-3083.1990.tb02792.x; HOLMSKOV U, 1993, IN PRESS GLYCOBIOLOG; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JENSENIUS JC, 1985, BIOSCIENCE REP, V5, P901, DOI 10.1007/BF01119902; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; KOZUTSUMI Y, 1980, BIOCHEM BIOPH RES CO, V95, P658, DOI 10.1016/0006-291X(80)90836-0; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LACHMANN PJ, 1968, J IMMUNOL, V100, P691; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL CB, 1965, ANAL BIOCHEM, V10, P358, DOI 10.1016/0003-2697(65)90278-2; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE YM, 1991, J BIOL CHEM, V266, P2715; LIM BL, 1993, IMMUNOLOGY, V78, P159; LOVELESS RW, 1989, BIOCHEM J, V258, P109, DOI 10.1042/bj2580109; LU J, 1990, J IMMUNOL, V144, P2287; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; MALHOTRA R, 1991, Complement and Inflammation, V8, P188; MANZKEINKE H, 1991, EUR J CELL BIOL, V57, P95; MIZOUCHI T, 1989, J BIOL CHEM, V264, P13834; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; OKA S, 1988, ARCH BIOCHEM BIOPHYS, V260, P257, DOI 10.1016/0003-9861(88)90448-1; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; STRANG CJ, 1986, BIOCHEM J, V234, P381, DOI 10.1042/bj2340381; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0	40	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10120	10125						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486682				2022-12-27	WOS:A1993LB80000029
J	RINI, JM; HARDMAN, KD; EINSPAHR, H; SUDDATH, FL; CARVER, JP				RINI, JM; HARDMAN, KD; EINSPAHR, H; SUDDATH, FL; CARVER, JP			X-RAY CRYSTAL-STRUCTURE OF A PEA LECTIN-TRIMANNOSIDE COMPLEX AT 2.6 ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING SPECIFICITY; LEAST-SQUARES REFINEMENT; CONCANAVALIN-A; METHYL 3,6-DI-O-(ALPHA-D-MANNOPYRANOSYL)-ALPHA-D-MANNOPYRANOSIDE; 6-A RESOLUTION; LENTIL-LECTINS; PISUM-SATIVUM; PROTEINS; OLIGOSACCHARIDES; SITE	The x-ray crystal structure of pea lectin, in complex with a methyl glycoside of the N-linked-type oligosaccharide trimannosyl core, methyl 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside, has been solved by molecular replacement and refined at 2.6-angstrom resolution. The R factor is 0.183 for all data in the 8.0 to 2.6 angstrom resolution range with an average atomic temperature factor of 26.1 angstrom2. Strong electron density for a single mannose residue is found in the monosaccharide-binding site suggesting that the trisaccharide binds primarily through one of the terminal alpha-linked mannose residues. The complex is stabilized by hydrogen bonds involving the protein residues Asp-81, Gly-99, Asn-125, Ala-217, and Glu-218, and the carbohydrate oxygen atoms O3, O4, O5, and O6. In addition, the carbohydrate makes van der Waals contacts with the protein, involving Phe-123 in particular. These interactions are very similar to those found in the monosaccharide complexes with concanavalin A and isolectin 1 of Lathyrus ochrus, confirming the structural relatedness of this family of proteins. Comparison of the pea lectin complex with the unliganded pea lectin and concanavalin A structures indicates differences in the conformation and water structure of the unliganded binding sites of these two proteins. Furthermore, a correlation between the position of the carbohydrate oxygen atoms in the complex and the bound water molecules in the unliganded binding sites is found. Binding of the trimannose core through a single terminal monosaccharide residue strongly argues that an additional fucose-binding site is responsible for the high affinity pea lectin-oligosaccharide interactions.	UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; UPJOHN CO, KALAMAZOO, MI 49001 USA; GEORGIA INST TECHNOL, SCH CHEM & BIOCHEM, ATLANTA, GA 30332 USA	University of Toronto; DuPont; Pfizer; University System of Georgia; Georgia Institute of Technology	RINI, JM (corresponding author), UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ONTARIO, CANADA.							AGARWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791, DOI 10.1107/S0567739478001618; ALLEN AK, 1976, BIOCHEM J, V155, P127, DOI 10.1042/bj1550127; BECKER JW, 1976, NATURE, V259, P406, DOI 10.1038/259406a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P1362, DOI 10.1021/bi00275a007; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; CARVER JP, 1985, BIOPOLYMERS, V24, P49, DOI 10.1002/bip.360240106; CARVER JP, 1989, CIBA F SYMP, V145, P6; CARVER JP, 1993, IN PRESS PURE APPL C; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6676, DOI 10.1021/bi00395a017; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DEBRAY H, 1984, FEBS LETT, V157, P257; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DEREWENDA ZS, 1981, ACTA CRYSTALLOGR A, V37, P407, DOI 10.1107/S0567739481000879; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HANSON JC, 1979, ACTA CRYSTALLOGR A, V35, P616, DOI 10.1107/S0567739479001443; HARDMAN KD, 1976, BIOCHEMISTRY-US, V15, P1120, DOI 10.1021/bi00650a026; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAIFU R, 1975, CARBOHYD RES, V40, P111, DOI 10.1016/S0008-6215(00)82673-7; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KUNDROT CE, 1987, ACTA CRYSTALLOGR B, V43, P544, DOI 10.1107/S0108768187097349; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LIENER IE, 1986, LECTINS PROPERTIES F, P33; Lis H, 1991, CURR OPIN STRUC BIOL, V1, P741, DOI 10.1016/0959-440X(91)90173-Q; MEEHAN EJ, 1982, J BIOL CHEM, V257, P13278; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAYMENT I, 1977, J APPL CRYSTALLOGR, V10, P365, DOI 10.1107/S0021889877013703; RINI JM, 1987, BIOCHEM CELL BIOL, V65, P338, DOI 10.1139/o87-043; RINI JM, 1986, J MOL BIOL, V189, P259, DOI 10.1016/0022-2836(86)90399-2; RINI JM, 1989, T AM CRYSTALLOGR ASS, V25, P51; RINI JM, 1987, THESIS U TORONTO TOR; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; STUBBS ME, 1986, J BIOL CHEM, V261, P6141; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TROWBRIDGE IS, 1974, J BIOL CHEM, V249, P6004; VANWAUWE JP, 1975, BIOCHIM BIOPHYS ACTA, V379, P456, DOI 10.1016/0005-2795(75)90152-X; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WINNIK FM, 1982, CARBOHYD RES, V103, P15, DOI 10.1016/S0008-6215(82)80004-9; YAMAMOTO K, 1982, CARBOHYD RES, V110, P283, DOI 10.1016/0008-6215(82)84010-X	56	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10126	10132						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486683				2022-12-27	WOS:A1993LB80000030
J	ROCQUE, WJ; MCWHERTER, CA; WOOD, DC; GORDON, JI				ROCQUE, WJ; MCWHERTER, CA; WOOD, DC; GORDON, JI			A COMPARATIVE-ANALYSIS OF THE KINETIC MECHANISM AND PEPTIDE SUBSTRATE-SPECIFICITY OF HUMAN AND SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA - PROTEIN N-MYRISTOYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; ESCHERICHIA-COLI; TRANSFORMING PROTEIN; CITRATE SYNTHASE; TYROSINE KINASE; FATTY-ACID; YEAST; MYRISTYLATION; TRANSFERASE; ACYLATION	Human myristoyl-CoA:protein N-myristoyltransferase (hNmt) catalyzes the transfer of myristate from CoA to the amino-terminal Gly residue of a number of cellular proteins involved in signal transduction pathways, to structural and nonstructural proteins encoded by retroviruses, hepadnaviruses, picornaviruses, and reoviruses, as well as to several transforming tyrosine kinases. hNmt has been purified 230-fold from an erythroleukemia cell line. The monomeric enzyme has no associated methionyl aminopeptidase activity. To determine the enzyme's kinetic mechanism, we examined the effect of covariation of subsaturating concentrations of myristoyl-CoA and peptide substrate on initial velocity. Double-reciprocal plots excluded a double displacement (ping-pong) mechanism. Product inhibition studies indicated that CoA was a noncompetitive inhibitor against myristoyl-CoA and a mixed-type inhibitor against peptide substrates. Together these results are consistent with a sequential ordered mechanism where, in a typical catalytic cycle, myristoyl-CoA binds to apoenzyme before peptide followed by release of the CoA and then myristoylpeptide products. This kinetic mechanism is identical to that described for Saccharomyces cerevisiae N-myristoyltransferase (Nmt1p) and emphasizes the impact that regulation of myristoyl-CoA pool size and accessibility may have in modulating protein N-myristoylation in these two species. Comparative studies of the peptide substrate specificities of hNmt and Nmt1p using a panel of 12 octapeptides revealed distinct differences in their tolerance for amino acid substitutions at positions 3, 4, 7, and 8 of parental peptides derived from the amino-terminal sequences of known N-myristoyl-proteins. This finding contrasts with our recent observation that the acyl-CoA substrate specificities of hNmt and Nmt1p are highly conserved and suggests that these differences in peptide recognition provide an opportunity to develop species-specific enzyme inhibitors.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; MONSANTO CO,MONSANTO CORP RES,ST LOUIS,MO 63198	Washington University (WUSTL); Monsanto					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27179, AI30188] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CHOW M, 1992, MYRISTOYLATION VIRAL, P59; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; DURONIO RJ, 1992, LIPID MODIFICATIONS, P21; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; JANC JW, 1992, BIOCHEMISTRY-US, V31, P6421, DOI 10.1021/bi00143a009; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PAIGE LA, 1989, J MED CHEM, V32, P1667; PERSING DH, 1987, J VIROL, V61, P1672, DOI 10.1128/JVI.61.5.1672-1677.1987; QINTRELL N, 1987, MOL CELL BIOL, V7, P2267; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1993, P NATL ACAD SCI USA, V90, P1087, DOI 10.1073/pnas.90.3.1087; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; Rudolph F B, 1979, Methods Enzymol, V63, P411; SAERMARK T, 1989, BIOCHEM SOC T, V17, P869, DOI 10.1042/bst0170869; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEGAL IH, 1975, ENZYME KINETICS BEHA, P505; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WAGNER AP, 1991, EUR J BIOCHEM, V195, P669; WANG LX, 1992, J BIOL CHEM, V267, P18983; WIEGAND G, 1986, ANNU REV BIOPHYS BIO, V15, P97; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591	61	104	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9964	9971						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486723				2022-12-27	WOS:A1993LB80000008
J	ARROYO, AG; GARCIAPARDO, A; SANCHEZMADRID, F				ARROYO, AG; GARCIAPARDO, A; SANCHEZMADRID, F			A HIGH-AFFINITY CONFORMATIONAL STATE ON VLA INTEGRIN HETERODIMERS INDUCED BY AN ANTI-BETA-1 CHAIN MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GPIIB-IIIA; FIBROBLASTIC CELLS; RECEPTOR AFFINITY; DIVALENT-CATIONS; BINDING DOMAIN; IIB-IIIA; T-CELLS; FIBRONECTIN; ADHESION; LIGAND	The VLA integrin subfamily includes receptors for extracellular matrix proteins as well as receptors involved in cell-cell adhesive interactions. We have previously described the up-regulation of VLA integrin-mediated cell attachment to different ligands by the anti-beta1 TS2/16 monoclonal antibody (mAb) (Arroyo, A. G., Sanchez-Mateos, P., Campanero, M. R., Martin-Padura, I., Dejana, E., and Sanchez-Madrid, F. (1992) J. Cell Biol. 117, 659-670). In this report, we have investigated the mechanism involved in this regulatory effect. The anti-beta1-mediated regulatory effect on cell adhesion did not require ''de novo'' protein synthesis, since it was not affected by pretreatment with either cycloheximide or actinomycin D. To quantitate the effect of the regulatory anti-beta1 TS2/16 mAb on the affinity of VLA-5 for its ligand, an RGD-containing fragment of fibronectin (FN80), we performed binding studies of radiolabeled soluble FN80 to U-937 cells. The affinity of VLA-5 for FN80 was enhanced about 4-fold in the presence of TS2/16 mAb (K(d) = 0.98 +/-0.07 muM) compared to the functionally irrelevant anti-beta1 Alex 1/4 mAb (K(d) = 4.23 +/- 0.92 muM), whereas no alteration in the number of binding sites was observed. Indeed, the anti-beta1 TS2/16 mAb is inducing this high affinity state on VLA heterodimers by a direct change on the conformation of these receptors as demonstrated by affinity chromatography analysis using extracellular matrix proteins covalently bound to Sepharose. The yield of VLA-5 fibronectin receptor bound to FN80-Sepharose columns was strongly increased upon treatment of U-937 cell lysates with mAb TS2/16. Moreover, higher concentrations of EDTA were required for eluting the VLA-5 integrin from this matrix. This up-regulatory effect was also observed with F(ab')2 and Fab fragments of the anti-beta1 TS2/16 mAb, and was also exerted on the purified VLA-5 receptor. Similarly, the yield of VLA-2 retained on a collagen I-Sepharose column was dramatically increased by pretreatment of A375 melanoma cell lysates with the mAb TS2/16. Altogether, these results indicate that the interaction of VLA beta1 heterodimers with their ligands can be regulated by switching between differently active conformations inherent to the alphabeta1 receptors.	UNIV AUTONOMA MADRID,HOSP PRINCESA,SECC IMMUNOL,C DIEGO LEON 62,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,MADRID 6,SPAIN	Autonomous University of Madrid; Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Arroyo, Alicia G./L-2796-2014; Garcia Pardo, Angeles/G-5987-2015; Sanchez-Madrid, Francisco/M-7889-2016	Arroyo, Alicia G./0000-0002-1536-3846; Garcia Pardo, Angeles/0000-0001-5577-2954; Sanchez-Madrid, Francisco/0000-0001-5303-0762				AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANCHEZMADRID F, 1992, SEMIN CELL BIOL, V3, P119; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	38	110	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9863	9868						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486666				2022-12-27	WOS:A1993LA68900101
J	BIRD, GSJ; ROSSIER, MF; OBIE, JF; PUTNEY, JW				BIRD, GSJ; ROSSIER, MF; OBIE, JF; PUTNEY, JW			SINUSOIDAL OSCILLATIONS IN INTRACELLULAR CALCIUM REQUIRING NEGATIVE FEEDBACK BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC ACINAR-CELLS; INOSITOL TRISPHOSPHATE; CYTOSOLIC CALCIUM; LACRIMAL CELLS; PHORBOL-ESTER; HORMONE; ACETYLCHOLINE; STIMULATION; HEPATOCYTES; TRANSIENT	Stimulation of mouse lacrimal acinar cells with submaximal concentrations of the muscarinic agonist, methacholine, resulted in an increase in intracellular calcium ([Ca2+]i), which took the form of sinusoidal oscillations. These oscillations were relatively constant (approximately 4-5/min) regardless of the methacholine concentration, suggesting that the oscillations arise from an oscillating negative feedback in the signal transduction pathway. This negative feedback appears to involve oscillations in protein kinase C activity because the oscillations were prevented by activation, inhibition, or down-regulation of protein C. Activation of protein kinase C with phorbol esters inhibited the methacholine-induced [Ca2+]i signal and formation of the Ca2+ mobilizing messenger, inositol 1,4,5-trisphosphate. [Ca2+]i signals elicited by intracellular introduction of inositol phosphates did not oscillate and were not affected by activators or inhibitors of protein kinase C. Thus, the constant frequency [Ca2+]i oscillations appear to result from a negative feedback loop involving inhibition of inositol trisphosphate production by protein kinase C.			BIRD, GSJ (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021; Rossier, Michel/AAW-2895-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748; 				BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; COOPER RH, 1985, J BIOL CHEM, V260, P3281; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P61, DOI 10.1016/0143-4160(91)90008-3; DRUMMOND AH, 1985, NATURE, V315, P752, DOI 10.1038/315752a0; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELPER JR, 1988, J BIOL CHEM, V263, P7610; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLANO I, 1987, J PHYSIOL-LONDON, V394, P239, DOI 10.1113/jphysiol.1987.sp016868; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; TAN YP, 1991, J PHYSIOL-LONDON, V433, P357, DOI 10.1113/jphysiol.1991.sp018430; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	32	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8425	8428						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473285				2022-12-27	WOS:A1993KX81100012
J	TAKAHASHI, Y; CAMPBELL, EA; HIRATA, Y; TAKAYAMA, T; LISTOWSKY, I				TAKAHASHI, Y; CAMPBELL, EA; HIRATA, Y; TAKAYAMA, T; LISTOWSKY, I			A BASIS FOR DIFFERENTIATING AMONG THE MULTIPLE HUMAN MU-GLUTATHIONE S-TRANSFERASES AND MOLECULAR-CLONING OF BRAIN GSTM5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-STILBENE OXIDE; LUNG-CANCER; RAT-BRAIN; GENE DELETION; EXPRESSION; SUSCEPTIBILITY; ISOENZYMES; MARKER; LIVER; IDENTIFICATION	Specific cDNA probes and antisera were employed to interpret genetic polymorphisms of human Mu-class glutathione S-transferases and to provide a basis for identifying individual forms in human tissues. A cDNA probe that cross-hybridized with various human and rodent Mu-glutathione S-transferase transcripts, hybridized with at least three discrete components by Northern analysis of RNA from human tissue. The smallest (1.3 kb) transcript was identified as the one that encodes GSTM3-3 subunits. A form designated GSTM5, was cloned from a human brain cDNA library and its sequence determined. The open reading frame of GSTM5 shared a high degree of homology with the sequences of other Mu-class glutathione S-transferases, but its 846-nucleotide 3'-noncoding region was unique and considerably larger than that of any of the other Mu forms. Specific synthetic peptide antigens were utilized to distinguish among Mu-class glutathione S-transferases in different tissues of representative individuals. The primary hepatic transcript was that encoding GSTM1-1 with much lesser amounts of GSTM3-3, but livers were devoid of GSTM2-2, and GSTM5-5. Immunoblots confirmed that null-phenotype individuals lacked the GSTM1 gene rather than its GSTM2 homologue that is nearly identical in its exon sequences. The null phenotype therefore was conspicuous in liver, where GSTM1-1 ordinarily was the predominant Mu transcript, but brain and testis contained all four forms. A general strategy was devised to distinguish among and assign primary structures to individual glutathione S-transferases from human tissue.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM07128] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ M, 1988, J BIOL CHEM, V263, P17627; ABRAMOVITZ M, 1987, J BIOL CHEM, V262, P7770; ABRAMOVITZ M, 1989, HEPATOLOGY, V9, P235, DOI 10.1002/hep.1840090212; BOARD PG, 1981, FEBS LETT, V135, P12, DOI 10.1016/0014-5793(81)80933-7; BROCKMOLLER J, 1992, BIOCHEM PHARMACOL, V43, P647, DOI 10.1016/0006-2952(92)90591-6; CAMMER W, 1989, J NEUROCHEM, V52, P876, DOI 10.1111/j.1471-4159.1989.tb02536.x; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; CARMICHAEL J, 1988, CARCINOGENESIS, V9, P1617, DOI 10.1093/carcin/9.9.1617; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541; DEJONG JL, 1991, BIOCHEM BIOPH RES CO, V180, P15, DOI 10.1016/S0006-291X(05)81248-3; Erickson B. W., 1976, PROTEINS, VII, P255; GUPTA S, 1990, CLIN CHEM ENZYM COMM, V3, P115; HECKBERT SR, 1992, J NATL CANCER I, V84, P414, DOI 10.1093/jnci/84.6.414; HUSSEY AJ, 1991, BIOCHEM J, V273, P323, DOI 10.1042/bj2730323; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; JENSSON H, 1985, METHOD ENZYMOL, V113, P504; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; Listowsky Irving, 1993, P397; LIU YH, 1991, CARCINOGENESIS, V12, P2269, DOI 10.1093/carcin/12.12.2269; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; ROOTS I, 1992, CLIN INVESTIGATOR, V70, P307; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDEGARD J, 1985, HUM GENET, V69, P66, DOI 10.1007/BF00295531; SEIDEGARD J, 1986, CARCINOGENESIS, V7, P751, DOI 10.1093/carcin/7.5.751; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33; SEIDEGARD J, 1988, CARCINOGENESIS, V9, P1211; STRANGE RC, 1991, CARCINOGENESIS, V12, P25, DOI 10.1093/carcin/12.1.25; STROHMEYER T, 1992, J UROLOGY, V147, P1424, DOI 10.1016/S0022-5347(17)37586-9; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; SUZUKI T, 1991, BIOCHEM J, V274, P405, DOI 10.1042/bj2740405; TAYLOR JB, 1991, BIOCHEM J, V274, P87; THEODORE C, 1985, BIOCHEM J, V225, P375, DOI 10.1042/bj2250375; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TSUCHIDA S, 1990, J BIOL CHEM, V265, P7150; VANPOPPEL G, 1992, CARCINOGENESIS, V13, P303, DOI 10.1093/carcin/13.2.303; VORACHEK WR, 1991, P NATL ACAD SCI USA, V88, P4443, DOI 10.1073/pnas.88.10.4443; WIENCKE JK, 1990, CANCER RES, V50, P1585; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533	45	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8893	8898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473333				2022-12-27	WOS:A1993KX81100076
J	BERNARDO, MM; DAY, DE; OLSON, ST; SHORE, JD				BERNARDO, MM; DAY, DE; OLSON, ST; SHORE, JD			SURFACE-INDEPENDENT ACCELERATION OF FACTOR-XII ACTIVATION BY ZINC IONS .1. KINETIC CHARACTERIZATION OF THE METAL-ION RATE ENHANCEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; ATOMIC-ABSORPTION SPECTROPHOTOMETRY; PROTEIN-PROTEIN INTERACTIONS; WASHED HUMAN-PLATELETS; COAGULATION FACTOR-XII; HIGH-MR KININOGEN; BLOOD-COAGULATION; CONTACT ACTIVATION; ENDOTHELIAL-CELLS; HAGEMAN-FACTOR	The effect of zinc ions (Zn(II)) on the activation of factor XII in the absence of a procoagulant surface was investigated by initial velocity kinetic studies at I = 0.15, pH 7.4, and 25-degrees-C. Zinc ions at concentrations greater than 160 muM potentiated 99-fold the k(cat)/K(M) for the activation of factor XII by kallikrein and, at an optimum concentration of 110 muM, accelerated 140-fold the apparent k(cat)/K(M) for factor XII autoactivation. High molecular weight kininogen had no effect on either metal-potentiated reaction. Analysis of the factor XII concentration dependence of initial activation rates revealed that Zn(II), at levels that saturate the effect, accelerates kallikrein activation of factor XII by lowering Km (from 52 to 7.3 muM) and raising k(cat) (from 2.6 to 31 min-1). For the autocatalytic activation reaction of factor XII in the presence of optimal Zn(II), apparent K(M) and k(cat) values of 2.4 muM and 0.041 min-1, respectively, were determined, but these parameters were not resolvable in the absence of the metal ion. Zinc ions minimally affected kallikrein enzymatic activity and inhibited factor XIIa enzymatic activity with K(I) values of 20-40 muM, suggesting that the rate-enhancing effects of the metal ion are due to interactions with the substrate (factor XII) rather than with the enzyme. The Zn(II) inhibition of factor XIIa enzymatic activity accounted for a decreased Zn(II) enhancement of factor XII autoactivation at high metal ion concentrations (> 110 muM). The Zn(II) concentration dependence of the acceleration of factor XII activation reactions were sigmoid and characterized by Hill coefficients of 3.3-4.3, suggesting that cooperative binding of at least four zinc ions to factor XII was responsible for the Zn(II) potentiating effect. The Zn(II) enhancement of the rates of factor XII activation decreased both above and below pH 7.4 with midpoint pH values of 6.5-7.0 and 8.0, consistent with histidine and possibly water ligands mediating Zn(II) binding to the protein. Despite an apparent weaker binding of Zn(II) to factor XII at pH 6.5, indistinguishable maximum accelerating effects of the metal ion were observed at saturation at this pH, indicating that the increased positive charge of factor XII resulting from protonation at the lower pH did not mimic the effect of Zn(II) binding. These results imply that zinc ions induce a conformational change in factor XII that makes it a better substrate for its enzyme activators.	HENRY FORD HOSP,DIV BIOCHEM RES,EDUC & RES BLDG,RM 3126,2799 W GRAND BLVD,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; BERINI L, 1983, COORDINATION CHEM ME, P1; BERNARDO MM, 1993, J BIOL CHEM, V268, P12477; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOCK PE, 1983, J BIOL CHEM, V258, P5079; BOCK PE, 1985, J BIOL CHEM, V260, P2434; BOCK PE, 1981, BIOCHEMISTRY-US, V20, P7258, DOI 10.1021/bi00528a032; BOUMA BN, 1986, NEW COMPREHENSIVE BI, V13, P103; CHAMBERS JL, 1974, BIOCHEM BIOPH RES CO, V59, P70, DOI 10.1016/S0006-291X(74)80175-0; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FLASCHKA HA, 1959, EDTA TITRATIONS, P63; FOLEY B, 1968, P SOC EXP BIOL MED, V128, P266; GORDON PR, 1982, AM J CLIN NUTR, V35, P113, DOI 10.1093/ajcn/35.1.113; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HEIMARK RL, 1981, METHOD ENZYMOL, V80, P157; HEYNS AD, 1985, BLOOD, V66, P213; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KAPLAN AP, 1987, BLOOD, V70, P1; KIEM J, 1979, CLIN CHEM, V25, P705; KOZIN F, 1988, INFLAMMATION BASIC P, P101; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; NEMERSON Y, 1988, BLOOD, V71, P1; NUJENS JH, 1989, J BIOL CHEM, V264, P12941; PRASAD AS, 1970, J LAB CLIN MED, V76, P416; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHOUSBOE I, 1990, EUR J BIOCHEM, V193, P495, DOI 10.1111/j.1432-1033.1990.tb19364.x; SCHOUSBOE I, 1991, EUR J BIOCHEM, V197, P309, DOI 10.1111/j.1432-1033.1991.tb15912.x; Segel I., 1975, ENZYME KINETICS, P371; SHIMADA T, 1987, J BIOCHEM-TOKYO, V102, P913, DOI 10.1093/oxfordjournals.jbchem.a122132; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SHORE JD, 1989, THROMB HAEMOSTASIS, V62, P15; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; TANS G, 1983, J BIOL CHEM, V258, P8215; TANS G, 1986, NEW COMPREHENSIVE BI, V13, P59; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; VALLEE BL, 1983, ZINC ENZYMES, P3; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WARD NI, 1979, ANAL CHIM ACTA, V105, P185, DOI 10.1016/S0003-2670(01)83750-8; WHITEHOUSE RC, 1983, CLIN CHEM, V29, P1974; WHITEHOUSE RC, 1982, CLIN CHEM, V28, P475; WOO J, 1984, CLIN DIAGNOSIS MANAG, P161	51	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12468	12476						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509386				2022-12-27	WOS:A1993LG65800038
J	HU, RQ; GAN, YX; LIU, JL; MILLER, D; ZOON, KC				HU, RQ; GAN, YX; LIU, JL; MILLER, D; ZOON, KC			EVIDENCE FOR MULTIPLE BINDING-SITES FOR SEVERAL COMPONENTS OF HUMAN LYMPHOBLASTOID INTERFERON-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-125-LABELED MOUSE INTERFERON; CELL-SURFACE RECEPTOR; HIGH-AFFINITY BINDING; COMMON RECEPTORS; GAMMA; EXPRESSION; BETA	The antiproliferative and competitive binding activities of 20 purified components of human lymphoblastoid interferon (IFN)-alpha were compared with that of recombinant human IFN-alpha2b on Daudi and AU937 cells. We observed broad ranges of antiproliferative activities of the IFN-alpha components on these cell lines. Daudi cells were more sensitive to the IFN-alpha components than AU937 cells; the concentrations of the components that resulted in 50% inhibition of cell growth ranged from 0.003 ng/ml to >10 ng/ml on Daudi cells and 0.05 ng/ml to >200 ng/ml on AU937 cells. Component o was the most active human IFN-alpha on both cell lines. Scatchard analysis demonstrated that the number of IFN-alpha2b binding sites is greater on Daudi cells (12,700 binding sites/cell) than AU937 cells (3,300 binding sites/cell); however, their receptor affinities were similar. Component o, which exhibited high antiproliferative activity on both cell lines, had low affinity for the IFN-alpha2b binding site on AU937 and Daudi cells. Several human IFN-alphas (components b', b'', and e) appeared to have high affinity binding sites but low antiproliferative activity on both Daudi and AU937 cells. These data suggest that there may be more than one binding site or receptor for human IFN-alpha, and/or there may be a multicomponent receptor involved in the biological actions of these molecules.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29,RM 130,8800 ROCKVILLE PIKE,BETHESDA,MD 20892; NICHHD,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Uniformed Services University of the Health Sciences - USA								AGUET M, 1980, NATURE, V284, P459, DOI 10.1038/284459a0; Aguet M, 1983, Interferon, V5, P1; AGUET M, 1984, VIROLOGY, V132, P211, DOI 10.1016/0042-6822(84)90105-3; AGUET M, 1981, VIROLOGY, V115, P249, DOI 10.1016/0042-6822(81)90108-2; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AGUET M, 1988, J INTERFERON RES, V9, pS15; ANDERSON P, 1982, J BIOL CHEM, V257, P1301; BELL DM, 1983, NATURE, V305, P319, DOI 10.1038/305319a0; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FRIEDMAN RM, 1967, SCIENCE, V156, P1760, DOI 10.1126/science.156.3783.1760; GROSSBERG SE, 1987, MECHANISMS INTERFERO, V2, P1; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; MCINNES B, 1989, J INTERFERON RES, V9, P305, DOI 10.1089/jir.1989.9.305; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MILLER D M, 1990, Journal of Interferon Research, V10, pS6; MOGENSEN KE, 1981, INT J CANCER, V28, P575, DOI 10.1002/ijc.2910280508; MUNSON PJ, 1987, USERS GUIDE LIGAND, P5; ORCHANSKY P, 1984, J INTERFERON RES, V4, P275, DOI 10.1089/jir.1984.4.275; SARKAR FH, 1984, P NATL ACAD SCI-BIOL, V81, P5160, DOI 10.1073/pnas.81.16.5160; SIEMERS R, 1988, J IMMUNOL, V141, P1550; STREULI M, 1980, SCIENCE, V209, P1343, DOI 10.1126/science.6158094; THOMPSON MR, 1985, J BIOL CHEM, V260, P563; TYMMS MJ, 1990, GENET ANAL-BIOMOL E, V7, P53, DOI 10.1016/0735-0651(90)90041-D; YONEHARA S, 1983, J BIOL CHEM, V258, P9046; YONEHARA S, 1983, J VIROL, V95, P1168; ZOON K, 1982, J BIOL CHEM, V257, P4695; ZOON KC, 1984, PHARMACOL THERAPEUT, V24, P259, DOI 10.1016/0163-7258(84)90037-8; ZOON KC, 1992, J BIOL CHEM, V267, P15210; ZOON KC, 1985, BIOL INTERFERON SYST, P55; ZOON KC, 1987, INTERFERON SYSTEM, P221; ZOON KC, 1984, BIOL INTERFERON SYST, P61	33	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12591	12595						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509399				2022-12-27	WOS:A1993LG65800055
J	SANTAMBROGIO, P; LEVI, S; COZZI, A; ROVIDA, E; ALBERTINI, A; AROSIO, P				SANTAMBROGIO, P; LEVI, S; COZZI, A; ROVIDA, E; ALBERTINI, A; AROSIO, P			PRODUCTION AND CHARACTERIZATION OF RECOMBINANT HETEROPOLYMERS OF HUMAN FERRITIN H-CHAIN AND L-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN; HUMAN-LIVER; APOFERRITIN; CELLS; ISOFERRITINS; MECHANISM; HETEROGENEITY; EXPRESSION; SITE	Vertebrate ferritins are iron storage proteins composed by 24 subunits of one or more types. The recombinant homopolymers of human ferritin H- and L-type chains differ in iron uptake and in physical stability, but the properties of heteropolymers with various proportions of H- and L-type chains cannot be predicted. Present study shows that unfolded human ferritin Hand L- type chains renature under similar conditions to form homopolymers indistinguishable from the native ones and that, when mixed, the unfolded H and L chains renature to form heteropolymers with restricted heterogeneity and with the expected H:L ratios. Seven of these ferritins with different H:L ratios were analyzed; electrophoretic mobility, immunological reactivity, and stability to guanidine denaturation varied as predicted, based on the homopolymers. In contrast, the rate of iron uptake, monitored by the variation of absorbance at 310 nm, increased in the ferritins that ranged in H chain content from 0 to 35%; further increments in H chains had no additional effect. This finding indicates that, under the present conditions, only a limited number of H chains are needed for the maximum rate of ferritin iron uptake. Variations of L- and H-type chains in vivo may thus have biological relevance.	UNIV MILAN, DEPT BIOMED SCI & TECHNOL, I-20132 MILAN, ITALY; CNR, IST TECHNOL BIOMED AVANZATI, I-20131 MILAN, ITALY; UNIV BRESCIA, INST CHEM, I-25124 BRESCIA, ITALY; UNIV MILAN, SCI INST SAN RAFFAELE, DEPT BIOL & TECHNOL RES, I-20132 MILAN, ITALY	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Brescia; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			arosio, paolo/E-6817-2010; Cozzi, Anna/AAN-3821-2020; levi, sonia/A-3161-2015; Santambrogio, Paolo/AAN-3837-2020	levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; arosio, paolo/0000-0002-5343-8992; albertini, alberto/0000-0002-7989-649X				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; AROSIO P, 1978, J BIOL CHEM, V253, P4451; AROSIO P, 1976, CANCER RES, V36, P1735; AROSIO P, 1989, IRON IMMUNITY CANCER, P55; BOYD D, 1985, J BIOL CHEM, V260, P1755; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; CAZZOLA M, 1983, BLOOD, V62, P1078; COZZI A, 1989, CLIN CHIM ACTA, V184, P197, DOI 10.1016/0009-8981(89)90052-1; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GERL M, 1987, EUR BIOPHYS J BIOPHY, V15, P103, DOI 10.1007/BF00257503; GERL M, 1988, BIOCHEMISTRY-US, V27, P4089, DOI 10.1021/bi00411a027; GERL M, 1987, BIOL CHEM H-S, V368, P387, DOI 10.1515/bchm3.1987.368.1.387; HARRISON PM, 1968, NATURE, V220, P578, DOI 10.1038/220578a0; HARRISON PM, 1987, BIOCHEM SOC T, V15, P744, DOI 10.1042/bst0150744; HARRISON PM, 1991, ADV INORG CHEM, V36, P449; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LAWSON DM, 1990, THESIS U SHEFFIELD S; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1987, GENE, V51, P269, DOI 10.1016/0378-1119(87)90315-5; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LIAU G, 1991, J BIOL CHEM, V266, P18819; LUZZAGO A, 1986, BIOCHIM BIOPHYS ACTA, V872, P61, DOI 10.1016/0167-4838(86)90147-0; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; OTSUKA S, 1981, BIOCHEMISTRY-US, V20, P5226, DOI 10.1021/bi00521a020; RUGGERI G, 1984, FERRITINS ISOFERRITI, P67; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; STEFANINI S, 1987, BIOCHEMISTRY-US, V26, P1831, DOI 10.1021/bi00381a007; STEFANINI S, 1982, BIOCHEMISTRY-US, V21, P2293, DOI 10.1021/bi00539a004; TESTA U, 1991, J BIOL CHEM, V266, P13925; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; VEZZONI P, 1986, BRIT J HAEMATOL, V62, P105, DOI 10.1111/j.1365-2141.1986.tb02905.x; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; YABLONSKI MJ, 1992, BIOCHEMISTRY-US, V31, P9680, DOI 10.1021/bi00155a022	37	156	162	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12744	12748						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509409				2022-12-27	WOS:A1993LG65800077
J	SCHUMACHER, MA; MACDONALD, JR; BJORKMAN, J; MOWBRAY, SL; BRENNAN, RG				SCHUMACHER, MA; MACDONALD, JR; BJORKMAN, J; MOWBRAY, SL; BRENNAN, RG			STRUCTURAL-ANALYSIS OF THE PURINE REPRESSOR, AN ESCHERICHIA-COLI DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC REPRESSOR; OPERATOR DNA; NUCLEOTIDE-SEQUENCE; GENE; MUTANT; FOLD; GALR; CYTR	The purine repressor protein, PurR, is a member the lac repressor, LacI, family of Escherichia coli DNA-binding proteins that bind DNA via a highly conserved N-terminal helix-turn-helix motif. Additionally, the members of this family display strong sequence homologies between their larger C-terminal effector binding/oligomerization domains. Analysis of the PurR primary and secondary structures reveals that its C-terminal corepressor binding domain is highly homologous to another group of E. coli-binding proteins, the periplasmic binding proteins, particularly to the ribose-binding protein (RBP). The high resolution x-ray structure of RBP allows this protein to serve as a template with which to model the predicted secondary structure of the corepressor binding domain of PurR. Similarly, the N-terminal DNA binding domain of PurR can be modeled using the NMR-determined structure of the corresponding region (residues 1-56) from LacI as a template. Combining the two, results in a description of the likely secondary structure topology of PurR and implicates residues important for corepressor binding and dimerization. CD spectroscopic studies on PurR, its corepressor binding domain and RBP result in secondary structure estimates nearly identical with those obtained by sequence analyses, thereby providing further corroborating physical evidence for this topological assignment.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOLEC BIOL, S-75224 UPPSALA, SWEDEN	Oregon Health & Science University; Swedish University of Agricultural Sciences			Mowbray, Sherry L/D-2141-2013	Brennan, Richard/0000-0001-7647-485X				ASLANIDIS C, 1990, J BACTERIOL, V172, P2178, DOI 10.1128/jb.172.4.2178-2180.1990; BARBIER CS, 1992, J BACTERIOL, V174, P2881, DOI 10.1128/JB.174.9.2881-2890.1992; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENNAN RG, 1986, CHEM SCRIPTA, V26B, P251; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; FENG DF, 1990, METHOD ENZYMOL, V183, P375; HENKIN TM, 1991, MOL MICROBIOL, V5, P575, DOI 10.1111/j.1365-2958.1991.tb00728.x; JAHREIS K, 1991, MOL GEN GENET, V226, P332, DOI 10.1007/BF00273623; JOHNSON CW, 1990, PROTEIN-STRUCT FUNCT, V7, P205; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MAUZY CA, 1992, PROTEIN SCI, V1, P831, DOI 10.1002/pro.5560010701; Mowbray S L, 1990, Receptor, V1, P41; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; OHLENDORF DH, 1983, J MOL EVOL, V19, P109, DOI 10.1007/BF02300748; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; REIDL J, 1989, J BACTERIOL, V171, P4888, DOI 10.1128/jb.171.9.4888-4899.1989; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; ROLFES RJ, 1990, J BACTERIOL, V172, P5758, DOI 10.1128/jb.172.10.5758-5766.1990; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SCHUMACHER MA, 1992, J MOL BIOL, V225, P1131, DOI 10.1016/0022-2836(92)90111-V; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEITZ TA, 1980, BIOMOL STRUCT CONFOR, V1, P425; STOKES HW, 1985, MOL BIOL EVOL, V2, P478; VALENTINHANSEN P, 1986, NUCLEIC ACIDS RES, V14, P2215, DOI 10.1093/nar/14.5.2215; VARTAK NB, 1991, RES MICROBIOL, V142, P951, DOI 10.1016/0923-2508(91)90005-U; VONWILCKENBERGM.B, 1982, P NATL ACAD SCI USA, V79, P2429; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3852, DOI 10.1021/bi00361a017; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	46	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12282	12288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509365				2022-12-27	WOS:A1993LG65800012
J	STUDWELLVAUGHAN, PS; ODONNELL, M				STUDWELLVAUGHAN, PS; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .5. THETA ENCODED BY HOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOLOENZYME; PURIFICATION; SUBUNIT; IDENTIFICATION; REPLICATION	The polIII core subassembly of DNA polymerase III holoenzyme is composed of the alpha (DNA polymerase), epsilon (editing exonuclease), and theta subunits. We have identified holE encoding theta (8.6 kDa) at 40.4 min, expressed and purified 300 mg of theta, and have studied its function by constituting the polIII core from pure alpha, epsilon, and theta subunits. The theta subunit binds the epsilon proofreader tightly, but it does not form a detectable complex with alpha. The epsilon subunit also binds to alpha (Maki, H., and Kornberg, A. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 4389-4392). Hence, the subunit arrangement of the polIII core is linear, alphaepsilontheta. Interaction of theta with epsilon slightly stimulated epsilon in excision of a 3' terminal mismatched nucleotide, suggesting a possible role for theta in fidelity.	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUTLAG D, 1969, BIOCHEM BIOPH RES CO, V37, P982, DOI 10.1016/0006-291X(69)90228-9; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG ZM, 1993, J BIOL CHEM, V268, P11758; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG A, 1991, DNA REPLICATION, P176; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1983, P NATL ACAD SCI-BIOL, V80, P7137, DOI 10.1073/pnas.80.23.7137; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI H, 1987, UCLA S MOL CELL BIOL, V127, P63; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ROWEN L, 1979, J BIOL CHEM, V253, P758; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH M, 1989, HDB BIOCH, pC1; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; WICKNER W, 1974, J BIOL CHEM, V249, P6244	29	85	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11785	11791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505306				2022-12-27	WOS:A1993LF28400050
J	CHAKRAVARTI, D; MAITRA, U				CHAKRAVARTI, D; MAITRA, U			EUKARYOTIC TRANSLATION INITIATION FACTOR-5 FROM SACCHAROMYCES-CEREVISIAE - CLONING, CHARACTERIZATION, AND EXPRESSION OF THE GENE ENCODING THE 45,346-DA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTES; TRANSFER-RNA; BINDING PROTEIN; ANTIBODY PROBES; FACTOR-II; YEAST; PURIFICATION; MITOCHONDRIAL; SEQUENCE; FORMS	Eukaryotic translation initiation factor 5 (eIF-5) catalyzes hydrolysis of GTP bound to a 40 S ribosomal initiation complex with the subsequent joining of a 60 S ribosomal subunit to form an 80 S initiation complex. The yeast gene that encodes eIF-5, designated TIF5, has been isolated and expressed in Escherichia coli to yield a catalytically active eIF-5 protein. TIF5 is a single-copy gene that maps on yeast chromosome XVI and is essential for cell viability. The gene contains an intron-free open reading frame that encodes a protein of calculated M(r) 45,346 in close agreement with the apparent molecular weight of eIF-5 isolated from yeast cells. Sequence analysis of the gene reveals several interesting features. First, the presence of two in-frame translational start sites located 51 base pairs apart suggests the possibility that two proteins, differing by an amino-terminal extension of 17 amino acids, could be generated from the TIF5 gene via differential translational starts. This would explain the presence, in yeast cell lysates, of two forms of eIF-5 differing in molecular weight by about 2,000. Second, the predicted amino acid sequence of eIF-5 contains sequence motifs characteristic of proteins of the GTPase super-family.			CHAKRAVARTI, D (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV BIOL, DEPT DEV BIOL & CANC, BRONX, NY 10461 USA.			Chakravarti, Debabrata/0000-0001-8446-8599	NCI NIH HHS [P30 CA13330] Funding Source: Medline; NIGMS NIH HHS [GM 15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BENNE R, 1978, J BIOL CHEM, V253, P3070; BLUM S, 1989, P NATL ACAD SCI USA, V86, P6043, DOI 10.1073/pnas.86.16.6043; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CIGAN AM, 1987, GENE, V59, P1; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; ELLIS SR, 1987, P NATL ACAD SCI USA, V84, P5172, DOI 10.1073/pnas.84.15.5172; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; GERRING SL, 1991, METHOD ENZYMOL, V194, P57; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, V1, P627; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KOZAK M, 1983, MICROBIOL REV, V47, P1; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LEWIN B, 1990, GENES, V4, P113; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MERRICK WC, 1975, J BIOL CHEM, V250, P5556; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEYER LJ, 1981, J BIOL CHEM, V256, P351; MILNER RJ, 1984, P NATL ACAD SCI-BIOL, V81, P713, DOI 10.1073/pnas.81.3.713; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SHERMAN F, 1986, LABORATORY COURSE MA; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; [No title captured]	49	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10524	10533						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486705				2022-12-27	WOS:A1993LB80000079
J	GALLWITZ, WE; MUNDY, GR; LEE, CH; QIAO, M; ROODMAN, GD; RAFTERY, M; GASKELL, SJ; BONEWALD, LF				GALLWITZ, WE; MUNDY, GR; LEE, CH; QIAO, M; ROODMAN, GD; RAFTERY, M; GASKELL, SJ; BONEWALD, LF			5-LIPOXYGENASE METABOLITES OF ARACHIDONIC-ACID STIMULATE ISOLATED OSTEOCLASTS TO RESORB CALCIFIED MATRICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; BONE-RESORPTION; LEUKOTRIENE SYNTHESIS; LIPOXYGENASE; RELEASE; INVITRO; CYCLOOXYGENASE; EXPRESSION; RECEPTOR; ANTIGENS	Bone resorption requires cooperation between osteoclasts and mononuclear accessory cells by mechanisms which have not been elucidated. Since multinucleated cells in giant cell tumors of bone have many phenotypic and functional characteristics of normal osteoclasts, we have examined the interaction between the bone-resorbing multinucleated cells and the distinct mono-nuclear stromal cells from these tumors. We have found that these mononuclear cells produce an activity which stimulates both giant cells from giant cell tumors and rodent osteoclasts to resorb bone in vitro. We have identified the activity and found that it represents several products of the 5-lipoxygenase pathway of arachidonic acid metabolism, namely 5-hydroxyeicosatetraenoic acid and the leukotrienes. These data indicate that 5-lipoxygenase metabolites stimulate isolated osteoclasts to resorb bone in vitro and may represent a mechanism by which mononuclear stromal cells in human giant cell tumors communicate with the giant cells. In addition, these results may explain a possible mechanism for communication between accessory cells and osteoclasts involved in normal bone resorption.	UNIV TEXAS, HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL & METAB, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine			Bonewald, Lynda/Q-3638-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039529] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39529] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATHANASOU NA, 1989, BRIT J CANCER, V59, P491, DOI 10.1038/bjc.1989.102; BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; BAND L, 1985, J CLIN INVEST, V76, P374; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; CHAMBERS TJ, 1983, CALCIFIED TISSUE INT, V35, P566, DOI 10.1007/BF02405095; CHAMBERS TJ, 1987, J CELL PHYSIOL, V132, P90, DOI 10.1002/jcp.1041320112; COLLINOSDOBY P, 1991, J BONE MINER RES, V6, P1353; COLLINS JL, 1989, J DENT RES, V109, P1817; COLLINS JL, 1987, J DENT RES, V66, P1771; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; ELATTAR TMA, 1983, J ORAL PATHOL MED, V12, P7; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOLDMAN DW, 1986, J IMMUNOL, V136, P4631; GOLDRING SR, 1986, CLIN ORTHOP RELAT R, P59; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HORTON MA, 1985, CANCER RES, V45, P5663; HUANG FC, 1990, J MED CHEM, V33, P1194, DOI 10.1021/jm00166a017; HUANG FC, 1989, J MED CHEM, V32, P1836, DOI 10.1021/jm00128a027; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; KHANDWALA A, 1987, BIOCHEM PHARMACOL, V36, P663, DOI 10.1016/0006-2952(87)90717-9; KOMIYA S, 1990, CLIN ORTHOP RELAT R, P304; LING L, 1988, ARCH PATHOL LAB MED, V112, P65; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1982, MOL CLONING LABORATO; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MCSHEEHY PM, 1987, J IMMUNOL, V138, P775; MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo-119-4-1654; MEGHJI S, 1988, PROSTAG OTH LIPID M, V36, P139, DOI 10.1016/0090-6980(88)90301-2; MOHAMMED AH, 1989, AM J ORTHOD DENTOFAC, V95, P231, DOI 10.1016/0889-5406(89)90053-X; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; OREFFO ROC, 1990, ENDOCRINOLOGY, V126, P3069, DOI 10.1210/endo-126-6-3069; OREFFO ROC, 1993, IN PRESS CLIN ORTHOP; OURSLER MJ, 1991, J BONE MINER RES, V6, P375; PARKER CW, 1987, ANNU REV IMMUNOL, V5, P65, DOI 10.1146/annurev.iy.05.040187.000433; PERRY HM, 1987, CALCIFIED TISSUE INT, V40, P298, DOI 10.1007/BF02555265; RAFTERY MJ, 1992, BIOL MASS SPECTROM, V21, P509, DOI 10.1002/bms.1200211008; RAISZ LG, 1984, BONE MINERAL RES ANN, V2, P286; REID GK, 1990, J BIOL CHEM, V265, P19818; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; SANDY JR, 1989, BONE MINER, V5, P155, DOI 10.1016/0169-6009(89)90093-7; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; VANINWEGEN RG, 1987, J PHARMACOL EXP THER, V241, P117; ZAMBONINZALLONE A, 1988, ANAT EMBRYOL, V159, P68; ZIBOH VA, 1986, CANCER RES, V46, P600	46	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10087	10094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486677				2022-12-27	WOS:A1993LB80000024
J	SAMBASIVAM, H; RASSOULI, M; MURRAY, RK; NAGPURKAR, A; MOOKERJEA, S; AZADI, P; DELL, A; MORRIS, HR				SAMBASIVAM, H; RASSOULI, M; MURRAY, RK; NAGPURKAR, A; MOOKERJEA, S; AZADI, P; DELL, A; MORRIS, HR			STUDIES ON THE CARBOHYDRATE MOIETY AND ON THE BIOSYNTHESIS OF RAT C-REACTIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLCHOLINE-BINDING-PROTEIN; ACUTE PHASE RESPONSE; AMYLOID-P-COMPONENT; SERUM; ACID; RABBIT; SECRETION	Rat C-reactive protein (CRP) is a pentameric glycoprotein composed of five apparently identical monomers, two of which form a disulfide-linked dimer (Rassouli, M., Sambasivam, H., Azadi, P., Dell, A., Morris, H. R., Nagpurkar, A., Mookerjea, S., and Murray, R. K. (1992) J. Biol. Chem. 267, 2947-2954). In this study, the nature of the oligosaccharide chain of rat CRP was investigated by fast atom bombardment-mass spectrometry (FAB-MS), and general features of its biosynthetic pathway were also analyzed. FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain, predominantly a disialylated biantennary structure, attached to Asn-128. The biosynthesis of rat CRP was studied by immunoprecipitation of CRP synthesized in vitro and by cultured hepatocytes. The results revealed that each monomer of rat CRP was synthesized individually as a single-chain precursor with a cleavable signal sequence. The translocated species was sensitive to digestion by endoglycosidase H (endo H), indicating that it possessed a high mannose oligosaccharide. Rat CRP acquired the ability to bind to phosphorylcholine-Sepharose and to form the dimeric and oligomeric species prior to acquiring resistance to endo H. Studies using tunicamycin revealed that the N-linked oligosaccharide present in rat CRP was not required for formation of its dimeric component, oligomerization, ability to bind to phosphorylcholine, or secretion. The non-glycosylated rat CRP, however, was still able to bind to phosphorylcholine-Sepharose and to be secreted by hepatocytes.	MEM UNIV NEWFOUNDLAND, DEPT BIOCHEM, ST JOHNS A1B 3X9, NEWFOUNDLAND, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND	Memorial University Newfoundland; University of Toronto; Imperial College London								AMATAYAKULCHANT.S, 1990, GLYCONJUGATE J, V7, P440; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS J, 1984, BIOCHIM BIOPHYS ACTA, V799, P97, DOI 10.1016/0304-4165(84)90281-2; DEBEER FC, 1982, IMMUNOLOGY, V45, P55; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; GEWURZ H, 1982, HOSP PRACT, V17, P67; GIULIAN GG, 1985, FED PROC, V44, P686; GRZELCZAK ZF, 1983, CAN J BIOCHEM CELL B, V61, P1233, DOI 10.1139/o83-159; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACINTYRE SS, 1983, BIOCHEM J, V210, P707, DOI 10.1042/bj2100707; MACINTYRE SS, 1988, METHOD ENZYMOL, V163, P383; NAGPURKAR A, 1988, BIOCHIM BIOPHYS ACTA, V967, P76, DOI 10.1016/0304-4165(88)90190-0; NAGPURKAR A, 1981, J BIOL CHEM, V256, P7440; PRESPER KA, 1985, ENZYMOLOGY POSTTRANS, P59; RANDELL E, 1990, BIOCHIM BIOPHYS ACTA, V1034, P281, DOI 10.1016/0304-4165(90)90051-W; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; ROBEY FA, 1983, J BIOL CHEM, V258, P3889; SAXENA U, 1985, CAN J BIOCHEM CELL B, V63, P1014, DOI 10.1139/o85-126; SEMPLE E, 1987, BIOCHEM BIOPH RES CO, V148, P449, DOI 10.1016/0006-291X(87)91132-6; SYIN C, 1986, J BIOL CHEM, V261, P5473; TUCCI A, 1983, J IMMUNOL, V131, P2416	28	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10007	10016						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486673				2022-12-27	WOS:A1993LB80000014
J	HERSHBERGER, PA; MITA, BC; TRIPATARA, A; DEHASETH, PL				HERSHBERGER, PA; MITA, BC; TRIPATARA, A; DEHASETH, PL			INTERFERENCE BY P(R)-BOUND RNA-POLYMERASE WITH P(RM) FUNCTION-INVITRO - MODULATION BY THE BACTERIOPHAGE-LAMBDA CI PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; POSITIVE CONTROL; GENE-REGULATION; RIGHT OPERATOR; PRM PROMOTER; REPRESSOR; MECHANISM; INITIATION; STEPS; OR3	Activation of the weak P(RM) promoter by cI protein is an essential process in the establishment of lysogeny. Much evidence has accumulated that cI protein binds cooperatively to the operators O(R)1 and O(R)2 and that protein at the O(R)2 site contacts RNA polymerase to facilitate open complex formation at the P(RM) promoter. We had shown previously in vitro that RNA polymerase situated at the nearby P(R) promoter could interfere with open complex formation at P(RM) and that an additional mechanism Of P(RM) activation in vitro involved cI-mediated RNA polymerase exclusion from P(R). Here we further characterize this second indirect mode of activation. We demonstrate that addition of cI and inactivation of the P(R) Promoter activate open complex formation at P(RM) similarly over the temperature range from 37 to 20-degrees-C in which the extent of activation decreases from 8- to 2-fold. We also show that the binding of cI protein to O(R)1 is sufficient to effect an increase in the rate of synthesis of abortive RNA products at P(RM). This result is difficult to explain based on direct cI-RNA polymerase contacts alone but is readily interpreted in terms of our previously proposed model involving the exclusion of an interfering RNA polymerase from binding at P(R).	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University				Hershberger, Pamela/0000-0003-0030-6520	NIGMS NIH HHS [GM 31808] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031808] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HERSHBERGER PA, 1991, J MOL BIOL, V222, P479, DOI 10.1016/0022-2836(91)90491-N; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; KOBLAN KS, 1992, BIOCHEMISTRY-US, V31, P57, DOI 10.1021/bi00116a010; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAURER R, 1980, J MOL BIOL, V139, P147, DOI 10.1016/0022-2836(80)90302-2; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; Ptashne M., 1986, A GENETIC SWITCH; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; WOODY ST, 1993, J MOL BIOL, V229, P37, DOI 10.1006/jmbi.1993.1006	14	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8943	8948						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473337				2022-12-27	WOS:A1993KX81100082
J	GANTZ, I; KONDA, Y; TASHIRO, T; SHIMOTO, Y; MIWA, H; MUNZERT, G; WATSON, SJ; DELVALLE, J; YAMADA, T				GANTZ, I; KONDA, Y; TASHIRO, T; SHIMOTO, Y; MIWA, H; MUNZERT, G; WATSON, SJ; DELVALLE, J; YAMADA, T			MOLECULAR-CLONING OF A NOVEL MELANOCORTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MSH; GENE; EXPRESSION; TISSUES; HORMONE; CELLS; DNA	Using the technique of the polymerase chain reaction primed with oligonucleotides based on the homologous transmembrane regions of seven transmembrane G protein-linked receptors, we isolated three full-length human genes that encode a novel subgroup of this receptor family. Recently, two of these receptors were identified as specific for alpha-melanocyte-stimulating hormone (alpha-MSH) and adrenocorticotropic hormone. We report the molecular cloning and pharmacologic characterization of a third member of this subgroup. The gene for this receptor encodes a protein of 361 amino acids in length. Its pharmacology characterizes it as an MSH receptor specific to the heptapeptide core common to adrenocorticotropic hormone and alpha-, beta-, and gamma-MSH. By Northern blot hybridization and polymerase chain reaction, it is expressed in brain, placental, and gut tissues but not in melanoma cells or in the adrenal gland. These findings may yield insight into the physiology of peptides derived from pro-opiomelanocortin post-translational processing.	UNIV MICHIGAN,MED CTR,DEPT SURG,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PSYCHIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034306, P30DK034933, K08DK001823] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK34306, K08-DK01823, P30DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN NA, 1990, J BIOL CHEM, V265, P13181; CHALLIS JRG, 1977, NATURE, V269, P818, DOI 10.1038/269818a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK D, 1978, NATURE, V273, P163, DOI 10.1038/273163a0; De Wied D, 1991, Methods Achiev Exp Pathol, V15, P167; DEBOLD CR, 1988, MOL ENDOCRINOL, V2, P862, DOI 10.1210/mend-2-9-862; DEWIED D, 1982, PHYSIOL REV, V62, P977; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; Garren L D, 1968, Vitam Horm, V26, P119; GUYER CA, 1990, J BIOL CHEM, V265, P17307; KRIEGER DT, 1982, BIOL REPROD, V26, P55, DOI 10.1095/biolreprod26.1.55; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MONTMAYEUR JP, 1991, FEBS LETT, V278, P239, DOI 10.1016/0014-5793(91)80125-M; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Sambrook J, 1989, MOL CLONING LABORATO; SILMAN RE, 1976, NATURE, V260, P716, DOI 10.1038/260716a0; TATRO JB, 1987, ENDOCRINOLOGY, V121, P1900, DOI 10.1210/endo-121-5-1900; TSONIS PA, 1988, BIOTECHNIQUES, V6, P950; WILSON JF, 1982, CLIN ENDOCRINOL, V17, P233	21	641	688	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8246	8250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463333				2022-12-27	WOS:A1993KW97900095
J	ASMAN, DC; TAKIMOTO, K; PITOT, HC; DUNN, TJ; LINDAHL, R				ASMAN, DC; TAKIMOTO, K; PITOT, HC; DUNN, TJ; LINDAHL, R			ORGANIZATION AND CHARACTERIZATION OF THE RAT CLASS-3 ALDEHYDE DEHYDROGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; EXPRESSION; LIVER; CDNA; INDUCTION; RECEPTOR; DIOXIN; RNA	Expression of class 3 aldehyde dehydrogenase (ALDH-3) is constitutive or inducible, depending on the tissue. ALDH-3 induction occurs both during neoplastic development and after exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). In order to study the regulation of ALDH-3 gene expression, ALDH-3 genomic sequences have been obtained from normal rat genomic DNA. Two overlapping genomic fragments (ALDH-UTR-1 and ALDH-NL2) contain the entire ALDH-3 gene along with considerable 5'- and 3'-flanking sequences. The rat ALDH-3 gene spans approximately 9 kilobases in length and consists of eleven exons; ten coding and one 5'-noncoding. The region 5' to exon one contains several putative transcription factor binding elements which may be important in the TCDD inducibility of this gene. These include a xenobiotic response element (XRE), a drug response element (DRE), LAP and Ap1 binding sites, and one Sp1 site. There are considerable differences in organization between the rat and human class 3 ALDH genes. Primer extension and RNase protection analysis indicate that both basal and TCDD-inducible expression of the ALDH-3 gene utilize the same multiple transcription start sites.	UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,414 E CLARK,VERMILLION,SD 57069; UNIV WISCONSIN,SCH MED,DEPT ONCOL & PATHOL,MADISON,WI 53706; UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	University of South Dakota; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA021103, P01CA022484, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22484, CA 21103, CA 07175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARLSTEDTDUKE JMB, 1979, CANCER RES, V39, P3172; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEITRICH RA, 1977, J BIOL CHEM, V252, P6169; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DUNN TJ, 1988, J BIOL CHEM, V263, P10878; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; HEMPEL J, 1989, BIOCHEMISTRY-US, V28, P1160, DOI 10.1021/bi00429a034; HEMPEL J, 1989, ENZYMOLOGY MOL BIOL, V2, P3; HSU LC, 1992, J BIOL CHEM, V267, P3030; INNIS MA, 1990, PCR PROTOCOLS; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; LIN KH, 1988, CANCER RES, V48, P7009; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; MARSELOS M, 1987, CHEM-BIOL INTERACT, V62, P75, DOI 10.1016/0009-2797(87)90080-9; NEBERT DW, 1990, ENVIRON HEALTH PERSP, V88, P13, DOI 10.2307/3431045; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; SAIKI RK, 1989, AMPLIFICATIONS, V1, P4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKIMOTO K, 1991, BIOCHEM BIOPH RES CO, V180, P953, DOI 10.1016/S0006-291X(05)81158-1; TAKIMOTO K, 1992, ARCH BIOCHEM BIOPHYS, V298, P492, DOI 10.1016/0003-9861(92)90440-8; TORRONEN R, 1981, CHEM-BIOL INTERACT, V36, P33, DOI 10.1016/0009-2797(81)90027-2; VASILIOU V, 1992, BIOCHEM BIOPH RES CO, V187, P413, DOI 10.1016/S0006-291X(05)81508-6; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019; YIN SJ, 1989, BIOCHEM GENET, V27, P321, DOI 10.1007/BF00554167	30	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12530	12536						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509394				2022-12-27	WOS:A1993LG65800047
J	MENDELOW, M; PROROK, M; SALERNO, A; LAWRENCE, DS				MENDELOW, M; PROROK, M; SALERNO, A; LAWRENCE, DS			ATPASE-PROMOTING DEAD-END INHIBITORS OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR DICHROIC EVIDENCE; CATALYTIC SUBUNIT; CONFORMATIONAL CHANGE; SITE INTERACTIONS; BOVINE HEART; HEXOKINASE; MECHANISM; SEQUENCE; TYROSINE; FAMILY	The cAMP-dependent protein kinase is a bifunctional enzyme, catalyzing the phosphorylation of the serine and threonine residues in peptides and proteins (kinase activity) as well as the phosphorylation of water (ATPase activity). We have found that several peptides, which serve as inhibitors of the kinase reaction, will either maintain or enhance the ATPase reaction catalyzed by the enzyme. Positively charged dipeptides (e.g. Arg-Arg), as well as small guanidino-containing compounds (e.g. guanethidine) block protein kinase activity yet enhance ATPase activity up to 3.5-fold over that exhibited by the enzyme in the absence of these compounds. In contrast, several non-phosphorylatable peptides, whose primary sequences are based on that of a known substrate (i.e. Leu-Arg-Arg-Ala-Ser-Leu-Gly), such as Leu-Arg-Arg-Ala-Ala-Leu-Gly, Leu-Arg-Arg-Ala-Phe-Leu-Gly, and Leu-Arg-Arg-Ala-Tyr-Leu-Gly, have little or no effect on the rate of the kinase-catalyzed hydrolysis of ATP. An exception to the latter observation is Leu-Arg-Arg-Ala-Cys-Leu-Gly, a cysteine-containing peptide that promotes the protein kinase-catalyzed ATPase reaction by 2.2-fold. We have also found that peptides that possess relatively large amino acid side chain moieties immediately following the arginine dyad (i.e. such as Phe, Tyr, Cys, or Asn at Xaa in Leu-Arg-Arg-Xaa-Ala-Leu-Gly) sharply reduce the rate of enzyme-catalyzed ATP hydrolysis. This suggests that in the presence of peptides containing an -Arg-Arg-Ala- sequence, the enzyme-bound gamma-phosphate of ATP is relatively accessible to water. In contrast, when the the latter alanine moiety is replaced by a larger residue, access by water to ATP appears to be hindered. These results indicate that certain structural features associated with the substrate or substrate analog have a profound influence on the manner by which these species interact with the protein kinase. Furthermore, the work described herein demonstrates that it is possible to block the physiologically important kinase reaction and simultaneously promote the energetically wasteful ATPase reaction.	SUNY Buffalo, DEPT CHEM, ACHESON HALL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; ARMSTRONG RN, 1979, P NATL ACAD SCI USA, V76, P722, DOI 10.1073/pnas.76.2.722; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DELAFUEN.G, 1970, EUR J BIOCHEM, V16, P226; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; FIRST EA, 1989, BIOCHEMISTRY-US, V28, P3606, DOI 10.1021/bi00434a068; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHT WB, 1989, BIOCHEMISTRY-US, V28, P5728, DOI 10.1021/bi00440a005; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P415; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; MOLL GW, 1976, J BIOL CHEM, V251, P3993; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; OBRIAN CA, 1991, BIOCHEMISTRY-US, V30, P2549, DOI 10.1021/bi00223a036; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REED J, 1984, BIOCHEMISTRY-US, V23, P968, DOI 10.1021/bi00300a026; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; SALERNO A, 1990, J BIOL CHEM, V265, P18079; SHOHAM M, 1982, BIOCHIM BIOPHYS ACTA, V705, P380, DOI 10.1016/0167-4838(82)90260-6; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; ZHENG JH, 1991, METHOD ENZYMOL, V200, P508	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12289	12296						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509366				2022-12-27	WOS:A1993LG65800013
J	TSUTSUI, K; TSUTSUI, K; OKADA, S; WATARAI, S; SEKI, S; YASUDA, T; SHOHMORI, T				TSUTSUI, K; TSUTSUI, K; OKADA, S; WATARAI, S; SEKI, S; YASUDA, T; SHOHMORI, T			IDENTIFICATION AND CHARACTERIZATION OF A NUCLEAR SCAFFOLD PROTEIN THAT BINDS THE MATRIX ATTACHMENT REGION DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II; MOLECULAR-CLONING; SUPERCOILED DNA; SITES; ENHANCER; CELLS; GENES; PURIFICATION; COMPONENT; ELEMENTS	The association of nuclear DNA with the nuclear matrix (scaffold) is mediated by defined segments of DNA called matrix association region (MAR). By using a plasmid harboring a portion of the Igkappa gene within which MAR had been located, we searched for proteins recognizing MAR in the nuclear scaffold components electrophoretically separated and blotted onto a membrane. In the presence of nonspecific competitor DNA, the labeled plasmid selectively bound to a protein with apparent molecular weight of 120,000 (designated SP120). The protein was purified directly from SDS-polyacrylamide gels and renatured by a guanidine hydrochloride procedure. The DNA region in the plasmid responsible for the binding to the solubilized SP120 coincided with the 365-base pair HindIII-HinfI fragment that had been identified as MAR. In solution, SP120 exhibited a cooperative mode of interaction with the end-labeled MAR fragment. Measurement of relative affinities of MAR subfragments to SP120 showed that the whole region is required for efficient binding. This is consistent with the minimal length for MAR estimated thus far by in situ mapping experiments. The MAR derived from another gene, fushitarazu, also bound specifically to SP120. Immunostaining of whole cells and isolated nuclei with a monoclonal antibody raised against SP120 indicated that the protein is localized in a nuclear skeletal structure. These results suggest the involvement of SP120 in the MAR-mediated anchorage of nuclear DNA to the nuclear scaffold.	OKAYAMA UNIV, SCH MED, INST CELLULAR & MOLEC BIOL, DEPT CELL CHEM, OKAYAMA 700, JAPAN; OKAYAMA UNIV, SCH MED, DEPT NEUROL, OKAYAMA 700, JAPAN	Okayama University; Okayama University	TSUTSUI, K (corresponding author), OKAYAMA UNIV, SCH MED, INST CELLULAR & MOLEC BIOL, DEPT MOLEC BIOL, 2-5-1 SHIKATA CHO, OKAYAMA 700, JAPAN.		Tsutsui, Ken/B-1863-2011; TSUTSUI, Kimiko M/B-1955-2011					ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADAMS LD, 1992, CURRENT PROTOCOLS MO; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; GASSER SM, 1989, INT REV CYTOL, V119, P57; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; IDE T, 1975, NATURE, V258, P445, DOI 10.1038/258445a0; ISHII K, 1983, J BIOL CHEM, V258, P2728; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; Kennett R H, 1979, Methods Enzymol, V58, P345; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIZUTANI M, 1991, NUCLEIC ACIDS RES, V19, P2907, DOI 10.1093/nar/19.11.2907; Reid L C, 1979, Methods Enzymol, V58, P152; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TSUTSUI K, 1989, J BIOL CHEM, V264, P7644; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; VERHEIJEN R, 1988, J CELL SCI, V90, P11; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J	29	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12886	12894						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509422				2022-12-27	WOS:A1993LG65800095
J	YAMADA, M; SUMI, K; MATSUSHITA, K; ADACHI, O; YAMADA, Y				YAMADA, M; SUMI, K; MATSUSHITA, K; ADACHI, O; YAMADA, Y			TOPOLOGICAL ANALYSIS OF QUINOPROTEIN GLUCOSE-DEHYDROGENASE IN ESCHERICHIA-COLI AND ITS UBIQUINONE-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACINETOBACTER-CALCOACETICUS; PYRROLOQUINOLINE QUINONE; NUCLEOTIDE-SEQUENCE; GENE FUSIONS; CLONING; DNA; VECTORS; SIGNALS; PROTEIN; CHAIN	Topological structure of quinoprotein glucose dehydrogenase in the inner membrane of Escherichia coli was determined by constructing protein fusions with alkaline phosphatase or beta-galactosidase. Analysis of the fusions revealed that the dehydrogenase possesses five membrane-spanning segments, and the N-terminal and C-terminal portions resided at the cytoplasmic and periplasmic side of the membrane, respectively. These results agreed with the hydropathy profile based on its primary structure. The topological structure suggests that the predicted binding site of the prosthetic group pyrroloquinoline quinone is located at the periplasmic side and that the amino acid residues corresponding to those that were presumed to interact with ubiquinone in one subunit of mitochondrial NADH dehydrogenase also occur at the periplasmic side. When the purified glucose dehydrogenase and cytochrome o ubiquinol oxidase were reconstituted together with ubiquinone into liposomes, a membrane potential could be generated by the electron transfer at the site of the ubiquinol oxidase but not of the dehydrogenase. These results suggest that glucose dehydrogenase has a ubiquinone reacting site close to the periplasmic side of the membrane, and thus its electron transfer to ubiquinone appears to be incapable of forming a proton electrochemical gradient across the inner membrane of E. coli.	YAMAGUCHI UNIV,SCH MED,DEPT PHARMACOL,YAMAGUCHI 753,JAPAN	Yamaguchi University	YAMADA, M (corresponding author), YAMAGUCHI UNIV,FAC AGR,DEPT BIOL CHEM,1677-1 YOSHIDA,YAMAGUCHI 753,JAPAN.			Yamada, Mamoru/0000-0003-4354-7324				AMEYAMA M, 1986, AGR BIOL CHEM TOKYO, V50, P49, DOI 10.1080/00021369.1986.10867348; AMEYAMA M, 1981, FEBS LETT, V130, P179, DOI 10.1016/0014-5793(81)81114-3; BIVILLE F, 1991, J GEN MICROBIOL, V137, P1775, DOI 10.1099/00221287-137-8-1775; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CLETONJANSEN AM, 1988, NUCLEIC ACIDS RES, V16, P6228, DOI 10.1093/nar/16.13.6228; CLETONJANSEN AM, 1990, J BACTERIOL, V172, P6308, DOI 10.1128/jb.172.11.6308-6315.1990; CLETONJANSEN AM, 1989, MOL GEN GENET, V217, P430, DOI 10.1007/BF02464914; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FRIEDRICH T, 1990, FEBS LETT, V265, P37, DOI 10.1016/0014-5793(90)80878-M; HOMMES RWJ, 1984, FEMS MICROBIOL LETT, V24, P329, DOI 10.1016/0378-1097(84)90274-X; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAYNE E, 1957, METHOD ENZYMOL, V3, P450; MACHLIN SM, 1988, J BACTERIOL, V170, P4739, DOI 10.1128/jb.170.10.4739-4747.1988; Malymy M., 1966, METHODS ENZYMOLOGY, V9, P639, DOI [10.1016/0076-6879(66)09129-8, DOI 10.1016/0076-6879(66)09129-8]; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA K, 1989, J BIOCHEM, V105, P633, DOI 10.1093/oxfordjournals.jbchem.a122716; MATSUSHITA K, 1987, J BACTERIOL, V169, P205, DOI 10.1128/jb.169.1.205-209.1987; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; MESSING J, 1983, METHOD ENZYMOL, V101, P20; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YAMADA M, 1984, EUR J BIOCHEM, V140, P249, DOI 10.1111/j.1432-1033.1984.tb08095.x; YAMADA M, 1993, J BACTERIOL, V175, P568, DOI 10.1128/JB.175.2.568-571.1993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12812	12817						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509415				2022-12-27	WOS:A1993LG65800086
J	HEDDI, A; LESTIENNE, P; WALLACE, DC; STEPIEN, G				HEDDI, A; LESTIENNE, P; WALLACE, DC; STEPIEN, G			MITOCHONDRIAL-DNA EXPRESSION IN MITOCHONDRIAL MYOPATHIES AND COORDINATED EXPRESSION OF NUCLEAR GENES INVOLVED IN ATP PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BETA-SUBUNIT; NUCLEOTIDE TRANSLOCATOR GENE; MUSCLE ADP/ATP TRANSLOCATOR; KEARNS-SAYRE SYNDROME; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; MAMMALIAN-CELLS; POINT MUTATION; TRANSCRIPTION; INVITRO	The expression of nuclear and mitochondrial oxidative phosphorylation (OXPHOS) genes was examined in the skeletal muscle of patients with Kearns-Sayre syndrome (KSS), myoclonic epilepsy associated with ragged red fibers (MERRF), and myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and compared with controls. In KSS muscle, mtDNA transcripts outside the deletion were elevated, while those within the deletion were reduced according to the percentage of deleted mtDNA molecules. In MERRF and MELAS muscle, mitochondrial transcripts levels were increased, but the increase was greater in MERRF muscle. The processing of mtDNA transcripts was reduced in all pathogenic muscles. This was true for full-length heavy and light strand transcripts as well as for the 16 S rRNA + tRNA(Leu) + ND1 transcript. However, the tRNA(Lys) level was reduced in all three muscles. In MELAS muscle, our results are not consistent with an impairment of transcription termination at the end of the 16 S mitochondrial rRNA. Finally, the transcription of the nuclear ATPsyn.beta and ANT1 genes was induced in parallel with the high level of mtDNA transcripts in MERRF and MELAS muscle, but was repressed in KSS muscle. The results demonstrate that the expression of nuclear and cytoplasmic OXPHOS genes is coordinated and that OXPHOS gene expression increases to compensate for respiratory deficiency. The repression of nuclear genes in KSS muscle could be a consequence of the segmental distribution of deleted mtDNA molecules in muscle cells.	CNRS, CTR GENET MOLEC & CELLULAIRE, UNITE MIXTE RECH 106, 43 BLVD 11 NOVEMBRE 1918, F-69622 VILLEURBANNE, FRANCE; CHRU, INSERM, U298, F-49033 ANGERS, FRANCE; EMORY UNIV, SCH MED, DEPT GENET & MOLEC MED, ATLANTA, GA 30322 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Emory University					NHLBI NIH HHS [HL45572] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BATTINI R, 1987, J BIOL CHEM, V262, P4355; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KU DH, 1990, J BIOL CHEM, V265, P16060; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; NAKASE H, 1990, AM J HUM GENET, V46, P418; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; NELSON I, 1992, NEUROPEDIATRICS, V23, P199, DOI 10.1055/s-2008-1071341; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TOMURA H, 1990, J BIOL CHEM, V265, P6525; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316	38	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12156	12163						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505336				2022-12-27	WOS:A1993LF28400103
J	KAUFMAN, RJ; MURTHARIEL, P; PITTMAN, DD; DAVIES, MV				KAUFMAN, RJ; MURTHARIEL, P; PITTMAN, DD; DAVIES, MV			CHARACTERIZATION OF WILD-TYPE AND SER(53) MUTANT EUKARYOTIC INITIATION FACTOR-4E OVEREXPRESSION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; INFECTED HELA-CELLS; MESSENGER-RNA; TRANSLATIONAL CONTROL; SECONDARY STRUCTURE; 5'-TERMINAL 7-METHYLGUANOSINE; STIMULATES PHOSPHORYLATION; INTERNAL INITIATION; GROWTH-FACTOR; FACTOR 4E	Eukaryotic translation initiation factor 4E (eIF-4E) is one component of the m7G-cap-binding protein complex eIF-4F and is required for cap-dependent translation initiation. The phosphorylation state of eIF-4E correlates with increased activity and a major phosphorylation site resides at serine 53. To further evaluate the role of eIF-4E phosphorylation, eIF-4E wild-type and two Ser53 mutants, Ser53Ala and Ser53Asp, were expressed at high level, representing almost 2% of the total cell protein, by transient transfection of COS-1 monkey cells. (PO4)-P-32 metabolic labeling of transfected cells demonstrated both Ser53 mutants were phosphorylated at an alternate serine residue. [S-35] Methionine pulse-labeling demonstrated that the wild-type and both Ser53 mutants were equally incorporated into the eIF-4F complex. The effect of wild-type and Ser53 mutant overexpression on cap-dependent translation initiation and internal translation initiation was monitored by cotransfection with an expression vector encoding a dicistronic mRNA for which the 5' cistron is translated in a cap-dependent manner, and the 3' cistron is translated by internal ribosome binding. Unexpectedly, overexpression of the wild-type or either mutant did not affect the efficiency of either cap-dependent or internal initiation. These results demonstrate that phosphorylation of eIF-4E at residue 53 is not required for interaction with p220 and suggest that Ser'' phosphorylation may not be required for cap-dependent translation initiation in this system.			KAUFMAN, RJ (corresponding author), GENET INST INC,CAMBRIDGE,MA 02140, USA.							ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P4895; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1990, J BIOL CHEM, V265, P7492; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1741; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LLOYD RE, 1988, VIROLOGY, V123, P60; LOCKARD RE, 1978, NUCLEIC ACIDS RES, V5, P2850; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MUTHUKRISHNAN S, 1975, NATURE, V255, P33, DOI 10.1038/255033a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; ROSE JK, 1976, NATURE, V262, P32, DOI 10.1038/262032a0; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; SONENBERG N, 1977, P NATL ACAD SCI USA, V74, P4288, DOI 10.1073/pnas.74.10.4288; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YAN RQ, 1992, J BIOL CHEM, V267, P23226	57	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11902	11909						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505316				2022-12-27	WOS:A1993LF28400067
J	HAYASHI, T; UENO, Y; OKAMOTO, T				HAYASHI, T; UENO, Y; OKAMOTO, T			OXIDOREDUCTIVE REGULATION OF NUCLEAR FACTOR-KAPPA-B - INVOLVEMENT OF A CELLULAR REDUCING CATALYST THIOREDOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; LONG-TERMINAL REPEAT; DNA-BINDING SUBUNIT; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; FACTOR-ALPHA; GENE-EXPRESSION; 65-KD SUBUNIT; T-CELLS	We have investigated an oxidoreductive regulatory pathway for the DNA binding activity of a pleiotropic cellular transcription factor, nuclear factor kappa B (NFkappaB), has been investigated by using NFkappaB prepared from the nucleus and the cytosol of the primary human T lymphocytes. We show that a cellular reducing catalyst thioredoxin (Trx) plays a major role in activation of the DNA binding of NFkappaB in vitro and stimulation of transcription from the NFkappaB-dependent gene expression. We demonstrate evidence suggesting that redox regulation of NFkappaB by Trx might be exerted at a step after dissociation of the inhibitory molecule IkappaB, a cytosolic-anchoring protein for NFkappaB. To examine the effect of Trx in intact cells, we performed transient assay with a chloramphenicol acetyltransferase-expressing plasmid under the control of human immunodeficiency virus (HIV) long terminal repeat and an effector plasmid expressing human Trx. The promoter activity from HIV long terminal repeat was greatly augmented by co-transfecting the Trx-expressing plasmid, whose effect was dependent on the NFkappaB-binding sites. These findings have suggested that cysteine residue(s) of NFkappaB might be involved in the DNA-recognition by NFkappaB and that the redox control mechanism mediated by Trx might have a regulatory role in the NFkappaB-mediated gene expression. These results may also provide a clue to understanding of the molecular process of AIDS pathogenesis and its possible biochemical intervention.	NATL CANC CTR,RES INST,DIV VIROL,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN; SCI UNIV TOKYO,FAC PHARMACEUT SCI,SHINJUKU KU,TOKYO 162,JAPAN	National Cancer Center - Japan; Tokyo University of Science								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWNELL E, 1989, ONCOGENE, V4, P935; BUHL R, 1989, LANCET, V2, P1294; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GREENE WC, 1990, ANNU REV IMMUNOL, V8, P453, DOI 10.1146/annurev.iy.08.040190.002321; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; ISRAEL N, 1989, J IMMUNOL, V143, P3956; JAMIESON C, 1991, J IMMUNOL, V147, P416; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; MORI S, 1990, JPN J CANCER RES, V81, P1124, DOI 10.1111/j.1349-7006.1990.tb02523.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1288; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; OKAMOTO T, 1992, VIROLOGY, V4, P811; ROEDERER M, 1991, AIDS RES HUM RETROV, V7, P563, DOI 10.1089/aid.1991.7.563; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH KC, 1966, BIOCHEMISTRY-US, V5, P2125, DOI 10.1021/bi00870a046; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TSUBOI A, 1991, INT IMMUNOL, V3, P807, DOI 10.1093/intimm/3.8.807; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	64	460	470	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11380	11388						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496188				2022-12-27	WOS:A1993LD46600096
J	REINHARDT, D; MANN, K; NISCHT, R; FOX, JW; CHU, ML; KRIEG, T; TIMPL, R				REINHARDT, D; MANN, K; NISCHT, R; FOX, JW; CHU, ML; KRIEG, T; TIMPL, R			MAPPING OF NIDOGEN BINDING-SITES FOR COLLAGEN TYPE-IV, HEPARAN-SULFATE PROTEOGLYCAN, AND ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; DENSITY LIPOPROTEIN-RECEPTOR; BASEMENT-MEMBRANE COLLAGEN; STRUCTURAL CHARACTERIZATION; LAMININ; PROTEIN; ENTACTIN; COMPLEX; PURIFICATION; GLYCOPROTEIN	Recombinant nidogen fragments comprising the globular domains G1 plus G2, the rod-like domain, and the rod connected to the globe G3 were prepared from the culture media of transfected human cell clones. In addition, domains G1 and G2 were separated from each other after cleavage with chymotrypsin. The purified fragments were characterized by N-terminal sequences, electrophoresis, electron microscopy, and radioimmunoassays and the cell clones by Northern hybridization. Transfection with a construct comprising a large part of domain G3 showed high mRNA levels but no secreted protein, indicating a protein folding problem. All these fragments were used as soluble and/or immobilized ligands in binding assays. This demonstrated major binding sites on domain G2 for collagen IV and heparan sulfate proteoglycan. Affinity chromatography on zinc- and cobalt-loaded columns showed binding of domains G2 and G3 and the rod. Protein binding, but not metal binding, was abolished by reduction and alkylation of nidogen. This allowed for the isolation of several zinc-binding tryptic peptides, four from G2, two from the rod, and one from the G3 domain. Most of these short peptides contained several histidines that are likely to mediate binding. Zinc inhibited efficiently G3-mediated nidogen binding to laminin at 4-degrees-C (IC50 approximately 5 muM) but less at higher temperatures. Similarly, zinc inhibited binding to collagen IV and proteoglycan at low temperatures but not at high (37-degrees-C) temperatures. This indicates a complex modulation of nidogen binding to other basement membrane proteins by some, but not all, transition metals. Whether the particularly striking effects shown for zinc are of biological relevance remains to be established.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV COLOGNE, DEPT DERMATOL, W-5000 COLOGNE, GERMANY; THOMAS JEFFERSON UNIV, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, DEPT DERMATOL, PHILADELPHIA, PA 19107 USA	Max Planck Society; University of Cologne; Jefferson University; Jefferson University			Reinhardt, Dieter P/A-3102-2008; Mann, Karlheinz/C-4254-2008	Reinhardt, Dieter P/0000-0001-6535-9872; 				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; AUMAILLEY M, 1993, KIDNEY INT, V43, P7, DOI 10.1038/ki.1993.3; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FALCHUK KH, 1987, PRINCIPLES INTERNAL, P418; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GERL M, 1991, EUR J BIOCHEM, V202, P167, DOI 10.1111/j.1432-1033.1991.tb16358.x; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HASSELL JR, 1991, J BIOL CHEM, V266, P22939; JACKSON MJ, 1989, ZINC HUMAN BIOL, P1; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NAGAYOSHI T, 1989, DNA-J MOLEC CELL BIO, V8, P581, DOI 10.1089/dna.1989.8.581; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PAULSSON M, 1986, EUR J BIOCHEM, V156, P467, DOI 10.1111/j.1432-1033.1986.tb09605.x; REINHARDT D, 1992, UNTERSUCHUNGEN STRUK; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; SMITH MC, 1990, ACS SYM SER, V427, P168; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; Williams RJP., 1989, ZINC HUMAN BIOL, P15, DOI 10.1007/978-1-4471-3879-2_2; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	39	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10881	10887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496153				2022-12-27	WOS:A1993LD46600028
J	RUSVAI, E; NARAYFEJESTOTH, A				RUSVAI, E; NARAYFEJESTOTH, A			A NEW ISOFORM OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE IN ALDOSTERONE TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MINERALOCORTICOID RECEPTOR; CORTICOSTEROID 11-BETA-DEHYDROGENASE; RAT-KIDNEY; LOCALIZATION; LIVER; SPECIFICITY; EXPRESSION; PROTECTOR; CLONING; GENE	11beta-Hydroxysteroid dehydrogenase has been proposed to play an important role in aldosterone target cells by degrading endogenous glucocorticoids, thus allowing aldosterone to bind to the relatively nonselective mineralocorticoid receptor. The physiologically important species of this enzyme in renal aldosterone target cells appears to be kinetically and antigenically distinct from the previously characterized liver enzyme. Here we show that 11beta-steroid dehydrogenase in the microsomal fraction of isolated renal collecting duct cells has a K(m) for corticosterone of 25.9 +/- 2.4 nM, about 100 times lower than the rat liver enzyme. Surprisingly, the collecting duct enzyme utilizes almost exclusively NAD as cofactor versus NADP used by the liver form. Conversion of corticosterone to 11-dehydrocorticosterone is 2.6 +/- 0.5 and 0.07 +/- 0.01 fmol/min/mg protein with 100 muM of NAD and NADP, respectively, demonstrating a 37.4 +/- 3.5-fold preference for NAD versus NADP. There is practically no conversion of 11-dehydrocorticosterone to corticosterone either with NADH or NADPH, indicating that in collecting duct cells the enzyme operates only in the direction of oxygenation. In addition, 11beta-steroid dehydrogenase activity is dose dependently inhibited by the end product 11-dehydrocorticosterone while the liver enzyme does not show end product inhibition. We conclude that renal collecting duct cells, the major physiological targets of aldosterone, are protected from circulating glucocorticoids by a hitherto undescribed enzyme of the 11-dehydrogenase family, which differs from the known liver enzyme in having a significantly higher affinity for corticosterone and a different cofactor requirement.	DARTMOUTH COLL SCH MED,DEPT PHYSIOL,LEBANON,NH 03756	Dartmouth College					NIDDK NIH HHS [DK 39523, DK 41841] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039523, R01DK041841] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEAUMONT K, 1983, ENDOCRINOLOGY, V113, P2043, DOI 10.1210/endo-113-6-2043; BONVALET JP, 1990, J CLIN INVEST, V86, P832, DOI 10.1172/JCI114781; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FEJESTOTH G, 1987, AM J PHYSIOL, V253, pF1303; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; KROZOWSKI Z, 1990, ENDOCRINOLOGY, V127, P3009, DOI 10.1210/endo-127-6-3009; KROZOWSKI Z, 1992, J BIOL CHEM, V267, P2569; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; MERCER WR, 1992, ENDOCRINOLOGY, V130, P540, DOI 10.1210/en.130.1.540; MOISAN MP, 1992, MOL ENDOCRINOL, V6, P1082, DOI 10.1210/me.6.7.1082; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; MONDER C, 1991, BIOCHIM BIOPHYS ACTA, V1115, P23, DOI 10.1016/0304-4165(91)90006-3; MONDER C, 1991, FASEB J, V5, P3047, DOI 10.1096/fasebj.5.15.1743437; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; NARAYFEJESTOTH A, 1990, AM J PHYSIOL, V259, pF672, DOI 10.1152/ajprenal.1990.259.4.F672; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; RUNDLE SE, 1989, ENDOCRINOLOGY, V125, P1700, DOI 10.1210/endo-125-3-1700; STEWART PM, 1991, ENDOCRINOLOGY, V128, P2129, DOI 10.1210/endo-128-4-2129; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; WALKER BR, 1992, ENDOCRINOLOGY, V131, P970, DOI 10.1210/en.131.2.970	23	244	245	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10717	10720						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496139				2022-12-27	WOS:A1993LD46600005
J	KOJIMA, I; MOGAMI, H; SHIBATA, H; OGATA, E				KOJIMA, I; MOGAMI, H; SHIBATA, H; OGATA, E			ROLE OF CALCIUM ENTRY AND PROTEIN-KINASE-C IN THE PROGRESSION ACTIVITY OF INSULIN-LIKE GROWTH FACTOR-I IN BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-THYROID CELLS; DNA-SYNTHESIS; INFLUX; INVOLVEMENT; INHIBITORS	We previously reported that insulin-like growth factor-I (IGF-I) stimulated calcium entry (Kojima, I., Matsunaga, H., Kurokawa, K., Ogata, E., and Nishimoto, I. (1988) J. Biol. Chem. 263, 16561-16567) and production of 1,2-diacylglycerol in IGF-responsive ''primed competent'' Balb/c 3T3 cells (Kojima, I., Kitaoka, M., and Ogata, E. (1990) J. Biol. Chem. 265, 16846-16850). The present study was conducted to determine a role of protein kinase C (PKC) in the progression activity of IGF-I. To monitor the activity of PKC in intact cells, we measured phosphorylation of a synthetic KRTLRR peptide, a substrate of PKC, immediately after the permeabilization of the cells with digitonin. When 1 nM IGF-I was added to primed competent cells, KRTLRR peptide phosphorylation was augmented. IGF-I induced more than 2-fold increase in KRTLRR peptide phosphorylation that was blocked by PKC19-36, a pseudosubstrate of PKC, which blocks the activity of the kinase, and Ro31-8220, an inhibitor of PKC. The phosphorylation remained elevated for up to 6 h. To assess the role of PKC in cell cycle progression, IGF-I-induced nuclear labeling was measured in the presence of Ro31-8220. Ro31-8220 reduced the rate of entrance into S phase when added in the first quarter of the G1 phase, but did not affect cell cycle progression when added at the second quarter or later. In contrast, reduction of extracellular calcium completely blocked cell cycle progression when done in the first, second, and third quarter but had no effect in the last quarter. These results indicate that IGF-I persistently activates PKC in primed competent cells, but the activation is required only for the initiation of progression. We conclude that IGF-I promotes cell cycle progression by calcium-dependent mechanisms that are largely independent of PKC.	JAPANESE FDN CANC RES,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research	KOJIMA, I (corresponding author), GUNMA UNIV,INST ENDOCRINOL,CELL BIOL RES UNIT,3-39-15 SHOWA MACHI,MAEBASHI,GUNMA 371,JAPAN.							BOYNTON AL, 1985, EXP CELL RES, V160, P197, DOI 10.1016/0014-4827(85)90248-4; BRENNERGATI L, 1988, J CLIN INVEST, V82, P1144, DOI 10.1172/JCI113672; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KOJIMA I, 1990, J BIOL CHEM, V265, P16846; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O	12	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10003	10006						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486672				2022-12-27	WOS:A1993LB80000013
J	WISHART, MJ; ANDREWS, PC; NICHOLS, R; BLEVINS, GT; LOGSDON, CD; WILLIAMS, JA				WISHART, MJ; ANDREWS, PC; NICHOLS, R; BLEVINS, GT; LOGSDON, CD; WILLIAMS, JA			IDENTIFICATION AND CLONING OF GP-3 FROM RAT PANCREATIC ACINAR ZYMOGEN GRANULES AS A GLYCOSYLATED MEMBRANE-ASSOCIATED LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ELECTROPHORETIC TRANSFER; NITROCELLULOSE SHEETS; POLYACRYLAMIDE GELS; SEQUENCE; CDNA; GLYCOPROTEIN; PURIFICATION; EXTRACTION; DIAGNOSIS	The protein components of highly purified secretory granule membranes and the granule contents from rat exocrine pancreas were characterized by two-dimensional polyacrylamide gel electrophoresis, protein staining, lectin absorption, and Western blotting with anti-secretory protein antibodies. NH2-terminal amino acid sequence was obtained for a approximately 53-kDa glycoprotein denoted GP-3, present only in granule membrane preparations where it was resistant to washing with Na2CO3 and KBr. The sequence of this protein showed homology to pancreatic lipase but was distinct from the NH2-terminal sequence of a 50-kDa content protein presumed to be secretory lipase. Polymerase chain reaction amplification with degenerate oligonucleotide primers to GP-3 and secretory lipase gave partial length subclones that were used to isolate clones from a rat pancreas cDNA library. Dideoxy sequencing of full-length subclones of GP-3 revealed the predicted amino acid sequence for a mature protein of 452 amino acids with a potential N-linked glycosylation site and a deglycosylated molecular weight of 50,860. The GP-3 sequence possesses the serine esterase consensus sequence G-X-S-X-G centered around Ser154 and the catalytic state triad Asp178-His265-Ser154 characteristic of pancreatic lipases. Northern blot analysis of various rat tissues showed GP-3 expression solely in pancreas. Comparison of GP-3 nucleotide and amino acid sequence, along with pancreatic lipases of various species including rat, shows extensive homologies to both proteins and reveals an underlying diversity in the pancreatic lipase family. Close homology is observed between GP-3 and a lipase molecule previously isolated from mouse cytotoxic T cells.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, COLL LITERATURE SCI & ARTS, DEPT BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	WISHART, MJ (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, 7744 MED SCI 2, ANN ARBOR, MI 48109 USA.			Andrews, Philip/0000-0001-6843-5420; Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045722, T32DK007367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32-DK-07367-12, DK-45722] Funding Source: Medline; NIGMS NIH HHS [5T32-GM08322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON L, 1988, 2 DIMENSIONAL GEL EL; ANDREWS PC, 1989, 3RD S PROT SOC SEATT; BEAUDOIN AR, 1980, BIOL NORMAL CANCEROU, P273; BENKOUKA F, 1982, EUR J BIOCHEM, V128, P331; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRADSHAW WS, 1972, BIOCHEMISTRY-US, V11, P1517, DOI 10.1021/bi00758a029; BURNHAM DB, 1985, BIOCHEM J, V227, P743, DOI 10.1042/bj2270743; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CHAILLAN C, 1992, BIOCHEM BIOPH RES CO, V184, P206, DOI 10.1016/0006-291X(92)91179-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTIE DL, 1990, BIOCHEM J, V270, P57, DOI 10.1042/bj2700057; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DECARO A, 1977, BIOCHIM BIOPHYS ACTA, V490, P411, DOI 10.1016/0005-2795(77)90016-2; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DELISLE RC, 1984, AM J PHYSIOL, V246, pG411, DOI 10.1152/ajpgi.1984.246.4.G411; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERICKSON PF, 1982, J IMMUNOL METHODS, V51, P241, DOI 10.1016/0022-1759(82)90263-0; FUKUOKA SI, 1991, NUCLEIC ACIDS RES, V18, P5900; GILLER T, 1992, J BIOL CHEM, V267, P16509; GO VLW, 1986, EXOCRINE PANCREAS BI; GOKE B, 1992, AM J PHYSIOL, V262, pC493, DOI 10.1152/ajpcell.1992.262.2.C493; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANSEN LJ, 1983, P NATL ACAD SCI-BIOL, V80, P4379, DOI 10.1073/pnas.80.14.4379; HARPER F, 1978, CAN J BIOCHEM CELL B, V56, P565, DOI 10.1139/o78-086; HIDE WA, 1992, J LIPID RES, V33, P167; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; KERFELEC B, 1992, EUR J BIOCHEM, V206, P279, DOI 10.1111/j.1432-1033.1992.tb16926.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LALIBERTE JF, 1982, J BIOL CHEM, V257, P3869; LAMBERT M, 1990, FEBS LETT, V271, P19, DOI 10.1016/0014-5793(90)80362-M; LEBEL D, 1984, BIOCHIM BIOPHYS ACTA, V769, P611, DOI 10.1016/0005-2736(84)90060-9; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEBEL D, 1980, J BIOL CHEM, V255, P1227; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LOTT JA, 1991, CLIN CHEM, V37, P361; LOWE ME, 1989, J BIOL CHEM, V264, P20042; LUTHIPENG QQ, 1992, FEBS LETT, V299, P111, DOI 10.1016/0014-5793(92)80112-T; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELDOLESI J, 1983, METHOD ENZYMOL, V98, P67; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; MILLER IL, 1988, CLIN CHEM, V34, P1289; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKABAYASHI Y, 1987, DIABETES, V36, P1054, DOI 10.2337/diabetes.36.9.1054; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P600, DOI 10.1016/0006-291X(91)91459-P; PAQUET MR, 1982, EUR J CELL BIOL, V28, P20; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE GA, 1975, J BIOL CHEM, V250, P5375; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; SCHWARZ H, 1992, BIOTECHNIQUES, V13, P205; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG K, 1989, METHOD ENZYMOL, V172, P687, DOI 10.1016/S0076-6879(89)72038-3; WICKERPLANQUART C, 1992, FEBS LETT, V296, P61, DOI 10.1016/0014-5793(92)80403-4; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	62	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10303	10311						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486693				2022-12-27	WOS:A1993LB80000052
J	NEILSON, EG; KALLURI, R; SUN, MJ; GUNWAR, S; DANOFF, T; MARIYAMA, M; MYERS, JC; REEDERS, ST; HUDSON, BG				NEILSON, EG; KALLURI, R; SUN, MJ; GUNWAR, S; DANOFF, T; MARIYAMA, M; MYERS, JC; REEDERS, ST; HUDSON, BG			SPECIFICITY OF GOODPASTURE AUTOANTIBODIES FOR THE RECOMBINANT NONCOLLAGENOUS DOMAINS OF HUMAN TYPE-IV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLOMERULAR-BASEMENT-MEMBRANE; ALPHA-2(IV) COLLAGEN; ALPHA-3(IV) CHAIN; ALPORT SYNDROME; IDENTIFICATION; LOCALIZATION; ANTIGEN; ALPHA-1-CHAIN; ALPHA-1(IV); ALPHA-5(IV)	Type IV collagen has recently emerged as a family composed of five known chains (alpha1-alpha5), each of which contains a carboxyl-terminal noncollagenous domain (NC1) of approximately 230 amino acids. The NC1 domain of the alpha3(IV) chain is the probable target for autoantibodies in patients with Goodpasture syndrome (GP), as evidenced from studies employing bovine type IV collagen. In the present experiments, the specificity of GP antibodies for the five NC1 domains of human type IV collagen was determined by using recombinant NC1 domains as the antigen. cDNAs encoding each NC1 domain were expressed in E. coli as fusion proteins with a 6-histidine amino-terminal leader. The recombinant NC1 monomers ralpha1(IV), ralpha2(IV), ralpha3(IV), ralpha4(IV), and ralpha5(IV) were purified by affinity chromatography to the fusion protein using a nickel resin column, and then characterized by electrophoresis and immunoblot analysis using chain-specific peptide antibodies. The specificity of GP antibodies from four patients to these recombinant proteins was then further evaluated by immunoblot analysis and enzyme-linked immunosorbent assay measurements. The GP antibodies reacted strongly with the ralpha3(IV) NC1 domain but were not reactive when tested against the other four recombinant monomers. In contrast, neither antisera from patients with two other forms of autoimmune disease (anti-tubular basement membrane disease and Wegener's syndrome) nor normal control sera bound to any of the recombinant NC1 moieties. These results unambiguously establish that GP antibodies are specifically targeted to the NC1 domain of the alpha3(IV) chain of human type IV collagen. The findings also establish a methodology for large scale preparation of ralpha3(IV) NC1 domain for use in diagnostic tests and development of therapeutic procedures and offer a strategy for the elucidation of a more complete GP epitope by site-directed mutagenesis.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,39TH & RAINBOW BLVD,KANSAS CITY,KS 66103; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV PENN,PENN CTR MOLEC STUDIES KIDNEY DIS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Kansas; University of Kansas Medical Center; Howard Hughes Medical Institute; Yale University; University of Pennsylvania; University of Pennsylvania			Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030280, R37DK030280, T32DK007006] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20553] Funding Source: Medline; NIDDK NIH HHS [DK-30280, DK-07006] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HUDSON B, 1991, PATHOBIOCHEMISTRY, P17; HUDSON BG, 1993, KIDNEY INT, V43, P135, DOI 10.1038/ki.1993.22; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KARP S, 1993, IN PRESS J IMMUNOL; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; MYERS JC, 1987, J BIOL CHEM, V262, P9231; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; QUINONES S, 1992, J BIOL CHEM, V267, P19780; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SMEETS HJM, 1992, KIDNEY INT, V42, P83, DOI 10.1038/ki.1992.264; SOININEN R, 1987, FEBS LETT, V225, P188; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P3838, DOI 10.1073/pnas.81.12.3838; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1992, J BIOL CHEM, V267, P12475	30	94	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8402	8405						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473281				2022-12-27	WOS:A1993KX81100006
J	VERCESI, AE; MORENO, SNJ; BERNARDES, CF; MEINICKE, AR; FERNANDES, EC; DOCAMPO, R				VERCESI, AE; MORENO, SNJ; BERNARDES, CF; MEINICKE, AR; FERNANDES, EC; DOCAMPO, R			THAPSIGARGIN CAUSES CA2+ RELEASE AND COLLAPSE OF THE MEMBRANE-POTENTIAL OF TRYPANOSOMA-BRUCEI MITOCHONDRIA INSITU AND OF ISOLATED RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM HOMEOSTASIS; CA-2+ TRANSPORT; SUPEROXIDE ANION; ARSENAZO-III; CRUZI; PERMEABILIZATION; GENERATION; NIGERICIN	Thapsigargin, previously reported to release Ca2+ from non-mitochondrial stores of different cell types, as well as nigericin, were found, when used at high concentrations, to release Ca2+ and collapse the membrane potential of Trypanosoma brucei bloodstream and procyclic trypomastigotes mitochondria in situ. At similarly high concentrations (>10 muM), thapsigargin was also found to release Ca2+ and collapse the membrane potential of isolated rat liver mitochondria. These results indicate that care should be taken when attributing the effects of thapsigargin in intact cells to the specific inhibition of the sarcoplasmic and endoplasmic reticulum Ca2+-ATPase family of calcium pumps. In addition, we have found no evidence for an increase in intracellular Ca2+ by release of the ion from intracellular stores by nigericin, measuring changes in cytosolic Ca2+ by dual wavelength spectrofluorometry in fura-2-loaded T. brucei bloodstream trypomastigotes or measuring Ca2+ transport in digitonin-permeabilized cells.	UNIV ILLINOIS,DEPT VET PATHOBIOL,2001 S LINCOLN AVE,URBANA,IL 61801; UNIV ESTADUAL CAMPINAS,DEPT BIOQUIM,BR-13081 CAMPINAS,SP,BRAZIL	University of Illinois System; University of Illinois Urbana-Champaign; Universidade Estadual de Campinas			Vercesi, Aníbal E/C-8767-2012	Vercesi, Anibal Eugenio/0000-0001-6671-7125				CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DOCAMPO R, 1989, J BIOL CHEM, V264, P108; DOCAMPO R, 1989, ARCH BIOCHEM BIOPHYS, V272, P122, DOI 10.1016/0003-9861(89)90202-6; DOCAMPO R, 1983, J BIOL CHEM, V258, P4920; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FERGUSON SM, 1971, J BIOL CHEM, V246, P5645; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; KLINE D, 1992, J BIOL CHEM, V267, P17624; MARKIN VS, 1975, J MEMBRANE BIOL, V25, P23, DOI 10.1007/BF01868566; METZ DC, 1992, J BIOL CHEM, V267, P20620; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; MORENO SNJ, 1992, MOL BIOCHEM PARASIT, V52, P251, DOI 10.1016/0166-6851(92)90057-Q; MORENO SNJ, 1984, J BIOL CHEM, V259, P4609; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; RUBEN L, 1992, EXP PARASITOL, V74, P332, DOI 10.1016/0014-4894(92)90157-6; RUBEN L, 1991, J BIOL CHEM, V266, P24351; Scarpa A, 1979, Methods Enzymol, V56, P301; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORO M, 1987, J MEMBRANE BIOL, V95, P1, DOI 10.1007/BF01869625; VERCESI AE, 1990, MOL BIOCHEM PARASIT, V42, P119, DOI 10.1016/0166-6851(90)90119-7; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; VERCESI AE, 1991, CELL CALCIUM, V12, P361, DOI 10.1016/0143-4160(91)90052-G; VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463	27	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8564	8568						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473301				2022-12-27	WOS:A1993KX81100031
J	DEUTSCHER, MP				DEUTSCHER, MP			RIBONUCLEASE MULTIPLICITY, DIVERSITY, AND COMPLEXITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MESSENGER-RNA STABILITY; ESCHERICHIA-COLI K-12; POLYNUCLEOTIDE PHOSPHORYLASE; PROCESSING ENZYME; GENE; PURIFICATION; DEGRADATION; SEQUENCE; EXORIBONUCLEASE; MUTANT				DEUTSCHER, MP (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA.				NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RELAT AR, V62, P10; AMITSUR M, 1989, EMBO J, V8, P2411, DOI 10.1002/j.1460-2075.1989.tb08371.x; APIRION D, 1974, BROOKHAVEN SYM BIOL, P286; AVIRAM M, 1975, BIOCHEM BIOPH RES CO, V65, P1303, DOI 10.1016/S0006-291X(75)80372-X; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BARDWELL JCA, 1989, EMBO J, V8, P3401, DOI 10.1002/j.1460-2075.1989.tb08504.x; BEPPU T, 1969, J BACTERIOL, V98, P888, DOI 10.1128/JB.98.3.888-897.1969; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Blackburn P, 1982, ENZYMES, VXV, P317; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CANNISTRARO VJ, 1989, EUR J BIOCHEM, V181, P363, DOI 10.1111/j.1432-1033.1989.tb14733.x; CANNISTRARO VJ, 1991, J BACTERIOL, V173, P4653, DOI 10.1128/jb.173.15.4653-4659.1991; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CEDERGREN R, 1987, FEBS LETT, V226, P63, DOI 10.1016/0014-5793(87)80551-3; CHANDA PK, 1985, J BACTERIOL, V161, P446, DOI 10.1128/JB.161.1.446-449.1985; CHELLADURAI BS, 1991, NUCLEIC ACIDS RES, V19, P1759, DOI 10.1093/nar/19.8.1759; Crouch R. J., 1982, NUCLEASES, P211; CUDNY H, 1981, J BIOL CHEM, V256, P5633; CUDNY H, 1981, BIOCHEM BIOPH RES CO, V98, P337, DOI 10.1016/0006-291X(81)91908-2; DEUTSCHER MP, 1984, CRC CR REV BIOCH MOL, V17, P45, DOI 10.3109/10409238409110269; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DEUTSCHER MP, 1988, TRENDS BIOCHEM SCI, V13, P136, DOI 10.1016/0968-0004(88)90070-9; DEUTSCHER MP, 1985, CELL, V40, P731, DOI 10.1016/0092-8674(85)90330-7; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; DUFFY JJ, 1972, J MOL BIOL, V64, P565, DOI 10.1016/0022-2836(72)90083-6; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; FN DP, 1964, J MOL BIOL, V8, P210; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GHOSH RK, 1978, J BIOL CHEM, V253, P997; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GUARNEROS G, 1990, BIOCHIMIE, V72, P771, DOI 10.1016/0300-9084(90)90186-K; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; IMBODEN MA, 1992, J BIOL CHEM, V267, P24601; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; ITO R, 1983, BIOCHIM BIOPHYS ACTA, V739, P27, DOI 10.1016/0167-4781(83)90040-4; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KING TC, 1986, MICROBIOL REV, V50, P428, DOI 10.1128/MMBR.50.4.428-451.1986; LASATER LS, 1984, BIOCHEMISTRY-US, V23, P4367, DOI 10.1021/bi00314a019; LENNETTE ET, 1972, FEBS LETT, V21, P286; LITTAUER UZ, 1982, ENZYMES B, V15, P518; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MARCH PE, 1990, NUCLEIC ACIDS RES, V18, P3293, DOI 10.1093/nar/18.11.3293; MAYER JE, 1983, J BIOL CHEM, V258, P5340; MEADOR J, 1990, EUR J BIOCHEM, V187, P549, DOI 10.1111/j.1432-1033.1990.tb15336.x; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; NASHIMOTO M, 1992, NUCLEIC ACIDS RES, V20, P3737, DOI 10.1093/nar/20.14.3737; NEU HC, 1964, BIOCHEM BIOPH RES CO, V14, P109, DOI 10.1016/0006-291X(64)90238-4; NIYOGI SK, 1975, J BIOL CHEM, V250, P7307; OHNISHI Y, 1972, NATURE-NEW BIOL, V238, P228, DOI 10.1038/newbio238228a0; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; PETERSEN C, 1992, MOL MICROBIOL, V6, P277, DOI 10.1111/j.1365-2958.1992.tb01469.x; PORTIER C, 1975, EUR J BIOCHEM, V55, P573, DOI 10.1111/j.1432-1033.1975.tb02194.x; PORTIER C, 1973, EUR J BIOCHEM, V40, P77, DOI 10.1111/j.1432-1033.1973.tb03170.x; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; QUESADA P, 1990, MOL CELL BIOCHEM, V94, P53; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; ROBERTLEMEUR M, 1992, EMBO J, V11, P2633, DOI 10.1002/j.1460-2075.1992.tb05329.x; ROBERTSON HD, 1990, METHOD ENZYMOL, V181, P189; SARKAR N, 1975, J BIOL CHEM, V250, P684; SATO S, 1975, BIOCHEM J, V145, P353, DOI 10.1042/bj1450353; Shen V, 1982, ENZYMES, V15, P501, DOI [10.1016/S1874-6047(08)60288-7, DOI 10.1016/S1874-6047(08)60288-7]; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; SRIVASTAVA SK, 1992, J BACTERIOL, V174, P56, DOI 10.1128/jb.174.1.56-62.1992; STEVENS A, 1980, J BIOL CHEM, V255, P3080; SUGI M, 1980, J BIOL CHEM, V255, P943; Takahashi K., 1982, ENZYMES, V15, p435 468; TOMESANYI T, 1985, J MOL BIOL, V185, P713; ZHANG J, 1989, J BIOL CHEM, V264, P18228; ZHANG JR, 1992, P NATL ACAD SCI USA, V89, P2605, DOI 10.1073/pnas.89.7.2605; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	78	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13011	13014						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514741				2022-12-27	WOS:A1993LH55300001
J	SPILLMANN, D; HARD, K; THOMASOATES, J; VLIEGENTHART, JFG; MISEVIC, G; BURGER, MM; FINNE, J				SPILLMANN, D; HARD, K; THOMASOATES, J; VLIEGENTHART, JFG; MISEVIC, G; BURGER, MM; FINNE, J			CHARACTERIZATION OF A NOVEL PYRUVYLATED CARBOHYDRATE UNIT IMPLICATED IN THE CELL-AGGREGATION OF THE MARINE SPONGE MICROCIONA-PROLIFERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; CHONDROITIN SULFATE; MASS SPECTROMETRY; PROTEIN LINKAGE; HIGH-RESOLUTION; CAPILLARY GLC; SEA-CUCUMBER; HUMAN-URINE; BODY WALL; BINDING	The species-specific Ca2+-dependent reaggregation of dissociated cells of the marine sponge Microciona prolifera is mediated by a large extracellular adhesion proteoglycan. The glycans of this molecule are involved in the interactions of the proteoglycan with itself and with the sponge cells. Monoclonal antibodies against the glycans block the aggregation of sponge cells (Misevic, G. N., Finne, J., and Burger, M. M. (1987) J. Biol. Chem. 262, 5870-5877). Proteoglycan oligosaccharides were prepared by partial acid hydrolysis of the isolated glycans, and their reactivity with the monoclonal antibodies was monitored after linkage to phospholipid and immunostaining of thin layer chromatograms. One major antibody-reactive oligosaccharide was detected and purified by ion-exchange chromatography and high performance liquid chromatography. H-1 NMR spectroscopy, fast atom bombardment-mass spectrometry, methylation analysis, and sequential chemical and enzymatic degradation studies indicated the structure [GRAPHICS] for the oligosaCcharide. The depyruvylated derivative of the oligosaccharide did not react with the aggregation-blocking antibody, which indicates that the pyruvate acetal is an essential part of the epitope.	FRIEDRICH MIESCHER INST, CH-4058 BASEL, SWITZERLAND; UNIV UTRECHT, BIJVOET CTR BIOMOLEC RES, DEPT BIOORGAN CHEM, 3508 TB UTRECHT, NETHERLANDS; UNIV UTRECHT, BIJVOET CTR BIOMOLEC RES, DEPT MASS SPECTROMETRY, 3508 TB UTRECHT, NETHERLANDS; UNIV HOSP BASEL, DEPT RES, CH-4031 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Utrecht University; Utrecht University; University of Basel	SPILLMANN, D (corresponding author), UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU 52, FINLAND.		Misevic, Gradimir/D-8294-2016; Finne, Jukka/B-6881-2008	Misevic, Gradimir/0000-0001-5047-2936; Finne, Jukka/0000-0002-8076-3344				ARAKI S, 1989, J BIOL CHEM, V264, P19922; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BJOERN S, 1991, J BIOL CHEM, V266, P11051; CHAPLIN MF, 1982, ANAL BIOCHEM, V123, P336, DOI 10.1016/0003-2697(82)90455-9; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DUDMAN WF, 1986, CARBOHYD RES, V145, P175, DOI 10.1016/S0008-6215(00)90428-2; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FONTANA JD, 1982, CARBOHYD RES, V108, P221, DOI 10.1016/S0008-6215(00)81792-9; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; Galtsoff PS, 1929, BIOL BULL-US, V57, P250, DOI 10.2307/1536826; GAREGG PJ, 1980, CARBOHYD RES, V78, P127, DOI 10.1016/S0008-6215(00)83666-6; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GILSERRANO A, 1990, CARBOHYD RES, V204, P103, DOI 10.1016/0008-6215(90)84025-P; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HEDBYS L, 1989, GLYCOCONJUGATE J, V6, P161, DOI 10.1007/BF01050645; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KARIYA Y, 1990, J BIOL CHEM, V265, P5081; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KLINGER MM, 1981, J BIOL CHEM, V256, P7932; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOJIMA N, 1988, EUR J BIOCHEM, V174, P255, DOI 10.1111/j.1432-1033.1988.tb14091.x; LAMPIO A, 1991, ANAL BIOCHEM, V197, P132, DOI 10.1016/0003-2697(91)90368-4; LARRIBA G, 1978, FEBS LETT, V95, P190, DOI 10.1016/0014-5793(78)80081-7; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; MAGNANI JL, 1985, ANAL BIOCHEM, V150, P13, DOI 10.1016/0003-2697(85)90435-X; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NIKKILA EA, 1960, SCAND J CLIN LAB INV, V12, P209, DOI 10.3109/00365516009062424; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; PARKKINEN J, 1987, METHOD ENZYMOL, V138, P289, DOI 10.1016/0076-6879(87)38024-3; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; VARNER JA, 1988, J BIOL CHEM, V263, P8498; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WATANABE Y, 1989, J BIOCHEM-TOKYO, V106, P972, DOI 10.1093/oxfordjournals.jbchem.a122984; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	51	72	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13378	13387						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514776				2022-12-27	WOS:A1993LH55300054
J	LIU, ZR; THOMPSON, KS; TOWLE, HC				LIU, ZR; THOMPSON, KS; TOWLE, HC			CARBOHYDRATE REGULATION OF THE RAT L-TYPE PYRUVATE-KINASE GENE REQUIRES 2 NUCLEAR FACTORS - LF-A1 AND A MEMBER OF THE C-MYC FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSCRIPTIONAL REGULATION; MAJOR LATE PROMOTER; DNA-BINDING; ACTIVATES TRANSCRIPTION; LIVER; EXPRESSION; PROTEIN; UPSTREAM; GLUCOSE; REGIONS	Transcription of the L-type pyruvate kinase (L-PK) gene is induced in response to increased carbohydrate metabolism in the liver. We have demonstrated previously that a segment of the 5'-flanking region of the L-PK gene between -183 and -96 is necessary and sufficient for the glucose response in primary hepatocytes. To explore the protein factors that are involved in carbohydrate regulation, we have performed mutational analyses and in vitro binding studies of this segment. Sequences critical for the glucose response were mapped from -171 to -124. This segment contains the consensus binding sites for two nuclear transcription factors: LF-A1 and MLTF. Both factors are capable of binding to the corresponding L-PK sites in vitro. Mutational and functional analyses indicated that LF-A1 is indeed involved in glucose induction of the L-PK gene. The PK MLTF-like site consists of two imperfect CACGTG motifs, the core binding site for a family of transcription factors related to c-myc. Unexpectedly, mutations in either motif that resulted in defective glucose stimulation retained in vitro binding to MLTF. Furthermore, an authentic MLTF binding site from the adenovirus major late promoter was not functionally interchangeable with the natural sequence. These data indicate that binding of MLTF, in presence of LF-A1, is not capable of supporting the glucose response. Conversion of either imperfect motif to CACGTG within the context of the mutations disrupting the opposite site restored the response to elevated glucose. Thus, the factor that recognizes the PK MLTF-like site and participates in mediating the carbohydrate response of the L-PK gene appears to be a member of the c-myc family distinct from MLTF.	UNIV MINNESOTA,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [DK 26919] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCUS AC, 1970, ANAL BIOCHEM, V37, P53, DOI 10.1016/0003-2697(70)90257-5; BACK DW, 1986, J BIOL CHEM, V261, P4190; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HROMAS R, 1986, NUCLEIC ACIDS RES, V14, P4837, DOI 10.1093/nar/14.12.4837; INOUE H, 1984, J BIOCHEM-TOKYO, V96, P1457, DOI 10.1093/oxfordjournals.jbchem.a134974; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARIASH CN, 1981, J CLIN INVEST, V68, P1485, DOI 10.1172/JCI110401; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOGUCHI T, 1991, BIOCHEM BIOPH RES CO, V181, P259, DOI 10.1016/S0006-291X(05)81411-1; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STROBL W, 1989, J BIOL CHEM, V264, P1190; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; YAMADA K, 1990, J BIOL CHEM, V265, P19885	37	123	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12787	12795						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509413				2022-12-27	WOS:A1993LG65800083
J	MARSTON, SB; REDWOOD, CS				MARSTON, SB; REDWOOD, CS			THE ESSENTIAL ROLE OF TROPOMYOSIN IN COOPERATIVE REGULATION OF SMOOTH-MUSCLE THIN FILAMENT ACTIVITY BY CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; HEAVY-MEROMYOSIN; MYOSIN SUBFRAGMENT-1; TROPONIN-TROPOMYOSIN; CA-2+ REGULATION; F-ACTIN; BINDING; SKELETAL; CALMODULIN; INHIBITION	We compared the mechanisms by which caldesmon inhibits actin and actin-tropomyosin activation of myosin subfragment 1 (S1) MgATPase activity. Caldesmon always inhibited actin activation by displacing S1 . ADP . P(i) from actin and inhibition required at least 0.7 caldesmon molecules bound per actin for 90% inhibition. Caldesmon inhibited actin-tropomyosin without any displacement of S1 . ADP . P(i); thus it inhibits a rate-limiting step. Inhibition is highly cooperative, requiring no more than one caldesmon bound per 10 actins for 90% inhibition of activation by actin and smooth muscle tropomyosin. The degree of cooperativity is defined by the tropomyosin since inhibition by skeletal tropomyosin requires up to one caldesmon bound per 4 actins for 90% inhibition under identical conditions. Both noncooperative inhibition of actin and cooperative, tropomyosin-dependent, inhibition are manifested by a fragment of caldesmon containing only the C-terminal 99 amino acids (658C), although this fragment does not itself bind to tropomyosin. The functional properties of 658C are very similar to striated muscle troponin I, consequently we propose a similar mechanism for tropomyosin-dependent regulation by caldesmon. Caldesmon binding switches actin-tropomyosin to the ''off'' or ''weak'' state and Ca2+/calmodulin binding to caldesmon blocks this switch and thus reactivates the actin filament.			MARSTON, SB (corresponding author), NATL HEART & LUNG INST, DEPT CARDIAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.			Marston, Steven/0000-0001-6054-6070				BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85; CHEN YD, 1992, BIOPHYS J, V63, P1063, DOI 10.1016/S0006-3495(92)81687-9; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HILL TL, 1981, BIOPHYS J, V35, P99, DOI 10.1016/S0006-3495(81)84777-7; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON SB, 1991, FEBS LETT, V292, P179, DOI 10.1016/0014-5793(91)80862-W; MARSTON SB, 1984, J MUSCLE RES CELL M, V5, P559, DOI 10.1007/BF00713261; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PRITCHARD K, 1993, BIOCHEM BIOPH RES CO, V190, P668, DOI 10.1006/bbrc.1993.1100; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBIESZEK A, 1982, J MOL BIOL, V157, P275, DOI 10.1016/0022-2836(82)90234-0; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	34	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12317	12320						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509369				2022-12-27	WOS:A1993LG65800017
J	ROBERTSON, MW				ROBERTSON, MW			PHAGE AND ESCHERICHIA-COLI EXPRESSION OF THE HUMAN HIGH-AFFINITY IMMUNOGLOBULIN-E-RECEPTOR ALPHA-SUBUNIT ECTODOMAIN - DOMAIN LOCALIZATION OF THE IGE-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; FILAMENTOUS PHAGE; VARIABLE DOMAINS; MAST-CELLS; ANTIBODY; CHAIN; RAT; PROTEINS; GENE; LIBRARIES	The high affinity IgE receptor is a multisubunit complex that participates in IgE-dependent activation of mast cells and basophils. The IgE-binding portion of the receptor resides exclusively in the alpha-subunit and specifically within the 180 residues of the mature extracytoplasmic portion. In this study the contiguous two-domain human alpha-subunit has been displayed on the surface of a filamentous bacteriophage in a form that specifically binds both human and murine IgE but not other isotypes. Phage display of the individual immunoglobulin-like domains reveals that the IgE-binding portion resides exclusively in the COOH-terminal domain and that this domain appears to bind IgE with lower affinity than the comparably displayed two-domain fragment. Phage display results using a chimeric rat-human alpha-subunit fragment suggest that structural elements within the NH2-terminal domain are necessary to impart high affinity IgE binding activity to the alpha-chain ectodomain. The two-domain human receptor fragment was also expressed in a soluble form from Escherichia coli and purified in one step by affinity chromatography. The solution binding of the purified receptor fragment to IgE was measured by fluorescence quench which afforded an approximate equilibrium affinity constant of 2 x 10(9) M-1 together with a stoichiometry of 1 receptor molecule/molecule of IgE. The complementary approach of phage display and E. coli expression used in this study represents a useful strategy for further analysis of discrete receptor epitope(s) that contribute to IgE binding activity.			ROBERTSON, MW (corresponding author), MRC,CTR PROT ENGN,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; CONRAD DH, 1983, J IMMUNOL, V130, P327; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAY LA, 1969, J MOL BIOL, V39, P265, DOI 10.1016/0022-2836(69)90316-7; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EISEN HN, 1964, METHOD MED RES, V10, P155; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEMPSTEAD BL, 1981, J BIOL CHEM, V256, P717; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JUNG V, 1990, NUCLEIC ACIDS RES, V18, P6156, DOI 10.1093/nar/18.20.6156; KANELLOPOULOS J, 1979, J BIOL CHEM, V254, P7691; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KULCZYCKI A, 1979, J BIOL CHEM, V254, P3187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LIU FT, 1980, J IMMUNOL, V124, P2728; LIU FT, 1988, P NATL ACAD SCI USA, V85, P5639, DOI 10.1073/pnas.85.15.5639; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PECOUD AR, 1981, J IMMUNOL, V126, P1624; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RISKE F, 1991, J BIOL CHEM, V266, P11245; SAMBROOK J, 1990, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; TEPLER I, 1989, J BIOL CHEM, V264, P5912; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WEBSTER RE, 1985, VIRUS STRUCTURE ASSE, P235	46	72	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12736	12743						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509408				2022-12-27	WOS:A1993LG65800076
J	VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB				VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB			GLYCOPROTEIN-BIOSYNTHESIS IN THE ALG3 SACCHAROMYCES-CEREVISIAE MUTANT .2. STRUCTURE OF NOVEL MAN6-10GLCNAC2 PROCESSING INTERMEDIATES ON SECRETED INVERTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; LIPID-LINKED OLIGOSACCHARIDES; YEAST EXTERNAL INVERTASE; PROTEIN GLYCOSYLATION; CORE OLIGOSACCHARIDES; ELONGATION; DEFICIENT; CELLS	Alg3 yeast mutants synthesize endoglycosidase H-resistant oligosaccharides whose precursor for elongation is Man1alpha-->2Man1alpha-->2Man1alpha-->3(Man1alpha--> 6) Man1beta-->4GlcNAc2 (Verostek, M. F., Atkinson, P. H., and Trimble, R. B. (1991) J. Biol. Chem. 266, 5547-5551). To characterize alg3 glycan elongation in vivo, oligosaccharides on alg3,sec18 invertase synthesized and secreted at 26-degrees-C were released with peptide-N4-N-acetyl-beta-glucosaminyl asparagine amidase and purified by Bio-Gel P-4 chromatography. Large (Man>30GlcNAc2) and intermediate (Man5-10GlcNAc2) sized oligosaccharides were pooled separately, and the smaller ones were exchanged with (H2O)-H-2 for one- and two-dimensional DQF-COSY H-1 NMR analyses at 500 MHz. Although there was no detectable substitution of the terminal alpha1,6-core-linked mannose, addition of alpha1,6-, alpha1,2-, and alpha1,3-mannoses to the alpha1,3-linked core branch of a majority of the Man5 precursor was analogous to core-filling reactions seen on wild type invertase glycans (Trimble, R. B., and Atkinson, P. H. (1986) J. Biol. Chem. 261, 9815-9824). Two additional types of oligosaccharide structures were found; those which retained glucose and those consistent with mannan elongation. Glucose retention appeared to be due to inefficient trimming from minor glucosylated intermediates, while mannan elongation was by extension of a new alpha1,6-linked branch from the alpha1,3-core-linked residue as seen in wild-type core oligosaccharides (Hernandez, L. M., Ballou, L., Alvarado, E., Gillece-Castro, B. L., Burlingame, A. L., and Ballou, C. E. (1989) J. Biol. Chem. 264, 11849-11856) or mnnl,mnn2,mnn10 processing intermediates (Ballou, L., Alvarado, E., Tsai, P-k., Dell, A., and Ballou, C. E. (1989) J. Biol. Chem. 264, 11857-11864). Thus, the alpha1,6-linked branch additions which form Man9GlcNAc2-PP-dolichol from Man5GlcNAc2-PP-dolichol appear to provide important structural information enabling efficient recognition by the endoplasmic reticulum-glucosyltransferases forming oligosaccharide-lipid as well as the glucosidases involved in early trimming reactions, but the alg3 mutant documents that they are unnecessary for normal yeast man-nan elongation.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES E524, POB 509, ALBANY, NY 12201 USA; MINIST AGR & FISHERIES TECHNOL, UPPER HUTT, NEW ZEALAND; SUNY, SCH PUBL HLTH, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; SUNY Maritime College					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA013402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NCI NIH HHS [CA13402, CA13330] Funding Source: Medline; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; ALVARADO E, 1991, BIOCHEMISTRY-US, V30, P881, DOI 10.1021/bi00218a001; BALLOU L, 1989, J BIOL CHEM, V264, P11857; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6607, DOI 10.1021/bi00526a014; CHAPMAN A, 1979, CELL, V17, P509, DOI 10.1016/0092-8674(79)90259-9; CHU FK, 1978, J BIOL CHEM, V253, P8691; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Goldstein A, 1975, Methods Enzymol, V42, P504; GOPAL PK, 1987, P NATL ACAD SCI USA, V84, P8824, DOI 10.1073/pnas.84.24.8824; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1979, J BIOL CHEM, V254, P2754; MCLEAN C, 1973, ANAL BIOCHEM, V55, P72, DOI 10.1016/0003-2697(73)90291-1; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROMERO PA, 1989, J BIOL CHEM, V264, P1946; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSAI PK, 1984, J BIOL CHEM, V259, P3805; TSAI PK, 1984, P NATL ACAD SCI-BIOL, V81, P6340, DOI 10.1073/pnas.81.20.6340; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	42	33	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12104	12115						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505334				2022-12-27	WOS:A1993LF28400096
J	COLAMONICI, OR; DOMANSKI, P				COLAMONICI, OR; DOMANSKI, P			IDENTIFICATION OF A NOVEL SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR LOCALIZED TO HUMAN CHROMOSOME-21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-INTERFERON; GAMMA-INTERFERON; CELLS; ANTIBODIES; EXPRESSION; CLONING; BINDING; GENE; CDNA	Expression in mouse cells of the cloned human IFN alpha receptor (IFNalphaR) subunit selectively confers response and binding to human IFNalpha8, indicating that other subunits are involved in IFNalpha binding. We report here that a new monoclonal antibody (mAb), termed IFNaRbeta1, recognizes a novel IFNalphaR subunit different from the one recently cloned and distinct from the alpha subunit recognized by the IFNalphaR3 mAb. The IFNaRbeta1 mAb blocks the biological effect of seven different Type I IFNs. Immunoprecipitations after cell surface iodination demonstrate that the IFNaRbeta1 mAb recognizes a protein with a molecular mass of 100 kDa in Daudi and U-266 cells that express normal IFNalphaR. However, a 55-kDa protein instead of the 100-kDa product was immunoprecipitated in the IFNalpha-resistant U-937 cell line that express the variant form of the receptor. We also demonstrate that the gene that codes for this novel IFNalphaR subunit maps to human chromosome 21, as do the cloned IFNalphaR subunit and the alpha subunit, indicating the existence of a locus on this chromosome that regulates binding for Type I IFNs.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago								BENOIT P, 1993, J IMMUNOL, V150, P707; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; EPSTEIN CJ, 1982, BIOCHEM BIOPH RES CO, V107, P1060, DOI 10.1016/0006-291X(82)90629-5; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MEISTER A, 1986, J GEN VIROL, V67, P1633, DOI 10.1099/0022-1317-67-8-1633; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, CANCER RES, V50, P2654; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; REVEL M, 1976, NATURE, V260, P139, DOI 10.1038/260139a0; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHULMAN LM, 1984, VIROLOGY, V137, P422, DOI 10.1016/0042-6822(84)90235-6; TAN YH, 1976, NATURE, V260, P141, DOI 10.1038/260141a0; TAN YH, 1974, SCIENCE, V186, P61, DOI 10.1126/science.186.4158.61; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; ZOON KC, 1984, PHARMACOL THERAPEUT, V24, P259, DOI 10.1016/0163-7258(84)90037-8	23	100	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10895	10899						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496154				2022-12-27	WOS:A1993LD46600030
J	COPELAND, WC; LAM, NK; WANG, TSF				COPELAND, WC; LAM, NK; WANG, TSF			FIDELITY STUDIES OF THE HUMAN DNA POLYMERASE-ALPHA - THE MOST CONSERVED REGION AMONG ALPHA-LIKE DNA-POLYMERASES IS RESPONSIBLE FOR METAL-INDUCED INFIDELITY IN DNA-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INSERTION FIDELITY; MANGANESE; TRIPHOSPHATE; EXTENSION; KINETICS; INVITRO	Mutational studies in the highly conserved region I domain of the human DNA polymerase alpha enzyme demonstrated a change in metal cation-specific catalysis. Here, we extend the investigation to include the fidelity of DNA synthesis by these mutants, studying misinsertion, mispair extension, and the nucleotide analog utilization. The fidelity of region I mutants and wild type human DNA polymerase alpha enzyme were analyzed with either Mg2+ or Mn2+ as the metal activator. Despite the known mutagenic effect of Mn2+ in causing polymerases to misinsert nucleotides and to utilize dideoxynucleotides, we have found that two region I mutants, D1002N and T1003S, which utilize Mn2+ in catalysis more effectively than Mg2+, actually have a 70- and 40-fold higher misinsertion fidelity, respectively, in Mn2+-catalyzed reactions than that of the wild type enzyme. The enhanced misinsertion fidelity of these two mutants in Mn2+-catalyzed reactions is due to K(m) discrimination of the incorrect nucleotide where the D1002N and T1003S had a 850- and 62-fold higher K(m) for insertion of incorrect than correct nucleotide, respectively. In Mg2+-catalyzed reactions, all of the region I mutants exhibited similar misinsertion efficiencies as the wild type polymerase. Study of mispair extension showed that in Mn2+-catalyzed reactions, the wild type polymerase alpha enzyme readily extended mispair termini. In contrast, the two region I mutants, D1002N and T1003S, were unable to extend the mispaired termini in either Mg2+- or Mn2+-catalyzed reactions. These results suggest that the side chains of region I amino acids play an essential role in the Mn2+-induced infidelity during DNA synthesis by human DNA polymerase alpha. The effects of the metal activator on the utilization of two nucleotide analogs, 3'-azido-3'-deoxythymidine triphosphate and ddCTP, by the region I mutants were also investigated.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NCI NIH HHS [CA14835] Funding Source: Medline; NIAID NIH HHS [AI28873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berg P, 1963, INFORMATIONAL MACROM, P467; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DUBE DK, 1975, BIOCHEM BIOPH RES CO, V67, P1041, DOI 10.1016/0006-291X(75)90779-2; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ELDEIRY WS, 1988, BIOCHEMISTRY-US, V27, P546, DOI 10.1021/bi00402a007; ENGLUND PT, 1969, J BIOL CHEM, V244, P3045; FREELANDGRAVES JH, 1988, NUTR REV, V46, P348; HALL ZW, 1968, J MOL BIOL, V36, P321, DOI 10.1016/0022-2836(68)90158-7; IRVING H, 1953, J CHEM SOC, V637, P3192; KORNBERG A, 1992, DNA REPLICATION, P126; KORNBERG A, 1992, DNA REPLICATION, P224; KRAUSS SW, 1980, BIOCHEMISTRY-US, V19, P220, DOI 10.1021/bi00542a033; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; ONO K, 1984, BIOMED PHARMACOTHER, V38, P382; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; SEAL G, 1979, J BIOL CHEM, V254, P5229; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	26	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11041	11049						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496165				2022-12-27	WOS:A1993LD46600050
J	PATE, E; FRANKSSKIBA, K; WHITE, H; COOKE, R				PATE, E; FRANKSSKIBA, K; WHITE, H; COOKE, R			THE USE OF DIFFERING NUCLEOTIDES TO INVESTIGATE CROSS-BRIDGE KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKINNED MUSCLE-FIBERS; RABBIT PSOAS FIBERS; SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; FORCE GENERATION; RANA-TEMPORARIA; CONTRACTION; PHOSPHATE; DISSOCIATION; MECHANISM	We have investigated the ability of the nucleotides GTP, CTP, and 1-N-etheno-2-aza-ATP (aza-ATP) to support contraction of chemically skinned rabbit psoas fibers. Working at 10-degrees-C, millimolar concentrations of all nucleotides relaxed fibers in the absence of calcium. In active fibers, GTP served as a very poor substrate, with isometric tension, isometric GTPase rate, and maximum shortening velocity (V(max)) all less than 10% of those obtained with ATP. Aza-ATP was only a slightly better substrate. CTP, on the other hand, was an effective substrate with mechanical parameters which were 65-100% those obtained with ATP, and with a hydrolysis rate that exceeded that of ATP. For all three ligands, V(max) followed Michaelis-Menten saturation behavior with values for K(m) which were from 2.5 to 12 times greater than that for ATP, showing that the analogs bound slowly to myosin in the fibers. Increasing concentrations of orthophosphate inhibited tension with CTP, to a lesser extent with aza-ATP, but not at all with GTP. A combination of the mechanical data obtained in fibers with the kinetic data obtained in solution (White, H. D., Belknap, B., and Jiang, W. (1993) J. Biol. Chem. 268, 10039-10045) is used to better define the actomyosin interaction in fibers.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; EASTERN VIRGINIA MED SCH,DEPT BIOCHEM,NORFOLK,VA 23501; WASHINGTON STATE UNIV,DEPT PURE & APPL MATH,PULLMAN,WA 99164; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Eastern Virginia Medical School; Washington State University; University of California System; University of California San Francisco					NHLBI NIH HHS [HL41776, HL32145] Funding Source: Medline; NIAMS NIH HHS [AR39643] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032145, R01HL041776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039643] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABBOTT RH, 1970, PFLUG ARCH EUR J PHY, V321, P223, DOI 10.1007/BF00588443; BELKNAP B, 1989, Biophysical Journal, V55, p269A; BELKNAP B, 1992, Biophysical Journal, V61, pA440; BLUM JJ, 1955, ARCH BIOCHEM BIOPHYS, V55, P486, DOI 10.1016/0003-9861(55)90428-8; BRENNER B, 1986, BIOPHYS J, V50, P685, DOI 10.1016/S0006-3495(86)83509-3; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P10490, DOI 10.1073/pnas.88.23.10490; Brenner B., 1990, MUSCLE MECH BIOLOGIC, P77; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; COOKE R, 1980, BIOCHEMISTRY-US, V19, P2265, DOI 10.1021/bi00551a042; COOKE R, 1979, BIOPHYS J, V28, P241, DOI 10.1016/S0006-3495(79)85174-7; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; COOKE R, 1988, J PHYSIOL-LONDON, V395, P77, DOI 10.1113/jphysiol.1988.sp016909; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; ECCLESTON JF, 1979, BIOCHEMISTRY-US, V18, P2896, DOI 10.1021/bi00580a034; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FERENCZI MA, 1984, J PHYSIOL-LONDON, V350, P519, DOI 10.1113/jphysiol.1984.sp015216; FERENCZI MA, 1982, BASIC BIOL MUSCLES C, P91; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V350, P497, DOI 10.1113/jphysiol.1984.sp015215; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; HASSELBACH W, 1956, BIOCHIM BIOPHYS ACTA, V20, P355, DOI 10.1016/0006-3002(56)90297-9; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIBBERD MG, 1985, SCIENCE, V228, P1317, DOI 10.1126/science.3159090; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOMSHER E, 1990, ANNU REV PHYSIOL, V52, P875, DOI 10.1146/annurev.ph.52.030190.004303; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; JAMES E, 1966, J BIOL CHEM, V241, P4758; JULIAN FJ, 1981, J PHYSIOL-LONDON, V311, P201, DOI 10.1113/jphysiol.1981.sp013581; KAWAI M, 1986, J MUSCLE RES CELL M, V7, P421, DOI 10.1007/BF01753585; KAWAI M, 1989, BIOPHYS J, V55, P595, DOI 10.1016/S0006-3495(89)82857-7; KIELLEY WW, 1956, J BIOL CHEM, V219, P95; KOMADA T, 1986, J BIOCHEM-TOKYO, V99, P1465; PATE E, 1989, PFLUG ARCH EUR J PHY, V414, P73, DOI 10.1007/BF00585629; PATE E, 1988, BIOPHYS J, V53, pA568; PATE E, 1991, BIOPHYS J, V59, P598, DOI 10.1016/S0006-3495(91)82275-5; PATE E, 1989, J MUSCLE RES CELL M, V10, P181, DOI 10.1007/BF01739809; PATE E, 1992, AM J PHYSIOL, V262, pC1039; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SLEEP J, 1986, BIOCHEMISTRY-US, V25, P1149, DOI 10.1021/bi00353a030; SMITH SJ, 1985, J BIOL CHEM, V260, P5156; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TONOMURA Y, 1973, MUSCLE PROTEINS MUSC, P259; WALKER JW, 1992, J BIOL CHEM, V267, P2459; WEBER A, 1969, J GEN PHYSIOL, V53, P781, DOI 10.1085/jgp.53.6.781; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YOUNT RG, 1963, J BIOL CHEM, V238, P1708	50	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10046	10053						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486676				2022-12-27	WOS:A1993LB80000019
J	PATEL, SS; HINGORANI, MM				PATEL, SS; HINGORANI, MM			OLIGOMERIC STRUCTURE OF BACTERIOPHAGE-T7 DNA PRIMASE HELICASE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-4 PROTEIN; ATP HYDROLYSIS; REPLICATION; MECHANISM; COMPONENT; SEQUENCE; HEXAMERS; ANTIGEN; RHO	The oligomeric structure of bacteriophage T7 gene 4 helicase/primase proteins was investigated using protein cross-linking and high pressure gel-filtration chromatography. Studies were carried out with both 4A' and 4B proteins. 4A' is a M64L mutant of 4A which has similar helicase and primase activities as the wild-type mixture of 4A and 4B proteins (Patel, S. S., Rosenberg, A. H., Studier, F. W., and Johnson, K. A. (1992) J. Biol. Chem. 267, 15013-15021), and 4B is the smaller protein which has only helicase activity. Chemical cross-linking of 4A' and 4B proteins with dimethyl suberimidate resulted in cross-linked species ranging from dimers to hexamers and beyond. The cross-linking time course, however, indicated that hexamers were the predominant species to accumulate in both 4A' and 4B proteins. The effect of MgNTP and DNA binding on oligomerization of the gene 4 proteins was investigated using high pressure gel-filtration chromatography at increasing protein concentrations. In the absence of added ligands, close to 100 muM protein-concentrations were required to form stable oligomers beyond dimers. However, in the presence of Mg-beta,gamma-methylene deoxythymidine triphosphate (nonhydrolyzable analog of dTTP), 4A' and 4B proteins assembled into stable hexamers at protein concentrations less than 8 muM. Addition of single-stranded DNA further stabilized the hexamer structure. Therefore, in the presence of a 60-nucleotide-long single-stranded DNA, hexamers were observed at protein concentrations as low as 0.2 muM. Nuclease protection experiments indicated that the 4A' and 4B hexamers protect about 60-65 bases of single-stranded DNA.			PATEL, SS (corresponding author), OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210, USA.							ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5247; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PATEL SS, 1992, J BIOL CHEM, V267, P15013; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SEO YS, 1991, J BIOL CHEM, V266, P13161; Valdes R Jr, 1979, Methods Enzymol, V61, P125; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YARRANTON GT, 1979, J BIOL CHEM, V254, P1997	29	118	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10668	10675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486715				2022-12-27	WOS:A1993LB80000098
J	ZHANG, H; GAO, YG; VANDERMAREL, GA; VANBOOM, JH; WANG, AHJ				ZHANG, H; GAO, YG; VANDERMAREL, GA; VANBOOM, JH; WANG, AHJ			SIMULTANEOUS INCORPORATIONS OF 2 ANTICANCER DRUGS INTO DNA - THE STRUCTURES OF FORMALDEHYDE-CROSS-LINKED ADDUCTS OF DAUNORUBICIN-D(CG(ARAC)GCG) AND DOXORUBICIN-D(CA(ARAC)GTG) COMPLEXES AT HIGH-RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; RNA; ARABINOSYLCYTOSINE; DAUNORUBICIN; NOGALAMYCIN; DAUNOMYCIN; PROSPECTS; LEUKEMIA	Anthracycline antibiotics (notably daunorubicin (DAU) and doxorubicin (DOX)) and nucleoside analog arabinosylcytosine (araC or (a)C) are important anticancer drugs. They are sometimes used together in the treatment of certain cancers. Both classes of compounds act by blocking DNA replication and transcription. To probe whether both drugs can be incorporated simultaneously into DNA and the possible structural consequences, we carried out x-ray diffraction analyses of the complexes between DAU/DOX and araC-containing DNA hexamers cross-linked with formaldehyde. The crystal structures were determined to high resolution (DAU-CG(a)CGCG, 1.2 angstrom, space group P4(1)2(1)2, R = 0.182, 3275 reflections; DOX-CA(a)CGTG, 1.5 angstrom, space group C2, R = 0.175, 3359 reflections), and they are similar to those of the previously studied DAU- and DOX-DNA complexes, despite different crystal packings. Two DAU/DOX molecules intercalate at both ends of the helix with their amino sugars in the minor groove. As in the structure of DAU-CGCGCG (Wang, A. H.-J., Gao, Y.-G., Liaw, Y.-C., and Li, Y. K. (1991) Biochemistry 30, 3812-3815), a covalent methylene bridge (from formaldehyde) between the N3' of daunosamine and the N2 of the guanine is formed in both adducts. In DOX-CA(a)CGTG, the two halves are slightly different with a root-mean-square deviation of 0.322 angstrom between them. The O-14 hydroxyls of the intercalated DOXs are within hydrogen bond distances to the O2P atoms of the A2p((a)C3) and A8p((a)C9) steps. The O2P-hydroxyl group from araC does not affect the binding of DAU-DOX or the conformation of the drug-DNA complexes. The results suggest that three major drug modifications on DNA, i.e., intercalation, covalent bond formation, and nucleoside analog incorporation, can coexist in the same DNA molecule without difficulty. When they occur in close proximity in DNA, they may provide an additive inhibitory effect for the target enzymes.	LEIDEN UNIV,GORLAEUS LABS,2300 RA LEIDEN,NETHERLANDS; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	Leiden University; Leiden University - Excl LUMC; University of Illinois System; University of Illinois Urbana-Champaign	WANG, AHJ (corresponding author), UNIV ILLINOIS,DIV BIOPHYS,URBANA,IL 61801, USA.				NATIONAL CANCER INSTITUTE [R01CA052506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041612] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52506] Funding Source: Medline; NIGMS NIH HHS [GM-41612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, CURR OPIN STRUC BIOL; ARAI T, 1979, TETRAHEDRON LETT, P2355; ARORA SK, 1991, J BIOMOL STRUCT DYN, V6, P489; DENNY WA, 1989, ANTI-CANCER DRUG DES, V4, P241; DEVROOM E, 1988, NUCLEIC ACIDS RES, V16, P2987, DOI 10.1093/nar/16.7.2987; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; GAO YG, 1991, P NATL ACAD SCI USA, V88, P4845, DOI 10.1073/pnas.88.11.4845; GAO YG, 1990, BIOCHEMISTRY-US, V29, P10307, DOI 10.1021/bi00497a004; HAGHBIN M, 1974, CANCER-AM CANCER SOC, V33, P1491, DOI 10.1002/1097-0142(197406)33:6<1491::AID-CNCR2820330604>3.0.CO;2-#; HENDRICKSON WA, 1979, BIOMOLECULAR STRUCTU, P43; ISHIGURO K, 1978, BIOCHEMISTRY-US, V17, P2545, DOI 10.1021/bi00606a014; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KEATING MJ, 1982, JAMA-J AM MED ASSOC, V248, P2481, DOI 10.1001/jama.248.19.2481; KIMURA K, 1990, AGR BIOL CHEM TOKYO, V54, P1645, DOI 10.1080/00021369.1990.10870198; KUCHTA RD, 1992, BIOCHEMISTRY-US, V31, P4720, DOI 10.1021/bi00134a027; KUFE DW, 1985, SEMIN ONCOL, V12, P34; LIAW YC, 1989, BIOCHEMISTRY-US, V28, P9913, DOI 10.1021/bi00452a006; Lown J.W., 1988, ANTHRACYCLINE ANTHRA; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; PROPST CL, 1992, NUCLEIC ACID TARGETE; PULLMAN B, 1990, MOL BASIS SEPECIFICI; RABINOVICH D, 1984, ACTA CRYSTALLOGR A, V40, P195, DOI 10.1107/S010876738400043X; Rosik LO, 1990, BIOCONJUGATE CHEM, V1, P251, DOI 10.1021/bc00004a004; SAKAI R, 1992, P NATL ACAD SCI USA, V89, P11456, DOI 10.1073/pnas.89.23.11456; SYGUSCH J, 1976, ACTA CRYSTALLOGR B, V32, P1139, DOI 10.1107/S0567740876004834; TAKAHASHI A, 1992, CHEM PHARM BULL, V40, P1313, DOI 10.1248/cpb.40.1313; TENG MK, 1989, BIOCHEMISTRY-US, V28, P4923, DOI 10.1021/bi00438a001; TOUGARD P, 1974, ACTA CRYSTALLOGR B, V30, P86, DOI 10.1107/S0567740874002251; UEDA I, 1984, ACTA CRYSTALLOGR C, V40, P1578, DOI 10.1107/S0108270184008775; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; WANG AHJ, 1984, SCIENCE, V225, P1115, DOI 10.1126/science.6474168; WANG AHJ, 1991, BIOCHEMISTRY-US, V30, P3812, DOI 10.1021/bi00230a002; WARPEHOSKI MA, 1988, CHEM RES TOXICOL, V1, P315, DOI 10.1021/tx00006a001; WESTENDORF J, 1989, CANCER RES, V49, P5262; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035; ZHANG H, 1992, BIOPOLYMERS, V32, P1559, DOI 10.1002/bip.360321113	38	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10095	10101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486678				2022-12-27	WOS:A1993LB80000025
J	FRELIN, C; BREITTMAYER, JP; VIGNE, P				FRELIN, C; BREITTMAYER, JP; VIGNE, P			ADP INDUCES INOSITOL PHOSPHATE-INDEPENDENT INTRACELLULAR CA2+ MOBILIZATION IN BRAIN CAPILLARY ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; SMOOTH-MUSCLE CELLS; BRILLIANT BLUE-G; EXTRACELLULAR ATP; CALCIUM MOBILIZATION; CA-2+ MOBILIZATION; REACTIVE BLUE-2; PHOSPHOLIPASE-C; TUMOR PROMOTER; THAPSIGARGIN	The action of adenine and uracyl nucleotides on rat brain capillary endothelial cells was investigated. ATP, UTP, and adenosine 5'-O-(3-thiotrisphosphate) activated phospholipase C and induced large increases in [Ca2+]i. ADP had a different action. At low concentrations (<10 muM), ADP induced the mobilization of a thapsigargin-sensitive intracellular Ca2+ store in the absence of measurable production of inositol phosphates. At larger concentrations (>30 mum), ADP activated phospholipase C. The actions of ATP and ADP and of UTP and ADP were additive. Those of ATP and UTP were not. In the presence of ATP or UTP, the dose-response curve for ADP action on [Ca2+]i was monophasic and corresponded to the high affinity responses. Finally, we observed that ADP did not desensitize cells to the actions of ATP and UTP. In contrast, cross-desensitization of the actions of ATP and UTP were observed. It is concluded that two types of receptors account for the actions of nucleotides: (i) a nucleotide that recognizes ATP and UTP and that is positively coupled to phospholipase C; and (ii) an ADP-specific receptor that induces the mobilization of a thapsigargin-sensitive intracellular Ca2+ pool in a manner independent of the formation of inositol phosphates.	UNIV NICE,FAC MED,INSERM,U343,F-06034 NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	FRELIN, C (corresponding author), CNRS 660,INST PHARMACOL MOLEC & CELLULAIRE,ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE.							AMBLER SK, 1987, MOL PHARMACOL, V32, P376; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; BOEYNAEMS JM, 1990, TRENDS PHARMACOL SCI, V11, P34, DOI 10.1016/0165-6147(90)90039-B; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; DUBYAK GR, 1985, J BIOL CHEM, V260, P653; GONZALEZ FA, 1989, J CELL PHYSIOL, V141, P606, DOI 10.1002/jcp.1041410320; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HOPWOOD AM, 1987, EUR J PHARMACOL, V136, P49, DOI 10.1016/0014-2999(87)90777-1; HOUSTON DA, 1987, J PHARMACOL EXP THER, V241, P501; INOUE K, 1991, BRIT J PHARMACOL, V102, P851, DOI 10.1111/j.1476-5381.1991.tb12265.x; KENNEDY C, 1985, EUR J PHARMACOL, V107, P161, DOI 10.1016/0014-2999(85)90055-X; KUROKI M, 1989, BIOCHIM BIOPHYS ACTA, V1012, P103, DOI 10.1016/0167-4889(89)90017-7; LEE HC, 1989, J BIOL CHEM, V264, P1608; MARSAULT R, 1992, J NEUROCHEM, V59, P942, DOI 10.1111/j.1471-4159.1992.tb08334.x; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MIHARA S, 1989, FEBS LETT, V259, P79, DOI 10.1016/0014-5793(89)81499-1; NEEDHAM L, 1987, EUR J PHARMACOL, V134, P199, DOI 10.1016/0014-2999(87)90166-X; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; SAGE SO, 1986, BIOCHEM BIOPH RES CO, V136, P1124, DOI 10.1016/0006-291X(86)90450-X; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; SOLTOFF SP, 1989, BIOCHEM BIOPH RES CO, V165, P1279, DOI 10.1016/0006-291X(89)92741-1; STUBBS EB, 1992, J IMMUNOL, V148, P2242; STUTCHFIELD J, 1990, FEBS LETT, V262, P256, DOI 10.1016/0014-5793(90)80204-V; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TASHJIAN AH, 1987, BIOCHEM J, V243, P305, DOI 10.1042/bj2430305; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; VIGNE P, 1992, BIOCHEM BIOPH RES CO, V183, P640, DOI 10.1016/0006-291X(92)90530-X; WILSON DB, 1985, J BIOL CHEM, V260, P3496; WOLF BA, 1986, J BIOL CHEM, V261, P3501	39	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8787	8792						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473322				2022-12-27	WOS:A1993KX81100062
J	KOGURE, K; SHINOHARA, Y; TERADA, H				KOGURE, K; SHINOHARA, Y; TERADA, H			EVOLUTION OF THE TYPE-II HEXOKINASE GENE BY DUPLICATION AND FUSION OF THE GLUCOKINASE GENE WITH CONSERVATION OF ITS ORGANIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; RAT-BRAIN HEXOKINASE; CLONED CDNA; ALPHA-FETOPROTEIN; TERMINAL HALVES; ISOZYME; ALBUMIN; CELL	The type I, II, and III isozymes of mammalian hexokinase (100 kDa) all consist of a duplicated, highly homologous peptide sequence, each half of which is very similar to that of glucokinase (type IV hexokinase, 50 kDa) and yeast hexokinase (50 kDa). We isolated a genomic clone of type II hexokinase that contained five exons encoding the C-terminal region of type II hexokinase. The positions of intron insertions of the isolated clone were found to be identical with those of the glucokinase gene, indicating that the type II hexokinase gene arose from the glucokinase gene. Furthermore, we prepared two DNA fragments of the type II hexokinase gene amplified from total genomic DNA. The exons in these fragments were found to be constructed by linkage of the coding region of the last exon and second exon of the glucokinase gene, indicating that the hexokinase gene arose by fusion of two glucokinase genes. These results clearly show that the mammalian hexokinase gene evolved from the glucokinase gene by gene duplication and fusion with conservation of the gene organization.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,SHOMACHI-1,TOKUSHIMA 770,JAPAN	Tokushima University								ANDREONE TL, 1989, J BIOL CHEM, V264, P363; GORIN MB, 1981, J BIOL CHEM, V256, P1954; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7	17	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8422	8424						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473284				2022-12-27	WOS:A1993KX81100011
J	MISHIMA, K; TSUCHIYA, M; NIGHTINGALE, MS; MOSS, J; VAUGHAN, M				MISHIMA, K; TSUCHIYA, M; NIGHTINGALE, MS; MOSS, J; VAUGHAN, M			ARD-1, A 64-KDA GUANINE NUCLEOTIDE-BINDING PROTEIN WITH A CARBOXYL-TERMINAL ADP-RIBOSYLATION FACTOR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; ADENYLATE-CYCLASE; REGULATORY COMPONENT; MESSENGER-RNA; BOVINE BRAIN; GTP; EXPRESSION; ACTIVATION; MECHANISM; ACID	Clones referred to as ARD 1 were isolated from human and rat cDNA libraries. ARD 1 genes encode a putative 64-kDa protein that contains an 18-kDa ADP-ribosylation factor (ARF) domain at the carboxyl terminus and is much larger than the other monomeric approximately 20-kDa guanine nucleotide-binding ARF proteins thus far identified. ARD 1 mRNAs of 3.7 and 4.1 kilobases were detected in all rat tissues as well as in mouse and rabbit brain, human fibroblasts, and human neuroblastoma cells but not in HL-60 cells. Based on sequence identities, ARD 1 is highly conserved between rat and human. The ARF domain of ARD 1 contains the consensus sequences believed to be involved in guanine nucleotide binding, which are conserved in the ARFs and other GTP-binding proteins. Recombinant ARD 1 or the ARF domain of ARD 1, which lacks the 15 amino acids corresponding to the amino-terminal regions of ARFs stimulated, in a GTP-dependent manner, cholera toxin ADP-ribosyltransferase activity in the presence of 0.3% Tween 20. It had no effect in the presence of SDS, dimyristoylphosphatidylcholine/cholate, or cardiolipin. These observations are consistent with the conclusion that the amino-terminal region of ARF proteins is not required for activation of cholera toxin. In addition, the characteristic features of ARF proteins may be found as domains of larger mammalian proteins.			MISHIMA, K (corresponding author), NHLBI,CELLULAR METAB LAB,BETHESDA,MD 20892, USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CM, 1992, J BIOL CHEM, V267, P9028; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MISHIMA K, 1992, J BIOL CHEM, V267, P24109; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066	46	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8801	8807						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473324				2022-12-27	WOS:A1993KX81100064
J	YOON, JK; LAU, LF				YOON, JK; LAU, LF			TRANSCRIPTIONAL ACTIVATION OF THE INDUCIBLE NUCLEAR RECEPTOR GENE NUR77 BY NERVE GROWTH-FACTOR AND MEMBRANE DEPOLARIZATION IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; C-FOS TRANSCRIPTION; DNA-BINDING SITE; NGFI-B; INDUCTION; CAMP; SUPERFAMILY; EXPRESSION	nur77 is an immediate-early gene inducible by nerve growth factor or membrane depolarization in the rat pheochromocytoma cell line PC12 and by serum growth factors in fibroblasts. The nur77-encoded protein is a member of the steroid/thyroid hormone receptor superfamily and can act as a potent transcription activator. The induction of nur77 in PC12 cells is rapid and transient, with kinetics similar to those of the c-fos protooncogene. Induction does not require de novo protein synthesis. Whereas transcriptional activation of c-fos by nerve growth factor in PC12 cells requires a 20-base pair serum response element in its promoter, there is no such sequence in the nur77 promoter. To understand the mechanism for the activation of nur77, we have analyzed the inducibility of a series of transfected nur77 minigenes using an S1 nuclease protection assay. We identified the sequence 22-86 nucleotides upstream of the transcription start site as necessary and sufficient for nur77 induction by nerve growth factor and membrane depolarization in PC12 cells. Sequences farther upstream enhance the induction. Analysis of base substitution mutations allowed us to identify three sequence elements within this region that are essential for induction. These sequence elements include two copies of an AP1-like element and a GC-rich sequence. Unlike transcriptional activation of c-fos, the sequence requirements for the activation of nur77 by nerve growth factor and membrane depolarization cannot be readily separated. Taken together, our data suggest that activation of nur77 and c-fos by nerve growth factor occurs through different mechanisms in PC12 cells.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA052220] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; METZ R, 1991, ONCOGENE, V6, P2165; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Treisman R, 1990, Semin Cancer Biol, V1, P47; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	51	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9148	9155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473354				2022-12-27	WOS:A1993KX81100109
J	CHEN, WN; LIM, HH; LIM, L				CHEN, WN; LIM, HH; LIM, L			THE CDC42 HOMOLOG FROM CAENORHABDITIS-ELEGANS - COMPLEMENTATION OF YEAST MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE GENE; ACTIVATING PROTEIN; MOLECULAR-CLONING; CELL POLARITY; RAS PROTEIN; IDENTIFICATION; ENCODES; G25K; PRODUCT	A Caenorhabditis elegans cDNA encoding a homologue of the p21 ras-related CDC42, designated as CDC42Ce, was isolated from a nematode mixed stage cDNA library. The encoded protein of 188 amino acid residues has 85% identity to both human G25K and CDC42Hs and 79 and 76% identity to the yeast CDC42Sp and CDC42Sc proteins, respectively. The CDC42Ce cDNA maps to a position on C. elegans chromosome II in close proximity to lin-26, a cell lineage gene. The CDC42Ce cDNA hybridizes to 2- and 1.5-kilobase mRNAs. Their expression is developmentally regulated with highest levels at the embryonic stage, decreasing progressively during development except for an increase of the more abundant 1.5-kilobase mRNA at the L3 stage. The glutathione S-transferase/CDC42Ce fusion protein expressed in Escherichia coli displays both GTP binding and intrinsic GTPase activities. The GTPase activity of CDC42Ce is moderately stimulated by human n-chimaerin, a GTPase-activating protein for the related p21 rac1. The CDC42Ce protein complements the temperature-sensitive lethal mutation cdc42-1 in yeast Saccharomyces cerevisiae. These data suggest that CDC42Ce is the C. elegans homologue of the yeast CDC42. The developmental expression pattern of mRNA and is biochemical properties of its encoded protein which are closely related to CErac1 suggest that the two p21s might be involved in related biological processes.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND	University of London; University College London	CHEN, WN (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.			Lim, Hong Hwa/0000-0002-0951-7220; , Yang/0000-0002-6620-8897				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHEN WI, 1993, J BIOL CHEM, V268, P320; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FAWELL E, 1992, GENE, V114, P153, DOI 10.1016/0378-1119(92)90724-4; GOLDEN A, 1992, BIOESSAYS, V14, P481, DOI 10.1002/bies.950140710; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART MJ, 1991, J BIOL CHEM, V266, P20840; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WOOD WB, 1988, NEMATODE CAENORHABDI, P602; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	31	52	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13280	13285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514766				2022-12-27	WOS:A1993LH55300041
J	RATAJCZAK, T; CARRELLO, A; MARK, PJ; WARNER, BJ; SIMPSON, RJ; MORITZ, RL; HOUSE, AK				RATAJCZAK, T; CARRELLO, A; MARK, PJ; WARNER, BJ; SIMPSON, RJ; MORITZ, RL; HOUSE, AK			THE CYCLOPHILIN COMPONENT OF THE UNACTIVATED ESTROGEN-RECEPTOR CONTAINS A TETRATRICOPEPTIDE REPEAT DOMAIN AND SHARES IDENTITY WITH P59 (FKBP59)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CELL GLUCOCORTICOID RECEPTOR; AMINO-ACID SEQUENCE; NON-DNA-BINDING; SACCHAROMYCES-CEREVISIAE; PROGESTERONE-RECEPTOR; 59-KILODALTON PROTEIN; STEROID-RECEPTORS; GENE; COMPLEXES	Using a rapid single-step affinity chromatography procedure we have isolated the unactivated estrogen receptor from bovine uterus. Results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western analyses for protein extracts recovered from affinity chromatography of receptor cytosols, either preincubated or untreated with estradiol, suggest a component structure for the intact oligomeric receptor which includes hsp90, hsp70, p59, a 40-kDa cyclophilin-related protein, and an uncharacterized 22-kDa protein species. We have chemically determined the amino acid sequences of eight peptides derived from the 40-kDa component and now report the cloning and primary sequence of a cDNA encoding this protein, which is designated estrogen receptor-binding cyclophilin (ERBC). Homology analyses confirm that ERBC is a new member of the cyclophilin family and contains a C-terminal domain with significant sequence homology to an internal region of p59, a binding protein for the immunosuppressant FK506 (FKBP59). This conserved region includes a 3-unit tetratricopeptide repeat domain bounded at the C terminus by a putative calmodulin binding site. We propose that the tetratricopeptide repeat domain mediates the protein interaction properties of ERBC and p59. Both immunophilins may have important roles in receptor assembly and may represent a new category of ligand- and calcium-dependent modulators of protein function.	SIR CHARLES GAIRDNER HOSP, QUEEN ELIZABETH II MED CTR, DEPT SURG, NEDLANDS, WA 6009, AUSTRALIA; LUDWIG INST CANC RES, JOINT PROT STRUCT LAB, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	University of Western Australia; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	RATAJCZAK, T (corresponding author), SIR CHARLES GAIRDNER HOSP, QUEEN ELIZABETH II MED CTR, DEPT ENDOCRINOL & DIABET, NEDLANDS, WA 6009, AUSTRALIA.		Mark, Peter/H-5365-2014; Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATRACHE V, 1985, J BIOL CHEM, V260, P5936; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOHMAN R J, 1990, New Biologist, V2, P663; HONORE B, 1992, J BIOL CHEM, V267, P8485; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RATAJCZAK T, 1989, J BIOL CHEM, V264, P13453; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RHEE SK, 1989, YEAST, V5, P149, DOI 10.1002/yea.320050304; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; RXIN M, 1991, J BIOL CHEM, V266, P24601; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SHREIBER SL, 1991, SCIENCE, V251, P283; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SPIK G, 1991, J BIOL CHEM, V266, P10735; STEARNE PA, 1985, J IMMUNOL, V134, P443; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; YEM AW, 1992, J BIOL CHEM, V267, P2868	51	169	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13187	13192						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514757				2022-12-27	WOS:A1993LH55300028
J	TIMMER, RT; BENKOWSKI, LA; SCHODIN, D; LAX, SR; METZ, AM; RAVEL, JM; BROWNING, KS				TIMMER, RT; BENKOWSKI, LA; SCHODIN, D; LAX, SR; METZ, AM; RAVEL, JM; BROWNING, KS			THE 5' AND 3' UNTRANSLATED REGIONS OF SATELLITE TOBACCO NECROSIS VIRUS-RNA AFFECT TRANSLATIONAL EFFICIENCY AND DEPENDENCE ON A 5' CAP STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; WHEAT-GERM; MESSENGER-RNA; ELONGATION-FACTORS; HETEROGENEITY; PURIFICATION; SEQUENCE; ATP	Satellite tobacco necrosis virus RNA (STNV RNA) is a naturally uncapped viral RNA that contains 1239 nucleotides: 29 in the 5' untranslated region (UTR), 591 in the coding region and 619 in the 3' UTR. Mutations were made in the 5' and 3' UTRs, and the effects of these mutations on translational efficiency and cap independence were measured in an in vitro translation system from wheat germ. Removal of the first 12 nucleotides or 10 changes in the nucleotide sequence of the 5' UTR reduced translational efficiency approximately 3-fold; capping of these 5' mutant mRNAs restored their translational efficiencies. Truncation of the 3' UTR to nucleotide 627 or 700, or deletion of nucleotides 627-737, reduced translational efficiency more than 20-fold; capping of these 3' mutant mRNAs restored their translational efficiencies. These modifications in the 3' UTR increased the concentration of initiation factor 4F required for translation. Chimeric mRNAs were constructed which contained the coding region of rabbit alpha-globin mRNA and either the 5' UTR, 3' UTR, or both the 5' and 3' UTRs of STNV RNA. Both the 5' and 3' UTRs of STNV RNA were necessary to obtain cap-independent translation. These findings indicate that interaction between 5' UTR and the region between nucleotides 627 and 737 in the 3' UTR are required for cap-independent translation.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Texas System; University of Texas Austin; University of Illinois System; University of Illinois Urbana-Champaign								ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1988, J BIOL CHEM, V263, P8380; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BROWNING KS, 1987, J BIOL CHEM, V262, P538; BROWNING KS, 1988, J BIOL CHEM, V263, P9630; DANTHINNE X, 1990, Mededelingen van de Faculteit Landbouwwetenschappen Universiteit Gent, V55, P1037; DANTHINNE X, 1991, VIROLOGY, V185, P605, DOI 10.1016/0042-6822(91)90531-F; DONISKELLER H, 1981, VIROLOGY, V110, P43, DOI 10.1016/0042-6822(81)90006-4; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HORST J, 1971, BIOCHEMISTRY-US, V10, P4748, DOI 10.1021/bi00801a022; KASSANIS B, 1961, J GEN MICROBIOL, V25, P459, DOI 10.1099/00221287-25-3-459; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LEUNG DW, 1979, BIOCHEMISTRY-US, V18, P1361, DOI 10.1021/bi00574a036; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; REICHMANN ME, 1964, P NATL ACAD SCI USA, V52, P1009, DOI 10.1073/pnas.52.4.1009; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SCHODIN DJ, 1990, FASEB J, V4, pA1845; SMITH RE, 1979, BIOCHEMISTRY-US, V18, P1366, DOI 10.1021/bi00574a037; YSEBAERT M, 1980, J MOL BIOL, V143, P273, DOI 10.1016/0022-2836(80)90190-4	22	90	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9504	9510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486640				2022-12-27	WOS:A1993LA68900055
J	HAUN, RS; MOSS, J; VAUGHAN, M				HAUN, RS; MOSS, J; VAUGHAN, M			CHARACTERIZATION OF THE HUMAN ADP-RIBOSYLATION FACTOR-III PROMOTER - TRANSCRIPTIONAL REGULATION OF A TATA-LESS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; CHOLERA-TOXIN; MAMMALIAN-CELLS; MESSENGER-RNA; PLASMID DNA; SEQUENCE; EXPRESSION; GENE; INITIATION; ACTIVATOR	The 5'-flanking region of the human ADP-ribosylation factor 3 gene contains the features of a housekeeping gene. It lacks a TATA or CAAT box, has several GC boxes within a highly GC-rich region, and utilizes multiple transcription initiation sites. The cis-acting elements involved in regulating expression of the gene were identified by transient transfections of IMR-32 neuroblastoma cells. Reporter plasmids were modified to facilitate construction of defined promoter deletions linked to chloramphenicol acetyltransferase or luciferase using ligation-independent cloning. Transfection analyses indicated that sequences within 58 base pairs of the transcription initiation site were necessary for full expression, in particular a sequence containing the 10-base pair palindrome TCTCGCGAGA. Electrophoretic mobility shift assays performed with IMR-32 nuclear extracts demonstrated that a DNA-binding protein, termed TLTF, bound to an oligonucleotide containing this palindrome. Competition experiments showed that mutations within the core of the palindrome abolished in vitro binding and that the same protein bound to a 5'-proximal sequence. Expression of the promoter containing a mutated palindrome was reduced dramatically, consistent with the conclusion that this region functions in vivo to control expression of the ARF3 gene.			HAUN, RS (corresponding author), NHLBI,CELLULAR METAB LAB,BLDG 10,RM 5N307,BETHESDA,MD 20892, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HAUN RS, 1992, BIOTECHNIQUES, V13, P515; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; LEE CM, 1992, J BIOL CHEM, V267, P9028; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772	42	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8793	8800						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473323				2022-12-27	WOS:A1993KX81100063
J	LITOSCH, I; SULKHOLUTSKAYA, I; WENG, C				LITOSCH, I; SULKHOLUTSKAYA, I; WENG, C			G-PROTEIN-MEDIATED INHIBITION OF PHOSPHOLIPASE-C ACTIVITY IN A SOLUBILIZED MEMBRANE PREPARATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY COMPONENT; GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; ACTIVATION; ANTIBODIES	In solubilized bovine brain membrane preparations AlF4- (20 muM AlCl3 plus 10 mM NaF) and 50 nM guanosine 5-O-(2-thiotriphosphate) (GTPgammaS) promoted a rapid but transient inhibition of phospholipase C (PLC) activity. Maximal inhibition was evident within 7 min of incubation, followed by reversal of inhibition. In contrast, 10 muM GTPgammaS did not induce inhibition of PLC activity but rather produced a time-dependent stimulation of PLC activity. GTPgammaS-dependent inhibition of PLC activity was concentration-dependent with half-maximal inhibition at 1 nM. Inhibition was antagonized by guanosine 5-O-(2-thiodiphosphate (GDPbetaS). Pertussis toxin delayed the onset of inhibition by GTPgammaS but did not prevent the inhibitory effect. Alpha(o)-GTPgammaS or alpha(o)-GDP had little effect on PLC activity. Alpha(i)-GTPgammaS and alpha(i)-GDP produced a 15% inhibition of PLC activity. Betagamma subunits did not inhibit basal PLC activity but did attenuate the net degree of inhibition due to GTPgammaS. Inhibition was associated with a decrease in the Ca2+ sensitivity of PLC. Preincubation of membranes with anti-PLC-beta1 antibody, but not anti-PLC-gamma1 or anti-PLC-delta1, prevented the GTPgammaS-mediated inhibition of PLC. These studies implicate PLC-beta1 as an effector system that is under negative modulation by a G protein-dependent mechanism.			LITOSCH, I (corresponding author), UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101, USA.				NIDDK NIH HHS [DK37007] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037007] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; ENJALBERT A, 1990, J BIOL CHEM, V265, P18816; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KATADA T, 1984, J BIOL CHEM, V259, P3568; KATADA T, 1984, J BIOL CHEM, V259, P3578; KATADA T, 1979, J BIOL CHEM, V254, P469; LEE CH, 1992, J BIOL CHEM, V267, P16044; LITOSCH I, 1989, BIOCHEM J, V261, P245, DOI 10.1042/bj2610245; LITOSCH I, 1991, J BIOL CHEM, V266, P4764; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMITH RM, 1974, CRITICAL STABILITY C, V1, P1; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, J BIOL CHEM, V263, P14497; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8692	8697						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473313				2022-12-27	WOS:A1993KX81100049
J	NEYA, S; FUNASAKI, N; SATO, T; IGARASHI, N; TANAKA, N				NEYA, S; FUNASAKI, N; SATO, T; IGARASHI, N; TANAKA, N			STRUCTURAL-ANALYSIS OF THE MYOGLOBIN RECONSTITUTED WITH IRON PORPHINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PROTON NMR-SPECTROSCOPY; CRYSTALLOGRAPHIC REFINEMENT; PROSTHETIC GROUP; HEME POCKET; METMYOGLOBIN; RESOLUTION; PORPHYRINS; APOMYOGLOBIN; HEMOPROTEINS	Sperm whale apomyoglobin was complexed with iron porphine to examine the influence of completely removed heme side chains on the entire molecular structure. Paramagnetic NMR peak from the proximal histidine of the deoxy protein ensured formation of the iron-histidine bond. Porphine pyrrole-proton NMR signals of the cyanmet and deoxy derivatives are unusually sharp single lines manifesting rapid heme rotation about the iron-histidine bond. X-ray crystallographic structure of the cyanmet derivative, determined with a final R factor of 0.21 for 11,808 independent reflections ranging from 7 to 1.8 angstrom, was resolved at 1.8 angstrom resolution. The result confirmed 1:1 coupling between apomyoglobin and iron porphine. The cyano ligand adopts a bent configuration with an Fe-C-N angle of 127-degrees and a Fe-CN distance of 1.89 angstrom. The overall globin structure and side chain conformations are remarkably similar to those of native myoglobin despite intensive disruption of the original heme-globin interactions. The native apoprotein structure unexpectedly conserved even after iron porphine insertion demonstrates that the complex polypeptide fold of holomyoglobin is more inherent in the amino acid sequence than is generally believed.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology	NEYA, S (corresponding author), KYOTO PHARMACEUT UNIV,DEPT PHYS CHEM,KYOTO 607,JAPAN.							ADLER AD, 1970, J INORG NUCL CHEM, V32, P2443, DOI 10.1016/0022-1902(70)80535-8; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, V21, P436, DOI 10.1126/science.178.4058.296; BRESLOW E, 1967, J BIOL CHEM, V242, P4149; BROWN KL, 1979, INORG CHIM ACTA, V37, pL153; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CHANCE B, 1966, J MOL BIOL, V17, P525, DOI 10.1016/S0022-2836(66)80162-6; CHANG CK, 1984, ARCH BIOCHEM BIOPHYS, V213, P366; CHEN BML, 1972, J AM CHEM SOC, V94, P4144, DOI 10.1021/ja00767a015; COCCO MJ, 1990, BIOCHEMISTRY-US, V29, P11067, DOI 10.1021/bi00502a008; DEATHERAGE JF, 1976, J MOL BIOL, V106, P678; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; FALK JE, 1964, PORPHYRINS METALLOPO, P242; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; Fischer H, 1936, LIEBIGS ANN CHEM, V521, P157; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FRYDMAN L, 1989, J AM CHEM SOC, V111, P7001, DOI 10.1021/ja00200a016; GOFF H, 1977, J AM CHEM SOC, V99, P6599, DOI 10.1021/ja00462a022; GOFF H, 1980, J AM CHEM SOC, V102, P3252, DOI 10.1021/ja00529a065; Goff H. M., 1983, IRON PORPHYRINS 1, P237; HARRISON SC, 1965, J BIOL CHEM, V240, P299; HAUKSSON JB, 1990, J AM CHEM SOC, V112, P6198, DOI 10.1021/ja00173a006; HONZATKO RB, 1985, J MOL BIOL, V184, P147, DOI 10.1016/0022-2836(85)90049-X; JOHNSON RD, 1983, J AM CHEM SOC, V105, P7205, DOI 10.1021/ja00362a050; KROL S, 1959, J ORG CHEM, V24, P2064; LAMAR GN, 1977, BIOCHEM BIOPH RES CO, V77, P104, DOI 10.1016/S0006-291X(77)80170-8; LECOMTE JTJ, 1990, BIOCHEMISTRY-US, V29, P11057, DOI 10.1021/bi00502a007; LI XY, 1991, J PHYS CHEM-US, V95, P4268, DOI 10.1021/j100164a020; MOMENTEAU M, 1985, J CHEM SOC PERK T 1, P61, DOI 10.1039/p19850000061; NEYA S, 1989, BIOCHIM BIOPHYS ACTA, V996, P226, DOI 10.1016/0167-4838(89)90251-3; NEYA S, 1987, J BIOL CHEM, V262, P6725; NEYA S, 1988, BIOCHIM BIOPHYS ACTA, V952, P150, DOI 10.1016/0167-4838(88)90110-0; NEYA S, 1988, J BIOL CHEM, V263, P8810; POULOS TL, 1978, J BIOL CHEM, V253, P3730; RADZISZEWSKI JG, 1991, J PHYS CHEM-US, V95, P1963, DOI 10.1021/j100158a015; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; Rothgeb T M, 1978, Methods Enzymol, V52, P473; Sano S., 1979, PORPHYRINS, V7, P377; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SATO T, 1992, BIOCHIM BIOPHYS ACTA, V1121, P1, DOI 10.1016/0167-4838(92)90329-C; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; WEISS C, 1965, J MOL SPECTROSC, V16, P415, DOI 10.1016/0022-2852(65)90132-3; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; WUTHRICH K, 1970, STRUCT BOND, V8, P53; ZHANG K, 1991, BIOCHEMISTRY-US, V30, P9116, DOI 10.1021/bi00101a030	48	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8935	8942						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473336				2022-12-27	WOS:A1993KX81100081
J	NAKAHARA, K; TANIMOTO, T; HATANO, K; USUDA, K; SHOUN, H				NAKAHARA, K; TANIMOTO, T; HATANO, K; USUDA, K; SHOUN, H			CYTOCHROME-P-450-55A1 (P-450DNIR) ACTS AS NITRIC-OXIDE REDUCTASE EMPLOYING NADH AS THE DIRECT ELECTRON-DONOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-OXYSPORUM; INDUCIBLE CYTOCHROME-P-450; PARACOCCUS-DENITRIFICANS; FUNGUS; PURIFICATION; CDNA; SEQUENCE; CLONING	Cytochrome P-450dNIR (P-450dNIR), involved in the fungal denitrification by Fusarium oxysporum, was purified to homogeneity. The cytochrome P-450 (P-450) exhibited a potent nitric oxide (NO) reductase activity to form nitrous oxide (N2O) employing NADH but not NADPH as the sole effective electron donor. The apparent maximum turnover rate against NO was estimated as high as 31,500 min-1. The stoichiometry of the reaction between NO:NADH:N2O was 2:1:1. The reaction required neither an artificial electron-carrying mediator nor other proteinaceous components. An anaerobic incubation of ferric P-450dNIR.NO complex, but not of free ferric P-450dNIR, resulted in rapid reduction of the P-450, indicating that P-450dNIR.NO complex was reduced directly by NADH. Spectral changes during catalytic turnover indicated that decomposition of the ferrous P-450.NO complex might be rate-limiting. The reaction was not inhibited by carbon monoxide at all, suggesting that the free ferrous P-450 is not formed during turnover. On the basis of these results a possible reaction mechanism was considered. The present results demonstrated not only the unique reaction catalyzed by P-450, but also the first P-450-dependent reaction where the electron transport from NAD(P)H to P-450 is not supported by other components. Now that the physiological function of P-450 55A1 (P-450dNIR) has been found, we propose to alter the trivial name to P-450nor.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba				Nakahara, Kazuhiko/0000-0002-7313-6879				CARR GJ, 1990, BIOCHEM J, V269, P423, DOI 10.1042/bj2690423; Dean, 1985, LANGES HDB CHEM, P3; DERMASTIA M, 1991, J BIOL CHEM, V266, P10899; FANG GH, 1986, NUCLEIC ACIDS RES, V14, P8061, DOI 10.1093/nar/14.20.8061; FERGUSON SJ, 1987, TRENDS BIOCHEM SCI, V12, P354, DOI 10.1016/0968-0004(87)90164-2; GOTOH O, 1993, IN PRESS CYTOCHROME; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KNOWLES R, 1982, MICROBIOL REV, V46, P43, DOI 10.1128/MMBR.46.1.43-70.1982; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; OMURA T, 1964, J BIOL CHEM, V239, P2370; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; SATO R, 1978, CYTOCHROME P450, P23; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; SHOUN H, 1989, FEBS LETT, V244, P11, DOI 10.1016/0014-5793(89)81151-2; SHOUN H, 1989, AGR BIOL CHEM TOKYO, V53, P2153, DOI 10.1080/00021369.1989.10869624; SHOUN H, 1991, J BIOL CHEM, V266, P11078; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; TANIMOTO T, 1992, BIOSCI BIOTECH BIOCH, V56, P2058, DOI 10.1271/bbb.56.2058; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	25	236	244	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8350	8355						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463342				2022-12-27	WOS:A1993KW97900109
J	BAUERLE, C; HO, MN; LINDORFER, MA; STEVENS, TH				BAUERLE, C; HO, MN; LINDORFER, MA; STEVENS, TH			THE SACCHAROMYCES-CEREVISIAE VMA6 GENE ENCODES THE 36-KDA SUBUNIT OF THE VACUOLAR H+-ATPASE MEMBRANE SECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; YEAST VACUOLE; PROTEIN; TRANSPORT; DRIVEN; DNA; NITROCELLULOSE; ACIDIFICATION; POLYPEPTIDE; VESICLES	The yeast vacuolar membrane proton-translocating ATPase (V-ATPase) is a multisubunit complex comprised of peripheral catalytic, and integral membrane domains. At least eight proteins cofractionate with purified preparations of the enzyme including 100-, 69-, 60-, 42-, 36-, 32-, 27-, and 17-kDa polypeptides (Kane, P. M., Yamashiro, C. T., and Stevens, T. H. (1989a) J. Biol. Chem. 264, 19236-19244). We took a reverse genetic approach to clone the structural gene for the 36-kDa subunit of the V-ATPase, VMA6. vma6 null mutants displayed growth characteristics typical of other vma mutants including sensitivity to media buffered at neutral pH or media containing 100 mM Ca2+. Vacuolar acidification was defective in vma6 cells and isolated vacuolar membrane preparations contained no detectable V-ATPase activity. The VMA6 gene encodes a hydrophilic polypeptide of 345 amino acids (predicted molecular mass 39.8-kDa). We present evidence that the VMA6 gene product (Vma6p) is a non-integral membrane component of the membrane pore domain and is required for V-ATPase complex assembly. Vma6p was removed from wild type vacuolar membranes by strong chaotropic agents such as alkaline Na2CO3 or 5M urea, which did not remove integral membrane polypeptides. In yeast cells lacking the integral membrane portion of the V-ATPase complex, Vma6p was unable to stably associate with vacuolar membranes. Conversely, in mutants specifically lacking Vma6p, components of the V-ATPase integral membrane domain were destabilized, and peripheral subunits failed to assemble onto vacuolar membranes. These results are discussed in the context of a developing model for V-ATPase assembly in yeast.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NIGMS NIH HHS [GM14329, GM38006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006, F32GM014329] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; ARAI H, 1988, J BIOL CHEM, V263, P8796; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P221; HO MN, 1993, IN PRESS J BIOL CHEM, V268; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1989, J CELL SCI, P161; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; REA PA, 1987, J BIOL CHEM, V262, P14745; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SUN SZ, 1987, J BIOL CHEM, V262, P14790; UEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WANG SY, 1988, J BIOL CHEM, V263, P17638; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	44	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12749	12757						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509410				2022-12-27	WOS:A1993LG65800078
J	FURLOW, JD; MURDOCH, FE; GORSKI, J				FURLOW, JD; MURDOCH, FE; GORSKI, J			HIGH-AFFINITY BINDING OF THE ESTROGEN-RECEPTOR TO A DNA RESPONSE ELEMENT DOES NOT REQUIRE HOMODIMER FORMATION OR ESTROGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL REGULATION; GLUCOCORTICOID RECEPTOR; LIGAND-BINDING; UTERINE CELLS; RAT UTERUS; DIMERIZATION; ANTIESTROGEN; COMPLEXES; GENE	We have developed an antibody-based DNA binding assay to study the effects of the absence or presence of an estrogen receptor agonist and two antagonists on the thermodynamic binding parameters for estrogen receptor binding to a consensus estrogen response element in vitro. We first demonstrate that antibodies raised against a region of the estrogen receptor directly adjacent to the DNA-binding domain do not interfere with the receptor's ability to preferentially bind to the vitellogenin estrogen response element in plasmid DNA. Exploiting this property to develop a quantitative DNA binding assay, we demonstrate that estrogen is not required for high affinity binding of the receptor for an oligonucleotide containing this element, nor do antiestrogens alter this interaction. In addition, we find that 1 mol of estrogen receptor is complexed with high affinity to 1 mol of vitellogenin estrogen response element, instead of two estrogen receptors/response element as would be predicted if estrogen receptor homodimer formation was required for high affinity DNA binding. Our data best fit a model in which the active estrogen receptor form is a monomer or heterodimer, but not a homodimer, and the regulatory role of estrogen on the estrogen receptor is the induction of protein-protein, but not protein-DNA, interactions.	UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				MURDOCH, FERN/0000-0001-5724-9681	NCI NIH HHS [CA18110] Funding Source: Medline; NICHD NIH HHS [HD08192, HD07259] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD008192, R01HD008192, T32HD007259] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA018110] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY A, 1980, J BIOL CHEM, V255, P2729; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK JH, 1978, J BIOL CHEM, V253, P7630; CURTIS SW, 1991, MOL ENDOCRINOL, V5, P959, DOI 10.1210/mend-5-7-959; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DARWISH H, 1991, J BIOL CHEM, V266, P551; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GORSKI J, 1976, ANNU REV PHYSIOL, V38, P425, DOI 10.1146/annurev.ph.38.030176.002233; GRODY WW, 1982, ENDOCR REV, V3, P141, DOI 10.1210/edrv-3-2-141; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HANSEN JC, 1986, J BIOL CHEM, V261, P13990; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLER MA, 1985, ENDOCRINOLOGY, V117, P515, DOI 10.1210/endo-117-2-515; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURDOCH FE, 1991, BIOCHEMISTRY-US, V30, P10838, DOI 10.1021/bi00109a005; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; MURDOCH FE, 1992, 74TH ANN M END SOC S, P114; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; PEALE FV, 1988, P NATL ACAD SCI USA, V85, P1038, DOI 10.1073/pnas.85.4.1038; REESE JC, 1992, NUCLEIC ACIDS RES, V19, P6505; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; SAKAI D, 1984, BIOCHEMISTRY-US, V23, P3541, DOI 10.1021/bi00310a024; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SHUPNIK MA, 1991, J BIOL CHEM, V266, P17084; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; WALENT JH, 1990, ENDOCRINOLOGY, V126, P2383, DOI 10.1210/endo-126-5-2383; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WILLIAMS D, 1972, P NATL ACAD SCI USA, V69, P3464, DOI 10.1073/pnas.69.11.3464	47	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12519	12525						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509392				2022-12-27	WOS:A1993LG65800045
J	HUGGINS, TG; WELLSKNECHT, MC; DETORIE, NA; BAYNES, JW; THORPE, SR				HUGGINS, TG; WELLSKNECHT, MC; DETORIE, NA; BAYNES, JW; THORPE, SR			FORMATION OF O-TYROSINE AND DITYROSINE IN PROTEINS DURING RADIOLYTIC AND METAL-CATALYZED OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-TRYPTOPHAN FLUORESCENCE; OXYGEN RADICALS; AMINO-ACIDS; HUMAN LENS; DEGRADATION; IDENTIFICATION; CONSEQUENCES; BITYROSINE; TURNOVER; DAMAGE	To evaluate their usefulness as chemical indicators of cumulative oxidative damage to proteins, we studied the kinetics and extent of formation of ortho-tyrosine (o-Tyr), dityrosine (DT), and dityrosine-like fluorescence (E(x) = 317 nm, E(m) = 407 nm) in the model proteins RNase and lysozyme exposed to radiolytic and metal-catalyzed (H2O2/Cu2+) oxidation (MCO). Although there were protein-dependent differences, o-Tyr, DT, and fluorescence increased coordinately during oxidation of the proteins in both oxidation systems. The contribution of DT to total dityrosine-like fluorescence in oxidized proteins varied from 2-100%, depending on the protein, type of oxidation, and extent of oxidative damage. In proteins exposed to MCO, DT typically accounted for >50% of the fluorescence at DT wavelengths. These studies indicate that o-Tyr and DT should be useful chemical markers of cumulative exposure of proteins to MCO in vitro and in vivo.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; RICHLAND MEM HOSP,DEPT MED PHYS,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019971, R01DK025373, R01DK019971] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19971, DK-25373] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AESCHBACH R, 1976, BIOCHIM BIOPHYS ACTA, V439, P292, DOI 10.1016/0005-2795(76)90064-7; AHMED MU, 1986, J BIOL CHEM, V261, P4889; AUGUSTEYN RC, 1981, MECHANISMS CATARACT, P71; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BOGUTA G, 1983, INT J RADIAT BIOL, V43, P249, DOI 10.1080/09553008314550301; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DAUGHERTY A, 1991, ROLE OXIDATION PATHO; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DIZDAROGLU M, 1983, INT J RADIAT BIOL, V2, P185; Fricke H., 1966, RADIATION DOSIMETRY, V2, P167; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GARCIACASTINEIRAS S, 1978, EXP EYE RES, V26, P461, DOI 10.1016/0014-4835(78)90132-X; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAYAISHI O, 1989, MED BIOCH CHEM ASPEC; HUNT JV, 1991, FREE RADICAL RES COM, V12-3, P115, DOI 10.3109/10715769109145775; KAREM L, 1990, J BIOL CHEM, V265, P11581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; SPADARO AC, 1979, ANAL BIOCHEM, V96, P317, DOI 10.1016/0003-2697(79)90587-6; SPECTOR A, 1975, EXP EYE RES, V21, P9, DOI 10.1016/0014-4835(75)90053-6; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; USHIJIMA Y, 1984, BIOCHEM BIOPH RES CO, V125, P916, DOI 10.1016/0006-291X(84)91370-6; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348	27	201	205	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12341	12347						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509373				2022-12-27	WOS:A1993LG65800021
J	KIEFFER, LJ; SENG, TW; LI, W; OSTERMAN, DG; HANDSCHUMACHER, RE; BAYNEY, RM				KIEFFER, LJ; SENG, TW; LI, W; OSTERMAN, DG; HANDSCHUMACHER, RE; BAYNEY, RM			CYCLOPHILIN-40, A PROTEIN WITH HOMOLOGY TO THE P59 COMPONENT OF THE STEROID-RECEPTOR COMPLEX - CLONING OF THE CDNA AND FURTHER CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; CYTOSOLIC-BINDING-PROTEIN; HEAT-SHOCK PROTEINS; T-CELL ACTIVATION; CYCLOSPORINE-A; ESCHERICHIA-COLI; IMMUNOSUPPRESSANT FK-506; ENDOPLASMIC-RETICULUM; PROGESTERONE-RECEPTOR	We have reported previously the isolation and preliminary characterization of a 40-kDa cyclosporin A (CsA)-binding protein, cyclophilin-40 (CyP-40). To determine the sequence of this protein, degenerate oligonucleotide primers based on bovine brain CyP-40 tryptic peptides were used to generate a polymerase chain reaction fragment of CyP-40 cDNA. This was used to isolate the complete cDNA from a human pancreatic islet cell library. Northern analysis indicated ubiquitous distribution of CyP-40 mRNA throughout human tissues. The CyP-18 domain of CyP-40 is most similar to maize CyP (64.3% identity), whereas 150 amino acids of the non-CyP-18 domain of CyP-40 share 30.7% identity with P59, a member of the steroid receptor complex. Failure to detect glycosylation and mass spectroscopy with isolated CyP-40 indicate minimal, if any, posttranslational modification. Employing a new assay for calcineurin protein phosphatase activity to compare the effects of CyP-40. CsA and CyP-18 CsA complexes, IC50 values of 320 nM +/- 20 and 195 nM +/- 15, respectively, were obtained. A chemical cross-linking study revealed that CyP-40 competes for I-125-Cyp-18 binding to calcineurin in the presence of CsA. The homology of CyP-40 to P59 suggests that CyP-40 might be involved in modulating the activity of biologically important receptors.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; MILES INC,INST INFLAMMAT & AUTOIMMUN,W HAVEN,CT 06516; MILES INC,INST MOLEC BIOLOG,W HAVEN,CT 06516	Yale University					NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040660] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA-09085-16] Funding Source: Medline; NIGMS NIH HHS [GM-40660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOSSARD MJ, 1991, BIOCHEM BIOPH RES CO, V176, P1142, DOI 10.1016/0006-291X(91)90404-U; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HENDERSON DJ, 1991, IMMUNOLOGY, V73, P316; HOLTZMAN DM, 1992, EMBO J, V11, P619, DOI 10.1002/j.1460-2075.1992.tb05094.x; JOHANSSON A, 1990, TRANSPLANTATION, V50, P1001, DOI 10.1097/00007890-199012000-00021; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MARIVET J, 1992, PLANT SCI, V84, P171, DOI 10.1016/0168-9452(92)90131-5; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PAU RN, 1989, TRENDS BIOCHEM SCI, V14, P183, DOI 10.1016/0968-0004(89)90271-5; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RENOIR JM, 1992, CR ACAD SCI III-VIE, V315, P421; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1991, TRANSPLANT P, V23, P1; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SPIK G, 1991, J BIOL CHEM, V266, P10735; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THALHAMMER T, 1992, EUR J BIOCHEM, V206, P31, DOI 10.1111/j.1432-1033.1992.tb16898.x; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; YEM AW, 1992, J BIOL CHEM, V267, P2868	63	123	126	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12303	12310						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509368				2022-12-27	WOS:A1993LG65800015
J	VADLAMUDI, RK; JI, TH; BULLA, LA				VADLAMUDI, RK; JI, TH; BULLA, LA			A SPECIFIC BINDING-PROTEIN FROM MANDUCA-SEXTA FOR THE INSECTICIDAL TOXIN OF BACILLUS-THURINGIENSIS SUBSP BERLINER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BUTTERFLY PIERIS-BRASSICAE; DELTA-ENDOTOXINS; ENTOMOCIDAL PROTOXIN; CRYSTAL PROTEINS; HIGH-AFFINITY; IDENTIFICATION; MIDGUT; VESICLES; SEQUENCE	Biopesticides based on the bacterium Bacillus thuringiensis have attracted wide attention as safe alternatives to chemical pesticides. In this paper, we report, for the first time, the identification and purification of a single binding protein from a lepidopteran insect, Manduca sexta, that is specific for a cryIA toxin of B. thuringiensis. The purified protein appeared as a single band of 210 kDa on a two-dimensional gel, had a pI of approximately 5.5, and stained with Schiff's reagent. The band material was sensitive to proteolytic digestion and was rich with acidic amino acids, indicating its protein nature. Radiolabeled toxin bound to the protein with a K(d) value of 708 pm and could be specifically blocked by unlabeled toxin but not by toxins from other subspecies of B. thuringiensis. This study lays the groundwork to clone the toxin binding protein and to determine the molecular mechanism(s) of toxin action.	UNIV WYOMING, DEPT MOLEC BIOL, POB 3944, LARAMIE, WY 82071 USA	University of Wyoming				Bulla, Lee/0000-0003-1789-7021				ARONSON AI, 1986, MICROBIOL REV, V50, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLA LA, 1981, J BIOL CHEM, V256, P3000; BULLA LA, 1977, J BACTERIOL, V130, P375, DOI 10.1128/JB.130.1.375-383.1977; CHILCOTT CN, 1988, J GEN MICROBIOL, V134, P2551; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HOFTE H, 1989, MICROBIOL REV, V53, P242; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; HURLEY JM, 1987, APPL ENVIRON MICROB, V126, P961; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SG, 1985, BIOCHEM BIOPH RES CO, V126, P953, DOI 10.1016/0006-291X(85)90278-5; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LILLEY M, 1980, J GEN MICROBIOL, V118, P1; LUTHY P, 1984, PATHOGENESIS INVERTE, P223; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCPHERSON SA, 1988, BIO-TECHNOL, V6, P61, DOI 10.1038/nbt0188-61; ODDOU P, 1991, EUR J BIOCHEM, V202, P673, DOI 10.1111/j.1432-1033.1991.tb16422.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SACCHI VF, 1986, FEBS LETT, V204, P213, DOI 10.1016/0014-5793(86)80814-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TYRELL DJ, 1981, J BACTERIOL, V145, P1052, DOI 10.1128/JB.145.2.1052-1062.1981; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WABIKO H, 1985, APPL ENVIRON MICROB, V49, P706, DOI 10.1128/AEM.49.3.706-708.1985; WABIKO H, 1986, DNA-J MOLEC CELL BIO, V5, P305, DOI 10.1089/dna.1986.5.305; WADA HG, 1979, J BIOL CHEM, V254, P2629; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3	32	154	178	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12334	12340						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509372				2022-12-27	WOS:A1993LG65800020
J	ALKSNE, LE; WARNER, JR				ALKSNE, LE; WARNER, JR			A NOVEL CLONING STRATEGY REVEALS THE GENE FOR THE YEAST HOMOLOG TO ESCHERICHIA-COLI RIBOSOMAL PROTEIN-S12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; PROMOTER ELEMENT; DNA; UPSTREAM; ACID; TRANSFORMATION; EXPRESSION; MUTANTS; SYSTEM	Using a novel technique designed to identify genes of Saccharomyces cerevisiae which carry introns, we have cloned two genes encoding ribosomal protein S28. although the genes differ by 15 nucleotides within their coding regions, they are predicted to encode identical proteins of 145 amino acids. The predicted amino acid sequence of S28 contains significant homology to ribosomal protein S25 of Tetrahymena thermophila and to ribosomal protein S12 of several archaebacteria, suggesting a relationship to S12 of Escherichia coli. Dot matrix analysis confirmed that regions of S12, especially those implicated in the accuracy of translation, have been conserved in S28 of S. cerevisiae. Either RPS28A or RPS28B alone can support growth, but heterozygous disruption of both genes abolishes the ability to sporulate. Haploids harboring a disruption of both genes cannot survive without an intact gene on a plasmid. RPS28A maps to the right arm of chromosome VII and RPS28B to the right arm of chromosome XVI.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13330] Funding Source: Medline; NIGMS NIH HHS [GM07491, GM25532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEQUARDCHABLAT M, 1984, MOL GEN GENET, V195, P294, DOI 10.1007/BF00332762; DEQUARDCHABLAT M, 1986, J MOL BIOL, V190, P167, DOI 10.1016/0022-2836(86)90290-1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FRIED HM, 1981, J BIOL CHEM, V256, P176; FUNATSU G, 1972, J MOL BIOL, V68, P547, DOI 10.1016/0022-2836(72)90108-8; GORENSTEIN C, 1977, MOL GEN GENET, V157, P327, DOI 10.1007/BF00268670; GORINI L, 1964, P NATL ACAD SCI USA, V5, P1995; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KURLAND CG, 1990, RIBOSOME, P513; LEE JC, 1991, YEASTS, V4, P489; LEER RJ, 1985, CURR GENET, V9, P273, DOI 10.1007/BF00419955; LOWELL DMB, 1990, MOL CELL BIOL, V10, P5235; NIELSEN H, 1986, EMBO J, V5, P2711, DOI 10.1002/j.1460-2075.1986.tb04555.x; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OTAKA E, 1981, MOL GEN GENET, V181, P176, DOI 10.1007/BF00268424; OZAKI M, 1969, NATURE, V222, P333, DOI 10.1038/222333a0; PEARSON NJ, 1982, CELL, V29, P347, DOI 10.1016/0092-8674(82)90151-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICARDBENNOUN M, 1982, FEBS LETT, V149, P167, DOI 10.1016/0014-5793(82)81094-6; PLANTA RJ, 1986, STRUCTURE FUNCTION G, P699; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SCHWINDINGER WF, 1984, NUCLEIC ACIDS RES, V12, P601, DOI 10.1093/nar/12.1Part2.601; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WARNER JR, 1982, MOL BIOL YEAST SACCH, P529; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	43	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10813	10819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496146				2022-12-27	WOS:A1993LD46600019
J	BROWNBRIDGE, GG; LOWE, PN; MOORE, KJM; SKINNER, RH; WEBB, MR				BROWNBRIDGE, GG; LOWE, PN; MOORE, KJM; SKINNER, RH; WEBB, MR			INTERACTION OF GTPASE-ACTIVATING PROTEINS (GAPS) WITH P21(RAS) MEASURED BY A NOVEL FLUORESCENCE ANISOTROPY METHOD - ESSENTIAL ROLE OF ARG-903 OF GAP IN ACTIVATION OF GTP HYDROLYSIS ON P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; GENE-PRODUCT; NEUROFIBROMATOSIS GENE; MECHANISM; DOMAIN; NUCLEOTIDES; MUTANTS; CLONING; SITE	Ras GTPase activating proteins (GAPs) contain an invariant motif, -FLR-, within the most conserved region of their catalytic domains. Certain mutations in this motif have greatly reduced activity (Skinner, R. H., Bradley, S., Brown, A. L., Johnson, N. J., Rhodes, S., Stammers, D. K., and Lowe, P. N. (1991) J. Biol. Chem. 266, 14163-14166), but it was not determined whether the reduced activity was due to loss of binding or impaired catalysis. In order to address this question, we have developed a simple physical method to study formation of GAP.p21ras complexes. This utilizes the increase of fluorescence anisotropy upon binding of GAP to p21ras complexed with 2'(3')-O-(N-methylanthraniloyl) (mant) derivatives of guanine nucleotides. Dissociation constants obtained for the catalytic domains of either p120-GAP (GAP-344) or neurofibromin (NF1-GRD) with normal and Leu-61 p21ras proteins are comparable with those obtained by kinetic methods. In the course of these studies, we found, in contrast to previous observations, that both GAP and NF1-GRD can weakly activate the GTPase of Leu-61 mutant p21, showing that Gln-61 is not absolutely required for the stimulation of GTPase activity by GAPs. The fluorescence anisotropy method allowed us to show that mutation of Arg-903, within the FLR motif of GAP, can result in protein defective in catalysis but not in binding to p21ras. These data suggest a direct role for this residue in catalyzing GTP hydrolysis on p21ras, possibly by contributing a catalytic group to the p21 active site. This method is independent of the catalytic activity of the proteins, and so it could be extended generally to the measurement of binding of effector molecules, exchange factors, or other macromolecules to guanine nucleotide-binding proteins.	NATL INST MED RES,DIV PHYS BIOCHEM,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	MRC National Institute for Medical Research; GlaxoSmithKline; Wellcome Research Laboratories				Webb, Martin/0000-0002-0134-9621				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; ECCLESTON JF, 1989, NATO ADV SCI I A-LIF, V165, P87; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HAZLETT TL, 1990, BIOPHYS J, V57, pA289; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; JAMESON DM, 1984, FLUORESCEIN HAPTEN I, P23; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; MOORE KJM, 1992, PHILOS T ROY SOC B, V336, P49, DOI 10.1098/rstb.1992.0043; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; REENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WEBB MR, 1992, BIOCHEM J, V287, P555, DOI 10.1042/bj2870555; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	37	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10914	10919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496156				2022-12-27	WOS:A1993LD46600033
J	MORRIS, JC; BERGERT, ER; MCCORMICK, DJ				MORRIS, JC; BERGERT, ER; MCCORMICK, DJ			STRUCTURE-FUNCTION STUDIES OF THE HUMAN THYROTROPIN RECEPTOR - INHIBITION OF BINDING OF LABELED THYROTROPIN (TSH) BY SYNTHETIC HUMAN TSH RECEPTOR PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID STIMULATING ANTIBODY; EPIDERMAL GROWTH-FACTOR; ALPHA-SUBUNIT PEPTIDES; GRAVES-DISEASE; LUTEINIZING-HORMONE; HUMAN CHORIOTROPIN; EXPRESSION; SEQUENCE; IMMUNOGLOBULIN; CLONING	We have probed the hormone binding regions of the entire putative extracellular domain of the human thyrotropin (TSH) receptor (hTSHr) using synthetic peptides. A series of 26 overlapping peptides comprising the complete sequence of the extracellular domain of hTSHr was synthesized. Each peptide (20 amino acid residues each) was tested for its ability to interact with TSH, as evidenced by inhibition of binding of labeled hormone to native, membrane bound TSH receptors. Four of the 26 peptides interacted with labeled TSH and inhibited its binding to thyroid membranes. The most potent of these peptides was 256-275, which inhibited I-125-bovine TSH binding with an IC50 of 31.7 +/- 1.3 muM. The remaining peptides were 16-35 (351 +/- 9.4 muM), 106-125 (282 +/- 20.5 muM), and 226-245 (951 +/- 245 muM). An additional peptide, 286-305, showed minimal activity, and the remaining 21 peptides showed no activity. Peptides 256-275, 106-125, and 16-35 also inhibited binding of I-125-human chorionic gonadotropin to ovarian membrane receptors, suggesting that those regions of the receptor are involved in binding of a common glycoprotein hormone structure such as the alpha-subunit. In contrast, peptides 226-245 and 286-305 did not inhibit human chorionic gonadotropin binding, suggesting that these two regions are involved in hormone-specific activity. Of interest is the finding that the latter two peptides are from regions of TSHr that are largely dis-homologous to the lutropin receptor, whereas the former three, with the exception of 16-35, are from regions that are largely homologous between the two receptors. The data suggest that multiple, discontinuous regions of the extracellular domain of hTSHr are involved in the binding of the hormone. Furthermore, the binding regions are localized to TSHr-specific sequences as well as to regions that are highly homologous to LHr. This suggests that homologous regions of the two receptors are likely to perform similar functions in the interaction with their specific hormone, suggesting that those regions may be involved in binding of the glycoprotein hormone common alpha-subunit.	MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55901	Mayo Clinic	MORRIS, JC (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,DIV ENDOCRINOL & METAB,ROCHESTER,MN 55905, USA.				NIDDK NIH HHS [DK42008] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042008] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATASSI MZ, 1991, P NATL ACAD SCI USA, V88, P3613, DOI 10.1073/pnas.88.9.3613; BURMAN KD, 1985, ENDOCR REV, V6, P183, DOI 10.1210/edrv-6-2-183; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDO T, 1991, BIOCHEM BIOPH RES CO, V177, P145, DOI 10.1016/0006-291X(91)91960-K; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; HUMPHRIES H, 1984, J ENDOCRINOL, V102, P57, DOI 10.1677/joe.0.1020057; KASAI K, 1985, HORM METAB RES, V17, P592, DOI 10.1055/s-2007-1013614; KEUTMANN HT, 1988, BIOCHEMISTRY-US, V27, P8939, DOI 10.1021/bi00425a010; KEUTMANN HT, 1992, MOL CELL ENDOCRINOL, V86, pC1, DOI 10.1016/0303-7207(92)90168-6; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MORI T, 1991, BIOCHEM BIOPH RES CO, V178, P165, DOI 10.1016/0006-291X(91)91794-D; MORRIS JC, 1988, J CLIN ENDOCR METAB, V67, P707, DOI 10.1210/jcem-67-4-707; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P456, DOI 10.1210/endo-123-1-456; MURAKAMI M, 1990, BIOCHEM BIOPH RES CO, V171, P512, DOI 10.1016/0006-291X(90)91423-P; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; OHMORI M, 1991, BIOCHEM BIOPH RES CO, V178, P733, DOI 10.1016/0006-291X(91)90169-8; REED DK, 1991, J BIOL CHEM, V266, P14251; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; TAHARA K, 1991, BIOCHEM BIOPH RES CO, V179, P70, DOI 10.1016/0006-291X(91)91335-A; TAKAHASHI H, 1978, J CLIN ENDOCR METAB, V47, P870, DOI 10.1210/jcem-47-4-870; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WESTERMARK K, 1985, MOL CELL ENDOCRINOL, V40, P17, DOI 10.1016/0303-7207(85)90153-4	31	84	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10900	10905						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496155				2022-12-27	WOS:A1993LD46600031
J	ZIEGLER, MM; GOLDBERG, ME; CHAFFOTTE, AF; BALDWIN, TO				ZIEGLER, MM; GOLDBERG, ME; CHAFFOTTE, AF; BALDWIN, TO			REFOLDING OF LUCIFERASE SUBUNITS FROM UREA AND ASSEMBLY OF THE ACTIVE HETERODIMER - EVIDENCE FOR FOLDING INTERMEDIATES THAT PRECEDE AND FOLLOW THE DIMERIZATION STEP ON THE PATHWAY TO THE ACTIVE FORM OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; BACTERIAL LUCIFERASE; VIBRIO-HARVEYI; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; BETA-SUBUNIT; LUXB GENE; BIOLUMINESCENCE; RENATURATION	Conditions have been established that allow reversible refolding of luciferase from 5 M urea. The kinetics of formation of the active enzyme showed a concentration-independent lag, suggesting the existence of intermediate structures on the pathway of refolding. The rate of approach to the final level of activity was strongly concentration-dependent at protein concentrations below 10 mug/ml, but at concentrations above about 20 mug/ml, the rate of approach to the final activity value did not change with concentration. The concentration dependence presumably reflects the second-order step yielding the heterodimeric structure. The finding that at concentrations above 20 mug/ml, the rate becomes insensitive to concentration suggests that under these conditions, some step subsequent to dimerization becomes rate-limiting. When the refolding reaction was initiated by dilution out of 5 M urea at 50 mug/ml followed at various times by a secondary dilution to a final concentration of 5 mug/ml, it was found that the increase in activity continued at the rate characteristic of the higher protein concentration for a period of about 1-2 min following the dilution before slowing to the rate expected for the lower protein concentration. These observations indicate that there are inactive heterodimeric species that form from assembly of the individual subunits and that these species must undergo further folding to yield the active heterodimeric species. At protein concentrations of 5-50 mug/ml, the final yield of active enzyme was about 65-85%, decreasing at higher and lower concentrations. At higher concentrations, aggregation probably accounts for the limit in recovery, whereas at lower concentrations, it appears that the reduced yield of activity is due to the competing process of the folding of one or both individual subunits into some form incompetent to interact with each other. These experiments demonstrate the existence of slow steps in the refolding of luciferase subunits from urea and the formation of the active heterodimeric structure, both preceding and following the dimerization. Furthermore, the failure of protein at low concentrations to efficiently reassemble into the active heterodimer is consistent with the prior finding that luciferase subunits produced independently in Escherichia coli fold into conformations that cannot interact to form the active heterodimer upon mixing (Waddle, J. J., Johnston, T. C., and Baldwin, T. O. (1987) Biochemistry 26, 4917-4921).	TEXAS A&M UNIV SYST, DEPT BIOCHEM & BIOPHYS, COLL STN, TX 77843 USA; TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, CTR MACROMOLEC DESIGN, COLL STN, TX 77843 USA; INST PASTEUR, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					FIC NIH HHS [1 FO6 TW016066-01] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDWIN TO, 1993, J BIOL CHEM, V268, P10766; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1979, P NATL ACAD SCI USA, V76, P4887, DOI 10.1073/pnas.76.10.4887; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BELAS R, 1982, SCIENCE, V218, P791, DOI 10.1126/science.10636771; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CLARK AC, 1993, J BIOL CHEM, V268, P10773; COHN DH, 1985, J BIOL CHEM, V260, P6139; FRIEDLAND J, 1967, P NATL ACAD SCI USA, V58, P2336, DOI 10.1073/pnas.58.6.2336; FRIEDLAND J, 1967, BIOCHEMISTRY-US, V9, P2893; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDBERG ME, 1985, TRENDS BIOCHEM SCI, V10, P388, DOI 10.1016/0968-0004(85)90066-0; GOLDBERG ME, 1980, PROTEIN FOLDING, P469; GUNSALUSMIGUEL A, 1972, J BIOL CHEM, V247, P398; HASTINGS JW, 1969, BIOCHEMISTRY-US, V8, P4681, DOI 10.1021/bi00840a004; HASTINGS JW, 1966, BIOLUMINESCENCE PROG, P151; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1991, IND UNIV C, P137; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MEIGHEN EA, 1970, BIOCHEMISTRY-US, V9, P4949; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; ORSINI G, 1978, J BIOL CHEM, V253, P3453; SINCLAIR JF, 1993, IN PRESS BIOCHEMISTR, V32; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TU SC, 1977, J BIOL CHEM, V252, P803; TU SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P342, DOI 10.1016/0003-9861(77)90120-5; TU SC, 1978, METHOD ENZYMOL, V57, P171; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WADDLE JJ, 1990, THESIS TEXAS AM U CO; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; ZIEGLER MM, 1981, CURR TOP BIOENERG, V12, P65	40	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10760	10765						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496142				2022-12-27	WOS:A1993LD46600011
J	FALZON, M; FEWELL, JW; KUFF, EL				FALZON, M; FEWELL, JW; KUFF, EL			EBP-80, A TRANSCRIPTION FACTOR CLOSELY RESEMBLING THE HUMAN AUTOANTIGEN KU, RECOGNIZES SINGLE-STRAND TO DOUBLE-STRAND TRANSITIONS IN DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; AUTO-ANTIGEN; PROTEIN; BINDING; CDNA; SEQUENCE; PROMOTER; AUTOANTIBODIES; PURIFICATION; MECHANISM	We have previously reported the purification and characterization of the transcription factor EBP-80 (Falzon, M., and Kuff, E. L. (1989) J. Biol. Chem. 264, 21915-21922). EBP-80 mediates the DNA methylation effect on transcription from an endogenous proviral long terminal repeat. Here we show that EBP-80 is very similar if not identical to the Ku autoantigen, a heterodimeric nuclear protein first detected by antibodies from autoimmune patients (Mimori, T., Akizuki, M., Yamagata, H., Inada, S., Yoshida, S., and Homma, M. (1981) J. Clin. Invest. 68, 611-620). A number of laboratories have shown that the Ku protein complex binds to free double-stranded DNA ends. In this study, we have examined the binding properties of EBP-80. EBP-80 binds single-stranded DNA with low affinity. Binding to random sequence double-stranded DNA depends on the length of the duplex and is optimal with oligomers of 30 and 32 base pairs; the protein complexes formed with these oligomers have K(d) values of 15-20 pM. It binds with comparable high affinities to blunt-ended duplex DNA, to duplex DNA ending in hairpin loops, and to constructs in which an internal segment of duplex DNA is flanked by single-strand extensions. EBP-80 also interacts effectively with circular duplex molecules containing a 30-nucleotide single-stranded region (gap) or a double-stranded segment of nonhomology (bubble), but only weakly with the corresponding closed circular construct made up entirely of duplex DNA. EBP-80 prefers A/T to G/C ends. The binding properties of EBP-80 are consistent with the hypothesis that it recognizes single- to double-strand transitions in DNA. A model is presented for the interaction of EBP-80 with its target sequence in the proviral long terminal repeat.			FALZON, M (corresponding author), NCI,BIOCHEM LAB,BLDG 37,RM 4C03,BETHESDA,MD 20892, USA.							ALLAWAY GP, 1990, BIOCHEM BIOPH RES CO, V168, P747, DOI 10.1016/0006-291X(90)92385-D; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; COWART M, 1991, BIOCHEMISTRY-US, V30, P788, DOI 10.1021/bi00217a032; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1988, J VIROL, V62, P4070, DOI 10.1128/JVI.62.11.4070-4077.1988; FALZON M, 1991, MOL CELL BIOL, V11, P117, DOI 10.1128/MCB.11.1.117; FALZON M, 1990, J BIOL CHEM, V265, P13084; FALZON M, 1989, J BIOL CHEM, V264, P21915; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRIFFITH AJ, 1992, MOL BIOL REP, V16, P91, DOI 10.1007/BF00419754; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LEROY JL, 1988, J MOL BIOL, V200, P223, DOI 10.1016/0022-2836(88)90236-7; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; YANEVA M, 1989, J BIOL CHEM, V264, P13407	30	217	218	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10546	10552						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486707				2022-12-27	WOS:A1993LB80000082
J	FARRELL, DH; HUANG, SM; DAVIE, EW				FARRELL, DH; HUANG, SM; DAVIE, EW			PROCESSING OF THE CARBOXYL 15-AMINO ACID EXTENSION IN THE ALPHA-CHAIN OF FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN FIBRINOGEN; PROTEINS; IDENTIFICATION; SECRETION; SEQUENCE; CLEAVAGE; ENZYME; FURIN; KEX2; PC2	The cDNA for the alpha-chain of human fibrinogen codes for 15 amino acids at the carboxyl terminus that are not found in the native protein circulating in plasma. In the present studies, experiments were designed to test whether the carboxyl extension was required for fibrinogen assembly or was simply the result of limited proteolysis and maturation of the protein during or following secretion. Baby hamster kidney cells were transfected with cDNAs coding for the alpha-, beta-, and gamma-chains, and the recombinant fibrinogen secreted into the cell culture medium was identified either with an antibody against the mature molecule or with an antibody directed toward the carboxyl extension of the alpha-chain. The secreted protein contained primarily two species of alpha-chains, including one with the carboxyl extension and one that was the same as that in plasma fibrinogen. A mutant fibrinogen, in which Arg-611 at the putative cleavage site in the alpha-chain was converted to Gly, was also readily assembled, and, in this case, the protein was secreted with the alpha-chain carboxyl extension. Similarly, a mutant fibrinogen that completely lacked the carboxyl extension of the alpha-chain was assembled and secreted from the transfected baby hamster kidney cells. These two mutants with modified alpha-chains were readily clotted by thrombin and cross-linked by factor XIIIa. These results indicate that the alpha-chain carboxyl extension in fibrinogen is not required for assembly or secretion of the molecule. Accordingly, it was concluded that the cleavage of the alpha-chain removing the carboxyl-terminal 15 amino acids is a normal and specific processing event occurring during the maturation of the protein.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BLOMBACK B, 1962, NATURE, V193, P883, DOI 10.1038/193883a0; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; CRABTREE GR, 1987, MOL BASIS BLOOD DISE, P645; DAVIDSON JM, 1975, BIOCHEMISTRY-US, V14, P5188, DOI 10.1021/bi00694a026; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FARRELL DH, 1989, BLOOD, V74, P55; FORMAN WB, 1964, JAMA-J AM MED ASSOC, V187, P128; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1978, H-S Z PHYSIOL CHEM, V359, P1757, DOI 10.1515/bchm2.1978.359.2.1757; HENSCHEN A, 1979, OPPESEYLERS Z PHYSL, V360, P1951; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, J BIOL CHEM, V268, P8919; IWANAGA S, 1968, BIOCHIM BIOPHYS ACTA, V160, P280, DOI 10.1016/0005-2795(68)90105-0; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOHN LD, 1974, P NATL ACAD SCI USA, V71, P40, DOI 10.1073/pnas.71.1.40; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MOSESSON MW, 1983, ANN NY ACAD SCI, V408, P97, DOI 10.1111/j.1749-6632.1983.tb23237.x; MULVIHILL ER, 1988, Patent No. 319944; NAKASHIMA A, 1992, BLOOD COAGUL FIBRIN, V3, P361, DOI 10.1097/00001721-199203040-00002; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROY SN, 1991, J BIOL CHEM, V266, P4758; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SHERAGA HA, 1957, ADV PROTEIN CHEM, V12, P1; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TOPFERPETERSEN E, 1976, H-S Z PHYSIOL CHEM, V357, P1509, DOI 10.1515/bchm2.1976.357.2.1509; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	39	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10351	10355						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486694				2022-12-27	WOS:A1993LB80000057
J	MINAMI, Y; KAWASAKI, H; SUZUKI, K; YAHARA, I				MINAMI, Y; KAWASAKI, H; SUZUKI, K; YAHARA, I			THE CALMODULIN-BINDING DOMAIN OF THE MOUSE 90-KDA HEAT-SHOCK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLUCOCORTICOID RECEPTOR; GEL-ELECTROPHORESIS; ACTIN-FILAMENTS; PURIFICATION; HSP90; QUANTITATION; ANTIBODIES; QUANTITIES; MEMBRANE	The mouse 90-kDa heat shock protein (HSP90) and Ca2+-calmodulin were cross-linked at an equimolar ratio using a carbodiimide zero-length cross-linker. To identify the calmodulin-binding domain(s) of HSP90, CNBr-cleaved peptide fragments of HSP90 were mixed with Ca2+-calmodulin and cross-linked. Amino acid sequence determination revealed that an HSP90alpha-derived peptide starting at the 486th amino acid residue was contained in the cross-linked products, which contains a calmodulin-binding motif (from Lys500 to Ile520). A similar motif is present also in HSP90beta (from Lys491 to Val511). The synthetic peptides corresponding to these putative calmodulin-binding sequences were found to be cross-linked with Ca2+-calmodulin and to prevent the cross-linking of HSP90 and Ca2+-calmodulin. Both HSP90alpha and HSP90beta bind Ca2+. The HSP90 peptides bind HSP90 and thereby inhibit the binding of Ca2+. In addition, the HSP90 peptides augment the self-oligomerization of HSP90 induced at elevated temperatures. These results suggest that the calmodulin-binding domain of HSP90 might interact with another part of the same molecule and that Ca2+-calmodulin might modulate the structure and function of HSP90 through abolishing the intramolecular interaction.	TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,HONKOMAGOME 3-18-22,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science			Kawasaki, Hiroshi/C-3048-2011	Kawasaki, Hiroshi/0000-0002-2517-159X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KANG HS, 1991, J BIOL CHEM, V266, P5643; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KELLEY PM, 1982, MOL CELL BIOL, V2, P267, DOI 10.1128/MCB.2.3.267; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1980, PROTEIN PHOSPHORYLAT, P61; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANKS KW, 1989, J CELL PHYSIOL, V140, P601, DOI 10.1002/jcp.1041400327; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SCHUH S, 1985, J BIOL CHEM, V260, P4292; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x	36	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9604	9610						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486648				2022-12-27	WOS:A1993LA68900069
J	LEHNER, R; KUKSIS, A				LEHNER, R; KUKSIS, A			TRIACYLGLYCEROL SYNTHESIS BY AN SN-1,2(2,3)-DIACYLGLYCEROL TRANSACYLASE FROM RAT INTESTINAL MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; ACYLTRANSFERASE ACTIVITY; ACID LIPASE; PURIFICATION; PROTEINS; LIVER	A membrane-associated sn-1,2(2,3)-diacylglycerol transacylase activity was purified 550-fold from the microsomes of rat intestinal villus cells. The enzyme was solubilized with the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and was isolated and purified by sequential chromatography on hydroxylapatite, an anion exchanger, Affi-Gel heparin and Cibacron blue A-agarose. SDS-polyacrylamide gel electrophoresis revealed two major closely migrating polypeptides of apparent molecular mass of 50 and 52 kDa. Incubation of the isolated enzyme with sn-1,2(2,3)dioleoyl-[2-H-3]glycerol yielded trioleoyl[2-H-3]glycerol and 2-oleoyl[2-H-3]glycerol. The synthesis of triacylglycerols was independent of acyl-CoA, as indicated by the absence of incorporation of radioactivity from [1-C-14]oleoyl-CoA into mono-, di-, or triacylglycerols under these conditions. The transacylase did not hydrolyze triacylglycerols readily and was not affected by the acyltransferase inhibitors, N-ethylmaleimide and 4,4'-diisothiocy-anostilbene-2,2'-disulfonate, while the lipase/hydrolase inhibitors NaF, phenylmethylsulfonyl fluoride, and diethyl p-nitrophenyl phosphate caused partial inactivation. The enzyme was specific toward 1(3)-positions of rac 1,2-diacylglycerols but did not utilize the -1,3-diacylglycerols or other neutral lipid esters effectively and was not capable of removing fatty acids from phosphatidylcholine or of transfer of fatty acids from X (unspecified enantiomer)- 1,2-diacylglycerol to lysophosphatidylcholine. Since the diacylglycerol transacylation did not lead to accumulation of either sn-1,2- or sn-2,3-diacylglycerols during incubation with the racemates, it is concluded that both sn-1,2- and sn-2,3-s are utilized at similar rates.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto				Lehner, Richard/0000-0002-6008-1805				BERGE RK, 1980, EUR J BIOCHEM, V111, P67; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; COLEMAN RA, 1985, BIOCHIM BIOPHYS ACTA, V834, P180, DOI 10.1016/0005-2760(85)90154-7; FAROOQUI AA, 1980, J CHROMATOGR, V184, P335, DOI 10.1016/S0021-9673(00)89004-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; ITABASHI Y, 1990, J LIPID RES, V31, P1711; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RAO RH, 1990, BIOCHIM BIOPHYS ACTA, V1043, P273, DOI 10.1016/0005-2760(90)90027-U; RAO RH, 1990, BIOCHIM BIOPHYS ACTA, V1046, P19, DOI 10.1016/0005-2760(90)90089-G; SANJANWALA M, 1989, BIOCHIM BIOPHYS ACTA, V1006, P203, DOI 10.1016/0005-2760(89)90197-5; SUGIURA T, 1985, BIOCHEM BIOPH RES CO, V133, P574, DOI 10.1016/0006-291X(85)90944-1; WAITE M, 1973, J BIOL CHEM, V248, P7985; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1991, J LIPID RES, V32, P1173	22	88	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8781	8786						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473321				2022-12-27	WOS:A1993KX81100061
J	SCEARCE, LM; LAZ, TM; HAZEL, TG; LAU, LF; TAUB, R				SCEARCE, LM; LAZ, TM; HAZEL, TG; LAU, LF; TAUB, R			RNR-1, A NUCLEAR RECEPTOR IN THE NGFI-B NUR77 FAMILY THAT IS RAPIDLY INDUCED IN REGENERATING LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE EXPRESSION; GROWTH-FACTOR; GENETIC RESPONSE; SUPERFAMILY; CELLS; IDENTIFICATION; SEQUENCE; MEMBER; CDNA; TRANSCRIPTION	Liver regeneration following partial hepatectomy provides one of the few systems for analysis of mitogenesis in the fully developed, intact animal. Immediate-early growth response genes, induced in the absence of prior protein synthesis, play an important regulatory role in the regenerative process. During screening of a subtracted cDNA library of immediate-early genes induced during liver regeneration, a novel member of the thyroid/steroid receptor superfamily, RNR-1 (regenerating liver nuclear receptor), was identified. This gene is not expressed in quiescent liver but is rapidly induced following partial hepatectomy and is specific to hepatic growth as it is not induced in other mitogen-treated cells. RNR-1 is also expressed in brain. A full-length cDNA clone of RNR-1 encodes a 66-kDa, 597-amino acid protein as verified by in vitro translation in reticulocyte lysate. RNR-1 is highly homologous to r-NGFI-B/m-Nur77 particularly in the DNA binding (94%) and putative ligand binding (59%) domains. Using a mobility shift assay, we have shown that RNR-1 specifically binds to the NGFI-B DNA half-site and forms a complex very similar in size to the Nur77 complex, suggesting that RNR-1 also may bind as a monomer. Consistent with this finding, the A box region important in mediating half-site binding is 100% conserved between r-NGFI-B/m-Nur77. Both RNR-1 and Nur77 strongly transactivate a reporter driven by a consensus r-NGFI-B/Nur77 binding site, and their effect together is additive. As both the RNR-1 and r-NGFI/m-nur77 genes are induced during liver regeneration, it is very possible that RNR-1 acts concomitantly with r-NGFI/m-Nur77 in regulating the expression of delayed-early genes during liver regeneration.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,PHILADELPHIA,PA 19104; UNIV ILLINOIS,COLL MED,DEPT GENET,CHICAGO,IL 60612	Howard Hughes Medical Institute; University of Pennsylvania; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHANG CS, 1987, NUCLEIC ACIDS RES, V15, P9603, DOI 10.1093/nar/15.22.9603; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAUSTO N, 1989, LAB INVEST, V60, P4; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERBOMEL P, 1984, CELL, V39, P6563; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MOHN KL, 1990, J BIOL CHEM, V265, P21914; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P393; PARKER MG, 1991, NUCLEAR HORMONE RECE; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAUB R, 1987, J BIOL CHEM, V262, P10893; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	38	117	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8855	8861						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473329				2022-12-27	WOS:A1993KX81100071
J	MASSIA, SP; RAO, SS; HUBBELL, JA				MASSIA, SP; RAO, SS; HUBBELL, JA			COVALENTLY IMMOBILIZED LAMININ PEPTIDE TYR-ILE-GLY-SER-ARG (YIGSR) SUPPORTS CELL SPREADING AND COLOCALIZATION OF THE 67-KILODALTON LAMININ RECEPTOR WITH ALPHA-ACTININ AND VINCULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TO-SUBSTRATE CONTACTS; EXTRACELLULAR-MATRIX; A-CHAIN; INTERFERENCE-REFLECTION; MULTIDOMAIN PROTEIN; SYNTHETIC PEPTIDE; ENDOTHELIAL-CELLS; MULTIPLE RECEPTORS; NEURITE OUTGROWTH	The laminin-based nonapeptide Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg (CDPGYIGSR) and pentapeptide Tyr-Ile-Gly-Ser-Arg (YIGSR) have been previously demonstrated to support the attachment of several cell types and to competitively bind to the 67-kDa high affinity laminin receptor. Cell attachment, but not spreading, on substrates containing adsorbed CDPGYIGSR or YIGSR was observed. In this report we describe YIGSR-mediated attachment and spreading of a wide variety of cell types. GYIGSRY promoted cell spreading and stress fiber formation when it was covalently immobilized through the amino-terminal Gly residue, used as a spacer arm. Spreading was not observed when adsorbed YIGSR peptide was used. Functionally blocking antiserum directed against the 67-kDa and related laminin-binding proteins blocked human foreskin fibroblast (HFF) spreading, but not attachment, on covalently grafted GYIGSRY substrates. However, functionally blocking antisera directed against the vitronectin receptor, integrin alpha(v)beta3, and the fibronectin receptor, integrin alpha5beta1, did not affect HFF spreading on these substrates. When HFFs spread on these substrates, the 67-kDa laminin receptor co-localized with the cytoplasmic proteins alpha-actinin and vinculin into discrete structures. These results suggest that the adhesion ligand YIGSR is solely sufficient for cell spreading when it is conformationally constrained by covalent attachment to a solid substrate, at least when attached via its amino terminus. Furthermore, the role of the 67-kDa laminin receptor in recognition of this ligand and mediating cell attachment is confirmed in this study. This report also provides the first evidence for direct or indirect association of this receptor with vinculin and alpha-actinin when YIGSR-mediated cell spreading occurs.	UNIV TEXAS,DEPT CHEM ENGN,AUSTIN,TX 78712; UNIV TEXAS,DEPT MECH ENGN,AUSTIN,TX 78712; UNIV TEXAS,DIV BIOL SCI,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4; ABERCROMBIE M, 1975, EXP CELL RES, V92, P57, DOI 10.1016/0014-4827(75)90636-9; BARLOW DP, 1984, EMBO J, V3, P2355, DOI 10.1002/j.1460-2075.1984.tb02140.x; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BLUM JL, 1989, ENVIRON HEALTH PERSP, V80, P71, DOI 10.2307/3430733; BROWN SS, 1983, P NATL ACAD SCI-BIOL, V80, P5927, DOI 10.1073/pnas.80.19.5927; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1986, Cancer Reviews, V4, P18; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; CODY RL, 1986, EXP CELL RES, V165, P107, DOI 10.1016/0014-4827(86)90536-7; COOPER AR, 1981, EUR J BIOCHEM, V119, P189, DOI 10.1111/j.1432-1033.1981.tb05593.x; DAVIS CM, 1991, EXP CELL RES, V193, P262, DOI 10.1016/0014-4827(91)90095-C; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEATH JP, 1978, J CELL SCI, V29, P197; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUARD TK, 1986, AM J PATHOL, V123, P365; HUBBELL JA, 1991, BIO-TECHNOL, V9, P568, DOI 10.1038/nbt0691-568; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; IZZARD CS, 1980, J CELL SCI, V42, P81; IZZARD CS, 1976, J CELL SCI, V21, P129; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MASSIA SP, 1992, J BIOL CHEM, V267, P10133; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; MCKELVEY DR, 1991, J PROTEIN CHEM, V10, P265, DOI 10.1007/BF01025625; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; MERCURIO AM, 1991, BIOESSAYS, V13, P469, DOI 10.1002/bies.950130907; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; PALM SL, 1985, BIOCHEMISTRY-US, V24, P7753, DOI 10.1021/bi00347a038; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; SAKAMOTO N, 1991, CANCER RES, V51, P903; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; TANDON NN, 1991, BIOCHEM J, V274, P535, DOI 10.1042/bj2740535; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1983, TRENDS BIOCHEM SCI, V8, P207, DOI 10.1016/0968-0004(83)90213-X; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WEHLAND J, 1979, J CELL SCI, V37, P259; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YANNARIELLOBROWN J, 1988, J CELL BIOL, V106, P1773, DOI 10.1083/jcb.106.5.1773; YOON PS, 1987, J IMMUNOL, V138, P259; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	81	164	179	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8053	8059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463322				2022-12-27	WOS:A1993KW97900069
J	REZAIE, AR; NEUENSCHWANDER, PF; MORRISSEY, JH; ESMON, CT				REZAIE, AR; NEUENSCHWANDER, PF; MORRISSEY, JH; ESMON, CT			ANALYSIS OF THE FUNCTIONS OF THE 1ST EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; AFFINITY CALCIUM-BINDING; PROTEIN-C; BLOOD-COAGULATION; ACTIVATION; REGION; PROTHROMBIN; SITE; THROMBIN; FRAGMENT	Upon activation, factor X participates in the prothrombin activation complex. Similar to 4-carboxyglutamic acid (Gla)-domainless protein C, the Gla-domainless factor X (GDFX) contains a high affinity Ca2+-binding site critical for the function of these molecules. In the case of protein C, we recently demonstrated that the high affinity Ca2+-binding site critical for activation is outside the first epidermal growth factor (EGF) homology domain. To examine if this is also true for factor X, we have expressed in human 293 cells a deletion mutant of factor X (E2FX) which lacks the entire Gla region as well as the NH2-terminal EGF homology region of factor X. Direct binding studies by equilibrium dialysis indicate that E2FX contains a single Ca2+-binding site with a dissociation constant (K(d)) of 154 +/- 48 muM. The functional properties of E2FX are equivalent or improved over those of GDFX. For instance, the factor X coagulant protein of Russell's viper venom activates E2FX three times faster than recombinant GDFX. Kinetic analysis of prothrombin activation in the absence of membranes indicates that activated GDFX and E2FX bind to factor Va with equal affinity (K(d) = 4.1 muM). The Ca2+ concentration required for half-maximal prothrombin activation rates in the above activation system shifted from 721 +/- 113 muM for activated GDFX to 193 +/- 64 muM for activated E2FX. GDFX and E2FX activation rates with the soluble tissue factor-factor VIIa complex were identical as was the Ca2+ dependence of the reaction. We conclude that E2FX retains a high affinity Ca2+-binding site and that the first EGF homology domain does not appear to have a positive functional role in the GDFX molecule. However, Ca2+ occupancy of the Ca2+-binding site in the first EGF domain of intact factor X may be essential for optimal prothrombin activation.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center			Morrissey, James H./GLR-5645-2022; Morrissey, James H/H-4933-2011	Morrissey, James H/0000-0002-1570-1569	NHLBI NIH HHS [R01 HL29807, F32 HL08710, R01 HL47014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, F32HL008710, R01HL047014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1973, THESIS WASHINGTON U; Esmon N L, 1987, Dev Biol Stand, V67, P75; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; MANN KG, 1990, BLOOD, V76, P1; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; MORITA T, 1984, J BIOL CHEM, V259, P5698; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1991, J BIOL CHEM, V266, P2453; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1991, BLOOD, V78, P1637; SUGO T, 1984, J BIOL CHEM, V259, P5705; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WILDGOOSE P, 1988, BIOCHEM BIOPH RES CO, V152, P1207, DOI 10.1016/S0006-291X(88)80413-3	33	65	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8176	8180						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463328				2022-12-27	WOS:A1993KW97900085
J	ANDERSON, JW; PULLEN, K; GEORGES, F; KLEVIT, RE; WAYGOOD, EB				ANDERSON, JW; PULLEN, K; GEORGES, F; KLEVIT, RE; WAYGOOD, EB			THE INVOLVEMENT OF THE ARGININE-17 RESIDUE IN THE ACTIVE-SITE OF THE HISTIDINE-CONTAINING PROTEIN, HPR, OF THE PHOSPHOENOLPYRUVATE - SUGAR PHOSPHOTRANSFERASE SYSTEM OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER-REACTIONS; PHOSPHOCARRIER PROTEIN; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; ENZYME-I; BACTERIAL PHOSPHOENOLPYRUVATE; STAPHYLOCOCCUS-AUREUS; DIRECTED MUTAGENESIS; N-ACETYLGLUCOSAMINE; TERTIARY STRUCTURE	Histidine-containing protein, HPr, of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system has an active site His-15 that is phosphorylated to form N(delta1)-P-histidine. The nearby conserved residue, Arg-17, has been replaced by: lysine, histidine, glutamate, glycine, serine, and cysteine. All mutations resulted in impairment of the phosphoacceptor function of HPr with enzyme I: k(cat)/K(m) values between 6% (Ser-17) and 0.1% (Glu-17), relative to wild type. Several sugar-specific enzymes II had different responses. Both the V(max) and K(m) of enzyme II(N-acetylglucosamine) were altered, while for enzyme II(mannose) only K(m) was affected, except for R17E. For both enzymes, k(cat)/K(m) values were between 0.5 and 3%, with R17E being 10-fold lower. Except for R17E, minimal effects were observed for enzyme II(mannitol). These results suggest that there are different rate-limiting steps in the enzymes II. Phosphohydrolysis properties and the pK(a) values for His-15 and phosphorylated His-15 determined by NMR for both wild type and mutant HPrs suggest that Arg-17 is partly responsible for the instability of P-His-15 and the depressed pK(a) values in wild type HPr. Other feature(s) of the tertiary structure influence the protonation of His-15 and the phosphohydrolysis properties of phosphorylated His-15.	UNIV SASKATCHEWAN, DEPT BIOCHEM, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; NATL RES COUNCIL CANADA, INST PLANT BIOTECHNOL, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA	University of Saskatchewan; University of Washington; University of Washington Seattle; National Research Council Canada					NIDDK NIH HHS [DK-35187] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK035187, R01DK035187] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; ANDERSON JW, 1992, BIOCHEM CELL BIOL, V70, P242, DOI 10.1139/o92-036; BENKOVIC SJ, 1971, J AM CHEM SOC, V93, P4009, DOI 10.1021/ja00745a032; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DOOIJEWAARD G, 1979, BIOCHEMISTRY-US, V18, P2996, DOI 10.1021/bi00581a014; EISERMANN R, 1991, EUR J BIOCHEM, V197, P9, DOI 10.1111/j.1432-1033.1991.tb15875.x; ELKABBANI OAL, 1987, J BIOL CHEM, V262, P12926; ERNI B, 1989, J BIOL CHEM, V264, P18733; GONZYTREBOUL G, 1989, MOL MICROBIOL, V3, P103, DOI 10.1111/j.1365-2958.1989.tb00109.x; GRENIER FC, 1986, J CELL BIOCHEM, V31, P97, DOI 10.1002/jcb.240310203; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; HAYS JB, 1973, J BIOL CHEM, V248, P941; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; JENCKS WP, 1965, J AM CHEM SOC, V87, P3199, DOI 10.1021/ja01092a035; JIA Z, 1992, THESIS U SASKATCHEWA; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; KALBITZER HR, 1991, BIOCHEMISTRY-US, V30, P11186, DOI 10.1021/bi00110a024; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY S, 1990, GENE, V86, P27, DOI 10.1016/0378-1119(90)90110-D; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MATEUCCI MD, 1981, J AM CHEM SOC, V103, P3186; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MISSET O, 1982, BIOCHEMISTRY-US, V21, P3139; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PERI KG, 1988, BIOCHEMISTRY-US, V27, P6054, DOI 10.1021/bi00416a034; PRASAD L, 1993, J BIOL CHEM, V268, P10705; REIZER J, 1992, J BIOL CHEM, V267, P9158; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1988, FASEB J, V2, P199, DOI 10.1096/fasebj.2.3.2832233; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SHARMA S, 1992, THESIS U SASKATCHEWA; STOCK JB, 1982, J BIOL CHEM, V257, P4543; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; TITGEMEYER F, 1991, THESIS U OSNABRUCK; VANDIJK AA, 1992, BIOCHEMISTRY-US, V31, P9063, DOI 10.1021/bi00152a050; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1986, BIOCHEMISTRY-US, V25, P4085, DOI 10.1021/bi00362a015; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WAYGOOD EB, 1989, FEMS MICROBIOL LETT, V63, P43, DOI 10.1016/0168-6445(89)90007-7; WAYGOOD EB, 1988, BIOCHEM CELL BIOL, V66, P76, DOI 10.1139/o88-010; WAYGOOD EB, 1987, SUGAR TRANSPORT META, P235; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	61	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12325	12333						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509371				2022-12-27	WOS:A1993LG65800019
J	HAMMEL, KE; JENSEN, KA; MOZUCH, MD; LANDUCCI, LL; TIEN, M; PEASE, EA				HAMMEL, KE; JENSEN, KA; MOZUCH, MD; LANDUCCI, LL; TIEN, M; PEASE, EA			LIGNINOLYSIS BY A PURIFIED LIGNIN PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS PHANEROCHAETE-CHRYSOSPORIUM; C-13 NMR-SPECTROSCOPY; WHITE-ROT FUNGI; VERATRYL ALCOHOL; DEGRADING BASIDIOMYCETE; MANGANESE PEROXIDASE; MODEL-COMPOUND; FREE-RADICALS; STEADY-STATE; OXALIC-ACID	The lignin peroxidases (LiPs) of white-rot basidiomycetes are generally thought to catalyze the oxidative cleavage of polymeric lignin in vivo. However, direct evidence for such a role has been lacking. In this investigation, C-14- and C-13-labeled synthetic lignins were oxidized with a purified isozyme of Phanerochaete chrysosporium LiP. Gel permeation chromatography of the radiolabeled polymers showed that LiP catalyzed their cleavage to give soluble lower-M(r) products. To a lesser extent, the enzyme also polymerized the lignins to give soluble higher-M(r) products. This result is attributable to the fact that purified LiP, unlike the intact fungus, provides no mechanism for the removal of lignin fragments that are susceptible to repolymerization. LiP catalysis also gave small quantities of insoluble, perhaps polymerized, lignin, but in lower yield than intact P. chrysosporium does. C-13 NMR experiments with C-13-labeled polymer showed that LiP cleaved it between C(alpha) and C(beta) of the propyl side chain to give benzylic aldehydes at C(alpha), in agreement with the cleavage mechanism hypothesized earlier. The data show that LiP catalysis accounts adequately for the initial steps of ligninolysis by P. chrysosporium in vivo.	PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIV PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	HAMMEL, KE (corresponding author), US FOREST SERV, FOREST PROD LAB, MADISON, WI 53705 USA.		Hammel, Kenneth/G-1890-2011	Hammel, Kenneth/0000-0002-2935-5847				ADLER E, 1977, WOOD SCI TECHNOL, V11, P169, DOI 10.1007/BF00365615; AKAMATSU Y, 1990, FEBS LETT, V269, P261, DOI 10.1016/0014-5793(90)81169-O; Allan GG, 1971, LIGNINS OCCURRENCE F, P511; BLANCHETTE RA, 1991, ANNU REV PHYTOPATHOL, V29, P381, DOI 10.1146/annurev.py.29.090191.002121; BLANCHETTE RA, 1989, APPL ENVIRON MICROB, V55, P1457, DOI 10.1128/AEM.55.6.1457-1465.1989; CAI DY, 1989, BIOCHEM BIOPH RES CO, V162, P464, DOI 10.1016/0006-291X(89)92020-2; Chen C. L., 1985, BIOSYNTHESIS BIODEGR, P535; CHUA MGS, 1983, HOLZFORSCHUNG, V37, P55, DOI 10.1515/hfsg.1983.37.2.55; CHUA MGS, 1982, HOLZFORSCHUNG, V36, P165, DOI 10.1515/hfsg.1982.36.4.165; CONNORS WJ, 1980, HOLZFORSCHUNG, V34, P80, DOI 10.1515/hfsg.1980.34.3.80; DANIEL G, 1989, APPL ENVIRON MICROB, V55, P874; Evans C. S., 1991, Biodegradation, V2, P93, DOI 10.1007/BF00114599; FAIX O, 1985, HOLZFORSCHUNG, V39, P203, DOI 10.1515/hfsg.1985.39.4.203; FURNISS BS, 1989, VOGELS TXB PRACTICAL, P695; GAGNAIRE D, 1977, MAKROMOL CHEM, V178, P1477; GALLIANO H, 1991, ENZYME MICROB TECH, V13, P478, DOI 10.1016/0141-0229(91)90005-U; GARCIA S, 1987, APPL ENVIRON MICROB, V53, P2384, DOI 10.1128/AEM.53.10.2384-2387.1987; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; GOLDSCHMID O, 1954, ANAL CHEM, V26, P1421, DOI 10.1021/ac60093a009; GORING DAI, 1971, LIGNINS OCCURRENCE F, P741; HAEMMERLI SD, 1986, FEMS MICROBIOL LETT, V35, P33, DOI 10.1111/j.1574-6968.1986.tb01494.x; HAIDER K, 1985, HOLZFORSCHUNG, V39, P23, DOI 10.1515/hfsg.1985.39.1.23; HAMMEL KE, 1986, P NATL ACAD SCI USA, V83, P3708, DOI 10.1073/pnas.83.11.3708; HAMMEL KE, 1991, ENZYME MICROB TECH, V13, P15, DOI 10.1016/0141-0229(91)90182-A; HAMMEL KE, 1986, J BIOL CHEM, V261, P6948; HAMMEL KE, 1985, J BIOL CHEM, V260, P8348; HARVEY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P59, DOI 10.1016/0167-4838(89)90062-9; KERN HW, 1989, HOLZFORSCHUNG, V43, P375, DOI 10.1515/hfsg.1989.43.6.375; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KERSTEN PJ, 1985, J BIOL CHEM, V260, P2609; KIRK TK, 1986, BIOCHEM J, V236, P279, DOI 10.1042/bj2360279; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KIRK TK, 1975, P NATL ACAD SCI USA, V72, P2515, DOI 10.1073/pnas.72.7.2515; KIRK TK, 1975, HOLZFORSCHUNG, V29, P56, DOI 10.1515/hfsg.1975.29.2.56; KIRK TK, 1986, ENZYME MICROB TECH, V8, P27, DOI 10.1016/0141-0229(86)90006-2; KIRK TK, 1978, ARCH MICROBIOL, V117, P277, DOI 10.1007/BF00738547; KIRK TK, 1970, ACTA CHEM SCAND, V24, P3379, DOI 10.3891/acta.chem.scand.24-3379; KIRK TK, 1990, METHOD ENZYMOL, V188, P159; KIRK TK, 1988, METHOD ENZYMOL, V161, P65; KOFUJITA H, 1991, MOKUZAI GAKKAISHI, V37, P555; LUNDQUIST K, 1978, PHYTOCHEMISTRY, V17, P1676, DOI 10.1016/S0031-9422(00)94674-0; MIKI K, 1986, BIOCHEMISTRY-US, V25, P4790, DOI 10.1021/bi00365a011; MILLIS CD, 1989, BIOCHEMISTRY-US, V28, P8484, DOI 10.1021/bi00447a032; NEWMAN J, 1986, HOLZFORSCHUNG, V40, P369, DOI 10.1515/hfsg.1986.40.6.369; ODIER E, 1988, BIOCHIMIE, V70, P847, DOI 10.1016/0300-9084(88)90117-4; ORTH AB, 1991, APPL ENVIRON MICROB, V57, P2591, DOI 10.1128/AEM.57.9.2591-2596.1991; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; PERIE FH, 1991, APPL ENVIRON MICROB, V57, P2240; POPP JL, 1990, BIOCHEMISTRY-US, V29, P10475, DOI 10.1021/bi00498a008; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; ROBERT D, 1989, HOLZFORSCHUNG, V43, P323, DOI 10.1515/hfsg.1989.43.5.323; RUEL K, 1991, APPL ENVIRON MICROB, V57, P374, DOI 10.1128/AEM.57.2.374-384.1991; Ruel K., 1985, BIOSYNTHESIS BIODEGR, P441; RUTTIMANN C, 1992, BIOTECHNOL APPL BIOC, V16, P64; RUTTIMANN C, 1992, BIOTECHNOLOGY PULP P, P243; SARKANEN S, 1991, J BIOL CHEM, V266, P3636; SCHOEMAKER HE, 1985, FEBS LETT, V183, P7, DOI 10.1016/0014-5793(85)80942-X; SCHUERCH C, 1952, J AM CHEM SOC, V74, P5061, DOI 10.1021/ja01140a020; SHIMADA M, 1981, ARCH MICROBIOL, V129, P321, DOI 10.1007/BF00414706; SREBOTNIK E, 1988, APPL ENVIRON MICROB, V54, P2608, DOI 10.1128/AEM.54.11.2608-2614.1988; STRUBE RE, 1963, ORG SYNTH, V4, P417; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; TIEN M, 1990, APPL ENVIRON MICROB, V56, P2540, DOI 10.1128/AEM.56.8.2540-2544.1990; TIEN M, 1984, P NATL ACAD SCI-BIOL, V81, P2280, DOI 10.1073/pnas.81.8.2280; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; UMEZAWA T, 1989, MOKUZAI GAKKAISHI, V35, P1014; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X; YAU WW, 1979, MODERN SIZE EXCLUSIO, P315; YOKOTA S, 1990, HOLZFORSCHUNG, V44, P271, DOI 10.1515/hfsg.1990.44.4.271	73	222	232	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12274	12281						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509364				2022-12-27	WOS:A1993LG65800011
J	IVEY, DM; GUFFANTI, AA; ZEMSKY, J; PINNER, E; KARPEL, R; PADAN, E; SCHULDINER, S; KRULWICH, TA				IVEY, DM; GUFFANTI, AA; ZEMSKY, J; PINNER, E; KARPEL, R; PADAN, E; SCHULDINER, S; KRULWICH, TA			CLONING AND CHARACTERIZATION OF A PUTATIVE CA2+/H+ ANTIPORTER GENE FROM ESCHERICHIA-COLI UPON FUNCTIONAL COMPLEMENTATION OF NA+/H+ ANTIPORTER-DEFICIENT STRAINS BY THE OVEREXPRESSED GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATIVE TRANSPOSON TN1545; MOLECULAR-CLONING; SARCOPLASMIC-RETICULUM; PROTON ANTIPORTER; SYSTEMS; SEQUENCE; PROTEIN; NHAA; EXPRESSION; MAGNESIUM	DNA libraries from alkaliphilic Bacillus firmus OF4 had been screened earlier (Ivey, D. M., Guffanti, A. A., Bossewitch, J. S., Padan, E., and Krulwich, T. A. (1991) J. Biol. Chem. 266, 23483-23489) for clones that would functionally complement a strain of Escherichia coli (NM81) with a deletion in one of its Na+/H+ antiporter genes. During those studies, an alkaliphile antiporter gene was hypothesized to have been incorporated into the chromosome of strain NM81, producing Na+-resistant NM8191. After introduction of a deletion in the second known E. coli Na+/H+ antiporter gene, libraries were prepared from NM8191 and screened for complementation of Na+/H+ antiporter-deficient mutants of E. coli. Instead of retrieving an alkaliphile gene, an unexpected E. coli gene was identified on the basis of its ability to restore Na+ resistance and membrane Na+/H+ antiporter activity to such mutant strains. The active open reading frame in the clone maps at 27 min on the E. coli chromosome and is identical in sequence to a wild type counterpart. It would be predicted to encode an extremely hydrophobic protein with multiple membrane-spanning regions and a molecular weight of 39,200. A region in one of the predicted hydrophilic loops in the gene product structure possesses striking sequence similarity to calsequestrin. The Ca2+/H+ antiporter activity of membranes from an E. coli transformant with a clone possessing only this open reading frame was indeed found to have enhanced pH-independent Ca2+/H+ antiporter activity. The Ca2+/H+ and Na+/H+ antiporter activities conferred by the clone were both inhibited by Mg2+. The gene was designated chaA and is proposed to be the structural gene for a Ca2+/H+ antiporter whose overexpression leads to resistance to growth inhibition by both calcium and sodium.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,1 GUSTAVE LEVY PL,NEW YORK,NY 10029; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; AMBUDKAR SV, 1990, BACTERIAL ENERGETICS, V12; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; BREY RN, 1979, J BACTERIOL, V139, P824, DOI 10.1128/JB.139.3.824-834.1979; BREY RN, 1978, BIOCHEM BIOPH RES CO, V83, P1588, DOI 10.1016/0006-291X(78)91403-1; BREY RN, 1979, J BIOL CHEM, V254, P1957; BROCKMAN RW, 1968, BIOCHEMISTRY-US, V7, P2554, DOI 10.1021/bi00847a016; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GIBSON MM, 1991, MOL MICROBIOL, V5, P2753, DOI 10.1111/j.1365-2958.1991.tb01984.x; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; IVEY DM, 1992, J BACTERIOL, V174, P4878, DOI 10.1128/JB.174.15.4878-4884.1992; IVEY DM, 1991, J BIOL CHEM, V266, P23483; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KOHARA Y, 1990, BACTERIAL CHROMOSOME, P29; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSK JE, 1968, J BIOL CHEM, V243, P2618; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NISHIMURA A, 1992, MICROBIOL REV, V56, P137, DOI 10.1128/MMBR.56.1.137-151.1992; PADAN E, 1989, J BIOL CHEM, V264, P20297; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; POYARTSALMERON C, 1989, EMBO J, V8, P2425, DOI 10.1002/j.1460-2075.1989.tb08373.x; POYARTSALMERON C, 1990, MOL MICROBIOL, V4, P1513, DOI 10.1111/j.1365-2958.1990.tb02062.x; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHULDINER S, 1992, ALKALI CATION TRANSP; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SILVER S, 1978, BACTERIAL TRANSPORT; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; THELEN P, 1991, J BACTERIOL, V173, P6553, DOI 10.1128/jb.173.20.6553-6557.1991; TSUCHIYA T, 1975, J BIOL CHEM, V250, P7687; WOISETSCHLAGER M, 1987, MOL GEN GENET, V207, P369, DOI 10.1007/BF00331603	43	169	173	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11296	11303						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496184				2022-12-27	WOS:A1993LD46600085
J	KIMURA, A; NISHIYORI, A; MURAKAMI, T; TSUKAMOTO, T; HATA, S; OSUMI, T; OKAMURA, R; MORI, M; TAKIGUCHI, M				KIMURA, A; NISHIYORI, A; MURAKAMI, T; TSUKAMOTO, T; HATA, S; OSUMI, T; OKAMURA, R; MORI, M; TAKIGUCHI, M			CHICKEN OVALBUMIN UPSTREAM PROMOTER-TRANSCRIPTION FACTOR (COUP-TF) REPRESSES TRANSCRIPTION FROM THE PROMOTER OF THE GENE FOR ORNITHINE TRANSCARBAMYLASE IN A MANNER ANTAGONISTIC TO HEPATOCYTE NUCLEAR FACTOR-IV (HNF-4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; DNA-BINDING PROTEINS; THYROID-HORMONE; RETINOIC-ACID; RAT-LIVER; CARBAMOYLTRANSFERASE GENE; DIFFERENTIAL REGULATION; INVITRO TRANSCRIPTION; MOLECULAR-CLONING; EXPRESSION VECTOR	Chicken ovalbumin upstream promoter-transcription factor (COUP-TF) and hepatocyte nuclear factor-4 (HNF-4) are orphan members of the steroid/thyroid receptor superfamily and exhibit ubiquitous and liver-enriched tissue distribution, respectively. The gene for rat ornithine transcarbamylase (OTC), an ornithine cycle enzyme, is mainly expressed in the liver and is under the control of the promoter and the 11-kilobase upstream enhancer, both of which are liver-selective. Two sites of the promoter region and two sites of the enhancer region of the OTC gene, as well as the ovalbumin promoter site, were recognized by both HNF-4 and COUP-TF, showing that these two factors have closely related binding specificities. Since HNF-4 activated expression from the OTC promoter in cotransfection analysis, this factor appears to participate in liver-selective activation of the OTC gene. On the other hand, COUP-TF repressed the expression from the OTC promoter, whereas it activated expression from several other promoters. Therefore, COUP-TF plays a dual regulatory role depending on the promoter context. Repression of a tissue-specific promoter by a ubiquitous transactivator and derepression by a related tissue-enriched transactivator is potentially an important mechanism for tissue-specific activation of a gene.	KUMAMOTO UNIV,SCH MED,DEPT MOLEC GENET,KUHONJI 4-24-1,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT OPHTHALMOL,KUMAMOTO 862,JAPAN; HIMEJI INST TECHNOL,KAMIGORI,HYOGO 67812,JAPAN	Kumamoto University; Kumamoto University; University of Hyogo								ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BEEKMAN JM, 1991, NUCLEIC ACIDS RES, V19, P5371, DOI 10.1093/nar/19.19.5371; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GLASS CK, 1988, CELL, V54, P3313; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HWUNG YP, 1988, J BIOL CHEM, V263, P13470; JONES SN, 1990, J BIOL CHEM, V265, P14684; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LINDGREN V, 1984, SCIENCE, V226, P698, DOI 10.1126/science.6494904; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIYAZAKI J, 1989, GENE, V79, P269; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; MURAKAMI T, 1989, DEV GENET, V10, P393, DOI 10.1002/dvg.1020100507; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; REUE K, 1988, J BIOL CHEM, V263, P6857; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RYALL J, 1985, EUR J BIOCHEM, V152, P287, DOI 10.1111/j.1432-1033.1985.tb09196.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAKIGUCHI M, 1987, P NATL ACAD SCI USA, V84, P6136, DOI 10.1073/pnas.84.17.6136; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WRAIGHT C, 1985, EUR J BIOCHEM, V153, P239, DOI 10.1111/j.1432-1033.1985.tb09292.x	66	115	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11125	11133						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496174				2022-12-27	WOS:A1993LD46600062
J	TADAKI, DK; NIYOGI, SK				TADAKI, DK; NIYOGI, SK			THE FUNCTIONAL IMPORTANCE OF HYDROPHOBICITY OF THE TYROSINE AT POSITION 13 OF HUMAN EPIDERMAL GROWTH-FACTOR IN RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR-MAGNETIC-RESONANCE; KINASE-ACTIVITY; RESIDUES; EGF; LEUCINE-47; H-1-NMR; DOMAIN	The tyrosine at position 13 of epidermal growth factor (EGF) has been implicated as playing a role in receptor binding due to its close proximity to the critical arginine 41 residue as well as its high degree of conservation in EGF and EGF-like proteins that can bind to the EGF receptor. Site-directed mutagenesis of tyrosine 13 in human EGF (hEGF) was employed to examine the role of this residue in ligand-receptor interaction. The removal of the hydroxyl moiety of the tyrosine by substitution with phenylalanine had little effect on the binding, indicating that it is not involved in any crucial hydrogen bonds with either the receptor or with other regions of the EGF molecule. The substitution of the aromatic tyrosine side-chain with the nonpolar leucine side-chain caused the receptor affinity to decrease only slightly, indicating that aromaticity of the amino acid at this site is also not critical. Substitutions with other hydrophobic residues, isoleucine, valine, and alanine, resulted in a significant decrease in receptor affinity as a function of decreasing hydrophobicity. Substitution of tyrosine 13 with the polar residues histidine and arginine markedly decreased receptor binding affinity, and complete removal of the side-chain by substitution with glycine dramatically lowered the binding affinity to 0.3% as compared to wild type. Analysis of three hEGF mutants, Tyr13-->Leu, Tyr13-->Arg, and Tyr13-->Gly, by circular dichroism showed that the major structural features of hEGF were not significantly altered. The results demonstrate that the decreased receptor affinities of these hEGF mutants are due to disruption of the functional contribution(s) of the tyrosine 13 residue rather than alteration(s) in the overall structural integrity. Overall, the results suggest that the tyrosine 13 side-chain plays a critical role in receptor binding by contributing to hydrophobic receptor-ligand interactions.	OAK RIDGE NATL LAB,DIV BIOL,UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,POB 2009,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,PROTEIN ENGN & MOLEC MUTAGENESIS PROGRAM,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory					NCI NIH HHS [CA 50735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CAMPION SR, 1993, J BIOL CHEM, V268, P1742; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1985, METHOD ENZYMOL, V109, P107; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; ENGLER DA, 1991, MOL CELL BIOL, V11, P2425, DOI 10.1128/MCB.11.5.2425; HELMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545; HOLLADAY LA, 1976, BIOCHEMISTRY-US, V15, P2624, DOI 10.1021/bi00657a023; HOMMEL U, 1991, BIOCHEMISTRY-US, V30, P8891, DOI 10.1021/bi00100a024; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P554, DOI 10.1093/oxfordjournals.jbchem.a122307; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MAYO KH, 1986, BIOCHEM J, V239, P13, DOI 10.1042/bj2390013; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; MOY FJ, 1989, P NATL ACAD SCI USA, V86, P9836, DOI 10.1073/pnas.86.24.9836; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; TADAKI DK, 1991, FASEB J, V5, pA1183; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	33	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10114	10119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486681				2022-12-27	WOS:A1993LB80000028
J	FABER, PW; VANROOIJ, HCJ; SCHIPPER, HJ; BRINKMANN, AO; TRAPMAN, J				FABER, PW; VANROOIJ, HCJ; SCHIPPER, HJ; BRINKMANN, AO; TRAPMAN, J			2 DIFFERENT, OVERLAPPING PATHWAYS OF TRANSCRIPTION INITIATION ARE ACTIVE ON THE TATA-LESS HUMAN ANDROGEN RECEPTOR PROMOTER - THE ROLE OF SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; RIBONUCLEIC-ACID; MAMMALIAN-CELLS; GENE-EXPRESSION; BINDING; DNA; ACTIVATION; SPECIFICITY; PROTEINS; COMPLEX	In this study, the minimal promoter requirements of the TATA-less human androgen receptor (hAR) gene promoter are described. The hAR promoter is characterized by a short GC-box (-59/-32) and a long homopurine stretch (-117/-60). Two major transcription initiation sites, AR transcription initiation site I (AR-TIS I, (+1/2/3)) and AR transcription initiation site II (AR-TIS II, (+12/13)) are located in a 13-base pair region (Faber, P. W., van Rooij, H. C. J., van der Korput, J. A. G. M., Baarends, W. M., Brinkmann, A. O., Grootegoed, J. A., and Trapman, J. (1991) J. Biol. Chem. 266, 10743-10749). Transient transfection of COS cells with hAR promoter deletion and mutant constructs, followed by RNA isolation and S1 nuclease protection analysis showed that the process of transcription initiation through AR-TIS I and AR-TIS II is regulated by different promoter sequences. The GC-box directed initiation from AR-TIS II but did not affect AR-TIS I utilization, which is dependent upon sequences between positions -5 and +57. Band shift analysis identified the transcription factor Sp1 as the protein interacting with the GC-box. A single Sp1 binding sequence was found to be present in the GC-box. Footprint analysis confirmed the interaction of Sp1 with this sequence. The differential initiation through AR-TIS I and AR-TIS II was substantiated by the introduction of point mutations in the Sp1 binding sequence: only mutations that specifically abolished Sp1 binding interfered with AR-TIS II utilization, but all mutations left AR-TIS I initiation intact.	ERASMUS UNIV,DEPT ENDOCRINOL & REPROD,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	FABER, PW (corresponding author), ERASMUS UNIV,DEPT PATHOL,3000 DR ROTTERDAM,NETHERLANDS.							BAARENDS WM, 1990, MOL CELL ENDOCRINOL, V74, P75, DOI 10.1016/0303-7207(90)90207-O; Battey, 1986, BASIC METHODS MOL BI; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRINKMANN AO, 1992, CANCER SURV, V14, P95; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coffey D S, 1987, Prog Clin Biol Res, V239, P1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FABER PW, 1991, J BIOL CHEM, V266, P10743; FABER PW, 1991, BIOCHEM J, V278, P269, DOI 10.1042/bj2780269; GOODRICH JA, 1991, TRENDS BIOCHEM SCI, V16, P394, DOI 10.1016/0968-0004(91)90162-O; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KASAI Y, 1992, MOL CELL BIOL, V12, P2884, DOI 10.1128/MCB.12.6.2884; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; MCPHAUL MJ, 1991, FASEB J, V5, P2910, DOI 10.1096/fasebj.5.14.1752359; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Sambrook J, 1989, MOL CLONING LABORATO; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAKANE KK, 1991, ENDOCRINOLOGY, V129, P1093, DOI 10.1210/endo-129-2-1093; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615	41	116	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9296	9301						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486625				2022-12-27	WOS:A1993LA68900025
J	FREER, SN				FREER, SN			KINETIC CHARACTERIZATION OF A BETA-GLUCOSIDASE FROM A YEAST, CANDIDA-WICKERHAMII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLODEXTRINS; FERMENTATION; CELLOBIOSE; HYDROLYSIS; ETHANOL; PURIFICATION; LUSITANIAE; CELLULOSE; STRAINS; ENZYME	The extracytoplasmic, cell-bound beta-1,4-glucosidase of Candida wickerhamii was characterized kinetically. The enzyme was found to produce glucose from cellobiose and cellodextrins (degree of polymerization from three to six) by catalyzing the removal of the terminal glucose moiety from the nonreducing end of these beta-glucans. The K(m) values for the series, cellobiose through cellohexaose, were 210.7, 106.6, 106.3, 105.9, and 79.8 mM, respectively, whereas the k(cat) values were 14.79, 13.24, 13.78, 15.13, and 7.66 mumol of glucose . min-1 . mg-1 of protein, respectively. A computer program was developed to estimate the integrated rate equation. When the above kinetic constants were used in the computer model, the predicted rates of glucose formation agreed well with the experimental data. Saccharomyces cerevisiae, which is unable to ferment cellobiose or cellodextrins, ferments glucose about twice as fast as C. wickerhamii. If S. cerevisiae is cultured on cellobiose or cellodextrins and,the purified C. wickerhamii beta-glucosidase is added to the S. cerevisiae culture at levels that mimic the production of beta-glucosidase by a C. wickerhamii culture with time, the two cultures produce ethanol at equivalent rates. This suggests that the rate-limiting step in the fermentation of cellobiose/cellodextrins by C. wickerhamii is the production of beta-glucosidase.			FREER, SN (corresponding author), USDA ARS, NATL CTR AGR UTILIZAT RES, FERMENTAT BIOCHEM RES UNIT, PEORIA, IL 61604 USA.							ALEXANDER JK, 1972, METHOD ENZYMOL, V28, P948; BLONDIN B, 1983, EUR J APPL MICROBIOL, V17, P1, DOI 10.1007/BF00510563; COUGHLAN MP, 1985, BIOTECHNOL GENET ENG, V3, P39, DOI 10.1080/02648725.1985.10647809; COUGHLAN MP, 1988, FEMS S, V43, P11; DESROCHERS M, 1981, APPL ENVIRON MICROB, V41, P222, DOI 10.1128/AEM.41.1.222-228.1981; DUERKSEN JD, 1958, J BIOL CHEM, V233, P1113; FLEMING LW, 1967, J BACTERIOL, V93, P135, DOI 10.1128/JB.93.1.135-141.1967; FREER SN, 1990, J BIOL CHEM, V265, P12864; FREER SN, 1985, APPL ENVIRON MICROB, V50, P152, DOI 10.1128/AEM.50.1.152-159.1985; FREER SN, 1991, APPL ENVIRON MICROB, V57, P655, DOI 10.1128/AEM.57.3.655-659.1991; FREER SN, 1983, BIOTECHNOL BIOENG, V25, P541, DOI 10.1002/bit.260250218; FREER SN, 1982, BIOTECHNOL LETT, V4, P453, DOI 10.1007/BF01134594; FREER SN, 1985, ARCH BIOCHEM BIOPHYS, V243, P515, DOI 10.1016/0003-9861(85)90528-4; GONDE P, 1982, J FERMENT TECHNOL, V60, P579; GONDE P, 1984, APPL ENVIRON MICROB, V48, P265; HIMMEL ME, 1986, J BIOL CHEM, V261, P2948; Ladisch M R, 1981, Basic Life Sci, V18, P55; LECLERC M, 1984, J GEN APPL MICROBIOL, V30, P509, DOI 10.2323/jgam.30.509; LEE YH, 1980, ADV BIOCHEM ENG, V17, P102; MILLER GL, 1960, ARCH BIOCHEM BIOPHYS, V91, P21, DOI 10.1016/0003-9861(60)90448-3; SEGAL IH, 1975, ENZYME KINETICS, P113; SHETH K, 1967, BIOCHIM BIOPHYS ACTA, V148, P808, DOI 10.1016/0304-4165(67)90057-8; STERNBERG D, 1977, CAN J MICROBIOL, V23, P139, DOI 10.1139/m77-020; TINGLE M, 1972, J BACTERIOL, V110, P196, DOI 10.1128/JB.110.1.196-201.1972	24	22	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9337	9342						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486628				2022-12-27	WOS:A1993LA68900031
J	PARRUTI, G; PERACCHIA, F; SALLESE, M; AMBROSINI, G; MASINI, M; ROTILIO, D; DEBLASI, A				PARRUTI, G; PERACCHIA, F; SALLESE, M; AMBROSINI, G; MASINI, M; ROTILIO, D; DEBLASI, A			MOLECULAR ANALYSIS OF HUMAN BETA-ARRESTIN-1 - CLONING, TISSUE DISTRIBUTION, AND REGULATION OF EXPRESSION - IDENTIFICATION OF 2 ISOFORMS GENERATED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL S-ANTIGEN; ADRENERGIC-RECEPTOR FUNCTION; REVEALS SIMILARITIES; ENDOTHELIAL-CELLS; 48-KDA PROTEIN; MESSENGER-RNA; PINEAL-GLAND; RHODOPSIN; GENE; DESENSITIZATION	The cDNA for human beta-arrestin-1 was cloned by polymerase chain reaction (PCR) and identified based on its remarkably high amino acid identity (98.6%) with the bovine sequence. Two alternatively spliced isoforms of human beta-arrestin-1, differing only in the presence or absence of 24 base pairs/8 amino acids within the sequence, were identified and called beta-arrestin-1A and beta-arrestin-1B, respectively. Both isoforms were found in all tissues tested. Southern blot analysis revealed the existence of a single gene for beta-arrestin-1, suggesting that the two isoforms are generated by alternative mRNA splicing. The possible presence of similar isoforms was investigated for the other members of the arrestin/beta-arrestin gene family by PCR. Two isoforms of arrestin were revealed in bovine peripheral blood leukocytes. The expression of beta-arrestin-1 was studied in several human tissues and cell types. High levels of beta-arrestin-1 mRNA and immunoreactivity were found in peripheral blood leukocytes. The possible regulation of the expression of beta-arrestin-1 was also investigated. Our work documents for the first time that the expression of beta-arrestin-1 is modulated by intracellular cAMP. Using two cell types, human endothelial cells and smooth muscle cells, we found that 6-8-h treatments with the cAMP-inducing agents cholera toxin, forskolin, iloprost, and isoproterenol raised beta-arrestin-1 mRNA by 2-4-fold. Forskolin preferentially increased beta-arrestin-1A expression in smooth muscle cells, as assessed by PCR. Beta-arrestin-1 immunoreactivity was 2-3-fold higher in smooth muscle cells exposed to forskolin for 8 h, compared with untreated controls. We conclude that (i) the finding of alternatively spliced isoforms of beta-arrestin-1 and arrestin documents a novel mechanism to generate diversity within the arrestin/beta-arrestin gene family; (ii) the abundant expression of beta-arrestin-1 in peripheral blood leukocytes further supports our previous suggestion of a major role for the betaARK/beta-arrestin system in regulating receptor-mediated immune functions; (iii) the increased expression of beta-arrestin-1 by cAMP suggests a new mechanism for the regulation of receptor-mediated responses.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,VIA NAZL,I-66030 SANTA MARIA IMBAR,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Sallese, Michele/J-5347-2016	Sallese, Michele/0000-0002-2555-3571				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BALCONI G, 1986, MED BIOL, V64, P231; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BREITMAN ML, 1991, J BIOL CHEM, V266, P15505; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DEBLASI A, 1986, J LAB CLIN MED, V107, P86; DONOSO LA, 1986, CURR EYE RES, V5, P995, DOI 10.3109/02713688608995181; FLING SP, 1991, J IMMUNOL, V147, P483; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KNOSPE V, 1988, CURR EYE RES, V7, P1137, DOI 10.3109/02713688809001885; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MERRYMAN CF, 1991, J IMMUNOL, V146, P75; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARRUTI G, 1993, J RECEPTOR RES, V13, P609, DOI 10.3109/10799899309073682; PARRUTI G, 1993, BIOCHEM BIOPH RES CO, V190, P475, DOI 10.1006/bbrc.1993.1072; PERACCHIA F, 1989, BIOCHEM BIOPH RES CO, V160, P977, DOI 10.1016/S0006-291X(89)80096-8; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; TSUDA M, 1991, EUR J BIOCHEM, V200, P95, DOI 10.1111/j.1432-1033.1991.tb21053.x; YAGLE MK, 1990, P NATL ACAD SCI USA, V87, P7255, DOI 10.1073/pnas.87.18.7255; YAMAKI K, 1988, FEBS LETT, V234, P39, DOI 10.1016/0014-5793(88)81298-5; YAMAKI K, 1990, J BIOL CHEM, V265, P20757	35	102	105	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9753	9761						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486659				2022-12-27	WOS:A1993LA68900088
J	ROSS, FP; CHAPPEL, J; ALVAREZ, JI; SANDER, D; BUTLER, WT; FARACHCARSON, MC; MINTZ, KA; ROBEY, PG; TEITELBAUM, SL; CHERESH, DA				ROSS, FP; CHAPPEL, J; ALVAREZ, JI; SANDER, D; BUTLER, WT; FARACHCARSON, MC; MINTZ, KA; ROBEY, PG; TEITELBAUM, SL; CHERESH, DA			INTERACTIONS BETWEEN THE BONE-MATRIX PROTEINS OSTEOPONTIN AND BONE SIALOPROTEIN AND THE OSTEOCLAST INTEGRIN ALPHA-V-BETA-3 POTENTIATE BONE-RESORPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; AMINO-ACID-SEQUENCE; CELL-ADHESION; VITRONECTIN RECEPTOR; RAT BONE; ALPHA-V; PHOSPHORYLATED GLYCOPROTEIN; MONONUCLEAR PHAGOCYTES; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR	We have investigated the mechanism by which osteoclasts adhere to and resorb bone. We show that these cells express beta1 and beta3 integrins which are involved in attachment to purified bone matrix proteins. Binding to osteopontin and bone sialoprotein is mediated by alpha(v)beta3, while a beta1 integrin is responsible for attachment to fibronectin. Both the rapid attachment by osteoclasts to intact bone particles and their subsequent resorption are blocked by a monoclonal antibody directed to the alpha(v)beta3 complex but not by an antibody against beta1 integrins. Attachment of osteoclasts to bone is also inhibited with soluble osteopontin, Arg-Gly-Asp-containing peptides derived from both osteopontin and bone sialoprotein, or a monospecific polyclonal antibody against osteopontin. We conclude that both osteoclast adherence to bone and subsequent resorption of its matrix are dependent on interactions between the bone matrix proteins osteopontin and/or bone sialoprotein and the integrin alpha(v)beta3. Moreover, collagen, which constitutes 90% of its organic matrix, is minimally involved in binding of chicken osteoclasts to bone.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV TEXAS, HLTH SCI CTR, DENT BRANCH, DEPT BIOL CHEM, HOUSTON, TX 77225 USA; NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA	Scripps Research Institute; University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	ROSS, FP (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS, MED CTR, DEPT PATHOL & LAB MED, 216 S KINGSHIGHWAY, ST LOUIS, MO 63110 USA.		Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Teitelbaum, Steven/0000-0002-4054-6679; Farach-Carson, Mary/0000-0002-4526-3088	NCI NIH HHS [CA50286, CA47526] Funding Source: Medline; NIAMS NIH HHS [AR39273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047526, R01CA050286, R37CA050286, U01CA047526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; BARSHAVIT Z, 1983, J CLIN INVEST, V72, P516, DOI 10.1172/JCI110999; BEACHAM DA, 1990, EXP CELL RES, V189, P69, DOI 10.1016/0014-4827(90)90258-C; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BODARY SC, 1990, J BIOL CHEM, V265, P5938; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORTON MA, 1989, J BONE MINER RES, V4, P803; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KNUDSEN KA, 1985, EXP CELL RES, V157, P218, DOI 10.1016/0014-4827(85)90164-8; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; MOYLE M, 1991, J BIOL CHEM, V266, P19650; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; OKA JA, 1986, J CELL BIOL, V103, P1055, DOI 10.1083/jcb.103.3.1055; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROBEY PG, 1989, J CELL BIOL, V108, P719, DOI 10.1083/jcb.108.2.719; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SAUK JJ, 1990, EXP CELL RES, V188, P105, DOI 10.1016/0014-4827(90)90283-G; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; VAES G, 1988, CLIN ORTHOP RELAT R, P239; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; ZHANG R, 1990, J BIOL CHEM, V265, P15375	57	486	516	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9901	9907						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486670				2022-12-27	WOS:A1993LA68900106
J	BAJZAR, L; NESHEIM, M				BAJZAR, L; NESHEIM, M			THE EFFECT OF ACTIVATED PROTEIN-C ON FIBRINOLYSIS IN CELL-FREE PLASMA CAN BE ATTRIBUTED SPECIFICALLY TO ATTENUATION OF PROTHROMBIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CLOT LYSIS; PLASMINOGEN-ACTIVATOR; WHOLE-BLOOD; FACTOR-VA; INHIBITOR; MECHANISM; COFACTOR; THROMBIN	The effect of human activated protein C (APC) on tissue plasminogen activator (tPA)-induced fibrinolysis was studied in cell free plasma and in a system of purified components. Clots were produced by adding plasma or a solution of fibrinogen and plasminogen to the wells of a microtiter plate containing small separated aliquots of Ca2+, thrombin, and tPA, plus and minus APC. Initial clotting and subsequent fibrinolysis were monitored continuously by turbidity. The lysis time of dialyzed normal human plasma (NHP) was longer than that of dialyzed barium citrate-adsorbed plasma (BAP). APC had no effect on the lysis time of BAP but shortened the lysis time of NHP to that of BAP. Two fractions were produced from material eluted from the barium citrate pellet by precipitation of selective components with polyethylene glycol 8000 (PEG). One fraction comprised materials which precipitated at 5% PEG (5% PF) and the other materials which precipitated between 5 and 40% PEG (5-40% PF). Both fractions together, but neither alone, prolonged the lysis time of BAP, an effect which could be reversed by APC. Fractionation of the 5% PF showed that the component with the required activity has properties of the procoagulant surface and can be replaced with vesicles of phosphatidylcholine/phosphatidylserine (PCPS). In addition, the 5-40% PF can be replaced with either the combination of purified coagulation Factors II, IX, and X or Factor II plus the prothrombin activator Factor Xa. When Factor Xa was used as the activator in BAP plus PSPC vesicles, a dose-dependent saturable increase in lysis time was observed with a half-maximal increase occurring at 32 pM Factor Xa. This effect was eliminated by APC. In a system of purified components comprising PCPS vesicles, Factors V and 11, protein S, plasminogen and fibrinogen; the prothrombin activators Factor Xa and ecarin both induced a prolongation of the lysis time. APC prevented prolongation by Factor Xa but not by ecarin. The time courses of the generation of thrombin and plasmin during fibrinolysis of clots produced from systems of purified components in the presence and absence of APC, and with Factor Xa as the prothrombin activator, were determined by standardized activity assays using chromogenic substrates. In the absence of APC the lysis time was 145 min, and prothrombin was quantitatively converted to thrombin. In the presence of APC, however, the lysis time was reduced to 100 min with no evidence for the activation of prothrombin. The time course of the generation of plasmin during lysis was retarded in the absence of APC. The final concentrations of plasmin produced in both conditions were indistinguishable, however. These data indicate that activation of prothrombin generates an as yet unidentified antifibrinolytic component(s), and the profibrinolytic effect of APC can be rationalized by its ability to inhibit the activation of prothrombin.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada								BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BURDICK MD, 1987, THROMB RES, V45, P413, DOI 10.1016/0049-3848(87)90230-1; COLUCCI M, 1984, J CLIN INVEST, V74, P200, DOI 10.1172/JCI111402; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; DANGELO A, 1987, BLOOD, V69, P231; DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235; DEFOUW NJ, 1987, THROMB HAEMOSTASIS, V57, P176; DEFOUW NJ, 1988, FIBRINOLYSIS, V2, P235; ELECTRICWALA A, 1990, Fibrinolysis, V4, P121; ESMON NL, 1982, J BIOL CHEM, V257, P859; FAY WP, 1989, BIOCHEMISTRY-US, V28, P5773, DOI 10.1021/bi00440a011; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; SAKATA Y, 1986, BLOOD, V68, P1218; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; TAYLOR FB, 1985, THROMB RES, V37, P155, DOI 10.1016/0049-3848(85)90042-8; TAYLOR FB, 1981, FED PROC, V40, P2092; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; VANHINSBERGH VWM, 1985, BLOOD, V65, P444; VLASUK G P, 1990, Fibrinolysis, V4, P8; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WEINSTEIN RE, 1991, THROMB RES, V63, P123, DOI 10.1016/0049-3848(91)90275-2; ZOLTON R P, 1973, Thrombosis Research, V3, P23, DOI 10.1016/0049-3848(73)90123-0	31	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8608	8616						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473306				2022-12-27	WOS:A1993KX81100037
J	LOW, MG; HUANG, KS				LOW, MG; HUANG, KS			PHOSPHATIDIC-ACID, LYSOPHOSPHATIDIC ACID, AND LIPID-A ARE INHIBITORS OF GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-D - SPECIFIC-INHIBITION OF A PHOSPHOLIPASE BY PRODUCT ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINNESOTA RE595 LIPOPOLYSACCHARIDE; D GPI-PLD; PLASMA; PURIFICATION; PROTEINS; RECEPTOR	Previous work has suggested that the glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) purified from bovine serum is inhibited by phosphatidic acid (PA). In this study we report on the specificity and mechanism of this phenomenon using [H-3]myristate-labeled variant surface glycoprotein dispersed in Nonidet P-40 as substrate. Inhibition of GPI-PLD by PAs (IC50 approximately 1 muM) was relatively independent of the length or degree of unsaturation of the fatty acyl chains. It was also observed that lysophosphatidic acid and several natural and synthetic lipid A preparations were inhibitory in the same concentration range. The inhibitory potency of PA, lysophosphatidic acid, and lipid A was dependent on the detergent concentration in the assay but in all cases this was in a large (i.e. >100-fold) molar excess over the inhibitor. The inhibitory lipids did not affect substrate availability nor did they reduce hydrolysis of variant surface glycoprotein by a bacterial phosphatidylinositol-specific phospholipase C. Studies with a wide range of other lipids, detergents, and phosphate esters indicated that inhibition was specific for lipids containing a phosphomonoester group. The data suggest that inhibition is due to a direct interaction between PA (or lipid A) and the GPI-PLD rather than an indirect effect on the substrate particle.	HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT PROT BIOCHEM, NUTLEY, NJ 07110 USA	Roche Holding	LOW, MG (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040083, R01GM035873, R55GM040083] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35873, GM-40083] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCHAUER H, 1990, J BIOL CHEM, V265, P9159; BANGHAM AD, 1962, BIOCHIM BIOPHYS ACTA, V59, P103, DOI 10.1016/0006-3002(62)90701-1; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BURSTEN SL, 1992, AM J PHYSIOL, V262, pC328, DOI 10.1152/ajpcell.1992.262.2.C328; CAROFF M, 1991, J BIOL CHEM, V266, P18543; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GRABAREK J, 1990, J BIOL CHEM, V265, P8117; HELLER M, 1992, BIOCHIM BIOPHYS ACTA, V1109, P109, DOI 10.1016/0005-2736(92)90073-U; HERELD D, 1986, J BIOL CHEM, V261, P3813; HOENER MC, 1992, EUR J BIOCHEM, V206, P747, DOI 10.1111/j.1432-1033.1992.tb16981.x; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; HUANG KS, 1990, J BIOL CHEM, V265, P17738; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JOHNSON RS, 1990, J BIOL CHEM, V265, P8108; Low M.G., 1992, LIPID MODIFICATION P, P117; Low M. G., 1990, MOL CELL BIOL MEMBRA, P35; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; MALIK AS, 1986, BIOCHEM J, V240, P519, DOI 10.1042/bj2400519; METZ CN, 1991, CELL BIOL INT REP, V15, P875, DOI 10.1016/0309-1651(91)90039-L; METZ CN, 1992, AM J PATHOL, V140, P1275; METZ CN, 1991, J BIOL CHEM, V266, P17733; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; QIAN Z, 1991, FASEB J, V5, P315, DOI 10.1096/fasebj.5.3.2001791; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SESKO AM, 1991, FASEB J, V5, pA839; SMYTH SS, 1992, J BIOL CHEM, V267, P15568; STUETZ P, 1991, INFECTIOUS DISEASE C, V5, P847; TSANG TC, 1992, FASEB J, V6, pA1922; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WAITE M, 1987, HDB LIPID RES, V5; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	37	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8480	8490						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473292				2022-12-27	WOS:A1993KX81100019
J	TANAKA, S; KAYTES, P; KURKINEN, M				TANAKA, S; KAYTES, P; KURKINEN, M			AN ENHANCER FOR TRANSCRIPTION OF COLLAGEN-IV GENES IS ACTIVATED BY F9 CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RESPONSIVE ELEMENT; BASEMENT-MEMBRANE COLLAGEN; HEAD-TO-HEAD; RETINOIC ACID; ALPHA-2(IV) COLLAGEN; STRUCTURAL ORGANIZATION; BIDIRECTIONAL PROMOTER; TERATOCARCINOMA CELLS; CARCINOMA-CELLS; EXPRESSION	Expression of collagen IV genes is developmentally regulated and cell type-specific. To identify transcriptional control elements for the mouse alpha2(IV) collagen gene, several promoter constructs were transiently transfected into mouse PYS-2 (parietal yolk sac) cells. Within the 5.5-kb (kilobase) upstream and 8.5-kb downstream sequences from the transcription start site, we have identified several regulatory active regions. Here, we report characterization of the most proximal 0.3-kb enhancer found at 4.5-kb upstream of the alpha2(IV) collagen gene. This enhancer is transcriptionally active in cells that make collagen IV such as PYS-2 cells and differentiated F9 cells, but has little if any activity in cells that do not make collagen IV including NIH 3T3 cells and undifferentiated F9 embryonal carcinoma stem cells. This enhancer, linked to the herpes simplex virus TK gene promoter, confers a cell type-specific and differentiation-induced expression on the TK gene as well. Mutational and 5' and 3' deletion analysis demonstrate that this enhancer activity requires two identical response elements (GAACAAT) present in the 0.3-kb enhancer sequence. In gel shift assay, the GAACAAT element forms a complex that is specific for cells that make collagen IV.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, PISCATAWAY, NJ 08854 USA; UPJOHN CO, KALAMAZOO, MI 49001 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pfizer					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034090] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34090] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BLUMBERG B, 1990, EXTRACELLULAR MATRIX, P115; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTTICE G, 1990, NUCLEIC ACIDS RES, V18, P3079, DOI 10.1093/nar/18.10.3079; BUTTICE G, 1990, J MOL EVOL, V30, P479, DOI 10.1007/BF02101102; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESPESETH AS, 1989, GENE DEV, V3, P1647, DOI 10.1101/gad.3.11.1647; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; GUO XD, 1989, J BIOL CHEM, V264, P17574; Hogan B. L. M, 1983, CANCER SURV, V2, P115; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KAYTES P, 1988, J BIOL CHEM, V263, P19274; KURKINEN M, 1985, ANN NY ACAD SCI, V460, P267, DOI 10.1111/j.1749-6632.1985.tb51174.x; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; OGAWA K, 1988, J BIOL CHEM, V263, P8384; PETTITT J, 1991, J BIOL CHEM, V266, P16149; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POLLNER R, 1990, ANN NY ACAD SCI, V580, P44, DOI 10.1111/j.1749-6632.1990.tb17916.x; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SANDELL LJ, 1990, EXTRACELLULAR MATRIX; SAUS J, 1989, J BIOL CHEM, V264, P6318; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SOININEN R, 1987, FEBS LETT, V225, P188; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VENKITARAMAN AR, 1989, NUCLEIC ACIDS RES, V17, P3314, DOI 10.1093/nar/17.8.3314; VUKICEVIC S, 1990, CELL, V63, P437, DOI 10.1016/0092-8674(90)90176-F; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WANG SY, 1988, J CELL PHYSIOL, V136, P305, DOI 10.1002/jcp.1041360213; YANG-YEN H-F, 1990, New Biologist, V2, P351	50	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8862	8870						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473330				2022-12-27	WOS:A1993KX81100072
J	ROESSER, JR; LIITTSCHWAGER, K; LEFF, SE				ROESSER, JR; LIITTSCHWAGER, K; LEFF, SE			REGULATION OF TISSUE-SPECIFIC SPLICING OF THE CALCITONIN CALCITONIN GENE-RELATED PEPTIDE GENE BY RNA-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DROSOPHILA DOUBLESEX GENE; SEXUAL-DIFFERENTIATION; NUCLEAR RIBONUCLEOPROTEINS; MUSCLE TROPOMYOSIN; TRANSFORMER GENE; SINGLE GENE; CGRP GENE; EXPRESSION; INVITRO	Transcripts of the rat calcitonin/calcitonin gene-related peptide (CGRP) gene are alternatively spliced in a tissue-specific manner resulting in the production of calcitonin mRNA and peptide in thyroid C cells and CGRP mRNA and peptide in neurons. Transfection studies using calcitonin and chimaeric human beta-globin/calcitonin exon minigene constructs showed that the splice acceptor and exon specific to calcitonin mRNA are spliced much less efficiently in CGRP-producing cells (F9 teratocarcinomas) than in cells that preferentially make calcitonin (HeLa cells). In vitro splicing of chimaeric human beta-globin/calcitonin transcripts in HeLa nuclear extracts were inhibited by the addition of nuclear extract from CGRP-favoring cells or tissues such as rat brain. This inhibition was specific as splicing of human beta-globin first intron transcripts was not affected by comparable amounts of rat brain extract. Fractionation of rat brain nuclear extracts allowed the partial purification of two brain-specific polypeptides of apparent molecular mass of 43 and 41 kDa which preferentially bind RNA containing the calcitonin-specific splice acceptor. Since these polypeptides cofractionate with the calcitonin mRNA-specific splicing inhibition activity, we suggest that they may mediate the inhibition of splicing observed in vitro and underlie, in part, the inefficient calcitonin mRNA production observed in CGRP-favoring cells in vivo.	STANFORD UNIV,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001404] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40125, GM 07149-17] Funding Source: Medline; NINDS NIH HHS [NS 01404] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADEMA GJ, 1990, NUCLEIC ACIDS RES, V18, P5365, DOI 10.1093/nar/18.18.5365; ADEMA GJ, 1991, BIOCHEM BIOPH RES CO, V178, P985, DOI 10.1016/0006-291X(91)90989-K; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; COTE GJ, 1991, NUCLEIC ACIDS RES, V19, P3601, DOI 10.1093/nar/19.13.3601; COTE GJ, 1992, NUCLEIC ACIDS RES, V20, P2361, DOI 10.1093/nar/20.9.2361; COTE GJ, 1990, MOL ENDOCRINOL, V4, P1744, DOI 10.1210/mend-4-11-1744; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; EDBROOKE MR, 1985, EMBO J, V4, P715, DOI 10.1002/j.1460-2075.1985.tb03688.x; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LIBRI D, 1989, J BIOL CHEM, V264, P2935; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; McKeown M, 1990, Genet Eng (N Y), V12, P139; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1988, GENE DEV, V2, P1262; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SABATE MI, 1985, J BIOL CHEM, V260, P2589; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SERRAFIN PR, 1988, GENE DEV, V2, P215; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; ZACHAR Z, 1987, EMBO J, V6, P4410; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; [No title captured]	63	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8366	8375						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463344				2022-12-27	WOS:A1993KW97900111
